PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HOGASEN, K; MOLLNES, TE; HARBOE, M				HOGASEN, K; MOLLNES, TE; HARBOE, M			HEPARIN-BINDING PROPERTIES OF VITRONECTIN ARE LINKED TO COMPLEX-FORMATION AS ILLUSTRATED BY INVITRO POLYMERIZATION AND BINDING TO THE TERMINAL COMPLEMENT COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACK COMPLEX; HUMAN S-PROTEIN; HUMAN-PLASMA; MONOCLONAL-ANTIBODIES; PLATELET-AGGREGATION; ANTITHROMBIN-III; CELL-SURFACE; NEOANTIGEN; INHIBITOR	Vitronectin (VN, complement S-protein) is a multifunctional protein which participates in cell adhesion, coagulation, fibrinolysis, and protection against complement lysis. VN is incorporated into several complexes, such as the terminal complement complex and thrombin-antithrombin III, and is bound to plasminogen activator inhibitor 1. The present study showed that purified VN spontaneously forms polymers of approximately 1000 kDa with a Stokes radius of 10 nm. The polymers are to a varying extent stabilized by disulfide bonds, but are quite stable even after reduction and alkylation, indicating the importance of noncovalent bonds. Plasma VN circulates mainly as a 65/75-kDa monomer containing a cryptic heparin-binding site which is exposed upon a conformational change induced by different stimuli, such as coagulation, heating, adsorption to surfaces, or exposure to acids, urea, or other denaturating agents. In the present study, VN was demonstrated to expose its heparin-binding site and its conformationally dependent 8E6 epitope when incorporated into the terminal complement complex. We suggest that exposure of the heparin-binding site and a putative hydrophobic binding site of VN are linked events dependent upon the same conformational change. In vivo, complex formation probably induces the heparin-binding site. Such a link might also explain why purified heparin-binding VN spontaneously forms polymers. The heparin-binding site may be involved in the elimination of multimolecular complexes containing VN.			HOGASEN, K (corresponding author), UNIV OSLO,NATL HOSP,INST IMMUNOL & RHEUMATOL,FR QVAMSGT 1,N-0172 OSLO 1,NORWAY.		Mollnes, Tom/ABI-5183-2020					AKAMA T, 1986, J BIOCHEM-TOKYO, V100, P1343, DOI 10.1093/oxfordjournals.jbchem.a121840; ASCH E, 1990, J CLIN INVEST, V85, P1372, DOI 10.1172/JCI114581; CHOI NH, 1990, INT IMMUNOL, V2, P413, DOI 10.1093/intimm/2.5.413; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; JENNE D, 1985, THROMB RES, V38, P401, DOI 10.1016/0049-3848(85)90138-0; KUBOTA K, 1990, BIOCHEM BIOPH RES CO, V167, P1355, DOI 10.1016/0006-291X(90)90672-A; MOHRI H, 1991, AM J CLIN PATHOL, V96, P605, DOI 10.1093/ajcp/96.5.605; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P197, DOI 10.1111/j.1365-3083.1985.tb01871.x; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P183, DOI 10.1111/j.1365-3083.1985.tb01870.x; Murphy B F, 1989, Int Immunol, V1, P551, DOI 10.1093/intimm/1.5.551; PODACK ER, 1977, J IMMUNOL, V119, P2024; PODACK ER, 1979, J BIOL CHEM, V254, P9908; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; SHIFMAN MA, 1982, J BIOL CHEM, V257, P3243; TOMASINI BR, 1988, BLOOD, V72, P903; WIMAN B, 1988, COMPLEMENT, V5, P180; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	21	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23076	23082						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385412				2022-12-27	WOS:A1992JY16300058
J	BENNETT, JL; SUNJOO, JY; CLAYTON, DA				BENNETT, JL; SUNJOO, JY; CLAYTON, DA			CHARACTERIZATION OF A XENOPUS-LAEVIS RIBONUCLEOPROTEIN ENDORIBONUCLEASE - ISOLATION OF THE RNA COMPONENT AND ITS EXPRESSION DURING DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MITOCHONDRIAL-DNA; NUCLEOLAR 7-2 RNA; SECONDARY STRUCTURE; AMPHIBIAN OOCYTES; OCTAMER MOTIF; RIBOSOMAL-RNA; NUCLEAR GENE; U3 SNRNA; MRP; SITE	In order to facilitate studies of the assembly and transport of the site-specific RNase mitochondrial RNA processing (MRP) ribonucleoprotein, we have characterized it from Xenopus laevis cells. X. laevis RNase MRP displayed a similar spectrum of cleavage activity to that produced by previously isolated mammalian nuclear enzymes. A 277-nucleotide RNA component of the ribonucleoprotein was identified; the gene for the RNA was isolated, sequenced, and found to be 66 and 63% similar to mouse and human RNase MRP RNAs, respectively. Despite the evolutionary distance from its mammalian counterparts, X. laevis RNase MRP RNA contains five regions of homology to the mammalian RNase MRP RNA. Four of these regions correspond to those previously identified as conserved between RNase MRP and RNase P RNAs; the fifth encompasses nucleotides recently discovered to be sufficient for autoantigen binding. The expression and assembly of Xenopus RNase MRP RNA were examined in frog oocytes and developing embryos. RNase MRP RNA was expressed throughout oogenesis; it started to accumulate at stage I and reached a maximum in stage IV. During embryogenesis RNase MRP RNA expression began to elevate at approximately stage 22 and continued to rise through the swimming tadpole stage. When injected into the nucleus of mature oocytes, the X. laevis RNase MRP RNA gene was expressed accurately, and transcripts were packaged into immunoprecipitable particles.			BENNETT, JL (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365, R01GM033088, R37GM033088] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33088-21, GM07365-15] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1990, EMBO J, V9, P3109, DOI 10.1002/j.1460-2075.1990.tb07508.x; BENNETT JL, 1990, MOL CELL BIOL, V10, P2191, DOI 10.1128/MCB.10.5.2191; BIRD AP, 1971, CHROMOSOMA, V35, P300, DOI 10.1007/BF00326280; BROWN DD, 1968, SCIENCE, V160, P272, DOI 10.1126/science.160.3825.272; BROWN DD, 1964, J MOL BIOL, V8, P669, DOI 10.1016/S0022-2836(64)80116-9; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; CAIZERGUESFERRER M, 1991, DEVELOPMENT, V112, P317; CALLEN JC, 1983, EXP CELL RES, V143, P115, DOI 10.1016/0014-4827(83)90114-3; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CHASE JW, 1972, DEV BIOL, V27, P504, DOI 10.1016/0012-1606(72)90189-3; CONDIE BG, 1987, DEVELOPMENT, V101, P93; CURRIE RA, 1989, MOL CELL BIOL, V9, P4239, DOI 10.1128/MCB.9.10.4239; Davidson E. H., 1986, GENE ACTIVITY EARLY; DORIA M, 1991, NUCLEIC ACIDS RES, V19, P2315, DOI 10.1093/nar/19.9.2315; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ELMEZIANE A, 1989, EMBO J, V8, P1649, DOI 10.1002/j.1460-2075.1989.tb03555.x; FORBES DJ, 1983, J CELL BIOL, V97, P62, DOI 10.1083/jcb.97.1.62; GALL JG, 1968, P NATL ACAD SCI USA, V60, P553, DOI 10.1073/pnas.60.2.553; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; HAMM J, 1990, RNA PROCESSING B; HASHIMOTO C, 1983, J BIOL CHEM, V258, P1379; HEASMAN J, 1984, DEV BIOL, V105, P458, DOI 10.1016/0012-1606(84)90303-8; HINKLEY CS, 1992, MOL CELL BIOL, V12, P638, DOI 10.1128/MCB.12.2.638; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KARWAN R, 1991, GENE DEV, V5, P1264, DOI 10.1101/gad.5.7.1264; KRESSMANN A, 1977, COLD SPRING HARB SYM, V42, P1077; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PARRY HD, 1989, NUCLEIC ACIDS RES, V17, P3633, DOI 10.1093/nar/17.10.3633; REDDY R, 1983, J BIOL CHEM, V258, P1383; REIMER G, 1988, EXP CELL RES, V176, P117, DOI 10.1016/0014-4827(88)90126-7; ROE BA, 1985, J BIOL CHEM, V260, P9759; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STEPHENS DL, 1981, ANAL BIOCHEM, V114, P299, DOI 10.1016/0003-2697(81)90485-1; TAYLOR MA, 1985, DEV BIOL, V110, P230, DOI 10.1016/0012-1606(85)90079-X; TOLLERVEY D, 1987, EMBO J, V6, P469, DOI 10.1002/j.1460-2075.1987.tb04777.x; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; TOPPER JN, 1990, J BIOL CHEM, V265, P13254; WALLACE RA, 1973, J EXP ZOOL, V184, P321, DOI 10.1002/jez.1401840305; WEBB AC, 1977, DEV BIOL, V56, P219, DOI 10.1016/0012-1606(77)90166-X; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; YUAN Y, 1989, J BIOL CHEM, V264, P14835; YUAN Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P33, DOI 10.1016/0167-4781(91)90081-V; YUAN Y, 1991, MOL CELL BIOL, V11, P5266, DOI 10.1128/MCB.11.10.5266	52	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21765	21772						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383227				2022-12-27	WOS:A1992JV01100079
J	METZ, DC; PATTO, RJ; MROZINSKI, JE; JENSEN, RT; TURNER, RJ; GARDNER, JD				METZ, DC; PATTO, RJ; MROZINSKI, JE; JENSEN, RT; TURNER, RJ; GARDNER, JD			THAPSIGARGIN DEFINES THE ROLES OF CELLULAR CALCIUM IN SECRETAGOGUE-STIMULATED ENZYME-SECRETION FROM PANCREATIC ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE CYTOSOLIC CALCIUM; GUINEA-PIG PANCREAS; AMYLASE RELEASE; INOSITOL TRISPHOSPHATE; TUMOR PROMOTER; PLASMA-MEMBRANE; SIGNAL TRANSDUCTION; EXOCRINE PANCREAS; DISPERSED ACINI; CYCLIC-AMP	In the present study we used thapsigargin (TG), an inhibitor of microsomal calcium ATPase, to evaluate the roles of free cytoplasmic calcium and intracellular stored calcium in secretagogue-stimulated enzyme secretion from rat pancreatic acini. Using microspectro-fluorimetry of fura-2-loaded pancreatic acini, we found that TG caused a sustained increase in free cytoplasmic calcium by mobilizing calcium from inositol 1, 4, 5-trisphosphate-sensitive intracellular stores and by increasing influx of extracellular calcium. TG also caused a small increase in basal amylase secretion, inhibited the stimulation of amylase secretion caused by secretagogues that increase inositol 1, 4, 5-trisphosphate, and potentiated the stimulation of amylase secretion caused by 12-O-tetradecanoylphorbol-13-acetate or secretagogues that increase cyclic adenosine 3',5'-monophosphate. Bombesin, which like TG increased free cytoplasmic calcium, also potentiated the stimulation of amylase secretion caused by secretagogues that increase cyclic adenosine 3',5'-monophosphate, but did not inhibit the stimulation of amylase secretion caused by secretagogues that increase inositol 1, 4, 5-trisphosphate. Finally, TG inhibited the sustained phase of cholecystokinin-stimulated amylase secretion and potentiated the time course of vasoactive intestinal peptide-stimulated amylase secretion. The present findings indicate that stimulation of amylase secretion by secretagogues that increase inositol 1, 4, 5-trisphosphate does not depend on increased free cytoplasmic calcium per se. In contrast, TG-induced potentiation of the stimulation of secretagogues that increase cellular cyclic adenosine 3',5'-monophosphate appears to result from increased free cytoplasmic calcium per se.	NIDR,CLIN INVEST & PATIENT CARE BRANCH,BETHESDA,MD 20892; NIDDKD,DIGEST DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BISSONNETTE BM, 1984, AM J PHYSIOL, V246, pG710, DOI 10.1152/ajpgi.1984.246.6.G710; CESKA M, 1969, CLIN CHIM ACTA, V26, P445, DOI 10.1016/0009-8981(69)90072-2; CESKA M, 1969, CLIN CHIM ACTA, V26, P437, DOI 10.1016/0009-8981(69)90071-0; CHEW CS, 1991, CELL REGUL, V2, P27, DOI 10.1091/mbc.2.1.27; DORMER RL, 1984, BIOCHEM BIOPH RES CO, V119, P876, DOI 10.1016/0006-291X(84)90855-6; ELY JA, 1991, J BIOL CHEM, V266, P18635; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GARDNER JD, 1977, J PHYSIOL-LONDON, V270, P439, DOI 10.1113/jphysiol.1977.sp011961; GARDNER JD, 1987, PHYSL GASTROINTESTIN, P1109; GARDNER JD, 1977, AM J PHYSIOL, V236, pE754; GARDNER JD, 1980, AM J PHYSIOL, pG458; GARDNER JD, 1981, PHYSL GASTROINTESTIN, P831; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOOTMAN SR, 1987, PHYSL GASTROINTESTIN, P1129; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KASS GEN, 1990, J BIOL CHEM, V265, P17486; KRAUSE KH, 1989, CELL CALCIUM, V10, P351, DOI 10.1016/0143-4160(89)90061-4; KRIMS PE, 1988, PANCREAS, V3, P383, DOI 10.1097/00006676-198808000-00003; KURAN CY, 1990, AM J PHYSIOL, V258, pC1006; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OCHS DL, 1985, AM J PHYSIOL, V249, pG389, DOI 10.1152/ajpgi.1985.249.3.G389; OGAMI Y, 1989, JPN J PHYSIOL, V39, P571, DOI 10.2170/jjphysiol.39.571; OHUCHI K, 1988, BRIT J PHARMACOL, V94, P917, DOI 10.1111/j.1476-5381.1988.tb11604.x; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; PANDOL SJ, 1989, CELL CALCIUM, V10, P255, DOI 10.1016/0143-4160(89)90008-0; PEIKIN SR, 1978, AM J PHYSIOL-ENDOC M, V235, P743; PETERSEN OH, 1991, CELL CALCIUM, V12, P135, DOI 10.1016/0143-4160(91)90015-7; POWERS RE, 1985, AM J PHYSIOL, V248, pC535, DOI 10.1152/ajpcell.1985.248.5.C535; PRALONG WF, 1988, FEBS LETT, V242, P7984; PUTNEY JW, 1983, BIOCHEM J, V212, P483, DOI 10.1042/bj2120483; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; SATO S, 1989, AM J PHYSIOL, V257, pG202, DOI 10.1152/ajpgi.1989.257.2.G202; SCHEELE G, 1979, J BIOL CHEM, V254, P346; STREB H, 1983, NATURE, V306, P6769; STUENKEL EL, 1989, BIOCHEM BIOPH RES CO, V158, P863, DOI 10.1016/0006-291X(89)92802-7; TAKEMURA H, 1990, CELL CALCIUM, V11, P11, DOI 10.1016/0143-4160(90)90044-U; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TRIMBLE ER, 1986, BIOCHEM J, V239, P257, DOI 10.1042/bj2390257; TRIMBLE ER, 1987, P NATL ACAD SCI USA, V84, P3146, DOI 10.1073/pnas.84.10.3146; TSUNODA Y, 1990, AM J PHYSIOL, V259, pG792, DOI 10.1152/ajpgi.1990.259.5.G792; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; VALDEZ IH, 1991, AM J PHYSIOL, V261, pG359, DOI 10.1152/ajpgi.1991.261.2.G359; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7	63	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20620	20629						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383205				2022-12-27	WOS:A1992JT97800021
J	WANG, F; MILLET, I; BOTTOMLY, K; VIGNERY, A				WANG, F; MILLET, I; BOTTOMLY, K; VIGNERY, A			CALCITONIN GENE-RELATED PEPTIDE INHIBITS INTERLEUKIN-2 PRODUCTION BY MURINE LYMPHOCYTES-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH-FACTOR; SKELETAL-MUSCLE; MESSENGER-RNA; EXPRESSION; CDNA; CGRP; ACTIVATION; CLONING; PROLIFERATION; NEUROPEPTIDE	Evidence from the literature suggests that the nervous and the immune systems closely interact via neuromediators, which affect the immune system, and cytokines, which control nerve cell growth and activity. Calcitonin gene-related peptide (CGRP) is a neuropeptide that has been identified in numerous tissues including immune organs and inhibits the proliferation of spleen cells. We investigated whether CGRP altered the function of T lymphocytes. We present evidence that CGRP induces a dose-dependent cAMP accumulation in interleukin 2-producing T(H1) cells and inhibits their production of interleukin 2. These effects are prevented by CGRP8-37, a CGRP antagonist that is missing the first 7 amino acids. This CGRP-mediated inhibition of interleukin 2 production is accompanied by a decrease in interleukin 2 mRNA accumulation. CGRP also inhibits the accumulation of mRNA coding for tumor necrosis factor-alpha and -beta and interferon-gamma. Thus, we have identified one mechanism by which CGRP inhibits the proliferation of spleen cells.	YALE UNIV, SCH MED, DEPT ORTHOPAED & REHABIL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT IMMUNOBIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University; Yale University					NIADDK NIH HHS [AM 35004] Funding Source: Medline; NIAMS NIH HHS [AR01694] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001694] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALVAREZ FJ, 1988, BRAIN RES, V442, P391, DOI 10.1016/0006-8993(88)91532-6; BELLINGER DL, 1990, ANN NY ACAD SCI, V594, P17; BENDTSEN F, 1991, J HEPATOL, V12, P118, DOI 10.1016/0168-8278(91)90920-7; BOTTOMLY K, 1991, CURRENT PROTOCOLS IM; CHIBA T, 1989, AM J PHYSIOL, V256, pE331, DOI 10.1152/ajpendo.1989.256.2.E331; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; GILLIS S, 1981, P NATL ACAD SCI-BIOL, V78, P1133, DOI 10.1073/pnas.78.2.1133; GILLIS S, 1978, J IMMUNOL, V120, P2027; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; Goetzl E J, 1990, Adv Immunol, V48, P161, DOI 10.1016/S0065-2776(08)60754-3; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; HEIJNEN CJ, 1991, IMMUNOL REV, V119, P41, DOI 10.1111/j.1600-065X.1991.tb00577.x; HOPPENER JWM, 1987, J CLIN ENDOCR METAB, V64, P809; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KROEMER G, 1989, IMMUNOL TODAY, V10, P246, DOI 10.1016/0167-5699(89)90262-4; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; LI CB, 1987, J IMMUNOL, V138, P4496; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MCGILLIS JP, 1991, J IMMUNOL, V147, P3482; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; NONG YH, 1989, J IMMUNOL, V143, P45; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; PAYAN DG, 1986, ADV IMMUNOL, V39, P299; PENNICA D, 1985, P NATL ACAD SCI USA, V82, P6060, DOI 10.1073/pnas.82.18.6060; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; RAPPAPORT RS, 1982, J EXP MED, V155, P943, DOI 10.1084/jem.155.3.943; ROBERTSON CN, 1990, J UROLOGY, V144, P614, DOI 10.1016/S0022-5347(17)39537-X; SAWADA S, 1987, J IMMUNOL, V139, P1797; SCHIFTER S, 1991, PEPTIDES, V12, P365, DOI 10.1016/0196-9781(91)90027-M; STEENBERGH PH, 1985, FEBS LETT, V183, P408, DOI 10.1016/0014-5793(85)80820-6; UMEDA Y, 1988, BIOCHEM BIOPH RES CO, V154, P227, DOI 10.1016/0006-291X(88)90674-2; VIGNERY A, 1991, AM J PHYSIOL, V261, pF1026, DOI 10.1152/ajprenal.1991.261.6.F1026; VIGNERY A, 1991, J CELL PHYSIOL, V149, P301, DOI 10.1002/jcp.1041490217; VIGNERY A, 1991, AM J PHYSIOL, V260, pF704, DOI 10.1152/ajprenal.1991.260.5.F704; VILLEMAIN F, 1987, ANN NY ACAD SCI, V496, P669, DOI 10.1111/j.1749-6632.1987.tb35828.x; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68; ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V158, P214, DOI 10.1016/S0006-291X(89)80200-1; ZIER KS, 1984, DIABETES, V33, P552, DOI 10.2337/diabetes.33.6.552	42	101	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21052	21057						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383217				2022-12-27	WOS:A1992JT97800085
J	ASAI, K; NAKANISHI, K; ISOBE, I; EKSIOGLU, YZ; HIRANO, A; HAMA, K; MIYAMOTO, T; KATO, T				ASAI, K; NAKANISHI, K; ISOBE, I; EKSIOGLU, YZ; HIRANO, A; HAMA, K; MIYAMOTO, T; KATO, T			NEUROTROPHIC ACTION OF GLIOSTATIN ON CORTICAL-NEURONS - IDENTITY OF GLIOSTATIN AND PLATELET-DERIVED ENDOTHELIAL-CELL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEURONOTROPHIC FACTOR; PURIFICATION; CULTURE; BRAIN; IDENTIFICATION; SPECIFICITY; EXPRESSION; CLONING; PROTEIN; GLIA	Gliostatin is a polypeptide growth inhibitor of apparent M(r) = 100,000 with a homodimeric structure comprising two 50-kDa subunits, acting on astrocyte as well as astrocytoma cells (Asai, K., Hirano, T., Kaneko, S., Moriyama, A., Nakanishi, K., Isobe, I., Eksioglu, Y. Z., and Kato, T. (1992) J. Neurochem., 59, 307-317). The amino acid sequences of 13 tryptic peptides including the amino terminus were completely identical to those of platelet-derived endothelial cell growth factor (PD-ECGF) (Ishikawa, F., Miyazono, K., Hellman, U., Drexler, H., Wernstedt, C., Hagiwara, K., Usuki, K., Takaku, F., Risau, W., and Heldin, C.-H. (1989) Nature 338, 557-562). Gliostatin and PD-ECGF, purified from human placenta, shared growth inhibition on glial cells and growth promotion on endothelial cells, and exhibited similar values for half-maximal dose of glial growth inhibition (ID50 = 1.3 nM) and the half-maximal concentration of endothelial growth promotion (EC50 = 1.0 nM), suggesting that both factors evoke the biological actions through an identical receptor on each cell surface. We have further demonstrated evidence of a novel neurotrophic action of gliostatin/PD-ECGF toward embryonic rat cortical neurons in culture. The half-maximal concentration of gliostatin/PD-ECGF for neurotrophic action was 0.3 nm. All actions on glial, endothelial, and neuronal cells, were abolished by a monoclonal antibody against gliostatin. These data indicate that gliostatin/PD-ECGF may play important roles on development and regeneration of the central nervous system and may also involve the induction of angiogenesis for the formation of blood brain barrier.	NAGOYA CITY UNIV,SCH MED,DEPT BIOREGULAT RES,MIZUHO KU,NAGOYA,AICHI 467,JAPAN; ONO PHARMACEUT CO LTD,MINASE RES INST,MISHIMA,OSAKA 618,JAPAN	Nagoya City University; Ono Pharmaceutical Co Ltd			Asai, Kiyofumi/H-2356-2014	Asai, Kiyofumi/0000-0001-7015-2251				ASAI K, 1992, J NEUROCHEM, V59, P307, DOI 10.1111/j.1471-4159.1992.tb08905.x; ASAI K, 1991, BRAIN RES, V556, P344, DOI 10.1016/0006-8993(91)90328-S; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BOOYSE FM, 1975, THROMB DIATH HAEMOST, V34, P825, DOI 10.1055/s-0038-1654001; DOHERTY P, 1984, J NEUROCHEM, V42, P116; EASTER SS, 1985, SCIENCE, V230, P507, DOI 10.1126/science.4048944; ENGELE J, 1991, J NEUROSCI, V11, P3070; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; FURUKAWA T, 1992, NATURE, V356, P668, DOI 10.1038/356668a0; HASHIDA S, 1984, Journal of Applied Biochemistry, V6, P56; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HORIUCHI I, 1985, NEUROCHEM INT, V7, P497, DOI 10.1016/0197-0186(85)90174-3; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; ITO J, 1987, NEUROCHEM INT, V11, P331, DOI 10.1016/0197-0186(87)90054-4; KATO K, 1981, J NEUROCHEM, V36, P793, DOI 10.1111/j.1471-4159.1981.tb01663.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LILIEN LE, 1988, NEURON, V1, P485; LIM R, 1987, DEV BRAIN RES, V33, P49, DOI 10.1016/0165-3806(87)90175-1; LIN LFH, 1990, J BIOL CHEM, V265, P8942; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANTHORPE M, 1986, BRAIN RES, V367, P282, DOI 10.1016/0006-8993(86)91603-3; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MIYAZONO K, 1985, BIOCHEM BIOPH RES CO, V126, P83, DOI 10.1016/0006-291X(85)90574-1; RUDGE JS, 1987, DEV BRAIN RES, V32, P103, DOI 10.1016/0165-3806(87)90143-X; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; THOENEN H, 1987, REV PHYSL BIOCH PHAR, V109, P146; USUKI K, 1991, J BIOL CHEM, V266, P20525; USUKI K, 1989, P NATL ACAD SCI USA, V86, P7427, DOI 10.1073/pnas.86.19.7427; USUKI K, 1990, CELL REGUL, V1, P557; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	36	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20311	20316						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400349				2022-12-27	WOS:A1992JR85800089
J	MOTOKURA, T; KEYOMARSI, K; KRONENBERG, HM; ARNOLD, A				MOTOKURA, T; KEYOMARSI, K; KRONENBERG, HM; ARNOLD, A			CLONING AND CHARACTERIZATION OF HUMAN CYCLIN D3, A CDNA CLOSELY RELATED IN SEQUENCE TO THE PRAD1 CYCLIN-D1 PROTOONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE MESSENGER-RNAS; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL-ABNORMALITIES; CANDIDATE ONCOGENE; GENE; G1; YEAST; TUMOR; RETINOBLASTOMAS	Cyclins regulate cell cycle progression by complexing with and activating cdc2 or related kinases. PRAD1/cyclin D1 is a recently discovered putative oncogene in several types of human tumors and may regulate G1-S phase progression. We have cloned a related human cDNA, called cyclin D3, from a placental cDNA library by cross-hybridization with PRAD1. In synchronized HeLa cells, the mRNA levels of PRAD1 and cyclin D3 were regulated reciprocally through the cell cycle: cyclin D3 mRNA levels peaked in S phase, where PRAD1 mRNA was lowest in S. In normal human mammary epithelial (70N) cells synchronized by growth factor deprivation and subsequent growth factor stimulation, PRAD1 expression peaked in G1 and declined before S phase, while cyclin D3 expression rose later in G1 and remained elevated in S. Therefore, the close relationship (53.1% identity) between PRAD1 and cyclin D3 does not necessarily imply redundant functions of these candidate G1 cyclins; they may have distinct roles in progression from G1 through S phase.	MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, FRUIT ST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELL GROWTH & REGULAT, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Keyomarsi, Khandan/H-2716-2016; Motokura, Toru/X-3682-2019	Keyomarsi, Khandan/0000-0002-5440-0849; 	NCI NIH HHS [CA08949, CA55909] Funding Source: Medline; NIDDK NIH HHS [DK11794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055909, F32CA008949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Battey, 1986, BASIC METHODS MOL BI; BENEDICT WF, 1983, CANCER GENET CYTOGEN, V10, P311, DOI 10.1016/0165-4608(83)90090-0; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUSNETSOVA LE, 1982, HUM GENET, V61, P201, DOI 10.1007/BF00296442; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1992, CYTOGENET CELL GENET, V61, P5, DOI 10.1159/000133359; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; PRIGOGINA EL, 1988, CANCER GENET CYTOGEN, V32, P183, DOI 10.1016/0165-4608(88)90281-6; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHOUTEN HC, 1990, CANCER GENET CYTOGEN, V47, P73, DOI 10.1016/0165-4608(90)90265-C; SQUIRE J, 1984, HUM GENET, V66, P46, DOI 10.1007/BF00275185; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	39	158	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20412	20415						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1383201				2022-12-27	WOS:A1992JR85800103
J	SHEFF, DR; RUBENSTEIN, PA				SHEFF, DR; RUBENSTEIN, PA			ISOLATION AND CHARACTERIZATION OF THE RAT-LIVER ACTIN N-ACETYLAMINOPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE AMINOPEPTIDASE; SACCHAROMYCES-CEREVISIAE; AMINO TERMINUS; PROTEINS; PURIFICATION; YEAST; CELL; FORMYLMETHIONINE; HEMOGLOBIN; HYDROLASE	Actins from most eukaryotes undergo a unique posttranslational modification of the amino terminus called "processing." Processing consists of the removal of an amino-terminal Ac-Met or Ac-Cys to leave an acidic amino-terminal residue. We have previously demonstrated that this reaction is not catalyzed by the ribosomally associated methionine aminopeptidase or by other previously described acetylaminopeptidases. Here we present the isolation and characterization of the actin N-acetylaminopeptidase (ANAP) from rat liver. A five-step purification protocol achieves a 4100-fold purification of the enzyme with an overall 8% recovery of activity. ANAP is a 77-kDa monomer with a pI of 4.6. Using unprocessed yeast actin as a substrate, the K(m) of ANAP is 3.5 muM. Purified ANAP was used to generate a polyclonal antibody. The antibody has been used along with activity assays to demonstrate the presence of ANAP in a variety of rat tissues. Finally, evidence is presented that in mammals, ANAP may function with a second, as yet unpurified, component to process actin amino termini.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa				Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337, R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33689, T32GM07337] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAGI T, 1969, J ANTIBIOT, V22, P283, DOI 10.7164/antibiotics.22.283; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; BROWN JL, 1979, J BIOL CHEM, V254, P1447; BROWN JL, 1976, J BIOL CHEM, V251, P1009; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANG YH, 1990, J BIOL CHEM, V265, P19892; COOK RK, 1991, J BIOL CHEM, V266, P16825; GADE W, 1978, J BIOL CHEM, V253, P5012; HANADA K, 1983, PROTEINASE INHIBITOR, P25; HENNESSEY ES, 1991, EUR J BIOCHEM, V197, P345, DOI 10.1111/j.1432-1033.1991.tb15917.x; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; KOBAYASHI K, 1987, J BIOL CHEM, V262, P11435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; RADHAKRISHNA G, 1988, MOL BIOL INTRACELLUL, P109; REDMAN KL, 1985, J BIOL CHEM, V260, P4857; RICH DH, 1985, BIOCHEMISTRY-US, V24, P3165, DOI 10.1021/bi00334a014; RUBENSTEIN PA, 1987, METHOD CELL BIOL, V28, P231; RUBENSTEINPA, 1986, MICROBIOLOGY, P283; SHEFF DR, 1989, J BIOL CHEM, V264, P11491; SHEFF DR, 1992, J BIOL CHEM, V267, P2671; Sherman F., 1986, METHODS YEAST GENETI; SOLOMON LR, 1985, J BIOL CHEM, V260, P7659; TRAUTSCHOLD I, 1967, BIOCHEM PHARMACOL, V16, P59, DOI 10.1016/0006-2952(67)90186-4; UMEZAWA H, 1982, ANNU REV MICROBIOL, V36, P75, DOI 10.1146/annurev.mi.36.100182.000451; Umezawa H, 1976, Methods Enzymol, V45, P678; WINSTON S, 1987, CURRENT PROTOCOLS MO, P1081; WITHEILER J, 1972, J BIOL CHEM, V247, P2217; YOSHIDA A, 1972, J BIOL CHEM, V247, P952; YOSHIDA A, 1970, P NATL ACAD SCI USA, V67, P1600, DOI 10.1073/pnas.67.3.1600	33	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20217	20224						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400339				2022-12-27	WOS:A1992JR85800075
J	BAUMANN, H; MORELLA, KK; CAMPOS, SP; CAO, Z; JAHREIS, GP				BAUMANN, H; MORELLA, KK; CAMPOS, SP; CAO, Z; JAHREIS, GP			ROLE OF CAAT-ENHANCER BINDING-PROTEIN ISOFORMS IN THE CYTOKINE REGULATION OF ACUTE-PHASE PLASMA-PROTEIN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALPHA-1-ACID GLYCOPROTEIN; TRANSCRIPTIONAL ACTIVATOR PROTEIN; GLUCOCORTICOID-RESPONSE ELEMENTS; HEPATOCYTE-STIMULATING FACTORS; C-REACTIVE PROTEIN; HAPTOGLOBIN GENE; ANGIOTENSINOGEN GENE; FIBRINOGEN GENES; NUCLEAR-PROTEIN; C/EBP FAMILY	Rat hepatic cells respond to interleukin (IL) -1, IL-6, and dexamethasone treatment by increasing the transcription rate of acute-phase plasma protein genes. The same conditions lead to changes in the expression of CAAT-enhancer binding protein (C/EBP) isoforms which are specific to the hepatic cell line. To identify the relationship between C/EBP isoforms and acute-phase protein gene activation, the hormone-specific expression of C/EBPalpha, beta, and delta was determined in H-35 and HTC cells and was compared to acute-phase liver. C/EBPbeta was found to be the principal isoform in hepatoma cells and to be strongly stimulated by cytokines and dexamethasone in H-35 cells. Transactivating functions were observed for all three C/EBP isoforms by cotransfection of CAT gene reporter constructs containing cytokine and glucocorticoid response elements of acute-phase protein genes and expression plasmids for mouse C/EBPalpha, beta, and delta into rat and human hepatoma cells. The degree of C/EBP-mediated transactivation was, however, extremely variable among the different regulatory elements. Transcription run-on reactions with nuclei from transiently transfected H-35 cells indicated that cotransfected C/EBPbeta increases basal expression of reporter gene constructs as well as the dexamethasone-mediated stimulation of constructs containing the glucocorticoid response elements of the rat alpha1-acid glycoprotein gene, but did not accelerate or enhance hormone-dependent transcription activation of reporter gene plasmids containing the IL-6 regulatory element of the beta-fibrinogen gene. Activation of the reporter gene constructs appeared to be temporally and quantitatively correlated with the amount of nuclear C/EBP as determined by two-dimensional Western and Southwestern blot analyses.	SUNY BUFFALO,BUFFALO,NY 14260; CHILDRENS HOSP,DEPT PEDIAT,DIV ENDOCRINOL,BUFFALO,NY 14222; CARNEGIE INST WASHINGTON,BALTIMORE,MD 21210	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Carnegie Institution for Science	BAUMANN, H (corresponding author), ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263, USA.				NCI NIH HHS [CA26122] Funding Source: Medline; NIDDK NIH HHS [DK33886] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033886] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; BAUMANN H, 1989, IN VITRO CELL DEV B, V25, P115; BAUMANN H, 1990, J BIOL CHEM, V265, P19420; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAUMANN H, 1986, J CELL BIOL, V102, P370, DOI 10.1083/jcb.102.2.370; BAUMANN H, 1983, J BIOL CHEM, V258, P563; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1986, MOL CELL BIOL, V6, P2551, DOI 10.1128/MCB.6.7.2551; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN HM, 1991, J BIOL CHEM, V266, P2946; CHENG J, 1990, NUCLEIC ACIDS RES, V18, P4261, DOI 10.1093/nar/18.14.4261; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Fey G H, 1990, Prog Liver Dis, V9, P89; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LI SP, 1990, J BIOL CHEM, V265, P4136; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; PROWSE KR, 1990, J BIOL CHEM, V261, P10201; PRUITT SC, 1988, GENE, V66, P121, DOI 10.1016/0378-1119(88)90230-2; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WILLIAMS PM, 1991, MOL CELL BIOL, V11, P4959, DOI 10.1128/MCB.11.10.4959; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; WON KA, 1991, MOL CELL BIOL, V11, P3001, DOI 10.1128/MCB.11.6.3001	45	131	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19744	19751						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382074				2022-12-27	WOS:A1992JP59300108
J	MASON, SW; LI, J; GREENBLATT, J				MASON, SW; LI, J; GREENBLATT, J			HOST FACTOR REQUIREMENTS FOR PROCESSIVE ANTITERMINATION OF TRANSCRIPTION AND SUPPRESSION OF PAUSING BY THE N-PROTEIN OF BACTERIOPHAGE-LAMBDA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-TERMINATION PROTEIN; NUSA GENE PROTEIN; PHAGE-LAMBDA; ESCHERICHIA-COLI; RNA-POLYMERASE; RECOGNITION SITE; COLIPHAGE-LAMBDA; NUT SITE; RHO; SEQUENCE	The N protein of phage lambda prevents termination of transcription by Escherichia coli RNA polymerase at Rho-dependent and -independent terminators in the lambda early operons. The modification of RNA polymerase by N requires an N-utilization (nut) site, present in each lambda early operon, and involves the E. coli factors NusA, NusB, NusG, and ribosomal protein S10. We show that, in the presence of NusA, N inhibits pausing by RNA polymerase and Rho-dependent termination in vitro at three sites in the lamda terminator tR1 which are located less than 100 base pairs downstream from nutR. NusA is also sufficient for partial antitermination at sites located farther downstream from nutL and nutR if there is a high concentration of N in the reaction. At low concentrations of N, the additional factors NusB, S10, and NusG are essential for antitermination at distal sites. In these conditions, the presence of NusA, NusB, S10, and NusG in the reaction enables N-modified RNA polymerase to elongate efficiently and processively through Rho-dependent and -independent terminators over distances as great as 7 kilobases downstream from the lambda nut sites. This substantial processivity of antitermination in vitro also occurs in vivo and probably reflects the stable association of N, NusA, NusB, S10, and NusG with RNA polymerase and nut site RNA in elongation complexes transcribing the lambda chromosome.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto; University of Toronto				Mason, Stephen/0000-0002-6662-9624				ADHYA S, 1974, P NATL ACAD SCI USA, V71, P2534, DOI 10.1073/pnas.71.6.2534; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; CHENG SWC, 1991, SCIENCE, V254, P1205, DOI 10.1126/science.1835546; COURT D, 1969, VIROLOGY, V39, P348, DOI 10.1016/0042-6822(69)90060-9; DAMBLY C, 1971, MOL GEN GENET, V113, P244, DOI 10.1007/BF00339545; Daniels D., 1983, LAMBDA 2, VII; DAS A, 1983, P NATL ACAD SCI-BIOL, V80, P5530, DOI 10.1073/pnas.80.18.5530; DAS A, 1985, P NATL ACAD SCI USA, V82, P4070, DOI 10.1073/pnas.82.12.4070; DAS A, 1984, CELL, V38, P165, DOI 10.1016/0092-8674(84)90537-3; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; FRANKLIN NC, 1974, J MOL BIOL, V185, P701; FRIEDMAN DI, 1990, GENE DEV, V4, P2210, DOI 10.1101/gad.4.12a.2210; FRIEDMAN DI, 1974, VIROLOGY, V58, P141, DOI 10.1016/0042-6822(74)90149-4; FRIEDMAN DI, 1973, J MOL BIOL, V81, P505, DOI 10.1016/0022-2836(73)90519-6; FRIEDMAN DI, 1976, VIROLOGY, V73, P119, DOI 10.1016/0042-6822(76)90066-0; FRIEDMAN DI, 1981, P NATL ACAD SCI-BIOL, V78, P1115, DOI 10.1073/pnas.78.2.1115; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2; GODA Y, 1985, NUCLEIC ACIDS RES, V13, P2569, DOI 10.1093/nar/13.7.2569; GOTTESMAN ME, 1980, J MOL BIOL, V140, P57, DOI 10.1016/0022-2836(80)90356-3; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GREENBLA.J, 1972, P NATL ACAD SCI USA, V69, P3606, DOI 10.1073/pnas.69.12.3606; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GREENBLATT J, 1980, J BIOL CHEM, V255, P1465; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KEPPEL F, 1974, Biochimie (Paris), V56, P1503; LAU LF, 1983, J BIOL CHEM, V258, P9391; LAU LF, 1985, J BIOL CHEM, V260, P574; LAU LF, 1982, P NATL ACAD SCI-BIOL, V79, P6171, DOI 10.1073/pnas.79.20.6171; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEASON KR, 1988, J BACTERIOL, V170, P5051, DOI 10.1128/jb.170.11.5051-5058.1988; LI J, 1992, J BIOL CHEM, V267, P6012; Maniatis T., 1982, MOL CLONING; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; OLSON ER, 1982, CELL, V31, P61, DOI 10.1016/0092-8674(82)90405-6; OPPENHEIM AB, 1982, J MOL BIOL, V158, P327, DOI 10.1016/0022-2836(82)90201-7; PELTZ SW, 1985, SCIENCE, V228, P91, DOI 10.1126/science.3156406; RICHARDSON JP, 1991, CELL, V64, P1047, DOI 10.1016/0092-8674(91)90257-Y; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; SCHMIDT MC, 1987, J MOL BIOL, V195, P809, DOI 10.1016/0022-2836(87)90486-4; STEINBERG RA, 1971, NATURE-NEW BIOL, V230, P76, DOI 10.1038/newbio230076a0; SULLIVAN SL, 1992, J BACTERIOL, V174, P1339, DOI 10.1128/jb.174.4.1339-1344.1992; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; SWINDLE J, 1988, J BIOL CHEM, V263, P10229; WARD DF, 1983, J MOL BIOL, V168, P73, DOI 10.1016/S0022-2836(83)80323-4; WHALEN W A, 1990, New Biologist, V2, P975; WHAOLEN W, 1988, P NATL ACAD SCI USA, V85, P2492; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; ZOU LL, 1991, J BIOL CHEM, V266, P10201; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4514, DOI 10.1073/pnas.84.13.4514	60	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19418	19426						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388170				2022-12-27	WOS:A1992JP59300062
J	ANDREE, HAM; STUART, MCA; HERMENS, WT; REUTELINGSPERGER, CPM; HEMKER, HC; FREDERIK, PM; WILLEMS, GM				ANDREE, HAM; STUART, MCA; HERMENS, WT; REUTELINGSPERGER, CPM; HEMKER, HC; FREDERIK, PM; WILLEMS, GM			CLUSTERING OF LIPID-BOUND ANNEXIN-V MAY EXPLAIN ITS ANTICOAGULANT EFFECT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BINDING-PROTEIN; VASCULAR ANTICOAGULANT; PROTHROMBINASE COMPLEX; UNILAMELLAR VESICLES; TISSUE FACTOR; INHIBITS COAGULATION; LIPOCORTIN FAMILY; FACTOR-VIIA; VAC-ALPHA; A-II	In 1985 we isolated a new vascular anticoagulant protein VAC-alpha, now called annexin V, with a high binding affinity (K(d) < 10(-10) M) for phospholipids. Its anticoagulant effect was attributed to displacement of coagulation factors from the phospholipid membrane. The present study demonstrates that the inhibition of prothrombinase activity by annexin V strongly depends on the curvature of the membrane surface and on the calcium concentration. Half-maximal inhibition of prothrombinase on and binding of annexin V to small vesicles, composed of 20% phosphatidylserine and 80% phosphatidylcholine, requires 2-3 mm calcium. With large vesicles and planar bilayers considerably less calcium is required for inhibition of prothrombinase and for lipid binding. Half-maximal binding of annexin V to large vesicles and to planar bilayers occurs at 0.7 and 0.2 mm calcium, respectively. This seemingly confirms the displacement model. The displacement of coagulation factors, however, proved to be incomplete, with residual surface concentrations of factors Xa, Va, and prothrombin sufficient for effective production of thrombin. Cryoelectron microscopy revealed that annexin V binding to large vesicles caused planar facets, indicating the formation of large sheets of clustered annexin V. Apparently, the formation of these two-dimensional arrays is promoted by calcium and hampered by high surface curvature. It is speculated that the complete inhibition (>99%) of prothrombinase activity by annexin V is caused by the reduced lateral mobility of prothrombin and factor Xa in rigid sheets of annexin V covering the membrane.	UNIV LIMBURG,CARDIOVASC RES INST,POB 616,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT PATHOL,ELECTRON MICROSCOPY UNIT,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT BIOCHEM,6200 MD MAASTRICHT,NETHERLANDS	Hasselt University; Maastricht University; Hasselt University; Maastricht University; Hasselt University; Maastricht University			Stuart, Marc/B-6274-2008	Stuart, Marc/0000-0003-0667-6338; Hemker, Coen/0000-0003-1669-2358				ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; BEVERS EM, 1982, EUR J BIOCHEM, V122, P81, DOI 10.1111/j.1432-1033.1982.tb05850.x; CARSON SD, 1988, THROMB RES, V50, P669, DOI 10.1016/0049-3848(88)90325-8; CHAP H, 1988, BIOCHEM BIOPH RES CO, V150, P972, DOI 10.1016/0006-291X(88)90724-3; CORSEL JW, 1986, J COLLOID INTERF SCI, V111, P544, DOI 10.1016/0021-9797(86)90058-5; CUYPERS PA, 1983, J BIOL CHEM, V258, P2426; DEKRUIJFF B, 1975, BIOCHIM BIOPHYS ACTA, V406, P6, DOI 10.1016/0005-2736(75)90038-3; FLAHERTY MJ, 1990, J LAB CLIN MED, V115, P174; FREDERIK PM, 1991, BIOCHIM BIOPHYS ACTA, V1062, P133, DOI 10.1016/0005-2736(91)90384-K; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4892, DOI 10.1021/bi00776a003; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P5572, DOI 10.1021/bi00391a053; GENDREAU MA, 1989, J BIOL CHEM, V264, P6972; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; GIESEN PLA, 1991, J BIOL CHEM, V266, P18720; GOVERSRIEMSLAG JWP, 1985, THROMB RES, V38, P375, DOI 10.1016/0049-3848(85)90136-7; GRAMZINSKI RA, 1989, BLOOD, V73, P983; HAUPTMANN R, 1989, EUR J BIOCHEM, V185, P63, DOI 10.1111/j.1432-1033.1989.tb15082.x; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; IWASAKI A, 1987, J BIOCHEM, V102, P1261, DOI 10.1093/oxfordjournals.jbchem.a122165; KONDO S, 1987, THROMB RES, V48, P449, DOI 10.1016/0049-3848(87)90402-6; KOP JMM, 1984, J BIOL CHEM, V259, P3993; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KUMAR A, 1984, BIOCHIM BIOPHYS ACTA, V769, P419, DOI 10.1016/0005-2736(84)90326-2; LENTZ BR, 1980, BIOCHEMISTRY-US, V19, P2555, DOI 10.1021/bi00553a003; LINDHOUT T, 1982, BIOCHEMISTRY-US, V21, P5494, DOI 10.1021/bi00265a018; MANN KG, 1990, BLOOD, V76, P1; MASSARI S, 1977, BIOCHEMISTRY-US, V16, P1189, DOI 10.1021/bi00625a025; MAURERFOGY I, 1988, EUR J BIOCHEM, V174, P585, DOI 10.1111/j.1432-1033.1988.tb14139.x; MICHAELSON DM, 1973, BIOCHEMISTRY-US, V12, P2637, DOI 10.1021/bi00738a014; MOSSER G, 1991, J MOL BIOL, V217, P241, DOI 10.1016/0022-2836(91)90538-H; NORDLUND JR, 1981, BIOCHEMISTRY-US, P6415; REUTELINGSPERGER CPM, 1985, EUR J BIOCHEM, V151, P625, DOI 10.1111/j.1432-1033.1985.tb09150.x; REUTELINGSPERGER CPM, 1988, EUR J BIOCHEM, V173, P171, DOI 10.1111/j.1432-1033.1988.tb13981.x; ROMISCH J, 1990, BIOCHEM J, V272, P223; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; WILLEMS G M, 1991, Journal of Biomaterials Science Polymer Edition, V2, P217	38	202	210	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17907	17912						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387643				2022-12-27	WOS:A1992JM22300065
J	SHIMADA, M; INABA, T; SHIMANO, H; GOTODA, T; WATANABE, Y; YAMAMOTO, K; MOTOYOSHI, K; YAZAKI, Y; YAMADA, N				SHIMADA, M; INABA, T; SHIMANO, H; GOTODA, T; WATANABE, Y; YAMAMOTO, K; MOTOYOSHI, K; YAZAKI, Y; YAMADA, N			PLATELET-DERIVED GROWTH-FACTOR BB-DIMER SUPPRESSES THE EXPRESSION OF MACROPHAGE COLONY-STIMULATING FACTOR IN HUMAN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; LOW-DENSITY LIPOPROTEINS; FACTOR-I RECEPTOR; HUMAN-MONOCYTES; M-CSF; IMMUNOBLOT ANALYSIS; ENDOTHELIAL-CELLS; APOLIPOPROTEIN-E; GENE-EXPRESSION; PROTO-ONCOGENE	Vascular smooth muscle cell is a major cell component involved in the process of atherosclerosis. In the present study, we investigated the effects of platelet-derived growth factor (PDGF)-BB dimer on the expression of macrophage-colony stimulating factor (M-CSF) in vascular smooth muscle cells isolated from human umbilical artery. On Northern blot analysis of total RNAs isolated from smooth muscle cells, with human cDNA for M-CSF, a marked dose-dependent reduction of mRNA level was found in PDGF-BB-treated smooth muscle cells. Cellular production of M-CSF was estimated by immunoblot analysis of cell lysate with specific polyclonal antibody against recombinant human M-CSF. A concentration of 10 ng/ml PDGF-BB significantly reduced M-CSF mass in smooth muscle cells compared with that in the absence of PDGF-BB. These results suggest that PDGF-BB plays an important role in the cellular metabolism of vascular wall by regulating the rate of M-CSF production in vascular smooth muscle cells.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	University of Tokyo			Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020	Shimano, Hitoshi/0000-0002-5562-5572; 				ABBOUD SL, 1991, BLOOD, V78, P103; BECKER S, 1987, J IMMUNOL, V139, P3703; BEISIEGEL U, 1982, J BIOL CHEM, V257, P3150; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DICORLETO PE, 1984, EXP CELL RES, V153, P167, DOI 10.1016/0014-4827(84)90458-0; FALKENBURG JHF, 1990, J IMMUNOL, V144, P4657; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; FISHERDZOGA K, 1973, EXP MOL PATHOL, V18, P162, DOI 10.1016/0014-4800(73)90014-2; GOTODA T, 1991, J BIOL CHEM, V266, P24757; HANAMURA T, 1988, BLOOD, V72, P886; HORIGUCHI J, 1987, BLOOD, V69, P1259; HUME DA, 1988, J IMMUNOL, V141, P3405; INABA T, 1992, J BIOL CHEM, V267, P5693; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; ISHIBASHI S, 1989, ARTERIOSCLEROSIS, V9, P650, DOI 10.1161/01.ATV.9.5.650; ISHIBASHI S, 1990, J BIOL CHEM, V265, P3040; ISHIZAKA Y, 1986, EXP HEMATOL, V14, P1; JAYE M, 1985, SCIENCE, V228, P882, DOI 10.1126/science.3890179; MAGEE DM, 1987, IMMUNOLOGY, V62, P373; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; METCALF D, 1986, BLOOD, V67, P257; MORI N, 1991, ARTERIOSCLER THROMB, V11, P1315, DOI 10.1161/01.ATV.11.5.1315; MOTOYOSHI K, 1978, BLOOD, V52, P1012; MUFSON RA, 1989, CELL IMMUNOL, V119, P182, DOI 10.1016/0008-8749(89)90234-7; MUNN DH, 1989, J EXP MED, V170, P511, DOI 10.1084/jem.170.2.511; NAKOINZ I, 1988, CELL IMMUNOL, V116, P331, DOI 10.1016/0008-8749(88)90235-3; NILSSON J, 1985, P NATL ACAD SCI USA, V82, P4418, DOI 10.1073/pnas.82.13.4418; OSTER W, 1987, BLOOD, V70, P1700; RAMBALDI A, 1987, BLOOD, V69, P1409; ROSS R, 1976, NEW ENGL J MED, V295, P420, DOI 10.1056/NEJM197608192950805; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SAMPSONJOHANNES A, 1988, J IMMUNOL, V141, P3680; SEELENTAG WK, 1987, EMBO J, V6, P2261, DOI 10.1002/j.1460-2075.1987.tb02499.x; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SHERR CJ, 1988, J CELL BIOCHEM, V38, P179, DOI 10.1002/jcb.240380305; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIMANO H, 1990, J BIOL CHEM, V265, P12869; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SIEFF CA, 1988, BLOOD, V72, P1316; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; SUZU S, 1991, BLOOD, V77, P2160; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; VELLENGA E, 1988, BLOOD, V71, P1529; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; YEUNG YG, 1987, P NATL ACAD SCI USA, V84, P1268, DOI 10.1073/pnas.84.5.1268; YOON TH, 1991, J BIOCHEM, V109, P204	48	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15455	15458						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379230				2022-12-27	WOS:A1992JG11300032
J	SKALHEGG, BS; LANDMARK, BF; DOSKELAND, SO; HANSSON, V; LEA, T; JAHNSEN, T				SKALHEGG, BS; LANDMARK, BF; DOSKELAND, SO; HANSSON, V; LEA, T; JAHNSEN, T			CYCLIC AMP-DEPENDENT PROTEIN-KINASE TYPE-I MEDIATES THE INHIBITORY EFFECTS OF 3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE ON CELL REPLICATION IN HUMAN LYMPHOCYTES-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; REGULATORY SUBUNIT RII; CAMP-BINDING-SITES; MOLECULAR-CLONING; CATALYTIC SUBUNIT; MONOCLONAL-ANTIBODIES; CDNA STRUCTURE; HUMAN TESTIS; SIGNAL TRANSDUCTION; NUCLEOTIDE ANALOGS	Human T lymphocytes were used as a model system to study the expression and roles of cAMP-dependent protein kinase isozymes (cAKI and cAKII) in cAMP-induced inhibition of cell replication. Human peripheral blood T lymphocytes expressed mRNA for the alpha-subforms (RI(alpha) and RII(alpha)) of the regulatory subunits of cAKI and cAKII and for the alpha- and beta-subforms (C(alpha) and C(beta)) of the catalytic subunits of cAK. At the protein level, RI(alpha) represented approximately 75% of the total R subunit activity, whereas RII(alpha) (phospho and dephospho forms) accounted for the remaining 25%. RII(beta) was not detected at either the mRNA or the protein level. The RI(alpha) protein was mainly (>75%) cytosolic, whereas RII(alpha) was almost exclusively (>90%) particulate associated. Treatment of proliferating T lymphocytes (activated through the CD3 cell surface marker) with 10 different cAMP analogs demonstrated that all inhibited cell replication in a concentration-dependent manner. The potency (as measured by the concentration giving 50% inhibition, IC50) of the cAMP analogs ranged from 30-mu-M for 8-chlorophenylthio-cAMP to 1100-mu-M for 8-piperidino-cAMP. A cAMP analog pair directed to activate cAKI (8-aminohexylamino-cAMP and 8-piperidino-cAMP) synergized in the inhibition of T lymphocyte proliferation, whereas a cAKII-directed cAMP analog pair (8-chlorophenylthio-cAMP and N-6-benzoyl-cAMP) did not. We conclude that activation of cAKI is sufficient to inhibit T lymphocyte proliferation. The membrane-bound cAKII may mediate cAMP actions not related to cell replication.	NATL HOSP NORWAY, INST IMMUNOL & RHEUMATOL, N-0027 OSLO 1, NORWAY; UNIV OSLO, INST MED BIOCHEM, N-0317 OSLO, NORWAY; UNIV BERGEN, DEPT ANAT, N-5009 BERGEN, NORWAY	University of Oslo; National Hospital Norway; University of Oslo; University of Bergen			Landmark, Brynjar/AAK-2165-2020; Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084; Doskeland, Stein Ove/0000-0002-4009-4756				ALEXANDER DR, 1989, IMMUNOL TODAY, V10, P200, DOI 10.1016/0167-5699(89)90325-3; ALTMAN A, 1990, CRIT REV IMMUNOL, V10, P347; BEEBE S, 1989, MOL ENDOCRINOL, V4, P465; BEEBE SJ, 1984, J BIOL CHEM, V259, P3539; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P118; BEEBE SJ, 1986, ENZYMES, V17, P43; BOYUM A, 1974, TISSUE ANTIGENS, V4, P269; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; BYUS CV, 1977, NATURE, V268, P63, DOI 10.1038/268063a0; CHAPLIN DD, 1980, BIOL BASIS IMMUNODEF, P269; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DOSKELAND SO, 1978, BIOCHEM BIOPH RES CO, V83, P542, DOI 10.1016/0006-291X(78)91024-0; DOSKELAND SO, 1981, INT J BIOCHEM, V13, P1, DOI 10.1016/0020-711X(81)90131-2; DOSKELAND SO, 1991, METH SURV I, V21, P103; EKANGER R, 1988, METHOD ENZYMOL, V159, P97; EKANGER R, 1985, J BIOL CHEM, V260, P3393; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HOLTE H, 1989, EUR J IMMUNOL, V19, P1221, DOI 10.1002/eji.1830190711; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KAMMER GM, 1988, P NATL ACAD SCI USA, V85, P792, DOI 10.1073/pnas.85.3.792; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KRAUSE DS, 1991, J IMMUNOL, V146, P2285; KVANTA A, 1991, BIOCHIM BIOPHYS ACTA, V1093, P178, DOI 10.1016/0167-4889(91)90120-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LEA T, 1985, SCAND J IMMUNOL, V22, P207, DOI 10.1111/j.1365-3083.1985.tb01873.x; LEE DC, 1983, P NATL ACAD SCI-BIOL, V80, P3608, DOI 10.1073/pnas.80.12.3608; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LOHMANN SM, 1988, METHOD ENZYMOL, V159, P183; MELSOM H, 1984, SCAND J HAEMATOL, V33, P27; OGREID D, 1989, EUR J BIOCHEM, V181, P19; OGREID D, 1983, BIOCHEMISTRY-US, V22, P1686; OGREID D, 1985, EUR J BIOCHEM, V150, P219, DOI 10.1111/j.1432-1033.1985.tb09010.x; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; PATEL MD, 1987, J BIOL CHEM, V262, P5831; RANNELS SR, 1980, J BIOL CHEM, V255, P7085; ROBINSONSTEINER AM, 1984, J BIOL CHEM, V259, P596; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SKALHEGG BS, 1992, J BIOL CHEM, V267, P5374; SMELAND E, 1985, SCAND J IMMUNOL, V21, P205, DOI 10.1111/j.1365-3083.1985.tb01422.x; SOLBERG R, 1991, BIOCHEM BIOPH RES CO, V176, P166, DOI 10.1016/0006-291X(91)90904-L; TAKAYAMA H, 1988, J BIOL CHEM, V263, P2330; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WALTER U, 1983, METHOD ENZYMOL, V99, P154; WELDON SL, 1985, J BIOL CHEM, V260, P6440	59	175	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15707	15714						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379235				2022-12-27	WOS:A1992JG11300070
J	LEE, TG; TOMITA, J; HOVANESSIAN, AG; KATZE, MG				LEE, TG; TOMITA, J; HOVANESSIAN, AG; KATZE, MG			CHARACTERIZATION AND REGULATION OF THE 58,000-DALTON CELLULAR INHIBITOR OF THE INTERFERON-INDUCED, DSRNA-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; ADENOVIRUS VAI RNA; MR 68,000; CELLS; INITIATION; AUTOPHOSPHORYLATION; PHOSPHORYLATION; 2-AMINOPURINE; PURIFICATION; EXPRESSION	The P68 protein kinase is a serine/threonine kinase induced by interferon treatment and activated by double-stranded RNAs (dsRNAs). Once activated, the kinase phosphorylates its natural substrate, the alpha-subunit of eukaryotic initiation factor 2 (eIF-2) leading to potential limitations in functional eIF-2 and decreases in protein synthesis initiation. We have recently purified from influenza virus-infected cells a P68 kinase inhibitor, found to be a 58-kDa cellular protein. We have now investigated the mechanisms by which the 58-kDa inhibitor regulates P68 kinase activity and how the inhibitor itself is controlled. The 58-kDa inhibitor did not function by degrading or sequestering the dsRNA activator of P68 but could repress phosphorylation of eIF-2 a by an already activated protein kinase. Utilizing antibody prepared against a 58-kDa-specific peptide, we showed that the 58-kDa proteins from infected and uninfected cells were present in equivalent amounts. Although kinase inhibitory activity could not be detected in crude uninfected cell extracts, ammonium sulfate treatment unmasked this activity and allowed purification of the cellular inhibitor with identical chromatographic properties as that from influenza virus-infected cells. Finally, we have identified and partially purified a specific inhibitor of the 58-kDa protein which we refer to as an "anti-inhibitor." Based on these data, we present a model depicting the complex regulation of the interferon-induced protein kinase in eukaryotic cells.	UNIV WASHINGTON,SCH MED,DEPT MICROBIOL SC42,SEATTLE,WA 98195; INST PASTEUR,UNITE VIROL & IMMUNOL CELLULAIRE,F-75724 PARIS 15,FRANCE	University of Washington; University of Washington Seattle; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris					NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [AI-22646] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKKARAJU GR, 1989, J BIOL CHEM, V264, P10321; BARBER GN, 1991, BIOCHEMISTRY-US, V30, P10356, DOI 10.1021/bi00106a038; BISCHOFF JR, 1989, VIROLOGY, V172, P106, DOI 10.1016/0042-6822(89)90112-8; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; CLARKE PA, 1990, EUR J BIOCHEM, V193, P635, DOI 10.1111/j.1432-1033.1990.tb19381.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DUBOIS MF, 1989, J BIOL CHEM, V264, P12165; ETKIND PR, 1975, J VIROL, V16, P1464, DOI 10.1128/JVI.16.6.1464-1475.1975; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOVANESSIAN AG, 1979, EUR J BIOCHEM, V93, P515, DOI 10.1111/j.1432-1033.1979.tb12850.x; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; Jagus R, 1981, Prog Nucleic Acid Res Mol Biol, V25, P127, DOI 10.1016/S0079-6603(08)60484-5; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KATZE MG, 1988, J VIROL, V62, P3710, DOI 10.1128/JVI.62.10.3710-3717.1988; KATZE MG, 1990, ENZYME, V44, P265, DOI 10.1159/000468764; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; LEBLEU B, 1976, P NATL ACAD SCI USA, V73, P335; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; MARAN A, 1988, VIROLOGY, V164, P106, DOI 10.1016/0042-6822(88)90625-3; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MELLITS KH, 1990, CELL, V61, P843, DOI 10.1016/0092-8674(90)90194-J; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; ROY S, 1991, J VIROL, V65, P632, DOI 10.1128/JVI.65.2.632-640.1991; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SAITO S, 1991, MICROBIOL IMMUNOL, V35, P1105, DOI 10.1111/j.1348-0421.1991.tb01632.x; SAMUEL C, 1979, P NATL ACAD SCI USA, V76, P515; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SENGUPTA DN, 1989, NUCLEIC ACIDS RES, V17, P969, DOI 10.1093/nar/17.3.969; SZYSZKA R, 1989, J BIOL CHEM, V264, P3827; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WATSON JC, 1991, VIROLOGY, V185, P206, DOI 10.1016/0042-6822(91)90768-7; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	45	97	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14238	14243						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378438				2022-12-27	WOS:A1992JD32500070
J	JOHANNES, G; BERGER, FG				JOHANNES, G; BERGER, FG			ALTERATIONS IN MESSENGER-RNA TRANSLATION AS A MECHANISM FOR THE MODIFICATION OF ENZYME-SYNTHESIS DURING EVOLUTION - THE ORNITHINE DECARBOXYLASE MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE KIDNEY; GENE-EXPRESSION; 5'-UNTRANSLATED REGION; REGULATORY ELEMENTS; NUCLEOTIDE-SEQUENCE; MOLECULAR-GENETICS; BETA-GLUCURONIDASE; TRANSCRIPTION; POLYAMINES; DNA	The expression of renal ornithine decarboxylase (ODC) is very different between the two murine species Mus domesticus and Mus pahari. The latter species contains a reduced level of ODC protein in the kidney, yet a normal concentration of ODC mRNA, indicating an alteration in translation, protein degradation, or both. We describe two lines of experimental evidence indicating that the efficiency of ODC mRNA translation is decreased in M. pahari. First, in vivo measurements showed that the rate of biosynthesis of the ODC polypeptide is reduced in M. pahari relative to M. domesticus. Second, polysome analyses indicated that, on average, the ODC mRNA of M. pahari binds fewer ribosomes. These effects, which are kidney-specific, lend support to the notion that renal ODC expression in the two species differs at the level of mRNA translation. A full-length cDNA copy of the ODC mRNA of M. pahari was isolated, and its sequence was compared with that of M. domesticus. In the 5'-untranslated region, which is likely to play an important role in controlling translation, the M. pahari transcript contains several single-base changes, as well as a 12-base deletion. These changes confer a distinct predicted secondary structure to this region of the mRNA and may be involved in reduced translation. We conclude that during evolution, modifications that alter the biosynthesis of specific proteins can occur at the translational level; these modifications exert their effects on translation in a transcript- and tissue-specific manner.	UNIV S CAROLINA, DEPT BIOL SCI, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NIDDK NIH HHS [DK 37265] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037265] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER FG, 1984, J BIOL CHEM, V259, P7941; BONHOMME F, 1986, CURR TOP MICROBIOL, V127, P19; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FISCHER JA, 1986, EMBO J, V5, P1275, DOI 10.1002/j.1460-2075.1986.tb04357.x; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GRENS A, 1990, J BIOL CHEM, V265, P11810; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMMOND ML, 1988, J BIOL CHEM, V263, P17785; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HICKOK NJ, 1986, P NATL ACAD SCI USA, V83, P594, DOI 10.1073/pnas.83.3.594; HICKOK NJ, 1990, GENE, V93, P257, DOI 10.1016/0378-1119(90)90233-H; HOLM I, 1989, BIOCHEM J, V258, P343, DOI 10.1042/bj2580343; ISOMAA VV, 1983, J BIOL CHEM, V258, P6735; ITO K, 1990, J BIOL CHEM, V265, P13036; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; KAFATOS FC, 1972, CURR TOP DEV BIOL, V7, P127; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KAHANA C, 1985, J BIOL CHEM, V260, P5390; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KATZ A, 1988, J BIOL CHEM, V263, P7604; KEW D, 1989, MOL ENDOCRINOL, V3, P1191, DOI 10.1210/mend-3-8-1191; KONTULA KK, 1984, P NATL ACAD SCI-BIOL, V81, P731, DOI 10.1073/pnas.81.3.731; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MELANITOU E, 1987, MOL ENDOCRINOL, V1, P266, DOI 10.1210/mend-1-3-266; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PAIGEN K, 1989, PROG NUCLEIC ACID RE, V37, P155; PAJUNEN AEI, 1982, J BIOL CHEM, V257, P8190; PALACIOS R, 1972, J BIOL CHEM, V247, P2316; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, J BIOL CHEM, V263, P11008; PERSSON L, 1988, J BIOL CHEM, V263, P3528; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RECHCIGL M, 1967, BIOCHEM BIOPH RES CO, V27, P119, DOI 10.1016/S0006-291X(67)80049-4; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RHEAUME C, 1989, MOL ENDOCRINOL, V3, P1243, DOI 10.1210/mend-3-8-1243; RHEAUME C, 1989, MOL CELL BIOL, V9, P477, DOI 10.1128/MCB.9.2.477; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEELY JE, 1983, J BIOL CHEM, V258, P2496; SEELY JE, 1983, METHOD ENZYMOL, V94, P158; SEELY JE, 1982, J BIOL CHEM, V257, P7549; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; TSENG-CRANK J, 1988, Molecular Biology and Evolution, V5, P442; WATSON G, 1988, MOL CELL BIOL, V8, P2117, DOI 10.1128/MCB.8.5.2117; WAWRZYNIAK CJ, 1989, GENETICS, V121, P119; WEN L, 1989, J BIOL CHEM, V264, P9016; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; WHITE MW, 1987, EUR J BIOCHEM, V170, P87, DOI 10.1111/j.1432-1033.1987.tb13670.x	56	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10108	10115						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374399				2022-12-27	WOS:A1992HT96500099
J	TSE, CM; BRANT, SR; WALKER, MS; POUYSSEGUR, J; DONOWITZ, M				TSE, CM; BRANT, SR; WALKER, MS; POUYSSEGUR, J; DONOWITZ, M			CLONING AND SEQUENCING OF A RABBIT CDNA-ENCODING AN INTESTINAL AND KIDNEY-SPECIFIC NA+/H+ EXCHANGER ISOFORM (NHE-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-H EXCHANGE; ILEAL BRUSH-BORDER; CHLORIDE TRANSPORT; MEMBRANE-VESICLES; DNA; ANTIPORTER; GLYCOPROTEIN; PROTEINS; SODIUM; RNA	We previously cloned, sequenced, and expressed two distinct mammalian Na+/H+ exchanger isoforms (NHE-1 and NHE-2). We report here the cloning of a composite cDNA which encodes a third mammalian isoform (NHE-3), which is expressed specifically in intestine and kidney. The protein deduced from the longest open reading frame of this composite sequence has 832 amino acids with a calculated M(r) of 92,747. The hydrophobicity plot of NHE-3 is very similar to that of NHE-1 and NHE-2. NHE-3 is also predicted to have 10-12 membrane-spanning domains and a long cytoplasmic domain which contains putative protein kinase phosphorylation motifs. NHE-3 exhibits overall 41% amino acid identity with NHE-1. NHE-3 is likely a glycoprotein as it has one potential N-linked glycosylation site, which is conserved in all NHEs identified. Northern blot analysis of poly(A+) RNA isolated from rabbit ileum using NHE-3 cDNA as a probe hybridized to a single 5.4-kilobase transcript. More detailed tissue distribution of message was performed by ribonuclease protection assay. It was found that NHE-3 message is only expressed in intestine and kidney, with the kidney cortex having the most abundant message, followed by intestine and kidney medulla. In intestine, ileum and ascending colon have the same amount of message, with much lesser amounts in jejunum. The message is absent from duodenum and descending colon, which lack the neutral NaCl absorptive process. Thus, NHE-3 might be involved in Na+ absorption in intestinal and renal epithelial cells.	CNRS,CTR BIOCHIM,F-06034 NICE,FRANCE; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21205	Centre National de la Recherche Scientifique (CNRS); Johns Hopkins University	TSE, CM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205, USA.				NIDDK NIH HHS [R01DK26523, T32DK07632, R29DK43778] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043778, T32DK007632, R01DK026523] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRINSTEIN S, 1983, J GEN PHYSIOL, V82, P619, DOI 10.1085/jgp.82.5.619; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAGGERTY C, 1988, P NATL ACAD SCI USA, V88, P6797; HELMS C, 1985, DNA-J MOLEC CELL BIO, V4, P39, DOI 10.1089/dna.1985.4.39; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; IGARASHI P, 1991, KIDNEY INT, V40, pS84; KINSELLA JL, 1981, AM J PHYSIOL, V241, pC220, DOI 10.1152/ajpcell.1981.241.5.C220; KNICKELBEIN R, 1985, AM J PHYSIOL, V249, pG236, DOI 10.1152/ajpgi.1985.249.2.G236; KNICKELBEIN R, 1983, AM J PHYSIOL, V245, pG504, DOI 10.1152/ajpgi.1983.245.4.G504; KNICKELBEIN RG, 1990, AM J PHYSIOL, V259, pG802, DOI 10.1152/ajpgi.1990.259.5.G802; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8128; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T, 1989, DECONTAMINATION DILU; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER RT, 1991, J BIOL CHEM, V266, P10813; PARIS S, 1984, J BIOL CHEM, V259, P989; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; RAJENDRAN VM, 1990, J BIOL CHEM, V265, P8408; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; TSE C M, 1991, Gastroenterology, V100, pA258; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WEISER MM, 1973, J BIOL CHEM, V248, P2536; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513	35	371	377	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9340	9346						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374392				2022-12-27	WOS:A1992HR85400097
J	SHADEL, GS; BALDWIN, TO				SHADEL, GS; BALDWIN, TO			POSITIVE AUTOREGULATION OF THE VIBRIO-FISCHERI LUXR GENE - LUXR AND AUTOINDUCER ACTIVATE CAMP-CATABOLITE GENE ACTIVATOR PROTEIN COMPLEX-INDEPENDENT AND COMPLEX-DEPENDENT LUXR TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RECEPTOR PROTEIN; BACTERIAL BIOLUMINESCENCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CYCLIC-AMP; IDENTIFICATION; LUCIFERASE; REGULON; LUMINESCENCE; EXPRESSION	The LuxR protein is a transcriptional activator involved in regulation of the genes required for bioluminescence (lux) in the marine bacterium Vibrio fischeri. Transcription of the two divergently oriented lux operons (luxR and luxICDABEG) is activated by LuxR in the presence of a diffusible inducer (autoinducer). Transcription of the luxR gene is subject to both positive and negative autoregulation as well as activation by the cAMP-catabolite gene activator protein complex (cAMP-CAP). Transcription of luxR was studied using both luminescence in vivo as a reporter and primer extension analysis of mRNA synthesized in vivo. Mutation of the lux CAP-binding site resulted in a reduction in luminescence from the reporter and the complete loss of luxR positive autoregulation. Positive autoregulation was restored if luxR was provided in trans, demonstrating that LuxR and autoinducer activate luxR transcription in the absence of cAMP-CAP. By means of primer extension analysis, three sites of initiation of luxR transcription were demonstrated; initiation at two of these sites required cAMP-CAP. The quantity of all three transcripts was increased in the presence of LuxR and autoinducer when a plasmid with a wild-type CAP-binding site was used. Initiation at the cAMP-CAP-dependent sites was not observed from a plasmid with a mutated CAP-binding site in the presence or absence of autoinducer even with luxR supplied in trans. Instead, with luxR supplied in trans, initiation at the cAMP-CAP-independent initiation site was specifically stimulated by LuxR and autoinducer. Thus, in the course of positive autoregulation, the LuxR protein activates transcription from two luxR promoters by a cAMP-CAP-dependent mechanism and a third promoter by a cAMP-CAP-independent mechanism.	TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843; TEXAS A&M UNIV SYST,CTR MACROMOLEC DESIGN,INST BIOSCI & TECHNOL,COLLEGE STN,TX 77843; TEXAS A&M UNIV SYST,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station					NIGMS NIH HHS [GM42428] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042428] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN TO, 1984, BIOCHEMISTRY-US, V23, P3663, DOI 10.1021/bi00311a014; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P326, DOI 10.1002/bio.1170040145; DEVINE JH, 1988, BIOCHEMISTRY-US, V27, P837, DOI 10.1021/bi00402a052; DEVINE JH, 1989, P NATL ACAD SCI USA, V86, P5688, DOI 10.1073/pnas.86.15.5688; DUNLAP PV, 1988, J BACTERIOL, V170, P4040, DOI 10.1128/jb.170.9.4040-4046.1988; DUNLAP PV, 1985, J BACTERIOL, V164, P45, DOI 10.1128/JB.164.1.45-50.1985; DUNLAP PV, 1989, J BACTERIOL, V171, P3549, DOI 10.1128/jb.171.6.3549-3552.1989; EBERHARD A, 1972, J BACTERIOL, V109, P1101, DOI 10.1128/JB.109.3.1101-1105.1972; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; ENGEBRECHT J, 1987, NUCLEIC ACIDS RES, V15, P10455, DOI 10.1093/nar/15.24.10455; ENGEBRECHT J, 1984, P NATL ACAD SCI-BIOL, V81, P4154, DOI 10.1073/pnas.81.13.4154; ENGEBRECHT J, 1983, CELL, V32, P773, DOI 10.1016/0092-8674(83)90063-6; Engebrecht J, 1986, GENET ENG, V8, P31; FRIEDRICH WF, 1983, ARCH MICROBIOL, V134, P87, DOI 10.1007/BF00407937; HASTINGS JW, 1963, J OPT SOC AM, V53, P1410, DOI 10.1364/JOSA.53.001410; KAPLAN HB, 1985, J BACTERIOL, V163, P1210, DOI 10.1128/JB.163.3.1210-1214.1985; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P1367; Maniatis T., 1982, MOL CLONING; NEALSON KH, 1970, J BACTERIOL, V104, P313, DOI 10.1128/JB.104.1.313-322.1970; NEALSON KH, 1972, P NATL ACAD SCI USA, V69, P1073, DOI 10.1073/pnas.69.5.1073; SHADEL GS, 1991, J BACTERIOL, V173, P568, DOI 10.1128/jb.173.2.568-574.1991; SHADEL GS, 1990, J BIOLUM CHEMILUM, V5, P99, DOI 10.1002/bio.1170050205; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; SHADEL GS, 1991, THESIS TEXAS AM U CO; SWARTZMAN E, 1990, J BACTERIOL, V172, P6797, DOI 10.1128/jb.172.12.6797-6802.1990; XIONG XF, 1991, J BACTERIOL, V173, P4570, DOI 10.1128/jb.173.15.4570-4577.1991	26	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7696	7702						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373136				2022-12-27	WOS:A1992HN48500071
J	BERRETTINI, M; SCHLEEF, RR; HEEB, MJ; HOPMEIER, P; GRIFFIN, JH				BERRETTINI, M; SCHLEEF, RR; HEEB, MJ; HOPMEIER, P; GRIFFIN, JH			ASSEMBLY AND EXPRESSION OF AN INTRINSIC FACTOR-IX ACTIVATOR COMPLEX ON THE SURFACE OF CULTURED HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; COAGULATION FACTOR-XI; WASHED HUMAN-PLATELETS; CONTACT ACTIVATION; HAGEMAN-FACTOR; TISSUE-FACTOR; HUMAN-PLASMA; LIGHT CHAIN; FUNCTIONAL-CHARACTERIZATION; PLASMINOGEN-ACTIVATOR	Endothelial cells expose specific receptors for blood clotting factors and, upon perturbation, can initiate and propagate the reactions of the extrinsic pathway of blood coagulation leading to fibrin formation on the cell surface. The existence of an intrinsic mechanism of Factor IX activation on cultured human umbilical vein cells (HUVECs) was investigated by studies of the interaction between HUVECs and two proteins of the contact activation system, the cofactor high molecular weight kininogen (H-kininogen) and the zymogen Factor XI. In the presence of zinc ions (10-300 muM), I-125-labeled H-kininogen bound to HUVECs in a time-dependent, reversible, and saturable manner, with calcium ions exerting an inhibitory effect on the zinc-dependent binding. Analysis of the binding data by the LIGAND computer program indicated that HUVECs, in the presence of 2 mM CaCl2 and 100 muM ZnCl2 at 37-degrees-C, bound 1.14 x 10(7) H-kininogen molecules per cell with an apparent dissociation constant of 55 nM. HUVEC-bound H-kininogen functions as the cell surface receptor for both I-125-labeled Factor XI and I-125-labeled Factor XIa, since HUVECs cultured in contact factor-depleted serum do not detectably bind either the zymogen or the enzyme in the absence of H-kininogen and zinc ions. In the presence of saturating concentrations of H-kininogen, 2 mM CaCl2 and 100 muM ZnCl2, the binding of I-125-labeled Factor XI and Factor XIa to HUVECs was time-dependent, reversible, and saturable, with apparent dissociation constants of 4.5 and 1.5 nM, respectively. HUVEC-bound complexes of H-kininogen and Factor XI generated Factor XIa activity only after the addition of purified Factor XIIa, and cell-bound Factor XIa in turn activated Factor IX, as documented by a H-3-labeled activation peptide release assay for H-3-Factor IX activation. The results indicate that cultured HUVECs provide a surface for the assembly and expression of an intrinsic Factor IX activator complex that may participate in the initiation of blood coagulation at sites of vascular injury.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute				Griffin, John/0000-0002-4302-2547	NHLBI NIH HHS [HL-21544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRETTINI M, 1989, J BIOL CHEM, V264, P11738; BERRETTINI M, 1986, BLOOD, V68, P455; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BOUMA BN, 1983, BLOOD, V62, P1123; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; COLUCCI M, 1983, J CLIN INVEST, V71, P1893, DOI 10.1172/JCI110945; ESMON NL, 1982, J BIOL CHEM, V257, P859; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIKAWA K, 1973, BIOCHEMISTRY-US, V12, P4938, DOI 10.1021/bi00748a019; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Griffin J H, 1976, Methods Enzymol, V45, P56; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMLE B, 1987, SEMIN THROMB HEMOST, V13, P106, DOI 10.1055/s-2007-1003480; LOSKUTOFF DJ, 1977, P NATL ACAD SCI USA, V74, P3093; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MAYNARD JR, 1977, BLOOD, V50, P387; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RODGERS GM, 1983, P NATL ACAD SCI-BIOL, V80, P7001, DOI 10.1073/pnas.80.22.7001; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SILVERBERG M, 1980, THROMB RES, V20, P173, DOI 10.1016/0049-3848(80)90383-7; SINHA D, 1984, J CLIN INVEST, V73, P1550, DOI 10.1172/JCI111361; STENFLO J, 1976, J BIOL CHEM, V251, P355; STERN D, 1985, P NATL ACAD SCI USA, V82, P2523, DOI 10.1073/pnas.82.8.2523; STERN DM, 1983, P NATL ACAD SCI-BIOL, V80, P4119, DOI 10.1073/pnas.80.13.4119; STERN DM, 1984, P NATL ACAD SCI-BIOL, V81, P913, DOI 10.1073/pnas.81.3.913; STERN DM, 1985, J BIOL CHEM, V260, P6717; TANS G, 1983, J BIOL CHEM, V258, P8215; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANDERGRAAF F, 1982, J BIOL CHEM, V257, P4300; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VANIWAARDEN F, 1988, BLOOD, V71, P1268; WALSH PN, 1986, BLOOD, V68, P225; WALSH PN, 1981, BLOOD, V57, P106; WEKSLER BB, 1977, P NATL ACAD SCI USA, V74, P3922, DOI 10.1073/pnas.74.9.3922; WIGGINS RC, 1977, P NATL ACAD SCI USA, V74, P4636, DOI 10.1073/pnas.74.10.4636; WIGGINS RC, 1980, J CLIN INVEST, V65, P197, DOI 10.1172/JCI109651; ZUR M, 1980, J BIOL CHEM, V255, P5703	47	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19833	19839						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400299				2022-12-27	WOS:A1992JR85800016
J	ENAN, E; LIU, PCC; MATSUMURA, F				ENAN, E; LIU, PCC; MATSUMURA, F			2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN CAUSES REDUCTION OF GLUCOSE TRANSPORTING ACTIVITIES IN THE PLASMA-MEMBRANES OF ADIPOSE-TISSUE AND PANCREAS FROM THE GUINEA-PIG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC CYTOSOL; TOXICITY; RATS; MECHANISM; INSULIN; TCDD; RECEPTOR; ENZYMES	Toxicity from 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure results in severe metabolic imbalances leading to a loss of fat stores in many animal species, a phenomenon known as the wasting syndrome. In this paper, we report that TCDD treatment at very low doses (0.03-1 mug/kg, single intraperitoneal injection) causes a profound reduction of glucose uptake by guinea pig adipose tissue, pancreas and brain. This effect of TCDD is dose-dependent, with a dose as small as 0.03 mug/kg resulting in a significant decrease. In adipose tissue, the decrease begins within 6 h of treatment and persists at least 28 days. The V(max) of glucose transport was decreased by TCDD treatment, whereas the K(m) was unchanged. Liver behaves oppositely to adipose tissue. At early stages of treatment (6-12 h) glucose uptake was depressed, while at later stages (24-96 h) it was increased. In situ (explant tissue culture) treatment with TCDD yields similar trends as in vivo studies for glucose uptake in all three tissues. In adipose tissue culture TCDD starts reducing glucose uptake after 30 minutes. The inhibitory potencies of three dioxin congeners on adipose glucose transporting activities follows the same order of their toxicities in vivo. TCDD's effect on glucose transport is sensitive to cytochalasin B, a specific inhibitor of glucose transporter proteins. Based on these observations and the importance of glucose transporters to cellular energy maintenance, we conclude that at least in guinea pigs the reduction of glucose transporters in various tissues is one of the major causes for TCDD-induced wasting syndrome, which is so prominent in this species.			ENAN, E (corresponding author), UNIV CALIF DAVIS,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616, USA.				NIEHS NIH HHS [ESO5233, ESO3575] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003575] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BREWSTER DW, 1988, BIOCHEM PHARMACOL, V37, P2247, DOI 10.1016/0006-2952(88)90588-6; BREWSTER DW, 1987, TOXICOL APPL PHARM, V89, P408, DOI 10.1016/0041-008X(87)90160-8; BREWSTER DW, 1984, BIOCHEM BIOPH RES CO, V122, P810, DOI 10.1016/S0006-291X(84)80106-0; BREWSTER DW, 1988, J TOXICOL ENV HEALTH, V25, P495, DOI 10.1080/15287398809531227; BREWSTER DW, 1985, THESIS MICHIGAN STAT; CHU DT, 1990, BIOCHEM SOC T, V18, P1247, DOI 10.1042/bst0181247; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; EBNER K, 1988, J ENVIRON SCI HEAL B, V23, P427, DOI 10.1080/03601238809372617; GASIEWICZ TA, 1980, TOXICOL APPL PHARM, V54, P469, DOI 10.1016/0041-008X(80)90174-X; GASIEWICZ TA, 1979, TOXICOL APPL PHARM, V51, P329, DOI 10.1016/0041-008X(79)90475-7; GREENLEE WF, 1979, J BIOL CHEM, V254, P9814; HENDLEY ED, 1987, AM J PHYSIOL, V253, pR434, DOI 10.1152/ajpregu.1987.253.3.R434; HORUK R, 1983, J BIOL CHEM, V258, P7425; ISMAIL SMM, 1991, PESTIC BIOCHEM PHYS, V39, P219, DOI 10.1016/0048-3575(91)90117-5; LAKSHMAN MR, 1989, J PHARMACOL EXP THER, V248, P62; OLSON JR, 1980, TOXICOL APPL PHARM, V55, P67, DOI 10.1016/0041-008X(80)90221-5; PETERSON RE, 1984, BRANBURY REPORT, V18, P291; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; POLAND A, 1984, BANBURY REPORT, V18, P1; PORTER EV, 1982, METHOD ENZYMOL, V90, P25; POTTER CL, 1983, TOXICOL APPL PHARM, V69, P89, DOI 10.1016/0041-008X(83)90123-0; ROZMAN KK, 1991, DIOXIN 91, P28; SCHWETZ B A, 1973, Environmental Health Perspectives, V5, P87, DOI 10.2307/3428117; SEEFELD MD, 1984, TOXICOL APPL PHARM, V73, P311, DOI 10.1016/0041-008X(84)90337-5; SWIFT LL, 1981, TOXICOL APPL PHARM, V59, P489, DOI 10.1016/0041-008X(81)90302-1; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; WEBER LWD, 1991, TOXICOLOGY, V66, P133, DOI 10.1016/0300-483X(91)90214-L	29	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19785	19791						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400292				2022-12-27	WOS:A1992JR85800008
J	WATT, SL; LUNSTRUM, GP; MCDONOUGH, AM; KEENE, DR; BURGESON, RE; MORRIS, NP				WATT, SL; LUNSTRUM, GP; MCDONOUGH, AM; KEENE, DR; BURGESON, RE; MORRIS, NP			CHARACTERIZATION OF COLLAGEN TYPE-XII AND TYPE-XIV FROM FETAL BOVINE CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAINS; IX COLLAGEN; EXTRACELLULAR-MATRIX; VITREOUS-HUMOR; II COLLAGEN; PROTEOGLYCAN; PROTEIN; MOLECULES; SEQUENCE; FIBRILS	The structurally related type XII-like collagen molecules TL-A and TL-B were recently identified in fetal bovine epiphyseal cartilage and subsequently shown to be collagen types XII and XIV, respectively. By indirect immunofluorescent staining of cartilage using monoclonal antibodies to the NC3 domains of each molecule, it was shown that type XII collagen was present predominantly around cartilage canals, the articular surface, subperichondrial margins, and the perichondrium, was less so in the remaining cartilage matrix, and was absent from the growth plate region. In the permanent cartilage of trachea, type XII stained somewhat more intensely in the margins beneath the loose connective tissue. Type XIV collagen localized more uniformly throughout the articular cartilage and was also absent from the growth plate region, whereas in tracheal cartilage, its distribution was similar to type XII. We have characterized the structure of these cartilage molecules and compared them with those from fetal bovine skin. Extraction of cartilage with 1 M NaCl and differential NaCl precipitation yields a fraction enriched for these two collagens. Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting with monoclonal antibodies to the large amino-terminal non-triple-helical domain, NC3, revealed the presence in cartilage of two forms of type XII collagen: type XIIB, the molecule previously identified in chick and bovine tissues, and type XIIA, a much larger form equivalent to the molecule recently identified in WISH-transformed epithelial cell culture medium (Lunstrum, G. P., McDonough, A. M., Marinkovich, M. P., Keene, D. R., Morris, N. P., and Burgeson, R. E. (1992) J. Biol. Chem. 267, 20087-20092). Digestion with bacterial collagenase shows that the increased mass is present in the NC3A domain. Additional purification by velocity sedimentation and observation of rotary-shadowed images demonstrates molecules with extended non-triple-helical arms approximately 80 nm in length analogous to the WISH cell molecules. Electrophoretic mobilities of bands corresponding to type XIIA, but not type XIIB, are sensitive to chondroitinase ABC, indicating that type XIIA is a chondroitin sulfate proteoglycan and that modification occurs predominantly within the NC3A domain distal to NC3B. Neither type XIIB from skin nor type XIIA from WISH cells are chondroitinase-sensitive. By similar analysis, a portion of the type XIV collagen chains in cartilage was also sensitive to chondroitinase digestion. Chondroitin sulfate is apparently not located on its NC3 domain. As in skin, collagen types XII and XIV have subtly different distributions within cartilage and type XII may have a tissue-specific structure.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT DERMATOL,PORTLAND,OR 97201; SHRINERS HOSP CRIPPLED CHILDREN,PORTLAND,OR	Oregon Health & Science University; Oregon Health & Science University					NIGMS NIH HHS [R29 GM38862] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; BREWTON RG, 1991, J BIOL CHEM, V266, P4752; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DUBLET B, 1989, J BIOL CHEM, V264, P13150; DUBLET B, 1991, J BIOL CHEM, V266, P6853; ENGVALL E, 1986, J CELL BIOL, V103, P2457, DOI 10.1083/jcb.103.6.2457; EYRE DR, 1991, SEMIN ARTHRITIS RHEU, V21, P2, DOI 10.1016/0049-0172(91)90035-X; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GORDON MK, 1989, CONNECT TISSUE RES, V20, P179, DOI 10.3109/03008208909023886; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; HUBER S, 1988, J BIOL CHEM, V263, P752; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; MURAGAKI Y, 1990, P NATL ACAD SCI USA, V87, P2400, DOI 10.1073/pnas.87.7.2400; NAKAHARA H, 1990, DEV BIOL, V142, P481, DOI 10.1016/0012-1606(90)90370-X; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; OLSEN BR, 1989, CONNECT TISSUE RES, V23, P115, DOI 10.3109/03008208909002411; RHODES C, 1988, J BIOL CHEM, V263, P6063; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SUGRUE SP, 1989, J CELL BIOL, V109, P938; SVOBODA KK, 1988, P NATL ACAD SCI USA, V85, P7496, DOI 10.1073/pnas.85.20.7496; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1991, BIOCHEM SOC T, V19, P820, DOI 10.1042/bst0190820; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; WRIGHT DW, 1988, J ULTRA MOL STRUCT R, V100, P224, DOI 10.1016/0889-1605(88)90039-0; WU JJ, 1989, CONNECT TISSUE RES, V20, P241, DOI 10.3109/03008208909023893; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5; YADA T, 1990, J BIOL CHEM, V265, P6992; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	40	98	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20093	20099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400327				2022-12-27	WOS:A1992JR85800056
J	DEFILIPPI, P; SILENGO, L; TARONE, G				DEFILIPPI, P; SILENGO, L; TARONE, G			ALPHA-6.BETA-1 INTEGRIN (LAMININ RECEPTOR) IS DOWN-REGULATED BY TUMOR-NECROSIS-FACTOR-ALPHA AND INTERLEUKIN-1 BETA IN HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; FIBRONECTIN RECEPTOR; ADHESION MOLECULES; IMMUNE INTERFERON; EXPRESSION; PROTEINS; ATTACHMENT; IDENTIFICATION; ACTIVATION; COLLAGEN	Endothelial cells from human umbilical vein (HEC) express several distinct integrin complexes that mediate the interaction with the basal membrane components. In this paper we show that treatment with tumor necrosis factor-alpha (TNF-alpha) down-regulates the expression of the laminin receptor alpha-6.beta-1 integrin in cultured HEC. After 48 h of treatment with TNF-alpha, the level of expression of the alpha-6.beta-1 complex reached 20% of the control value. The down-regulation of the alpha-6.beta-1 integrin is caused by a decreased expression of the alpha-6 subunit, whereas the synthesis of the beta-1 subunit remains constant. Northern blot analysis shows that the decreased level of alpha-6 subunit synthesis is caused by down-regulation of alpha-6 mRNA in TNF-alpha-treated HEC. TNF-alpha treatment does not alter the expression of alpha-2, alpha-3, and alpha-5 integrins, also present on endothelial cell surface, thus showing that this cytokine has a selective action on distinct integrin complexes. Down-regulation of alpha-6.beta-1 correlates with pronounced reduction in adhesion of TNF-alpha-treated HEC to laminin, but not to fibronectin-coated culture dishes. In addition to TNF-alpha, interleukin-1-beta also decreases the expression of the alpha-6.beta-1 integrin and reduces adhesion to laminin, thus suggesting that this regulation plays an important role in inflammation.			DEFILIPPI, P (corresponding author), UNIV TURIN,DIPARTIMENTO GENET BIOL & CHIM MED,VIA SANTENA 5BIS,I-10126 TURIN,ITALY.		DEFILIPPI, Paola/L-2232-2014	Tarone, Guido/0000-0003-4805-086X; Defilippi, Paola/0000-0001-6427-4906				ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONFORTI G, 1989, BLOOD, V73, P1576; CONNOLLY DT, 1986, ANAL BIOCHEM, V152, P136, DOI 10.1016/0003-2697(86)90131-4; DANIELSON PE, 1988, DNA CELL BIOL, V7, P2261; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; DEJANA E, 1988, BLOOD, V71, P566; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; GIMBRONE MA, 1976, PROGR HEMOSTASIS THR, P1; GOODMAN SL, 1991, J CELL BIOL, V113, P931, DOI 10.1083/jcb.113.4.931; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; JIRIK FR, 1989, J IMMUNOL, V142, P144; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LAPIERRE LA, 1988, J EXP MED, V167, P794, DOI 10.1084/jem.167.3.794; MAUVIEL A, 1991, J INVEST DERMATOL, V96, P243, DOI 10.1111/1523-1747.ep12462185; MOCCHETTI I, 1987, NEUROPHARMACOLOGY, V26, P855, DOI 10.1016/0028-3908(87)90062-1; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; POBER JS, 1988, AM J PATHOL, V133, P426; POBER JS, 1991, LAB INVEST, V64, P301; POBER JS, 1986, J IMMUNOL, V137, P1893; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; ROSSINO P, 1990, EXP CELL RES, V189, P100, DOI 10.1016/0014-4827(90)90262-9; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SEELENTAG WK, 1987, EMBO J, V6, P2261, DOI 10.1002/j.1460-2075.1987.tb02499.x; SHALABY MR, 1989, CELL IMMUNOL, V121, P372, DOI 10.1016/0008-8749(89)90036-1; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; STOLPEN AH, 1986, AM J PATHOL, V123, P16; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TARONE G, 1990, J LIPID MEDIATOR, V2, pS45; TARONE G, 1982, J CELL BIOL, V94, P179, DOI 10.1083/jcb.94.1.179; VANHINSBERGH VWM, 1990, BLOOD, V75, P1991; VOGEL BE, 1990, J BIOL CHEM, V265, P5934	46	95	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18303	18307						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388151				2022-12-27	WOS:A1992JN50200012
J	GUO, NH; KRUTZSCH, HC; VOGEL, T; ROBERTS, DD				GUO, NH; KRUTZSCH, HC; VOGEL, T; ROBERTS, DD			INTERACTIONS OF A LAMININ-BINDING PEPTIDE FROM A 33-KDA PROTEIN RELATED TO THE 67-KDA LAMININ RECEPTOR WITH LAMININ AND MELANOMA-CELLS ARE HEPARIN-DEPENDENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; INTEGRIN ALPHA-7-BETA-1; MALIGNANT MELANOCYTES; SULFATED GLYCOLIPIDS; SYNTHETIC PEPTIDE; THROMBOSPONDIN; GLYCOPROTEIN; ADHESION; EXPRESSION; MIGRATION	A laminin-binding peptide (peptide G), predicted from the cDNA sequence for a 33-kDa protein related to the 67-kDa laminin receptor, specifically inhibits binding of laminin to heparin and sulfatide. Since the peptide binds directly to heparin and inhibits interaction of another heparin-binding protein with the same sulfated ligands, this inhibition is due to direct competition for binding to sulfated glycoconjugates rather than an indirect effect of interaction with the binding site on laminin for the 67-kDa receptor. Direct binding of laminin to the peptide is also inhibited by heparin. This interaction may result from contamination of the laminin with heparan sulfate, as binding is enhanced by the addition of substoichiometric amounts of heparin but inhibited by excess heparin and two heparin-binding proteins. Furthermore, laminin binds more avidly to a heparin-binding peptide derived from thrombospondin than to the putative receptor peptide. Adhesion of A2058 melanoma cells on immobilized peptide G is also heparin-dependent, whereas adhesion of the cells on laminin is not. Antibodies to the beta-1-integrin chain or laminin block adhesion of the melanoma cells to laminin but not to peptide G. Thus, the reported inhibition of melanoma cell adhesion to endothelial cells by peptide G may result from inhibition of binding of laminin or other proteins to sulfated glycoconjugate receptors rather than from specific inhibition of laminin binding to the 67-kDa receptor.	NCI,PATHOL LAB,BLDG 10,RM 2A33,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AUTH D, 1992, P NATL ACAD SCI USA, V89, P4368, DOI 10.1073/pnas.89.10.4368; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CASTRONOVO V, 1991, CANCER RES, V51, P5672; CASTRONOVO V, 1991, J BIOL CHEM, V266, P20440; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; DAVIS SC, 1992, J BIOL CHEM, V267, P5508; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; FUNAHASHI M, 1982, ANAL BIOCHEM, V126, P414, DOI 10.1016/0003-2697(82)90537-1; GEOGHEGAN T, 1979, P NATL ACAD SCI USA, V76, P5587, DOI 10.1073/pnas.76.11.5587; GROSSO LE, 1991, BIOCHEMISTRY-US, V30, P3346, DOI 10.1021/bi00227a026; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KEPPEL E, 1991, J CELL SCI, V100, P789; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; RAMOS DM, 1990, CANCER RES, V50, P728; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; TARABOLETTI G, 1990, J BIOL CHEM, V265, P12253; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; ZABRENETZKY VS, 1990, CANCER RES, V50, P5937	29	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17743	17747						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387642				2022-12-27	WOS:A1992JM22300043
J	SOLTOFF, SP; RABIN, SL; CANTLEY, LC; KAPLAN, DR				SOLTOFF, SP; RABIN, SL; CANTLEY, LC; KAPLAN, DR			NERVE GROWTH-FACTOR PROMOTES THE ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE AND ITS ASSOCIATION WITH THE TRK TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SIGNALING PROTEINS; PC12 PHEOCHROMOCYTOMA CELLS; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; PROTOONCOGENE PRODUCT; PROTO-ONCOGENE; NGF RECEPTOR; LOW-AFFINITY; PHOSPHORYLATION; BINDING	We investigated the involvement of phosphatidylinositol 3-kinase (PtdIns 3-kinase) in the initiation of signal transduction by nerve growth factor (NGF) in the rat pheochromocytoma PC12 cell line. PtdIns 3-kinase catalyzes the formation of phosphoinositides with phosphate in the D-3 position of the inositol ring and previously has been found to associate with other activated protein tyrosine kinases, including growth factor receptor tyrosine kinases. Anti-phosphotyrosine immunoprecipitates had PtdIns 3-kinase activity that reached a maximum (9 times the basal activity) after a 5-min exposure of PC12 cells to NGF (100 ng/ml). Since NGF activates the tyrosine kinase activity of gp140trk, the protein product of the trk proto-oncogene, we also examined the association of PtdIns 3-kinase with gp140trk. Anti-gp140trk immunoprecipitates from NGF-stimulated PC12 cells had increased PtdIns 3-kinase activity compared to that of unstimulated cells, and larger increases were detected in cells overexpressing gp140trk, indicating that PtdIns 3-kinase associates with gp140trk. NGF produced large increases in [P-32]phosphatidylinositol 3,4-bisphosphate and [P-32]phosphatidylinositol 3,4,5-trisphosphate in PC12 cells labeled with [P-32]orthophosphate, indicating an increase in PtdIns 3-kinase activity in intact cells. Using an anti-85-kDa PtdIns 3-kinase subunit antibody, we found that NGF promoted the tyrosine phosphorylation of an 85-kDa protein and two proteins close to 110 kDa. These studies demonstrate that NGF activates PtdIns 3-kinase and promotes its association with gp140trk and also show that NGF promotes the tyrosine phosphorylation of the 85-kDa subunit of PtdIns 3-kinase. Thus, PtdIns 3-kinase activation appears to be involved in differentiation as well as mitogenic responses.	NCI, FREDERICK CANC RES & DEV CTR, BASIC RES PROGRAM, ADV BIOSCI LAB, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	SOLTOFF, SP (corresponding author), TUFTS UNIV, DEPT PHYSIOL, 136 HARRISON AVE, BOSTON, MA 02111 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041890, R01GM041890] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIGMS NIH HHS [GM-41890, R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HERBST R, 1991, J BIOL CHEM, V266, P19908; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MUTOH T, 1988, J BIOL CHEM, V263, P15853; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TSAO H, 1990, J BIOL CHEM, V265, P15471; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650	48	224	228	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17472	17477						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380963				2022-12-27	WOS:A1992JL05300110
J	WANG, XY; UHLER, MD; BILLESTRUP, N; NORSTEDT, G; TALAMANTES, F; NIELSEN, JH; CARTERSU, C				WANG, XY; UHLER, MD; BILLESTRUP, N; NORSTEDT, G; TALAMANTES, F; NIELSEN, JH; CARTERSU, C			EVIDENCE FOR ASSOCIATION OF THE CLONED LIVER GROWTH-HORMONE RECEPTOR WITH A TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT INSULINOMA CELLS; ADIPOSE CONVERSION; PROTEIN-KINASE; IL-2 RECEPTOR; PHOSPHORYLATION; IDENTIFICATION; METABOLISM; ADIPOCYTES; FAMILY; DNA	The ability of the cloned liver growth hormone (GH) receptor, when expressed in mammalian cell lines, to copurify with tyrosine kinase activity and be tyrosyl phosphorylated was examined. I-125-human growth hormone-GH receptor complexes isolated from COS-7 cells transiently expressing high levels of the cloned liver GH receptor bound to anti-phosphotyrosine antibody, suggesting that the cloned GH receptor is tyrosyl phosphorylated in vivo. GH-GH receptor complexes purified from transfected COS-7 cells using anti-GH antibody incorporated P-32 when incubated with [gamma-P-32]ATP, indicating association of tyrosine kinase activity with cloned liver GH receptor. The level of phosphorylation of the GH receptor was very low, as compared with the endogenous GH receptor in 3T3-F442A cells, suggesting that tyrosine kinase activity is not intrinsic to the cloned GH receptor but rather resides with a kinase present at low levels in the COS-7 cells. To test whether a higher level of GH receptor phosphorylation would be observed when the GH receptor was expressed in a different cell line, GH receptor cDNAs were stably transfected into mouse L and CHO cells, which have few or no endogenous GH receptors, and RIN5-AH cells, which do express endogenous GH receptors. In vivo tyrosyl phosphorylation of the cloned GH receptor in mouse L cells and in vitro phosphorylation of the cloned GH receptor in both L and CHO cells were higher than in transfected COS-7 cells but still substantially lower than in untransfected 3T3-F442A cells. Significantly increased P-32 incorporation into tyrosyl residues in GH receptors in the in vitro kinase assay was demonstrated for GH receptors isolated from the transfected RIN5-AH cells. These studies show that the cloned liver GH receptor can be tyrosyl phosphorylated when expressed in a variety of cell types. The finding that the level of phosphorylation of GH receptor appears to vary with cell type is consistent with the cloned liver GH receptor being a substrate for an associated tyrosine kinase and with the amount of such a GH receptor-associated tyrosine kinase being cell type-specific.	KAROLINSKA INST,CTR BIOTECHNOL,S-14152 HUDDINGE,SWEDEN; UNIV MICHIGAN,SCH MED,DEPT BIOCHEM,ANN ARBOR,MI 48109; HAGEDORN RES LAB,DK-2820 GENTOFTE,DENMARK; UNIV CALIF SANTA CRUZ,DEPT BIOL,SANTA CRUZ,CA 95064	Karolinska Institutet; University of Michigan System; University of Michigan; Novo Nordisk; Hagedorn Research Institute; University of California System; University of California Santa Cruz	WANG, XY (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109, USA.			Nielsen, Jens Hoiriis/0000-0001-8252-3048; Billestrup, Nils/0000-0002-4968-8067	NIDDK NIH HHS [DK-42361, R01 DK034171, DK-34171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042361, R01DK034171, R37DK034171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; DEUTSCH PJ, 1982, J BIOL CHEM, V257, P5350; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NIXON T, 1983, J CELL PHYSIOL, V115, P291, DOI 10.1002/jcp.1041150312; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHWARTZ J, 1988, ENDOCRINOLOGY, V122, P2247; SMITH WC, 1988, MOL ENDOCRINOL, V2, P108, DOI 10.1210/mend-2-2-108; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WINSTON LA, 1992, J BIOL CHEM, V267, P4747	27	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17390	17396						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380961				2022-12-27	WOS:A1992JL05300098
J	WELLER, A; ISENMANN, S; VESTWEBER, D				WELLER, A; ISENMANN, S; VESTWEBER, D			CLONING OF THE MOUSE ENDOTHELIAL SELECTINS - EXPRESSION OF BOTH E-SELECTIN AND P-SELECTIN IS INDUCIBLE BY TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; LEUKOCYTE ADHESION MOLECULE-1; LYMPHOCYTE HOMING RECEPTOR; WEIBEL-PALADE BODIES; CELL-ADHESION; ADULT TISSUES; NEUTROPHILS; GMP-140; PLATELETS; GENE	E-selectin (ELAM-1) and P-selectin (GMP-140, PADGEM, CD62) have both been described as human endothelial cell adhesion molecules for neutrophils and monocytes. Cell surface appearance of these two proteins on human umbilical vein endothelial cells can be regulated by different mechanisms: E-selectin is transcriptionally induced, within hours, by tumor necrosis factor-alpha (TNF-alpha) while P-selectin is transported from storage granules to the plasma membrane within minutes upon induction by various stimulating agents. We have obtained cDNA clones covering the full-length coding sequence of the homologous mouse proteins for both endothelial selectins. We show that synthesis of mouse P-selectin, like that of E-selectin, is transiently induced by TNF-alpha in several endothelioma cell lines derived from different mouse tissues. This induction was monitored on both the RNA as well as the protein level. The TNF induced, newly synthesized P-selectin protein was detected on the cell surface. Protein expression of P-selectin increased with a slightly lower rate than expression of E-selectin. In organ cultures of lung tissue from TNF-injected mice, the synthesis of P-selectin was clearly elevated compared to control mice. The bovine P-selectin homolog recognized by cross-reaction with anti-mouse P-selectin antibodies was also TNF-inducible in primary capillary endothelial cells from adrenal cortex and in aorta-derived endothelial cells. Thus, P-selectin can be regulated on two different levels. While the transport of stored P-selectin to the cell surface is controlled by regulated secretion of storage granules, the synthesis and surface expression can be induced by TNF-alpha similarly to that of E-selectin.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,STUBEWEG 51,W-7800 FREIBURG,GERMANY	Max Planck Society			Isenmann, Stefan/AAJ-3788-2020					BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GALANOS C, 1979, ZBL BAKT-INT J MED M, V243, P226; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HESSION C, 1991, J BIOL CHEM, V266, P6682; JOHNSTON GI, 1989, J BIOL CHEM, V264, P1816; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KNAPP W, 1989, BLOOD, V74, P1448; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; ORD DC, 1990, J BIOL CHEM, V265, P7760; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUH R, 1986, P NATL ACAD SCI USA, V83, P1364, DOI 10.1073/pnas.83.5.1364; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; VESTWEBER D, 1984, EXP CELL RES, V152, P169, DOI 10.1016/0014-4827(84)90241-6; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; WILLIAMS RL, 1988, CELL, V52, P121	50	360	368	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15176	15183						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378846				2022-12-27	WOS:A1992JF08800098
J	SOOS, MA; FIELD, CE; LAMMERS, R; ULLRICH, A; ZHANG, B; ROTH, RA; ANDERSEN, AS; KJELDSEN, T; SIDDLE, K				SOOS, MA; FIELD, CE; LAMMERS, R; ULLRICH, A; ZHANG, B; ROTH, RA; ANDERSEN, AS; KJELDSEN, T; SIDDLE, K			A PANEL OF MONOCLONAL-ANTIBODIES FOR THE TYPE-I INSULIN-LIKE GROWTH-FACTOR RECEPTOR - EPITOPE MAPPING, EFFECTS ON LIGAND-BINDING, AND BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID SYNTHESIS; HIGH-AFFINITY BINDING; STRUCTURAL BASIS; HUMAN-PLACENTA; HYBRID RECEPTORS; KINASE-ACTIVITY; SOMATOMEDIN-C; IGF-I; CELLS; FIBROBLASTS	We obtained 20 mouse monoclonal antibodies specific for human type I insulin-like growth factor (IGF) receptors, using transfected cells expressing high levels of receptors (IGF-1R/3T3 cells) as immunogen. The antibodies immunoprecipitated receptor.I-125-IGF-I complexes and biosynthetically labeled receptors from IGF-1R/3T3 cells but did not react with human insulin receptors or rat type I IGF receptors. Several antibodies stimulated DNA synthesis in IGF-1R/3T3 cells, but the maximum stimulation was only 25% of that produced by IGF-I. The antibodies fell into seven groups recognizing distinct epitopes and with different effects on receptor function. All the antibodies reacted with the extracellular portion of the receptor, and epitopes were localized to specific domains by investigating their reaction with a series of chimeric IGF/insulin receptor constructs. Binding of IGF-I was inhibited up to 90% by antibody 24-60 reacting in the region 184-283, and by antibody 24-57 reacting in the region 440-586. IGF-I binding was stimulated up to 2.5-fold by antibodies 4-52 and 16-13 reacting in the region 62-184, and by antibody 26-3 reacting downstream of 283. The latter two groups of antibodies also dramatically stimulated insulin binding to intact IGF-1R/3T3 cells (by up to 50-fold), and potentiated insulin stimulation of DNA synthesis. Scatchard analysis indicated that in the presence of these antibodies, the affinity of the type I IGF receptor for insulin was comparable with that of the insulin receptor. These data indicate that regions both within and outside the cysteine-rich domain of the receptor alpha-subunit are important in determining the affinity and specificity of ligand binding. These antibodies promise to be valuable tools in resolving issues of IGF-I receptor heterogeneity and in studying the structure and function of classical type I receptors and insulin/IGF receptor hybrids.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND; MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,W-8033 MARTINSRIED,GERMANY; STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305; NOVO NORDISK AS,DIABET RES,DK-2880 BAGSVAERD,DENMARK	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Max Planck Society; Stanford University; Novo Nordisk				Kjeldsen, Thomas/0000-0003-0094-9286	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDRIDES TK, 1989, J BIOL CHEM, V264, P12922; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; BURANT CF, 1987, BIOCHEM BIOPH RES CO, V147, P100, DOI 10.1016/S0006-291X(87)80092-X; CARA JF, 1988, ENDOCRINOLOGY, V123, P1341, DOI 10.1210/endo-123-3-1341; CASELLA SJ, 1986, J BIOL CHEM, V261, P9268; CONOVER CA, 1987, J CELL PHYSIOL, V133, P560, DOI 10.1002/jcp.1041330318; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; DURONIO V, 1988, RECEPT BIOCH METHO B, V12, P19; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FELTZ SM, 1988, BIOCHEMISTRY-US, V27, P3234, DOI 10.1021/bi00409a017; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; FURLANETTO RW, 1987, J CLIN ENDOCR METAB, V64, P1142, DOI 10.1210/jcem-64-6-1142; Galfre G, 1981, Methods Enzymol, V73, P3; GAMMELTOFT S, 1984, PHYSIOL REV, V64, P1321, DOI 10.1152/physrev.1984.64.4.1321; GAROFALO RS, 1989, MOL CELL BIOL, V9, P2806, DOI 10.1128/MCB.9.7.2806; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; JACOBS S, 1986, ENDOCRINOLOGY, V118, P223, DOI 10.1210/endo-118-1-223; JONAS HA, 1989, BIOCHEM J, V257, P101, DOI 10.1042/bj2570101; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MISRA P, 1986, J CLIN ENDOCR METAB, V63, P1400, DOI 10.1210/jcem-63-6-1400; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PANG DT, 1984, J BIOL CHEM, V259, P8589; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SHIER P, 1989, J BIOL CHEM, V264, P14605; SHIMIZU M, 1986, AM J PHYSIOL, V251, pE611, DOI 10.1152/ajpendo.1986.251.5.E611; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SOOS MA, 1989, P NATL ACAD SCI USA, V86, P5217, DOI 10.1073/pnas.86.14.5217; SOOS MA, 1991, MODERN CONCEPTS INSU, P461; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STEELEPERKINS G, 1990, BIOCHEM BIOPH RES CO, V171, P1244, DOI 10.1016/0006-291X(90)90819-9; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; TAYLOR R, 1987, BIOCHEM J, V242, P123, DOI 10.1042/bj2420123; TOLLEFSEN SE, 1987, J BIOL CHEM, V262, P16461; TOLLEFSEN SE, 1988, J BIOL CHEM, V263, P16267; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WALDBILLIG RJ, 1988, BIOCHEM BIOPH RES CO, V151, P1105, DOI 10.1016/S0006-291X(88)80480-7; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	60	107	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12955	12963						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1377676				2022-12-27	WOS:A1992HZ48300084
J	LAVAN, BE; KUHNE, MR; GARNER, CW; ANDERSON, D; REEDIJK, M; PAWSON, T; LIENHARD, GE				LAVAN, BE; KUHNE, MR; GARNER, CW; ANDERSON, D; REEDIJK, M; PAWSON, T; LIENHARD, GE			THE ASSOCIATION OF INSULIN-ELICITED PHOSPHOTYROSINE PROTEINS WITH SRC HOMOLOGY-2 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; RECEPTOR KINASE; PHOSPHORYLATION; PURIFICATION; 3-KINASE; BINDING	The interactions of the phosphotyrosine (Tyr(P))-containing proteins in basal and insulin-stimulated 3T3-L1 adipocytes with src homology 2 (SH2) domains from phosphatidylinositol 3-kinase (PI3K), ras GTPase-activating protein (GAP), and phospholipase C-gamma have been examined. The Tyr(P) forms of the insulin receptor and its 160-kDa substrate protein (pp160) associated with fusion proteins containing either or both the SH2 domains of PI3K, but not with fusion proteins containing the two SH2 domains of GAP or phospholipase C-gamma. These results demonstrate a specificity for the association of the Tyr(P) form of the insulin receptor and pp160 with SH2 domains that parallels the reported effects of insulin on PI3K, GAP, and phospholipase C-gamma in vivo. Immunoprecipitates of pp160 from the cytosol of insulin-treated, but not basal, 3T3-L1 adipocytes contained PI3K activity. Moreover, the Tyr(P) form of pp160 with associated PI3K activity migrated at 10 S on a sucrose velocity gradient, whereas the Tyr(P) form without associated activity migrated at 6 S. These findings indicate that the Tyr(P) form of pp160 associates directly with PI3K in vivo.	DARTMOUTH COLL,DEPT BIOCHEM,HANOVER,NH 03755; TEXAS TECH UNIV,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,LUBBOCK,TX 79430; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	Dartmouth College; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013					ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FROST SC, 1985, J BIOL CHEM, V260, P2646; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RAY LB, 1988, J BIOL CHEM, V263, P12721; RICE KM, 1992, IN PRESS J BIOL CHEM; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SUN JX, 1991, NATURE, V352, P73	24	109	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11631	11636						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375946				2022-12-27	WOS:A1992HX16900106
J	MUNOZ, P; GUMA, A; CAMPS, M; FURRIOLS, M; TESTAR, X; PALACIN, M; ZORZANO, A				MUNOZ, P; GUMA, A; CAMPS, M; FURRIOLS, M; TESTAR, X; PALACIN, M; ZORZANO, A			VANADATE STIMULATES SYSTEM-A AMINO-ACID-TRANSPORT ACTIVITY IN SKELETAL-MUSCLE - EVIDENCE FOR THE INVOLVEMENT OF INTRACELLULAR-PH AS A MEDIATOR OF VANADATE ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; PHOSPHOTYROSYL-PROTEIN PHOSPHATASE; NA+ ELECTROCHEMICAL GRADIENT; RECEPTOR TYROSINE KINASE; INSULIN-RECEPTOR; GLYCOGEN-SYNTHASE; GLUCOSE-METABOLISM; PLASMA-MEMBRANE; INHIBITION; ADIPOCYTES	Sodium orthovanadate caused a 2-fold stimulation of system A transport activity in soleus muscle, as assessed by the uptake of the nonmetabolizable analog 2-(methylamino)isobutyric acid (MeAIB). The effect of vanadate on system A was rapid, concentration-dependent and was characterized by an increased V(max) without modification of K(m) for MeAIB. Under these conditions, vanadate also activated 3-O-methylglucose uptake and lactate production. The effects of vanadate on muscle metabolism showed a complex interaction with the effects of insulin. Thus, the stimulatory effects of vanadate and insulin on MeAIB and 3-O-methylglucose uptake were not additive; however, the effects of insulin and vanadate on lactate production were additive. In spite of the lack of additivity, insulin- and vanadate-induced stimulation of system A differed in their sensitivity to gramicidin D, being the vanadate effect more susceptible to inhibition by gramicidin D than the insulin effect. System A transport activity shows a dependence on pH, and recent results suggest the presence of critical histidine residues on the A carrier that may be responsible for its pH dependence (Bertran, J., Roca, A., Pola, E., Testar, X., Zorzano, A. & Palacin, M. (1991) J. Biol. Chem. 266, 798-802). In this regard, a rise in extracellular pH led to a substantial activation of system A. Furthermore, lowering of muscle intracellular pH induced by ethylisopropylamiloride (EIPA), a specific inhibitor of sodium/proton exchange activity, led to inhibition of system A. This suggests that critical histidine residues are present in an intracellular localization on the A carrier. Furthermore, the rate of muscle glycolysis was also altered in response to a rise in extracellular pH or to EIPA treatment. Regarding the mechanisms involved in vanadate action, vanadate treatment in the incubated soleus muscle did not cause any significant stimulation of tyrosine kinase activity after partial purification of muscle insulin receptors. On the other hand, vanadate but not insulin caused a substantial increase in muscle intracellular pH as assessed by 5,5'-dimethyloxazolidine-2, 4-dione equilibrium. This effect of vanadate on intracellular pH was not due to activation of the sodium/proton exchanger, since it was not blocked by EIPA. Based on these findings, we suggest that alkalinization of muscle intracellular pH might mediate the effects of vanadate on system A and on glycolysis.	UNIV BARCELONA,FAC BIOL,DEPT BIOQUIM & FISIOL,AVDA DIAGONAL 645,E-08028 BARCELONA,SPAIN	University of Barcelona			Palacín, Manuel/G-9786-2015; Gumà, Anna/C-5165-2017; Zorzano, Antonio/R-5479-2018; Camps, Marta/F-6557-2016	Gumà, Anna/0000-0001-9390-5252; Camps, Marta/0000-0001-5392-1792; Palacin, Manuel/0000-0002-8670-293X; Furriols, Marc/0000-0002-0656-1912				AICKIN CC, 1977, J PHYSIOL-LONDON, V267, P791; BERTRAN J, 1991, J BIOL CHEM, V266, P798; BRACY DS, 1986, J BIOL CHEM, V261, P1514; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPS M, 1990, ENDOCRINOLOGY, V127, P2561, DOI 10.1210/endo-127-5-2561; CANTLEY LC, 1979, J BIOL CHEM, V254, P1781; CANTLEY LC, 1977, J BIOL CHEM, V252, P7421; CARIAPPA R, 1990, J BIOL CHEM, V265, P1470; CASSEL D, 1984, BIOCHEM BIOPH RES CO, V118, P675, DOI 10.1016/0006-291X(84)91356-1; CHALLISS RAJ, 1987, BIOCHEM PHARMACOL, V36, P357, DOI 10.1016/0006-2952(87)90294-2; CLARK AS, 1985, BIOCHEM J, V232, P273, DOI 10.1042/bj2320273; CONNETT RJ, 1987, J APPL PHYSIOL, V63, P2360, DOI 10.1152/jappl.1987.63.6.2360; DEGANI H, 1981, BIOCHEMISTRY-US, V20, P5795, DOI 10.1021/bi00523a023; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FEHLMANN M, 1979, J BIOL CHEM, V254, P431; GOODMAN MN, 1974, DIABETES, V23, P881, DOI 10.2337/diab.23.11.881; GREEN A, 1986, BIOCHEM J, V238, P663, DOI 10.1042/bj2380663; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; GUIDOTTI GG, 1975, BIOCHIM BIOPHYS ACTA, V406, P264, DOI 10.1016/0005-2736(75)90009-7; GUMA A, 1988, BIOCHEM J, V253, P625, DOI 10.1042/bj2530625; GUMA A, 1992, BIOCHEM J, V281, P407, DOI 10.1042/bj2810407; HAGGERTY JG, 1985, BIOCHEM BIOPH RES CO, V127, P759, DOI 10.1016/S0006-291X(85)80008-5; JAMES DE, 1986, J BIOL CHEM, V261, P4939; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KIPNIS DM, 1958, BIOCHIM BIOPHYS ACTA, V28, P226, DOI 10.1016/0006-3002(58)90466-9; KLIP A, 1986, AM J PHYSIOL, V250, pC720, DOI 10.1152/ajpcell.1986.250.5.C720; KRISTENSEN LO, 1986, BIOCHIM BIOPHYS ACTA, V855, P49, DOI 10.1016/0005-2736(86)90187-2; LECAM A, 1977, J BIOL CHEM, V252, P148; LEMARCHANDBRUSTEL Y, 1982, AM J PHYSIOL, V243, pE74, DOI 10.1152/ajpendo.1982.243.1.E74; MAIZELS EZ, 1977, BIOCHEM J, V162, P557, DOI 10.1042/bj1620557; MARONI BJ, 1990, AM J PHYSIOL, V258, pF1304, DOI 10.1152/ajprenal.1990.258.5.F1304; MARONI BJ, 1986, AM J PHYSIOL, V251, pF81, DOI 10.1152/ajprenal.1986.251.1.F81; MEYER RA, 1983, FED PROC, V42, P1248; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; MOORE RD, 1979, BIOCHEM BIOPH RES CO, V91, P900, DOI 10.1016/0006-291X(79)91964-8; NECHAY BR, 1984, ANNU REV PHARMACOL, V24, P501; ORZANO A, 1985, AM J PHYSIOL, V248, pE546; PAN JW, 1988, P NATL ACAD SCI USA, V85, P7836, DOI 10.1073/pnas.85.21.7836; ROSSETTI L, 1989, J CLIN INVEST, V84, P892, DOI 10.1172/JCI114250; SCHECHTER Y, 1990, DIABETES, V39, P1; SIPS HJ, 1980, EUR J BIOCHEM, V105, P217, DOI 10.1111/j.1432-1033.1980.tb04492.x; SPRIET LL, 1987, J APPL PHYSIOL, V62, P616, DOI 10.1152/jappl.1987.62.2.616; STROUT HV, 1989, ENDOCRINOLOGY, V124, P1918, DOI 10.1210/endo-124-4-1918; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWARUP G, 1982, J BIOL CHEM, V257, P7298; TAMURA S, 1983, BIOCHEM BIOPH RES CO, V113, P80, DOI 10.1016/0006-291X(83)90434-5; TAMURA S, 1984, J BIOL CHEM, V259, P6650; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; VIGNE P, 1984, EMBO J, V3, P1865, DOI 10.1002/j.1460-2075.1984.tb02060.x; WADDELL WJ, 1959, J CLIN INVEST, V38, P720, DOI 10.1172/JCI103852; ZORZANO A, 1986, AM J PHYSIOL, V251, pE21, DOI 10.1152/ajpendo.1986.251.1.E21; ZORZANO A, 1986, BIOCHEM BIOPH RES CO, V134, P1342, DOI 10.1016/0006-291X(86)90397-9	53	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10381	10388						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375219				2022-12-27	WOS:A1992HV09000030
J	ERICKSON, PR; HERZBERG, MC; TIERNEY, G				ERICKSON, PR; HERZBERG, MC; TIERNEY, G			CROSS-REACTIVE IMMUNODETERMINANTS ON STREPTOCOCCUS-SANGUIS AND COLLAGEN - PREDICTING A STRUCTURAL MOTIF OF PLATELET-INTERACTIVE DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDS GLYCOPROTEIN-IIB; MONOCLONAL-ANTIBODY; SECONDARY-STRUCTURE; AGGREGATORY SITES; IV CD36; ADHESION; PROTEINS; SURFACE; INHIBITION; RECEPTOR	Cross-reactive immunodeterminants on a fibril-associated surface antigen of Streptococcus sanguis and types I and III collagen participate in the induction of aggregation of human platelets. To further understand the basis for this apparent molecular mimicry, anti-type-specific collagen antibodies, anti-KPGEPGPK (an analogue of platelet-interactive domains on collagen) and a panel of KPGEPGPK-like synthetic peptides were used as probes. When collagen or S. sanguis cells were pretreated with the anti-collagen antisera, the induction of aggregation of platelet-rich plasma was greatly delayed or abrogated. These anti-collagen antibodies also neutralized KPGEPGPK and purified S. sanguis platelet-interactive antigens as inhibitors of S. sanguis or collagen-induced aggregation of platelets in plasma. In immunoblot analyses, these anti-collagen antibodies reacted with S. sanguis platelet-interactive antigens. Additionally, antisera against the platelet-interactive antigen of S. sanguis selectively reacted with undigested type I collagen and with fragments CB3 and CB6 of cyanogen bromide-treated type I collagen. Finally, when platelets were pretreated with synthetic peptides containing specific amino acid substitutions within the KPGEPGPK sequence, the time to onset of platelet-rich plasma aggregation by both agonists was altered. The hierarchical pattern of responses of platelets to these peptides and predictions of the structural changes produced by simulated insertions of each peptide into the CB4 sequence of type III collagen suggested conformational requirements for interactions with platelets. Thus, these data show that cross-reactive immunodeterminants of S. sanguis and collagen induce platelet aggregation. The platelet-interactive domains are predicted to be characterized by a structural motif with the consensus sequence X-P-G-E-P/Q-G-P-X.	UNIV MINNESOTA,SCH DENT,DEPT PREVENT SCI,17-164C MOOS HS TOWER,515 DELAWARE ST SE,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH DENT,GRAD PROGRAM ORAL BIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIDCR NIH HHS [DE08590, DE05501, DE00224] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008590, R01DE005501] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BALLEISEN L, 1979, BIOCHEM J, V184, P683, DOI 10.1042/bj1840683; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; CHIANG TM, 1976, J BIOL CHEM, V251, P6347; CHIANG TM, 1987, J IMMUNOL, V139, P887; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; COLLER BS, 1989, BLOOD, V74, P182; ERICKSON PR, 1990, J BIOL CHEM, V265, P14080; ERICKSON PR, 1987, J IMMUNOL, V138, P3360; FITZSIMMONS CM, 1986, THROMB HAEMOSTASIS, V56, P95; GALLOWAY D, 1982, COLLAGEN HLTH DISEAS, P528; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; GOODFRIEND TL, 1964, SCIENCE, V144, P1344, DOI 10.1126/science.144.3624.1344; HERZBERG MC, 1983, INFECT IMMUN, V42, P394, DOI 10.1128/IAI.42.1.394-401.1983; HERZBERG MC, 1979, J BIOL CHEM, V254, P1487; HERZBERG MC, 1983, INFECT IMMUN, V39, P1457, DOI 10.1128/IAI.39.3.1457-1469.1983; HERZBERG MC, 1990, INFECT IMMUN, V58, P4117, DOI 10.1128/IAI.58.12.4117-4125.1990; HERZBERG MC, 1990, INFECT IMMUN, V58, P515, DOI 10.1128/IAI.58.2.515-522.1990; HERZBERG MC, 1985, MOL BASIS ORAL MICRO, P53; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOUDIJK WPM, 1985, J CLIN INVEST, V75, P531, DOI 10.1172/JCI111729; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEGRAND YJ, 1980, BIOCHEM BIOPH RES CO, V96, P1579, DOI 10.1016/0006-291X(80)91354-6; MILLER EJ, 1971, BIOCHEM BIOPH RES CO, V42, P1024, DOI 10.1016/0006-291X(71)90006-4; MORTON LF, 1989, BIOCHEM J, V258, P157, DOI 10.1042/bj2580157; MORTON LF, 1987, BIOCHEM J, V248, P483, DOI 10.1042/bj2480483; NACHMAN RL, 1985, PLATELET MEMBRANE GL, P245; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; SANTORO SA, 1980, THROMB HAEMOSTASIS, V43, P158; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SHADLE PJ, 1984, J CELL BIOL, V99, P2048, DOI 10.1083/jcb.99.6.2048; SIKARIS K, 1989, COMPUT APPL BIOSCI, V5, P323; SOBERAY AH, 1987, THROMB HAEMOSTASIS, V57, P222; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; ZIJENAH LS, 1990, THROMB RES, V59, P553, DOI 10.1016/0049-3848(90)90415-9	39	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10018	10023						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374395				2022-12-27	WOS:A1992HT96500086
J	FUJISAWASEHARA, A; NABESHIMA, Y; KOMIYA, T; UETSUKI, T; ASAKURA, A; NABESHIMA, Y				FUJISAWASEHARA, A; NABESHIMA, Y; KOMIYA, T; UETSUKI, T; ASAKURA, A; NABESHIMA, Y			DIFFERENTIAL TRANSACTIVATION OF MUSCLE-SPECIFIC REGULATORY ELEMENTS INCLUDING THE MYSOSIN LIGHT CHAIN BOX BY CHICKEN MYOD, MYOGENIN, AND MRF4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN GENE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CLONAL ANALYSIS; NUCLEAR FACTOR; DNA-BINDING; EXPRESSION; FAMILY; ENHANCER; SKELETAL; REGION	We have isolated cDNAs encoding a chicken homologue of MRF4 (cMRF4) in addition to chicken MyoD (CMD1) and myogenin (c-myogenin) described previously. In. an attempt to understand the roles that cMRF4, CMD1, and c-myogenin play in chicken myogenesis, the effects of these factors on muscle-specific cis-elements identified in regulatory regions of myosin alkali light chain (MLC) genes were examined. The promoter analysis of some of MLC genes has revealed two sorts of muscle-specific positive regulatory elements to date, an enhancer located upstream of the adult type LC1 gene and a cis-element, termed an MLC box, conserved among promoters of various MLC genes. The LC1 enhancer was exclusively trans-activated by CMD1. Although c-myogenin also activated transcription driven by the LC1 promoter, it was suggested that c-myogenin requires a cis-element(s) other than the CMD1-responsive enhancer. Chicken MRF4 could not trans-activate any of the constructs containing the LC1 promoter. In contrast, the promoter of the embryonic L23 gene was trans-activated by all of the three factors. From deletion and mutation analysis, the MLC box was shown to be involved in their positive regulation. These results extend previous observations that individual myogenic regulatory factors exhibit different capabilities in transcriptional activation of muscle-specific genes by acting distinctively upon their regulatory elements.			FUJISAWASEHARA, A (corresponding author), NATL INST NEUROSCI,NATL CTR NEUROL & PSYCHIAT,DIV MOLEC GENET,4-1-1 OGAWAHIGASHI,KODAIRA,TOKYO 187,JAPAN.		Asakura, Atsushi/H-2745-2019	Asakura, Atsushi/0000-0001-8078-1027				ABE H, 1986, DEV BIOL, V118, P42, DOI 10.1016/0012-1606(86)90071-0; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EDWARDS YN, 1985, MOL CELL BIOL, V5, P2147, DOI 10.1128/MCB.5.8.2147; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUBLER U, 1983, GENE, V25, P262; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; KIM DW, 1990, GENE, V9, P217; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NABESHIMA Y, 1988, J MOL BIOL, V204, P497, DOI 10.1016/0022-2836(88)90350-6; NABESHIMA Y, 1987, J BIOL CHEM, V262, P10608; NABESHIMA Y, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P33; NABESHIMA YI, 1984, NATURE, V308, P333, DOI 10.1038/308333a0; NAKAMURA S, 1988, J MOL BIOL, V203, P895, DOI 10.1016/0022-2836(88)90115-5; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SHIRAKATA M, 1988, MOL CELL BIOL, V8, P2581, DOI 10.1128/MCB.8.6.2581; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKANOOHMURO H, 1985, J CELL BIOL, V100, P2025, DOI 10.1083/jcb.100.6.2025; UETSUKI T, 1990, MOL CELL BIOL, V10, P2562, DOI 10.1128/MCB.10.6.2562; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITE NK, 1975, DEV BIOL, V44, P346, DOI 10.1016/0012-1606(75)90405-4; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	47	56	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10031	10038						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374396				2022-12-27	WOS:A1992HT96500088
J	LU, HS; CLOGSTON, CL; NARHI, LO; MEREWETHER, LA; PEARL, WR; BOONE, TC				LU, HS; CLOGSTON, CL; NARHI, LO; MEREWETHER, LA; PEARL, WR; BOONE, TC			FOLDING AND OXIDATION OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR PRODUCED IN ESCHERICHIA-COLI - CHARACTERIZATION OF THE DISULFIDE-REDUCED INTERMEDIATES AND CYSTEINE -] SERINE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; CHEMOTHERAPY; PROTEINS; NEUTROPENIA; CELLS	The folding and oxidation of recombinant human granulocyte colony-stimulating factor solubilized from Escherichia coli inclusion bodies was investigated. During the folding process, two intermediates, I1 and I2, were detected by kinetic studies using high performance liquid chromatography. I1 exists transiently and disappears quickly with the concomitant formation of I2. In contrast, I2 requires a longer time to fold into the final oxidized form, N. CuSO4 catalysis increases the folding rate of I2 from I2, while CuSO4 and elevated temperature (37-degrees-C) have a dramatic effect on the folding rate of N from I2. These observations suggest the following sequential oxidative folding pathway. [GRAPHICS] Peptide map analysis of the iodoacetate-labeled intermediates revealed that I1 represents the fully reduced granulocyte colony-stimulating factor containing 5 free cysteines; I2 is the partially oxidized species containing a single Cys36-Cys42 disulfide bond; and N, the final folded form, has two disulfide bonds. The physicochemical properties and biological activities of I1, I2, N, and several Cys --> Ser analogs made by site-directed mutagenesis were further investigated. In guanidine hydrochloride-induced denaturation studies, the disulfide-reduced intermediates and the analogs missing either of the disulfide bonds are conformationally less stable than those of the wild type molecule or the analog with the free Cys at position 17 changed to Ser. Recombinant human granulocyte colony stimulating factor lacking either disulfide bond or both has overall secondary and tertiary structures different from those of the wild type molecule and exhibits lower biological activity. These studies show that disulfide bond formation is crucial for maintaining the molecule in a properly folded and biologically active form.			LU, HS (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.							BERGER EG, 1982, EXPERIENTIA, V38, P1129, DOI 10.1007/BF01959725; BRONCHUD MH, 1987, BRIT J CANCER, V56, P809, DOI 10.1038/bjc.1987.295; CECIL R, 1959, ADV PROTEIN CHEM, V14, P255, DOI 10.1016/S0065-3233(08)60613-0; COHEN AM, 1987, P NATL ACAD SCI USA, V84, P2484, DOI 10.1073/pnas.84.8.2484; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1977, J MOL BIOL, V113, P295, DOI 10.1016/0022-2836(77)90143-7; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FERNANDEZDIEZ M J, 1964, Arch Biochem Biophys, V107, P449; FHELIS C, 1982, PROTEIN FOLDING; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; LU HS, 1989, ARCH BIOCHEM BIOPHYS, V268, P81, DOI 10.1016/0003-9861(89)90567-5; MANNING MC, 1989, PHARM RES-DORDR, V6, P903, DOI 10.1023/A:1015929109894; METCALF D, 1984, HEMOPOIETIC COLONIES; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; NARHI LO, 1991, J PROTEIN CHEM, V10, P359, DOI 10.1007/BF01025250; OHEDA M, 1988, J BIOCHEM-TOKYO, V103, P544, DOI 10.1093/oxfordjournals.jbchem.a122305; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; SOUZA LM, 1989, Patent No. 4810643; TAKAGI T, 1963, BIOCHEM BIOPH RES CO, V13, P353, DOI 10.1016/0006-291X(63)90347-4; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TSUCHIYA M, 1986, P NATL ACAD SCI USA, V83, P7633, DOI 10.1073/pnas.83.20.7633; YUTANI K, 1968, J BIOCHEM-TOKYO, V64, P449, DOI 10.1093/oxfordjournals.jbchem.a128916; ZSEBO KM, 1986, IMMUNOBIOLOGY, V172, P175, DOI 10.1016/S0171-2985(86)80097-3	28	85	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8770	8777						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374379				2022-12-27	WOS:A1992HR85400013
J	DAIFOTIS, AG; WEIR, EC; DREYER, BE; BROADUS, AE				DAIFOTIS, AG; WEIR, EC; DREYER, BE; BROADUS, AE			STRETCH-INDUCED PARATHYROID HORMONE-RELATED PEPTIDE GENE-EXPRESSION IN THE RAT UTERUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RIBONUCLEIC-ACID; SMOOTH-MUSCLE; MYOMETRIUM	We previously observed a peak in parathyroid hormone-related peptide (PTHrP) mRNA expression in preterm rat myometrium and found that this peak was dependent on intrauterine occupancy. We explored the possibility that mechanotransduction might control PTHrP gene expression in the uterus. This was done by developing an intrauterine balloon system that allowed us to reproduce experimentally the mechanical effects of the fetal pup in utero. An increase in PTHrP mRNA in the unoccupied horn of a unilaterally pregnant rat could be elicited as rapidly as 1 h after balloon inflation and was maintained for up to 72 h. The same response was seen in uterine horns from virgin animals and could be reproduced by three different methods of imposing a physical stretch. Balloon-induced stretch also increased mRNA expression in a muscle bath system in vitro. Mechanotransduction appears to be largely, if not entirely, responsible for the preterm peak in PTHrP mRNA expression.	YALE UNIV,DEPT INTERNAL MED,DIV ENDOCRINE,NEW HAVEN,CT 06510; YALE UNIV,COMPARAT MED SECT,NEW HAVEN,CT 06510; YALE UNIV,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR030102, R01AR030102] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 30102] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CASEY L, 1992, J CLIN ENDOCR METAB, V74, P950; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FERGUSON JE, 1992, P NATL ACAD SCI USA, V89, P8384, DOI 10.1073/pnas.89.17.8384; Fuchs A. R., 1969, Biology of Reproduction, V1, P344, DOI 10.1095/biolreprod1.4.344; FUCHS AR, 1983, CAN J BIOCHEM CELL B, V61, P615, DOI 10.1139/o83-077; GUTKOWSKA J, 1989, ENDOCR REV, V10, P519, DOI 10.1210/edrv-10-4-519; KAWANO M, 1988, PROSTAGLANDINS, V35, P305, DOI 10.1016/0090-6980(88)90125-6; KOMURO I, 1991, J BIOL CHEM, V266, P1265; MOK LLS, 1989, J BONE MINER RES, V4, P433; PHILLIPPE M, 1992, LIFE SCI, V50, P1189, DOI 10.1016/0024-3205(92)90462-X; SHEW RL, 1991, J BONE MINER RES, V6, P955; STEWART AF, 1990, J CLIN ENDOCR METAB, V71, P1410, DOI 10.1210/jcem-71-6-1410; THIEDE MA, 1991, ENDOCRINOLOGY, V128, P2317, DOI 10.1210/endo-128-5-2317; THIEDE MA, 1990, P NATL ACAD SCI USA, V87, P6969, DOI 10.1073/pnas.87.18.6969; THIEDE MA, 1991, ENDOCRINOLOGY, V129, P1958, DOI 10.1210/endo-129-4-1958; WATHES DC, 1982, J REPROD FERTIL, V65, P497, DOI 10.1530/jrf.0.0650497; WATSONP, 1991, FASEB J, V5, P2013; YAMAMOTO M, 1992, P NATL ACAD SCI USA, V89, P5326, DOI 10.1073/pnas.89.12.5326	18	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23455	23458						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385422				2022-12-27	WOS:A1992JZ23900006
J	REING, J; DURKIN, ME; CHUNG, AE				REING, J; DURKIN, ME; CHUNG, AE			LAMININ-B1 EXPRESSION IS REQUIRED FOR LAMININ DEPOSITION INTO THE EXTRACELLULAR-MATRIX OF PC12-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE PROTEINS; NERVE GROWTH-FACTOR; CELL-LINE PC12; NEURITE OUTGROWTH; MESSENGER-RNA; A-CHAIN; MONOCLONAL-ANTIBODIES; MULTIDOMAIN PROTEIN; IV COLLAGEN; F9 CELLS	The extracellular matrix of rat pheochromocytoma PC12 cells was shown by indirect immunofluorescence to consist of a network of fibronectin. The matrix did not contain laminin. The cells synthesized messenger RNA for fibronectin, laminin B2, and s-laminin but not for entactin or the B1 and A chains of laminin. Laminin B2 but not laminin B1 was detectable in the culture medium and in cell lysates. A full-length cDNA clone for the B1 chain of laminin was constructed in the plasmid p-444, which contains the neomycin-resistance marker and human beta-actin promoter. PC12 cells were transfected with this recombinant plasmid, and stable neomycin-resistant clones were isolated and characterized. Clones that synthesized laminin B1 messenger RNA were found to deposit a laminin-containing matrix. In many of these clones the deposition of the fibronectin matrix was greatly diminished. The laminin matrix was predominantly localized in the intercellular spaces forming a honeycomb pattern. The morphology of the laminin-synthesizing transfected cells was markedly different from the parental cells. The cells grew in tight clusters that were resistant to dissociating agents. It is concluded that the B1 chain of laminin contains information that is required for the formation of a stable laminin-containing extracellular matrix network either by interaction with cell surface receptors or other extracellular matrix components. Furthermore, expression of the laminin B1 gene may be a central regulatory point in determining extracellular matrix composition during embryogenesis.	UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA-21246] Funding Source: Medline; NIGMS NIH HHS [GM-25690] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025690] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BEGOVAC PC, 1990, J CELL BIOL, V110, P461, DOI 10.1083/jcb.110.2.461; CARLIN BE, 1983, J BIOL CHEM, V258, P7729; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; CHUNG AE, 1977, CANCER RES, V37, P2072; DARRIBERE T, 1990, J CELL BIOL, V110, P1813, DOI 10.1083/jcb.110.5.1813; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DONG LJ, 1991, DIFFERENTIATION, V48, P157, DOI 10.1111/j.1432-0436.1991.tb00254.x; DURKIN ME, 1986, DIFFERENTIATION, V32, P260, DOI 10.1111/j.1432-0436.1986.tb00582.x; DURKIN ME, 1988, BIOCHEMISTRY-US, V27, P5198, DOI 10.1021/bi00414a038; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; FUR JL, 1986, J HISTOCHEM CYTOCHEM, V34, P483, DOI 10.1177/34.4.3512698; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GREEN TL, 1992, J BIOL CHEM, V267, P2014; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JAFFE R, 1984, LAB INVEST, V51, P88; KESHMIRIAN J, 1989, J NEUROCYTOL, V18, P491, DOI 10.1007/BF01474545; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMOUREUX P, 1990, J CELL BIOL, V110, P71, DOI 10.1083/jcb.110.1.71; LAURIE GW, 1989, J CELL BIOL, V109, P1351, DOI 10.1083/jcb.109.3.1351; Maniatis T., 1982, MOL CLONING; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MCDONALD JA, 1988, ANNU REV BIOCHEM, V57, P375; MCKEOWNLONGO PJ, 1988, FIBRONECTIN, P163; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SEIF I, 1991, Methods in Molecular and Cellular Biology, V2, P216; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOMASELLI KJ, 1988, J CELL BIOL, V107, P1241, DOI 10.1083/jcb.107.3.1241; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAN YJ, 1984, J CELL BIOL, V98, P971, DOI 10.1083/jcb.98.3.971; WU CY, 1988, BIOCHEMISTRY-US, V27, P8780, DOI 10.1021/bi00424a014	42	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23143	23150						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385414				2022-12-27	WOS:A1992JY16300068
J	VANHUIJSDUIJNEN, RH; WHELAN, J; PESCINI, R; BECKERANDRE, M; SCHENK, AM; DELAMARTER, JF				VANHUIJSDUIJNEN, RH; WHELAN, J; PESCINI, R; BECKERANDRE, M; SCHENK, AM; DELAMARTER, JF			A T-CELL ENHANCER COOPERATES WITH NF-KAPPA-B TO YIELD CYTOKINE INDUCTION OF E-SELECTIN GENE-TRANSCRIPTION IN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; BINDING PROTEINS; EXPRESSION; ELAM-1; ACTIVATION; CLONING; SITES	ELAM1 (endothelial leukocyte adhesion molecule 1, also known as E-selectin) is a highly tissue-specific adhesion molecule that is transiently and exclusively expressed on cytokine-induced endothelial cells. We have identified two proximal ELAM1 promoter elements and their DNA-binding factors that are, in addition to NF-kappaB, essential for ELAM1 transcription. Mutation of either element in promoter constructs carrying the first 383 nucleotides of the ELAM1 promoter markedly diminished the expression of a fused chloramphenicol acetyltransferase reporter gene. Although multimers of either element failed to display enhancer activity on its own, fusion of the most upstream of these to the NF-kappaB element had a strong stimulatory effect. This site, ACATCAT, is recognized by a factor we have called NF-ELAM1. The site corresponds to NF-ELAM1's preferential binding sequence (A/T)CA(G/T)CA(G/T) as determined in a target definition assay. This element is identical to the T-cell deltaA enhancer found in the T-cell receptor-alpha, -beta, and CD3delta genes. Our results suggest that the deltaA/NF-ELAM1 element can function as a modulator of NF-kappaB in endothelial cells both as well as a T-cell enhancer.			VANHUIJSDUIJNEN, RH (corresponding author), GLAXO INST MOLEC BIOL,CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND.		Whelan, James/F-6402-2011; van Huijsduijnen, Rob A.M. Hooft/B-3653-2009	Whelan, James/0000-0001-5754-025X; van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424				AUASUBEL FM, 1989, CURRENT PROTOCOLS MO; BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BECKERANDRE M, 1992, EUR J BIOCHEM, V206, P401, DOI 10.1111/j.1432-1033.1992.tb16940.x; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CARLOS T, 1991, J BLOOD, V77, P2266; COLLINS T, 1991, J BIOL CHEM, V266, P2466; CULLEN BR, 1987, METHOD ENZYMOL, V152, P692; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; FICKLING SA, 1992, IN PRESS EXP CELL RE; GEORGOPOULOS K, 1990, EMBO J, V9, P109, DOI 10.1002/j.1460-2075.1990.tb08086.x; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; LARIGAN D, 1992, DNA CELL BIOL, V11, P149; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; VANHUIJSDUIJNEN RH, 1992, BIOTECHNIQUES, V12, P6; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253	32	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22385	22391						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385398				2022-12-27	WOS:A1992JW71900063
J	KAMATH, AV; YANOFSKY, C				KAMATH, AV; YANOFSKY, C			CHARACTERIZATION OF THE TRYPTOPHANASE OPERON OF PROTEUS-VULGARIS - CLONING, NUCLEOTIDE-SEQUENCE, AMINO-ACID HOMOLOGY, AND INVITRO SYNTHESIS OF THE LEADER PEPTIDE AND REGULATORY ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; STRUCTURAL GENE; INDOLE-LYASE; EXPRESSION; RESIDUES; MECHANISM; TRANSPORT; INDUCTION; SITE	The tryptophanase (tna) operon of Proteus vulgaris was cloned and characterized and found to be organized similarly to the tna operon of Escherichia coli. Both operons contain two major structural genes, tnaA and tnaB, that encode tryptophanase and a tryptophan permease, respectively. tnaA of P. vulgaris is preceded by a transcribed leader region, encoding a 34-residue leader peptide, TnaC, that contains a single tryptophan residue. The tnaC coding region also has a boxA-like sequence. Regulatory studies performed in P. vulgaris, and with a plasmid carrying the P. vulgaris tna operon in E. coli, established that expression of the Proteus operon was induced by tryptophan and was subject to catabolite repression. Site-directed mutagenesis studies established that translation of the tnaC coding region was essential for induction. Synthesis of the P. vulgaris leader peptide was demonstrated in an in vitro coupled transcription-translation system. Interestingly, the 5 amino acid residues of the TnaC peptide surrounding the sole tryptophan residue are identical in P. vulgaris and E. coli. We conclude that the tna operon of P. vulgaris is also regulated by tryptophan-induced transcription antitermination. Homology of tryptophanase and tryptophan permease of P. vulgaris to related proteins from other species is described.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM009738, R37GM009738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 09738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BILEZIKIAN JP, 1967, J MOL BIOL, V27, P495, DOI 10.1016/0022-2836(67)90054-X; BOTSFORD JL, 1971, J BACTERIOL, V105, P303, DOI 10.1128/JB.105.1.303-312.1971; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DEELEY MC, 1981, J BACTERIOL, V147, P787, DOI 10.1128/JB.147.3.787-796.1981; DEMOSS RD, 1969, J BACTERIOL, V98, P167, DOI 10.1128/JB.98.1.167-171.1969; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GOLLNICK P, 1990, J BACTERIOL, V172, P3100, DOI 10.1128/jb.172.6.3100-3107.1990; HEATWOLE VM, 1991, J BACTERIOL, V173, P108, DOI 10.1128/jb.173.1.108-115.1991; HENIKOFF S, 1987, METHOD ENZYMOL, V125, P157; HOCH JA, 1966, BIOCHEMISTRY-US, V5, P2229, DOI 10.1021/bi00871a011; HOFFMAN PS, 1981, J BACTERIOL, V148, P736, DOI 10.1128/JB.148.2.736-738.1981; IWAMORI S, 1991, J FERMENT BIOENG, V72, P147, DOI 10.1016/0922-338X(91)90207-W; KAGAMIYAMA H, 1972, J BIOL CHEM, V247, P1576; KAZARINOFF MN, 1977, J BIOL CHEM, V252, P7598; LOWRY OH, 1951, J BIOL CHEM, V193, P265; METZLER CM, 1991, J BIOL CHEM, V266, P9374; MILES EW, 1986, VITAMIN B6 PYRIDOXAL, P253; Miller J.H., 1972, EXPT MOL GENETICS; NAKAMURA K, 1979, J BACTERIOL, V137, P595, DOI 10.1128/JB.137.1.595-604.1979; NEWTON WA, 1964, P NATL ACAD SCI USA, V51, P382, DOI 10.1073/pnas.51.3.382; NIHIRA T, 1979, EUR J BIOCHEM, V101, P341, DOI 10.1111/j.1432-1033.1979.tb19726.x; PHILLIPS RS, 1990, BIOCHEMISTRY-US, V29, P8608, DOI 10.1021/bi00489a016; PHILLIPS RS, 1989, J BIOL CHEM, V264, P10627; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARSERO JP, 1991, J BACTERIOL, V173, P3231, DOI 10.1128/JB.173.10.3231-3234.1991; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMARD C, 1975, CAN J MICROBIOL, V21, P841, DOI 10.1139/m75-125; SIMARD C, 1975, CAN J MICROBIOL, V21, P828, DOI 10.1139/m75-123; SIMPSON RB, 1980, NUCLEIC ACIDS RES, V8, P759; SMITH OH, 1962, METHOD ENZYMOL, V5, P794, DOI 10.1016/S0076-6879(62)05315-X; SNELL EE, 1975, ADV ENZYMOL RAMB, V42, P287; STEWART V, 1986, J BACTERIOL, V166, P217, DOI 10.1128/jb.166.1.217-223.1986; STEWART V, 1986, J BACTERIOL, V167, P383, DOI 10.1128/jb.167.1.383-386.1986; STEWART V, 1985, J BACTERIOL, V164, P731, DOI 10.1128/JB.164.2.731-740.1985; SUBBIAH S, 1989, J MOL BIOL, V209, P539, DOI 10.1016/0022-2836(89)90592-5; SUELTER CH, 1976, FEBS LETT, V66, P230, DOI 10.1016/0014-5793(76)80510-8; TAWATA Y, 1991, FEBS LETT, V284, P270; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WOOKEY PJ, 1991, J BACTERIOL, V170, P4946; YANOFSKY C, 1991, J BACTERIOL, V173, P6009, DOI 10.1128/jb.173.19.6009-6017.1991; YOSHIDA H, 1974, FEBS LETT, V48, P56, DOI 10.1016/0014-5793(74)81061-6; ZUBAY G, 1970, LACTOSE OPERON	45	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19978	19985						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400314				2022-12-27	WOS:A1992JR85800039
J	ZUTTER, MM; FONG, AM; KRIGMAN, HR; SANTORO, SA				ZUTTER, MM; FONG, AM; KRIGMAN, HR; SANTORO, SA			DIFFERENTIAL REGULATION OF THE ALPHA-2-BETA-1 AND ALPHA-IIB BETA-3 INTEGRIN GENES DURING MEGAKARYOCYTIC DIFFERENTIATION OF PLURIPOTENTIAL K562 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIIA; FIBRONECTIN RECEPTOR; TRANSCRIPTIONAL REGULATION; TERMINAL DIFFERENTIATION; DECREASED EXPRESSION; ADHESION RECEPTORS; MEMBRANE-RECEPTORS; LINE; SUBUNIT; ALPHA-5-BETA-1-INTEGRIN	Expression of the alpha2beta1 and alpha(IIb)beta3 integrin genes is differentially regulated during megakaryocytic differentiation of pluripotent K562 cells induced with phorbol 12,13-dibutyrate. Upon megakaryocytic differentiation, steady-state alpha2 mRNA increased markedly from the undetectable level present in the uninduced cells. The level of beta1 mRNA did not change. Expression of alpha(IIb)beta3 is regulated differently. Beta3 mRNA was undetectable in uninduced cells but increased significantly following induction. Alpha(IIb) mRNA was detectable at a low level prior to induction, but at an increased level following differentiation. Altered mRNA stability did not contribute to changes in mRNA levels. Nuclear run-off experiments revealed a 20-fold increase in alpha2 gene transcription upon megakaryocytic differentiation, but no change in transcription of the beta1 gene. Transcription of both the alpha(IIb) and beta3 genes increased 10- and 5-fold, respectively. Thus, the increase in alpha2beta1 protein which accompanies the megakaryocytic differentiation of K562 cells is a consequence of the increased steady-state level of alpha2 mRNA due to transcriptional activation of the alpha2 gene. The long-lived beta1 mRNA is not altered during differentiation. In contrast, increased alpha(IIb)beta3 protein appears due to increased steady-state levels of both alpha(IIb) and beta3 mRNAs that result from transcriptional activation of both integrin genes.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,BOX 8118,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [T32 HL07038, HL 40506] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040506, T32HL007038] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AGURA ED, 1992, BLOOD, V79, P602; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; ALBELDA SM, 1990, CANCER RES, V50, P6757; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BROWER DL, 1989, NATURE, V342, P285, DOI 10.1038/342285a0; BURGER SR, 1992, IN PRESS EXP CELL RE; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN WT, 1986, J CELL BIOL, V103, P1073, DOI 10.1083/jcb.103.3.1073; CLARK RAF, 1990, J INVEST DERMATOL, V94, pS128, DOI 10.1111/1523-1747.ep12876104; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Davis L, 1986, BASIC METHODS MOL BI, P51; DEDHAR S, 1989, J CELL PHYSIOL, V138, P291, DOI 10.1002/jcp.1041380210; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GILTAY JC, 1988, BLOOD, V71, P1171; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HEINO J, 1989, J BIOL CHEM, V264, P380; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HICKSTEIN DD, 1988, J BIOL CHEM, V263, P13863; HICKSTEIN DD, 1989, J BIOL CHEM, V264, P21812; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KORETZ K, 1991, AM J PATHOL, V138, P741; LEARY JF, 1987, LEUKEMIA RES, V11, P807, DOI 10.1016/0145-2126(87)90065-8; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOZZIO BB, 1979, LEUKEMIA RES, V3, P363, DOI 10.1016/0145-2126(79)90033-X; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; UZAN G, 1991, J BIOL CHEM, V266, P8932; VOLK T, 1990, CELL, V63, P525, DOI 10.1016/0092-8674(90)90449-O; ZIMRIN AB, 1988, J CLIN INVEST, V81, P1470, DOI 10.1172/JCI113478; ZUTTER MM, 1990, AM J PATHOL, V137, P863	48	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20233	20238						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400341				2022-12-27	WOS:A1992JR85800077
J	HIZI, A; SHAHARABANY, M				HIZI, A; SHAHARABANY, M			FUNCTIONAL-ANALYSIS OF NOVEL SELECTIVE MUTANTS OF THE REVERSE-TRANSCRIPTASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA-POLYMERASE; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; H ACTIVITIES; RIBONUCLEASE; MUTAGENESIS; EXPRESSION; DOMAIN; PREDICTIONS	We have generated by site-directed mutagenesis plasmids that induce the synthesis of specific mutants of the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1). These recombinant mutants of HIV-1 RT, designed on the basis of our previous studies of HIV-1 and HIV-2 RTs, were analyzed for structure-function relationship by assessing their RNA-dependent and DNA-dependent DNA polymerase as well as the ribonuclease H activities. Three groups of mutants were studied. 1) We have investigated the importance of the only two sets of highly conserved double prolines found in the sequence of HIV-1 RT. The results indicate that the conversion of either one or both prolines (at positions 225 and 226) to threonines have no significant effect on all catalytic activities of the enzyme. The mutants in which prolines 419 and 420 were individually modified to threonines exhibit full activities, whereas the double proline 419/420 mutant lost most of its RNase H activity (although the DNA polymerase function was fully retained). 2) We have deleted phenylalanine 346 from HIV-1 RT, which is absent in wild type HIV-2 RT. This mutant of HIV-1 RT lost practically all catalytic activities. 3) A mutant of HIV-1 RT in which a cysteine residue substituted for alanine 446, was found to be slightly hyperactive for both DNA polymerase and RNase H activities.			HIZI, A (corresponding author), TEL AVIV UNIV,SACKLER SCH MED,DEPT CELL BIOL & HISTOL,IL-69978 TEL AVIV,ISRAEL.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027035] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27035] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HIZI A, 1992, J BIOL CHEM, V267, P1293; HIZI A, 1991, VIROLOGY, V180, P339, DOI 10.1016/0042-6822(91)90038-D; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1991, J BIOL CHEM, V266, P6230; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; MULLER B, 1991, J BIOL CHEM, V266, P14709; MYERS G, 1991, HUMAN RETROVIRUSES A; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHAHARABANY M, 1991, AIDS RES HUM RETROV, V7, P883, DOI 10.1089/aid.1991.7.883; SHAHARABANY M, 1992, J BIOL CHEM, V267, P3674; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; VARMUS H, 1989, MOBILE DNA, P53; Weiss R, 1985, RNA TUMOR VIRUSES	23	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18255	18258						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382052				2022-12-27	WOS:A1992JN50200002
J	LIN, JJ; SANCAR, A				LIN, JJ; SANCAR, A			ACTIVE-SITE OF (A)BC EXCINUCLEASE .1. EVIDENCE FOR 5' INCISION BY UVRC THROUGH A CATALYTIC SITE INVOLVING ASP399, ASP438, ASP466, AND HIS538 RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; ESCHERICHIA-COLI; 3'-5' EXONUCLEASE; ABC EXCINUCLEASE; MECHANISM; NUCLEASE; PROTEIN; COMPLEX; REPAIR; PURIFICATION	(A)BC excinuclease of Escherichia coli removes damaged nucleotides from DNA by hydrolyzing the 8th phosphodiester bond 5' and the 5th phosphodiester bond 3' to the modified base. The activity results from the ordered action of UvrA, UvrB, and UvrC proteins. The role of UvrA is to help assemble the UvrB.DNA complex, and it is not involved in the actual incision reactions which are carried out by UvrB and UvrC. To investigate the role of UvrC in the nuclease activity a subset of His, Asp, and Glu residues in the C-terminal half of the protein were mutagenized in vitro. The effect of these mutations on UV resistance in vivo and incision activity in vitro were investigated. Mutations, H538F, D399A, D438A, and D466A conferred extreme UV sensitivity. Enzyme reconstituted with these mutant proteins carried out normal 3' incision but was completely defective in 5' incision activity. Our data suggest that UvrC makes the 5' incision by employing a mechanism whereby the three carboxylates acting in concert with H538 and a Mg2+ ion facilitate nucleophilic attack by an active site water molecule.			LIN, JJ (corresponding author), UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.		Lin, Jing-Jer/G-8068-2015	LIN, JING-JER/0000-0001-8250-7398	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; CHEN NY, 1989, J GEN MICROBIOL, V135, P2931; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DEUTSCH WA, 1976, J BACTERIOL, V125, P220, DOI 10.1128/JB.125.1.220-224.1976; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAHM A, 1991, NUCLEIC ACIDS MOL BI, V5, P171; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6824, DOI 10.1073/pnas.88.15.6824; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NISHIKAWA S, 1987, BIOCHEMISTRY-US, V26, P8620, DOI 10.1021/bi00400a019; OGAWA H, 1968, MOL GEN GENET, V101, P227, DOI 10.1007/BF00271625; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; RUPP WD, 1968, J MOL BIOL, V31, P292; Saenger W, 1991, CURR OPIN STRUC BIOL, V1, P130, DOI 10.1016/0959-440X(91)90021-K; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCAR GB, 1984, NUCLEIC ACIDS RES, V12, P4593, DOI 10.1093/nar/12.11.4593; SEEBERG E, 1982, P NATL ACAD SCI-BIOL, V79, P988, DOI 10.1073/pnas.79.4.988; SEEBERG E, 1980, J BACTERIOL, V144, P97, DOI 10.1128/JB.144.1.97-104.1980; SELBY CP, 1988, BIOCHEMISTRY-US, V27, P7184, DOI 10.1021/bi00419a004; STRYER L, 1988, BIOCHEMISTRY-US, P219; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; TANG MS, 1985, J BACTERIOL, V161, P933, DOI 10.1128/JB.161.3.933-938.1985; TANG MS, 1991, J MOL BIOL, V220, P855, DOI 10.1016/0022-2836(91)90358-D; THIELKING V, 1991, BIOCHEMISTRY-US, V30, P6416, DOI 10.1021/bi00240a011; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; WEBER DJ, 1991, BIOCHEMISTRY-US, V30, P6103, DOI 10.1021/bi00239a004; XU SY, 1991, J BIOL CHEM, V266, P4425	37	113	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17688	17692						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387639				2022-12-27	WOS:A1992JM22300034
J	MORREAU, H; GALJART, NJ; WILLEMSEN, R; GILLEMANS, N; ZHOU, XY; DAZZO, A				MORREAU, H; GALJART, NJ; WILLEMSEN, R; GILLEMANS, N; ZHOU, XY; DAZZO, A			HUMAN LYSOSOMAL PROTECTIVE PROTEIN - GLYCOSYLATION, INTRACELLULAR-TRANSPORT, AND ASSOCIATION WITH BETA-GALACTOSIDASE IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER KIDNEY-CELLS; GLYCOPROTEIN DEGRADATION; HUMAN-FIBROBLASTS; MOLECULAR-WEIGHT; CATHEPSIN-D; RAT-LIVER; NEURAMINIDASE; CDNA; EXPRESSION; CLONING	In lysosomes beta-galactosidase and neuraminidase acquire a stable and active conformation through their association with the protective protein. The latter is homologous to serine carboxypeptidases and has cathepsin A-like activity which is distinct from its protective function towards the two glycosidases. To define signals in the human protective protein important for its intracellular transport, and to determine the site of its association with beta-galactosidase, we have generated a set of mutated protective protein cDNAs carrying targeted base substitutions. These mutants were either singly transfected into COS-1 cells or cotransfected together with wild type human beta-galactosidase. We show that all point mutations cause either a complete or partial retention of the protective protein precursor in the endoplasmic reticulum. This abnormal accumulation leads to degradation of the mutant proteins probably in this compartment. Only the oligosaccharide chain on the 32-kDa subunit acquires the mannose 6-phosphate recognition marker, the one on the 20-kDa subunit seems to be merely essential for the stability of the mature protein. In cotransfection experiments, wild type beta-galactosidase and protective protein appear to assemble already as precursors, soon after synthesis, in the endoplasmic reticulum. Mutated protective protein precursors that are retained in the endoplasmic reticulum or pre-Golgi complex interact with and withhold normal beta-galactosidase molecules in the same compartments, thereby preventing their normal routing.	ERASMUS UNIV,CTR MED GENET,DEPT CELL BIOL & GENET,POB 1738,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam			Galjart, Niels/D-1146-2010; zhou, xingyu/GXF-7454-2022	Galjart, Niels/0000-0003-1964-3607; 				BREDDAM K, 1986, CARLSBERG RES COMMUN, V51, P83, DOI 10.1007/BF02907561; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; DONG JM, 1989, J BIOL CHEM, V264, P7377; FRISCH A, 1981, J BIOL CHEM, V256, P8242; GALJAARD H, 1980, GENETIC METABOLIC DI; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; HORST M, 1991, BIOCHEM J, V273, P355, DOI 10.1042/bj2730355; ISIDORO C, 1991, BIOCHEM J, V273, P363, DOI 10.1042/bj2730363; JACKMAN HL, 1992, J BIOL CHEM, V267, P2872; JACKMAN HL, 1990, J BIOL CHEM, V265, P11265; LAU MMH, 1989, J BIOL CHEM, V264, P21376; LAZZARINO DA, 1988, J BIOL CHEM, V263, P10118; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MORREAU H, 1989, J BIOL CHEM, V264, P20655; MURPHY G, 1988, NUCLEIC ACIDS RES, V16, P5198, DOI 10.1093/nar/16.11.5198; NANBA E, 1990, BIOCHEM BIOPH RES CO, V173, P141, DOI 10.1016/S0006-291X(05)81033-2; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OSHIMA A, 1988, BIOCHEM BIOPH RES CO, V157, P238, DOI 10.1016/S0006-291X(88)80038-X; PALMERI S, 1986, AM J HUM GENET, V38, P137; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; POTIER M, 1990, BIOCHEM J, V267, P197, DOI 10.1042/bj2670197; PROIA RL, 1984, J BIOL CHEM, V259, P3350; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIBE R, 1990, BIOMED BIOCHIM ACTA, V49, P547; SEGAL HL, 1984, CURR TOP CELL REGUL, V24, P229; TAYLOR S, 1973, ANAL BIOCHEM, V56, P140, DOI 10.1016/0003-2697(73)90178-4; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VERHEIJEN F, 1982, BIOCHEM BIOPH RES CO, V108, P868, DOI 10.1016/0006-291X(82)90911-1; VERHEIJEN FW, 1985, EUR J BIOCHEM, V149, P315, DOI 10.1111/j.1432-1033.1985.tb08928.x; WILLEMSEN R, 1986, EUR J CELL BIOL, V40, P9; WINKLER JR, 1984, J BIOL CHEM, V259, P5369; YAMAMOTO Y, 1987, INT J BIOCHEM, V19, P435, DOI 10.1016/0020-711X(87)90064-4; YAMAMOTO Y, 1990, DNA CELL BIOL, V9, P119, DOI 10.1089/dna.1990.9.119; YAMAMOTO Y, 1982, J BIOCHEM, V92, P13, DOI 10.1093/oxfordjournals.jbchem.a133910; ZHOU XY, 1991, EMBO J, V10, P4041, DOI 10.1002/j.1460-2075.1991.tb04980.x	42	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17949	17956						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387645				2022-12-27	WOS:A1992JM22300072
J	FARSETTI, A; DESVERGNE, B; HALLENBECK, P; ROBBINS, J; NIKODEM, VM				FARSETTI, A; DESVERGNE, B; HALLENBECK, P; ROBBINS, J; NIKODEM, VM			CHARACTERIZATION OF MYELIN BASIC-PROTEIN THYROID-HORMONE RESPONSE ELEMENT AND ITS FUNCTION IN THE CONTEXT OF NATIVE AND HETEROLOGOUS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIC ENZYME GENE; RETINOIC-ACID; NUCLEAR RECEPTORS; BINDING; TRANSCRIPTION; EXPRESSION; CELLS; BRAIN	In this report we have characterized further the myelin basic protein (MBP) gene thyroid hormone response element (TRE) by functional and binding analysis. Mutation and deletion experiments revealed that this TRE, confined to the sequences -184 to -167 of the MBP promoter, is able to function as a classical regulatory element in the context of the native and a heterologous promoter. it is comprised of two regions, containing a motif that is highly conserved among other TREs: AGGACA, arranged as an inverted palindrome. Any mutation within the footprinted region impaired receptor binding and function. Moreover, the deletion of sequences outside of the receptor footprinted region (MBP-TRE-18) resulted in a higher triiodothyronine responsiveness and a concomitant increase in receptor-dependent, hormone-independent repression. Results of transfection assays showed that both receptors alpha and beta-elicit indistinguishable triiodothyronine responses when the MBP-TRE functions as a regulator of a heterologous promoter activity. However, a preferential beta-receptor transactivation was observed when the MBP-TRE was placed in the context of its native promoter.	NIDDKD,GENET & BIOCHEM BRANCH,BLDG 10,RM 8N317,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Farsetti, Antonella/I-8710-2018; Desvergne, Beatrice/C-8892-2016	Farsetti, Antonella/0000-0002-8603-7925; Desvergne, Beatrice/0000-0001-5483-288X				BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARBARESE E, 1978, J NEUROCHEM, V31, P779, DOI 10.1111/j.1471-4159.1978.tb00110.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PETTY KJ, 1989, J BIOL CHEM, V264, P11483; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAP J, 1989, NATURE, V340, P342; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZELLER NK, 1984, P NATL ACAD SCI-BIOL, V81, P18, DOI 10.1073/pnas.81.1.18	32	148	150	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15784	15788						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379237				2022-12-27	WOS:A1992JG11300080
J	YU, YG; WEISS, RL				YU, YG; WEISS, RL			ARGININE TRANSPORT IN MITOCHONDRIA OF NEUROSPORA-CRASSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; VACUOLAR MEMBRANE; WILD-TYPE; ORNITHINE; LOCALIZATION; POKY	Transport of arginine into mitochondria of Neurospora crassa has been studied. Arginine transport was found to be saturable (K(m) = 6.5 mM) and to have a pH optimum of pH 7.5. Mitochondrial arginine transport appeared to be facilitated transport rather than active transport because: (i) the arginine concentration within the mitochondrial matrix after transport was similar to that of the reaction medium, and (ii) uncouplers and substrates of oxidative phosphorylation did not affect the transport rate. The basic amino acids ornithine, lysine, and D-arginine inhibited arginine transport. The arginine transport system could be irreversibly blocked by treating mitochondria with the reactive arginine derivative, N-nitrobenzyloxycarbonyl-arginyl diazomethane.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036552] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36552] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON DL, 1981, BIOCHEMISTRY-US, V20, P7064, DOI 10.1021/bi00528a002; BASABE JR, 1976, ANAL BIOCHEM, V92, P356; BORKOVICH KA, 1987, J BIOL CHEM, V262, P7081; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYLA J, 1977, FEBS LETT, V72, P331; COTY WA, 1974, J BIOL CHEM, V249, P2593; CRAMER CL, 1983, ANAL BIOCHEM, V128, P384, DOI 10.1016/0003-2697(83)90390-1; CYBIS J, 1975, J BACTERIOL, V123, P196, DOI 10.1128/JB.123.1.196-202.1975; DAVIS RH, 1988, TRENDS BIOCHEM SCI, V13, P101, DOI 10.1016/0968-0004(88)90050-3; DAVIS RH, 1962, ARCH BIOCHEM BIOPHYS, V97, P185, DOI 10.1016/0003-9861(62)90063-2; DAVIS RH, 1983, J BACTERIOL, V154, P1046, DOI 10.1128/JB.154.3.1046-1053.1983; GAMBLE JG, 1973, J BIOL CHEM, V248, P610; HINDE RW, 1986, J BIOL CHEM, V261, P5848; HOMMES FA, 1983, BIOCHEM MED METAB B, V30, P313, DOI 10.1016/0006-2944(83)90022-4; KADOWAKI H, 1976, BIOCHIM BIOPHYS ACTA, V437, P158, DOI 10.1016/0304-4165(76)90357-3; KATKOCIN DM, 1976, J BACTERIOL, V127, P1270, DOI 10.1128/JB.127.3.1270-1277.1976; KELLER DM, 1968, BIOCHIM BIOPHYS ACTA, V153, P113, DOI 10.1016/0005-2728(68)90151-5; KWONG E, 1982, J NUTR, V112, P2081; LAMBOWITZ AM, 1972, J BIOL CHEM, V247, P4850; LAMBOWITZ AM, 1972, J BIOL CHEM, V247, P4859; MCGIVAN JD, 1977, BIOCHEM J, V162, P147, DOI 10.1042/bj1620147; PAEK YL, 1989, J BIOL CHEM, V264, P7285; SHIH VE, 1981, J INHERIT METAB DIS, V4, P95, DOI 10.1007/BF02263608; SUBRAMANIAN KN, 1973, J BACTERIOL, V115, P284, DOI 10.1128/JB.115.1.284-290.1973; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; WEISS RL, 1976, J BACTERIOL, V126, P1173, DOI 10.1128/JB.126.3.1173-1179.1976; WEISS RL, 1973, J BIOL CHEM, V248, P5409; WOLF EC, 1980, J BIOL CHEM, V255, P9189; ZEREZ CR, 1986, J BIOL CHEM, V261, P8877	29	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15491	15495						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386360				2022-12-27	WOS:A1992JG11300038
J	ZWIEB, C				ZWIEB, C			RECOGNITION OF A TETRANUCLEOTIDE LOOP OF SIGNAL RECOGNITION PARTICLE RNA BY PROTEIN-SRP19	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7SL RNA; ESCHERICHIA-COLI; CENTRAL DOMAIN; RIBOSOMAL-RNA; 4.5S RNA; SRP-RNA; SEQUENCE; BINDING; TRANSLOCATION; COMPONENT	The interaction of protein SRP19 with the RNA component of human signal recognition particle (SRP) was studied by site-directed mutagenesis of the SRP RNA. The effects of nucleotide changes in the tetranucleotide loop (tetraloop) of helix 6 showed that SRP19 recognizes a tetraloop in a sequence-specific manner. Adenosine 149 at the third position of the tetraloop was essential for binding. In contrast, changes of the base at the second position had no effect. Mutations that disrupt or compensate individual SRP RNA helices were generated to investigate the importance of base pairing and to identify other binding sites. Considerable base pairing was essential in helix 6. Another SRP19-binding site was located in the distal part of helix 8. The primary sequences of the tetraloop-binding protein SRP19 and of bacterial ribosomal protein S15 are shown to be similar.			ZWIEB, C (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MOLEC BIOL, HIGHWAY 271 N, POB 2003, TYLER, TX 75710 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005958] Funding Source: NIH RePORTER; NCRR NIH HHS [2-S07-RR-05958-04] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDREAZZOLI M, 1991, EMBO J, V10, P767, DOI 10.1002/j.1460-2075.1991.tb08008.x; ANDREWS DW, 1987, EMBO J, V6, P3471, DOI 10.1002/j.1460-2075.1987.tb02671.x; ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901; ARNDT E, 1986, FEBS LETT, V194, P227, DOI 10.1016/0014-5793(86)80090-4; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; GUNDELFINGER ED, 1983, NUCLEIC ACIDS RES, V11, P7363, DOI 10.1093/nar/11.21.7363; GUNDELFINGER ED, 1984, EMBO J, V3, P2325, DOI 10.1002/j.1460-2075.1984.tb02134.x; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; HELD WA, 1974, J BIOL CHEM, V249, P3103; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P9431, DOI 10.1093/nar/16.20.9431; MANIATIS T, 1982, MOL CLONING LABORATO, P173; Maxam A M, 1980, Methods Enzymol, V65, P499; MIZUSHIMA S, 1970, NATURE, V226, P1214, DOI 10.1038/2261214a0; MORINAGA T, 1976, FEBS LETT, V64, P307, DOI 10.1016/0014-5793(76)80316-X; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PREHN S, 1987, EMBO J, V6, P2093, DOI 10.1002/j.1460-2075.1987.tb02475.x; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P2719, DOI 10.1093/nar/16.6.2719; SVENSSON P, 1988, J MOL BIOL, V200, P301, DOI 10.1016/0022-2836(88)90242-2; UHLENBECK OC, 1990, NATURE, V346, P613, DOI 10.1038/346613a0; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; ZWIEB C, 1988, ENDOCYT CELL RES, V5, P327; ZWIEB C, 1991, NUCLEIC ACIDS RES, V19, P2955, DOI 10.1093/nar/19.11.2955; ZWIEB C, 1989, BIOCHEM CELL BIOL, V67, P434, DOI 10.1139/o89-069; ZWIEB C, 1991, BIOCHEM CELL BIOL, V69, P649, DOI 10.1139/o91-096; ZWIEB C, 1986, NUCLEIC ACIDS RES, V14, P4639, DOI 10.1093/nar/14.11.4639; ZWIEB C, 1991, BIOMETHODS, V5, P245; ZWIEB C, 1989, PROG NUCLEIC ACID RE, V37, P207	39	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15650	15656						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379233				2022-12-27	WOS:A1992JG11300062
J	FOLKMAN, J; SHING, Y				FOLKMAN, J; SHING, Y			ANGIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FIBROBLAST GROWTH-FACTOR; ENDOTHELIAL-CELL MITOGEN; VASCULAR-PERMEABILITY FACTOR; TUMOR NECROSIS FACTOR; BOVINE BRAIN; EXTRACELLULAR-MATRIX; FACTOR-ALPHA; NEOVASCULARIZATION INVIVO; DNA-SYNTHESIS; ACIDIC FGF		HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	FOLKMAN, J (corresponding author), CHILDRENS HOSP MED CTR,DEPT SURG,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003557] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BAIRD A, 1991, FIBROBLAST GROWTH FA, V638; BANDA MJ, 1982, P NATL ACAD SCI-BIOL, V79, P7773, DOI 10.1073/pnas.79.24.7773; BENEZRA D, 1978, AM J OPHTHALMOL, V86, P455, DOI 10.1016/0002-9394(78)90289-1; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BICKNELL R, 1989, P NATL ACAD SCI USA, V86, P1573, DOI 10.1073/pnas.86.5.1573; BICKNELL R, 1988, P NATL ACAD SCI USA, V85, P5961, DOI 10.1073/pnas.85.16.5961; BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; BREM SS, 1990, AM J PATHOL, V137, P1121; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DENEKAMP J, 1991, RADIOTHER ONCOL, V1, P103; DERYNCK R, 1990, MOL REPROD DEV, V27, P3, DOI 10.1002/mrd.1080270104; DOBSON DE, 1990, CELL, V61, P223, DOI 10.1016/0092-8674(90)90803-M; DUSSEAU JW, 1986, CIRC RES, V59, P163, DOI 10.1161/01.RES.59.2.163; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; DVORAK HF, 1988, AM J PATHOL, V133, P95; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; EZEKOWITZ RAB, 1992, NEW ENGL J MED, V326, P1456, DOI 10.1056/NEJM199205283262203; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; FOLKMAN J, 1990, Journal of Cell Biology, V111, p223A; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FOLKMAN J, 1991, ANN SURG, V214, P414, DOI 10.1097/00000658-199110000-00006; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; FOLKMAN J, 1987, NATURE, V329, P671, DOI 10.1038/329671a0; Folkman J., 1987, THROMB DIATH HAEMO, P583; FOLKMAN J, 1991, BIOL THERAPY CANCER, P743; FOLKMAN J, 1992, IN PRESS CANCER MED; FORM DM, 1983, P SOC EXP BIOL MED, V172, P214; FRASER RA, 1979, CURRENT ADV BASIC CL, P29; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; FUJIMOTO K, 1991, BIOCHEM BIOPH RES CO, V180, P386, DOI 10.1016/S0006-291X(05)81305-1; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; Gospodarowicz D, 1990, Curr Top Dev Biol, V24, P57, DOI 10.1016/S0070-2153(08)60084-8; GRAEBER JE, 1990, PROSTAGLANDINS, V39, P665, DOI 10.1016/0090-6980(90)90026-R; GROSS J L, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P79; HORI A, 1991, CANCER RES, V51, P6180; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIMMELMAN D, 1987, CELL, V51, P869; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; KULL FC, 1987, SCIENCE, V236, P843, DOI 10.1126/science.2437656; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LOBB RR, 1985, BIOCHEMISTRY-US, V24, P4969, DOI 10.1021/bi00340a001; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MASFERRER JL, 1991, EXP EYE RES, V52, P417, DOI 10.1016/0014-4835(91)90037-F; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MOSCATELLI D, 1991, ANN NY ACAD SCI, V638, P177, DOI 10.1111/j.1749-6632.1991.tb49028.x; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; NGUYEN M, 1991, Journal of Cell Biology, V115, p69A; ODEDRA R, 1991, PHARMACOL THERAPEUT, V49, P111, DOI 10.1016/0163-7258(91)90025-H; OIKAWA T, 1992, JPN J CANCER RES, V3, P6; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; PAPRAEGER AC, 1991, SCIENCE, V252, P1705; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PEPPER MS, 1992, ANGIOGENESIS KEY PRI, P137; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; POLVERINI PJ, 1984, LAB INVEST, V51, P635; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; RAJU KS, 1984, CANCER RES, V44, P1579; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROBSON MC, 1992, IN PRESS ANN SURG; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; Rosenthal RA, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011010; SACHS L, 1990, CANCER-AM CANCER SOC, V65, P2196, DOI 10.1002/1097-0142(19900515)65:10<2196::AID-CNCR2820651006>3.0.CO;2-Y; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCHULZEOSTHOFF K, 1990, AM J PATHOL, V137, P85; SEDDON A, 1991, ANN NY ACAD SCI, V638, P98, DOI 10.1111/j.1749-6632.1991.tb49021.x; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SHING Y, 1983, J CELL BIOL, V97, pA395; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SHING Y, 1990, ANAL BIOCHEM, V185, P108, DOI 10.1016/0003-2697(90)90263-9; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHING Y, 1988, J BIOL CHEM, V263, P9059; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; STCLAIR DK, 1987, P NATL ACAD SCI USA, V84, P8330; STEINER R, 1992, ANGIOGENESIS KEY PRI; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; THOMAS KA, 1984, P NATL ACAD SCI-BIOL, V81, P357, DOI 10.1073/pnas.81.2.357; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TOGARI A, 1985, J NEUROSCI, V5, P307; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WAGNER JA, 1986, J CELL BIOL, V103, P1363, DOI 10.1083/jcb.103.4.1363; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Whalen GF, 1989, GROWTH FACTORS, V1, P157, DOI 10.3109/08977198909029125; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZICHE M, 1982, JNCI-J NATL CANCER I, V69, P475	113	3199	3595	1	177	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10931	10934						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375931				2022-12-27	WOS:A1992HX16900001
J	POWERS, PA; LIU, SY; HOGAN, K; GREGG, RG				POWERS, PA; LIU, SY; HOGAN, K; GREGG, RG			SKELETAL-MUSCLE AND BRAIN ISOFORMS OF A BETA-SUBUNIT OF HUMAN VOLTAGE-DEPENDENT CALCIUM CHANNELS ARE ENCODED BY A SINGLE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DIHYDROPYRIDINE RECEPTOR; PROTEIN-KINASE; FUNCTIONAL EXPRESSION; VERTEBRATE CELLS; GAMMA-SUBUNIT; PHOSPHORYLATION; CDNA; ALPHA-1-SUBUNIT; CLONING	Clones of the beta1-subunit of the voltage-dependent calcium channel (VDCC) from human skeletal muscle and hippocampus cDNA libraries, and from human genomic libraries, were isolated using a human skeletal muscle beta1 cDNA probe generated by polymerase chain reaction. The skeletal muscle beta1 cDNA (beta1M) encodes a protein of 523 amino acids that is 97% identical to the rabbit skeletal muscle beta-subunit. Two different cDNAs, beta1B1 and beta1B2, were obtained from the human hippocampus library. The beta1B1 transcript encodes a protein of 478 amino acids that is identical to the skeletal muscle beta-subunit (beta1M), except for an internal region of 52 amino acids. The beta1B2 transcript encodes a protein of 596 amino acids. The beta1B2 polypeptide is identical to the beta1B1 polypeptide at amino acids 1-444; however, it has a unique 152 amino acid carboxyl terminus. Like beta1B1, it differs from beta1M at the internal 52 amino acids. Analysis of the beta1 gene structure demonstrates that these three cDNAs represent transcripts encoded by a single beta1 gene. Transcripts from the beta1 gene were detected in RNA from skeletal muscle, heart, spleen, and brain, but not in RNA from liver, stomach, or kidney.	UNIV WISCONSIN,DEPT PEDIAT,MADISON,WI 53706; UNIV WISCONSIN,WAISMAN CTR MENTAL RETARDAT & HUMAN DEV,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	POWERS, PA (corresponding author), UNIV WISCONSIN,DEPT ANESTHESIOL,MADISON,WI 53706, USA.			Gregg, Ronald/0000-0001-5805-224X				ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER CL, 1987, J BIOL CHEM, V262, P509; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; Hille B, 1984, IONIC CHANNELS EXCIT; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; IMAGAWA T, 1987, J BIOL CHEM, V262, P8333; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q	37	77	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22967	22972						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385409				2022-12-27	WOS:A1992JY16300042
J	MALCOLM, KC; FITZPATRICK, FA				MALCOLM, KC; FITZPATRICK, FA			EPOXYEICOSATRIENOIC ACIDS INHIBIT CA2+ ENTRY INTO PLATELETS STIMULATED BY THAPSIGARGIN AND THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROLEUKEMIA-CELLS; ARACHIDONIC-ACID; INTRACELLULAR CALCIUM; MESANGIAL CELLS; PLASMA-MEMBRANE; HEL CELLS; EPOXYGENASE; METABOLITES; MOBILIZATION; AGGREGATION	The epoxyeicosatrienoic acids derived from the cytochrome P-450 pathway of arachidonic acid metabolism have a unique platelet antiaggregatory profile. This prompted us to examine their influence on cellular Ca2+ mobilization. 14,15-cis-Epoxyeicosatrienoic acid and related compounds inhibited the rise in cytosolic Ca2+ following agonist stimulation of platelets by thapsigargin, a receptor-independent agonist, and thrombin, a receptor-dependent agonist. The epoxyeicosatrienoic acids selectively inhibited the entry of Ca2+ from the exterior of the platelets but did not alter Ca2+ discharge from intracellular pools. The magnitude of inhibition by 14,15-cis-epoxyeicosatrienoic acid was proportional to the rate of Ca2+ entry. 14,15-cis-Epoxyeicosatrienoic acid also inhibited the rate of influx of Mn2+, a cation which enters platelets via pathways similar to Ca2+. The magnitude of inhibition was proportional to the rate of Mn2+ entry, suggesting that epoxyeicosatrienoic acids act on divalent cation channels in a fashion which depends on the state of opening of the channel. Selective inhibition of Ca2+ entry into platelets may account for the antiaggregatory effects of the epoxyeicosatrienoic acids. We are unaware of other endogenous compounds exhibiting this property, suggesting that epoxyeicosatrienoic acids may be useful to probe agonist-stimulated Ca2+ mobilization in nonexcitable cells.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL C-236, 4200 E 9TH AVE, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041026] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM41026] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTROM K, 1992, J BIOL CHEM, V267, P3686; BERNSTROM K, 1991, MOL PHARMACOL, V39, P114; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRASS LF, 1991, J BIOL CHEM, V266, P958; CAPDEVILA JH, 1987, BIOCHEM BIOPH RES CO, V146, P638, DOI 10.1016/0006-291X(87)90576-6; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; CHARO IF, 1976, BIOCHEM BIOPH RES CO, V72, P1462, DOI 10.1016/S0006-291X(76)80178-7; CONRAD GW, 1986, J CELL BIOL, V103, P439, DOI 10.1083/jcb.103.2.439; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; FITZPATRICK FA, 1986, J BIOL CHEM, V261, P5334; FORCE T, 1990, CLIN RES, V38, pA371; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALENDA SP, 1990, BIOCHEM J, V267, P479, DOI 10.1042/bj2670479; HALLAM TJ, 1985, J PHYSIOL-LONDON, V368, P131, DOI 10.1113/jphysiol.1985.sp015850; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; JONES DA, 1991, BIOCHEM BIOPH RES CO, V180, P8, DOI 10.1016/S0006-291X(05)81247-1; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KARARA A, 1990, FEBS LETT, V268, P227, DOI 10.1016/0014-5793(90)81014-F; KUTSKY P, 1983, PROSTAGLANDINS, V26, P13, DOI 10.1016/0090-6980(83)90070-9; LANIADOSCHWARTZMAN M, 1988, J BIOL CHEM, V263, P2536; MALCOLM KC, 1992, J PHARMACOL EXP THER, V260, P1244; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCGIFF JC, 1988, CLIN PHYSIOL BIOCH, V6, P179; MERRITT JE, 1988, J BIOL CHEM, V263, P6161; MUSTARD JF, 1989, METHOD ENZYMOL, V169, P3; OLIW EH, 1982, J BIOL CHEM, V257, P3771; OZAKI Y, 1992, CELL CALCIUM, V13, P19, DOI 10.1016/0143-4160(92)90026-O; PFISTER SL, 1991, AM J PHYSIOL, V261, pH843, DOI 10.1152/ajpheart.1991.261.3.H843; PRITCHARD KA, 1990, AM J PATHOL, V136, P1383; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RITTENHOUSESIMMONS S, 1977, J CLIN INVEST, V60, P495, DOI 10.1172/JCI108801; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SNYDER G, 1986, BIOCHEM BIOPH RES CO, V139, P1188, DOI 10.1016/S0006-291X(86)80303-5; SULDAN Z, 1991, BLOOD, V78, P2887; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; TOTO R, 1987, BIOCHIM BIOPHYS ACTA, V919, P132, DOI 10.1016/0005-2760(87)90199-8; YOSHIDA S, 1990, ARCH BIOCHEM BIOPHYS, V280, P346, DOI 10.1016/0003-9861(90)90340-5; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	43	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19854	19858						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400301				2022-12-27	WOS:A1992JR85800019
J	METSIS, M; CINTRA, A; SOLFRINI, V; ERNFORS, P; BORTOLOTTI, F; MORRASUTTI, DG; OSTENSON, CG; EFENDIC, S; AGERBERTH, B; MUTT, V; PERSSON, H; FUXE, K				METSIS, M; CINTRA, A; SOLFRINI, V; ERNFORS, P; BORTOLOTTI, F; MORRASUTTI, DG; OSTENSON, CG; EFENDIC, S; AGERBERTH, B; MUTT, V; PERSSON, H; FUXE, K			MOLECULAR-CLONING OF PEC-60 AND EXPRESSION OF ITS MESSENGER-RNA AND PEPTIDE IN THE GASTROINTESTINAL-TRACT AND IMMUNE-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN-INHIBITOR; SEQUENCE; RAT; ACID	The peptide PEC-60, structurally related to the pancreatic secretory trypsin inhibitor, inhibits glucose-induced insulin secretion. Here we report on the structure of a cDNA clone from pig duodenum encoding PEC-60. The cDNA encodes a 86-amino acid long precursor protein containing a 26-amino acid signal sequence, implying that the mature PEC-60 peptide is secreted from cells. Analysis of porcine duodenum demonstrated a high expression of a 0.6-kilobase long PEC-60 mRNA in this tissue, as well as the presence of strong PEC-60-like immunoreactivity in the cytoplasm of the majority of the goblet cells of the epithelium. High levels of PEC-60 mRNA were also found in the bone marrow and the peripheral blood and moderate levels in the spleen. A strong PEC-60-like immunoreactivity was localized in the monocytes of peripheral blood. Radioimmunoassay revealed high levels of pig PEC-60-like immunoreactivity in pig plasma suggesting that the PEC-60 peptide is efficiently released from cells. These findings imply that the gastrointestinal peptide PEC-60 is formed, stored, and secreted from monocytes present within the bone marrow and in the peripheral blood, indicating a role of the PEC-60 peptide in the immune system in addition to its function as a gastrointestinal peptide.	KAROLINSKA INST,DEPT HISTOL & NEUROBIOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT ENDOCRINOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT BIOCHEM,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	METSIS, M (corresponding author), KAROLINSKA INST,DEPT MED CHEM,MOLEC NEUROBIOL LAB,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.		Metsis, Madis/F-7080-2016	Metsis, Madis/0000-0003-1667-677X; Fuxe, Kjell/0000-0001-8491-4288				AGERBERTH B, 1989, P NATL ACAD SCI USA, V86, P8590, DOI 10.1073/pnas.86.21.8590; AHREN B, 1991, PANCREAS, V6, P324, DOI 10.1097/00006676-199105000-00010; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DESCHENES RJ, 1984, P NATL ACAD SCI-BIOL, V81, P726, DOI 10.1073/pnas.81.3.726; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERICSSON A, 1987, P NATL ACAD SCI USA, V84, P5585, DOI 10.1073/pnas.84.16.5585; FUKUOKA SI, 1989, NUCLEIC ACIDS RES, V17, P10111, DOI 10.1093/nar/17.23.10111; FUXE K, 1991, ACTA PHYSIOL SCAND, V143, P357, DOI 10.1111/j.1748-1716.1991.tb09244.x; FUXE K, 1990, 20TH ANN M SOC NEUR, V16, P800; GREENE LJ, 1969, J BIOL CHEM, V244, P2646; HOKFELT T, 1980, NATURE, V284, P515, DOI 10.1038/284515a0; ITOH N, 1983, NATURE, V304, P547, DOI 10.1038/304547a0; KAZAL LA, 1948, J AM CHEM SOC, V70, P3034, DOI 10.1021/ja01189a060; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Mutt V., 1988, ADV METAB DISORD, V11, P1; PERSSON H, 1988, NEUROPEPTIDE, P43; PROUDFOOT NJ, 1974, NATURE, V252, P359, DOI 10.1038/252359a0; SAID SI, 1988, ADV METAB DISORD, V11, P369; SAMBROOK J, 1990, MOL CLONING LABORATO; TSCHESCHE H, 1970, EUR J BIOCHEM, V16, P187, DOI 10.1111/j.1432-1033.1970.tb01071.x; UHL GR, 1986, IN SITU HYBRIDIZATIO; VANDERHAEGHEN JJ, 1975, NATURE, V257, P604, DOI 10.1038/257604a0; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; ZAMBONI L, 1967, J CELL BIOL, V35, P148	25	17	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19829	19832						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400298				2022-12-27	WOS:A1992JR85800015
J	TAMEMOTO, H; KADOWAKI, T; TOBE, K; UEKI, K; IZUMI, T; CHATANI, Y; KOHNO, M; KASUGA, M; YAZAKI, Y; AKANUMA, Y				TAMEMOTO, H; KADOWAKI, T; TOBE, K; UEKI, K; IZUMI, T; CHATANI, Y; KOHNO, M; KASUGA, M; YAZAKI, Y; AKANUMA, Y			BIPHASIC ACTIVATION OF 2 MITOGEN-ACTIVATED PROTEIN-KINASES DURING THE CELL-CYCLE IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; MAP KINASE; FIBROBLASTIC CELLS; SENSITIVE METHOD; XENOPUS OOCYTES; INSULIN; INVITRO; MATURATION	We studied mitogen-activated protein kinase (MAPK) activities during the cell cycle of Chinese hamster ovary (CHO) cells using site-specific antibodies against extracellular signal-regulated kinase-1, a 44-kDa MAPK (Boulton, T. G., Yancopoulos, G. D., Gregory, J. S., Slauer, C., Moomaw, C., Hsu, J., and Cobb, M. H. (1990) Science 249, 64-67). These antibodies detected two distinct MAPKs (44- and 42-kDa MAPKs) in CHO cells. CHO cells were arrested at metaphase in the M phase by treatment with nocodazole, and activities of MAPKs were analyzed at specific time points after release from arrest. Immune complex kinase assay and renaturation and phosphorylation assay in substrate-containing gel revealed that both 44- and 42-kDa MAPKs had activities in the G1 through S and G2/M phases and were activated biphasically, in the G1 phase and around the M phase. MAPKs were inactivated in metaphase-arrested cells. The amount of MAPKs did not change significantly in the cell cycle. In the G1, S, and G2/M phases, MAPKs were phosphorylated on both tyrosine and threonine residues and dephosphorylated in metaphase-arrested cells. Our data suggest that MAPKs may play some role in the cell cycle other than G0/G1 transition.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN; GIFU PHARMACEUT UNIV,DEPT BIOL,GIFU 502,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	University of Tokyo; Asahi Life Foundation; Gifu Pharmaceutical University; Kobe University								AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDO A, 1992, J BIOL CHEM, V267, P12788; AYN NG, 1990, J BIOL CHEM, V265, P11487; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HOSHI M, 1988, J BIOL CHEM, V263, P5396; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOBEY RA, 1967, J CELL PHYSIOL, V70, P63, DOI 10.1002/jcp.1040700109	31	143	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20293	20297						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400347				2022-12-27	WOS:A1992JR85800086
J	KOBAYASHI, S; HIGASHI, N; SUZUKI, K; GOTO, S; YUMOTO, K; ANZAI, K				KOBAYASHI, S; HIGASHI, N; SUZUKI, K; GOTO, S; YUMOTO, K; ANZAI, K			THE 10-S BC-1 RIBONUCLEOPROTEIN PARTICLE CONTAINS IDENTIFIER SEQUENCE-BINDING PROTEINS THAT INTERACT WITH AN ARRAY OF GCAAG/CTTGC MOTIFS BETWEEN SPLIT PROMOTER SEQUENCES FOR RNA POLYMERASE-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL BC1 RNA; TRANSCRIPTION FACTOR; 5S RNA; ENDOPLASMIC-RETICULUM; GENE-EXPRESSION; MESSENGER-RNA; BRAIN; ELEMENTS; REPEAT; CDNA	BC-1 RNA is a brain-specific small RNA transcript of identifier sequences present in the somas and dendrites of neurons. We recently reported that the RNA is complexed with a protein(s) to form a 10 S ribonucleoprotein particle (Kobayashi, S., Goto, S., and Anzai, K. (1991) J. Biol. Chem. 266, 4726-4730). We demonstrate here that this 10 S BC-1 ribonucleoprotein particle contains a DNA-binding protein(s) (Bp-1 protein) capable of interacting with a region between split promoter sequences for RNA polymerase III within the identifier sequences. The region has short inverted repeats: a perfect octanucleotide repeat (GCGCTTGCCTAGCAAGCGC) and an imperfect heptanucleotide repeat (GCCTAGCAAGCGCAAGGC), each of which contains a GCAAG/CTTGC motif. We also demonstrate that the binding of this protein either to the array of pentamer motifs or to BC-1 RNA is mutually exclusive. The molecular masses of photo-cross-linking adducts of Bp-1 protein to a P-32-labeled GCAAG/CTTGC motif-specific probe were estimated to be about 31 and 36 kDa, indicating that two species of Bp-1 proteins may be present in the brain.	NIHON UNIV,COLL PHARM,DIV BIOCHEM,FUNABASHI,CHIBA 274,JAPAN; TOHO UNIV,SCH PHARMACEUT SCI,DEPT BIOCHEM,MIYAMA,JAPAN	Nihon University; Toho University								ANZAI K, 1987, MECH AGEING DEV, V39, P129, DOI 10.1016/0047-6374(87)90004-2; ANZAI K, 1986, J NEUROCHEM, V47, P673; ANZAI K, 1988, MOL BRAIN RES, V4, P273, DOI 10.1016/0169-328X(88)90036-8; ANZAI K, 1987, MOL BRAIN RES, V2, P43, DOI 10.1016/0169-328X(87)90019-2; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CARBON P, 1991, EMBO J, V10, P599, DOI 10.1002/j.1460-2075.1991.tb07987.x; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHODOSH LA, 1987, CURRENT PROTOCOL MOL; DANIELS GR, 1985, NATURE, V317, P819, DOI 10.1038/317819a0; DECHIARA TM, 1987, P NATL ACAD SCI USA, V84, P2624, DOI 10.1073/pnas.84.9.2624; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FUNG WP, 1988, J BIOL CHEM, V263, P480; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KOBAYASHI S, 1991, J BIOL CHEM, V266, P4726; LAWRENCE CB, 1985, NUCLEIC ACIDS RES, V13, P4239, DOI 10.1093/nar/13.12.4239; LIAO XB, 1989, P NATL ACAD SCI USA, V86, P4137, DOI 10.1073/pnas.86.11.4137; Maniatis T, 1989, DECONTAMINATION DILU; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MCKINNON RD, 1987, MOL CELL BIOL, V7, P2148, DOI 10.1128/MCB.7.6.2148; MCKINNON RD, 1986, P NATL ACAD SCI USA, V83, P3751, DOI 10.1073/pnas.83.11.3751; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; RHODES D, 1986, CELL, V46, P123, DOI 10.1016/0092-8674(86)90866-4; SAKAMOTO K, 1985, J MOL EVOL, V22, P134, DOI 10.1007/BF02101691; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPIENZA C, 1986, NATURE, V319, P418, DOI 10.1038/319418a0; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SPRAGUE KU, 1980, CELL, V22, P171, DOI 10.1016/0092-8674(80)90165-8; SUTCLIFFE JG, 1984, SCIENCE, V225, P1308, DOI 10.1126/science.6474179; SUTCLIFFE JG, 1982, P NATL ACAD SCI-BIOL, V79, P4942, DOI 10.1073/pnas.79.16.4942; SUTCLIFFE JG, 1984, NATURE, V308, P237, DOI 10.1038/308237a0; TIEDGE H, 1991, P NATL ACAD SCI USA, V88, P2093, DOI 10.1073/pnas.88.6.2093; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0	43	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18291	18297						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382053				2022-12-27	WOS:A1992JN50200010
J	LEVY, H; GOKHMAN, I; ZAMIR, A				LEVY, H; GOKHMAN, I; ZAMIR, A			REGULATION AND LIGHT-HARVESTING COMPLEX-II ASSOCIATION OF A DUNALIELLA PROTEIN HOMOLOGOUS TO EARLY LIGHT-INDUCED PROTEINS IN HIGHER-PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOTOLERANT ALGA DUNALIELLA; BETA-CAROTENE ACCUMULATION; PHOTOSYSTEM-II; BARDAWIL; BIOSYNTHESIS; SYSTEM; GENE; EXPRESSION	The unicellular green alga Dunaliella bardawil responds to high light, nutrient deprivation, and several other types of stress by massive accumulation of beta-carotene. We have previously cloned a nuclear gene, cbr, that is co-induced with accelerated carotenogenesis. The predicted product of cbr is closely related to early light-induced proteins (Elips) of higher plants, and also shows resemblance to chlorophyll a/b-binding proteins. In the present study, the determination of the cbr transcription start site supported the previously proposed site of translation initiation. Antibodies raised against a synthetic oligopeptide matching the predicted sequence of Cbr recognized two polypeptides of apparently 17 and 19 kDa that were induced in parallel to cbr transcript accumulation in highly illuminated or sulfate-starved D. bardawil cells. The antibodies also cross-reacted with an approximately 20-kDa polypeptide in sulfate-starved Dunaliella salina. In both D. bardawil and D. salina, Cbr was found exclusively in the thylakoid membranes. After mild solubilization, Cbr co-fractionated with light-harvesting complex II (LHCII) in sucrose gradient centrifugation and gel electrophoresis and was specifically associated with a minor LHCII complex. An occasionally observed, faster mobility Cbr form, free of LHCII, was probably released from the larger complex. These results support the conclusion that Cbr belongs to a class of stress-induced proteins transiently associated with antennae complexes.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALLEN KD, 1991, ANAL BIOCHEM, V194, P214, DOI 10.1016/0003-2697(91)90170-X; BENAMOTZ A, 1981, TRENDS BIOCHEM SCI, V6, P297, DOI 10.1016/0968-0004(81)90106-7; BENAMOTZ A, 1983, PLANT PHYSIOL, V72, P593, DOI 10.1104/pp.72.3.593; BERMAN J, 1985, J BIOL CHEM, V260, P5240; BRAMLEY PM, 1988, CURR TOP CELL REGUL, V29, P291; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GREEN BR, 1988, PHOTOSYNTH RES, V15, P3, DOI 10.1007/BF00054985; GRIMM B, 1989, PLANT MOL BIOL, V13, P583, DOI 10.1007/BF00027318; GRIMM B, 1987, EUR J BIOCHEM, V167, P493, DOI 10.1111/j.1432-1033.1987.tb13364.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P75; KIRK MM, 1985, CELL, V41, P419, DOI 10.1016/S0092-8674(85)80015-5; KLEINIG H, 1989, ANNU REV PLANT PHYS, V40, P39, DOI 10.1146/annurev.pp.40.060189.000351; KOLANUS W, 1987, MOL GEN GENET, V209, P234, DOI 10.1007/BF00329648; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1991, J BIOL CHEM, V266, P13698; LERS A, 1990, PLANT PHYSIOL, V93, P389, DOI 10.1104/pp.93.2.389; LERS A, 1989, MOL GEN GENET, V216, P138, DOI 10.1007/BF00332242; LIVEANU V, 1986, J BIOL CHEM, V261, P5296; Maxam A M, 1980, Methods Enzymol, V65, P499; MEYER G, 1984, EUR J BIOCHEM, V138, P201, DOI 10.1111/j.1432-1033.1984.tb07900.x; PETER GF, 1991, J BIOL CHEM, V266, P16745; PICK U, 1987, PLANT PHYSIOL, V85, P194, DOI 10.1104/pp.85.1.194; SHAISH A, 1991, J PHYCOL, V27, P652, DOI 10.1111/j.0022-3646.1991.00652.x; YOUNG A, 1990, STRESS RESPONSES PLA, P87	25	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18831	18836						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382063				2022-12-27	WOS:A1992JN50200088
J	FACKLER, MJ; CIVIN, CI; MAY, WS				FACKLER, MJ; CIVIN, CI; MAY, WS			UP-REGULATION OF SURFACE CD34 IS ASSOCIATED WITH PROTEIN-KINASE C-MEDIATED HYPERPHOSPHORYLATION OF CD34	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGENITOR CELLS; ANTIGENIC ANALYSIS; PHORBOL ESTER; BONE-MARROW; PHOSPHORYLATION; RECEPTOR; ANTIBODY; INTERNALIZATION; IDENTIFICATION; HEMATOPOIESIS	CD34 is a transmembrane sialoglycoprotein expressed by early hematopoietic progenitor cells as well as endothelial cells. Previously we found that CD34 is rapidly and stoichiometrically phosphorylated by activated protein kinase C (PKC) (Fackler, M. J., Civin, C. I., Sutherland, D. R., Baker, M. A., and May, W. S. (1990) J. Biol. Chem. 265, 11056-11061). In the present study, we find dose-dependent up-regulation of CD34 surface expression following treatment of normal human CD34+ bone marrow progenitor cells, cord blood-derived KMT-2, or KG1a myeloid leukemia cells with the PKC activator 12-O-tetradecanoylphorbol-13-acetate. Up-regulation begins within 1 min of treatment, is maximal by 30 min, is maintained for at least 3 h, and is associated with CD34 hyperphosphorylation. A specific inhibitor of PKC, 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)hexan-amide (NPC 15437), blocks both up-regulation and hyperphosphorylation of CD34. CD34 up-regulation is independent of transcription and/or translation and results from the recruitment of preformed intracellular CD34. The endocytosis rate of surface CD34 is unaltered by 12-O-tetradecanoylphorbol-13-acetate. Thus, activation of PKC mediates increased surface expression of the CD34 molecule possibly as a result of phosphorylation of CD34.	JOHNS HOPKINS ONCOL CTR, 424 N BOND ST, BALTIMORE, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine					NATIONAL CANCER INSTITUTE [R01CA047993, R01CA044649] Funding Source: NIH RePORTER; NCI NIH HHS [CA47993, CA44649] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHM JL, 1981, BLOOD, V58, P1119; ANDREWS RG, 1986, BLOOD, V67, P842; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; CHATILA TA, 1988, J IMMUNOL, V140, P4308; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Civin C. L., 1989, LEUKOCYTE TYPING, P818; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1987, EXP HEMATOL, V15, P10; CIVIN CI, 1990, PROG CLIN BIOL RES, V333, P387; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; FACKLER MJ, 1990, J BIOL CHEM, V265, P11056; FERRERO D, 1983, BLOOD, V61, P171; FINA L, 1990, BLOOD, V75, P2417; KATAYAMA N, 1989, BLOOD, V73, P123; KATZ FE, 1985, LEUKEMIA RES, V9, P191, DOI 10.1016/0145-2126(85)90082-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIESI P, 1989, FEBS LETT, V244, P141, DOI 10.1016/0014-5793(89)81180-9; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MAY WS, 1987, J BIOL CHEM, V262, P16710; MERRILL JT, 1990, J IMMUNOL, V145, P2608; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; SHOJI M, 1987, CANCER RES, V47, P6363; SIMMONS DL, 1992, J IMMUNOL, V148, P267; STEVENS DA, 1991, J BIOL CHEM, V266, P4151; STRAUSS LC, 1991, AM J PEDIAT HEMATOL, V13, P217; SULLIVAN JP, 1991, FEBS LETT, V285, P120, DOI 10.1016/0014-5793(91)80739-P; SUTHERLAND DR, 1988, LEUKEMIA, V2, P793; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; TAMURA S, 1990, BLOOD, V76, P501; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	32	53	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17540	17546						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381351				2022-12-27	WOS:A1992JM22300013
J	GRASSL, SM				GRASSL, SM			HUMAN PLACENTAL BRUSH-BORDER MEMBRANE NA+-BIOTIN COTRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL CORTEX; VESICLES; TRANSPORT; KIDNEY	Membrane transport pathways for transplacental transfer of the water-soluble vitamin biotin were investigated by assessing the possible presence of a Na+-biotin cotransport mechanism in the maternal-facing membrane of human placental epithelial cells. The presence of Na+-biotin cotransport was determined from radiolabeled tracer flux measurements of biotin uptake using preparations of purified brush-border membrane vesicles. The imposition of an inwardly directed Na+ gradient stimulated vesicle uptake of biotin to levels approximately 25-fold greater than those observed at equilibrium. The voltage sensitivity of Na+ gradient-driven biotin uptake suggested Na+-biotin cotransport is electrogenic occurring with net transfer of positive charge. A kinetic analysis of the activation of biotin uptake by increasing Na+ was most consistent with an interaction of Na+ at 2 sites in the transport protein. Static head determinations used to identify the magnitude of opposing driving forces bringing flux through the cotransport mechanism to equilibrium indicated a coupling ratio of 2 Na+ per biotin. Substrate specificity studies using chemical analogues of biotin suggested both the terminal carboxylic acid of the valeric acid side chain and a second nucleus of anionic charge were important determinants for substrate interaction with the cotransport protein. Initial rate determinations of biotin uptake indicate biotin interacts with a single saturable site (K(m) = 21-mu-M) with a maximal transport rate of 4.5 nmol/mg/min. The results of this study provide evidence for an electrogenic Na+-biotin cotransport mechanism in the maternal-facing membrane of human placental epithelial cells.			GRASSL, SM (corresponding author), SUNY SYRACUSE,HLTH SCI CTR,DEPT PHARMACOL,SYRACUSE,NY 13210, USA.				NIDDK NIH HHS [DK37907] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK037907] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1981, AM J PHYSIOL, V240, pF1, DOI 10.1152/ajprenal.1981.240.1.F1; BAUR B, 1990, AM J PHYSIOL, V258, pF840, DOI 10.1152/ajprenal.1990.258.4.F840; BOWERS GN, 1966, CLIN CHEM, V12, P70; EARL DCN, 1965, BIOCHEM J, V94, P721, DOI 10.1042/bj0940721; GRASSL SM, 1989, J BIOL CHEM, V264, P11103; GRASSL SM, 1987, J BIOL CHEM, V262, P2682; ILLSLEY NP, 1990, BIOCHIM BIOPHYS ACTA, V1029, P218, DOI 10.1016/0005-2736(90)90157-J; JORGENSEN PL, 1968, BIOCHIM BIOPHYS ACTA, V151, P212, DOI 10.1016/0005-2744(68)90176-9; KELLY LK, 1987, AM J PHYSIOL, V252, pC38; Machlin, 1991, HDB VITAMINS; OGIN C, 1989, BIOCHIM BIOPHYS ACTA, V980, P248, DOI 10.1016/0005-2736(89)90406-9; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PODEVIN RA, 1986, BIOCHIM BIOPHYS ACTA, V856, P471, DOI 10.1016/0005-2736(86)90138-0; SAID HM, 1987, AM J PHYSIOL, V253, pG631, DOI 10.1152/ajpgi.1987.253.5.G631; SAID HM, 1991, AM J PHYSIOL, V261, pR94, DOI 10.1152/ajpregu.1991.261.1.R94; SAID HM, 1988, BIOCHIM BIOPHYS ACTA, V945, P195, DOI 10.1016/0005-2736(88)90482-8; Segel I. H., 1975, ENZYME KINETICS, P360; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; SPENCER PD, 1988, BIOCHEM MED METAB B, V40, P95, DOI 10.1016/0885-4505(88)90109-0; TRUMAN P, 1984, BIOCHIM BIOPHYS ACTA, V779, P129; TURNER RJ, 1983, J MEMBRANE BIOL, V76, P1, DOI 10.1007/BF01871450; TURNER RJ, 1982, J MEMBRANE BIOL, V67, P73, DOI 10.1007/BF01868649; WALLACH DFH, 1966, METHOD ENZYMOL, V8, P165; WATANABE T, 1990, TERATOLOGY, V42, P295, DOI 10.1002/tera.1420420313	24	33	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17760	17765						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381353				2022-12-27	WOS:A1992JM22300046
J	BARGON, J; TRAPNELL, BC; YOSHIMURA, K; DALEMANS, W; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG				BARGON, J; TRAPNELL, BC; YOSHIMURA, K; DALEMANS, W; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG			EXPRESSION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE CAN BE REGULATED BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; EPITHELIAL-CELLS; MESSENGER-RNA; NONSENSE MUTATIONS; AIRWAY EPITHELIA; XENOPUS OOCYTES; PHORBOL ESTER; CAMP; IDENTIFICATION; CALCIUM	Epithelial cells utilize at least two types of apical Cl- channels, the cAMP-activated cystic fibrosis transmembrane conductance regulator (CFTR) and the Ca2+/calmodulin-dependent Cl- channel. While phorbol ester (PMA) activates only CFTR-dependent Cl- secretion and the Ca2+ ionophore A23187 only the Ca2+/calmodulin-dependent Cl- secretion, PMA and A23187 share the ability to down-regulate expression of the CFTR gene at the transcriptional level. Since both PMA and A23187 can activate protein kinases, we hypothesized that protein kinase pathways may be involved in the regulation of CFTR gene expression. Exposure of HT-29 human colon carcinoma cells to the protein kinase C activator SC9 down-regulated CFTR mRNA levels in a dose-dependent fashion, similar to that seen with PMA. The reduction in CFTR transcript levels by SC9 and PMA was blocked by H7, an inhibitor of protein kinases. In a similar fashion, the down-regulation of CFTR transcript levels by A23187 was blocked by H7 as well as staurosporine, another protein kinase inhibitor. Interestingly, both H7 and staurosporine themselves increased CFTR mRNA levels. Quantification of CFTR gene transcription rate showed a reduction by SC9 (similar to that with PMA and A23187) that was prevented by H7 and that H7 by itself increased CFTR transcription. Together, these observations suggest that protein kinase pathways, likely including protein kinase C, are involved in the regulation of CFTR gene expression, with activation or inhibition of protein kinase activity down-regulating or up-regulating CFTR gene expression, respectively.	NHLBI, PULM BRANCH, BLDG 10, RM 6D03, BETHESDA, MD 20892 USA; TRANSGENE SA, F-67082 STRASBOURG, FRANCE	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Transgene SA								ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARGON J, 1992, MOL CELL BIOL, V12, P1872, DOI 10.1128/MCB.12.4.1872; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BLUMBERG PM, 1988, CANCER RES, V48, P1; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU JL, 1991, J BIOL CHEM, V266, P24471; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; CUPPENS H, 1990, J MED GENET, V27, P717, DOI 10.1136/jmg.27.11.717; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUANG K-P, 1990, Biofactors, V2, P171; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; ITO M, 1986, BIOCHEMISTRY-US, V25, P4179, DOI 10.1021/bi00363a002; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTROSERAFIZADEH C, 1991, J BIOL CHEM, V266, P4495; NISHINO H, 1986, BIOCHIM BIOPHYS ACTA, V889, P236, DOI 10.1016/0167-4889(86)90109-6; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHUTTE J, 1988, P NATL ACAD SCI USA, V85, P2257; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TIEMEIER DC, 1977, GENE, V2, P173, DOI 10.1016/0378-1119(77)90016-6; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WELSH MJ, 1990, FASEB J, V4, P2717; WHITE FL, 1987, J FUTURES MARKETS, V7, P109, DOI 10.1002/fut.3990070111; YANAGIHARA N, 1991, J NEUROCHEM, V56, P294, DOI 10.1111/j.1471-4159.1991.tb02595.x; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	52	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16056	16060						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379589				2022-12-27	WOS:A1992JJ45800013
J	PARK, S; MARSHALL, MS; GIBBS, JB; JOVE, R				PARK, S; MARSHALL, MS; GIBBS, JB; JOVE, R			RECONSTITUTION OF INTERACTIONS BETWEEN THE SRC TYROSINE KINASES AND RAS GTPASE-ACTIVATING PROTEIN USING A BACULOVIRUS EXPRESSION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; SARCOMA-VIRUS; GROWTH-FACTOR; P21 GTPASE; GAP; BINDING; PHOSPHORYLATION; TRANSFORMATION; PP60C-SRC; ONCOGENE	Ras GTPase-activating protein (GAP) has been implicated in mitogenic signal transduction downstream of oncogenic and receptor tyrosine kinases. Previous studies have suggested that GAP is phosphorylated by oncogenic viral Src (v-Src) and that GAP is associated with a complex containing normal cellular Src (c-Src) in vertebrate fibroblasts. To investigate molecular interactions between the Src kinases and GAP, we developed an in vitro system for reconstituting Src-GAP complexes. For this purpose, we constructed recombinant baculovirus vectors that direct expression of Rous sarcoma virus v-Src, chicken c-Src, and bovine GAP in infected Sf9 insect cells. In vitro reconstitution experiments using baculovirus-expressed proteins demonstrate that both v-Src and c-Src associate in complexes with GAP. In addition, in vitro and in vivo phosphorylation analyses indicate that GAP serves as a substrate for both the v-Src and c-Src tyrosine kinases. To determine which structural features of GAP are involved in interactions with the Src kinases, we constructed recombinant baculoviruses that encode deletion mutants of bovine GAP. Deletion of the GAP amino-terminal portion containing Src homology 2 regions, which are highly conserved structural motifs postulated to mediate interactions among proteins, diminishes GAP phosphorylation and association with Src. This reconstitution system should facilitate further studies of molecular interactions between the Src kinases and GAP.	UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, 6606 MED SCI 2, ANN ARBOR, MI 48109 USA; INDIANA UNIV, MED CTR, DEPT MED, HEMATOL ONCOL SECT, INDIANAPOLIS, IN 46202 USA; MERCK SHARP & DOHME LTD, DEPT CANC RES, W POINT, PA 19486 USA	University of Michigan System; University of Michigan; Indiana University System; Indiana University-Purdue University Indianapolis; Merck & Company				Park, Soochul/0000-0002-7029-3414	NCI NIH HHS [CA47809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1990, ADP RIBOSYLATING TOX, P381; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; PIWNICAWORMS H, 1988, CURRENT PROTOCOLS MO, pCH16; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SUDOL M, 1992, IN PRESS MOL BASIS H; SUMMERS MD, 1988, MANUAL METHODS BACUL; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0	51	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11612	11618						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375945				2022-12-27	WOS:A1992HX16900103
J	SALUJA, AK; DAWRA, RK; LERCH, MM; STEER, ML				SALUJA, AK; DAWRA, RK; LERCH, MM; STEER, ML			CCK-JMV-180, AN ANALOG OF CHOLECYSTOKININ, RELEASES INTRACELLULAR CALCIUM FROM AN INOSITOL TRISPHOSPHATE-INDEPENDENT POOL IN RAT PANCREATIC ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT PROCESSES; AMYLASE SECRETION; EXOCRINE PANCREAS; ENZYME-SECRETION; NEOMYCIN; BINDING; CA-2+; PHOSPHATES; RECEPTORS; INVITRO	In pancreatic acinar cells cholecystokinin and its analogs, caerulein and CCK-JMV-180, stimulate an increase in intracellular free [Ca2+] by releasing Ca2+ from non-mitochondrial intracellular pools. It is generally believed that the caerulein-induced release of Ca2+ is mediated by phospholipase C-catalyzed production of 1,4,5-inositol trisphosphate (IP3). In this study we have investigated the source and mechanism of Ca2+ release induced by CCK-JMV-180 using streptolysin O-permeabilized pancreatic acinar cells. Caerulein-stimulated release of Ca2+ was completely blocked by either neomycin, an inhibitor of phospholipase C, or by heparin, an IP3 receptor antagonist. These observations are compatible with the conclusion that caerulein releases Ca2+ from an IP3-sensitive pool. In contrast to caerulein, however, CCK-JMV-180-stimulated release of Ca2+ was not blocked by either neomycin or by heparin, indicating that CCK-JMV-180 releases Ca2+ by mechanisms which do not involve the generation or action of IP3. CCK-JMV-180 stimulated the release of Ca2+ even after the IP3-sensitive pool had been completely emptied by prior exposure to a supramaximally stimulating concentration of IP3 (40-mu-M). Prestimulation of permeabilized acini with 20 mM caffeine did not abolish the CCK-JMV-180-induced Ca2+ release. These results indicate that CCK-JMV-180 stimulates release of Ca2+ from a hitherto uncharacterized intracellular storage pool which is insensitive to either IP3 or caffeine.	BETH ISRAEL HOSP, DEPT SURG, 330 BROOKLINE AVE, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, HARVARD DIGEST DIS CTR, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263	PHS HHS [31396] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMADOR E, 1963, CLIN CHEM, V9, P391; BERRIDGE MJ, 1988, PHOSPHOINOSITIDES RE, P25; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUZZONE R, 1990, GASTROENTEROLOGY, V99, P1157, DOI 10.1016/0016-5085(90)90640-M; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRYKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LIGNON MF, 1987, GASTRIN CHOLECYSTOKI, P57; MARCHE P, 1983, J PHARMACOL EXP THER, V227, P415; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; OHSHIO G, 1989, PANCREAS, V4, P739, DOI 10.1097/00006676-198912000-00013; ORSULAKOVA A, 1976, J NEUROCHEM, V26, P285, DOI 10.1111/j.1471-4159.1976.tb04478.x; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P536, DOI 10.1016/0006-291X(91)91450-Q; PIERRE KJ, 1976, CLIN CHEM, V22, P1219; POWERS RE, 1985, BIOCHEM BIOPH RES CO, V131, P284, DOI 10.1016/0006-291X(85)91800-5; POWERS RE, 1986, J CLIN INVEST, V77, P1668, DOI 10.1172/JCI112484; PRENTKI M, 1986, FEBS LETT, V197, P285, DOI 10.1016/0014-5793(86)80343-X; PUTNEY JW, 1983, BIOCHEM J, V212, P483, DOI 10.1042/bj2120483; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; RUBIN RP, 1984, BIOCHEM J, V219, P655, DOI 10.1042/bj2190655; SALUJA A, 1986, AM J PHYSIOL, V250, pC413, DOI 10.1152/ajpcell.1986.250.3.C413; SALUJA AK, 1989, P NATL ACAD SCI USA, V86, P8968, DOI 10.1073/pnas.86.22.8968; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V164, P8, DOI 10.1016/0006-291X(89)91675-6; SANKARAN H, 1982, AM J PHYSIOL, V242, pG250, DOI 10.1152/ajpgi.1982.242.3.G250; SANKARAN H, 1980, J BIOL CHEM, V255, P1849; SCHACHT J, 1976, J NEUROCHEM, V27, P1119, DOI 10.1111/j.1471-4159.1976.tb00318.x; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091	34	84	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11202	11207						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375937				2022-12-27	WOS:A1992HX16900044
J	JAYARAMAN, T; BRILLANTES, AM; TIMERMAN, AP; FLEISCHER, S; ERDJUMENTBROMAGE, H; TEMPST, P; MARKS, AR				JAYARAMAN, T; BRILLANTES, AM; TIMERMAN, AP; FLEISCHER, S; ERDJUMENTBROMAGE, H; TEMPST, P; MARKS, AR			FK506 BINDING-PROTEIN ASSOCIATED WITH THE CALCIUM RELEASE CHANNEL (RYANODINE RECEPTOR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCLE SARCOPLASMIC-RETICULUM; FAST SKELETAL-MUSCLE; JUNCTIONAL TERMINAL CISTERNAE; CIS-TRANS ISOMERASE; MOLECULAR-CLONING; PURIFICATION; CYCLOPHILIN; DISTINCT; FORMS; CDNA	The calcium release channel (CRC)/ryanodine receptor (RyRec) has been identified as the foot structure of the sarcoplasmic reticulum (SR) and provides the pathway for calcium efflux required for excitation-contraction coupling in skeletal muscle. The CRC has previously been reported to consist of four identical 565-kDa protomers. We now report the identification of a 12-kDa protein which is tightly associated with highly purified RyRec from rabbit skeletal muscle SR. N-terminal amino acid sequencing and cDNA cloning demonstrates that the 12-kDa protein from fast twitch skeletal muscle is the binding protein for the immunosuppressant drug FK506. In humans, FK506 binds to the 12-kDa FK506-binding protein (FKBP12) and blocks calcium-dependent T cell activation. We find that FKBP12 and the RyRec are tightly associated in skeletal muscle SR on the basis of: 1) co-purification through sequential heparin-agarose, hydroxylapatite, and size exclusion chromatography columns; 2) co-immunoprecipitation of the RyRec and FKBP12 with anti-FKBP12 antibodies; and 3) subcellular localization of both proteins to the terminal cisternae of the SR, and not in the longitudinal tubules of SR, in fast twitch skeletal muscle. The molar ratio of FKBP12 to RyRec in highly purified RyRec preparations is approximately 1:4, indicating that one FKBP12 molecule is associated with each calcium release channel/foot structure.	MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, MOLEC BIOL PROGRAM, NEW YORK, NY 10021 USA; CUNY MT SINAI SCH MED, DEPT MED, DIV MOLEC MED, NEW YORK, NY 10029 USA; VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA	Memorial Sloan Kettering Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Vanderbilt University	JAYARAMAN, T (corresponding author), CUNY MT SINAI SCH MED, DEPT MED, BROOKDALE CTR, MOLEC BIOL, NEW YORK, NY 10029 USA.			Erdjument-Bromage, Hediye/0000-0003-0224-3594				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CHU A, 1987, ARCH BIOCHEM BIOPHYS, V258, P13, DOI 10.1016/0003-9861(87)90317-1; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; HARLOW E, 1988, ANTIBODIES LABORATOR; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; INUI M, 1987, J BIOL CHEM, V262, P1740; INUI M, 1988, METHOD ENZYMOL, V157, P490; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARKS AR, 1986, J STEROID BIOCHEM, V24, P1097, DOI 10.1016/0022-4731(86)90369-9; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; PINE P S, 1992, Biophysical Journal, V61, pA391; SAITO A, 1989, Biophysical Journal, V55, p206A; SAITO A, 1988, J CELL BIOL, V107, P211, DOI 10.1083/jcb.107.1.211; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SMITH KA, 1988, INTERLEUKIN, V2, P1; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	36	468	487	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9474	9477						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374404				2022-12-27	WOS:A1992HT96500007
J	HERRIN, DL; BATTEY, JF; GREER, K; SCHMIDT, GW				HERRIN, DL; BATTEY, JF; GREER, K; SCHMIDT, GW			REGULATION OF CHLOROPHYLL APOPROTEIN EXPRESSION AND ACCUMULATION - REQUIREMENTS FOR CAROTENOIDS AND CHLOROPHYLL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-B-PROTEIN; RIBULOSE BISPHOSPHATE CARBOXYLASE; ACTIVE PHOTOSYSTEM-II; CHLAMYDOMONAS-REINHARDTII; MESSENGER-RNA; CROSSED IMMUNOELECTROPHORESIS; DODECYL-SULFATE; CELL-CYCLE; LIGHT; MUTANT	Chlorophyll apoprotein accumulation and expression were examined in mutants of Chlamydomonas reinhardtii blocked at specific steps of carotenoid or chlorophyll synthesis. In the absence of carotenoids: 1) apoproteins of the core and light-harvesting complexes of photosystem I (CCI and LHCI, respectively) and photosystem II (CCII and LHCII, respectively) do not accumulate; 2) mRNAs for the CCI, CCII, and LHCII apoproteins accumulate to normal levels; and 3) synthesis of the chlorophyll apoproteins is differentially affected, or in some cases, not affected. In the absence of chlorophylls: 1) the apoproteins fail to accumulate; 2) mRNA levels for CCI and CCII apoproteins are relatively unchanged; 3) levels of LHCII apoprotein mRNA, but not rates of LHCII mRNA synthesis, are reduced in a light-dependent chlorophyll-synthesis mutant (ya12); and 4) synthesis of chlorophyll apoproteins is differentially affected or not affected in the case of several chloroplast-encoded apoproteins. These results demonstrate a direct role for carotenoids as well as chlorophylls in the stabilization of certain chlorophyll apoproteins and, for others, possibly in their translation. The data also indicate a role for chlorophyll synthesis in the stability of LHCII mRNA.	UNIV GEORGIA,DEPT BOT,ATHENS,GA 30602	University System of Georgia; University of Georgia			Herrin, David/M-1372-2019					ANDERSON JM, 1986, ANNU REV PLANT PHYS, V37, P93, DOI 10.1146/annurev.arplant.37.1.93; APEL K, 1979, EUR J BIOCHEM, V97, P183, DOI 10.1111/j.1432-1033.1979.tb13101.x; BENNETT J, 1981, EUR J BIOCHEM, V118, P61, DOI 10.1111/j.1432-1033.1981.tb05486.x; BREIDENBACH E, 1990, BIOCHIM BIOPHYS ACTA, V1048, P209, DOI 10.1016/0167-4781(90)90058-A; BRITTON G, 1986, REGULATION CHLOROPLA, P125; CHUA NH, 1979, J BIOL CHEM, V254, P215; DELEPELAIRE P, 1981, J BIOL CHEM, V256, P9300; DINER BA, 1980, EUR J BIOCHEM, V110, P521, DOI 10.1111/j.1432-1033.1980.tb04894.x; EICHENBERGER W, 1986, PHYSIOL PLANTARUM, V66, P589, DOI 10.1111/j.1399-3054.1986.tb05584.x; FORD C, 1982, MOL GEN GENET, V187, P286, DOI 10.1007/BF00331130; GOLDSCHMIDTCLERMONT M, 1986, J MOL BIOL, V191, P421, DOI 10.1016/0022-2836(86)90137-3; GREER K, 1988, WATER OXIDATION COMP; GREER KL, 1986, PLANT PHYSIOL, V82, P114, DOI 10.1104/pp.82.1.114; HAGAKI T, 1986, PLANT CELL PHYSL, V27, P1241; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HERRIN DL, 1986, J CELL BIOL, V103, P1837, DOI 10.1083/jcb.103.5.1837; HERRIN DL, 1987, ARCH BIOCHEM BIOPHYS, V254, P397, DOI 10.1016/0003-9861(87)90117-2; Herrin DL, 1987, PROGR PHOTOSYNTHESIS, P645; HERRIN DL, 1988, J BIOL CHEM, V263; HOOBER JK, 1990, PLANT PHYSIOL, V92, P419, DOI 10.1104/pp.92.2.419; HOOBER JK, 1982, J CELL BIOL, V95, P52; HOOBER JK, 1987, BIOCH PLANTS, V10, P1; HUMBECK K, 1989, PLANTA, V179, P242, DOI 10.1007/BF00393695; IKEUCHI M, 1987, PROGR PHOTOSYNTHESIS, V2, P805; JANERO DR, 1981, ANAL BIOCHEM, V111, P283, DOI 10.1016/0003-2697(81)90565-0; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; JOHANNINGMEIER U, 1988, EUR J BIOCHEM, V177, P417, DOI 10.1111/j.1432-1033.1988.tb14391.x; KINDLE KL, 1987, PLANT MOL BIOL, V9, P547, DOI 10.1007/BF00020532; LEVINE RP, 1970, ANNU REV GENET, V4, P397, DOI 10.1146/annurev.ge.04.120170.002145; MALNOE P, 1988, J CELL BIOL, V106, P609, DOI 10.1083/jcb.106.3.609; Maniatis T., 1982, MOL CLONING; MARRS KA, 1991, PLANTA, V183, P327, DOI 10.1007/BF00197729; Mathis P., 1982, CAROTENOIDS CHEM BIO, P339; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MAYFIELD SP, 1986, PLANT PHYSIOL, V82, P760, DOI 10.1104/pp.82.3.760; MISHKIND ML, 1985, CURR TOP PLANT BIOCH, V4, P34; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NICHOLSONGUTHRIE CS, 1987, ARCH BIOCHEM BIOPHYS, V252, P570, DOI 10.1016/0003-9861(87)90064-6; PLUMLEY FG, 1989, P NATL ACAD SCI USA, V86, P2678, DOI 10.1073/pnas.86.8.2678; PLUMLEY FG, 1983, ANAL BIOCHEM, V134, P86, DOI 10.1016/0003-2697(83)90267-1; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; PLUMLEY FG, 1986, PLANT PHYSIOL, V80, P685, DOI 10.1104/pp.80.3.685; ROMER S, 1990, PLANTA, V182, P216, DOI 10.1007/BF00197114; SIEBURTH LE, 1991, PLANT CELL, V3, P175, DOI 10.2307/3869287; SILVERTHORNE J, 1984, P NATL ACAD SCI-BIOL, V81, P1112, DOI 10.1073/pnas.81.4.1112; THORNBER JP, 1986, ENCY PLANT PHYSL, V19, P98; WOLLMAN FA, 1982, BIOCHIM BIOPHYS ACTA, V680, P352, DOI 10.1016/0005-2728(82)90149-9	48	81	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8260	8269						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373722				2022-12-27	WOS:A1992HQ18500047
J	LINNEKIN, D; EVANS, G; MICHIEL, D; FARRAR, WL				LINNEKIN, D; EVANS, G; MICHIEL, D; FARRAR, WL			CHARACTERIZATION OF A 97-KDA PHOSPHOTYROSYLPROTEIN REGULATED BY MULTIPLE CYTOKINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RECEPTOR-BETA-CHAIN; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CELL-LINE; ERYTHROPOIETIN RECEPTOR; INTERLEUKIN-2 RECEPTOR; GM-CSF; RAPID PHOSPHORYLATION; EXPRESSION CLONING	We have examined the signal transduction pathways of a number of cytokines that interact with receptors that are members of the hematopoietin receptor superfamily. A 97-kDa protein was phosphorylated on tyrosine in response to stimulation of appropriate target cells with interleukin (IL)-2, IL-3, granulocyte-macrophage colony-stimulating factor (CSF), granulocyte-CSF, or erythropoietin. These data suggest that a 97-kDa phosphotyrosylprotein represents a point of convergence for signal transduction by a number of growth factor receptors that do not have homology with any known protein tyrosine kinase. To address the possibility that p97 may represent a tyrosine kinase involved in multiple signal transduction pathways, we tested the capacity of this protein to bind a tyrosine kinase substrate or ATP. Indeed, a 97-kDa phosphotyrosylprotein purified from IL-2-stimulated lymphoid cells as well as granulocyte-macrophage-CSF-stimulated myeloid cells bound to a polymer of glutamic acid and tyrosine which is a tyrosine kinase substrate. Further, a 97-kDa phosphotyrosylprotein present in both lineages also bound 8-azido-ATP. These data indicate that a 97-kDa phosphotyrosylprotein with properties consistent with those of a protein tyrosine kinase is involved in the signal transduction pathways of certain members of the newly identified hematopoietin receptor superfamily and may represent an early point of convergence in the stimulus-response coupling of multiple cytokine receptors.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, MOLEC IMMUNOREGULAT LAB, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR,DYN CORP, PROGRAM RESOURCES INC, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, DYN CORP, PROGRAM RESOURCES INC, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELGHANY M, 1990, P NATL ACAD SCI USA, V87, P7061, DOI 10.1073/pnas.87.18.7061; BRAUN S, 1984, J BIOL CHEM, V259, P2051; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; D'Andrea AD, 1990, CURR OPIN CELL BIOL, V2, P648, DOI 10.1016/0955-0674(90)90106-O; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DOI T, 1989, EUR J IMMUNOL, V19, P2375, DOI 10.1002/eji.1830191229; EVANS SW, 1987, BIOCHEM J, V244, P683, DOI 10.1042/bj2440683; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FARRAR WL, 1990, ANN NY ACAD SCI, V594, P240; GARCIA GG, 1992, BIOCHEM J, V285, P851, DOI 10.1042/bj2850851; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GLAZER RI, 1987, ANAL BIOCHEM, V164, P2124; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1991, BLOOD, V77, P243; KANAKURA Y, 1990, BLOOD, V76, P706; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; MICHIEL DF, 1991, CYTOKINE, V3, P428, DOI 10.1016/1043-4666(91)90047-H; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SANTOLI D, 1987, J IMMUNOL, V139, P3348; SORENSEN PHB, 1989, BLOOD, V73, P406; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; ULRICH A, 1990, CELL, V61, P203; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; ZU Y, 1990, BIOCHEMISTRY-US, V29, P105	36	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23993	23998						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385430				2022-12-27	WOS:A1992JZ23900084
J	WARD, SG; REIF, K; LEY, S; FRY, MJ; WATERFIELD, MD; CANTRELL, DA				WARD, SG; REIF, K; LEY, S; FRY, MJ; WATERFIELD, MD; CANTRELL, DA			REGULATION OF PHOSPHOINOSITIDE KINASES IN T-CELLS - EVIDENCE THAT PHOSPHATIDYLINOSITOL 3-KINASE IS NOT A SUBSTRATE FOR T-CELL ANTIGEN RECEPTOR-REGULATED TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; SIGNAL TRANSDUCTION; LYMPHOCYTES-T; BOVINE BRAIN; INTACT-CELLS; RAT-LIVER; ACTIVATION; PROTEIN; PHOSPHORYLATION; PATHWAY	A phosphoinositide kinase that can phosphorylate phosphatidylinositol (PtdIns) is present in 4G10 monoclonal antibody (mAb) phosphotyrosine immunoprecipitates isolated from T cells activated via the T cell antigen receptor (TCR).CD3 complex. This PtdIns kinase is not the PtdIns 3-kinase that associates with activated protein tyrosine kinases in fibroblasts, since Western blotting and immunoprecipitation experiments with antibodies specific for the p85alpha subunit of the PtdIns 3-kinase indicate that this polypeptide is not immunoprecipitated by the 4G10 mAb from TCR. CD3-activated Jurkat cells. Moreover, immunoprecipitated PtdIns 3-kinase isolated from T cells with p85 antibodies is inhibited when PtdIns is presented in Nonidet P-40, whereas the PtdIns kinase activity present in 4G10 mAb phosphotyrosine immunoprecipitates is enhanced in the presence of Nonidet P-40. In vitro kinase assays of PtdIns 3-kinase immunoprecipitated with p85 antibodies from T cells indicate that it associates with a serine kinase that can phosphorylate a p85 polypeptide. However, no protein tyrosine kinase activity capable of tyrosine phosphorylating p85 in vitro associates with p85alpha immunoprecipitates in quiescent or TCR.CD3-activated T cells. These data suggest that the TCR.CD3 complex does not regulate PtdIns 3-kinase activity by a mechanism that involves protein tyrosine kinases.	IMPERIAL CANC RES FUND,LYMPHOCYTE ACTIVAT LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,CELL SURFACE BIOCHEM LAB,LONDON WC2A 3PX,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	Cancer Research UK; Cancer Research UK; Ludwig Institute for Cancer Research			Ward, Stephen/AAE-4341-2020; Reif, Karin/AAD-4692-2020	Reif, Karin/0000-0001-5490-8389; Fry, Michael/0000-0001-8518-1370; Ward, Stephen G./0000-0002-6795-6002				ALEXANDER DR, 1990, BIOCHEM J, V268, P303, DOI 10.1042/bj2680303; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BAGNASCO M, 1989, EUR J IMMUNOL, V19, P823, DOI 10.1002/eji.1830190507; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTLEY LJ, 1992, CELL BIOCH B S, V16, P175; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COCHET C, 1991, J BIOL CHEM, V266, P637; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FREIDRICH B, 1989, EUR J IMMUNOL, V19, P17; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; IMBODEN JB, 1985, IMMUNOL TODAY, V6, P328, DOI 10.1016/0167-5699(85)90129-X; INOKUCHI S, 1990, J BIOL CHEM, V265, P5983; ISAKOV N, 1987, IMMUNOL REV, V95, P89, DOI 10.1111/j.1600-065X.1987.tb00501.x; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7772; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MARAIS RM, 1989, EUR J BIOCHEM, V181, P401; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MERIDA I, 1991, J IMMUNOL, V147, P2202; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OFLYNN K, 1984, BIOCHEM J, V219, P661, DOI 10.1042/bj2190661; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANTALEO G, 1987, EUR J IMMUNOL, V17, P55, DOI 10.1002/eji.1830170110; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5433; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; REDIJK M, 1992, EMBO J, V11, P1365; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; THOMPSON PA, 1992, ONCOGENE, V7, P719; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6836, DOI 10.1073/pnas.81.21.6836; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZACHARY I, 1991, J BIOL CHEM, V266, P24126	56	53	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23862	23869						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385426				2022-12-27	WOS:A1992JZ23900065
J	LEE, TC; UEMURA, Y; SNYDER, F				LEE, TC; UEMURA, Y; SNYDER, F			A NOVEL COA-INDEPENDENT TRANSACETYLASE PRODUCES THE ETHANOLAMINE PLASMALOGEN AND ACYL ANALOGS OF PLATELET-ACTIVATING-FACTOR (PAF) WITH PAF AS THE ACETATE DONOR IN HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; VASCULAR ENDOTHELIAL-CELLS; HUMAN NEUTROPHILS; LIPID EXTRACT; BOVINE BRAIN; RAT SPLEEN; ACETYLTRANSFERASE; BIOSYNTHESIS; MICROSOMES; 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE	In this study, we demonstrate the presence of unique membrane-associated transacetylase that transfers the acetate group from platelet-activating factor (PAF) to lysoplasmalogen (in the presence of EDTA and sodium acetate) with the formation of 1-alk-1-enyl-2-acetyl-sn-glycero-3-phosphoethanolamine (alk-1-enylacetyl-GPE). The identity of alk-1-enylacetyl-GPE was confirmed by acid hydrolysis, phospholipases A2 or C treatment and derivatization by fluorodinitrobenzene. The transacetylase has no requirement for Ca2+, Mg2+, or CoA and a broad pH optimum (7.0-8.0) with K(m) values of 12.0 muM for PAF and 106.4 muM for lysoplasmalogens. The enzyme activity from the isolated membrane fraction is not change when whole cells are supplemented with 20:4, induce to differentiate into granulocytes, or treated with ionophore A23187. Radyllyso-sn-glycero-3-phosphocholine (GPC), radyllyso-GPE, acyllyso-sn-glycero-3-phosphoserine (GPS), acyllyso-sn-glycero-3-phosphoinositol (GPI), alkyllyso-sn-glycero-3-phosphate (GP), acyllyso-GP, or cis-9-octadecen-1-ol can also serve as acetate acceptors, whereas alkylglycerol, acylglycerol, or cholesterol are inactive. Differences in substrate acceptor specificity, sensitivity toward phenylmethylsulfonyl fluoride, and response to temperature suggest that the CoA-independent transacetylase and the CoA-independent transacylase that transfers long-chain acyl moieties are two separate enzymes. With intact differentiated HL-60 cells, [H-3]acetate from [H-3]PAF can be incorporated into alk-1-enylacetyl-GPE in the presence of ionophore A23187, but not in its absence. Moreover, phospholipase A2 inhibitors (p-bromophenacyl bromide and mepacrine) block the transacetylation process in whole cell system. These results indicate the production of alk-1-enyllyso-GPE is a rate-limiting factor for the subsequent transacetylation step during cell activation. We conclude that the transacetylase may participate in the biosynthesis of ethanolamine plasmalogen and acyl analogs of PAF, in vivo, fine-tuning of PAF biological responses, and cross-talk between de novo and remodeling pathways of PAF biosynthesis.			LEE, TC (corresponding author), OAK RIDGE ASSOCIATED UNIV,DIV MED SCI,OAK RIDGE,TN 37831, USA.				NHLBI NIH HHS [HL35495-05A1, HL27109-11A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027109, R01HL035495] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BILLAH MM, 1986, J BIOL CHEM, V261, P5824; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; GARCIA MC, 1991, BIOCHIM BIOPHYS ACTA, V1083, P37, DOI 10.1016/0005-2760(91)90122-X; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P511, DOI 10.1016/0167-4889(85)90218-6; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; LEE TC, 1985, J BIOL CHEM, V260, P952; LEE TC, 1988, J BIOL CHEM, V263, P1755; LEE TC, 1986, J BIOL CHEM, V261, P5373; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MAVIS RD, 1972, J BIOL CHEM, V247, P2835; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; MUELLER HW, 1991, BIOCHEM BIOPH RES CO, V176, P1557, DOI 10.1016/0006-291X(91)90465-J; NEILANDS JB, 1955, OUTLINES ENZYME CHEM; NIETO ML, 1991, J BIOL CHEM, V266, P18699; NINIO E, 1982, BIOCHIM BIOPHYS ACTA, V710, P23, DOI 10.1016/0005-2760(82)90185-0; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; QIAN CG, 1989, J LIPID MEDIATOR, V1, P113; RENKONEN O, 1968, J LIPID RES, V9, P34; RENOOIJ W, 1981, BIOCHIM BIOPHYS ACTA, V663, P545, DOI 10.1016/0005-2760(81)90182-X; SATOUCHI K, 1987, LIPIDS, V22, P285, DOI 10.1007/BF02533994; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; SNYDER F, 1992, PROG LIPID RES, V31, P65, DOI 10.1016/0163-7827(92)90016-C; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; SUGIURA T, 1990, BIOCHIM BIOPHYS ACTA, V1047, P223, DOI 10.1016/0005-2760(90)90520-8; TESSNER TG, 1987, J BIOL CHEM, V262, P12660; TESSNER TG, 1990, J BIOL CHEM, V265, P21032; TOKUMURA A, 1987, BIOCHEM BIOPH RES CO, V145, P415, DOI 10.1016/0006-291X(87)91338-6; TOKUMURA A, 1989, J LIPID RES, V30, P219; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; WHATLEY RE, 1992, PROSTAGLANDINS, V43, P21, DOI 10.1016/0090-6980(92)90061-W; WINKLER JD, 1991, BIOCHIM BIOPHYS ACTA, V1081, P3239; WOODARD DS, 1987, J BIOL CHEM, V262, P2520; WYKLE RL, 1980, J BIOL CHEM, V255, P256; YASUDA K, 1988, BIOMED ENVIRON MASS, V16, P137, DOI 10.1002/bms.1200160124	42	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19992	20001						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400315				2022-12-27	WOS:A1992JR85800041
J	DAVIS, LH; DAVIS, JQ; BENNETT, V				DAVIS, LH; DAVIS, JQ; BENNETT, V			ANKYRIN REGULATION - AN ALTERNATIVELY SPLICED SEGMENT OF THE REGULATORY DOMAIN FUNCTIONS AS AN INTRAMOLECULAR MODULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE ANKYRIN; CYTOPLASMIC DOMAIN; ANION-EXCHANGER; BRAIN ANKYRIN; BINDING-SITES; MEMBRANE; SPECTRIN; ASSOCIATION; ISOFORM; PHOSPHORYLATION	This study of two forms of ankyrin (protein 2.1 and 2.2) from human erythrocytes has revealed a role for alternate exon usage at the level of regulation of protein interactions. The smaller form of ankyrin (protein 2.2), which lacks a portion of the regulatory domain due to alternative splicing of pre-mRNA, exhibits increased affinity for the cytoplasmic domain of the anion exchanger, spectrin, and tubulin. Direct evidence that at least one of these associations is modulated by the alternatively spliced segment of the regulatory domain is provided by experiments utilizing a polypeptide that is comprised of residues 1513-1674 corresponding to the portion of the regulatory domain missing from protein 2.2. Addition of this regulatory domain polypeptide to binding assays reversed the increase in affinity of protein 2.2 for the anion exchanger. The inhibitory activity of the regulatory domain polypeptide in these assays is accompanied by a direct interaction with a site that is available on the smaller form of ankyrin and is distinct from the binding site for the anion exchanger. These results support the idea that the alternatively spliced segment within the regulatory domain of erythrocyte ankyrin performs a repressor function and acts through an allosteric mechanism involving interaction(s) at a site separate from the binding site for the anion exchanger.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University	DAVIS, LH (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.				NIADDK NIH HHS [AM29808] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM029808] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT V, 1981, P NATL ACAD SCI-BIOL, V78, P7550, DOI 10.1073/pnas.78.12.7550; BENNETT V, 1978, J BIOL CHEM, V253, P2292; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; DAVIS JQ, 1986, J BIOL CHEM, V261, P6198; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; GEORGATOS SD, 1985, J CELL BIOL, V100, P1955, DOI 10.1083/jcb.100.6.1955; HALL TG, 1987, J BIOL CHEM, V262, P10537; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KUNIMOTO M, 1991, J CELL BIOL, V115, P1319, DOI 10.1083/jcb.115.5.1319; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LAMBERT S, 1991, J CELL BIOL, V115, P43; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU PW, 1985, J BIOL CHEM, V260, P4958; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS L, 1991, J CELL BIOL, V114, P1243; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOONG CJ, 1987, ARCH BIOCHEM BIOPHYS, V254, P509, DOI 10.1016/0003-9861(87)90131-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANG TK, 1988, P NATL ACAD SCI USA, V85, P3713, DOI 10.1073/pnas.85.11.3713; VOTER WA, 1984, J BIOL CHEM, V259, P430	30	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18966	18972						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388161				2022-12-27	WOS:A1992JN50200107
J	IWAMOTO, T; HAGIWARA, M; HIDAKA, H; ISOMURA, T; KIOUSSIS, D; NAKASHIMA, I				IWAMOTO, T; HAGIWARA, M; HIDAKA, H; ISOMURA, T; KIOUSSIS, D; NAKASHIMA, I			ACCELERATED PROLIFERATION AND INTERLEUKIN-2 PRODUCTION OF THYMOCYTES BY STIMULATION OF SOLUBLE ANTI-CD3 MONOCLONAL-ANTIBODY IN TRANSGENIC MICE CARRYING A RABBIT PROTEIN KINASE-C-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; HUMAN LYMPHOCYTES-T; TYROSINE KINASE; ANTIGEN RECEPTOR; MOLECULAR-CLONING; GENE-EXPRESSION; FAMILY; ISOZYMES; COMPLEX; CD2	Protein kinase C (PKC) has been believed to play an important role in the differentiation/proliferation of various kinds of mammalian cells. To analyze its function in living animals, we have established a transgenic mouse line carrying rabbit protein kinase C-alpha cDNA under the control of the regulatory element of human CD2. Thymocytes of these transgenic mice overexpressed PKC-alpha. Interestingly, the increase of PKC-alpha was detected mainly in membrane fractions of transgenic thymocytes. Although the transgenic thymocytes did not show any distinct proliferative features in vivo, they displayed a unique property to extensively proliferate and produce interleukin-2 (IL-2) in response to the stimulation by a soluble form of anti-CD3 monoclonal antibody (mAb), an incomplete agonist for proliferation of normal thymocytes. Furthermore, costimulation of the phorbol 12-myristate 13-acetate and anti-CD3 mAb intensely provoked the transgenic thymocytes to release IL-2. For the first time this result provided the direct evidence that PKC-alpha translocated to the cell membrane of thymocytes works as an active second messenger of the T cell receptor-CD3 complex-delivered signal for proliferation and IL-2 production.	NAGOYA UNIV,SCH MED,DEPT IMMUNOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT PHARMACOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT RADIOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND	Nagoya University; Nagoya University; Nagoya University; MRC National Institute for Medical Research								ALEXANDER DR, 1989, IMMUNOL TODAY, V10, P200, DOI 10.1016/0167-5699(89)90325-3; ANDERSON MLM, 1985, NUCLEIC ACID HYBRIDI, P73; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BERRY N, 1989, J IMMUNOL, V143, P1407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FINN OJ, 1991, J IMMUNOL, V146, P1099; FREIREMOAR J, 1991, J IMMUNOL, V147, P405; GILLIS S, 1978, J IMMUNOL, V120, P2027; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGIWARA M, 1990, CANCER RES, V50, P5515; HARA T, 1985, J EXP MED, V161, P641, DOI 10.1084/jem.161.4.641; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HOGAN B, 1986, MANIPULATING MOUSE E, P79; IWAMOTO T, 1990, ONCOGENE, V5, P535; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LUCAS S, 1990, FEBS LETT, V260, P53, DOI 10.1016/0014-5793(90)80064-P; MANGER B, 1987, J IMMUNOL, V139, P2755; NAKASHIMA I, 1991, J IMMUNOL, V147, P1153; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAYRE PH, 1987, P NATL ACAD SCI USA, V84, P2941, DOI 10.1073/pnas.84.9.2941; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHEARMAN MS, 1988, FEBS LETT, V234, P387, DOI 10.1016/0014-5793(88)80122-4; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; YAGITA H, 1988, J IMMUNOL, V140, P1321; YAMAMOTO Y, 1986, J BIOCHEM-TOKYO, V100, P333, DOI 10.1093/oxfordjournals.jbchem.a121719; ZHANG YH, 1992, IMMUNOL LETT, V32, P147, DOI 10.1016/0165-2478(92)90107-Y	38	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18644	18648						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382058				2022-12-27	WOS:A1992JN50200061
J	MUKAI, H; MUNEKATA, E; HIGASHIJIMA, T				MUKAI, H; MUNEKATA, E; HIGASHIJIMA, T			G-PROTEIN ANTAGONISTS - A NOVEL HYDROPHOBIC PEPTIDE COMPETES WITH RECEPTOR FOR G-PROTEIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; RECONSTITUTED PHOSPHOLIPID-VESICLES; BETA-ADRENERGIC-RECEPTOR; SUBSTANCE-P; REGULATORY PROTEINS; WASP VENOM; STRUCTURAL DETERMINANTS; SYNTHETIC PEPTIDES; COUPLED RECEPTORS; DIRECT ACTIVATION	A substance P (SP) analog, [D-Pro4,D-Trp7,9,10] SP4-11, is known to inhibit the actions of various structurally unrelated messenger molecules as well as SP. Our studies on the effects of this peptide on the regulation of purified G proteins by receptor showed that at least some of the biological effects of the peptide can be explained by the ability of the peptide to block the activation of G proteins by receptors. Here we report that a novel truncated SP-related peptide, pGlu-Gln-D-Trp-Phe-D-Trp-D-Trp-Met-NH2, inhibited the activation of G(i) or G(o) by M2 muscarinic cholinergic receptor (M2 mAChR) or of G(s) by beta-adrenergic receptor in the reconstituted phospholipid vesicles, assayed by receptor-promoted GTP hydrolysis. The inhibition by the peptide was apparently reversible and competitive with respect to receptor binding to G proteins; the inhibition could be overcome by increasing the concentration of receptor in the vesicles and was not altered by changes in the concentration of G protein. The competing effects of the peptide were used to analyze the effect of agonist on receptor-G protein interaction. The concentration change of muscarinic agonist did not alter the inhibitory effects of the peptide on M2 mAChR-promoted GTPase by G(o), which is consistent with the idea that agonist increases the regulatory efficiency of the receptor but does not alter its affinity for G proteins. This new group of compounds (G protein antagonists) is a promising tool to study receptor-G protein interaction quantitatively.	UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba	MUKAI, H (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040676] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40676] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH, P173; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BUTLER SJ, 1988, BIOCHEM J, V251, P201, DOI 10.1042/bj2510201; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; FABREGAT I, 1990, J CELL PHYSIOL, V145, P88, DOI 10.1002/jcp.1041450113; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FOLKERS K, 1984, BRIT J PHARMACOL, V83, P449, DOI 10.1111/j.1476-5381.1984.tb16506.x; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA K, 1985, J BIOL CHEM, V260, P7927; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIGASHIJIMA T, 1987, PEPTIDE CHEM 1986, P75; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1945; HUANG RRC, 1990, MOL PHARMACOL, V37, P304; JOYCEBRADY M, 1991, J BIOL CHEM, V266, P6859; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KURIHARA H, 1986, CELL TISSUE RES, V243, P311; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MATESIC DF, 1989, J BIOL CHEM, V264, P21638; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; MUKAI H, 1987, AM J PHYSIOL, V252, pE765, DOI 10.1152/ajpendo.1987.252.6.E765; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; ORLOWSKA A, 1987, INT J PEPT PROT RES, V30, P141; PARKER EM, 1991, J BIOL CHEM, V266, P519; PERIANIN A, 1989, J IMMUNOL, V143, P1669; PIOTROWSKI W, 1984, AGENTS ACTIONS, V14, P420, DOI 10.1007/BF01973842; PIOTROWSKI W, 1985, N-S ARCH PHARMACOL, V331, P364, DOI 10.1007/BF00500821; READ GW, 1979, J PHARMACOL EXP THER, V211, P711; REGOLI D, 1990, TRENDS PHARMACOL SCI, V11, P400, DOI 10.1016/0165-6147(90)90144-W; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; TOMITA U, 1991, BIOCHEM BIOPH RES CO, V178, P400, DOI 10.1016/0006-291X(91)91827-Y; TOMITA U, 1991, J BIOCHEM-TOKYO, V109, P184, DOI 10.1093/oxfordjournals.jbchem.a123342; WILLUWEIT B, 1988, BIOCHEM J, V249, P857, DOI 10.1042/bj2490857; YOKOKAWA N, 1989, BIOCHEM BIOPH RES CO, V158, P712, DOI 10.1016/0006-291X(89)92779-4; ZHANG L, 1988, BIOCHIM BIOPHYS ACTA, V972, P37, DOI 10.1016/0167-4889(88)90100-0	47	124	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16237	16243						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379592				2022-12-27	WOS:A1992JJ45800040
J	LIU, Z; DIAZ, LA; HAAS, AL; GIUDICE, GJ				LIU, Z; DIAZ, LA; HAAS, AL; GIUDICE, GJ			CDNA CLONING OF A NOVEL HUMAN UBIQUITIN CARRIER PROTEIN - AN ANTIGENIC DOMAIN SPECIFICALLY RECOGNIZED BY ENDEMIC PEMPHIGUS FOLIACEUS AUTOANTIBODIES IS ENCODED IN A SECONDARY READING FRAME OF THIS HUMAN EPIDERMAL TRANSCRIPT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; DESMOSOMAL GLYCOPROTEIN; CADHERIN FAMILY; FOGO-SELVAGEM; CONJUGATING ENZYME; ESCHERICHIA-COLI; MESSENGER-RNAS; YEAST RAD6; GENE; DEGRADATION	Autoantibodies from a patient suffering from endemic pemphigus foliaceus (EPF), a blistering skin disease, were used to screen a lambda-gt11 human keratinocyte cDNA library. One immunoreactive cDNA clone (lambda-EPF5) containing a 900-base pair insert was isolated and subjected to further analysis. Eight of 25 EPF sera were shown to react with the EPF5 fusion protein on immunoblots. The EPF5 cDNA insert hybridized with a 1.2-kilobase epidermal RNA transcript on a Northern blot. Sequence analysis revealed that lambda-EPF5 contained the complete coding sequence for a 24-kDa polypeptide exhibiting significant sequence homology with a family of enzymes known as ubiquitin carrier proteins, or E2s, which are an essential component of the ubiquitin-protein conjugation system. The homology was particularly high in the core region containing the active site cysteine. The keratinocyte ubiquitin carrier protein expressed in bacteria, and isolated either intact or as a glutathione S-transferase fusion protein, exhibited the ability to form a thiol ester linkage with ubiquitin in a ubiquitin activating enzyme (E1)-dependent manner, a characteristic property of ubiquitin carrier proteins. The E2 enzyme encoded by clone EPF5 is the first member of this protein family to be cloned from an epidermal source. Interestingly, the EPF autoantibody-reactive epitope and the ubiquitin carrier protein were shown to be encoded in two different translational reading frames. The relevance of the cloned EPF epitope in the pathogenesis of this autoimmune disorder remains to be determined.	MED COLL WISCONSIN,DEPT DERMATOL,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226; VET ADM MED CTR,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032081, R01AR032599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR32081, R01-AR32599] Funding Source: Medline; NIGMS NIH HHS [R01-GM34009] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEUTNER EH, 1968, P SOC EXP BIOL MED, V127, P81; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; COX BS, 1968, MUTAT RES, V6, P37, DOI 10.1016/0027-5107(68)90101-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAZ LA, 1989, J AM ACAD DERMATOL, V20, P657, DOI 10.1016/S0190-9622(89)70079-7; DIAZ LA, 1989, J INVEST DERMATOL, V92, P4, DOI 10.1111/1523-1747.ep13070394; DIAZ LA, 1990, J CLIN INVEST, V86, P1088, DOI 10.1172/JCI114812; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; EYRE RW, 1987, J EXP MED, V165, P1719, DOI 10.1084/jem.165.6.1719; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GIUDICE GJ, 1991, J CLIN INVEST, V87, P734, DOI 10.1172/JCI115054; GIUDICE GJ, 1987, CELL, V48, P453, DOI 10.1016/0092-8674(87)90196-6; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; JORDON RE, 1967, J AMER MED ASSOC, V200, P751, DOI 10.1001/jama.200.9.751; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KOULU L, 1984, J EXP MED, V160, P1509, DOI 10.1084/jem.160.5.1509; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEVER WF, 1965, PEMPHIGUS PEMPHIGOID, P75; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; PICKART CM, 1988, UBIQUITIN, P77; Rechsteiner M., 1988, UBIQUITIN; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; ROCK B, 1990, J CLIN INVEST, V85, P296, DOI 10.1172/JCI114426; ROCK B, 1989, NEW ENGL J MED, V320, P1463, DOI 10.1056/NEJM198906013202206; ROSCOE JT, 1985, J INVEST DERMATOL, V85, P538, DOI 10.1111/1523-1747.ep12277362; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANLEY JR, 1986, J IMMUNOL, V136, P1227; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; SULLIVAN ML, 1989, P NATL ACAD SCI USA, V86, P9861, DOI 10.1073/pnas.86.24.9861; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANEDEN W, 1991, BIOCHEM SOC T, V19, P171, DOI 10.1042/bst0190171; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	55	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15829	15835						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379239				2022-12-27	WOS:A1992JG11300087
J	RAHMAN, MA; NELSON, H; WEISSBACH, H; BROT, N				RAHMAN, MA; NELSON, H; WEISSBACH, H; BROT, N			CLONING, SEQUENCING, AND EXPRESSION OF THE ESCHERICHIA-COLI PEPTIDE METHIONINE SULFOXIDE REDUCTASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED ALPHA-1-PROTEINASE INHIBITOR; ENZYMATIC REDUCTION; PROTEINS; RESIDUES; BIOCHEMISTRY; DNA; THIOREDOXIN; PROBES; FLUID	The gene encoding peptide methionine sulfoxide reductase was cloned from an Escherichia coli genomic library using an oligonucleotide probe based on the amino-terminal sequence of the protein. The nucleotide sequence revealed that the gene codes for a polypeptide of 212 amino acid residues with a calculated molecular weight of 23,314. The protein has been overexpressed in E. coli and is present as a soluble active species.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								ABRAMS WR, 1981, P NATL ACAD SCI-BIOL, V78, P7483, DOI 10.1073/pnas.78.12.7483; Ausubel FM, 1988, MOL REPROD DEV; BLACK S, 1960, J BIOL CHEM, V235, P2910; BROT N, 1981, P NATL ACAD SCI-BIOL, V78, P2155, DOI 10.1073/pnas.78.4.2155; BROT N, 1991, BIOFACTORS, V3, P91; BROT N, 1982, ANAL BIOCHEM, V122, P291, DOI 10.1016/0003-2697(82)90283-4; BROT N, 1984, METHOD ENZYMOL, V107, P352; BROT N, 1982, TRENDS BIOCHEM SCI, V7, P137, DOI 10.1016/0968-0004(82)90204-3; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; Brot N., 1988, CHEM FUNCT GROUPS, P851; CARP H, 1982, P NATL ACAD SCI-BIOL, V79, P2041, DOI 10.1073/pnas.79.6.2041; COCHRANE CG, 1983, J CLIN INVEST, V71, P754, DOI 10.1172/JCI110823; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EJIRI SI, 1979, J BACTERIOL, V139, P161, DOI 10.1128/JB.139.1.161-164.1979; FLISS H, 1982, BIOCHEM BIOPH RES CO, V109, P194, DOI 10.1016/0006-291X(82)91584-4; GARNER MH, 1980, P NATL ACAD SCI-BIOL, V77, P1274, DOI 10.1073/pnas.77.3.1274; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUNKAPILLER MW, 1986, METHODS PROTEIN MICR, P315; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANCHEZ J, 1983, PLANT PHYSIOL, V73, P619, DOI 10.1104/pp.73.3.619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; SPECTOR A, 1982, BIOCHEM BIOPH RES CO, V108, P429, DOI 10.1016/0006-291X(82)91884-8; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRUSCOTT RJW, 1977, BIOCHIM BIOPHYS ACTA, V492, P43, DOI 10.1016/0005-2795(77)90212-4; WALLACE RB, 1981, NUCLEIC ACIDS RES, V9, P879, DOI 10.1093/nar/9.4.879; WONG PS, 1980, BIOCHEM BIOPH RES CO, V96, P1449, DOI 10.1016/0006-291X(80)90113-8; 1992, TAQ DYEDEOXY TERMINA; 1990, STEP BY STEP PROTOCO	35	66	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15549	15551						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386361				2022-12-27	WOS:A1992JG11300047
J	REINES, D; GHANOUNI, P; LI, QQ; MOTE, J				REINES, D; GHANOUNI, P; LI, QQ; MOTE, J			THE RNA POLYMERASE-II ELONGATION COMPLEX - FACTOR-DEPENDENT TRANSCRIPTION ELONGATION INVOLVES NASCENT RNA CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-S-II; FACTOR-SII; PREMATURE TERMINATION; TERNARY COMPLEXES; DNA-SEQUENCE; GENE; PURIFICATION; INVITRO; INVIVO; TFIIS	Regulation of transcription elongation is an important mechanism in controlling eukaryotic gene expression. SII is an RNA polymerase II-binding protein that stimulates transcription elongation and also activates nascent transcript cleavage by RNA polymerase II in elongation complexes in vitro (Reines, D. (1992) J. Biol. Chem. 267, 3795-3800). Here we show that SII-dependent in vitro transcription through an arrest site in a human gene is preceded by nascent transcript cleavage. RNA cleavage appeared to be an obligatory step in the SII activation process. Recombinant SII activated cleavage while a truncated derivative lacking polymerase binding activity did not. Cleavage was not restricted to an elongation complex arrested at this particular site, showing that nascent RNA hydrolysis is a general property of RNA polymerase II elongation complexes. These data support a model whereby SII stimulates elongation via a ribonuclease activity of the elongation complex.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University	REINES, D (corresponding author), EMORY UNIV,SCH MED,GRAD PROGRAM BIOCHEM & MOLEC BIOL,ATLANTA,GA 30322, USA.		excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NIGMS NIH HHS [GM-46331, R01 GM046331] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; ATKINSON MR, 1969, BIOCHEMISTRY-US, V8, P4897, DOI 10.1021/bi00840a037; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; CHAFIN DR, 1991, J BIOL CHEM, V266, P9256; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CLARK AB, 1991, MOL CELL BIOL, V11, P2576, DOI 10.1128/MCB.11.5.2576; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; COOPERMAN BS, 1982, METHOD ENZYMOL, V87, P526; DEUTSCHER MP, 1969, J BIOL CHEM, V244, P3019; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; HORIKOSHI N, 1990, J BIOL CHEM, V265, P11854; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; HUET J, 1976, NATURE, V261, P431, DOI 10.1038/261431a0; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KIPLING D, 1991, NATURE, V353, P509, DOI 10.1038/353509a0; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADERIOUS A, 1984, P NATL ACAD SCI-BIOL, V81, P5931, DOI 10.1073/pnas.81.19.5931; MAITRA U, 1967, J BIOL CHEM, V242, P4897; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; MOK M, 1984, MOL CELL BIOL, V4, P2031, DOI 10.1128/MCB.4.10.2031; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1991, ANAL BIOCHEM, V196, P367, DOI 10.1016/0003-2697(91)90480-H; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1991, J BIOL CHEM, V266, P10510; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SHIRAI T, 1991, P NATL ACAD SCI USA, V88, P9056, DOI 10.1073/pnas.88.20.9056; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; SPINDLER SR, 1979, BIOCHEMISTRY-US, V18, P4042, DOI 10.1021/bi00585a031; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TABOR S, 1990, J BIOL CHEM, V265, P8322; THAYER GC, 1985, MOL GEN GENET, V199, P55, DOI 10.1007/BF00327509; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	48	101	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15516	15522						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379232				2022-12-27	WOS:A1992JG11300042
J	CELANO, P; BERCHTOLD, CM; KIZER, DL; WEERARATNA, A; NELKIN, BD; BAYLIN, SB; CASERO, RA				CELANO, P; BERCHTOLD, CM; KIZER, DL; WEERARATNA, A; NELKIN, BD; BAYLIN, SB; CASERO, RA			CHARACTERIZATION OF AN ENDOGENOUS RNA TRANSCRIPT WITH HOMOLOGY TO THE ANTISENSE STRAND OF THE HUMAN C-MYC GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON CARCINOMA-CELLS; MESSENGER-RNA; ALU SEQUENCE; EXPRESSION; COMPLEMENTARY; POLYAMINES; PROMOTER; ELEMENT; CHROMATOGRAPHY; BACTERIOPHAGE	In addition to being regulated by a complex array of cis- and trans-acting factors, c-myc protooncogene expression may be modulated by antisense RNA transcripts. Our previous studies have determined that depletion of intracellular polyamines by alpha-difluoromethylornithine results in a marked decrease in the transcription of the human c-myc gene. Because of reports that antisense transcription occurs in the 5' and 3' regions of this gene, we used a genomic clone of the human c-myc gene to ascertain whether polyamine depletion might induce an antisense RNA transcript. These studies demonstrate that polyamine depletion of the human colon cancer cell line COLO 320 results in induction of an endogenous RNA transcript with high homology to the antisense strand of the second intervening sequence (PvuII-RsaI) of the c-myc gene. Furthermore, during such depletion, steady state levels of this transcript vary inversely to the sense direction c-myc RNA. RNase protection studies suggest that the antisense transcript may arise from a different gene locus than the c-myc gene. To further identify the origins of this RNA, a cDNA library was generated from size-selected RNA and screened with c-myc sequences. A 438-base pair cDNA was isolated with almost-equal-to 85% homology, to a 285-base region in the second intron of the c-myc gene. Computer homology analysis further reveals that a 120-base region within this cDNA also has almost-equal-to 85% homology to the antisense strands of a number of genes, including the growth-related genes, N-myc, p53, and thymidine kinase. These studies provide the initial characterization of an endogenous antisense RNA transcript which could influence cell growth by modulating the expression of c-myc and other genes.			CELANO, P (corresponding author), JOHNS HOPKINS ONCOL CTR LABS,424 N BOND ST,BALTIMORE,MD 21231, USA.			Casero, Robert/0000-0001-5653-3306	NATIONAL CANCER INSTITUTE [R01CA051085, R29CA047492, R29CA051068] Funding Source: NIH RePORTER; NCI NIH HHS [CA51085, CA47492, CA 51068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADENIYIJONES S, 1985, NATURE, V317, P81, DOI 10.1038/317081a0; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CALABRETTA B, 1991, CANCER RES, V51, P4505; CELANO P, 1989, J BIOL CHEM, V264, P8922; CELANO P, 1988, J BIOL CHEM, V263, P5491; CELANO P, 1989, BIOCHEM BIOPH RES CO, V165, P384, DOI 10.1016/0006-291X(89)91082-6; CESARENI G, 1991, TRENDS GENET, V7, P230, DOI 10.1016/0168-9525(91)90370-6; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; INOUYE M, 1988, GENE, V72, P25, DOI 10.1016/0378-1119(88)90124-2; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KINDY MS, 1987, MOL CELL BIOL, V7, P2857, DOI 10.1128/MCB.7.8.2857; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MARCUSSEKURA CJ, 1988, ANAL BIOCHEM, V172, P289, DOI 10.1016/0003-2697(88)90447-2; MCCARTHY TL, 1983, BIOCHEMISTRY-US, V22, P935, DOI 10.1021/bi00273a035; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; SAFFER JD, 1989, MOL CELL BIOL, V9, P355, DOI 10.1128/MCB.9.2.355; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIMONS RW, 1988, GENE, V72, P35, DOI 10.1016/0378-1119(88)90125-4; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; ULLU E, 1982, CELL, V29, P195, DOI 10.1016/0092-8674(82)90103-9; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; VILIJN F, 1989, J BIOL CHEM, V264, P11901; WEIKKILA R, 1987, NATURE, V328, P445; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209	49	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15092	15096						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378845				2022-12-27	WOS:A1992JF08800086
J	NYKJAER, A; PETERSEN, CM; MOLLER, B; JENSEN, PH; MOESTRUP, SK; HOLTET, TL; ETZERODT, M; THOGERSEN, HC; MUNCH, M; ANDREASEN, PA; GLIEMANN, J				NYKJAER, A; PETERSEN, CM; MOLLER, B; JENSEN, PH; MOESTRUP, SK; HOLTET, TL; ETZERODT, M; THOGERSEN, HC; MUNCH, M; ANDREASEN, PA; GLIEMANN, J			PURIFIED ALPHA-2-MACROGLOBULIN RECEPTOR LDL RECEPTOR-RELATED PROTEIN BINDS UROKINASE-BULLET-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 COMPLEX - EVIDENCE THAT THE ALPHA-2-MACROGLOBULIN RECEPTOR MEDIATES CELLULAR DEGRADATION OF UROKINASE RECEPTOR-BOUND COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONOCLONAL-ANTIBODIES; HUMAN-MONOCYTES; PURIFICATION; IDENTIFICATION; EXPRESSION; SEQUENCE; CONFORMATION; MOLECULE; FRAGMENT; SURFACE	Complexes between I-125-labeled urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) bound to purified alpha-2-macroglobulin (alpha-2M) receptor (alpha-2MR)/low density lipoprotein receptor-related protein (LRP). No binding was observed when using uPA. The magnitude of uPA . PAI-1 binding was comparable with that of the alpha-2MR-associated protein (alpha-2MRAP). Binding of uPA . PAI-1 was blocked by natural and recombinant alpha-2MRAP, and about 80% inhibited by complexes between tissue-type plasminogen activator (tPA) and PAI-1, and by a monoclonal anti-PAI-1 antibody. In human monocytes, uPA . PAI-1, like uPA and its amino-terminal fragment, bound to the urokinase receptor (uPAR). Degradation of uPAR-bound I-125 uPA . PAI-1 was 3-4-fold enhanced as compared with uncomplexed uPAR-bound uPA. The inhibitor-enhanced uPA degradation was blocked by r-alpha-2MRAP and inhibited by polyclonal anti-alpha-2MR/LRP antibodies. This is taken as evidence for mediation of internalization and degradation of uPAR-bound uPA . PAI-1 by alpha-2MR/LRP.	AARHUS UNIV,DEPT CLIN IMMUNOL,DK-8000 AARHUS,DENMARK; AARHUS UNIV,GENE EXPRESS LAB,DK-8000 AARHUS,DENMARK; AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS,DENMARK	Aarhus University; Aarhus University; Aarhus University	NYKJAER, A (corresponding author), AARHUS UNIV,INST MED BIOCHEM,OLE WORMS ALLE,BLDG 170,DK-8000 AARHUS,DENMARK.		Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Nykjaer, Anders/0000-0001-6422-6736; Jensen, Poul Henning/0000-0002-4439-9020				ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; GRONDAHLHANSEN J, 1987, J INVEST DERMATOL, V88, P28, DOI 10.1111/1523-1747.ep12464827; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NIELSEN LS, 1986, THROMB HAEMOSTASIS, V55, P206; NYKJAER A, 1992, FEBS LETT, V300, P13, DOI 10.1016/0014-5793(92)80154-9; NYKJAER A, 1990, BIOCHIM BIOPHYS ACTA, V1052, P399, DOI 10.1016/0167-4889(90)90149-8; PETERSEN CM, 1987, SCAND J CLIN LAB INV, V47, P55; PLOUG M, 1991, J BIOL CHEM, V266, P1926; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86	36	460	472	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14543	14546						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378833				2022-12-27	WOS:A1992JF08800008
J	KUNKEL, GR; DANZEISER, DA				KUNKEL, GR; DANZEISER, DA			FORMATION OF A TEMPLATE COMMITTED COMPLEX ON THE PROMOTER OF A GENE FOR THE U6 SMALL NUCLEAR-RNA FROM THE HUMAN REQUIRES MULTIPLE SEQUENCE ELEMENTS, INCLUDING THE DISTAL REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTION; UPSTREAM PROMOTER; EFFICIENT TRANSCRIPTION; FUNCTIONAL ELEMENTS; U2 SNRNA; ENHANCER; INITIATION; INVITRO; U1; INTERMEDIATE	Vertebrate U6 small nuclear RNA (snRNA) loci exemplify a novel class of polymerase III-transcribed genes that lack an intragenic control region (ICR). Instead important transcriptional control elements are located in the 5'-flanking region and resemble those found in promoters and enhancers of polymerase II-transcribed genes. These include a proximal sequence element (PSE), a TATA element, and a distal region containing, at least, an octamer motif. We have used Sarkosyl to characterize steps in U6 promoter transcription in vitro in an unfractionated S100 extract and find very similar properties to those of the adenovirus VA1 gene that contains an ICR. Preformed preinitiation complexes are stable to 0.015% Sarkosyl and can undergo multiple rounds of initiation upon addition of nucleoside triphosphates. A higher concentration (0.075%) prevents reinitiation. In addition, we have investigated the formation of transcription complexes on this promoter in a S100 extract using a template competition assay. No stable complexes are detected with plasmid templates that contain clustered point mutations in the PSE nor with DNAs lacking the U6 5'-flanking region. A plasmid template containing mutations in the TATA element is partially deficient in competitive ability. Furthermore, the distal region upstream of position -148 is necessary for efficient stable complex formation. Within this region, the consensus octamer motif is one component needed to form complexes that withstand competition by a wild-type U6 promoter. The human U2 gene enhancer ligated to the U6 proximal region supports formation of a complex that competes at an intermediate level.			KUNKEL, GR (corresponding author), TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843, USA.			Kunkel, Gary/0000-0002-4199-369X				ACH RA, 1991, NUCLEIC ACIDS RES, V19, P4209, DOI 10.1093/nar/19.15.4209; ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; BAER M, 1990, NUCLEIC ACIDS RES, V18, P97, DOI 10.1093/nar/18.1.97; BARK C, 1987, NATURE, V328, P356, DOI 10.1038/328356a0; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; COOLEY L, 1982, P NATL ACAD SCI-BIOL, V79, P6475, DOI 10.1073/pnas.79.21.6475; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; DINGERMANN T, 1983, J BIOL CHEM, V258, P395; FUHRMAN SA, 1984, J BIOL CHEM, V259, P1934; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GUNDERSON SI, 1988, J BIOL CHEM, V263, P17603; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; JANSON L, 1987, NUCLEIC ACIDS RES, V15, P4997, DOI 10.1093/nar/15.13.4997; KELEKAR A, 1990, MOL BIOL REP, V14, P173, DOI 10.1007/BF00360463; KLEINERT H, 1988, NUCLEIC ACIDS RES, V16, P1319, DOI 10.1093/nar/16.4.1319; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; KROL A, 1987, NUCLEIC ACIDS RES, V15, P2463, DOI 10.1093/nar/15.6.2463; KUNKEL GR, 1986, P NATL ACAD SCI USA, V83, P8575, DOI 10.1073/pnas.83.22.8575; KUNKEL GR, 1989, NUCLEIC ACIDS RES, V17, P7371, DOI 10.1093/nar/17.18.7371; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; LASSAR AB, 1983, SCIENCE, V222, P760; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MANGIN M, 1986, EMBO J, V5, P987, DOI 10.1002/j.1460-2075.1986.tb04313.x; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MATTAJ IW, 1985, NATURE, V316, P163, DOI 10.1038/316163a0; MCNAMARA KJ, 1987, NUCLEIC ACIDS RES, V15, P9239, DOI 10.1093/nar/15.22.9239; MURPHY JT, 1987, J BIOL CHEM, V262, P1795; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; REDDY R, 1988, J BIOL CHEM, V263, P15980; REDDY R, 1987, J BIOL CHEM, V262, P75; ROEBUCK KA, 1987, MOL CELL BIOL, V7, P4185, DOI 10.1128/MCB.7.12.4185; ROEBUCK KA, 1990, MOL CELL BIOL, V10, P341, DOI 10.1128/MCB.10.1.341; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SETZER DR, 1985, J BIOL CHEM, V260, P2483; SIMMEN KA, 1990, NUCLEIC ACIDS RES, V18, P5649, DOI 10.1093/nar/18.19.5649; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; TEBB G, 1988, EMBO J, V7, P3785, DOI 10.1002/j.1460-2075.1988.tb03263.x; TEBB G, 1989, MOL CELL BIOL, V9, P1682, DOI 10.1128/MCB.9.4.1682; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WIEBEN ED, 1991, NUCLEIC ACIDS RES, V19, P2869, DOI 10.1093/nar/19.11.2869; WILLIAMS JB, 1990, METHOD ENZYMOL, V181, P451; YUAN Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P33, DOI 10.1016/0167-4781(91)90081-V; ZAMROD Z, 1990, NUCLEIC ACIDS RES, V18, P7323, DOI 10.1093/nar/18.24.7323	61	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14250	14258						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378440				2022-12-27	WOS:A1992JD32500072
J	HUMPHRIES, DE; NICODEMUS, CF; SCHILLER, V; STEVENS, RL				HUMPHRIES, DE; NICODEMUS, CF; SCHILLER, V; STEVENS, RL			THE HUMAN SERGLYCIN GENE - NUCLEOTIDE-SEQUENCE AND METHYLATION PATTERN IN HUMAN PROMYELOCYTIC LEUKEMIA HL-60 CELLS AND T-LYMPHOBLAST MOLT-4 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; SECRETORY GRANULE PROTEOGLYCANS; HUMAN-PLATELET PROTEOGLYCAN; MOUSE MAST-CELL; PEPTIDE CORE; DNA METHYLATION; MOLECULAR-CLONING; HEPARIN PROTEOGLYCANS; MESSENGER-RNA; ALU FAMILY	The complete nucleotide sequence of the 16.7-kb human gene that encodes the peptide core (serglycin) of a secretory granule proteoglycan was determined, thus representing the first proteoglycan peptide core gene to be sequenced in its entirety. The exons, intron 1, and intron 2 comprised 7, 53, and 40% of the gene, respectively. Nineteen Alu-repetitive DNA sequences were interspersed in the gene, accounting for 28% of the total nucleotides in intron 1 and 40% of the nucleotides in intron 2. The nucleotide sequence was then used in an examination of the methylation pattern of the human serglycin gene in human promyelocytic leukemia HL-60 cells that contain serglycin mRNA and in T-lymphoblast Molt-4 cells that do not. With polymerase chain reaction methodology, 13 DNA probes of 250-880 base pairs in length were generated that corresponded to unique, non-Alu sequences spaced throughout the entire human serglycin gene. When blots containing genomic DNA digested with HpaII or MspI were examined with these genomic probes, it was discovered that the 5'-flanking region and intron 1 of the serglycin gene in HL-60 cells were both substantially less methylated than intron 2. In contrast, the entire serglycin gene in Molt-4 cells was highly methylated. Because hypomethylated genes generally are transcribed more efficiently than hypermethylated genes, the high level of serglycin mRNA in HL-60 cells probably is a consequence of the low level of methylation of intron 1 and the 5'-flanking region of the serglycin gene in these cells.	HARVARD UNIV,SCH MED,DEPT VET AFFAIRS OUTPATIENT CLIN,SEELEY MUDD BLDG,RM 617,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005950] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-05950] Funding Source: Medline; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-23483] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; ADANY R, 1991, BIOCHEM J, V276, P301, DOI 10.1042/bj2760301; ADANY R, 1990, J BIOL CHEM, V265, P11389; ALLIEL PM, 1988, FEBS LETT, V236, P123, DOI 10.1016/0014-5793(88)80298-9; ANGERTH T, 1990, GENE, V93, P235, DOI 10.1016/0378-1119(90)90230-O; ARIGA T, 1990, GENOMICS, V8, P607, DOI 10.1016/0888-7543(90)90246-Q; AVRAHAM S, 1992, J BIOL CHEM, V267, P610; AVRAHAM S, 1988, J BIOL CHEM, V263, P7292; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BOURDON MA, 1987, MOL CELL BIOL, V7, P33, DOI 10.1128/MCB.7.1.33; BOURDON MA, 1986, J BIOL CHEM, V261, P12253; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DONEHOWER LA, 1989, NUCLEIC ACIDS RES, V17, P699, DOI 10.1093/nar/17.2.699; FORSBERG LS, 1988, BIOCHIM BIOPHYS ACTA, V967, P416, DOI 10.1016/0304-4165(88)90105-5; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; KRILIS SA, 1992, BLOOD, V79, P144, DOI 10.1182/blood.V79.1.144.bloodjournal791144; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; LISKA DJ, 1990, CELL REGUL, V1, P487, DOI 10.1091/mbc.1.6.487; LOHMANDER LS, 1990, J BIOL CHEM, V265, P5802; MACDERMOTT RP, 1985, J EXP MED, V162, P1771, DOI 10.1084/jem.162.6.1771; MATTEI MG, 1989, HUM GENET, V82, P87, DOI 10.1007/BF00288281; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; METCALFE DD, 1980, J BIOL CHEM, V255, P1753; NICODEMUS CF, 1990, J BIOL CHEM, V265, P5889; RAZIN E, 1982, J BIOL CHEM, V257, P7229; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; RHODES C, 1939, NUCLEIC ACIDS RES, V19, P1933; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; ROTHENBERG ME, 1988, J BIOL CHEM, V263, P13901; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING, P916; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID CW, 1985, MOL EVOLUTIONARY GEN, P323; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; SLAGEL V, 1987, MOL BIOL EVOL, V4, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STELLRECHT CM, 1989, NUCLEIC ACIDS RES, V17, P7523, DOI 10.1093/nar/17.18.7523; STEVENS RL, 1985, J BIOL CHEM, V260, P4194; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; STEVENS RL, 1986, J IMMUNOL, V137, P291; STEVENS RL, 1988, J BIOL CHEM, V263, P7287; TANAKA K, 1983, CELL, V35, P457, DOI 10.1016/0092-8674(83)90179-4; TANTRAVAHI RV, 1986, P NATL ACAD SCI USA, V83, P9207, DOI 10.1073/pnas.83.23.9207; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON HL, 1988, J IMMUNOL, V140, P2708; ULLU E, 1982, CELL, V29, P195, DOI 10.1016/0092-8674(82)90103-9; WAALWIJK C, 1978, NUCLEIC ACIDS RES, V5, P3231, DOI 10.1093/nar/5.9.3231; WANG LQ, 1991, J BIOL CHEM, V266, P19878; WILLARD C, 1987, J MOL EVOL, V26, P180, DOI 10.1007/BF02099850; WOODSSAMUELS P, 1991, GENOMICS, V10, P94, DOI 10.1016/0888-7543(91)90489-2; YURT RW, 1977, J BIOL CHEM, V252, P518; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	63	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13558	13563						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377686				2022-12-27	WOS:A1992JB74600073
J	MCDONOUGH, PM; GLEMBOTSKI, CC				MCDONOUGH, PM; GLEMBOTSKI, CC			INDUCTION OF ATRIAL-NATRIURETIC-FACTOR AND MYOSIN LIGHT CHAIN-2 GENE-EXPRESSION IN CULTURED VENTRICULAR MYOCYTES BY ELECTRICAL-STIMULATION OF CONTRACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEART-CELLS; ALPHA-1-ADRENERGIC RECEPTOR; MEMBRANE DEPOLARIZATION; CARDIAC MYOCYTES; RAT; HYPERTROPHY; GROWTH; TRANSCRIPTION; SEQUENCES; PATHWAYS	While hormonal stimuli and mechanical stretch can induce cardiac-specific gene expression and in some cases cellular hypertrophy, the relationship between myocyte contraction frequency, gene expression, and myocyte growth has not been well characterized. In this study a new model system was developed in which cultures of neonatal rat ventricular myocytes were subjected to long term pacing of contractions with pulsatile electrical stimulation. Myocytes submitted to electrical stimulation for 3 days displayed dramatic increases in cellular size and myofibrillar organization, and a 5-10-fold increase in the expression of the cardiac genes atrial natriuretic factor and myosin light chain-2. Atrial natriuretic factor expression induced by electrical stimulation of contractions was inhibited by nifedipine or W7, indicating a dependence on calcium influx and calmodulin activity. Phosphoinositide hydrolysis and cAMP formation were not affected by electrical stimulation suggesting that gene induction occurred independently of the activation of protein kinases C or A above basal levels. These findings show that the cellular events associated with contraction, such as changes in cytoplasmic free calcium levels and/or cellular stretch, may serve as important determinants of myocyte growth and cardiac gene expression.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; SAN DIEGO STATE UNIV,INST MOLEC BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University; California State University System; San Diego State University					NINDS NIH HHS [NS-25037] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BLOCH KD, 1986, CELL, V47, P695, DOI 10.1016/0092-8674(86)90512-X; BREVET A, 1976, SCIENCE, V193, P1152, DOI 10.1126/science.959833; BROWNSON C, 1988, MUSCLE NERVE, V11, P1183, DOI 10.1002/mus.880111113; DESNOS C, 1990, DEV BRAIN RES, V52, P161, DOI 10.1016/0165-3806(90)90231-M; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; JOHNSON CL, 1990, AM J PHYSIOL, V258, pC533, DOI 10.1152/ajpcell.1990.258.3.C533; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KUMAR CC, 1986, J BIOL CHEM, V261, P2866; LEE HR, 1988, J BIOL CHEM, V263, P7352; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MCDERMOTT P, 1985, AM J PHYSIOL, V249, pH763, DOI 10.1152/ajpheart.1985.249.4.H763; MCDERMOTT PJ, 1991, J BIOL CHEM, V266, P4409; MERCADIER JJ, 1989, AM J PHYSIOL, V257, pH979, DOI 10.1152/ajpheart.1989.257.3.H979; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SAMAREL AM, 1991, AM J PHYSIOL, V261, pH1067, DOI 10.1152/ajpheart.1991.261.4.H1067; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SEI CA, 1991, J BIOL CHEM, V266, P15910; SEIDMAN CE, 1988, P NATL ACAD SCI USA, V85, P4104, DOI 10.1073/pnas.85.11.4104; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1989, J MOL CELL CARDIOL, V21, P79, DOI 10.1016/0022-2828(89)90774-8; UNDERWOOD LE, 1987, AM J PHYSIOL, V252, pC450, DOI 10.1152/ajpcell.1987.252.4.C450; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WIER G, 1990, ANNU REV PHYSIOL, V52, P467; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	37	103	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11665	11668						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376309				2022-12-27	WOS:A1992HY94700002
J	HANCOCK, K; LEBLANC, AJ; DONZE, D; HAJDUK, SL				HANCOCK, K; LEBLANC, AJ; DONZE, D; HAJDUK, SL			IDENTIFICATION OF NUCLEAR ENCODED PRECURSOR TRANSFER-RNAS WITHIN THE MITOCHONDRION OF TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICED TRANSFER-RNA; YEAST MITOCHONDRIA; LIGASE ACTIVITIES; RIBONUCLEASE-P; PROTEIN IMPORT; DNA; TRANSCRIPTION; ORGANIZATION; TRANSPORT; GENES	RNAs that function in mitochondria are typically encoded by the mitochondrial DNA. However, the mitochondrial tRNAs of Trypanosoma brucei are encoded by the nuclear DNA and therefore must be imported into the mitochondrion. It is becoming evident that RNA import into mitochondria is phylogenetically widespread and is essential for cellular processes, but virtually nothing is known about the mechanism of RNA import. We have identified and characterized mitochondrial precursor tRNAs in T. brucei. The identification of mitochondrially located precursor tRNAs clearly indicates that mitochondrial tRNAs are imported as precursors. The mitochondrial precursor tRNAs hybridize to cloned nuclear tRNA genes, label with [alpha-P-32]CTP using yeast tRNA nucleotidyltransferase and in isolated mitochondria via an endogenous nucleotidyltransferase-like activity, and are processed to mature tRNAs by Escherichia coli and yeast mitochondrial RNase P. We show that T. brucei mitochondrial extract contains an RNase P activity capable of processing a prokaryotic tRNA precursor as well as the T. brucei tRNA precursors. Precursors for tRNA(Asn) and tRNA(Leu) were detected on Northern blots of mitochondrial RNA, and the 5' ends of these RNAs were characterized by primer extension analysis. The structure of the precursor tRNAs and the significance of nuclear encoded precursor tRNAs within the mitochondrion are discussed.	UNIV ALABAMA, SCH MED, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [AI21401] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021401, R21AI021401] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; ALTMAN S, 1990, J BIOL CHEM, V265, P20053; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CAMPBELL DA, 1989, MOL BIOCHEM PARASIT, V37, P257, DOI 10.1016/0166-6851(89)90157-6; CAMPBELL DA, 1989, NUCLEIC ACIDS RES, V17, P9479, DOI 10.1093/nar/17.22.9479; CHEN JY, 1990, J BIOL CHEM, V265, P16221; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DELP G, 1991, NUCLEIC ACIDS RES, V19, P713, DOI 10.1093/nar/19.4.713; DEROBERTIS EM, 1981, CELL, V23, P89, DOI 10.1016/0092-8674(81)90273-7; DEUTSCHER MP, 1984, CRC CR REV BIOCH MOL, V17, P45, DOI 10.3109/10409238409110269; DEUTSCHER MP, 1982, ENZYMES, V15, P183, DOI DOI 10.1016/S1874-6047(08)60279-6; FAIRLAMB AH, 1978, J CELL BIOL, V76, P293, DOI 10.1083/jcb.76.2.293; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOPINATHAN KP, 1990, TRANSFER RNAS OTHER, P103; GRAY MW, 1988, PHILOS T R SOC B, V319, P135, DOI 10.1098/rstb.1988.0038; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HANCOCK K, 1992, IN PRESS NUCLEIC ACI, V20; HANICJOYCE PJ, 1990, J BIOL CHEM, V265, P13782; HARADA F, 1975, NUCLEIC ACIDS RES, V2, P865, DOI 10.1093/nar/2.6.865; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; JOYCE PBM, 1989, NUCLEIC ACIDS RES, V17, P5461, DOI 10.1093/nar/17.14.5461; MARCHFELDER A, 1990, NUCLEIC ACIDS RES, V18, P1401, DOI 10.1093/nar/18.6.1401; MARECHALDROUARD L, 1988, NUCLEIC ACIDS RES, V16, P4777, DOI 10.1093/nar/16.11.4777; MARECHALDROUARD L, 1990, NUCLEIC ACIDS RES, V18, P3689, DOI 10.1093/nar/18.13.3689; MARTIN NC, 1985, J BIOL CHEM, V260, P1479; MELTON DA, 1980, NATURE, V284, P143, DOI 10.1038/284143a0; MOTTRAM JC, 1991, NUCLEIC ACIDS RES, V19, P3995, DOI 10.1093/nar/19.14.3995; MOTTRAM JC, 1991, J BIOL CHEM, V266, P18313; NISHIKURA K, 1981, J MOL BIOL, V145, P405, DOI 10.1016/0022-2836(81)90212-6; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; PACE NR, 1990, J BIOL CHEM, V265, P3587; PADAYATTY JD, 1990, TRANSFER RNAS OTHER, P129; PRITCHARD AE, 1990, NUCLEIC ACIDS RES, V18, P173, DOI 10.1093/nar/18.1.173; Sambrook J, 1989, MOL CLONING LABORATO; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SLOOF P, 1985, NUCLEIC ACIDS RES, V13, P4171, DOI 10.1093/nar/13.11.4171; SUYAMA Y, 1967, BIOCHEMISTRY-US, V6, P2829, DOI 10.1021/bi00861a025; SUYAMA Y, 1978, ARCH BIOCHEM BIOPHYS, V191, P437, DOI 10.1016/0003-9861(78)90382-X; SUYAMA Y, 1986, CURR GENET, V10, P411, DOI 10.1007/BF00418415; TOBIAN JA, 1985, CELL, V43, P415, DOI 10.1016/0092-8674(85)90171-0; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; VESTWEBER D, 1989, NATURE, V338, P170, DOI 10.1038/338170a0; WHITE TC, 1987, NUCLEIC ACIDS RES, V15, P3275, DOI 10.1093/nar/15.8.3275; ZASLOFF M, 1982, NATURE, V300, P81, DOI 10.1038/300081a0; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	48	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23963	23971						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385429				2022-12-27	WOS:A1992JZ23900080
J	ANDRESS, DL; BIRNBAUM, RS				ANDRESS, DL; BIRNBAUM, RS			HUMAN OSTEOBLAST-DERIVED INSULIN-LIKE GROWTH-FACTOR (IGF) BINDING PROTEIN-5 STIMULATES OSTEOBLAST MITOGENESIS AND POTENTIATES IGF ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR (IGF)-BINDING PROTEIN-1; MESSENGER RIBONUCLEIC-ACID; VASCULAR ENDOTHELIAL-CELLS; FETAL-RAT BONE; FACTOR-I; ENRICHED CULTURES; DNA-SYNTHESIS; COLLAGEN-SYNTHESIS; MOLECULAR-CLONING; INHIBITS BINDING	Insulin-like growth factor (IGF)-binding proteins (IGFBPs) either inhibit or enhance IGF-stimulated cellular effects. While inhibition occurs by sequestration of IGF from cell-surface receptors, the exact mechanism of IGF-enhancement remains undefined. Human osteoblast-like bone cells in culture secrete several IGF-binding proteins, one of which we have previously identified as IGFBP-5. In this study we purified a 23-kDa IGFBP-5 from cultures of human osteoblast-like cells using ligand affinity chromatography and reversed-phase high performance liquid chromatography and tested its bioactivity in serum-free cultures of normal mouse osteoblast-like cells. Binding studies with radioiodinated IGF showed similar and relatively low affinities for IGF-I and IGF-II consistent with a carboxyl truncated IGF-binding protein. Mitogenic assays demonstrated that the binding protein, when coincubated with IGF-I or -II, enhanced mitogenesis. This enhancement was unique from other binding proteins in not requiring a preincubation period or serum cofactors. Furthermore, the osteoblast-derived IGFBP-5 stimulated mitogenesis in the absence of exogenous or endogenous IGF. Using radioiodinated IGFBP-5 we found that the binding protein could associate with the osteoblast surface, an effect which did not require IGF nor an interaction with the IGF receptors. We suggest that osteoblast-derived IGFBP-5 may stimulate osteoblast mitogenesis in at least two ways, by association with IGF and by a second pathway that is independent of IGF receptor activation.	VET ADM MED CTR,CTR GERIAT RES EDUC & CLIN,TACOMA,WA 98493; VET ADM MED CTR,RES SERV,SEATTLE,WA 98108; VET ADM MED CTR,RES SERV,TACOMA,WA 98493; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98108	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	ANDRESS, DL (corresponding author), VET ADM MED CTR,MED SERV,111A,1660 S COLUMBIAN WAY,SEATTLE,WA 98108, USA.							ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BENNETT A, 1984, ENDOCRINOLOGY, V115, P1577, DOI 10.1210/endo-115-4-1577; BICSAK TA, 1990, ENDOCRINOLOGY, V126, P2184, DOI 10.1210/endo-126-4-2184; BLAT C, 1989, J BIOL CHEM, V264, P12449; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BOOTH BA, 1990, ENDOCRINOLOGY, V127, P2630, DOI 10.1210/endo-127-6-2630; BOWSHER RR, 1991, ENDOCRINOLOGY, V128, P815; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BURCH WM, 1990, J CLIN ENDOCR METAB, V70, P173, DOI 10.1210/jcem-70-1-173; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CANALIS E, 1988, ENDOCRINOLOGY, V122, P22, DOI 10.1210/endo-122-1-22; CANALIS E, 1988, J CLIN INVEST, V81, P277, DOI 10.1172/JCI113318; CANALIS E, 1991, ENDOCRINOLOGY, V129, P2457, DOI 10.1210/endo-129-5-2457; CANALIS E, 1988, CALCIFIED TISSUE INT, V43, P346, DOI 10.1007/BF02553277; CENTRELLA M, 1990, ENDOCRINOLOGY, V126, P39, DOI 10.1210/endo-126-1-39; CHEN TL, 1991, ENDOCRINOLOGY, V128, P2489, DOI 10.1210/endo-128-5-2489; CHEN TL, 1991, CALCIFIED TISSUE INT, V48, P278, DOI 10.1007/BF02556380; CLEMMONS DR, 1990, J CELL PHYSIOL, V145, P129, DOI 10.1002/jcp.1041450118; CLEMMONS DR, 1986, J CLIN INVEST, V77, P1548, DOI 10.1172/JCI112470; CLEMMONS DR, 1991, MODERN CONCEPTS INSU, P475; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DEUL TF, 1987, ANN REV CELL BIOL, V3, P4533; ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo-125-2-825; ERNST M, 1990, ENDOCRINOLOGY, V127, P807, DOI 10.1210/endo-127-2-807; FEYEN JHM, 1991, J BIOL CHEM, V266, P19469; FROLIK CA, 1988, BIOCHEM BIOPH RES CO, V151, P1011, DOI 10.1016/S0006-291X(88)80466-2; GOPINATH R, 1989, J ENDOCRINOL, V120, P231, DOI 10.1677/joe.0.1200231; HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES JI, 1991, P NATL ACAD SCI USA, V88, P7481, DOI 10.1073/pnas.88.17.7481; JONES JI, 1992, 74TH ANN M END SOC S, P372; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KNAUER DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7252, DOI 10.1073/pnas.77.12.7252; KOISTINEN R, 1990, BIOCHEM BIOPH RES CO, V173, P408, DOI 10.1016/S0006-291X(05)81073-3; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; LIPFORD GB, 1990, ANAL BIOCHEM, V187, P133, DOI 10.1016/0003-2697(90)90430-H; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1990, ENDOCRINOLOGY, V126, P1569, DOI 10.1210/endo-126-3-1569; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MOHAN S, 1988, BIOCHIM BIOPHYS ACTA, V966, P44, DOI 10.1016/0304-4165(88)90127-4; MOHAN S, 1989, J CELL PHYSIOL, V140, P169, DOI 10.1002/jcp.1041400120; MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338; RITVOS O, 1988, ENDOCRINOLOGY, V122, P2150, DOI 10.1210/endo-122-5-2150; ROSS M, 1989, BIOCHEM J, V258, P267, DOI 10.1042/bj2580267; SCHMID C, 1991, BIOCHEM BIOPH RES CO, V179, P579, DOI 10.1016/0006-291X(91)91410-E; SCHMID C, 1989, BIOCHEM BIOPH RES CO, V160, P788, DOI 10.1016/0006-291X(89)92502-3; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; TRESSEL TJ, 1991, BIOCHEM BIOPH RES CO, V178, P625, DOI 10.1016/0006-291X(91)90154-Y; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	59	323	332	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22467	22472						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385400				2022-12-27	WOS:A1992JW71900075
J	MIZUUCHI, K				MIZUUCHI, K			POLYNUCLEOTIDYL TRANSFER-REACTIONS IN TRANSPOSITIONAL DNA RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PHAGE-MU TRANSPOSASE; STRAND TRANSFER; BACTERIOPHAGE-MU; RETROVIRAL DNA; B-PROTEIN; TETRAHYMENA RIBOZYME; TN10 TRANSPOSITION; TARGET SITE; VIRAL-DNA; INTEGRATION				MIZUUCHI, K (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.							ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BAKER TA, 1992, IN PRESS GENES DEV; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; Berg DE, 1989, MOBILE DNA; BETERMIER M, 1990, MOL MICROBIOL, V3, P1159; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; BURGIN AB, 1992, IN PRESS P NATL ACAD; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CHOLS H, 1990, J BIOL CHEM, V265, P14697; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DESMET L, 1989, MOL MICROBIOL, V3, P1145, DOI 10.1111/j.1365-2958.1989.tb00265.x; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; ENGELMAN A, 1992, IN PRESS J VIROL; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GAMAS P, 1992, NUCLEIC ACIDS RES, V20, P2525, DOI 10.1093/nar/20.10.2525; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HANIFORD DB, 1991, CELL, V64, P171; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HANIFORD DB, 1992, IN PRESS CURR OPIN G; HARSHEY RM, 1986, J GENET, V65, P159, DOI 10.1007/BF02931149; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1991, P NATL ACAD SCI USA, V88, P4695, DOI 10.1073/pnas.88.11.4695; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; PAN GH, 1992, J BIOL CHEM, V267, P12397; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; RUBY SW, 1991, TRENDS GENET, V7, P79; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VANGENT DC, 1992, IN PRESS P NATL ACAD; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	56	122	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21273	21276						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383220				2022-12-27	WOS:A1992JV01100001
J	BALBONA, K; TRAN, H; GODYNA, S; INGHAM, KC; STRICKLAND, DK; ARGRAVES, WS				BALBONA, K; TRAN, H; GODYNA, S; INGHAM, KC; STRICKLAND, DK; ARGRAVES, WS			FIBULIN BINDS TO ITSELF AND TO THE CARBOXYL-TERMINAL HEPARIN-BINDING REGION OF FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA FIBRONECTIN; EXTRACELLULAR-MATRIX; PROTEIN; DOMAINS; GLYCOPROTEIN; COMPONENT; SITE; C1Q	Fibulin is a recently described extracellular matrix (ECM) and plasma glycoprotein (Argraves, W. S., Tran, H., Burgess, W. H., and Dickerson, K. (1990) J. Cell Biol. 111, 3155-3164). In this report, ligand affinity chromatography and solid-phase binding analyses were performed to determine which ECM protein(s) interact with fibulin. Fibulin-Sepharose bound two polypeptides of 240 and 100 kDa from the culture medium of metabolically radiolabeled fibroblasts. These two proteins were identified as fibronectin (FN) and fibulin, respectively, based on their electrophoretic behavior and reactivity with monoclonal antibodies. Consistent with the findings of affinity chromatography, fibulin bound to surfaces coated with FN (either plasma or cellular form) or fibulin but not with other ECM proteins, such as laminin, merosin, and types I and IV collagen. The binding of fibulin to solid-phase FN was estimated to have a K(d) of 139 nM, whereas the K(d) for self-interaction was 322 nM. Evaluation of proteolytic fragments from all regions of FN allowed a fibulin-binding site to be localized within a 23-kDa heparin-binding fragment containing type III repeats 13-14. Heparin did not compete for the interaction between fibulin and FN, suggesting that the binding sites for fibulin and heparin are distinct.	AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855	American Red Cross					NIGMS NIH HHS [GM-42912] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; HYNES RO, 1989, SPRINGER SERIES MOL, P39; INGHAM KC, 1983, MOL IMMUNOL, V20, P287, DOI 10.1016/0161-5890(83)90068-8; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; INGHAM KC, 1985, EUR J BIOCHEM, V148, P219, DOI 10.1111/j.1432-1033.1985.tb08828.x; ISEMURA M, 1987, J BIOL CHEM, V262, P8926; KIMIZUKA F, 1991, J BIOCHEM-TOKYO, V110, P284, DOI 10.1093/oxfordjournals.jbchem.a123572; KLUGE M, 1990, EUR J BIOCHEM, V193, P651, DOI 10.1111/j.1432-1033.1990.tb19383.x; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN DM, 1990, J BIOL CHEM, V265, P5317; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MOSESSON MW, 1975, BIOCHIM BIOPHYS ACTA, V386, P509, DOI 10.1016/0005-2795(75)90294-9; Mosher D F, 1980, Prog Hemost Thromb, V5, P111; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SALONEN EM, 1984, J BIOL CHEM, V259, P1496; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SPENCE SG, 1992, DEV BIOL, V151, P473, DOI 10.1016/0012-1606(92)90186-K	24	97	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20120	20125						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400330				2022-12-27	WOS:A1992JR85800060
J	CHANDRASEKARAN, EV; JAIN, RK; MATTA, KL				CHANDRASEKARAN, EV; JAIN, RK; MATTA, KL			MUCIN BIOSYNTHESIS REVISITED - THE ENZYMATIC TRANSFER OF GAL IN BETA-1,3 LINKAGE TO THE GALNAC MOIETY OF THE CORE STRUCTURE R(1)-GLCNAC-BETA-1,6GALNAC-ALPHA-O-R(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDES; GLYCOPROTEINS; TRACHEA	Synthetic glycosides containing the core, -GlcNAcbeta1,6GalNAcalpha-, acted as acceptors for beta-galactosyltransferase of human ovarian tumor. A significant amount of Gal was transferred from UDP-Gal (100 nmol) to the alpha-benzylglycoside of LacNAcbeta1,6GalNAc (LGBn) (25.1 nmol of Gal) and the alpha-ortho-nitrophenylglycosides of LacNAcbeta1,6GalNAc (22.0 nmol of Gal), GlcNAcbeta1,6GalNAc (15.5 nmol of Gal), and Fucalpha1,3GlcNAcbeta1,6GalNAc (25.9 nmol of Gal); LacNAcbeta1,6(Galbeta1,3)GalNAcalpha-O-Bn (where Bn is benzyl) was almost inactive (only 1.2 nmol of Gal), indicating the Gal transfer to the alpha-GalNAc moiety. The product from LGBn was isolated in microgram quantities and identified by fast atom bombardment mass spectrometry as LacNAcbeta1,6(Galbeta1,3)GalNAcalpha-O-Bn. The alphaGalNAc:beta1,3Gal transferase was present in high concentration in ovarian tumor tissue (ovarian cancer serum --> 1.4; ascitic fluid --> 0.9; tumor --> 17.4). Asialo Cowper's gland mucin (ACGM) at 5 mg/ml reaction mixture inhibited the transfer of Gal to LGBn (25.2 and 53.4% respectively for 2 and 18 h incubation at 37-degrees-C); inhibition by LGBn was 13.4 and 24.5%, respectively. In contrast to the inhibition by ACGM (25.2-31.6%), there was substantial increase (13.4-35. 7%) in the inhibition by LGBn, when the incubation for 2 h at 37-degrees-C was continued for 40 h at 4-degrees-C, indicating the high affinity of LGBn for the enzyme at lower temp. K(m) for LGBn in presence of ACGM was 7.6 mM and in absence, 2.7 mm; K(m) for ACGM (M(r) 200,000) in presence of LGBn was 16.1 muM and K(i) for ACGM (as the inhibitor) was 41.7 muM. In comparison with two normal ovarian tissues, the enzyme was found to be low (55-67%) in three ovarian tumors and high (146-260%) in two ovarian and one uterus tumors, as measured with ACGM; the synthetic acceptors showed similar activities. The enzyme had nearly the same extent of activity in the pH range 6-8. Fucalpha1,3GlcNAcbeta1,6GalNAcalpha-O-ONP had the highest affinity for the enzyme. The present study demonstrates the feasibility of beta1,3Gal attachment on alphaGalNAc, which has already been substituted by beta1,6GlcNAc, then elongated by beta1,4Gal and also terminated by alpha1,3Fuc.			CHANDRASEKARAN, EV (corresponding author), ROSWELL PK CANC INST,DEPT GYNECOL ONCOL,BUFFALO,NY 14263, USA.				NATIONAL CANCER INSTITUTE [R01CA035329] Funding Source: NIH RePORTER; NCI NIH HHS [CA35329] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIGAD G, 1962, J BIOL CHEM, V237, P2736; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; BROCKHAUSEN I, 1992, BIOCHEM CELL BIOL, V70, P99, DOI 10.1139/o92-015; HANISCH FG, 1986, EUR J BIOCHEM, V155, P239, DOI 10.1111/j.1432-1033.1986.tb09482.x; HOUNSELL EF, 1985, EUR J BIOCHEM, V148, P367, DOI 10.1111/j.1432-1033.1985.tb08848.x; JAIN RK, 1992, CARBOHYD RES, V288, P243; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; LUDOWIEG.JJ, 1968, CARBOHYD RES, V8, P185, DOI 10.1016/S0008-6215(00)80154-8; MENDICINO J, 1982, J BIOL CHEM, V257, P3987; SHEARES BT, 1983, J BIOL CHEM, V258, P9893; VANHALBEEK H, 1985, FEBS LETT, V187, P81, DOI 10.1016/0014-5793(85)81219-9; WILLIAMS D, 1980, J BIOL CHEM, V255, P1253; YAZAWA S, 1990, ANAL BIOCHEM, V187, P374, DOI 10.1016/0003-2697(90)90472-L; YAZAWA S, 1986, CARBOHYD RES, V149, P241, DOI 10.1016/S0008-6215(00)90381-1	14	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19929	19937						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400309				2022-12-27	WOS:A1992JR85800032
J	BERGUM, PW; GARDELL, SJ				BERGUM, PW; GARDELL, SJ			VAMPIRE BAT SALIVARY PLASMINOGEN-ACTIVATOR EXHIBITS A STRICT AND FASTIDIOUS REQUIREMENT FOR POLYMERIC FIBRIN AS ITS COFACTOR, UNLIKE HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR - A KINETIC-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; DEGRADATION PRODUCTS; KRINGLE-2 DOMAIN; HUMAN-PLASMA; ONE-CHAIN; BINDING; CLEAVAGE; CLONING; FINGER	The vampire bat salivary plasminogen activator (BatPA) is virtually inactive toward Glu-plasminogen in the absence of a fibrin-like cofactor, unlike human tissue-type plasminogen activator (tPA) (the k(cat)/K(m) values were 4 and 470 M-1 s-1, respectively). In the presence of fibrin II, tPA and BatPA activated Gluplasminogen with comparable catalytic efficiencies (158,000 and 174,000 M-1 s-1, respectively). BatPA's cofactor requirement was partially satisfied by polymeric fibrin I (54,000 m-1 s-1), but monomeric fibrin I was virtually ineffective (970 m-1 s-1). By comparison, a variety of monomeric and polymeric fibrin-like species markedly enhanced tPA-mediated activation of Glu-plasminogen. Fragment X polymer was 2-fold better but 9-fold worse as cofactor for tPA and BatPA, respectively, relative to fibrin II. Fibrinogen, devoid of plasminogen, was a 10-fold better cofactor for tPA than fibrinogen rigorously depleted of plasminogen, Factor XIII, and fibronectin; the enhanced stimulatory effect of the less-purified fibrinogen was apparently due to the presence of Factor XIII. By contrast, the two fibrinogen preparations were equally poor cofactors of BatPA-mediated activation of Glu-plasminogen. BatPA possessed only 23 and 4% of the catalytic efficiencies of tPA and two-chain tPA, respectively, in hydrolyzing the chromogenic substrate Spectrozyme tPA. However in the presence of fibrin II, BatPA and tPA exhibited similar k(cat)/K(m) values for the hydrolysis of Spectrozyme tPA. Our data revealed that BatPA, unlike tPA, displayed a strict and fastidious requirement for polymeric fibrin I or II. Consequently, BatPA may preferentially promote plasmin generation during a narrow temporal window of fibrin formation and dissolution.	MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,W POINT,PA 19486	Merck & Company								ANDREASEN PA, 1991, FIBRINOLYSIS, V5, P207, DOI 10.1016/0268-9499(91)90002-L; ARNOLD AER, 1989, J AM COLL CARDIOL, V14, P581, DOI 10.1016/0735-1097(89)90096-X; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BERGUM P W, 1990, Fibrinolysis, V4, P86; Blomback B., 1956, ARK KEMI, V10, P415; CAMIOLO SM, 1971, P SOC EXP BIOL MED, V138, P277; CARSON SD, 1985, COMPUT PROG BIOMED, V19, P151, DOI 10.1016/0010-468X(85)90006-6; COLLEN D, 1988, ANNU REV MED, V39, P405, DOI 10.1146/annurev.me.39.020188.002201; DEMUNK GAW, 1989, BIOCHEMISTRY-US, V28, P7318, DOI 10.1021/bi00444a026; FRETTO LJ, 1978, J BIOL CHEM, V253, P2184; GAFFNEY PJ, 1973, BIOCHIM BIOPHYS ACTA, V295, P308, DOI 10.1016/0005-2795(73)90098-6; GARDELL SJ, 1990, BLOOD, V76, P2560; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; GARDELL SJ, 1991, CIRCULATION, V84, P244, DOI 10.1161/01.CIR.84.1.244; GREENBERG CS, 1982, J BIOL CHEM, V257, P6096; Hantgan RR, 1987, HEMOSTASIS THROMBOSI, P269; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; JANUS TJ, 1983, BIOCHEMISTRY-US, V22, P2669; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MELLOTT MJ, 1992, ARTERIOSCLER THROMB, V12, P212, DOI 10.1161/01.ATV.12.2.212; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NIEUWENHUIZEN W, 1988, TISSUE TYPE PLASMINO, V1, P171; NIEUWENHUIZEN W, 1985, FIBRINOGEN STRUCTURA, P331; NORRMAN B, 1985, EUR J BIOCHEM, V149, P193, DOI 10.1111/j.1432-1033.1985.tb08911.x; NOSSEL HL, 1981, NATURE, V291, P165, DOI 10.1038/291165a0; OWEN J, 1987, J CLIN INVEST, V79, P1642, DOI 10.1172/JCI113001; PANNEKOEK H, 1988, Fibrinolysis, V2, P123, DOI 10.1016/0268-9499(88)90025-2; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; SHEN LL, 1977, J BIOL CHEM, V252, P6184; SOBEL BE, 1987, CIRCULATION, V76, P39; STUMP DC, 1989, CIRCULATION, V80, P1222, DOI 10.1161/01.CIR.80.5.1222; SUENSON E, 1990, J BIOL CHEM, V265, P22228; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; TOPOL EJ, 1989, SEMIN HEMATOL, V26, P25; URANO T, 1988, BIOCHEM BIOPH RES CO, V150, P45, DOI 10.1016/0006-291X(88)90484-6; URANO T, 1988, BIOCHEMISTRY-US, V27, P6522, DOI 10.1021/bi00417a049; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; WALLEN P, 1970, BIOCHIM BIOPHYS ACTA, V221, P20, DOI 10.1016/0005-2795(70)90194-7	42	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17726	17731						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387641				2022-12-27	WOS:A1992JM22300040
J	LACEY, SF; REARDON, JE; FURFINE, ES; KUNKEL, TA; BEBENEK, K; ECKERT, KA; KEMP, SD; LARDER, BA				LACEY, SF; REARDON, JE; FURFINE, ES; KUNKEL, TA; BEBENEK, K; ECKERT, KA; KEMP, SD; LARDER, BA			BIOCHEMICAL-STUDIES ON THE REVERSE-TRANSCRIPTASE AND RNASE-H ACTIVITIES FROM HUMAN-IMMUNODEFICIENCY-VIRUS STRAINS RESISTANT TO 3'-AZIDO-3'-DEOXYTHYMIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACEBO-CONTROLLED TRIAL; ZIDOVUDINE AZT; DNA-POLYMERASE; DOUBLE-BLIND; HIV; 5'-TRIPHOSPHATE; SENSITIVITY; SPECIFICITY; MUTATIONS; EFFICACY	A series of biochemical investigations to compare the DNA polymerase and RNase H functions of the reverse transcriptases (RTs) corresponding to azidothymidine (AZT)-sensitive and -resistant human immunodeficiency virus (HIV) strains are described. Steady-state kinetic studies with purified recombinant enzymes utilizing several templates and three inhibitors, 3'azido-3'deoxythymidine triphosphate (AZTTP), 3-aminothymidine 5'-triphosphate, and 2',3'-didehydro-2',3'-dideoxythymidine 5'-triphosphate, found consistent 2-4-fold differences between the enzymes from the two strains over a wide pH range. A strong pH dependence for all three inhibitors was found at pH values below 7.4 and suggested an ionizable group on the enzyme with a pK of about 7. The sensitivities of the RNase H activities of the two enzymes to AZTTP and AZTMP were also compared and found to be similar. The nucleotide incorporation fidelities of recombinant RTs corresponding to AZT-sensitive and -resistant clinical isolates were compared and the error specificities determined. No significant differences were found. Both enzymes were equally able to incorporate AZTTP into an elongating M13 DNA strand with concomitant chain termination. Purified wild-type and mutant virions from cell-culture supernatants were compared in "endogenous" DNA synthesis reactions, and the sensitivities of this activity to AZTTP were found to be similar. The contrast between the small differences found in this study and the high level of viral resistance in tissue culture presumably reflects an incomplete understanding of AZT inhibition of HIV in the cell.	WELLCOME RES LABS,DEPT EXPTL THERAPY,RES TRIANGLE PK,NC 27709; NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709	Wellcome Research Laboratories; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	LACEY, SF (corresponding author), WELLCOME RES LABS,DEPT MOLEC SCI,BECKENHAM BR3 3BS,KENT,ENGLAND.		Larder, Brendan/AAB-3106-2020; Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FURFINE ES, 1991, J BIOL CHEM, V266, P406; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HANDLON AL, 1988, PHARMACEUT RES, V5, P297, DOI 10.1023/A:1015926720740; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REMINGTON KM, 1991, J VIROL, V65, P308, DOI 10.1128/JVI.65.1.308-312.1991; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TAN CK, 1991, BIOCHEMISTRY-US, V30, P4831, DOI 10.1021/bi00234a001; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; WAINBERG MA, 1990, ANN NY ACAD SCI, V616, P346	23	127	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15789	15794						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379238				2022-12-27	WOS:A1992JG11300081
J	BEPPU, M; MIZUKAMI, A; ANDO, K; KIKUGAWA, K				BEPPU, M; MIZUKAMI, A; ANDO, K; KIKUGAWA, K			ANTIGENIC DETERMINANTS OF SENESCENT ANTIGEN OF HUMAN ERYTHROCYTES ARE LOCATED IN SIALYLATED CARBOHYDRATE CHAINS OF BAND-3 GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDO-BETA-GALACTOSIDASE; BLOOD-GROUP I; STRUCTURAL REQUIREMENTS; MEMBRANE-PROTEIN; BINDING; CELLS; OLIGOSACCHARIDES; SURFACE; MOIETY; LACTOSAMINOGLYCAN	Naturally occurring IgG autoantibody against Band 3 glycoprotein of human erythrocyte membrane (anti-Band 3) recognizes the erythrocytes modified with oxidizing or SH-blocking agents as well as senescent erythrocytes. Location of the antigenic determinants of Band 3 this autoantibody recognizes was investigated by competitive inhibition studies of the antibody binding to the modified cells. Autologous IgG binds to the modified erythrocytes, and purified Band 3 totally inhibits the binding. This inhibitory activity of Band 3 was not affected by digestion of Band 3 with various proteases. Treatment of Band 3 with endo-beta-galactosidase that destroys the poly-N-acetyllactosaminyl sugar chain of Band 3 or with neuraminidase resulted in loss of the inhibitory activity. Oligosaccharides released from Band 3 by hydrazinolysis effectively inhibited the binding of autologous IgG and I-125-labeled purified anti-Band 3 to the modified cells, whereas the oligosaccharides depleted of acidic components did not. Endo-beta-galactosidase and neuraminidase destroyed the activity of the oligosaccharides, but alpha-L-fucosidase did not. Furthermore, human lactoferrin that contains sialylated two N-acetyllactosaminyl units also exhibited potent inhibitory activity, and the activity was destroyed by endo-beta-galactosidase and neuraminidase. These results indicate that the antigenic determinants of Band 3 are located in sialylated poly-N-acetyllactosaminyl sugar chains. Based on this finding, mechanism of appearance of the antigen on senescent erythrocytes recognized by anti-Band 3 (senescent antigen) was discussed.	TOKYO COLL PHARM,1432-1 HORINOUCHI,HACHIOJI,TOKYO 19203,JAPAN	Tokyo University of Pharmacy & Life Sciences								ALDERMAN EM, 1980, BLOOD, V55, P817; AMINOFF D, 1985, CELLULAR MOL ASPECTS, P279; BEPPU M, 1990, J BIOL CHEM, V265, P3226; BEPPU M, IN PRESS J PHARMACOB; DRICKAMER LK, 1978, J BIOL CHEM, V253, P7242; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FOURNET B, 1978, BIOCHEMISTRY-US, V17, P5206, DOI 10.1021/bi00617a021; FUKUDA M, 1980, P NATL ACAD SCI-BIOL, V77, P3474, DOI 10.1073/pnas.77.6.3474; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1978, J BIOL CHEM, V253, P2419; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; FUKUDA MN, 1976, J BIOL CHEM, V251, P6218; FURTHMAYR H, 1975, BIOCHEM BIOPH RES CO, V65, P113, DOI 10.1016/S0006-291X(75)80068-4; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IRIMURA T, 1981, BIOCHEMISTRY-US, V20, P560, DOI 10.1021/bi00506a018; JAY DG, 1986, BIOCHEMISTRY-US, V25, P554, DOI 10.1021/bi00351a006; KAY MMB, 1983, P NATL ACAD SCI-BIOL, V80, P1631, DOI 10.1073/pnas.80.6.1631; KAY MMB, 1978, J SUPRAMOL STR CELL, V9, P555, DOI 10.1002/jss.400090409; KAY MMB, 1981, NATURE, V289, P491, DOI 10.1038/289491a0; KAY MMB, 1990, P NATL ACAD SCI USA, V87, P5734, DOI 10.1073/pnas.87.15.5734; KHANSARI N, 1983, MECH AGEING DEV, V21, P49, DOI 10.1016/0047-6374(83)90015-5; LOW PS, 1985, SCIENCE, V227, P531, DOI 10.1126/science.2578228; LUTS HU, 1983, BIOMED BIOCHIM ACTA, V402, pS117; LUTS HU, 1984, J IMMUNOL, V133, P2610; MARCHESI VT, 1971, SCIENCE, V174, P1247, DOI 10.1126/science.174.4015.1247; MATSUMOTO A, 1982, J BIOCHEM-TOKYO, V91, P143, DOI 10.1093/oxfordjournals.jbchem.a133671; NIEMANN H, 1978, BIOCHEM BIOPH RES CO, V81, P1286, DOI 10.1016/0006-291X(78)91275-5; PRUZANSKI W, 1977, NEW ENGL J MED, V297, P583, DOI 10.1056/NEJM197709152971105; SCHLEPPERSCHAFER J, 1983, BIOCHEM BIOPH RES CO, V115, P551, DOI 10.1016/S0006-291X(83)80180-6; SCHLUTER K, 1986, P NATL ACAD SCI USA, V83, P6137, DOI 10.1073/pnas.83.16.6137; Spiro R G, 1973, Adv Protein Chem, V27, P349, DOI 10.1016/S0065-3233(08)60451-9; THOMAS DB, 1974, EUR J IMMUNOL, V4, P819, DOI 10.1002/eji.1830041210; TSUJI T, 1980, BIOCHEM J, V187, P677, DOI 10.1042/bj1870677; TSUJI T, 1981, J BIOL CHEM, V256, P497; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; VAYSSE J, 1986, P NATL ACAD SCI USA, V83, P1339, DOI 10.1073/pnas.83.5.1339; WATANABE K, 1979, J BIOL CHEM, V254, P3221; YAMAMOTO K, 1987, AGR BIOL CHEM TOKYO, V51, P1995, DOI 10.1080/00021369.1987.10868324	39	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14691	14696						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378838				2022-12-27	WOS:A1992JF08800032
J	YUAN, HB; DOUGLAS, MG				YUAN, HB; DOUGLAS, MG			THE MITOCHONDRIAL F1ATPASE ALPHA-SUBUNIT IS NECESSARY FOR EFFICIENT IMPORT OF MITOCHONDRIAL PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; YEAST NUCLEAR GENE; COMPLEX; TRANSLOCATION; F1-ATPASE; VIABILITY; MATRIX; ATPASE	The mitochondrial import and assembly of the F1ATPase subunits requires, respectively, the participation of the molecular chaperones hsp70SSA1 and hsp70SSC1 and other components operating on opposite sides of the mitochondrial membrane. In previous studies, both the homology and the assembly properties of the F1ATPase alpha-subunit (ATP1p) compared to the groEL homologue, hsp60, have led to the proposal that this subunit could exhibit chaperone-like activity. In this report the extent to which this subunit participates in protein transport has been determined by comparing import into mitochondria that lack the F1ATPase alpha-subunit (DELTA-ATP1) versus mitochondria that lack the other major catalytic subunit, the F1ATPase beta-subunit (DELTA-ATP2). Yeast mutants lacking the alpha-subunit but not the beta-subunit grow much more slowly than expected on fermentable carbon sources and exhibit delayed kinetics of protein import for several mitochondrial precursors such as the F1-beta subunit, hsp60MIF4 and subunits 4 and 5 of the cytochrome oxidase. In vitro and in vivo the F1-beta-subunit precursor accumulates as a translocation intermediate in absence of the F1-alpha-subunit. In the absence of both the ATPase subunits yeast grows at the same rate as a strain lacking only the beta-subunit, and import of mitochondrial precursors is restored to that of wild type. These data indicate that the F1-alpha-subunit likely functions as an "assembly partner" to influence protein import rather than functioning directly as a chaperone. These data are discussed in light of the relationship between the import and assembly of proteins in mitochondria.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CB 7260 FAC LAB OFF BLDG,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036537] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36537] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; AVNI A, 1991, J BIOL CHEM, V266, P7317; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BOUSQUET I, 1991, EMBO J, V10, P2023, DOI 10.1002/j.1460-2075.1991.tb07732.x; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DOUGLAS MG, 1991, INTRACELLULAR TRAFFI, P658; GASSER SM, 1982, J BIOL CHEM, V257, P3034; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; HALLBERG E, 1989, NATURE, V337, P620; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HOWRWICH A, 1990, CURR OPIN CELL BIOL, V2, P625; HWANG ST, 1991, J BIOL CHEM, V266, P21083; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; LUIS A, 1990, J BIOL CHEM, V265, P7413; Maniatis T., 1982, MOL CLONING; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; PFANNER N, 1990, J BIOL CHEM, V265, P16324; REID GA, 1982, J BIOL CHEM, V257, P3062; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SHERMAN F, 1979, METHODS YEAST GENETI, P1; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	36	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14697	14702						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386080				2022-12-27	WOS:A1992JF08800033
J	LOYA, S; TAL, R; HUGHES, SH; HIZI, A				LOYA, S; TAL, R; HUGHES, SH; HIZI, A			THE EFFECTS OF CYSTEINE MUTATIONS ON THE CATALYTIC ACTIVITIES OF THE REVERSE-TRANSCRIPTASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DNA-POLYMERASE; ESCHERICHIA-COLI; RETROVIRUS; AIDS	The reverse transcriptase (RT) of the human immunodeficiency virus type 1 (HIV-1) has only 2 cysteine residues at positions 38 and 280. In order to investigate the role of these cysteines in the structure and function of the enzyme, we have previously modified each of the cysteines to serines employing site-directed mutagenesis. Two of the mutant forms of HIV-1 RT, the single mutant of cysteine 280 and a double mutant with both cysteines modified, were purified. In the present study we have compared the catalytic properties of the DNA-polymerizing and the ribonuclease H (RNase H) functions of the two mutant RTs to those of the native enzyme. The results indicate that the single mutant RT closely resembles the wild type enzyme in almost all the catalytic functions tested. The double cysteine mutant RT, on the other hand, exhibits several unique features. First, the specific activities of the RNA- and DNA-directed DNA synthesis are significantly lower than the corresponding activities of the other two enzymes. This probably results from the lower V(max) values exhibited by the double mutant RT, since the K(m) values calculated for all enzymes were similar. Second, the most outstanding differences are associated with the RNase H activity of the double mutant RT. The specific activity of RNase H is about 4-fold higher than the wild type and the single mutant RTs. Furthermore, the heat stability of the RNase H function of the double mutated RT is at least 15-fold higher than that of the other two RTs. The substantial resistance to heat denaturation is apparent only for the RNase H activity, since the DNA polymerizing function of the double mutant RT is as sensitive to heat denaturation as the other two proteins.	TEL AVIV UNIV,SACKLER SCH MED,DEPT CELL BIOL & HISTOL,IL-69978 TEL AVIV,ISRAEL; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21701	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIAID NIH HHS [R0I-AI 27035] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027035] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AULD DS, 1974, P NATL ACAD SCI USA, V71, P2091, DOI 10.1073/pnas.71.5.2091; AULD DS, 1975, BIOCHEM BIOPH RES CO, V62, P296, DOI 10.1016/S0006-291X(75)80137-9; BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMNER I, 1987, METALLOTHIONEIN, V2, P81; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HIZI A, 1980, J VIROL, V34, P795, DOI 10.1128/JVI.34.3.795-801.1980; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HIZI A, 1992, J BIOL CHEM, V267, P1293; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1991, J BIOL CHEM, V266, P6230; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KORENBERG A, 1982, DNA REPLICATION; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MITSUYA H, 1991, FASEB J, V5, P2369, DOI 10.1096/fasebj.5.10.1712326; MYERS G, 1990, HUMAN RETROVIRUSES A; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SPANOS A, 1981, NUCLEIC ACIDS RES, V9, P1825, DOI 10.1093/nar/9.8.1825; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; Weiss R, 1982, RNA TUMOR VIRUSES; Weiss R, 1985, RNA TUMOR VIRUSES; YARCHOAN R, 1991, BLOOD, V78, P859	29	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13879	13883						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378433				2022-12-27	WOS:A1992JD32500017
J	WHITE, RT; DAMM, D; HANCOCK, N; ROSEN, BS; LOWELL, BB; USHER, P; FLIER, JS; SPIEGELMAN, BM				WHITE, RT; DAMM, D; HANCOCK, N; ROSEN, BS; LOWELL, BB; USHER, P; FLIER, JS; SPIEGELMAN, BM			HUMAN ADIPSIN IS IDENTICAL TO COMPLEMENT FACTOR-D AND IS EXPRESSED AT HIGH-LEVELS IN ADIPOSE-TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASE HOMOLOG; AMINO-ACID-SEQUENCE; INSULIN-RECEPTOR; MESSENGER-RNA; FACTOR-B; BIOSYNTHESIS; PROTEINS; MONOCYTES; PATHWAY; CELLS	A cDNA for human adipsin was isolated and shown to encode a protein sharing 98% amino acid sequence similarity with the protein sequence previously determined for purified natural human complement factor D. Like mouse adipsin, recombinant human adipsin displays the enzymatic activity of human complement factor D, cleaving complement factor B only when B is complexed with activated complement component C3. We conclude that human adipsin is equivalent to complement factor D and that adipsin is the homologue of factor D in rodents. Adipose tissue is a major site of synthesis of human adipsin/complement factor D mRNA, but unlike the case in rodents, human adipsin mRNA is also expressed in monocytes/macrophages. The data presented here, demonstrating the equivalence of human adipsin to complement factor D and its high level of expression in fat, suggest a previously unsuspected role for adipose tissue in immune system biology.	UNIV EDINBURGH,AGR & FOOD RES COUNCIL,CTR GENOME RES,EDINBURGH EH9 3JQ,SCOTLAND; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	University of Edinburgh; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	WHITE, RT (corresponding author), CALIF BIOTECHNOL INC,2450 BAYSHORE PKWY,MT VIEW,CA 94043, USA.		Flier, jeffrey/AAG-6223-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405, R01DK031405, R01DK042539] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31405, DK42539] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNUM SR, 1985, J IMMUNOL, V134, P1799; BEATTY DW, 1981, CLIN IMMUNOL IMMUNOP, V18, P334, DOI 10.1016/0090-1229(81)90126-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; DECEULAER C, 1980, IMMUNOLOGY, V41, P37; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GROSSO LE, 1985, CANCER RES, V45, P847; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JANATOVA J, 1980, BIOCHEMISTRY-US, V19, P4471; KING GL, 1980, J CLIN INVEST, V66, P130, DOI 10.1172/JCI109826; LESAVRE PH, 1979, J IMMUNOL, V123, P529; Maniatis T., 1982, MOL CLONING; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; NIEMANN MA, 1984, BIOCHEMISTRY-US, V23, P2482, DOI 10.1021/bi00306a025; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; TAYLOR SI, 1981, P NATL ACAD SCI-BIOL, V78, P7157, DOI 10.1073/pnas.78.11.7157; TOMANA M, 1985, MOL IMMUNOL, V22, P107, DOI 10.1016/S0161-5890(85)80004-3; WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; XU QY, 1988, ANAL BIOCHEM, V170, P19, DOI 10.1016/0003-2697(88)90084-X	26	300	323	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9210	9213						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374388				2022-12-27	WOS:A1992HR85400077
J	OTSU, K; KINSELLA, JL; KOH, E; FROEHLICH, JP				OTSU, K; KINSELLA, JL; KOH, E; FROEHLICH, JP			PROTON DEPENDENCE OF THE PARTIAL REACTIONS OF THE SODIUM-PROTON EXCHANGER IN RENAL BRUSH-BORDER MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; INTRACELLULAR PH REGULATION; PRESTEADY-STATE KINETICS; FROG SKIN; VESICLES; AMILORIDE; ANTIPORT; KIDNEY; MECHANISM; TRANSPORT	The pre-steady state time dependence of Na+ accumulation by the Na+-H+ exchanger in renal brush border membrane vesicles was investigated at 0-degrees-C by a manual mixing technique using amiloride to quench the reaction. Dilution of acid-loaded (pH(i) 5.7) vesicles into an alkaline medium (pH(o) 7.7) containing 1 mM Na-22(+) produced a time course of amiloride-sensitive Na+ uptake that consisted of three distinct phases: 1) a lag, 2) a monoexponential "burst," and 3) a linear or steady state phase. Experiments testing for the presence of Na-22(+) backflux, residual Na+ binding to the membrane, and hysteresis were negative, lending support to the hypothesis that the burst phase corresponds to Na+ translocation during the initial turnover of Na+-H+ exchanger. Lowering the internal pH increased the amount of Na+ uptake in each of the phases without affecting the apparent burst rate, whereas lowering the external pH inhibited Na+ uptake while increasing the duration of the lag phase. The pattern of inhibition produced by external H+ was of the simple competitive type, indicating that Na+ and H+ share a common binding site. Steady state Na+ uptake showed a sigmoidal dependence on internal pH (Hill coefficient = 1.67), consistent with the presence of an internal allosteric H+ activation site. Alkaline loading conditions (pH(i) 7.7), which favor desaturation of the internal H+ binding sites, completely abolished Na+ uptake in the steady state. In contrast, Na+ accumulation during the burst phase was reduced to 25% of an acid-loaded (pH(i) 5.7) control. The persistence of the burst phase and the disappearance of steady state Na+ uptake under alkaline loading conditions suggest that recycling of the H+-loaded exchanger is a late event in the transport cycle that follows Na+ translocation (ping-pong mechanism) and controls the steady state rate of Na+ accumulation. Activation of the recycling step involves sequential binding of H+ to the allosteric and transport sites, thus accounting for the cooperative dependence of steady state Na+ uptake on the internal [H+].	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA; NIA,CARDIOVASC SCI LAB,BALTIMORE,MD 21224	University of Toronto; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								ARONSON PS, 1983, J BIOL CHEM, V258, P6767; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; Booth A G, 1974, Biochem J, V142, P575; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; CHOEN J, 1988, J BIOL CHEM, V263, P2309; CUTHBERT AW, 1974, MOL PHARMACOL, V10, P880; CUTHBERT AW, 1978, BRIT J PHARMACOL, V63, P139, DOI 10.1111/j.1476-5381.1978.tb07783.x; FRIEDEN C, 1970, J BIOL CHEM, V245, P5788; FROEHLICH O, 1986, BIOCHIM BIOPHYS ACTA, V864, P169; Frost AA, 1961, KINETICS MECHANISM, P166; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; IVES HE, 1983, J BIOL CHEM, V258, P9710; KINSELLA J, 1984, J BIOL CHEM, V259, P3224; KINSELLA JL, 1980, AM J PHYSIOL, V238, pF461, DOI 10.1152/ajprenal.1980.238.6.F461; KINSELLA JL, 1982, BIOCHIM BIOPHYS ACTA, V689, P161, DOI 10.1016/0005-2736(82)90200-0; KINSELLA JL, 1979, BIOCHIM BIOPHYS ACTA, V552, P468, DOI 10.1016/0005-2736(79)90191-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOODY WJ, 1981, J PHYSIOL-LONDON, V316, P293, DOI 10.1113/jphysiol.1981.sp013788; MURER H, 1976, BIOCHEM J, V154, P597, DOI 10.1042/bj1540597; Neet K E, 1980, Methods Enzymol, V64, P192; OTSU K, 1989, P NATL ACAD SCI USA, V86, P4818, DOI 10.1073/pnas.86.13.4818; OTSU K, 1986, BIOPHYS J, V49, pA553; OTSU K, 1988, BIOPHYS J, V53, pA341; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; PARIS S, 1983, J BIOL CHEM, V258, P3503; RINDLER MJ, 1981, J BIOL CHEM, V256, P820; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Segel I.H., 1975, ENZYME KINETICS, P353; VIGNE P, 1985, J BIOL CHEM, V260, P4120; VIGNE P, 1982, J BIOL CHEM, V257, P9394; WARNOCK DG, 1982, AM J PHYSIOL, V242, pF733, DOI 10.1152/ajprenal.1982.242.6.F733; WIERZBICKI W, 1990, J MEMBRANE BIOL, V117, P11, DOI 10.1007/BF01871562	35	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8089	8096						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373720				2022-12-27	WOS:A1992HQ18500022
J	SIGURSKJOLD, BW; BUNDLE, DR				SIGURSKJOLD, BW; BUNDLE, DR			THERMODYNAMICS OF OLIGOSACCHARIDE BINDING TO A MONOCLONAL-ANTIBODY SPECIFIC FOR A SALMONELLA O-ANTIGEN POINT TO HYDROPHOBIC INTERACTIONS IN THE BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYOL-WATER INTERACTIONS; HEAT-CAPACITY; CARBOHYDRATE INTERACTIONS; MAGNETIC-RESONANCE; PROTEIN-STRUCTURE; AQUEOUS-SOLUTIONS; COMBINING SITES; SEROGROUP-A; STABILITY; MONOSACCHARIDES	The thermodynamic characteristics of oligosaccharide binding to an antibody binding site that is dominated by aromatic amino acids suggest that the hydrophobic effect contributes substantially to complex formation as well as hydrogen bonding and van der Waals interactions. A detailed titration microcalorimetric study on the temperature dependence of the binding of a trisaccharide, representing the epitope of a Salmonella O-antigen, showed that its maximum binding to the monoclonal antibody Se155-4 occurs just below room temperature and both enthalpy and entropy changes are strongly dependent on temperature in a mutually compensating manner. The heat capacity change also shows an unusually strong temperature dependence being large and negative above room temperature and positive below. van't Hoff analysis of the temperature dependence of the binding constant yielded a biphasic curve with two apparent intrinsic enthalpy estimations (approximately -100 kJ mol-1 above 18-degrees-C and approximately +100 kJ mol-1 below), each very different from the calorimetrically determined enthalpies (ranging from about -60 kJ mol-1 to -20 kJ mol-1). This was interpreted as being due to large enthalpy contributions from concomitant reactions, most notably changes in solvation. Linear plots, -DELTA-H0 versus -T-DELTA-S0, observed for temperature-dependent measurements mirror the behavior seen for a series of functional group replacements, suggesting that the molecular and physical origin of these phenomena are closely related and linked to the role of water in complex formation. The thermodynamic results are compared to the mode of binding determined from a 2.05-angstrom resolution structure of the Fab-oligosaccharide complex, and with literature data for the heat capacities of sugars in aqueous solution and for the thermodynamics of carbohydrate binding to transport proteins and lectins.			SIGURSKJOLD, BW (corresponding author), NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA K1A 0R6, ONTARIO, CANADA.							ANAND NN, 1991, GENE, V100, P39, DOI 10.1016/0378-1119(91)90347-E; ANAND NN, 1990, PROTEIN ENG, V3, P541, DOI 10.1093/protein/3.6.541; ANAND NN, 1991, J BIOL CHEM, V266, P21874; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BOCK K, 1987, PURE APPL CHEM, V59, P1447, DOI 10.1351/pac198759111447; BOCK K, 1984, CARBOHYD RES, V130, P35, DOI 10.1016/0008-6215(84)85268-4; BOCK K, 1984, CARBOHYD RES, V130, P23, DOI 10.1016/0008-6215(84)85267-2; BOCK K, 1990, STUDIES NATURAL PROD, V7, P29; BONNER OD, 1976, J CHEM THERMODYN, V8, P105, DOI 10.1016/0021-9614(76)90082-3; BUNDLE DR, 1989, PURE APPL CHEM, V61, P1171, DOI 10.1351/pac198961071171; CABANI S, 1981, J SOLUTION CHEM, V10, P563, DOI 10.1007/BF00646936; CARVER JP, 1989, CIBA F SYMP, V145, P6; Cesaro A., 1986, THERMODYNAMIC DATA B, P177; CYGLER M, 1991, SCIENCE, V215, P489; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DIPAOLA G, 1977, CAN J CHEM, V55, P3825, DOI 10.1139/v77-540; FRANKS F, 1991, PURE APPL CHEM, V63, P1367, DOI 10.1351/pac199163101367; FRANKS F, 1987, PURE APPL CHEM, V59, P1189, DOI 10.1351/pac198759091189; FUKADA H, 1983, J BIOL CHEM, V258, P3193; GILL SJ, 1985, J PHYS CHEM-US, V89, P3758, DOI 10.1021/j100263a034; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HEARN RP, 1971, BIOCHEMISTRY-US, V10, P806; HINDSGAUL O, 1985, CAN J CHEM, V63, P2653, DOI 10.1139/v85-440; HINZ HJ, 1979, BIOCHEMISTRY-US, V18, P3084, DOI 10.1021/bi00581a027; JOHNSON LN, 1988, CURR TOP MICROBIOL, V139, P81; KAWAIZUMI F, 1981, B CHEM SOC JPN, V54, P2282, DOI 10.1246/bcsj.54.2282; KAWAIZUMI F, 1981, J CHEM THERMODYN, V13, P89, DOI 10.1016/S0021-9614(81)80013-4; LEMIEUX RU, 1991, CIBA F SYMP, V158, P231; LEMIEUX RU, 1978, NOUV J CHIM, V2, P321; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LEMIEUX RU, 1985, 8TH P INT S MED CHEM, P329; LIAN YN, 1982, ACTA CHEM SCAND A, V36, P735, DOI 10.3891/acta.chem.scand.36a-0735; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; MAHANTA SK, 1990, BIOCHEM J, V265, P831, DOI 10.1042/bj2650831; MIYAJIMA K, 1983, B CHEM SOC JPN, V56, P1620, DOI 10.1246/bcsj.56.1620; MIYAJIMA K, 1985, B CHEM SOC JPN, V58, P2595, DOI 10.1246/bcsj.58.2595; MORIN PE, 1991, BIOCHEMISTRY-US, V30, P8494, DOI 10.1021/bi00098a030; MUKKUR TKS, 1984, CRC CR REV BIOCH MOL, V16, P133, DOI 10.3109/10409238409102301; MULLER N, 1990, ACCOUNTS CHEM RES, V23, P23, DOI 10.1021/ar00169a005; NEUROHR KJ, 1982, BIOCHEMISTRY-US, V21, P498, DOI 10.1021/bi00532a013; NICHOLS N, 1976, J CHEM THERMODYN, V8, P1081, DOI 10.1016/0021-9614(76)90139-7; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PRIVALOV PL, 1989, ANNU REV BIOPHYS BIO, V18, P47, DOI 10.1146/annurev.biophys.18.1.47; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; SWAMY MJ, 1991, CARBOHYD RES, V213, P59; TANFORD C, 1980, HYDROPHOBIC EFFECT; WIESINGER H, 1986, THERMODYNAMIC DATA B, P211; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOOD RH, 1990, P NATL ACAD SCI USA, V87, P946, DOI 10.1073/pnas.87.3.946; ZIDOVETZKI R, 1988, MOL IMMUNOL, V25, P379, DOI 10.1016/0161-5890(88)90032-6	57	106	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8371	8376						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373726				2022-12-27	WOS:A1992HQ18500065
J	YIN, TG; MIYAZAWA, K; YANG, YC				YIN, TG; MIYAZAWA, K; YANG, YC			CHARACTERIZATION OF INTERLEUKIN-11 RECEPTOR AND PROTEIN TYROSINE PHOSPHORYLATION INDUCED BY INTERLEUKIN-11 IN MOUSE 3T3-L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; LIPOPROTEIN-LIPASE; MOLECULAR-CLONING; GENE-EXPRESSION; CACHECTIN; FIBROBLASTS; ADIPOCYTES; CACHEXIA; INVITRO; SIGNAL	In this study, we have characterized the biochemical nature of interleukin (IL)-11 receptors (IL-11R) and determined the possible signal transduction pathways mediated by IL-11 in 3T3-L1 mouse preadipocytes. The results show that IL-11 strongly inhibited lipoprotein lipase activity and adipogenesis in 3T3-L1 cells, and the suppression of lipoprotein lipase activity by IL-11 was controlled at the post-transcriptional level. The ability of IL-11 to inhibit lipoprotein lipase activity and adipogenesis therefore reflected the expression of functional IL-11R on the cell surface. Scatchard plot analysis according to specific binding data revealed the existence of a single class of high affinity IL-11R with a K(d) of 3.49 x 10(-10) M and a receptor density of 5140 sites/cell on 3T3-L1 cells. Affinity cross-linking studies with I-125-IL-11 indicated that IL-11R consists of a single polypeptide chain of 151 kDa in size. Furthermore, we have studied the role of protein tyrosine phosphorylation in the IL-11R-linked signal transduction pathways. The results show that IL-11R ligation rapidly and transiently stimulated tyrosine phosphorylation of 152-, 94-, 47-, and 44-kDa proteins. This effect is specific for IL-11 since neutralizing antibody to IL-11 abrogated IL-11-induced tyrosine phosphorylation, and other cytokines such as IL-6 and IL-1-alpha did not change the tyrosine phosphorylation pattern in 3T3-L1 cells. These results suggest that IL-11R is closely linked to a functional protein-tyrosine kinase pathway, and tyrosine phosphorylation may be a key step in the initiation of the IL-11R-mediated transmembrane signaling.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,975 W WALNUT ST,IB 540,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis								BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BEUTLER BA, 1985, J IMMUNOL, V135, P3972; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRUNO E, 1991, EXP HEMATOL, V19, P378; CANNISTRA SA, 1990, P NATL ACAD SCI USA, V87, P93, DOI 10.1073/pnas.87.1.93; GIMBLE JM, 1989, MOL CELL BIOL, V9, P4587, DOI 10.1128/MCB.9.11.4587; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KEAY S, 1980, P NATL ACAD SCI-BIOL, V77, P4099, DOI 10.1073/pnas.77.7.4099; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; MORI M, 1989, BIOCHEM BIOPH RES CO, V160, P1085, DOI 10.1016/S0006-291X(89)80114-7; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MUSASHI M, 1991, P NATL ACAD SCI USA, V88, P765, DOI 10.1073/pnas.88.3.765; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; PATTON JS, 1986, P NATL ACAD SCI USA, V83, P8313, DOI 10.1073/pnas.83.21.8313; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PRICE SR, 1986, BIOCHIM BIOPHYS ACTA, V889, P374, DOI 10.1016/0167-4889(86)90201-6; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHACKELFORD DA, 1991, CELL REGUL, V2, P73, DOI 10.1091/mbc.2.1.73; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YIN TG, 1992, J EXP MED, V175, P211, DOI 10.1084/jem.175.1.211; ZECHNER R, 1988, MOL CELL BIOL, V8, P2394, DOI 10.1128/MCB.8.6.2394	33	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8347	8351						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373723				2022-12-27	WOS:A1992HQ18500061
J	HAYASHI, H; KAMOHARA, S; NISHIOKA, Y; KANAI, F; MIYAKE, N; FUKUI, Y; SHIBASAKI, F; TAKENAWA, T; EBINA, Y				HAYASHI, H; KAMOHARA, S; NISHIOKA, Y; KANAI, F; MIYAKE, N; FUKUI, Y; SHIBASAKI, F; TAKENAWA, T; EBINA, Y			INSULIN-TREATMENT STIMULATES THE TYROSINE PHOSPHORYLATION OF THE ALPHA-TYPE 85-KDA SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; RECEPTOR KINASE-ACTIVITY; EPIDERMAL GROWTH-FACTOR; PDGF BETA-RECEPTOR; BOVINE BRAIN; INTACT-CELLS; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; SERINE KINASE	After adding insulin to cells overexpressing the insulin receptor, the activity of phosphatidylinositol (PI) 3-kinase in the anti-phosphotyrosine immunoprecipitates was rapidly and greatly increased. This enzyme may therefore be a substrate for the insulin receptor tyrosine kinase and may be one of the mediators of insulin signal transduction. However, it is unclear whether or not activated tyrosine kinase of the insulin receptor directly phosphorylates PI 3-kinase at tyrosine residue(s) and whether insulin stimulates the specific activity of PI 3-kinase. We reported previously that the 85-kDa subunit of purified PI 3-kinase was phosphorylated at tyrosine residue(s) by the insulin receptor in vitro. To examine the tyrosine phosphorylation of PI 3-kinase and change of its activity by insulin treatment in vivo, we used a specific antibody to the 85-kDa subunit of PI 3-kinase. The activity of PI 3-kinase in immunoprecipitates with the antibody against the p85 subunit of PI 3-kinase was increased about 3-fold by insulin treatment of cells overexpressing insulin receptors. Insulin treatment also stimulated the tyrosine, serine, and threonine phosphorylation of the alpha-type 85-kDa subunit of PI 3-kinase in vivo. Phosphatase treatment of the immunoprecipitates abolished the increase in PI 3-kinase activity. The phosphorylation(s) of the kinase itself, tyrosine phosphorylation(s) of associated protein(s), or the complex formation of the phosphorylated PI 3-kinase with associated proteins may increase the activity of PI 3-kinase.	UNIV TOKUSHIMA,INST ENZYME RES,DEPT ENZYME GENET,3-18-15 KURAMOTO CHO,TOKUSHIMA 770,JAPAN; UNIV TOKYO,DEPT AGR CHEM,BIOCHEM LAB,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN	Tokushima University; University of Tokyo			Fukui, Yasuhisa/E-8806-2010	Hayashi, Hideki/0000-0003-4585-6542; Kamohara, Seika/0000-0002-2482-6611				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALLOTTI R, 1986, BIOCHEM BIOPH RES CO, V139, P179, DOI 10.1016/S0006-291X(86)80096-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; KASUGA M, 1982, J BIOL CHEM, V257, P9891; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7526; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MORGAN DO, 1986, P NATL ACAD SCI USA, V83, P328, DOI 10.1073/pnas.83.2.328; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANG DT, 1985, J BIOL CHEM, V260, P7131; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG P, 1990, HDB EXPT PHARM INSUL, V92, P209; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STADTMAUER LA, 1983, J BIOL CHEM, V258, P6682; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; ULLICH A, 1985, NATURE, V313, P756; WHITE MF, 1985, J BIOL CHEM, V260, P9470; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	52	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22575	22580						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385401				2022-12-27	WOS:A1992JW71900091
J	ROUET, P; RAGUENEZ, G; TRONCHE, F; YANIV, M; NGUYEN, C; SALIER, JP				ROUET, P; RAGUENEZ, G; TRONCHE, F; YANIV, M; NGUYEN, C; SALIER, JP			A POTENT ENHANCER MADE OF CLUSTERED LIVER-SPECIFIC ELEMENTS IN THE TRANSCRIPTION CONTROL SEQUENCES OF HUMAN ALPHA-1-MICROGLOBULIN BIKUNIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TRYPSIN INHIBITOR; REACTIVE PROTEIN PROMOTER; SITE-DIRECTED MUTAGENESIS; RAT ALBUMIN PROMOTER; NUCLEAR FACTORS; BINDING PROTEIN; HEPATOMA-CELLS; DNA-BINDING; TRANSTHYRETIN; REGION	Alpha1-microglobulin (A1M) and bikunin are plasma proteins which are present both as free molecules and as complexes with either IgA heavy chains for A1M or the H1, H2, and H3 heavy chains of the inter-alpha-inhibitor family for bikunin. Mature A1M and bikunin originate from the cleavage of an A1M/bikunin precursor (ABP) synthesized from a single gene with liver-specific expression. Five kilobases of the 5'-flanking region of the human ABP gene were sequenced. Deletion mutants of this region subcloned upstream of a CAT reporter gene were transfected into HepG2 hepatoma cells. A segment covering the -2.7- to -2.8-kb area is required for full activity of the ABP gene. This segment contains a cluster of six elements (boxes 1-6, 5' to 3') which are potential binding sites for the liver-enriched trans-acting factors HNF-1, HNF-4, HNF-3, HNF-1, HNF-3, and HNF-4, respectively. This cluster enhances the activity of heterologous minimal promoters in a position- and distance-independent fashion in HepG2 cells. This enhancer activity is restricted to liver cells as the cluster is unable to activate promoters in Chinese hamster ovary (CHO) or HeLa cells. By band-shift experiments we have shown that the liver-enriched transcription factors HNF-1, or HNF-3, do bind to boxes 1 and 4, or 3, respectively. The combination of a weak promoter and a strong distant and liver-specific enhancer distinguishes the ABP gene from most other plasma protein genes expressed in hepatocytes.	INSERM,U78,BP 73,F-76233 BOIS GUILLAUME,FRANCE; EUROPEAN INST PEPTIDE RES,F-76233 BOIS GUILLAUME,FRANCE; INST PASTEUR,CNRS,UNITE VIRUS ONCOGENES 1149,F-75724 PARIS,FRANCE; INSERM,U136,F-13288 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)			TRONCHE, François/F-3895-2011; Nguyen, Catherine/M-4119-2016	Nguyen, Catherine/0000-0001-9376-6360; Rouet, Philippe/0000-0001-6204-2079				AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; COSTA RH, 1991, NUCLEIC ACIDS RES, V19, P4139, DOI 10.1093/nar/19.15.4139; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; De Simone V, 1991, CURR OPIN CELL BIOL, V3, P960, DOI 10.1016/0955-0674(91)90114-E; DIARRAMEHRPOUR M, 1990, EUR J BIOCHEM, V191, P131, DOI 10.1111/j.1432-1033.1990.tb19102.x; ESCRIBANO J, 1988, BIOCHEM BIOPH RES CO, V155, P1424, DOI 10.1016/S0006-291X(88)81300-7; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Gebhard W., 1986, PROTEINASE INHIBITOR, P389; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HAM J, 1991, EMBO J, V10, P2931, DOI 10.1002/j.1460-2075.1991.tb07843.x; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MCKEEHAN WL, 1986, J BIOL CHEM, V261, P5378; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PETROPOULOS I, 1991, J BIOL CHEM, V266, P24220; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; RAYMONDJEAN M, 1991, NUCLEIC ACIDS RES, V19, P6145, DOI 10.1093/nar/19.22.6145; ROUET P, 1992, IN PRESS BIOTECHNIQU; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SALIER JP, 1987, P NATL ACAD SCI USA, V84, P8272, DOI 10.1073/pnas.84.23.8272; Sambrook J, 1989, MOL CLONING LABORATO; TONIATTI C, 1990, EMBO J, V9, P4467, DOI 10.1002/j.1460-2075.1990.tb07897.x; TRONCHE F, 1991, J MOL BIOL, V222, P31, DOI 10.1016/0022-2836(91)90735-O; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; VETR H, 1991, BIOL CHEM HOPPESEYLE, V371, P1185; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	40	53	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20765	20773						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383209				2022-12-27	WOS:A1992JT97800041
J	HATA, A; RIDINGER, DN; SUTHERLAND, SD; EMI, M; KWONG, LK; SHUHUA, J; LUBBERS, A; GUYGRAND, B; BASDEVANT, A; IVERIUS, PH; WILSON, DE; LALOUEL, JM				HATA, A; RIDINGER, DN; SUTHERLAND, SD; EMI, M; KWONG, LK; SHUHUA, J; LUBBERS, A; GUYGRAND, B; BASDEVANT, A; IVERIUS, PH; WILSON, DE; LALOUEL, JM			MISSENSE MUTATIONS IN EXON-5 OF THE HUMAN LIPOPROTEIN-LIPASE GENE - INACTIVATION CORRELATES WITH LOSS OF DIMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC TRIGLYCERIDE LIPASE; RADIATION INACTIVATION; NONSENSE MUTATION; ADIPOSE-TISSUE; I HYPERLIPOPROTEINEMIA; MOLECULAR-PROPERTIES; POSTHEPARIN PLASMA; PANCREATIC LIPASE; DNA-SEQUENCE; BOVINE-MILK	Most missense mutations of the lipoprotein lipase (LPL) gene identified among LPL-deficient subjects cluster in a segment of the sequence that encodes the catalytic triad as well as functional elements involved in the activation of the lipase at lipid-water interfaces. Consequently, loss of activity may result either from direct alterations of such functional elements or from less specific effects on protein folding and stability. This issue was addressed by examining biochemical properties of four such variants (A176T, G188E, G195E, and S244T) in a heterologous expression system (COS-1 cells). Variant G195E (GGA --> GAA) was previously unreported. In all instances, inactive enzyme was recovered in medium, albeit at reduced levels. Cellular synthesis and extracellular degradation were similar to those for wild type, suggesting that reduced secretion resulted from increased intracellular degradation. When cell extracts were subjected to heparin-Superose affinity chromatography followed by elution on a linear salt gradient, all variants exhibited a single, inactive, low affinity immunoreactive peak. By contrast, wild-type enzyme presented an additional, high affinity, active species, which we interpret as homodimeric enzyme. Substitution of the active-site serine (S132A) led to loss of activity but maintenance of the high affinity species. When large amounts of the G188E variant were applied to the column, small but significant amounts of high affinity, active enzyme were recovered. Systematic substitutions at residue 188 showed that only glycine could accommodate structural constraints at this position. We conclude that the mutations examined did not impart lipase deficiency by affecting specific functional elements of the enzyme. Rather, they appear to affect protein folding and stability, and thereby formation and maintenance of subunit assembly.	HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84132 USA; VET AFFAIRS MED CTR, SALT LAKE CITY, UT 84148 USA; UNIV UTAH, HLTH SCI CTR, DEPT INTERNAL MED, DIV ENDOCRINOL & METAB, SALT LAKE CITY, UT 84132 USA; HOP HOTEL DIEU, SERV NUTR, PARIS, FRANCE; DEPT HUMAN GENET, SALT LAKE CITY, UT 84132 USA	Howard Hughes Medical Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039593, R01HL045753, R01HL145753] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00064] Funding Source: Medline; NHLBI NIH HHS [HL39593, HL45753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMEIS D, 1991, J CLIN INVEST, V87, P1165, DOI 10.1172/JCI115114; ASHBY P, 1978, BIOCHEM J, V171, P305, DOI 10.1042/bj1710305; AUGUSTIN J, 1978, J BIOL CHEM, V253, P2912; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BENGTSSON G, 1981, EUR J BIOCHEM, V113, P547, DOI 10.1111/j.1432-1033.1981.tb05097.x; BENGTSSON G, 1979, BIOCHIM BIOPHYS ACTA, V575, P471, DOI 10.1016/0005-2760(79)90118-8; BENGTSSONOLIVECRONA G, 1985, BIOCHEM J, V226, P409, DOI 10.1042/bj2260409; BENSADOU.A, 1974, J BIOL CHEM, V249, P2220; BLOW D, 1991, NATURE, V351, P444, DOI 10.1038/351444a0; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; Brunzell J D, 1986, Adv Exp Med Biol, V201, P227; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BURDETTE RA, 1986, J BIOL CHEM, V261, P2016; CHAJEKSHAUL T, 1988, BIOCHIM BIOPHYS ACTA, V963, P183, DOI 10.1016/0005-2760(88)90279-2; CHEN GH, 1989, P NATL ACAD SCI USA, V86, P3447, DOI 10.1073/pnas.86.10.3447; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DATTA S, 1988, J BIOL CHEM, V263, P1107; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; DICHEK HL, 1991, J BIOL CHEM, V266, P473; EMI M, 1990, J BIOL CHEM, V265, P5910; EMI M, 1990, AM J HUM GENET, V47, P107; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; GARFINKEL AS, 1972, J LIPID RES, V13, P63; GARFINKEL AS, 1983, J LIPID RES, V24, P775; GARFINKEL AS, 1987, PLASMA LIPOPROTEINS, P335; GOTODA T, 1991, J CLIN INVEST, V88, P1856, DOI 10.1172/JCI115507; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HATA A, 1990, AM J HUM GENET, V47, P721; Hayden M.R., 1991, CURRENT OPINION LIPI, V2, P104; HENDERSON HE, 1990, MOL BIOL MED, V7, P511; HENDERSON HE, 1991, J CLIN INVEST, V87, P2005, DOI 10.1172/JCI115229; IKEDA Y, 1989, BIOCHIM BIOPHYS ACTA, V1003, P254, DOI 10.1016/0005-2760(89)90231-2; Iverius P H, 1986, Methods Enzymol, V129, P691; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; KEMPNER ES, 1991, METHOD ENZYMOL, V197, P280; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALOUEL JM, 1992, CURR OPIN LIPIDOL, V3, P86; MA YH, 1991, NEW ENGL J MED, V324, P1761, DOI 10.1056/NEJM199106203242502; MA YH, 1992, J BIOL CHEM, V267, P1918; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; OLIVECRONA T, 1971, BIOCHEM BIOPH RES CO, V43, P524, DOI 10.1016/0006-291X(71)90645-0; OLIVECRONA T, 1982, EUR J BIOCHEM, V124, P629, DOI 10.1111/j.1432-1033.1982.tb06640.x; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PAULWEBER B, 1991, ATHEROSCLEROSIS, V86, P239, DOI 10.1016/0021-9150(91)90220-W; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; QUINN D, 1983, PROG LIPID RES, V22, P35, DOI 10.1016/0163-7827(83)90003-6; SARDA L, 1958, BIOCHIM BIOPHYS ACTA, V30, P513, DOI 10.1016/0006-3002(58)90097-0; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Smith L.C., 1984, P263; SOCORRO L, 1985, J BIOL CHEM, V260, P6324; TAKAGI A, 1992, J CLIN INVEST, V89, P581, DOI 10.1172/JCI115624; VANNIER C, 1989, J BIOL CHEM, V264, P13206; WALLACE DM, 1987, METHOD ENZYMOL, V152, P33; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WALLINDER L, 1982, BIOCHIM BIOPHYS ACTA, V711, P107, DOI 10.1016/0005-2760(82)90015-7; WANG CS, 1992, BIOCHIM BIOPHYS ACTA, V1123, P1, DOI 10.1016/0005-2760(92)90165-R; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	71	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20132	20139						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400331				2022-12-27	WOS:A1992JR85800062
J	MUTHUCHAMY, M; PAJAK, L; WIECZOREK, DF				MUTHUCHAMY, M; PAJAK, L; WIECZOREK, DF			INDUCTION OF ENDOGENOUS MYOSIN LIGHT CHAIN-1 AND CARDIAC ALPHA-ACTIN EXPRESSION IN L6E9 CELLS BY MYOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; MYOGENIC DETERMINATION FACTORS; CREATINE-KINASE GENE; SKELETAL-MUSCLE; REGULATORY FACTORS; DNA-BINDING; FUNCTIONAL-ACTIVITY; XENOPUS-EMBRYOS; MYC HOMOLOGY; DIFFERENTIATION	Rat L6E9 muscle cells commit to terminal differentiation by forming a large muscle syncitia complete with the expression of a large number of muscle-specific contractile protein genes. To determine whether these cells, which fail to synthesize MLC (myosin light chain) 1 and cardiac alpha-actin, exhibit a deficiency in the expression of muscle determination genes, we measured expression of MyoD1, myogenin, Myf-5, and MRF-4. Results show these cells do not synthesize MyoD1, yet express the other myogenic determination genes. Transient expression of exogenous MyoD1 in these cells is sufficient to activate endogenous MLC 1 and cardiac alpha-actin mRNA synthesis during muscle differentiation. Previously undetected myosin heavy chain (MHC) isoforms (beta-MHC and perinatal MHC) are also transcribed at low levels in L6E9 muscle cells, and in MyoD1-transfected L6E9 cells no change occurs in their expression. Furthermore, treatment with the demethylating agent 5-azacytidine activates expression of the endogenous MyoD1 gene in L6E9 cells and, subsequently, rescues deficiencies in their myogenic biochemical program. These results demonstrate that the endogenous MyoD1 gene in L6E9 cells is not defective and can be functionally activated. Also, the MyoD1 protein plays an essential role, which cannot be compensated by other known muscle determination proteins, in the induction of MLC 1 and cardiac alpha-actin expression.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46826] Funding Source: Medline; NIAMS NIH HHS [AR 39423] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; BILLETER R, 1988, MOL CELL BIOL, V8, P1361, DOI 10.1128/MCB.8.3.1361; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; COHEN A, 1988, NUCLEIC ACIDS RES, V16, P10037, DOI 10.1093/nar/16.21.10037; DAUBAS P, 1988, NUCLEIC ACIDS RES, V16, P1251, DOI 10.1093/nar/16.4.1251; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Favaloro J, 1980, Methods Enzymol, V65, P718; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; HICKEY R, 1986, MOL CELL BIOL, V6, P3287, DOI 10.1128/MCB.6.9.3287; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOPWOOD ND, 1991, DEVELOPMENT, V111, P551; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; MAYER Y, 1984, NUCLEIC ACIDS RES, V12, P1087, DOI 10.1093/nar/12.2.1087; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PAJAK L, 1991, DEV BIOL, V145, P28, DOI 10.1016/0012-1606(91)90210-T; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; PERIASAMY M, 1984, J BIOL CHEM, V259, P3573; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAYLOR MV, 1991, GENE DEV, V5, P1149, DOI 10.1101/gad.5.7.1149; TAYLOR SM, 1982, J CELL PHYSIOL, V111, P187, DOI 10.1002/jcp.1041110210; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WIECZOREK DF, 1985, J CELL BIOL, V101, P618, DOI 10.1083/jcb.101.2.618; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	58	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18728	18734						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382061				2022-12-27	WOS:A1992JN50200074
J	THEROUX, SJ; LATOUR, DA; STANLEY, K; RADEN, DL; DAVIS, RJ				THEROUX, SJ; LATOUR, DA; STANLEY, K; RADEN, DL; DAVIS, RJ			SIGNAL TRANSDUCTION BY THE EPIDERMAL GROWTH-FACTOR RECEPTOR IS ATTENUATED BY A COOH-TERMINAL DOMAIN SERINE PHOSPHORYLATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; LIGAND-INDUCED INTERNALIZATION; TISSUE-SPECIFIC TRANSFORMATION; TYROSINE KINASE; EGF RECEPTOR; HUMAN-FIBROBLASTS; A431 CELLS; ERBB; THREONINE; BINDING	It has been proposed that the acute desensitization of epidermal growth factor receptor (EGF-R) function can be accounted for, in part, by the effect of EGF to increase phosphorylation of the receptor at Ser1046/7 (Countaway, J. L., Nairn, A. C., and Davis, R. J. (1992) J. Biol. Chem. 267, 1129-1140). Here, we show that the mutational removal of this phosphorylation site causes an activation of EGF-R function and a potentiation of signal transduction. The mechanism of potentiation results from 1) defective down-regulation of the EGF-R when cells are incubated with high concentrations of EGF; and 2) increased EGF-stimulated tyrosine phosphorylation. The increased EGF-stimulated phosphorylation is associated with an alteration of the apparent specificity of tyrosine phosphorylation and is independent of the down-regulation defect. Together, these data strongly support the hypothesis that Ser1046/7 is a biologically significant site of regulatory phosphorylation of the EGF-R.	UNIV MASSACHUSETTS, SCH MED,DEPT BIOCHEM & MOLEC BIOL, PROGRAM MOLEC MED,HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL CANCER INSTITUTE [R03CA053396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER; NCI NIH HHS [CA53396] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOWEN S, 1991, J BIOL CHEM, V266, P1162; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHINKERS M, 1986, J BIOL CHEM, V261, P8295; COCHET C, 1984, J BIOL CHEM, V259, P2553; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; CUNNINGHAM TW, 1989, J BIOL CHEM, V264, P15351; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DAVIS RJ, 1986, EMBO J, V5, P653, DOI 10.1002/j.1460-2075.1986.tb04263.x; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LEISTER KJ, 1989, P NATL ACAD SCI USA, V86, P783, DOI 10.1073/pnas.86.3.783; LUND KA, 1990, J BIOL CHEM, V265, P20517; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MATRISIAN LM, 1982, ANAL BIOCHEM, V125, P339, DOI 10.1016/0003-2697(82)90015-X; MCCUNE BK, 1990, J BIOL CHEM, V265, P9715; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PESSIN JE, 1983, J BIOL CHEM, V258, P7386; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; TRACY SE, 1985, J VIROL, V54, P304, DOI 10.1128/JVI.54.2.304-310.1985; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATERS CM, 1990, BIOCHEMISTRY-US, V29, P3563, DOI 10.1021/bi00466a020; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1982, J BIOL CHEM, V257, P4222	45	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16620	16626						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379601				2022-12-27	WOS:A1992JJ45800097
J	JIA, S; VANDUSEN, WJ; DIEHL, RE; KOHL, NE; DIXON, RAF; ELLISTON, KO; STERN, AM; FRIEDMAN, PA				JIA, S; VANDUSEN, WJ; DIEHL, RE; KOHL, NE; DIXON, RAF; ELLISTON, KO; STERN, AM; FRIEDMAN, PA			CDNA CLONING AND EXPRESSION OF BOVINE ASPARTYL (ASPARAGINYL) BETA-HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FACTOR-LIKE DOMAIN; HUMAN FACTOR-IX; HYDROXYASPARTIC ACID; PROLYL 4-HYDROXYLASE; MOLECULAR-CLONING; RNA TRANSCRIPTS; POINT MUTATIONS; DNA-POLYMERASE; ALPHA-SUBUNIT	Aspartyl (asparaginyl) beta-hydroxylase which specifically hydroxylates 1 Asp or Asn residue in certain epidermal growth factor-like domains of a number of proteins, has been previously purified to apparent homogeneity from detergent-solubilized bovine liver microsomes (Wang, Q., VanDusen, W. J., Petroski, C. J., Garsky, V. M., Stern, A. M., and Friedman, P. A. (1991) J. Biol. Chem. 266, 14004-14010). Three oligonucleotides, corresponding to three amino acid sequences of the purified hydroxylase, were used to screen bovine cDNA libraries. Several overlapping positive cDNA clones containing a full length open reading frame of 754 amino acids encoding a 85-kDa protein were isolated, and a cDNA, containing the full length open reading frame, was constructed from two of these clones. The resulting clone was then transcribed and translated in vitro to produce recombinant protein which possessed Asp beta-hydroxylase activity. These results constitute proof that the protein purified from bovine liver is an Asp beta-hydroxylase. Comparisons of deduced amino acid sequences of two other alpha-ketoglutarate-dependent dioxygenases, prolyl-4-hydroxylase and lysyl hydroxylase, with that of Asp beta-hydroxylase showed no significant homologies. Indeed, Asp beta-hydroxylase appears to be unique as no striking homology was found with known protein sequences. Furthermore, structural predictions derived from the deduced amino acid sequence are in accord with earlier Stokes' radius and sedimentation coefficient determinations of the enzyme, suggesting that the enzyme contains a relatively compact carboxyl-terminal catalytic domain and an extended amino terminus. This amino-terminal region has a potential transmembrane type II signal-anchor domain that could direct the catalytic domain into the lumen of the endoplasmic reticulum.	MERCK SHARP & DOHME LTD,WP44-204,W POINT,PA 19486	Merck & Company				Stern, Andrew/0000-0002-8437-2957; Elliston, Keith/0000-0002-9110-9233				ARLAUD GJ, 1987, FEBS LETT, V222, P129, DOI 10.1016/0014-5793(87)80205-3; BASSUK JA, 1989, P NATL ACAD SCI USA, V86, P7382, DOI 10.1073/pnas.86.19.7382; BERG RA, 1979, J BIOL CHEM, V254, P3111; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAKENBERG T, 1983, P NATL ACAD SCI-BIOL, V80, P1802, DOI 10.1073/pnas.80.7.1802; ENGLEMAN DM, 1986, ANN REV BIOPHYS CHEM, V15, P321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNLUND P, 1983, J BIOL CHEM, V258, P12059; GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609; GRONKE RS, 1990, J BIOL CHEM, V265, P8558; GRONKE RS, 1988, J CELL BIOL, V107, P4689; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; KIVIRIKKO KI, 1980, ENZYMOLOGY POST TRAN, P53; KOHL NE, 1991, J BIOL CHEM, V266, P18884; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MCMULLEN BA, 1983, BIOCHEM BIOPH RES CO, V115, P8, DOI 10.1016/0006-291X(83)90961-0; MORITA T, 1984, J BIOL CHEM, V259, P5689; MYLLYLA R, 1991, J BIOL CHEM, V266, P2805; NIELSEN DA, 1986, NUCLEIC ACIDS RES, V14, P5936, DOI 10.1093/nar/14.14.5936; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; STENFLO J, 1989, P NATL ACAD SCI USA, V86, P444, DOI 10.1073/pnas.86.2.444; SUGO T, 1984, J BIOL CHEM, V259, P5705; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURPEENNIEMIHUJANEN TM, 1980, BIOCHEM J, V189, P247, DOI 10.1042/bj1890247; TURPEENNIEMIHUJANEN TM, 1981, COLLAGEN REL RES, V1, P355; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WANG QP, 1991, J BIOL CHEM, V266, P14004	41	76	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14322	14327						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378441				2022-12-27	WOS:A1992JD32500082
J	SPRINGHORN, JP; ELLINGSEN, O; BERGER, HJ; KELLY, RA; SMITH, TW				SPRINGHORN, JP; ELLINGSEN, O; BERGER, HJ; KELLY, RA; SMITH, TW			TRANSCRIPTIONAL REGULATION IN CARDIAC-MUSCLE - COORDINATE EXPRESSION OF ID WITH A NEONATAL PHENOTYPE DURING DEVELOPMENT AND FOLLOWING A HYPERTROPHIC STIMULUS IN ADULT-RAT VENTRICULAR MYOCYTES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ALPHA-ACTIN; CELLS; DIFFERENTIATION; SKELETAL; CULTURE; HEART; GROWTH; GENE; ACCUMULATION	The transcriptional regulatory mechanisms in heart muscle that direct cardiac development and allow for a flexible, adaptive response to physiologic stress are not well understood. We demonstrate that a negative regulator of gene transcription termed Id that has been described predominantly in proliferating cell lines and in undifferentiated tissue during growth, is expressed in freshly isolated terminally differentiated adult rat ventricular myocytes, in contrast to most other tissues in the adult rat. Id mRNA expression is regulated in ventricular myocytes during post-natal development, peaking at the transition from hyperplastic to hypertrophic growth at day 17 in the rat, declining subsequently to lower, stable levels in adult myocytes. Although Id mRNA becomes undetectable in adult ventricular myocytes 48 h following isolation in the absence of serum, it can be rapidly reinduced by an alpha-adrenergic agonist, accompanied by increased protein synthesis and the reexpression, in defined media, of the neonatal genes prepro-ANP and skeletal muscle alpha-actin. Thus, the differential regulation of Id during cardiac development, the presence of Id mRNA in normal cardiac myocytes, and its increased expression following a hypertrophic stimulus all suggest a role for this transcriptional regulator in the control of cardiac muscle cell phenotype.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	SPRINGHORN, JP (corresponding author), BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036141, R37HL036141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUGAISKY LB, 1989, CIRC RES, V64, P493, DOI 10.1161/01.RES.64.3.493; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CLAYCOMB WC, 1980, DEV BIOL, V80, P466, DOI 10.1016/0012-1606(80)90419-4; CLAYCOMB WC, 1988, BIOCHEM J, V255, P617; CLAYCOMB WC, 1977, BIOCHEM J, V168, P599, DOI 10.1042/bj1680599; CLAYCOMB WC, 1983, ADV EXP MED BIOL, V161, P249; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EID H, 1992, IN PRESS CIRC RES; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; IKEDA U, 1990, CARDIOSCIENCE, V1, P225; IKEDA U, 1991, AM J PHYSIOL, V260, pH953, DOI 10.1152/ajpheart.1991.260.3.H953; KEMP PR, 1991, BIOCHEM J, V277, P285, DOI 10.1042/bj2770285; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NAG AC, 1981, TISSUE CELL, V13, P515, DOI 10.1016/0040-8166(81)90023-9; NAG AC, 1985, CARDIAC MORPHOGENESI, P24; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; Piper H, 1990, CELL CULTURE TECHNIQ, P36; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; SCHIAFFINO S, 1989, CIRC RES, V64, P937, DOI 10.1161/01.RES.64.5.937; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SMITH WR, 1989, CELLULAR MOL BIOL MU, P359; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; UENO H, 1988, J CELL BIOL, V107, P1911, DOI 10.1083/jcb.107.5.1911; VOLZ A, 1991, J MOL CELL CARDIOL, V23, P161, DOI 10.1016/0022-2828(91)90103-S; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; WINEGRAD S, 1990, P NATL ACAD SCI USA, V87, P2456, DOI 10.1073/pnas.87.7.2456; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; ZAK R, 1984, GROWTH HEART HLTH DI, P169	45	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14360	14365						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378442				2022-12-27	WOS:A1992JD32500087
J	POPOV, KM; ZHAO, Y; SHIMOMURA, Y; KUNTZ, MJ; HARRIS, RA				POPOV, KM; ZHAO, Y; SHIMOMURA, Y; KUNTZ, MJ; HARRIS, RA			BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE KINASE - MOLECULAR-CLONING, EXPRESSION, AND SEQUENCE SIMILARITY WITH HISTIDINE PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-LIVER; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; BOVINE KIDNEY; COMPLEX; HEART; PHOSPHORYLATION; FAMILY; GENES; LOCUS	A cDNA for branched-chain alpha-ketoacid dehydrogenase kinase was cloned from a rat heart cDNA library. The cDNA had an open reading frame encoding a protein of 382 amino acid residues with a calculated molecular weight of 43,280. The clone codes for the branched-chain alpha-ketoacid dehydrogenase kinase based on the following: 1) the deduced amino acid sequence contained the partial sequence of the kinase determined by direct sequencing; 2) expression of the cDNA in Escherichia coli resulted in synthesis of a 43,000-Da protein that was recognized specifically by kinase antibodies; and 3) enzyme activity that phosphorylated and inactivated the branched-chain alpha-ketoacid dehydrogenase complex was found in extracts of E. coli expressing the protein. Northern blot analysis indicated the mRNA for the branched-chain alpha-ketoacid dehydrogenase kinase was more abundant in rat heart than in rat liver, as expected from the relative amounts of kinase activity expressed in these tissues. The deduced sequence of the kinase aligned with a high degree of similarity within subdomains characteristic of procaryotic histidine protein kinases. This first mitochondrial protein kinase to be cloned appears more closely related in sequence to procaryotic histidine protein kinases than to eucaryotic serine/threonine protein kinases.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 635 BARNHILL DR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NIADDK NIH HHS [AM 20542] Funding Source: Medline; NIDDK NIH HHS [DK 19259] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019259] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BEGGS M, 1987, FEBS LETT, V215, P13, DOI 10.1016/0014-5793(87)80104-7; COMEAU DE, 1985, J BACTERIOL, V164, P578, DOI 10.1128/JB.164.2.578-584.1985; COOK KG, 1984, EUR J BIOCHEM, V145, P587, DOI 10.1111/j.1432-1033.1984.tb08597.x; ESPINAL J, 1986, BIOCHEM J, V237, P285, DOI 10.1042/bj2370285; GILLIM SE, 1983, BIOCHEM BIOPH RES CO, V111, P74, DOI 10.1016/S0006-291X(83)80119-3; GOETTFERT M, 1990, P NATL ACAD SCI USA, V87, P2680; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; HENNER DJ, 1988, J BACTERIOL, V170, P5102, DOI 10.1128/jb.170.11.5102-5109.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU KS, 1982, FEBS LETT, V144, P57, DOI 10.1016/0014-5793(82)80568-1; LEROUX B, 1987, EMBO J, V6, P849, DOI 10.1002/j.1460-2075.1987.tb04830.x; MAKINO K, 1986, J MOL BIOL, V192, P549, DOI 10.1016/0022-2836(86)90275-5; MCFARLANE SA, 1985, NUCLEIC ACIDS RES, V13, P7591; PAXTON R, 1986, ARCH BIOCHEM BIOPHYS, V244, P187, DOI 10.1016/0003-9861(86)90108-6; PAXTON R, 1984, ARCH BIOCHEM BIOPHYS, V231, P48, DOI 10.1016/0003-9861(84)90361-8; PEREGO M, 1989, J BACTERIOL, V171, P6187, DOI 10.1128/jb.171.11.6187-6196.1989; Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V; Reed LJ, 1987, ENZYMES, P77; ROISE D, 1988, J BIOL CHEM, V263, P4509; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOMURA Y, 1991, FEBS LETT, V288, P95, DOI 10.1016/0014-5793(91)81010-6; SHIMOMURA Y, 1990, ARCH BIOCHEM BIOPHYS, V283, P293, DOI 10.1016/0003-9861(90)90645-F; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WIRTZ E, 1991, MOL BIOCHEM PARASIT, V47, P119, DOI 10.1016/0166-6851(91)90154-X	29	152	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13127	13130						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377677				2022-12-27	WOS:A1992JB74600004
J	BIRCHMACHIN, MA; FARNSWORTH, L; ACKRELL, BAC; COCHRAN, B; JACKSON, S; BINDOFF, LA; AITKEN, A; DIAMOND, AG; TURNBULL, DM				BIRCHMACHIN, MA; FARNSWORTH, L; ACKRELL, BAC; COCHRAN, B; JACKSON, S; BINDOFF, LA; AITKEN, A; DIAMOND, AG; TURNBULL, DM			THE SEQUENCE OF THE FLAVOPROTEIN SUBUNIT OF BOVINE HEART SUCCINATE-DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; AMINO-ACID-SEQUENCE; FUMARATE REDUCTASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; COMPLEX-II; UBIQUINONE OXIDOREDUCTASE; MITOCHONDRIAL PROTEIN; BINDING-SITE; ACTIVE-SITE	The cDNA sequence of the flavoprotein subunit of bovine heart succinate dehydrogenase is reported. This is the first complete eukaryotic sequence of the flavoprotein subunit to be characterized, and it encodes a 665-amino acid protein that consists of a presequence and a 621-residue mature protein. The deduced bovine sequence shows homology to the corresponding peptides of prokaryotic succinate dehydrogenase and the related fumarate reductases; in particular, there is good overall homology (48%) to the flavoprotein subunit of Escherichia coli succinate dehydrogenase. The conserved sequences comprising the active site and those involved in FAD binding are also found in the bovine protein. The active site of the bovine polypeptide contains a cysteine that confers sensitivity of the enzyme to sulfhydryl reagents; this cysteine is only present in some sequences and thus provides a discriminatory biochemical marker. A putative flavoprotein subunit of human placental succinate dehydrogenase (partial sequence) that lacks this critical cysteine (Malcovati, M., Marchetti, T., Zanelli, T., and Tenchini, M. L. (1991) in Flavins and Flavoproteins 1990 (Curti, B., Ronchi, S., and Zanetti, G., eds) pp. 727-730, Walter de Gruyter & Co., Berlin) has only 16% homology to the bovine heart flavoprotein subunit. However, we show that the enzyme from human placenta is as sensitive to N-ethylmaleimide as that from bovine tissues. In addition, a transcript in human placenta and muscle hybridizes to the bovine heart flavoprotein cDNA and is the same size as that in bovine tissues.	UNIV NEWCASTLE UPON TYNE, DEPT MED, Newcastle Upon Tyne NE2 4HH, ENGLAND; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; VET ADM MED CTR, SAN FRANCISCO, CA 94121 USA; NATL INST MED RES, DIV GENES & CELLULAR CONTROLS, PROT STRUCT LAB, LONDON NW7 1AA, ENGLAND	Newcastle University - UK; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); MRC National Institute for Medical Research	BIRCHMACHIN, MA (corresponding author), UNIV NEWCASTLE UPON TYNE, DIV CLIN NEUROSCI, Newcastle Upon Tyne NE2 4HH, ENGLAND.			Bindoff, Laurence/0000-0003-0988-276X	NHLBI NIH HHS [HL-16251, HL-22050] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022050, P01HL016251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackrell B A, 1978, Methods Enzymol, V53, P466; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1980, J BIOL CHEM, V255, P2761; ACKRELL BAC, 1977, J BIOL CHEM, V252, P6963; ACKRELL BAC, 1989, ARCH BIOCHEM BIOPHYS, V268, P26, DOI 10.1016/0003-9861(89)90561-4; AITKEN A, 1989, PROTEIN SEQUENCING P, P43; CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLAY VJ, 1988, BIOCHEM BIOPH RES CO, V157, P1423, DOI 10.1016/S0006-291X(88)81034-9; COLE ST, 1987, EUR J BIOCHEM, V167, P481, DOI 10.1111/j.1432-1033.1987.tb13362.x; COLE ST, 1982, EUR J BIOCHEM, V122, P479; COLE ST, 1982, EUR J BIOCHEM, V126, P211, DOI 10.1111/j.1432-1033.1982.tb06768.x; DARLISON MG, 1984, BIOCHEM J, V223, P507, DOI 10.1042/bj2230507; DAVIS KA, 1971, BIOCHEMISTRY-US, V10, P2509; DESNUELLE C, 1989, BIOCHEM BIOPH RES CO, V163, P695, DOI 10.1016/0006-291X(89)92279-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEST H, 1980, FEMS MICROBIOL LETT, V7, P73, DOI 10.1111/j.1574-6941.1980.tb01579.x; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GOULD SJ, 1989, P NATL ACAD SCI USA, V86, P1934, DOI 10.1073/pnas.86.6.1934; HALLER RG, 1991, J CLIN INVEST, V88, P1197, DOI 10.1172/JCI115422; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HEDERSTEDT L, 1989, BIOCHEM J, V260, P491, DOI 10.1042/bj2600491; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KENNEY WC, 1976, J BIOL CHEM, V251, P2369; KENNEY WC, 1975, J BIOL CHEM, V250, P3089; KENNEY WC, 1972, J BIOL CHEM, V247, P4510; KENNEY WC, 1977, FEBS LETT, V73, P239, DOI 10.1016/0014-5793(77)80989-7; KITA K, 1990, BIOCHEM BIOPH RES CO, V166, P101, DOI 10.1016/0006-291X(90)91916-G; KOTLYAR AB, 1984, BIOCHIM BIOPHYS ACTA, V784, P24, DOI 10.1016/0167-4838(84)90168-7; KOTLYAR AB, 1984, BIOCHEM INT, V8, P545; LAUTERBACH F, 1990, ARCH MICROBIOL, V154, P386, DOI 10.1007/BF00276536; MALCOVATI M, 1991, FLAVINS AND FLAVOPROTEINS 1990, P727; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; PHILLIPS MK, 1987, J BACTERIOL, V169, P864, DOI 10.1128/jb.169.2.864-873.1987; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RICE DW, 1984, J MOL BIOL, V174, P483, DOI 10.1016/0022-2836(84)90332-2; Riordan J.F., 1967, METHOD ENZYMOL, V11, P541; SALACH JI, 1987, METHOD ENZYMOL, V142, P627; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P6749, DOI 10.1073/pnas.78.11.6749; VINOGRAD.AD, 1972, BIOCHEM BIOPH RES CO, V49, P441, DOI 10.1016/0006-291X(72)90430-5; VINOGRADOV A D, 1986, Biokhimiya, V51, P1944; VINOGRADOV AD, 1976, EUR J BIOCHEM, V63, P365, DOI 10.1111/j.1432-1033.1976.tb10238.x; WALKER WH, 1970, J BIOL CHEM, V245, P4224; WEINER JH, 1979, J BIOL CHEM, V254, P8590; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; YAO Y, 1986, IRON SULFUR PROTEIN, P240; YU CA, 1980, BIOCHEMISTRY-US, V19, P3579, DOI 10.1021/bi00556a025	55	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11553	11558						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375942				2022-12-27	WOS:A1992HX16900094
J	BIRGE, RB; FAJARDO, JE; MAYER, BJ; HANAFUSA, H				BIRGE, RB; FAJARDO, JE; MAYER, BJ; HANAFUSA, H			TYROSINE-PHOSPHORYLATED EPIDERMAL GROWTH-FACTOR RECEPTOR AND CELLULAR P130 PROVIDE HIGH-AFFINITY BINDING SUBSTRATES TO ANALYZE CRK-PHOSPHOTYROSINE-DEPENDENT INTERACTIONS INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; PROTEIN-KINASE; PDGF RECEPTOR; EGF RECEPTOR; SEQUENCE SIMILARITY; ONCOGENE PRODUCT; HUMAN-PLACENTA; ASSOCIATION; DOMAINS	The genome of CT10 avian sarcoma virus encodes a 47-kDa fusion protein that consists of viral gag sequences fused to a cell-derived sequence containing SH2 and SH3 domains (v-crk). Genetic and biochemical evidence suggests that v-Crk can induce transformation of chicken embryo fibroblasts by influencing the activity of cellular proteins involved in growth regulation. In this report, we have developed an in vitro microtiter assay to study the binding of bacterially expressed glutathione S-transferase-fusion proteins of v-Crk and its cellular homolog, c-Crk, to the phosphorylated epidermal growth factor receptor (EGFR). Competitive binding data are presented that compare the abilities of heterologous glutathione S-transferase-fusion proteins containing GAPSH2[N], AblSH2, SrcSH2, and PLC-gamma-SH2[N] sequences to inhibit Crk binding. Results indicate that both full-length Crk and GAPSH2[N] bind the phosphorylated EGFR with high affinity and can quantitatively compete the binding of each other by competitive enzyme-linked immunosorbent assay. Binding of full-length Crk or the isolated SH2 domains of GAP or Abl resulted in a significant protection of phosphorylated EGFR against dephosphorylation by cellular phosphatase activity, but did not appear to stimulate the intrinsic tyrosine kinase activity of the EGFR. To extend these findings to p130, the major phosphotyrosine-containing protein in CT10-transformed cells, we utilized a nitrocellulose filter binding assay. Results demonstrate high affinity binding of Crk toward denatured p130 and, as is the case for phosphorylated EGFR, Crk binding can partially protect p130 from phosphatase activity. However, no apparent competition of Crk binding was noted with heterologous SH2-containing proteins including GAPSH2[N], suggesting a possible specificity of Crk-p130 binding. These data are consistent with a direct role of SH2 in the modulation of cellular phosphotyrosine status in vivo.	ROCKEFELLER UNIV,DEPT MOLEC ONCOL,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA044356, R01CA051462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007233] Funding Source: NIH RePORTER; NCI NIH HHS [CA51462, CA44356-03] Funding Source: Medline; NIAID NIH HHS [AI-07233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4380; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; PIGA A, 1985, EXP CELL RES, V159, P103, DOI 10.1016/S0014-4827(85)80041-0; SHEU SH, 1991, NATURE, V352, P736; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640	37	118	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10588	10595						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375224				2022-12-27	WOS:A1992HV09000057
J	WIEST, DK; WANG, D; HAWLEY, DK				WIEST, DK; WANG, D; HAWLEY, DK			MECHANISTIC STUDIES OF TRANSCRIPTION ARREST AT THE ADENOVIRUS MAJOR LATE ATTENUATION SITE - COMPARISON OF PURIFIED RNA POLYMERASE-II AND WASHED ELONGATION COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF THYMUS; PREMATURE TERMINATION; INITIATION-FACTOR; FUNCTIONAL STEPS; GENE-EXPRESSION; LATE PROMOTER; MONKEY CELLS; FACTOR-SII; PURIFICATION; INVITRO	Transcription elongation in a nuclear extract in vitro is efficiently blocked by Sarkosyl at a specific site downstream of the adenovirus major late (ML) promoter at which regulated transcription arrest has also been observed in vivo. In the experiments reported here, we examined the response of the polymerase to the ML attenuation site in two assay systems: 1) purified RNA polymerase II (Pol II) transcribing tailed templates and 2) elongation complexes formed on immobilized templates and then depleted of elongation factors by extensive washing. Efficient site-specific arrest occurred in both systems, demonstrating that recognition of the site is an intrinsic property of the polymerase. However, the elongation properties of washed elongation complexes and purified pol II were not equivalent. In particular, the efficiency of arrest of washed elongation complexes was influenced both by the promoter from which transcription was initiated and by DNA sequences upstream from the attenuation site that did not contribute to the arrest of purified pol II. The polymerase and washed elongation complexes both remained in stable ternary complexes at the ML site with a lifetime of hours; addition of the elongation factor SII to these complexes promoted resumption of elongation. The efficiency of arrest in both systems was dependent on the solution concentration of the nucleotide incorporated at +187 (just beyond the attenuation site), indicating that pausing is an important part of the arrest mechanism. Based on this and other findings, we argue that the polymerase assumes an altered, elongation-incompetent conformation when arrest occurs.	UNIV OREGON,DEPT CHEM,EUGENE,OR 97403; UNIV OREGON,DEPT BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT MOLEC BIOL,EUGENE,OR 97403	University of Oregon; University of Oregon; University of Oregon								ALONI Y, 1985, CRC CR REV BIOCH MOL, V18, P327, DOI 10.3109/10409238509086785; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BENGAL E, 1989, J BIOL CHEM, V264, P18926; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENGAL E, 1989, J BIOL CHEM, V264, P9791; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1988, J BIOL CHEM, V263, P10812; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; JOHNSTON JM, 1985, J VIROL, V56, P378, DOI 10.1128/JVI.56.2.378-385.1985; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KESSLER M, 1989, J BIOL CHEM, V264, P9785; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MADERIOUS A, 1984, P NATL ACAD SCI-BIOL, V81, P5931, DOI 10.1073/pnas.81.19.5931; MOK M, 1984, MOL CELL BIOL, V4, P2031, DOI 10.1128/MCB.4.10.2031; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1989, J BIOL CHEM, V264, P10799; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; Sambrook J, 1989, MOL CLONING LABORATO; SEIBERG M, 1989, J VIROL, V63, P4093, DOI 10.1128/JVI.63.9.4093-4096.1989; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SILVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPENCER CA, 1990, ONCOGENE, V5, P777; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782	38	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7733	7744						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373137				2022-12-27	WOS:A1992HN48500076
J	RUI, H; DJEU, JY; EVANS, GA; KELLY, PA; FARRAR, WL				RUI, H; DJEU, JY; EVANS, GA; KELLY, PA; FARRAR, WL			PROLACTIN RECEPTOR TRIGGERING - EVIDENCE FOR RAPID TYROSINE KINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-HORMONE RECEPTOR; ERYTHROPOIETIN RECEPTOR; SIGNAL TRANSDUCTION; EXPRESSION CLONING; MOLECULAR-CLONING; PROTEIN-KINASE; LIGAND-BINDING; CYTOPLASMIC REGION; LYMPHOMA-CELLS	The mechanism of action of prolactin (PRL) has remained obscure despite the unveiling of the primary structure of PRL receptors. The present study demonstrates rapid PRL receptor-mediated tyrosine phosphorylation of at least three cellular proteins, designated p120, p97, and p40, in a rat T-lymphoma (Nb2-11C) as revealed by antiphosphotyrosine immunoblotting. One of the phosphotyrosyl proteins, p120, co-purified with activated PRL receptor complexes obtained using either anti-ligand or anti-receptor antibodies. Furthermore, in vitro incubation of affinity-purified PRL receptor complexes from PRL-stimulated cells with ATP in the presence of a tyrosine phosphatase inhibitor, resulted in a 10-15-fold increase in the phosphotyrosine content of p120, as revealed by antiphosphotyrosine immunoblotting. Parallel experiments utilizing [gamma-P-32]ATP confirmed a rapid and time-dependent incorporation of phosphate into p120 in the same affinity-purified PRL receptor complexes. These data provide strong evidence for the involvement of a tyrosine kinase in PRL signal transduction and suggest the presence of a tyrosine kinase within the activated PRL receptor complex.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, MOLEC IMMUNOREGULAT LAB, FREDERICK, MD 21702 USA; UNIV S FLORIDA, H LEE MOFFITT CANC INST & RES CTR, TAMPA, FL 33612 USA; NCI, FREDERICK CANC RES & DEV CTR,DYNCORP, PROGRAM RESOURCES INC, BIOL CARCINOGENESIS DEV PROGRAM, FREDERICK, MD 21702 USA; FAC MED NECKER ENFANTS MALAD, INSERM, U344, UNITE ENDOCRINOL MOLEC, F-75730 PARIS 15, FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; State University System of Florida; University of South Florida; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Kelly, Paul/A-7951-2008		FIC NIH HHS [5FO5 TWO4300-02] Funding Source: Medline; NCI NIH HHS [N01-CO-74102] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004300] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1991, J BIOL CHEM, V266, P20110; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; FARRAR WL, 1991, LYMPHOKINE CYTOK RES, V10, P291; FERRIS DK, 1989, LYMPHOKINE RES, V8, P215; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOUT PW, 1980, CANCER RES, V40, P2433; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, P NATL ACAD SCI USA, V87, P9655; HUGHES JP, 1985, ANNU REV PHYSIOL, V47, P469, DOI 10.1146/annurev.ph.47.030185.002345; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KORNBERG LJ, 1989, BIOCHIM BIOPHYS ACTA, V1011, P205, DOI 10.1016/0167-4889(89)90211-5; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NICOLL CS, 1980, FED PROC, V39, P2563; OKAMURA H, 1989, ENDOCRINOLOGY, V124, P2499, DOI 10.1210/endo-124-5-2499; RAYHEL EJ, 1988, BIOCHEM J, V249, P333, DOI 10.1042/bj2490333; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; RUSSELL DH, 1989, TRENDS PHARMACOL SCI, V10, P40, DOI 10.1016/0165-6147(89)90106-5; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STUBBART JR, 1991, ENDOCRINOLOGY, V129, P1659, DOI 10.1210/endo-129-3-1659; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBB CF, 1988, BIOCHEM J, V250, P215, DOI 10.1042/bj2500215; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YULEE LY, 1990, MOL CELL ENDOCRINOL, V68, P21; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	49	123	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24076	24081						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385436				2022-12-27	WOS:A1992JZ23900097
J	SCHAEFER, EM; ERICKSON, HP; FEDERWISCH, M; WOLLMER, A; ELLIS, L				SCHAEFER, EM; ERICKSON, HP; FEDERWISCH, M; WOLLMER, A; ELLIS, L			STRUCTURAL ORGANIZATION OF THE HUMAN INSULIN-RECEPTOR ECTODOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-I RECEPTOR; TYROSINE KINASE; LIGAND-BINDING; MONOCLONAL-ANTIBODIES; ELECTRON-MICROSCOPY; EXTRACELLULAR DOMAIN; TRYPTOPHAN RESIDUES; FLUORESCENCE DECAY; CIRCULAR-DICHROISM	To provide an experimental system amenable to a detailed biochemical and structural investigation of the extracellular (ligand binding) domain of the insulin receptor, we developed a mammalian heterologous cell expression system from which tens of milligrams of the soluble secreted ectodomain (the IR921 protein) can be routinely purified using methods that do not require harsh elution conditions. The purified IR921 protein has a Stokes radius of 6.8 nm and a sedimentation coefficient of 9.8 S, from which we calculate a hydrodynamic mass of 281 kDa. Electron microscopic images, using both rotary shadowing and negative staining techniques, demonstrate a characteristic substructure for the IR921 protein consisting of two elongated arms, with a globular domain at each end, connected to each other at a point somewhat off-center to form a Y structure. Analysis using circular dichroism and fluorescence spectroscopy illustrate that insulin binding results in conformational changes in the ectodomain. Furthermore, fluorescence anisotropy decay data reveal segmental mobility within the IR921 protein that is successively frozen as a result of insulin binding, in contrast to results obtained in a previous study of the epidermal growth factor receptor ectodomain. This result suggests a divergence in hormone-induced signaling mechanisms used by the insulin and epidermal growth factor receptors.	TEXAS A&M UNIV SYST, INST BIOSCI & TECHNOL, 2121 HOLCOMBE, HOUSTON, TX 77030 USA; DUKE UNIV, SCH MED, DEPT CELL BIOL, DURHAM, NC 27710 USA; RHEIN WESTFAL TH AACHENKLINIKUM, INST BIOCHEM, W-5100 AACHEN, GERMANY	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Duke University; RWTH Aachen University; RWTH Aachen University Hospital					NCI NIH HHS [CA47056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047056, R37CA047056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BARKLEY MD, 1981, J CHEM PHYS, V75, P3581, DOI 10.1063/1.442468; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BARON MD, 1981, BIOCHEMISTRY-US, V20, P4156, DOI 10.1021/bi00517a032; BUCCI E, 1988, BIOPHYS CHEM, V30, P199, DOI 10.1016/0301-4622(88)85017-8; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; BUSH CA, 1980, BIOCHEMISTRY-US, V19, P501, DOI 10.1021/bi00544a017; BUSH CA, 1982, J BIOL CHEM, V257, P8199; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; CHRISTIANSEN K, 1991, P NATL ACAD SCI USA, V88, P249, DOI 10.1073/pnas.88.1.249; COLLIER E, 1991, DIABETES, V40, P197, DOI 10.2337/diabetes.40.2.197; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUDICH EI, 1978, FEBS LETT, V89, P89, DOI 10.1016/0014-5793(78)80529-8; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; Ellis L, 1988, J Mol Recognit, V1, P25, DOI 10.1002/jmr.300010106; ELLIS L, 1991, BIOCHEM SOC T, V19, P426, DOI 10.1042/bst0190426; ELLIS L, 1988, J VIROL, V62, P1634, DOI 10.1128/JVI.62.5.1634-1639.1988; ERICKSON HP, 1982, BIOPHYS J, V37, pA96; FABRY M, 1992, J BIOL CHEM, V267, P8950; FLORKE RR, 1990, EUR J BIOCHEM, V191, P473, DOI 10.1111/j.1432-1033.1990.tb19146.x; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HANSON DC, 1981, BIOCHEMISTRY-US, V20, P6842, DOI 10.1021/bi00527a016; HERRERA R, 1988, J BIOL CHEM, V263, P5560; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOUYAMA T, 1989, EUR J BIOCHEM, V182, P517, DOI 10.1111/j.1432-1033.1989.tb14858.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J R, 1986, Methods Enzymol, V131, P518; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LAX I, 1990, CELL REGUL, V1, P173, DOI 10.1091/mbc.1.2.173; LEAHY DJ, 1992, IN PRESS SCIENCE; LEENDERS HRM, 1990, EUR BIOPHYS J, V18, P43, DOI 10.1007/BF00185419; LIPARI G, 1980, BIOPHYS J, V30, P489, DOI 10.1016/S0006-3495(80)85109-5; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; MURTHY MRN, 1981, J MOL BIOL, V152, P465, DOI 10.1016/0022-2836(81)90254-0; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; RENSCHEIDT H, 1984, EUR J BIOCHEM, V142, P7, DOI 10.1111/j.1432-1033.1984.tb08243.x; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAITO Y, 1981, PHOTOCHEM PHOTOBIOL, V33, P289, DOI 10.1111/j.1751-1097.1981.tb05420.x; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; SISSOM JF, 1991, BIOCHEM BIOPH RES CO, V177, P764, DOI 10.1016/0006-291X(91)91854-6; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WEGENER WA, 1980, J CHEM PHYS, V73, P4086, DOI 10.1063/1.440595; WHITTAKER J, 1988, J BIOL CHEM, V263, P3063; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; WU DG, 1990, P NATL ACAD SCI USA, V87, P3151, DOI 10.1073/pnas.87.8.3151; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	69	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23393	23402						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385419				2022-12-27	WOS:A1992JY16300104
J	MA, Q; CUI, K; XIAO, F; LU, AYH; YANG, CS				MA, Q; CUI, K; XIAO, F; LU, AYH; YANG, CS			IDENTIFICATION OF A GLYCINE-RICH SEQUENCE AS AN NAD(P)H-BINDING SITE AND TYROSINE-128 AS A DICUMAROL-BINDING SITE IN RAT-LIVER NAD(P)H-QUINONE OXIDOREDUCTASE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DT-DIAPHORASE; REDUCTASE; CDNA; DEHYDROGENASE; PROTEINS; PURIFICATION; QUINONES; NUCLEOTIDE; PREDICTION	Site-directed mutagenesis was utilized to identify binding sites for NAD(P)H and dicumarol in rat liver NAD(P)H:quinone oxidoreductase (NQOR, EC 1.6.99.2). The mutant cDNA clones were generated by a procedure based on the polymerase chain reaction and were expressed in Escherichia coli. The mutant enzymes were purified to apparent homogeneity as judged by SDS-polyacrylamide gel electrophoresis and were found to contain 2 FADs/enzyme molecule identical with that of the wild-type NQOR. Purified mutant enzymes Y128D, G150F, G150V, S151F, and Y155D showed dramatic decreases in activities in the reduction of dichlorophenolindophenol in comparison with the activities of the wild-type enzyme, whereas the activities of F124L, T127V, T127E, Y128V, Y128F, S151A, and Y155V were similar to those of NQOR. Enzyme kinetic analysis revealed that the K(m) values of T127E, Y128D, G150F, G150V, S151F, and Y155D were, respectively, 4-, 2-, 13-, 5-, 26-, and 19-fold higher than the K(m) of NQOR for NADPH, and were, respectively, 2-, 3-, 7-, 3-, 20-, and 11-fold higher than that of NQOR for NADH. The k(cat) values of Y128D, G150F, and G150V were also much lower than those of NQOR, but the k(cat) values of other mutants were similar to those of the wild-type enzyme. The K(m) values of the mutants for dichlorophenolindophenol were the same or slightly higher than that of NQOR. The apparent inhibition constants (K(i)) for dicumarol on Y128V and F124L were elevated 12 and 8 times, respectively. Similar, but smaller, changes on K(i) for 4-hydroxycoumarin were also observed. This study demonstrated that residues Gly150, Ser151, and Tyr155 in the glycine-rich region of NQOR are essential for NADPH and NADH binding and Tyr128 is important for dicumarol binding. Based on the results of the study, it is proposed that the glycine-rich region of the enzyme, along with other residues around the region, forms a beta sheet-turn-alpha helix structure important for the binding of the pyrophosphate group of NADPH and NADH.	RUTGERS STATE UNIV,COLL PHARM,CANC RES LAB,PISCATAWAY,NJ 08855; MERCK SHARP & DOHME LTD,DEPT ANIM & EXPLORATORY DRUG METAB,RAHWAY,NJ 07065	Rutgers State University New Brunswick; Merck & Company					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003938] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03938, ES05022] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ATALLAH AS, 1988, BIOCHEM PHARMACOL, V37, P2451, DOI 10.1016/0006-2952(88)90373-5; BAYNEY RM, 1987, J BIOL CHEM, V262, P572; BIELLMANN JF, 1979, EUR J BIOCHEM, V102, P107, DOI 10.1111/j.1432-1033.1979.tb06268.x; CHESIS PL, 1984, P NATL ACAD SCI-BIOL, V81, P1696, DOI 10.1073/pnas.81.6.1696; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; HANIU M, 1988, BIOCHEMISTRY-US, V27, P6877, DOI 10.1021/bi00418a033; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HUANG MT, 1987, CHEM SCRIPTA, V27A, P49; HUANG MT, 1979, J BIOL CHEM, V254, P3930; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; KAPPLUS PA, 1991, SCIENCE, V251, P60; KRAUTHSIEGEL RL, 1982, EUR J BIOCHEM, V121, P259, DOI 10.1111/j.1432-1033.1982.tb05780.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWTON MP, 1990, J BIOL CHEM, V265, P5855; LIND C, 1976, MICROSOMES DRUG OXID, P362; LIU XF, 1989, MOL PHARMACOL, V35, P818; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA Q, 1990, ARCH BIOCHEM BIOPHYS, V283, P311, DOI 10.1016/0003-9861(90)90648-I; MA QA, 1992, ARCH BIOCHEM BIOPHYS, V294, P434, DOI 10.1016/0003-9861(92)90708-5; MONKS TJ, 1992, TOXICOL APPL PHARM, V112, P1; MYSZKA DG, 1991, J BIOL CHEM, V266, P4789; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OTULAKOWSKI G, 1987, J BIOL CHEM, V262, P17313; PROCHESKA HJ, 1989, ARCH BIOCHEM BIOPHYS, V267, P529; ROBERTSON JA, 1986, J BIOL CHEM, V261, P5794; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SMITH MT, 1985, J TOXICOL ENV HEALTH, V16, P665, DOI 10.1080/15287398509530776; SUGIMURA T, 1966, CANCER RES, V26, P1717; THOR H, 1982, J BIOL CHEM, V257, P2419; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	35	58	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22298	22304						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385397				2022-12-27	WOS:A1992JW71900049
J	STUEHR, DJ; IKEDASAITO, M				STUEHR, DJ; IKEDASAITO, M			SPECTRAL CHARACTERIZATION OF BRAIN AND MACROPHAGE NITRIC-OXIDE SYNTHASES - CYTOCHROME-P-450-LIKE HEMEPROTEINS THAT CONTAIN A FLAVIN SEMIQUINONE RADICAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOCHROME P-450 REDUCTASE; L-ARGININE; PHENYLALANINE-HYDROXYLASE; SPECTROSCOPIC PROPERTIES; MURINE MACROPHAGES; LIGAND COMPLEXES; FLAVOPROTEIN; STATE; IDENTIFICATION; PURIFICATION	Nitric oxide (NO) is synthesized in mammals where it acts as a signal molecule for neurotransmission, vasorelaxation, and cytotoxicity. The NO synthases isolated from brain and cytokine-activated macrophages are FAD- and FMN-containing flavoproteins that display considerable sequence homology to NADPH-cytochrome P-450 reductase. However, the nature of their catalytic centers is unknown. We have found that both isoenzymes contain 2 mol of iron-protoporphyrin IX/mol of enzyme homodimer. The optical and EPR spectroscopic properties of the heme groups were found to be remarkably similar to those of high-spin cytochrome P-450. The heme iron in the resting NO synthase is ferric and five-coordinate with a cysteine thiolate as the proximal axial ligand. In addition, the EPR spectra of the resting NO synthases contained a free radical signal attributable to a bound flavin semiquinone that appeared to interact magnetically with the ferric heme iron. NO production was inhibited by carbon monoxide, implying a role for the heme groups in catalysis.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Case Western Reserve University	STUEHR, DJ (corresponding author), CLEVELAND CLIN, IMMUNOL SECT, CLEVELAND, OH 44195 USA.		Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008		NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039492, R01GM039359] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM39492, GM39359] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brunori, 1972, HEMOGLOBIN MYOGLOBIN; CHEVION M, 1977, J BIOL CHEM, V252, P3637; DAVIS MD, 1989, J BIOL CHEM, V264, P8585; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; DIX TA, 1987, BIOCHEMISTRY-US, V26, P3354, DOI 10.1021/bi00386a016; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; Joseph M.H., 1986, HPLC SMALL MOL PRACT; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; NAHRI LO, 1986, J BIOL CHEM, V261, P7160; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; Ohnishi T, 1982, IRON SULFUR PROTEINS, V4, P285; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; OTVOS JD, 1986, BIOCHEMISTRY-US, V25, P7220, DOI 10.1021/bi00370a068; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PRINCE RC, 1988, BIOCHIM BIOPHYS ACTA, V952, P220, DOI 10.1016/0167-4838(88)90119-7; SALERNO JC, 1980, BIOCHEM J, V192, P759; SATO M, 1977, BIOCHIM BIOPHYS ACTA, V498, P403, DOI 10.1016/0304-4165(77)90279-3; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SLAPPENDEL S, 1982, BIOCHIM BIOPHYS ACTA, V708, P259, DOI 10.1016/0167-4838(82)90435-6; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TSAI R, 1970, P NATL ACAD SCI USA, V66, P1157, DOI 10.1073/pnas.66.4.1157; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WHITE RE, 1982, J BIOL CHEM, V257, P3073; WHITTAKER JW, 1984, J BIOL CHEM, V259, P4476; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YU CA, 1974, J BIOL CHEM, V249, P94	52	363	363	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20547	20550						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383204				2022-12-27	WOS:A1992JT97800007
J	DEENEY, JT; TORNHEIM, K; KORCHAK, HM; PRENTKI, M; CORKEY, BE				DEENEY, JT; TORNHEIM, K; KORCHAK, HM; PRENTKI, M; CORKEY, BE			ACYL-COA ESTERS MODULATE INTRACELLULAR CA2+ HANDLING BY PERMEABILIZED CLONAL PANCREATIC BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RINM5F INSULINOMA CELLS; ACID-BINDING-PROTEIN; ATP ADP RATIO; FATTY-ACIDS; COENZYME-A; FREE CA-2+; MALONYL-COA; CARNITINE ACYLTRANSFERASE; STARVED RATS; KINASE-C	Cytosolic free Ca2+ rises in pancreatic beta-cells in response to glucose stimulation and is part of the coupling to insulin secretion. This study evaluates a possible role for cytosolic long chain acyl-CoA esters in modulating Ca2+ handling by clonal beta-cells (HIT). Intact cells incubated with 20 muM free palmitic acid exhibited a 40% decrease in basal cytosolic free Ca2+. In contrast, acyl-CoA esters, up to a chain length of 16, but not the corresponding fatty acids, significantly lowered the Ca2+ set point maintained by cells permeabilized with saponin. The maximum response to the various acyl-CoA esters increased with increasing chain length, with no differences in the half-maximally effective concentration of 0.5 muM. Long chain acyl-CoA esters caused a 40-50% increase in Ca-45(2+) influx into a non-mitochondrial pool in the permeabilized HIT cells, consistent with a stimulatory effect on the endoplasmic reticulum Ca2+-ATPase activity, but did not affect inositol 1,4,5-trisphosphate-induced Ca2+-efflux. Thapsigargin, an inhibitor of endoplasmic reticulum Ca2+-ATPase activity, blocked the decrease in the Ca2+ set point caused by acyl-CoA esters. The ability of acyl-CoA esters to lower the Ca2+ set point depended on the ATP/ADP ratio (or free ADP); the Ca2+ set point was lowered by 36 +/- 3.6% at an ATP/ADP ratio of 90 and by 14 +/- 1.9% at an ATP/ADP ratio of 7. Depletion of cellular protein kinase C did not prevent the acyl-CoA-induced lowering of the Ca2+ set point. These findings suggest that the increases in long chain acyl-CoA esters may play a role in restoring cytosolic free Ca2+ through activation of Ca2+-ATPases.	BOSTON UNIV, SCH MED, DIV DIABET & METAB, BOSTON, MA 02118 USA; UNIV PENN, SCH MED, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA; UNIV GENEVA, CTR MED UNIV, DIV BIOCHIM CLIN, CH-1211 GENEVA 4, SWITZERLAND	Boston University; University of Pennsylvania; University of Geneva			; Corkey, Barbara/E-7712-2015	Tornheim, Keith/0000-0002-6235-5128; Deeney, Jude/0000-0003-0988-9419; Corkey, Barbara/0000-0002-5467-1630	NIDDK NIH HHS [DK35914, DK31559] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035914, R37DK035914, R01DK031559] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGIUS L, 1987, CLIN SCI, V73, P3, DOI 10.1042/cs0730003; ANDERSON MP, 1990, P NATL ACAD SCI USA, V87, P7334, DOI 10.1073/pnas.87.18.7334; BERNE C, 1975, BIOCHEM J, V152, P667, DOI 10.1042/bj1520667; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOYLAN JG, 1992, BIOCHEMISTRY-US, V31, P557, DOI 10.1021/bi00117a037; BRONFMAN M, 1988, BIOCHEM BIOPH RES CO, V152, P987, DOI 10.1016/S0006-291X(88)80381-4; BURRIER RE, 1987, BIOCHIM BIOPHYS ACTA, V919, P221, DOI 10.1016/0005-2760(87)90261-X; CAMPILLO JE, 1979, DIABETOLOGIA, V16, P267, DOI 10.1007/BF01221954; CHANCE B, 1975, ANAL BIOCHEM, V66, P498, DOI 10.1016/0003-2697(75)90617-X; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; CORKEY BE, 1988, METHOD ENZYMOL, V166, P55; CORKEY BE, 1988, J BIOL CHEM, V263, P4247; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; CORKEY BE, 1990, PROG CLIN BIOL RES, V321, P217; CORKEY BE, 1988, J BIOL CHEM, V263, P4254; CRESPIN SR, 1973, J CLIN INVEST, V52, P1979, DOI 10.1172/JCI107382; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; FARESE RV, 1986, ENDOCRINOLOGY, V118, P1498, DOI 10.1210/endo-118-4-1498; GOBERNA R, 1974, HORM METAB RES, V6, P256, DOI 10.1055/s-0028-1093862; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HUANG WH, 1989, J BIOL CHEM, V264, P2605; HUANG WH, 1986, BIOCHEM INT, V12, P521; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MATSCHINSKY FM, 1989, INT CONGR SER, V800, P17; MCGARRY JD, 1981, BIOCHEM J, V200, P217, DOI 10.1042/bj2000217; MCGARRY JD, 1979, J BIOL CHEM, V254, P8163; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; POWELL GL, 1985, FED PROC, V44, P81; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PRENTKI M, 1983, J BIOL CHEM, V258, P7597; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TIPPETT PS, 1982, J BIOL CHEM, V257, P2839; TIPPETT PS, 1982, J BIOL CHEM, V257, P2846; TORNHEIM K, 1991, J BIOL CHEM, V266, P15675; VARA E, 1986, METABOLISM, V35, P266, DOI 10.1016/0026-0495(86)90212-X; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; Williamson J R, 1979, Methods Enzymol, V55, P200; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; WOLDEGIORGIS G, 1985, ANAL BIOCHEM, V150, P8, DOI 10.1016/0003-2697(85)90434-8; WOLDEGIORGIS G, 1982, J BIOL CHEM, V257, P4783; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026	50	89	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19840	19845						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400300				2022-12-27	WOS:A1992JR85800017
J	DAI, ZH; STILES, AD; MOATSSTAATS, B; VANWYK, JJ; DERCOLE, AJ				DAI, ZH; STILES, AD; MOATSSTAATS, B; VANWYK, JJ; DERCOLE, AJ			INTERACTION OF SECRETED INSULIN-LIKE GROWTH FACTOR-I (IGF-I) WITH CELL-SURFACE RECEPTORS IS THE DOMINANT MECHANISM OF IGF-IS AUTOCRINE ACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; SOMATOMEDIN-C; TISSUE CONCENTRATIONS; EPITHELIAL-CELLS; RAT; DNA; TRANSFORMATION; STIMULATION; CULTURE; BINDING	In a prior report we presented evidence that insulin-like growth factor-I (IGF-I) can act in an autocrine fashion by demonstrating that FRTL-5 cells transfected with hIGF-IA fusion genes express and secrete biologically active IGF-I that renders the stimulation of DNA synthesis in FRTL-5 cells independent of their requirement for exogenous IGFs or insulin. To determine if IGF-I's autocrine actions require secretion or can be mediated by interactions with intracellular receptors, we have created a new line of FRTL-5 cells that express a mutant IGF-IA precursor containing the endoplasmic reticulum retention amino acid sequence, Lys-Asp-Glu-Leu (KDEL), at its carboxyl terminus. The mutant IGF-IA/KDEL precursor expressed by stably transfected FRTL-5 cells was shown to be retained intracellularly and to have biological activity comparable with mature IGF-I, as judged by the activity of partially purified IGF-IA/KDEL in wild type FRTL-5 cells. Expression of IGF-IA/KDEL in FRTL-5 cells, however, neither augmented TSH-stimulated DNA synthesis nor stimulated IGF-binding protein-5 expression, as does IGF-IA expression in transfected FRTL-5 cells and the addition of exogenous IGF-I to wild type FRTL-5 cells. IGF-IA/KDEL expression, however, desensitized FRTL-5 cells to the actions of exogenous IGF-I despite having only minimal effects on cell surface type I receptor number, suggesting that intracellular IGF-I is capable of significant biological actions. The failure of IGF-IA/KDEL to replicate the actions of secreted IGF-I, taken together with the findings that a monoclonal antibody against IGF-I blocked IGF-I's actions in IGF-I-secreting transfected FRTL-5 cells, provides evidence that IGF-I secretion and interaction with cell surface type I IGF receptors is the dominant mechanism of IGF-I's autocrine actions.	UNIV N CAROLINA,DEPT PEDIAT,CB 7220,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL-38902] Funding Source: Medline; NICHD NIH HHS [HD-08299] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD008299] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038902] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CASCIERI MA, 1988, ENDOCRINOLOGY, V122, P1314, DOI 10.1210/endo-122-4-1314; CHATELAIN P, 1991, ACTA PAEDIATR SC   S, V80, P92; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMMONS DR, 1991, ADV EXP MED BIOL, V293, P113; CONOVER CA, 1988, ACTA ENDOCRINOL-COP, V118, P513, DOI 10.1530/acta.0.1180513; DAI ZH, 1992, ENDOCRINOLOGY, V130, P3175, DOI 10.1210/en.130.6.3175; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FURLANETTO RW, 1977, J CLIN INVEST, V60, P648, DOI 10.1172/JCI108816; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; HEATON JH, 1986, ENDOCRINOLOGY, V118, P2555, DOI 10.1210/endo-118-6-2555; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; LEROITH D, 1991, MOL CELL ENDOCRINOL, V77, pC57, DOI 10.1016/0303-7207(91)90054-V; MACIEL RMB, 1988, J CLIN INVEST, V82, P1546, DOI 10.1172/JCI113764; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MATHEWS LS, 1987, GROWTH HORMONE BASIC, P373; MCCUSKER RH, 1988, J CELL PHYSIOL, V137, P505, DOI 10.1002/jcp.1041370316; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; RETSCHBOGART GZ, 1990, AM J RESP CELL MOL, V3, P227, DOI 10.1165/ajrcmb/3.3.227; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; STILES AD, 1989, AM J RESP CELL MOL, V1, P21, DOI 10.1165/ajrcmb/1.1.21; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRAMONTANO D, 1986, ENDOCRINOLOGY, V119, P940, DOI 10.1210/endo-119-2-940; VANWYK JJ, 1987, GROWTH HORMONE BASIC, P337; VANWYK JJ, 1986, HUMAN GROWTH HORMONE, P585; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	37	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19565	19571						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382073				2022-12-27	WOS:A1992JP59300082
J	FUJIMORI, T; JENCKS, WP				FUJIMORI, T; JENCKS, WP			THE KINETICS FOR THE PHOSPHORYL TRANSFER STEPS OF THE SARCOPLASMIC-RETICULUM CALCIUM ATPASE ARE THE SAME WITH STRONTIUM AND WITH CALCIUM BOUND TO THE TRANSPORT SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMITING CONFORMATIONAL CHANGE; TRANSIENT-STATE KINETICS; ADENOSINE-TRIPHOSPHATASE; ENERGY INTERCONVERSION; CA2+-DEPENDENT ATPASE; REACTION-MECHANISM; ACETYL PHOSPHATE; MULTIPLE METALS; INDUCED RELEASE; BINDING-SITES	Rate constants for most of the steps of the reaction cycle of the sarcoplasmic reticulum calcium-ATPase are similar or identical with Ca2+ or Sr2+ as the transported ions in spite of the large differences in the size and affinity of Ca2+ and Sr2+ (5 mM MgCl2, 100 mM KCl, pH 7.0,25-degrees-C). Phosphorylation of (c)E.Sr2 and (c)E. Ca2 by ATP occurs with k(p) = 220-235 s-1, whereas phosphorylation of E.ATP + Ca2+ or Sr2+ is consistent with k(b) = 50-70 s-1. Hydrolysis of E approximately P.Sr2 and E approximately P. Ca2 occurs with k(t) = 20 s-1, and the addition of 7 mm ADP to E approximately P.Sr2 or to E approximately P-Ca2 gives a burst of approximately 43% dephosphorylation, followed by dephosphorylation with k = 46 s-1. However, one Sr2+ ion dissociates from (c)E.Sr2 and from (c)E.ATP.Sr2 with k congruent-to 120 s-1, whereas one Ca2+ ion dissociates from (c)E.Ca2 with k = 38 s-1 and from (c)E.ATP.Ca2 with k = 80 s-1.	BRANDEIS UNIV, DEPT BIOCHEM, WALTHAM, MA 02254 USA	Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020888, R01GM020888] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20888] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; BERMAN MC, 1990, BIOCHIM BIOPHYS ACTA, V1029, P235, DOI 10.1016/0005-2736(90)90159-L; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; COTTON FA, 1988, ADV INORG CHEM RAD, P144; de Meis L, 1977, Biochemistry, V16, P4455, DOI 10.1021/bi00639a020; de Meis L, 1974, Biochemistry, V13, P5032, DOI 10.1021/bi00721a026; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; Edsall J T, 1978, Adv Biophys, V10, P137; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; FERNANDEZBELDA F, 1986, BIOCHEMISTRY-US, V25, P8083, DOI 10.1021/bi00372a043; FROEHLICH JP, 1985, BIOCHEMISTRY-US, V24, P126, DOI 10.1021/bi00322a018; FROEHLICH JP, 1980, FED PROC, V39, P2151; FUJIMORI T, 1990, J BIOL CHEM, V265, P16262; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; GUIMARAESMOTTA H, 1984, J BIOL CHEM, V259, P8699; HANEL AM, 1990, BIOCHEMISTRY-US, V29, P5210, DOI 10.1021/bi00473a030; HANEL AM, 1991, BIOCHEMISTRY-US, V30, P11320, DOI 10.1021/bi00111a019; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HIROMI K, 1979, KINETICS FAST ENZYME, P220; HOLGUIN JA, 1986, ARCH BIOCHEM BIOPHYS, V251, P9, DOI 10.1016/0003-9861(86)90045-7; IKEMOTO N, 1975, J BIOL CHEM, V250, P7219; INESI G, 1980, J BIOL CHEM, V255, P3025; JENCKS WP, 1983, CURR TOP MEMBR TRANS, V19, P1; KHANANSHVILI D, 1990, FEBS LETT, V260, P83, DOI 10.1016/0014-5793(90)80071-P; KNOWLES AF, 1975, J BIOL CHEM, V250, P1949; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MAKINOSE M, 1973, FEBS LETT, V37, P140, DOI 10.1016/0014-5793(73)80443-0; MERMIER P, 1976, EUR J BIOCHEM, V69, P79, DOI 10.1111/j.1432-1033.1976.tb10860.x; NAKAMURA J, 1986, BIOCHIM BIOPHYS ACTA, V870, P495, DOI 10.1016/0167-4838(86)90258-X; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P11331, DOI 10.1021/bi00111a020; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P8626, DOI 10.1021/bi00423a018; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICKART CM, 1984, J BIOL CHEM, V259, P1629; PICKART CM, 1982, J BIOL CHEM, V257, P5319; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; STEINFELD JI, 1989, CHEM KINETICS DYNAMI, P27; SUMIDA M, 1980, J BIOL CHEM, V255, P1497; TAKAKUWA Y, 1979, BIOCHEM BIOPH RES CO, V88, P1209, DOI 10.1016/0006-291X(79)91108-2; VERJOVSKIALMEIDA S, 1978, BIOCHEMISTRY-US, V17, P5006, DOI 10.1021/bi00616a023; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P11524; WANG T, 1986, J BIOL CHEM, V261, P6307; WEBER A, 1966, BIOCHEM Z, V345, P329; YAMADA S, 1972, J BIOCHEM, V72, P417, DOI 10.1093/oxfordjournals.jbchem.a129917	56	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18466	18474						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388154				2022-12-27	WOS:A1992JN50200038
J	HOYERHANSEN, G; RONNE, E; SOLBERG, H; BEHRENDT, N; PLOUG, M; LUND, LR; ELLIS, V; DANO, K				HOYERHANSEN, G; RONNE, E; SOLBERG, H; BEHRENDT, N; PLOUG, M; LUND, LR; ELLIS, V; DANO, K			UROKINASE PLASMINOGEN-ACTIVATOR CLEAVES ITS CELL-SURFACE RECEPTOR RELEASING THE LIGAND-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ONCOGENIC VIRUS; U937 MONOCYTES; SYSTEM; ENZYME; DEGRADATION; POTENTIATION; INHIBITORS; EXPRESSION; ANTIBODIES	The cellular receptor for urokinase-type plasminogen activator (uPAR) is a glycolipid-anchored three-domain membrane protein playing a central role in pericellular plasminogen activation. We have found that urokinase (uPA) can cleave its receptor between domains 1 and 2 generating a cell-associated uPAR variant without ligand-binding properties. In extracts of U937 cells there are two uPAR variants which after complete deglycosylation have apparent molecular masses of 35,000 and 27,000. Analysis with monoclonal antibodies showed that these variants represented the intact uPAR and a two-domain form, uPAR(2+3), lacking ligand-binding domain 1. Trypsin treatment showed that both variants are present on the outside of the cells. Addition to the culture medium of an anticatalytic monoclonal antibody to uPA inhibited the formation of the uPAR(2+3), indicating that uPA is involved in its generation. Purified uPAR can be cleaved directly by uPA as well as by plasmin. The uPA-catalyzed cleavage does not require binding of the protease to the receptor through its epidermal growth factor-like receptor-binding domain, since low molecular weight uPA that lacks this domain also cleaves uPAR. This unusual reaction in which a specific binding protein is proteolytically inactivated by its own ligand may represent a regulatory step in the plasminogen activation cascade.			HOYERHANSEN, G (corresponding author), RIGSHOSP, FINSEN INST, STRANDBLVD 49, DK-2100 COPENHAGEN, DENMARK.		Ellis, Vincent/D-1860-2009	Ellis, Vincent/0000-0003-1956-073X; Ploug, Michael/0000-0003-2215-4265; Behrendt, Niels/0000-0003-1833-3922				APPELLA E, 1987, J BIOL CHEM, V262, P4437; BARON-VAN EVERCOOREN A, 1987, DEV BRAIN RES, V36, P101, DOI 10.1016/0165-3806(87)90068-X; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; COHEN SD, 1981, J IMMUNOL, V126, P1415; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DANO K, 1990, UCLA SYM BI, V131, P173; DANO K, 1979, BIOCHIM BIOPHYS ACTA, V566, P138, DOI 10.1016/0005-2744(79)90256-0; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DANO K, 1980, BIOCHIM BIOPHYS ACTA, V630, P146, DOI 10.1016/0304-4165(80)90146-4; DANO K, 1989, CANCER METASTASIS, P98; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; KALTOFT K, 1982, P NATL ACAD SCI-BIOL, V79, P3720, DOI 10.1073/pnas.79.12.3720; KIRCHHEIMER JC, 1989, EUR J BIOCHEM, V181, P103, DOI 10.1111/j.1432-1033.1989.tb14699.x; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND LR, 1991, J BIOL CHEM, V266, P5177; NIELSEN LS, 1986, J IMMUNOASSAY, V7, P209, DOI 10.1080/01971528608060467; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; OLSON D, 1992, J BIOL CHEM, V267, P9129; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; SCHALLER J, 1985, EUR J BIOCHEM, V149, P267, DOI 10.1111/j.1432-1033.1985.tb08921.x; SOLBERG H, 1992, EUR J BIOCHEM, V205, P451, DOI 10.1111/j.1432-1033.1992.tb16799.x; SOTTRUPJENSEN L, 1975, P NATL ACAD SCI USA, V72, P2577, DOI 10.1073/pnas.72.7.2577; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; SUMMARIA L, 1975, J BIOL CHEM, V250, P3988; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	38	230	238	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18224	18229						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381366				2022-12-27	WOS:A1992JM22300113
J	LUO, JY; KRAKOW, JS				LUO, JY; KRAKOW, JS			CHARACTERIZATION AND EPITOPE MAPPING OF MONOCLONAL-ANTIBODIES DIRECTED AGAINST THE BETA'-SUBUNIT OF THE ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGEST SUBUNIT; ANTIGENIC DETERMINANTS; PROMOTER SYSTEM; ALPHA-SUBUNIT; SIGMA-SUBUNIT; NUSA PROTEIN; BETA-SUBUNIT; CORE ENZYME; TRANSCRIPTION; GENE	Monoclonal antibodies (mAbs) raised against the beta'subunit of the Escherichia coli RNA polymerase were used to probe the structure and function of this subunit. Of the five anti-beta'monoclonal antibodies studied, only mAb 311G2 is a strong inhibitor of RNA polymerase activity. This antibody binds to an epitope which is exposed in both the assembled holoenzyme and isolated beta'subunit. In contrast, the null antibodies bind to the free beta' subunit but very weakly to native RNA polymerase. It would appear that the beta'domain in which their epitopes reside is either conformationally altered or blocked due to interaction with other subunits in native RNA polymerase. In order to locate the positions of the epitopes for these five monoclonal antibodies, a series of overlapping deletion mutants have been constructed by partial restriction and religation of the beta'gene present in pT7-beta' (Zalenskaya, K., Lee, J., Gujuluva, C. N., Shin, Y. K., Slutsky, M., nd Goldfarb, A. (1990) Gene 89, 7-12). The presence of the epitopes for each of the anti-beta' monoclonal antibodies was assessed by Western blotting. The results indicate that the epitopes for mAb 340F11, mAb 370F3, mAb 371D6, and mAb 372B2 are located between amino acids 817-876. This region may be important in enzyme assembly or subunit-subunit interaction. The epitope for the inhibitory antibody, mAb 311G2, is located between amino acids 1047-1093. This region may be involved in the catalytic function of RNA polymerase.	CUNY HUNTER COLL,DEPT BIOL SCI,NEW YORK,NY 10021	City University of New York (CUNY) System; Hunter College (CUNY)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022619] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22619] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHEARN JM, 1987, J BIOL CHEM, V262, P10695; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BINNIE C, 1986, P NATL ACAD SCI USA, V83, P5943, DOI 10.1073/pnas.83.16.5943; BORIKHOV S, 1991, J BIOL CHEM, V266, P23932; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; COGGINS JR, 1977, BIOCHEMISTRY-US, V16, P1111, DOI 10.1021/bi00625a013; DALLAVENEZIA N, 1990, J BIOL CHEM, V265, P8122; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DISSINGER S, 1990, J BIOL CHEM, V265, P7662; DJAVADIOHANIANCE L, 1986, BIOCHEMISTRY-US, V25, P2502, DOI 10.1021/bi00357a033; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; FUJITA N, 1987, MOL GEN GENET, V210, P10, DOI 10.1007/BF00337752; GIBSON W, 1981, ANAL BIOCHEM, V118, P1, DOI 10.1016/0003-2697(81)90147-0; GOLDFARB A, 1981, NUCLEIC ACIDS RES, V9, P4863, DOI 10.1093/nar/9.19.4863; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HILLEL Z, 1977, BIOCHEMISTRY-US, V16, P3334, DOI 10.1021/bi00634a008; HODGES RS, 1988, J BIOL CHEM, V263, P11768; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; Ishihama A, 1981, Adv Biophys, V14, P1; ITO K, 1991, J BACTERIOL, V173, P1492, DOI 10.1128/jb.173.4.1492-1501.1991; JIN J, 1989, MOL GEN GENET, V216, P269, DOI 10.1007/BF00334365; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KNAPP S, 1990, BIOTECHNIQUES, V8, P280; KUMAR SA, 1981, PROG BIOPHYS MOL BIO, V38, P165, DOI 10.1016/0079-6107(81)90013-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDICK R, 1990, J BACTERIOL, V172, P2844, DOI 10.1128/jb.172.6.2844-2854.1990; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LAZCANO A, 1988, J MOL EVOL, V27, P365, DOI 10.1007/BF02101199; LEDERER H, 1991, J MOL BIOL, V219, P747, DOI 10.1016/0022-2836(91)90669-W; LESLEY SA, 1987, J BIOL CHEM, V262, P5404; LEVINE BJ, 1980, BIOCHEMISTRY-US, V19, P4808, DOI 10.1021/bi00562a015; LISITSYN NA, 1988, EUR J BIOCHEM, V177, P363, DOI 10.1111/j.1432-1033.1988.tb14385.x; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; NAKAMURA Y, 1989, GENE, V80, P13, DOI 10.1016/0378-1119(89)90245-X; NAWRATH C, 1990, MOL GEN GENET, V223, P65, DOI 10.1007/BF00315798; NIKIFOROV VG, 1983, FEBS LETT, V158, P113, DOI 10.1016/0014-5793(83)80687-5; PETERSEN SK, 1991, J BACTEIROL, V173, P520; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.ge.19.120185.002035; RIFTINA F, 1990, BIOCHEMISTRY-US, V29, P4440, DOI 10.1021/bi00470a026; RIFTINA F, 1989, BIOCHEMISTRY-US, V28, P3299, DOI 10.1021/bi00434a027; ROCKWELL P, 1985, BIOCHEMISTRY-US, V24, P3240, DOI 10.1021/bi00334a025; ROCKWELL P, 1986, THESIS CITY U NEW YO; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	55	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18175	18181						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381365				2022-12-27	WOS:A1992JM22300106
J	TOZAWA, K; ODAKA, M; DATE, T; YOSHIDA, M				TOZAWA, K; ODAKA, M; DATE, T; YOSHIDA, M			MOLECULAR DISSECTION OF THE BETA-SUBUNIT OF F1-ATPASE INTO PEPTIDE-FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATE SYNTHASE; MITOCHONDRIAL ATP SYNTHASE; THERMOPHILIC BACTERIUM PS3; ESCHERICHIA-COLI; ADENINE-NUCLEOTIDES; GLUTAMIC-ACID; BINDING; RECONSTITUTION; MUTAGENESIS; COMPLEX	Partial digestion of the native beta-subunit of F1-ATPase from the thermophilic Bacillus strain PS3 by three different proteases produced a limited number of peptide fragments. In most cases, the peptides remained associated, and the gross structure of the beta-subunit was not destroyed. Furthermore, most peptides were able to reassociate into the form of the beta-subunit after denaturating urea treatment. Therefore, the cleaved sites are most likely located in water-exposed loop regions in the tertiary structure of the protein. Almost all peptides were analyzed, and 17 cleaved sites were determined. From the analysis of the distribution of cleaved sites and deletions or insertions in the multiple amino acid sequence alignment of proteins homologous to the beta-subunit, locations of five loops and four candidate loops in the beta-subunit are suggested. There are two large loops in the central region of the beta-subunit sequence, and dicyclohexylcarbodiimide-reactive Glu190 is located in one of them. Tyr341, involved in putative catalytic ATP binding, is also found in one of the loops. Then, taking cleaved sites as a reference, two kinds of expression plasmids, each of which carried genes of two complementary peptide fragments, 1-193 and 198-473 or 1-284 and 285-473, were constructed and expressed in Escherichia coli. For each plasmid, two peptides were coexpressed, associated into a stable beta-subunit form in E. coli cells, and purified without dissociation. When these beta-subunits were denatured by urea and applied to polyacrylamide gel without denaturant, a protein band with the same mobility as that of the beta-subunit appeared, indicating that reassociation of peptide fragments into the form of the beta-subunit occurred upon removal of urea. These beta-subunits retained the ability to reconstitute the alpha-3-beta-3-gamma complexes even though the efficiency of reconstitution and the recovered ATPase activities were decreased. These complexes were stable at high or low temperature, and ATPase activities were sensitive to inhibition by N3-.	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, R-1, YOKOHAMA, KANAGAWA 227, JAPAN; KANAZAWA MED UNIV, DEPT BIOCHEM, KAHOKU, ISHIKAWA 92002, JAPAN	Tokyo Institute of Technology; Kanazawa Medical University			Odaka, Masafumi/C-2378-2013					BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUNN SD, 1980, J BIOL CHEM, V255, P113; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GARBOCZI DN, 1990, J BIOL CHEM, V265, P14632; GARBOCZI DN, 1988, J BIOL CHEM, V263, P15694; HISABORI T, 1986, J BIOCHEM-TOKYO, V100, P663, DOI 10.1093/oxfordjournals.jbchem.a121758; ISSARTEL JP, 1984, BIOCHEMISTRY-US, V23, P6591, DOI 10.1021/bi00321a048; KAGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P923, DOI 10.1093/oxfordjournals.jbchem.a121805; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; ODAKA M, 1990, BIOCHEM BIOPH RES CO, V168, P372, DOI 10.1016/0006-291X(90)91718-8; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; OHTA S, 1980, J BIOCHEM-TOKYO, V87, P1609, DOI 10.1093/oxfordjournals.jbchem.a132904; OHTSUBO M, 1987, BIOCHEM BIOPH RES CO, V146, P705, DOI 10.1016/0006-291X(87)90586-9; SATOH H, 1989, SEKAGAKU, V91; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; THORNTON JM, 1991, NATURE, V354, P105, DOI 10.1038/354105a0; TSUTSUMI S, 1991, BIOCHIM BIOPHYS ACTA, V1098, P13, DOI 10.1016/0005-2728(91)90003-7; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1979, J BIOL CHEM, V254, P9525; YOSHIDA M, 1981, J BIOL CHEM, V256, P148; YOSHIDA M, 1982, J BIOL CHEM, V257, P33; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480	29	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16484	16490						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1386603				2022-12-27	WOS:A1992JJ45800077
J	BIRNBERG, NC; STORK, PJS; HEMMICK, LM				BIRNBERG, NC; STORK, PJS; HEMMICK, LM			EXPRESSION OF THE C-HARVEY RAS ONCOGENE ALTERS PEPTIDE-SYNTHESIS IN THE NEUROSECRETORY CELL-LINE ATT20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PITUITARY-CELLS; PC12 CELLS; NEURONAL DIFFERENTIATION; GROWTH-FACTOR; GENE; ADRENOCORTICOTROPIN; TRANSCRIPTION; INHIBITION; PROTEINS; FOS	Ras proteins are enriched in neurosecretory cells suggesting that ras may play an important role in regulating the differentiated properties of such cells. We introduced the human H-ras oncogene, EJ-ras, into the model secretory cell line AtT20 to determine the effects of ras oncogene expression on neuropeptide synthesis and release. We report here that both of these processes are changed in ras-transfected AtT20 cells. Stimulated release of the pituitary hormone corticotropin is reduced, and transcription of the gene encoding its precursor, proopiomelanocortin, is down-regulated. At the same time, expression of other genes, both housekeeping and neural-specific, remain relatively unchanged. The alteration of proopiomelanocortin expression in AtT20 cells following ras oncogene transformation supports the hypothesis that ras may play a role in the determination of the differentiated phenotype of neurosecretory cells.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University	BIRNBERG, NC (corresponding author), YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510, USA.							ADLER M, 1983, P NATL ACAD SCI-BIOL, V80, P2086, DOI 10.1073/pnas.80.7.2086; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Battey, 1986, BASIC METHODS MOL BI; BIRNBERG NC, 1983, P NATL ACAD SCI-BIOL, V80, P6982, DOI 10.1073/pnas.80.22.6982; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CARNEY WP, 1988, CLIN CHEM, V34, P1696; CHERA PG, 1987, P NATL ACAD SCI USA, V84, P3234; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FLAMM RE, 1990, PFLUG ARCH EUR J PHY, V416, P120, DOI 10.1007/BF00370232; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HANLEY MR, 1987, NATURE, V328, P668, DOI 10.1038/328668a0; HEMMICK LM, 1992, J NEUROSCI, V12, P2007; HERBERT E, 1978, ENDOCRINOLOGY, V102, P218, DOI 10.1210/endo-102-1-218; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; MIZOGUCHI A, 1989, MOL BRAIN RES, V5, P31, DOI 10.1016/0169-328X(89)90015-6; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PHILLIPS M, 1982, ENDOCRINOLOGY, V110, P892; ROBERTS JL, 1978, BIOCHEMISTRY-US, V17, P3609, DOI 10.1021/bi00610a030; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; STORK P, 1991, ONCOGENE, V6, P857; SUPRENANT A, 1982, J CELL BIOL, V95, P559; SWANSON ME, 1986, J CELL BIOL, V103, P485, DOI 10.1083/jcb.103.2.485; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; UHLER M, 1983, J BIOL CHEM, V258, P257	32	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15464	15468						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379231				2022-12-27	WOS:A1992JG11300034
J	MAGAGNIN, S; BERTRAN, J; WERNER, A; MARKOVICH, D; BIBER, J; PALACIN, M; MURER, H				MAGAGNIN, S; BERTRAN, J; WERNER, A; MARKOVICH, D; BIBER, J; PALACIN, M; MURER, H			POLY(A)(+) RNA FROM RABBIT INTESTINAL-MUCOSA INDUCES B(0,+) AND Y(+) AMINO-ACID-TRANSPORT ACTIVITIES IN XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER VESICLES; ECOTROPIC RETROVIRUS RECEPTOR; CULTURED ANIMAL-CELLS; EXPRESSION CLONING; COTRANSPORT SYSTEM; MEMBRANE-VESICLES; MOUSE BLASTOCYSTS; CYSTINE UPTAKE; PROTEIN; KIDNEY	Injection of poly(A)+ RNA (mRNA) isolated from rabbit intestinal mucosa into Xenopus laevis oocytes results in an increase in sodium-independent uptake of L-[H-3]leucine, L-[S-35]cystine, and L-[H-3]arginine. This uptake activity is related to an mRNA species corresponding to the recently isolated rabbit kidney cortex cDNA clone rBAT (related to b0,+ amino acid transporter; Bertran, J., Werner, A., Stange, G., Markovich, D., Moore, M. L., Biber, J., Testar, X., Zorzano, A., Palacin, M., and Murer, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 281, 717-723) and to a protein involved in amino acid transport via system y+. This conclusion is based on the following observations: 1) mRNA isolated from mucosa of duodenum, jejunum, and ileum, but not from colon, induces sodium-independent uptake of L-leucine, L-cystine, and L-arginine. 2) In Northern blot analysis, mRNA isolated from mucosa of duodenum, jejunum, and ileum, but not from colon, hybridizes to an rBAT cDNA probe, with signals of 2.2-2.3 kilobases and 3.7-3.9 kilobases. 3) mRNA isolated from mucosa of jejunum induces sodium-independent uptake of L-leucine and L-cystine which shows an inhibition pattern corresponding to system b0,+; the inhibition pattern of mRNA-induced uptake of L-arginine is compatible with the contribution of system b0,+ and y+. 4) Hybrid depletion with an rBAT antisense oligonucleotide greatly prevents the mRNA-dependent induction of uptake of L-cystine (>90%) and of L-leucine (approximately 75%); it reduces to about 50% the induction of L-arginine uptake. 5) After separation of mRNA on a sucrose density gradient, the fractions resulting in expression of b0,+ transport activity were also those hybridizing with rBAT cDNA; induction of transport activity from these fractions was also sensitive to hybrid depletion. 6) The mRNA-induced component Of L-arginine uptake which is resistant to rBAT hybrid depletion is inhibited by L-homoserine, only in the presence of sodium; thus, it is related to a system y+-like activity.	UNIV ZURICH,INST PHYSIOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND	University of Zurich			Palacín, Manuel/G-9786-2015; Markovich, Daniel/F-7884-2012	Palacin, Manuel/0000-0002-8670-293X				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; AOSHIMA H, 1988, ARCH BIOCHEM BIOPHYS, V265, P73, DOI 10.1016/0003-9861(88)90372-4; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BERTRAN J, 1992, IN PRESS P NATL ACAD; CAMPA MJ, 1989, J CELL PHYSIOL, V141, P645, DOI 10.1002/jcp.1041410324; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1969, J BIOL CHEM, V244, P1497; COADY MJ, 1990, ARCH BIOCHEM BIOPHYS, V283, P130, DOI 10.1016/0003-9861(90)90622-6; FOREMAN JW, 1980, METABOLISM, V29, P53, DOI 10.1016/0026-0495(80)90098-0; FURESZ TC, 1991, AM J PHYSIOL, V261, pC246, DOI 10.1152/ajpcell.1991.261.2.C246; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCNAMARA PD, 1981, BIOCHEM J, V194, P443, DOI 10.1042/bj1940443; MIRCHEFF AK, 1982, J MEMBRANE BIOL, V64, P113, DOI 10.1007/BF01870773; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NCMANARA PD, 1991, J BIOL CHEM, V266, P986; OZEGOVIC B, 1982, BIOSCIENCE REP, V2, P913, DOI 10.1007/BF01114898; PALACIN M, 1990, BIOCHEM J, V270, P189, DOI 10.1042/bj2700189; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; TARNUZZER RW, 1990, J BIOL CHEM, V265, P13914; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TATE SS, 1989, ARCH BIOCHEM BIOPHYS, V275, P591, DOI 10.1016/0003-9861(89)90405-0; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; VANWINKLE LJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P173, DOI 10.1016/0304-4157(88)90024-X; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WERNER A, 1990, J BIOL CHEM, V265, P12331; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1982, J BIOL CHEM, V257, P4443	38	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15384	15390						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379228				2022-12-27	WOS:A1992JG11300022
J	ZHANG, K; WANG, ZQ; GLUCK, S				ZHANG, K; WANG, ZQ; GLUCK, S			A CYTOSOLIC INHIBITOR OF VACUOLAR H+-ATPASES FROM MAMMALIAN KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; AMINO-ACID-SEQUENCE; BOVINE KIDNEY; URINARY ACIDIFICATION; HEART-MITOCHONDRIA; PROTEIN INHIBITOR; PROTON PUMP; PURIFICATION; ELECTROPHORESIS; NA+,K+-ATPASE	Regulation of the vacuolar H+-ATPase in organellar and transepithelial acidification has been attributed to the effects of the proton electrochemical gradient across the membrane or to changes in the number of proton pumps. We now report the identification and purification of a protein from bovine kidney cytosol that inhibits both ATPase activity and proton translocating activity of vacuolar H+-ATPases. Its relative molecular weight (M(r)) is 6300, similar to that for protein inhibitors of the mitochondrial F0F1-ATPase. The newly identified cytosolic inhibitor protein may participate in the physiologic regulation of the vacuolar H+-ATPase by suppressing activity directly.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS,SCH MED,DIV RENAL, 216 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038848, P01DK009976] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR32087] Funding Source: Medline; NIDDK NIH HHS [DK38848, DK09976] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASTANI B, 1991, J CLIN INVEST, V88, P126, DOI 10.1172/JCI115268; BROWN D, 1988, NATURE, V331, P622, DOI 10.1038/331622a0; CHU A, 1988, METHOD ENZYMOL, V157, P36; CINTRON NM, 1979, J BIOL CHEM, V254, P3439; DIANOUX AC, 1987, EUR J BIOCHEM, V163, P155, DOI 10.1111/j.1432-1033.1987.tb10749.x; EBNER E, 1977, J BIOL CHEM, V252, P671; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRANGIONE B, 1981, P NATL ACAD SCI-BIOL, V78, P7403, DOI 10.1073/pnas.78.12.7403; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GLUCK S, 1988, AM J PHYSIOL, V254, pF71, DOI 10.1152/ajprenal.1988.254.1.F71; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; GLUCK S, 1984, J CLIN INVEST, V73, P1704, DOI 10.1172/JCI111378; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; HARRIS DA, 1986, EUR J BIOCHEM, V157, P181, DOI 10.1111/j.1432-1033.1986.tb09654.x; HASHIMOTO T, 1990, J BIOCHEM-TOKYO, V107, P17; HUSAIN I, 1985, BIOCHIM BIOPHYS ACTA, V806, P64, DOI 10.1016/0005-2728(85)90082-9; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; KLEIN G, 1980, BIOCHEMISTRY-US, V19, P2919, DOI 10.1021/bi00554a016; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Penefsky H S, 1979, Methods Enzymol, V55, P304; POWER J, 1983, BIOCHIM BIOPHYS ACTA, V724, P128, DOI 10.1016/0005-2728(83)90034-8; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; ROUSLIN W, 1987, J BIOL CHEM, V262, P3472; SATRE M, 1975, BIOCHIM BIOPHYS ACTA, V387, P241, DOI 10.1016/0005-2728(75)90107-3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINMETZ PR, 1986, AM J PHYSIOL, V251, pF173, DOI 10.1152/ajprenal.1986.251.2.F173; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; YAMADA EW, 1988, J BIOL CHEM, V263, P11498; ZHANG K, 1992, J BIOL CHEM, V267, P9701	32	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14539	14542						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386077				2022-12-27	WOS:A1992JF08800007
J	ARYSTARKHOVA, E; GASPARIAN, M; MODYANOV, NN; SWEADNER, KJ				ARYSTARKHOVA, E; GASPARIAN, M; MODYANOV, NN; SWEADNER, KJ			NA,K-ATPASE EXTRACELLULAR SURFACE PROBED WITH A MONOCLONAL-ANTIBODY THAT ENHANCES OUABAIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SODIUM DODECYL-SULFATE; ALPHA-SUBUNIT; CATALYTIC SUBUNIT; GEL-ELECTROPHORESIS; NA+/K+-ATPASE; NA+,K+-ATPASE; PROTEINS; RAT; IDENTIFICATION	The Na,K-stimulated ATPase is inhibited by extracellular cardiac glycosides, which bind to the enzyme's alpha-subunit. We used a monoclonal antibody, VG4, as a probe of the extracellular surface. The antibody was specific for Na,K-ATPase and bound to intact cells. The epitope was mapped to the first extracellular loop (H1-H2) of alpha, using a combination of techniques including trypsinolysis, N-terminal sequence of a fragment containing the determinant, and analysis of the effects of species-specific sequence differences. The antibody inhibited Na,K-ATPase activity under certain circumstances, indicating that the H1-H2 loop participates in conformational changes that are transmitted to the active site. Mutations in the H1-H2 loop have been shown by others to affect ouabain affinity. Ouabain and the antibody acted synergistically to inhibit the enzyme, which seemingly supported the hypothesis that the H1-H2 loop is an essential part of the cardiac glycoside binding site. Direct measurements of the binding of [H-3]ouabain, however, indicated that VG, enhanced rather than inhibited binding, presumably by promoting favorable conformation changes. The data suggest the possibility that the cardiac glycoside binding site may be intramembrane rather than extracellular.	MASSACHUSETTS GEN HOSP, DEPT NEUROSURG RES, WELLMAN 4, FRUIT ST, BOSTON, MA 02114 USA; MM SHEMYAKIN BIOORGAN CHEM INST, MOSCOW 117871, USSR; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Harvard University; Harvard Medical School			Gasparian, Marine/J-6725-2018; Chernyak, Boris V/D-9917-2012	Chernyak, Boris V/0000-0003-1523-0864; Gasparian, Marine/0000-0003-2308-2574	NHLBI NIH HHS [HL 36271] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALL WJ, 1987, BIOCHEM BIOPH RES CO, V148, P246, DOI 10.1016/0006-291X(87)91102-8; BALL WJ, 1984, BIOCHEMISTRY-US, V23, P2275, DOI 10.1021/bi00305a029; BALL WJ, 1986, BIOCHEMISTRY-US, V25, P7155, DOI 10.1021/bi00370a058; BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; CANFIELD V, 1990, MOL CELL BIOL, V10, P1367, DOI 10.1128/MCB.10.4.1367; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EMANUEL JR, 1989, MOL CELL BIOL, V9, P3744, DOI 10.1128/MCB.9.9.3744; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; GLYNN IM, 1964, PHARMACOL REV, V16, P381; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KANO I, 1990, BIOCHEM CELL BIOL, V68, P1262, DOI 10.1139/o90-187; KENT RB, 1987, SCIENCE, V237, P901, DOI 10.1126/science.3039660; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1991, SOC GEN PHY, V46, P1; LUCKIE DB, 1991, FEBS LETT, V281, P231, DOI 10.1016/0014-5793(91)80400-W; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MCPARLAND RA, 1991, SODIUM PUMP RECENT D, P297; NOGUCHI S, 1988, BIOCHEM BIOPH RES CO, V155, P1237, DOI 10.1016/S0006-291X(88)81272-5; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; ROSSI B, 1988, METHOD ENZYMOL, V156, P323; SATOH K, 1989, BIOCHIM BIOPHYS ACTA, V994, P104, DOI 10.1016/0167-4838(89)90149-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHENK DB, 1983, P NATL ACAD SCI-BIOL, V80, P5281, DOI 10.1073/pnas.80.17.5281; STAHL WL, 1990, J HISTOCHEM CYTOCHEM, V38, P1099, DOI 10.1177/38.8.2164057; SWEADNER KJ, 1991, ANAL BIOCHEM, V194, P130, DOI 10.1016/0003-2697(91)90159-Q; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; Thomas R., 1990, ADV DRUG RES, P311; URAYAMA O, 1985, J BIOCHEM-TOKYO, V98, P209, DOI 10.1093/oxfordjournals.jbchem.a135260; URAYAMA O, 1990, BIOCHIM BIOPHYS ACTA, V1040, P267, DOI 10.1016/0167-4838(90)90086-U; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201	41	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13694	13701						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377691				2022-12-27	WOS:A1992JB74600094
J	BREUER, W; KARTNER, N; RIORDAN, JR; CABANTCHIK, ZI				BREUER, W; KARTNER, N; RIORDAN, JR; CABANTCHIK, ZI			INDUCTION OF EXPRESSION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; GENE	The cystic fibrosis transmembrane conductance regulator (CFTR) was studied in HT-29 human colonic carcinoma cells with the aim of assessing possible mechanisms of up-regulation of its expression. CFTR was identified and quantified in total cell extracts by Western immunoblots using a monoclonal anti-CFTR antibody and was functionally assessed by tracer Cl- efflux from intact cells. It was found that various stimuli that lead to a sustained (greater-than-or-equal-to 8 h) elevation of intracellular cyclic AMP elicited a marked and specific increase in CFTR expression in cell membranes and concomitant activation of Cl- secretion. Further activation of Cl- secretion was obtained by additional short term activation by cyclic AMP analogues or cyclic AMP-inducing agents. Blockers of transcription or translation largely depressed the cAMP-mediated induction of CFTR levels and associated function, indicating that the inductive phenomenon was at the transcriptional level. The results imply the involvement of putative cyclic AMP responsive (and related) elements that are present in the CFTR gene promoter and that are known to modulate eukaryotic gene expression. Activation of these elements by various stimuli might provide pharmacological tools for up-regulation of CFTR expression at both biochemical and physiological levels.	HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	BREUER, W (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL.				NHLBI NIH HHS [HL 40158] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040158] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEULEMANS J, 1991, PED PULM S, V6, P251; KREUSEL KM, 1991, AM J PHYSIOL, V261, pC574, DOI 10.1152/ajpcell.1991.261.4.C574; LOHRMANN E, 1990, PFLUG ARCH EUR J PHY, V418, pR236; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MONTROSERAFIZADEH C, 1991, J BIOL CHEM, V266, P4495; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1059; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SOOD RC, 1991, PEDIATR PULM S, V6, pA226; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	23	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10465	10469						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375221				2022-12-27	WOS:A1992HV09000041
J	RAN, S; FULLER, CM; ARRATE, MP; LATORRE, R; BENOS, DJ				RAN, S; FULLER, CM; ARRATE, MP; LATORRE, R; BENOS, DJ			FUNCTIONAL RECONSTITUTION OF A CHLORIDE CHANNEL PROTEIN FROM BOVINE TRACHEA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; ION CHANNELS; POTASSIUM CHANNELS; EPITHELIUM; MEMBRANES; VESICLES; PART	We characterized the electrophysiological properties of a chloride channel protein isolated from bovine trachea after incorporation into planar lipid bilayers, and studied the effects of thiol-modulating agents on channel regulation both in bilayers and vesicular iodide uptake studies. Our experiments showed that this protein formed perfectly anion-selective channels in the bilayer, with an anion permeability sequence of I- (2.1) > NO3- (1.7) > Br- (1.2) > Cl- (1.0). The conductance of this channel was 25-30 picosiemens in 150 mM Cl-, and saturated with increasing chloride concentration. This channel could be completely inhibited by 4,4'-bis(isothiocyano)-2,2'-stilbenedisulfonate. Immunoblot analysis, using polyclonal antibodies (anti-p38), revealed one major band at 140 kDa. Upon reduction with dithiothreitol, 64- and 38-kDa polypeptides were observed. Functional experiments showed that reduction was accompanied by loss of I-125- uptake and single-channel activity. In the presence of dithiothreitol, only the low molecular mass protein forms (64 and 38 kDa) were detected by anti-p38 antibodies on Western blots. Cross-linking of S-S bonds with Cu2+-o-phenanthroline led to activation of chloride channels in vesicles and bilayers. Over-aggregation of chloride channels by this S-S cross-linking reagent caused inhibition of I-125- uptake by 80-100% and the abolishment of single-channel activity. We propose that the native chloride channel from bovine trachea can exist in vivo in different structural and functional forms depending upon its thiol-disulfide oxidation reduction status. The oxidized form has a molecular mass of 140 kDa and represents a fully active chloride channel. Inactivation of this channel might occur by over-aggregation of protein subunits, or by dissociation of the 140-kDa subunit by disulfide bond reduction.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV CHILE,DEPT BIOL,CTR ESTUDIOS CIENT SANTIAGO,SANTIAGO,CHILE	University of Alabama System; University of Alabama Birmingham; Universidad de Chile			Fuller, Cathy/B-4046-2011		NIDDK NIH HHS [DK 42017] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK042017] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ O, 1985, J ELECTROPHYSIOL TEC, V12, P159; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ASANO S, 1987, J BIOL CHEM, V262, P13263; Bormann J, 1988, Adv Biochem Psychopharmacol, V45, P47; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; FRIZZELL RA, 1990, CURRENT TOPICS MEMBR, V37, P247; HALM DR, 1988, AM J PHYSIOL, V254, pC505, DOI 10.1152/ajpcell.1988.254.4.C505; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LUKACS GL, 1990, J GEN PHYSIOL, V96, P707, DOI 10.1085/jgp.96.4.707; MORRIS AP, 1992, IN PRESS AM J PHYSL; PRESTON CL, 1992, IN PRESS AM J PHYSL; RAN S, 1991, J BIOL CHEM, V266, P4782; RAN S, 1992, J BIOL CHEM, V267, P3618; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; THINNES FP, 1990, BIOL CHEM H-S, V371, P1047, DOI 10.1515/bchm3.1990.371.2.1047; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P5340; TSAI LM, 1991, J GEN PHYSIOL, V98, P723, DOI 10.1085/jgp.98.4.723; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WELSH MJ, 1985, P NATL ACAD SCI USA, V82, P8823, DOI 10.1073/pnas.82.24.8823; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WELSH MJ, 1986, PFLUG ARCH EUR J PHY, V407, pS116, DOI 10.1007/BF00584940; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WHITE MM, 1981, BIOPHYS J, V35, P455, DOI 10.1016/S0006-3495(81)84801-1	27	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20630	20637						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383206				2022-12-27	WOS:A1992JT97800022
J	LALA, AK; KAUL, P				LALA, AK; KAUL, P			INCREASED EXPOSURE OF HYDROPHOBIC SURFACE IN MOLTEN GLOBULE STATE OF ALPHA-LACTALBUMIN - FLUORESCENCE AND HYDROPHOBIC PHOTOLABELING STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPACT STATE; PROTEIN; ION; PH; TRYPTOPHYL; VESICLES; BINDING; FUSION; NMR	The involvement of molten globule state as a distinct intermediate in the denaturation process in proteins is well documented. However, the structural characterization of such an intermediate is far from complete. We have, using fluorescence and fluorescence quenching, studied the molten globule state of bovine alpha-lactalbumin. Unlike the native state, where all the 4 tryptophans are buried in the protein, 2 tryptophans are exposed in the molten globule state. Using the hydrophobic photoactivable reagent [H-3]diazofluorene, we observe an increased hydrophobic exposure in the molten globule state. These structural characteristics conform to the current views on the molten globule state, i.e. it has similar secondary structure but a poorly defined tertiary structure. Our fluorescence studies indicate the involvement of a premolten globule state in the native to molten globule state transition. This premolten globule state exists at pH 5.0 and has a very compact structure involving increased hydrophobic interactions in the protein interior. These results are also supported by circular dichroism studies.			LALA, AK (corresponding author), INDIAN INST TECHNOL,DEPT CHEM,BIOMEMBRANE LAB,BOMBAY 400076,INDIA.							ANJANEYULU PSR, 1984, INDIAN J CHEM B, V23, P802; BARSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BREW K, 1970, J BIOL CHEM, V245, P4559; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; DOLGIKH DA, 1985, EUR BIOPHYS J BIOPHY, V13, P109, DOI 10.1007/BF00256531; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; HANSSENS I, 1980, BIOCHIM BIOPHYS ACTA, V602, P539, DOI 10.1016/0005-2736(80)90333-8; HANSSENS I, 1984, BIOCHEM BIOPH RES CO, V119, P509, DOI 10.1016/S0006-291X(84)80277-6; JIANG JX, 1990, J BIOL CHEM, V265, P8636; KIM J, 1986, BIOCHEMISTRY-US, V25, P7867, DOI 10.1021/bi00372a012; KOGA K, 1985, BIOCHEMISTRY-US, V24, P7257, DOI 10.1021/bi00346a035; KRONMAN MJ, 1965, BIOCHEMISTRY-US, V4, P526, DOI 10.1021/bi00879a023; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KRONMAN MJ, 1972, BIOCHIM BIOPHYS ACTA, V285, P124, DOI 10.1016/0005-2795(72)90186-9; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1978, BIOPHYS CHEM, V8, P247, DOI 10.1016/0301-4622(78)87006-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LINDAHL L, 1984, ANAL BIOCHEM, V140, P390; MITANI M, 1986, J BIOL CHEM, V261, P8824; MUSCI G, 1984, BIOCHEMISTRY-US, V95, P1098; Parker C. A., 1968, PHOTOLUMINESCENCE SO, P220; PRADHAN D, 1987, J BIOL CHEM, V262, P8242; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; ROBBINS FM, 1970, BIOCHIM BIOPHYS ACTA, V221, P234, DOI 10.1016/0005-2795(70)90263-1; ROBBINS FM, 1972, J BIOL CHEM, V247, P3062; Stern O, 1919, PHYS Z, V20, P183; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847	30	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19914	19918						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400308				2022-12-27	WOS:A1992JR85800029
J	MOFFAT, GJ; VIK, DP; NOACK, D; TACK, BF				MOFFAT, GJ; VIK, DP; NOACK, D; TACK, BF			COMPLETE STRUCTURE OF THE MURINE C4B-BINDING PROTEIN GENE AND REGULATION OF ITS EXPRESSION BY DEXAMETHASONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; GLUCOCORTICOID RECEPTOR-BINDING; ALTERNATIVE PATHWAY PROTEINS; DECAY-ACCELERATING FACTOR; ACUTE-PHASE PROTEIN; CALF THYMUS DNA; MESSENGER-RNA; C4-BINDING PROTEIN; FACTOR-H; TRANSCRIPTION FACTORS	C4b-binding protein (C4BP) is involved in the fluid-phase regulation of the classical pathway of complement. A murine genomic library was screened, and five clones were selected that covered the remaining four exons in the 5'-region of the C4BP gene. Together with previous work (Barnum, S. R., Kristensen, T., Chaplin, D. D., Seldin, M. F., and Tack, B. F. (1989) Biochemistry 28, 8312-8317), the entire C4BP gene has now been shown to be 23 kilobases (kb) long and comprised of 10 exons ranging in size from 86 to 442 base pairs (bp). Primer extension analysis revealed the major transcription start site to be 46 bp upstream of the published cDNA start site. Northern blot analysis of RNA isolated from several mouse tissues demonstrated that the C4BP gene is expressed in a liver-specific manner. Several regions homologous to known response elements were identified upstream of the C4BP gene including a strong hepatocyte nuclear factor 1 binding site and four putative glucocorticoid response elements. Furthermore, dexamethasone increased C4BP mRNA and protein levels in the mouse liver cell line, NMuLi. The stimulation of C4BP gene expression was rapid and independent of protein synthesis. These results suggest dexamethasone induction of the C4BP gene is a primary response and therefore a transcriptional effect. Inhibition of the dexamethasone effect on C4BP by actinomycin D supports this theory. These studies also provide evidence that, for optimal induction of the C4BP gene, the glucocorticoid receptor complex may cooperatively interact with accessory transcription factors. It is likely that stimulation of C4BP gene expression by dexamethasone may allude to a mechanism by which glucocorticoids exert their anti-inflammatory effects.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NCRR NIH HHS [MO1 RR00833] Funding Source: Medline; NIAID NIH HHS [AI17354] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI017354] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTUS MS, 1991, J BIOL CHEM, V266, P21190; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASO T, 1991, BIOCHEM BIOPH RES CO, V174, P222, DOI 10.1016/0006-291X(91)90509-6; BANKIER AT, 1983, TECHNIQUES NUCLEIC A, V85, P1; BARNUM SR, 1989, BIOCHEMISTRY-US, V28, P8312, DOI 10.1021/bi00447a008; BARNUM SR, 1990, COMPLEMENT INFLAMMAT, V7, P71, DOI 10.1159/000463131; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1983, J BIOL CHEM, V258, P563; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BORA NS, 1989, J EXP MED, V169, P597, DOI 10.1084/jem.169.2.597; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BURGE J, 1981, J IMMUNOL, V126, P232; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARROLL MC, 1988, J EXP MED, V167, P1271, DOI 10.1084/jem.167.4.1271; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P989, DOI 10.1021/bi00456a022; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P996, DOI 10.1021/bi00456a023; Chen C L, 1980, Ann N Y Acad Sci, V349, P28, DOI 10.1111/j.1749-6632.1980.tb29512.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDINGLEY MG, 1988, NUCLEIC ACIDS RES, V16, P609, DOI 10.1093/nar/16.2.609; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DAUCHEL H, 1990, EUR J IMMUNOL, V20, P1669, DOI 10.1002/eji.1830200808; DECORDOBA SR, 1991, J EXP MED, V173, P1073, DOI 10.1084/jem.173.5.1073; DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERREIRA A, 1977, J EXP MED, V146, P1001, DOI 10.1084/jem.146.4.1001; FUJISAKU A, 1989, J BIOL CHEM, V264, P2118; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HILLARP A, 1988, J BIOL CHEM, V263, P12759; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAIDOH T, 1981, J IMMUNOL, V126, P463; KARIN M, 1980, NATURE, V286, P295, DOI 10.1038/286295a0; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KATZ Y, 1988, J IMMUNOL, V141, P559; KESAVAN P, 1990, ONCOGENE, V5, P483; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRISTENSEN T, 1987, BIOCHEMISTRY-US, V26, P4668, DOI 10.1021/bi00389a012; LAPPIN DF, 1990, BIOCHEM J, V271, P767, DOI 10.1042/bj2710767; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MOFFAT GJ, 1989, CLIN EXP IMMUNOL, V78, P54; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; MUNOZCANOVES P, 1989, BIOCHEMISTRY-US, V28, P9891, DOI 10.1021/bi00452a002; NAGASAWA S, 1980, J IMMUNOL, V125, P578; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; POST TW, 1990, J IMMUNOL, V144, P740; POST TW, 1989, FASEB J, V3, P368; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; REYCAMPOS J, 1988, J EXP MED, V167, P664, DOI 10.1084/jem.167.2.664; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RINGOLD GM, 1977, P NATL ACAD SCI USA, V74, P2879, DOI 10.1073/pnas.74.7.2879; RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964; RINGOLD GM, 1975, CELL, V6, P299, DOI 10.1016/0092-8674(75)90181-6; RIPOCHE J, 1988, J EXP MED, V168, P1917, DOI 10.1084/jem.168.5.1917; SAEKI T, 1989, BIOCHEM BIOPH RES CO, V164, P1446, DOI 10.1016/0006-291X(89)91832-9; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; VIK DP, 1989, CURR TOP MICROBIOL I, V153, P147; WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WONG WT, 1991, BIOCHEM J, V275, P313, DOI 10.1042/bj2750313; WONG WW, 1989, J EXP MED, V169, P847, DOI 10.1084/jem.169.3.847; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG HY, 1991, J BIOL CHEM, V266, P24332	78	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20400	20406						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400358				2022-12-27	WOS:A1992JR85800101
J	WALKER, FJ				WALKER, FJ			CHARACTERIZATION OF THE INTERACTION BETWEEN THE HEAVY AND LIGHT-CHAINS OF BOVINE FACTOR-VA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; HUMAN FACTOR-VIII; CALCIUM-BINDING SITE; COAGULATION FACTOR-V; ISOLATED SUBUNITS; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; FACTOR-XA; EXPRESSION; THROMBIN	Bovine factor Va has been previously been shown to consist of heavy (M(r) = 94,000) and light chains (M(r) = 81,000), that interact in a manner dependent upon the presence of either calcium or manganese ions. In an attempt to understand the mechanism of subunit interaction we have studied the effects of temperature and ions on factor Va stability. The rates of formation of factor Va from isolated chains and dissociation were temperature-dependent with an energy of activation of 6.2 and 1.3 kcal mol-1, respectively. The yield of factor Va from isolated chains was inversely related to the amount of time the chains were incubated at 4-degrees-C. Incubation of individual chains revealed that the heavy chain is cold-labile, an effect that is reversible. Manganese ion was observed to prevent the conversion to the inactive form. High salt tends to stabilize the two-chain structure of factor Va, but is inhibitory to its formation from isolated chains. High concentrations of either manganese or calcium ions also inhibited reconstitution of activity. The light chain, in particular, was sensitive to the presence of manganese or calcium ion. Heavy chain that had been cleaved by activated protein C had a weakened interaction with the light chain, and the resulting complex had no procoagulant activity. Cooling of the heavy chain to 4-degrees-C enhanced its intrinsic fluorescence. Manganese ion prevented some of this enhancement. The heavy chain fluorescence returned to the room temperature value with a half-life of approximately 10 min. In the presence of manganese ion relaxation was accelerated. The intrinsic fluorescence of activated protein C-cleaved heavy chain was not increased when the temperature was decreased. These data suggest that the heavy chain can exist in two forms. Elevated temperature converts it to a form that can bind ions and have a productive interaction with the light chain. However, conditions that prevent the heavy chain from combining with the light chain also stabilize the two subunit structure, suggesting that the high affinity of the complex is due to conformational changes that occur after chain interaction.	UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,CTR HLTH,DEPT LAB MED,FARMINGTON,CT 06032	University of Connecticut; University of Connecticut	WALKER, FJ (corresponding author), AMER RED CROSS,BLOOD SERV,209 FARMINGTON AVE,FARMINGTON,CT 06032, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040328] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40328] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; ESMON CT, 1979, J BIOL CHEM, V254, P964; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; GUINTO ER, 1982, J BIOL CHEM, V257, P38; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HIBBARD LS, 1980, J BIOL CHEM, V255, P638; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; LAROCCA D, 1991, CANCER RES, V51, P4994; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; TRACY PB, 1979, J BIOL CHEM, V254, P354; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019; VANDEWAART P, 1984, BIOCHIM BIOPHYS ACTA, V799, P38, DOI 10.1016/0304-4165(84)90324-6; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	27	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19896	19900						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400306				2022-12-27	WOS:A1992JR85800026
J	SUN, XC; GARLID, KD				SUN, XC; GARLID, KD			ON THE MECHANISM BY WHICH BUPIVACAINE CONDUCTS PROTONS ACROSS THE MEMBRANES OF MITOCHONDRIA AND LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; LOCAL-ANESTHETICS; LIGHT-SCATTERING; K+-TRANSPORT; RECONSTITUTION; CONTRACTION; EXCHANGER; MATRIX; ACIDS	Bupivacaine and etidocaine possess the remarkable property of stimulating mitochondrial respiration to levels comparable with those observed with classical anionic protonophores (Dabadie, P., Bendriss, P., Erny, P., and Mazat, J. P. (1987) FEBS Lett. 226, 77-82). We show that these amphiphilic amines conduct protons across the membranes of mitochondria and liposomes and stimulate respiration by a true proton-ophoretic mechanism. The kinetics of drug-induced H+ flux exhibited integer Hill coefficients that were greater than two under all conditions, suggesting that multimers are required for H+ transport. When the energy barrier for ion transport was lowered in mitochondria, by increasing the membrane potential, or in liposomes, by adding phloretin, the Hill coefficients decreased to lower integer numbers. Protonophoretic activity depended exclusively on medium concentration of free base, leading us to conclude that bupivacaine and etidocaine conduct protons as associated, intramembrane multimers of the free base. Bupivacaine-induced H+ leak was ohmic rather than nonohmic, as would be expected of a mobile charged carrier. This kinetic behavior seems improbable for a multimeric mobile carrier mechanism and suggests a channel mechanism, in which ohmicity results from splitting of the energy barrier by energy wells along the transport pathway (Garlid, K. D., Beavis, A. D., and Ratkje, S. K. (1989) Biochim. Biophys. Acta 976, 109-120). We hypothesize that bupivacaine and etidocaine act by a novel "flickering channel" mechanism, in which transient linear complexes of free base molecules provide weak binding sites (energy wells) for protons within lipid bilayer membranes.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699					Garlid, Keith/0000-0002-6777-1235	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36573] Funding Source: Medline; NIGMS NIH HHS [GM 31086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN OS, 1976, J GEN PHYSIOL, V67, P749, DOI 10.1085/jgp.67.6.749; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; DABADIE P, 1987, FEBS LETT, V226, P77, DOI 10.1016/0014-5793(87)80554-9; DORDICK RS, 1980, J BIOL CHEM, V255, P299; ELEDJAM JJ, 1989, ANESTH ANALG, V69, P732; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; GARLID KD, 1979, BIOCHEM BIOPH RES CO, V87, P842, DOI 10.1016/0006-291X(79)92034-5; GARLID KD, 1983, J BIOL CHEM, V258, P7974; GARLID KD, 1980, J BIOL CHEM, V255, P1273; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GARLID KD, 1986, J BIOL CHEM, V261, P1529; JEZEK P, 1990, J BIOL CHEM, V265, P10522; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LUVISETTO S, 1990, J BIOENERG BIOMEMBR, V22, P635, DOI 10.1007/BF00809068; MCLAUGHLIN SGA, 1980, PHYSIOL REV, V60, P825, DOI 10.1152/physrev.1980.60.3.825; Mitchell P, 1966, CHEMIOSMOTIC COUPLIN; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; SEEMAN P, 1972, PHARMACOL REV, V24, P583; STRICHARTZ GR, 1990, ANESTH ANALG, V71, P158; TERADA H, 1990, J BIOL CHEM, V265, P7837; TERADA H, 1990, ENVIRON HEALTH PERSP, V87, P213, DOI 10.2307/3431027; TONINELLO A, 1988, J BIOL CHEM, V263, P19407	24	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19147	19154						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382068				2022-12-27	WOS:A1992JP59300024
J	DALLMANN, HG; FLYNN, TG; DUNN, SD				DALLMANN, HG; FLYNN, TG; DUNN, SD			DETERMINATION OF THE 1-ETHYL-3-[(3-DIMETHYLAMINO)PROPYL]-CARBODIIMIDE-INDUCED CROSS-LINK BETWEEN THE BETA AND EPSILON SUBUNITS OF ESCHERICHIA-COLI F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; MITOCHONDRIAL ATP-SYNTHASE; BINDING CHANGE MECHANISM; OXIDATIVE-PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE; UNC OPERON; SECONDARY-STRUCTURE; PROTEINS; F1	The zero-length cross-link between the inhibitory epsilon-subunit and one of three catalytic beta-subunits of Escherichia coli F1-ATPase (alpha-3-beta-3-gamma-delta-epsilon), induced by a water-soluble carbodiimide, 1-ethyl-3-[(3-dimethylamino) propyl]-carbodiimide (EDC), has been determined at the amino acid level. Lability of cross-linked beta-epsilon to base suggested an ester cross-link rather than the expected amide. A 10-kDa cross-linked CNBr fragment derived from beta-epsilon was identified by electrophoresis on high percentage polyacrylamide gels. Sequence analysis of this peptide revealed the constituent peptides to be Asp-380 to Met-431 of beta and Glu-96 to Met-138 of epsilon. Glu-381 of beta was absent from cycle 2 indicating that it was one of the cross-linked residues, but no potential cross-linked residue in epsilon was identified in this analysis. A form of epsilon containing a methionine residue in place of Val-112 (epsilon-V112M) was produced by site-directed mutagenesis. Epsilon-V112M was incorporated into F1-ATPase which was then cross-linked with EDC. An 8-kDa cross-linked CNBr fragment of beta-epsilon-V112M was shown to contain the peptide of epsilon between residues Glu-96 and Met-112 and the peptide of beta between residues Asp-380 and Met-431. Again residue Glu-381 of beta was notably reduced and no missing residue from the epsilon-peptide could be identified, but the peptide sequence limited the possible choices to Ser-106, Ser-107, or Ser-108. Furthermore, an epsilon-mutant in which Ser-108 was replaced by cysteine could no longer be cross-linked to a beta-subunit in F1-ATPase by EDC. Both mutant forms of epsilon-supported growth of an uncC-deficient E. coli strain and inhibited F1-ATPase. These results indicate that the EDC-induced cross-link between the beta and epsilon-subunits of F1-ATPase is an ester linkage between beta-Glu-381 and, likely, epsilon-Ser-108. As these residues must be located immediately adjacent to one another in F1-ATPase, our results define a site of subunit-subunit contact between beta and epsilon.	UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON N6A 5C1, ONTARIO, CANADA; QUEENS UNIV, DEPT BIOCHEM, KINGSTON K7L 3N6, ONTARIO, CANADA	Western University (University of Western Ontario); Queens University - Canada			Dunn, Stanley/D-3418-2013					AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; BRUSILOW WSA, 1983, J BACTERIOL, V155, P1265, DOI 10.1128/JB.155.3.1265-1270.1983; BULLOUGH DA, 1989, J BIOL CHEM, V264, P9155; CARTER P, 1987, METHOD ENZYMOL, V154, P382; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; CROSS RL, 1984, CURR TOP CELL REGUL, V24, P335; CURTIS SE, 1987, J BACTERIOL, V169, P80, DOI 10.1128/jb.169.1.80-86.1987; DOWNIE JA, 1980, J BACTERIOL, V143, P8, DOI 10.1128/JB.143.1.8-17.1980; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1980, J BIOL CHEM, V255, P113; DUNN SD, 1985, J BIOL CHEM, V260, P418; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FALK G, 1985, BIOCHEM J, V228, P391, DOI 10.1042/bj2280391; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBSON F, 1978, J BACTERIOL, V134, P728, DOI 10.1128/JB.134.3.728-736.1978; GIBSON F, 1977, BIOCHEM J, V162, P665, DOI 10.1042/bj1620665; HAWTHORNE CA, 1988, BIOCHEM BIOPH RES CO, V151, P926; JACKSON PJ, 1988, FEBS LETT, V229, P224, DOI 10.1016/0014-5793(88)80832-9; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; KUKI M, 1988, J BIOL CHEM, V263, P17437; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; LARSON RJ, 1977, BIOCHEMISTRY-US, V16, P4266, DOI 10.1021/bi00638a021; LEE RSF, 1989, FEBS LETT, V253, P269, DOI 10.1016/0014-5793(89)80973-1; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; Maniatis T., 1982, MOL CLONING; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; OHTA S, 1988, J BIOL CHEM, V263, P11257; PASSADOR L, 1989, J BACTERIOL, V171, P6234, DOI 10.1128/jb.171.11.6234-6242.1989; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; PATEL AM, 1992, J BACTERIOL, V174, P3541, DOI 10.1128/JB.174.11.3541-3548.1992; SAISHU T, 1986, BIOCHIM BIOPHYS ACTA, V867, P97, DOI 10.1016/0167-4781(86)90069-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; TOZER RG, 1987, J BIOL CHEM, V262, P10706; TYBULEWICZ VLJ, 1984, J MOL BIOL, V179, P185, DOI 10.1016/0022-2836(84)90465-0; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; WALDMEYER B, 1985, J BIOL CHEM, V260, P5184; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WILLING A, 1990, J BIOL CHEM, V265, P6596; WOOD JM, 1987, J BIOL CHEM, V262, P2180; [No title captured]	58	83	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18953	18960						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388160				2022-12-27	WOS:A1992JN50200105
J	WADZINSKI, BE; EISFELDER, BJ; PERUSKI, LF; MUMBY, MC; JOHNSON, GL				WADZINSKI, BE; EISFELDER, BJ; PERUSKI, LF; MUMBY, MC; JOHNSON, GL			NH2-TERMINAL MODIFICATION OF THE PHOSPHATASE-2A CATALYTIC SUBUNIT ALLOWS FUNCTIONAL EXPRESSION IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-T-ANTIGEN; PROTEIN-KINASE-C; TRANSFORMATION; ACTIVATION; INHIBITION; SEQUENCE; FORM	Functional expression of recombinant wild-type phosphatase 2A catalytic subunit has been unsuccessful in the past. A nine-amino-acid peptide sequence (YPYDVPDYA) derived from the influenza hemagglutinin protein was used to modify the NH2 and/or COOH terminus of the phosphatase 2A catalytic subunit. Addition of the nine-amino-acid sequence at the NH2 terminus allowed recombinant phosphatase 2A expression as a predominantly cytosolic phosphatase 2A enzyme. The 12CA5 monoclonal antibody that recognizes the nine-amino-acid hemagglutinin peptide sequence was used to immunoprecipitate the epitope-tagged phosphatase 2A catalytic subunit. Assay of the immunoprecipitated epitope-tagged phosphatase 2A demonstrated an okadaic acid-sensitive dephosphorylation of [P-32] histone H1 and [P-32]myelin basic protein similar to that measured with the wild-type enzyme. Functional phosphatase activity could be demonstrated for the NH2-terminal modified phosphatase 2A catalytic subunit following transient expression in COS cells or stable expression in Rat1a cells. In contrast, the COOH-terminal-modified phosphatase 2A catalytic subunit was very poorly expressed. The NH2-, COOH-modified subunit, having the nine-amino-acid hemagglutinin peptide sequence encoded at both termini of the polypeptide, was also expressed as a functional phosphatase 2A enzyme. Thus, NH2-terminal modification of the phosphatase 2A catalytic subunit results in a functional plasmid-expressed enzyme. The unique nine-amino-acid epitope-tag sequence also provides a method to easily resolve the recombinant phosphatase 2A from the endogenous wild-type gene product and related phosphatases expressed in cells.	NATL JEWISH CTR IMMUNOL & RESP MED, DIV BASIC SCI, 1400 JACKSON ST, DENVER, CO 80206 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA	National Jewish Health; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31107] Funding Source: Medline; NIDDK NIH HHS [DK37871] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11487; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEE WW, 1989, J BIOL CHEM, V264, P5687; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JAKES S, 1988, BIOCHIM BIOPHYS ACTA, V967, P11, DOI 10.1016/0304-4165(88)90182-1; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; MUMBY MC, 1991, CELL REGUL, V2, P589, DOI 10.1091/mbc.2.8.589; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; OSAWA S, 1990, MOL CELL BIOL, V10, P2931, DOI 10.1128/MCB.10.6.2931; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WADZINSKI BE, 1990, J BIOL CHEM, V265, P21504; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	24	63	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16883	16888						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380955				2022-12-27	WOS:A1992JL05300027
J	BARRUECO, JR; OLEARY, DF; SIROTNAK, FM				BARRUECO, JR; OLEARY, DF; SIROTNAK, FM			METABOLIC TURNOVER OF METHOTREXATE POLYGLUTAMATES IN LYSOSOMES DERIVED FROM S180 CELLS - DEFINITION OF A 2-STEP PROCESS LIMITED BY MEDIATED LYSOSOMAL PERMEATION OF POLYGLUTAMATES AND ACTIVATING REDUCED SULFHYDRYL COMPOUNDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST LYSOSOMES; GAMMA-GLUTAMYL; TRANSPORT-SYSTEM; CYTO-TOXICITY; HYDROLASE; INVITRO; POLYGLUTAMYLATION; PROTEOLYSIS; CYSTEINE; TUMOR	Transport and metabolic turnover of methotrexate (MTX) polyglutamates were examined in lysosomes derived from S180 cells. These studies extend prior work from this laboratory (Barrueco, J. R., and Sirotnak, F. M. (1991) J. Biol. Chem 266, 11732-11737) which described basic properties of a facilitative transport system in lysosomes capable of mediating intralysosomal accumulation of MTX polyglutamates. In the present report, we show that the rate of turnover of MTX polyglutamates in lysosomes, which releases MTX in the extralysosomal space, is limited by the extent of mediated intralysosomal accumulation of the polyglutamate and reduced sulfhydryls that activate the enzyme folylpolyglutamate hydrolase. Evidence is presented that cysteine functions as the naturally occurring reduced sulfhydryl compound in lysosomes being equipotent to 2-mercaptoethanol as an activator of folylpolyglutamate hydrolase. Folylpolyglutamate hydrolase in permeabilized lysosomes from S180 cells exhibited a low pH optimum characteristic of a lysosomal enzyme, was activated at concentrations of reduced sulfhydryl at 0.1 mM and above, and exhibited K(m) values in the range of 0.2-3-mu-M that decreased with increase in polyglutamate chain length. Values for K(m) for MTX polyglutamates of folylpolyglutamate hydrolase activity were 100-200-fold lower than values for K(m) or K(i) for facilitated intralysosomal transport, whereas capacities for both processes were similar. This relationship between the kinetic properties of each process ensures efficient hydrolysis of MTX polyglutamates within the lysosome.	MEM SLOAN KETTERING CANC CTR,MOLEC THERAPEUT LAB,PROGRAM MOLEC PHARMACOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [CA 08748, CA 22764, CA 18856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA018856, R01CA022764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRUECO JR, 1991, J BIOL CHEM, V266, P11732; CHABNER BA, 1982, PHARM PRINCIPLES CAN, P229; COOPER AJL, 1983, ANN REV BIOCH, V52, P189; ELSENHANS B, 1984, J BIOL CHEM, V259, P6364; FABRE I, 1984, CANCER RES, V44, P3190; Hall C W, 1978, Methods Enzymol, V50, P439; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; KISLIUK RL, 1984, FOLATE ANTAGONISTS T, V1, P1; LLOYD JB, 1986, BIOCHEM J, V237, P271, DOI 10.1042/bj2370271; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; MEGO JL, 1985, BIOCHIM BIOPHYS ACTA, V841, P139, DOI 10.1016/0304-4165(85)90014-5; MEGO JL, 1984, BIOCHEM J, V218, P775, DOI 10.1042/bj2180775; PISONI RL, 1989, J BIOL CHEM, V264, P4850; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; PISONI RL, 1987, J BIOL CHEM, V262, P6010; POSER RG, 1981, CANCER RES, V41, P4441; PRIEST DG, 1982, MOL CELL BIOCHEM, V43, P81, DOI 10.1007/BF00423095; SAMUELS LL, 1986, CANCER RES, V46, P2230; SAMUELS LL, 1985, CANCER RES, V45, P1488; SILINK M, 1975, J BIOL CHEM, V250, P5982; SIROTNAK FM, 1978, BIOCHEM PHARMACOL, V27, P1821, DOI 10.1016/0006-2952(78)90025-4; SMITH ML, 1987, J BIOL CHEM, V262, P1244; WANG TTY, 1986, J BIOL CHEM, V261, P3551	24	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15356	15361						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379226				2022-12-27	WOS:A1992JG11300018
J	BONNER, JC; GOODELL, AL; LASKY, JA; HOFFMAN, MR				BONNER, JC; GOODELL, AL; LASKY, JA; HOFFMAN, MR			REVERSIBLE BINDING OF PLATELET-DERIVED GROWTH FACTOR-AA, FACTOR-AB, AND FACTOR-BB ISOFORMS TO A SIMILAR SITE ON THE SLOW AND FAST CONFORMATIONS OF ALPHA-2-MACROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDIOPATHIC PULMONARY FIBROSIS; ALPHA-MACROGLOBULIN; ALVEOLAR MACROPHAGES; HUMAN-FIBROBLASTS; FACTOR-BETA; PROTEASE COMPLEXES; SURFACE-RECEPTORS; FAST FORMS; PDGF; CELLS	The mechanism by which the platelet-derived growth factor (PDGF)-binding protein, alpha-2-macroglobulin (alpha-2M), modulates PDGF bioactivity is unknown, but could involve reversible PDGF-alpha-2M binding. Herein we report that >70% of I-125-PDGF-BB or -AB complexed to alpha-2M was dissociated by SDS-denaturation followed by SDS-polyacrylamide gel electrophoresis, i.e. most of the binding was noncovalent. Reduction of the PDGF.alpha-2M complex following denaturation dissociated the cytokine from alpha-2M by >90%, suggesting covalent disulfide bond formation. Approximately 50% of the growth factor was dissociated by lowering the pH from 7.5 to 4.0. I-125-PDGF-BB bound alpha-2M in a time-dependent manner (t1/2 = approximately 1 h), reaching equilibrium after 4 h. The I-125-pDGF.BB/alpha-2M complex dissociated more slowly (t1/2 = approximately 2.5 h). "Slow" and "fast" alpha-2M bound nearly equal amounts of PDGF-AB or -BB. Trypsin treatment converted PDGF-BB/alpha-2M complex to the fast conformation but did not release bound I-125-PDGF-BB. All PDGF-isoforms (AA, -AB, and -BB) competed for binding with I-125-PDGF-BB binding to slow alpha-2M and fast alpha-2M-methylamine by 65-80%. Other cytokines that bind alpha-2M (transforming growth factor-beta-1 and -beta-2, tumor necrosis factor-alpha, basic fibroblast growth factor, interleukin-1-beta, and -6) did not compete for I-125-PDGF-BB binding slow alpha-2M, but transforming growth factor-beta-1 and basic fibroblast growth factor inhibited I-125-PDGF-BB binding alpha-2M-methylamine by 30-50%. The reversible nature of the PDGF.alpha-2M complex could allow for targeted PDGF release near mesenchymal cells which possess PDGF receptors.	UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill	BONNER, JC (corresponding author), NIEHS, PULM PATHOBIOL LAB, POB 12233, RES TRIANGLE PK, NC 27709 USA.			Hoffman, Maureane/0000-0001-7123-0100				ADHAM NF, 1969, ARCH BIOCHEM BIOPHYS, V132, P175, DOI 10.1016/0003-9861(69)90351-8; ANTONIADES HN, 1990, J CLIN INVEST, V86, P1055, DOI 10.1172/JCI114808; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BONNER JC, 1990, J CELL PHYSIOL, V145, P1, DOI 10.1002/jcp.1041450102; BONNER JC, 1991, AM J RESP CELL MOL, V5, P539, DOI 10.1165/ajrcmb/5.6.539; BONNER JC, 1989, AM J RESP CELL MOL, V1, P171, DOI 10.1165/ajrcmb/1.3.171; BORTH W, 1989, J BIOL CHEM, V264, P5818; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DAVIDSEN O, 1985, BIOCHIM BIOPHYS ACTA, V846, P85, DOI 10.1016/0167-4889(85)90113-2; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; GANROT PO, 1966, CLIN CHIM ACTA, V14, P493, DOI 10.1016/0009-8981(66)90037-4; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1990, J CELL SCI, V96, P193; HOFFMAN MR, 1987, J IMMUNOL, V139, P1885; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; HUANG JS, 1983, J CELL BIOL, V97, P383, DOI 10.1083/jcb.97.2.383; HUANG SS, 1988, J BIOL CHEM, V263, P1535; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JAMES K, 1980, TRENDS BIOCHEM SCI, V5, P43, DOI 10.1016/S0968-0004(80)80094-6; KAPLAN J, 1979, J BIOL CHEM, V254, P7323; KAPLAN J, 1981, J BIOL CHEM, V256, P7705; KOO PH, 1989, J NEUROSCI RES, V22, P247, DOI 10.1002/jnr.490220304; LAMARRE J, 1991, BIOCHIM BIOPHYS ACTA, V1091, P197, DOI 10.1016/0167-4889(91)90062-3; LAMARRE J, 1990, LAB INVEST, V62, P545; LAMARRE J, 1991, LAB INVEST, V65, P3; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MARYNEN P, 1983, ANN NY ACAD SCI, V421, P401, DOI 10.1111/j.1749-6632.1983.tb18133.x; MATSUDA T, 1989, J IMMUNOL, V142, P148; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; MOSHER DF, 1976, J EXP MED, V143, P462, DOI 10.1084/jem.143.2.462; NAGAOKA I, 1990, J CLIN INVEST, V85, P2023, DOI 10.1172/JCI114669; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NELLES LP, 1980, BIOCHIM BIOPHYS ACTA, V623, P46, DOI 10.1016/0005-2795(80)90006-9; NEY KA, 1985, BIOCHEMISTRY-US, V24, P4586, DOI 10.1021/bi00338a016; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OSORNIOVARGAS AR, 1990, AM J RESP CELL MOL, V3, P595, DOI 10.1165/ajrcmb/3.6.595; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; RAINES EW, 1984, P NATL ACAD SCI-BIOL, V81, P3424, DOI 10.1073/pnas.81.11.3424; RAINES EW, 1990, PEPTIDE GROWTH FACTO, P173; ROSS R, 1981, ARTERIOSCLEROSIS, V1, P293, DOI 10.1161/01.ATV.1.5.293; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SJOLUND M, 1988, J CELL BIOL, V106, P403, DOI 10.1083/jcb.106.2.403; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; SOTTRUPJENSEN L, 1987, PLASMA PROTEINS, P192; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; WHITE R, 1980, LUNG, V158, P9, DOI 10.1007/BF02713697; WILLINGHAM MC, 1979, J CELL BIOL, V82, P614, DOI 10.1083/jcb.82.3.614; WOLLENBERG GK, 1991, AM J PATHOL, V138, P265	54	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12837	12844						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1377675				2022-12-27	WOS:A1992HZ48300069
J	BURGESS, JW; WADA, I; LING, N; KHAN, MN; BERGERON, JJM; POSNER, BI				BURGESS, JW; WADA, I; LING, N; KHAN, MN; BERGERON, JJM; POSNER, BI			DECREASE IN BETA-SUBUNIT PHOSPHOTYROSINE CORRELATES WITH INTERNALIZATION AND ACTIVATION OF THE ENDOSOMAL INSULIN-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; RAT ADIPOCYTES; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANE; HEPATOMA-CELLS; INTACT-CELLS; PHOSPHORYLATION; AUTOPHOSPHORYLATION; LIVER; ENDOCYTOSIS	In a previous study, we showed that the rat hepatic insulin receptor (IR) kinase of endosomes (ENs) was transiently activated to levels exceeding those of plasma membrane (PM) receptors following insulin injection. Phosphatase treatment of EN receptors abolished IR kinase activation implicating beta-subunit autophosphorylation as a mediator of the activation process (Khan, M. N., Baquiran, G., Brule, C., Burgess, J., Foster, B., Bergeron, J. J. M., and Posner, B. I. (1989) J. Biol. Chem. 264, 12931-12940). In the present study, the phosphotyrosine (PY) content of the IR beta-subunit in PM and ENs was estimated by two different methods. In one method, direct in vivo labeling with P-32(i) followed by receptor immunoprecipitation was carried out. In the second method, immunoblotting with antibodies against the submembrane domain of the IR beta-subunit, encompassing residue 960 (alpha-960), and with antibodies against PY (alpha-PY) was used to determine the content of PY/beta-subunit in PM and ENs following injection of insulin. By both methods, it was round that the PY content of PM IR was significantly greater than that of IR in ENs. With doses of 1.5-mu-g of insulin/100 g body weight (50% receptor occupancy) or 15-mu-g/100 g body weight (receptor saturation), the PY/beta-subunit of PM IR attained a level 2.0 to 2.5-fold of that observed for the IR of ENs. Surprisingly, the IR of ENs incorporated 3 to 5 times more PY/beta-subunit than those of PM consequent to autophosphorylation. Exogenous IR kinase activity (poly(Glu:Tyr)) in PM changed only slightly with insulin dose. In contrast, EN receptors exhibited a dose-dependent increase in kinase activity coincident with the decrease in PY/beta-subunit levels. A comparison of the proportion of receptor and kinase activity immunoprecipitated by alpha-PY both before and after autophosphorylation indicated that ENs but not PM contained a small population of lightly phosphorylated but highly activated receptors. Since Thr12-Lys (IR kinase residues 1142-1153) efficiently inhibited IR autophosphorylation of both PM and EN receptors, Tris phosphorylation of beta-subunit regulatory tyrosines was unlikely. These results may be explicable by a dephosphorylation-dependent activation of IR kinase, as seen with the src family of tyrosine kinases.	WHITTIER INST DIABET & ENDOCRINOL,LA JOLLA,CA 92093; MCGILL UNIV,DEPT ANAT,MONTREAL H3A 1A1,QUEBEC,CANADA; ROYAL VICTORIA HOSP,DEPT MED,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; McGill University; Royal Victoria Hospital	BURGESS, JW (corresponding author), ROYAL VICTORIA HOSP,POLYPEPTIDE HORMONE LAB,MONTREAL H3A 1A1,QUEBEC,CANADA.		Posner, Barry/B-6733-2008; Bergeron, John/AAW-1893-2021	Wada, Ikuo/0000-0001-5668-6994	PHS HHS [R01-DI 19573] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AZUMA K, 1991, J BIOL CHEM, V266, P4831; BACKER JM, 1989, J BIOL CHEM, V264, P1694; BACKER JM, 1989, P NATL ACAD SCI USA, V86, P3209, DOI 10.1073/pnas.86.9.3209; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BALLOTTI R, 1987, BIOCHEM J, V241, P99, DOI 10.1042/bj2410099; BENOIT R, 1987, NEUROMETHODS, V6; BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENGLAND PJ, 1976, ANAL BIOCHEM, V75, P429, DOI 10.1016/0003-2697(76)90096-8; FEHLMANN M, 1982, J CELL BIOL, V93, P82, DOI 10.1083/jcb.93.1.82; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GREEN A, 1982, P NATL ACAD SCI-BIOL, V79, P427, DOI 10.1073/pnas.79.2.427; HARI J, 1987, J BIOL CHEM, V262, P15341; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KADOTA S, 1987, BIOCHEM BIOPH RES CO, V147, P259, DOI 10.1016/S0006-291X(87)80115-8; KAY DG, 1986, J BIOL CHEM, V261, P8473; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KHAN MN, 1985, DIABETES, V34, P1025, DOI 10.2337/diabetes.34.10.1025; KLEIN HH, 1987, J BIOL CHEM, V262, P10557; KLEIN HH, 1986, J BIOL CHEM, V261, P4691; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEYEROVITCH J, 1991, J CLIN INVEST, V87, P1286, DOI 10.1172/JCI115131; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MORGAN DO, 1986, P NATL ACAD SCI USA, V83, P328, DOI 10.1073/pnas.83.2.328; MORRISON BD, 1987, J BIOL CHEM, V262, P2861; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; OKADA M, 1989, J BIOL CHEM, V264, P20886; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PANG DT, 1985, J BIOL CHEM, V260, P7131; PILCH PF, 1979, J BIOL CHEM, V254, P3375; POSNER BI, 1980, J BIOL CHEM, V255, P735; POSNER BI, 1982, J CELL BIOL, V93, P560, DOI 10.1083/jcb.93.3.560; POSNER BI, 1987, INSULIN INSULIN LIKE, P1; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SMITH RM, 1990, ENDOCRINOLOGY, V126, P1551, DOI 10.1210/endo-126-3-1551; TAMURA S, 1984, J BIOL CHEM, V259, P6650; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; THIES RS, 1989, J BIOL CHEM, V264, P12820; THIES RS, 1990, J BIOL CHEM, V265, P10132; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WHITE MF, 1986, ENZYMES, V17, P247; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YIP CC, 1978, J BIOL CHEM, V253, P1743; YU KT, 1986, J BIOL CHEM, V261, P4715	61	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10077	10086						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374397				2022-12-27	WOS:A1992HT96500095
J	CHEN, SRW; ZHANG, L; MACLENNAN, DH				CHEN, SRW; ZHANG, L; MACLENNAN, DH			CHARACTERIZATION OF A CA2+ BINDING AND REGULATORY SITE IN THE CA2+ RELEASE CHANNEL (RYANODINE RECEPTOR) OF RABBIT SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE; CA-2+ RELEASE; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; PLANAR BILAYERS; PROTEINS; COMPLEX; CDNA; PURIFICATION; RECONSTITUTION	A region in the skeletal muscle ryanodine receptor between amino acids 4014 and 4765 was expressed as a trpE fusion protein. Overlay studies revealed that this region bound Ca2+ and ruthenium red, an indicator of Ca2+-binding sites. Ca2+ binding was mapped to subregion 13b between amino acids 4246 and 4377, encompassing a predicted high affinity Ca2+-binding site, and to subregion 13c between amino acids 4364 and 4529, encompassing two predicted high affinity Ca2+-binding sites. Ca2+ binding was then mapped to three shorter sequences, 22(13b1), 36(13c1), and 35(13c2), amino acids long, each encompassing one of the three predicted Ca2+-binding sites. Site-directed polyclonal antibodies were raised against these three short sequences and purified on antigen affinity columns. The antibody against sequence 13c2, lying between residues 4478 and 4512, specifically recognized both denatured and native forms of the ryanodine receptor, suggesting that at least part of the 35 amino acid sequence containing the Ca2+-binding site is surface-exposed. The affinity purified antibody increased the Ca2+ sensitivity of ryanodine receptor channels incorporated into planar lipid bilayers, resulting in increased open probability and opening time without altering channel conductance. The antibody-activated channel was still modulated by Ca2+, Mg2+, ATP, ryanodine, and ruthenium red. These observations suggest that sequence 13c2 may be involved in Ca2+-induced Ca2+ release.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto								ANDERSON K, 1989, J BIOL CHEM, V264, P1329; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CHEN SRW, 1992, FASEB J, V6, P22; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FILL M, 1991, BIOCHEM J, V273, P449, DOI 10.1042/bj2730449; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; HYMEL L, 1988, BIOCHEM BIOPH RES CO, V152, P308, DOI 10.1016/S0006-291X(88)80715-0; INUI M, 1987, J BIOL CHEM, V262, P1740; KIRINO Y, 1983, J BIOCHEM-TOKYO, V94, P1111, DOI 10.1093/oxfordjournals.jbchem.a134454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, BIOCHEM BIOPH RES CO, V151, P441, DOI 10.1016/0006-291X(88)90613-4; LAI FA, 1987, BIOCHEM BIOPH RES CO, V143, P704, DOI 10.1016/0006-291X(87)91411-2; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; NAGASAKI K, 1983, J BIOCHEM-TOKYO, V94, P1101, DOI 10.1093/oxfordjournals.jbchem.a134453; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; Sambrook J, 1989, MOL CLONING LABORATO; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	36	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23318	23326						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385418				2022-12-27	WOS:A1992JY16300093
J	PAULAIS, M; TURNER, RJ				PAULAIS, M; TURNER, RJ			ACTIVATION OF THE NA+-K+-2CL- COTRANSPORTER IN RAT PAROTID ACINAR-CELLS BY ALUMINUM FLUORIDE AND PHOSPHATASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKADAIC ACID; PROTEIN PHOSPHATASES; CELLULAR-REGULATION; NA+/H+ EXCHANGE; SECRETION; CALCIUM; BINDING; TISSUES; VOLUME; CL	The bumetanide-sensitive component of pH(i) recovery from an NH4Cl-induced acute alkaline load was used as a measure of Na+-K+-2Cl- cotransport activity in rat parotid acini. Acinar treatment with NaF/AlCl3 (15 mM NaF plus 10 muM AlCl3) induced a 5-fold stimulation in the initial rate of bumetanide-sensitive pH(i) recovery. This effect was dependent on NaF concentration (K1/2 almost-equal-to 7 mM) and was blunted in the presence of the Al3+ chelator desferal mesylate suggesting that it might be due to the aluminofluoride ion, AlF4-. NaF/AlCl3 treatment did not increase acinar intracellular cAMP levels but did result in an increase in intracellular calcium concentration (from 87 +/- 5 to 181 +/- 2 nM) and in acinar cell shrinkage (12 +/- 1 %). But the stimulation of the Na+-K+-2Cl- cotransporter by NaF/AlCl3 persisted in acini which had been depleted of their intracellular Ca2+ stores. In these acini no effect of NaF/AlCl3 on intracellular calcium or cell volume was observed, indicating that stimulation of the cotransporter was not secondary to either of these phenomena. The effect of NaF/AlCl3 on the cotransporter was blocked by the protein kinase inhibitor K252a indicating the involvement of a protein phosphorylation event. This result is consistent with either NaF/AlCl3-dependent protein kinase activation or phosphatase inhibition. The stimulation of the cotransporter by NaF/AlCl3 was mimicked by the protein phosphatase inhibitor calyculin A; however, this effect was not blocked by K252a suggesting that a different protein kinase from that associated with NaF/AlCl3 may be involved. The data indicate that the Na+-K+-2Cl- cotransporter in this tissue is under tight regulatory control, in all likelihood via multiple protein kinase/phosphatase systems. The physiological roles of these regulatory events in modulating acinar fluid secretion driven by the Na+-K+-2Cl-cotransporter remain to be elucidated.	NIDR,CLIN INVEST & PATIENT CARE BRANCH,BLDG 10,RM 1A06,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Paulais, Marc/Q-6692-2017; Paulais, Marc/E-5623-2017	Paulais, Marc/0000-0002-4895-2110; 				BAUM BJ, 1990, METHOD ENZYMOL, V192, P26; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; COOK DI, 1989, HDB PHYSL 6, V3, P1; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; ISHIHARA H, 1985, BIOCHEM BIOPH RES CO, V159, P933; IWATSUKI N, 1985, JPN J PHYSIOL, V35, P933, DOI 10.2170/jjphysiol.35.933; MACKENZIE CW, 1980, BIOCHIM BIOPHYS ACTA, V614, P413, DOI 10.1016/0005-2744(80)90231-4; MANGANEL M, 1991, J BIOL CHEM, V266, P10182; MELVIN JE, 1988, J BIOL CHEM, V263, P19564; MELVIN JE, 1992, AM J PHYSIOL, V262, pG393, DOI 10.1152/ajpgi.1992.262.3.G393; MELVIN JE, 1987, BIOCHEM BIOPH RES CO, V145, P754, DOI 10.1016/0006-291X(87)91029-1; MERTZ LM, 1990, AM J PHYSIOL, V258, pC654, DOI 10.1152/ajpcell.1990.258.4.C654; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; PAULAIS M, 1992, J CLIN INVEST, V89, P1142, DOI 10.1172/JCI115695; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; PIRANI D, 1987, PFLUG ARCH EUR J PHY, V408, P178, DOI 10.1007/BF00581349; RALL TW, 1958, J BIOL CHEM, V232, P1065; SHACTERNOIMAN E, 1983, J BIOL CHEM, V258, P4214; SHAHED AR, 1988, J DENT RES, V67, P462, DOI 10.1177/00220345880670020501; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TOJYO Y, 1991, AM J PHYSIOL, V260, pC194, DOI 10.1152/ajpcell.1991.260.2.C194; TURNER RJ, 1986, J MEMBRANE BIOL, V94, P143, DOI 10.1007/BF01871194; TURNER RJ, 1992, BIOL SALIVARY GLANDS; Wiseman A., 1970, HDB EXPT PHARM, P48	36	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21558	21563						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383225				2022-12-27	WOS:A1992JV01100047
J	BLOCK, C; FREYERMUTH, S; BEYERSMANN, D; MALVIYA, AN				BLOCK, C; FREYERMUTH, S; BEYERSMANN, D; MALVIYA, AN			ROLE OF CADMIUM IN ACTIVATING NUCLEAR-PROTEIN KINASE-C AND THE ENZYME BINDING TO NUCLEAR-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; PHORBOL ESTER; PLASMA-MEMBRANE; TRANSCRIPTION FACTOR; CELLULAR-REGULATION; NIH-3T3 CELLS; ZINC; RECEPTOR; ASSOCIATION; METALLOTHIONEIN	Specific effects of cadmium on nuclear protein kinase C activity were found with 3T3/10T1/2 mouse fibroblast and rat liver nuclei. Treatment of the mouse fibroblasts in culture with 12-O-tetradecanoylphorbol-13-acetate resulted in the stimulation of nuclear protein kinase C activity in a "fixed" pool which is defined by its resistance to chelator extraction, whereas the chelator extractable enzyme activity, defined as the "labile" pool was unaffected. Cadmium was found to potentiate the effect of the phorbol ester, directed specifically to nuclei, since the particulate protein kinase C activity was not changed under similar treatment. In a reconstituted system consisting of rat liver nuclei and rat brain protein kinase C, cadmium stimulated the binding of the enzyme to a 105-kDa nuclear protein. The binding of a 105-kDa protein to protein kinase C is attributed strictly due to the cadmium effect, whereas a 50-kDa protein binding to protein kinase C was only enhanced by cadmium. We propose a mechanistic model, where cadmium substitutes zinc in the regulatory domain of protein kinase C rendering the putative protein-protein binding site exposed.	CNRS, CTR NEUROCHIM STRASBOURG, NEUROBIOL MOLEC INTERACT CELLULAIRES LAB, F-67084 STRASBOURG, FRANCE; UNIV BREMEN, INST ZELLBIOL & BIOCHEM, W-2800 BREMEN 33, GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Bremen								ANDERSEN RD, 1990, NUCLEIC ACIDS RES, V18, P6049, DOI 10.1093/nar/18.20.6049; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BELL RM, 1991, J BIOL CHEM, V266, P631; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; GARDNER KH, 1991, BIOCHEMISTRY-US, V30, P11292, DOI 10.1021/bi00111a015; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; HEINRICH U, 1989, EXP PATHOL-JENA, V37, P253, DOI 10.1016/S0232-1513(89)80063-5; HOVECAR BA, 1991, J BIOL CHEM, V266, P28; HUBBARD SR, 1991, SCIENCE, V254, P1776; KISS Z, 1988, FEBS LETT, V231, P41, DOI 10.1016/0014-5793(88)80698-7; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; MALVIYA AN, 1992, TRENDS BIOCHEM SCI, V17, P176, DOI 10.1016/0968-0004(92)90259-C; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAN T, 1990, BIOCHEMISTRY-US, V29, P9218, DOI 10.1021/bi00491a016; PAPADOPOULOS V, 1989, J CELL BIOL, V108, P553, DOI 10.1083/jcb.108.2.553; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PEI J, 1990, J BIOL CHEM, V265, P14061; ROGUE P, 1990, J BIOL CHEM, V265, P4161; SIMONS TJB, 1991, J MEMBRANE BIOL, V123, P63, DOI 10.1007/BF01993964; SMITH JB, 1989, J BIOL CHEM, V264, P7115; SPEIZER LA, 1989, J BIOL CHEM, V264, P5581; TANAKA S, 1991, FEBS LETT, V294, P267, DOI 10.1016/0014-5793(91)81445-E; THOMAS TP, 1988, CANCER RES, V48, P1910; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WITTERS LA, 1985, NATURE, V315, P777, DOI 10.1038/315777a0; WOLF M, 1985, J BIOL CHEM, V260, P5718; ZALEWSKI PD, 1990, FEBS LETT, V273, P131, DOI 10.1016/0014-5793(90)81067-X	37	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19824	19828						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400297				2022-12-27	WOS:A1992JR85800014
J	KUMAR, R; GARDNER, MF; RICHMAN, DD; HOSTETLER, KY				KUMAR, R; GARDNER, MF; RICHMAN, DD; HOSTETLER, KY			EQUAL INHIBITION OF HIV REPLICATION BY STEREOISOMERS OF PHOSPHATIDYL-AZIDOTHYMIDINE - LACK OF STEREOSPECIFICITY OF LYSOSOMAL PHOSPHOLIPASE-A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; PURIFICATION; AGENTS; ASSAY; A2	Glycerol-1-P and glycerol-3-P stereoisomers of dipalmitoylphosphatidylazidothymidine were synthesized and found to have equal antiretroviral activity in HIV-infected HT4-6C cells. It was anticipated that the glycerol-1-P isomer would be less active because of slow metabolic conversion by cellular phospholipases A and C, but the antiretroviral results suggested that the human cell line (HT4-6C) may have phospholipases capable of hydrolyzing 2,3-dipalmitoyl-sn-glycerol-1-phospho-5'-azidothymidine (AZT). To evaluate this possibility, we purified lysosomal phospholipase A1, an enzyme known to play a major role in cellular phospholipid catabolism. This enzyme rapidly hydrolyzed both the sn-1 and sn-3 isomers of dipalmitoylphosphatidyl-AZT. We synthesized sn-2,3-dipalmitoyl-glycero-1-phosphocholine and found that it is also hydrolyzed readily by lysosomal phospholipase A1 although the V(max), 59 mumol mg-1 h-1, is slightly lower than that of the sn-1,2-dipalmitoyl-glycero-3-phosphocholine, 89 mumol mg-1 h-1. In conclusion, our studies show that sn-2,3-dipalmitoyl-glycerol-1-phospho-AZT is equal in antiviral activity to sn-1,2-dipalmitoyl-glycero-3-phospho-AZT in HIV-infected HT4-6C cells. This surprising result is due in part to the lack of stereospecificity of lysosomal phospholipase A1.	UNIV CALIF SAN DIEGO, DEPT MED 0676, DIV ENDOCRINOL & METAB, 306 CLIN SCI BLDG, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; VICAL INC, SAN DIEGO, CA 92121 USA; VET ADM MED CTR, SAN DIEGO, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Hostetler, Karl/0000-0002-1155-2885	DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB067019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027670, U01AI030457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HB-67019] Funding Source: Medline; NIAID NIH HHS [AI-27670, AI-30457] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG YY, 1967, J BIOL CHEM, V242, P516; HOSTETLER KY, 1991, J BIOL CHEM, V266, P11714; HOSTETLER KY, 1991, METHOD ENZYMOL, V197, P125; HOSTETLER KY, 1982, J BIOL CHEM, V257, P13367; HOSTETLER KY, 1990, J BIOL CHEM, V265, P6112; KUBO M, 1987, J PHARMACOL EXP THER, V240, P88; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; STEIM JM, 1990, BIOCHEM BIOPH RES CO, V171, P451, DOI 10.1016/0006-291X(90)91414-N; VANDEENEN LLM, 1963, BIOCHIM BIOPHYS ACTA, V70, P538; VANDENBOSCH H, 1968, BIOCHIM BIOPHYS ACTA, V164, P215, DOI 10.1016/0005-2760(68)90148-3; WAITE M, 1967, BIOCHIM BIOPHYS ACTA, V137, P498, DOI 10.1016/0005-2760(67)90131-2; WAITE M, 1971, BIOCHEMISTRY-US, V10, P2377, DOI 10.1021/bi00788a031; WELLS MA, 1971, BIOCHIM BIOPHYS ACTA, V248, P80, DOI 10.1016/0005-2760(71)90077-4; WELLS MA, 1969, METHOD ENZYMOL, V14, P178	17	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20288	20292						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400346				2022-12-27	WOS:A1992JR85800085
J	BURK, SE; SHULL, GE				BURK, SE; SHULL, GE			STRUCTURE OF THE RAT PLASMA-MEMBRANE CA2+-ATPASE ISOFORM-3 GENE AND CHARACTERIZATION OF ALTERNATIVE SPLICING AND TRANSCRIPTION PRODUCTS - SKELETAL MUSCLE-SPECIFIC SPLICING RESULTS IN A PLASMA-MEMBRANE CA2+-ATPASE WITH A NOVEL CALMODULIN-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP ISOFORMS; MOLECULAR-CLONING; CA-2+-ATPASE GENE; CA-2+-TRANSPORTING ATPASE; MESSENGER-RNA; CA-2+ PUMP; CA2+ PUMP; SEQUENCES; BRAIN; SITE	We have isolated the rat gene encoding isoform 3 of the plasma membrane Ca2+-ATPase (PMCA3) and have determined its exon/intron organization. The PMCA3 gene contains 24 exons and spans approximately 70 kilobases. In addition, we have analyzed the splicing and polyadenylation patterns leading to the production of an alternative 4.5-kilobase (PMCA3) skeletal muscle mRNA that differs from the previously characterized 7.5-kilobase brain mRNA (Greeb, J., and Shull, G. E. (1989) J. Biol. Chem. 264, 18569-18576). cDNA cloning, Northern blot hybridization, and polymerase chain reaction analyses of the 4.5-kilobase mRNA demonstrate (i) the inclusion of a novel 68-nucleotide exon (exon 22) that is specific for skeletal muscle and significantly alters the calmodulin-binding domain and (ii) the utilization of an alternative polyadenylation site following exon 23 which eliminates the last coding exon (exon 24) and 3'-untranslated sequence of the 7.5-kilobase mRNA. We have also identified a 42-nucleotide exon (exon 8) that is included in the skeletal muscle PMCA3 mRNAs, but may be either included or excluded in the brain mRNAs. Exon 8 is inserted immediately before the sequence encoding a putative phospholipid binding domain and thus may alter regulatory interactions of the enzyme with acidic phospholipids.	UNIV CINCINNATI, COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL, 231 BETHESDA AVE,ML 524, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041558] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41558] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; BRANDT P, 1992, J BIOL CHEM, V267, P4376; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; GREEB J, 1989, J BIOL CHEM, V264, P18569; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; GUNTESKIHAMBLIN AM, 1992, IN PRESS BIOCHEMISTR; KAHN I, 1991, BIOCHEM J, V277, P345; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; KUO TH, 1991, J BIOL CHEM, V266, P2520; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; Maxam A M, 1980, Methods Enzymol, V65, P499; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEWMAN PR, 1990, DNA CELL BIOL, V9, P749, DOI 10.1089/dna.1990.9.749; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; Rasmussen H, 1990, Curr Top Cell Regul, V31, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL MM, 1989, J BIOL CHEM, V264, P17532; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WERNKE G R, 1989, Biophysical Journal, V55, p390A; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670; ZARVITCH E, 1990, BIOCHEMISTRY-US, V29, P8070	31	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19683	19690						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388171				2022-12-27	WOS:A1992JP59300099
J	SHI, GY; HAU, JS; WANG, SJ; WU, IS; CHANG, BI; LIN, MT; CHOW, YH; CHANG, WC; WING, LYC; JEN, CJ; WU, HL				SHI, GY; HAU, JS; WANG, SJ; WU, IS; CHANG, BI; LIN, MT; CHOW, YH; CHANG, WC; WING, LYC; JEN, CJ; WU, HL			PLASMIN AND THE REGULATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BIOSYNTHESIS IN HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FAST-ACTING INHIBITOR; MESSENGER-RNA LEVELS; MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; STREPTOKINASE COMPLEX; FIBRINOLYTIC-ACTIVITY; BINDING-SITES; THROMBIN; RELEASE	Plasmin inhibited the biosynthesis of tissue-type plasminogen activator (tPA) antigen by human umbilical vein endothelial cells (HUVEC) in a dose-dependent manner. The amount of tPA antigen found in the 24-h conditioned medium of cells treated with 100 nM plasmin for 1 h was 20-30% of that in the control group. However, in contrast to tPA, such treatment led to a 3-fold increase in plasminogen activator inhibitor (PAI) activity, whereas the amount of PAI type 1 antigen was unchanged. The effects of plasmin on HUVEC were binding- and catalytic activity-dependent and were specifically blocked by epsilon-aminocaproic acid. Microplasmin, which has no kringle domains, was less effective in reducing tPA antigen biosynthesis or enhancing PAI activity in HUVEC. Kringle domains of plasmin affected neither tPA antigen nor PAI activity of the cells. Other proteases including chymotrypsin, trypsin, and collagenase at comparable concentrations did not have a significant effect on the biosynthesis of tPA antigen or PAI activity of HUVEC. Thrombin stimulated the biosynthesis of tPA and PAI-1 antigens by HUVEC. Thrombin also stimulated an increase in the protein kinase activity in HUVEC, whereas plasmin inhibited the protein kinase activity of the cells. It is possible that plasmin regulates the biosynthesis of tPA in HUVEC through the signal transduction pathway involving protein kinase.	NATL CHENG KUNG UNIV, COLL MED, DEPT BIOCHEM, TAINAN 701, TAIWAN; NATL CHENG KUNG UNIV, COLL MED, DEPT PHARMACOL, TAINAN, TAIWAN; NATL CHENG KUNG UNIV, COLL MED, DEPT PHYSIOL, TAINAN, TAIWAN	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University			Chow, Yen-Hung/E-3863-2010					ANDREOTTI F, 1988, AM J CARDIOL, V62, P635, DOI 10.1016/0002-9149(88)90669-8; BACHMANN F, 1984, SEMIN THROMB HEMOST, V10, P6, DOI 10.1055/s-2007-1004403; BARNATHAN ES, 1988, J BIOL CHEM, V263, P7792; BAUER PI, 1984, BIOCHEM J, V218, P119, DOI 10.1042/bj2180119; CALIFF RM, 1992, AM J CARDIOL, V69, pA12, DOI 10.1016/0002-9149(92)91168-4; DICHEK D, 1989, BLOOD, V74, P222; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; ESMON CT, 1983, BLOOD, V62, P1155; GRAM J, 1987, ACTA MED SCAND, V221, P149; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HAJJAR KA, 1990, J BIOL CHEM, V265, P2908; HAJJAR KA, 1991, J BIOL CHEM, V266, P21962; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HANSS M, 1987, J LAB CLIN MED, V109, P97; HUANG RS, 1991, J BIOL CHEM, V266, P18435; JOHNSON AJ, 1969, THROMB DIATH HAEMOST, V21, P259; KOOISTRA T, 1991, ARTERIOSCLER THROMB, V11, P1042, DOI 10.1161/01.ATV.11.4.1042; KRUITHOF EKO, 1984, BLOOD, V64, P907; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN EG, 1989, J BIOL CHEM, V264, P16030; LEVIN EG, 1983, P NATL ACAD SCI-BIOL, V80, P6804, DOI 10.1073/pnas.80.22.6804; LEVIN EG, 1979, THROMB RES, V15, P869, DOI 10.1016/0049-3848(79)90195-6; LEVIN EG, 1982, J CELL BIOL, V94, P631, DOI 10.1083/jcb.94.3.631; LEVIN EG, 1988, J BIOL CHEM, V263, P9360; LEVIN EG, 1986, THROMB HAEMOSTASIS, V56, P115; LEVIN EG, 1991, J BIOL CHEM, V266, P174; LEVIN EG, 1984, J CLIN INVEST, V74, P1988, DOI 10.1172/JCI111620; LOLLAR P, 1980, J BIOL CHEM, V255, P279; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LOSKUTOFF DJ, 1983, P NATL ACAD SCI-BIOL, V80, P2956, DOI 10.1073/pnas.80.10.2956; LOSKUTOFF DJ, 1979, J CLIN INVEST, V64, P329, DOI 10.1172/JCI109457; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARDER VJ, 1988, NEW ENGL J MED, V318, P1585, DOI 10.1056/NEJM198806163182406; MARDER VJ, 1988, NEW ENGL J MED, V318, P1512, DOI 10.1056/NEJM198806093182306; NILSSON IM, 1985, BRIT MED J, V290, P1453, DOI 10.1136/bmj.290.6480.1453; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RAMAKRISHNAN V, 1990, J BIOL CHEM, V265, P2755; RUNGE MS, 1989, CIRCULATION, V79, P217, DOI 10.1161/01.CIR.79.2.217; RUSSELL ME, 1990, J BIOL CHEM, V265, P2569; SANTELL L, 1988, J BIOL CHEM, V263, P16802; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SHI GY, 1988, J BIOL CHEM, V263, P17071; SHI GY, 1990, THROMB RES, V58, P317, DOI 10.1016/0049-3848(90)90101-H; SPRENGERS ED, 1987, BLOOD, V69, P381; SUMMARIA L, 1976, J BIOL CHEM, V251, P5810; VANHINSBERGH VWM, 1987, THROMB HAEMOSTASIS, V57, P148; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392; VERSTRAETE M, 1986, BLOOD, V67, P1529; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WIMAN B, 1990, AM J CARDIOL, V66, pG54, DOI 10.1016/0002-9149(90)90397-J; WIMAN B, 1985, J LAB CLIN MED, V105, P265; WU HL, 1990, J BIOL CHEM, V265, P19658; WU HL, 1987, P NATL ACAD SCI USA, V84, P8292, DOI 10.1073/pnas.84.23.8292; WU HL, 1987, P NATL ACAD SCI USA, V84, P8793, DOI 10.1073/pnas.84.24.8793	55	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19363	19368						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388168				2022-12-27	WOS:A1992JP59300053
J	VASSILATIS, DK; DESPOMMIER, D; MISEK, DE; POLVERE, RI; GOLD, AM; VANDERPLOEG, LHT				VASSILATIS, DK; DESPOMMIER, D; MISEK, DE; POLVERE, RI; GOLD, AM; VANDERPLOEG, LHT			ANALYSIS OF A 43-KDA GLYCOPROTEIN FROM THE INTRACELLULAR PARASITIC NEMATODE TRICHINELLA-SPIRALIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-PARTICLE FRACTION; GEL-ELECTROPHORESIS; MUSCLE LARVA; DNA-BINDING; PROTEINS; ANTIGENS; EXPRESSION; INFECTION; CLONING; CELLS	The L1 larvae of the parasitic nematode Trichinella spiralis invade skeletal muscle and initiate a process that has been interpreted to represent skeletal muscle dedifferentiation. In this process, the infected region of the muscle cell is converted into a unique structure, called the Nurse cell. The nematode T. spiralis can survive for tens of years within the cytoplasm of the Nurse cell and secretes proteins into the cytoplasm that are believed to play a role in mediating the Nurse cell formation or maintenance. We have cloned a cDNA encoding the T. spiralis-derived, 43-kDa secreted protein. Structural analysis of the predicted 344-amino acid sequence revealed an N terminally located signal peptide and a potential helix-loop-helix motif in the main body of the protein. Antibodies raised against the 43-kDa recombinant protein were used in immunocytolocalizations of T. spiralis-infected skeletal muscle sections. These antibodies strongly stained the Nurse cell nuclei and the nematode itself. Specific, though slightly weaker staining also occurred in the Nurse cell cytoplasm. In Western blots, the antibodies react with the 43-kDa protein but also detected at least two other T. spiralis-secreted proteins. DNA hybridizations reveal at least one additional 43-kDa-related sequence encoded in the T. spiralis genome. We conclude that either the 43-kDa protein and/or a closely related 43-kDa family member is secreted into the muscle and translocates to the muscle-derived nuclei. This model may provide insights into the mechanisms involved in Nurse cell formation.	COLUMBIA UNIV,SCH PUBL HLTH,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV,SCH PUBL HLTH,DIV TROP MED,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NIAID NIH HHS [R01-AI-10627-21] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI010627] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BASTEN A, 1970, J EXP MED, V131, P1288, DOI 10.1084/jem.131.6.1288; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOEDTKER H, 1971, BIOCHIM BIOPHYS ACTA, V240, P448, DOI 10.1016/0005-2787(71)90539-9; DESPOMMIER D, 1975, AM J PATHOL, V78, P477; DESPOMMIER D, 1975, EXP PARASITOL, V37, P108, DOI 10.1016/0014-4894(75)90058-2; DESPOMMIER D, 1991, J PARASITOL, V77, P290, DOI 10.2307/3283099; DESPOMMIER DD, 1976, J PARASITOL, V62, P775, DOI 10.2307/3278960; DESPOMMIER DD, 1981, J PARASITOL, V67, P332, DOI 10.2307/3280552; DESPOMMIER DD, 1977, PARASITOLOGY, V74, P109, DOI 10.1017/S0031182000047570; DESPOMMIER DD, 1981, EXP PARASITOL, V51, P279, DOI 10.1016/0014-4894(81)90116-8; DESPOMMIER DD, 1990, EXP PARASITOL, V71, P27, DOI 10.1016/0014-4894(90)90005-W; DESPOMMIER DD, 1976, MUSCULATURE ECOLOGIC, P270; GARDINER CH, 1976, J PARASITOL, V62, P865, DOI 10.2307/3279174; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLD AM, 1990, MOL BIOCHEM PARASIT, V41, P187, DOI 10.1016/0166-6851(90)90181-K; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARBOE N, 1973, MANUAL QUANTITATIVE, P161; HARLEY JP, 1971, EXP PARASITOL, V30, P11, DOI 10.1016/0014-4894(71)90064-6; JASMER DP, 1990, EXP PARASITOL, V70, P452, DOI 10.1016/0014-4894(90)90130-5; JEFFREYS AJ, 1977, CELL, V12, P429, DOI 10.1016/0092-8674(77)90119-2; KHAN ZA, 1966, J PARASITOL, V52, P248, DOI 10.2307/3276480; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZEK WJ, 1971, J PARASITOL, V57, P1015, DOI 10.2307/3277858; KOZEK WJ, 1971, J PARASITOL, V57, P1029, DOI 10.2307/3277860; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MASMER DP, 1991, EXP PARASITOL, V72, P321; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; RIBASMUJAL D, 1968, VIRCHOWS ARCH A, V345, P154, DOI 10.1007/BF00548649; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART GL, 1973, THESIS RICE U HOUSTO; SU XZ, 1991, MOL BIOCHEM PARASIT, V45, P331, DOI 10.1016/0166-6851(91)90101-B; TEPPEMA JS, 1973, PARASITOLOGY, V66, P291, DOI 10.1017/S0031182000045224; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; VILLELLA JB, 1958, J PARASITOL, V44, P41	38	76	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18459	18465						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382055				2022-12-27	WOS:A1992JN50200037
J	AMMENDOLA, R; MESURACA, M; RUSSO, T; CIMINO, F				AMMENDOLA, R; MESURACA, M; RUSSO, T; CIMINO, F			SP1-DNA BINDING-EFFICIENCY IS HIGHLY REDUCED IN NUCLEAR EXTRACTS FROM AGED RAT-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; DNA-BINDING; TRANSCRIPTION FACTORS; MESSENGER-RNA; GENE-EXPRESSION; PROMOTER; PROTEIN; MOUSE; SP1; LIVER	To explore the role of transcriptional factors in the genesis of the senescent phenotype, nuclear extracts from 4- and 30-month-old rat brains were analyzed for the presence of DNA-binding proteins able to interact with double-stranded oligonucleotides containing recognition sites for sequence-specific DNA-binding factors. Gel shift assays revealed that the DNA-binding efficiency of Sp1 is significantly reduced in aged animals compared to young ones, whereas CTF/NF1 and AP1 from young and old rat nuclear extracts bind their DNA targets with the same efficiency. The quantitative analysis of Spl by immunoblotting indicated that equivalent quantities and degrees of heterogeneity of Spl protein are present in both nuclear extracts, suggesting that the observed difference is not due to a different expression of this transcriptional factor. DNase I footprinting of the heavy chain ferritin gene promoter, which contains a Sp1 binding site, demonstrated that the nuclear extract from 30-month-old rat brain does not protect the region involved in the regulation of the H ferritin gene by Sp1. This results in a reduction of about 50% of the expression of the H ferritin mRNA in aged rat brains. Furthermore, the Sp1 binding sites present in the SV40 early promoter are not protected in a DNase I footprinting assay where a nuclear extract from 30-month-old rat brain was used as a source of DNA binding proteins. Liver nuclear extracts prepared from young and aged rats demonstrated that a decrease of Sp1 binding efficiency is similarly present in this tissue.	UNIV NAPOLI FEDERICO 2, DIPARTIMENTO BIOCHIM & BIOTECNOL MED, VIA S PANSINI 5, I-80131 NAPLES, ITALY	University of Naples Federico II			Russo, Tommaso/K-1331-2016	Russo, Tommaso/0000-0003-4426-0106; AMMENDOLA, Rosario/0000-0003-1655-8028; MESURACA, Maria/0000-0002-5455-168X				AMMENDOLA R, 1990, MOL CELL BIOL, V10, P387, DOI 10.1128/MCB.10.1.387; BEVILACQUA MA, 1992, GENE, V111, P255, DOI 10.1016/0378-1119(92)90696-M; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHATTERJEE B, 1981, J BIOL CHEM, V256, P5939; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CINADER B, 1989, GENOME, V31, P361, DOI 10.1139/g89-055; COSTANZO F, 1984, EMBO J, V3, P23, DOI 10.1002/j.1460-2075.1984.tb01756.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; FLEMING JE, 1988, P NATL ACAD SCI USA, V85, P4099, DOI 10.1073/pnas.85.11.4099; FRIEDMAN V, 1990, MECH AGEING DEV, V52, P27, DOI 10.1016/0047-6374(90)90142-3; FUKUDA H, 1990, EUR J BIOCHEM, V188, P517, DOI 10.1111/j.1432-1033.1990.tb15430.x; GAUCHAT J-F, 1988, Aging Immunology and Infectious Disease, V1, P191; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYFLICK L, 1985, EXP GERONTOL, V20, P145, DOI 10.1016/0531-5565(85)90032-4; IACOPINO AM, 1990, P NATL ACAD SCI USA, V87, P4078, DOI 10.1073/pnas.87.11.4078; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI DD, 1988, LIFE SCI, V43, P1215; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NAGEL JE, 1988, J CLIN INVEST, V81, P1096, DOI 10.1172/JCI113422; ONO T, 1985, GERONTOLOGY, V31, P362, DOI 10.1159/000212725; ONO T, 1978, P NATL ACAD SCI USA, V75, P4431, DOI 10.1073/pnas.75.9.4431; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SIERRA F, 1989, MOL CELL BIOL, V9, P5610, DOI 10.1128/MCB.9.12.5610; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SMITH JR, 1980, MECH AGEING DEV, V13, P387, DOI 10.1016/0047-6374(80)90080-9; TOOZE J, 1981, MOL BIOL TUMOR VIR 2; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; WU WT, 1986, CELL IMMUNOL, V100, P224, DOI 10.1016/0008-8749(86)90021-3; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773	51	119	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17944	17948						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381357				2022-12-27	WOS:A1992JM22300071
J	PEPINSKY, B; HESSION, C; CHEN, LL; MOY, P; BURKLY, L; JAKUBOWSKI, A; CHOW, EP; BENJAMIN, C; CHIROSSO, G; LUHOWSKYJ, S; LOBB, R				PEPINSKY, B; HESSION, C; CHEN, LL; MOY, P; BURKLY, L; JAKUBOWSKI, A; CHOW, EP; BENJAMIN, C; CHIROSSO, G; LUHOWSKYJ, S; LOBB, R			STRUCTURE-FUNCTION STUDIES ON VASCULAR CELL-ADHESION MOLECULE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION; ENDOTHELIAL-CELLS; EOSINOPHIL ADHERENCE; MONOCLONAL-ANTIBODY; ICAM-1 CD54; VCAM-1; RECEPTOR; BINDING; DOMAINS; MAC-1	Vascular cell adhesion molecule-1 (VCAM1) is a member of the immunoglobulin (Ig) superfamily which interacts with the integrin very late antigen-4 (VLA4). The VCAM1/VLA4 interaction mediates both adhesion and signal transduction and is thought to play an important role in inflammatory and immune responses in vivo. The major form of human VCAM1 contains seven extracellular Ig-like domains, with domain 1 designated as the most N-terminal. We have examined the relationship between human VCAM1 structure and function using a combination of domain truncation mutants and proteolytic fragmentation of recombinant soluble VCAM1. We have characterized two regions of VCAM1, localized to domains 4 and 5, which are highly sensitive to proteolytic cleavage, localized the epitope of the blocking monoclonal antibody 4B9 to domain 1, and found that domains 1-3 are sufficient for both its adhesive function and its ability to initiate T cell activation.	BIOGEN INC, 14 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA	Biogen								AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BENJAMIN C, 1990, BIOCHEM BIOPH RES CO, V171, P348, DOI 10.1016/0006-291X(90)91400-M; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BURKLY LC, 1991, EUR J IMMUNOL, V21, P2871, DOI 10.1002/eji.1830211132; CARLOS TM, 1990, BLOOD, V76, P965; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CYBULSKY MI, 1991, AM J PATHOL, V138, P815; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; HESSION C, 1991, J BIOL CHEM, V266, P6682; HESSION C, 1992, BIOCHEM BIOPH RES CO, V183, P163, DOI 10.1016/0006-291X(92)91623-X; HORLEY KJ, 1989, EMBO J, V8, P2889, DOI 10.1002/j.1460-2075.1989.tb08437.x; HOUEN G, 1991, ANAL BIOCHEM, V193, P186, DOI 10.1016/0003-2697(91)90006-F; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LOBB R, 1991, BIOCHEM BIOPH RES CO, V178, P1498, DOI 10.1016/0006-291X(91)91063-I; LOBB RR, 1991, ADHESION ITS ROLE IN, P1; LOBB RR, 1991, CELLULAR MOL MECHANI, V2, P151; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; POLTE T, 1990, NUCLEIC ACIDS RES, V18, P5901, DOI 10.1093/nar/18.19.5901; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WALSH GM, 1991, J IMMUNOL, V146, P3419; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; WELLER PF, 1991, J EXP MED, V173, P1553; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	40	78	84	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17820	17826						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381355				2022-12-27	WOS:A1992JM22300054
J	VANDIJK, MCM; KRUIJT, JK; BOERS, W; LINTHORST, C; VANBERKEL, TJC				VANDIJK, MCM; KRUIJT, JK; BOERS, W; LINTHORST, C; VANBERKEL, TJC			DISTINCT PROPERTIES OF THE RECOGNITION SITES FOR BETA-VERY LOW-DENSITY-LIPOPROTEIN (REMNANT RECEPTOR) AND ALPHA-2-MACROGLOBULIN (LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN) ON RAT PARENCHYMAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E; CHYLOMICRON REMNANTS; LDL-RECEPTOR; HIGH-AFFINITY; LIVER-CELLS; BINDING; HEPATOCYTES; CLEARANCE; COMPLEX; PLASMA	The properties of the recognition sites for alpha-2-macroglobulin (alpha-2-macroglobulin receptor; low density lipoprotein receptor-related protein) and beta-migrating very low density lipoprotein (beta-VLDL) (remnant receptor) on rat parenchymal cells were directly compared to analyze whether both substrates are recognized and internalized by the same receptor system. In cholesterol-fed rats, the large circulating pool of beta-VLDL is unable to diminish the liver uptake of I-125-labeled alpha-2-macroglobulin, while liver uptake of I-125-labeled beta-VLDL in these rats is reduced by 87.3% at 10 min after injection. In vitro competition studies with isolated parenchymal liver cells demonstrate that the binding of I-125-labeled alpha-2-macroglobulin to rat parenchymal cells is not effectively competed for by beta-VLDL, whether this lipoprotein is additionally enriched in apolipoprotein E or not. Binding of alpha-2-macroglobulin to parenchymal cells requires the presence of calcium, while binding of beta-VLDL does not. Incubation of parenchymal cells for 1 h with proteinase K reduced the subsequent binding of alpha-2-macroglobulin by 90.1%, while the binding of beta-VLDL was reduced by only 20.2%. In the presence of monensin, the association of alpha-2-macroglobulin to parenchymal cells at 2 h of incubation was reduced by 64.7%, while the association of beta-VLDL was not affected. Preincubation of parenchymal cells with monensin for 60 min at 37-degrees-C reduced the subsequent binding of alpha-2-macroglobulin by 54.5%, while binding of beta-VLDL was only reduced by 14.6%. The results indicate that the recognition sites for alpha-2-macroglobulin and beta-VLDL on rat parenchymal cells do exert different properties and are therefore likely to reside on different molecules.	LEIDEN UNIV,SYLVIUS LAB,CTR BIOPHARMACEUT SCI,DIV BIOPHARMACEUT,POB 9503,2300 RA LEIDEN,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,VANGOOL LAB EXPTL INTERNAL MED,1105 AZ AMSTERDAM,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam			Van Berkel, Theo/ABD-7677-2021					ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1988, ARTERIOSCLEROSIS, V8, P288, DOI 10.1161/01.ATV.8.3.288; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BIJSTERBOSCH MK, 1989, MOL PHARMACOL, V36, P484; CASTER WO, 1955, AM J PHYSIOL, V183, P317, DOI 10.1152/ajplegacy.1955.183.2.317; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; DAVIDSEN O, 1985, BIOCHIM BIOPHYS ACTA, V846, P85, DOI 10.1016/0167-4889(85)90113-2; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HARKES L, 1989, EUR J BIOCHEM, V180, P241, DOI 10.1111/j.1432-1033.1989.tb14639.x; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOEG JM, 1985, SCIENCE, V227, P759, DOI 10.1126/science.2982214; HUI DY, 1986, J BIOL CHEM, V261, P4256; HUI DY, 1981, J BIOL CHEM, V256, P5646; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KAPLAN J, 1980, CELL, V19, P197, DOI 10.1016/0092-8674(80)90401-8; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VANTOL A, 1978, ATHEROSCLEROSIS, V29, P449, DOI 10.1016/0021-9150(78)90173-9; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696	35	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17732	17737						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381352				2022-12-27	WOS:A1992JM22300041
J	WOOD, JN; LILLYCROP, KA; DENT, CL; NINKINA, NN; BEECH, MM; WILLOUGHBY, JJ; WINTER, J; LATCHMAN, DS				WOOD, JN; LILLYCROP, KA; DENT, CL; NINKINA, NN; BEECH, MM; WILLOUGHBY, JJ; WINTER, J; LATCHMAN, DS			REGULATION OF EXPRESSION OF THE NEURONAL POU PROTEIN OCT-2 BY NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; SIMPLEX VIRUS LATENCY; NEUROTROPHIC FACTOR; SENSORY NEURONS; B-CELL; GENE; RECEPTOR; TRANSCRIPTION; ENCODES; INVITRO	POU proteins are a class of homeobox-containing transcription factors that regulate tissue-specific gene expression and influence cell differentiation and function. We have investigated the possible role of such factors in mediating the actions of nerve growth factor (NGF) on sensory neurons. NGF has been found to have differential effects on the levels of three POU protein transcription factors that are expressed in adult rat sensory neurons. A sensory neuron octamer-binding protein with the properties of the transcription factor Oct-2 is up-regulated 3-4-fold by NGF, as measured by mobility shift assays using nuclear extracts from adult rat dorsal root ganglion neurons grown in the presence or absence of NGF. Quantitation of Oct-2 mRNA by polymerase chain reaction amplification of RNA from such cells shows a parallel increase in Oct-2 mRNA levels. In contrast, the levels of mRNA encoding the ubiquitous POU protein Oct-1 or the neuron-specific POU protein Brn-3, also present in sensory neurons, are unaffected by NGF. These observations suggest a role for Oct-2 in mediating transcriptional effects induced by NGF. In particular, as Oct-2 is known to inhibit herpes simplex virus immediate-early gene expression in neuronal cells, these findings provide a mechanism for the known action of NGF in the maintenance of latent herpes virus infections in sensory neurons.	SANDOZ INST MED RES, LONDON WC1E 6BN, ENGLAND	Novartis; Sandoz	WOOD, JN (corresponding author), UNIV COLL & MIDDLESEX HOSP SCH MED, MED MOLEC BIOL UNIT, WINDEYER BLDG, CLEVELAND ST, LONDON W1P 6DB, ENGLAND.		Ninkina, Natalia N/A-1732-2011					BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BROAD PM, 1989, NUCLEIC ACIDS RES, V17, P6999, DOI 10.1093/nar/17.17.6999; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DENT CL, 1991, BIOCHEM J, V277, P541, DOI 10.1042/bj2770541; DENT CL, 1991, MOL CELL BIOL, V11, P3925, DOI 10.1128/MCB.11.8.3925; FALKNER FG, 1986, NUCLEIC ACIDS RES, V14, P8819, DOI 10.1093/nar/14.22.8819; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KEMP LM, 1990, NEURON, V4, P215, DOI 10.1016/0896-6273(90)90096-X; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LATCHMAN DS, 1992, IN PRESS BIOCH SOC T; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; LILLYCROP KA, 1991, NEURON, V7, P381, DOI 10.1016/0896-6273(91)90290-G; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUDA K, 1978, P NATL ACAD SCI USA, V75, P4042, DOI 10.1073/pnas.75.8.4042; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; WILCOX CL, 1988, J VIROL, V62, P393, DOI 10.1128/JVI.62.2.393-399.1988; WILCOX CL, 1990, J NEUROSCI, V10, P1268; WINTER J, 1988, NEURON, V1, P973, DOI 10.1016/0896-6273(88)90154-7; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	35	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17787	17791						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381354				2022-12-27	WOS:A1992JM22300050
J	GILLER, T; BUCHWALD, P; BLUMKAELIN, D; HUNZIKER, W				GILLER, T; BUCHWALD, P; BLUMKAELIN, D; HUNZIKER, W			2 NOVEL HUMAN PANCREATIC LIPASE RELATED PROTEINS, HPLRP1 AND HPLRP2 - DIFFERENCES IN COLIPASE DEPENDENCE AND IN LIPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-LIPASE; GENE FAMILY; CLONING; SEQUENCE; CDNA; EXPRESSION; DNA	We have isolated cDNAs coding for two novel human pancreatic lipase (hPL)-related human proteins, referred to as hPL-related proteins 1 and 2 (hPLRP1 and hPLRP2) and for hPL. The two novel proteins show an amino acid sequence identity to hPL of 68 and 65% for hPLRP1 and 2, respectively. All three proteins are secreted into the medium after transfection of COS cells with the corresponding cDNAs. The size of the three expressed proteins is similar and ranges between 45 and 50 kDa. The expressed hPLRP2 shows a lipolytic activity that is, however, in contrast to that of hPL only marginally dependent on the presence of colipase, whereas hPLRP1 shows no activity in this assay. A Northern analysis of normal human pancreas mRNA shows that the expression levels of hPLRP1 and hPLRP2 are about 4-fold and 24-fold lower, respectively, than that of hPL. hPLRP2 is, additionally, most closely related to a lipase reported to be expressed in mouse T-cells. A comparison of the sequences of the three proteins with sequences described as pancreatic lipases of other animal species shows three subfamilies of closer kinship. This suggests that the two novel proteins also exist in other species and that some of the sequences reported to be pancreatic lipase might more likely be the orthologues of hPLRP1 or hPLRP2 in those species.	F HOFFMANN LA ROCHE & CO LTD, NEW TECHNOL, PHARMA RES, DEPT BIOL, BLDG 66-605, CH-4002 BASEL, SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD, PRECLIN, PHARMA RES, DEPT METAB DIS, CH-4002 BASEL, SWITZERLAND	Roche Holding; Roche Holding								BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BODMER MW, 1987, BIOCHIM BIOPHYS ACTA, V909, P237, DOI 10.1016/0167-4781(87)90083-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECARO J, 1981, BIOCHIM BIOPHYS ACTA, V671, P129, DOI 10.1016/0005-2795(81)90126-4; GRUSBY MJ, 1990, CELL, V60, P451, DOI 10.1016/0092-8674(90)90596-7; HADVARY P, 1988, BIOCHEM J, V256, P357, DOI 10.1042/bj2560357; Kerfelec B, 1986, Pancreas, V1, P430, DOI 10.1097/00006676-198609000-00007; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PFAHL MR, 1991, P NATL ACAD SCI USA, V88, P8272; Sambrook J, 1989, MOL CLONING LABORATO; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; STAHNKE G, 1987, DIFFERENTIATION, V35, P45, DOI 10.1111/j.1432-0436.1987.tb00150.x; STERNBY B, 1981, COMP BIOCHEM PHYS B, V68, P15, DOI 10.1016/0305-0491(81)90173-5; WICKERPLANQUART C, 1992, FEBS LETT, V296, P61, DOI 10.1016/0014-5793(92)80403-4; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	19	150	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16509	16516						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379598				2022-12-27	WOS:A1992JJ45800081
J	ERNST, LK; VANDEWINKEL, JGJ; CHIU, IM; ANDERSON, CL				ERNST, LK; VANDEWINKEL, JGJ; CHIU, IM; ANDERSON, CL			3 GENES FOR THE HUMAN HIGH-AFFINITY FC RECEPTOR FOR IGG (FC-GAMMA-RI) ENCODE 4 DISTINCT TRANSCRIPTION PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CELL-LINE; MESSENGER-RNA; EXPRESSION; CLONING; CHAIN; DNA; CHROMOSOME-1; ORGANIZATION; SELECTION; SEQUENCE	Three distinct but closely related classes of receptors that bind the Fc portion of immunoglobulin G (Fc-gamma-RI, -II, and -III) have been identified in humans. Only Fc-gamma-RI has high affinity for ligand and has a unique third extracellular domain (EC3). We have characterized three genes for human Fc-gamma-RI (A, B, and C). Each gene consists of six exons, spans 9.4 kilobase pairs, and localizes to chromosome 1. Although they are remarkably similar, genes B and C are notably different from A; in-frame stop codons are present in the EC3 domain of genes B and C, and deletions occur in a splice donor sequence of gene B. Four distinct Fc-gamma-RI transcripts were analyzed. One transcript, from gene A, would encode a transmembrane receptor with three external domains. A second transcript, an alternatively spliced product of gene B, would encode a two-external domain transmembrane receptor. Two transcripts, from genes B and C, have stop codons in EC3 and would be predicted to generate secreted receptors.	OHIO STATE UNIV,COLL MED,DEPT INTERNAL MED,2054 DAVIS MED RES CTR,480 W 9TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR COMPREHENS CANC,COLUMBUS,OH 43210; UNIV UTRECHT HOSP,DEPT IMMUNOL,3511 GV UTRECHT,NETHERLANDS	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Utrecht University; Utrecht University Medical Center			Chiu, Ing-Ming/B-1534-2008		NATIONAL CANCER INSTITUTE [R01CA044983] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA44983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ALLEN JM, 1988, NUCLEIC ACIDS RES, V16, P11824, DOI 10.1093/nar/16.24.11824; ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; CALVO CF, 1986, EUR J IMMUNOL, V16, P25, DOI 10.1002/eji.1830160106; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FRIDMAN WH, 1990, FC RECEPTORS ACTION, P335; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; GRUNDY HO, 1989, IMMUNOGENETICS, V29, P331, DOI 10.1007/BF00352843; HULETT MD, 1991, J IMMUNOL, V147, P1863; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LECONIAT M, 1990, IMMUNOGENETICS, V32, P182; Maniatis T., 1982, MOL CLONING; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; PAN L, 1990, J IMMUNOL, V145, P267; PELTZ GA, 1989, P NATL ACAD SCI USA, V86, P1013, DOI 10.1073/pnas.86.3.1013; PERUSSIA B, 1983, J EXP MED, V158, P1092, DOI 10.1084/jem.158.4.1092; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; QU ZX, 1988, J EXP MED, V167, P1195, DOI 10.1084/jem.167.3.1195; Ravetch J.V., 1990, FC RECEPTORS ACTION, P211; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; ROTH MS, 1990, TRANSPLANTATION, V49, P714, DOI 10.1097/00007890-199004000-00012; SAMMARTINO L, 1988, IMMUNOGENETICS, V28, P380, DOI 10.1007/BF00364238; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Seldin MF, 1988, GENOMICS, V2, P48, DOI 10.1016/0888-7543(88)90108-5; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAUNTON DE, 1989, J EXP MED, V169, P1087, DOI 10.1084/jem.169.3.1087; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13499; VARIN N, 1989, EUR J IMMUNOL, V19, P2263, DOI 10.1002/eji.1830191213; WARMERDAM PAM, 1990, J EXP MED, V172, P19, DOI 10.1084/jem.172.1.19; WATSON ML, 1990, J EXP MED, V172, P263, DOI 10.1084/jem.172.1.263; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; YANG Z, 1990, P NATL ACAD SCI USA, V87, P9226, DOI 10.1073/pnas.87.23.9226; YU CY, 1989, EMBO J, V8, P3727, DOI 10.1002/j.1460-2075.1989.tb08548.x	37	87	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15692	15700						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379234				2022-12-27	WOS:A1992JG11300068
J	GAMBEL, AM; DESROSIERS, MG; MENICK, DR				GAMBEL, AM; DESROSIERS, MG; MENICK, DR			CHARACTERIZATION OF A P-TYPE CA2+-ATPASE FROM FLAVOBACTERIUM-ODORATUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CALCIUM-TRANSPORT; SARCOPLASMIC-RETICULUM; STREPTOCOCCUS-FAECALIS; MEMBRANE-VESICLES; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; K+-ATPASE; CA-2+-ATPASE; SYSTEMS	In most bacterial cell types studied, low intracellular free calcium is maintained by a variety of secondary exchangers which utilize transmembrane ion gradients. Prokaryotic calcium ATPases appear to be extremely uncommon, and none have been reported in Gram-negative organisms. We demonstrate ATP-dependent calcium uptake in everted membrane vesicles of Flavobacterium odoratum, a common Gram-negative soil and water bacterium. Calcium is transported with an apparent initial rate of 10 nmol/min mg of protein. It is inhibited by 20-mu-M orthovanadate, a specific P-type ATPase inhibitor, but significantly, it is unaffected by the addition of N-ethylmaleimide, N,N-dicyclohexylcarbodiimide, valinomycin, or nigericin. Because the Ca2+-ATPase makes up a high proportion of the total ATPase activity it is easily detected by a soluble ATP hydrolysis assay, with an initial rate for calcium-dependent ATPase activity in vesicles of 25-40 nmol/min.mg at pH 7.8 and 25-degrees-C. The calcium-dependent activity is preferentially solubilized by the detergent C12E8 and can be precipitated at 55-80% ammonium sulfate in a fraction free of other contaminating ATPase activities. This partially purified fraction is enriched 15-fold and demonstrates an apparent K(m) for calcium of 2-mu-M, and for ATP of 130-mu-M. The IC50 for vanadate is 1.6-mu-M. These values are similar to those obtained for the eukaryotic sarcoplasmic reticulum calcium ATPase. The enzyme is rapidly phosphorylated by [gamma-P-32]ATP in a calcium-dependent, vanadate-inhibitable manner. The phosphorylated species migrates with an apparent molecular mass of 60 kDa by NaDodSO4-polyacrylamide gel electrophoresis, and the phosphoryl group is sensitive to alkaline conditions, a characteristic of the acylphosphate linkage found in ATPases. These data demonstrate that the majority of calcium transport in F. odoratum is facilitated by a P-type ATPase.	MED UNIV S CAROLINA,DEPT MED,DIV CARDIOL,171 ASHLEY AVE,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT BIOCHEM,CHARLESTON,SC 29425; MED UNIV S CAROLINA,GAZES CARDIAC RES INST,CHARLESTON,SC 29425	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina					PHS HHS [R01 44202] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMBUDKAR SV, 1986, J BIOL CHEM, V261, P5596; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; ANDO A, 1981, BIOCHIM BIOPHYS ACTA, V640, P179, DOI 10.1016/0005-2736(81)90543-5; BELLIVEAU JW, 1978, ARCH BIOCHEM BIOPHYS, V186, P98, DOI 10.1016/0003-9861(78)90468-X; BHATTACHARYYA P, 1976, J BIOL CHEM, V251, P5614; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN RW, 1968, BIOCHEMISTRY-US, V7, P2554, DOI 10.1021/bi00847a016; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; DAVIDSON VL, 1981, BIOCHIM BIOPHYS ACTA, V637, P53, DOI 10.1016/0005-2728(81)90209-7; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1969, BIOCHIM BIOPHYS ACTA, V172, P343; DEVRIJ W, 1985, J BACTERIOL, V164, P1294, DOI 10.1128/JB.164.3.1294-1300.1985; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJIMORI T, 1990, J BIOL CHEM, V265, P16262; FURST P, 1985, J BIOL CHEM, V260, P50; Futai M., 1987, ION TRANSPORT PROKAR, P4; GOLUB EE, 1974, J BACTERIOL, V119, P840, DOI 10.1128/JB.119.3.840-843.1974; HASSELBACH W, 1974, MEMBRANE ADENOSINE T, V4, P159; HIGHSMITH SR, 1983, J BIOL CHEM, V258, P6858; HOUNG HS, 1986, J BACTERIOL, V168, P1040, DOI 10.1128/jb.168.2.1040-1044.1986; HUGENTOBLER G, 1983, J BIOL CHEM, V258, P7611; INESI G, 1971, SCIENCE, V171, P901, DOI 10.1126/science.171.3974.901; JASPER P, 1978, J BACTERIOL, V133, P1323, DOI 10.1128/JB.133.3.1323-1328.1978; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KOBAYASHI H, 1978, J BIOL CHEM, V253, P2085; KOSKKOSICKA D, 1983, BIOCHEMISTRY-US, V22, P2559, DOI 10.1021/bi00279a037; KUMAR G, 1979, EUR J BIOCHEM, V100, P365, DOI 10.1111/j.1432-1033.1979.tb04179.x; LOCKAU W, 1982, Z NATURFORSCH C, V37, P658; LOCKAU W, 1983, BIOCH BOPHYS ACTA, V773, P124; Lynn A.R., 1987, ION TRANSPORT PROKAR, P181; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MATSUSHITA T, 1986, EUR J BIOCHEM, V156, P95, DOI 10.1111/j.1432-1033.1986.tb09553.x; NELSON N, 1980, METHOD ENZYMOL, V69, P301; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; ROSEN BP, 1987, BIOCHIM BIOPHYS ACTA, V906, P101, DOI 10.1016/0304-4157(87)90007-4; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Silhavy T. J., 1984, EXPT GENE FUSIONS; SILVER S, 1975, J BACTERIOL, V122, P880, DOI 10.1128/JB.122.3.880-885.1975; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; SOLIOZ M, 1987, J BIOL CHEM, V262, P7358; SOLIOZ M, 1980, CALCIUM BINDING PROT, P101; TSUCHIYA T, 1975, J BIOL CHEM, V250, P7687; Walderhaug M.O., 1987, ION TRANSPORT PROKAR, P85	47	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15923	15931						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386366				2022-12-27	WOS:A1992JG11300099
J	TOKI, S; TSUKUDA, E; NOZAWA, M; NONAKA, H; YOSHIDA, M; MATSUDA, Y				TOKI, S; TSUKUDA, E; NOZAWA, M; NONAKA, H; YOSHIDA, M; MATSUDA, Y			THE ES-242S, NOVEL N-METHYL-D-ASPARTATE ANTAGONISTS OF MICROBIAL ORIGIN, INTERACT WITH BOTH THE NEUROTRANSMITTER RECOGNITION SITE AND THE ION CHANNEL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE MODULATORY SITE; EXCITATORY AMINO-ACIDS; RAT-BRAIN MEMBRANES; NMDA RECEPTOR; HIPPOCAMPAL-NEURONS; L-GLUTAMATE; TRICYCLIC ANTIDEPRESSANTS; SELECTIVE ANTAGONIST; SYNAPTIC PLASTICITY; HIGHER AFFINITY	ES-242-1 approximately 5 are novel microbial bioxanthracenes which do not contain nitrogen. The ES-242s inhibited the binding of [H-3]TCP and [H-3]CGS19755 to the N-methyl-D-aspartate (NMDA) receptor complex. They had no effect on the binding of the specific ligands for the non-NMDA receptor. The biochemical and pharmacological properties of ES-242-1 were fully examined since it is the most potent of the five compounds. ES-242-1 is highly specific for the NMDA receptor; it has no effect on other receptors. Kinetic analyses indicated that ES-242-1 inhibited the binding of [H-3] TCP and [H-3]CGS19755 in a competitive manner, respectively, suggesting that ES-242-1 interacts with both the transmitter recognition site and the channel domain. ES-242-1 selectively inhibited NMDA-induced Ca2+ influx in primary cultures of mouse hippocampal neurons. ES-242-1 also specifically blocked the increase in cyclic GMP accumulation induced by NMDA or L-glutamate in rat cerebellar slices. In a concentration range of 0.1-1.0-mu-M, ES-242-1 was as potent as MK-801 in preventing glutamate-induced neurotoxicity in primary cultures of mouse hippocampal neurons. These results show that ES-242-1 is a potent and specific antagonist for the NMDA receptor. The antagonistic properties of the ES-242s appear to be due to a novel mechanism of action at the NMDA receptor.	KYOWA HAKKO KOGYO CO LTD,PHARMACEUT RES LABS,NAGAIZUMI,SHIZUOKA 411,JAPAN	Kyowa Kirin Ltd	TOKI, S (corresponding author), KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,3-6-6 ASAHIMACHI,MACHIDA,TOKYO 194,JAPAN.							BAUD J, 1989, NEUROSCI LETT, V107, P184, DOI 10.1016/0304-3940(89)90814-8; BILLARD W, 1984, LIFE SCI, V35, P1885, DOI 10.1016/0024-3205(84)90540-X; BLOOM JW, 1987, LIFE SCI, V41, P491, DOI 10.1016/0024-3205(87)90226-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; BRUNS RF, 1980, P NATL ACAD SCI-BIOL, V77, P5547, DOI 10.1073/pnas.77.9.5547; BRUNS RF, 1986, MOL PHARMACOL, V29, P331; CHANG RSL, 1978, EUR J PHARMACOL, V48, P463, DOI 10.1016/0014-2999(78)90177-2; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; FOSTER AC, 1989, J NEUROSCI, V9, P2191; GAITKOWSKI GA, 1983, NATURE, V304, P65; GARTHWAITE J, 1978, NATURE, V275, P328, DOI 10.1038/275328a0; GOZLAN H, 1983, NATURE, V305, P140, DOI 10.1038/305140a0; GREENBERG DA, 1976, LIFE SCI, V19, P69, DOI 10.1016/0024-3205(76)90375-1; HONEY CR, 1985, NEUROSCI LETT, V61, P135, DOI 10.1016/0304-3940(85)90414-8; KEANA JFW, 1989, P NATL ACAD SCI USA, V86, P5631, DOI 10.1073/pnas.86.14.5631; KEMP JA, 1987, TRENDS PHARMACOL SCI, V8, P414, DOI 10.1016/0165-6147(87)90223-9; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; KOE BK, 1989, EUR J PHARMACOL, V161, P263; LODGE D, 1990, TRENDS PHARMACOL SCI, V11, P81, DOI 10.1016/0165-6147(90)90323-Z; LONDON ED, 1979, MOL PHARMACOL, V15, P492; MACDERMOTT AB, 1987, TRENDS NEUROSCI, V10, P280, DOI 10.1016/0166-2236(87)90173-1; MARVIZON JCG, 1988, EUR J PHARMACOL, V151, P157, DOI 10.1016/0014-2999(88)90709-1; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MURPHY DE, 1987, NEUROCHEM RES, V12, P775, DOI 10.1007/BF00971514; MURPHY DE, 1987, J PHARMACOL EXP THER, V240, P778; MURPHY DE, 1988, BRIT J PHARMACOL, V95, P932, DOI 10.1111/j.1476-5381.1988.tb11723.x; OLVERMAN HJ, 1984, NATURE, V307, P460, DOI 10.1038/307460a0; PEROUTKA SJ, 1988, EUR J PHARMACOL, V148, P297, DOI 10.1016/0014-2999(88)90579-1; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; PETERSON C, 1989, DEV BRAIN RES, V48, P187, DOI 10.1016/0165-3806(89)90075-8; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SERNAGOR E, 1989, NEURON, V2, P1221, DOI 10.1016/0896-6273(89)90306-1; SILLS MA, 1989, MOL PHARMACOL, V36, P160; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; SONDERS MS, 1988, TRENDS NEUROSCI, V11, P37, DOI 10.1016/0166-2236(88)90048-3; THOMSON AM, 1989, TRENDS NEUROSCI, V12, P349, DOI 10.1016/0166-2236(89)90042-8; TOKI S, 1992, J ANTIBIOT, V45, P88, DOI 10.7164/antibiotics.45.88; TOKI S, 1992, IN PRESS J ANTIBIOT; VIGNON J, 1983, BRAIN RES, V280, P194, DOI 10.1016/0006-8993(83)91193-9; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; YUZAKI M, 1990, BRAIN RES, V517, P51, DOI 10.1016/0006-8993(90)91006-3	50	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14884	14892						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378842				2022-12-27	WOS:A1992JF08800059
J	ULBRANDT, ND; LONDON, E; OLIVER, DB				ULBRANDT, ND; LONDON, E; OLIVER, DB			DEEP PENETRATION OF A PORTION OF ESCHERICHIA-COLI SECA PROTEIN INTO MODEL MEMBRANES IS PROMOTED BY ANIONIC PHOSPHOLIPIDS AND BY PARTIAL UNFOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; TRANSLOCATION ATPASE; PRECURSOR PROTEINS; PLASMA-MEMBRANE; INNER MEMBRANES; TRIGGER FACTOR; PH; VESICLES; FLUORESCENCE; CONFORMATION	SecA protein, a principal component of the protein export machinery of Escherichia coli, is found both in the cytoplasm and inner membrane of cells. Previous in vitro and in vivo studies demonstrated that the interaction of SecA with the inner membrane requires the presence of physiological levels of anionic (acidic) phospholipids. In this report the degree of SecA insertion into model membranes and the conformational changes associated with this event have been examined. The extent of association of SecA with model membranes was determined by photolabeling with a hydrophobic reagent, and the depth of insertion of the protein into the phospholipid bilayer was determined by the amount of quenching of SecA fluorescence by both brominated and spin-labeled phospholipids. These methods demonstrated that SecA penetrates deep within the acyl chain region of the phospholipid bilayer. It was also found that SecA penetration into vesicles was associated with a major conformational change in the protein. This change can be induced by higher temperatures and involves a partial unfolding event as judged by differential scanning calorimetry, SecA fluorescence and increased sensitivity to proteolysis. These properties suggest the induction of a molten-globule-like conformation in a portion of the SecA polypeptide. This change was also induced at lower temperatures by the presence of membranes containing a physiological amount of the anionic phospholipid, phosphatidylglycerol. The partial unfolding and concomitant deep insertion of SecA into membranes may aid in the insertion of precursor proteins into the inner membrane and may influence possible interactions between SecA and the integral membrane export machinery components.	SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	ULBRANDT, ND (corresponding author), SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031986, R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42033, GM 31986] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Cabelli RJ, 1991, THESIS STATE U NEW Y; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DOLGIKH DA, 1985, EUR BIOPHYS J BIOPHY, V13, P109, DOI 10.1007/BF00256531; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; EVERETT J, 1986, J BIOL CHEM, V261, P6725; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HU VW, 1984, J BIOL CHEM, V259, P2226; HUGHSON FM, 1991, BIOCHEMISTRY-US, V30, P4113, DOI 10.1021/bi00231a001; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; JIANG JX, 1990, J BIOL CHEM, V265, P8636; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; KUMAMOTO C, 1983, J BACTERIOL, V163, P267; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MARKELLO T, 1985, BIOCHEMISTRY-US, V24, P2895, DOI 10.1021/bi00333a012; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; MITCHELL WM, 1969, BIOCHIM BIOPHYS ACTA, V178, P194, DOI 10.1016/0005-2744(69)90150-8; MORRISON WR, 1964, ANAL BIOCHEM, V7, P218, DOI 10.1016/0003-2697(64)90231-3; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RAMSAY G, 1989, BIOCHEMISTRY-US, V28, P529, DOI 10.1021/bi00428a018; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SHINKAI A, 1990, BIOCHEM BIOPH RES CO, V172, P1217, DOI 10.1016/0006-291X(90)91578-G; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; ZHAO JM, 1986, P NATL ACAD SCI USA, V83, P2002, DOI 10.1073/pnas.83.7.2002	54	167	167	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15184	15192						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386084				2022-12-27	WOS:A1992JF08800099
J	ILTZSCH, MH; BIEBER, D; VIJAYASARATHY, S; WEBSTER, P; ZURITA, M; DING, JZ; MANSOUR, TE				ILTZSCH, MH; BIEBER, D; VIJAYASARATHY, S; WEBSTER, P; ZURITA, M; DING, JZ; MANSOUR, TE			CLONING AND CHARACTERIZATION OF A CDNA CODING FOR THE ALPHA-SUBUNIT OF A STIMULATORY G-PROTEIN FROM SCHISTOSOMA-MANSONI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ADENYLATE-CYCLASE; GTP-BINDING PROTEINS; FASCIOLA-HEPATICA; SEQUENCE; ACID; RECEPTORS; FAMILY	Guanine nucleotide-binding proteins (G proteins) mediate signals between serotonin receptors and adenylate cyclase in Schistosoma mansoni. A bovine G(s-alpha) cDNA probe was used to isolate a cDNA clone, SG12, encoding the entire alpha-subunit of a G protein of S. mansoni. The cDNA is 1897 base pairs long, contains an open reading frame of 1137 base pairs, and codes for a deduced protein of 379 amino acids. The putative protein encoded by the clone has an exact amino acid match with bovine G(s-alpha) of 65% and a 78% match when conserved amino acid substitutions are considered. In contrast, the exact and conserved matches of the schistosome alpha-subunit with bovine G(i) are 41 and 61%, respectively. A comparison of the deduced amino acid sequence of SG12 with a variety of different G-alpha proteins indicates that all the major structural features characteristic of a G(s-alpha) protein are present in the S. mansoni gene. The schistosome clone contains the putative site for ADP-ribosylation by cholera toxin found in G(s-alpha) but does not contain the ADP-ribosylation site for pertussis toxin present in G(i-alpha). The amino acids are completely conserved at the GTP-binding sites. On a Northern blot, the cDNA hybridizes to a major band of 3.1 kilobases in RNA from adult schistosomes. The message appears to be absent in miracidia and cercariae, but a faint 3.1-kilobase band is visible in the early schistosomule stage preceding adulthood. This evidence, when added to previous biochemical data, indicates that the expression of this gene is developmentally controlled.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305	Stanford University					NIAID NIH HHS [AI 16501] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016501] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASCH PF, 1981, J PARASITOL, V67, P179, DOI 10.2307/3280632; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ESTEY SJ, 1987, MOL BIOCHEM PARASIT, V26, P47, DOI 10.1016/0166-6851(87)90129-0; FEINBERG A, 1982, ANAL BIOCHEM, V132, P6; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GILMAN A, 1987, ANN REV BIOCH, V5, P615; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HUYNH TV, 1985, DNA PRACTICAL APPROA, V1; ITOH H, 1991, J BIOL CHEM, V266, P16226; KASSCHAU MR, 1982, NATURE, V296, P66, DOI 10.1038/296066a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KAZIRO Y, 1990, ADP RIBOSYLATING TOX, P189; LAZDINS JK, 1982, EXP PARASITOL, V53, P39, DOI 10.1016/0014-4894(82)90090-X; MANSOUR JM, 1989, MOL BIOCHEM PARASIT, V36, P11, DOI 10.1016/0166-6851(89)90195-3; MANSOUR JM, 1986, MOL BIOCHEM PARASIT, V21, P139, DOI 10.1016/0166-6851(86)90017-4; MANSOUR TE, 1984, ADV PARASIT, V23, P1, DOI 10.1016/S0065-308X(08)60284-5; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NUKADA T, 1986, FEBS LETT, V197, P305, DOI 10.1016/0014-5793(86)80347-7; QUAN F, 1989, P NATL ACAD SCI USA, V86, P4321, DOI 10.1073/pnas.86.11.4321; QUAN F, 1991, P NATL ACAD SCI USA, V88, P1898, DOI 10.1073/pnas.88.5.1898; RESTEY SJ, 1988, MOL BIOCHEM PARASIT, V30, P67; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SUBBIAH S, 1989, J MOL BIOL, V209, P539, DOI 10.1016/0022-2836(89)90592-5; WEST RE, 1985, J BIOL CHEM, V260, P4428; YUCKENBERG PD, 1987, EXP PARASITOL, V63, P301, DOI 10.1016/0014-4894(87)90177-9	35	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14504	14508						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378444				2022-12-27	WOS:A1992JD32500108
J	HOFFMAN, P; YAFFE, MB; HOFFMAN, BL; YEI, SP; WOLD, WSM; CARLIN, C				HOFFMAN, P; YAFFE, MB; HOFFMAN, BL; YEI, SP; WOLD, WSM; CARLIN, C			CHARACTERIZATION OF THE ADENOVIRUS-E3 PROTEIN THAT DOWN-REGULATES THE EPIDERMAL GROWTH-FACTOR RECEPTOR - EVIDENCE FOR INTERMOLECULAR DISULFIDE BONDING AND PLASMA-MEMBRANE LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGION E3; CELL-SURFACE; INTRACELLULAR-TRANSPORT; TRANSFERRIN RECEPTOR; SIGNAL PEPTIDASE; BREFELDIN-A; A431 CELLS; SEQUENCE; BIOSYNTHESIS; GLYCOPROTEIN	We have characterized the biosynthesis and processing of a 91 amino acid hydrophobic integral membrane protein encoded by human group C adenoviruses which down-regulates the EGF receptor (Carlin, C. R., Tollefson, A. E., Brady, H. A., Hoffman, B. L., and Wold, W. S. M. (1989) Cell 57, 135-144). Previous studies have shown that two immunologically related proteins are produced in vivo, a 13.7-kDa protein encoded by E3 message f and a 11.3-kDa protein derived from 13.7 kDa by proteolysis (Hoffman, B. L., Ullrich, A., Wold, W. S. M., and Carlin, C. R. (1990) Mol. Cell. Biol. 10, 5521-5524; Tollefson, A. E., Krajcsi, P., Yei, S., Carlin, C. R., and Wold, W. S. M. (1990) J. Virol. 64, 794-801). We report here that the 13.7- and 11.3-kDa proteins form intermolecular disulfide bonds cotranslationally at Cys-31 and tend to migrate as high molecular weight aggregates under nonreducing conditions. Both proteins are also present at the cell surface, as evidenced by specific immunoprecipitation from intact monolayers enzymatically labeled with I-125. Moreover, an antiserum specific for a putative extracellular epitope recognizes the same viral proteins as antibodies directed against a C-terminal synthetic 15-mer. The 13.7- and 11.3-kDa proteins are detected at early time points during pulse-chase radiolabeling of infected cells, do not undergo any further changes in molecular weight, and focus at their predicted isoelectric points (7.4 and 7.2, respectively). Identical results are obtained in stable transfectants constitutively expressing only 13.7 and 11.3 kDa, suggesting that biosynthesis and processing is not dependent on other viral proteins. These results have been incorporated into a computer-based model to predict the orientation of 13.7 and 11.3 kDa in the lipid bilayer. This model provides a basis for testing predictions regarding the topology of the viral proteins, as well as putative interactions with heterologous proteins in the microenvironment of the plasma membrane that cause down-regulation of the epidermal growth factor receptor.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; ST LOUIS UNIV,SCH MED,INST MOLEC VIROL,ST LOUIS,MO 63110	Case Western Reserve University; Saint Louis University				Hoffman, Brian/0000-0003-2576-9345	NCI NIH HHS [CA-49540] Funding Source: Medline; NHLBI NIH HHS [HL07653] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049540] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007653] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEN DP, 1976, IMMUNOGENETICS, V3, P209, DOI 10.1007/BF01576954; ADEN DP, 1978, NATURE, V271, P375, DOI 10.1038/271375a0; ALVAREZ E, 1989, EMBO J, V8, P2231, DOI 10.1002/j.1460-2075.1989.tb08347.x; BLOMQUIST MC, 1984, P NATL ACAD SCI-BIOL, V81, P7363, DOI 10.1073/pnas.81.23.7363; BRADY HA, 1988, MOL CELL BIOL, V8, P3291, DOI 10.1128/MCB.8.8.3291; BRADY HA, 1987, NUCLEIC ACIDS RES, V15, P9397, DOI 10.1093/nar/15.22.9397; CARLIN CR, 1989, CELL, V57, P135, DOI 10.1016/0092-8674(89)90179-7; CARLIN CR, 1984, J BIOL CHEM, V259, P7902; CARLIN CR, 1982, P NATL ACAD SCI-BIOL, V79, P5026, DOI 10.1073/pnas.79.16.5026; CARLIN CR, 1988, MOL CELL BIOL, V8, P25, DOI 10.1128/MCB.8.1.25; CLADARAS C, 1985, VIROLOGY, V140, P28, DOI 10.1016/0042-6822(85)90443-X; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; Flint S. J, 1981, DNA TUMOR VIRUSES; FLOMENBERG PR, 1988, J VIROL, V62, P4431, DOI 10.1128/JVI.62.11.4431-4437.1988; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Green M, 1979, Methods Enzymol, V58, P425; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5876; HERISSE J, 1980, NUCLEIC ACIDS RES, V8, P2173, DOI 10.1093/nar/8.10.2173; HOFFMAN BL, 1990, MOL CELL BIOL, V10, P5521, DOI 10.1128/MCB.10.10.5521; HOFFMAN P, 1992, J VIROL, V66, P197, DOI 10.1128/JVI.66.1.197-203.1992; HONG JS, 1988, VIROLOGY, V167, P545, DOI 10.1016/S0042-6822(88)90117-1; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; HYNES RO, 1977, P NATL ACAD SCI USA, V74, P2855, DOI 10.1073/pnas.74.7.2855; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; KELLY TJ, 1973, J VIROL, V12, P643, DOI 10.1128/JVI.12.3.643-652.1973; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KRAJCSI P, 1992, VIROLOGY, V187, P131, DOI 10.1016/0042-6822(92)90302-6; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIGNAS C, 1986, GENE, V50, P173, DOI 10.1016/0378-1119(86)90322-7; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; SUTHERLAND R, 1981, P NATL ACAD SCI-BIOL, V78, P4515, DOI 10.1073/pnas.78.7.4515; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOLLEFSON AE, 1990, J VIROL, V64, P794, DOI 10.1128/JVI.64.2.794-801.1990; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WEISSMAN AM, 1986, NATURE, V324, P480, DOI 10.1038/324480a0; WOLD WSM, 1985, J BIOL CHEM, V260, P2424	64	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13480	13487						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377684				2022-12-27	WOS:A1992JB74600062
J	CHEN, L; MAO, SJT; LARSEN, WJ				CHEN, L; MAO, SJT; LARSEN, WJ			IDENTIFICATION OF A FACTOR IN FETAL BOVINE SERUM THAT STABILIZES THE CUMULUS EXTRACELLULAR-MATRIX - A ROLE FOR A MEMBER OF THE INTER-ALPHA-TRYPSIN INHIBITOR FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONIC-ACID SYNTHESIS; PROTEINASE-INHIBITORS; HUMAN-PLASMA; LIMITED PROTEOLYSIS; RELEASED INHIBITOR; GLYCOPROTEIN EDC1; FOLLICULAR-FLUID; CELL COMPLEXES; EXPANSION; SEQUENCE	Fetal bovine serum (FBS) has been widely used in the culture of cumulus-oocyte complexes, since it is believed that FBS stabilizes the expanding cumulus extracellular matrix. In this study, we have identified a factor in FBS that is responsible for this effect. FBS was first fractionated by stepwise precipitation with ammonium sulfate followed by high performance liquid chromatography (HPLC) on a gel filtration column. Active fractions, as determined by their ability to stabilize the cumulus extracellular matrix in a bioassay system, were further purified by HPLC on DEAE ion-exchange and gel filtration columns. The purified factor was exhibited as a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with an apparent M(r) 150,000 and a single peak on a C-8 reverse-phase HPLC. The sequence of the first 14 NH2-terminal amino acids was determined by Edman degradation, revealing significant sequence identity of the bovine serum factor with the light chain shared by members of the inter-alpha-trypsin inhibitor family. Western blot analysis using anti-human I-alpha-I IgG shows that the antibody reacts positively with the purified factor, and immunodepletion of FBS with anti-I-alpha-I antibody agarose eliminated its ability to stabilize the extracellular matrix. This factor is found in mouse follicular fluid collected 6 h following human chorionic gonadotropin injection to stimulate ovulation, but not in unstimulated mice. Anti-I-alpha-I-positive epitopes were also localized within the cumulus extracellular matrix of mouse preovulatory follicles in immunocytochemical preparations using anti-human I-alpha-I IgG, supporting the possibility that this molecule or molecules may diffuse into follicular fluid after an ovulatory stimulus to act as structural linkers that ensure normal cumulus expansion, through stabilization of the cumulus extracellular matrix thus supporting the process of ovulation.	UNIV CINCINNATI,COLL MED,DEPT ANAT & CELL BIOL,MAIL LOCATION 521,CINCINNATI,OH 45267; MARION MERRELL DOW RES INST,CINCINNATI,OH 45215	University System of Ohio; University of Cincinnati; Dow Chemical Company								BLANDAU RL, 1971, PATHWAYS CONCEPTION; CARDIN AD, 1986, J BIOL CHEM, V261, P6744; CHAWLA RK, 1978, J IMMUNOL, V121, P1636; CHAWLA RK, 1990, J CELL BIOCHEM, V42, P207, DOI 10.1002/jcb.240420404; CHEN L, 1990, MOL REPROD DEV, V26, P236, DOI 10.1002/mrd.1080260307; CRAN DG, 1976, ACTA ENDOCRINOL-COP, V82, P631, DOI 10.1530/acta.0.0820631; DEKEL N, 1978, GAMETE RES, V1, P47, DOI 10.1002/mrd.1120010108; DEKEL N, 1979, BIOL REPROD, V23, P9; DIARRAMEHRPOUR M, 1989, EUR J BIOCHEM, V179, P147, DOI 10.1111/j.1432-1033.1989.tb14532.x; DOWNS SM, 1986, GAMETE RES, V15, P115, DOI 10.1002/mrd.1120150203; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; EPPIG JJ, 1980, BIOL REPROD, V22, P629, DOI 10.1093/biolreprod/22.3.629; EPPIG JJ, 1979, J EXP ZOOL, V208, P111, DOI 10.1002/jez.1402080112; EPPIG JJ, 1979, NATURE, V281, P483, DOI 10.1038/281483a0; FRANCK C, 1983, SCAND J CLIN LAB INV, V43, P151; Gebhard W., 1986, PROTEINASE INHIBITOR, P389; GWATKIN RBL, 1977, FERTILIZATION MAN MA; HOCHSTRASSER K, 1983, H-S Z PHYSIOL CHEM, V364, P1679, DOI 10.1515/bchm2.1983.364.2.1679; HOCHSTRASSER K, 1981, H-S Z PHYSIOL CHEM, V362, P1357, DOI 10.1515/bchm2.1981.362.2.1357; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; JESSEN TE, 1988, FEBS LETT, V230, P195, DOI 10.1016/0014-5793(88)80670-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN WJ, 1989, FOLLICULAR DEV OVULA, P87; Larsen WJ, 1991, ULTRASTRUCTURE OVARY, P45; MAHIBROWN CA, 1983, GAMETE RES, V8, P1, DOI 10.1002/mrd.1120080102; MAO SJT, 1987, ANAL BIOCHEM, V161, P514, DOI 10.1016/0003-2697(87)90482-9; MCKEEHAN WL, 1986, J BIOL CHEM, V261, P5378; MORII M, 1985, BIOL CHEM H-S, V366, P19, DOI 10.1515/bchm3.1985.366.1.19; ODUM L, 1990, BIOL CHEM H-S, V371, P1153, DOI 10.1515/bchm3.1990.371.2.1153; PIKO L, 1969, FERTILIZATION, V2, P325; POTEMPA J, 1989, J BIOL CHEM, V264, P15109; PRATT CW, 1987, BIOCHEMISTRY-US, V26, P2855, DOI 10.1021/bi00384a029; RASP G, 1987, BIOL CHEM H-S, V368, P727, DOI 10.1515/bchm3.1987.368.1.727; REISINGER P, 1985, BIOL CHEM H-S, V366, P479, DOI 10.1515/bchm3.1985.366.1.479; SALIER JP, 1983, ANAL BIOCHEM, V133, P336, DOI 10.1016/0003-2697(83)90093-3; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SATO E, 1978, J REPROD FERTIL, V54, P263, DOI 10.1530/jrf.0.0540263; SCHREITMULLER T, 1987, BIOL CHEM H-S, V368, P963, DOI 10.1515/bchm3.1987.368.2.963; SHALGI R, 1973, FERTIL STERIL, V24, P429; SLUSS PM, 1987, ENDOCRINOLOGY, V120, P1477, DOI 10.1210/endo-120-4-1477; Steinbuch M, 1976, Methods Enzymol, V45, P760; TADANO Y, 1978, HISTOCHEMISTRY, V57, P203, DOI 10.1007/BF00492080; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VETR H, 1989, FEBS LETT, V245, P137, DOI 10.1016/0014-5793(89)80207-8; YOSHIMURA Y, 1987, FERTIL STERIL, V47, P22	47	207	212	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12380	12386						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376324				2022-12-27	WOS:A1992HY94700109
J	KLATT, P; HEINZEL, B; JOHN, M; KASTNER, M; BOHME, E; MAYER, B				KLATT, P; HEINZEL, B; JOHN, M; KASTNER, M; BOHME, E; MAYER, B			CA2+/CALMODULIN-DEPENDENT CYTOCHROME-C REDUCTASE-ACTIVITY OF BRAIN NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLYL CYCLASE; RAT-LIVER MICROSOMES; L-ARGININE; P-450 REDUCTASE; BOVINE LUNG; PURIFICATION; CALMODULIN; ACTIVATOR; OXIDATION; COFACTOR	Nitric oxide acts as a widespread signal molecule and represents the endogenous activator of soluble guanylyl cyclase. In endothelial cells and brain tissue, NO is enzymatically formed from L-arginine by Ca2+/calmodulin-regulated NO synthases which require NADPH, tetrahydrobiopterin, and molecular oxygen as cofactors. Here we show that purified brain NO synthase binds to cytochrome c-agarose and exhibits superoxide dismutase-insensitive cytochrome c reductase activity with a V(max) of 10.2-mu-mol x mg-1 x min-1 and a K(m) of 34.1-mu-M. Cytochrome c reduction was largely dependent on Ca2+/calmodulin and cochromatographed with L-citrulline formation during gel filtration. When reconstituted with cytochrome P450, NO synthase induced a moderate Ca2+-independent hydroxylation of N-ethylmorphine. NO synthase also reduced the artificial electron acceptors nitro blue tetrazolium and 2,6-dichlorophenolindophenol. Cytochrome c, 2,6-dichlorophenolindophenol, and nitro blue tetrazolium inhibited NO synthase activity determined as formation Of L-citrulline from 0.1 mM L-arginine in a concentration-dependent manner with half-maximal effects at 166, 41, and 7.3-mu-M, respectively. These results suggest that NO synthase may participate in cellular electron transfer processes and that a variety of electron-acceptors may interfere with NO formation due to the broad substrate specificity of the reductase domain of NO synthase.	GRAZ UNIV,INST PHARMACOL & TOXICOL,UNIV PL 2,A-8010 GRAZ,AUSTRIA; FREE UNIV BERLIN,INST PHARMACOL,W-1000 BERLIN 33,GERMANY; FREE UNIV BERLIN,INST TOXICOL & EMBRYOPHARMACOL,W-1000 BERLIN 33,GERMANY	University of Graz; Free University of Berlin; Free University of Berlin			Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494				BENVENISTE I, 1991, BIOCHEM BIOPH RES CO, V177, P105, DOI 10.1016/0006-291X(91)91954-B; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; COCHIN J, 1959, J PHARMACOL EXP THER, V125, P105; Estabrook R W, 1978, Methods Enzymol, V52, P43; ESTABROOK RW, 1982, OXYGENASES OXYGEN ME, P371; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GUENGERICH FP, 1980, ARCH BIOCHEM BIOPHYS, V205, P365, DOI 10.1016/0003-9861(80)90119-8; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; KAUFMAN S, 1959, J BIOL CHEM, V234, P2677; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KOJIMA H, 1987, J BIOCHEM-TOKYO, V102, P1083, DOI 10.1093/oxfordjournals.jbchem.a122146; KUONEN DR, 1988, J NEUROCHEM, V50, P1017, DOI 10.1111/j.1471-4159.1988.tb10567.x; KUWADA M, 1985, BIOCHIM BIOPHYS ACTA, V830, P45; KUWAHARA T, 1984, BIOCHEM BIOPH RES CO, V124, P121, DOI 10.1016/0006-291X(84)90925-2; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER B, 1989, FEBS LETT, V256, P211, DOI 10.1016/0014-5793(89)81750-8; MAYER B, 1991, J CARDIOVASC PHARM, V17, pS46, DOI 10.1097/00005344-199117003-00009; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PALACIOS M, 1989, BIOCHEM BIOPH RES CO, V165, P802, DOI 10.1016/S0006-291X(89)80037-3; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VERMILION JL, 1974, BIOCHEM BIOPH RES CO, V60, P1315, DOI 10.1016/0006-291X(74)90341-6; YUI Y, 1991, J BIOL CHEM, V266, P12544; YUI Y, 1991, J BIOL CHEM, V266, P3369	42	206	207	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11374	11378						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375940				2022-12-27	WOS:A1992HX16900068
J	STENMARK, H; ARIANSEN, S; AFANASIEV, BN; OLSNES, S				STENMARK, H; ARIANSEN, S; AFANASIEV, BN; OLSNES, S			INTERACTIONS OF DIPHTHERIA-TOXIN B-FRAGMENT WITH CELLS - ROLE OF AMINO-TERMINAL AND CARBOXYL-TERMINAL REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW PH; ENTRY; MEMBRANE; MOLECULE; MUTANTS	The B-fragment of diphtheria toxin binds to cell surface receptors and facilitates entry of the enzymatically active A-fragment into the cytosol. The roles of the amino- and carboxyl-terminal regions of the B-fragment in interactions with the cell membrane were studied by measuring specific binding, insertion into membranes at low pH, and formation of cation-selective channels, as well as by toxicity measurements after association with active A-fragment. Deletion of the amino-terminal 12 amino acids of the B-fragment did not affect its ability to bind to receptors and to form ion channels at low pH, whereas both abilities were strongly impaired when one more amino acid (Trp206) was removed. Replacement of the amino-terminal 31 residues with an amphipathic sequence from human apolipoprotein A1 restored receptor binding but not ion channel formation. The binding to cells was virtually abolished when 9 residues were deleted from the carboxyl terminus. Deletion of only 4 residues or extension by 12 residues did not prevent specific binding, but reduced insertion, channel formation, and toxicity. Those deletions that reduced receptor binding ability increased the trypsin sensitivity of the B-fragment. The results indicate that the amino- and carboxyl-terminal regions of diphtheria toxin B-fragment are important for receptor binding, possibly because they contribute to keep the B-fragment in a binding-competent conformation. Small alterations in the carboxyl-terminal end reduced insertion, channel formation, and toxicity more than the ability of the B-fragment to bind to cells.	WA ENGELHARDT MOLEC BIOL INST,MOSCOW,USSR	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	STENMARK, H (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,MONTEBELLO,OSLO 3,NORWAY.		Stenmark, Harald/B-8868-2008					BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; Frankel A. E., 1988, IMMUNOTOXINS; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOTTE P, 1980, J CELL BIOL, V87, P837, DOI 10.1083/jcb.87.3.837; MADSHUS IH, 1991, J BIOL CHEM, V266, P17446; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; OLSNES S, 1989, J BIOL CHEM, V264, P12749; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; Olsnes S, 1991, Semin Cell Biol, V2, P7; PAPPENHEIMER AM, 1972, IMMUNOCHEMISTRY, V9, P891, DOI 10.1016/0019-2791(72)90163-2; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; ROGNE S, 1986, HUM GENET, V72, P68, DOI 10.1007/BF00278820; ROLF JM, 1990, J BIOL CHEM, V265, P7331; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; STENMARK H, 1989, EMBO J, V8, P2849, DOI 10.1002/j.1460-2075.1989.tb08432.x; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; STENMARK H, 1991, MOL MICROBIOL, V5, P595, DOI 10.1111/j.1365-2958.1991.tb00730.x; WILSON BA, 1990, BIOCHEMISTRY-US, V29, P8643, DOI 10.1021/bi00489a021	23	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8957	8962						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374382				2022-12-27	WOS:A1992HR85400041
J	BALDWIN, AN; BITLER, CM; WELCHER, AA; SHOOTER, EM				BALDWIN, AN; BITLER, CM; WELCHER, AA; SHOOTER, EM			STUDIES ON THE STRUCTURE AND BINDING-PROPERTIES OF THE CYSTEINE-RICH DOMAIN OF RAT LOW AFFINITY NERVE GROWTH-FACTOR RECEPTOR (P75NGFR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; GLOBULAR-PROTEINS; CRYSTAL-STRUCTURE; BLOOD-COAGULATION; DISTANCE GEOMETRY; EXPRESSION; CELLS; GENE	The binding domain of p75NGFR contains four "repeats" of a 6-cysteine pattern. To test whether these repeats have any structural or functional independence, each repeat has been separately deleted. In each case, deletion led to the loss of most nerve growth factor (NGF) binding activity. The epitopes of two monoclonal antibodies, MC 192 and 271c, could be distinguished, however. Repeat IV was found to be unnecessary for binding MC192, whereas Repeat I was not required for binding 217c. This suggests that either terminal repeat can be removed without loss of native-like structure in the remaining repeats. Trp155 in the fourth repeat forms an essential part of the 217c epitope but is not required for either MC192 or NGF binding. Deletion of the linker region between the membrane-spanning domain and the cysteine-rich domain does not affect the binding of NGF or MC192, and has only a slight, if any, effect on 217c binding. Cyclic permutation of the four repeats failed to yield protein capable of binding NGF or MC192.			BALDWIN, AN (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305, USA.				NINDS NIH HHS [NS042270] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLENDOERFER KL, 1990, P NATL ACAD SCI USA, V87, P187, DOI 10.1073/pnas.87.1.187; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CLORE GM, 1987, EMBO J, V6, P529, DOI 10.1002/j.1460-2075.1987.tb04785.x; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; FERRARI G, 1991, EXP NEUROL, V112, P183, DOI 10.1016/0014-4886(91)90068-N; GOLDENBERG DP, 1983, J MOL BIOL, V165, P407, DOI 10.1016/S0022-2836(83)80265-4; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KOHDA D, 1989, BIOCHEMISTRY-US, V28, P953, DOI 10.1021/bi00429a005; KUMAR S, 1990, J NEUROSCI RES, V27, P408, DOI 10.1002/jnr.490270320; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LAX I, 1991, J BIOL CHEM, V266, P13828; LEDBETTER JA, 1981, J EXP MED, V153, P1503, DOI 10.1084/jem.153.6.1503; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MONTELIONE GT, 1986, P NATL ACAD SCI USA, V83, P8594, DOI 10.1073/pnas.83.22.8594; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PEASE JHB, 1988, BIOCHEMISTRY-US, V27, P8491, DOI 10.1021/bi00422a029; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REES B, 1990, J MOL BIOL, V214, P281, DOI 10.1016/0022-2836(90)90161-E; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SQUINTO SP, 1991, CELL, V65, P1; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; THORNTON JM, 1983, J MOL BIOL, V167, P443, DOI 10.1016/S0022-2836(83)80344-1; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UPTON C, 1987, VIROLOGY, V160, P20, DOI 10.1016/0042-6822(87)90039-0; VISSAVAJJHALA P, 1990, J BIOL CHEM, V265, P4746; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WRIGHT CS, 1977, J MOL BIOL, V111, P439, DOI 10.1016/S0022-2836(77)80063-6; YAN H, 1991, J BIOL CHEM, V266, P12099; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	53	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8352	8359						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373724				2022-12-27	WOS:A1992HQ18500062
J	CHAO, R; KHAN, W; HANNUN, YA				CHAO, R; KHAN, W; HANNUN, YA			RETINOBLASTOMA PROTEIN DEPHOSPHORYLATION INDUCED BY D-ERYTHRO-SPHINGOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE-PRODUCT; CELL-CYCLE; KINASE-C; SUSCEPTIBILITY GENE; PHOSPHORYLATION; SPHINGOLIPIDS; INHIBITION; DIFFERENTIATION; MODULATION; COMPLEX	The retinoblastoma gene product (Rb), a nuclear phosphoprotein, functions as a tumor suppressor that is inactivated in retinoblastoma and other malignancies. The hypophosphorylated forms of Rb are observed in the G0/G1 phase of the cell cycle, whereas the hyperphosphorylated forms predominate in S and G2/M phases, suggesting that phosphorylation/dephosphorylation of Rb may regulate progression through the growth cycle. However, little is known about the intracellular signals that regulate phosphorylation/dephosphorylation of Rb. We show that D-erythro-sphingosine potently induces early dephosphorylation of Rb. Initial dephosphorylation was observed as early as 1 h after treatment of hematopoietic cells with sphingosine, whereas complete shift to the dephosphorylated form was seen 4 h after treatment. These effects occurred at concentrations of sphingosine as low as 100-500 nM, with maximal effects observed at 1-2.5 muM. These effects were specific to sphingosine, inasmuch as other lipids, amphiphiles, and long chain amino bases, as well as structural analogs of sphingosine, failed to induce dephosphorylation of Rb. Also, activation of second messenger systems including protein kinase C, cAMP-dependent kinases, and calcium ionophores, as well as inhibition of serine/threonine protein phosphatases, failed to induce dephosphorylation of Rb. Induction of Rb dephosphorylation by sphingosine preceded inhibition of growth and a specific arrest in the G0/G1 phase of the cell cycle. These studies, for the first time, identify an intracellular activator of Rb.	DUKE UNIV,MED CTR,DEPT MED,BOX 3355,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; THORNTHWAITE JT, 1980, CYTOMETRY, V1, P229, DOI 10.1002/cyto.990010309; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILSON E, 1988, J BIOL CHEM, V263, P9304	28	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23459	23462						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385423				2022-12-27	WOS:A1992JZ23900007
J	BALLOU, LR; CHAO, CP; HOLNESS, MA; BARKER, SC; RAGHOW, R				BALLOU, LR; CHAO, CP; HOLNESS, MA; BARKER, SC; RAGHOW, R			INTERLEUKIN-1-MEDIATED PGE2 PRODUCTION AND SPHINGOMYELIN METABOLISM - EVIDENCE FOR THE REGULATION OF CYCLOOXYGENASE GENE-EXPRESSION BY SPHINGOSINE AND CERAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; LEUKEMIA HL-60 CELLS; GH3 PITUITARY-CELLS; PROSTAGLANDIN-E2 PRODUCTION; FACTOR RECEPTOR; PHORBOL ESTERS; SYNTHASE; DIFFERENTIATION; STIMULATION	We recently demonstrated that sphingosine enhances interleukin-1beta (IL-1)-mediated prostaglandin E2 (PGE2) production in human dermal fibroblasts (Ballou, L. R., Barker, S. C., Postlethwaite, A. E., and Kang, A. H. (1990) J. Immunol. 145, 4245-4251). Because sphingosine and ceramide are interconvertable, we extended previous studies by treating cells with C2-ceramide (C2-cer), a membrane-soluble analogue of ceramide, and found that C2-cer stimulates IL-1-mediated PGE2 production to the same degree as sphingosine. In an effort to elucidate the mechanistic basis by which sphingosine and C2-cer affect PGE2 production, we examined the effect of these molecules on the expression of genes encoding cyclooxygenase (EC 1.14.99.1, Cox) and phospholipase A2 (EC 3.1.1.4, PLA2), the rate-limiting enzymes in PGE2 biosynthesis. We found that sphingosine and C2-cer treatment resulted in an 8-fold induction of Cox mRNA within 1-2 h which declined thereafter; concomitant changes in Cox protein were also observed. In contrast, expression of phospholipase A2 remained unaltered. We also found that IL-1-mediated PGE2 production was dramatically enhanced in cells treated simultaneously with sphingomyelinase which led us to directly test the effect of IL-1 on sphingomyelin turnover. IL-1 treatment induced the hydrolysis of a significant fraction of prelabeled sphingomyelin which was accompanied by increased levels of intracellular ceramide. Taken together, our results suggest that enhanced Cox expression may account for the observed enhancement of IL-1-mediated PGE2 production by sphingosine and C2-cer. These data also suggest that endogenous sphingomyelin metabolites, generated in response to IL-1, may play an important role in IL-1 signal transduction.	UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT PHARMACOL,MEMPHIS,TN 38163; VET AFFAIRS MED CTR,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	BALLOU, LR (corresponding author), UNIV TENNESSEE CTR HLTH SCI,DEPT MED,DIV CONNECT TISSUE DIS,956 COURT AVE,RM G326,MEMPHIS,TN 38163, USA.				NIAMS NIH HHS [AR39166, AR26034] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026034, P50AR039166] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAILEY JM, 1985, J LIPID RES, V26, P54; BALLOU LR, 1990, J IMMUNOL, V145, P4245; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANG J, 1986, J IMMUNOL, V136, P1283; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DIAZ A, 1989, J BIOL CHEM, V264, P11554; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ELIAS JA, 1987, J IMMUNOL, V138, P3812; ERCOLANI L, 1988, J BIOL CHEM, V263, P15355; FU JY, 1990, J BIOL CHEM, V265, P16737; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HUBSCHER G., 1960, JOUR LIPID RES, V1, P433; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; MAJERUS PW, 1984, CELL, V37, P701, DOI 10.1016/0092-8674(84)90405-7; MCKNIGHT SG, 1991, CURR OPIN BIOL, V3, P213; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PREISS J, 1986, J BIOL CHEM, V261, P8579; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RAZ A, 1988, J BIOL CHEM, V263, P3022; ROSSI V, 1985, SCIENCE, V229, P174, DOI 10.1126/science.2409598; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WU KK, 1988, J BIOL CHEM, V263, P19043; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	36	277	280	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20044	20050						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400321				2022-12-27	WOS:A1992JR85800049
J	HOLLOWAY, MP; LAGAMMA, EF				HOLLOWAY, MP; LAGAMMA, EF			TISSUE-SPECIFIC DNASEI HYPERSENSITIVITY REGIONS ARE LOCATED IN THE 5'-REGION OF THE RAT PREPROENKEPHALIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROENKEPHALIN GENE; CAMP-INDUCIBLE ENHANCER; MESSENGER-RNA; ADRENAL-MEDULLA; TRANSCRIPTIONAL REGULATION; DEPENDENT REGULATION; MUSCARINIC RECEPTOR; TRANSGENIC MICE; CYCLIC-AMP; EXPRESSION	Extracellular stimuli affecting mechanisms of transcriptional control of the preproenkephalin gene link stimulus-secretion-synthesis coupling to transmitter phenotypic expression. In order to define distal and proximal genomic regions that might participate in transcriptionally active protein-DNA interactions, DNaseI hypersensitivity assays were conducted. Four DNaseI-hypersensitive regions were identified at -3000, -2500, -1800, and -200 base pairs (bp) relative to the somatic start site. The appearance of a site over the proximal promoter/enhancer region (-200 bp) is of interest since we and others have published a detailed footprint and functional analysis of this region using rat tissues. While liver (which does not express proenkephalin mRNA) displays essentially no hypersensitivity here, adrenal gland preparations show a strong signal and striatal tissue a significantly weaker signal. Cholinergic induction of proenkephalin mRNA was not associated with a change in hypersensitivity pattern. These data suggest that chromatin structure may have an influence on preproenkephalin transcriptional control and that cholinergic-inducible cis-acting DNA elements may reside within subdomains of at least these four hypersensitivity sites. Understanding the basis of this open chromatin structure should aid in identifying genomic mechanisms involved in tissue-specific expression and suggest avenues of future study.	SUNY STONY BROOK,DEPT PEDIAT,HSC 11-060,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				LaGamma, Edmund/0000-0001-9720-1949				ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; BLACK IB, 1987, SCIENCE, V236, P1263, DOI 10.1126/science.2884727; BORSOOK D, 1991, Society for Neuroscience Abstracts, V17, P546; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DURKIN RC, 1992, BIOCHIM BIOPHYS ACTA, V1131, P349, DOI 10.1016/0167-4781(92)90040-7; FERNANDO JCR, 1991, EUR J PHARM-MOLEC PH, V207, P297, DOI 10.1016/0922-4106(91)90003-Z; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; JOSHI J, 1991, MOL ENDOCRINOL, V5, P1069, DOI 10.1210/mend-5-8-1069; KESHET E, 1989, EMBO J, V8, P2917, DOI 10.1002/j.1460-2075.1989.tb08441.x; KEW D, 1990, MOL ENDOCRINOL, V4, P337, DOI 10.1210/mend-4-2-337; KILPATRICK DL, 1985, P NATL ACAD SCI USA, V82, P7467, DOI 10.1073/pnas.82.21.7467; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; KUENZLE CC, 1983, COLD SPRING HARB SYM, V48, P493, DOI 10.1101/SQB.1983.048.01.054; La Gamma E F, 1991, Mol Cell Neurosci, V2, P427; La Gamma E F, 1991, Mol Cell Neurosci, V2, P517; LAGAMMA EF, 1989, INT J DEV NEUROSCI, V7, P499, DOI 10.1016/0736-5748(89)90009-9; LAGAMMA EF, 1989, MOL BRAIN RES, V5, P131, DOI 10.1016/0169-328X(89)90004-1; LAGAMMA EF, 1988, MOL BIOL STRESS, P153; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; LOHR D, 1985, NUCLEIC ACIDS RES, V13, P8409, DOI 10.1093/nar/13.23.8409; MIRKOVITCH J, 1991, GENE DEV, V5, P83, DOI 10.1101/gad.5.1.83; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORI N, 1990, COLD SH Q B, V55, P255; RATTNER A, 1991, MOL CELL BIOL, V11, P1017, DOI 10.1128/MCB.11.2.1017; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROSEN H, 1984, J BIOL CHEM, V259, P4309; ROSEN H, 1991, P NATL ACAD SCI USA, V88, P3705, DOI 10.1073/pnas.88.9.3705; SCHULTZBERG M, 1978, NEUROSCIENCE, V3, P1169, DOI 10.1016/0306-4522(78)90137-9; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; UHL GR, 1988, J NEUROSCI, V8, P4755; VANDENBERGH DJ, 1989, NEURON, V3, P507, DOI 10.1016/0896-6273(89)90209-2; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WEISINGER B, 1992, J BIOL CHEM, V267, P4508; WOTTON D, 1989, P NATL ACAD SCI USA, V86, P4195, DOI 10.1073/pnas.86.11.4195; WU C, 1984, NATURE, V309, P329; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; YOSHIKAWA K, 1989, FEBS LETT, V246, P193, DOI 10.1016/0014-5793(89)80281-9; ZINN SA, 1991, J BIOL CHEM, V266, P23850	49	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19819	19823						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400296				2022-12-27	WOS:A1992JR85800013
J	PENNYPACKER, KR; HONG, JS; DOUGLASS, J; MCMILLIAN, MK				PENNYPACKER, KR; HONG, JS; DOUGLASS, J; MCMILLIAN, MK			CONSTITUTIVE EXPRESSION OF AP-1 TRANSCRIPTION FACTORS IN THE RAT ADRENAL - EFFECTS OF NICOTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; NERVE GROWTH-FACTOR; C-FOS EXPRESSION; MESSENGER-RNA; PHOSPHORYLATION; JUN; ACTIVATION; PROTEINS; PROENKEPHALIN; MEDULLA	The AP-1 proteins (c-fos and fos-related antigens and jun proteins) are transcription factors that are induced in most cells by various stimuli, but the expression of these proteins is low or undetectable in the basal state. Our data indicate that the rat adrenal gland contains a basally expressed elevated level of AP-1 proteins and mRNAs (40- and 35-kDa fos-related antigens, a 39-kDa c-jun protein, c-jun, junB, and junD mRNA), as well as high basal AP-1 DNA binding activity. Both the medulla and cortex contained equivalent levels of fos-related antigens and c-jun protein; however, the majority of AP-1 DNA binding was detected in the medulla. Handling of rats for several days prior to sacrifice failed to affect protein expression or binding; on the other hand, repeated injections of nicotine increased AP-1 DNA binding. A single nicotine injection 60 min prior to removing the adrenals caused a significant reduction in AP-1 DNA binding without any detectable changes in AP-1 protein expression. Pretreatment of adrenal nuclear extracts with alkaline phosphatase prior to incubation with the AP-1 oligomer decreased binding activity. Thus, unlike most tissues where AP-1 DNA binding activity is controlled by increased expression of AP-1 proteins, DNA binding in the rat adrenal gland appears to be controlled at the post-translational level, possibly through dephosphorylation.	OREGON HLTH SCI UNIV,INST VOLLUM,PORTLAND,OR 97201	Oregon Health & Science University	PENNYPACKER, KR (corresponding author), NIEHS,NEUROPHARMACOL SECT,MOLEC & INTEGRAT NEUROSCI LAB,MD 14-06,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Pennypacker, Keith/I-5092-2012; Hong, Jau-Shyong/F-1920-2019	Hong, Jau-Shyong/0000-0002-3056-8401				BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE AJ, 1992, J NEUROCHEM, V58, P1420, DOI 10.1111/j.1471-4159.1992.tb11358.x; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DECRISTOFARO JD, 1990, NEUROSCIENCE, V35, P203, DOI 10.1016/0306-4522(90)90135-Q; DRAGUNOW M, 1987, NATURE, V210, P249; FOSSOM L, 1991, J NEUROCHEM, V7, P2070; FOSSOM LH, 1991, MOL PHARMACOL, V40, P193; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GUBITS RM, 1988, MOL BRAIN RES, V3, P197, DOI 10.1016/0169-328X(88)90067-8; KANAMATSU T, 1986, P NATL ACAD SCI USA, V83, P9245, DOI 10.1073/pnas.83.23.9245; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; LAGAMMA EF, 1989, MOL BRAIN RES, V5, P17, DOI 10.1016/0169-328X(89)90013-2; LAGAMMA EF, 1988, DEV BRAIN RES, V39, P177, DOI 10.1016/0165-3806(88)90021-1; LAGAMMA EF, 1985, P NATL ACAD SCI USA, V82, P8252, DOI 10.1073/pnas.82.23.8252; LAGAMMA EF, 1984, SCIENCE, V224, P1102, DOI 10.1126/science.6144183; MANEK JR, 1990, GENE DEV, V4, P955; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; PELTOHUIKKO M, 1991, NEUROSCI LETT, V126, P163, DOI 10.1016/0304-3940(91)90544-4; PENNYPACKER KR, IN PRESS MOL BRAIN R; PENNYPACKER KR, 1992, IN PRESS J NEUROCHEM; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; ROBERTSON GS, 1989, EUR J PHARMACOL, V159, P99, DOI 10.1016/0014-2999(89)90049-6; RYSECK RP, 1991, ONCOGENE, V6, P533; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SAKAURAIYAMASHI.T, 1991, EUR J NEUROSCI, V3, P764; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291	39	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20148	20152						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400333				2022-12-27	WOS:A1992JR85800064
J	CECH, TR; HERSCHLAG, D; PICCIRILLI, JA; PYLE, AM				CECH, TR; HERSCHLAG, D; PICCIRILLI, JA; PYLE, AM			RNA CATALYSIS BY A GROUP-I RIBOZYME - DEVELOPING A MODEL FOR TRANSITION-STATE STABILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TETRAHYMENA-THERMOPHILA RIBOZYME; RIBONUCLEIC-ACID PRECURSOR; SELF-SPLICING RNA; INTERVENING SEQUENCE; BINDING-SITE; ENDORIBONUCLEASE ACTIVITY; BIOLOGICAL CATALYSIS; KINETIC DESCRIPTION; PHOSPHORYL TRANSFER; CLEAVAGE				CECH, TR (corresponding author), UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309, USA.							ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5631, DOI 10.1021/bi00670a032; BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CLELAND WW, 1975, ACCOUNTS CHEM RES, V8, P145, DOI 10.1021/ar50089a001; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FERSHT AR, 1974, PROC R SOC SER B-BIO, V187, P397, DOI 10.1098/rspb.1974.0084; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P5172, DOI 10.1021/bi00473a025; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; JAFFE EK, 1978, J BIOL CHEM, V253, P4823; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PACE NR, 1985, ORIGINS LIFE EVOL B, V16, P97, DOI 10.1007/BF01809465; PACE NR, 1990, J BIOL CHEM, V265, P3587; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SUGIMOTO N, 1989, CHEM LETT, P2223, DOI 10.1246/cl.1989.2223; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YARUS M, 1992, J MOL BIOL, V225, P945, DOI 10.1016/0022-2836(92)90095-2; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7; ZAUG AJ, 1985, BIOCHEMISTRY-US, V24, P6211, DOI 10.1021/bi00343a027; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008; ZAUG AJ, 1986, BIOCHEMISTRY-US, V25, P4478, DOI 10.1021/bi00364a002	58	106	114	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17479	17482						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381347				2022-12-27	WOS:A1992JM22300001
J	KRIKOS, A; LAHERTY, CD; DIXIT, VM				KRIKOS, A; LAHERTY, CD; DIXIT, VM			TRANSCRIPTIONAL ACTIVATION OF THE TUMOR-NECROSIS-FACTOR ALPHA-INDUCIBLE ZINC FINGER PROTEIN, A20, IS MEDIATED BY KAPPA-B ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; NUCLEAR FACTOR BINDING; LONG TERMINAL REPEAT; THROMBOSPONDIN GENE; ENHANCER ELEMENTS; HUMAN FIBROBLASTS; DNA METHYLATION; INDUCTION; EXPRESSION; SEQUENCE	A20 was first identified as a tumor necrosis factor (TNF) primary response transcript encoding a 790-amino acid protein with a unique zinc finger motif. Recently, A20 was shown to protect cells from TNF-induced cytotoxicity in a variety of cell lines. Nuclear run-on studies previously established that TNF activates A20 at the transcriptional level. To further characterize the mechanism by which TNF activates the A20 gene, we have cloned the A20 5'-flanking sequences and identified TNF-responsive elements within the promoter. The transcription initiation site was mapped by both primer extension and S1 nuclease protection experiments to a position 4.2 kilobases kB upstream of the initiator methionine; the first and second exon were separated by a 3.9-kb intron. Sequences upstream of the transcription start site were 76% GC-rich and contained six Sp1 binding sites and a TATA-like sequence at -29 but lacked a consensus CCAAT site. Transfection of Jurkat T-cells with an array of A20 promoter CAT constructs showed that two kappa-B elements residing at -54 and -66 were required for induction by TNF. Supporting this notion, DNA electrophoretic mobility shift assays using nuclear extracts from unstimulated and TNF-stimulated Jurkat cells demonstrated kappa-B-specific binding of a TNF-activated factor to an end-labeled probe containing the two A20 kappa-B sequences. Finally, evidence obtained from cotransfection experiments showed that A20 negatively regulated its own expression.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,1301 CATHERINE ST,POB 0602,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CELLULAR & MOLEC BIOL PROGRAM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NHLBI NIH HHS [HL-45351] Funding Source: Medline; NIAMS NIH HHS [AR-20557] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANISOWICZ A, 1991, J IMMUNOL, V147, P520; ASUBEL FM, 1989, CURRENT PROTOCOLS MO; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P409; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRUNFELD C, 1990, ADV INTERNAL MED, V35, P44; HERR W, 1991, HORMONAL CONTROL GEN, P25; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KRASNOW SW, 1991, CYTOKINE, V3, P1; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Sambrook J, 1989, MOL CLONING LABORATO; SARMA V, 1992, J IMMUNOL, V148, P3302; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Wallach D, 1986, Interferon, V7, P89; WALLACH D, 1984, J IMMUNOL, V132, P2464; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WOLF FW, 1992, J BIOL CHEM, V267, P1317; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	46	373	386	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17971	17976						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381359				2022-12-27	WOS:A1992JM22300075
J	ROMER, S; DHARLINGUE, A; CAMARA, B; SCHANTZ, R; KUNTZ, M				ROMER, S; DHARLINGUE, A; CAMARA, B; SCHANTZ, R; KUNTZ, M			CYSTEINE SYNTHASE FROM CAPSICUM-ANNUUM CHROMOPLASTS - CHARACTERIZATION AND CDNA CLONING OF AN UP-REGULATED ENZYME DURING FRUIT-DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-REDUCTASE; ESCHERICHIA-COLI; HIGHER-PLANTS; BIOSYNTHESIS; METABOLISM; PURIFICATION; LOCALIZATION; EXPRESSION; PLASTIDS; ISOFORMS	Cysteine synthase (O-acetylserine sulfhydrylase) has been purified to homogeneity from bell pepper (Capsicum annuum) fruit chromoplasts. This enzyme consists of two subunits of 35 kDa. Immunocytochemical localization experiments confirmed the plastid location of this enzyme. A full-length cDNA was isolated from an expression library of C. annuum. The deduced peptide sequence revealed high similarity between the C. annuum cysteine synthase and its bacterial counterparts. In vitro transcription and translation of the cDNA and subsequent import experiments demonstrated that the encoded cysteine synthase is located in the plastids. The steady-state level of the cysteine synthase mRNA is almost constant in dark-grown hypocotyls, leaves, and fruits. However, a slight increase in this mRNA level was detected during fruit development (when the 25 S rRNA was taken as an internal standard). Similarly, the cysteine synthase activity in plastids was found to increase during fruit development and reaches the highest levels in the chromoplasts of red fruits. To address the physiological role of this phenomenon, we have shown that cysteine is engaged in the active metabolism of glutathione. Thus, in connection with the previous demonstration of an active tocopherol metabolism, it is concluded that differentiation of chloroplast to chromoplast in C. annuum involves an active synthesis of potential antioxidants or redox modulators.	UNIV STRASBOURG 1, CNRS, INST BIOL MOLEC PLANTES, 12 RUE GEN ZIMMER, F-67084 STRASBOURG, FRANCE; UNIV BORDEAUX 1, F-33405 TALENCE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universite de Bordeaux								ALOSI MC, 1988, PLANT PHYSIOL, V86, P1089, DOI 10.1104/pp.86.4.1089; ALSCHER RG, 1989, PHYSIOL PLANTARUM, V77, P457, DOI 10.1111/j.1399-3054.1989.tb05667.x; ANDERSON JV, 1990, PLANT PHYSIOL, V94, P1402, DOI 10.1104/pp.94.3.1402; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; BOGORAD L, 1983, METHOD ENZYMOL, V97, P524; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; CAMARA B, 1989, CUR TOP PL, V2, P141; CAMARA B, 1985, METHOD ENZYMOL, V110, P244; CAMARA B, 1982, PLANT PHYSIOL, V70, P1562, DOI 10.1104/pp.70.5.1562; CORUZZI GM, 1991, PLANT SCI, V74, P145, DOI 10.1016/0168-9452(91)90040-F; DOGBO O, 1988, P NATL ACAD SCI USA, V85, P7054, DOI 10.1073/pnas.85.19.7054; DOGBO O, 1987, PLANT SCI, V49, P89, DOI 10.1016/0168-9452(87)90005-7; FLETCHER BL, 1973, ANAL BIOCHEM, V52, P1, DOI 10.1016/0003-2697(73)90327-8; FUCHS Y, 1981, PLANT CELL PHYSIOL, V22, P733; HOCK NB, 1978, PHYTOCHEMISTRY, V17, P879; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; Kirk J., 1978, PLASTIDS, P525; KLAPHECK S, 1990, METHODS PLANT BIOCH, V3, P355; KUNTZ M, 1992, PLANT J, V2, P25; KUNTZ M, 1989, MOL GEN GENET, V216, P156, DOI 10.1007/BF00332245; LECH K, 1987, CURRENT PROTOCOLS MO, V1, P111; LIVNE A, 1988, PLANT PHYSIOL, V87, P239, DOI 10.1104/pp.87.1.239; LUNN JE, 1990, PLANT PHYSIOL, V94, P1345, DOI 10.1104/pp.94.3.1345; MAGUIRE YP, 1975, NATURE, V258, P599, DOI 10.1038/258599a0; MURAKOSHI I, 1985, PHYTOCHEMISTRY, V24, P1907, DOI 10.1016/S0031-9422(00)83090-3; NAKAMURA K, 1989, AGR BIOL CHEM TOKYO, V53, P2537, DOI 10.1080/00021369.1989.10869671; PATE JS, 1989, TRANSPORT PHOTOASSIM, P138; RENNENBERG H, 1982, PHYTOCHEMISTRY, V21, P2771, DOI 10.1016/0031-9422(80)85045-X; SAUNDERS SE, 1990, NUCLEIC ACIDS RES, V18, P4948, DOI 10.1093/nar/18.16.4948; Schmidt A., 1990, METHODS PLANT BIOCH, V3, P349, DOI DOI 10.1016/B978-0-12-461013-2.50031-9; SCHREIER PH, 1988, PLANT MOL BIOL MAN B, V5, P1; SIRKO A, 1990, J BACTERIOL, V172, P3351, DOI 10.1128/jb.172.6.3351-3357.1990; THOMSON WW, 1980, ANNU REV PLANT PHYS, V31, P375, DOI 10.1146/annurev.pp.31.060180.002111; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535	36	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17966	17970						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381358				2022-12-27	WOS:A1992JM22300074
J	WANG, S; DENG, LP; MILNE, RW; TALL, AR				WANG, S; DENG, LP; MILNE, RW; TALL, AR			IDENTIFICATION OF A SEQUENCE WITHIN THE C-TERMINAL-26 AMINO-ACIDS OF CHOLESTERYL ESTER TRANSFER PROTEIN RESPONSIBLE FOR BINDING A NEUTRALIZING MONOCLONAL-ANTIBODY AND NECESSARY FOR NEUTRAL LIPID TRANSFER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HIGH-DENSITY LIPOPROTEINS; HUMAN-PLASMA; MUTAGENESIS; CLONING	The cholesteryl ester transfer protein (CETP; 476 amino acids) mediates the transfer of neutral lipids and phospholipids between plasma lipoproteins. Previous studies showed that the epitope of a neutralizing monoclonal antibody (TP2) was located within the C-terminal 26 amino acids (aa) of CETP. To determine possible involvement of this region in lipid transfer activities, we generated six deletion mutants between Arg-451 and Leu-475 by in vitro mutagenesis and expressed mutant proteins in mammalian cells. Only deletion mutants between aa Phe-463 and Leu-475 failed to bind TP2; these mutant proteins were well secreted by cells but showed markedly reduced cholesteryl ester transfer activity. One of the deletion mutants (DELTA-470-475) showed similar reductions in cholesteryl ester and triglyceride transfer activities but normal or increased phospholipid transfer activity. Limited proteolysis of this mutant protein indicated a similar overall folding pattern to the wild-type protein. Thus, aa between Phe-463 and Leu-475 are necessary for binding TP2. Deletions within this sequence selectively impair neutral lipid transfer activity, suggesting a direct involvement in neutral lipid transfer.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, DIV MOLEC MED, 630 W 168TH ST, NEW YORK, NY 10032 USA; CLIN RES INST MONTREAL, MONTREAL H2W 1R7, QUEBEC, CANADA	Columbia University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Tall, Alan/AAT-8528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022682, R37HL022682] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22682] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1991, J BIOL CHEM, V266, P10796; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AUYOUNG J, 1992, P NATL ACAD SCI USA, V89, P4094, DOI 10.1073/pnas.89.9.4094; BARTER PJ, 1980, J LIPID RES, V21, P238; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; GLOMSET JA, 1968, J LIPID RES, V9, P155; HESLER CB, 1988, J BIOL CHEM, V263, P5020; IHM J, 1982, J LIPID RES, V23, P1328; INAZU A, 1992, BIOCHEMISTRY-US, V31, P2352, DOI 10.1021/bi00123a021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORTON RE, 1982, J LIPID RES, V23, P1058; SAMMETT D, 1985, J BIOL CHEM, V260, P6687; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; SWENSON TL, 1989, J BIOL CHEM, V264; TALL AR, 1986, J LIPID RES, V27, P361; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WANG S, 1991, BIOCHEMISTRY-US, V30, P3484, DOI 10.1021/bi00228a019	20	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17487	17490						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381349				2022-12-27	WOS:A1992JM22300003
J	STYLIANOU, E; ONEILL, LAJ; RAWLINSON, L; EDBROOKE, MR; WOO, P; SAKLATVALA, J				STYLIANOU, E; ONEILL, LAJ; RAWLINSON, L; EDBROOKE, MR; WOO, P; SAKLATVALA, J			INTERLEUKIN-1 INDUCES NF-KAPPA-B THROUGH ITS TYPE-I BUT NOT ITS TYPE-II RECEPTOR IN LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING SUBUNIT; HUMAN-IMMUNODEFICIENCY-VIRUS; IL-1 RECEPTOR; FACTOR-ALPHA; TRANSCRIPTION FACTOR; HUMAN-FIBROBLASTS; GENE-EXPRESSION; PHORBOL ESTER; MESSENGER-RNA	It is not known whether one or both of the interleukin 1 (IL1) receptors mediates the induction of the DNA-binding protein NF-kappa-B. Nuclear extracts of the murine lines EL4.NOB.1 and 70Z/3, which bear the type I (80 kDa) and type II (67 kDa) IL1 receptor, respectively, were analyzed by an electrophoretic mobility shift assay. A 265-base pair sequence of the human serum amyloid A gene or a synthetic oligonucleotide each containing the NF-kappa-B site were used as the DNA probes. IL1 induction of NF-kappa-B was rapid (optimal at 15-30 min) and transient in both cell types. The IL1 receptor antagonist (IL1ra), which binds strongly to the type I receptor, inhibited the NF-kappa-B response in both cell lines. IL1ra did not bind to the type II receptor on 70Z/3 cells as judged by competition for binding with I-125-IL1-alpha. When I-125-IL1ra binding to 70Z/3 cells was measured, a small number (10/cell) of high affinity sites (K(d) = 5 x 10(-12) M) were detected. These were likely to have been type I receptor because an antibody to this inhibited the NF-kappa-B induction in 70Z/3 cells (as well as EL4). Potential signal transduction mechanisms involving protein kinase C or oxygen radicals were studied. Phorbol 12-myristate 13-acetate induced NF-kappa-B with a similar time course to IL1 in 70Z/3 but only after 4 h in EL4.IL1 was unaffected by a protein kinase C inhibitor (staurosporine). H2O2 did not mimic IL1, and IL1 was not inhibited by an antioxidant. The type I receptor mediates the induction of NF-kappa-B in response to IL1 via a signaling mechanism that still remains to be identified.	UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN 2,IRELAND; CLIN RES CTR,MOLEC RHEUMATOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND	Trinity College Dublin	STYLIANOU, E (corresponding author), STRANGEWAYS RES LAB,CYTOKINE BIOCHEM GRP,CAMBRIDGE CB1 4RN,ENGLAND.							BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; BAUERLE PA, 1989, GENE DEV, V3, P1689; BIRD TA, 1988, J BIOL CHEM, V263, P12063; BIRD TA, 1990, J BIOL CHEM, V265, P235; BIRD TA, 1990, J BIOL CHEM, V265, P13578; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DRIPPS DJ, 1991, J BIOL CHEM, V266, P20311; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GUESDON F, 1991, J IMMUNOL, V147, P3402; GUY GR, 1991, J BIOL CHEM, V266, P14343; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARUCHA PT, 1991, J IMMUNOL, V147, P2603; MATSUSHIMA K, 1986, J IMMUNOL, V136, P4496; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; WOO P, 1987, J BIOL CHEM, V262, P15790	47	214	218	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15836	15841						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386364				2022-12-27	WOS:A1992JG11300088
J	BROOKS, SF; HERGET, T; BROAD, S; ROZENGURT, E				BROOKS, SF; HERGET, T; BROAD, S; ROZENGURT, E			THE EXPRESSION OF 80K/MARCKS, A MAJOR SUBSTRATE OF PROTEIN-KINASE-C (PKC), IS DOWN-REGULATED THROUGH BOTH PKC-DEPENDENT AND PKC-INDEPENDENT PATHWAYS - EFFECTS OF BOMBESIN, PLATELET-DERIVED GROWTH-FACTOR, AND CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; AMINO-ACID-SEQUENCE; STRUCTURALLY RELATED PEPTIDES; AFFINITY CROSS-LINKING; PHORBOL ESTERS; CYCLIC-AMP; DNA-SYNTHESIS; RAPIDLY STIMULATE; QUIESCENT FIBROBLASTS; CELLULAR SUBSTRATE	We have examined the regulation of expression of 80K/MARCKS, a major and specific protein kinase C (PKC) substrate of Swiss 3T3 fibroblasts. Addition of bombesin (10 nm) to confluent quiescent cultures of these cells induced a dramatic and sustained down-regulation of 80-kDa mRNA and protein levels to a minimum of 5% of control within 8 and 48 h, respectively, without depletion of PKC activity. In contrast, the effect of phorbol 12,13-dibutyrate on 80K/MARCKS mRNA levels was transient, and recovery of these transcripts correlated with the loss of PKC activity. The ability of bombesin to down-regulate 80K/MARCKS mRNA levels was dose-dependent (ED50 0.5 nm) and was abolished by both the specific bombesin antagonist [Leu13-psi(CH2NH),Leu14]bombesin and by prior depletion of PKC. Of a range of agents tested, platelet-derived growth factor (PDGF), but not insulin or Ca2+ ionophore, also down-regulated 80K/MARCKS mRNA to 24% of control within 5 h. Prior down-regulation of PKC abolished the effect of PDGF at a concentration of 7 ng/ml. Surprisingly, at higher doses (25 ng/ml), PDGF induced the down-regulation of 80K/MARCKS mRNA in a PKC-independent manner. Furthermore, elevation of cAMP, either through receptor-mediated mechanisms (e.g. prostaglandin E1) or by direct stimulation of adenylate cyclase (e.g. forskolin), also caused a marked dose-dependent depletion of 80K/MARCKS mRNA levels, which were further reduced by co-administration with cAMP-phosphodiesterase inhibitors. The rate of transcription of the 80K/MARCKS gene was unaltered by treatment of cells with either bombesin, PDGF, or forskolin/1-methyl-3-isobutylxanthine. These results indicate a role for both PKC-dependent and -independent pathways in growth factor-induced down-regulation of 80K/MARCKS expression, through a post-transcriptional mechanism.	IMPERIAL CANC RES FUND,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BROOKS SF, 1990, FEBS LETT, V268, P291, DOI 10.1016/0014-5793(90)81030-R; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1989, FEBS LETT, V255, P149, DOI 10.1016/0014-5793(89)81079-8; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; ESCRIBANO J, 1988, J CELL PHYSIOL, V137, P223, DOI 10.1002/jcp.1041370204; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HERGET T, 1986, EMBO J, V5, P659, DOI 10.1002/j.1460-2075.1986.tb04264.x; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; HIRAI M, 1989, J CELL PHYSIOL, V139, P9, DOI 10.1002/jcp.1041390103; HORNBECK P, 1989, MOL CELL BIOL, V9, P3727, DOI 10.1128/MCB.9.9.3727; HORNBECK P, 1986, J BIOL CHEM, V261, P4817; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; ISACKE CM, 1986, EMBO J, V5, P2889, DOI 10.1002/j.1460-2075.1986.tb04584.x; ISSANDOU M, 1989, BIOCHEM BIOPH RES CO, V163, P201, DOI 10.1016/0006-291X(89)92121-9; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; LINDNER D, 1992, J BIOL CHEM, V267, P24; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MILLAR JBA, 1988, J CELL PHYSIOL, V137, P214, DOI 10.1002/jcp.1041370203; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; MORRIS C, 1988, FEBS LETT, V231, P311, DOI 10.1016/0014-5793(88)80840-8; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1987, P NATL ACAD SCI USA, V84, P2282, DOI 10.1073/pnas.84.8.2282; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; ROZENGURT E, 1982, J CELL PHYSIOL, V112, P243, DOI 10.1002/jcp.1041120213; ROZENGURT E, 1982, EXP CELL RES, V139, P71, DOI 10.1016/0014-4827(82)90319-6; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1983, J CELL PHYSIOL, V116, P379, DOI 10.1002/jcp.1041160316; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SINNETTSMITH J, 1988, J CELL BIOCHEM, V38, P237, DOI 10.1002/jcb.240380403; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TAKUWA N, 1987, J BIOL CHEM, V262, P182; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	64	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14212	14218						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378435				2022-12-27	WOS:A1992JD32500066
J	LYTTON, J; WESTLIN, M; BURK, SE; SHULL, GE; MACLENNAN, DH				LYTTON, J; WESTLIN, M; BURK, SE; SHULL, GE; MACLENNAN, DH			FUNCTIONAL COMPARISONS BETWEEN ISOFORMS OF THE SARCOPLASMIC OR ENDOPLASMIC-RETICULUM FAMILY OF CALCIUM PUMPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CA-2+ ATPASE; CA-2+-ATPASE; MUSCLE; EXPRESSION; TRANSPORT; BINDING; MUTATION; KIDNEY; CDNAS	ATP-dependent calcium pumps that reside in intracellular organelles are encoded by a family of structurally related enzymes, termed the sarcoplasmic or endoplasmic reticulum Ca2+-ATPases (SERCA), which each have a distinct pattern of tissue-specific and developmentally regulated expression. A COS-1 cell expression system was used to examine the biochemical properties of the isoforms: SERCA1 (fast-twitch skeletal muscle), SERCA2a (cardiac/slow-twitch skeletal muscle), SERCA2b (ubiquitous smooth- and non-muscle), and SERCA3 (non-muscle). Each isoform was expressed efficiently and appeared to be targeted to the endoplasmic reticulum. All isoforms displayed qualitatively similar enzymatic properties and were activated by calcium in a cooperative manner with a Hill coefficient of 2. The quantitative properties of SERCA1 and SERCA2a (the muscle isoforms) were identical in all respects. SERCA2b, however, appeared to have a lower turnover rate for both calcium transport and ATP hydrolysis. SERCA3 displayed a reduced apparent affinity for calcium, an increased apparent affinity for vanadate, and an altered pH dependence when compared with the other isoforms. These properties are consistent with an enzyme in which the equilibrium between the E1 and E2 conformations is shifted toward the E2 state.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ONTARIO, CANADA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV CINCINNATI, COLL MED RES, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45221 USA	Harvard University; Brigham & Women's Hospital; University of Toronto; Harvard University; Harvard Medical School; University System of Ohio; University of Cincinnati	LYTTON, J (corresponding author), BRIGHAM & WOMENS HOSP, DIV RENAL, 75 FRANCIS ST, BOSTON, MA 02115 USA.			Lytton, Jonathan/0000-0003-4770-2512	NIDDK NIH HHS [DK42879] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042879] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CANTLEY LC, 1977, J BIOL CHEM, V252, P7421; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHAMBERLAIN BK, 1988, METHOD ENZYMOL, V157, P91; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; FUJII J, 1990, FEBS LETT, V273, P232, DOI 10.1016/0014-5793(90)81092-3; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1985, ENZYMES BIOL MEMBR, V3, P157; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY D, 1990, J BIOL CHEM, V265, P19524; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; LYTTON J, 1992, Current Opinion in Cell Biology, V4, P220, DOI 10.1016/0955-0674(92)90036-C; LYTTON J, 1991, J BIOL CHEM, V266, P17067; LYTTON J, 1991, Biophysical Journal, V59, p249A; LYTTON J, 1991, HEART CARDIOVASCULAR, P1203; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, CELL MOTIL CYTOSKEL, V14, P26, DOI 10.1002/cm.970140107; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SPAMER C, 1987, J BIOL CHEM, V262, P7782; TADA M, 1988, METHOD ENZYMOL, V157, P107; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEBER K, 1969, J BIOL CHEM, V244, P4406	40	566	571	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14483	14489						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1385815				2022-12-27	WOS:A1992JD32500105
J	MACLEOD, JN; LEE, AK; LIEBHABER, SA; COOKE, NE				MACLEOD, JN; LEE, AK; LIEBHABER, SA; COOKE, NE			DEVELOPMENTAL CONTROL AND ALTERNATIVE SPLICING OF THE PLACENTALLY EXPRESSED TRANSCRIPTS FROM THE HUMAN GROWTH-HORMONE GENE-CLUSTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC SOMATOMAMMOTROPIN; LACTOGEN MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; GLOBIN GENES; DNA; VARIANT; BINDING; EVOLUTION; PROMOTER; FAMILY	Four of the five genes in the human growth hormone gene cluster are expressed in the villous layer of the placenta. We report that the expression of these genes, hCS-A, hCS-B, hCS-L, and hGH-V, are coordinately induced during fetal development, increasing between 12 and 20 weeks of gestation and then plateauing through term. Within the context of this coordinate activation, these genes are expressed at widely different levels and are alternatively spliced in different patterns. There is a developmentally regulated switch in the relative expression of the two chorionic somatomammotropin genes, hCS-A and hCS-B. Starting from approximately equal levels at 8 weeks of gestation, hCS-A is expressed 5-fold more abundantly than hCS-B by term. The proportion of alternatively spliced hGH-V transcripts that retain intron 4 is also developmentally regulated, increasing 3-fold during gestation to 15% at term. A small percentage of hCS transcripts stably retain intron 4 through gestation, the majority derived from the hCS-A gene. hCS-L transcripts undergo two distinct, developmentally stable, splicing pathways between exons 2 and 3. These result from the absence of the normal splice-donor site in intron 2 and the activation of two cryptic splice-acceptor sites. Despite high levels of sequence identity, the four placentally expressed genes in the growth hormone cluster generate a complex set of mRNAs based on alternative splicing and developmental regulation during gestation.	UNIV PENN,DEPT MED,727 CLIN RES BLDG,422 CURIE BLVD,PHILADELPHIA,PA 19104; UNIV PENN,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,DEPT GENET,PHILADELPHIA,PA 19104	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania					NICHD NIH HHS [HD 25147] Funding Source: Medline; NIDDK NIH HHS [DK 08357, DK 08228] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD025147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008228, F32DK008357] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBITAR M, 1991, MOL CELL BIOL, V11, P3786, DOI 10.1128/MCB.11.7.3786; ALBITAR M, 1992, BLOOD, V79, P2471; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BARSH GS, 1983, NUCLEIC ACIDS RES, V11, P3939, DOI 10.1093/nar/11.12.3939; BECK JS, 1970, NEW ENGL J MED, V283, P189, DOI 10.1056/NEJM197007232830408; BOIME I, 1976, J BIOL CHEM, V251, P820; BRAUNSTEIN GD, 1980, AM J OBSTET GYNECOL, V138, P1205, DOI 10.1016/S0002-9378(16)32793-4; BUSTER JE, 1989, ENDOCRINOLOGY, V3, P2049; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOKE NE, 1988, J BIOL CHEM, V263, P9001; COOKE NE, 1988, J CLIN INVEST, V82, P270, DOI 10.1172/JCI113582; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; ESTES PA, 1990, J BIOL CHEM, V265, P19863; FITZPATRICK SL, 1990, MOL ENDOCRINOL, V4, P1815, DOI 10.1210/mend-4-12-1815; FRANKENNE F, 1988, J CLIN ENDOCR METAB, V66, P1171, DOI 10.1210/jcem-66-6-1171; GEORGE DL, 1981, HUM GENET, V57, P138; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMER D H, 1982, Journal of Molecular and Applied Genetics, V1, P273; HIRT H, 1987, DNA-J MOLEC CELL BIO, V6, P59, DOI 10.1089/dna.1987.6.59; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEMAIGRE FP, 1989, DNA-J MOLEC CELL BIO, V8, P149, DOI 10.1089/dna.1.1989.8.149; Lewis U J, 1980, Recent Prog Horm Res, V36, P477; LIEBHABER SA, 1986, J BIOL CHEM, V261, P14301; LIEBHABER SA, 1985, J CLIN INVEST, V76, P1057, DOI 10.1172/JCI112058; LIEBHABER SA, 1989, J CLIN INVEST, V83, P1985, DOI 10.1172/JCI114108; LIEBHABER SA, 1980, P NATL ACAD SCI-BIOL, V77, P7054, DOI 10.1073/pnas.77.12.7054; LIEBHABER SA, 1986, J BIOL CHEM, V261, P5327; MCLEOD JF, 1989, J BIOL CHEM, V264, P21760; MCWILLIAMS D, 1977, P NATL ACAD SCI USA, V74, P1024, DOI 10.1073/pnas.74.3.1024; MICHELSON AM, 1980, CELL, V22, P371, DOI 10.1016/0092-8674(80)90347-5; NACHTIGAL MW, 1989, NUCLEIC ACIDS RES, V17, P4327, DOI 10.1093/nar/17.11.4327; NICKEL BE, 1991, ENDOCRINOLOGY, V128, P2353, DOI 10.1210/endo-128-5-2353; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAY J, 1989, ENDOCRINOLOGY, V125, P566, DOI 10.1210/endo-125-1-566; ROGERS BL, 1986, NUCLEIC ACIDS RES, V14, P7647, DOI 10.1093/nar/14.19.7647; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SELBY MJ, 1984, J BIOL CHEM, V259, P3131; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; ULLOAAGUIRRE A, 1987, J CLIN ENDOCR METAB, V64, P1002, DOI 10.1210/jcem-64-5-1002; WALKER WH, 1990, J BIOL CHEM, V265, P12940; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367	47	84	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14219	14226						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378436				2022-12-27	WOS:A1992JD32500067
J	BANO, M; WORLAND, P; KIDWELL, WR; LIPPMAN, ME; DICKSON, RB				BANO, M; WORLAND, P; KIDWELL, WR; LIPPMAN, ME; DICKSON, RB			RECEPTOR-INDUCED PHOSPHORYLATION BY MAMMARY-DERIVED GROWTH FACTOR-I IN MAMMARY EPITHELIAL-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; HUMAN-MILK; PROLIFERATION; PURIFICATION; FIBROBLASTS; SERUM	Previous work has shown that a mammary-derived growth factor (MDGF1), a human milk-derived, acidic, 62-kDa, N-glycosylated growth factor binds to cell surface receptors and stimulates proliferation of mammary epithelial cells. An 18-amino acid N-terminal partial sequence of the factor did not show any homology to other known growth factors or proteins. Using polyclonal antiserum raised against the synthetic peptide, we demonstrated that conditioned medium prepared from human breast cancer cell lines contains the factor. The antibody could adsorb the biological activity of the factor present in the conditioned medium. Earlier experiments on receptor cross-linking indicated that the receptor was approximately 120-140 kDa. Since tyrosine phosphorylation plays a crucial role in cell proliferation and cell transformation, experiments were conducted to find out whether MDGF1 induces the appearance of phosphotyrosine in MDGF1-receptor-positive MDA-MB 468, MCF-7, and 184A1N4 cell lines compared to receptor-negative lines. Western blot analysis using monoclonal antiphosphotyrosine indicated that MDGF1 induces phosphotyrosine in a 180-185-kDa protein in MDGF1 receptor-positive cell lines. Phosphorylation was not blocked and phosphorylated proteins were not immunoprecipitated by an antibody directed against the binding site of the EGF receptor. Cell membrane fractionation demonstrated that phosphorylation induced by MDGF1 was membrane-associated. The nature of this 180-185-kDa protein and its possible relationship to the MDGF1 receptor are under investigation.	GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; CELLCO ADV BIOREACTORS INC,GERMANTOWN,MD 20874	Georgetown University								BANO M, 1992, BIOCHEMISTRY-US, V31, P610, DOI 10.1021/bi00117a044; BANO M, 1990, J BIOL CHEM, V265, P1874; BANO M, 1985, J BIOL CHEM, V260, P5745; BANO M, 1983, J BIOL CHEM, V258, P2729; HOLLENBERG MD, 1979, VITAM HORM, V37, P69; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JAMES R, 1984, ANNU REV BIOCHEM, V53, P259; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; Kidwell W. R., 1985, Human lactation. Milk components and methodologies, P209; KIDWELL WR, 1984, CELL CULTURE METHODS, V2, P105; KIDWELL WR, 1980, CONTROL MECHANISMS A, P333; Klagsbrun M., 1984, Growth Maturation Factors, V2, P161; KLAGSBRUN M, 1980, J CELL BIOL, V84, P808, DOI 10.1083/jcb.84.3.808; KLAGSBRUN M, 1978, P NATL ACAD SCI USA, V75, P5057, DOI 10.1073/pnas.75.10.5057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWKO WM, 1981, CANCER RES, V42, P2855; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SERENI A, 1981, CELL BIOL INT REP, V5, P339, DOI 10.1016/0309-1651(81)90003-5; SHING YW, 1984, CELL CULTURE METHODS, V1, P159; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WICHA MS, 1979, EXP CELL RES, V124, P181, DOI 10.1016/0014-4827(79)90268-4; WICHA MS, 1980, DEV BIOL, V80, P253, DOI 10.1016/0012-1606(80)90402-9; YARDEN Y, 1985, J BIOL CHEM, V260, P315; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10389	10392						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375220				2022-12-27	WOS:A1992HV09000031
J	ZHANG, DE; RABEK, JP; HSIEH, CC; TORRESRAMOS, C; PAPACONSTANTINOU, J				ZHANG, DE; RABEK, JP; HSIEH, CC; TORRESRAMOS, C; PAPACONSTANTINOU, J			FUNCTIONAL-ANALYSIS OF THE MOUSE ALPHA-FETOPROTEIN ENHANCERS AND THEIR SUBFRAGMENTS IN PRIMARY MOUSE HEPATOCYTE CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-BINDING SITES; GENE-EXPRESSION; NUCLEAR FACTOR; ALPHA-1-FETOPROTEIN GENE; IMMUNOGLOBULIN ENHANCER; TRANSCRIPTION FACTOR; ALBUMIN GENES; C/EBP FAMILY; ELEMENTS; LIVER	We have compared the activities of mouse alpha-fetoprotein (AFP) enhancers I, II, and III with their minimal enhancer fragments (Mers) I, II, and III and with the entire 7-kilobase pair enhancer domain by transient expression assay in primary fetal mouse liver cells. The level of expression directed by the AFP promoter [p(-1009)AFPcat] alone is stimulated at least 10-fold by the entire AFP enhancer domain (-1009 to -6983). Enhancer I can drive the level of chloramphenicol acetyltransferase activity equivalent to that of the entire enhancer domain, whereas the increase in activity by enhancers II and III is significantly lower (1.5-fold). MersI, II, and III all mediate a greater increase in activity than their corresponding enhancer regions. The increase with MerI is 16-fold. Using DNase I protection analyses we identified 3 protein-binding regions in MerI; site Ia binds liver and brain nuclear proteins; site Ib binds liver, kidney, and brain nuclear proteins as well as purified C/EBP; site Ic binds liver and kidney nuclear proteins. Site-specific mutation of Ia, Ib, or Ic showed a 10-25% reduction in chloramphenicol acetyltransferase expression; deletion of the C/EBP-binding site in Ib showed a 45% reduction in activity and mutation of all 3 sites (Ia, Ib, and Ic) resulted in a 75% reduction in activity. Our studies indicate no single trans-acting factor is absolutely essential for enhancer activity, and that the enhancer activity of Merl is mediated via a combinatorial and additive mechanism.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston			Papaconstantinou, John/E-3312-2010		NATIONAL CANCER INSTITUTE [R01CA031472] Funding Source: NIH RePORTER; NCI NIH HHS [CA31472] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, BIOCHEMISTRY-US, V31, P1928, DOI 10.1021/bi00122a005; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GODBOUT R, 1986, MOL CELL BIOL, V6, P477, DOI 10.1128/MCB.6.2.477; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; KADESCH T, 1986, NUCLEIC ACIDS RES, V14, P8209, DOI 10.1093/nar/14.20.8209; KRUMLAUF R, 1985, MOL CELL BIOL, V5, P1639, DOI 10.1128/MCB.5.7.1639; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MOLNE M, 1989, NUCLEIC ACIDS RES, V17, P3447, DOI 10.1093/nar/17.9.3447; POLIARD A, 1990, J BIOL CHEM, V265, P2137; RABEK JP, 1992, IN PRESS BOCH BIOPHY; Sambrook J, 1989, MOL CLONING LABORATO; SAWADAISHI K, 1988, MOL CELL BIOL, V8, P5179, DOI 10.1128/MCB.8.12.5179; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; WIDEN SG, 1986, P NATL ACAD SCI USA, V83, P8196, DOI 10.1073/pnas.83.21.8196; XANTHOPOULOS KG, 1989, P NATL ACAD SCI USA, V86, P4117, DOI 10.1073/pnas.86.11.4117; ZHANG DE, 1990, J BIOL CHEM, V265, P3382; ZHANG DE, 1991, J BIOL CHEM, V266, P21179; ZHANG DE, 1990, J CELL BIOL, V11, pA121	39	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10676	10682						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375227				2022-12-27	WOS:A1992HV09000071
J	SILVERMAN, TA; NOGUCHI, M; SAFER, B				SILVERMAN, TA; NOGUCHI, M; SAFER, B			ROLE OF SEQUENCES WITHIN THE 1ST INTRON IN THE REGULATION OF EXPRESSION OF EUKARYOTIC INITIATION FACTOR-2-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIREFLY LUCIFERASE; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MAMMALIAN-CELLS; TRANSCRIPTION; DNA; IDENTIFICATION; LYMPHOCYTES; ACTIVATION; PROMOTER	Resting human peripheral blood T cells synthesize proteins at very low rates and contain very low levels of eukaryotic initiation factor (eIF) 2-alpha mRNA. Daring mitogenic activation, the level of eIF-2-alpha mRNA increases at least 50-fold, an effect thought to be due primarily to intranuclear stabilization of the primary transcript (Cohen, R. B., Boal, T. R., and Safer, B. (1990) EMBO J. 9, 3831-3837). Analysis of sequences within the first intron revealed a region with homology to the "initiator" (Inr) sequence first described by Smale and Baltimore (Smale, S. T., and Baltimore, D. (1989) Cell 57, 103-113). This Inr element is positioned 450 bases downstream of the eIF-2-alpha promoter and is oriented to generate an overlapping antisense transcript. Deletion or mutation of the Inr element results in a reproducible 5-8-fold increase in the activity of an eIF-2-alpha promoter-driven CAT reporter gene and a corresponding 2.5-fold decrease in activity of an antisense driven luciferase reporter gene in vivo in 293 cells. In vitro transcription analysis also reveals antisense transcripts which depend on an intact Inr element and whose 5' ends map to sequences surrounding the Inr consensus sequence. A potential role for double-stranded RNA generated by these overlapping divergent transcription units in the regulation of eIF-2-alpha gene expression in T cells is suggested.	NHLBI,PROT & RNA BIOSYNTH SECT,MOLEC HEMATOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								AHERN T, 1975, EXP CELL RES, V92, P513, DOI 10.1016/0014-4827(75)90410-3; ASHMAN RF, 1984, FUNDAMENTAL IMMUNOLO, P267; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BOAL TR, 1991, THESIS G WASHINGTON; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; COOPER HL, 1977, J CELL PHYSIOL, V93, P213, DOI 10.1002/jcp.1040930207; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUANG S, 1989, MOL CELL BIOL, V9, P3679, DOI 10.1128/MCB.9.9.3679; HUMBELIN M, 1989, GENE AMST, V8, P315; JACOB WF, 1989, J BIOL CHEM, V264, P20372; KAY JE, 1971, BIOCHIM BIOPHYS ACTA, V247, P322, DOI 10.1016/0005-2787(71)90680-0; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; Sambrook J, 1989, MOL CLONING LABORATO; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; UDEY MC, 1981, J IMMUNOL, V126, P1106; WETTENHALL REH, 1979, BIOCHIM BIOPHYS ACTA, V432, P312; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; [No title captured]	27	37	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9738	9742						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374407				2022-12-27	WOS:A1992HT96500047
J	BERNARDI, P				BERNARDI, P			MODULATION OF THE MITOCHONDRIAL CYCLOSPORINE-A-SENSITIVE PERMEABILITY TRANSITION PORE BY THE PROTON ELECTROCHEMICAL GRADIENT - EVIDENCE THAT THE PORE CAN BE OPENED BY MEMBRANE DEPOLARIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; OXIDATIVE STRESS; HEART-MITOCHONDRIA; INNER MEMBRANE; CA-2+-DEPENDENT PORE; RUTHENIUM RED; CALCIUM; PHOSPHOLIPASE-A2; PURIFICATION; INHIBITION	This paper reports an investigation on the relationship between the proton electrochemical gradient (DELTA-mu(H+)) and the cyclosporin A-sensitive permeability transition pore (PTP) in rat liver mitochondria. Using the SH group cross-linker phenylarsine oxide as the inducer, we show that both matrix pH and the membrane potential can modulate the process of PTP induction independently of Ca2+. We find that membrane depolarization induces the PTP per se when pH(i) is above 7.0, while at acidic matrix pH values PTP induction is effectively prevented. Since Ca2+ uptake leads to major modifications of the DELTA-mu(H+) (i.e. matrix alkalinization and membrane depolarization), we have explored the possibility that the Ca2+-induced changes of the DELTA-mu(H+) may contribute to PTP induction by Ca2+. Our data in mitochondria treated with Ca2+ plus N-ethylmaleimide and Ca2+ plus phosphate show that membrane depolarization is a powerful inducer of the PTP. Taken together, our observations indicate that the PTP can be controlled directly by the DELTA-mu(H+) both in the absence and presence of Ca2+, and suggest that a collapse of the membrane potential may be the cause rather than the consequence of PTP induction under many experimental conditions. Thus, many inducers may converge on dissipation of the membrane potential component of the DELTA-mu(H+) by a variety of mechanisms.	UNIV PADUA, INST GEN PATHOL, BIOPHYS & MEMBRANE BIOL, I-35121 PADUA, ITALY	University of Padua	BERNARDI, P (corresponding author), UNIV PADUA, SCH MED, CNR, STUDY PHYSIOL MITOCHONDRIA UNIT, VIA TRIESTE 75, I-35121 PADUA, ITALY.		Bernardi, Paolo/C-3656-2008	Bernardi, Paolo/0000-0001-9187-3736				ALNASSER I, 1986, BIOCHEM J, V239, P19, DOI 10.1042/bj2390019; AZZONE GF, 1984, CURR TOP BIOENERG, V13, P1; BEATRICE MC, 1980, J BIOL CHEM, V255, P8663; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1983, BIOCHIM BIOPHYS ACTA, V724, P212, DOI 10.1016/0005-2728(83)90140-8; BERNARDI P, 1992, MECHANICS SWELLING C; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V936, P139, DOI 10.1016/0005-2728(88)90261-7; CHAVEZ E, 1988, J BIOL CHEM, V263, P3582; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; FLETCHER JM, 1961, J CHEM SOC, P2000, DOI 10.1039/jr9610002000; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Garlid K.D., 1988, INTEGRATION MITOCHON, P259; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; HUNTER FE, 1955, J BIOL CHEM, V216, P357; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; LEQUOC K, 1982, ARCH BIOCHEM BIOPHYS, V216, P639, DOI 10.1016/0003-9861(82)90254-5; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23, DOI 10.1016/0005-2728(72)90094-1; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; NOVGORODOV SA, 1987, J BIOENERG BIOMEMBR, V19, P191, DOI 10.1007/BF00762412; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; Siliprandi N, 1978, FUNCTIONS GLUTATHION, P139; STONER HB, 1973, J PHYSIOL-LONDON, V232, P285, DOI 10.1113/jphysiol.1973.sp010270; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; WAITE M, 1971, BIOCHEMISTRY-US, V10, P2377, DOI 10.1021/bi00788a031; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004; ZURINI M, 1981, EUR J BIOCHEM, V119, P517, DOI 10.1111/j.1432-1033.1981.tb05638.x	42	397	406	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8834	8839						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374381				2022-12-27	WOS:A1992HR85400023
J	CHAN, BMC; ELICES, MJ; MURPHY, E; HEMLER, ME				CHAN, BMC; ELICES, MJ; MURPHY, E; HEMLER, ME			ADHESION TO VASCULAR CELL-ADHESION MOLECULE-1 AND FIBRONECTIN - COMPARISON OF ALPHA-4-BETA-1 (VLA-4) AND ALPHA-4-BETA-7 ON THE HUMAN B-CELL LINE JY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; INTESTINAL LYMPHOCYTES; PLASMA FIBRONECTIN; INTEGRIN VLA-4; BINDING-SITE; BETA-SUBUNIT; T-CELLS; RECEPTOR; ATTACHMENT; IDENTIFICATION	Most mononuclear leukocytes and cell lines express the integrin alpha-4-beta-1 (VLA-4) heterodimer. In this study we have used Northern blotting and immunoprecipitation experiments to demonstrate that a B lymphoblastoid cell line (JY) expressed the integrin beta-7 subunit in association with alpha-4. These alpha-4-beta-7-positive JY cells bound poorly or not at all to VLA-4 ligands (soluble form of vascular cell adhesion molecule 1 (sVCAM-1) and the CS1 region of fibronectin). In contrast, a beta-1-positive variant of JY cells (selected to express a mixture of alpha-4-beta-1 and alpha-4-beta-7) bound avidly to VLA-4 ligands, and this binding was completely inhibitable by anti-alpha-4 and anti-beta-1 monoclonal antibodies. Thus, beta-1 expression appears to be a critically important component of VLA-4-mediated binding to its ligands. After either JY or JY-beta-1 cells were stimulated for 15 min with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate, the majority of adhesion to VCAM or fibronectin remained alpha-4- and beta-1-dependent, but a low amount of adhesion to sVCAM-1 or fibronectin became alpha-4-dependent, beta-1-independent, thus suggesting a role for alpha-4-beta-7. In summary, we have found (i) that alpha-4-beta-7 makes little or no contribution to fibronectin or VCAM-1 binding on unstimulated JY cells, (ii) that alpha-4-beta-7 perhaps makes a minor contribution to ligand binding on 12-O-tetradecanoylphorbol-13-acetate-stimulated cells, and (iii) that alpha-4-beta-1 is the functionally dominant VCAM-1 and fibronectin receptor even when expressed in relatively low amounts compared to alpha-4-beta-7.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42368] Funding Source: Medline; NIGMS NIH HHS [GM-38903] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALLAVENA P, 1991, J EXP MED, V173, P439, DOI 10.1084/jem.173.2.439; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BODARY SC, 1989, J BIOL CHEM, V264, P18859; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CERFBENSUSSAN N, 1986, J IMMUNOL, V136, P76; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GARCIAPARDO A, 1987, BIOCHEM J, V241, P923, DOI 10.1042/bj2410923; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1982, J IMMUNOL, V129, P2734; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HOLZMANN B, 1989, IMMUNOL REV, V108, P45, DOI 10.1111/j.1600-065X.1989.tb00012.x; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P109; KILSHAW PJ, 1990, EUR J IMMUNOL, V20, P2201, DOI 10.1002/eji.1830201008; KISHIMOTO TK, 1987, CELL, V50, P193, DOI 10.1016/0092-8674(87)90215-7; KOOPMAN G, 1991, J EXP MED, V173, P1297, DOI 10.1084/jem.173.6.1297; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; LOBB R, 1991, BIOCHEM BIOPH RES CO, V178, P1498, DOI 10.1016/0006-291X(91)91063-I; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; OTOOLE TE, 1989, BLOOD, V74, P14; PARKER CM, 1992, IN PRESS P NATL ACAD; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SCHIEFERDECKER HL, 1990, J IMMUNOL, V144, P2541; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SPRINGER TA, 1984, J EXP MED, V160, P1901, DOI 10.1084/jem.160.6.1901; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; WALSH GM, 1991, J IMMUNOL, V146, P3419; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097; YUAN Q, 1991, BIOCHEM BIOPH RES CO, V176, P1443, DOI 10.1016/0006-291X(91)90448-G	59	244	248	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8366	8370						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373725				2022-12-27	WOS:A1992HQ18500064
J	LEE, S; FRANCOEUR, AM; LIU, S; WANG, E				LEE, S; FRANCOEUR, AM; LIU, S; WANG, E			TISSUE-SPECIFIC EXPRESSION IN MAMMALIAN BRAIN, HEART, AND MUSCLE OF S1, A MEMBER OF THE ELONGATION FACTOR-1-ALPHA GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 1-ALPHA EF-1-ALPHA; 2 GENES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; CHROMOSOMAL GENE; BINDING PROTEIN; FACTOR-I; XENOPUS; YEAST; TRANSCRIPT	Elongation factor-1 alpha (EF-1alpha) is an ubiquitous protein that functions in peptide elongation during mRNA translation. We previously reported the isolation of a rat S1 protein that is antigenically related to statin, a nonproliferation-specific protein; this S1 gene shares a high degree of homology to EF-1alpha. We constructed specific riboprobes to the two genes, based on the difference in the 3' noncoding regions of both S1 and EF-1alpha mRNAs. Northern analysis and RNase protection assays have revealed that S1 mRNA is present only in brain, heart, and muscle, while EF-1alpha mRNA has been detected in all tissues surveyed so far. The same tissue specificity has been observed in mouse, suggesting that S1 expression is conserved between these two mammalian species. S1 transcript was detected in late brain embryogenesis (day 20), but in lower amounts than in 3-month-old adult brain. We show that the relative levels of both S1 and EF-1alpha transcripts and their respective tissue abundances remain unchanged during the aging process. The function of S1 is not yet known; but these results suggest that it may be involved in specific control mechanisms for protein synthesis in tissues where cells (i.e. neurons and myocytes) are permanently locked in a state of nonproliferation.	MCGILL UNIV,JEWISH GEN HOSP,LADY DAVIS INST MED RES,BLOOMFIELD CTR RES AGING,MONTREAL H3T 1E2,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,DEPT ANAT,MONTREAL H3A 2T5,QUEBEC,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University					NIA NIH HHS [AG 07444] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG007444, R01AG007444] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANN DK, 1992, J BIOL CHEM, V267, P699; ANN DK, 1991, J BIOL CHEM, V266, P10429; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; CAVALLIUS J, 1989, T AGING RES, V13, P125; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPARD NJ, 1991, J CELL BIOL, V112, P237, DOI 10.1083/jcb.112.2.237; DEVER TE, 1989, J BIOL CHEM, V264, P20518; DJE MK, 1990, NUCLEIC ACIDS RES, V18, P3489, DOI 10.1093/nar/18.12.3489; GIORDANO T, 1989, EXP GERONTOL, V24, P501, DOI 10.1016/0531-5565(89)90056-9; GREENBERG JR, 1987, FEBS LETT, V224, P54, DOI 10.1016/0014-5793(87)80421-0; HAYASHI Y, 1989, J BIOCHEM-TOKYO, V106, P560, DOI 10.1093/oxfordjournals.jbchem.a122895; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVEMANN B, 1988, NUCLEIC ACIDS RES, V16, P3175, DOI 10.1093/nar/16.8.3175; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LU X, 1989, Nucleic Acids Research, V17, P442, DOI 10.1093/nar/17.1.442; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; OHTA K, 1990, J BIOL CHEM, V265, P3240; RATTAN SIS, 1991, MUTAT RES, V256, P115, DOI 10.1016/0921-8734(91)90005-V; RATTAN SIS, 1986, C INSERM, V147, P135; Sambrook J, 1989, MOL CLONING LABORATO; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SONG JM, 1989, MOL CELL BIOL, V9, P4571, DOI 10.1128/MCB.9.10.4571; SUNDSTROM P, 1990, J BACTERIOL, V172, P2036, DOI 10.1128/jb.172.4.2036-2045.1990; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VANHEMERT FJ, 1984, EMBO J, V3, P1109, DOI 10.1002/j.1460-2075.1984.tb01937.x; WALLDORF U, 1985, P NATL ACAD SCI USA, V82, P5795, DOI 10.1073/pnas.82.17.5795; WEBSTER GC, 1985, MOL BIOL AGING GENE, P263; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	29	103	107	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24064	24068						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385435				2022-12-27	WOS:A1992JZ23900095
J	GROVES, JD; TANNER, MJA				GROVES, JD; TANNER, MJA			GLYCOPHORIN-A FACILITATES THE EXPRESSION OF HUMAN BAND-3-MEDIATED ANION TRANSPORT IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; AMINO-ACID SEQUENCE; RED-CELL MEMBRANE; EXCHANGE PROTEIN; SIALOGLYCOPROTEIN-ALPHA; MONOCLONAL-ANTIBODIES; MESSENGER-RNAS; BAND-3 PROTEIN; CDNA SEQUENCE; WRB-ANTIGEN	The effects of human red cell glycophorin A (GPA) on the expression of the human erythrocyte anion transporter (band 3, AE1) has been examined in Xenopus oocytes. The coexpression of GPA with band 3 increased stilbene disulfonate-sensitive chloride transport into the oocytes. The effect of GPA was particularly noticeable at low band 3 concentrations and less marked at high band 3 cRNA concentrations. The enhancement of chloride transport was specific to GPA and was not observed when either glycophorin B or glycophorin C was coexpressed with band 3. Immunoprecipitations of whole oocyte homogenates showed the amount of band 3 synthesized was not affected by GPA at subsaturating cRNA concentrations. More band 3 was detected at the oocyte surface by immunoprecipitation when GPA was also expressed. Chymotrypsin treatment of intact oocytes was also used to assess surface band 3 and greater cleavage of band 3 by chymotrypsin was observed when GPA was present. Band 3 synthesis and assembly into canine pancreatic microsomes in the reticulocyte cell-free translation system was not altered by cotranslation of GPA. We suggest that GPA facilitates the translocation of band 3 to the plasma membrane at some point during band 3 biosynthesis in Xenopus oocytes. However, GPA is not essential for the expression of band 3 in red cells, since GPA-deficient individuals have apparently normal levels of band 3. Other GPA-independent mechanisms must also allow translocation of band 3 to the surface membrane in erythroid cells and oocytes. GPA may affect the rate of accumulation of band 3 at the cell surface, rather than the final level in the plasma membrane.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol								ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; ANSTEE DJ, 1986, BRIT J HAEMATOL, V64, P211, DOI 10.1111/j.1365-2141.1986.tb04113.x; ANSTEE DJ, 1982, MEMBRANES TRANSPORT, V2, P427; Ausubel FM, 1991, CURRENT PROTOCOLS MO, V1; BARTEL D, 1989, EMBO J, V4, P1927; BERGER SL, 1987, METHOD ENZYMOL, V152, P227; BLANCHARD D, 1987, J BIOL CHEM, V262, P5808; BULLER AL, 1990, J MEMBRANE BIOL, V115, P179, DOI 10.1007/BF01869456; CASEY JR, 1991, J BIOL CHEM, V266, P15726; COLIN Y, 1986, J BIOL CHEM, V261, P229; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COX JV, 1987, J CELL BIOL, V105, P1405, DOI 10.1083/jcb.105.3.1405; DAHR W, 1986, BIOL CHEM H-S, V367, P1033, DOI 10.1515/bchm3.1986.367.2.1033; DAHR W, 1975, J IMMUNOGENET, V2, P249; DAHR W, 1986, RECENT ADV BLOOD GRO, P23; GAHMBERG CG, 1976, J BIOL CHEM, V251, P6108; GARCIA AM, 1989, J BIOL CHEM, V264, P19607; HIGH S, 1987, BIOCHEM J, V243, P277, DOI 10.1042/bj2430277; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; KIM HRC, 1988, MOL CELL BIOL, V8, P4416, DOI 10.1128/MCB.8.10.4416; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOURY MJ, 1987, J CELL PHYSIOL, V133, P438, DOI 10.1002/jcp.1041330304; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1989, ANNU REV CELL BIOL, V5, P427; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MARCHESI VT, 1976, ANNU REV BIOCHEM, V45, P667, DOI 10.1146/annurev.bi.45.070176.003315; MARTON LSG, 1973, BIOCHEM BIOPH RES CO, V52, P1457, DOI 10.1016/0006-291X(73)90664-5; MAWBY WJ, 1982, BIOCHEM J, V205, P465, DOI 10.1042/bj2050465; MERRY AH, 1986, BIOCHEM J, V233, P93, DOI 10.1042/bj2330093; MORGAN M, 1985, EMBO J, V4, P1927, DOI 10.1002/j.1460-2075.1985.tb03872.x; NIGG EA, 1980, BIOCHEMISTRY-US, V19, P1887, DOI 10.1021/bi00550a024; OKUBO K, 1991, J BIOL CHEM, V266, P16420; RIDGWELL K, 1983, BIOCHEM J, V209, P273, DOI 10.1042/bj2090273; SCHEELE G, 1980, J CELL BIOL, V87, P611, DOI 10.1083/jcb.87.3.611; SIEBERT PD, 1987, P NATL ACAD SCI USA, V84, P6735, DOI 10.1073/pnas.84.19.6735; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TANNER MJA, 1976, BIOCHEM J, V155, P701, DOI 10.1042/bj1550701; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TANNER MJA, 1976, BIOCHEM J, V153, P271, DOI 10.1042/bj1530271; TATE CG, 1988, BIOCHEM J, V254, P743, DOI 10.1042/bj2540743; TELEN MJ, 1990, BLOOD, V76, P842; TOKUNAGA E, 1979, J IMMUNOGENET, V6, P383; TOMITA M, 1975, P NATL ACAD SCI USA, V72, P2964, DOI 10.1073/pnas.72.8.2964; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211; YANNOUKAKOS D, 1991, BLOOD, V78, P1117	49	151	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22163	22170						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385395				2022-12-27	WOS:A1992JW71900029
J	BLOMQUIST, JF; BAENZIGER, JU				BLOMQUIST, JF; BAENZIGER, JU			DIFFERENTIAL SORTING OF LUTROPIN AND THE FREE ALPHA-SUBUNIT IN CULTURED BOVINE PITUITARY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; GONADOTROPIN-RELEASING HORMONE; HAMSTER OVARY CELLS; FOLLICLE-STIMULATING-HORMONE; GLYCOPROTEIN HORMONES; LUTEINIZING-HORMONE; SIALYLATED OLIGOSACCHARIDES; STRUCTURAL ELUCIDATION; SECRETION; THYROTROPIN	The glycoprotein hormones lutropin (LH) and follitropin (FSH) are both synthesized by gonadotrophs in the anterior pituitary but are stored in separate secretory granules prior to secretion. Despite having highly homologous beta-subunits and alpha-subunits with the identical amino acid sequence, the Asn-linked oligosaccharides on LH terminate with SO4-GalNAc while those on FSH terminate with sialic acid-Gal. In addition to LH and FSH, gonadotrophs secrete uncombined (free) alpha-subunit which bears the same sulfated oligosaccharides as LH. We have examined the synthesis and secretion of LH and free alpha-subunit in primary cultures of bovine pituitary cells in order to determine if the sulfated oligosaccharides have any impact on sorting. Our results show that newly synthesized free alpha-subunit is secreted exclusively via the constitutive pathway with a t1/2 of 1.8 h and is never found in dense-core secretory granules. In contrast, LH dimer is secreted by both the constitutive and the regulated pathways. Constitutive secretion and arrival in a dense secretory granule both occur with t1/2 values of 1-1.5 h for newly synthesized LH. Sulfation occurs immediately prior to arrival of LH in the secretory granule and is followed by a period of 1-1.5 h before the LH-containing granules become sensitive to release by gonadotropin releasing hormone. As a result the t1/2 for LH secretion in the presence of gonadotropin releasing hormone is 3.5 h. Sulfation of the free alpha-subunit oligosaccharides is not, therefore, sufficient to direct the alpha-subunit to secretory granules, and the information required for directing LH to granules must reside either in the beta-subunit or the alphabeta-complex.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Baenziger, Jacques U/E-9430-2012		NIDDK NIH HHS [R01-DK41738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; CLAYTON RN, 1989, J ENDOCRINOL, V120, P11, DOI 10.1677/joe.0.1200011; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; CORLESS CL, 1985, ENDOCRINOLOGY, V117, P1699, DOI 10.1210/endo-117-4-1699; DACHEUX F, 1976, CELL TISSUE RES, V174, P245, DOI 10.1007/BF00222162; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; INOUE K, 1984, CELL TISSUE RES, V235, P77; KAETZEL DM, 1988, J BIOL CHEM, V263, P6344; KEENE JL, 1989, J BIOL CHEM, V264, P4769; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P95, DOI 10.1210/mend-2-2-95; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Rennels E G, 1980, Int Rev Physiol, V22, P1; SCHALLY AV, 1971, SCIENCE, V173, P1036, DOI 10.1126/science.173.4001.1036; STANNARD BS, 1988, J BIOL CHEM, V263, P8309; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; WEISS J, 1990, ENDOCRINOLOGY, V127, P2364, DOI 10.1210/endo-127-5-2364; WHITCOMB RW, 1990, J CLIN ENDOCR METAB, V70, P1654, DOI 10.1210/jcem-70-6-1654; WINTERS SJ, 1985, J CLIN ENDOCR METAB, V60, P344, DOI 10.1210/jcem-60-2-344; YING SY, 1988, ENDOCR REV, V9, P267, DOI 10.1210/edrv-9-2-267	26	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20798	20803						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383211				2022-12-27	WOS:A1992JT97800046
J	BRADFORD, PG; WANG, XH; JIN, YY; HUI, P				BRADFORD, PG; WANG, XH; JIN, YY; HUI, P			TRANSCRIPTIONAL REGULATION AND INCREASED FUNCTIONAL EXPRESSION OF THE INOSITOL TRISPHOSPHATE RECEPTOR IN RETINOIC ACID-TREATED HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; HUMAN-NEUTROPHILS; NUCLEOTIDE-SEQUENCE; FREE CALCIUM; BETA-ACTIN; DIFFERENTIATION; 1,4,5-TRISPHOSPHATE; PROTEIN; CDNA; INDUCTION	The inositol trisphosphate (InsP3) receptor is an essential regulator of intracellular calcium in many cells including chemoattractant- and cytokine-stimulated neutrophils and differentiated promyelocytic leukemic (HL-60) cells. We examined the expression and function of the InsP3 receptor and the transcriptional regulation of the InsP3 receptor gene in HL-60 cells and in HL-60 cells treated for 1-5 days with 1 muM retinoic acid. Radioligand binding studies using membranes from control and retinoic acid-treated HL-60 cells showed that the B(max) of InsP3 receptor increased progressively from 0.24 to 0.69 pmol/mg protein during 5 days retinoic acid treatment with no change in K(D) (19 nM). During this period, maximal InsP3-stimulated Ca2+ mobilization increased 2-3-fold. InsP3 receptor mRNA was present at low levels in HL-60 cells but was increased significantly after treatment with retinoic acid, reaching maximal levels of approximately 4-fold greater than untreated cells after 4 days treatment with retinoic acid. Nuclear run-on assays indicated that the elevated steady state level of InsP3 receptor mRNA in retinoic acid-treated HL-60 cells was primarily the result of enhanced transcription of the InsP3 receptor gene. Furthermore, the transcriptional enhancing effect of retinoic acid was seen in the presence of cycloheximide, suggesting that the InsP3 receptor gene is directly regulated by retinoic acid. The studies also demonstrate that the InsP3 receptor mRNA is rapidly degraded in HL-60 cells by a mechanism that also requires protein synthesis.			BRADFORD, PG (corresponding author), SUNY BUFFALO,DEPT PHARMACOL & THERAPEUT,BUFFALO,NY 14214, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039588] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39588] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD PG, 1985, MOL PHARMACOL, V27, P74; BRADFORD PG, 1986, J BIOL CHEM, V261, P5644; BRADFORD PG, 1991, BIOCHEM J, V280, P205, DOI 10.1042/bj2800205; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASTAIGNE S, 1990, BLOOD, V76, P1704; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; COLLINS SJ, 1987, BLOOD, V70, P1233; DOUGHERTY RW, 1984, BIOCHEM J, V222, P307, DOI 10.1042/bj2220307; FURUICHI T, 1989, NUCLEIC ACIDS RES, V17, P5385, DOI 10.1093/nar/17.13.5385; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HICKSTEIN DD, 1988, J BIOL CHEM, V263, P13863; HICKSTEIN DD, 1989, J BIOL CHEM, V264, P21812; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NIEDEL J, 1980, P NATL ACAD SCI-BIOL, V77, P1000, DOI 10.1073/pnas.77.2.1000; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ EL, 1988, CANCER RES, V48, P2683; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SMOLEN JE, 1985, J IMMUNOL, V134, P1859; SMOLEN JE, 1990, HEMATOLOGY, P780; SPAT A, 1986, NATURE, V319, P514, DOI 10.1038/319514a0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WHITE JR, 1983, BIOCHEM BIOPH RES CO, V113, P44, DOI 10.1016/0006-291X(83)90429-1; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077	34	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20959	20964						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383213				2022-12-27	WOS:A1992JT97800071
J	MONIA, BP; JOHNSTON, JF; ECKER, DJ; ZOUNES, MA; LIMA, WF; FREIER, SM				MONIA, BP; JOHNSTON, JF; ECKER, DJ; ZOUNES, MA; LIMA, WF; FREIER, SM			SELECTIVE-INHIBITION OF MUTANT HA-RAS MESSENGER-RNA EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER-CARCINOMA ONCOGENE; PRECURSOR PROTEIN GENE; DOUBLE-HELIX FORMATION; ALZHEIMERS-DISEASE; POINT MUTATION; STRUCTURAL FEATURES; GTPASE ACTIVITY; P21 EXPRESSION; HUMAN CANCER; ANTI-SENSE	A biological reporter gene assay was employed to determine the crucial parameters for maximizing selective targeting of a Ha-ras codon 12 point mutation (G --> T) using phosphorothioate antisense oligonucleotides. We have tested a series of oligonucleotides ranging in length between 5 and 25 bases, each centered around the codon 12 point mutation. Our results indicate that selective targeting of this point mutation can be achieved with phosphorothioate antisense oligonucleotides, but this selectivity is critically dependent upon oligonucleotide length and concentration. The maximum selectivity observed in antisense experiments, 5-fold for a 17-base oligonucleotide, was closely predicted by a simple thermodynamic model that relates the fraction of mutant to wild type target bound as a function of oligonucleotide concentration and affinity. These results suggest thermodynamic analysis of oligonucleotide/target interactions is useful in predicting the specificity that can be achieved by an antisense oligonucleotide targeted to a single base point mutation.	ISIS PHARMACEUT, DEPT MED CHEM, CARLSBAD, CA 92008 USA	Isis Pharmaceuticals Inc	MONIA, BP (corresponding author), ISIS PHARMACEUT, DEPT MOLEC & CELLULAR BIOL, 2280 FARADAY AVE, CARLSBAD, CA 92008 USA.			Ecker, David/0000-0003-4350-9037				ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BAVISOTTO L, 1991, J EXP MED, V174, P1097, DOI 10.1084/jem.174.5.1097; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BORER PN, 1974, J MOL BIOL, V86, P843, DOI 10.1016/0022-2836(74)90357-X; BOS JL, 1989, CANCER RES, V49, P4682; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BROWN D, 1989, ONCOGENE RES, V4, P243; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CARTWRIGHT T, 1992, CHIMICAOGGI, V32, P26; CHANG EH, 1989, ANTI-CANCER DRUG DES, V4, P221; CHANG EH, 1991, BIOCHEMISTRY-US, V30, P8283, DOI 10.1021/bi00098a001; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DAAKA Y, 1990, ONCOGENE RES, V5, P267; DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOLNICK BJ, 1990, BIOCHEM PHARMACOL, V40, P671, DOI 10.1016/0006-2952(90)90300-A; FREIER SM, 1985, BIOCHEMISTRY-US, V24, P4533, DOI 10.1021/bi00338a008; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILES RV, 1992, ANTI-CANCER DRUG DES, V7, P37; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAUSEN P, 1970, EUR J BIOCHEM, V14, P278, DOI 10.1111/j.1432-1033.1970.tb00287.x; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HELENE C, 1989, OLIGODEOXYNUCLEOTIDE, P137; HOKE GD, 1991, NUCLEIC ACIDS RES, V19, P5743, DOI 10.1093/nar/19.20.5743; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEVY Y, 1991, J CLIN INVEST, V88, P696, DOI 10.1172/JCI115355; MAHER LJ, 1988, NUCLEIC ACIDS RES, V16, P3341, DOI 10.1093/nar/16.8.3341; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MANSON J, 1990, LYMPHOKINE RES, V9, P35; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MORRISON RS, 1991, J BIOL CHEM, V266, P728; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; PETERSHEIM M, 1983, BIOCHEMISTRY-US, V22, P256, DOI 10.1021/bi00271a004; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAISONBEHMOARAS T, 1991, EMBO J, V10, P1111, DOI 10.1002/j.1460-2075.1991.tb08051.x; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1988, CANCER RES, V48, P2659; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TANAKA T, 1992, J EXP MED, V175, P597, DOI 10.1084/jem.175.2.597; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TIDD DM, 1988, ANTI-CANCER DRUG DES, V3, P117; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952; WEINBERG RA, 1988, CANCER-AM CANCER SOC, V61, P1963, DOI 10.1002/1097-0142(19880515)61:10<1963::AID-CNCR2820611005>3.0.CO;2-8; WU T, 1990, J ORG CHEM, V55, P4717, DOI 10.1021/jo00302a044; WU TF, 1989, NUCLEIC ACIDS RES, V17, P3501, DOI 10.1093/nar/17.9.3501; YU Z, 1989, Journal of Experimental Pathology (New York), V4, P97; ZON G, 1988, PHARM RES-DORDR, V5, P539, DOI 10.1023/A:1015985728434	69	240	286	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19954	19962						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400312				2022-12-27	WOS:A1992JR85800036
J	MAZUMDER, S; MUKHERJEE, T; GHOSH, J; RAY, M; BHADURI, A				MAZUMDER, S; MUKHERJEE, T; GHOSH, J; RAY, M; BHADURI, A			ALLOSTERIC MODULATION OF LEISHMANIA-DONOVANI PLASMA-MEMBRANE CA2+-ATPASE BY ENDOGENOUS CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-MEMBRANE; CA-2+-DEPENDENT ATPASE; INTRACELLULAR CALCIUM; TRYPANOSOMA-BRUCEI; PROTEIN; PROMASTIGOTES; CA-2+-ATPASE; PURIFICATION; TRANSPORT; CRUZI	The plasma membrane of the human pathogen Leishmania donovani possesses a high-affinity transmembrane Ca2+-ATPase that has its catalytic site oriented toward the cytoplasmic milieu (Ghosh, J., Ray, M., Sarkar, S., and Bhaduri, A. (1990) J. Biol. Chem. 265, 11345-11351). When the enzyme is studied in its more authentic, physiologically relevant, membrane-associated form, it exhibits pronounced sigmoidal kinetics with Ca2+ (K0.5 almost-equal-to 700 nM) in a trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid buffering system that effectively complexes all available Mg2+. Addition of exogenous Mg2+ (60-mu-m) completely abolishes sigmoidicity and establishes strictly hyperbolic kinetics, and the K(m) for Ca2+ reduces to 100 nM. Mg2+ can be replaced by heterologous calmodulin. The exclusive dependence of the enzyme on only Ca2+ for its activity and its positive allosteric modulation by Mg2+ distinguish this enzyme from other well-characterized plasma membrane Ca2+-ATPases. Employing this Ca2+-ATPase as the assay system, a soluble endogenous activating protein factor was purified that, by several criteria, corresponds to authentic calmodulin. The parasite calmodulin shifts the kinetics to hyperbolic kinetics, increases the V(max) 2-fold, and most important lowers the K(m) (almost-equal-to 100 nm) to a physiological level. The interaction with endogenous calmodulin thus converts the enzyme from a totally inactive to a fully active state.	JADAVPUR UNIV,DEPT PHARM,DIV VIRAL DIS,CALCUTTA 700032,W BENGAL,INDIA	Jadavpur University	MAZUMDER, S (corresponding author), INDIAN INST EXPTL MED,DIV ENZYME,LEISHMANIA GRP,4 RAJA SC MULLICK RD,CALCUTTA 700032,W BENGAL,INDIA.							ALEXANDER J, 1975, J PROTOZOOL, V22, P502, DOI 10.1111/j.1550-7408.1975.tb05219.x; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BENAIM G, 1990, BIOCHIM BIOPHYS ACTA, V1027, P79, DOI 10.1016/0005-2736(90)90051-O; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.physiol.53.1.531; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CHAKRABORTY P, 1988, MOL BIOCHEM PARASIT, V28, P55, DOI 10.1016/0166-6851(88)90180-6; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DWYER DM, 1984, MOL BIOCHEM PARASIT, V10, P139, DOI 10.1016/0166-6851(84)90002-1; GHOSH J, 1990, J BIOL CHEM, V265, P11345; GIETZEN K, 1981, BIOCHEM BIOPH RES CO, V101, P418, DOI 10.1016/0006-291X(81)91276-6; GOMEZ ML, 1989, MOL BIOCHEM PARASIT, V36, P101, DOI 10.1016/0166-6851(89)90182-5; IWASA Y, 1982, FEBS LETT, V142, P67, DOI 10.1016/0014-5793(82)80221-4; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOWRY OH, 1957, METHOD ENZYMOL, V3, P845; Martell A. E., 1971, SPECIAL PUBLICATION, V17; MCLAUGHLIN J, 1985, MOL BIOCHEM PARASIT, V15, P189, DOI 10.1016/0166-6851(85)90119-7; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; ONEAL SG, 1979, BIOCHEM BIOPH RES CO, V89, P845, DOI 10.1016/0006-291X(79)91855-2; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; PHILOSOPH H, 1989, J BIOL CHEM, V264, P10420; RASMUSSEN H, 1977, PHYSIOL REV, V57, P421, DOI 10.1152/physrev.1977.57.3.421; SCARBOROUGH GA, 1975, J BIOL CHEM, V250, P1106; SEEBECK T, 1983, MOL BIOCHEM PARASIT, V9, P197, DOI 10.1016/0166-6851(83)90097-X; SILLEN LG, 1971, SPECIAL PUBLICATION, V25; TELLEZINON MT, 1985, MOL BIOCHEM PARASIT, V17, P143, DOI 10.1016/0166-6851(85)90013-1; TRAVIS SM, 1986, BIOCHIM BIOPHYS ACTA, V862, P39, DOI 10.1016/0005-2736(86)90466-9; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; TUANA BS, 1982, J BIOL CHEM, V257, P4440; VANMAN TC, 1983, METHOD ENZYMOL, V102, P296; VOORHEIS HP, 1982, J BIOL CHEM, V257, P2300; WANG JH, 1977, J BIOL CHEM, V252, P4175; ZILBERSTEIN D, 1988, BIOCHEM J, V256, P13, DOI 10.1042/bj2560013; ZILBERSTEIN D, 1985, P NATL ACAD SCI USA, V82, P1716, DOI 10.1073/pnas.82.6.1716; [No title captured]	38	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18440	18446						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388152				2022-12-27	WOS:A1992JN50200034
J	SHIMAMURA, M; OKU, M; YAMAGATA, T				SHIMAMURA, M; OKU, M; YAMAGATA, T			A NOVEL GANGLIOSIDE EXPRESSED BY MOUSE HEMATOPOIETIC-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; BONE-MARROW CELLS; GRANULOCYTIC DIFFERENTIATION; LYMPHOCYTES-T; GLYCOSPHINGOLIPIDS; THYMOCYTES; SEQUENCE; CERAMIDE; GAMMA; DISIALOGANGLIOSIDE	Mouse progenitor T cell-derived cell lines were established by fusion of cells of hematopoietic organs such as bone marrow and fetal liver with T lymphoma (BW5147) to determine their characteristic cell-surface components. The hybridomas with the phenotype of Thy-1+,CD3-,CD4-,CD8- and expression of T cell receptor gene mRNA (BM216 and FL339) were selected for progenitor T cell-derived cell lines, and their ganglioside compositions were studied. A ganglioside component with a mobility slightly faster than that of bovine brain G(D1a). on high-performance thin-layer chromatography was found in the cell extracts of these cell lines as one of the most abundant components and was absent in the extract of the parental cell line (BW5147). The structure of the ganglioside was determined to be: NeuAc-alpha-Gal-beta-Gal-beta,-Gal-alpha-Gal-beta-Glc-beta-ceramide. Gangliosides with such a sequence have never been found before, suggesting the possibility that the ganglioside is expressed as a surface marker of the cells in hematopoietic organs committed to a specific cell lineage, presumably to T cell lineage.	MITSUBISHI KASEI INST LIFE SCI, GLYCOCONJUGATE RES LAB, MACHIDA, TOKYO 194, JAPAN		SHIMAMURA, M (corresponding author), MITSUBISHI KASEI INST LIFE SCI, MOLEC IMMUNOL LAB, 11 MINAMIOOYA, MACHIDA, TOKYO 194, JAPAN.							AIHARA Y, 1986, EUR J IMMUNOL, V16, P1391, DOI 10.1002/eji.1830161113; AIZAWA S, 1988, P NATL ACAD SCI USA, V85, P3180, DOI 10.1073/pnas.85.9.3180; ARAKAWA M, 1974, J BIOCHEM, V75, P707, DOI 10.1093/oxfordjournals.jbchem.a130443; BARTOSZEWICZ Z, 1986, CARBOHYD RES, V151, P77, DOI 10.1016/S0008-6215(00)90331-8; BECKER DM, 1985, NATURE, V317, P430, DOI 10.1038/317430a0; CALAME K, 1988, ADV IMMUNOL, V43, P235; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DABROWSKI J, 1981, ARCH BIOCHEM BIOPHYS, V210, P405, DOI 10.1016/0003-9861(81)90203-4; DABROWSKI U, 1984, J BIOL CHEM, V259, P7648; EZINE S, 1984, NATURE, V309, P629, DOI 10.1038/309629a0; GASA S, 1983, J LIPID RES, V24, P174; HAKOMORI S, 1986, SCI AM, V254, P44, DOI 10.1038/scientificamerican0586-44; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; ITO K, 1989, P NATL ACAD SCI USA, V86, P631, DOI 10.1073/pnas.86.2.631; ITO M, 1986, J BIOL CHEM, V261, P14278; IWAMORI M, 1990, P JPN C BIOCH LIPIDS, V32, P117; IWAMOTO A, 1986, J EXP MED, V163, P1203, DOI 10.1084/jem.163.5.1203; KNIEP B, 1983, BIOCHEMISTRY-US, V22, P251, DOI 10.1021/bi00271a003; KOEFFLER HP, 1983, BLOOD, V62, P709; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; Maniatis T., 1982, MOL CLONING; MUTHING J, 1987, EUR J BIOCHEM, V163, P407, DOI 10.1111/j.1432-1033.1987.tb10813.x; MUTHING J, 1989, BIOCHEMISTRY-US, V28, P2923; NAKAMURA K, 1991, J BIOCHEM-TOKYO, V110, P832, DOI 10.1093/oxfordjournals.jbchem.a123667; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; NOJIRI H, 1985, CANCER RES, V45, P6100; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; Reinhold V N, 1972, Methods Enzymol, V25, P244, DOI 10.1016/S0076-6879(72)25021-2; SHIMAMURA M, 1988, J BIOL CHEM, V263, P12124; SHIMAMURA M, 1991, FEBS LETT, V290, P213, DOI 10.1016/0014-5793(91)81262-7; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; TAKAGAKI Y, 1989, J IMMUNOL, V142, P2112; TAKI T, 1985, J BIOL CHEM, V260, P6219; TAKI T, 1982, J BIOCHEM-TOKYO, V91, P665, DOI 10.1093/oxfordjournals.jbchem.a133739; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TRENTIN JJ, 1971, AM J PATHOL, V65, P621; WOLF NS, 1979, CLIN HAEMATOL, V8, P469	41	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18810	18813						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388159				2022-12-27	WOS:A1992JN50200085
J	BERNDT, JA; KIM, JG; HUDSON, LD				BERNDT, JA; KIM, JG; HUDSON, LD			IDENTIFICATION OF CIS-REGULATORY ELEMENTS IN THE MYELIN PROTEOLIPID PROTEIN (PLP) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN-SPECIFIC TRANSCRIPTION; BASIC-PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; MAMMALIAN-CELLS; INVITRO TRANSCRIPTION; BINDING-PROTEINS; RAPID ASSAY; GLIAL-CELLS; JC VIRUS; EXPRESSION	Regulatory elements of the proteolipid protein (PLP) gene were identified physically by footprinting and gel mobility shift assays and functionally by transfecting glial cell lines with PLP-chloramphenicol acetyltransferase chimeric genes. In both human and rat glial cells, only several hundred base pairs of upstream sequence were sufficient for high level activity of the human PLP promoter. This region contains five sites that contact nuclear proteins in vitro. More distal recognition sites may exist, as regions upstream of -524 displayed silencing activity indicative of a negative regulatory element. A series of site directed mutations revealed one essential positive element (ATGGA at -118) which is found in other genes encoding myelin proteins. Our combined biochemical and functional analyses indicate that the key cis sites for maximal tissue-specific expression of PLP in cultured glial cells are clustered near the promoter. Within this cluster are several conserved motifs that may coordinate the regulation of myelin-specific genes.	NINCDS, VIRAL & MOLEC PATHOGENESIS LAB, BLDG 36, RM 5D04, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								AMEMIYA K, 1989, J BIOL CHEM, V264, P7025; AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BRITTEN RJ, 1971, Q REV BIOL, V46, P111, DOI 10.1086/406830; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEVINEBEACH K, 1990, J BIOL CHEM, V265, P13830; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EASTMAN A, 1987, BIOTECHNIQUES, V5, P730; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; GARDINIER MV, 1988, J NEUROCHEM, V51, P360; GENCIC S, 1990, J NEUROSCI, V10, P117; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOUT O, 1991, Society for Neuroscience Abstracts, V17, P375; HOLTER W, 1989, EXP CELL RES, V184, P546, DOI 10.1016/0014-4827(89)90353-4; HUDSON LD, 1987, P NATL ACAD SCI USA, V84, P1454, DOI 10.1073/pnas.84.5.1454; HUDSON LD, 1989, P NATL ACAD SCI USA, V86, P8128, DOI 10.1073/pnas.86.20.8128; HUDSON LD, 1990, SEMIN NEUROSCI, V2, P483; Hudson Lynn D., 1992, P677; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KAMHOLZ J, 1988, J NEUROSCI RES, V21, P62, DOI 10.1002/jnr.490210110; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KERR D, 1991, J BIOL CHEM, V266, P15876; KUMAR S, 1989, P NATL ACAD SCI USA, V86, P6807, DOI 10.1073/pnas.86.17.6807; LASHGARI MS, 1990, J CLIN INVEST, V86, P1671, DOI 10.1172/JCI114890; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1990, SEMIN NEUROSCI, V2, P437; LEVINE SM, 1990, DEV NEUROSCI-BASEL, V12, P235, DOI 10.1159/000111853; MACKLIN WB, 1987, J NEUROSCI RES, V18, P383, DOI 10.1002/jnr.490180302; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MATTHIEU J-M, 1991, Journal of Neurochemistry, V57, pS13; MATTHIEU JM, 1990, NEUROL NEUR, V59, P109; MCKINNON RD, 1986, P NATL ACAD SCI USA, V83, P3751, DOI 10.1073/pnas.83.11.3751; MCKINNON RD, 1986, MICROINJECTION ORGAN, P199; MIRKSY R, 1990, SEMIN NEUROSCI, V2, P423; MIURA M, 1989, GENE, V75, P31; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NADON N, 1989, J CELL BIOCH B S, V13, P181; NAVA KA, 1991, J NEUROSCI, V11, P3060; NAVE KA, 1987, P NATL ACAD SCI USA, V84, P5665, DOI 10.1073/pnas.84.16.5665; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Richardson WD, 1990, SEMIN NEUROSCI, V2, P445; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHINDLER P, 1990, J NEUROCHEM, V55, P2079, DOI 10.1111/j.1471-4159.1990.tb05798.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUBERT D, 1986, J NEUROSCI, V6, P2829; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; TAMURA TA, 1989, MOL CELL BIOL, V9, P3122, DOI 10.1128/MCB.9.7.3122; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VERDI JM, 1989, J NEUROCHEM, V52, P321, DOI 10.1111/j.1471-4159.1989.tb10935.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807	55	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14730	14737						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378839				2022-12-27	WOS:A1992JF08800037
J	FRYER, HJL; KELLY, GM; MOLINARO, L; HOCKFIELD, S				FRYER, HJL; KELLY, GM; MOLINARO, L; HOCKFIELD, S			THE HIGH-MOLECULAR-WEIGHT CAT-301 CHONDROITIN SULFATE PROTEOGLYCAN FROM BRAIN IS RELATED TO THE LARGE AGGREGATING PROTEOGLYCAN FROM CARTILAGE, AGGRECAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATERAL GENICULATE-NUCLEUS; MONOCLONAL-ANTIBODY CAT-301; HYALURONATE-BINDING PROTEIN; CENTRAL NERVOUS-SYSTEM; MAMMALIAN CENTRAL NEURONS; CREST CELL-MIGRATION; AMINO-ACID SEQUENCE; KERATAN SULFATE; VISUAL-CORTEX; CORE PROTEIN	Monoclonal antibodies Cat-301 and Cat-304 nize a neuronal cell surface-associated chondroitin sulfate proteoglycan (CSPG), which is expressed during critical periods of postnatal development in the mammalian central nervous system (CNS). In the present study we show that the CNS CSPG identified by Cat-301/304 is similar to aggrecan, the high molecular weight CSPG from cartilage. By Western blot analysis, cartilaginous tissues, which are rich sources of can, have a high concentration of a high mol weight CSPG which is immunoreactive with Cat-301 and 304. The Cat-301 and 304 epitopes, however, are partially masked by chondroitin sulfate glycosaminoglycan and are unmasked by digestion of the antigen with chondroitinase ABC. Although the antigen from both cartilage and CNS can be purified by CsCl buoyant density gradient centrifugation, a standard technique for purifying aggrecan, most of the antigen from the CNS has a lower buoyant density than that of cartilage. This may be due, in part, to the paucity of keratan sulfate substitution on the CNS antigen compared with that of the cartilage antigen. Both the CNs and cartilage antigens bind to hyaluronic acid, a feature characteristic of aggrecan. The physiochemical, biochemical, and functional properties of the Cat-301/304 antigen from cartilage are identical to aggrecan. The CNS antigen is similar, but not identical, to the cartilage antigen, and may thus represent another member of the family of high molecular weight CSPGs which bind to and aggregate with hyaluronic acid.			FRYER, HJL (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510, USA.				NEI NIH HHS [EY06511] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; AQUINO DA, 1984, J CELL BIOL, V99, P1117, DOI 10.1083/jcb.99.3.1117; ATOJI Y, 1990, ACTA ANAT, V139, P151; BERTOLOTTO A, 1990, J NEUROL SCI, V100, P113, DOI 10.1016/0022-510X(90)90021-E; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIGNAMI A, 1986, J NEUROCYTOL, V15, P671, DOI 10.1007/BF01611865; BIGNAMI A, 1986, P NATL ACAD SCI USA, V83, P3518, DOI 10.1073/pnas.83.10.3518; BONDAREFF W, 1967, Z ZELLFORSCH MIK ANA, V81, P366, DOI 10.1007/BF00342761; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARNEY SL, 1988, PHYSIOL REV, V68, P859; CATERSON B, 1983, J BIOL CHEM, V258, P8848; CRAWFORD T, 1988, BIOCHIM BIOPHYS ACTA, V964, P183, DOI 10.1016/0304-4165(88)90165-1; CROSSIN KL, 1990, EXP NEUROL, V109, P6, DOI 10.1016/S0014-4886(05)80004-4; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DEYOE EA, 1990, VISUAL NEUROSCI, V5, P67, DOI 10.1017/S0952523800000080; DOEGE K, 1986, P NATL ACAD SCI USA, V83, P3761, DOI 10.1073/pnas.83.11.3761; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE K, 1990, BIOCHEM SOC T, V18, P200, DOI 10.1042/bst0180200; DOEGE K, 1990, EXTRACELLULAR MATRIX, P137; FRYER H J L, 1990, Society for Neuroscience Abstracts, V16, P496; FUJITA SC, 1989, NEUROSCI RES, V7, P117, DOI 10.1016/0168-0102(89)90052-7; GANONG BR, 1991, ANAL BIOCHEM, V193, P35, DOI 10.1016/0003-2697(91)90039-V; GOWDA DC, 1989, BIOCHEMISTRY-US, V28, P4468, DOI 10.1021/bi00436a052; GUIMARAES A, 1990, J NEUROSCI, V10, P3014; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; HENDRY SHC, 1988, J NEUROSCI, V8, P518; HOCKFIELD S, 1990, J COMP NEUROL, V300, P320, DOI 10.1002/cne.903000305; HOCKFIELD S, 1990, COLD SPRING HARB SYM, V55, P505; HOCKFIELD S, 1983, P NATL ACAD SCI-BIOL, V80, P5758, DOI 10.1073/pnas.80.18.5758; HOCKFIELD S, 1990, P NATL ACAD SCI USA, V87, P3027, DOI 10.1073/pnas.87.8.3027; Hockfield S., 1990, Seminars in Developmental Biology, V1, P55; HOCKFIELD S, 1983, COLD SPRING HARB SYM, V48, P877, DOI 10.1101/SQB.1983.048.01.090; HOCKFIELD S, 1989, NEUROIMMUNE NETWORKS, P57; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; KALB RG, 1990, NEUROSCIENCE, V34, P391, DOI 10.1016/0306-4522(90)90148-W; KALB RG, 1988, J NEUROSCI, V8, P2350; KALB RG, 1990, SCIENCE, V250, P294, DOI 10.1126/science.2145629; KIANG WL, 1981, J BIOL CHEM, V256, P529; KIANG WL, 1978, BIOCHEMISTRY-US, V17, P3841, DOI 10.1021/bi00611a025; KONGTAWELERT P, 1990, ANAL BIOCHEM, V185, P313, DOI 10.1016/0003-2697(90)90300-X; KRUEGER RC, 1990, J BIOL CHEM, V265, P12088; KRUEGER RC, 1987, ANAL BIOCHEM, V167, P295, DOI 10.1016/0003-2697(87)90167-9; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; LACY BE, 1987, J CELL BIOL, V105, P1395, DOI 10.1083/jcb.105.3.1395; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOLIS RU, 1989, DEV NEUROSCI-BASEL, V11, P276, DOI 10.1159/000111906; MARKS MS, 1990, J NEUROCHEM, V54, P171, DOI 10.1111/j.1471-4159.1990.tb13298.x; MCGUIRE PK, 1989, J COMP NEUROL, V288, P280, DOI 10.1002/cne.902880207; MCKAY RDG, 1982, P NATL ACAD SCI-BIOL, V79, P6747, DOI 10.1073/pnas.79.21.6747; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUIR D, 1989, J CELL BIOL, V109, P2353, DOI 10.1083/jcb.109.5.2353; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1986, J BIOL CHEM, V261, P3519; NORLING B, 1984, BIOCHEM J, V221, P845, DOI 10.1042/bj2210845; NORLING B, 1978, BIOCHEM BIOPH RES CO, V84, P914, DOI 10.1016/0006-291X(78)91670-4; NORMAND G, 1988, J NEUROCHEM, V51, P665, DOI 10.1111/j.1471-4159.1988.tb01796.x; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; OOHIRA A, 1988, J BIOL CHEM, V263, P10240; OOHIRA A, 1991, J NEUROSCI, V11, P822; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; PERRIS R, 1987, J CELL BIOL, V105, P2511, DOI 10.1083/jcb.105.6.2511; RICH AM, 1981, NATURE, V293, P224, DOI 10.1038/293224a0; ROSENBERG LC, 1986, ARTICULAR CARTILAGE, P39; SAI S, 1986, P NATL ACAD SCI USA, V83, P5081, DOI 10.1073/pnas.83.14.5081; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1991, J BIOL CHEM, V266, P8198; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STEINDLER DA, 1990, EXP NEUROL, V109, P35, DOI 10.1016/S0014-4886(05)80007-X; STREIT A, 1990, J NEUROCHEM, V55, P1494, DOI 10.1111/j.1471-4159.1990.tb04931.x; SUR M, 1988, J NEUROSCI, V8, P874; TAN SS, 1987, P NATL ACAD SCI USA, V84, P7977, DOI 10.1073/pnas.84.22.7977; TOSNEY KW, 1985, DEV BIOL, V109, P193, DOI 10.1016/0012-1606(85)90360-4; TOSNEY KW, 1990, EXP NEUROL, V109, P75, DOI 10.1016/S0014-4886(05)80010-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATANABE E, 1989, NEUROSCIENCE, V29, P645, DOI 10.1016/0306-4522(89)90137-1; WHITE CJB, 1977, J NEUROCHEM, V28, P581, DOI 10.1111/j.1471-4159.1977.tb10429.x; WOLFFE EJ, 1990, J BIOL CHEM, V265, P341; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YONEDA M, 1990, J BIOL CHEM, V265, P5247; ZAREMBA S, 1989, NEURON, V2, P1207, DOI 10.1016/0896-6273(89)90305-X; ZAREMBA S, 1990, J NEUROSCI, V10, P2985; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	88	85	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9874	9883						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374409				2022-12-27	WOS:A1992HT96500068
J	NINOMIYA, H; STEWART, BH; ROLLINS, SA; ZHAO, J; BOTHWELL, ALM; SIMS, PJ				NINOMIYA, H; STEWART, BH; ROLLINS, SA; ZHAO, J; BOTHWELL, ALM; SIMS, PJ			CONTRIBUTION OF THE N-LINKED CARBOHYDRATE OF ERYTHROCYTE ANTIGEN CD59 TO ITS COMPLEMENT-INHIBITORY ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID LATERAL DIFFUSION; MEMBRANE ATTACK COMPLEX; BIOLOGICAL-ACTIVITY; REGULATORY CONTROL; BLOOD-PLATELETS; LYMPHOID-CELLS; PROTEIN; C5B-9; SURFACE; SPECIFICITY	The contribution of N-linked carbohydrate to the complement-inhibitory function of the human erythrocyte membrane glycoprotein, CD59, was investigated. Amino acid sequence analysis of tryptic peptides labeled with [H-3]borohydride revealed an N-linked carbohydrate moiety at the Asn18 residue. No O-linked carbohydrate was detected, as judged by the failure of asialo-CD59 to bind peanut agglutinin and by its resistance to digestion by O-glycanase. The apparent molecular mass of CD59 was reduced from 18-20 to 14 kDa upon complete digestion with N-glycanase, with no detectable proteolysis. N-glycanase digestion of CD59 was associated with an 88 +/- 4% loss of the complement-inhibitory activity of the protein, as assessed by its capacity to protect chicken erythrocytes from lysis by the human C5b-9 proteins. By contrast, no change in function was observed after digestion of CD59 with neuraminidase, under conditions that removed > 60% of [H-3]sialic acid residues. Despite loss of functional activity after N-glycanase digestion, we detected no change in the capacity of the deglycosylated CD59 to incorporate into erythrocyte membranes or to bind specifically and with species selectivity to the C8 and C9 components of the membrane attack complex. In order to alter the branched-chain structure of the N-linked carbohydrate of CD59 without enzymatic digestion, Chinese hamster ovary (CHO) cells transfected with cDNA for human CD59 were grown in the alpha-mannosidase inhibitor, 1-deoxymannojirimycin, resulting in conversion of approximately 70% of the membrane glycoprotein to a high mannose. When grown in the presence of 1-deoxymannojirimycin, the C5b-9-inhibitory activity of CD59 expressed on the surface of the transfected CHO cells was reduced by an amount comparable to that observed for the N-glycanase digested protein. Taken together, these data suggest that normal glycosylation of Asn18 in CD59 is required for the normal expression of its complement-inhibitory activity on membrane surfaces, although these N-linked sugar residues do not contribute to CD59's affinity for the C8 and C9 components of the C5b-9 complex.	OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,OKLAHOMA CITY,OK 73190; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Yale University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R37HL036061, R01HL036061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040924] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36946, HL36061] Funding Source: Medline; NIGMS NIH HHS [GM40924] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULOW R, 1988, BIOCHEMISTRY-US, V27, P2384; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; HAMILTON KK, 1990, BLOOD, V76, P2572; HARADA R, 1990, J IMMUNOL, V144, P1823; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MERI S, 1990, IMMUNOLOGY, V71, P1; NODA K, 1991, Complement and Inflammation, V8, P199; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; OKADA H, 1983, EUR J IMMUNOL, V13, P340, DOI 10.1002/eji.1830130413; OKADA N, 1989, J IMMUNOL, V143, P2262; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; PHILBRICK WM, 1990, EUR J IMMUNOL, V20, P87, DOI 10.1002/eji.1830200113; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; SIMS PJ, 1989, J BIOL CHEM, V264, P19228; SUGITA Y, 1989, J BIOCHEM-TOKYO, V106, P589, DOI 10.1093/oxfordjournals.jbchem.a122900; SUTTAJIT M, 1971, J BIOL CHEM, V246, P3405; TAKEUCHI M, 1990, J BIOL CHEM, V265, P12127; WIEDMER T, 1985, J BIOL CHEM, V260, P8014; ZHAO J, 1991, J BIOL CHEM, V266, P13418	27	70	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8404	8410						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373727				2022-12-27	WOS:A1992HQ18500070
J	MURPHY, PM; OZCELIK, T; KENNEY, RT; TIFFANY, HL; MCDERMOTT, D; FRANCKE, U				MURPHY, PM; OZCELIK, T; KENNEY, RT; TIFFANY, HL; MCDERMOTT, D; FRANCKE, U			A STRUCTURAL HOMOLOG OF THE N-FORMYL PEPTIDE RECEPTOR - CHARACTERIZATION AND CHROMOSOME MAPPING OF A PEPTIDE CHEMOATTRACTANT RECEPTOR FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; XENOPUS OOCYTES; WASP VENOM; CDNA; CLONING; EXPRESSION; MASTOPARAN; SEQUENCE; BINDING; GENES	Phagocytic cells of many higher species express calcium mobilizing G protein-coupled receptors for bacterial N-formyl peptides which mediate chemotaxis, degranulation, and the respiratory burst. cDNA encoding an N-formyl peptide receptor (FPR) has been reported. We now report the isolation of a closely related cDNA, 2.6 kilobase pairs in length, which we have designated as the FPRL1 receptor cDNA (FPRL1 = formyl peptide receptor like-1). FPR and the FPRL1 receptor derive from small, single-copy genes, both of which are located on human chromosome 19. The gene loci are designated FPR1 and FPRL1, respectively. Both FPR and FPRL1 cDNA cross-hybridize under high stringency conditions with a third gene, designated as FPRL2, which does not appear to be expressed in neutrophils. In contrast, transcripts for both the FPRL1 receptor and FPR are detected only in differentiated myeloid cells; the distribution of N-formyl peptide binding sites is also restricted to mature myeloid cells. FPRL1 cDNA encodes a 351-amino acid polypeptide whose sequence is 69% identical to that of FPR. G protein-coupled receptors that exhibit this degree of structural similarity typically possess a conserved ligand specificity. However, the FPRL1 receptor does not bind prototype N-formyl peptide ligands when expressed in heterologous cell types. These results suggest that FPR1 may be the only gene that is expressed by neutrophils that encodes a receptor capable of binding prototype N-formyl peptides. Moreover, discovery of the FPRL1 receptor indicates the existence of another as yet unidentified peptide that may recruit neutrophils to sites of inflammation.	HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, DEPT PEDIAT, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	MURPHY, PM (corresponding author), NIAID, HOST DEF LAB, BLDG 10, RM 11N113, BETHESDA, MD 20892 USA.		McDermott, David/AAP-2459-2021	McDermott, David/0000-0001-6978-0867	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000298] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00298] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOUGHMAN JA, 1986, J CRAN GENET DEV BIO, V6, P341; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P389; DOOLITTLE RF, 1990, METHOD ENZYMOL, V183, P659; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FRANCKE U, 1986, COLD SPRING HARB SYM, V51, P855, DOI 10.1101/SQB.1986.051.01.099; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GOLDSTEIN IM, 1988, INFLAMMATION BASIC P, P55; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HSIEH CL, 1989, SOMAT CELL MOLEC GEN, V15, P579, DOI 10.1007/BF01534919; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOO C, 1982, BIOCHEM BIOPH RES CO, V106, P442, DOI 10.1016/0006-291X(82)91130-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MALECH HL, 1985, J BIOL CHEM, V260, P2509; MANIATIS T, 1982, MOL CLONING LABORATO, P320; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MIYAKE Y, 1983, BIOCHIM BIOPHYS ACTA, V758, P181, DOI 10.1016/0304-4165(83)90300-8; MURPHY PM, 1990, FEBS LETT, V261, P353, DOI 10.1016/0014-5793(90)80590-F; MURPHY PM, 1990, NUCLEIC ACIDS RES, V18, P1896, DOI 10.1093/nar/18.7.1896; MURPHY PM, 1991, J BIOL CHEM, V266, P12560; MURPHY PM, 1990, J IMMUNOL, V145, P2227; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; ODOWD BF, 1991, ENCY HUM BIOL, V1, P81; PEREZ HD, 1991, J CLIN INVEST, V87, P971, DOI 10.1172/JCI115105; ROT A, 1987, P NATL ACAD SCI USA, V84, P7967, DOI 10.1073/pnas.84.22.7967; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; SHIFFER M, 1967, BIOPHYS J, V7, P121; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; WANG CR, 1991, CELL, V66, P1; WESS J, 1990, MOL PHARMACOL, V38, P517; WILSON SP, 1989, FEBS LETT, V247, P239, DOI 10.1016/0014-5793(89)81343-2; YAKOTA Y, 1989, J BIOL CHEM, V264, P17649	47	203	213	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7637	7643						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373134				2022-12-27	WOS:A1992HN48500063
J	SHARIFI, BG; LAFLEUR, DW; PIROLA, CJ; FORRESTER, JS; FAGIN, JA				SHARIFI, BG; LAFLEUR, DW; PIROLA, CJ; FORRESTER, JS; FAGIN, JA			ANGIOTENSIN-II REGULATES TENASCIN GENE-EXPRESSION IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; CHICK MYOTENDINOUS ANTIGEN; MESSENGER-RNA; MOLECULAR-FORMS; FIBRONECTIN; TISSUES; CYTOTACTIN; GROWTH; SITES; ATHEROSCLEROSIS	Angiotensin II, a vasoactive peptide, has been implicated in the pathophysiology of a number of vascular wall abnormalities. Since aberrant extracellular matrix deposition contributes to the pathogenesis of vessel wall disease, we examined the potential involvement of angiotensin II in the regulation of extracellular matrix synthesis by vascular smooth muscle cells. Immunoprecipitation of newly synthesized matrix proteins showed that, under serum-free conditions, cultured vascular smooth muscle cells constitutively produced high levels of fibronectin, small amounts of laminin, and a barely detectable amount of tenascin. Angiotensin II treatment increased synthesis of a 230-kDa tenascin glycoprotein by 9-fold and fibronectin synthesis by only 30-40% during a 24-h treatment period, without stimulating laminin production or a general increase in the synthesis of secreted proteins. Concomitant treatment with saralasin, a competitive inhibitor of angiotensin II, prevented the stimulation observed with angiotensin II. The stimulation of immunoprecipitable tenascin was preceded by an increase in tenascin mRNA. Levels of tenascin transcripts (8.4 and 7.0 kilobase) were significantly increased within 2 h after angiotensin II treatment, reached a maximum (10- to 12-fold) by 4 h, and remained elevated after 18 h. The induction was completely blocked by actinomycin D. Serum also induced tenascin mRNA, but with a different time course. Serum induction of tenascin mRNA was also evident at 2 h, maximal at 4 h, but declined to control levels at 8 h. These results indicate that angiotensin II exerts a rapid and selective stimulation of tenascin biosynthesis, at least in part at a transcriptional level. This suggests that angiotensin II may alter the composition of the extracellular matrix of the vessel wall by stimulating synthesis of the antiadhesive protein tenascin.			SHARIFI, BG (corresponding author), UNIV CALIF LOS ANGELES, SCH MED,CEDARS SINAI MED CTR,DIV CARDIOL, DAVIS BLDG 1016, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA.			Pirola, Carlos/0000-0001-8234-4058				AUFDERHEIDE E, 1988, J CELL BIOL, V107, P2341, DOI 10.1083/jcb.107.6.2341; BARNES MJ, 1985, COLLAGEN REL RES, V5, P65; BELL L, 1990, AM J PATHOL, V137, P7; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BOBIK A, 1990, BIOCHEM BIOPH RES CO, V166, P580, DOI 10.1016/0006-291X(90)90848-H; BOURDON MA, 1985, J CELL BIOCHEM, V28, P183, DOI 10.1002/jcb.240280302; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CHAMLEYCAMPBELL JH, 1981, ATHEROSCLEROSIS, V40, P347, DOI 10.1016/0021-9150(81)90145-3; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; CHIQUETEHRISMANN R, 1990, FASEB J, V4, P2598, DOI 10.1096/fasebj.4.9.1693347; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANILOFF JK, 1989, J CELL BIOL, V108, P625, DOI 10.1083/jcb.108.2.625; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; ERICKSON HP, 1987, J CELL BIOL, V105, P1387, DOI 10.1083/jcb.105.3.1387; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FORNEYPRESCOTT M, 1991, AM J PATHOL, V139, P1291; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; GATCHALIAN CL, 1989, J CELL BIOL, V108, P1873, DOI 10.1083/jcb.108.5.1873; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1990, CLIN RES, V38, pA287; GRIENDLING KK, 1988, CLIN EXP PHARMACOL P, V15, P105, DOI 10.1111/j.1440-1681.1988.tb01051.x; GRUMET M, 1985, P NATL ACAD SCI USA, V82, P8075, DOI 10.1073/pnas.82.23.8075; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HEICKENDORFF L, 1988, INT J BIOCHEM, V20, P381, DOI 10.1016/0020-711X(88)90205-4; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KOUKOULIS GK, 1991, HUM PATHOL, V22, P636, DOI 10.1016/0046-8177(91)90285-W; LEE YH, 1988, CANCER RES, V48, P2904; LIAU G, 1989, J BIOL CHEM, V264, P10315; LYONSGIORDANO B, 1987, BIOCHEM BIOPH RES CO, V148, P1264, DOI 10.1016/S0006-291X(87)80269-3; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, HYPERTENSION, V13, P706, DOI 10.1161/01.HYP.13.6.706; OYAMA F, 1991, CANCER RES, V51, P4876; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SMITH JB, 1984, P NATL ACAD SCI-BIOL, V81, P7812, DOI 10.1073/pnas.81.24.7812; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355	44	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23910	23915						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385427				2022-12-27	WOS:A1992JZ23900072
J	MOLLER, C; HANSSON, A; ENBERG, B; LOBIE, PE; NORSTEDT, G				MOLLER, C; HANSSON, A; ENBERG, B; LOBIE, PE; NORSTEDT, G			GROWTH-HORMONE (GH) INDUCTION OF TYROSINE PHOSPHORYLATION AND ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASES IN CELLS TRANSFECTED WITH RAT GH RECEPTOR CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; SERINE THREONINE KINASES; BINDING-PROTEIN; GENE-EXPRESSION; MESSENGER-RNA; HUMAN-SERUM; FACTOR-I; INSULIN; ASSAY; IDENTIFICATION	The mechanism of growth hormone (GH) action was studied in Chinese hamster ovary (CHO) cells transfected with GH receptor cDNA. Cytosolic extracts from GH- or phorbol ester (12-O-tetradecanoyl 4beta-phorbol 13-acetate)-treated cells, transfected with full-length GH receptor cDNA, had an enhanced ability to phosphorylate myelin basic protein. Myelin basic protein, a substrate for mitogen-activated protein (MAP) kinase, was maximally phosphorylated using extracts from cells treated with 50 nm bovine GH for 10 min. In addition, GH treatment resulted in an increased cell proliferation by 30-60%. GH and 12-O-tetradecanoyl 4beta-phorbol 13-acetate cause tyrosine phosphorylation of two proteins with M(r) of 40,000 and 42,000 that are also recognized by MAP kinase antibodies. These proteins were identified as MAP kinases by analyzing phosphotyrosine immunoprecipitates on Western blots using MAP kinase antibodies. In addition, GH induces mitogenicity, as well as MAP kinase activation, in CHO cells expressing a receptor in which 184 amino acids had been deleted in the carboxyl-terminal part of the intracellular domain. No GH effects were seen in untransfected cells, in CHO cells expressing a truncated GH receptor containing only 5 of 349 amino acids in the intracellular domain, or in cells expressing the soluble GH-binding protein. In conclusion, our data show that GH treatment of CHO cells, reconstituted with GH receptors, initiates a phosphorylation cascade which includes MAP kinase.	UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,ST LUCIA,QLD 4072,AUSTRALIA; KAROLINSKA INST,NOVUM,DEPT MED NUTR,S-14157 HUDDINGE,SWEDEN; KAROLINSKA INST,DEPT PHYSIOL CHEM,S-10401 STOCKHOLM 60,SWEDEN	University of Queensland; Karolinska Institutet; Karolinska Institutet	MOLLER, C (corresponding author), KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN.							AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AMIT T, 1990, J CLIN ENDOCR METAB, V71, P474, DOI 10.1210/jcem-71-2-474; BARNARD R, 1991, ENDOCRINOLOGY, V128, P1459, DOI 10.1210/endo-128-3-1459; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BILLESTRUP N, 1985, ENDOCRINOLOGY, V116, P1175, DOI 10.1210/endo-116-3-1175; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAHILL AL, 1991, J NEUROCHEM, V57, P1832, DOI 10.1111/j.1471-4159.1991.tb06392.x; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; COCHET C, 1991, J BIOL CHEM, V266, P637; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSSON A, 1991, CELL SIGNAL, V3, P293, DOI 10.1016/0898-6568(91)90057-2; HERINGTON AC, 1987, MOL CELL ENDOCRINOL, V53, P203, DOI 10.1016/0303-7207(87)90175-4; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOBIE PE, 1991, J BIOL CHEM, V266, P22645; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLER J, 1991, Current Biology, V1, P334, DOI 10.1016/0960-9822(91)90104-5; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MEJER KE, 1991, J BIOL CHEM, V266, P1914; MELLOUL D, 1984, EMBO J, V3, P983, DOI 10.1002/j.1460-2075.1984.tb01917.x; MOLLER C, 1991, J MOL ENDOCRINOL, V7, P213, DOI 10.1677/jme.0.0070213; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PALEN E, 1987, J BIOL CHEM, V262, P3518; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SLOOTWEG MC, 1991, J MOL ENDOCRINOL, V6, P179, DOI 10.1677/jme.0.0060179; STUBBART JR, 1991, ENDOCRINOLOGY, V129, P1659, DOI 10.1210/endo-129-3-1659; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	41	151	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23403	23408						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385420				2022-12-27	WOS:A1992JY16300105
J	ZHANG, GH; MELVIN, JE				ZHANG, GH; MELVIN, JE			SECRETAGOGUE-INDUCED MOBILIZATION OF AN INTRACELLULAR MG2+ POOL IN RAT SUBLINGUAL MUCOUS ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; CYTOSOLIC FREE MAGNESIUM; PAROTID ACINI; INOSITOL TRISPHOSPHATE; FLUORESCENT INDICATOR; CALCIUM RELEASE; CA-2+ RELEASE; TRANSPORT; MG-2+; CL	The regulation of the intracellular free Mg2+ concentration ([Mg2+]i) was monitored in rat sublingual mucous acini using dual wavelength microfluorometry of the Mg2+-sensitive dye mag-fura-2. Acini attached to coverslips and superfused continuously with a Mg2+-containing medium (0.8 mM) have a steady-state [Mg2+]i of 0.35 +/- 0.01 mM. Adjusting the extra-cellular Mg2+ concentration to 0 and 10 mM or removing extracellular Na+ did not alter the resting [Mg2+]i. Stimulation with the Ca 2+-mobilizing, muscarinic agonist, carbachol, induced a sustained increase in [Mg2+]i (approximately 50%; t1/2 < 20 s; K(d) approximately 1.5 muM), the magnitude and the duration of which were unchanged in Mg2+-depleted medium indicating that the rise in [Mg2+]i was generated by Mg2+ release from an intracellular Mg2+ pool. Forskolin, which increases the intracellular cAMP content, produced a small, transient increase in the [Mg2+]i (<10%). Muscarinic stimulation in a Ca2+-free medium blunted the initial increase in [Mg2+]i by approximately 50%, whereas the sustained increase in [Mg2+]i was lost. When the muscarinic-induced increase in [Ca2+]i, was blocked by 8-(diethylamino)octyl 3,4,5-trimethoxybenzoate, an inhibitor of the agonist-sensitive intracellular Ca2+ release pathway, both the initial and the sustained phases of the increase in [Mg2+]i were virtually eliminated. Thapsigargin and 2,5-di-(terbutyl)-1,4-benzohydroquinone, which increase [Ca2+]i by inhibiting microsomal Ca2+-ATPase, caused a dramatic increase in [Mg2+]i. Stimulation in a Na+-free medium or in the presence of bumetanide, an inhibitor of Na+/K+/2Cl-cotransport blunted the agonist-induced rise in [Mg2+]i (approximately 50%), whereas ouabain, a Na+,K+-ATPase inhibitor, had no significant effect. FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone), a mitochondrial uncoupler, mobilized an intracellular Mg2+ pool as well. The carbachol-induced increase in [Mg2+]i was markedly inhibited by FCCP (approximately 80%), suggesting that the same pool(s) of Mg2+ were primarily involved. The above results provide strong evidence that Ca2+-mobilizing agonists increase cytoplasmic free [Mg2+] by releasing an intracellular pool of Mg2+ that is associated with a rise in the [Na+]i.	UNIV ROCHESTER,DEPT DENT RES,601 ELMWOOD AVE,BOX 611,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT NEUROBIOL & ANAT,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NIDCR NIH HHS [P50 DE07003, R01 DE08921] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE007003] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMBUDKAR IS, 1988, PFLUG ARCH EUR J PHY, V412, P75, DOI 10.1007/BF00583733; BAUM BJ, 1987, J DENT RES, V66, P628, DOI 10.1177/00220345870660S204; BURI A, 1990, EXP PHYSIOL, V75, P751, DOI 10.1113/expphysiol.1990.sp003457; Cittadini A, 1991, Magnes Res, V4, P23; COOK DI, 1988, PFLUG ARCH EUR J PHY, V413, P67, DOI 10.1007/BF00581230; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; DAI LJ, 1991, J CLIN INVEST, V88, P1255, DOI 10.1172/JCI115429; DELPIRE E, 1991, J PHYSIOL-LONDON, V441, P219, DOI 10.1113/jphysiol.1991.sp018747; DISSING S, 1990, AM J PHYSIOL, V259, pG1044, DOI 10.1152/ajpgi.1990.259.6.G1044; FERAY JC, 1986, BIOCHIM BIOPHYS ACTA, V856, P76, DOI 10.1016/0005-2736(86)90012-X; FLATMAN PW, 1988, J PHYSIOL-LONDON, V397, P471, DOI 10.1113/jphysiol.1988.sp017013; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; FRENKEL EJ, 1989, J PHYSIOL-LONDON, V414, P385, DOI 10.1113/jphysiol.1989.sp017694; FUJISE H, 1988, J PHYSIOL-LONDON, V405, P605, DOI 10.1113/jphysiol.1988.sp017351; GRUBBS RD, 1991, AM J PHYSIOL, V260, pC1158, DOI 10.1152/ajpcell.1991.260.6.C1158; GRUBBS RD, 1984, J BIOL CHEM, V259, P2184; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLEMETTE G, 1991, CELL CALCIUM, V12, P51, DOI 10.1016/0143-4160(91)90084-R; GYLFE E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P82, DOI 10.1016/0167-4889(90)90094-T; HORN VJ, 1988, J BIOL CHEM, V263, P12454; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; ISHIJIMA S, 1991, AM J PHYSIOL, V261, pC1074, DOI 10.1152/ajpcell.1991.261.6.C1074; IWATSUKI N, 1985, JPN J PHYSIOL, V35, P933, DOI 10.2170/jjphysiol.35.933; LANDIS CA, 1979, J PHYSIOL-LONDON, V297, P369, DOI 10.1113/jphysiol.1979.sp013045; LENNARD R, 1991, J PHYSIOL-LONDON, V435, P483, DOI 10.1113/jphysiol.1991.sp018520; MANGANEL M, 1989, J MEMBRANE BIOL, V111, P191, DOI 10.1007/BF01871782; MARUYAMA Y, 1983, NATURE, V302, P827, DOI 10.1038/302827a0; MATSUKAWA R, 1990, ARCH BIOCHEM BIOPHYS, V280, P362, DOI 10.1016/0003-9861(90)90343-W; MCMILLIAN MK, 1987, BIOCHEM BIOPH RES CO, V148, P1017, DOI 10.1016/S0006-291X(87)80233-4; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MELVIN JE, 1991, AM J PHYSIOL, V261, pG1043, DOI 10.1152/ajpgi.1991.261.6.G1043; MELVIN JE, 1991, MECH AGEING DEV, V61, P33, DOI 10.1016/0047-6374(91)90005-K; MERTZ LM, 1992, J MEMBRANE BIOL, V126, P183; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MURPHY E, 1989, P NATL ACAD SCI USA, V86, P2981, DOI 10.1073/pnas.86.8.2981; NAKAYAMA S, 1991, J PHYSIOL-LONDON, V435, P559, DOI 10.1113/jphysiol.1991.sp018525; NAUNTOFTE B, 1988, AM J PHYSIOL, V255, pC508, DOI 10.1152/ajpcell.1988.255.4.C508; NAUNTOFTE B, 1986, AM J PHYSIOL, V251, pC175, DOI 10.1152/ajpcell.1986.251.2.C175; PETERSEN OH, 1988, ANNU REV PHYSIOL, V50, P65; PUTNEY JW, 1976, J PHARMACOL EXP THER, V198, P375; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; ROMANI A, 1991, J BIOL CHEM, V266, P24376; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; SCHACHTER M, 1990, BIOCHIM BIOPHYS ACTA, V1035, P378, DOI 10.1016/0304-4165(90)90103-4; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; SQUIRE LG, 1987, BIOCHIM BIOPHYS ACTA, V899, P171, DOI 10.1016/0005-2736(87)90397-X; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TURNER RJ, 1986, J MEMBRANE BIOL, V94, P143, DOI 10.1007/BF01871194; TURNER RJ, 1992, BIOL SALIVARY GLANDS, P105; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; ZHANG GH, 1992, IN PRESS AM J PHYSL; [No title captured]	52	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20721	20727						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383208				2022-12-27	WOS:A1992JT97800034
J	KAO, J; RYAN, J; BRETT, G; CHEN, JX; SHEN, H; FAN, YG; GODMAN, G; FAMILLETTI, PC; WANG, F; PAN, YCE; STERN, D; CLAUSS, M				KAO, J; RYAN, J; BRETT, G; CHEN, JX; SHEN, H; FAN, YG; GODMAN, G; FAMILLETTI, PC; WANG, F; PAN, YCE; STERN, D; CLAUSS, M			ENDOTHELIAL MONOCYTE-ACTIVATING POLYPEPTIDE-II - A NOVEL TUMOR-DERIVED POLYPEPTIDE THAT ACTIVATES HOST-RESPONSE MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR-PERMEABILITY FACTOR; NECROSIS FACTOR-ALPHA; PROCOAGULANT ACTIVITY; TISSUE FACTOR; VONWILLEBRAND-FACTOR; MURINE TUMORS; CELLS SECRETE; GROWTH-FACTOR; INTERLEUKIN-1; EXPRESSION	An important means by which tumor cells influence the vasculature is through the production of soluble mediators altering vascular properties. A almost-equal-to 22-kDa polypeptide was purified to homogeneity from conditioned medium of murine methylcholanthrene A (meth A) fibrosarcoma cells by ion-exchange chromatography and preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), based on its ability to induce tissue factor procoagulant activity in endothelial cells (ECs). The final product migrated as a broad band on reduced and nonreduced SDS-PAGE and had an unique amino-terminal sequence. This meth A-derived polypeptide modulated EC coagulant properties through the induction of tissue factor, induced monocyte migration and tissue factor expression, and was also chemotactic for granulocytes. Injection of the polypeptide into mouse footpads resulted in an inflammatory response with tissue swelling and polymorphonuclear leukocyte infiltration. The ability of this mediator to activate ECs and monocytes has led us to name it EMAP II (endothelial monocyte-activating polypeptide). EMAP II is distinct from a previously described almost-equal-to 40-kDa meth A-derived polypeptide termed EMAP I. Through its potential to activate host effector mechanisms, EMAP II could contribute to the biology of immunogenic tumors, such as the meth A fibrosarcoma.	HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT PROT BIOCHEM,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT BIOPROC DEV,NUTLEY,NJ 07110	Roche Holding; Roche Holding	KAO, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,PES 11-518,630 W 168TH ST,NEW YORK,NY 10032, USA.			Clauss, Matthias/0000-0001-5180-3899	NHLBI NIH HHS [HL42833, HL42507, HL21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042507, P50HL021006, R01HL042833] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON PJ, 1985, ANAL BIOCHEM, V148, P105, DOI 10.1016/0003-2697(85)90634-7; ASHER A, 1987, J IMMUNOL, V138, P963; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAUS SM, 1991, BLOOD, V78, P376; CLAUSS M, 1990, J BIOL CHEM, V265, P7078; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONWAY EM, 1989, THROMB RES, V53, P231, DOI 10.1016/0049-3848(89)90098-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FAMILLETTI PC, 1988, BIO-TECHNOL, V6, P41, DOI 10.1038/nbt0188-41; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; GRANSTEIN RD, 1986, J CLIN INVEST, V77, P1020, DOI 10.1172/JCI112354; HARANAKA K, 1984, INT J CANCER, V34, P263, DOI 10.1002/ijc.2910340219; HUMPHREYS M, 1989, J IMMUNOL METHODS, V120, P271; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KARPATI RM, 1991, J IMMUNOL, V146, P2043; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCARROLL DR, 1985, J CLIN INVEST, V75, P1089, DOI 10.1172/JCI111802; MURRAY JC, 1989, BRIT J CANCER, V60, P729, DOI 10.1038/bjc.1989.348; NAWROTH P, 1988, J EXP MED, V168, P6637; NAWROTH P, 1986, J EXP MED, V164, P740; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; OLD L, 1961, CANCER RES, V1, P1281; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PALLADINO MA, 1987, J IMMUNOL, V138, P4023; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; QUINTANA A, 1983, EUR J CANCER CLIN ON, V19, P1031, DOI 10.1016/0277-5379(83)90073-1; RUFF MR, 1980, J IMMUNOL, V125, P1671; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WEBB DSA, 1991, J IMMUNOL, V146, P3682	46	161	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20239	20247						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400342				2022-12-27	WOS:A1992JR85800078
J	VAIRO, G; COCKS, BG; CRAGOE, EJ; HAMILTON, JA				VAIRO, G; COCKS, BG; CRAGOE, EJ; HAMILTON, JA			SELECTIVE SUPPRESSION OF GROWTH FACTOR-INDUCED CELL-CYCLE GENE-EXPRESSION BY NA+/H+ ANTIPORT INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MARROW-DERIVED MACROPHAGES; PROLIFERATION SIGNALS; MURINE MACROPHAGES; S-PHASE; ACTIVATION; AGENTS; CSF-1; STIMULATION; AMILORIDE; EXCHANGE	Activation of Na+/H+ exchange activity is a ubiquitous response to growth factors and has been implicated in the mitogenic response. Little is known of how the antiport influences events in the nucleus which ultimately control the cell cycle. Using potent Na+/H+ exchange inhibitors we show for normal mouse bone marrow-derived macrophages that this activity is required for the colony-stimulating factor-1-induced gene expression of the M1 and M2 subunits of ribonucleotide reductase, an enzyme critical for DNA synthesis. Suppression of M1 and M2 mRNA levels occurred when the inhibitors were added up to 8 h after the growth factor, mirroring their ability to prevent entry into S phase at similar times. Antiport activity was not required for the induction of other genes associated with cell cycle progression including proliferating cell nuclear antigen and the G1 cyclin, CYL1. These results highlight the differential expression of various cell cycle-associated genes and demonstrates that non-coordinate regulation of CYL1 cyclin and DNA synthesis gene expression can occur. The selective dependence of ribonucleotide reductase subunit gene expression on Na+/H+ exchange activity may provide a biochemical basis for the requirement of persistent antiporter activity during G1 for subsequent entry into S phase.			VAIRO, G (corresponding author), UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT MED, PARKVILLE, VIC 3050, AUSTRALIA.			Hamilton, John A/0000-0002-9493-9224				ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; COCKS BG, 1992, J BIOL CHEM, V267, P12307; CRAGOE EJ, 1967, J MED CHEM, V10, P66, DOI 10.1021/jm00313a014; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GARCIA ML, 1990, J BIOL CHEM, V265, P3763; GORDON CB, 1986, EMBO J, V5, P2981, DOI 10.1002/j.1460-2075.1986.tb04595.x; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAMILTON JA, 1992, J IMMUNOL, V148, P4028; HAMILTON JA, 1991, BLOOD, V77, P616; HAMILTON JA, 1988, J CELL PHYSIOL, V134, P405, DOI 10.1002/jcp.1041340311; HUME DA, 1983, J CELL PHYSIOL, V117, P189, DOI 10.1002/jcp.1041170209; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KNIGHT KR, 1992, J LEUKOCYTE BIOL, V51, P350, DOI 10.1002/jlb.51.4.350; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANN GJ, 1988, CANCER RES, V48, P5151; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; METCALF D, 1984, HEMOPOIETIC COLONIES; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VAIRO G, 1991, J IMMUNOL, V146, P3469; VAIRO G, 1990, J BIOL CHEM, V265, P16929; VAIRO G, 1988, J CELL PHYSIOL, V134, P13, DOI 10.1002/jcp.1041340103; VAIRO G, 1992, J CELL PHYSIOL, V151, P630, DOI 10.1002/jcp.1041510324; WHETTON AD, 1986, EMBO J, V5, P3281, DOI 10.1002/j.1460-2075.1986.tb04640.x; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	32	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19043	19046						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382066				2022-12-27	WOS:A1992JP59300006
J	BELUNIS, CJ; MDLULI, KE; RAETZ, CRH; NANO, FE				BELUNIS, CJ; MDLULI, KE; RAETZ, CRH; NANO, FE			A NOVEL 3-DEOXY-D-MANNO-OCTULOSONIC ACID TRANSFERASE FROM CHLAMYDIA-TRACHOMATIS REQUIRED FOR EXPRESSION OF THE GENUS-SPECIFIC EPITOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE EPITOPE; ANTIGEN; IDENTIFICATION; BIOSYNTHESIS; PSITTACI	DNA cloned from Chlamydia trachomatis is able to direct the formation of the genus-specific lipopolysaccharide epitope of chlamydiae in enteric Gram-negative bacteria. We now demonstrate that a single C. trachomatis gene (gseA) is sufficient to impart this trait to Escherichia coli. The deduced amino acid sequence of gseA shows 23% identity (66% similarity) to kdtA, an E. coli gene that codes for a bifunctional enzyme catalyzing the addition of two 3-deoxy-D-manno-octulosonic acid (Kdo) residues to lipid A precursors (Clementz, T., and Raetz, C. R. H. (1991) J. Biol. Chem. 266, 9687-9696). Extracts of E. coli expressing gseA transfer at least one additional Kdo unit from CMP-Kdo to precursors already bearing the two Kdo residues attached by the kdtA gene product. Introduction of gseA into an E. coli mutant with a thermolabile kdtA gene product endows cell extracts with the ability to transfer not only the third but also the first two Kdos to lipid A precursors, demonstrating that the C. trachomatis enzyme is at least trifunctional. Given the similarities of these two Kdo transferases and the essentiality of Kdo in Gram-negative bacteria, lipopolysaccharide biosynthesis may be a target for development of novel drugs effective against chlamydiae.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,POB 2000,RAHWAY,NJ 07065; UNIV VICTORIA,CANADIAN BACTERIAL DIS NETWORK,VICTORIA V8W 3P6,BC,CANADA; UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 3P6,BC,CANADA	Merck & Company; University of Victoria; University of Victoria				Nano, Francis/0000-0002-9363-7830				BAVOIL P, 1984, INFECT IMMUN, V44, P479, DOI 10.1128/IAI.44.2.479-485.1984; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BRADE H, 1987, P NATL ACAD SCI USA, V84, P2508, DOI 10.1073/pnas.84.8.2508; BRADE L, 1987, INFECT IMMUN, V55, P482, DOI 10.1128/IAI.55.2.482-486.1987; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; CALDWELL HD, 1984, INFECT IMMUN, V44, P306, DOI 10.1128/IAI.44.2.306-314.1984; CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; COLLINS J, 1979, GENE, V6, P29, DOI 10.1016/0378-1119(79)90083-0; Dawson CR, 1981, GUIDE TRACHOMA CONTR, P8; DHIR SP, 1971, INFECT IMMUN, V4, P725, DOI 10.1128/IAI.4.6.725-730.1971; DREYFUSS G, 1984, MOL CELL BIOL, V4, P414; FRIIS RR, 1972, J BACTERIOL, V110, P706, DOI 10.1128/JB.110.2.706-721.1972; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HATCH TP, 1984, J BACTERIOL, V157, P13, DOI 10.1128/JB.157.1.13-20.1984; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Maniatis T., 1982, MOL CLONING; NANO FE, 1985, SCIENCE, V228, P742, DOI 10.1126/science.2581315; NANO FE, 1986, CHLAMYDIAL INFECTION, P129; NEWHALL WJ, 1983, J BACTERIOL, V154, P998, DOI 10.1128/JB.154.2.998-1001.1983; NURMINEN M, 1983, SCIENCE, V220, P1279, DOI 10.1126/science.6344216; PEREZMARTINEZ JA, 1985, INFECT IMMUN, V50, P905, DOI 10.1128/IAI.50.3.905-910.1985; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDINIA LM, 1989, J BACTERIOL, V171, P335, DOI 10.1128/jb.171.1.335-341.1989; SCHACHTER J, 1980, ANNU REV MICROBIOL, V34, P285, DOI 10.1146/annurev.mi.34.100180.001441; SCHACHTER J, 1978, NEW ENGL J MED, V298, P428, DOI 10.1056/NEJM197802232980805; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	31	74	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18702	18707						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382060				2022-12-27	WOS:A1992JN50200070
J	LIN, JJ; PHILLIPS, AM; HEARST, JE; SANCAR, A				LIN, JJ; PHILLIPS, AM; HEARST, JE; SANCAR, A			ACTIVE-SITE OF (A)BC EXCINUCLEASE .2. BINDING, BENDING, AND CATALYSIS MUTANTS OF UVRB REVEAL A DIRECT ROLE IN 3' AND AN INDIRECT ROLE IN 5' INCISION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION REPAIR; ESCHERICHIA-COLI UVRAB; ENZYMATIC-PROPERTIES; PROTEIN COMPLEX; DUPLEX DNA; GENE; SEQUENCE; STRAND; ADDUCT; ENDONUCLEASE	UvrB plays a central role in (A)BC excinuclease. To study its role in the incision reactions, conserved His and Asp residues in this subunit were mutagenized. All His and the majority of Asp mutants behaved like wild-type protein in vivo and in vitro. However, three mutants, D337A, D478A, and D510A, either completely or partially abolished UvrB activity. All three mutant proteins associate with UvrA normally but D337A and D510A were unable to bind to DNA specifically. The UvrB-D478A mutant bound to DNA specifically but failed to denature and kink the DNA. However, UvrB-D478A was efficiently loaded onto DNA preincised at the 3' site and promoted near- normal incision by UvrC at the 5' site. We propose that D478 is involved in bending DNA and catalysis of the 3' incision and that the 3' incision precedes the 5' incision. UvrB* which is missing the carboxyl-terminal 43 amino acids binds to, and kinks DNA but is unable to make the 3' incision suggesting that it is missing a residue involved in catalysis. This residue was identified to be E639 by site-specific mutagenesis.	LAWRENCE BERKELEY LAB,DIV CHEM BIODYNAM,BERKELEY,CA 94720; LAWRENCE BERKELEY LAB,DEPT CHEM,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	LIN, JJ (corresponding author), UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.		Lin, Jing-Jer/G-8068-2015		NIGMS NIH HHS [GM32833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BACKENDORF C, 1986, NUCLEIC ACIDS RES, V14, P2637; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; CHEN NY, 1989, J GEN MICROBIOL, V135, P2931; GORBALENYA AE, 1990, J MOL BIOL, V213, P583, DOI 10.1016/S0022-2836(05)80243-8; HAROSH I, 1991, NUCLEIC ACIDS RES, V19, P6331, DOI 10.1093/nar/19.22.6331; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAHM A, 1991, NUCLEIC ACIDS MOL BI, V5, P171; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6824, DOI 10.1073/pnas.88.15.6824; LIN JJ, 1992, J BIOL CHEM, V267, P17688; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3841; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1992, J BIOL CHEM, V267, P780; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; PAGE JD, 1990, BIOCHEMISTRY-US, V29, P1016, DOI 10.1021/bi00456a026; Saenger W, 1991, CURR OPIN STRUC BIOL, V1, P130, DOI 10.1016/0959-440X(91)90021-K; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCAR GB, 1984, NUCLEIC ACIDS RES, V12, P4593, DOI 10.1093/nar/12.11.4593; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; SEDGWICK B, 1989, J BACTERIOL, V171, P2249, DOI 10.1128/jb.171.4.2249-2251.1989; SEEBERG E, 1990, P NATL ACAD SCI USA, V87, P191, DOI 10.1073/pnas.87.1.191; SEEBERG E, 1982, P NATL ACAD SCI-BIOL, V79, P988, DOI 10.1073/pnas.79.4.988; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SELBY CP, 1991, BIOCHEMISTRY-US, V30, P3841, DOI 10.1021/bi00230a006; SELBY CP, 1988, BIOCHEMISTRY-US, V27, P7184, DOI 10.1021/bi00419a004; SHI Q, 1992, J MOL BIOL, V220, P425; SHIOTA S, 1988, MOL GEN GENET, V213, P21, DOI 10.1007/BF00333393; SVOBODA DL, 1991, THESIS WASHINGTON U; TANG MS, 1988, BIOCHEMISTRY-US, V27, P893, DOI 10.1021/bi00403a009; THIELKING V, 1991, BIOCHEMISTRY-US, V30, P6416, DOI 10.1021/bi00240a011; VANHOUTEN B, 1988, J BIOL CHEM, V263, P16553; VISSE R, 1991, J BIOL CHEM, V266, P7609; XU SY, 1991, J BIOL CHEM, V266, P4425; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	43	95	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17693	17700						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387640				2022-12-27	WOS:A1992JM22300035
J	DELOREY, TM; OLSEN, RW				DELOREY, TM; OLSEN, RW			GAMMA-AMINOBUTYRIC ACIDA RECEPTOR STRUCTURE AND FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GABA-A RECEPTOR; CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE-C; SUBUNIT MESSENGER-RNAS; RAT-BRAIN; ALPHA-SUBUNIT; BENZODIAZEPINE RECEPTOR; BETA-SUBUNIT; BINDING; SITE		UNIV CALIF LOS ANGELES,SCH MED,MENTAL RETARDAT RES CTR,DEPT PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIAAA NIH HHS [AA07680] Funding Source: Medline; NINDS NIH HHS [NS28772, NS22071] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028772, R01NS022071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA007680, R01AA007680] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BENKE D, 1991, FEBS LETT, V283, P145, DOI 10.1016/0014-5793(91)80573-L; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BROWNING MD, NEUROCHEM RES, V18, P95; BUREAU M, 1990, MOL PHARMACOL, V37, P497; BUREAU MH, 1992, J BIOL CHEM, V269, P8679; CASH DJ, 1987, BIOCHEMISTRY-US, V26, P7562, DOI 10.1021/bi00398a005; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DELOREY TM, 1992, J NEUROCHEM, V58, P2162, DOI 10.1111/j.1471-4159.1992.tb10959.x; DELOREY TM, 1992, IN PRESS SOC NEUR AB, V18; DENG L, 1986, BIOCHEM BIOPH RES CO, V138, P1308, DOI 10.1016/S0006-291X(86)80425-9; DUNN SMJ, 1989, BIOCHEMISTRY-US, V28, P2551, DOI 10.1021/bi00432a031; ENDO S, 1992, IN PRESS J NEUROCHEM; Enna SJ, 1987, PSYCHOPHARMACOLOGY 3, P265; HUH KH, 1992, IN PRESS SOC NEUR AB, V18; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; KIM HY, 1992, IN PRESS SOC NEUR AB, V18; LEIDENHEIMER NJ, 1991, J NEUROCHEM, V57, P722, DOI 10.1111/j.1471-4159.1991.tb03806.x; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MACLENNAN AJ, 1991, NEUROSCIENCE, V43, P369, DOI 10.1016/0306-4522(91)90301-4; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MCKERNAN RM, 1991, NEURON, V7, P667, DOI 10.1016/0896-6273(91)90379-E; MEIER E, 1984, J NEUROCHEM, V43, P1737, DOI 10.1111/j.1471-4159.1984.tb06102.x; MICHELSON HB, 1991, SCIENCE, V253, P1420, DOI 10.1126/science.1654594; MOHLER H, 1977, SCIENCE, V198, P849, DOI 10.1126/science.918669; MOHLER H, 1980, P NATL ACAD SCI-BIOL, V77, P1666, DOI 10.1073/pnas.77.3.1666; MONTPIED P, 1991, J BIOL CHEM, V266, P6011; MONTPIED P, 1991, MOL PHARMACOL, V39, P157; OLSEN RW, 1991, ANN NY ACAD SCI, V625, P145; OLSEN RW, 1991, NEUROCHEM RES, V16, P317, DOI 10.1007/BF00966095; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; PUIA G, 1991, MOL PHARMACOL, V39, P691; SAKMANN B, 1992, NEURON, V8, P613, DOI 10.1016/0896-6273(92)90084-Q; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIEGHART W, 1983, J NEUROCHEM, V41, P47, DOI 10.1111/j.1471-4159.1983.tb11812.x; SIGEL E, 1991, FEBS LETT, V291, P150, DOI 10.1016/0014-5793(91)81124-Q; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMITH GB, 1992, IN PRESS SOC NEUR AB, V18; SQUIRES RF, 1983, MOL PHARMACOL, V23, P326; SQUIRES RF, 1977, NATURE, V266, P732, DOI 10.1038/266732a0; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; STEPHENSON FA, 1989, BIOCHEM J, V264, P199, DOI 10.1042/bj2640199; STUDY RE, 1981, P NATL ACAD SCI-BIOL, V78, P7180, DOI 10.1073/pnas.78.11.7180; TICKU MK, 1978, MOL PHARMACOL, V14, P391; TWYMAN RE, 1991, BIOPHYS J, V59, P256; WAFFORD KA, 1991, NEURON, V7, P27, DOI 10.1016/0896-6273(91)90071-7; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; WISDEN W, 1992, J NEUROSCI, V12, P1040; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x; ZUKIN SR, 1974, P NATL ACAD SCI USA, V71, P4802, DOI 10.1073/pnas.71.12.4802	56	204	208	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16747	16750						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380954				2022-12-27	WOS:A1992JL05300001
J	MARSTON, SB; REDWOOD, CS				MARSTON, SB; REDWOOD, CS			INHIBITION OF ACTIN-TROPOMYOSIN ACTIVATION OF MYOSIN MGATPASE ACTIVITY BY THE SMOOTH-MUSCLE REGULATORY PROTEIN CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIVE THIN-FILAMENTS; HEAVY-MEROMYOSIN; ATPASE ACTIVITY; SKELETAL-MUSCLE; CA-2+ REGULATION; F-ACTIN; BINDING; CALMODULIN; ACTOMYOSIN; MECHANISM	Caldesmon inhibition of actin-tropomyosin activation of myosin MgATPase activity was investigated. >90% inhibition of ATPase activation correlated with 0.035-0.1 caldesmon bound per actin monomer over a wide range of conditions. Caldesmon inhibited sheep aorta actin-tropomyosin activation of skeletal muscle heavy meromyosin (HMM) by 85%, but had no effect on the binding affinity of HMM . ADP . P(i) to actin. At ratios of 2 and 0.12 subfragment 1 (S1):1 actin, addition of caldesmon inhibited the ATPase activation by up to 95%, but did not alter the fraction of S1 . ADP . P(i) associated with actin-tropomyosin. We concluded that caldesmon inhibited actomyosin ATPase by slowing the rate-limiting step of the activation pathway. At concentrations comparable to the ATPase measurements, S1 displaced caldesmon from native thin filaments both in the absence (rigor) and the presence of MgATP. We therefore concluded that caldesmon could displace S1 . ADP . P(i) from actin-tropomyosin only under exceptional circumstances. An expressed mutant of caldesmon comprising just the C-terminal 99 amino acids bound actin 10 times weaker than whole caldesmon but otherwise inhibited actin-tropomyosin activation with the same potency and same mechanism as intact caldesmon. Thus, the entire inhibitory function of caldesmon resides in its extreme C terminus.			MARSTON, SB (corresponding author), NATL HEART & LUNG INST, DEPT CARDIAC MED, LONDON SW3 6LY, ENGLAND.			Marston, Steven/0000-0001-6054-6070	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BREMEL RD, 1973, COLD SPRING HARB SYM, V37, P267, DOI 10.1101/SQB.1973.037.01.037; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHALOVICH JM, 1988, CELL BIOPHYS, V12, P73, DOI 10.1007/BF02918351; CHALOVICH JM, 1991, J MUSCLE RES CELL M, V12, P503, DOI 10.1007/BF01738438; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; HAEBERLE J R, 1991, Biophysical Journal, V59, p58A; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; IKEBE M, 1988, J BIOL CHEM, V263, P3055; LASH JA, 1986, J BIOL CHEM, V261, P6155; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON S, 1990, BIOCHEM J, V272, P305, DOI 10.1042/bj2720305; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MARSTON S, 1988, FEBS LETT, V238, P147, DOI 10.1016/0014-5793(88)80245-X; MARSTON S, 1975, BIOCHEMISTRY-US, V14, P3868, DOI 10.1021/bi00688a021; MARSTON SB, 1982, BIOCHEM J, V203, P453, DOI 10.1042/bj2030453; MARSTON SB, 1984, J MUSCLE RES CELL M, V5, P559, DOI 10.1007/BF00713261; MARSTON SB, 1983, PROG BIOPHYS MOL BIO, V41, P1, DOI 10.1016/0079-6107(83)90024-X; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1988, BIOCHEM BIOPH RES CO, V155, P197, DOI 10.1016/S0006-291X(88)81068-4; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1989, BIOCHEM J, V259, P303, DOI 10.1042/bj2590303; MARSTON SB, 1980, BIOCHEM J, V185, P355, DOI 10.1042/bj1850355; MARSTON SB, 1991, MUSCLE MOTILITY, V2, P351; MURPHY RA, 1979, ANNU REV PHYSIOL, V41, P737, DOI 10.1146/annurev.ph.41.030179.003513; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; REDWOOD CS, 1990, FEBS LETT, V270, P53, DOI 10.1016/0014-5793(90)81233-E; REDWOOD CS, 1992, J MUSCLE RES CELL M, V13, P251; REDWOOD CS, 1992, THESIS LONDON U; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; Straub F.B., 1942, STUDIES I MED CHEM U, P3; TAGGART MJ, 1988, FEBS LETT, V242, P171, DOI 10.1016/0014-5793(88)81009-3; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VELAZ L, 1990, J BIOL CHEM, V265, P2929	42	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16796	16800						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1387396				2022-12-27	WOS:A1992JL05300012
J	PAK, Y; HUANG, LC; LILLEY, KJ; LARNER, J				PAK, Y; HUANG, LC; LILLEY, KJ; LARNER, J			INVIVO CONVERSION OF [H-3] MYOINOSITOL TO [H-3] CHIROINOSITOL IN RAT-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; COVALENTLY BOUND INOSITOL; INSULIN MEDIATORS; TORPEDO ACETYLCHOLINESTERASE; IDENTIFICATION; PURIFICATION; MYOINOSITOL; MECHANISM; KIDNEY; LIVER	We report here the in vivo conversion of [H-3]myoinositol to [H-3]chiroinositol. After labeling intraperitoneally with [H-3]myoinositol for 3 days to reach radioisotope equilibrium in urine, [H-3]chiroinositol was isolated from tissues and purified after 6 N HCl hydrolysis by two sequential paper chromatographies and high performance liquid chromatography (HPLC). Percent conversion of [H-3]myoinositol to [H-3]chiroinositol was highest in urine (36%), liver (8.8%), muscle (8.8%), and blood (7.6%) with intestine, brain, kidney, spleen, and heart decreasing in percentage from 2.8 to 0.7%. Labeling of other inositol isomers including scyllo-, neo-, and epi-, and mucoinositol was minimal, approximately 0.06% of [H-3]myoinositol. Glucose was unlabeled, but glucuronate, the product of myoinositol oxidation, was labeled up to 1.5% of the [H-3] myoinositol. Acid hydrolysates of combined inositol-containing phospholipids contain significant labeled chiroinositol. [H-3]Phosphatidylinositols and [H-3]glycosylphosphatidylinositols were extracted from liver, muscle, and blood, isolated by thin layer chromatography, and inositols purified by HPLC after acid hydrolysis. Percent conversion of [H-3]myoinositol to [H-3] chiroinositol was highest in blood (60.4%) followed by muscle (7.7%) and liver (2.2%).	UNIV VIRGINIA, SCH MED, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia				Pak, Yunbae/0000-0002-8594-5673	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK014334, P30DK038942] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK14334, P30 DK38942] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOGARDUS C, 1984, J CLIN INVEST, V73, P1185, DOI 10.1172/JCI111304; CLEMENTS RS, 1979, J LAB CLIN MED, V93, P210; DAUGHADAY WH, 1955, J BIOL CHEM, V212, P869; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DENTON RM, 1989, ANN NY ACAD SCI, V573, P285, DOI 10.1111/j.1749-6632.1989.tb15005.x; DREW EA, 1983, PHYSL BIOCH STORAGE; EISENBER.F, 1967, J BIOL CHEM, V242, P1375; FUTERMAN AH, 1985, BIOCHEM BIOPH RES CO, V129, P312, DOI 10.1016/0006-291X(85)91439-1; HIPPS PP, 1982, METHOD ENZYMOL, V89, P593; HIPPS PP, 1973, BIOCHEMISTRY-US, V12, P4705, DOI 10.1021/bi00747a025; HOFFMANNOSTENHO.O, 1978, CYCLITOLS PHOSPHOINO, P233; HOLUB BJ, 1985, INOSITOL PHOSPHOINOS, P31; KELLY KL, 1987, P NATL ACAD SCI USA, V84, P6404, DOI 10.1073/pnas.84.18.6404; KENNINGTON AS, 1990, NEW ENGL J MED, V323, P373, DOI 10.1056/NEJM199008093230603; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LARNER J, 1989, ANN NY ACAD SCI, V573, P297, DOI 10.1111/j.1749-6632.1989.tb15006.x; LARNER J, 1988, COLD SPRING HARB SYM, V53, P965, DOI 10.1101/SQB.1988.053.01.111; LARNER J, 1988, BIOCHEM BIOPH RES CO, V151, P1416, DOI 10.1016/S0006-291X(88)80520-5; LOW MG, 1987, BIOCHEM J, V241, P615, DOI 10.1042/bj2410615; MALCHOFF CD, 1987, ENDOCRINOLOGY, V120, P1327, DOI 10.1210/endo-120-4-1327; MATO JM, 1987, BIOCHEM BIOPH RES CO, V146, P764, DOI 10.1016/0006-291X(87)90595-X; MATO JM, 1987, J BIOL CHEM, V262, P2131; MICHELL R H, 1986, P1; NIWA T, 1983, J CHROMATOGR, V277, P25, DOI 10.1016/S0378-4347(00)84820-3; REDDY CC, 1981, J BIOL CHEM, V256, P8510; ROMERO G, 1988, SCIENCE, V240, P509, DOI 10.1126/science.3282305; ROMERO G, 1992, IN PRESS ADV PHARM; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5793, DOI 10.1073/pnas.83.16.5793; SHEN L, 1967, ARCH BIOCHEM BIOPHYS, V122, P474, DOI 10.1016/0003-9861(67)90221-4; UMEZAWA H, 1965, J ANTIBIOT TOKYO A, V18, P1; WALTER EI, 1990, J IMMUNOL, V144, P1030; WANG WT, 1990, ANAL BIOCHEM, V188, P432, DOI 10.1016/0003-2697(90)90632-J; WOBER G, 1969, MONATSH CHEM, V100, P369, DOI 10.1007/BF00938275; WRIGHT RS, 1971, J CHROMATOGR, V59, P220, DOI 10.1016/S0021-9673(01)80033-9	35	85	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16904	16910						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1387397				2022-12-27	WOS:A1992JL05300030
J	ALDAPE, RA; FUTER, O; DECENZO, MT; JARRETT, BP; MURCKO, MA; LIVINGSTON, DJ				ALDAPE, RA; FUTER, O; DECENZO, MT; JARRETT, BP; MURCKO, MA; LIVINGSTON, DJ			CHARGED SURFACE RESIDUES OF FKBP12 PARTICIPATE IN FORMATION OF THE FKBP12-FK506-CALCINEURIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN FK506-BINDING PROTEIN; PEPTIDYL-PROLYL ISOMERASE; T-CELL ACTIVATION; IMMUNOSUPPRESSANT FK506; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; ATOMIC-STRUCTURE; RAPAMYCIN; CYCLOPHILIN; DISTINCT	The mechanism of FK506 immunosuppression has been proposed to proceed by formation of a tight-binding complex with the intracellular 12-kDa FK506-binding protein (FKBP12). The FK506-FKBP12 complex then acts as a specific high-affinity inhibitor of the intracellular protein phosphatase PP2B (calcineurin), interrupting downstream dephosphorylation events required for T-cell activation. Site-directed mutagenesis of many of the surface residues of FKBP12 has no significant effect on its affinity for calcineurin. We have identified, however, three FKBP12 surface residues (Asp-37, Arg-42, and His-87) proximal to a solvent-exposed segment of bound FK506 that may be direct contacts in the calcineurin complex. Site-directed mutagenesis of two of these residues decreases the affinity of FKBP12-FK506 for calcineurin (K(i)) from 6 nm for wild-type FKBP12 to 3.7-mu-M for a R42K/H87V double mutant, without affecting the peptidylprolyl isomerase activity or FK506 affinity of the mutant protein. These FKBP12 mutations along with several substitutions on FK506 known to affect calcineurin binding form a roughly 100-angstrom2 region of the FKBP12-FK506 complex surface that is likely to be within the calcineurin binding site.	VERTEX PHARMACEUT INC, 40 ALLSTON ST, CAMBRIDGE, MA 02139 USA	Vertex Pharmaceuticals								BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; DUMONT FJ, 1990, J IMMUNOL, V144, P251; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P677; KLEE CB, 1988, MOL ASPECTS CELL REG, V5, P225; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; NELSON PA, 1991, GENE, V109, P255, DOI 10.1016/0378-1119(91)90617-K; PARK ST, 1992, J BIOL CHEM, V267, P3316; ROSBOROUGH SL, 1991, TRANSPLANT P, V23, P2891; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302	31	131	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16029	16032						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379588				2022-12-27	WOS:A1992JJ45800007
J	LEE, SW; WULFKUHLE, JD; OTTO, JJ				LEE, SW; WULFKUHLE, JD; OTTO, JJ			VINCULIN BINDING-SITE MAPPED ON TALIN WITH AN ANTIIDIOTYPIC ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL PROTEIN VINCULIN; OVERLAY TECHNIQUE; IDENTIFICATION; PURIFICATION; CLEAVAGE; SEQUENCE; DOMAIN; MUSCLE	Vinculin and talin are major adhesion plaque components which interact in vitro and presumably in vivo. The amino acid sequence of talin is now known so details of its domain structure can be mapped. We localized vinculin binding sites in the talin sequence by overlaying peptide maps of talin with an anti-idiotypic vinculin antibody that recognizes talin and with I-125-vinculin. A rabbit injected only twice with vinculin and producing anti-vinculin antibodies spontaneously generated a second antibody that recognizes talin. Vinculin and anti-vinculin antibodies specifically compete with this second antibody for binding to talin as determined by solid-phase binding and overlay assays. The antibody is thus most likely an anti-idiotypic antibody which mimics a region of vinculin that interacts with talin. The binding site of the anti-idiotypic antibody on talin was mapped to the 196 amino acids spanning residues 1653 to 1848. A second vinculin binding site identified with an I-125-vinculin blot overlay technique was located between residues 483 and 1652. The observation that talin has two immunologically distinct vinculin binding sites suggests that vinculin may have two different talin binding sites or one "complex" site with two interacting regions.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus								BECKERLE MC, 1990, CELL MOTIL CYTOSKEL, V16, P7, DOI 10.1002/cm.970160103; BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JONES P, 1989, J CELL BIOL, V109, P2917, DOI 10.1083/jcb.109.6.2917; KILIC F, 1991, J BIOL CHEM, V266, P8734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OHALLORAN T, 1986, BIOCHIM BIOPHYS ACTA, V869, P337, DOI 10.1016/0167-4838(86)90074-9; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; OTTO JJ, 1990, CELL MOTIL CYTOSKEL, V16, P1, DOI 10.1002/cm.970160102; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; WILKINS JA, 1983, BIOCHEM BIOPH RES CO, V116, P1026, DOI 10.1016/S0006-291X(83)80245-9	16	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16355	16358						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379597				2022-12-27	WOS:A1992JJ45800058
J	TAKEDA, A; WU, JJ; MAIZEL, AL				TAKEDA, A; WU, JJ; MAIZEL, AL			EVIDENCE FOR MONOMERIC AND DIMERIC FORMS OF CD45 ASSOCIATED WITH A 30-KDA PHOSPHORYLATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; TYROSINE PHOSPHATASE CD45; LEUKOCYTE-COMMON ANTIGEN; HUMAN LYMPHOCYTES-T; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; TRANSFERRIN RECEPTOR; ADHESION MOLECULE; MESSENGER-RNA	Glycoprotein CD45, a transmembrane protein tyrosine phosphatase of leukocytes, is topographically similar to the epidermal growth factor receptor, a transmembrane tyrosine kinase. Since the latter is thought to be allosterically regulated through conversion between monomeric and dimeric forms, we sought to determine whether CD45 undergoes similar oligomerization. Our analysis, employing a thiol-cleavable and homobifunctional chemical cross-linker, dithiobis succinimidyl propionate, revealed that CD45 indeed formed homodimers. In addition, a protein of molecular mass 30,000 daltons (30 kDa) was found to be associated with both the CD45 monomer and dimer. The 30-kDa protein was phosphorylated and was not labeled by cell surface radioiodination. Distinct differences in protein tyrosine phosphatase activity were detected among the various populations of CD45 separated by sucrose gradient ultracentrifugation. However, the differences observed could not be explained simply by dimerization and instead suggest the presence of other factor(s) involved in the regulation of CD45 enzyme activity.	MIRIAM HOSP, DEPT PATHOL, PROVIDENCE, RI 02906 USA	Lifespan Health Rhode Island; Miriam Hospital	TAKEDA, A (corresponding author), BROWN UNIV, ROGER WILLIAMS MED CTR, DEPT PATHOL, PROVIDENCE, RI 02908 USA.				NCI NIH HHS [CA 45148, P30 CA13943] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA045148, P30CA013943] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; CIKES M, 1973, J NATL CANCER I, V50, P347, DOI 10.1093/jnci/50.2.347; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; CONE RE, 1976, IMMUNOCHEMISTRY, V13, P571, DOI 10.1016/0019-2791(76)90168-3; ENNS CA, 1991, J BIOL CHEM, V266, P13272; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KIENER PA, 1989, J IMMUNOL, V143, P23; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; LESLEY J, 1984, CELL IMMUNOL, V83, P14, DOI 10.1016/0008-8749(84)90220-X; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; OMARY MB, 1980, J BIOL CHEM, V255, P1662; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RUTISHAUSER U, 1982, P NATL ACAD SCI-BIOL, V79, P685, DOI 10.1073/pnas.79.2.685; SAGA Y, 1986, P NATL ACAD SCI USA, V83, P6940, DOI 10.1073/pnas.83.18.6940; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; WANG K, 1975, J BIOL CHEM, V250, P6622; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	50	84	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16651	16659						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1386605				2022-12-27	WOS:A1992JJ45800101
J	KIEFER, MC; SCHMID, C; WALDVOGEL, M; SCHLAPFER, I; FUTO, E; MASIARZ, FR; GREEN, K; BARR, PJ; ZAPF, J				KIEFER, MC; SCHMID, C; WALDVOGEL, M; SCHLAPFER, I; FUTO, E; MASIARZ, FR; GREEN, K; BARR, PJ; ZAPF, J			CHARACTERIZATION OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-4, PROTEIN-5, AND PROTEIN-6 PRODUCED IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRAPANCREATIC TUMOR HYPOGLYCEMIA; SARCOMA CELL-LINE; IGF-I; CARRIER PROTEIN; SACCHAROMYCES-CEREVISIAE; HUMAN-SERUM; EXPRESSION; CLONING; SEQUENCE; DNA	The insulin-like growth factor binding protein (IGFBP) family comprises six structurally distinct, but highly homologous proteins. They have been identified in serum and other biological fluids, tissue extracts, and cell culture media. We have recently cloned cDNAs encoding human IGFBP-4, -5, and -6 and have now expressed these BPs in yeast as ubiquitin (Ub)-IGFBP fusion proteins. Western ligand blotting with I-125-IGF II under nonreducing conditions of recombinant human (rh) IGFBP-containing yeast lysates revealed specific binding bands for IGFBP-4, -5, and -6 at apparent molecular masses of 24-26, 30-32, and 24-26 kDa, respectively, indicating processing of the fusion proteins. High-performance liquid chromatography-purified rhIGFBPs had virually the same amino acid composition, amino acid number, and NH2-terminal sequences as the native BPs. Except for the affinity of rhIGFBP-6 for IGF I (K(a) = 8.5 x 10(8) M-1), the affinity constants of the three IGFBPs for IGF I and II lie between 1.7 and 3.3 x 10(10) M-1, i.e. 25-100 times higher than the IGF I and II affinities of the type I IGF receptor. When present in excess, rhIGFBP-4, -5, and -6 inhibited IGF I- and II-stimulated DNA and glycogen synthesis in human osteoblastic cells, but rhIGFBP-6 had only a weak inhibitory effect on IGF I in agreement with its relatively lower IGF I affinity constant. The results of this study show that the primary effect of the three rhIGFBPs is the attenuation of IGF activity and suggest that IGFBPs contribute to the control of IGF-mediated cell growth and metabolism.	UNIV HOSP ZURICH,DEPT MED,METAB UNIT,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital	KIEFER, MC (corresponding author), CHIRON CORP,EMERYVILLE,CA 94608, USA.			Schmid, Christoph/0000-0003-2080-4439				ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; BARR PJ, 1986, BIOTECHNIQUES, V4, P428; BARR PJ, 1987, J EXP MED, V165, P1160, DOI 10.1084/jem.165.4.1160; BARR PJ, 1991, EXPRESSION SYSTEMS P, P51; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; BICSAK TA, 1991, BIOL REPROD, V44, P599, DOI 10.1095/biolreprod44.4.599; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; BREWER MT, 1988, BIOCHEM BIOPH RES CO, V152, P1289, DOI 10.1016/S0006-291X(88)80425-X; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; BROWN AL, 1989, J BIOL CHEM, V264, P5148; BUSBY WH, 1989, ENDOCRINOLOGY, V125, P773, DOI 10.1210/endo-125-2-773; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P710, DOI 10.1210/endo-129-2-710; CULOUSCOU JM, 1991, J CANCER RES, V51, P2813; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; ERNST M, 1990, ENDOCRINOLOGY, V127, P807, DOI 10.1210/endo-127-2-807; FEYEN JHM, 1991, J BIOL CHEM, V266, P19469; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1919; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; JULKUNEN M, 1988, FEBS LETT, V236, P295, DOI 10.1016/0014-5793(88)80041-3; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KNAUER DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7252, DOI 10.1073/pnas.77.12.7252; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTHMAN H, 1989, EUR J BIOCHEM, V180, P259, DOI 10.1111/j.1432-1033.1989.tb14641.x; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MEULI C, 1978, DIABETOLOGIA, V14, P255, DOI 10.1007/BF01219425; MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338; NILSON BL, 1984, ANAL BIOCHEM, V141, P311; NISSLEY SP, 1991, MODERN CONCEPTS INSU; RECHLER MM, 1991, PEPTIDE GROWTH FACTO, V1; RINAS U, 1990, BIO-TECHNOL, V8, P543, DOI 10.1038/nbt0690-543; RODAN SB, 1989, J ENDOCRINOL, V122, P219, DOI 10.1677/joe.0.1220219; RODAN SB, 1987, CANCER RES, V47, P4961; ROGHANI M, 1991, J CLIN ENDOCR METAB, V73, P658, DOI 10.1210/jcem-73-3-658; SABIN EA, 1989, BIO-TECHNOL, V7, P705, DOI 10.1038/nbt0789-705; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMID C, 1991, BIOCHEM BIOPH RES CO, V179, P579, DOI 10.1016/0006-291X(91)91410-E; SCHMID C, 1983, FEBS LETT, V161, P117, DOI 10.1016/0014-5793(83)80742-X; SCHMID C, 1984, FEBS LETT, V173, P48, DOI 10.1016/0014-5793(84)81015-7; SCHMID C, 1983, CALCIFIED TISSUE INT, V35, P578, DOI 10.1007/BF02405097; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SHUSTER JR, 1989, YEAST GENETIC ENG, P83; Spratt SK, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037503; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; TSENG LYH, 1989, MOL ENDOCRINOL, V3, P1559, DOI 10.1210/mend-3-10-1559; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAPF J, 1990, J CLIN INVEST, V86, P952, DOI 10.1172/JCI114797; ZAPF J, 1977, CLIN CHEM, V23, P677; ZAPF J, 1979, J CLIN INVEST, V63, P1077, DOI 10.1172/JCI109377; ZAPF J, 1989, P NATL ACAD SCI USA, V86, P3813, DOI 10.1073/pnas.86.10.3813; ZAPF J, 1990, J BIOL CHEM, V265, P14892	66	186	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12692	12699						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1377672				2022-12-27	WOS:A1992HZ48300049
J	DEBYSER, Z; VANDAMME, AM; PAUWELS, R; BABA, M; DESMYTER, J; DE CLERCQ, E				DEBYSER, Z; VANDAMME, AM; PAUWELS, R; BABA, M; DESMYTER, J; DE CLERCQ, E			KINETICS OF INHIBITION OF ENDOGENOUS HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE TRANSCRIPTION BY 2',3'-DIDEOXYNUCLEOSIDE 5'-TRIPHOSPHATE, TETRAHYDROIMIDAZO-[4,5,1-JK][1,4]-BENZODIAZEPIN-2(1H)-THIONE, AND 1-[(2-HYDROXYETHOXY)METHYL]-6-(PHENYLTHIO)THYMINE DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REPLICATION; SUBSTRATE; AGENTS	Recently, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H-)-one and -thione (TIBO) and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) compounds have been shown to be potent, selective, and specific inhibitors of human immunodeficiency virus type 1 (HIV-1) replication in vitro. They interact with the reverse transcriptase of HIV-1 in a way different from that of previously studied reverse transcriptase (RT) inhibitors. We established an endogenous RT assay, starting from intact HIV-1 virions. This assay mimics the reverse transcription process in the HIV-infected cell more closely than RT assays with artificial templates. We investigated the inhibition of endogenous HIV-I reverse transcription by the TIBO derivative (+)-(S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo [4,5,1-jk]-[1,4]-benzodiazepin-2(1H)-thione (R-82150) in comparison with the HEPT derivative 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and 2',3'-dideoxyguanosine 5'-triphosphate. The kinetics and characteristics of RT inhibition by TIBO in the endogenous RT assay were similar to those found previously for the exogenous RT assay (following addition of exogenous template/primer); thus, RT inhibition by TIBO was specific for HIV-1 and the extent of RT inhibition was dependent on which of the four substrates (dATP, dTTP, dGTP, and dCTP) was present in limited concentrations. Of the three enzymatic activities, RNA-dependent DNA polymerization was preferentially inhibited, and inhibition was not competitive with respect to the natural substrates. HIV-1 RT behaved as an allosteric enzyme, which means that positive cooperativity for binding of the substrate was observed. TIBO behaved as an allosteric inhibitor by causing a concentration-dependent decrease in this cooperativity.	FUKUSHIMA MED SCH, DEPT MICROBIOL, FUKUSHIMA 96012, JAPAN	Fukushima Medical University	DEBYSER, Z (corresponding author), CATHOLIC UNIV LEUVEN, REGA INST MED RES, MINDERBROEDERSSTR 10, B-3000 LOUVAIN, BELGIUM.		Vandamme, Anne-Mieke/I-4127-2012; Baba, Masanori/G-3867-2011	Vandamme, Anne-Mieke/0000-0002-6594-2766; De Clercq, Erik/0000-0002-2985-8890				BABA M, 1991, MOL PHARMACOL, V39, P805; BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356; BASU A, 1989, J BIOL CHEM, V264, P8746; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BERTAZZONI U, 1989, CLIN CHIM ACTA, V183, P101, DOI 10.1016/0009-8981(89)90280-5; BORROTOESODA K, 1991, J VIROL, V65, P1952, DOI 10.1128/JVI.65.4.1952-1959.1991; BUCKHEIT RW, 1991, AIDS RES HUM RETROV, V7, P295, DOI 10.1089/aid.1991.7.295; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DEBYSER Z, 1992, MOL PHARMACOL, V41, P203; FRANK KB, 1991, J BIOL CHEM, V266, P14232; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; GONTIJO NF, 1990, FOCUS, V12, P55; HERDEWIJN P, 1987, J MED CHEM, V30, P1270, DOI 10.1021/jm00391a003; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; KUKLA MJ, 1991, J MED CHEM, V34, P746, DOI 10.1021/jm00106a040; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MIYASAKA T, 1989, J MED CHEM, V32, P2507, DOI 10.1021/jm00132a002; MYERS G, 1990, HUMAN RETROVIRUSES A; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; REARDON JE, 1990, J BIOL CHEM, V265, P20302; TAN CK, 1991, BIOCHEMISTRY-US, V30, P2651, DOI 10.1021/bi00224a013; VARMUS H, 1982, MOL BIOL TUMOR VIRUS, V5, P414; WHITE EL, 1991, ANTIVIR RES, V16, P257, DOI 10.1016/0166-3542(91)90005-C; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; YONG WH, 1990, AIDS, V4, P199, DOI 10.1097/00002030-199003000-00004	27	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11769	11776						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376311				2022-12-27	WOS:A1992HY94700022
J	FALNES, PO; MADSHUS, IH; SANDVIG, K; OLSNES, S				FALNES, PO; MADSHUS, IH; SANDVIG, K; OLSNES, S			REPLACEMENT OF NEGATIVE BY POSITIVE CHARGES IN THE PRESUMED MEMBRANE-INSERTED PART OF DIPHTHERIA TOXIN-B FRAGMENT - EFFECT ON MEMBRANE TRANSLOCATION AND ON FORMATION OF CATION CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW PH; CELLS; ENTRY; MUTANTS; MOLECULE; CYTOSOL	Diphtheria toxin B fragment is capable of forming cation-selective channels in the plasma membrane. Such channels may be involved in the translocation of the toxin A fragment to the cytosol. Seven negatively charged amino acids in the B fragment were replaced one by one by lysines, followed by studies of cytotoxicity and channel-forming ability of the different mutants. The mutant D392K showed a strong reduction in binding to cell surface receptors. Of the six mutants that showed wild-type binding affinity, the two mutants D295K and D318K were very inefficient in forming channels. These two mutants had the lowest ability to mediate A fragment translocation. The mutant E362K was able both to induce cation channel formation and to mediate A fragment translocation at a higher pH value than the wild-type B fragment. The results support the notion that formation of cation channels is of importance for the translocation of the A fragment across the plasma membrane, and they indicate that the pH requirement for translocation of the A fragment to the cytosol is partly determined by the B fragment.			FALNES, PO (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,MONTEBELLO,N-0310 OSLO 3,NORWAY.		Falnes, Pål Ø./AAA-4581-2020	Falnes, Pal/0000-0001-8114-6025				BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MOSKAUG JO, 1989, J BIOL CHEM, V264, P11367; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; OLSNES S, 1980, J BIOL CHEM, V255, P284; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1986, J BIOL CHEM, V261, P1639; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STENMARK H, 1989, EMBO J, V8, P2849, DOI 10.1002/j.1460-2075.1989.tb08432.x; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; STENMARK H, 1991, MOL MICROBIOL, V5, P595, DOI 10.1111/j.1365-2958.1991.tb00730.x; UCHIDA T, 1972, SCIENCE, V175, P901, DOI 10.1126/science.175.4024.901; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	25	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12284	12290						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376320				2022-12-27	WOS:A1992HY94700094
J	ZHELEZNYAK, A; BROWN, EJ				ZHELEZNYAK, A; BROWN, EJ			IMMUNOGLOBULIN-MEDIATED PHAGOCYTOSIS BY HUMAN MONOCYTES REQUIRES PROTEIN-KINASE-C ACTIVATION - EVIDENCE FOR PROTEIN-KINASE-C TRANSLOCATION TO PHAGOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE PLASMA-MEMBRANE; SIGNAL TRANSDUCTION; RESPIRATORY BURST; RECEPTORS; MECHANISM; POTENT; DIFFERENTIATION; NEUTROPHILS; INHIBITORS; ANTIGEN	This study has investigated the role of protein kinase C (PKC) activation in IgG-mediated phagocytosis by human monocytes. Incubation of monocytes with IgG-opsonized targets increased membrane-associated PKC approximately 2-fold. Kinetic studies showed that the translocation of PKC to membrane occurred before significant ingestion took place. The pharmacologic PKC inhibitor H7 inhibited IgG-dependent ingestion with ID50 of 20-mu-M, while the structurally related isoquinoline sulfonamide HA1004 had no effect at this concentration. Staurosporine and calphostin C, PKC inhibitors which have different mechanisms of actions than H7, also inhibited ingestion. Depletion of PKC by prolonged incubation with phorbol esters also inhibited phagocytosis, and dose-response curves showed a strong correlation between the extent of PKC depletion and the extent of inhibition of ingestion. Finally, phagosomes were isolated by sucrose density centrifugation of cells disrupted 5 min after the initiation of phagocytosis. Measurement of PKC activity and immunoreactivity in the phagosomes showed that PKC was concentrated in the phagosome membrane approximately 5-fold compared to the uninvolved plasma membrane. Together, these data suggest that PKC activation is an early, essential step in the efficient ingestion of IgG-opsonized targets by monocytes.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV INFECT DIS,CAMPUS BOX 8051,660 S EUCLID ST,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BROWN EJ, 1988, J CLIN INVEST, V81, P365, DOI 10.1172/JCI113328; BROWN EJ, 1991, CURR OPIN IMMUNOL, V3, P76, DOI 10.1016/0952-7915(91)90081-B; BROWN EJ, 1987, J IMMUNOL, V139, P3777; BROZNA JP, 1988, J IMMUNOL, V141, P1642; DINARELLO CA, 1985, J CLIN IMMUNOL, V5, P287, DOI 10.1007/BF00918247; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; EPPELL BA, 1989, J IMMUNOL, V143, P4141; GRAHAM IL, 1991, J IMMUNOL, V146, P685; GRESHAM HD, 1990, J BIOL CHEM, V265, P7819; GRIFFIN FM, 1975, J EXP MED, V142, P1263, DOI 10.1084/jem.142.5.1263; GRIFFIN FM, 1976, J EXP MED, V144, P788, DOI 10.1084/jem.144.3.788; GRIFFIN FM, 1974, J EXP MED, V139, P323, DOI 10.1084/jem.139.2.323; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; JOINER KA, 1989, J CELL BIOL, V109, P2771, DOI 10.1083/jcb.109.6.2771; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LENNARTZ MR, 1990, J CELL BIOL, V111, P214; LORENZ RG, 1990, J IMMUNOL, V144, P1600; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MELLMAN IS, 1983, J CELL BIOL, V96, P887, DOI 10.1083/jcb.96.3.887; METCALF JA, 1986, LABORATORY MANUAL NE; Metchnikoff ME., 1884, VIRCHOWS ARCH PATH A, V9, P177, DOI [10.1007/BF02361555, DOI 10.1007/BF02361555]; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; ROSALES C, 1992, J BIOL CHEM, V267, P5265; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAWYER DW, 1985, SCIENCE, V230, P663, DOI 10.1126/science.4048951; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703	29	103	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12042	12048						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376316				2022-12-27	WOS:A1992HY94700061
J	THOMIS, DC; FLOYDSMITH, G; SAMUEL, CE				THOMIS, DC; FLOYDSMITH, G; SAMUEL, CE			MECHANISM OF INTERFERON ACTION - CDNA STRUCTURE AND REGULATION OF A NOVEL SPLICE-SITE VARIANT OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE-A FROM INTERFERON-TREATED HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-2; MOLECULAR-CLONING; MOUSE FIBROBLASTS; GENE-EXPRESSION; MESSENGER-RNA; C-ALPHA; PHOSPHORYLATION; FAMILY; SEQUENCES; ISOFORMS	A molecular cDNA clone (KIN27) was isolated that encodes a novel variant of the catalytic subunit C-alpha of the human cyclic AMP-dependent protein kinase (PKA). Analysis of PKA genomic sequence data revealed that the KIN27 variant transcripts likely result from alternative splice-site selection of the C-alpha gene transcripts. The KIN27 cDNA has therefore been designated C-alpha-2. RNA amplification by polymerase chain reaction revealed that KIN27 C-alpha-2 splice-site variant RNA and PKA C-alpha RNA were both expressed in the amnion U and HeLa human cell lines. C-alpha RNA was about 3- to 5-fold more abundant than C-alpha-2 RNA. Interferon treatment decreased the steady-state amount of the C-alpha-2 RNA relative to C-alpha RNA. These results suggest that alternative splicing may contribute to the structural heterogeneity of C subunits expressed in human cells and that interferon may affect this process.	UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,DIV MOLEC & CELLULAR BIOL,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,GRAD PROGRAM BIOCHEM & MOLEC BIOL,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara					NIAID NIH HHS [AI-20611, AI-12520] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012520, R01AI020611, R37AI012520] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATWATER JA, 1987, VIROLOGY, V159, P350, DOI 10.1016/0042-6822(87)90473-9; ATWATER JA, 1982, VIROLOGY, V123, P206, DOI 10.1016/0042-6822(82)90306-3; BANERJEE DK, 1983, VIROLOGY, V129, P230, DOI 10.1016/0042-6822(83)90411-7; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BERRY MJ, 1985, J BIOL CHEM, V260, P1240; BEUSHAUSEN S, 1988, NEURON, V1, P853, DOI 10.1016/0896-6273(88)90133-X; BISCHOFF JR, 1989, VIROLOGY, V172, P106, DOI 10.1016/0042-6822(89)90112-8; CHEN U, 1990, MOL IMMUNOL, V27, P1249; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARELBELLAN A, 1988, J IMMUNOL, V141, P1012; KARATHANASIS SK, 1983, NATURE, V301, P718, DOI 10.1038/301718a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LASKY SR, 1982, J BIOL CHEM, V257, P1087; LEFF SE, 1987, CELL, V48, P517, DOI 10.1016/0092-8674(87)90202-9; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAMUEL CE, 1988, PROG NUCLEIC ACID RE, V35, P27, DOI 10.1016/S0079-6603(08)60609-1; SAMUEL CE, 1979, P NATL ACAD SCI USA, V76, P600, DOI 10.1073/pnas.76.2.600; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SAMUEL CE, 1983, VIROLOGY, V130, P474, DOI 10.1016/0042-6822(83)90101-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPERLING J, 1991, P NATL ACAD SCI USA, V88, P10377, DOI 10.1073/pnas.88.23.10377; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; THOMIS DC, 1992, J VIROL, V66, P2519, DOI 10.1128/JVI.66.4.2519-2522.1992; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WANG AM, 1990, PCR PROTOCOLS GUIDE, P70; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WIEMANN S, 1991, J BIOL CHEM, V266, P5140; ZHANG XT, 1989, BIOCHEM BIOPH RES CO, V164, P176, DOI 10.1016/0006-291X(89)91699-9; [No title captured]	44	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10723	10728						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375229				2022-12-27	WOS:A1992HV09000078
J	SANDBERG, K; JI, H; CLARK, AJL; SHAPIRA, H; CATT, KJ				SANDBERG, K; JI, H; CLARK, AJL; SHAPIRA, H; CATT, KJ			CLONING AND EXPRESSION OF A NOVEL ANGIOTENSIN-II RECEPTOR SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADRENAL GLOMERULOSA CELLS; ADRENERGIC-RECEPTORS; CALCIUM; ACTIVATION; OOCYTES; RAT	Angiotensin II (AII) is a major regulator of cardiovascular function and fluid homeostasis. Recently. the cDNA for an AII receptor (AT1) was cloned from rat smooth muscle and bovine adrenal. To search for AII receptor subtypes, we amplified rat adrenal cortex cDNA by PCR using primers based on the AT1 receptor. The product was distinct from the AT1 receptor as indicated by restriction enzyme analysis and DNA sequencing. A full-length cDNA clone (2.2 kilobase pairs) encoding a novel All receptor (AT3) Was obtained by screening an adrenal cortex library. The AT3 cDNA encodes a M(r) 40,959 protein with 95% amino acid identity to the rat smooth muscle receptor, but the overall nucleotide similarity is 71% due to low homology in the 5'- (58%) and 3'- (62%) untranslated regions. Expressed AT3 receptors in Xenopus oocytes and COS-7 cells mediate agonist-induced Ca2+ mobilization but are pharmacologically distinct from the AT1 receptors. AT3 mRNA is most abundant in the adrenal cortex and pituitary and differs from AT1 mRNA in its tissue distribution. The structural features of the AT3 receptor, including two additional potential phosphorylation sites for protein kinase C, could be related to the distinctive binding properties of the adrenal and vascular receptors and to their differential regulation during altered sodium intake.	NINCDS,NEUROCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	SANDBERG, K (corresponding author), NICHHD,ENDOCRINOL & REPROD RES BRANCH,BLDG 10,RM B1-L400,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							AGUILERA G, 1981, CIRC RES, V49, P751, DOI 10.1161/01.RES.49.3.751; AGUILERA G, 1979, ENDOCRINOLOGY, V104, P1279, DOI 10.1210/endo-104-5-1279; AMBROZ C, 1991, BIOCHIM BIOPHYS ACTA, V1133, P107, DOI 10.1016/0167-4889(91)90248-V; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BALLA T, 1991, MOL PHARMACOL, V40, P401; CARSON MC, 1987, MOL ENDOCRINOL, V1, P147, DOI 10.1210/mend-1-2-147; CATT KJ, 1987, J STEROID BIOCHEM, V27, P915, DOI 10.1016/0022-4731(87)90168-3; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; DOUGLAS JG, 1987, AM J PHYSIOL, V253, pF1, DOI 10.1152/ajprenal.1987.253.1.F1; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HAUSDORFF WP, 1988, ENDOCRINOLOGY, V123, P2818, DOI 10.1210/endo-123-6-2818; JI H, 1991, MOL PHARMACOL, V39, P120; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEFKOWITZ RJ, 1988, COLD SPRING HARB SYM, V53, P507, DOI 10.1101/SQB.1988.053.01.058; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MILLAN MA, 1989, SCIENCE, V244, P1340, DOI 10.1126/science.2734613; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; PEACH MJ, 1990, J CARDIOVASC PHARM, V16, P525; PHILLIPS MI, 1987, ANNU REV PHYSIOL, V49, P413, DOI 10.1146/annurev.physiol.49.1.413; POBINER BF, 1985, J BIOL CHEM, V260, P6200; Sambrook J, 1989, MOL CLONING LABORATO; SANDBERG K, 1988, FEBS LETT, V241, P177, DOI 10.1016/0014-5793(88)81055-X; SANDBERG K, 1991, FEBS LETT, V284, P281, DOI 10.1016/0014-5793(91)80704-7; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SHAPIRA H, 1990, BIOPHYS J, V57, P1281, DOI 10.1016/S0006-3495(90)82646-1; SVETIC A, 1991, J IMMUNOL, V147, P2391; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5	28	274	276	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9455	9458						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374402				2022-12-27	WOS:A1992HT96500002
J	DALTON, SL; MARCANTONIO, EE; ASSOIAN, RK				DALTON, SL; MARCANTONIO, EE; ASSOIAN, RK			CELL ATTACHMENT CONTROLS FIBRONECTIN AND ALPHA-5-BETA-1 INTEGRIN LEVELS IN FIBROBLASTS - IMPLICATIONS FOR ANCHORAGE-DEPENDENT AND ANCHORAGE-INDEPENDENT GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO FIBROBLASTS; VIRUS-TRANSFORMED CELLS; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; SURFACE PROTEIN; RECEPTORS; ADHESION; COLLAGENASE; TRANSLATION; DOMAIN	We have examined the effect of cell attachment on fibronectin and alpha-5-beta-1 integrin levels in three distinct anchorage-dependent fibroblast cell lines. Analysis of long-term biosynthetically labeled proteins from parallel cultures of adherent and nonadherent cells showed that the steady-state level of extracellular fibronectin is decreased upon loss of attachment. Pulse labeling studies and Northern blot analyses showed that the decrease occurs post-synthetically. A combined approach of surface radioiodination and biosynthetic labeling also demonstrated a selective post-synthetic decrease in cell-surface expression of the alpha-5-beta-1 integrin upon loss of cell attachment. Overall, we estimate that extracellular fibronectin and cell surface alpha-5-beta-1 integrin levels are reduced 5-7-fold in NIH-3T3, 15-20-fold in AKR-2B, and 50-fold in NRK fibroblasts. Finally, we find decreased total (serum- and cell-derived) fibronectin bound to the surface of nonadherent cells consistent with the reduced expression of alpha-5-beta-1 integrin. These results demonstrate a systematic down-regulation of fibronectin and its major receptor upon loss of attachment and suggest a potential mechanism involved in maintenance of the anchorage-dependent phenotype.	COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR REPROD SCI, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University					NICHD NIH HHS [HD05077] Funding Source: Medline; NIGMS NIH HHS [GM07367] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD005077] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; ASSOIAN RK, 1989, ANAL BIOCHEM, V177, P95, DOI 10.1016/0003-2697(89)90020-1; BENECKE BJ, 1978, CELL, V14, P931, DOI 10.1016/0092-8674(78)90347-1; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; CAYANIS E, 1990, J BIOL CHEM, V265, P10829; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DHAWAN J, 1991, J BIOL CHEM, V266, P8470; DHAWAN J, 1990, J BIOL CHEM, V265, P9015; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; HYNES RO, 1990, FIBRONECTINS, P301; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; KESKIOJA J, 1980, CANCER RES, V40, P4722; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MATSUHISA T, 1981, EXP CELL RES, V135, P393, DOI 10.1016/0014-4827(81)90176-2; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MOSES HL, 1985, CANCER CELL, V3, P65; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; OLIVER N, 1983, CELL, V33, P287, DOI 10.1016/0092-8674(83)90357-4; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; QUIGLEY JP, 1987, P NATL ACAD SCI USA, V84, P2776, DOI 10.1073/pnas.84.9.2776; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SPORN MB, 1984, CANCER CELL, V1, P1; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WERB Z, 1986, J CELL BIOL, V102, P697, DOI 10.1083/jcb.102.3.697; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	44	63	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8186	8191						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373721				2022-12-27	WOS:A1992HQ18500036
J	KANAYA, S; NAKAI, C; KONISHI, A; INOUE, H; OHTSUKA, E; IKEHARA, M				KANAYA, S; NAKAI, C; KONISHI, A; INOUE, H; OHTSUKA, E; IKEHARA, M			A HYBRID RIBONUCLEASE-H - A NOVEL RNA CLEAVING ENZYME WITH SEQUENCE-SPECIFIC RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; SELECTIVE CLEAVAGE; DNA-SEQUENCE; OLIGONUCLEOTIDES; GENE; OLIGORIBONUCLEOTIDES; IDENTIFICATION; TRANSLATION; RESIDUES	A hybrid enzyme which site-specifically hydrolyzes RNA was created by covalently linking an oligodeoxyribonucleotide to Escherichia coli ribonuclease HI, an enzyme which specifically cleaves RNA moiety of DNA/RNA hybrids. A cysteine residue was substituted for Glu135 by site-directed mutagenesis in the mutant enzyme, in which all 3 free cysteine residues were replaced by alanine (Kanaya, S., Kimura, S., Katsuda, C., and Ikehara, M. (1990) Biochem. J. 271, 59-66), and coupled with a maleimide group, which is attached to the 5' terminus of the nonadeoxyribonucleotide (5'-GTCATCTCC-3') with a flexible tether. The resulting hybrid enzyme, d9-C135/RNase H, cleaved the phosphodiester bond between the fifth and sixth residues of the complementary nonaribonucleotide, without addition of the oligodeoxyribonucleotide. The nonaribonucleotide is cleaved by the wild-type or unmodified mutant enzyme only when the complementary oligodeoxyribonucleotide is present. When the kinetic parameters of the hybrid enzyme for the hydrolysis of the nonaribonucleotide were compared with those of the unmodified mutant enzyme for the hydrolysis of the nonanucleotide duplex, the hybrid enzyme exhibited a 7- and 4-fold decreases in the K(m) and k(cat) values, respectively, indicating that it performs multiple turnovers and has a sufficiently high hydrolytic activity. Hybrid ribonucleases H with various oligodeoxyribonucleotides in size and sequence, therefore, might be used as excellent tools for structural and functional studies of RNA.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	KANAYA, S (corresponding author), PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN.							ATABEKOV KJ, 1988, FEBS LETT, V232, P96, DOI 10.1016/0014-5793(88)80393-4; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; CARTER BJ, 1990, P NATL ACAD SCI USA, V87, P9373, DOI 10.1073/pnas.87.23.9373; CARUTHERS MH, 1985, SCIENCE, V230, P281, DOI 10.1126/science.3863253; COREY DR, 1987, SCIENCE, V238, P1401, DOI 10.1126/science.3685986; CROUCH R J, 1990, New Biologist, V2, P771; Crouch RJ, 1985, NUCLEASES, P211; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; FASMAN GD, 1975, HDB BIOCH MOL BIOL, V1, P580; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HAYASE Y, 1990, BIOCHEMISTRY-US, V29, P8793, DOI 10.1021/bi00489a041; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; ITAYA M, 1990, P NATL ACAD SCI USA, V87, P8587, DOI 10.1073/pnas.87.21.8587; IWAI S, 1990, TETRAHEDRON, V46, P6673, DOI 10.1016/S0040-4020(01)87858-3; JAY E, 1974, NUCLEIC ACIDS RES, V1, P331, DOI 10.1093/nar/1.3.331; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KITAGAWA T, 1981, CHEM PHARM BULL, V29, P1130; KOIZUMI M, 1989, NUCLEIC ACIDS RES, V17, P7059, DOI 10.1093/nar/17.17.7059; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; METELEV VG, 1988, FEBS LETT, V226, P232, DOI 10.1016/0014-5793(88)81429-7; MILLER HI, 1973, J BIOL CHEM, V248, P2621; Miller J. H., 1972, EXPT MOL GENETICS, P433; MINSHULL J, 1986, NUCLEIC ACIDS RES, V14, P6433, DOI 10.1093/nar/14.16.6433; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NELSON PS, 1989, NUCLEIC ACIDS RES, V17, P7179, DOI 10.1093/nar/17.18.7179; SAISONBEHMOARAS T, 1991, EMBO J, V10, P1111, DOI 10.1002/j.1460-2075.1991.tb08051.x; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SHIBAHARA S, 1987, NUCLEIC ACIDS RES, V15, P4403, DOI 10.1093/nar/15.11.4403; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; ZUCKERMANN RN, 1988, J AM CHEM SOC, V110, P1614, DOI 10.1021/ja00213a040; ZUCKERMANN RN, 1988, J AM CHEM SOC, V110, P6592, DOI 10.1021/ja00227a066; ZUCKERMANN RN, 1989, P NATL ACAD SCI USA, V86, P1766, DOI 10.1073/pnas.86.6.1766	43	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8492	8498						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373729				2022-12-27	WOS:A1992HQ18500083
J	NAG, B; PASSMORE, D; KENDRICK, T; BHAYANI, H; SHARMA, SD				NAG, B; PASSMORE, D; KENDRICK, T; BHAYANI, H; SHARMA, SD			N-LINKED OLIGOSACCHARIDES OF MURINE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II MOLECULE - ROLE IN ANTIGENIC PEPTIDE BINDING, T-CELL RECOGNITION, AND CLONAL NONRESPONSIVENESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IA MOLECULES; DIFFERENTIAL GLYCOSYLATION; SURFACE EXPRESSION; LIPID-MEMBRANES; ALPHA-CHAINS; PURIFIED IA; B-CELLS; SEQUENCE; MUTAGENESIS; DOMAIN	To evaluate the functional role of the N-linked oligosaccharides of major histocompatibility complex (MHC) class II molecules, affinity-purified murine IA(s) class II molecules were deglycosylated in the presence of asparagine amidase enzyme. The deglycosylated IA(s) molecules were characterized by 12% SDS-polyacrylamide gel analysis under reduced and native conditions and the complete enzymatic removal of all three N-linked sugar components from the alpha/beta heterodimer was confirmed by lectin-link Western blot analysis. Like the native IA(s) molecules, the deglycosylated IA(s) molecules were fully capable of binding an antigenic peptide from myelin basic protein MBP(89-101). The kinetics of dissociation of preformed complexes of IA(s).MBP(89-101) and deglycosylated IA(s).MBP(89-101) were compared at 4 and at 37-degrees-C. Both complexes were equally stable at 4-degrees-C; however, at 37-degrees-C the deglycosylated IA(s).MBP(89-101) complexes showed an increased rate of dissociation as compared with the native IA(s).MBP(89-101) complexes. When tested for their ability to recognize the T cell receptor on T cells, both complexes bound to cloned HS-1 T cells that recognize and respond to IA(s).MBP (89-101). Finally, the complexes of deglycosylated IA(s).MBP(89-101) were tested for the induction of in vitro nonresponsiveness and compared with native IA(s).MBP(89-101) complexes. Both complexes were capable of inducing 95-100% nonresponsiveness in a proliferation assay. These results suggest that the N-linked oligosaccharide of MHC class II molecules may not be essential for either antigenic peptide binding or T cell recognition. In addition results obtained here provide evidence that the carbohydrate moities of MHC class II molecules may not be involved in induction of T cell clonal anergy.			NAG, B (corresponding author), ANERGEN INC,REDWOOD CITY,CA 94063, USA.							BARBOSA JA, 1987, J EXP MED, V166, P1329, DOI 10.1084/jem.166.5.1329; BENOIST CO, 1983, P NATL ACAD SCI-BIOL, V80, P534, DOI 10.1073/pnas.80.2.534; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CHOI E, 1983, SCIENCE, V221, P283, DOI 10.1126/science.6407114; COWING C, 1983, P NATL ACAD SCI-BIOL, V80, P6000, DOI 10.1073/pnas.80.19.6000; CULLEN SE, 1981, J IMMUNOL, V127, P1478; ESTESS P, 1986, P NATL ACAD SCI USA, V83, P3594, DOI 10.1073/pnas.83.11.3594; FROHMAN M, 1985, J IMMUNOL, V134, P2269; GOLDSTEIN SAN, 1985, J EXP MED, V162, P1381, DOI 10.1084/jem.162.4.1381; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KRIEGER J, 1988, J IMMUNOL, V140, P388; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MIYAZAKI J, 1986, J EXP MED, V163, P856, DOI 10.1084/jem.163.4.856; NAG B, 1992, J IMMUNOL, V148, P2040; NAG B, 1991, J IMMUNOL METHODS, V142, P105, DOI 10.1016/0022-1759(91)90297-S; NAG B, 1992, J IMMUNOL, V148, P369; NEEL D, 1987, BIOCHEM J, V244, P433, DOI 10.1042/bj2440433; PASSMORE D, 1992, IN PRESS J IMMUNOL M; QUILL H, 1987, J IMMUNOL, V138, P3704; ROOF RW, 1990, P NATL ACAD SCI USA, V87, P1735, DOI 10.1073/pnas.87.5.1735; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SANTOSAGUADO J, 1987, MOL CELL BIOL, V7, P982, DOI 10.1128/MCB.7.3.982; SHARMA SD, 1991, P NATL ACAD SCI USA, V88, P11465, DOI 10.1073/pnas.88.24.11465; SHIROISHI T, 1985, J IMMUNOL, V134, P623; SWIEDLER SJ, 1985, J BIOL CHEM, V260, P4046; TROTTER J, 1985, J IMMUNOL, V134, P2322; WATTS TH, 1986, P NATL ACAD SCI USA, V83, P9660, DOI 10.1073/pnas.83.24.9660; WEI BY, 1991, J IMMUNOL, V146, P2358	30	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22624	22629						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385402				2022-12-27	WOS:A1992JW71900098
J	SASAKI, T; NAKA, M; NAKAMURA, F; TANAKA, T				SASAKI, T; NAKA, M; NAKAMURA, F; TANAKA, T			RUTHENIUM RED INHIBITS THE BINDING OF CALCIUM TO CALMODULIN REQUIRED FOR ENZYME ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; LIGHT CHAIN KINASE; SMOOTH-MUSCLE MYOSIN; RABBIT SKELETAL-MUSCLE; TRYPTIC FRAGMENTS; PYRUVATE-DEHYDROGENASE; MARINE-INVERTEBRATES; MODULATOR PROTEIN; BOVINE HEART; SEA-ANEMONE	The Ca2+-calmodulin (CaM)-dependent activation of myosin light chain kinase is inhibited by ruthenium red competitively with respect to Ca2+, with a K(i) value of 8.6 muM. The binding of Ca2+ to CaM is inhibited by micromolar concentrations of ruthenium red. In the absence of Ca2+, CaM has two binding sites for ruthenium red with the dissociation constants of 0.36 and 8.7 muM, respectively. Ca2+ antagonizes the binding of ruthenium red to the low-affinity site on CaM. Binding of ruthenium red to the high-affinity site is not affected by Ca2+. The low- and high-affinity sites for ruthenium red are shown to be located in the NH2-terminal half and the COOH-terminal half of CaM, respectively. Lower concentrations of ruthenium red are needed for enzyme inactivation than for the dissociation of enzyme-CaM-Sepharose complex, suggesting these events have different Ca2+ requirements. Moreover, ruthenium red inhibits Ca2+-induced contraction of depolarized vascular smooth muscle in a competitive manner with respect to Ca2+. These results suggest that ruthenium red may be a new type of CaM antagonist that inhibits the binding of Ca2+ to CaM and thereby inhibits Ca2+-CaM-dependent enzymes and smooth muscle contraction competitively with respect to Ca2+.	MIE UNIV,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,2-174 EDOBASHI,TSU,MIE 514,JAPAN	Mie University								Adair GS, 1925, J BIOL CHEM, V63, P529; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; ADELSTEIN RS, 1978, J BIOL CHEM, V253, P8347; ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ANDERSSON A, 1983, EUR J BIOCHEM, V134, P459, DOI 10.1111/j.1432-1033.1983.tb07589.x; Beavo J A, 1974, Methods Enzymol, V38, P299; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; COX JA, 1981, J BIOL CHEM, V256, P3218; COX JA, 1988, CALCIUM CALCIUM BIND, P141; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3962; DABROWSKA R, 1978, BIOCHEMISTRY-US, V17, P253, DOI 10.1021/bi00595a010; Dahlquist F W, 1978, Methods Enzymol, V48, P270; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DONATO R, 1989, CELL CALCIUM, V10, P81, DOI 10.1016/0143-4160(89)90048-1; ENDO T, 1985, ENDOCRINOLOGY, V117, P527, DOI 10.1210/endo-117-2-527; FORBES MS, 1979, CELL TISSUE RES, V200, P367; FORSEN S, 1986, CALCIUM CELL FUNCTIO, V6, P113; GUERINI D, 1985, ANAL BIOCHEM, V150, P178, DOI 10.1016/0003-2697(85)90458-0; GUERINI D, 1984, J BIOL CHEM, V259, P5172; GUPTA MP, 1989, CAN J CARDIOL, V5, P55; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HANSFORD RG, 1987, BIOCHEM J, V241, P145, DOI 10.1042/bj2410145; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HIDAKA H, 1976, J BIOL CHEM, V251, P7508; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; HIDAKA H, 1980, MOL PHARMACOL, V17, P66; HUANG CY, 1981, P NATL ACAD SCI-BIOL, V78, P871, DOI 10.1073/pnas.78.2.871; IKURA M, 1984, BIOCHEMISTRY-US, V23, P3124, DOI 10.1021/bi00309a003; INAGAKI M, 1983, PHARMACOLOGY, V27, P125, DOI 10.1159/000137861; KINCAID RL, 1986, P NATL ACAD SCI USA, V83, P1193, DOI 10.1073/pnas.83.5.1193; KINCAID RL, 1984, ADV CYCLIC NUCL PROT, V16, P77; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1978, BIOCHEMISTRY-US, V17, P120, DOI 10.1021/bi00594a017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTE DC, 1979, BIOCHEMISTRY-US, V18, P2820, DOI 10.1021/bi00580a021; LEVIN RM, 1977, MOL PHARMACOL, V13, P690; LINSE S, 1991, J BIOL CHEM, V266, P8050; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MASUOKA H, 1990, BIOCHEM BIOPH RES CO, V169, P315, DOI 10.1016/0006-291X(90)91470-D; MCCORMACK JG, 1983, BIOCHEM J, V214, P581, DOI 10.1042/bj2140581; MILLS JS, 1985, J BIOL CHEM, V260, P5100; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; MINOWA O, 1984, J BIOCHEM-TOKYO, V96, P1175, DOI 10.1093/oxfordjournals.jbchem.a134935; NACCACHE PH, 1980, BIOCHEM BIOPH RES CO, V97, P62, DOI 10.1016/S0006-291X(80)80134-3; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; Smith RM, 1974, CRITICAL STABILITY C, V1-6; TANAKA T, 1980, BIOCHEM BIOPH RES CO, V92, P313, DOI 10.1016/0006-291X(80)91554-5; TANAKA T, 1983, PHARMACOLOGY, V26, P249, DOI 10.1159/000137808; TANAKA T, 1986, MOL PHARMACOL, V29, P264; TEO TS, 1973, J BIOL CHEM, V248, P5950; VOGEL HJ, 1984, BIOCHEM BIOPH RES CO, V122, P1350, DOI 10.1016/0006-291X(84)91240-3; WALSH M, 1977, J BIOL CHEM, V252, P7440; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869	59	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21518	21523						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383224				2022-12-27	WOS:A1992JV01100041
J	BISHOPRIC, NH; SATO, B; WEBSTER, KA				BISHOPRIC, NH; SATO, B; WEBSTER, KA			BETA-ADRENERGIC REGULATION OF A MYOCARDIAL ACTIN GENE VIA A CYCLIC AMP-INDEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; CA-2+ RELEASE CHANNEL; RAT CARDIAC MYOCYTES; PROTEIN-KINASE-C; SARCOPLASMIC-RETICULUM; CALCIUM IONOPHORE; CELL HYPERTROPHY; SKELETAL-MUSCLE; GROWTH-FACTOR; HUMAN-HEART	The skeletal alpha-actin gene encodes a major component of the embryonic cardiac sarcomere that is strongly and selectively re-induced during beta-adrenoceptor-mediated hypertrophy in neonatal rat cardiac myocytes. We present evidence that beta-adrenergic induction of this gene is mediated, not by cAMP, but by a calcium-dependent pathway involving ryanodine-sensitive calcium stores. Nifedipine-induced blockade of the plasma membrane L-type calcium entry channel prevented induction of skeletal alpha-actin mRNA by isoproterenol. Activation of calcium entry by the dihydropyridine agonist Bay K8644 independently induced skeletal alpha-actin mRNA, as did cholera toxin-mediated activation of G(s). Induction of skeletal alpha-actin mRNA by compounds that directly elevate cAMP was weak relative to their effects on other cAMP-dependent phenomena and required calcium entry. In addition, selective inhibition of protein kinase A with KT5720 did not block beta-adrenergic induction of skeletal alpha-actin. Calcium ionophore A23187 did not induce skeletal actin, but prevented its induction by isoproterenol. Ryanodine had bimodal effects: 10(-10) M ryanodine induced skeletal alpha-actin mRNA, whereas 10(-6) M ryanodine prevented skeletal actin induction by beta-adrenergic stimuli. We postulate that beta-adrenergic stimulation of skeletal alpha-actin mRNA requires G-protein-coupled calcium channel activation and compartmentalized calcium release in a manner independent of the cAMP/protein kinase A signal pathway.	DEPT VET AFFAIRS MED CTR,CARDIOVASC RES INST,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BISHOPRIC, NH (corresponding author), SRI INT,DIV LIFE SCI M111,333 RAVENSWOOD AVE,MENLO PK,CA 94025, USA.			Webster, Keith A/0000-0002-6431-3642	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044578, R01HL044578] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44578] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BOHELER KR, 1991, J CLIN INVEST, V88, P323, DOI 10.1172/JCI115295; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BRISTOW MR, 1984, J CLIN INVEST, V74, P212, DOI 10.1172/JCI111404; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CITRI Y, 1980, NATURE, V287, P297, DOI 10.1038/287297a0; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROVE JR, 1987, SCIENCE, V238, P530; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; HUNTER DR, 1983, CIRC RES, V53, P703, DOI 10.1161/01.RES.53.5.703; INUI M, 1987, J BIOL CHEM, V262, P15637; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LANGER GA, 1990, AM J PHYSIOL, V259, pH592, DOI 10.1152/ajpheart.1990.259.2.H592; LAPOINTE MC, 1990, HYPERTENSION, V15, P20, DOI 10.1161/01.HYP.15.1.20; LIPP P, 1990, FEBS LETT, V275, P181, DOI 10.1016/0014-5793(90)81467-3; LYNCH C, 1991, AM J PHYSIOL, V260, pH785, DOI 10.1152/ajpheart.1991.260.3.H785; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; REUTER H, 1982, NATURE, V297, P501, DOI 10.1038/297501a0; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; ROCHASINGH KJ, 1989, CIRCULATION S2, V80, P93; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SEI CA, 1991, J BIOL CHEM, V266, P15910; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHUNTOH H, 1988, J NEUROCHEM, V51, P1565, DOI 10.1111/j.1471-4159.1988.tb01126.x; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; SUTKO JL, 1985, FED PROC, V44, P2984; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; TARAZI RC, 1983, AM J MED, V75, P80, DOI 10.1016/0002-9343(83)90123-7; WEBSTER KA, 1992, IN PRESS J MOL CELL; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	46	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20932	20936						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383212				2022-12-27	WOS:A1992JT97800067
J	EISEMAN, E; BOLEN, JB				EISEMAN, E; BOLEN, JB			SIGNAL TRANSDUCTION BY THE CYTOPLASMIC DOMAINS OF FC-EPSILON-RI-GAMMA AND TCR-ZETA IN RAT BASOPHILIC LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; PROTEIN-TYROSINE KINASE; HIGH-AFFINITY RECEPTOR; T-CELL; ANTIGEN RECEPTOR; IMMUNOGLOBULIN-E; TRANSFECTED CELLS; MOLECULAR-CLONING; SURFACE EXPRESSION; IGE RECEPTOR	The gamma subunit of the high affinity IgE receptor, FcepsilonRI, is a member of a family of proteins which form disulfide-linked dimers. This family also includes the zeta- and eta-chains of the T cell receptor. Engagement of FcepsilonRI activates src-related protein tyrosine kinases in basophils and mast cells. However, the role of individual subunits of FcepsilonRI in this activation is still not known. In an effort to determine the function of FcepsilonRI-gamma, we used chimeric proteins containing the extracellular and transmembrane domains of the alpha chain of the human interleukin 2 receptor (Tac) and the cytoplasmic domains of either T cell receptor-zeta or FcepsilonRI-gamma. We show that while cross-linking of the Tac chimeras in the rat basophilic leukemia cell line RBL-2H3 resulted in the tyrosine phosphorylation of a subset of proteins and a portion of the degranulation normally observed after FcepsilonRI-mediated stimulation, no detectable activation of p56lyn or pp60c-src was observed. In contrast, an apparent transient deactivation of these two kinases was observed after Tac chimera cross-linking. These observations suggest that FcepsilonRI-gamma is responsible for some, but not all, of the signaling that occurs after engagement of its receptor, and that other receptor subunits may also play important roles in this signaling process.			EISEMAN, E (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, POB 4000, PRINCETON, NJ 08543 USA.							ALBER G, 1991, J BIOL CHEM, V266, P22613; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; BANIYASH M, 1989, J BIOL CHEM, V264, P13252; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOLEN JB, 1991, ADV CANCER RES, V57, P103; EISEMAN E, 1992, NATURE, V355, P78; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HUPPI KD, 1991, J IMMUNOL, V143, P3787; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; KUROSAKI T, 1992, J EXP MED, V175, P447, DOI 10.1084/jem.175.2.447; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LECONIAT M, 1990, IMMUNOGENETICS, V32, P183, DOI 10.1007/BF02114971; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LETOURNEUR F, 1989, IMMUNOGENETICS, V29, P265, DOI 10.1007/BF00717911; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; OHNO H, 1990, INT IMMUNOL, V2, P1117, DOI 10.1093/intimm/2.11.1117; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RODEWALD HR, 1991, J BIOL CHEM, V266, P15974; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VARINBLANK N, 1990, J BIOL CHEM, V265, P15685; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	46	50	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21027	21032						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383215				2022-12-27	WOS:A1992JT97800081
J	ADAMSON, P; MARSHALL, CJ; HALL, A; TILBROOK, PA				ADAMSON, P; MARSHALL, CJ; HALL, A; TILBROOK, PA			POSTTRANSLATIONAL MODIFICATIONS OF P21(RHO)PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; BOVINE BRAIN MEMBRANES; C-TERMINAL CYSTEINE; RHOA GENE-PRODUCT; GAMMA-SUBUNIT; ISOPRENOID MODIFICATION; PRENYLATED PROTEINS; METHYL-ESTER; RAS PROTEINS; IDENTIFICATION	Post-translational modifications of the ras proteins, which are required for plasma membrane localization and biological function of the proteins, have been shown to include prenylation and carboxymethylation at the carboxyl terminal cysteine residue of the cysteine-aliphatic amino acid-aliphatic amino acid-any amino acid (CAAX) box. In addition, p21Ha-ras and p21N-ras, but not p21K-ras (B), are palmitoylated. The three mammalian rho proteins (A, B, and C) are also members of the ras superfamily but have distinct biological activities and different intracellular distributions from p21(ras). Analysis showed all three rho proteins are modified by a COOH-terminal carboxymethylation similar to p21ras, whereas p21rhoC labeled with [H-3]mevalonic acid in vivo revealed the presence of a C20 prenoid, similar to that already described for p21rhoA. However, in vivo and in vitro studies of p21rhoB showed this protein to be modified by both C15 and C20 prenoids. Mutation of C193 in the CAAX box abolished prenylation, whereas mutation of the adjacent C192 resulted in a significant reduction in the amount of the C20, but not C15 prenoid, recovered from p21rhoB. In vivo labeling studies with [H-3]palmitic acid and mutational analysis showed that both cysteine residues at 189 and 192 upstream of the CAAX box in p21rhoB are sites for palmitoylation. We conclude that there are different populations of post-translationally modified p21rhoB in the cell and that the sequence specificity for geranylgeranyl- and farnesyltransferases may be more complicated than previously proposed.	INST CANC RES, CHESTER BEATTY LABS, CELL & MOLEC BIOL SECT, 237 FULHAM RD, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ADMSON P, 1992, IN PRESS J CELL BIOL; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BINSTOCK J, 1984, METHOD ENZYMOL, V106, P310; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; EPSTEIN WW, 1990, P NATL ACAD SCI USA, V87, P7352, DOI 10.1073/pnas.87.19.7352; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANCOCK JF, 1992, IN PRESS RAS SUPER F; HORI Y, 1991, ONCOGENE, V6, P515; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MOORES SL, 1991, J BIOL CHEM, V266, P14603; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	41	331	339	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20033	20038						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400319				2022-12-27	WOS:A1992JR85800047
J	LUNSTRUM, GP; MCDONOUGH, AM; MARINKOVICH, MP; KEENE, DR; MORRIS, NP; BURGESON, RE				LUNSTRUM, GP; MCDONOUGH, AM; MARINKOVICH, MP; KEENE, DR; MORRIS, NP; BURGESON, RE			IDENTIFICATION AND PARTIAL-PURIFICATION OF A LARGE, VARIANT FORM OF TYPE-XII COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IX COLLAGEN; EXTRACELLULAR-MATRIX; ANCHORING FIBRILS; LAMININ VARIANTS; VII PROCOLLAGEN; VITREOUS-HUMOR; II COLLAGEN; CARTILAGE; PROTEOGLYCAN; MOLECULE	A large, alternate form of type XII collagen has been identified in cultures of the human epidermoid cell line WISH. This form, designated XIIA, is comprised of alpha chains that are approximately 90 kDa larger than the 220-kDa alpha chain previously characterized in extracts of fetal chicken and bovine tissues. Results from both collagenase digestion and rotary shadow analysis of partially purified material show that the increase is due to a larger NC3 domain. While both the large (XIIA) and the small (XIIB) forms of type XII collagen are identified in pulse-chase radiolabeling of fetal bovine skin explant culture, they are not related in a precursor-product fashion. Inhibition studies with alpha,alpha'-dipyridyl indicate that proper folding of the collagen helix is required for complete assembly and secretion of type XIIA in WISH cell culture. The 310-kDa alpha1A chain is likely to represent the bovine equivalent of a second translation product, estimated to be 340 kDa, predicted from analysis of one complete chick cDNA sequence. Additionally, the amino-terminal amino acid sequence of the 220-kDa bovine alpha1B chain was determined. This sequence is very near a potential alternate splice site predicted from analysis of chicken type XII cDNA.	SHRINERS HOSP CRIPPLED CHILDREN, 3101 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT DERMATOL, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University								AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; BACHINGER HP, 1990, J BIOL CHEM, V265, P10095; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BREWTON RG, 1991, J BIOL CHEM, V266, P4752; BURGESON RE, 1988, ANNU REV CELL BIOL, V4, P551, DOI 10.1146/annurev.cb.04.110188.003003; DUBLET B, 1990, ANN NY ACAD SCI, V580, P436, DOI 10.1111/j.1749-6632.1990.tb17953.x; DUBLET B, 1989, J BIOL CHEM, V264, P13150; DUBLET B, 1991, J BIOL CHEM, V266, P6853; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; EYRE DR, 1991, ARTICULAR CARTILAGE, P119; GORDON MK, 1989, CONNECT TISSUE RES, V20, P179, DOI 10.3109/03008208909023886; GORDON MK, 1989, J BIOL CHEM, V264, P19772; GORDON MK, 1991, EUR J BIOCHEM, V201, P333, DOI 10.1111/j.1432-1033.1991.tb16290.x; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; LUNSTRUM GP, 1987, J BIOL CHEM, V262, P13706; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; PAULSSON M, 1991, J BIOL CHEM, V266, P17545; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SHIMOKOMAKI M, 1990, ANN NY ACAD SCI, V580, P1, DOI 10.1111/j.1749-6632.1990.tb17912.x; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VANDERREST M, 1985, J BIOL CHEM, V260, P220; VAUGHAN L, 1985, J BIOL CHEM, V260, P4758; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; WATT SL, 1992, J BIOL CHEM, V267, P20093; WU JJ, 1989, CONNECT TISSUE RES, V20, P241, DOI 10.3109/03008208909023893; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5; YADA T, 1990, J BIOL CHEM, V265, P6992; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209; YAMAUCHI M, 1986, BIOCHEMISTRY-US, V25, P1997, DOI 10.1021/bi00356a024	37	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20087	20092						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400326				2022-12-27	WOS:A1992JR85800055
J	PILON, M; RIETVELD, AG; WEISBEEK, PJ; DEKRUIJFF, B				PILON, M; RIETVELD, AG; WEISBEEK, PJ; DEKRUIJFF, B			SECONDARY STRUCTURE AND FOLDING OF A FUNCTIONAL CHLOROPLAST PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIT PEPTIDE; SPINACH FERREDOXIN; ESCHERICHIA-COLI; APOCYTOCHROME-C; IMPORT RECEPTOR; TRANSLOCATION; BINDING; MITOCHONDRIAL; TRANSPORT; ENVELOPE	Ferredoxin is a chloroplast stroma protein which is cytosolically synthesized as a precursor with an amino-terminal extension called the transit sequence that is needed for the post-translational uptake by the chloroplast. To characterize the secondary and tertiary structure elements, the full precursor, the holo- and apo- (without iron-sulfur cluster) forms of the mature protein, and the chemically synthesized transit peptide were obtained and analyzed separately. Circular dichroism, tryptophan fluorescence quenching, and protease accessibility experiments indicate that the precursor has a low content of defined secondary structure and resembles unfolded proteins; these properties are due to both the mature part and the transit sequence. This result provides an explanation for the lack of cytosolic factor requirement of this protein for import. In an import competition assay, the isolated transit peptide had an affinity for the chloroplasts comparable to the full precursor. Interestingly and of possible importance to the import process, the transit peptide has conformational flexibility as it adopts alternative secondary structures in different environments.	UNIV UTRECHT,DEPT MOLEC CELL BIOL,3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,3584 CH UTRECHT,NETHERLANDS	Utrecht University; Utrecht University	PILON, M (corresponding author), UNIV UTRECHT,INST MOLEC BIOL & MED BIOTECHNOL,PADUALAAN 8,3584 CH UTRECHT,NETHERLANDS.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchanan BB, 1971, METHOD ENZYMOL, V23, P413, DOI [10.1016/S0076-6879(71)23115-3, DOI 10.1016/S0076-6879(71)23115-3]; BUVINGER WE, 1989, J BIOL CHEM, V264, P1195; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHUA NH, 1979, J CELL BIOL, V81, P461, DOI 10.1083/jcb.81.3.461; DAHLINC, 1991, PLANT CELL, V3, P1131; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DEJONGH HHJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P105, DOI 10.1016/0005-2736(90)90442-Q; DELLACIOPPA G, 1986, P NATL ACAD SCI USA, V83, P6873, DOI 10.1073/pnas.83.18.6873; DELLACIOPPA G, 1988, EMBO J, V7, P1299, DOI 10.1002/j.1460-2075.1988.tb02944.x; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JONES JD, 1990, J BIOENERG BIOMEMBR, V22, P213, DOI 10.1007/BF00763166; JORDI W, 1989, J BIOL CHEM, V264, P2292; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAGANI S, 1984, EUR J BIOCHEM, V142, P361, DOI 10.1111/j.1432-1033.1984.tb08295.x; PAGANI S, 1986, BIOCHIM BIOPHYS ACTA, V870, P538, DOI 10.1016/0167-4838(86)90263-3; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; Parker C. A., 1968, PHOTOLUMINESCENCE SO, P220; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PILON M, 1990, J BIOL CHEM, V265, P3358; PILON M, 1992, J BIOL CHEM, V267, P2548; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; REID GA, 1982, J BIOL CHEM, V257, P3062; REISS B, 1987, MOL GEN GENET, V209, P116, DOI 10.1007/BF00329845; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1989, MOL GEN GENET, V216, P178, DOI 10.1007/BF00332249; SMEEKENS S, 1987, PLANT MOL BIOL, V9, P377, DOI 10.1007/BF00014912; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; THEG SM, 1989, J BIOL CHEM, V264, P6730; TSUKIHARA T, 1981, J BIOCHEM-TOKYO, V90, P1763, DOI 10.1093/oxfordjournals.jbchem.a133654; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANTHOF R, 1991, FEBS LETT, V291, P350, DOI 10.1016/0014-5793(91)81318-3; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WALKER DA, 1987, METHOD ENZYMOL, V148, P145; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; YOCUM CF, 1982, METHODS CHLOROPLAST, P973	54	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19907	19913						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400307				2022-12-27	WOS:A1992JR85800028
J	GHERSA, P; VANHUIJSDUIJNEN, RH; WHELAN, J; DELAMARTER, JF				GHERSA, P; VANHUIJSDUIJNEN, RH; WHELAN, J; DELAMARTER, JF			LABILE PROTEINS PLAY A DUAL ROLE IN THE CONTROL OF ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE-1 (ELAM-1) GENE-REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR NECROSIS FACTOR; HISTONE MESSENGER-RNA; GROWTH-FACTOR; C-FOS; ACTIN GENE; SYNTHESIS INHIBITORS; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; TISSUE FACTOR	Endothelial leukocyte adhesion molecule-1 (ELAM-1) is a membrane protein exclusively expressed on endothelial cells, where it plays a key role in the inflammatory response by adhering to a subset of leukocytes. The expression of the ELAM-1 gene is very tightly regulated. ELAM-1 is undetectable in uninduced cells, and it is transiently expressed following cytokine induction. Treatment of resting endothelial cells with three different protein synthesis inhibitors, cycloheximide (CHX), anisomycin, and emetine, caused an increase in the steady-state level of ELAM-1 mRNA above that observed with IL (interleukin)-l alone. Furthermore, ELAM-1 mRNA was found in the presence of all three protein synthesis inhibitors without IL-1 treatment. Analysis of the mRNA half-life indicated that the protein synthesis inhibitors act, in part, by stabilizing ELAM-1 mRNA. In addition, protein synthesis inhibitors potentiate the effect of IL-1beta at the level of transcription initiation as shown by nuclear run-on experiments. The NFkappaB-like binding activity to the ELAM-1 promoter sequence induced by IL-1beta is augmented by inhibitors of protein synthesis. The NFkappaB binding sequence was found to be necessary and sufficient for superinduction of the ELAM-1 gene by CHX. These results show that regulation at the level of protein synthesis is implicated in the overall regulation of ELAM-1 gene expression. Mechanisms which could explain these effects are discussed.			GHERSA, P (corresponding author), GLAXO INST MOLEC BIOL,14 CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND.		Hooft van Huijsduijnen, Rob/B-3653-2009	Hooft van Huijsduijnen, Rob/0000-0002-2261-9424				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAKER EJ, 1986, MOL CELL BIOL, V6, P54, DOI 10.1128/MCB.6.1.54; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; COX GS, 1990, J BIOL CHEM, V265, P13190; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; CULLEN BR, 1987, METHOD ENZYMOL, V152, P692; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GONG ZY, 1988, MOL CELL BIOL, V8, P3518, DOI 10.1128/MCB.8.8.3518; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PESTKA S, 1971, ANNU REV MICROBIOL, V25, P487, DOI 10.1146/annurev.mi.25.100171.002415; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PONTECORVI A, 1988, EMBO J, V7, P1489, DOI 10.1002/j.1460-2075.1988.tb02967.x; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964; RUCO LP, 1990, AM J PATHOL, V137, P1163; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIVE HL, 1984, MOL CELL BIOL, V4, P2723, DOI 10.1128/MCB.4.12.2723; STIMAC E, 1984, MOL CELL BIOL, V4, P2082, DOI 10.1128/MCB.4.10.2082; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232	50	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19226	19232						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382069				2022-12-27	WOS:A1992JP59300035
J	DSCHIDA, WJ; BOWMAN, BJ				DSCHIDA, WJ; BOWMAN, BJ			STRUCTURE OF THE VACUOLAR ATPASE FROM NEUROSPORA-CRASSA AS DETERMINED BY ELECTRON-MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASES; TRANSLOCATING ATPASES; QUATERNARY STRUCTURE; F1-LIKE STRUCTURE; PLASMA-MEMBRANES; PURIFICATION; F1; TRIPHOSPHATASE; MITOCHONDRIA; HOMOLOGY	We have examined the structure of the vacuolar ATPase of Neurospora crassa using negatively stained preparations of vacuolar membranes and of detergent-solubilized and gradient-purified ATPase complexes. We also examined the peripheral sector (V1) of the enzyme after it had been removed and purified. Using different stains, vacuolar membranes displayed ball-and-stalk structures similar to those of the intact mitochondrial ATPase. However, the vacuolar ATPase was clearly different from the mitochondrial ATPase in both size and structural features. The vacuolar enzyme had a much larger head domain with a distinct cleft down the middle of the complex. This domain was held above the membrane by a prominent stalk. Most intriguing was the presence of basal components. These structures appeared to project from the vacuolar membrane near the base of the stalks. Detergent-solubilized, gradient-purified ATPases displayed the same head, stalk, and basal features as those found with the intact enzyme on vacuolar membranes. The mitochondrial ATPase was significantly smaller, and no clefted head domains or basal components were observed. When V1 and F1 particles were directly compared, a significant difference in size and shape between these two soluble ATPase sectors was apparent. V1 retained all of the features seen in the globular head of the intact complex: V-shaped, triangular, and square forms around a stain-filled core.	UNIV CALIF SANTA CRUZ, DEPT BIOL, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz					NIGMS NIH HHS [GM 28703, GM 08132] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008132, R01GM028703] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOWMAN BJ, 1981, J BIOL CHEM, V256, P2343; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; BOWMAN EJ, 1988, METHOD ENZYMOL, V157, P562; BOWMAN R, 1992, GENE, V114, P157; BROWN D, 1987, J CELL BIOL, V105, P1637, DOI 10.1083/jcb.105.4.1637; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; KANASEKI T, 1969, J CELL BIOL, V42, P202, DOI 10.1083/jcb.42.1.202; KLINK R, 1991, BOT ACTA, V104, P122, DOI 10.1111/j.1438-8677.1991.tb00207.x; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1991, FEBS LETT, V291, P92, DOI 10.1016/0014-5793(91)81111-K; MORRE DJ, 1991, PLANTA, V184, P343, DOI 10.1007/BF00195335; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; SCHMIDT W, 1982, EUR J CELL BIOL, V27, P96; Sebald W, 1979, Methods Enzymol, V55, P344; SEBALD W, 1984, HPLUS ATPASE ATP SYN, P67; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; TAIZ SL, 1991, BOT ACTA, V104, P117, DOI 10.1111/j.1438-8677.1991.tb00206.x; TIEDGE H, 1983, EUR J BIOCHEM, V132, P37, DOI 10.1111/j.1432-1033.1983.tb07322.x; TSUPRUN VL, 1984, FEBS LETT, V167, P285, DOI 10.1016/0014-5793(84)80144-1; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	31	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18783	18789						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388158				2022-12-27	WOS:A1992JN50200081
J	FEVE, B; BAUDE, B; KRIEF, S; STROSBERG, AD; PAIRAULT, J; EMORINE, LJ				FEVE, B; BAUDE, B; KRIEF, S; STROSBERG, AD; PAIRAULT, J; EMORINE, LJ			INHIBITION BY DEXAMETHASONE OF BETA-3-ADRENERGIC RECEPTOR RESPONSIVENESS IN 3T3-F442A ADIPOCYTES - EVIDENCE FOR A TRANSCRIPTIONAL MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HAMSTER BETA-2-ADRENERGIC RECEPTOR; BROWN ADIPOSE-TISSUE; MESSENGER-RNA LEVELS; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; MOLECULAR CHARACTERIZATION; 3T3-L1 PREADIPOCYTES; DNA-BINDING; C-JUN	Modulation of beta-3-adrenergic receptor (beta-3AR) expression by dexamethasone was investigated in the murine 3T3-F442A adipocytic cell line. In untreated cells, a major population of binding sites (62,000-114,000 sites/cell) of low affinity for (-)-[H-3] CGP12177 and (-)-[I-125]iodocyanopindolol (corresponding to the beta-3AR subtype) was present along with a minor population (6,500-8,000 sites/cell) of sites of high affinity for the radioligands (corresponding to a mixture of the beta-1 and beta-2AR subtypes). Long-term exposure of the cells to 250 nM dexamethasone led to a sharp decrease in beta-3AR density (less than 5,000 sites/cell) which paralleled a diminished potency of the beta-3AR-selective agonists BRL37344 and CGP12177 to stimulate the production of intracellular cAMP. Analysis of RNA by polymerase chain reaction and nuclear run-on assays indicated that dexamethasone inhibited the synthesis of beta-3AR mRNA, resulting in 4-8-fold decrease in the steady-state levels of this mRNA. The down-regulation of beta-3AR protein and cellular mRNA appeared to be mediated by the receptor for glucocorticoids as assessed by the antagonistic action of the anti-glucocorticoid RU38486.	HOP HENRI MONDOR,CNRS,INSERM,U282,F-94010 CRETEIL,FRANCE; UNIV PARIS 07,INST COCHIN GENET MOLEC,F-75221 PARIS 05,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Gustave-Eiffel; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				Feve, Bruno/0000-0001-6577-9009; Krief, Stephane/0000-0002-5543-731X				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; ARCH JRS, 1989, P NUTR SOC, V48, P215, DOI 10.1079/PNS19890032; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAUN T, 1970, P NATL ACAD SCI USA, V66, P995, DOI 10.1073/pnas.66.3.995; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHALLISS RAJ, 1988, BIOCHEM PHARMACOL, V37, P947, DOI 10.1016/0006-2952(88)90186-4; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; EMORINE LJ, 1991, BIOCHEM PHARMACOL, V41, P853, DOI 10.1016/0006-2952(91)90188-B; EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; EXTON J H, 1987, Diabetes Metabolism Reviews, V3, P163; EXTON JH, 1972, J BIOL CHEM, V247, P3579; FEVE B, 1991, J BIOL CHEM, V266, P20329; FEVE B, 1990, J BIOL CHEM, V265, P16343; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GUEST SJ, 1990, J BIOL CHEM, V265, P5370; HAINQUE B, 1987, BIOCHIM BIOPHYS ACTA, V931, P347, DOI 10.1016/0167-4889(87)90226-6; HOLLENGA C, 1990, HORM METAB RES, V22, P17, DOI 10.1055/s-2007-1004839; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; JONES MD, 1989, NUCLEIC ACIDS RES, V17, P8387, DOI 10.1093/nar/17.20.8387; KENT RS, 1980, MOL PHARMACOL, V17, P14; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; LAI E, 1982, J BIOL CHEM, V257, P6691; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALBON CC, 1988, TRENDS PHARMACOL SCI, V9, P33, DOI 10.1016/0165-6147(88)90240-4; MALBON CC, 1988, BIOCHEM BIOPH RES CO, V154, P676, DOI 10.1016/0006-291X(88)90192-1; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MOUSTAID N, 1990, J CELL BIOCHEM, V42, P243, DOI 10.1002/jcb.240420407; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUZIN P, 1991, J BIOL CHEM, V266, P24053; MUZZIN P, 1988, BIOCHEM BIOPH RES CO, V156, P375, DOI 10.1016/S0006-291X(88)80851-9; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NAKADA MT, 1987, MOL PHARMACOL, V31, P377; NAKADA MT, 1989, BIOCHEM J, V260, P53, DOI 10.1042/bj2600053; PAIRAULT J, 1982, EUR J BIOCHEM, V127, P351, DOI 10.1111/j.1432-1033.1982.tb06879.x; PHILIBERT D, 1984, ADRENAL STEROID ANTA, P77; PHILLIPS M, 1986, J BIOL CHEM, V261, P821; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SKALA J, 1971, CAN J PHYSIOL PHARM, V49, P501, DOI 10.1139/y71-064; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P1083; STAEHELIN M, 1983, J BIOL CHEM, V258, P3496; VANDERTUIG JG, 1984, LIFE SCI, V34, P1423, DOI 10.1016/0024-3205(84)90056-0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YORK DA, 1985, AM J PHYSIOL, V249, pE299, DOI 10.1152/ajpendo.1985.249.3.E299; ZAAGSMA J, 1990, TRENDS PHARMACOL SCI, V11, P3, DOI 10.1016/0165-6147(90)90032-4	56	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15909	15915						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379241				2022-12-27	WOS:A1992JG11300097
J	LEV, S; YARDEN, Y; GIVOL, D				LEV, S; YARDEN, Y; GIVOL, D			DIMERIZATION AND ACTIVATION OF THE KIT RECEPTOR BY MONOVALENT AND BIVALENT BINDING OF THE STEM-CELL FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; PDGF BETA-RECEPTOR; SPOTTING W LOCUS; ONCOGENE C-KIT; EGF RECEPTOR; SIGNAL TRANSDUCTION; PROTO-ONCOGENE; LIGAND-BINDING; CDNA CLONING	The protooncogene c-kit encodes a tyrosine kinase receptor for the stem cell factor (SCF). Mutants of c-kit were shown to confer a pleiotropic defective phenotype and often display negative dominance in heterozygous mice. To explore the involvement of receptor dimerization in this genetic phenomenon, we employed both a human ligand, which does not recognize the murine receptor, and a rodent SCF, which binds to the human receptor with 100-fold reduced affinity as compared with human SCF. SCF binding to living cells was found to induce rapid and complete receptor dimerization that involved activation of the catalytic tyrosine kinase function. Although receptor dimerization can be attributed to the dimeric nature of the ligand, no dissociation of Kit dimers occurred at high excess of SCF, suggesting that receptor-receptor interactions are also involved in dimer stabilization. This was supported by in vitro formation of heterodimers between the human and murine Kit proteins through monovalent binding of species-specific human SCF. By coexpression of human and mouse Kit in murine fibroblasts, we found that receptor heterodimerization in living cells involved an increase in the affinity of human Kit for rat SCF and also an accelerated rate of receptor down-regulation. When a human Kit mutant lacking the kinase insert domain was coexpressed with the murine wild-type receptor, we observed a significant decrease in both the activation of the intact tyrosine kinase and its coupling to an effector protein, namely phosphatidylinositol 3'-kinase. Our results favor a receptor activation model that assumes an initial step of monovalent ligand binding, followed by an intermediate receptor dimer bound by one arm of the ligand molecule. This model predicts the existence of an intrinsic receptor dimerization site and provides a structural basis for genetic dominance of mutant SCF receptors.			LEV, S (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		Lev, Sima/AAP-7880-2020; YARDEN, YOSEF/K-1467-2012	Lev, Sima/0000-0002-2108-3330; 	NCI NIH HHS [CA 53120] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; BLUMEJENSEN P, 1991, EMBO J, V10, P4124; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; ELDAR H, 1990, J BIOL CHEM, V265, P13290; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1989, EUR J BIOCHEM, V184, P487, DOI 10.1111/j.1432-1033.1989.tb15041.x; HERBST R, 1991, J BIOL CHEM, V266, P19908; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P924; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KARNAKARA P, 1991, BIOCHEMISTRY-US, V30, P1761; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KELLY JD, 1991, J BIOL CHEM, V266, P8987; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1991, J BIOL CHEM, V266, P13828; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LEV S, 1992, J BIOL CHEM, V267, P10866; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; Silvers W.K., 1979, COAT COLORS MICE, P206; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1985, J BIOL CHEM, V260, P315; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	54	131	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15970	15977						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379243				2022-12-27	WOS:A1992JG11300106
J	RESTLE, T; PAWLITA, M; SCZAKIEL, G; MULLER, B; GOODY, RS				RESTLE, T; PAWLITA, M; SCZAKIEL, G; MULLER, B; GOODY, RS			STRUCTURE-FUNCTION-RELATIONSHIPS OF HIV-1 REVERSE-TRANSCRIPTASE DETERMINED USING MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; ESCHERICHIA-COLI; HTLV-III; RNASE-H; MUTATIONAL ANALYSIS; DOMAIN-STRUCTURE; CELL-LINE; VIRUS; EXPRESSION; AIDS	The reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is one of the main targets in approaches to the chemotherapy of AIDS. A detailed knowledge of structure-function relationships of this enzyme is a prerequisite for rational drug design. We have used monoclonal antibodies as tools to identify functionally important regions of the protein. The preparation of 23 murine monoclonal antibodies (mAb) against HIV-1 reverse transcriptase and their different effects on the enzyme are described. The interaction of purified mAbs with HIV-1 RT was demonstrated by enzyme-linked immunosorbent assay (ELISA), Western blots, and high performance liquid chromatography size exclusion chromatography. One of the antibodies also recognized recombinant HIV-2 RT. Antibody binding epitopes on HIV-1 RT were analyzed by immunoblotting using cyanogen bromide fragmented RT, C-terminally truncated mutants, and a peptide ELISA employing 15-mer synthetic overlapping peptides spanning nearly the complete polypeptide chain. The epitopes were mapped within three domains corresponding to amino acids 200-230, 300-428, and 528-560. Two mAbs show neutralizing properties on enzymatic functions of RT. One affects the polymerase activity and to a certain degree the RNase H activity of the enzyme, whereas the other inhibits the latter activity exclusively. mAb 28, which blocks the polymerase activity, interferes with the nucleotide binding region of RT, as shown by fluorescence spectroscopy using a labeled template/primer complex. By investigating the antibody effects on dimer formation of the heterodimeric enzyme, three domains corresponding to amino acids 230-300, 350-428, and residues around amino acid 540 involved in protein-protein interactions were localized.	DEUTSCH KREBSFORSCHUNGSZENTRUM,FORSCH SCHWERPUNKT ANGEW TUMORVIROL,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)	RESTLE, T (corresponding author), MAX PLANCK INST MED RES,BIOPHYS ABT,JAHNSTR 29,W-6900 HEIDELBERG 1,GERMANY.		Pawlita, Labor/C-9720-2011; Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444; Muller, Barbara/0000-0001-5726-5585; Pawlita, Michael/0000-0002-4720-8306				BAILLON JG, 1991, NEW BIOL, V3, P1015; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; CHANDRA A, 1986, FEBS LETT, V200, P327, DOI 10.1016/0014-5793(86)81162-0; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DEVICO A, 1991, VIROLOGY, V185, P387, DOI 10.1016/0042-6822(91)90786-B; DEVICO AL, 1989, AIDS RES HUM RETROV, V5, P51, DOI 10.1089/aid.1989.5.51; DEVICO AL, 1991, J BIOL CHEM, V266, P6774; FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298; FERNS RB, 1991, AIDS RES HUM RETROV, V7, P307, DOI 10.1089/aid.1991.7.307; FERRIS AL, 1990, VIROLOGY, V175, P456, DOI 10.1016/0042-6822(90)90430-Y; HAHN BH, 1984, NATURE, V312, P166, DOI 10.1038/312166a0; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; IKUTA K, 1989, VIROLOGY, V170, P408, DOI 10.1016/0042-6822(89)90431-5; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; JUNG V, 1990, NUCLEIC ACIDS RES, V18, P6156, DOI 10.1093/nar/18.20.6156; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KRAUS G, 1990, EUR J BIOCHEM, V192, P207, DOI 10.1111/j.1432-1033.1990.tb19216.x; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; LUKE W, 1990, BIOCHEMISTRY-US, V29, P1764; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; MORRIS GE, 1987, BIOCHEM J, V248, P53, DOI 10.1042/bj2480053; MOUS J, 1988, J VIROL, V62, P1433, DOI 10.1128/JVI.62.4.1433-1436.1988; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; MULLER B, 1991, J BIOL CHEM, V266, P14709; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NORTH TW, 1990, J BIOL CHEM, V265, P5121; ORVELL C, 1991, J GEN VIROL, V72, P1913, DOI 10.1099/0022-1317-72-8-1913; PADBERG C, 1989, AIDS RES HUM RETROV, V5, P61, DOI 10.1089/aid.1989.5.61; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; PWALITA M, 1981, J EXP MED, V154, P1946; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RESTLE T, 1992, FEBS LETT, V300, P97, DOI 10.1016/0014-5793(92)80172-D; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; TANESE N, 1986, J VIROL, V59, P743, DOI 10.1128/JVI.59.3.743-745.1986; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VERMA IM, 1981, ENZYMES, V14, P87; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504	52	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14654	14661						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378837				2022-12-27	WOS:A1992JF08800027
J	MEINKOTH, JL; GOLDSMITH, PK; SPIEGEL, AM; FERAMISCO, JR; BURROW, GN				MEINKOTH, JL; GOLDSMITH, PK; SPIEGEL, AM; FERAMISCO, JR; BURROW, GN			INHIBITION OF THYROTROPIN-INDUCED DNA-SYNTHESIS IN THYROID FOLLICULAR CELLS BY MICROINJECTION OF AN ANTIBODY TO THE STIMULATORY G-PROTEIN OF ADENYLATE-CYCLASE, G(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; DIBUTYRYL-CYCLIC-AMP; FOS MESSENGER-RNAS; C-FOS; FRTL5 CELLS; THYROGLOBULIN GENE; INCREASE LEVELS; INSULIN; EXPRESSION; CULTURE	Thyrotropin (TSH) is an important regulator of thyroid follicular cells. While its-role in the maintenance of differentiated functions is undisputed, its role as a mitogen is less clear. TSH induces DNA synthesis and cell proliferation in some cells, while in others, TSH is mitogenic only in the presence of additional growth factors such as insulin-like growth factor-1. TSH causes elevations in intracellular cAMP and is thought to utilize this second messenger system in its mitogenic action. We studied TSH as a mitogen in Wistar rat thyroid cells (WRT) (Brandi, M. L., Rotella, C. M., Mavilia, C., Franceschelli, F., Tanini, A., and Toccafondi, R. (1987) Mol. Cell. Endocrinol. 54, 91-103) and examined the role of the guanine nucleotide binding protein, G(s), in its mitogenic action. WRT cells synthesized DNA in response to TSH and elevations in cAMP. In addition, TSH caused a rapid stimulation of an indicator gene whose expression is regulated by cAMP response elements. Following microinjection of an inhibitory polyclonal antibody raised against the G(s) protein, both TSH-induced changes in gene expression and DNA synthesis were significantly reduced. These results demonstrate that virtually all of the mitogenic action of TSH is transduced through the G(s) protein in WRT cells, presumably through the regulation of adenylate cyclase. Whether all or only part of TSH action is mediated by cAMP and the cAMP-dependent protein kinase remains to be determined.	UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; NIDDKD, MOLEC PATHOPHYSIOL BRANCH, BETHESDA, MD 20892 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	MEINKOTH, JL (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED 0613K, LA JOLLA, CA 92093 USA.		Meinkoth, Judy L/G-2900-2010					ALBANESE C, 1991, MOL ENDOCRINOL, V5, P693, DOI 10.1210/mend-5-5-693; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BONE EA, 1986, ENDOCRINOLOGY, V119, P2193, DOI 10.1210/endo-119-5-2193; BRANDI ML, 1987, MOL CELL ENDOCRINOL, V54, P91, DOI 10.1016/0303-7207(87)90142-0; BRENNERGATI L, 1988, J CLIN INVEST, V82, P1144, DOI 10.1172/JCI113672; COLLETTA G, 1986, SCIENCE, V233, P458, DOI 10.1126/science.3726540; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CONDORELLI G, 1989, J BIOL CHEM, V264, P12633; CORDA D, 1987, EUR J BIOCHEM, V166, P475, DOI 10.1111/j.1432-1033.1987.tb13540.x; DAMANTE G, 1988, BIOCHEM BIOPH RES CO, V151, P1194, DOI 10.1016/S0006-291X(88)80492-3; DERE WH, 1985, ENDOCRINOLOGY, V117, P2249, DOI 10.1210/endo-117-5-2249; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Eggo MC, 1990, GROWTH FACTORS, V2, P99, DOI 10.3109/08977199009071497; GERARD C, 1982, BIOCHIM BIOPHYS ACTA, V710, P359, DOI 10.1016/0005-2760(82)90119-9; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; ISOZAKI O, 1987, MOL ENDOCRINOL, V1, P839, DOI 10.1210/mend-1-11-839; JAVAUX F, 1991, NUCLEIC ACIDS RES, V19, P1121, DOI 10.1093/nar/19.5.1121; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE NT, 1991, ENDOCRINOLOGY, V128, P111, DOI 10.1210/endo-128-1-111; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1990, HORM METAB RES, V23, P51; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOSES AC, 1989, ENDOCRINOLOGY, V125, P2758, DOI 10.1210/endo-125-5-2758; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; REUSE S, 1986, BIOCHEM BIOPH RES CO, V141, P1066, DOI 10.1016/S0006-291X(86)80152-8; REUSE S, 1990, EXP CELL RES, V189, P33, DOI 10.1016/0014-4827(90)90253-7; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROGER PP, 1983, J ENDOCRINOL, V96, P241, DOI 10.1677/joe.0.0960241; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; ROTELLA CM, 1989, MOL CELL ENDOCRINOL, V65, P63, DOI 10.1016/0303-7207(89)90166-4; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SUAREZ HG, 1991, ONCOGENE, V6, P677; TRAMONTANO D, 1986, J BIOL CHEM, V261, P3919; TRAMONTANO D, 1986, ENDOCRINOLOGY, V119, P940, DOI 10.1210/endo-119-2-940; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; VANHEUVERSWYN B, 1984, P NATL ACAD SCI-BIOL, V81, P5941; YATANI A, 1988, J BIOL CHEM, V263, P9887; ZAKARIJA M, 1989, ENDOCRINOLOGY, V125, P1253, DOI 10.1210/endo-125-3-1253	47	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13239	13245						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377681				2022-12-27	WOS:A1992JB74600025
J	KIM, YA; SHRIVER, B; QUAY, T; HERSH, LB				KIM, YA; SHRIVER, B; QUAY, T; HERSH, LB			ANALYSIS OF THE IMPORTANCE OF ARGININE-102 IN NEUTRAL ENDOPEPTIDASE (ENKEPHALINASE) CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; SITE-DIRECTED MUTAGENESIS; 24.11 ENKEPHALINASE; ACTIVE-SITE; METALLOENDOPEPTIDASE INHIBITOR; ANTIHYPERTENSIVE ACTIVITY; LEUKEMIA ANTIGEN; EC 3.4.24.11; RAT-KIDNEY; THERMOLYSIN	Neutral endopeptidase 24.11 contains an active site arginine believed to function in substrate binding. This arginine is thought to form an ionic interaction with the COOH-terminal carboxylate of NEP substrates. The functionality of arginine 102 has been investigated by using site-directed mutagenesis to produce mutants in which this residue was converted to a lysine, glycine, glutamine, or glutamate. All of the mutants exhibited essentially full activity as determined with a synthetic peptide amide, glutaryl-Ala-Ala-Phe-4-methoxy-2-naphthylamide. In contrast, activity was detected only with the wild-type enzyme and the lysine mutant using a synthetic substrate containing a free COOH-terminal carboxylate, dansyl-Gly-Trp-Gly. Inhibition studies with the physiologically active peptide substrates substance P, endothelin, and angiotensin 1, as well as substance P free acid, [D-Ala2,Leu5]enkephalin, and [D-Ala2,Leu5]enkephalinamide indicated a lack of importance of arginine 102 in substrate binding. With [D-Ala2,Met5]enkephalin and the chemotactic peptide, N-formyl-Met-Leu-Phe, a significant decrease in affinity is observed with the arginine 102 mutants. These results suggest that the contribution of arginine 102 to substrate binding is dependent upon the strength of other subsite interactions. Examination of dipeptides as inhibitors indicates that the nature and orientation of the P'2 residue is important in determining the strength of the interaction of arginine 102 with its substrates.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER; NIDA NIH HHS [DA02243] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BATEMAN RC, 1989, J BIOL CHEM, V264, P6151; BEAUMONT A, 1986, BIOCHEM BIOPH RES CO, V139, P733, DOI 10.1016/S0006-291X(86)80052-3; BEAUMONT A, 1991, J BIOL CHEM, V266, P214; BRALET J, 1990, EUR J PHARMACOL, V179, P57, DOI 10.1016/0014-2999(90)90401-Q; CASEY ML, 1991, J BIOL CHEM, V266, P23041; CHIPKIN R E, 1986, Drugs of the Future, V11, P593; COLMAN PM, 1972, J MOL BIOL, V70, P701, DOI 10.1016/0022-2836(72)90569-4; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; DEVAULT A, 1988, FEBS LETT, V231, P54, DOI 10.1016/0014-5793(88)80701-4; GEE NS, 1985, BIOCHEM J, V228, P119, DOI 10.1042/bj2280119; GROS C, 1989, P NATL ACAD SCI USA, V86, P7580, DOI 10.1073/pnas.86.19.7580; HELIN K, 1991, EUR J PHARMACOL, V198, P23, DOI 10.1016/0014-2999(91)90557-7; HERSH LB, 1986, LIFE SCI, V38, P1151, DOI 10.1016/0024-3205(86)90168-2; HERSH LB, 1986, J BIOL CHEM, V261, P6433; JACKSON DG, 1986, J BIOL CHEM, V261, P8649; KAHN JC, 1990, LANCET, V335, P118, DOI 10.1016/0140-6736(90)90595-V; KERR MA, 1974, BIOCHEM J, V137, P489, DOI 10.1042/bj1370489; KESTER WR, 1977, BIOCHEMISTRY-US, V16, P2506, DOI 10.1021/bi00630a030; KOEHN JA, 1987, J BIOL CHEM, V262, P11623; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LECOMTE JM, 1990, EUR J PHARMACOL, V179, P65, DOI 10.1016/0014-2999(90)90402-R; LEFRANCOIS P, 1990, LANCET, V336, P307, DOI 10.1016/0140-6736(90)91837-Z; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; LLORENS C, 1981, EUR J PHARMACOL, V69, P113, DOI 10.1016/0014-2999(81)90609-9; MALFROY B, 1982, BIOCHEM BIOPH RES CO, V106, P276, DOI 10.1016/0006-291X(82)91106-8; MALFROY B, 1987, BIOCHEM BIOPH RES CO, V143, P58, DOI 10.1016/0006-291X(87)90629-2; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; NORTHRIDGE DB, 1989, LANCET, V2, P591; POZSGAY M, 1986, BIOCHEMISTRY-US, V25, P1292, DOI 10.1021/bi00354a015; RONCO P, 1988, LAB INVEST, V58, P210; SCHWARTZ JC, 1985, TRENDS PHARMACOL SCI, V6, P472, DOI 10.1016/0165-6147(85)90226-3; SEYMOUR AA, 1989, HYPERTENSION, V14, P87, DOI 10.1161/01.HYP.14.1.87; SHIPP MA, 1991, P NATL ACAD SCI USA, V88, P10662, DOI 10.1073/pnas.88.23.10662; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SOKOLOVSKY M, 1990, P NATL ACAD SCI USA, V87, P4702, DOI 10.1073/pnas.87.12.4702; SONNENBERG JL, 1988, PEPTIDES, V9, P173, DOI 10.1016/0196-9781(88)90024-1; STEPHENSON SL, 1987, BIOCHEM J, V243, P183, DOI 10.1042/bj2430183; SYBERTZ EJ, 1989, J PHARMACOL EXP THER, V250, P624; SYBERTZ EJ, 1990, HYPERTENSION, V15, P152, DOI 10.1161/01.HYP.15.2.152; TRAPANI AJ, 1989, J CARDIOVASC PHARM, V14, P419, DOI 10.1097/00005344-198909000-00010; VEMULAPALLI S, 1988, AM J HYPERTENS, V1, pA106; VIJAYARAGHAVAN J, 1990, BIOCHEMISTRY-US, V29, P8052, DOI 10.1021/bi00487a009; VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150	44	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12330	12335						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376321				2022-12-27	WOS:A1992HY94700101
J	MOSS, J; STANLEY, SJ; NIGHTINGALE, MS; MURTAGH, JJ; MONACO, L; MISHIMA, K; CHEN, HC; WILLIAMSON, KC; TSAI, SC				MOSS, J; STANLEY, SJ; NIGHTINGALE, MS; MURTAGH, JJ; MONACO, L; MISHIMA, K; CHEN, HC; WILLIAMSON, KC; TSAI, SC			MOLECULAR AND IMMUNOLOGICAL CHARACTERIZATION OF ADP-RIBOSYLARGININE HYDROLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; AMINO-ACID SEQUENCE; TURKEY ERYTHROCYTES; RIBOSYLTRANSFERASE ACTIVITY; SUBSTRATE-SPECIFICITY; RIBOSYLATION FACTOR; CHOLERA-TOXIN; PROTEIN; NUCLEOTIDE; IDENTIFICATION	Mono-ADP-ribosylation is a reversible modification of proteins with NAD:arginine ADP-ribosyltransferases and ADP-ribosylarginine hydrolases catalyzing the forward and reverse reactions, respectively. Hydrolase activities were present in a variety of animal species, with the highest specific activities found in rat and mouse brain, spleen, and testis. Rat and mouse hydrolases were dithiothreitol- and Mg2+-dependent, whereas the bovine and guinea pig enzymes were dithiothreitol-independent. A rat brain hydrolase was purified approximately 20,000-fold and represented the major approximately 39-kDa protein on denaturing gels. Immunoaffinity-purified rabbit polyclonal antibodies reacted with 39-kDa proteins from turkey erythrocytes and rat, mouse, and calf brains. A rat brain cDNA library was screened using oligonucleotide and polymerase chain reaction-generated cDNA probes. Inserts from two overlapping clones yielded a composite sequence that included a 1086-base pair open reading frame, which contained amino acid sequences found in the purified hydrolase. A hydrolase fusion protein, synthesized in Escherichia coli, reacted with anti-39-kDa polyclonal antibodies and exhibited Mg2+- and dithiothreitol-dependent hydrolase activity. A coding region cDNA hybridized readily to a 1.7-kilobase band in rat and mouse poly(A)+ RNA, but poorly to bovine, chicken, rabbit, and human poly(A)+ RNA. The immunological and molecular biological data are consistent with partial conservation of hydrolase structure across animal species.	NICHHD, ENDOCRINOL & REPROD RES BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	MOSS, J (corresponding author), NHLBI, CELLULAR METAB LAB, ROOM 5N-307, BLDG 10, BETHESDA, MD 20892 USA.		Monaco, Lucia/A-4031-2010					Aktories K, 1990, ADP RIBOSYLATING TOX, P79; BIRNBAUMER L, 1990, ADP RIBOSYLATING TOX, P225; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BODLEY JW, 1990, ADP RIBOSYLATING TOX, P21; CHANG YC, 1986, BIOCHEM BIOPH RES CO, V139, P932, DOI 10.1016/S0006-291X(86)80267-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; FITZMAURICE WP, 1989, MOL GEN GENET, V218, P340, DOI 10.1007/BF00331287; Higuchi R., 1989, PCR TECHNOLOGY, P61; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; IGLEWSKI WJ, 1990, ADP RIBOSYLATING TOX, P511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEW AM, 1989, NUCLEIC ACIDS RES, V17, P5859, DOI 10.1093/nar/17.14.5859; MITCHELL LG, 1989, ANAL BIOCHEM, V178, P239, DOI 10.1016/0003-2697(89)90631-3; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOSS J, 1979, J BIOL CHEM, V254, P8891; MOSS J, 1988, BIOCHEMISTRY-US, V27, P5819, DOI 10.1021/bi00415a063; MOSS J, 1977, J BIOL CHEM, V252, P2455; MOSS J, 1980, J BIOL CHEM, V255, P5838; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MOSS J, 1986, BIOCHEMISTRY-US, V25, P5408, DOI 10.1021/bi00367a010; MOSS J, 1985, P NATL ACAD SCI USA, V82, P5603, DOI 10.1073/pnas.82.17.5603; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; ROSENTHAL A, 1990, NUCLEIC ACIDS RES, V18, P3095, DOI 10.1093/nar/18.10.3095; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TANUMA S, 1990, FEBS LETT, V261, P381, DOI 10.1016/0014-5793(90)80597-C; TANUMA S, 1989, BIOCHIM BIOPHYS ACTA, V1010, P246, DOI 10.1016/0167-4889(89)90168-7; TANUMA S, 1987, J BIOCHEM-TOKYO, V101, P821, DOI 10.1093/jb/101.3.821; TANUMA S, 1988, J BIOL CHEM, V263, P5485; UHLEN M, 1989, NATURE, V340, P733, DOI 10.1038/340733a0; UI M, 1990, ADP RIBOSYLATING TOX, P45; WEST RE, 1985, J BIOL CHEM, V260, P4428; WICK MJ, 1990, ADP RIBOSYLATING TOX, P31; Williamson K., 1990, ADP RIBOSYLATING TOX, P493	39	107	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10481	10488						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375222				2022-12-27	WOS:A1992HV09000043
J	TILLY, BC; WINTER, MC; OSTEDGAARD, LS; ORIORDAN, C; SMITH, AE; WELSH, MJ				TILLY, BC; WINTER, MC; OSTEDGAARD, LS; ORIORDAN, C; SMITH, AE; WELSH, MJ			CYCLIC AMP-DEPENDENT PROTEIN-KINASE ACTIVATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CHLORIDE CHANNELS IN PLANAR LIPID BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSPORT; GENE; IDENTIFICATION; RECONSTITUTION; MEMBRANES	Membrane vesicles, prepared from mouse NIH-3T3 fibroblasts and Chinese hamster ovary cells expressing high levels of cystic fibrosis transmembrane conductance regulator (CFTR), were fused with Mueller-Rudin planar lipid bilayers. Upon addition of the catalytic subunit of cAMP-dependent protein kinase and ATP, low conductance Cl--selective ion channels were observed in 10 of 16 experiments. The channels had a linear current-voltage relationship and a unitary conductance of approximately 6.5 pS. The channels were more permeable to Cl- than to I- and showed no appreciable time-dependent voltage activation. In contrast, addition of cAMP-dependent protein kinase and ATP to lipid bilayers fused with vesicles prepared from mock transfected (n = 14) cells failed to activate Cl-channels. These data support the conclusion that CFTR is a Cl- channel. They indicate that it can be reconstituted in a planar lipid bilayer and that the biophysical and regulatory properties are very similar to those observed in the native cell membrane. These data also argue against the requirement for loosely associated factors for regulation or function of the channel.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,500 EMRB,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Sanofi-Aventis; Genzyme Corporation				Welsh, Michael/0000-0002-1646-6206; Ostedgaard, Lynda/0000-0001-7717-3442				AMES GF, 1990, FEMS MICROBIOL REV, V6, P429; ANDERSEN OS, 1986, ION CHANNEL RECONSTI, P385; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC902, DOI 10.1152/ajpcell.1989.256.4.C902; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CORONADO R, 1992, IN PRESS METHODS ENZ; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; REINHARDT R, 1987, J MEMBRANE BIOL, V95, P47, DOI 10.1007/BF01869629; REINHART PH, 1991, J NEUROSCI, V11, P1627; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VALDIVIA HH, 1988, SCIENCE, V242, P1441, DOI 10.1126/science.2462280	28	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9470	9473						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374403				2022-12-27	WOS:A1992HT96500006
J	KUNZ, D; GERARD, NP; GERARD, C				KUNZ, D; GERARD, NP; GERARD, C			THE HUMAN-LEUKOCYTE PLATELET-ACTIVATING-FACTOR RECEPTOR - CDNA CLONING, CELL-SURFACE EXPRESSION, AND CONSTRUCTION OF A NOVEL EPITOPE-BEARING ANALOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-K RECEPTOR; RABBIT PLATELETS; CHROMOSOME LOCALIZATION; MOLECULAR-CLONING; GASTRIC TISSUES; MEMBRANES; BINDING; GENE; TRACHEAL; ACID	A human myeloid transcript of approximately 4 kilobases was cloned as a cDNA from an expression library based on homology with the guinea pig cDNA recently described by Honda et al. (Honda, Z-1., Nakamura, M., Miki, I., Minami, M., Watanabe, T., Seyama, Y., Okado, H., Tok, H., Ito, K., Miyamato, T., and Shimizu, T. (1991) Nature 349, 342-346) as a receptor for platelet-activating factor (PAF). The cloned DNA confers high affinity binding sites for platelet-activating factor when transfected into COS-7 cells and has binding and desensitization properties similar to the human leukocyte receptor. Southern analysis using this cDNA indicates that the PAF receptor gene is present as a single copy in the human genome. The deduced protein sequence predicts seven hydrophobic regions for the PAF receptor, characteristic of the rhodopsin gene family, and is 83% identical to the deduced protein sequence of the corresponding guinea pig molecule. A modified human PAF receptor cDNA was constructed by inserting an additional 30 nucleotides after the 5'-ATG, encoding the amino acid sequence MDYKDDDDKEF, which is specifically recognized by a monoclonal antibody. The modified cDNA encodes a functional PAF receptor and is detected by antibody on the membrane of transfected COS-7 cells. The use of this construct supports the structural model for the rhodopsin-like superfamily of receptors which places the NH2-terminal sequence on the extracellular side of the membrane, and should additionally be useful for affinity purification of the receptor protein.	CHILDRENS HOSP MED CTR, DEPT PEDIAT, DIV PULM, 320 LONGWOOD AVE, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, INA SUE PERLMUTTER LAB, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, THORNDIKE LAB, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036162, R37HL036162] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36162] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAAS F, 1984, HUM GENET, V67, P301, DOI 10.1007/BF00291357; BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1057; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GERARD NP, 1990, BIOCHEMISTRY-US, V29, P9274, DOI 10.1021/bi00491a024; GERARD NP, 1991, BIOCHEMISTRY-US, V30, P10640, DOI 10.1021/bi00108a006; GERARD NP, 1990, J BIOL CHEM, V265, P20455; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HENSON PM, 1970, J EXP MED, V131, P287, DOI 10.1084/jem.131.2.287; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HOMMA H, 1987, J BIOL CHEM, V262, P10582; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1983, BIOCHEMISTRY-US, V22, P4756, DOI 10.1021/bi00289a022; HWANG SB, 1988, J BIOL CHEM, V263, P3225; HWANG SB, 1986, J BIOL CHEM, V261, P532; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; LAD PM, 1985, BIOCHEM BIOPH RES CO, V129, P632, DOI 10.1016/0006-291X(85)91938-2; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NG DS, 1988, EUR J PHARMACOL, V154, P47, DOI 10.1016/0014-2999(88)90361-5; PAULSON SK, 1990, P SOC EXP BIOL MED, V195, P247; PINKARD RN, 1979, J IMMUNOL, V123, P1847; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SNYDER F, 1987, PLATELET ACTIVATING; STIMLER NP, 1981, AM J PATHOL, V105, P64; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TOKUMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1044, P91, DOI 10.1016/0005-2760(90)90223-K; WANG HY, 1989, J BIOL CHEM, V264, P14424; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	33	181	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9101	9106						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374385				2022-12-27	WOS:A1992HR85400062
J	KIM, IC; CHA, JH; KIM, JR; JANG, SY; SEO, BC; CHEONG, TK; LEE, DS; CHOI, YD; PARK, KH				KIM, IC; CHA, JH; KIM, JR; JANG, SY; SEO, BC; CHEONG, TK; LEE, DS; CHOI, YD; PARK, KH			CATALYTIC PROPERTIES OF THE CLONED AMYLASE FROM BACILLUS-LICHENIFORMIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOGENIC ALPHA-AMYLASE; PULLULANASE NOR ISOPULLULANASE; NUCLEOTIDE-SEQUENCE; THERMOACTINOMYCES-VULGARIS; MEGATERIUM AMYLASE; MOLECULAR-CLONING; UNIQUE TYPE; STEAROTHERMOPHILUS; GENE; NEOPULLULANASE	A gene encoding a new amylolytic enzyme of Bacillus licheniformis (BLMA) has been cloned, and we characterized the enzyme expressed in Escherichia coli. The genomic DNA of B. licheniformis was double-digested with EcoRI and BamHI and ligated the pBR322. The transformed E. coli was selected by its amylolytic activity, which carries the recombinant plasmid pIJ322 containing a 3.5-kilobase fragment of B. licheniformis DNA. The purified enzyme encoded by pIJ322 was capable of hydrolyzing pullulan and cyclodextrin as well as starch. It was active over a pH range of 6-8 and its optimum temperature was 50-degrees-C. The molecular weight of the enzyme was 64,000, and the isoelectric point was 5.4. It degraded soluble starch by cleaving maltose units preferentially but did not attack alpha-1,6-linkage. The enzyme also hydrolyzed pullulan to panose units exclusively. In the presence of glucose, however, it transferred the panosyl moiety to glucose with the formation of alpha-1,6-linkage. The specificity of transferring activity is evident from the result of the maltosyl-transferring reaction which produces isopanose from maltotriose and glucose. The molecular structure of the enzyme deduced from the nucleotide sequence of the clone maintains limited similarity in the conserved regions to the other amylolytic enzymes.	SEOUL NATL UNIV,NEW BIOMAT AGR RES CTR,SUWON 441744,SOUTH KOREA; GENET ENGN RES INST,TAEJON 305601,SOUTH KOREA; SEOUL NATL UNIV,DEPT FOOD SCI & TECHNOL,SUWON 441744,SOUTH KOREA; SEOUL NATL UNIV,DEPT AGR CHEM,SUWON 441744,SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)				Choi, Yang Do/0000-0003-4706-5154				BENDER H, 1961, BIOCHEM Z, V334, P79; BLIESMER BO, 1973, J BACTERIOL, V113, P526, DOI 10.1128/JB.113.1.526-528.1973; CAMPBELL LL, 1955, ARCH BIOCHEM BIOPHYS, V54, P154, DOI 10.1016/0003-9861(55)90018-7; DAVID MH, 1987, STARCH-STARKE, V39, P436, DOI 10.1002/star.19870391208; DUBNAU D, 1971, J MOL BIOL, V56, P209, DOI 10.1016/0022-2836(71)90460-8; FRAHN JL, 1959, AUST J CHEM, V12, P65, DOI 10.1071/CH9590065; HEBEDA RE, 1988, STARCH-STARKE, V40, P33, DOI 10.1002/star.19880400109; IMANAKA T, 1989, J BACTERIOL, V171, P369, DOI 10.1128/jb.171.1.369-374.1989; KANEKO T, 1988, J GEN MICROBIOL, V134, P97; KIM IC, 1991, THESIS SEOUL NATIONA; KIM JR, 1991, THESIS SEOUL NATIONA; KURIKI T, 1989, J GEN MICROBIOL, V135, P1521; KURIKI T, 1988, J BACTERIOL, V170, P1554, DOI 10.1128/jb.170.4.1554-1559.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; OHBA R, 1975, AGR BIOL CHEM TOKYO, V39, P967, DOI 10.1080/00021369.1975.10861719; PARK JH, 1990, THESIS SEOUL NATIONA; ROGERS JC, 1985, BIOCHEM BIOPH RES CO, V128, P470, DOI 10.1016/0006-291X(85)91702-4; SAKANO Y, 1971, AGR BIOL CHEM TOKYO, V35, P971, DOI 10.1080/00021369.1971.10860023; SAKANO Y, 1982, AGR BIOL CHEM TOKYO, V46, P1121, DOI 10.1080/00021369.1982.10865223; SAKANO Y, 1972, ARCH BIOCHEM BIOPHYS, V153, P180, DOI 10.1016/0003-9861(72)90434-1; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU M, 1978, AGR BIOL CHEM TOKYO, V42, P1681, DOI 10.1080/00021369.1978.10863231; SUZUKI Y, 1985, APPL MICROBIOL BIOT, V21, P20; SUZUKI Y, 1987, STARCH-STARKE, V39, P211, DOI 10.1002/star.19870390608; YUUKI T, 1985, J BIOCHEM-TOKYO, V98, P1147, DOI 10.1093/oxfordjournals.jbchem.a135381	26	101	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22108	22114						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385394				2022-12-27	WOS:A1992JW71900022
J	KOOY, J; TOH, BH; PETTITT, JM; ERLICH, R; GLEESON, PA				KOOY, J; TOH, BH; PETTITT, JM; ERLICH, R; GLEESON, PA			HUMAN AUTOANTIBODIES AS REAGENTS TO CONSERVED GOLGI COMPONENTS - CHARACTERIZATION OF A PERIPHERAL, 230-KDA COMPARTMENT-SPECIFIC GOLGI PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; BREFELDIN-A; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODY; CELL BIOLOGY; APPARATUS; IDENTIFICATION; COMPLEX; NETWORK; CISTERNAE	We have used a serum from a patient with Sjogren's syndrome containing high titer (100,000) anti-Golgi autoantibodies and lower titer (20,000) anti-nuclear autoantibodies to characterize the Golgi complex. The Sjogren's syndrome serum immunoprecipitated a number of components of molecular mass 35-230 kDa from detergent extracts of [S-35]methionine-labeled HeLa cells; at high dilution, the serum precipitated one major 230-kDa component. Using the Sjogren's syndrome serum, cDNA clones encoding the Golgi autoantigen were isolated from a lambdagt11 HeLa cell cDNA library. Autoantibodies from the Sjogren's syndrome serum, affinity purified from a recombinant bacterial fusion protein generated from one of the cDNA clones, showed Golgi staining of human, mouse, and chicken cells by immunofluorescence. The purified autoantibodies immunoprecipitated and immunoblotted a 230-kDa component. A rabbit anitserum raised to the recombinant fusion protein specifically stained the Golgi complex by immunofluorescence and reacted with a 230-kDa protein by immunoprecipitation and immunoblotting. The 230-kDa protein was recovered in both the 100,000 x g sedimentable and soluble fractions in cell lysates and in the aqueous phase of Triton X-114 extracts. The 230-kDa autoantigen was dissociated from the Golgi complex by 15-min brefeldin A treatment, dissociation kinetics similar to that of mannosidase II. However, unlike mannosidase II, autoantigen staining was markedly reduced after drug treatment. Removal of brefeldin A resulted in reassociation of the autoantigen with the Golgi complex. The epitopes recognized by the affinity purified human and rabbit antibodies were ultrastructurally localized to the cytosolic face of one side of the Golgi stack, probably the trans-face. Taken together, the 230-kDa protein is a conserved, peripheral membrane component specifically associated with one Golgi compartment. We suggest that this peripheral Golgi protein may have a role in the compartment-specific structural organization of the Golgi or in sorting and transport of proteins.	MONASH UNIV, ALFRED HOSP,SCH MED,DEPT PATHOL & IMMUNOL, COMMERCIAL RD, MELBOURNE, VIC 3181, AUSTRALIA	Florey Institute of Neuroscience & Mental Health; Monash University				Gleeson, Paul/0000-0002-5336-6503				AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BLASCHEK MA, 1988, SCAND J RHEUMATOL, V17, P291, DOI 10.3109/03009748809098799; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHICHEPORTICHE Y, 1984, J CELL BIOL, V99, P2200, DOI 10.1083/jcb.99.6.2200; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FRANZUSOFF A, 1992, NATURE, V355, P173, DOI 10.1038/355173a0; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; FRITZLER MJ, 1984, J IMMUNOL, V132, P2904; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411; KOOY J, 1991, IMMUNOLOGY, V72, P418; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; RALTON JE, 1989, EUR J BIOCHEM, V186, P637, DOI 10.1111/j.1432-1033.1989.tb15254.x; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; REEVES WH, 1986, P NATL ACAD SCI USA, V83, P9507, DOI 10.1073/pnas.83.24.9507; RODRIGUEZ JL, 1982, CLIN EXP IMMUNOL, V49, P579; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; SCHICKEDANZ J, 1986, VIROLOGY, V148, P47, DOI 10.1016/0042-6822(86)90402-2; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRAUS W, 1982, J HISTOCHEM CYTOCHEM, V30, P491, DOI 10.1177/30.5.6176617; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; TAN EM, 1989, J CLIN INVEST, V84, P1, DOI 10.1172/JCI114127; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WILSON DW, 1991, TRENDS BIOCHEM SCI, V16, P334, DOI 10.1016/0968-0004(91)90138-L; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	47	104	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20255	20263						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400343				2022-12-27	WOS:A1992JR85800080
J	KAUR, P; ROSEN, BP				KAUR, P; ROSEN, BP			MUTAGENESIS OF THE C-TERMINAL NUCLEOTIDE-BINDING SITE OF AN ANION-TRANSLOCATING ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ARSENATE RESISTANCE; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; MOLECULAR CHARACTERIZATION; CATALYTIC SUBUNIT; ADENYLATE KINASE; CYSTIC-FIBROSIS; EXCISION REPAIR; P-GLYCOPROTEIN; ARSA PROTEIN	An oxyanion-translocating ATPase encoded by a bacterial plasmid confers resistance to antimonials and arsenicals in Escherichia coli by extrusion of the toxic oxyanions from the cytosol. The anion pump is composed of two polypeptides, the ArsA and ArsB proteins. Purified ArsA protein is an oxyanion-stimulated ATPase with two nucleotide-binding consensus sequences, one in the N-terminal half and one in the C-terminal half of the protein. The ArsA protein can be labeled with [alpha-P-32]ATP by a UV-catalyzed reaction. Previously reported mutations in the N-terminal site abolish photoadduct formation. Using site-directed mutagenesis the glycine-rich region of the C-terminal putative nucleotide-binding sequence was altered. Three C-terminal site mutant proteins (GR337, KE340, KN340) were analyzed, as well as one additional N-terminal mutant protein (KE21). Strains bearing the mutated plasmids were arsenite sensitive to varying degrees. The purified ArsA protein from mutant KE340 retained approximately 20% of the wild type oxyanion-stimulated ATPase activity, while the purified proteins from the other mutants were catalytically inactive. The KE21 mutation in the N-terminal nucleotide-binding site eliminated photoadduct formation with [alpha-P-32] ATP, while the purified proteins with mutations in the C-terminal site retained the ability to form a photoadduct. Each mutant protein was capable of forming a membrane-bound complex in arsB expressing strains. These results suggest first that both sites are required for resistance and ATPase activity, and second that the conserved lysyl residue in the glycine-rich loop of the C-terminal nucleotide-binding site is not essential for catalytic activity.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, 540 E CANFIELD AVE, DETROIT, MI 48201 USA	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19793] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; BELL AW, 1986, J BIOL CHEM, V261, P7652; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHEN CM, 1986, J BIOL CHEM, V261, P5030; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; FRANCISCO MJDS, 1989, MOL MICROBIOL, V3, P15, DOI 10.1111/j.1365-2958.1989.tb00098.x; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; HSU CM, 1989, J BIOL CHEM, V264, P17349; HSU CM, 1991, J BIOL CHEM, V266, P2327; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KARKARIA CE, 1991, ARCH BIOCHEM BIOPHYS, V288, P107, DOI 10.1016/0003-9861(91)90170-N; KAUR P, 1992, PLASMID, V27, P29, DOI 10.1016/0147-619X(92)90004-T; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MEVARECH M, 1980, P NATL ACAD SCI-BIOL, V77, P6476, DOI 10.1073/pnas.77.11.6476; MOBLEY HLT, 1983, MOL GEN GENET, V191, P421, DOI 10.1007/BF00425757; MOBLEY HLT, 1982, P NATL ACAD SCI-BIOL, V79, P6119, DOI 10.1073/pnas.79.20.6119; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; RAO R, 1988, J BIOL CHEM, V263, P15957; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SENIOR AE, 1985, CURR TOP MEMBR TRANS, V23, P135; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SILVER S, 1982, P NATL ACAD SCI-BIOL, V79, P6114, DOI 10.1073/pnas.79.20.6114; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; TISA LS, 1990, J BIOENERG BIOMEMBR, V22, P493, DOI 10.1007/BF00762959; TISA LS, 1990, J BIOL CHEM, V265, P190; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; YUE VT, 1977, BIOCHEMISTRY-US, V16, P4678, DOI 10.1021/bi00640a023; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	46	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19272	19277						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388167				2022-12-27	WOS:A1992JP59300041
J	MONTROSERAFIZADEH, C; BLACKMON, DL; HAMOSH, A; OLIVA, MM; HAWKINS, AL; CURRISTIN, SM; GRIFFIN, CA; YANG, VW; GUGGINO, WB; CUTTING, GR; MONTROSE, MH				MONTROSERAFIZADEH, C; BLACKMON, DL; HAMOSH, A; OLIVA, MM; HAWKINS, AL; CURRISTIN, SM; GRIFFIN, CA; YANG, VW; GUGGINO, WB; CUTTING, GR; MONTROSE, MH			REGULATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE-TRANSCRIPTION AND ALTERNATIVE RNA SPLICING IN A MODEL OF DEVELOPING INTESTINAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; NUCLEOTIDE-BINDING; CHLORIDE CHANNEL; RIBONUCLEIC-ACID; CELL POLARITY; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; GENERATION; TRANSPORT	Transcriptional and post-transcriptional regulation of CFTR (cystic fibrosis transmembrane conductance regulator) gene expression was studied in HT29 cells. It is known that the abundance of CFTR mRNA increases during differentiation of pluripotent HT29-18 cells and is maintained at high levels in the stably differentiated HT29-18-C1 subclone. Nuclear run-on assays suggest that increased transcription of the CFTR gene explains the increased abundance of total CFTR mRNA in differentiated HT29 cells. The increased transcription cannot be ascribed to cell cycle-dependent expression of the CFTR gene or to changes in CFTR gene copy number between subcloned cells. Similar to native tissue cells, differentiated HT29 cells contain low copy numbers of CFTR transcripts (1-5/cell), and a portion of the CFTR transcripts are alternatively spliced to remove exon 9 (and make 9- mRNA). During differentiation of HT29-18 cells, the absolute amount of full-length CFTR mRNA increases 8-fold, whereas the amount of 9- mRNA increases 18-fold. The fraction of 9- mRNA in the CFTR mRNA pool is increased in differentiated HT29 cells. The results show that gene transcription regulates the abundance of CFTR transcripts and that regulatory control of alternative RNA splicing may also be a cellular mechanism to modulate CFTR function.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,ROSS RES BLDG,RM 930,720 RUTLAND ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; NIA,GERONTOL RES CTR,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)				Oliva-Hemker, Maria/0000-0002-4054-7372	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM041015] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47122] Funding Source: Medline; NIGMS NIH HHS [GM41015] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1989, MOL BIOL CELL, P727; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; AUSBEL FM, 1991, CURRENT PROTOCOLS MO; BALLABIO A, 1990, NATURE, V343, P220, DOI 10.1038/343220a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; BLACKMON DL, 1982, ANAL BIOCHEM, V200, P352; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; CUPPENS H, 1990, J MED GENET, V27, P717, DOI 10.1136/jmg.27.11.717; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; EDMONDS M, 1971, P NATL ACAD SCI USA, V68, P1336, DOI 10.1073/pnas.68.6.1336; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAWKINS AL, 1991, CANCER GENET CYTOGEN, V54, P11, DOI 10.1016/0165-4608(91)90024-O; HAY R, 1988, AM TYPE CULTURE COLL; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LEBIVIC A, 1987, BIOL CELL, V60, P209; LEBIVIC A, 1988, P NATL ACAD SCI USA, V85, P136; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MALOSIO ML, 1991, J BIOL CHEM, V266, P2048; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCCORMACK K, 1990, BIOCHEM BIOPH RES CO, V171, P1361, DOI 10.1016/0006-291X(90)90836-C; MONTROSE MH, 1989, J MEMBRANE BIOL, V108, P31, DOI 10.1007/BF01870423; MONTROSERAFIZADEH C, 1991, J BIOL CHEM, V266, P4495; NEUTRA M, 1989, DIFFERENTIATION INTE, P363; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PHILLIPS TE, 1988, GASTROENTEROLOGY, V94, P1390, DOI 10.1016/0016-5085(88)90678-6; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STRONG TV, 1990, PEDIATR PULMON S, V5, P195; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZEITLIN PL, 1992, P NATL ACAD SCI USA, V89, P344, DOI 10.1073/pnas.89.1.344	47	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19299	19305						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382071				2022-12-27	WOS:A1992JP59300044
J	HUETTINGER, M; RETZEK, H; HERMANN, M; GOLDENBERG, H				HUETTINGER, M; RETZEK, H; HERMANN, M; GOLDENBERG, H			LACTOFERRIN SPECIFICALLY INHIBITS ENDOCYTOSIS OF CHYLOMICRON REMNANTS BUT NOT ALPHA-MACROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; RAT-LIVER; APOLIPOPROTEIN-E; ALPHA-2-MACROGLOBULIN RECEPTOR; PARENCHYMAL-CELLS; CULTURED-CELLS; LDL RECEPTOR; PLASMA; CLEARANCE	Our recently found nonlipoprotein inhibitor of chylomicron remnant uptake, lactoferrin, has been investigated in vivo and in vitro. Lipoprotein lipase extracted triglycerides from chylomicrons, doubly labeled with [H-3]retinol/[C-14]oleate, in the presence of lactoferrin normally. The subsequent uptake of remnants into liver was retarded considerably. In the intact rat, chylomicron remnants (CRs), predominantly labeled in the apoB48 moiety by I-125, were excluded from the hepatic endosomal compartment in the presence of lactoferrin as shown in subcellular fractionation studies of rat livers. In tissue culture, internalization of [I-125]chylomicron remnants was inhibited in the presence of 14 pM lactoferrin by 70%. Upon removal of lactoferrin, internalization was rapidly restored. Protease digestion eliminated the inhibitory effect completely. Modification of arginine residues with cyclohexanedione reversibly removed the inhibitory potency of lactoferrin. We located by molecular modeling an alpha-helical segment in lactoferrin on the exposed surface of the molecule containing the sequence Arg-X-X-Arg-Lys-X-Arg, which resembles the receptor recognition structure in apolipoprotein E (apoE). This firmly established ligand correspondence with apoE, the candidate ligand for CR recognition by the receptor. Finally, the postulated second function of low density lipoprotein receptor-related protein, uptake of alpha-2-macroglobulin (alpha-2M) was found to be distinct from lipoprotein binding, since lactoferrin inhibited CR but not alpha-2M internalization. In addition, CR uptake was not affected by alpha-2M. We conclude that if a bifunctional receptor were to operate, its diverse functions were exerted by independently operating substructures. The results of our in vivo and cell culture experiments are, however, entirely compatible with the existence of two receptors as well.			HUETTINGER, M (corresponding author), UNIV VIENNA,DEPT MED CHEM,WAHRINGERSTR 10,A-1090 VIENNA,AUSTRIA.			Retzek, Helmut/0000-0002-2256-7687; Hermann, Marcela/0000-0003-2298-4269				ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BLOMHOFF R, 1985, J BIOL CHEM, V260, P3566; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DYER CA, 1991, J BIOL CHEM, V266, P22803; EVANS WH, 1985, METHOD ENZYMOL, V109, P246; GALLOWAY CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3334, DOI 10.1073/pnas.80.11.3334; GMEINER BM, 1985, BIOCHIM BIOPHYS ACTA, V829, P76, DOI 10.1016/0167-4838(85)90070-6; GOLDENBERG H, 1988, BIOCHIM BIOPHYS ACTA, V968, P331, DOI 10.1016/0167-4889(88)90024-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HERZ J, 1990, J BIOL CHEM, V265, P21355; HUETTINGER M, 1984, J CLIN INVEST, V74, P1017, DOI 10.1172/JCI111469; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MAHLEY RW, 1980, P NATL ACAD SCI-BIOL, V77, P225, DOI 10.1073/pnas.77.1.225; REGOECZI E, 1985, AM J PHYSIOL, V248, pG8, DOI 10.1152/ajpgi.1985.248.1.G8; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; Smith E L, 1977, Methods Enzymol, V47, P156; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604; VANBERKEL TJC, 1983, BIOCHEM J, V216, P71, DOI 10.1042/bj2160071; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VANDYKE RW, 1984, P NATL ACAD SCI-BIOL, V81, P3108; WATTIAUX R, 1986, BIOCHEM BIOPH RES CO, V136, P504, DOI 10.1016/0006-291X(86)90469-9	32	82	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18551	18557						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382056				2022-12-27	WOS:A1992JN50200049
J	ULRICH, MJ; GRAY, WJ; LEY, TJ				ULRICH, MJ; GRAY, WJ; LEY, TJ			AN INTRAMOLECULAR DNA TRIPLEX IS DISRUPTED BY POINT MUTATIONS ASSOCIATED WITH HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLOBIN-GENE; INCREASES PROMOTER STRENGTH; SUPERCOILED PLASMIDS; BINDING-SITES; H-DNA; NUCLEAR PROTEINS; ERYTHROID-CELLS; HELIX FORMATION; MIRROR REPEATS; BRITISH FORM	Several investigators have suggested that secondary structures in DNA may be involved with physiologic gene regulatory processes in higher organisms. This hypothesis has been difficult to prove, however, since naturally occurring mutations that alter secondary DNA structures have not yet been identified. In this report, we describe a secondary DNA structure upstream from the human gamma-globin genes; this structure is formed in a homopyrimidine-homopurine tract and is stabilized by acidic pH and negative supercoiling of plasmid DNA. Since this structure is asymmetrically cleaved by S1 nuclease, it probably contains a single-stranded region and an intramolecular triplex. The single-stranded region is actually accessible for Watson-Crick base pairing with exogenous oligomers, a characteristic that permitted us to directly map the secondary DNA structure without additional chemical modifications of the supercoiled DNA. Five different point mutations just downstream from the single-stranded region are associated with hereditary persistence of fetal hemoglobin; four of these mutations dramatically reduce the stability of the secondary DNA structure, suggesting that these mutations alter formation of the intramolecular triplex by destabilizing critical Hoogsteen (triple-stranded) base pairs. These mutations may therefore represent a novel class of genetic defects that alter gene expression by changing the interaction of a critical regulatory molecule with a secondary DNA structure.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS,MED CTR,DEPT MED, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS,MED CTR,DEPT GENET, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)					NCI NIH HHS [CA-49712] Funding Source: Medline; NIDDK NIH HHS [DK-38682] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038682, R01DK038682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELOTSERKOVSKII BP, 1990, NUCLEIC ACIDS RES, V18, P6621, DOI 10.1093/nar/18.22.6621; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; CATALA F, 1989, NUCLEIC ACIDS RES, V17, P3811, DOI 10.1093/nar/17.10.3811; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; COCKERILL PN, 1983, BIOCHEM BIOPH RES CO, V112, P547, DOI 10.1016/0006-291X(83)91499-7; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; COLLINS FS, 1984, BLOOD, V64, P1292; COLLINS FS, 1985, NATURE, V313, P325, DOI 10.1038/313325a0; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P4894, DOI 10.1073/pnas.81.15.4894; COOK PR, 1975, J CELL SCI, V19, P261; COSTA FF, 1991, BLOOD, V76, P1896; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; ECONOMOU EP, 1991, BLOOD, V77, P174; FISCHER KD, 1990, NUCLEIC ACIDS RES, V18, P5685, DOI 10.1093/nar/18.19.5685; FOURCADEPERONNET F, 1992, J VIROL, V66, P1682, DOI 10.1128/JVI.66.3.1682-1687.1992; GELINAS R, 1985, NATURE, V313, P323, DOI 10.1038/313323a0; GELINAS R, 1986, BLOOD, V67, P1777; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GIGLIONI B, 1984, EMBO J, V3, P2641, DOI 10.1002/j.1460-2075.1984.tb02187.x; GILMAN JG, 1988, BLOOD, V72, P78; GILMAN JG, 1988, BRIT J HAEMATOL, V68, P455; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GLIKIN GC, 1983, NATURE, V303, P770, DOI 10.1038/303770a0; GLOVER JNM, 1990, BIOCHEMISTRY-US, V29, P11110, DOI 10.1021/bi00502a014; GRAY WJ, 1985, BLOOD, V66, pA71; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; GUMUCIO DL, 1991, BLOOD, V78, P1853; GUMUCIO DL, 1990, BLOOD, V75, P756; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; GUMUCIO DL, 1991, JH S CONT M, P277; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KIYAMA R, 1991, P NATL ACAD SCI USA, V88, P10450, DOI 10.1073/pnas.88.23.10450; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KOHWISHIGEMATSU T, 1983, P NATL ACAD SCI-BIOL, V80, P4389, DOI 10.1073/pnas.80.14.4389; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LAVELLE D, 1991, P NATL ACAD SCI USA, V88, P7318, DOI 10.1073/pnas.88.16.7318; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LEY TJ, 1991, BLOOD, V77, P1146; LLOYD JA, 1989, NUCLEIC ACIDS RES, V17, P4339, DOI 10.1093/nar/17.11.4339; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MARGOT JB, 1985, J MOL BIOL, V184, P195, DOI 10.1016/0022-2836(85)90373-0; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MCDONAGH KT, 1991, J BIOL CHEM, V266, P11965; METHERALL JE, 1988, AM J HUM GENET, V42, P476; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; NICKOL JM, 1983, CELL, V35, P467, DOI 10.1016/0092-8674(83)90180-0; NICOLIS S, 1989, NUCLEIC ACIDS RES, V17, P5509, DOI 10.1093/nar/17.14.5509; ONEILL D, 1991, P NATL ACAD SCI USA, V88, P8953, DOI 10.1073/pnas.88.20.8953; ONEILL D, 1990, NUCLEIC ACIDS RES, V18, P1977, DOI 10.1093/nar/18.8.1977; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; OTTOLENGHI S, 1988, BLOOD, V71, P815; PEREZSTABLE C, 1990, MOL CELL BIOL, V10, P1116, DOI 10.1128/MCB.10.3.1116; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; PURUCKER M, 1990, NUCLEIC ACIDS RES, V18, P7407, DOI 10.1093/nar/18.24.7407; RIXON MW, 1990, BIOCHEMISTRY-US, V29, P4393, DOI 10.1021/bi00470a019; RIXON MW, 1988, MOL CELL BIOL, V8, P713, DOI 10.1128/MCB.8.2.713; RONCHI A, 1989, NUCLEIC ACIDS RES, V17, P10231, DOI 10.1093/nar/17.24.10231; RUNKEL L, 1986, NUCLEIC ACIDS RES, V14, P7143, DOI 10.1093/nar/14.18.7143; SAAVEDRA RA, 1986, CELL, V45, P65, DOI 10.1016/0092-8674(86)90538-6; SCHON E, 1983, CELL, V35, P837, DOI 10.1016/0092-8674(83)90116-2; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; STAMATOYANNOPOULOS G, 1991, SCIENCE, V252, P383, DOI 10.1126/science.2017679; STOMING TA, 1989, BLOOD, V73, P329; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; SURREY S, 1988, BLOOD, V71, P807; SYKES K, 1990, MOL CELL BIOL, V10, P95, DOI 10.1128/MCB.10.1.95; TANAKA M, 1990, ANN NY ACAD SCI, V612, P167; TATE VE, 1986, BLOOD, V68, P1389; TSUTSUI K, 1988, J BIOL CHEM, V263, P7235; ULRICH MJ, 1990, BLOOD, V75, P990; WABER PG, 1986, BLOOD, V67, P551; WANG JNC, 1985, J BIOL CHEM, V260, P8194; WANG ZY, 1992, J BIOL CHEM, V267, P13669; WEINTRAUB H, 1986, CELL, V46, P115, DOI 10.1016/0092-8674(86)90865-2; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YANG KG, 1988, BLOOD, V71, P1414; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	90	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18649	18658						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382059				2022-12-27	WOS:A1992JN50200062
J	KLINE, D; KLINE, JT				KLINE, D; KLINE, JT			THAPSIGARGIN ACTIVATES A CALCIUM INFLUX PATHWAY IN THE UNFERTILIZED MOUSE EGG AND SUPPRESSES REPETITIVE CALCIUM TRANSIENTS IN THE FERTILIZED EGG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; LACRIMAL ACINAR-CELLS; GOLDEN-HAMSTER EGGS; TUMOR PROMOTER; INOSITOL PHOSPHATES; PLASMA-MEMBRANE; CA-2+; ENTRY; OSCILLATIONS; INHIBITION	At fertilization, the sperm initiates development of the mouse egg by inducing a large transient increase in the intracellular Ca2+ concentration ([Ca2+]i), which is followed by repetitive transient increases in [Ca2+]i. To determine how the repetitive Ca2+ transients are produced, thapsigargin, an inhibitor of the endoplasmic reticulum Ca-ATPase, was used to deplete intracellular Ca2+ stores within the egg. In the unfertilized egg, thapsigargin (1-50-mu-M) caused a slowly rising and falling transient increase in [Ca2+]i with or without extracellular Ca2+. An influx pathway for Ca2+ is activated by thapsigargin, since an immediate increase in [Ca2+]i occurred when Ca2+ was added to eggs after thapsigargin treatment in a Ca2+,Mg2+-free medium. This suggests that Ca2+ entry in the mouse egg may be coupled to the emptying of an intracellular store. The magnitude of the first Ca2+ transient at fertilization was reduced by as much as 84% in eggs pretreated with thapsigargin. Reduction of extracellular Ca2+, by addition of a Ca2+ chelator, suppressed the repetitive Ca2+ transients following fertilization. The Ca2+ transients also require filling of an intracellular store; they were suppressed when thapsigargin was added before or after fertilization. These results support the hypothesis that the first sperm-induced Ca2+ transient at fertilization depletes an intracellular Ca2+ store, triggering an increase in plasma membrane Ca2+ permeability, and that the enhanced Ca2+ influx causes repetitive Ca2+ transients due to the periodic filling and emptying of an intracellular Ca2+ store.			KLINE, D (corresponding author), KENT STATE UNIV, DEPT BIOL SCI, KENT, OH 44242 USA.		Kline, Douglas/AAH-5955-2020	Kline, Douglas/0000-0003-2555-6729	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026032] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26032] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BIAN JH, 1991, J BIOL CHEM, V266, P8801; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DUPONT G, 1991, CELL CALCIUM, V12, P73, DOI 10.1016/0143-4160(91)90010-C; ELY JA, 1991, J BIOL CHEM, V266, P18635; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; GRODEN DL, 1991, CELL CALCIUM, V12, P279, DOI 10.1016/0143-4160(91)90002-V; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hiramoto Y, 1984, Cell Struct Funct, V9 Suppl, ps139; HOGAN B, 1986, MANIPULATING MOUSE E; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JAFFE LF, 1990, NATO ADV SCI I H-CEL, V45, P389; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; KLINE D, 1992, Biophysical Journal, V61, pA124; KWAN CY, 1990, J BIOL CHEM, V265, P678; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MUALLEM S, 1991, BIOCHEM J, V279, P367, DOI 10.1042/bj2790367; PAPP B, 1991, J BIOL CHEM, V266, P14593; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; POLVERINO AJ, 1991, BIOCHEM J, V278, P849, DOI 10.1042/bj2780849; PRESTON SF, 1991, CELL REGUL, V2, P915, DOI 10.1091/mbc.2.11.915; PUTNEY JW, 1990, PHARMACOL THERAPEUT, V48, P427, DOI 10.1016/0163-7258(90)90059-B; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466	42	128	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17624	17630						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387638				2022-12-27	WOS:A1992JM22300025
J	LEUNG, LLK; LI, WX; MCGREGOR, JL; ALBRECHT, G; HOWARD, RJ				LEUNG, LLK; LI, WX; MCGREGOR, JL; ALBRECHT, G; HOWARD, RJ			CD36 PEPTIDES ENHANCE OR INHIBIT CD36-THROMBOSPONDIN BINDING - A 2-STEP PROCESS OF LIGAND-RECEPTOR INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; PLATELET THROMBOSPONDIN; ADHESIVE GLYCOPROTEIN; MEMBRANE GLYCOPROTEIN; CELL-ADHESION; GPIIB-IIIA; PARASITIZED ERYTHROCYTES; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS	CD36 (glycoprotein IV or IIIB) is an integral plasma membrane protein of wide cellular distribution and functions as a receptor site for thrombospondin (TSP), an adhesive protein important in cell-cell and cell-matrix interactions. OKM5, a monoclonal anti-CD36 antibody, has been reported to block CD36 cell adhesive functions suggesting that the OKM5 epitope on CD36 is functionally important. A panel of 10 synthetic CD36 peptides was made. One peptide, P139-155, specifically inhibited the immunoadsorption of CD36 by OKM5, and P139-155 was directly immunoadsorbed by OKM5, indicating that CD36 sequence 139-155 represents part of the OKM5 epitope. TSP bound to immobilized P139-155 in a dose-dependent and saturable manner. Surprisingly, P139-155 significantly augmented, instead of inhibited, binding of CD36 to TSP. This peptide did not induce platelet aggregation but augmented ADP- and collagen-induced aggregation in platelet-rich plasma. Another CD36 peptide, P93-110, which had no effect on OKM5 immunoadsorption, blocked binding of CD36 to immobilized TSP and partially inhibited collagen-induced platelet aggregation. P93-110 by itself did not bind to TSP; however, in the presence of P139-155, there was a marked enhancement of P93-110 binding to TSP, with a stoichiometry consistent with the trimeric nature of TSP. The data suggest that CD36-TSP interaction is a two-step process; the sequence 139-155 region of CD36 binds first to TSP, triggering a change in TSP to reveal a second site, which binds the 93-110 region of CD36 with high affinity. CD36 peptides can be used as stimulators or inhibitors in cellular adhesive events involving TSP-CD36 interaction. Conformational changes leading to the exposure or activation of high affinity binding sites may occur in both the receptor and the ligand upon cell-cell and cell-matrix adhesion.	STANFORD UNIV,MED CTR,SCH MED,DIV HEMATOL,STANFORD,CA 94305; INSERM,F-69008 LYON,FRANCE; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	Stanford University; Institut National de la Sante et de la Recherche Medicale (Inserm); Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042943] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01-HL42943] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCH AS, 1991, J BIOL CHEM, V266, P1740; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BACONBAGULEY T, 1990, J BIOL CHEM, V265, P2317; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BEISO P, 1990, BIOCHIM BIOPHYS ACTA, V1033, P7, DOI 10.1016/0304-4165(90)90186-Z; CLEZARDIN P, 1986, EUR J BIOCHEM, V154, P95, DOI 10.1111/j.1432-1033.1986.tb09363.x; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; HOWARD RJ, 1989, BLOOD, V74, P2603; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; KIEFFER N, 1989, BIOCHEM J, V262, P835, DOI 10.1042/bj2620835; KIEFFER N, 1991, BIOCHIM BIOPHYS ACTA, V77, P2649; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; LAHAV J, 1982, CELL, V31, P253, DOI 10.1016/0092-8674(82)90425-1; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1986, BLOOD, V67, P1197; LEUNG LLK, 1982, J CLIN INVEST, V70, P542, DOI 10.1172/JCI110646; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MCPHERSON J, 1981, J BIOL CHEM, V256, P1330; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; OCKENHOUSE CF, 1991, P NATL ACAD SCI USA, V88, P3175, DOI 10.1073/pnas.88.8.3175; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OCKENHOUSE CF, 1991, SCIENCE, V88, P3175; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1980, J BIOL CHEM, V255, P1629; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SHEBUSKI RJ, 1989, J BIOL CHEM, V264, P21550; SILVERSTEIN RL, 1986, ARTERIOSCLEROSIS, V6, P245, DOI 10.1161/01.ATV.6.3.245; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; WIKNER NE, 1987, J INVEST DERMATOL, V88, P207, DOI 10.1111/1523-1747.ep12525350; YASUDA T, 1988, J CLIN INVEST, V81, P1284, DOI 10.1172/JCI113446	46	82	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18244	18250						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381367				2022-12-27	WOS:A1992JM22300116
J	SARDANA, VV; EMINI, EA; GOTLIB, L; GRAHAM, DJ; LINEBERGER, DW; LONG, WJ; SCHLABACH, AJ; WOLFGANG, JA; CONDRA, JH				SARDANA, VV; EMINI, EA; GOTLIB, L; GRAHAM, DJ; LINEBERGER, DW; LONG, WJ; SCHLABACH, AJ; WOLFGANG, JA; CONDRA, JH			FUNCTIONAL-ANALYSIS OF HIV-1 REVERSE-TRANSCRIPTASE AMINO-ACIDS INVOLVED IN RESISTANCE TO MULTIPLE NONNUCLEOSIDE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BINDING-SITE; SENSITIVITY; AIDS; DERIVATIVES; THERAPY; AZT; REPLICATION; MUTANTS; POTENT	Several novel, structurally distinct classes of specific human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) nonnucleoside inhibitors have been described recently. These include the pyridinone derivatives L-697,639, L-697,661, and L-696,229 as well as BI-RG-587 and the tetrahydroimidazo[4,5,1-j,k]-benzodiazepin-2(1H)-one and -thione compounds. Previous studies have implicated involvement of the RT amino acid residues at positions 103, 181, and 188 in the activity of the compounds. Accordingly, HIV-1 RT mutants containing a series of amino acid substitutions at these positions were constructed. The relative resistance of purified mutant enzymes to each of the inhibitors was assessed. This analysis established the functional equivalence of the three inhibitor classes and provided evidence for the interaction of the 103 site with the 181/188 region. Amino acid substitutions at these positions were also found to influence RT sensitivity to inhibition by phosphonoformate, thereby suggesting a close association between this pyrophosphate analog's binding site in RT and the binding site of the nonnucleoside inhibitors. In addition, aromatic stacking of the amino acid side groups at residues 181 and 188 was suggested to be required for inhibitor activity.			SARDANA, VV (corresponding author), MERCK SHARP & DOHME LTD,DEPT VIRUS & CELL BIOL,W16-206,W POINT,PA 19486, USA.							BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; BUTLER KM, 1991, NEW ENGL J MED, V324, P137, DOI 10.1056/NEJM199101173240301; COHEN KA, 1991, J BIOL CHEM, V266, P14670; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; CONDRA JH, 1992, ANTIMICROB AGENTS CH, V36, P1441, DOI 10.1128/AAC.36.7.1441; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRANK KB, 1991, J BIOL CHEM, V266, P14232; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND S, 1990, J INFECT DIS, V161, P3265; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; Maniatis T., 1982, MOL CLONING; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; ROOKE R, 1989, AIDS, V3, P411, DOI 10.1097/00002030-198907000-00001; SAARI WS, 1991, J MED CHEM, V34, P2922, DOI 10.1021/jm00113a036; SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; WHITE EL, 1991, ANTIVIR RES, V16, P257, DOI 10.1016/0166-3542(91)90005-C; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	31	110	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17526	17530						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381350				2022-12-27	WOS:A1992JM22300011
J	SHENG, ZQ; WU, K; CARRAWAY, KL; FREGIEN, N				SHENG, ZQ; WU, K; CARRAWAY, KL; FREGIEN, N			MOLECULAR-CLONING OF THE TRANSMEMBRANE COMPONENT OF THE 13762 MAMMARY ADENOCARCINOMA SIALOMUCIN COMPLEX - A NEW MEMBER OF THE EPIDERMAL GROWTH-FACTOR SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE SIALOMUCIN; TUMOR; GLYCOPROTEINS; PROTEIN; MUCIN; GENE; PRECURSOR; EPISIALIN; SEQUENCE; DOMAIN	Ascites sublines of the 13762 rat mammary adenocarcinoma have a cell surface sialomucin complex composed of the sialomucin ascites sialoglycoprotein-1 (ASGP-1) and the membrane-associated glycoprotein ASGP-2. The sialomucin complex is synthesized as a high M(r) precursor, pre-sialomucin complex (pSMC-1). To characterize the structure of the membrane-associated component of this complex, a lambda-gt11 cDNA expression library was constructed using mRNA from 13762 rat mammary adenocarcinoma cells and screened with polyclonal antibody against ASGP-2. The strongest antibody-binding clone, designated lambda-ASGP2.9-1, had a 1.3-kilobase (kb) insert, and hybridized to a 9-kb transcript in 13762 cell mRNA. The large size of this transcript was expected, since the estimated molecular mass of pSMC-1 is >250 kDa. To obtain the full sequence of ASGP-2, a longer cDNA (5.4 kb), designated pASGP1/2.1, was subsequently cloned by screening a plasmid library with an oligonucleotide complementary to the 5' end of the phage insert. The amino acid sequence derived from nucleotide sequence of pASGP1/2.1 showed a 12-amino acid identity with amino acid sequence obtained from the NH2 terminus of ASGP-2, indicating the entire ASGP-2 coding region was included in the cDNA. Furthermore, an 18-amino acid identity with the NH2 terminus of a 6-kDa CNBr fragment of ASGP-2 was also observed in the cDNA sequence. The polypeptide contains several distinct domains, including a hydrophobic transmembrane domain, a short (20 residue) COOH-terminal cytoplasmic tail, and a large extracellular domain with 24 potential N-glycosylation sites. These properties correspond to features of ASGP-2 and pSMC-1 predicted by previous biochemical studies. Most interestingly, the extracellular domain contains two cysteine-rich sequences, each of which has a segment with strong similarities to proteins with epidermal growth factor activity. Since our recent studies show that ASGP-2 can modulate epidermal growth factor receptor phosphorylation activity, these results provide structural evidence to support the role of the heterodimeric sialomucin complex as a bifunctional modulator of cellular interactions and cell proliferation.	UNIV MIAMI, SCH MED, DEPT MOLEC BIOL & BIOCHEM, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT CELL BIOL & ANAT, MIAMI, FL 33101 USA	University of Miami; University of Miami					NCI NIH HHS [CA 52498, CA 31695] Funding Source: Medline; NIAMS NIH HHS [AR 38872] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031695, R01CA052498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038872] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BHARATHAN S, 1990, CANCER RES, V50, P5250; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CARRAWAY KL, 1986, MOL CELL BIOCHEM, V72, P109; CARRAWAY KL, 1992, FASEB J, V6, pA47; CARRAWAY KL, 1988, RECOGNITION MECHANIS, P20; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CODINGTON JF, 1983, BIOMEMBRANE, V11, P207; DAVIS C G, 1990, New Biologist, V2, P410; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; ENGEL J, 1989, FEBS LETT, V21, P1; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; HULL SR, 1991, J BIOL CHEM, V266, P13580; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MAINE EM, 1990, BIOESSAYS, V12, P265, DOI 10.1002/bies.950120604; Maniatis T., 1982, MOL CLONING; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; ROBERTON AM, 1989, BIOCHEM J, V261, P637, DOI 10.1042/bj2610637; SHENG Z, 1989, J CELL BIOCHEM, V40, P453, DOI 10.1002/jcb.240400406; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1986, CANCER RES, V46, P4543; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; STECK PA, 1983, EXP CELL RES, V147, P255, DOI 10.1016/0014-4827(83)90208-2; VOS HL, 1991, BIOCHEM BIOPH RES CO, V181, P121, DOI 10.1016/S0006-291X(05)81390-7; XU GQ, 1992, J BIOL CHEM, V267, P5401; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	36	116	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16341	16346						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379596				2022-12-27	WOS:A1992JJ45800056
J	CAMACHOHUBNER, C; BUSBY, WH; MCCUSKER, RH; WRIGHT, G; CLEMMONS, DR				CAMACHOHUBNER, C; BUSBY, WH; MCCUSKER, RH; WRIGHT, G; CLEMMONS, DR			IDENTIFICATION OF THE FORMS OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEINS PRODUCED BY HUMAN FIBROBLASTS AND THE MECHANISMS THAT REGULATE THEIR SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR IGF BINDING; CULTURED HUMAN-FIBROBLASTS; HUMAN-SKIN FIBROBLASTS; SMOOTH-MUSCLE CELLS; FACTOR-I; SOMATOMEDIN-C; DNA-SYNTHESIS; PURIFICATION; RELEASE; PLASMA	Human fibroblasts secrete insulin-like growth factor-binding proteins (IGFBPs) that can modify insulin-like growth factor (IGF) I action. We have determined the molecular identities of three forms of IGFBPs that are secreted by human fibroblasts in vitro. Ligand blot analysis of fibroblast conditioned media revealed that the M(r) 43,000 and 39,000 forms were the most abundant, but that M(r) 31,000 and 24,000 forms were also present. An antiserum that was specific for IGFBP-5 reacted with the M(r) 31,000 form, and an IGFBP-4-specific antiserum recognized only the M(r) 24,000 form. The M(r) 39,000 and 43,000 forms were detected by IGFBP-3 antiserum. Further proof that fibroblasts synthesized these forms of IGFBPs was obtained by Northern blotting. A cDNA probe for IGFBP-3 hybridized with a 2.4-kilobase (kb) transcript, whereas a cDNA probe for IGFBP-5 recognized a single 6.0-kb transcript, and an IGFBP-4 cDNA probe recognized 2.2- and 2.0-kb transcripts. IGF-I and -II caused a minimal (<43%) increase in IGFBP-5 mRNA abundance and had no effect on IGFBP-4 mRNA abundance. IGF-I and -II (100 ng/ml) stimulated 6-8-fold increases in IGFBP-5 levels, whereas IGFBP-4 was inhibited. Insulin failed to elicit any change in IGFBP-5, suggesting that binding of the IGFs to IGFBPs was required to detect the increase. Immunoblotting for IGFBP-5 revealed an M(r) 23,000 (non-IGF-I-binding) fragment. To determine if the IGFs were influencing proteolytic degradation of IGFBP-5, pure IGFBP-5 was added to fibroblast cultures and incubated for 4 h at 37-degrees-C. The amount of fragment formation was attenuated by the presence of IGF-I and -II, but not insulin, suggesting that this is a mechanism by which the IGFs act to modulate IGFBP-5 concentration. In contrast to the IGFs, forskolin, which increased IGFBP-4 and -5 mRNA abundance and secretion, had no effect on fragment formation. The results show that human fibroblasts synthesize and secrete IGFBP-3, -4, and -5 and that changes in intracellular cAMP regulate synthesis, whereas the IGFs regulate IGFBP-4 and -5 levels by post-transcriptional mechanisms.			CAMACHOHUBNER, C (corresponding author), UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599, USA.				NATIONAL INSTITUTE ON AGING [R01AG002331, R37AG002331] Funding Source: NIH RePORTER; NIA NIH HHS [AG02331] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS SO, 1984, ENDOCRINOLOGY, V115, P520, DOI 10.1210/endo-115-2-520; ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; ATKISON PR, 1980, ENDOCRINOLOGY, V106, P2006, DOI 10.1210/endo-106-6-2006; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEMMONS DR, 1984, J CLIN ENDOCR METAB, V58, P850, DOI 10.1210/jcem-58-5-850; CLEMMONS DR, 1990, J BIOL CHEM, V265, P12210; CLEMMONS DR, 1986, J BIOL CHEM, V261, P293; CLEMMONS DR, 1987, MOL ENDOCRINOL, V1, P339, DOI 10.1210/mend-1-5-339; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P643, DOI 10.1210/endo-127-2-643; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HAWKE D, 1987, USER B; HILL DJ, 1989, J ENDOCRINOL, V122, P87, DOI 10.1677/joe.0.1220087; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MARTIN JL, 1991, ENDOCRINOLOGY, V128, P1425, DOI 10.1210/endo-128-3-1425; MARTIN JL, 1988, ENDOCRINOLOGY, V123, P1907, DOI 10.1210/endo-123-4-1907; MCCUSKER RH, 1988, ENDOCRINOLOGY, V122, P2071, DOI 10.1210/endo-122-5-2071; MCCUSKER RH, 1990, J CELL PHYSIOL, V144, P244, DOI 10.1002/jcp.1041440210; MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SVOBODA ME, 1980, BIOCHEMISTRY-US, V19, P790, DOI 10.1021/bi00545a027; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176	35	295	299	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11949	11956						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376315				2022-12-27	WOS:A1992HY94700046
J	OEHM, A; BEHRMANN, I; FALK, W; PAWLITA, M; MAIER, G; KLAS, C; LIWEBER, M; RICHARDS, S; DHEIN, J; TRAUTH, BC; PONSTINGL, H; KRAMMER, PH				OEHM, A; BEHRMANN, I; FALK, W; PAWLITA, M; MAIER, G; KLAS, C; LIWEBER, M; RICHARDS, S; DHEIN, J; TRAUTH, BC; PONSTINGL, H; KRAMMER, PH			PURIFICATION AND MOLECULAR-CLONING OF THE APO-1 CELL-SURFACE ANTIGEN, A MEMBER OF THE TUMOR-NECROSIS-FACTOR NERVE GROWTH-FACTOR RECEPTOR SUPERFAMILY - SEQUENCE IDENTITY WITH THE FAS ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; POLYACRYLAMIDE GELS; EXPRESSION; PROTEINS; APOPTOSIS; LYMPHOCYTES; CLEAVAGE; GENES	The APO-1 antigen as defined by the mouse monoclonal antibody anti-APO-1 was previously found to be expressed on the cell surface of activated human T and B lymphocytes and a variety of malignant human lymphoid cell lines. Cross-linking of the APO-1 antigen by anti-APO-1 induced programmed cell death, apoptosis, of APO-1 positive cells. To characterize the APO-1 cell surface molecule and to better understand its role in induction of apoptosis, the APO-1 protein was purified to homogeneity from membranes of SKW6.4 B lymphoblastoid cells by solubilization with sodium deoxycholate, affinity chromatography with anti-APO-1 antibody, and reversed phase high performance liquid chromatography. Each purification step was followed by an APO-1-specific solid phase enzyme-linked immunosorbent assay using the monoclonal antibody anti-APO-1. In sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the APO-1 antigen was found to be a membrane glycoprotein of 48-kDa. Endoproteinase-cleaved peptides of the APO-1 protein were subjected to amino acid sequencing, and corresponding oligonucleotides were used to identify a full-length APO-1 cDNA clone from an SKW6.4 cDNA library. The deduced amino acid sequence of APO-1 showed sequence identity with the Fas antigen, a cysteine-rich transmembrane protein of 335 amino acids with significant similarity to the members of the tumor necrosis factor/nerve growth factor receptor superfamily. The APO-1 antigen was expressed upon transfection of APO-1 cDNA into BL60-P7 Burkitt's lymphoma cells and conferred sensitivity towards anti-APO-1-induced apoptosis to the transfectants.	GERMAN CANC RES CTR,INST IMMUNOL & GENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,INST APPL TUMOR VIROL,W-6900 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,INST CELL & TUMOR BIOL,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)			Pawlita, Labor/C-9720-2011	Behrmann, Iris/0000-0003-3688-3645; Pawlita, Michael/0000-0002-4720-8306; Dhein, Jens/0000-0002-7200-2967				ARVIEUX J, 1988, PRACTICAL APPROACH S, P113; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; INUI S, 1989, LEUCOCYTE TYPING, V4, P93; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KOHLER HR, 1990, ULTRASTRUCT PATHOL, V14, P513; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAMMER PH, 1991, APOPTOSIS MOL BASIS, P87; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UPTON C, 1987, VIROLOGY, V160, P20, DOI 10.1016/0042-6822(87)90039-0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WOLF J, 1990, CANCER RES, V50, P3095; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	29	881	932	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10709	10715						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375228				2022-12-27	WOS:A1992HV09000076
J	YU, H; GOODMAN, MF				YU, H; GOODMAN, MF			COMPARISON OF HIV-1 AND AVIAN-MYELOBLASTOSIS VIRUS REVERSE-TRANSCRIPTASE FIDELITY ON RNA AND DNA TEMPLATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE INSERTION FIDELITY; BASE SUBSTITUTION; KINETICS; REPLICATION; MECHANISM; THERMODYNAMICS; PROCESSIVITY; RETROVIRUS; EXTENSION	A comparison of the fidelity of reverse transcriptases (RT) from human immunodeficiency virus (HIV-1) and avian myeloblastosis virus (AMV) is made using RNA and DNA primer-template molecules in vitro. Selected template target sites containing either uracil or thymine are used to measure nucleotide insertion fidelities and to compare the efficiency of extending mismatched nucleotides at primer 3'-termini. HIV-1 reverse transcriptase is observed to incorporate as many as three consecutive mismatches and to continue efficient elongation from mismatched primer 3'-termini without discernible pausing. Nucleotide misinsertion and mispair extension efficiencies are similar for both enzymes on RNA and DNA templates having identical surrounding sequence. HIV-1 and AMV reverse transcriptases form G.T and G.U mismatches most efficiently, between 1.6 x 10(-4) and 7 x 10(-4), and both enzymes extend G-U with exceptionally high efficiencies, 2.7 x 10(-2) for HIV- 1 RT and 4.5 x 10(-2) for AMV RT. Extension of the G.T mismatch is similar for AMV RT (5.8 X 10(-2)) but 20-fold less efficient for HIV-1 RT. C.U and C.T mismatches are formed by both enzymes in a frequency range of 4.4 x 10(-5)-2.4 x 10(-4). HIV-1 RT extends these mismatches with slightly higher efficiencies ( 5.5 x 10(-3)-5.9 x 10(-3)) than AMV RT (5.6 x 10(-4)-2.1 x 10(-3)). Insertion of dTMP opposite U and T occur at about 1 X 10(-4)-2 x 10(-4) for HIV-1 RT. For AMV RT, formation of T.U mispairs occurs with an 8-fold lower efficiency, whereas insertion of dTMP opposite T is not detected. This particular DNA template sequence generates a pause site for AMV RT but not HIV-1 RT. HIV-1 RT dissociation rate constants are about 8-fold larger from a DNA primer bound to a DNA template (0.5 s-1), as compared with an RNA template (0.06 s-1) at one site, and are at most 2-fold larger at another site. The equilibrium binding constant for HIV-1 RT bound to DNA primed RNA and DNA templates appears to be similar, K(D) approximately 2.5 nm. Values of k(pol) from 0.3 to 1.5 nucleotides/s are obtained for HIV-1 RT at the RNA and DNA template sites used to measure insertion and extension fidelity. The relatively high efficiency of mispair extension catalyzed by reverse transcriptases with both RNA and DNA templates suggests that a significant component of retroviral genetic variability may be related to the ability of reverse transcriptases to continue efficient synthesis of DNA containing mismatches on both RNA and DNA templates.	UNIV SO CALIF,DEPT BIOL SCI,MOLEC BIOL SECT,ACBR RM 239,UNIV PK,LOS ANGELES,CA 90089	University of Southern California					NIGMS NIH HHS [GM21422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021422, R37GM021422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1991, J BIOL CHEM, V266, P3937; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DELSAL G, 1980, NUCLEIC ACIDS RES, V15, P10047; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; DUDDING LR, 1991, BIOCHEMISTRY-US, V30, P10499; FERSHT A, 1985, ENZYME STRUCTURE MEC, P112; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; GOODMAN MF, 1988, MUTAT RES, V200, P11, DOI 10.1016/0027-5107(88)90067-X; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KRUG MS, 1991, BIOCHEMISTRY-US, V30, P10614, DOI 10.1021/bi00108a003; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; LEIDER JM, 1988, J VIROL, V62, P3084, DOI 10.1128/JVI.62.9.3084-3091.1988; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MAJUMDAR C, 1989, BIOCHEMISTRY-US, V28, P1340, DOI 10.1021/bi00429a060; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MYERS G, 1987, HUMAN RETROVIRUSES A, V1, P1; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; REARDON JE, 1990, J BIOL CHEM, V265, P20302; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SAUER RT, 1983, J MOL BIOL, V168, P699, DOI 10.1016/S0022-2836(83)80070-9; TAKEUCHI Y, 1988, J VIROL, V62, P3900, DOI 10.1128/JVI.62.10.3900-3902.1988; WEBER J, 1989, NUCLEIC ACIDS RES, V17, P1379, DOI 10.1093/nar/17.4.1379	36	153	156	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10888	10896						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375233				2022-12-27	WOS:A1992HV09000101
J	NAKAGAWA, Y; RIVERA, V; LARNER, AC				NAKAGAWA, Y; RIVERA, V; LARNER, AC			A ROLE FOR THE NA/K-ATPASE IN THE CONTROL OF HUMAN C-FOS AND C-JUN TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; EPIDERMAL GROWTH-FACTOR; PROTO-ONCOGENE FOS; 12-O-TETRADECANOYL PHORBOL-13-ACETATE; MEDIATE INDUCTION; GENE-EXPRESSION; INTERFERON; DNA; SEQUENCES; RNA	The c-fos proto-oncogene is known to be regulated by a variety of hormones, growth factors, and other conditions that alter cellular metabolism. The regulation of c-fos RNA concentrations is known to occur both by altered RNA half-life and/or changes in the transcription rate of the gene. In most cases thus far investigated, induction of c-fos transcription by growth factors occurs very rapidly and transiently. Results presented in this paper show that ouabain, a specific inhibitor of the Na/K-ATPase increases the transcription of c-fos, as well as c-jun, in a variety of cultured cells. However, in contrast to other agents that induce c-fos and c-jun expression, the increased transcription rate of these genes in the presence of ouabain required several hours and remained elevated for at least 16 h. NIH 3T3 cells that have been transfected with deletions of the human c-fos promoter have enabled us to define at least two elements within the promotor that are regulated by ouabain. These include the serum response element and a region between 123 and 222 base pairs 5' to the start site of transcription. We speculate that regulation of the intracellular ion balance through changes in Na/K pump activity may be a general mechanism by which basal transcriptional activity of c-fos is modulated.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	US Food & Drug Administration (FDA); Harvard University; Harvard Medical School								AKAI H, 1989, J BIOL CHEM, V264, P3252; BEVEREN CV, 1983, CELL, V32, P1241; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CURRAN T, 1987, BIOESSAYS, V7, P225; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; ENGLISH LH, 1985, J BIOL CHEM, V260, P1114; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GEERING K, 1986, CURR TOP MEMBR TRANS, V27, P221; GOMI K, 1986, CANCER RES, V46, P6211; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KNIGHT E, 1985, P NATL ACAD SCI USA, V82, P1151, DOI 10.1073/pnas.82.4.1151; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LARNER AC, 1986, J BIOL CHEM, V261, P453; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; YAMATO K, 1989, BLOOD, V74, P1314	35	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					8785	8788						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374380				2022-12-27	WOS:A1992HR85400015
J	PANDIELLA, A; BOSENBERG, MW; HUANG, EJ; BESMER, P; MASSAGUE, J				PANDIELLA, A; BOSENBERG, MW; HUANG, EJ; BESMER, P; MASSAGUE, J			CLEAVAGE OF MEMBRANE-ANCHORED GROWTH-FACTORS INVOLVES DISTINCT PROTEASE ACTIVITIES REGULATED THROUGH COMMON MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA; CELL-SURFACE; FACTOR RECEPTORS; ENOL LACTONES; GENE-PRODUCT; KIT LIGAND; PRECURSOR; CHYMOTRYPSIN; EXPRESSION; SEQUENCE	The membrane-anchored forms of transforming growth factor-alpha (TGF-alpha) and stem cell growth factors (Kit ligands) KL-1 and KL-2 are converted to soluble growth factor forms by a regulated proteolytic cleavage process. Each of these proteins is cleaved at a distinct site, however their cleavage is activated via a common set of intracellular signaling mechanisms. By using a panel of protease inhibitors, we show here that at least two cell-associated serine protease activities with distinct specificities participate in membrane growth factor cleavage. Two serine protease inhibitors of broad specificity, diisopropylfluorophosphate and 3,4-dichloroisocoumarin, prevent the cleavage of proTGF-alpha and KL-1 but not that of KL-2. Of the agents tested, N-tosyl-L-phenylalanine chloromethyl ketone and various haloenol lactone derivatives are the most potent inhibitors of cleavage of all three membrane growth factors. It is concluded that cleavage of membrane-anchored growth factors involves a proteolytic system with multiple serine protease activities regulated through common mechanisms.	MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	PANDIELLA, A (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.		Huang, Eric J./AAH-7997-2019; Pandiella, Atanasio/O-5180-2014	Huang, Eric J./0000-0002-5381-3801; Pandiella, Atanasio/0000-0002-4704-8971; Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [R01CA053559] Funding Source: NIH RePORTER; NCI NIH HHS [CA53559] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; DANIELS SB, 1983, J BIOL CHEM, V258, P5046; DANIELS SB, 1986, BIOCHEMISTRY-US, V25, P1436, DOI 10.1021/bi00354a037; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LU HS, 1991, J BIOL CHEM, V266, P8102; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; NOCKA K, 1990, CELL, V63, P225; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; Powell J.L., 1986, PROTEINASE INHIBITOR, P55; Powers J.C., 1986, PROTEINASE INHIBITOR, P219; REED PE, 1991, J BIOL CHEM, V266, P13; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RICH DH, 1986, PROTEINASE INHIBITOR, P153; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; STEIN J, 1991, ONCOGENE, V6, P601; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; TEIXIDO J, 1987, NATURE, V326, P883, DOI 10.1038/326883a0; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	49	115	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24028	24033						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385433				2022-12-27	WOS:A1992JZ23900089
J	GOLDERNOVOSELSKY, E; FORTE, TM; NICHOLS, AV; RUBIN, EM				GOLDERNOVOSELSKY, E; FORTE, TM; NICHOLS, AV; RUBIN, EM			APOLIPOPROTEIN-A-I EXPRESSION AND HIGH-DENSITY-LIPOPROTEIN DISTRIBUTION IN TRANSGENIC MICE DURING DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRADIENT GEL-ELECTROPHORESIS; PLASMA-LEVELS; SIZE; GENE; RAT	The developmental changes in apoAI expression in human apolipoprotein AI (apoAI) transgenic and non-transgenic control mice and the effect of these changes on high density lipoprotein (HDL) sizes were investigated. Results demonstrated that both human and mouse apoAI mRNA levels sharply increased following delivery and then decreased prior to weaning. Unlike the changes in apoAI mRNA, plasma apoAI concentration and HDL mass increased following delivery and remained elevated as the animals matured. In these animals, parallel increases in plasma apoAI and HDL mass with development were accompanied by increases in HDL particle sizes. Control mice demonstrated a monodisperse population of particles that increased in particle size from 7.5 nm (at 2 days prior to birth) to 9.8 nm (at 13 days after birth). The latter is similar to the adult HDL size and distribution. Transgenic mice, unlike controls, exhibited several distinct HDL populations, which also increased in size as animals matured. These results suggest that post-transcriptional factors are important in regulating apoAI plasma levels and that developmental changes in plasma apoAI concentrations are associated with changes in HDL size distribution.	LAWRENCE BERKELEY LAB,DIV LIFE SCI,BLDG 74,1 CYCLOTRON RD,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley					NHLBI NIH HHS [HL07279, HL46281, HL18574] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007279, R01HL046281, P01HL018574] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; CHAJEKSHAUL T, 1991, P NATL ACAD SCI USA, V88, P6731, DOI 10.1073/pnas.88.15.6731; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P16380; FERNANDOWARNAKULASURIYA GJP, 1983, J LIPID RES, V24, P1626; FORTE TM, 1981, LIPIDS, V16, P240, DOI 10.1007/BF02535023; FORTE TM, 1988, J PARENTER ENTERAL N, V13, P490; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; HENNING SJ, 1981, AM J PHYSIOL, V241, pG199, DOI 10.1152/ajpgi.1981.241.3.G199; Maniatis T., 1982, MOL CLONING; MILLER JCE, 1983, P NATL ACAD SCI-BIOL, V80, P1511, DOI 10.1073/pnas.80.6.1511; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; WALSH A, 1989, J BIOL CHEM, V264, P6488	15	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20787	20790						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383210				2022-12-27	WOS:A1992JT97800044
J	BUSAM, KJ; ROBERTS, AB; SPORN, MB				BUSAM, KJ; ROBERTS, AB; SPORN, MB			INHIBITION OF MITOGEN-INDUCED C-FOS EXPRESSION IN MELANOMA-CELLS BY RETINOIC ACID INVOLVES THE SERUM RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; INDUCIBLE BINDING; GENE-EXPRESSION; ANTISENSE RNA; VITAMIN-A; TRANSCRIPTION; INDUCTION; ACTIVATION; SEQUENCES; ONCOGENE	To investigate the mechanism(s) by which all-trans-retinoic acid (RA) inhibits cell growth, we studied its effect on the expression of c-fos and c-jun in B16 melanoma cells. RA differentially inhibited proto-oncogene induction by mitogens, such as phorbol 12-myristate 13-acetate and serum. Suppression of c-fos was achieved with doses of RA as low as 10(-10) M and required pretreatment of cells with RA for a minimum of 2 h. In contrast, inhibition of c-jun required pretreatment for greater than 16 h with at least 10(-8) M RA and coincided with the observed decrease in cell growth. RA blocked c-fos induction by inhibiting transcription. This inhibition of transcription occurs through the serum response element (SRE), since the SRE alone was sufficient to confer down-regulation by RA to a minimal c-fos promoter construct. Thus, the SRE plays a critical role in the suppression of c-fos transcription by RA.	NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BUESCHER M, 1988, Oncogene, V3, P301; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1984, CELL, V36, P259; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; KOENIG H, 1989, EMBO (European Molecular Biology Organization) Journal, V8, P2559; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LEVINE N, 1980, LANCET, V2, P224; LOTAN R, 1979, CANCER RES, V39, P4767; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MENGER H, 1988, BLOOD, V72, P567; MILLER AD, 1984, CELL, V36, P51; MILLER WH, 1990, ONCOGENE, V5, P511; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; REPRESA J, 1990, DEVELOPMENT, V110, P1081; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RIVERA V M, 1990, New Biologist, V2, P751; ROBERTS AB, 1984, RETINOIDS, V2, P209; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VELCICH A, 1990, MOL CELL BIOL, V9, P3576; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YANGYEN HF, 1991, NEW BIOL, V3, P1206	55	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19971	19977						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400313				2022-12-27	WOS:A1992JR85800038
J	KIM, HK; STORCH, J				KIM, HK; STORCH, J			MECHANISM OF FREE FATTY-ACID TRANSFER FROM RAT-HEART FATTY ACID-BINDING PROTEIN TO PHOSPHOLIPID-MEMBRANES - EVIDENCE FOR A COLLISIONAL PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-DISTRIBUTION; UNILAMELLAR VESICLES; ENERGY-PRODUCTION; LIVER; KINETICS; CHOLESTEROL; P2-PROTEIN; PALMITATE; ADIPOCYTE; EXCHANGE	Fatty acid binding proteins (FABP) are a family of low molecular weight proteins found in many tissues that actively utilize free fatty acids (ffa). FABP would be expected to have a particularly important role in the heart, where over 80% of energy requirements are derived from oxidation of long chain fatty acids. The precise physiological function of heart FABP (H-FABP) has not been definitively identified, although it is thought to play a role in intracellular ffa transport. To examine the possible role of H-FABP in cardiac myocyte transfer of ffa, we examined the transfer of fluorescent anthroyloxy ffa (AOffa) from H-FABP to model phospholipid membranes, using a resonance energy transfer assay. In contrast to previous observations of ffa transfer from liver FABP and from membranes, transfer from H-FABP to membranes appears to occur by a different mechanism. AO-palmitate (16:0) transfer was 1.5-fold slower than AO-stearate (18:0) transfer, and mono-unsaturation did not affect the transfer rate. The AOffa transfer rate from H-FABP increased with increasing ionic strength and decreased slightly between pH 7 and 9. These results suggest that the rate of ffa transfer from H-FABP to membranes is independent of the ffa aqueous solubility. Thermodynamic analysis showed that the free energy of activation for the ffa transfer process arises primarily from an enthalpic component, with only a small entropic contribution, again suggesting the lack of an aqueous phase route of ffa delivery. Finally, the ffa transfer rate was found to be directly dependent on the concentration of acceptor membranes. These data therefore suggest that transfer of AOffa from H-FABP to membranes may occur via collisional interactions between the protein and membranes.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health				Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389, R29DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38389, R01 DK038389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BORCHERS T, 1989, BIOCHIM BIOPHYS ACTA, V1002, P54, DOI 10.1016/0005-2760(89)90063-5; CHARLTON SC, 1982, BIOCHEMISTRY-US, V21, P4023, DOI 10.1021/bi00260a018; CISTOLA DP, 1989, BIOCHEMISTRY-US, V28, P3628, DOI 10.1021/bi00434a072; CISTOLA DP, 1988, BIOCHEMISTRY-US, V27, P711, DOI 10.1021/bi00402a033; CRISMAN TS, 1987, J MOL CELL CARDIOL, V19, P423, DOI 10.1016/S0022-2828(87)80394-2; DAWIDOWICZ EA, 1987, CURR TOP MEMBR TRANS, V29, P175; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; FOURNIER NC, 1983, J BIOL CHEM, V258, P2929; FOURNIER NC, 1983, BIOCHEMISTRY-US, V22, P1863, DOI 10.1021/bi00277a019; FOURNIER NC, 1985, BIOCHEMISTRY-US, V24, P2387, DOI 10.1021/bi00330a039; GLATZ JFC, 1984, J BIOL CHEM, V259, P4295; GLATZ JFC, 1985, INT J BIOCHEM, V17, P13, DOI 10.1016/0020-711X(85)90080-1; GLATZ JFC, 1985, CHEM PHYS LIPIDS, V38, P115, DOI 10.1016/0009-3084(85)90061-1; GLATZ JFC, 1985, BIOCHIM BIOPHYS ACTA, V837, P57, DOI 10.1016/0005-2760(85)90085-2; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; Gomori G, 1942, J LAB CLIN MED, V27, P955; GURD FRN, 1960, LIPID CHEM, P283; HUANG C, 1974, METHOD ENZYMOL, V32, P212; JAGSCHIES G, 1985, EUR J BIOCHEM, V452, P537; KIM HK, 1992, J BIOL CHEM, V267, P77; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSEY JB, 1984, BIOCHIM BIOPHYS ACTA, V794, P274, DOI 10.1016/0005-2760(84)90156-5; MASSEY JB, 1982, BIOCHEMISTRY-US, V21, P3630, DOI 10.1021/bi00258a016; MASSEY JB, 1981, J BIOL CHEM, V257, P5444; MCLEAN LR, 1984, BIOCHIM BIOPHYS ACTA, V776, P21, DOI 10.1016/0005-2736(84)90246-3; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; OFFNER GD, 1986, J BIOL CHEM, V261, P5584; POWNALL HJ, 1991, BIOCHEMISTRY-US, V30, P5690; ROSEMAN MA, 1980, BIOCHEMISTRY-US, V19, P439, DOI 10.1021/bi00544a006; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1986, J BIOL CHEM, V261, P8218; SADDIK M, 1991, J BIOL CHEM, V266, P8162; SAID B, 1984, J BIOL CHEM, V259, P1155; STORCH J, 1990, J BIOL CHEM, V265, P7827; STORCH J, 1990, MOL CELL BIOCHEM, V98, P141; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P8708; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; THILO L, 1977, BIOCHIM BIOPHYS ACTA, V469, P326, DOI 10.1016/0005-2736(77)90168-7; TRAPP BD, 1984, J NEUROCHEM, V43, P944, DOI 10.1111/j.1471-4159.1984.tb12828.x; UYEMURA K, 1977, J NEUROCHEM, V29, P61, DOI 10.1111/j.1471-4159.1977.tb03924.x; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001; [No title captured]	47	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20051	20056						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400322				2022-12-27	WOS:A1992JR85800050
J	MAHONY, WB; DOMIN, BA; DALUGE, SM; MILLER, WH; ZIMMERMAN, TP				MAHONY, WB; DOMIN, BA; DALUGE, SM; MILLER, WH; ZIMMERMAN, TP			ENANTIOMERIC SELECTIVITY OF CARBOVIR TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN-ERYTHROCYTE-MEMBRANE; MOUSE LEUKEMIA-CELLS; ANTI-HIV ACTIVITY; NONFACILITATED DIFFUSION; CELLULAR PHARMACOLOGY; ADENOSINE TRANSPORT; NUCLEOSIDE ANALOG; REVERSE-TRANSCRIPTASE; MAMMALIAN-CELLS	Carbovir (9-[4alpha-(hydroxymethyl)cyclopent-2-ene-1alpha-yl]guanine) (CBV) is a carbocyclic analogue of 2',3'-dideoxyguanosine that exhibits potent and selective in vitro activity against human immunodeficiency virus. Antiviral activity is associated with only the (-)-enantiomer. The transport characteristics of both (-)-CBV and (+)-CBV were investigated in human erythrocytes at 37-degrees-C using a papaverine-stop assay. The influx of both enantiomers appeared saturable and was inhibited >90% by a combination of adenine (a low K(m) permeant of the nucleobase carrier) and dilazep (a potent inhibitor of nucleoside transport). The influx of (-)-CBV and (+)-CBV proceeded primarily via the nucleobase carrier with V(max) (picomoles/second/5 mul of cells)/K(m) (millimolar) values of 17/0.12 and 140/1.9, respectively. To a lesser extent, the influx of (-)-CBV and (+)-CBV also occurred via the nucleoside transporter. Although both compounds exhibited a similar low affinity for this latter carrier (K(m) approximately 2 mM), the V(max) for (-)-CBV influx was approximately 4-fold higher than the V(max) for (+)-CBV influx. We conclude that both CBV enantiomers enter human erythrocytes by two transporters that are enantiomerically selective.	WELLCOME RES LABS, DIV ORGAN CHEM, RES TRIANGLE PK, NC 27709 USA	Wellcome Research Laboratories	MAHONY, WB (corresponding author), WELLCOME RES LABS, DIV EXPTL THERAPY, 3030 CORNWALLIS RD, RES TRIANGLE PK, NC 27709 USA.							AGARWAL RP, 1989, AIDS RES HUM RETROV, V5, P541, DOI 10.1089/aid.1989.5.541; AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0; AUGUST EM, 1991, MOL PHARMACOL, V39, P246; BECKETT AH, 1991, BIOCHEM SOC T, V19, P443, DOI 10.1042/bst0190443; BONDOC LL, 1990, BIOCHEMISTRY-US, V29, P9839, DOI 10.1021/bi00494a013; BROUWER KR, 1990, DRUG METAB DISPOS, V18, P1078; BUSSO ME, 1990, AIDS RES HUM RETROV, V6, P1139, DOI 10.1089/aid.1990.6.1139; CARTER SG, 1990, ANTIMICROB AGENTS CH, V34, P1297, DOI 10.1128/AAC.34.6.1297; CLELAND WW, 1963, NATURE, V198, P463, DOI 10.1038/198463a0; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; COATES JAV, 1991, ANTIVIR RES, V15, P161, DOI 10.1016/0166-3542(91)90033-N; COOK RD, 1990, STATISTICAL METHODOL, P180; COONEY DA, 1986, BIOCHEM PHARMACOL, V35, P2065, DOI 10.1016/0006-2952(86)90571-X; DAGNINO L, 1991, J BIOL CHEM, V266, P6312; DEMIRANDA P, 1983, J ANTIMICROB CHEMOTH, V12, P29, DOI 10.1093/jac/12.suppl_B.29; DMIN BA, 1990, P AM ASSOC CANC RES, V31, P10; DOMIN BA, 1988, BIOCHEM BIOPH RES CO, V154, P825, DOI 10.1016/0006-291X(88)90214-8; DOMIN BA, 1988, J BIOL CHEM, V263, P9276; EXALL AM, 1991, J CHEM SOC PERK T 1, P2467, DOI 10.1039/p19910002467; GATI WP, 1984, BIOCHEM PHARMACOL, V33, P3325, DOI 10.1016/0006-2952(84)90101-1; GATI WP, 1989, BIOCHEM J, V263, P957, DOI 10.1042/bj2630957; GU JG, 1991, J NEUROCHEM, V56, P548, DOI 10.1111/j.1471-4159.1991.tb08184.x; HUANG SH, 1991, PHARMACEUT RES, V8, P739, DOI 10.1023/A:1015850017201; LEATHERBARROW RJ, 1990, ANAL BIOCHEM, V184, P274, DOI 10.1016/0003-2697(90)90680-8; MAGNANI M, 1989, BIOCHEM INT, V19, P227; MAHER TJ, 1991, DRUG DEVELOP RES, V24, P149, DOI 10.1002/ddr.430240202; MAHONY WB, 1986, ANAL BIOCHEM, V154, P235, DOI 10.1016/0003-2697(86)90521-X; MAHONY WB, 1988, J BIOL CHEM, V263, P9285; MAHONY WB, 1991, BIOCHEM PHARMACOL, V41, P263, DOI 10.1016/0006-2952(91)90485-N; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PATERSON ARP, 1981, PHARMACOL THERAPEUT, V12, P515, DOI 10.1016/0163-7258(81)90096-6; PATERSON ARP, 1983, REGULATORY FUNCTION, P203; PATERSON ARP, 1991, ROLE ADENOSINE ADENI, P133; PATERSON ARP, 1986, MEMBRANE TRANSPORT A, P309; PLAGEMANN PGW, 1989, BIOCHIM BIOPHYS ACTA, V1010, P7, DOI 10.1016/0167-4889(89)90177-8; PLAGEMANN PGW, 1984, BIOCHEM PHARMACOL, V33, P1783, DOI 10.1016/0006-2952(84)90350-2; PLAGEMANN PGW, 1989, BIOCHEM PHARMACOL, V38, P3469, DOI 10.1016/0006-2952(89)90116-0; PLAGEMANN PGW, 1989, MOL PHARMACOL, V36, P185; PRUS KL, 1990, CANCER RES, V50, P1817; SCHAEFFER HJ, 1978, NATURE, V272, P583, DOI 10.1038/272583a0; SCOTT AK, 1991, DRUG NEWS PERSPECT, V4, P476; SEGAL IH, 1975, ENZYME KINETICS, P39; SPECTOR T, 1981, ANAL BIOCHEM, V115, P403, DOI 10.1016/0003-2697(81)90025-7; TAUBE RA, 1972, BIOCHIM BIOPHYS ACTA, V255, P6, DOI 10.1016/0005-2736(72)90003-X; ULLMAN B, 1988, J BIOL CHEM, V263, P12391; VINCE R, 1990, BIOCHEM BIOPH RES CO, V168, P912, DOI 10.1016/0006-291X(90)91115-9; VINCE R, 1988, BIOCHEM BIOPH RES CO, V156, P1046, DOI 10.1016/S0006-291X(88)80950-1; VINCE R, 1990, J MED CHEM, V33, P17, DOI 10.1021/jm00163a004; WHITE EL, 1989, BIOCHEM BIOPH RES CO, V161, P393, DOI 10.1016/0006-291X(89)92611-9; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; ZIMMERMAN TP, 1978, P NATL ACAD SCI USA, V75, P6220, DOI 10.1073/pnas.75.12.6220; ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748	52	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19792	19797						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400293				2022-12-27	WOS:A1992JR85800009
J	VANVELDHOVEN, PP; VANHOVE, G; ASSELBERGHS, S; EYSSEN, HJ; MANNAERTS, GP				VANVELDHOVEN, PP; VANHOVE, G; ASSELBERGHS, S; EYSSEN, HJ; MANNAERTS, GP			SUBSTRATE SPECIFICITIES OF RAT-LIVER PEROXISOMAL ACYL-COA OXIDASES - PALMITOYL-COA OXIDASE (INDUCIBLE ACYL-COA OXIDASE), PRISTANOYL-COA OXIDASE (NONINDUCIBLE ACYL-COA OXIDASE), AND TRIHYDROXYCOPROSTANOYL-COA OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; FATTY-ACID OXIDATION; BETA-OXIDATION; SUBCELLULAR-LOCALIZATION; ZELLWEGER SYNDROME; SKIN FIBROBLASTS; LIGNOCERIC ACID; GLUTARYL-COA; CHAIN; METABOLISM	Rat liver peroxisomes contain three acyl-CoA oxidases: palmitoyl-CoA oxidase, pristanoyl-CoA oxidase, and trihydroxycoprostanoyl-CoA oxidase. The three oxidases were separated by anion-exchange chromatography of a partially purified oxidase preparation, and the column eluate was analyzed for oxidase activity with different acyl-CoAs. Short chain mono (hexanoyl-) and dicarboxylyl (glutaryl-)-CoAs and prostaglandin E2-CoA were oxidized exclusively by palmitoyl-CoA oxidase. Long chain mono (palmitoyl-) and dicarboxylyl (hexadecanedioyl-) -CoAs were oxidized by palmitoyl-CoA oxidase and pristanoyl-CoA oxidase, the former enzyme catalyzing approximately 70% of the total eluate activity. The very long chain lignoceroyl-CoA was also oxidized by palmitoyl-CoA oxidase and pristanoyl-CoA oxidase, the latter enzyme catalyzing approximately 65% of the total eluate activity. Long chain 2-methyl branched acyl-CoAs (2-methylpalmitoyl-CoA and pristanoyl-CoA) were oxidized for approximately 90% by pristanoyl-CoA oxidase, the remaining activity being catalyzed by trihydroxycoprostanoyl-CoA oxidase. The short chain 2-methylhexanoyl-CoA was oxidized by trihydroxycoprostanoyl-CoA oxidase and pristanoyl-CoA oxidase (approximately 60 and 40%, respectively, of the total eluate activity). Trihydroxycoprostanoyl-CoA was oxidized exclusively by trihydroxycoprostanoyl-CoA oxidase. No oxidase activity was found with isovaleryl-CoA and isobutyryl-CoA. Substrate dependences of palmitoyl-CoA oxidase and pristanoyl-CoA oxidase were very similar when assayed with the same (common) substrate. Since the two oxidases were purified to a similar extent and with a similar yield, the contribution of each enzyme to substrate oxidation in the column eluate probably reflects its contribution in the intact liver.	REGA INST,B-3000 LOUVAIN,BELGIUM	KU Leuven	VANVELDHOVEN, PP (corresponding author), CATHOLIC UNIV LEUVEN,CAMPUS GASTHUISBERG,AFDELING FARMACOL,B-3000 LOUVAIN,BELGIUM.		, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564				BENNETT MJ, 1991, J INHERIT METAB DIS, V14, P165, DOI 10.1007/BF01800589; CASTEELS M, 1988, J BIOL CHEM, V263, P4654; CASTEELS M, 1990, J LIPID RES, V31, P1865; CERDAN S, 1988, J BIOL CHEM, V263, P11664; CHEN RF, 1967, J BIOL CHEM, V242, P173; DICZFALUSY U, 1991, J CLIN INVEST, V88, P978, DOI 10.1172/JCI115401; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FOERSTER EC, 1981, BIOCHEM J, V196, P705, DOI 10.1042/bj1960705; FURATA S, 1982, BIOCHEM BIOPH RES CO, V105, P639; GERBLING H, 1989, PLANT PHYSIOL, V91, P1387, DOI 10.1104/pp.91.4.1387; GERBLING H, 1988, PLANT PHYSIOL, V88, P13, DOI 10.1104/pp.88.1.13; INESTROSA NC, 1980, BIOCHEM BIOPH RES CO, V95, P7, DOI 10.1016/0006-291X(80)90696-8; JAKOBS BS, 1991, BIOCHEM BIOPH RES CO, V178, P842, DOI 10.1016/0006-291X(91)90967-C; JEDLITSCHKY G, 1991, J BIOL CHEM, V266, P24763; KASE BF, 1986, BIOCHIM BIOPHYS ACTA, V877, P37, DOI 10.1016/0005-2760(86)90115-3; KASE F, 1983, J LIPID RES, V24, P1560; KAWAGUCHI A, 1981, J BIOCHEM-TOKYO, V89, P337, DOI 10.1093/oxfordjournals.jbchem.a133207; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LAZO O, 1990, J LIPID RES, V31, P583; LEIGHTON F, 1989, J BIOL CHEM, V264, P10347; MANNAERTS GP, 1990, BIOCHEM SOC T, V18, P87, DOI 10.1042/bst0180087; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MANNAERTS GP, 1991, NESTLE NUTR WORKS SE, V24, P1; MIURA S, 1984, J BIOL CHEM, V259, P6397; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MOSER HW, 1989, METABOLIC BASIS INHE, V2, P1511; OSUMI T, 1980, J BIOCHEM, V87, P1735, DOI 10.1093/oxfordjournals.jbchem.a132918; POLLTHE BT, 1988, AM J HUM GENET, V42, P422; POOSCH MS, 1989, BIOCHIM BIOPHYS ACTA, V1006, P291, DOI 10.1016/0005-2760(89)90016-7; PRYDZ K, 1986, J LIPID RES, V27, P622; RICHARDS EW, 1990, BIOCHIM BIOPHYS ACTA, V1044, P361, DOI 10.1016/0005-2760(90)90081-8; SCHEPERS L, 1988, J BIOL CHEM, V263, P2724; SCHEPERS L, 1990, J BIOL CHEM, V265, P5242; SINGH I, 1981, BIOCHEM BIOPH RES CO, V102, P1223, DOI 10.1016/S0006-291X(81)80142-8; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SKORIN C, 1992, BIOCHEM J, V281, P561, DOI 10.1042/bj2810561; SUZUKI H, 1989, BIOCHIM BIOPHYS ACTA, V990, P25, DOI 10.1016/S0304-4165(89)80007-8; THOMAS J, 1980, BIOCHEM J, V190, P485, DOI 10.1042/bj1900485; TSUNEOKA M, 1988, J BIOCHEM-TOKYO, V104, P560, DOI 10.1093/oxfordjournals.jbchem.a122510; VAMECQ J, 1984, BIOCHEM J, V221, P203, DOI 10.1042/bj2210203; VANHOVE G, 1991, J BIOL CHEM, V266, P24670; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P24676; WANDERS RJA, 1990, J INHERIT METAB DIS, V13, P4, DOI 10.1007/BF01799330; WANDERS RJA, 1991, CLIN CHIM ACTA, V202, P123, DOI 10.1016/0009-8981(91)90043-C; WANDERS RJA, 1990, BIOCHEM BIOPH RES CO, V172, P490, DOI 10.1016/0006-291X(90)90699-N	46	126	126	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20065	20074						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400324				2022-12-27	WOS:A1992JR85800052
J	WALTER, MR; COOK, WJ; ZHAO, BG; CAMERON, RP; EALICK, SE; WALTER, RL; REICHERT, P; NAGABHUSHAN, TL; TROTTA, PP; BUGG, CE				WALTER, MR; COOK, WJ; ZHAO, BG; CAMERON, RP; EALICK, SE; WALTER, RL; REICHERT, P; NAGABHUSHAN, TL; TROTTA, PP; BUGG, CE			CRYSTAL-STRUCTURE OF RECOMBINANT HUMAN INTERLEUKIN-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-I; 3-DIMENSIONAL STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; INTERFERON-GAMMA; ESCHERICHIA-COLI; GROWTH-HORMONE; CDNA CLONE; T-CELLS; LYMPHOCYTES; RECEPTOR	The crystal structure of recombinant human interleukin-4 (rhuIL-4) was initially determined at 3.5-angstrom resolution by multiple isomorphous replacement techniques and subsequently refined to a resolution of 2.35 angstrom by simulated annealing. The final crystallographic R-factor, based on all data in the range 6.0-2.35 angstrom (7470 reflections), is 0.232. Bond lengths and bond angles in the molecule have root mean square deviations from ideal values of 0.016 angstrom and 2.4-degrees, respectively. The overall structure is highly compact and globular with a predominantly hydrophobic core. The main structural feature of rhuIL-4 is a four alpha-helix bundle, which composes approximately 58% of the structure. The helices are arranged in a left-handed antiparallel bundle with two overhand connections. Within these connections is a two-stranded antiparallel beta-sheet. Both the tertiary and secondary structures of rhuIL-4 are similar to those of human granulocyte-macrophage colony-stimulating factor. Critical regions for receptor binding are proposed.	UNIV ALABAMA,CTR MACROMOLEC CRYSTALLOG,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294; SCHERING PLOUGH CORP,RES INST,BLOOMFIELD,NJ 07003	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Merck & Company; Schering Plough Corporation	WALTER, MR (corresponding author), UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294, USA.				NCI NIH HHS [CA-13148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BANCHEREAU J, 1990, HEMATOPOIETIC GROWTH, P433; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BOEY H, 1989, J ALLERGY CLIN IMMUN, V83, P978, DOI 10.1016/0091-6749(89)90115-2; BOSCO M, 1990, J IMMUNOL, V145, P3136; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CABRILLAT H, 1987, BIOCHEM BIOPH RES CO, V149, P995, DOI 10.1016/0006-291X(87)90507-9; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; COOK WJ, 1991, J MOL BIOL, V218, P675, DOI 10.1016/0022-2836(91)90253-3; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CURTIS BM, 1991, PROTEINS, V11, P111, DOI 10.1002/prot.340110204; DEFRANCE T, 1987, J IMMUNOL, V139, P1135; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GRACE MJ, 1989, 7TH P INT C IMM, P213; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KARRAY S, 1988, J EXP MED, V168, P85, DOI 10.1084/jem.168.1.85; KAWAKAMI Y, 1988, J EXP MED, V168, P2183, DOI 10.1084/jem.168.6.2183; LE HV, 1988, J BIOL CHEM, V263, P10817; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LUNDELL D, 1990, J IND MICROBIOL, V5, P215, DOI 10.1007/BF01569679; MCKNIGHT AJ, 1991, EUR J IMMUNOL, V21, P1187, DOI 10.1002/eji.1830210514; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1991, BLOOD, V77, P1859; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; POSTLETHWAITE AE, 1991, J CLIN INVEST, V87, P2147, DOI 10.1172/JCI115247; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; RAMANATHAN L, 1989, BIOCHIM BIOPHYS ACTA, V1007, P283, DOI 10.1016/0167-4781(89)90149-8; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; SENDA T, 1990, P JPN ACAD B-PHYS, V66, P77, DOI 10.2183/pjab.66.77; SPITS H, 1988, J IMMUNOL, V141, P29; SPITS H, 1987, J IMMUNOL, V139, P1442; TAYLOR CW, 1990, BLOOD, V75, P1114; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; TROTTA PP, 1991, AM J REPROD IMMUNOL, V25, P124, DOI 10.1111/j.1600-0897.1991.tb01079.x; TUNGEKAR MF, 1991, CANCER RES, V51, P261; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WERSALL P, 1991, CANCER IMMUNOL IMMUN, V33, P45, DOI 10.1007/BF01742527; WINDSOR WT, 1990, BIOPHYS J, V57, pA423; WINDSOR WT, 1991, BIOCHEMISTRY-US, V30, P1259, DOI 10.1021/bi00219a014; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894	52	125	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20371	20376						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400355				2022-12-27	WOS:A1992JR85800097
J	ZALATAN, F; PLATT, T				ZALATAN, F; PLATT, T			EFFECTS OF DECREASED CYTOSINE CONTENT ON RHO-INTERACTION WITH THE RHO-DEPENDENT TERMINATOR TRP T' IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TERMINATION; TRYPTOPHAN OPERON; ATPASE ACTIVITY; MESSENGER-RNA; MUTAGENESIS; EXPRESSION; SEQUENCE; MUTANTS; SITES	We have introduced multiple cytosine-to-uracil mutations in the rho-dependent transcription terminator trp t' and have characterized a subset of the resulting mutant derivatives in vitro for termination efficiency, affinity for rho, and stimulation of rho-ATPase activity. No specific cytosine residue appears to be required for termination, and at least 13 of the 28 cytosine residues in the 104 nucleotide trp t' region can be mutated with little effect on termination efficiency. One derivative with 11 mutations is significantly less efficient than other derivatives with a similar number of mutations, implying that the pattern of alterations, as well as the number, can affect termination efficiency. Derivatives with 20 and 28 cytosines mutated are non-functional in termination, consistent with the idea that cytosines are required for rho-dependent termination. Our results are inconsistent, however, with the hypothesis that the termination efficiency is directly related to the cytosine/guanine ratio in the nascent transcript. The results support the idea that neither RNA binding affinity nor ATPase activation per se are accurate predictors of rho-dependent termination efficiency.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NIGMS NIH HHS [GM22830] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIFANO P, 1991, CELL, V64, P553; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4635; BUTLER JS, 1987, P NATL ACAD SCI USA, V84, P4022, DOI 10.1073/pnas.84.12.4022; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; DAS A, 1976, P NATL ACAD SCI USA, V73, P1959, DOI 10.1073/pnas.73.6.1959; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; FOLK WR, 1983, CELL, V33, P585, DOI 10.1016/0092-8674(83)90439-7; GALLOWAY JL, 1988, J BIOL CHEM, V263, P1761; GALLOWAY JL, 1986, REGULATION GENE EXPR, P155; GUARENTE L, 1979, J MOL BIOL, V132, P189; HART CM, 1991, J BIOL CHEM, V266, P24140; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; INOKO H, 1977, P NATL ACAD SCI USA, V74, P1162, DOI 10.1073/pnas.74.3.1162; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDICK R, 1990, J MOL BIOL, V216, P25, DOI 10.1016/S0022-2836(05)80058-0; LOWERY C, 1977, J BIOL CHEM, V252, P1375; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; Miller J.H., 1972, EXPT MOL GENETICS; MINKLEY EG, 1973, J MOL BIOL, V78, P577, DOI 10.1016/0022-2836(73)90479-8; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; MOTT JE, 1985, EMBO J, V4, P1887, DOI 10.1002/j.1460-2075.1985.tb03865.x; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PLATT T, 1992, IN PRESS TRANSCRIPTI; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; WU AM, 1980, CELL, V19, P829, DOI 10.1016/0092-8674(80)90073-2	34	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19082	19088						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388163				2022-12-27	WOS:A1992JP59300014
J	DEEG, MA; HUMPHREY, DR; YANG, SH; FERGUSON, TR; REINHOLD, VN; ROSENBERRY, TL				DEEG, MA; HUMPHREY, DR; YANG, SH; FERGUSON, TR; REINHOLD, VN; ROSENBERRY, TL			GLYCAN COMPONENTS IN THE GLYCOINOSITOL PHOSPHOLIPID ANCHOR OF HUMAN ERYTHROCYTE ACETYLCHOLINESTERASE - NOVEL FRAGMENTS PRODUCED BY TRIFLUOROACETIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; VARIANT SURFACE GLYCOPROTEIN; MASS-SPECTROMETRY; LEISHMANIA-MAJOR; PROTEINS; IDENTIFICATION; INOSITOL	Inositol glycans were prepared from reductively radiomethylated human erythrocyte acetylcholinesterase by sequential treatment with Proteinase K, methanolic KOH, and phosphatidylinositol-specific phospholipase C. Four glycans denoted alpha-delta were resolved by anion exchange high performance liquid chromatography (HPLC). Each glycan was subjected to hydrolysis in 4 M trifluoroacetic acid, and their hexose and hexose phosphate compositions were determined by anion exchange HPLC. The predominant glycan a showed a relative stoichiometry of 2 mannoses, 1 mannose 6-phosphate, 1 radiomethylated glucosamine, 1 radiomethylated ethanolamine, and 1 inositol. In contrast, the stoichiometry of glycan-beta was 1 mannose, 2 mannose 6-phosphates, 1 radiomethylated glucosamine, 2 radiomethylated ethanolamines, and 1 inositol. Glycans-alpha and beta were analyzed by electrospray ionization-mass spectrometry, and respective parent ions of m/z 1266 and 1417 were observed. The fragmentation pattern produced by collision-induced dissociation mass spectrometry of these parent ions was consistent with a common linear core glycan sequence prior to radiomethylation of ethanolamine-phosphate-mannose-mannose-mannose-glucosamine-inositol. Glycan-alpha contained a single additional radiomethylated phosphoethanolamine branching from the mannose adjacent to glucosamine, whereas glycan-beta contained two additional radiomethylated phosphoethanolamines, one branching from each of the mannoses nearest to glucosamine. Trifluoroacetic acid hydrolysis did not cleave within the N,N-dimethylglucosamine-inositol-phosphate moiety in these glycans, and this component was resolved by anion exchange HPLC and structurally confirmed by mass spectrometry. Dephosphorylation of this component by treatment with 50% HF produced N,N-dimethylglucosamine-inositol, and this conjugate was shown to have a characteristic elution time on cation exchange chromatography in an amino acid analyzer. Both of these fragments involving an intact radiomethylated glucosamine-inositol bond are proposed as new diagnostic indicators in the search for minor glycoinositol phospholipids in cells and tissues.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA; HARVARD UNIV, SCH PUBL HLTH, DIV BIOL SCI, BOSTON, MA 02115 USA	Case Western Reserve University; Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008441, P01DK038181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016577] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38181, DK08441] Funding Source: Medline; NINDS NIH HHS [NS16577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN MA, 1990, ANAL BIOCHEM, V191, P174, DOI 10.1016/0003-2697(90)90405-X; BUTIKOFER P, 1990, J BIOL CHEM, V265, P18983; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEEG MA, 1992, J BIOL CHEM, V267, P18581; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GNAGEY AL, 1987, J BIOL CHEM, V262, P13290; HAAS R, 1985, ANAL BIOCHEM, V148, P154, DOI 10.1016/0003-2697(85)90640-2; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HENNER DJ, 1988, NUCLEIC ACIDS RES, V16, P10383, DOI 10.1093/nar/16.21.10383; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, BIOCHEM BIOPH RES CO, V150, P271, DOI 10.1016/0006-291X(88)90516-5; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; ROSENBERRY TL, 1989, METHOD CELL BIOL, V32, P231; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SMITH R, 1987, BIOCHEM J, V248, P285, DOI 10.1042/bj2480285; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; WALTER EI, 1990, J IMMUNOL, V144, P1030	27	98	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18573	18580						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388156				2022-12-27	WOS:A1992JN50200052
J	HOFMANN, KP; PULVERMULLER, A; BUCZYLKO, J; VANHOOSER, P; PALCZEWSKI, K				HOFMANN, KP; PULVERMULLER, A; BUCZYLKO, J; VANHOOSER, P; PALCZEWSKI, K			THE ROLE OF ARRESTIN AND RETINOIDS IN THE REGENERATION PATHWAY OF RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; G-PROTEIN; METARHODOPSIN-II; 48-KDA PROTEIN; DISK MEMBRANE; SCHIFF-BASE; ACTIVATION; BINDING; LIGHT; MECHANISM	Phototransduction results from a cascade of reactions that culminate in a neuronal signal. Photoisomerization of rhodopsin's chromophore, 11-cis-retinal to all-trans-retinal, leads to the formation of the activated photoproduct metarhodopsin II (Meta II). Subsequently, Meta II initiates the excitation events by activating many copies of the rod cell-specific G-proteins (G(t) or transducin). To terminate the signal, the long-lived Meta II must be quenched. Deactivation of Meta II involves phosphorylation by rhodopsin kinase followed by the binding of arrestin. In order to recycle rhodopsin for phototransduction, arrestin must dissociate, and the chromophore must be replaced. In this study, we show that the reduction of the photolyzed chromophore all-trans-retinal to all-trans-retinol is essential for recycling photoactivated rhodopsin. Once this reduction has occurred, the arrestin blockade of the receptor is removed, the chromophore site becomes accessible for regeneration, and the phosphates can be hydrolyzed. If the reduction does not occur, we demonstrate that free all-trans-retinal can react with the apoprotein to form pseudo-photoproducts that are spectrally identical to the photoinduced metarhodopsin species (Meta I/II/III). The Meta II-like product, M380, interacts tightly with arrestin and kinase, however, it does not measurably interact with G(t). The persistent blockade by arrestin and the low affinity for G(t) together prevent activation of the visual cascade. Therefore, any insufficiency in the reduction of all-trans-retinal to all-trans-retinol may lead to the accumulation of M380-arrestin in situ, which may effect adaptational processes.	GOOD SAMARITAN HOSP,RS DOW NEUROL SCI INST,1120 NW 20TH AVE,PORTLAND,OR 97209; UNIV FREIBURG,INST BIOPHYS & STRAHLENBIOL,W-7800 FREIBURG,GERMANY	University of Freiburg					PHS HHS [09339] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAUMANN C, 1972, J PHYSIOL-LONDON, V222, P643, DOI 10.1113/jphysiol.1972.sp009819; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CHABRE M, 1979, VISION RES, V19, P1005, DOI 10.1016/0042-6989(79)90226-8; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CUSANOVICH MA, 1982, METHOD ENZYMOL, V81, P443; DUGGAN DE, 1957, ARCH BIOCHEM BIOPHYS, V68, P1, DOI 10.1016/0003-9861(57)90320-X; FUTTERMAN S, 1964, J BIOL CHEM, V239, P81; GRAYKELLER MP, 1990, J BIOL CHEM, V265, P15323; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; HOFMANN KP, 1983, BIOCHIM BIOPHYS ACTA, V725, P60, DOI 10.1016/0005-2728(83)90224-4; HOFMANN KP, 1992, SIGNAL TRANSDUCTION, P71; KAHLERT M, 1990, NATURE, V345, P537, DOI 10.1038/345537a0; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1991, FEBS LETT, V295, P195, DOI 10.1016/0014-5793(91)81416-6; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PEPPERBERG DR, 1988, P NATL ACAD SCI USA, V85, P5531, DOI 10.1073/pnas.85.15.5531; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHLEICHER A, 1987, J MEMBRANE BIOL, V95, P271, DOI 10.1007/BF01869489; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	31	137	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15701	15706						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386362				2022-12-27	WOS:A1992JG11300069
J	LUKACS, GL; CHANG, XB; KARTNER, N; ROTSTEIN, OD; RIORDAN, JR; GRINSTEIN, S				LUKACS, GL; CHANG, XB; KARTNER, N; ROTSTEIN, OD; RIORDAN, JR; GRINSTEIN, S			THE CYSTIC-FIBROSIS TRANSMEMBRANE REGULATOR IS PRESENT AND FUNCTIONAL IN ENDOSOMES - ROLE AS A DETERMINANT OF ENDOSOMAL PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CONDUCTANCE; CELLS; GENE; ACIDIFICATION; MEMBRANE; IDENTIFICATION; EXPRESSION; TRANSPORT; ATPASES; CAMP	Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), which lead to defective Cl- conductance in epithelial cells. While the CFTR gene product has been detected in the plasma membrane, its presence and functional role in the membranes of intracellular compartments remain to be established. The purpose of the present experiments was to functionally localize CFTR in the endosomal membrane and to test the role of the associated Cl- conductance in the regulation of endosomal pH (PH(en)). When using conductive protonophores, the net H+ flux across the endosomal membrane of Chinese hamster ovary (CHO) cells is limited by the movement of counterions. Thus, ionic permeability could be estimated indirectly, from the changes in pH(en) determined fluorimetrically. Measurements in situ and in a cell-free microsomal preparation indicate the presence of a protein kinase A (PKA)-activated anion conductance in endosomes from CHO cells transfected with CFTR, but not in endosomes from wild-type or mock-transfected cells. In endosomes isolated from CFTR-expressing cells, the stimulatory effect of PKA was diminished by a specific peptide inhibitor of PKA, by alkaline phosphatase treatment or by a monoclonal antibody against the second nucleotide binding fold of CFTR. Increasing counterion permeability by phosphorylation of CFTR or by addition of valinomycin failed to alter the rate or extent of endosomal acidification in situ. Our observations indicate that functional CFTR, susceptible to activation by PKA, is present in endosomes of transfected CHO cells. More importantly, the data suggest that factors other than counterion permeability are the major determinants of pH(en).	HOSP SICK CHILDREN, RES INST, TORONTO M5G 1X8, ONTARIO, CANADA; TORONTO GEN HOSP, DEPT SURG, TORONTO M5G 2C4, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital				Lukacs, Gergely/0000-0003-0900-0675				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ALAWQATI Q, 1989, METHOD ENZYMOL, V172, P49; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BACKER JM, 1991, BIOCHEM PHARMACOL, V41, P1267, DOI 10.1016/0006-2952(91)90097-O; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BEAR CE, 1992, AM J PHYSIOL, V262, pC251, DOI 10.1152/ajpcell.1992.262.1.C251; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADBURY NA, 1992, AM J PHYSIOL, V262, pC752, DOI 10.1152/ajpcell.1992.262.3.C752; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARRIS WH, 1991, J CLIN INVEST, V88, P1; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603; WADE JB, 1986, ANNU REV PHYSIOL, V48, P213; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; XIE XS, 1983, J BIOL CHEM, V258, P4834; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713	34	120	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14568	14572						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378835				2022-12-27	WOS:A1992JF08800014
J	STEPIEN, G; TORRONI, A; CHUNG, AB; HODGE, JA; WALLACE, DC				STEPIEN, G; TORRONI, A; CHUNG, AB; HODGE, JA; WALLACE, DC			DIFFERENTIAL EXPRESSION OF ADENINE-NUCLEOTIDE TRANSLOCATOR ISOFORMS IN MAMMALIAN-TISSUES AND DURING MUSCLE-CELL DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SYNTHASE BETA-SUBUNIT; ADP ATP TRANSLOCASE; MITOCHONDRIAL-DNA GENES; HUMAN SKELETAL-MUSCLE; ADP/ATP TRANSLOCATOR; SEQUENCE-ANALYSIS; MOLECULAR-CLONING; HUMAN-LYMPHOCYTES; ALPHA-SUBUNIT	The adenine nucleotide translocator (ANT) catalyzes the exchange of ADP and ATP across the mitochondrial internal membrane. Its three isoforms, ANT1, ANT2, and ANT3 are coded by differentially regulated nuclear genes. The patterns of expression of these genes in human, bovine, and mouse tissue are similar. ANT1 is highly expressed in heart and skeletal muscle and is induced during myoblast differentiation. It is coordinately regulated with the nuclear gene for the mitochondrial ATP synthase beta-subunit, with which it shares the positive muscle cis element, the OXBOX. ANT2 is either absent or weakly expressed in all tissues. ANT3 is ubiquitously expressed in all tissues, and its transcript level is proportional to the level of oxidative metabolism. The tissue-specific expression of the ANT gene family thus provides insight into the molecular basis of the differential reliance of mammalian tissues on oxidative phosphorylation.	EMORY UNIV,SCH MED,DEPT GENET & MOLEC MED,ATLANTA,GA 30322	Emory University			Torroni, Antonio/E-1557-2011	Torroni, Antonio/0000-0002-4163-4478	NHLBI NIH HHS [HL-45572] Funding Source: Medline; NINDS NIH HHS [NS-21328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BREEN GAM, 1988, BIOCHEM BIOPH RES CO, V152, P264, DOI 10.1016/S0006-291X(88)80709-5; BUCKLER AJ, 1988, MOL CELL BIOL, V8, P1371, DOI 10.1128/MCB.8.3.1371; CHEN ST, 1990, SOMAT CELL MOLEC GEN, V16, P143, DOI 10.1007/BF01233044; CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; DICKMAN KG, 1989, AM J PHYSIOL, V257, pC333, DOI 10.1152/ajpcell.1989.257.2.C333; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; KACZMAREK L, 1985, BIOCHEM BIOPH RES CO, V133, P410, DOI 10.1016/0006-291X(85)90921-0; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KADENBACH B, 1990, BIOCHIM BIOPHYS ACTA, V1015, P368, DOI 10.1016/0005-2728(90)90042-3; KAGAWA Y, 1990, INT J BIOCHEM, V22, P219; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; KU DH, 1990, J BIOL CHEM, V265, P16060; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; Li W. H., 1985, MOL EVOLUTIONARY GEN, P1; LIGHTOWLERS R, 1990, J BIOL CHEM, V265, P2677; LOMAX MI, 1989, TRENDS BIOCHEM SCI, V14, P501, DOI 10.1016/0968-0004(89)90185-0; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; RASMUSSEN UB, 1986, BIOCHEM BIOPH RES CO, V138, P850, DOI 10.1016/S0006-291X(86)80574-5; SACCONE C, 1991, EUR J BIOCHEM, V195, P151, DOI 10.1111/j.1432-1033.1991.tb15688.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; SCHULTHEISS HP, 1984, EUR J BIOCHEM, V143, P599, DOI 10.1111/j.1432-1033.1984.tb08412.x; SEELAN RS, 1991, J BIOL CHEM, V266, P19752; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; TOMURA H, 1990, J BIOL CHEM, V265, P6525; TORRONI A, 1990, J BIOL CHEM, V265, P20589; VANBEEUMEN JJ, 1990, FEBS LETT, V263, P213, DOI 10.1016/0014-5793(90)81376-Y; WALKER JE, 1989, BIOCHEMISTRY-US, V28, P4702, DOI 10.1021/bi00437a029; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; YANAMURA W, 1988, BIOCHEMISTRY-US, V27, P4909, DOI 10.1021/bi00413a048	48	242	247	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14592	14597						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378836				2022-12-27	WOS:A1992JF08800018
J	HO, YS; PFARR, D; STRICKLER, J; ROSENBERG, M				HO, YS; PFARR, D; STRICKLER, J; ROSENBERG, M			CHARACTERIZATION OF THE TRANSCRIPTION ACTIVATOR PROTEIN-C1 OF BACTERIOPHAGE-P22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLIPHAGE-LAMBDA; PHAGE-LAMBDA; LYSOGENIC DEVELOPMENT; CII PROTEIN; PROMOTER; GENE; SEQUENCES; ESTABLISHMENT; SPECIFICITY; MUTATIONS	We cloned, expressed, and purified the positive regulatory protein C1 of the temperate phage P22 of Salmonella typhimurium. The purified protein was characterized as to its amino acid composition, protein sequence, molecular weight, and antigenicity. P22 C1 was shown to be a tetrameric protein composed of four identical subunits with M(r) = 10,000. Moreover, we identified and characterized two P22 C1-dependent phage promoters, P(RE) and P(a23), whose function was completely dependent on Cl both in vitro and in vivo. These two promoters share a common TTGCN6TTGC/T motif in their -35 regions, the same motif recognized by the analogous phage lambda-transcription activator protein cII. P22 C1 protein bound selectively to this region and centered on the TTGC repeat motif. Binding and transcription experiments demonstrated that the two promoters respond coordinately to C1 activation. Last, in contrast to lambda-cII, the C1 protein exhibited little cooperativity with Escherichia coli RNA polymerase for DNA binding, but because of its stronger inherent binding ability, achieved an overall promoter affinity similar to that observed for cII at its cognate promoter signals.			HO, YS (corresponding author), SMITHKLINE & BEECHAM PHARMACEUT,BIOPHARMACEUT RES & DEV,DEPT MACROMOLEC SCI,KING OF PRUSSIA,PA 19406, USA.							BACKHAUS H, 1984, GENE, V32, P289, DOI 10.1016/0378-1119(84)90004-0; BOTSTEIN D, 1974, NATURE, V251, P584, DOI 10.1038/251584a0; COURT D, 1975, VIROLOGY, V63, P484, DOI 10.1016/0042-6822(75)90321-9; DAVIS RW, 1980, ADV BACTERIAL GENET, P202; ECHOLS H, 1971, P NATL ACAD SCI USA, V68, P2190, DOI 10.1073/pnas.68.9.2190; Echols H., 1980, MOL GENETICS DEV, P1; EDSALL JT, 1953, PROTEINS, P549; EISEN H, 1968, R HEBD SEANC ACAD SC, V266, P1176; FIEN K, 1984, GENE, V32, P141, DOI 10.1016/0378-1119(84)90042-8; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GEMSKI P, 1972, P NATL ACAD SCI USA, V69, P3110, DOI 10.1073/pnas.69.11.3110; GOUGH M, 1975, MOL GEN GENET, V138, P71, DOI 10.1007/BF00268829; Gros E., 1967, METHOD ENZYMOL, V11, P238; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWKE D, 1982, ANAL BIOCHEM, V120, P302, DOI 10.1016/0003-2697(82)90351-7; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HILLIKER S, 1978, VIROLOGY, V86, P37, DOI 10.1016/0042-6822(78)90005-3; HILLIKER S, 1976, J MOL BIOL, V106, P537, DOI 10.1016/0022-2836(76)90251-5; Ho Y.-S., 1986, REGULATION GENE EXPR, P79; HO YS, 1985, J BIOL CHEM, V260, P1838; HO YS, 1988, GENE DEV, V2, P184, DOI 10.1101/gad.2.2.184; HO YS, 1983, NATURE, V304, P703, DOI 10.1038/304703a0; HO YS, 1982, J BIOL CHEM, V257, P9128; HO YS, 1988, BACTERIOPHAGES, V2, P725; HOOPES BC, 1985, P NATL ACAD SCI USA, V82, P3134, DOI 10.1073/pnas.82.10.3134; JONES MO, 1979, P NATL ACAD SCI USA, V76, P150, DOI 10.1073/pnas.76.1.150; KAISER AD, 1957, VIROLOGY, V3, P42, DOI 10.1016/0042-6822(57)90022-3; LEONG JM, 1985, J BIOL CHEM, V260, P4468; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; McKenney K, 1981, Gene Amplif Anal, V2, P383; MCMACKEN R, 1970, J MOL BIOL, V49, P639, DOI 10.1016/0022-2836(70)90288-3; NAKANISHI S, 1974, CELL, V3, P39, DOI 10.1016/0092-8674(74)90035-X; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PLACE N, 1984, J MOL BIOL, V180, P865, DOI 10.1016/0022-2836(84)90261-4; Poteete A. R., 1988, BACTERIOPHAGES, V2, P647; RILEY M, 1984, J BACTERIOL, V156, P655; ROSENBERG M, 1983, METHOD ENZYMOL, V101, P123; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SCHMEISSNER U, 1980, P NATL ACAD SCI-BIOL, V77, P3191, DOI 10.1073/pnas.77.6.3191; SHIMATAKE H, 1981, NATURE, V292, P128, DOI 10.1038/292128a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIGGINS BA, 1985, J VIROL, V56, P1030, DOI 10.1128/JVI.56.3.1030-1033.1985; WINSTON F, 1981, J MOL BIOL, V152, P233, DOI 10.1016/0022-2836(81)90241-2; WINSTON F, 1981, J MOL BIOL, V152, P209, DOI 10.1016/0022-2836(81)90240-0; WULFF DL, 1987, GENETICS, V115, P597; Wulff DL, 1983, LAMBDA, VII, P53	48	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14388	14397						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1385814				2022-12-27	WOS:A1992JD32500091
J	JANSSEN, OE; REFETOFF, S				JANSSEN, OE; REFETOFF, S			INVITRO EXPRESSION OF THYROXINE-BINDING GLOBULIN (TBG) VARIANTS - IMPAIRED SECRETION OF TBG(PRO-227) BUT NOT TBG(PRO-113)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ANTITRYPSIN DEFICIENCY; AUSTRALIAN ABORIGINES; INHERITED ABNORMALITY; ENDOPLASMIC-RETICULUM; AMERICAN BLACKS; SEQUENCE; SERUM; MUTATION; GENE; GLYCOSYLATION	Thyroxine-binding globulin (TBG) is a glycoprotein that transports thyroid hormones in blood. Of two naturally occurring variants in man that harbor single proline substitutions (TBG-CD5 and TBG-Montreal), only TBG-CD5 manifests as complete TBG deficiency. In order to determine the pathophysiology of these TBG disorders, we expressed TBG-CD5 and TBG-Montreal (TBG-M), as well as the common type TBG (TBG-C) in reticulocyte lysate and Xenopus oocytes. Vectors encoding the three TBG types were constructed, transcribed in vitro, and their products of cell-free translation and processing by canine microsomal membranes were analyzed. TBG-C and TBG-M had identical mobility on denaturing polyacrylamide gel electrophoresis but could be distinguished by differences in thyroxine (T4) binding. TBG-CD5 had altered electrophoretic mobility and did not bind T4. TBG-C and TBG-M expressed in microinjected Xenopus oocytes showed properties similar to their respective serum forms, whereas TBG-CD5 was found in small amounts only intracellularly. Our results confirm that the previously described alanine 113 to proline substitution is responsible for the altered properties of TBG-M. The substitution of leucine 227 by proline in TBG-CD5 appears to impair its cotranslational processing and secretion.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,JOSEPH P KENNEDY JR MENTAL RETARDAT RES CTR,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago			Refetoff, Samuel/ABB-1263-2021	Refetoff, Samuel/0000-0003-0164-8231	NIDDK NIH HHS [DK 15070] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015070, R37DK015070] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTALENA L, 1990, ENDOCR REV, V11, P47, DOI 10.1210/edrv-11-1-47; BERTENSHAW R, 1991, AM J HUM GENET, V48, P741; BERTENSHAW RH, 1992, IN PRESS BIOCH BIOPH; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FLINK IL, 1986, P NATL ACAD SCI USA, V83, P7708, DOI 10.1073/pnas.83.20.7708; FOREMAN RC, 1987, BIOSCIENCE REP, V7, P307, DOI 10.1007/BF01121452; FRAIZER GC, 1990, J CLIN INVEST, V86, P1878; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GERSHENGORN MC, 1977, J BIOL CHEM, V252, P8713; GILLES AM, 1986, P NATL ACAD SCI USA, V83, P5798, DOI 10.1073/pnas.83.16.5798; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOCMAN G, 1981, REV PHYSL BIOCH PHAR, V81, P45; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IBRAHIMI I, 1987, J BIOL CHEM, V262, P10189; JANSSEN OE, 1991, HUM GENET, V87, P119, DOI 10.1007/BF00204164; JANSSEN OE, 1992, TRENDS ENDOCRIN MET, V3, P49, DOI 10.1016/1043-2760(92)90043-Z; KAMBE F, 1992, MOL ENDOCRINOL, V6, P443, DOI 10.1210/me.6.3.443; KESSLER SW, 1976, J IMMUNOL, V117, P1482; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI PZ, 1991, METABOLISM, V40, P1231, DOI 10.1016/0026-0495(91)90221-H; LIEBHABER SA, 1983, J CLIN INVEST, V71, P461, DOI 10.1172/JCI110790; MALLER JL, 1983, METHOD ENZYMOL, V99, P219; MORI Y, 1988, J CLIN ENDOCR METAB, V67, P727, DOI 10.1210/jcem-67-4-727; MORI Y, 1990, J CLIN ENDOCR METAB, V70, P804, DOI 10.1210/jcem-70-3-804; MORI Y, 1989, MOL ENDOCRINOL, V3, P575, DOI 10.1210/mend-3-3-575; MURATA Y, 1985, J ENDOCRINOL INVEST, V8, P225, DOI 10.1007/BF03348482; MURATA Y, 1986, ENDOCRINOLOGY, V118, P1614, DOI 10.1210/endo-118-4-1614; MURATA Y, 1986, NEW ENGL J MED, V314, P694, DOI 10.1056/NEJM198603133141107; POLLER W, 1991, HUM GENET, V86, P522; REFETOFF S, 1989, ENDOCR REV, V10, P275, DOI 10.1210/edrv-10-3-275; REFETOFF S, 1984, J CLIN ENDOCR METAB, V59, P269, DOI 10.1210/jcem-59-2-269; REFETOFF S, 1989, ENDOCRINOLOGY, P541; ROBBINS J, 1978, RECENT PROG HORM RES, V84, P477; SAIKI RK, 1988, SCIENCE, V239, P481; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNE DH, 1989, J CLIN ENDOCR METAB, V68, P114, DOI 10.1210/jcem-68-1-114; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIFERS RN, 1989, AM J RESP CELL MOL, V1, P341, DOI 10.1165/ajrcmb/1.5.341; TAKAMATSU J, 1986, J CLIN ENDOCR METAB, V63, P80, DOI 10.1210/jcem-63-1-80; TAKAMATSU J, 1987, J CLIN INVEST, V79, P833, DOI 10.1172/JCI112891; TAKEDA K, 1989, J CLIN INVEST, V83, P1344, DOI 10.1172/JCI114021; TRENT JM, 1987, AM J HUM GENET, V41, P428; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; VERBANAC KM, 1986, J BIOL CHEM, V261, P9979; WALTZ MR, 1990, J ENDOCRINOL INVEST, V13, P343, DOI 10.1007/BF03349576; WEISS R, 1989, CLIN RES, V37, pA536; YAMAMORI I, 1991, J CLIN ENDOCR METAB, V73, P262, DOI 10.1210/jcem-73-2-262; ZINN AB, 1978, J BIOL CHEM, V253, P6768	53	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13998	14004						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378434				2022-12-27	WOS:A1992JD32500036
J	CIAMBRONE, GJ; MCKEOWNLONGO, PJ				CIAMBRONE, GJ; MCKEOWNLONGO, PJ			VITRONECTIN REGULATES THE SYNTHESIS AND LOCALIZATION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IN HT-1080 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BOUND UROKINASE; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; AMNIOTIC MEMBRANE; INHIBITOR TYPE-1; HUMAN-MONOCYTES; SARCOMA-CELLS; INVASION; DEGRADATION; PURIFICATION	The effect of extracellular matrix composition on the location, amount, and activity of cell-associated urokinase-type plasminogen activator was tested using HT-1080 cells adherent to either fibronectin or vitronectin. Specific immunoprecipitation of newly synthesized urokinase indicated that cells adherent to fibronectin synthesized 2-3-fold more urokinase than cells adherent to vitronectin. Complexes of urokinase and plasminogen activator inhibitor type 1 (PAI-1) were detected in cell layers of vitronectin-adherent but not fibronectin-adherent cells. Inhibition of PAI-1 using a neutralizing monoclonal antibody resulted in a 3-fold increase in urokinase enzymatic activity on vitronectin adherent cells. Urokinase activity on fibronectin adherent cells was only slightly increased following PAI-1 neutralization. Examination of both HT-1080 and normal human fibroblast cells by immunofluorescent microscopy localized urokinase-type plasminogen activator to discrete; focal areas underneath cells adherent to vitronectin. Urokinase was not detectable by immunofluorescence on cells adherent to fibronectin. The addition of exogenous prourokinase to locate urokinase receptors on adherent HT-1080 cells indicated that the focal localization of cell-surface urokinase resulted from the clustering of urokinase receptors following adhesion to vitronectin but not fibronectin-coated substrates. These results suggest that vitronectin can contribute to the control of cell-surface plasmin activity by regulating the synthesis of urokinase and directing the localization of urokinase receptors.	UNION UNIV, DEPT PHYSIOL & CELL BIOL, NEIL HELLMAN MED RES BLDG, ALBANY, NY 12208 USA	Union College					NCI NIH HHS [CA-37785] Funding Source: Medline; NHLBI NIH HHS [HL-07194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037785] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; CAJOT JF, 1990, P NATL ACAD SCI USA, V87, P6939, DOI 10.1073/pnas.87.18.6939; CIAMBRONE GJ, 1990, J CELL BIOL, V111, P2183, DOI 10.1083/jcb.111.5.2183; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FAIRBAIRN S, 1985, J CELL BIOL, V101, P1790, DOI 10.1083/jcb.101.5.1790; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; KIRCHHEIMER JC, 1990, J IMMUNOL, V145, P1518; KIRCHHEIMER JC, 1989, J IMMUNOL, V143, P2634; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KOLEGA J, 1982, J CELL SCI, V54, P23; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1989, J BIOL CHEM, V264, P936; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NEWMAN E D, 1991, Journal of Cell Biology, V115, p128A; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; REICH R, 1988, CANCER RES, V48, P3307; RIFKIN DB, 1989, AM REV RESPIR DIS, V140, P1112, DOI 10.1164/ajrccm/140.4.1112; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STREULI CH, 1990, J CELL BIOL, V110, P1405; TSUBOI R, 1990, INT J CANCER, V46, P56, DOI 10.1002/ijc.2910460112; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	42	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13617	13622						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377687				2022-12-27	WOS:A1992JB74600082
J	PICCIOTTO, MR; COHN, JA; BERTUZZI, G; GREENGARD, P; NAIRN, AC				PICCIOTTO, MR; COHN, JA; BERTUZZI, G; GREENGARD, P; NAIRN, AC			PHOSPHORYLATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CHANNELS; AIRWAY EPITHELIA; CALCIUM; PHOSPHOPROTEIN; IDENTIFICATION; ACTIVATION; EXPRESSION; SUBSTRATE; DARPP-32	Regulation of epithelial chloride flux, which is defective in patients with cystic fibrosis, may be mediated by phosphorylation of the cystic fibrosis transmembrane conductance regulator (CFTR) by cyclic AMP-dependent protein kinase (PKA) or protein kinase C (PKC). Part of the R-domain of CFTR (termed CF-2) was expressed in and purified from Escherichia coli. CF-2 was phosphorylated on seryl residues by PKA, PKC, cyclic GMP-dependent protein kinase (PKG), and calcium/calmodulin-dependent protein kinase I (CaM kinase I). Direct amino acid sequencing and peptide mapping of CF-2 revealed that serines 660, 700, 737, and 813 as well as serine 768, serine 795, or both were phosphorylated by PKA and PKG, and serines 686 and 790 were phosphorylated by PKC. CFTR was phosphorylated in vitro by PKA, PKC, or PKG on the same sites that were phosphorylated in CF-2. Kinetic analysis of phosphorylation of CF-2 and of synthetic peptides confirmed that these sites were excellent substrates for PKA, PKC, or PKG. CFTR was immunoprecipitated from T84 cells labeled with P-32(i). Its phosphorylation was stimulated in response to agents that activated either PKA or PKC. Peptide mapping confirmed that CFTR was phosphorylated at several sites identified in vitro. Thus, regulation of CFTR is likely to occur through direct phosphorylation of the R-domain by protein kinases stimulated by different second messenger pathways.	DUKE UNIV,DEPT MED,DURHAM,NC 27706; VET ADM MED CTR,DURHAM,NC 27705	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	PICCIOTTO, MR (corresponding author), ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021, USA.		Picciotto, Marina R./F-8747-2012	Picciotto, Marina R./0000-0002-4404-1280; Nairn, Angus/0000-0002-7075-0195	NIDDK NIH HHS [DK 40701] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040701, R29DK040701] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; CHANG CF, 1991, J BIOL CHEM, V266, P16395; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COHN JA, 1992, IN PRESS P NATL ACAD, V89; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FRIZZELL RA, 1991, NATURE, V350, P277, DOI 10.1038/350277a0; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAND RJA, 1979, BIOCHEM J, V177, P521, DOI 10.1042/bj1770521; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HOLMES CFB, 1987, FEBS LETT, V215, P21, DOI 10.1016/0014-5793(87)80106-0; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LIN M, 1992, IN PRESS AM J PHYSL; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MARSHALL J, 1991, J BIOL CHEM, V266, P22749; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MORAN O, 1991, FEBS LETT, V279, P256, DOI 10.1016/0014-5793(91)80162-V; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WALTER U, 1980, J BIOL CHEM, V255, P3757; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877; YAMAGATA Y, 1991, J BIOL CHEM, V266, P15391	54	279	280	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12742	12752						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1377674				2022-12-27	WOS:A1992HZ48300056
J	ATTALI, B; ROMEY, G; HONORE, E; SCHMIDALLIANA, A; MATTEI, MG; LESAGE, F; RICARD, P; BARHANIN, J; LAZDUNSKI, M				ATTALI, B; ROMEY, G; HONORE, E; SCHMIDALLIANA, A; MATTEI, MG; LESAGE, F; RICARD, P; BARHANIN, J; LAZDUNSKI, M			CLONING, FUNCTIONAL EXPRESSION, AND REGULATION OF 2 K+ CHANNELS IN HUMAN LYMPHOCYTES-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNELS; CELL ACTIVATION; MEMBRANE-PROTEIN; ION CHANNELS; PATCH-CLAMP; RAT UTERUS; DIVERSITY; CALCIUM; CHARYBDOTOXIN; GENE	Low stringency screening of a Jurkat cDNA library with a rat brain K+ channel (RCK1) probe has resulted in the isolation of HLK3, a voltage-gated K+ channel. In Xenopus oocytes, the HLK3 clone directs the expression of a rapidly activating transient outward K+ current similar to the type n K+ current recorded in Jurkat T cells. The HLK3 gene is located on the short arm of human chromosome 1 (p13.3). Polymerase chain reaction was used to clone HIsK from Jurkat cDNA. The HIsK clone shares the same sequence with a previously described genomic clone (Murai, T., Kazikuka, A., Takumi, T., Ohkubo, H., and Nakanishi, S. (1989) Biochem. Biophys. Res. Commun. 161, 176-181). In Xenopus oocytes, it encodes a slowly activating, noninactivating K+ channel which cannot be recorded in Jurkat cells by conventional patch-clamp techniques. Transcripts of both clones are present at a similar level before and after activation of purified human T lymphocytes and Jurkat cells, reflecting a constitutive expression of K+ channel messages. This finding is in good agreement with the electrophysiological results for type n K+ current density on the same cells. HLK3 current is very sensitive to the scorpion toxin charybdotoxin (IC50 = 0.8 nM). HIsK current is totally insensitive to this toxin but is blocked by the antiarrhythmic clofilium (IC50 = 80-mu-M). While charybdotoxin has no effect on interleukin 2 mRNA induction, clofilium potently inhibits interleukin 2 mRNA expression upon mitogen-induced T cell activation. It is concluded that the HLK3 channel is not an important component of the T cell mitogenic response. Other targets for K+ channel blockers, such as the HIsK protein, could be involved in the activation process.	SOPHIA ANTIPOLIS, INST PHARMACOL MOLEC & CELLULAIRE, 660 ROUTE LUCIOLES, F-06560 VALBONNE, FRANCE; HOP ENFANTS LA TIMONE, CTR GENET MED, INSERM, U242, F-13385 MARSEILLE 05, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Lesage, Florian/D-5097-2011; Lesage, Florian/P-9780-2019; SCHMID-ALLIANA, Annie/P-4366-2016	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106; HONORE, Eric/0000-0002-8007-0919; SCHMID-ALLIANA, Annie/0000-0003-2321-7408				AMIGORENA S, 1990, J IMMUNOL, V144, P2038; ARENA JP, 1988, MOL PHARMACOL, V34, P60; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BREGESTOVSKI P, 1986, NATURE, V319, P776, DOI 10.1038/319776a0; CAHALAN MD, 1985, J PHYSIOL-LONDON, V358, P197, DOI 10.1113/jphysiol.1985.sp015548; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK NS, 1989, POTASSIUM CHANNELS S, P182; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P405, DOI 10.1085/jgp.89.3.405; DEUTSCH C, 1986, J PHYSIOL-LONDON, V372, P405, DOI 10.1113/jphysiol.1986.sp016016; DEUTSCH C, 1984, J CELL BIOL, V98, P885, DOI 10.1083/jcb.98.3.885; DEUTSCH C, 1991, J BIOL CHEM, V266, P3668; DOUGLASS J, 1990, J IMMUNOL, V144, P4841; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; FUJITA T, 1983, P NATL ACAD SCI-BIOL, V80, P7437, DOI 10.1073/pnas.80.24.7437; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GRINSTEIN S, 1990, J GEN PHYSIOL, V95, P97, DOI 10.1085/jgp.95.1.97; GRINSTEIN S, 1989, PHYSIOL REV, V69, P417, DOI 10.1152/physrev.1989.69.2.417; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Hille B, 1984, IONIC CHANNELS EXCIT; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; HUET S, 1986, J IMMUNOL, V137, P1420; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE SC, 1988, AM J PHYSIOL, V254, pC286, DOI 10.1152/ajpcell.1988.254.2.C286; LEWIS RS, 1988, TRENDS NEUROSCI, V11, P214, DOI 10.1016/0166-2236(88)90129-4; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MOCZYDLOWSKI E, 1988, J MEMBRANE BIOL, V105, P95, DOI 10.1007/BF02009164; MURAI T, 1989, BIOCHEM BIOPH RES CO, V161, P176, DOI 10.1016/0006-291X(89)91577-5; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PRAGNELL M, 1990, NEURON, V4, P807, DOI 10.1016/0896-6273(90)90207-V; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; RANDRIAMAMPITA C, 1991, CELL CALCIUM, V12, P313, DOI 10.1016/0143-4160(91)90005-Y; REHM H, 1991, FASEB J, V5, P164, DOI 10.1096/fasebj.5.2.2004663; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SANDS SB, 1989, J GEN PHYSIOL, V93, P1061, DOI 10.1085/jgp.93.6.1061; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLICHTER L, 1986, P NATL ACAD SCI USA, V83, P451, DOI 10.1073/pnas.83.2.451; SEGEL GB, 1979, J CLIN INVEST, V64, P834, DOI 10.1172/JCI109531; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	55	131	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8650	8657						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373731				2022-12-27	WOS:A1992HQ18500103
J	TOMAREV, SI; ZINOVIEVA, RD; PIATIGORSKY, J				TOMAREV, SI; ZINOVIEVA, RD; PIATIGORSKY, J			CHARACTERIZATION OF SQUID CRYSTALLIN GENES - COMPARISON WITH MAMMALIAN GLUTATHIONE-S-TRANSFERASE GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLING INDUCIBLE EXPRESSION; EYE LENS CRYSTALLINS; YA SUBUNIT GENE; PHYSICOCHEMICAL CHARACTERIZATION; EVOLUTIONARY STRATEGY; NUCLEOTIDE-SEQUENCE; P-GENE; PROTEINS; DNA; PROMOTER	Previous experiments have indicated that the crystallins of the squid lens (S-crystallins) are evolutionarily related to glutathione S-transferases (GST) (EC 2.5.1.18). Here we confirm by peptide sequencing that the crystallins of the lens of the squid Ommastrephes sloani pacificus comprise a family of GST-like proteins. Squid lens extracts showed 400 times less GST activity than those of liver using 1-chloro-2,4-dinitrobenzene as a substrate, suggesting that the abundant GST-like crystallins lack enzymatic activity. Four different cDNAs (pSL20-1, pSL18, pSL11, and pSL4) showed 20-25% similarity in homologous regions with mammalian GST polypeptides. pSL20-1, pSL18, and pSL4 each encode an S-crystallin with a unique internal peptide that is unrelated to mammalian GSTs or any other sequence in GenBank. The S-crystallin family is encoded in a minimum of 9-10 genes, and the exon-intron structures of at least two of these (SL20-1 and SL11) are similar to those of the mammalian GST genes. The SL20-1 gene has six exons, with the its unique internal peptide encoded precisely in exon 4; the SL11 gene lacks a unique internal peptide and has five exons. Experiments using bacterial chloramphenicol acetyltransferase as a reporter gene showed that at least 84 and 111 base pairs of 5'-flanking sequence are needed for function of the SL20-1 and SL11 promoters, respectively, in a transfected rabbit lens epithelial cell line (N/N1003A). Within these regions each has a putative TATA box and an upstream AP-1 site overlapping with antioxidant responsive-like elements, which are regulatory elements in the rat GST Ya and quinone reductase genes responsive to oxidative stress.			TOMAREV, SI (corresponding author), NIA,MOLEC & DEV BIOL LAB,BETHESDA,MD 20892, USA.							ALI MA, 1982, NATO ADV SCI I SER A, V74, P1; AWASTHI YC, 1980, EXP EYE RES, V30, P29, DOI 10.1016/0014-4835(80)90121-9; BEALE AJ, 1963, LANCET, V2, P640; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BLOEMENDAL H, 1982, CRC CR REV BIOCH MOL, V12, P1, DOI 10.3109/10409238209105849; BORRAS T, 1988, DEV BIOL, V127, P209, DOI 10.1016/0012-1606(88)90202-3; BRAHMA SK, 1978, J EMBRYOL EXP MORPH, V46, P11; CHIOU SH, 1984, J BIOCHEM-TOKYO, V95, P75, DOI 10.1093/oxfordjournals.jbchem.a134605; CHIOU SH, 1988, FEBS LETT, V241, P261, DOI 10.1016/0014-5793(88)81073-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRONIN TW, 1986, AM ZOOL, V26, P403; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1986, J MOL EVOL, V24, P121, DOI 10.1007/BF02099960; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HALBERT SP, 1963, PROG ALLERGY, V7, P107, DOI 10.1159/000314087; HARRIS J, 1991, COMP BIOCHEM PHYS B, V98, P511, DOI 10.1016/0305-0491(91)90245-9; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HESSE JE, 1986, P NATL ACAD SCI USA, V83, P4312, DOI 10.1073/pnas.83.12.4312; KANEHISA M, 1988, IDEAS 88 USER MANUAL; KIM RY, 1991, GENE, V103, P193, DOI 10.1016/0378-1119(91)90273-E; LAI HCJ, 1984, J BIOL CHEM, V259, P5536; LOK S, 1989, NUCLEIC ACIDS RES, V17, P3563, DOI 10.1093/nar/17.9.3563; LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MANSKI W, 1965, PROTIDES BIOL FLUIDS, P117; Maxam A M, 1980, Methods Enzymol, V65, P499; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OKUDA A, 1989, J BIOL CHEM, V264, P16919; OKUDA A, 1987, J BIOL CHEM, V262, P3858; PACKARD A, 1972, BIOL REV, V47, P241, DOI 10.1111/j.1469-185X.1972.tb00975.x; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1989, J COMP PHYSIOL A, V164, P577, DOI 10.1007/BF00614500; PIATIGORSKY J, 1989, FASEB J, V3, P1933, DOI 10.1096/fasebj.3.8.2656357; PIATIGORSKY J, 1991, ADV DEV BIOCH, V1, P211; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; QUITSCHKE WW, 1989, MOL CELL BIOL, V9, P3218, DOI 10.1128/MCB.9.8.3218; RAO PV, 1992, J BIOL CHEM, V267, P96; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; RHOADS DM, 1987, BIOCHEM BIOPH RES CO, V145, P474, DOI 10.1016/0006-291X(87)91345-3; ROTH HJ, 1991, MOL CELL BIOL, V11, P1488, DOI 10.1128/MCB.11.3.1488; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEZEN RJ, 1982, BIOCHIM BIOPHYS ACTA, V704, P304, DOI 10.1016/0167-4838(82)90160-1; Spector A., 1991, OXIDATIVE STRESS OXI, P529; SUGUOKA Y, 1985, NUCLEIC ACIDS RES, V13, P6049, DOI 10.1093/nar/13.17.6049; TELAKOWSKIHOPKINS CA, 1986, P NATL ACAD SCI USA, V83, P9393, DOI 10.1073/pnas.83.24.9393; TOMAREV SI, 1988, NATURE, V336, P86, DOI 10.1038/336086a0; TOMAREV SI, 1991, J BIOL CHEM, V266, P24226; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZINOVIEVA RD, 1990, DOKL AKAD NAUK SSSR+, V310, P222	62	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8604	8612						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373730				2022-12-27	WOS:A1992HQ18500097
J	PLATANIAS, LC; COLAMONICI, OR				PLATANIAS, LC; COLAMONICI, OR			INTERFERON-ALPHA INDUCES RAPID TYROSINE PHOSPHORYLATION OF THE ALPHA-SUBUNIT OF ITS RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TRANSCRIPTIONAL INDUCTION; HUMAN-CELLS; BINDING; EXPRESSION; ACTIVATION; HYDROLYSIS; GENES	The mechanisms of generation of second messengers after binding of interferon alpha (IFNalpha) to its receptor remain unknown. We have studied the phosphorylation of the alpha subunit of the IFNalpha receptor, which is recognized by the monoclonal antibody IFNa receptor 3. Immunoblotting experiments showed that IFNalpha induced rapid tyrosine phosphorylation of the alpha subunit in the IFNalpha-sensitive H-929, U-266, and Daudi cell lines. Immunoprecipitation experiments performed with P-32-labeled cells showed that the alpha subunit is phosphorylated before IFNalpha treatment and that the level of phosphorylation increases after IFNalpha stimulation. Phosphoamino acid analysis confirmed the IFNalpha-induced tyrosine phosphorylation and demonstrated that the base-line phosphorylation corresponded to serine phosphorylation that increased 50% upon IFNalpha treatment. Tyrosine phosphorylation of the alpha subunit was time- and dose-dependent, further demonstrating the specificity of the process. Phosphorylation of the alpha subunit of the receptor occurred rapidly after IFNalpha binding, both at 37 and 4-degrees-C. Exposure of the cells to the tyrosine kinase inhibitor genistein blocked the IFNalpha-induced tyrosine phosphorylation of this subunit of the IFNalpha receptor. In contrast H7, a specific protein kinase C inhibitor, and acute and chronic exposure to phorbol esters had no effect on tyrosine phosphorylation, suggesting that protein kinase C does not regulate the tyrosine phosphorylation of the alpha subunit of the IFNalpha receptor. No IFNalpha-induced tyrosine phosphorylation was observed in the IFNalpha-resistant U-937 cell line that expresses a variant IFNalpha receptor. Altogether these data suggest that tyrosine phosphorylation of the a subunit may play a role in the signal transduction pathway of IFNalpha.	UNIV CHICAGO,DEPT MED,HEMATOL ONCOL SECT,CHICAGO,IL 60615	University of Chicago					NATIONAL CANCER INSTITUTE [R35CA042557] Funding Source: NIH RePORTER; NCI NIH HHS [CA42557] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUET M, 1980, NATURE, V284, P459, DOI 10.1038/284459a0; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GAZDAR AF, 1986, BLOOD, V67, P1542; IMPROTA T, 1992, J INTERFERON RES, V12, P87, DOI 10.1089/jir.1992.12.87; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1988, EMBO J, V7, P3779, DOI 10.1002/j.1460-2075.1988.tb03262.x; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LARNER AC, 1986, J BIOL CHEM, V261, P453; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1989, GENE DEV, V3, P1203; NASAO H, 1990, J EXP MED, V171, P637; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1991, PHARMACOL THERAPEUT, V52, P149, DOI 10.1016/0163-7258(91)90005-7; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PFEFFERLM, 1991, P NATL ACAD SCI USA, V88, P7998; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; SHARON M, 1989, J IMMUNOL, V143, P2530; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	28	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24053	24057						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385434				2022-12-27	WOS:A1992JZ23900093
J	WHITE, DM; MIKOL, DD; ESPINOSA, R; WEIMER, B; LEBEAU, MM; STEFANSSON, K				WHITE, DM; MIKOL, DD; ESPINOSA, R; WEIMER, B; LEBEAU, MM; STEFANSSON, K			STRUCTURE AND CHROMOSOMAL LOCALIZATION OF THE HUMAN GENE FOR A BRAIN FORM OF PROSTAGLANDIN-D2 SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2U GLOBULIN GENE; HEXABRACHION TENASCIN GENE; SLEEP-INDUCING SUBSTANCE; RETINOL-BINDING PROTEIN; D SYNTHETASE; SEQUENCE-ANALYSIS; RAT-BRAIN; EXPRESSION; GLYCOPROTEIN; FAMILY	We have cloned and characterized the human gene for the 21-kDa brain form of prostaglandin D2 synthase. The gene was isolated from a human genomic lambda library and spans 3600 base pairs. It consists of seven exons and six introns. Southern blot analysis indicates that there is a single copy of the gene in the haploid genome. The transcriptional start site was mapped to a G residue 74 base pairs 5' of the ATG initiation codon. A TATA box-like element (ATAAATA) is situated 21 base pairs upstream of the mRNA start site. The gene was mapped to chromosome 9 bands q34.2-q34.3. The gene bears close resemblance to the genes for murine major urinary protein and ovine beta-lactoglobulin.	UNIV CHICAGO, DEPT NEUROL, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL NEUROPATHOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, HEMATOL ONCOL SECT, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago			Stefansson, Kari/AAE-7187-2019		NCI NIH HHS [CA 42557, CA40046] Funding Source: Medline; NHLBI NIH HHS [HL 07237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040046, R35CA042557] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1988, J MOL BIOL, V199, P415, DOI 10.1016/0022-2836(88)90614-6; BERMAN P, 1987, CELL, V51, P135, DOI 10.1016/0092-8674(87)90018-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOY HA, 1989, J BIOL CHEM, V264, P1754; CHRISTHAZELHOF E, 1976, BIOCHIM BIOPHYS ACTA, V450, P450, DOI 10.1016/0005-2760(76)90018-7; CLARK AJ, 1984, EMBO J, V3, P1045, DOI 10.1002/j.1460-2075.1984.tb01925.x; CONNOR JM, 1987, J MED GENET, V24, P544, DOI 10.1136/jmg.24.9.544; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLAN KP, 1982, J BIOL CHEM, V257, P13527; Fahn S, 1988, Adv Neurol, V50, P1; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORSTERMANN U, 1984, PROSTAGLANDINS, V27, P913, DOI 10.1016/S0090-6980(84)80010-6; FORSTERMANN U, 1982, BRAIN RES, V240, P303, DOI 10.1016/0006-8993(82)90225-6; FRYER AE, 1987, LANCET, V1, P659; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; GULCHER JR, 1990, GENOMICS, V6, P616, DOI 10.1016/0888-7543(90)90495-G; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; HAYAISHI O, 1991, FASEB J, V5, P2575, DOI 10.1096/fasebj.5.11.1907936; HAYAISHI O, 1983, ADV PROSTAG THROMB L, V12, P333; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; KINOSHITA F, 1982, ENDOCRINOLOGY, V110, P2207, DOI 10.1210/endo-110-6-2207; KWIATKOWSKI DJ, 1991, AM J HUM GENET, V48, P121; KWIATKOWSKI DJ, 1991, AM J HUM GENET, V49, P366; LAYCHOCK SG, 1980, PHARMACOL BIOCHEM BE, V12, P747, DOI 10.1016/0091-3057(80)90161-6; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MIKOL DD, 1988, J CELL BIOL, V106, P1273, DOI 10.1083/jcb.106.4.1273; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; ONOE H, 1988, P NATL ACAD SCI USA, V85, P4082, DOI 10.1073/pnas.85.11.4082; PENTREATH VW, 1990, T ROY SOC TROP MED H, V84, P795, DOI 10.1016/0035-9203(90)90085-S; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; POVEY S, 1991, CYTOGENET CELL GENET, V58, P403, DOI 10.1159/000133169; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SAEEDABDELHALIM M, 1980, J NEUROCHEM, V34, P1331, DOI 10.1111/j.1471-4159.1980.tb09980.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SHIMIZU T, 1979, J BIOL CHEM, V254, P5222; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SOARES VD, 1987, MOL CELL BIOL, V7, P3749; UENO R, 1983, P NATL ACAD SCI-BIOL, V80, P1735, DOI 10.1073/pnas.80.6.1735; UENO R, 1982, P NATL ACAD SCI-BIOL, V79, P6093, DOI 10.1073/pnas.79.19.6093; Urade Y, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P549; URADE Y, 1989, J BIOL CHEM, V264, P1041; URADE Y, 1987, J BIOL CHEM, V262, P15132; URADE Y, 1987, J BIOL CHEM, V262, P3820; WINDERICKX J, 1987, EUR J BIOCHEM, V165, P521, DOI 10.1111/j.1432-1033.1987.tb11470.x; [No title captured]	50	56	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23202	23208						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385416				2022-12-27	WOS:A1992JY16300077
J	FOLLI, F; SAAD, MJA; BACKER, JM; KAHN, CR				FOLLI, F; SAAD, MJA; BACKER, JM; KAHN, CR			INSULIN STIMULATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY AND ASSOCIATION WITH INSULIN-RECEPTOR SUBSTRATE-1 IN LIVER AND MUSCLE OF THE INTACT RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; GROWTH FACTOR-I; DEPENDENT DIABETES-MELLITUS; KINASE-ACTIVITY; TYROSINE PHOSPHORYLATION; SKELETAL-MUSCLE; ENDOGENOUS SUBSTRATE; SIGNAL TRANSDUCTION; PDGF RECEPTOR; PROTEINS	Growth factors stimulate the enzyme phosphatidylinositol (PI) 3-kinase in cells in culture. Insulin rapidly stimulates tyrosine phosphorylation of its endogenous substrate, insulin receptor substrate 1 (IRS-1), and in vitro IRS-1 associates with PI 3-kinase, thus activating the enzyme. We have examined whether insulin is capable of stimulating the PI 3-kinase pathway in two physiological target tissues for the actions of insulin in vivo, liver and skeletal muscle. After intraportal injection of insulin into anesthetized rats, there was a 2-fold stimulation of total hepatic PI 3-kinase activity in liver and muscle extracts and a 10- to 20-fold increase in PI 3-kinase activity immunoprecipitated with anti-IRS-1 antibodies. Stimulation of PI 3-kinase was accompanied by an association between this enzyme and IRS-1 as detected by immunoprecipitation of liver and muscle extracts with anti-IRS-1 antibodies and Western blotting with antibodies to the 85-kDa subunit of PI 3-kinase. Immunoprecipitation with anti-p85 antibodies and phosphotyrosine immunoblotting revealed no tyrosine phosphorylation of PI 3-kinase, but demonstrated co-precipitation of tyrosine-phosphorylated IRS-1, as well as another phosphotyrosine protein of approximately 135-140 kDa. Thus, IRS-1 phosphorylation plays a significant role in the activation of PI 3-kinase in vivo by insulin.	HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Harvard Medical School	FOLLI, F (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215, USA.		folli, franco/J-2795-2018; Saad, Mario/ABD-8262-2020; Kahn, Ronald/AAY-2435-2021	folli, franco/0000-0001-9824-5222; Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK 36836, DK 33201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNER P, 1987, DIABETOLOGIA, V30, P437, DOI 10.1007/BF00292549; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BEGUINOT F, 1989, ENDOCRINOLOGY, V125, P1599, DOI 10.1210/endo-125-3-1599; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARO JF, 1986, J CLIN INVEST, V78, P249, DOI 10.1172/JCI112558; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CONDORELLI G, 1989, J BIOL CHEM, V264, P12633; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRIEDENBERG GR, 1987, J CLIN INVEST, V79, P240; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; OBERMAIERKUSSER B, 1989, J BIOL CHEM, V264, P9497; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAAD MJA, 1992, IN PRESS J CLIN INVE; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKAYAMA S, 1988, J CLIN ENDOCR METAB, V66, P992, DOI 10.1210/jcem-66-5-992; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YONEZAWA K, 1992, J BIOL CHEM, V267, P440	59	244	250	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22171	22177						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385396				2022-12-27	WOS:A1992JW71900030
J	HECK, DE; LASKIN, DL; GARDNER, CR; LASKIN, JD				HECK, DE; LASKIN, DL; GARDNER, CR; LASKIN, JD			EPIDERMAL GROWTH-FACTOR SUPPRESSES NITRIC-OXIDE AND HYDROGEN-PEROXIDE PRODUCTION BY KERATINOCYTES - POTENTIAL ROLE FOR NITRIC-OXIDE IN THE REGULATION OF WOUND-HEALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE KINASE-ACTIVITY; MACROPHAGE-INDUCED ANGIOGENESIS; HEPATOCYTE PROTEIN-SYNTHESIS; NECROSIS FACTOR-ALPHA; L-ARGININE; ULTRAVIOLET-LIGHT; INHIBITION; CELLS; OXIDATION; INDUCTION	In the skin, wounding initiates a complex array of physiological processes mediated by growth factors and inflammatory mediators which stimulate tissue repair and protect against infection. We report that primary cultures of human keratinocytes and a mouse keratinocyte cell line respond to the inflammatory stimuli gamma-interferon and lipopolysaccharide or tumor necrosis factor-alpha by producing nitric oxide and hydrogen peroxide, two reactive mediators that are important in nonspecific host defense. Nitric oxide is produced by the l-arginine- and NADPH-dependent enzyme, nitric oxide synthase. In murine keratinocytes, optimal enzymatic activity was found to be dependent on Ca2+ and calmodulin as well as on glutathione. Inflammatory mediators were also found to inhibit the growth of keratinocytes, an effect that could be reversed by a nitric oxide synthase inhibitor. Epidermal growth factor (EGF), which promotes wound healing by stimulating cellular proliferation, was found to be a potent antagonist of reactive nitrogen and reactive oxygen intermediate production by keratinocytes. EGF also reversed the growth inhibitory actions of the inflammatory mediators. These data suggest that nitric oxide produced by keratinocytes is important in the control of cellular proliferation during wound healing. Our findings that EGF effectively regulates the production of free radicals by keratinocytes may represent an important pathway by which this growth factor not only stimulates epidermal cell proliferation but also facilitates the resolution of inflammation following wounding.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ENVIRONM & COMMUNITY MED,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,DEPT PHARMACOL & TOXICOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick				Laskin, Debra/0000-0003-1832-7311				BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; BASS DA, 1983, J IMMUNOL, V130, P1910; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; DING A, 1990, J IMMUNOL, V145, P940; FAALAND CA, 1991, MOL CELL BIOL, V11, P2697, DOI 10.1128/MCB.11.5.2697; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRINNELL F, 1990, J TRAUMA, V30, pS144; HECK DE, 1991, CANCER CHEMOTH PHARM, V28, P344, DOI 10.1007/BF00685687; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HUNT TK, 1988, TRAUMA SEPSIS SHOCK, P443; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; KWON NS, 1989, J BIOL CHEM, V264, P20496; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; MCCORD JM, 1978, ANN INTERN MED, V89, P122, DOI 10.7326/0003-4819-89-1-122; MERMELSTEIN FH, 1989, MOL PHARMACOL, V36, P848; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKANE N, 1992, FASEB J, V6, pA36; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PUNJABI C, 1992, IN PRESS J IMMUNOL; RADI R, 1991, J BIOL CHEM, V266, P4244; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SEGAL W, 1989, HUMAN MONOCYTES, P94; STUEHR DJ, 1987, J IMMUNOL, V139, P518; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARIO G, 1991, J IMMUNOL, V146, P3469; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WOLFF DJ, 1992, BIOCHEM J, V285, P201, DOI 10.1042/bj2850201	38	258	267	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21277	21280						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383221				2022-12-27	WOS:A1992JV01100002
J	BURKE, PA; GRIFFIN, RG; KLIBANOV, AM				BURKE, PA; GRIFFIN, RG; KLIBANOV, AM			SOLID-STATE NMR ASSESSMENT OF ENZYME ACTIVE-CENTER STRUCTURE UNDER NONAQUEOUS CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; ORGANIC-SOLVENTS; CHLOROMETHYL KETONE; ALPHA-CHYMOTRYPSIN; INHIBITOR COMPLEX; C-13 NMR; SERINE PROTEASES; LINE-SHAPES; TRYPSIN; CATALYSIS	By using solid-state NMR spectroscopy, the integrity of the active center of alpha-chymotrypsin was investigated under a variety of nonaqueous conditions. Specifically, C-13 cross-polarization/magic angle spinning NMR was used to analyze the ability of alpha-chymotrypsin to stabilize a transition state intermediate analog after freezing, drying, and addition of organic solvents (both anhydrous and hydrated) to the resultant powder. Lyophilization disrupted 42 +/- 5% of the active centers; it was determined that this occurred during drying, as opposed to freezing. Seven anhydrous solvents caused 0-50% additional disruption, which occurred immediately on addition of the solvent to the enzyme powder. The extent of structural integrity loss correlated with the solvent hydrophobicity, indicating that further dehydration, i.e. stripping of water retained by the enzyme during lyophilization, was the cause. Enzyme samples prepared with lyoprotecting additives, sucrose and ammonium sulfate, exhibited varying degrees of stabilization against the drying step of lyophilization. Moreover, when hydrophilic anhydrous solvents, which had the highest propensity to strip bound water, were added to the resultant enzyme powders, no additional damage occurred.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; MIT,FRANCIS BITTER NATL MAGNET LAB,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM 39794] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM039794, R01GM039794] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS KAH, 1990, J AM CHEM SOC, V112, P9418, DOI 10.1021/ja00181a068; AFFLECK R, 1992, P NATL ACAD SCI USA, V89, P1100, DOI 10.1073/pnas.89.3.1100; Akhadov Y.Y, 2013, DIELECTRIC PROPERTIE; ALLEN PJ, 1991, J MAGN RESON, V92, P614, DOI 10.1016/0022-2364(91)90357-Y; BURKE PA, 1989, J AM CHEM SOC, V111, P8290, DOI 10.1021/ja00203a046; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; DORDICK JS, 1989, ENZYME MICROB TECH, V11, P194, DOI 10.1016/0141-0229(89)90094-X; FARNEY DE, 1963, J AM CHEM SOC, V85, P997; FINK AL, 1986, CRYOBIOLOGY, V23, P28, DOI 10.1016/0011-2240(86)90015-5; Finney J. L., 1984, Comments on Molecular and Cellular Biophysics. Comments on Modern Biology: Part A, V2, P129; FINUCANE MD, 1989, BIOCHEM J, V258, P853, DOI 10.1042/bj2580853; FISHBEIN WN, 1979, ADV CHEM SER, V180, P55; FITZPATRICK PA, 1991, J AM CHEM SOC, V113, P3166, DOI 10.1021/ja00008a054; Franks F., 1985, BIOPHYSICS BIOCH LOW; GORMAN LAS, 1992, BIOTECHNOL BIOENG, V39, P392, DOI 10.1002/bit.260390405; GRIFFIN RG, 1981, TIME DOMAIN SURFACE; GUINN RM, 1991, BIOTECHNOL BIOENG, V37, P303, DOI 10.1002/bit.260370403; Gurd F R, 1979, Adv Protein Chem, V33, P73, DOI 10.1016/S0065-3233(08)60459-3; HARNED HS, 1964, PHYSICAL CHEM ELECTR; HUANG TH, 1984, BIOCHEMISTRY-US, V23, P5933, DOI 10.1021/bi00320a007; Janz G., 1972, NONAQUEOUS ELECTROLY, V1; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KANERVA LT, 1989, J AM CHEM SOC, V111, P6864, DOI 10.1021/ja00199a069; KENIRY MA, 1984, NATURE, V307, P383, DOI 10.1038/307383a0; KLIBANOV AM, 1989, TRENDS BIOCHEM SCI, V14, P141, DOI 10.1016/0968-0004(89)90146-1; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAITINEN HA, 1975, CHEM ANAL; LIANG TC, 1987, BIOCHEMISTRY-US, V26, P7603, DOI 10.1021/bi00398a011; LIU WR, 1991, BIOTECHNOL BIOENG, V37, P177, DOI 10.1002/bit.260370210; MALTHOUSE JPG, 1983, J AM CHEM SOC, V105, P1685, DOI 10.1021/ja00344a062; MALTHOUSE JPG, 1985, BIOCHEMISTRY-US, V24, P3478, DOI 10.1021/bi00335a014; MATTHEWS HR, 1977, BIOCHIM BIOPHYS ACTA, V497, P1, DOI 10.1016/0304-4165(77)90134-9; Mehring M., 1983, HIGH RESOLUTION NMR; Milton Silverstein R., 1981, SPECTROMETRIC IDENTI; ONG EB, 1965, J BIOL CHEM, V240, P694; Perrin D. D., 2012, BUFFERS PH METAL ION; PRZYBYCIEN TM, 1989, BIOCHIM BIOPHYS ACTA, V995, P231, DOI 10.1016/0167-4838(89)90041-1; Rekker RF., 1977, HYDROPHOBIC FRAGMENT; RICE DM, 1981, J AM CHEM SOC, V103, P7707, DOI 10.1021/ja00416a002; Robinson R.A., 1959, ELECTROLYTE SOLUTION, DOI DOI 10.1073?PNAS.0305836101; Rupley J. A., 1980, ACS S SERIES, V127, P111; RUPLEY JA, 1983, TRENDS BIOCHEM SCI, V8, P18, DOI 10.1016/0968-0004(83)90063-4; RUSSELL AJ, 1988, J BIOL CHEM, V263, P11624; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SCHULZE B, 1991, BIOTECHNOL BIOENG, V38, P1001, DOI 10.1002/bit.260380907; SCOTT AI, 1986, TETRAHEDRON, V42, P3269, DOI 10.1016/S0040-4020(01)87391-9; SEGAL DM, 1971, BIOCHEMISTRY-US, V10, P3728; SINGER SJ, 1962, ADV PROTEIN CHEM, V17, P1; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; WAGNER G, 1976, BIOPHYS STRUCT MECH, V2, P139, DOI 10.1007/BF00863706; WAGNER G, 1983, Q REV BIOPHYS, V16, P1, DOI 10.1017/S0033583500004911; WITTEBORT RJ, 1987, J CHEM PHYS, V86, P5411, DOI 10.1063/1.452565; ZAKS A, 1986, J AM CHEM SOC, V108, P2767, DOI 10.1021/ja00270a053; ZAKS A, 1988, J BIOL CHEM, V263, P3194; ZAKS A, 1988, J BIOL CHEM, V263, P8017	57	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20057	20064						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400323				2022-12-27	WOS:A1992JR85800051
J	OHLSEN, KL; GRALLA, JD				OHLSEN, KL; GRALLA, JD			DNA MELTING WITHIN STABLE CLOSED COMPLEXES AT THE ESCHERICHIA-COLI RRNB P1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL STRINGENT CONTROL; FACTOR-INDEPENDENT ACTIVATION; RIBOSOMAL-RNA TRANSCRIPTION; RATE-DEPENDENT REGULATION; LAC PS PROMOTER; GUANOSINE TETRAPHOSPHATE; UPSTREAM ACTIVATION; MECHANISM INVIVO; POLYMERASE; INVITRO	Several transcription complexes are shown to form on the E. coli ribosomal rrnB P1 promoter in vitro. These include two closed complexes that are sensitive to heparin attack, and one open complex. The closed complexes are unusual in that they are both highly specific and stable, properties associated with the atypical DNA sequence of this promoter. The effector ppGpp does not prevent closed complex formation but does reduce the level of open complexes that form.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM 35754, GM 07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754, T32GM007185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOROWIEC JA, 1987, J MOL BIOL, V195, P89, DOI 10.1016/0022-2836(87)90329-9; BOROWIEC JA, 1985, J MOL BIOL, V184, P587, DOI 10.1016/0022-2836(85)90305-5; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CASHEL M, 1969, J BIOL CHEM, V244, P3133; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; GAAL T, 1989, J BACTERIOL, V171, P4852, DOI 10.1128/jb.171.9.4852-4861.1989; GLASER G, 1983, NATURE, V302, P74, DOI 10.1038/302074a0; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GOURSE RL, 1983, CELL, V32, P1347, DOI 10.1016/0092-8674(83)90315-X; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; HAMMING J, 1980, NUCLEIC ACIDS RES, V8, P3947, DOI 10.1093/nar/8.17.3947; HOFER B, 1985, NUCLEIC ACIDS RES, V13, P5995, DOI 10.1093/nar/13.16.5995; Jinks-Robertson S., 1987, ESCHERICHIA COLI SAL, P1358; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KINGSTON RE, 1981, J MOL BIOL, V146, P433, DOI 10.1016/0022-2836(81)90041-3; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; LAMOND AI, 1985, CELL, V41, P6, DOI 10.1016/0092-8674(85)90050-9; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LAZZARINI RA, 1971, J BIOL CHEM, V246, P420; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MECSAS J, 1991, J MOL BIOL, V220, P585, DOI 10.1016/0022-2836(91)90102-C; MEIKLEJOHN AL, 1989, J MOL BIOL, V207, P661, DOI 10.1016/0022-2836(89)90236-2; MIURA A, 1981, CELL, V25, P773, DOI 10.1016/0092-8674(81)90185-9; NEIDHARDT FC, 1963, BIOCHIM BIOPHYS ACTA, V68, P365; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; OHLSEN KL, 1992, IN PRESS MOL MICROBI; OOSTRA BA, 1977, MOL GEN GENET, V152, P1, DOI 10.1007/BF00264932; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, J MOL BIOL, V202, P107, DOI 10.1016/0022-2836(88)90523-2; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; STEFANO JE, 1982, P NATL ACAD SCI-BIOL, V79, P1069, DOI 10.1073/pnas.79.4.1069; STENT GS, 1961, P NATL ACAD SCI USA, V47, P2005, DOI 10.1073/pnas.47.12.2005; VANOOYEN AJJ, 1976, CELL, V8, P123, DOI 10.1016/0092-8674(76)90193-8; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133	44	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19813	19818						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400295				2022-12-27	WOS:A1992JR85800012
J	REDL, B; HOLZFEIND, P; LOTTSPEICH, F				REDL, B; HOLZFEIND, P; LOTTSPEICH, F			CDNA CLONING AND SEQUENCING REVEALS HUMAN TEAR PREALBUMIN TO BE A MEMBER OF THE LIPOPHILIC-LIGAND CARRIER PROTEIN SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; BETA-LACTOGLOBULIN; MOLECULAR-CLONING; ALPHA-1-ACID GLYCOPROTEIN; LACRIMAL GLAND; MESSENGER-RNA; LACTOFERRIN; RESOLUTION; HOMOLOGY; FLUID	The gene encoding human tear prealbumin, a major component of the protein fraction of tear fluid, was cloned from total cDNA of lacrimal gland by polymerase chain reaction using synthetic oligonucleotides derived from N-terminal amino acid sequences of the purified protein. Sequence analysis and a computer-assisted homology search revealed this protein to be a member of the lipocalin superfamily, consisting of hydrophobic-ligand carriers. The deduced amino acid sequence of tear prealbumin shares 58% identity with von Ebner's gland protein from rat, which is supposed to be involved in taste reception. In addition, significant homology has also been found with other members of the lipocalins, e.g. with beta-lactoglobulin. The predicted secondary structure of tear prealbumin resembles that of beta-lactoglobulin in the number and positions of nine beta-sheets and one alpha-helix at the C-terminal part of the protein, thus indicating a three-dimensional structure similar to beta-lactoglobulin. Protein sequencing revealed that the observed electrophoretic heterogeneity of tear prealbumin is due to subtle differences at the N terminus of the protein. The function of tear prealbumin as a lipophilic carrier was further supported by the fact that it binds [H-3]retinol in vitro. Although this protein was originally described to be tear-specific, a tear prealbumin-specific antiserum also reacted with proteins of human saliva, sweat, and nasal mucus.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Max Planck Society	REDL, B (corresponding author), UNIV INNSBRUCK,FAK MED,INST MIKROBIOL,FRITZ PREGLSTR 3,A-6020 INNSBRUCK,AUSTRIA.							AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; ALEXANDER LJ, 1989, NUCLEIC ACIDS RES, V17, P6739, DOI 10.1093/nar/17.16.6739; ALLANSMITH M, 1967, IMMUNOLOGY, V12, P225; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; ANDREWS JS, 1970, EXP EYE RES, V10, P223, DOI 10.1016/S0014-4835(70)80032-X; BAIER G, 1990, J CHROMATOGR-BIOMED, V525, P319, DOI 10.1016/S0378-4347(00)83408-8; BONAVIDA B, 1969, NATURE, V221, P375, DOI 10.1038/221375a0; BOONSTRA A, 1988, CURR EYE RES, V7, P893, DOI 10.3109/02713688808997246; BROEKHUYSE RM, 1974, INVEST OPHTH VISUAL, V13, P550; BROOKS DE, 1986, J BIOL CHEM, V26, P4956; CANCEDDA FD, 1990, J BIOL CHEM, V265, P19060; CHAO CCW, 1986, CURR EYE RES, V5, P895, DOI 10.3109/02713688608995169; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLLET C, 1989, BIOCHEM BIOPH RES CO, V164, P1380, DOI 10.1016/0006-291X(89)91822-6; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P542; DENTE L, 1985, NUCLEIC ACIDS RES, V13, P3941, DOI 10.1093/nar/13.11.3941; Fleming A, 1922, BRIT J EXP PATHOL, V3, P252; FORD LO, 1974, J MOL BIOL, V88, P349, DOI 10.1016/0022-2836(74)90487-2; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GACHON AM, 1979, EXP EYE RES, V29, P539, DOI 10.1016/0014-4835(79)90154-4; GACHON AM, 1982, CURR EYE RES, V5, P301; GAZQUEZ JMCD, 1989, ENZYME, V41, P116, DOI 10.1159/000469063; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; HENZEL WJ, 1988, J BIOL CHEM, V263, P16682; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; JANSSEN PT, 1983, EXP EYE RES, V36, P773, DOI 10.1016/0014-4835(83)90031-3; JANSSEN PT, 1983, INVEST OPHTH VIS SCI, V24, P623; JOSEPHSON AS, 1968, J IMMUNOL, V100, P1080; JULKUNEN M, 1988, P NATL ACAD SCI USA, V85, P8845, DOI 10.1073/pnas.85.23.8845; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; PEVSNER J, 1990, J BIOL CHEM, V265, P6118; PEVSNER J, 1985, P NATL ACAD SCI USA, V82, P3050, DOI 10.1073/pnas.82.9.3050; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER M, 1976, J BIOL CHEM, V251, P4330; SCHMALE H, 1990, NATURE, V343, P366, DOI 10.1038/343366a0; SELSTED ME, 1982, EXP EYE RES, V34, P305, DOI 10.1016/0014-4835(82)90079-3; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SPENCE AM, 1989, P NATL ACAD SCI USA, V86, P7843, DOI 10.1073/pnas.86.20.7843; SPENCE AM, 1989, P NATL ACAD SCI USA, V86, P5463; UBELS JL, 1986, INVEST OPHTH VIS SCI, V27, P1261; UBELS JL, 1989, INVEST OPHTH VIS SCI, V30, P952; VANHAERINGEN NJ, 1981, SURV OPHTHALMOL, V26, P84, DOI 10.1016/0039-6257(81)90145-4; VANHAERINGEN NJ, 1974, EXP EYE RES, V20, P271; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEINBERG ED, 1974, SCIENCE, V184, P952, DOI 10.1126/science.184.4140.952; YOUNG WH, 1973, AM J OPTOM PHYS OPT, V50, P12	57	146	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20282	20287						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400345				2022-12-27	WOS:A1992JR85800084
J	SUN, AQ; YUKSEL, KU; GRACY, RW				SUN, AQ; YUKSEL, KU; GRACY, RW			INTERACTIONS BETWEEN THE CATALYTIC CENTERS AND SUBUNIT INTERFACE OF TRIOSEPHOSPHATE ISOMERASE PROBED BY REFOLDING, ACTIVE-SITE MODIFICATION, AND SUBUNIT EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSE PHOSPHATE ISOMERASE; PROTEIN-TURNOVER; REACTION PATHWAY; PHOSPHOGLYCOLOHYDROXAMATE COMPLEX; MAGNETIC-RESONANCE; PIG-HEART; ENZYME; INACTIVATION; DEGRADATION; INTERMEDIATE	The effects of unfolding, refolding, and hybridization of triosephosphate isomerase (TPI) subunits from different species and subunits which have been specifically modified at the active site have been examined. These effects have been evaluated in terms of changes in catalytic parameters, CD spectra, and susceptibility to denaturation. Dissociation followed by reassociation yields an active dimer but with increased K(m), reduced k(cat), and increased susceptibility to inactivation and unfolding in denaturants. These data suggest that while the general structure of the refolded dimer is similar to the native enzyme, its complete original structure is not restored. Covalent reaction of the active site Glu165 with the substrate analogue 3-chloroacetol phosphate (CAP) results in dimers with increased susceptibility to unfolding and inactivation by denaturants (i.e. the rates of inactivation and unfolding are (TPI(CAP))2 > (TPI-TPI(CAP)) > (TPI)2). These data point to the interactions between the catalytic center and the subunit interface. Subunits of TPI from different species, in spite of structural differences at the subunit interface, hybridized to active heterodimers. Subunit hybridization was random among monomers from different mammals, preferential between yeast and mammalian or avian monomers. Hybridization did not occur between avian and mammalian monomers under these conditions. These data provide information on the elements in the interface of the dimer and the relationship of the catalytic center with the subunit interface.	UNIV TEXAS, TEXAS COLL OSTEOPATH MED, DEPT BIOCHEM & MOLEC BIOL, MOLEC AGING UNIT, FT WORTH, TX 76107 USA	University of Texas System; University of Texas Arlington					NATIONAL INSTITUTE ON AGING [R37AG001274, R01AG001274] Funding Source: NIH RePORTER; NIA NIH HHS [AG 01274] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHERN TJ, 1987, P NATL ACAD SCI USA, V84, P675, DOI 10.1073/pnas.84.3.675; ALBER T, 1982, Journal of Molecular and Applied Genetics, V1, P419; ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; Anfinsen C B, 1967, Harvey Lect, V61, P95; ARTAVANISTSAKON.C, 1974, THESIS U CAMBRIDGE; BASH PA, 1991, BIOCHEMISTRY-US, V30, P5826, DOI 10.1021/bi00238a003; BLACKLOW SC, 1991, BIOCHEMISTRY-US, V30, P8470, DOI 10.1021/bi00098a026; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN FK, 1987, J MOL BIOL, V198, P533, DOI 10.1016/0022-2836(87)90298-1; BROWNE CA, 1976, J MOL BIOL, V100, P319, DOI 10.1016/S0022-2836(76)80066-6; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CORRAN PH, 1975, BIOCHEM J, V145, P335, DOI 10.1042/bj1450335; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; DAVENPORT RC, 1991, BIOCHEMISTRY-US, V30, P5821, DOI 10.1021/bi00238a002; DICE JF, 1973, J BIOL CHEM, V248, P4220; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GOLDBERG AL, 1974, ANNU REV BIOCHEM, V43, P835, DOI 10.1146/annurev.bi.43.070174.004155; GRACY RW, 1990, PROG CLIN BIOL RES, V344, P787; HARTMAN FC, 1971, BIOCHEMISTRY-US, V10, P146, DOI 10.1021/bi00777a021; HARTMAN FC, 1973, BIOCHEM BIOPH RES CO, V52, P388, DOI 10.1016/0006-291X(73)90723-7; JACOBSON T M, 1990, Protein Expression and Purification, V1, P9, DOI 10.1016/1046-5928(90)90038-Z; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES RB, 1979, BIOCHEM J, V179, P623, DOI 10.1042/bj1790623; KOVIMES EA, 1991, BIOCHEMISTRY-US, V30, P3011; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; LINDSAY CD, 1991, BIOCHEMISTRY-US, V30, P9034, DOI 10.1021/bi00101a018; LODI PJ, 1991, BIOCHEMISTRY-US, V30, P6948, DOI 10.1021/bi00242a020; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; LU HS, 1984, J BIOL CHEM, V259, P1958; MAIZEL JV, 1971, METHOD VIROL, V5, P180; MCLENDON G, 1978, J BIOL CHEM, V253, P6335; RAZ A, 1990, BIOCHEM J, V269, P603, DOI 10.1042/bj2690603; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; ROZACKY EE, 1971, ARCH BIOCHEM BIOPHYS, V146, P312, DOI 10.1016/S0003-9861(71)80069-3; SALO DC, 1990, J BIOL CHEM, V265, P11919; SCHNACKERZ KD, 1990, BIOCHEM BIOPH RES CO, V173, P736, DOI 10.1016/S0006-291X(05)80097-X; SCHNACKERZ KD, 1991, EUR J BIOCHEM, V199, P231, DOI 10.1111/j.1432-1033.1991.tb16114.x; SEGAL HL, 1974, J BIOL CHEM, V249, P267; SNAPKA RM, 1974, COMP BIOCHEM PHYSIOL, V49, P733, DOI 10.1016/0305-0491(74)90259-4; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STRAUS D, 1985, P NATL ACAD SCI USA, V82, P2014, DOI 10.1073/pnas.82.7.2014; SUN AW, 1992, ARCH BIOCHEM BIOPHYS, V293, P382, DOI 10.1016/0003-9861(92)90410-X; TOLLEFSBOL TO, 1982, MECH AGEING DEV, V20, P93, DOI 10.1016/0047-6374(82)90061-6; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WEST SM, 1990, BIOCHIM BIOPHYS ACTA, V1037, P332, DOI 10.1016/0167-4838(90)90034-D; WEST SM, 1990, BIOCHEM J, V265, P45, DOI 10.1042/bj2650045; WIERENGA RK, 1991, J MOL BIOL, V220, P995, DOI 10.1016/0022-2836(91)90368-G; WIERENGA RK, 1991, PROTEINS, V10, P33, DOI 10.1002/prot.340100105; YUAN PM, 1981, MECH AGEING DEV, V17, P151, DOI 10.1016/0047-6374(81)90081-6; YUKSEL KU, 1986, ARCH BIOCHEM BIOPHYS, V248, P452, DOI 10.1016/0003-9861(86)90498-4; YUKSEL KU, 1991, STUDY ENZYMES, V2, P457	54	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20168	20174						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400336				2022-12-27	WOS:A1992JR85800068
J	THOMAS, PJ; GARBOCZI, DN; PEDERSEN, PL				THOMAS, PJ; GARBOCZI, DN; PEDERSEN, PL			MUTATIONAL ANALYSIS OF THE CONSENSUS NUCLEOTIDE BINDING SEQUENCES IN THE RAT-LIVER MITOCHONDRIAL ATP SYNTHASE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; ADENOSINE-TRIPHOSPHATE SYNTHASE; ION MOTIVE ATPASES; ESCHERICHIA-COLI; ADENYLATE KINASE; OXIDATIVE-PHOSPHORYLATION; ADENINE-NUCLEOTIDES; CDNA CLONING; F1 MOIETY	The coupling step in the biosynthesis of ATP in biological systems is generally believed to involve an energy-requiring release of ATP bound to the beta-subunit of the ATP synthase complex. A molecular description of the ATP binding site on the beta-subunit is, therefore, critical to understanding the mechanism of coupling in the enzyme. Previously, we reported that a purified, bacterially expressed rat liver beta-subunit binds adenine nucleotides tightly and specifically (Garboczi, D. N., Hullihen, J. H., and Pedersen, P. L. (1988) J. Biol. Chem. 263, 15694-15698). In order to assess the contribution of various regions of the isolated beta-subunit to the ATP binding site we have systematically deleted four different regions: the N-terminal region, the Walker A consensus region, the Walker B consensus region (Walker, J. E., Saraste, M., Runswick, M. J., and Gay, N. (1982) EMBO J. 1, 945-951), and a "C" region, which, like the A and B regions, bears homology to adenylate kinase. Plasmids directing the expression of double deletions of A and B regions, and B and C regions were also constructed. In addition, 2 residues outside of these regions, His-177 and Tyr-345, which have been predicted to play a central role in nucleotide binding, were mutated. Rabbit antisera to synthetic peptides of the A and C regions verified the identity of the bacterially expressed mutant proteins. Seven of the eight mutant proteins overexpressed in Escherichia coli were resistant to E. coli proteases in the preparative stages, as predicted for compact folded proteins. Furthermore, circular dichroism spectropolarimetry revealed no profound structural alterations in the purified mutant proteins. Relative to the overexpressed full-length beta-subunit, the mutant lacking the A consensus region suffered a 30-fold loss of affinity for ATP and a loss of specificity for 2'(3')-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate (TNP-ATP) over 2'(3')-O-(2,4,6-trinitrophenyl)adenosine 5'-monophosphate. The mutant proteins lacking either the N-terminal region or the B region exhibited nucleotide binding properties similar to the full-length beta-subunit, whereas the mutant protein lacking the C region suffered an order of magnitude reduction in affinity for ATP. The affinity of the A and B region double deletion was indistinguishable from the A region deletion in regard to TNP-ATP binding, while the double deletion mutant lacking the B and C regions was not stably expressed in the E. coli SE6004. Mutant proteins bearing the single-site changes, His-177 --> Gln or Tyr-345 --> Cys, exhibited nearly identical binding properties to that of the full-length beta-subunit. This is the first study in which regions of the isolated beta-subunit of an ATP synthase complex have been systematically assessed by mutational analysis for their contribution to ATP binding. The results indicate that the A consensus sequence contributes over one-half of the total binding energy, with the C region making a significant contribution. The N-terminal region, the B region, Tyr-345, and His-177 appear to play little or no role in ATP binding.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, MOLEC & CELLULAR BIOENERGET LAB, BALTIMORE, MD 21205 USA	Johns Hopkins University			Thomas, Philip J/F-7115-2012		NCI NIH HHS [CA 10951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA010951, R37CA010951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS WW, 1984, J BIOL CHEM, V259, P4378; ARMSTRONG SK, 1990, J BIOL CHEM, V265, P14536; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOULAY F, 1985, BIOCHEMISTRY-US, V24, P7372, DOI 10.1021/bi00346a052; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DUBOSE RF, 1989, P NATL ACAD SCI USA, V86, P9966, DOI 10.1073/pnas.86.24.9966; ENGER U, 1987, J MOL BIOL, V195, P649; FRASCH WD, 1989, J BIOL CHEM, V264, P5064; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GARBOCZI DN, 1990, J BIOL CHEM, V265, P14632; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; GARBOCZI DN, 1988, J BIOL CHEM, V263, P15694; GARIN J, 1986, BIOCHEMISTRY-US, V25, P4431, DOI 10.1021/bi00363a039; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; Harlow E., 1988, ANTIBODIES LABORATOR, P633; HARRIS DA, 1985, BIOCHEMISTRY-US, V24, P3876, DOI 10.1021/bi00336a010; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V463, P245, DOI 10.1016/0304-4173(78)90002-2; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAGAWA Y, 1989, FEBS LETT, V249, P67, DOI 10.1016/0014-5793(89)80017-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JH, 1990, J BIOL CHEM, V265, P4664; LEWIS MJ, 1992, J BIOL CHEM, V267, P3482; LUNARDI J, 1987, J BIOL CHEM, V262, P15172; MILLS DA, 1991, J BIOL CHEM, V266, P7440; MITCHELL P, 1987, INTEGRATION CONTROL, P231; MUELLER DM, 1989, BIOCHEM BIOPH RES CO, V164, P381, DOI 10.1016/0006-291X(89)91730-0; OHTA S, 1988, J BIOL CHEM, V263, P11257; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PEDERSEN PL, 1987, BIOCHEMISTRY-US, V26, P8631, DOI 10.1021/bi00400a021; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; RAO R, 1988, J BIOL CHEM, V263, P5569; REIF AE, 1969, IMMUNOCHEMISTRY, V6, P723, DOI 10.1016/0019-2791(67)90136-X; ROSE T, 1991, J BIOL CHEM, V266, P10781; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WEBER J, 1992, J BIOL CHEM, V267, P1712; WILLIAMS N, 1987, BIOCHEMISTRY-US, V26, P162, DOI 10.1021/bi00375a023; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; WISE JG, 1990, J BIOL CHEM, V265, P10403; WYNN RM, 1992, J BIOL CHEM, V267, P1881; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; [No title captured]	67	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20331	20338						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400352				2022-12-27	WOS:A1992JR85800092
J	WANG, RW; NEWTON, DJ; HUSKEY, SEW; MCKEEVER, BM; PICKETT, CB; LU, AYH				WANG, RW; NEWTON, DJ; HUSKEY, SEW; MCKEEVER, BM; PICKETT, CB; LU, AYH			SITE-DIRECTED MUTAGENESIS OF GLUTATHIONE-S-TRANSFERASE YAYA - IMPORTANT ROLES OF TYROSINE-9 AND ASPARTIC ACID-101 IN CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; CLASS-PI; ESCHERICHIA-COLI; LIVER; RAT; PROTEINS; TETRACHLORO-1,4-BENZOQUINONE; INHIBITION; EXPRESSION; MECHANISM	The roles of tyrosine 9 and aspartic acid 101 in the catalytic mechanism of rat glutathione S-transferase YaYa were studied by site-directed mutagenesis. Replacement of tyrosine 9 with phenylalanine (Y9F), threonine (Y9T), histidine (Y9H), or valine (Y9V) resulted in mutant enzymes with less than 5% catalytic activity of the wild type enzymes. Kinetic studies with purified Y9F and Y9T mutants demonstrated poor catalytic efficiencies which were largely due to a drastic decrease in k(cat). The estimated pK(a) values of the sulfhydryl group of glutathione bound to Y9F and Y9T mutant enzymes were 8.5 to 8.7, similar to the chemical reaction, in contrast to the estimated pK(a) value of 6.7 to 6.8 for the glutathione enzyme complex of wild type glutathione S-transferase. These results indicate that tyrosine 9 is directly responsible for the lowering of the pK(a) of the sulfhydryl group of glutathione, presumably due to the stabilization of the thiolate anion through hydrogen bonding with the hydroxyl group of tyrosine. To examine the role of aspartic acid in the binding of glutathione to YaYa, 4 conserved aspartic acid residues at positions 61, 93, 101, and 157 were changed to glutamic acid and asparagine. All mutant enzymes retained either full or partial activity except D157N, which was virtually inactive. Kinetic studies with four mutant enzymes (D93E, D93N, D101E, and D101N) indicate that only D101N exhibited a 5-fold increase in K(m) toward glutathione. Also, the binding of this mutant to the affinity column was greatly reduced. These results demonstrate that aspartic acid 101 plays an important role in glutathione interaction to YaYa. The role of aspartic acid 157 in catalysis remains to be determined.	MERCK FROSST CTR THERAPEUT RES,POINTE CLAIRE H9R 4P8,QUEBEC,CANADA; MERCK SHARP & DOHME LTD,DEPT BIOPHYS CHEM,RAHWAY,NJ 07065	Merck & Company; Merck & Company	WANG, RW (corresponding author), MERCK SHARP & DOHME LTD,DEPT ANIM & EXPLORATORY DRUG METAB,RY80A12,POB 2000,RAHWAY,NJ 07065, USA.							ADANG AEP, 1991, BIOCHEM J, V278, P63, DOI 10.1042/bj2780063; ADANG AEP, 1988, BIOCHEM J, V255, P721; ADANG AEP, 1989, BIOCHEM J, V264, P759, DOI 10.1042/bj2640759; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; Asaoka K, 1989, J Enzyme Inhib, V3, P77, DOI 10.3109/14756368909030366; AWASTHI YC, 1987, BIOCHEM BIOPH RES CO, V143, P965, DOI 10.1016/0006-291X(87)90345-7; BENSON AM, 1977, P NATL ACAD SCI USA, V74, P158, DOI 10.1073/pnas.74.1.158; BENSON AM, 1976, BIOCHEM BIOPH RES CO, V69, P1073, DOI 10.1016/0006-291X(76)90482-4; BOYER TD, 1989, HEPATOLOGY, V9, P486, DOI 10.1002/hep.1840090324; CARNE T, 1979, BIOCHEM J, V177, P433, DOI 10.1042/bj1770433; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CHEN WJ, 1988, BIOCHEMISTRY-US, V27, P647, DOI 10.1021/bi00402a023; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; COLLIER GS, 1979, BIOCHEM J, V179, P281, DOI 10.1042/bj1790281; DELBOCCIO G, 1991, J BIOL CHEM, V266, P13777; DESIDERI A, 1991, J BIOL CHEM, V266, P2063; DIRR HW, 1991, EUR J BIOCHEM, V196, P693, DOI 10.1111/j.1432-1033.1991.tb15867.x; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYES JD, 1986, BIOCHEM J, V233, P779, DOI 10.1042/bj2330779; HSIEH JC, 1991, BIOCHEM J, V278, P293, DOI 10.1042/bj2780293; HUSKEY SEW, 1991, J AM CHEM SOC, V113, P2283, DOI 10.1021/ja00006a056; JAKOBY WB, 1984, BIOCHEM PHARMACOL, V33, P2539, DOI 10.1016/0006-2952(84)90621-X; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINEMEYER DL, 1987, BIO-TECHNOL, V5, P960, DOI 10.1038/nbt0987-960; LIU SX, 1992, J BIOL CHEM, V267, P4296; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1981, Methods Enzymol, V77, P231; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REDDY CC, 1981, BIOCHEM BIOPH RES CO, V101, P970; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SHEN HT, 1991, BIOCHEM BIOPH RES CO, V179, P790; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; STENBERG G, 1991, BIOCHEM J, V274, P549, DOI 10.1042/bj2740549; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANOMMEN B, 1988, J BIOL CHEM, V263, P12939; VANOMMEN B, 1989, EUR J BIOCHEM, V181, P423; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; WANG RW, 1992, ARCH BIOCHEM BIOPHYS, V297, P86, DOI 10.1016/0003-9861(92)90644-C; WANG RW, 1989, ARCH BIOCHEM BIOPHYS, V269, P536, DOI 10.1016/0003-9861(89)90137-9; WANG RW, 1991, ARCH BIOCHEM BIOPHYS, V286, P574, DOI 10.1016/0003-9861(91)90082-T; WIDERSTEN M, 1991, FEBS LETT, V293, P156, DOI 10.1016/0014-5793(91)81175-8; ZHANG PH, 1991, J BIOL CHEM, V266, P19475	50	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19866	19871						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400302				2022-12-27	WOS:A1992JR85800021
J	GUPTAROY, B; COHEN, CM				GUPTAROY, B; COHEN, CM			MATURATION OF MURINE ERYTHROLEUKEMIA-CELLS COMMITTED TO DIFFERENTIATION REQUIRES PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PHORBOL ESTER; HL-60 CELLS; ERYTHROID-DIFFERENTIATION; MONOCYTIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; MOLECULAR HETEROGENEITY; CELLULAR-REGULATION; ADDITIONAL MEMBERS; MEMBRANE-PROTEINS	Treatment of murine erythroleukemia cells (MELC) attached to fibronectin-coated dishes with dimethyl sulfoxide causes the cells to become committed to the erythroid differentiation pathway. These cells mature extensively and acquire the characteristics of erythroid cells. The cells lose their cell-surface fibronectin receptors and accumulate red cell-specific membrane proteins, such as band 3, in amounts comparable to those in erythrocytes. Previous studies of MELC have shown that the presence of protein kinase C (PKC) is required for commitment to differentiation, but that the level of PKC activity declines progressively during maturation. In this study, we have established a role for PKC in the maturation of MELC committed to differentiation. Our results show that down-regulation of PKC by addition of phorbol 12-myristate 13-acetate (PMA) to committed MELC blocks subsequent maturation of the cells. Treatment of MELC with the PKC inhibitors H7 and sphingosine had similar effects. Down-regulation of PKC was assayed by measuring cytosolic PKC activity as well as by Western blotting using PKC antibodies. MELC maturation was monitored by loss of the cell-surface fibronectin receptor, release of cells from fibronectin plates, and accumulation of the band 3 anion transport protein. Immunoprecipitation of surface-labeled proteins by an anti-fibronectin receptor (integrin) antibody showed that PMA-treated cultures had more fibronectin receptor protein than untreated cultures 6 days post-induction. As a result, cultures of committed MELC treated with PMA remained attached to fibronectin-coated plates, whereas non-PMA-treated cells were released into the culture medium. Furthermore, PKC-depleted cells accumulated much smaller amounts of band 3 protein and band 3 mRNA than did non-PKC-depleted controls. Our results show that although PKC activity declines progressively during post-commitment maturation of MELC, its continued presence is critical for the process of cellular maturation.	TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111	Tufts University; Tufts University	GUPTAROY, B (corresponding author), ST ELIZABETH HOSP,DEPT BIOMED RES,BOSTON,MA 02135, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024382] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 24382] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMO S, 1989, J CELL BIOL, V108, P153, DOI 10.1083/jcb.108.1.153; BALAZOVICH KJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P247, DOI 10.1016/0167-4889(87)90141-8; BERNARDI P, 1987, J CELL BIOL, V105, P489, DOI 10.1083/jcb.105.1.489; CHEN ZX, 1982, P NATL ACAD SCI-BIOL, V79, P471, DOI 10.1073/pnas.79.2.471; COHEN CM, 1986, J BIOL CHEM, V261, P7701; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DURHAM JP, 1985, FEBS LETT, V185, P157, DOI 10.1016/0014-5793(85)80761-4; FALETTO DL, 1985, CELL, V43, P315, DOI 10.1016/0092-8674(85)90037-6; FELIPO V, 1990, J BIOL CHEM, V265, P9599; FIBACH E, 1977, CANCER RES, V37, P440; GAZITT Y, 1978, CANCER RES, V38, P3779; GAZITT Y, 1978, EXP CELL RES, V117, P413, DOI 10.1016/0014-4827(78)90154-4; GODSON C, 1990, J BIOL CHEM, V265, P8369; GUSELLA J, 1976, CELL, V9, P211; HAGIWARA M, 1990, BIOCHEM BIOPH RES CO, V168, P161, DOI 10.1016/0006-291X(90)91688-O; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HENSOLD JO, 1991, BLOOD, V77, P1362; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOMMA Y, 1988, CANCER RES, V48, P2744; HUANG FL, 1987, J BIOL CHEM, V262, P15714; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUBBARD BD, 1979, J CELL BIOL, V80, P166, DOI 10.1083/jcb.80.1.166; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KIKKAWA U, 1988, COLD SPRING HARB SYM, V53, P97, DOI 10.1101/SQB.1988.053.01.015; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KIRSCH IR, 1985, LEUKEMIA RECENT ADV, P91; KONNO Y, 1989, J BIOCHEM-TOKYO, V106, P673, DOI 10.1093/oxfordjournals.jbchem.a122915; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNERT ME, 1988, J CELL BIOL, V107, P413, DOI 10.1083/jcb.107.2.413; LING E, 1988, J BIOL CHEM, V263, P2209; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYMAN GH, 1976, BIOCHIM BIOPHYS ACTA, V448, P460, DOI 10.1016/0005-2736(76)90300-X; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARKS PA, 1987, CANCER RES, V47, P659; MARKS PA, 1990, TUMOR SUPPRESSOR GEN, P201; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; MINANA MD, 1989, FEBS LETT, V255, P184, DOI 10.1016/0014-5793(89)81087-7; MULER CP, 1980, CELL BIOPHYS, V2, P233; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; PALFREY HC, 1985, J BIOL CHEM, V260, P6021; PATEL VP, 1987, J CELL BIOL, V105, P3105, DOI 10.1083/jcb.105.6.3105; PATEL VP, 1986, J CELL BIOL, V102, P449, DOI 10.1083/jcb.102.2.449; PATEL VP, 1985, P NATL ACAD SCI USA, V82, P440, DOI 10.1073/pnas.82.2.440; PATEL VP, 1984, SCIENCE, V224, P996, DOI 10.1126/science.6585955; PELOSIN JM, 1990, BIOCHEM BIOPH RES CO, V169, P1040, DOI 10.1016/0006-291X(90)91999-9; PFEFFER SR, 1981, BIOCHIM BIOPHYS ACTA, V641, P254, DOI 10.1016/0005-2736(81)90589-7; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RAVAL PJ, 1985, BIOCHEM J, V232, P43, DOI 10.1042/bj2320043; RIFKIND RA, 1987, BLOOD CELLS, V13, P277; ROGUE P, 1990, J BIOL CHEM, V265, P4161; RUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862; Sambrook J, 1989, MOL CLONING LABORATO; SEFTON BM, 1973, J VIROL, V11, P730, DOI 10.1128/JVI.11.5.730-735.1973; SELDEN RF, 1990, CURRENT PROTOCOLS MO; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; STONE RM, 1988, BLOOD, V72, P739; STONE RM, 1988, BLOOD, V72, P208; STRULOVICI B, 1989, BIOCHEMISTRY-US, V28, P3569, DOI 10.1021/bi00434a063; TODOKORO K, 1986, BIOCHEM BIOPH RES CO, V135, P1112, DOI 10.1016/0006-291X(86)91043-0; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TSIFTSOGLOU AS, 1985, INT J CELL CLONING, V3, P349, DOI 10.1002/stem.5530030602; VOLLOCH V, 1982, J CELL BIOL, V93, P390, DOI 10.1083/jcb.93.2.390; ZYLBERKATZ E, 1985, CANCER RES, V45, P5159	70	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15326	15333						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386358				2022-12-27	WOS:A1992JG11300014
J	HIRATSUKA, T				HIRATSUKA, T			SPATIAL PROXIMITY OF ATP-SENSITIVE TRYPTOPHANYL RESIDUE(S) AND CYS-697 IN MYOSIN ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SKELETAL-MUSCLE MYOSIN; GLYCINE-RICH LOOP; ADENOSINE-TRIPHOSPHATASE; HEAVY-CHAIN; CROSS-LINKING; SUBFRAGMENT-1; FRAGMENT; PEPTIDE; TRANSMISSION	The reactive thiol Cys-697 (SH2) in myosin ATPase was labeled with a fluorescent analog of maleimide, 2-(4'-maleimidylanilino)naphthalene-6-sulfonic acid (MIANS) (Hiratsuka, T. (1992) J. Biol. Chem. 267, 14941-14948). Although the tryptophan fluorescence of myosin subfragment-1 (S-1) was slightly affected by incorporation of the MIANS fluorophore, the tryptophan fluorescence of the resultant S-1 derivative (MIANS-S-1) was enhanced by ATP in a manner similar to that of unlabeled S-1. The quenching of tryptophan fluorescence of MIANS-S-1 was shown to result from a transfer of the excitation energy from tryptophanyl residue(s) to the MIANS fluorophore attached to SH2, which absorbed and fluoresced maximally at 325 and 418 nm, respectively. The energy transfer measurements were performed in the presence of acrylamide and compared to those performed in the absence of the quencher. The energy transfer efficiencies were found to be unaltered by acrylamide, indicating that the observed fluorescence energy transfer is originated exclusively from the tryptophanyl residue(s) that are not affected by acrylamide, i.e. the ATP-sensitive tryptophanyl residue(s) of S-1 (Torgerson, P. M. (1984) Biochemistry 23,3002-3007). The distance between the tryptophanyl residue(s) and Cys-697 was calculated to be 27 angstrom assuming a single donor-acceptor pair. Trp-510 is proposed to be one of the ATP-sensitive tryptophanyl residues.			HIRATSUKA, T (corresponding author), ASAHIKAWA MED COLL,DEPT CHEM,ASAHIKAWA,HOKKAIDO 078,JAPAN.							BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BALINT M, 1978, ARCH BIOCHEM BIOPHYS, V190, P793, DOI 10.1016/0003-9861(78)90339-9; BOTTS J, 1989, P NATL ACAD SCI USA, V86, P2204, DOI 10.1073/pnas.86.7.2204; CHANCE B, 1957, ARCH BIOCHEM BIOPHYS, V71, P130, DOI 10.1016/0003-9861(57)90015-2; CHAUSSEPIED P, 1988, BIOCHEMISTRY-US, V27, P1778, DOI 10.1021/bi00405a059; CREMO CR, 1989, J BIOL CHEM, V264, P6608; ELZINGA M, 1977, P NATL ACAD SCI USA, V74, P4281, DOI 10.1073/pnas.74.10.4281; Fairclough R H, 1978, Methods Enzymol, V48, P347; Forster T., 1966, MODERN QUANTUM CHEM, P93; HIRATSUKA T, 1986, BIOCHEMISTRY-US, V25, P2101, DOI 10.1021/bi00356a039; HIRATSUKA T, 1987, BIOCHEMISTRY-US, V26, P3168, DOI 10.1021/bi00385a034; HIRATSUKA T, 1988, BIOCHEMISTRY-US, V27, P4110, DOI 10.1021/bi00411a030; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18791; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14941; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; MORITA F, 1967, J BIOL CHEM, V242, P4501; OKAMOTO Y, 1985, P NATL ACAD SCI USA, V82, P1575, DOI 10.1073/pnas.82.6.1575; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; REISLER E, 1982, METHOD ENZYMOL, V85, P84; SEKINE T, 1964, BIOCHIM BIOPHYS ACTA, V81, P336, DOI 10.1016/0926-6569(64)90049-5; SUTOH K, 1988, BIOCHEMISTRY-US, V27, P2964, DOI 10.1021/bi00408a045; SUZUKI R, 1987, J BIOL CHEM, V262, P11410; TANII I, 1985, J BIOCHEM, V98, P1201, DOI 10.1093/oxfordjournals.jbchem.a135386; TONG SW, 1990, J BIOL CHEM, V265, P4893; TORGERSON PM, 1984, BIOCHEMISTRY-US, V23, P3002, DOI 10.1021/bi00308a024; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UE K, 1987, BIOCHEMISTRY-US, V26, P1889, DOI 10.1021/bi00381a016; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WERBER MM, 1987, BIOCHEMISTRY-US, V26, P2903, DOI 10.1021/bi00384a035; WERBER MM, 1972, BIOCHEMISTRY-US, V11, P2872, DOI 10.1021/bi00765a021; YAMAGUCHI M, 1966, J BIOCHEM, V59, P24, DOI 10.1093/oxfordjournals.jbchem.a128254; YAMASHITA T, 1974, J BIOCHEM, V75, P447, DOI 10.1093/oxfordjournals.jbchem.a130413	35	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14949	14954						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386083				2022-12-27	WOS:A1992JF08800068
J	SCHLEMMER, SR; SIROTNAK, FM				SCHLEMMER, SR; SIROTNAK, FM			ENERGY-DEPENDENT EFFLUX OF METHOTREXATE IN L1210 LEUKEMIA-CELLS - EVIDENCE FOR THE ROLE OF AN ATPASE OBTAINED WITH INSIDE-OUT PLASMA-MEMBRANE VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE ANALOG TRANSPORT; TUMOR-CELLS; MULTIDRUG-RESISTANCE; GENETIC-VARIANTS; IDENTIFICATION; INHIBITION; PROTEINS; SYSTEMS; INVITRO; INFLUX	Earlier studies from our laboratory (Dembo, M., Sirotnak F. M., and Moccio, D. M. (1984) J. Membr. Biol. 78, 9-17) suggested that methotrexate (MTX) efflux from L1210 cells was mediated predominantly by an ATP-dependent, outwardly directed, mechanism. To examine this process further, we utilized predominately (74%) inside-out plasma membrane vesicle preparations derived from an L1210 cell variant (L1210/R24) with 15-fold reduced V(max) for [H-3]MTX influx. Efflux of [H-3]MTX, under nonionic buffer conditions, in these inside-out membrane vesicles was temperature and ATP dependent (apparent K(m) = 0.40 +/- 0.06 mM), osmotically sensitive, and unaffected by protonophores. The presence of K+, Na+, Cl-, and HCO3- at their physiological concentrations had no effect on [H-3] MTX efflux. Other triphosphonucleotides (GTP and CTP), but not a nonhydrolyzable analogue, adenosine-5'-O-(3-thiotriphosphate) (ATP-gamma-S), could also stimulate efflux, but to a lesser extent. Also, ATP-gamma-S and orthovanadate were potent inhibitors of ATP-dependent efflux of [H-3]MTX. Other experiments revealed a system with low saturability for [H-3]MTX during efflux (apparent K(m) = 46 +/- 7-mu-M), but extremely high capacity (106 +/- 15 pmol/min/mg protein), and a pH optimum in the range of 5.5-6. However, appreciable efflux was measured in the physiological range of pH 6.7-6.9. A number of inhibitors or copermeants for ATP-dependent [H-3]MTX efflux in intact L1210 cells were inhibitors of ATP-dependent efflux in inside-out plasma membrane vesicles, including, cholate, bromosulfophthalein, verapamil, quinidine, and reserpine. These findings and other results showing that bromosulfophthalein will completely inhibit efflux are consistent with a role for an ATPase in [H-3]MTX efflux, and suggest that the process under study is the bromosulfophthalein-sensitive, ATP-dependent route responsible for the majority of [H-3]MTX efflux in intact L1210 cells.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC PHARMACOL & THERAPEUT,MOLEC THERAPEUT LAB,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,ITHACA,NY 14853	Memorial Sloan Kettering Cancer Center; Cornell University					NATIONAL CANCER INSTITUTE [R01CA046673, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46673, CA 08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BIEDLER JL, 1983, CANCER TREAT REP, V67, P859; BRANDENBERGER H, 1953, HELV CHIM ACTA, V36, P900, DOI 10.1002/hlca.19530360422; CHELLO PL, 1980, MOL PHARMACOL, V18, P274; DEMBO M, 1984, J MEMBRANE BIOL, V78, P9, DOI 10.1007/BF01872527; DEMBO M, 1976, BIOCHIM BIOPHYS ACTA, V448, P505, DOI 10.1016/0005-2736(76)90303-5; DEPIERRE JW, 1973, J CELL BIOL, V56, P275, DOI 10.1083/jcb.56.2.275; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; GREEN DE, 1955, J BIOL CHEM, V217, P551; HAKALA MT, 1965, BIOCHIM BIOPHYS ACTA, V102, P210, DOI 10.1016/0926-6585(65)90214-1; HENDERSON GB, 1988, CANCER RES, V48, P5995; HENDERSON GB, 1990, BIOCHIM BIOPHYS ACTA, V1051, P60, DOI 10.1016/0167-4889(90)90174-C; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; HENDERSON GB, 1987, J BIOL CHEM, V262, P571; HISSIN PJ, 1978, BIOCHIM BIOPHYS ACTA, V508, P401, DOI 10.1016/0005-2736(78)90342-5; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P693; KREBS EG, 1955, METHOD ENZYMOL, V1, P407, DOI 10.1016/0076-6879(55)01066-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARIN R, 1986, BIOCHIM BIOPHYS ACTA, V858, P195, DOI 10.1016/0005-2736(86)90306-8; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; NEWKIRK JD, 1971, BIOCHIM BIOPHYS ACTA, V225, P224, DOI 10.1016/0005-2736(71)90215-X; ROBINSON JD, 1979, BIOCHIM BIOPHYS ACTA, V549, P145, DOI 10.1016/0304-4173(79)90013-2; SAMUELS LL, 1985, CANCER RES, V45, P1488; SIMONS TJB, 1979, NATURE, V281, P337, DOI 10.1038/281337a0; SIROTNAK FM, 1985, CANCER RES, V45, P4732; SIROTNAK FM, 1981, CANCER RES, V41, P966; SIROTNAK FM, 1974, CANCER RES, V34, P371; SIROTNAK FM, 1991, CANCER RES, V51, P1412; SIROTNAK FM, 1980, PHARMACOL THERAPEUT, V8, P71, DOI 10.1016/0163-7258(80)90060-1; SIROTNAK FM, 1984, J BIOL CHEM, V259, P3139; SIROTNAK FM, 1986, J BIOL CHEM, V261, P1150; SIROTNAK FM, 1987, BIOCHEM PHARMACOL, V36, P1659, DOI 10.1016/0006-2952(87)90051-7; YANG CH, 1983, J MEMBRANE BIOL, V75, P11, DOI 10.1007/BF01870795; YANG CH, 1982, J MEMBRANE BIOL, V68, P19, DOI 10.1007/BF01872250; YANG CH, 1988, J BIOL CHEM, V263, P9703	42	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14746	14752						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386081				2022-12-27	WOS:A1992JF08800039
J	ALVAREZ, J; MONTERO, M; GARCIASANCHO, J				ALVAREZ, J; MONTERO, M; GARCIASANCHO, J			HIGH-AFFINITY INHIBITION OF CA2+-DEPENDENT K+ CHANNELS BY CYTOCHROME-P-450 INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RED-CELL; INSIDE-OUT VESICLES; ASCITES TUMOR-CELLS; CA-2+-ACTIVATED K+; INTRACELLULAR CALCIUM; ERYTHROCYTE-MEMBRANE; POTASSIUM CHANNELS; ANTIFUNGAL AGENTS; ELECTRON-DONORS; TRANSPORT	The Ca2+-dependent K+ channel of human red cells was inhibited with high affinity by several imidazole antimycotics which are potent inhibitors of cytochrome P-450. IC50 values were (in mu-M): clotrimazole, 0.05; tioconazole, 0.3; miconazole, 1.5; econazole, 1.8. Inhibition of the channel was also found with other drugs with known cytochrome P-450 inhibitory effect. However, no inhibition was obtained with carbon monoxide (CO). This suggests that, given the high selectivity of the above inhibitors for the heme moiety, a different but closely related to cytochrome P-450 kind of hemoprotein may be involved in the regulation of the red cell Ca2+-dependent K+ channel. Clotrimazole also inhibited two other charybdotoxin-sensitive Ca2+-dependent K+ channels, those of rat thymocytes (IC50 = 0.1-0.2-mu-M) and of Ehrlich ascites tumor cells (IC50 = 0.5-mu-M). Imidazole antimycotics inhibit also receptor-operated Ca2+ channels (Montero, M., Alvarez, J. and Garcia-Sancho, J. (1991) Biochem. J. 277, 73-79). This suggests that both Ca2+ and Ca2+-dependent K+ channels might have a similar regulatory mechanism involving a cytochrome.	UNIV VALLADOLID, FAC MED, DEPT BIOQUIM & BIOL MOLEC & FISIOL, E-47005 VALLADOLID, SPAIN	Universidad de Valladolid			Alvarez, Javier/K-8210-2014; Montero, Mayte/K-8212-2014; Garcia-Sancho, Javier/K-2975-2014	Alvarez, Javier/0000-0003-0636-5521; Montero, Mayte/0000-0001-7702-6653; Garcia-Sancho, Javier/0000-0003-4573-7930				ABIA A, 1986, BIOCHIM BIOPHYS ACTA, V856, P403, DOI 10.1016/0005-2736(86)90054-4; ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; ALVAREZ J, 1986, BIOCHIM BIOPHYS ACTA, V856, P408, DOI 10.1016/0005-2736(86)90055-6; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ALVAREZ J, 1984, BIOCHIM BIOPHYS ACTA, V771, P23, DOI 10.1016/0005-2736(84)90105-6; ALVAREZ J, 1986, BIOCHIM BIOPHYS ACTA, V860, P25, DOI 10.1016/0005-2736(86)90494-3; ALVAREZ J, 1985, J PHYSIOL-LONDON, V369, pP113; ALVAREZ J, 1989, RED CELL MEMBRANE, P201; ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; ARTALEJO AR, 1988, BIOCHIM BIOPHYS ACTA, V941, P48, DOI 10.1016/0005-2736(88)90212-X; AYUB M, 1988, J STEROID BIOCHEM, V31, P65, DOI 10.1016/0022-4731(88)90207-5; BALLARD SA, 1988, BIOCHEM PHARMACOL, V37, P4643, DOI 10.1016/0006-2952(88)90333-4; BARAN DT, 1973, BIOCHIM BIOPHYS ACTA, V307, P627, DOI 10.1016/0005-2736(73)90307-6; BLISARD KS, 1979, J BIOL CHEM, V254, P5104; BRUDER G, 1980, BIOCHIM BIOPHYS ACTA, V600, P739, DOI 10.1016/0005-2736(80)90477-0; BRUDER G, 1978, EXP CELL RES, V117, P207, DOI 10.1016/0014-4827(78)90443-3; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COSSUM PA, 1988, BIOPHARM DRUG DISPOS, V9, P321, DOI 10.1002/bod.2510090402; GALLIN EK, 1988, BIOPHYS J, V53, pA548; GARCIASANCHO J, 1979, BIOCHIM BIOPHYS ACTA, V556, P118, DOI 10.1016/0005-2736(79)90424-3; GARCIASANCHO J, 1989, METHOD ENZYMOL, V173, P368; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V508, P236, DOI 10.1016/0005-2736(78)90327-9; GRINSTEIN S, 1983, J CELL PHYSIOL, V116, P352, DOI 10.1002/jcp.1041160313; GRYGORCZYK R, 1983, CELL CALCIUM, V4, P499, DOI 10.1016/0143-4160(83)90025-8; HERMANN A, 1987, J GEN PHYSIOL, V90, P27, DOI 10.1085/jgp.90.1.27; HOFFMANN EK, 1985, FED PROC, V44, P2513; HOFFMANN EK, 1986, J MEMBRANE BIOL, V91, P227, DOI 10.1007/BF01868816; HULTQUIST DE, 1971, BIOCHIM BIOPHYS ACTA, V229, P33, DOI 10.1016/0005-2795(71)90314-X; INUI Y, 1966, J GEN PHYSIOL, V50, P203, DOI 10.1085/jgp.50.1.203; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LEVINSON C, 1990, BIOCHIM BIOPHYS ACTA, V1021, P1, DOI 10.1016/0005-2736(90)90375-X; LEW VL, 1976, NATURE, V263, P336, DOI 10.1038/263336a0; LEW VL, 1985, CELL CALCIUM, V6, P15, DOI 10.1016/0143-4160(85)90031-4; LEW VL, 1989, METHOD ENZYMOL, V173, P100; LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613; MAHAUT-SMITH M P, 1989, Pfluegers Archiv European Journal of Physiology, V414, pS164, DOI 10.1007/BF00582284; MAHAUTSMITH MP, 1989, J PHYSIOL-LONDON, V415, P69, DOI 10.1113/jphysiol.1989.sp017712; MASON JI, 1985, BIOCHEM PHARMACOL, V34, P1087, DOI 10.1016/0006-2952(85)90613-6; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MINER C, 1983, BIOCHIM BIOPHYS ACTA, V727, P266, DOI 10.1016/0005-2736(83)90412-1; MOCZYDLOWSKI E, 1988, J MEMBRANE BIOL, V105, P95, DOI 10.1007/BF02009164; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MURRAY M, 1990, PHARMACOL REV, V42, P85; OMURA T, 1964, J BIOL CHEM, V239, P2379; PAPANDREOU P, 1989, CLIN CHIM ACTA, V181, P189, DOI 10.1016/0009-8981(89)90187-3; REICHSTEIN E, 1981, J MEMBRANE BIOL, V59, P57, DOI 10.1007/BF01870821; RODRIGUES AD, 1987, BIOCHEM PHARMACOL, V36, P4277, DOI 10.1016/0006-2952(87)90670-8; ROGERSON TD, 1977, BIOCHEM PHARMACOL, V26, P1039, DOI 10.1016/0006-2952(77)90241-6; SANCHEZ A, 1986, REV ESP FISIOL, V42, P459; SHEETS JJ, 1986, BIOCHEM PHARMACOL, V35, P487, DOI 10.1016/0006-2952(86)90224-8; SIMONS TJB, 1976, J PHYSIOL-LONDON, V288, P481; STARKE DW, 1984, MOL PHARMACOL, V25, P467; Steck T L, 1974, Methods Enzymol, V31, P172; SZE H, 1979, BIOCHIM BIOPHYS ACTA, V554, P180, DOI 10.1016/0005-2736(79)90017-8; VALDEOLMILLOS M, 1982, BIOCHIM BIOPHYS ACTA, V685, P273, DOI 10.1016/0005-2736(82)90067-0; VANDENBOSSCHE H, 1983, BIOCHEM SOC T, V11, P665, DOI 10.1042/bst0110665; WOLFF D, 1988, J MEMBRANE BIOL, V106, P243, DOI 10.1007/BF01872162; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0; YUBISUI T, 1988, BIOCHIM BIOPHYS ACTA, V936, P447, DOI 10.1016/0005-2728(88)90022-9; ZAMUDIO I, 1966, BIOCHIM BIOPHYS ACTA, V120, P165, DOI 10.1016/0926-6585(66)90290-1	61	251	257	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11789	11793						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376313				2022-12-27	WOS:A1992HY94700025
J	HORRIGAN, SK; RICH, CB; STREETEN, BW; LI, ZY; FOSTER, JA				HORRIGAN, SK; RICH, CB; STREETEN, BW; LI, ZY; FOSTER, JA			CHARACTERIZATION OF AN ASSOCIATED MICROFIBRIL PROTEIN THROUGH RECOMBINANT-DNA TECHNIQUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN SYNTHESIS; GLYCOPROTEIN; CELLS; AORTA; ACID; TRANSLATION; SEQUENCES; TISSUES; CULTURE; CLONING	The complete primary structure of a new extracellular protein associated with elastic fiber microfibrils was determined by recombinant DNA techniques. Antiserum to insoluble bovine ocular zonule protein was used to screen a lambda-gt11 cDNA expression library constructed from whole chick embryo poly(A)+ RNA. The cDNAs encoding immunoreactive fusion polypeptides were then used to rescreen the library by plaque hybridization. Nucleotide sequencing of overlapping cDNA clones revealed an open translation reading frame of 1326 bases beginning at an initiation start sequence and ending at a stop codon. The contiguous cDNA sequence contains a 3'-untranslated region of 563 bases with a possible polyadenylation site 16 bases upstream from the poly(A) tail. Primer extension of chick aortic mRNA taken together with the sequence data, reveals a 5'-untranslated region of 95 bases extending upstream from the translation start site. Northern blot analyses indicated that the isolated cDNA hybridized with a 2.1-kilobase mRNA in preparations, of whole chick embryo and chick embryonic aortic, heart, and muscle RNAs. The initial translation protein encoded by the cDNA is 53,932 kDa and possesses a hydrophilic amino acid composition with glutamic acid comprising 22% of the total amino acid residues. Antiserum was elicited to a synthetic peptide sequence (14 amino acids) encoded within the deduced protein primary structure. Western blots of extracted proteins from chick embryonic aortae cultured in the presence of beta-aminopropionitrile showed that the medium and a mild salt extract contained an immunoreactive protein possessing an apparent molecular mass of 58,000 whereas harsh denaturants extracted a 32,000-kDa protein. Pulse-chase experiments using radiolabeled lysine showed that the newly synthesized 58,000-kDa protein was chased into a 32,000-kDa protein within a 2-24-h period. Immunoelectron microscopy of tissue sections from chick aortae, bovine nuchal ligament, and human ocular zonules showed that the peptide-elicited antibody localized specifically to ultrastructurally definable microfibril structures.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, 80 E CONCORD ST, BOSTON, MA 02118 USA; SYRACUSE UNIV, DEPT BIOL, SYRACUSE, NY 13244 USA; SUNY HLTH SCI CTR, DEPT OPHTHALMOL, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PATHOL, SYRACUSE, NY 13210 USA	Boston University; Syracuse University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NEI NIH HHS [EY01602] Funding Source: Medline; NHLBI NIH HHS [HL30061, HL46100] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY001602] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046100, R01HL030061] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAULE VJ, 1988, BIOCHEM BIOPH RES CO, V154, P1054, DOI 10.1016/0006-291X(88)90247-1; BRESSAN GM, 1983, J BIOL CHEM, V258, P3262; CAMPAGNONE R, 1987, LAB INVEST, V56, P224; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; COLOMBATTI A, 1988, J BIOL CHEM, V263, P17534; COLOMBATTI A, 1985, J CELL BIOL, V100, P18, DOI 10.1083/jcb.100.1.18; COLOMBATTI A, 1987, COLLAGEN REL RES, V7, P259; FAHRENBACH WH, 1966, ANAT RECORD, V155, P563, DOI 10.1002/ar.1091550409; FOSTER JA, 1988, LAB INVEST, V58, P667; FOSTER JA, 1980, BIOCHEMISTRY-US, V19, P857, DOI 10.1021/bi00546a005; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; GIBSON MA, 1983, CELL BIOL, V65, P345; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HORRIGAN SK, 1990, THESIS SYRACUSE U; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JUNG A, 1980, P NATL ACAD SCI-BIOL, V77, P5759, DOI 10.1073/pnas.77.10.5759; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KOBAYASHI R, 1989, J BIOL CHEM, V264, P17437; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KUCICH U, 1988, J CELL BIOL, V107, P3415; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LOW FN, 1961, ANAT RECORD, V139, P105, DOI 10.1002/ar.1091390203; Maniatis T., 1982, MOL CLONING; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; PARTRIDGE SM, 1962, ADV PROTEIN CHEM, V17, P227; POLLOCK J, 1990, J BIOL CHEM, V265, P3697; RICHMOND VL, 1981, BIOCHIM BIOPHYS ACTA, V669, P193, DOI 10.1016/0005-2795(81)90240-3; ROSS R, 1973, J HISTOCHEM CYTOCHEM, V21, P199, DOI 10.1177/21.3.199; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SERAFINIFRACASSINI A, 1981, BIOCHEMISTRY-US, V20, P5424, DOI 10.1021/bi00522a011; STREETEN BW, 1988, CURR EYE RES, V7, P139, DOI 10.3109/02713688808995743; STREETEN BW, 1983, INVEST OPHTH VIS SCI, V24, P119; STREETEN BW, 1981, INVEST OPHTH VIS SCI, V21, P130; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	40	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10087	10095						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374398				2022-12-27	WOS:A1992HT96500096
J	BUSIEK, DF; ROSS, FP; MCDONNELL, S; MURPHY, G; MATRISIAN, LM; WELGUS, HG				BUSIEK, DF; ROSS, FP; MCDONNELL, S; MURPHY, G; MATRISIAN, LM; WELGUS, HG			THE MATRIX METALLOPROTEASE MATRILYSIN (PUMP) IS EXPRESSED IN DEVELOPING HUMAN MONONUCLEAR PHAGOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; HUMAN ALVEOLAR MACROPHAGES; SUBSTRATE-SPECIFICITY; TISSUE INHIBITOR; CYSTEINE SWITCH; GENE FAMILY; STROMELYSIN; PURIFICATION; ACTIVATION; HOMOLOGY	Matrilysin (PUMP, MMP-7) is a member of the metalloprotease gene family, whose constituents are responsible for the remodeling of extracellular matrix. The matrilysin protein is a 28-kDa zymogen possessing catalytic activities against a broad range of extracellular matrix substrates including proteoglycans, gelatin, fibronectin, laminin, and elastin. To gain insights into the biological expression of matrilysin in human cell types, we generated a monospecific, polyclonal antibody against a 16-amino acid sequence derived from its catalytic domain, a region which lacked significant homology with other matrix metalloenzymes. We found this antibody capable of precipitating a 28-kDa protein from the conditioned media of human bone marrow-derived promonocytes and human peripheral blood monocytes cultivated in vitro. Promonocyte matrilysin was rapidly converted to a 19-kDa form by organomercurial activation. While matrilysin was constitutively synthesized by bone marrow-derived promonocytes, its secretion was markedly up-regulated by the mononuclear phagocyte activator, lipopolysaccharide. Furthermore, despite its expression in monocyte precursors, blood monocytes, and monocyte-derived macrophages, matrilysin was not synthesized by human alveolar macrophages under any tested condition. In situ hybridization studies with matrilysin cRNA confirmed the presence of specific mRNA in both human promonocytes and monocytes. Moreover, a marked increase in hybridizable mRNA was observed with lipopolysaccharide treatment suggesting that matrilysin synthesis is pretranslationally regulated. In summary, this represents the first report documenting constitutive and regulated synthesis of matrilysin by a normal human cell type and suggests that matrilysin is expressed as a significant secreted product of mononuclear phagocytes at an intermediate stage of cellular differentiation.	WASHINGTON UNIV,JEWISH HOSP,MED CTR,DEPT MED,DIV DERMATOL,216 S KINGSHIGHWAY,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP,MED CTR,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP,MED CTR,DEPT PATHOL,ST LOUIS,MO 63110; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232; STRANGEWAYS RES LAB,DEPT CELL & MOLEC BIOL,CAMBRIDGE CB1 4RN,ENGLAND	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Vanderbilt University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087, R01AR035805] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29594] Funding Source: Medline; NIAMS NIH HHS [AR-32087, AR-35805] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		BAINTON DF, 1978, J CLIN INVEST, V68, P1555; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; CAMPBELL EJ, 1987, J BIOL CHEM, V262, P15862; CARACCIOLO D, 1987, J EXP MED, V166, P1851, DOI 10.1084/jem.166.6.1851; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CURY JD, 1988, J IMMUNOL, V141, P4306; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; SANDERSON RJ, 1977, J IMMUNOL, V118, P1409; Senior R. M., 1981, METHODS STUDYING MON, P69; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WEBB EC, 1992, IN PRESS RECOMMENDAT; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918	34	108	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9087	9092						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374384				2022-12-27	WOS:A1992HR85400060
J	BENHAMOU, M; STEPHAN, V; ROBBINS, KC; SIRAGANIAN, RP				BENHAMOU, M; STEPHAN, V; ROBBINS, KC; SIRAGANIAN, RP			HIGH-AFFINITY IGE RECEPTOR-MEDIATED STIMULATION OF RAT BASOPHILIC LEUKEMIA (RBL-2H3) CELLS INDUCES EARLY AND LATE PROTEIN-TYROSINE PHOSPHORYLATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTAMINE-RELEASE; MAST-CELLS; KINASE-C; SECRETION; ACTIVATION; EXOCYTOSIS; MEMBRANE; P60C-SRC; SIGNALS	We reported previously that stimulation of RBL-2H3 cells through the high-affinity IgE receptor resulted in tyrosine phosphorylation of a 72-kDa protein (pp72) that was coupled to signal transduction. In the present study, although pp72 tyrosine phosphorylation was induced only by antigen triggering, stimulation of RBL-2H3 cells by either antigen or the calcium-ionophore A23187 led to increased tyrosine phosphorylation of a 110-kDa protein (pp110). This tyrosine phosphorylated protein was also observed when RBL-2H3 cells were transfected with the G protein-coupled m3 muscarinic receptor and then stimulated to secrete with carbachol. In contrast to tyrosine phosphorylation of pp72, antigen-induced pp110 tyrosine phosphorylation required extracellular calcium, was absent in cells depleted of protein kinase C, and was detected between 1 and 5 min after stimulation. The protein-tyrosine kinase inhibitor genistein blocked both histamine release and tyrosine phosphorylation induced by A23187. Altogether, the data suggest a role for pp110 in secretion. However, protein kinase C activation induced pp110 tyrosine phosphorylation but not histamine release demonstrating that pp110 tyrosine phosphorylation alone is not sufficient for degranulation. We conclude that tyrosine phosphorylation of pp72 is associated with the early steps of IgE receptor-generated signaling, whereas pp110 tyrosine phosphorylation occurs secondary to calcium influx and protein kinase C activation.	NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	BENHAMOU, M (corresponding author), NIDR,IMMUNOL LAB,BLDG 10,RM IA31,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Benhamou, Marc/0000-0001-7763-3795				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BORDIER C, 1979, J BIOL CHEM, V254, P2565; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; OLIVER JM, 1988, PROG ALLERGY, V42, P184; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; RENDU F, 1989, BLOOD, V73, P1545; SIEGHART W, 1978, NATURE, V275, P329, DOI 10.1038/275329a0; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; THEOHARIDES TC, 1980, SCIENCE, V207, P80, DOI 10.1126/science.6153130	20	103	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7310	7314						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373133				2022-12-27	WOS:A1992HN48500020
J	HURST, RS; KAVANAUGH, MP; YAKEL, J; ADELMAN, JP; NORTH, RA				HURST, RS; KAVANAUGH, MP; YAKEL, J; ADELMAN, JP; NORTH, RA			COOPERATIVE INTERACTIONS AMONG SUBUNITS OF A VOLTAGE-DEPENDENT POTASSIUM CHANNEL - EVIDENCE FROM EXPRESSION OF CONCATENATED CDNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ION CHANNELS; AMINO-ACID-RESIDUES; SHAKER K+-CHANNELS; XENOPUS OOCYTES; MUTATIONS; S4-SEQUENCE	Four copies of the coding sequence for a voltage-dependent potassium channel (RBK1, rat Kv1.1) were ligated contiguously and transcribed in vitro. The resulting RNA encodes four covalently linked subunit domains ([4]RBK1). Injection of this RNA into Xenopus oocytes resulted in the expression of voltage-dependent potassium currents. A single amino acid substitution, Tyr --> Val, located within the outer mouth of the pore, introduced into the equivalent position of any of the four domains, reduced affinity for external tetraethylammonium by approximately the same amount. In constructs containing 0, 1, 2, 3, or 4 Tyr residues the free energy of binding tetraethylammonium was linearly related to the number of Tyr residues. A different amino acid substitution, Leu --> Ile, located in the S4 region, was made in the equivalent position of one, two, three, or four domains. The depolarization required for channel activation increased approximately linearly with the number of Ile residues, whereas models of independent gating of each domain predict marked nonlinearity. Expression of this concatenated channel provides direct evidence that voltage-dependent potassium channels have four subunits positioned symmetrically around a central permeation pathway and that these subunits interact cooperatively during channel activation.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University			North, Richard/GQA-6156-2022	Yakel, Jerrel/0000-0001-5463-674X	NIDA NIH HHS [DA03160] Funding Source: Medline; NINDS NIH HHS [NS28504] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003160, R37DA003160] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; BECKH S, 1990, EMBO J, V9, P777, DOI 10.1002/j.1460-2075.1990.tb08173.x; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANDY KG, 1991, NATURE, V352, P26, DOI 10.1038/352026b0; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DREWE JA, 1992, J NEUROSCI, V12, P538; DURELL SR, 1992, BIOPHYS J, V62, P243; GIUDICIORTICONI MT, 1990, EUR J BIOCHEM, V194, P483, DOI 10.1111/j.1432-1033.1990.tb15642.x; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HURST RS, 1991, MOL PHARMACOL, V40, P572; ISAACOFF EY, 1990, NATURE, V345, P530; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5	26	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23742	23745						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385425				2022-12-27	WOS:A1992JZ23900049
J	MA, WJ; HOLZ, RW; UHLER, MD				MA, WJ; HOLZ, RW; UHLER, MD			EXPRESSION OF A CDNA FOR A NEURONAL CALCIUM-CHANNEL ALPHA-1 SUBUNIT ENHANCES SECRETION FROM ADRENAL CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; HUMAN GROWTH-HORMONE; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; GENE-EXPRESSION; CA2+ CHANNELS; IDENTIFICATION; EXOCYTOSIS; ACTIVATION; RECEPTOR	A synthetic oligonucleotide was used to isolate mouse brain cDNA clones coding for a brain isoform of the alpha1 subunit of the voltage-sensitive Ca2+ channel. Twenty-six independent cDNA clones were isolated and sequenced. All the cDNA clones reported here showed high homology to the rat brain class C cDNA sequence (Snutch, T. P., Tomlinson, W. J., Leonard, J. P., and Gilbert, M. M. (1991) Neuron 7, 45-57). Comparison of the individual mouse brain class C (mbC) cDNA sequences indicated the presence of four regions within the alpha1 subunit coding sequence where alternative splicing can take place in mouse brain and raise the possibility that combinatorial arrangement of these splice variants could give rise to a heterogenous class of mbC transcripts. Northern blot analysis demonstrated that mbC mRNA sequences could be detected in highest abundance in mouse heart, at lower levels in mouse brain and spinal cord, and not at all in liver or skeletal muscle. An expression vector for one isoform of the mbC alpha1 subunit cDNA was constructed using the human cytomegalovirus promoter to direct expression, and this expression vector was used in a novel transfection assay of primary cultures of bovine adrenal chromaffin cells. Transfection of the mbC alpha1 subunit expression vector increased the secretion of human growth hormone derived from a cotransfected human growth hormone expression vector after stimulation with elevated K+ or the dihydropyridine agonist, Bay K8644. These experiments suggest that this isoform of the mbC alpha1 subunit is functional in the transfected chromaffin cells and that the number of Ca2+ channels is a limiting component in the secretion from chromaffin cells in culture.	UNIV MICHIGAN, MENTAL HLTH RES INST, 205 ZINA PITCHER PL, ANN ARBOR, MI 48109 USA; CHINESE ACAD SCI, SHANGHAI INST MATERIA MED, SHANGHAI, PEOPLES R CHINA; UNIV MICHIGAN, DEPT PHARMACOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atlas D, 1990, Curr Top Cell Regul, V31, P129; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DAY RN, 1990, MOL ENDOCRINOL, V4, P736, DOI 10.1210/mend-4-5-736; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEBOLD RJ, 1992, P NATL ACAD SCI USA, V89, P1497, DOI 10.1073/pnas.89.4.1497; HOLZ RW, 1982, J NEUROCHEM, V39, P635, DOI 10.1111/j.1471-4159.1982.tb07940.x; HOLZ RW, 1991, ANN NY ACAD SCI, V635, P382, DOI 10.1111/j.1749-6632.1991.tb36506.x; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; ROSS ME, 1990, J NEUROSCI, V10, P520; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WAYMIRE JC, 1983, J NEUROSCI METH, V7, P329, DOI 10.1016/0165-0270(83)90026-2	32	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22728	22732						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385406				2022-12-27	WOS:A1992JY16300008
J	BJORKHEM, I; BUCHMANN, M; BYSTROM, S				BJORKHEM, I; BUCHMANN, M; BYSTROM, S			MECHANISM AND STEREOCHEMISTRY IN THE SEQUENTIAL ENZYMATIC SATURATION OF THE 2 DOUBLE-BONDS IN CHOLESTA-4,6-DIEN-3-ONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYCHOLIC-ACID; CHOLIC-ACID; RAT-LIVER; 7-ALPHA-DEHYDROXYLATION	The mechanism and stereochemistry in connection with enzymatic conversion of cholesta-4,6-dien-3-one into cholestanol was studied. Rat and mouse liver microsomes are able to catalyze NADPH-dependent sequential saturation of the two double bonds. Evidence was obtained that the saturation of the DELTA6-double bond includes transfer of a hydride ion from the B-side of the cofactor to the 7-position of the steroid (mainly 7beta-position), followed by addition of a proton to the 6alpha-position (mainly trans addition). The saturation of the DELTA4-double bond includes transfer of a hydride ion from the B-side of the cofactor to the 5alpha-position of the steroid followed by addition of a proton to the 4beta-position (trans addition). The reduction of the 3-oxo group was found to involve transfer of a hydride ion from the B-side of the cofactor NADPH to the 3alpha-position of the steroid. The results are in accord with the contention that the enzymatic saturation of the two double bonds involves a polarization of the 3-oxo group making C-7 electrophilic and C-6 nucleophilic in connection with the saturation of the DELTA6-double bond and C-5 electrophilic and C-4 nucleophilic in connection with the saturation of the DELTA4-double bond.	UNIV OSLO,RIKSHOSP,DEPT CLIN BIOCHEM,N-0027 OSLO,NORWAY; ROYAL INST TECHNOL,DEPT ORGAN CHEM,S-10044 STOCKHOLM 70,SWEDEN	University of Oslo; National Hospital Norway; Royal Institute of Technology	BJORKHEM, I (corresponding author), HUDDINGE HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN.			Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190				ARINGER L, 1971, STEROIDS, V18, P381, DOI 10.1016/0039-128X(71)90052-3; BERGSTROM S, 1958, J AM CHEM SOC, V80, P2337, DOI 10.1021/ja01542a081; BJORKHEM I, 1969, EUR J BIOCHEM, V8, P345, DOI 10.1111/j.1432-1033.1969.tb00534.x; BJORKHEM I, 1973, EUR J BIOCHEM, V33, P364, DOI 10.1111/j.1432-1033.1973.tb02691.x; BJORKHEM I, 1969, EUR J BIOCHEM, V7, P413, DOI 10.1111/j.1432-1033.1969.tb19625.x; BJORKHEM I, 1989, J LIPID RES, V30, P1033; BJORKHEM I, 1988, J LIPID RES, V29, P136; BJORKHEM I, 1970, EUR J BIOCHEM, V12, P80, DOI 10.1111/j.1432-1033.1970.tb00823.x; BJORKHEM I, 1971, EUR J BIOCHEM, V20, P340, DOI 10.1111/j.1432-1033.1971.tb01399.x; BJORKHEM I, 1971, EUR J BIOCHEM, V18, P299; BJORKHEM I, 1967, EUR J BIOCHEM, V2, P503; BJORKHEM I, 1989, METABOLIC BASIS INHE, P1283; Bothner-By A.A., 1965, ADV MAGNETIC OPTICAL, VVolume 1, P195; BUCHMANN MS, 1987, BIOCHIM BIOPHYS ACTA, V922, P111, DOI 10.1016/0005-2760(87)90144-5; DANIELSSON H, 1960, ACTA CHEM SCAND, V14, P846, DOI 10.3891/acta.chem.scand.14-0846; HYLEMON PB, 1991, J LIPID RES, V32, P89; KANDUTCH AAJ, 1963, LIPID RES, V4, P179; MAKITA M., 1963, ANALYT BIOCHEM, V5, P523, DOI 10.1016/0003-2697(63)90072-1; SAMUELSSON B, 1960, J BIOL CHEM, V235, P361; SKREDE S, 1988, J LIPID RES, V29, P157; WILTON DC, 1966, BIOCHEM J, V98, P29	21	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19872	19875						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400303				2022-12-27	WOS:A1992JR85800022
J	FENG, Y; FORGAC, M				FENG, Y; FORGAC, M			A NOVEL MECHANISM FOR REGULATION OF VACUOLAR ACIDIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; VESICLE PROTON PUMP; H+-ATPASE; SUBUNIT; SITE; PHOSPHORYLATION; NA+,K+-ATPASE; GLUTATHIONE; HOMOLOGY; KINASE	We have recently demonstrated that Cys-254 of the 73-kDa A subunit of the clathrin-coated vesicle (H+)-ATPase is responsible for sensitivity of the enzyme to sulfhydryl reagents (Feng, Y., and Forgac, M. (1992) J. Biol. Chem. 267, 5817-5822). In the present study we observe that for the purified enzyme, disulfide bond formation causes inactivation of proton transport which is reversed by dithiothreitol (DTT). DTT also restores activity of the oxidized enzyme following treatment with N-ethylmaleimide (NEM). These results indicate that disulfide bond formation between the NEM-reactive cysteine (Cys-254) and a closely proximal cysteine residue leads to inactivation of the (H+)-ATPase. To test whether sulfhydryl-disulfide bond interchange may play a role in regulating vacuolar acidification in vivo, we have determined what fraction of the (H+)-ATPase is disulfide-bonded in native clathrin-coated vesicles. Vesicles were isolated under conditions that prevent any change in the oxidation state of the sulfhydryl groups. NEM treatment of vesicles causes nearly complete loss of activity while subsequent treatment with DTT restores 50% of the activity of the fully reduced vesicles. By contrast, treatment of fully reduced vesicles with NEM leads to inactivation which is not reversed by DTT. These results indicate that a significant fraction of the clathrin-coated vesicle (H+)-ATPase exists in an inactive, disulfide-bonded state and suggest that sulfhydryl-disulfide bond interconversion may play a role in controlling vacuolar (H+)-ATPase (V-ATPase) activity in vivo.	TUFTS UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02111 USA	Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK 34928] Funding Source: Medline; NIGMS NIH HHS [R01 GM034478, GM 34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P960; ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; FENG Y, 1992, J BIOL CHEM, V267, P5817; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; HIRATA R, 1990, J BIOL CHEM, V265, P6726; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; LAW MY, 1983, BIOCHEM J, V210, P899, DOI 10.1042/bj2100899; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; McCarty RE, 1988, LIGHT ENERGY TRANSDU, P290; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; NESS GC, 1985, J BIOL CHEM, V260, P2391; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; YSERN X, 1988, J BIOENERG BIOMEMBR, V20, P423, DOI 10.1007/BF00762202; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZHANG K, 1992, J BIOL CHEM, V267, P9701; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	33	79	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19769	19772						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400289				2022-12-27	WOS:A1992JR85800005
J	FUJIWARA, K; OKAMURAIKEDA, K; MOTOKAWA, Y				FUJIWARA, K; OKAMURAIKEDA, K; MOTOKAWA, Y			EXPRESSION OF MATURE BOVINE H-PROTEIN OF THE GLYCINE CLEAVAGE SYSTEM IN ESCHERICHIA-COLI AND INVITRO LIPOYLATION OF THE APOFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE MULTIENZYME COMPLEXES; LIPOYLLYSINE RESIDUE; T-PROTEIN; ACID; MECHANISM; MUTAGENESIS; SEQUENCE; DOMAINS	H-protein, a component of the glycine cleavage system with lipoic acid as a prosthetic group, was expressed in Escherichia coli using a T7 RNA polymerase plasmid expression system. After induction with 25 muM isopropyl-beta-D-thiogalactopyranoside, bacteria harboring the recombinant plasmid expressed mature bovine H-protein as a soluble form at a level of about 10% of the total bacterial protein. Little of the H-protein was lipoylated in E. coli cultured without added lipoate, but when the cells were cultured in medium supplemented with 30 muM lipoate, about 10% of the recombinant protein expressed was the correctly lipoylated active form, 10% was an inactive aberrantly modified form, presumably with an octanoyl group, and the remaining 80% was the unlipoylated apoform. Each of the three forms was purified to homogeneity and shown to have the same NH2-terminal amino acid sequence as that of native bovine H-protein. The specific activity of the lipoylated form of H-protein expressed was consistent with that of H-protein purified from bovine liver. The purified recombinant apo-H-protein was lipoylated and consequently activated in vitro with lipoyl-AMP as a lipoyl donor by lipoyltransferase purified 150-fold from bovine liver mitochondria. The lipoylation was dependent on lipoyl-AMP, apo-H-protein, and lipoyltransferase. The partially purified lipoyltransferase had no lipoate-activating activity. These results provide the first evidence that in mammals two consecutive reactions are required for the attachment of lipoic acid to the acceptor protein: the activation of lipoic acid to lipoyl-AMP catalyzed by lipoate-activating enzyme and the transfer of the lipoyl group to an N(epsilon)-amino group of a lysine residue to apoprotein by lipoyl-AMP:N(epsilon)-lysine lipoyltransferase.	UNIV TOKUSHIMA,INST ENVIRONM RES,KURAMOTOCHO 3 CHOME,TOKUSHIMA 770,JAPAN	Tokushima University								ALI ST, 1990, MOL MICROBIOL, V4, P943, DOI 10.1111/j.1365-2958.1990.tb00667.x; BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; DARDEL F, 1990, FEBS LETT, V264, P206, DOI 10.1016/0014-5793(90)80249-I; FUJIWARA K, 1991, FEBS LETT, V293, P115, DOI 10.1016/0014-5793(91)81164-4; FUJIWARA K, 1983, J BIOL CHEM, V258, P8156; FUJIWARA K, 1986, J BIOL CHEM, V261, P8836; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; FUJIWARA K, 1984, J BIOL CHEM, V259, P664; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; HIRAGA K, 1980, J BIOL CHEM, V255, P1671; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OKAMURAIKEDA K, 1987, J BIOL CHEM, V262, P6746; PACKMAN LC, 1991, BIOCHEM J, V277, P153, DOI 10.1042/bj2770153; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1958, J BIOL CHEM, V232, P123; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSUNODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395, DOI 10.1016/0003-9861(67)90366-9; WHITE RH, 1980, BIOCHEMISTRY-US, V19, P15, DOI 10.1021/bi00542a003	22	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20011	20016						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400316				2022-12-27	WOS:A1992JR85800043
J	QUEHENBERGER, O; PROSSNITZ, ER; COCHRANE, CG; YE, RD				QUEHENBERGER, O; PROSSNITZ, ER; COCHRANE, CG; YE, RD			ABSENCE OF GI-PROTEINS IN THE SF9 INSECT CELL - CHARACTERIZATION OF THE UNCOUPLED RECOMBINANT N-FORMYL PEPTIDE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTUSSIS TOXIN SUBSTRATE; BETA-ADRENERGIC-RECEPTOR; POLYMORPHONUCLEAR LEUKOCYTES; CHEMOATTRACTANT RECEPTOR; SIGNAL TRANSDUCTION; GUANINE-NUCLEOTIDES; HUMAN-GRANULOCYTES; NEUTROPHIL; MEMBRANES; LIGAND	We investigated the interaction of the N-formyl peptide receptor (NFPR) with G proteins in infected Sf9 insect cells expressing the recombinant NFPR. Recombinant receptor expression of up to 27 pmol/mg protein was achieved in these cells. The receptor was recognized by an antiserum raised against an NFPR carboxyl-terminal peptide, and displayed specific and saturable binding of the formyl peptide ligand fMet-Leu[H-3]Phe. Scatchard analysis of the binding data yielded a dissociation constant of approximately 62 nM, a binding affinity of 60- to 120-fold lower than that of the high affinity sites in neutrophils and in transfected mammalian cell lines expressing the NFPR. That this low binding affinity was due to a lack of receptor coupling to G protein was suggested by the failure of guanine nucleotides to regulate receptor affinity and by the lack of formyl peptide-stimulated GTPase activity in these cells. Furthermore, immunoblotting with an anti-G(i) antibody and ADP-ribosylation experiments indicated that the approximately 40-kDa G(ialpha) subunit, which couples to the NFPR in neutrophils, is not present in Sf9 cell membranes. Thus, the current study provides for the first time evidence that a major G protein is absent in the Sf9 insect cells. Potential applications of the Sf9 system for in vitro reconstitution of the NFPR-G protein interaction are discussed.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Ye, Richard/ABF-2413-2020; Prossnitz, Eric R./B-4543-2008; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Prossnitz, Eric/0000-0001-9190-8302	NIGMS NIH HHS [GM46572] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046572] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RA, 1986, BIOCHIM BIOPHYS ACTA, V882, P271, DOI 10.1016/0304-4165(86)90248-5; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; Cochrane CG, 1990, CELLULAR MOL MECHANI, P83; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DOLMATCH B, 1983, J BIOL CHEM, V258, P7570; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; KOO C, 1982, BIOCHEM BIOPH RES CO, V106, P442, DOI 10.1016/0006-291X(82)91130-5; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; MALECH HL, 1985, J BIOL CHEM, V260, P2509; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; PARKER EM, 1991, J BIOL CHEM, V266, P519; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PARKOS CA, 1985, J BIOL CHEM, V260, P6541; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; SKLAR LA, 1987, J BIOL CHEM, V262, P135; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TOLLEY JO, 1987, J LEUKOCYTE BIOL, V42, P43, DOI 10.1002/jlb.42.1.43; WILDE MW, 1989, J BIOL CHEM, V264, P190; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y	25	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19757	19760						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400288				2022-12-27	WOS:A1992JR85800002
J	STRITTMATTER, P; KITTLER, JM; COGHILL, JE				STRITTMATTER, P; KITTLER, JM; COGHILL, JE			CHARACTERIZATION OF THE ROLE OF LYSINE 110 OF NADH-CYTOCHROME-B5 REDUCTASE IN THE BINDING AND OXIDATION OF NADH BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; CYTOCHROME B5 REDUCTASE; GLUTATHIONE-REDUCTASE; ACTIVE-SITES; ACID; SEQUENCE; PARTICIPATION; DESATURATION; INVOLVEMENT; RESIDUES	An expression vector for bovine NADH-cytochrome b5 reductase was used for site-directed mutagenesis of lysine 110, the residue previously implicated in NADH interactions with this flavoprotein. Replacement of this basic residue with an uncharged glutamine resulted in an increase of 3 orders of magnitude in the K(m) for NADH and a decrease in k(cat) of an order of magnitude, strongly implicating lysine 110 in both binding of NADH to the reductase and the orientation of the reduced nicotinamide group for rapid hydride ion transfer to the flavin. Substitution of lysine 110 by histidine, to provide a pH-sensitive positive charge at this position in the neutral pH range, exhibited only a moderate 25-fold increase in K(m) and a normal k(cat) at pH 6.0, whereas at pH 8.5 the K(m) for NADH rose to 238 muM with a decrease of 45% over unmodified enzyme in the k(cat). A similar pH sensitivity in the inhibition constant for adenosine diphosphate ribose, lacking only the nicotinamide moiety of NADH, emphasizes the crucial role of the positive charge at this locus and is consistent with charge-pairing of lysine 110 with the pyrophosphate group of NADH or adenosine diphosphate ribose.			STRITTMATTER, P (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015924] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15924] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; DAILEY HA, 1979, J BIOL CHEM, V254, P5388; HACKETT CS, 1984, J BIOL CHEM, V259, P3275; HACKETT CS, 1988, J BIOL CHEM, V263, P7539; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KEYES SR, 1979, J BIOL CHEM, V254, P7778; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVERDE A, 1968, J BIOL CHEM, V243, P5779; MIKI K, 1987, J BIOL CHEM, V262, P11801; OKAYASU T, 1977, LIPIDS, V12, P267, DOI 10.1007/BF02533345; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; ROGERS MJ, 1975, J BIOL CHEM, V250, P5713; ROGERS MJ, 1973, J BIOL CHEM, V248, P800; SHIRABE K, 1991, J BIOL CHEM, V266, P7531; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; SPATZ L, 1973, J BIOL CHEM, V248, P793; STRITTMATTER P, 1956, J BIOL CHEM, V221, P277; STRITTMATTER P, 1958, J BIOL CHEM, V233, P748; STRITTMATTER P, 1959, J BIOL CHEM, V234, P2665; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; STRITTMATTER P, 1992, J BIOL CHEM, V267, P2519; STRITTMATTER P, 1990, J BIOL CHEM, V265, P21709; YUBISUI T, 1991, J BIOL CHEM, V266, P66	30	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20164	20167						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400335				2022-12-27	WOS:A1992JR85800067
J	TEMPLIN, MF; EDWARDS, DH; HOLTJE, JV				TEMPLIN, MF; EDWARDS, DH; HOLTJE, JV			A MUREIN HYDROLASE IS THE SPECIFIC TARGET OF BULGECIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE LYTIC TRANSGLYCOSYLASE; BETA-LACTAM ANTIBIOTICS; PERFORMANCE LIQUID-CHROMATOGRAPHY; PENICILLIN-BINDING-PROTEINS; GRAM-NEGATIVE BACTERIA; SLT GENE; CLONING; OVEREXPRESSION; ELONGATION; ATTACHMENT	A deletion in the structural gene for the soluble lytic transglycosylase, the predominant murein hydrolase in the soluble fraction of Escherichia coli, has been constructed. The mutant grows normally but exhibits increased sensitivity toward mecillinam, a beta-lactam specific for penicillin-binding protein 2. In the presence of furazlocillin or other beta-lactams with a specificity for penicillin-binding protein 3 which normally cause filamentation, bulges were formed prior to rapid bacteriolysis. Similar morphological alterations are known to develop in wild type E. coli cells when furazlocillin is combined with bulgecin, an antibiotic of unusual glucosaminyl structure. It turned out that bulgecin specifically inhibits the Sl-transglycosylase in a noncompetitive manner. Since bulgecin shows some structural analogy to the murein subunits we postulate that the soluble lytic transglycosylase, in addition to its active site, has a recognition site for specific murein structures. The possibility of an allosteric modulation of the activity of the enzyme by changes in the structure of the murein sacculus is discussed.	UNIV EDINBURGH,DEPT MOLEC BIOL,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND	University of Edinburgh	HOLTJE, JV (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,BIOCHEM ABT,SPEMANNSTR 35,W-7400 TUBINGEN,GERMANY.							BETZNER AS, 1990, FEMS MICROBIOL LETT, V67, P161, DOI 10.1016/0378-1097(90)90187-U; BETZNER AS, 1989, MOL GEN GENET, V219, P489, DOI 10.1007/BF00259625; BOTTA GA, 1981, J BACTERIOL, V145, P333, DOI 10.1128/JB.145.1.333-340.1981; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; ENGEL H, 1991, J BACTERIOL, V173, P6773, DOI 10.1128/jb.173.21.6773-6782.1991; GIUDICELLI S, 1984, J BACTERIOL, V158, P1188, DOI 10.1128/JB.158.3.1188-1190.1984; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HARZ H, 1990, ANAL BIOCHEM, V190, P120, DOI 10.1016/0003-2697(90)90144-X; HOLTJE JV, 1991, J GEN MICROBIOL, V137, P441, DOI 10.1099/00221287-137-3-441; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; HOLTJE JV, 1976, J BIOL CHEM, V251, P4199; HOLTJE JV, 1985, MOL CYTOLOGY ESCHERI, P77; IMADA A, 1982, J ANTIBIOT, V35, P1400, DOI 10.7164/antibiotics.35.1400; IZAKI K, 1966, P NATL ACAD SCI USA, V55, P656, DOI 10.1073/pnas.55.3.656; KOCH AL, 1990, RES MICROBIOL, V141, P529, DOI 10.1016/0923-2508(90)90017-K; KOCH AL, 1990, FEMS MICROBIOL REV, V88, P15; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; METT H, 1980, J BACTERIOL, V144, P45, DOI 10.1128/JB.144.1.45-52.1980; Miller J.H., 1972, EXPT MOL GENETICS; NAKAO M, 1986, ANTIMICROB AGENTS CH, V30, P414, DOI 10.1128/AAC.30.3.414; ROEDER W, 1979, MOL GEN GENET, V176, P361, DOI 10.1007/BF00333098; Rogers H.J., 1980, MICROBIAL CELL WALK, P190; ROGERS HJ, 1971, J BACTERIOL, V108, P1235, DOI 10.1128/JB.108.3.1235-1243.1971; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZ U, 1969, J MOL BIOL, V41, P419, DOI 10.1016/0022-2836(69)90285-X; SHIMADA K, 1972, J MOL BIOL, V63, P483, DOI 10.1016/0022-2836(72)90443-3; SHINAGAWA S, 1985, J ANTIBIOT, V38, P17, DOI 10.7164/antibiotics.38.17; SHOCKMAN GD, 1965, BACTERIOL REV, V29, P345, DOI 10.1128/MMBR.29.3.345-358.1965; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; TOMASZ A, 1979, ANNU REV MICROBIOL, V33, P113, DOI 10.1146/annurev.mi.33.100179.000553; Tomasz A., 1983, TARGET PENICILLIN, P155; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALDERICH B, 1991, J BACTERIOL, V173, P5668, DOI 10.1128/jb.173.18.5668-5676.1991; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; WEIDEL W, 1964, ADV ENZYMOL REL S BI, V26, P193; WILSON K, 1990, CURRENT PROTOCOLS MO; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	41	94	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20039	20043						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400320				2022-12-27	WOS:A1992JR85800048
J	KRIEG, J; HUNTER, T				KRIEG, J; HUNTER, T			IDENTIFICATION OF THE 2 MAJOR EPIDERMAL GROWTH FACTOR-INDUCED TYROSINE PHOSPHORYLATION SITES IN THE MICROVILLAR CORE PROTEIN EZRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; A-431 CELLS; KINASE-ACTIVITY; FACTOR RECEPTOR; EGF RECEPTOR; PHOSPHATIDYLINOSITOL KINASE; TRANSFORMING PROTEIN; FIBRONECTIN RECEPTOR; SIGNAL TRANSDUCTION; T-ANTIGEN	In response to epidermal growth factor (EGF) the microvillar core protein ezrin is phosphorylated transiently to a high level on tyrosine residues in human epidermoid carcinoma A431 cells. Here we report the identification of the tyrosine phosphorylation sites in ezrin using bacterially expressed protein as a substrate for in vitro phosphorylation with the EGF receptor. The two major phosphotyrosine-containing peptides observed in vivo were also phosphorylated in vitro. By secondary digestions and site-directed mutagenesis tyrosines 145 and 353 were identified as the sites of phosphorylation. One of the sites, Tyr145, lies in the N-terminal region of homology that is common to the band 4.1-talin-ezrin protein family. This tyrosine residue and its vicinal amino acids are conserved throughout the family members, including radixin, moesin, and the two phosphotyrosine phosphatases, PTP H1 and PTP MEG, but not in band 4.1 or talin. Tyr353 is localized within the alpha-helical domain of ezrin and comparison of the protein sequences reveals that this site is unique to ezrin.	SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA	Salk Institute					NATIONAL CANCER INSTITUTE [R35CA039780] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BIRGBAUER E, 1989, J CELL BIOL, V109, P1609, DOI 10.1083/jcb.109.4.1609; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CARPENTIER JL, 1986, EXP CELL RES, V166, P312, DOI 10.1016/0014-4827(86)90479-9; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; COOPER JA, 1983, J VIROL, V48, P752, DOI 10.1128/JVI.48.3.752-764.1983; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1981, J CELL BIOL, V91, P878, DOI 10.1083/jcb.91.3.878; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; CORREAS I, 1986, J BIOL CHEM, V261, P3310; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; FAVA RA, 1984, J BIOL CHEM, V259, P2636; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; HUNTER T, 1986, ENZYMES, V17, P191; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LETO TL, 1986, MEMBRANE SKELETONS C, P201; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTINPEREZ J, 1989, J CELL BIOL, V109, P577, DOI 10.1083/jcb.109.2.577; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MINXIANG G, 1991, P NATL ACAD SCI USA, V88, P5867; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PAKKANEN R, 1987, J HISTOCHEM CYTOCHEM, V35, P809, DOI 10.1177/35.8.3298422; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; RADKE K, 1979, P NATL ACAD SCI USA, V76, P5212, DOI 10.1073/pnas.76.10.5212; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	60	172	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19258	19265						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382070				2022-12-27	WOS:A1992JP59300039
J	CHINKERS, M; WILSON, EM				CHINKERS, M; WILSON, EM			LIGAND-INDEPENDENT OLIGOMERIZATION OF NATRIURETIC PEPTIDE RECEPTORS - IDENTIFICATION OF HETEROMERIC RECEPTORS AND A DOMINANT NEGATIVE MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICULATE GUANYLATE-CYCLASE; ADRENAL ZONA GLOMERULOSA; EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; EXTRACELLULAR DOMAIN; POLYACRYLAMIDE GELS; CATALYTIC ACTIVITY; ACTIVITY REQUIRES; ENZYME SUBUNITS; ATRIAL	Activation of many single-transmembrane receptors requires ligand-induced receptor oligomerization. We have examined the oligomerization of the atrial natriuretic peptide receptor, NPR-A, using epitope-tagged receptor in a co-immunoprecipitation assay. Unlike other single-transmembrane receptors, NPR-A oligomerized in a ligand-independent fashion. Extracellular receptor sequences were both necessary and sufficient for oligomer formation. NPR-A was also able to oligomerize with the related natriuretic peptide receptor, NPR-B. A truncated NPR-A lacking most of the cytoplasmic domain blocked activation of the full-length receptor, presumably through formation of an inactive heteromer. These results indicate that oligomerization of this single-transmembrane receptor is important for the transduction of a conformational change across the plasma membrane but are not consistent with models in which natriuretic peptide receptor oligomerization serves merely to bring intracellular domains together.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University	CHINKERS, M (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047063] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47063] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GILL GN, 1987, MOL CELL ENDOCRINOL, V51, P169, DOI 10.1016/0303-7207(87)90027-X; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; HAYFLICK JS, 1992, J NEUROSCI, V12, P705; HRUBY DE, 1979, J VIROL, V29, P705, DOI 10.1128/JVI.29.2.705-715.1979; ISHIDO M, 1986, BIOCHEM BIOPH RES CO, V140, P101, DOI 10.1016/0006-291X(86)91063-6; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; KOJIMA M, 1990, FEBS LETT, V276, P209, DOI 10.1016/0014-5793(90)80544-S; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITMAN DC, 1988, J BIOL CHEM, V263, P3720; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MANNIX ET, 1991, J APPL PHYSIOL, V71, P1340, DOI 10.1152/jappl.1991.71.4.1340; MELOCHE S, 1986, MOL PHARMACOL, V30, P537; MELOCHE S, 1987, J BIOL CHEM, V262, P10252; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MINAMINO N, 1991, BIOCHEM BIOPH RES CO, V179, P535, DOI 10.1016/0006-291X(91)91404-Z; MUKOYAMA M, 1991, BIOCHEM BIOPH RES CO, V180, P431, DOI 10.1016/S0006-291X(05)81311-7; NAKANE M, 1990, J BIOL CHEM, V265, P16841; OGAWA Y, 1991, CIRC RES, V69, P491, DOI 10.1161/01.RES.69.2.491; PORTER JG, 1989, J BIOL CHEM, V264, P14179; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; RADANY EW, 1983, J BIOL CHEM, V258, P8346; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ S, 1991, TRENDS PHARMACOL SCI, V12, P116, DOI 10.1016/0165-6147(91)90519-X; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; TANG WJ, 1991, J BIOL CHEM, V266, P8595; THORPE DS, 1991, BIOCHEM BIOPH RES CO, V180, P538, DOI 10.1016/S0006-291X(05)81098-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA S, 1991, BIOCHEM BIOPH RES CO, V175, P759, DOI 10.1016/0006-291X(91)91631-L; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILCOX JN, 1991, MOL CELL BIOL, V11, P3454, DOI 10.1128/MCB.11.7.3454	57	121	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18589	18597						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382057				2022-12-27	WOS:A1992JN50200054
J	HOCHHAUSER, D; STANWAY, CA; HARRIS, AL; HICKSON, ID				HOCHHAUSER, D; STANWAY, CA; HARRIS, AL; HICKSON, ID			CLONING AND CHARACTERIZATION OF THE 5'-FLANKING REGION OF THE HUMAN TOPOISOMERASE-II-ALPHA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAKAGE-REUNION REACTION; THYMIDINE KINASE GENE; HUMAN-LEUKEMIA CELLS; DNA TOPOISOMERASES; EXPRESSION; RECOMBINATION; SEGREGATION; CHROMOSOMES; CEREVISIAE; SEQUENCE	Topoisomerases are essential enzymes for DNA metabolism in prokaryotes and eukaryotes. In human cells, DNA topoisomerase II enzyme activity can be modulated by both viral transformation and changes in proliferation status. To identify elements important for regulation of topoisomerase II-alpha gene expression, genomic DNA clones covering the 5'-end of the gene were isolated. The intron/exon structure of a 2.5-kilobase region encompassing the translation start site was determined. Transcription was found to initiate at multiple sites clustered around 90 base pairs 5' to the ATG initiation codon. Transient expression of chimeric topoisomerase II-reporter gene constructs in HeLa cells revealed that the 5'-flanking region exhibited promoter activity. The region -90 to -1 upstream of the major transcription start site was shown by deletion analysis to include a promoter. This minimal promoter lacks a TATA box, is moderately GC-rich, and contains a high frequency of CpG dinucleotides; characteristic of a "housekeeping" gene promoter. Maximal promoter activity was observed using a fragment extending to position -562. Putative regulatory elements are contained within and immediately upstream of the minimal promoter region. The regulatory region of the topoisomerase II-alpha gene identified here is similar in basic structure to those of the human thymidine kinase and DNA polymerase alpha-genes, which are also controlled by proliferation-specific factors.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,OXFORD OX3 9DU,ENGLAND	University of Oxford			Hickson, Ian/AAJ-7548-2020; Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Hochhauser, Daniel/0000-0001-5522-9281; Hickson, Ian/0000-0002-0583-566X				BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BENSON JD, 1990, J VIROL, V64, P9, DOI 10.1128/JVI.64.1.9-15.1990; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BODLEY AL, 1987, NATL CANCER I MONOGR, V4, P31; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; CONSTANTINOU A, 1989, CANCER RES, V49, P1110; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLEMINGTON E, 1987, GENE, V52, P267, DOI 10.1016/0378-1119(87)90053-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIANG YH, 1988, CANCER RES, V48, P3230; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROSS W, 1984, CANCER RES, V44, P5857; Sambrook J, 1989, MOL CLONING LABORATO; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEBB CD, 1991, CANCER RES, V51, P6543; WOESSNER RD, 1990, CANCER RES, V50, P2901; ZWELLING LA, 1988, CANCER RES, V48, P6625	33	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18961	18965						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382064				2022-12-27	WOS:A1992JN50200106
J	BO, XN; SIMON, J; BURNSTOCK, G; BARNARD, EA				BO, XN; SIMON, J; BURNSTOCK, G; BARNARD, EA			SOLUBILIZATION AND MOLECULAR-SIZE DETERMINATION OF THE P(2X) PURINOCEPTOR FROM RAT VAS-DEFERENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P2Y PURINERGIC RECEPTOR; SENSORY NEURONS; URINARY-BLADDER; SMOOTH-MUSCLE; BINDING-SITES; ATP; PROTEIN; P2-PURINOCEPTORS; AFFINITY; SURAMIN	Membranes of the rat vas deferens were shown to contain a high density of binding sites for [H-3]alpha,beta-methylene ATP ([H-3]alpha,beta-MeATP), a ligand selective for the P2X purinoceptor. Analysis demonstrated two classes, of high affinity (K(d) = 1.8 nM, B(max) (maximum density) = 9.3 pmol/mg of protein) and of low affinity (K(d) = 34 nM, B(max) = 29 pmol/mg of protein). The high affinity [H-3]alpha,beta-MeATP binding sites were successfully solubilized with 2% digitonin: the K(d) was then 1.6 nM. Both the association and dissociation of the receptor-ligand complex were rapid (half-time for association = 6.5 min). The rank order of potency of purinergic ligands in displacing [H-3]alpha,beta-MeATP binding from the solubilized preparation was in accord with the pharmacological criteria for P2X purinoceptors. The receptor-detergent complex was separated by sucrose gradient ultracentrifugation from the ATPase enzymes also present in the preparation. The sedimentation coefficient of the receptor-detergent complex was 12.1 S. It was shown that [H-3]alpha,beta-MeATP can function as a photoaffinity labeling reagent upon exposure to ultraviolet light; in the rat vas deferens membranes, it thus became cross-linked in a specific manner to a polypeptide of apparent molecular mass = 62,000 daltons, proposed to be the ligand-binding subunit of the functional P2X purinoceptor.	MRC,MOLEC NEUROBIOL UNIT,CAMBRIDGE CB2 2QH,ENGLAND; UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,CTR NEUROSCI,LONDON WC1E 6BT,ENGLAND	University of London; University College London; University of London; University College London			Bo, Xuenong/E-9845-2012	Bo, Xuenong/0000-0002-9202-3562	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM KI, 1984, BIOCHEMISTRY-US, V23, P1176, DOI 10.1021/bi00301a023; BAGINSKI ES, 1967, CLIN CHIM ACTA, V15, P155, DOI 10.1016/0009-8981(67)90340-3; BARNARD EA, 1992, RECEPTOR SUBUNITS CO, P163; BASU A, 1987, J BIOL CHEM, V262, P2369; Bean B P, 1990, Ion Channels, V2, P169; BEAN BP, 1990, J NEUROSCI, V10, P1; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BO X, 1990, BRIT J PHARMACOL, V101, P291, DOI 10.1111/j.1476-5381.1990.tb12703.x; BO XO, 1989, J AUTONOM NERV SYST, V28, P85, DOI 10.1016/0165-1838(89)90010-6; BOUVIER MM, 1991, EUR J NEUROSCI, V3, P285, DOI 10.1111/j.1460-9568.1991.tb00090.x; BOYER JL, 1989, J BIOL CHEM, V264, P884; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNSTOCK G, 1991, NUCLEOS NUCLEOT NUCL, V10, P917, DOI 10.1080/07328319108047230; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; CUSACK NJ, 1990, ANN NY ACAD SCI, V603, P172; DAVIDSON JS, 1990, ENDOCRINOLOGY, V126, P80, DOI 10.1210/endo-126-1-80; DUNN PM, 1988, BRIT J PHARMACOL, V93, P243, DOI 10.1111/j.1476-5381.1988.tb11427.x; FORTES PAG, 1973, BIOCHIM BIOPHYS ACTA, V318, P262, DOI 10.1016/0005-2736(73)90119-3; FRIEL DD, 1988, J PHYSIOL-LONDON, V401, P361, DOI 10.1113/jphysiol.1988.sp017167; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HOURANI SMO, 1989, GEN PHARMACOL, V20, P413, DOI 10.1016/0306-3623(89)90188-2; HOYLE CHV, 1990, BRIT J PHARMACOL, V99, P617, DOI 10.1111/j.1476-5381.1990.tb12979.x; HOYLE CHV, 1989, ADENOSINE NERVOUS SY, P43; JEFFS RA, 1991, MOL PHARMACOL, V40, P85; KRISHTAL OA, 1988, BRIT J PHARMACOL, V95, P1057, DOI 10.1111/j.1476-5381.1988.tb11739.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MAMALAKI C, 1989, J NEUROCHEM, V52, P124, DOI 10.1111/j.1471-4159.1989.tb10906.x; MODAK MJ, 1982, J BIOL CHEM, V257, P5105; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAZAWA K, 1990, NEUROSCI LETT, V119, P5, DOI 10.1016/0304-3940(90)90741-Q; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; RUGGIERI MR, 1990, J UROLOGY, V144, P176, DOI 10.1016/S0022-5347(17)39405-3; SALT TE, 1983, NEUROSCI LETT, V35, P53, DOI 10.1016/0304-3940(83)90526-8; SIMON J, 1984, J NEUROCHEM, V43, P957, DOI 10.1111/j.1471-4159.1984.tb12830.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHITE TD, 1988, PHARMACOL THERAPEUT, V38, P129, DOI 10.1016/0163-7258(88)90095-2	41	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17581	17587						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387637				2022-12-27	WOS:A1992JM22300019
J	GRINSTEIN, S; FURUYA, W				GRINSTEIN, S; FURUYA, W			CHEMOATTRACTANT-INDUCED TYROSINE PHOSPHORYLATION AND ACTIVATION OF MICROTUBULE-ASSOCIATED PROTEIN-KINASE IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT PERITONEAL NEUTROPHILS; PHOSPHOTYROSYL PROTEIN; RESPIRATORY BURST; THREONINE; IDENTIFICATION; OXIDASE; ERKS	Activation of human neutrophils by the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (fMLP) induces tyrosine phosphorylation of several polypeptides, including a prominent band of almost-equal-to 41 kDa. A polypeptide of identical electrophoretic mobility was recognized by a monoclonal antibody raised against a sequence corresponding to amino acids 325-345 of ERK-1, one of a family of mitogen-activated protein (MAP) kinases. To establish the possible identity of these polypeptides, extracts from control and fMLP-treated cells were immunoprecipitated with immobilized antiphosphotyrosine antibodies. Reactivity with anti-ERK-1 antibodies was observed only in the precipitate of chemoattractant-stimulated cells. These data imply that a MAP kinase constitutes at least part of the tyrosine-phosphorylated 41-kDa polypeptide. By using an in vitro renaturation assay, treatment of intact cells with fMLP was found to stimulate several protein kinases, including one of almost-equal-to 41 kDa. Renaturation of samples immunoprecipitated with antiphosphotyrosine antibodies revealed the presence of an active protein kinase in chemoattractant-stimulated, but not in control cells. The immunoprecipitated kinase comigrated with the 41-kDa tyrosine phosphorylated polypeptide and the anti-ERK-1 reactive band. We conclude that a MAP kinase closely related or identical to ERK-1 is tyrosine phosphorylated and activated when human neutrophils are stimulated by chemotactic peptides. The rapid phosphorylation of this kinase, which is apparent within seconds, is compatible with a role in the activation of the respiratory burst and/or other neutrophil responses.			GRINSTEIN, S (corresponding author), HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.							BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BERKOW RL, 1990, BLOOD, V75, P2445; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CAMPOSGONZALEZ R, 1991, CELL REGUL, V2, P663, DOI 10.1091/mbc.2.8.663; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GOMEZCAMBRONERO J, 1991, NATURE, V353, P170; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; HUANG CK, 1990, BIOCHEM J, V269, P431, DOI 10.1042/bj2690431; HUANG CK, 1989, MEMBRANE BIOCHEM, V8, P61, DOI 10.3109/09687688909082261; LAMBETH JD, 1988, J BIOENERG BIOMEMBR, V20, P709, DOI 10.1007/BF00762549; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; TAUBER AI, 1987, BLOOD, V69, P711; TORRES M, 1991, Journal of Cell Biology, V115, p274A	24	141	144	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18122	18125						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381363				2022-12-27	WOS:A1992JM22300098
J	GORMAN, DM; ITOH, N; JENKINS, NA; GILBERT, DJ; COPELAND, NG; MIYAJIMA, A				GORMAN, DM; ITOH, N; JENKINS, NA; GILBERT, DJ; COPELAND, NG; MIYAJIMA, A			CHROMOSOMAL LOCALIZATION AND ORGANIZATION OF THE MURINE GENES ENCODING THE BETA-SUBUNITS (AIC2A AND AIC2B) OF THE INTERLEUKIN-3, GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR, AND INTERLEUKIN-5 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN RECEPTOR; GM-CSF RECEPTOR; BINDING PROTEIN; 2ND SUBUNIT; CELL-LINE; MACROPHAGE; CLONING; TRANSCRIPTION; RECONSTITUTION; IDENTIFICATION	Chromosomal genes for two mouse homologous beta-subunits (AIC2A and AIC2B) of the interleukin-3, granulocyte/macrophage colony-stimulating factor, and interleukin-5 receptors were characterized. Both AIC2A and AIC2B genes were present on a 250-kilobase MluI restriction fragment and were mapped on murine chromosome 15 (these loci were provisionally designated as Il3rb-1 (AIC2A) and Il3rb-2 (AIC2B)), closely linked to the c-sis locus. Both genes consist of 14 exons and span about 28 kb each. The major transcription inititation sites of both genes were mapped at 194 bp from the initiation codon. These genes are 95% identical up to 700 bp from the transcription initiation sites. Potential recognition sequences for hemopoietic transcription factors including GATA-1 and PU.1 in addition to a TATA-like sequence are present in the 5'-flanking region. A stretch of 20 bp including the initiation site is homologous to the corresponding region of the erythropoietin receptor and the interleukin-7 receptor genes and to the initiator sequence of the adeno-associated virus P5 promoter, suggesting a possible role in transcription initiation. Comparison of the exon/intron boundaries of AIC2A and AIC2B genes with those of other members of the cytokine receptor superfamily reveals a conserved evolutionary structure. Isolation of various forms of AIC2 cDNAs reveals differential splicing of the transcripts.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,901 CALIF AVE,PALO ALTO,CA 94304; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ADV BIOSCI LAB,BASIC RES PROGRAM,FREDERICK,MD 21702	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BARLOW DP, 1987, EMBO J, V6, P617, DOI 10.1002/j.1460-2075.1987.tb04799.x; BRANNAN CI, 1992, IN PRESS GENOMICS; BUDEL LM, 1990, BLOOD, V75, P1439; CAMPBELL HD, 1992, GENOMICS, V12, P179, DOI 10.1016/0888-7543(92)90428-U; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; ELLIOTT MJ, 1989, BLOOD, V74, P2349; GESNER TG, 1988, J CELL PHYSIOL, V136, P493, DOI 10.1002/jcp.1041360314; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; Green EL, 1981, GENETICS PROBABILITY, P77; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1991, CELL, V66, P115; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEBEAU MM, 1989, BLOOD, V73, P647; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; MAOUCHE L, 1991, BLOOD, V78, P2557; MARIN DIK, 1990, NATURE, V344, P444; MIGLIACCIO AR, 1991, P NATL ACAD SCI USA, V88, P11086, DOI 10.1073/pnas.88.24.11086; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; NOGUCHI CT, 1991, BLOOD, V78, P2548; OGOROCHI T, 1992, BLOOD, V79, P895; PARK LS, 1989, J BIOL CHEM, V264, P5420; PLEIMAN CM, 1991, MOL CELL BIOL, V11, P3052, DOI 10.1128/MCB.11.6.3052; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SCHREURS J, 1991, INT IMMUNOL, V3, P1231, DOI 10.1093/intimm/3.12.1231; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO Y, 1992, J IMMUNOL, V148, P259; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAKETAZU F, 1991, J CELL PHYSIOL, V146, P251, DOI 10.1002/jcp.1041460209; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Wrighton N, 1992, GROWTH FACTORS, V6, P103, DOI 10.3109/08977199209011014; YANG YC, 1988, BLOOD, V71, P958; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675	46	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15842	15848						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386365				2022-12-27	WOS:A1992JG11300089
J	DELSERT, CD; ROSENFELD, MG				DELSERT, CD; ROSENFELD, MG			A TISSUE-SPECIFIC SMALL NUCLEAR RIBONUCLEOPROTEIN AND THE REGULATED SPLICING OF THE CALCITONIN CALCITONIN GENE-RELATED PROTEIN TRANSCRIPT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RAT PITUITARY; CGRP GENE; EXPRESSION; POLYPEPTIDE; BINDING; SITE; SEQUENCE; ELEMENTS; CELLS	Based on a correlation between expression patterns of an abundant tissue-specific small nuclear ribonucleoprotein (N protein) and the calcitonin gene-related protein (CGRP) splicing choice, a small nuclear ribonucleoprotein (the N factor) has been hypothesized to potentially function as a trans-acting factor involved in the regulation of the alternative splicing of the calcitonin/CGRP transcript. RNA analysis indicated that most rat, human, and simian cell lines and tissues making the CGRP mRNA splicing choice expressed the N factor mRNA. These data led us to address the effect of ectopic expression of the N factor in HeLa cells, which exhibit a calcitonin splicing choice when expressing the calcitonin/CGRP gene. Expression of the N factor exerts no effect on the calcitonin/CGRP splicing choice in HeLa cells. Furthermore, several cell lines such as the human 293 cell line make the CGRP mRNA splicing choice in the absence of any detectable level of the mRNA encoding the N factor. Together, these data reveal that the N protein is neither sufficient nor required for the tissue-specific CGRP splicing decision and that the N protein is not the trans-acting factor regulating the alternative splicing of the calcitonin/CGRP gene.	UNIV CALIF SAN DIEGO,SCH MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego	DELSERT, CD (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093, USA.							AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; Anderson C W, 1988, Virus Genes, V1, P149, DOI 10.1007/BF00555934; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRENSHAW EB, 1987, CELL, V49, P389, DOI 10.1016/0092-8674(87)90291-1; DELSERT C, 1989, MOL CELL BIOL, V9, P4364, DOI 10.1128/MCB.9.10.4364; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAMM J, 1987, EMBO J, V6, P3479, DOI 10.1002/j.1460-2075.1987.tb02672.x; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LEFF SE, 1987, CELL, V48, P517, DOI 10.1016/0092-8674(87)90202-9; LI S, 1989, P NATL ACAD SCI USA, V86, P9778, DOI 10.1073/pnas.86.24.9778; MCALLISTER G, 1989, EMBO J, V8, P1177, DOI 10.1002/j.1460-2075.1989.tb03489.x; MCALLISTER G, 1988, P NATL ACAD SCI USA, V85, P5296, DOI 10.1073/pnas.85.14.5296; MIRELL CJ, 1986, MOL CELL ENDOCRINOL, V47, P145, DOI 10.1016/0303-7207(86)90026-2; REYMOND MJ, 1984, ACTA ENDOCRINOL-COP, V106, P459, DOI 10.1530/acta.0.1060459; ROKEACH LA, 1989, J BIOL CHEM, V264, P5024; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SCHMAUSS C, 1989, NUCLEIC ACIDS RES, V17, P1733, DOI 10.1093/nar/17.4.1733; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SHARPE NG, 1990, MOL CELL BIOL, V10, P6817, DOI 10.1128/MCB.10.12.6817; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STEITZ JA, 1987, STRUCTURE FUNCTION M, P71; STOLARSKYFREDMAN L, 1990, MOL ENDOCRINOL, V4, P497, DOI 10.1210/mend-4-3-497; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; TAN EM, 1982, ADV IMMUNOL, V33, P167, DOI 10.1016/S0065-2776(08)60836-6; VANDAM A, 1989, EMBO J, V8, P3853, DOI 10.1002/j.1460-2075.1989.tb08563.x; WOPPMANN A, 1990, NUCLEIC ACIDS RES, V18, P4427, DOI 10.1093/nar/18.15.4427	36	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14573	14579						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386079				2022-12-27	WOS:A1992JF08800015
J	JIN, YJ; BURAKOFF, SJ; BIERER, BE				JIN, YJ; BURAKOFF, SJ; BIERER, BE			MOLECULAR-CLONING OF A 25-KDA HIGH-AFFINITY RAPAMYCIN BINDING-PROTEIN, FKBP25	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; T-CELL ACTIVATION; IMMUNOSUPPRESSANT FK506; FK506-BINDING PROTEIN; MACROLIDES FK-506; DISTINCT; CYCLOPHILIN; IMMUNOPHILIN; CYCLOSPORINE	Two FK506 binding proteins of molecular mass 12 kDa (FKBP12) and 13 kDa (FKBP13) have been identified as common cellular receptors of the immunosuppressants FK506 and rapamycin. Here we report the molecular cloning and overexpression of a 25-kDa rapamycin and FK506 binding protein (termed FKBP25) with peptidylprolyl cis-trans-isomerase (PPIase) activity. The amino acid sequence, predicted from the FKBP25 cDNA, shares identity with FKBP12 (44%) and FKBP13 (47%) in the C-terminal 97 amino acids. Unlike either FKBP12 or FKBP13, the nucleotide sequence of FKBP25 contains a number of putative nuclear localization sequences. The PPIase activity of recombinant FKBP25 was comparable with that of FKBP12. The PPIase activity of FKBP25 was far more sensitive to inhibition by rapamycin (IC50 = 50 nM) than FK506 (IC50 = 400 nM). PPIase activity of 100 nM FKBP25 was almost completely inhibited by 150 nm rapamycin while only 90% inhibition was achieved by 4-mu-M FK506. These data demonstrate that FKBP25 has a higher affinity for rapamycin than for FK506 and suggest that this cellular receptor may be an important target molecule for immunosuppression by rapamycin.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	JIN, YJ (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115, USA.			Bierer, Barbara/0000-0001-6448-8170				BIERER BE, 1991, EUR J IMMUNOL, V21, P439, DOI 10.1002/eji.1830210228; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ENG CP, 1984, J ANTIBIOT, V37, P1231, DOI 10.7164/antibiotics.37.1231; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; METCALFE SM, 1990, TRANSPLANTATION, V49, P798, DOI 10.1097/00007890-199004000-00028; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; MORRIS RE, 1991, IMMUNOL TODAY, V12, P137; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROBERTS BL, 1986, NUCLEOCYTOPLASMIC TR, P185; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WICKER LS, 1990, EUR J IMMUNOL, V20, P2277, DOI 10.1002/eji.1830201017	29	84	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10942	10945						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375932				2022-12-27	WOS:A1992HX16900004
J	LERNER, DR; RAIKHEL, NV				LERNER, DR; RAIKHEL, NV			THE GENE FOR STINGING NETTLE LECTIN (URTICA-DIOICA AGGLUTININ) ENCODES BOTH A LECTIN AND A CHITINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BARLEY LECTIN; DNA; CLONING; TOBACCO; ENDOCHITINASE; ACCUMULATION; RHIZOMES	Chitin-binding proteins are present in a wide range of plant species, including both monocots and dicots, even though these plants contain no chitin. To investigate the relationship between in vitro antifungal and insecticidal activities of chitin-binding proteins and their unknown endogenous functions, the stinging nettle lectin (Urtica dioica agglutinin, UDA) cDNA was cloned using a synthetic gene as the probe. The nettle lectin cDNA clone contained an open reading frame encoding 374 amino acids. Analysis of the deduced amino acid sequence revealed a 21-amino acid putative signal sequence and the 86 amino acids encoding the two chitin-binding domains of nettle lectin. These domains were fused to a 19-amino acid "spacer" domain and a 244-amino acid carboxyl extension with partial identity to a chitinase catalytic domain. The authenticity of the cDNA clone was confirmed by deduced amino acid sequence identity with sequence data obtained from tryptic digests, RNA gel blot, and polymerase chain reaction analyses. RNA gel blot analysis also showed the nettle lectin message was present primarily in rhizomes and inflorescence (with immature seeds) but not in leaves or stems. Chitinase enzymatic activity was found when the chitinase-like domain alone or the chitinase-like domain with the chitin-binding domains were expressed in Escherichia coli. This is the first example of a chitin-binding protein with both a duplication of the 43-amino acid chitin-binding domain and a fusion of the chitin-binding domains to a structurally unrelated domain, the chitinase domain.	MICHIGAN STATE UNIV,DEPT ENERGY,PLANT RES LAB,E LANSING,MI 48824	Michigan State University								BEDNAREK SY, 1991, PLANT CELL, V3, P1195, DOI 10.1105/tpc.3.11.1195; BEDNAREK SY, 1990, PLANT CELL, V2, P1145, DOI 10.1105/tpc.2.12.1145; BROEKAERT WF, 1989, SCIENCE, V245, P1100, DOI 10.1126/science.245.4922.1100; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; CHAPOT MP, 1986, FEBS LETT, V195, P231, DOI 10.1016/0014-5793(86)80166-1; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; DALE RMK, 1987, METHOD ENZYMOL, V155, P204; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAIT MJ, 1980, NUCL ACIDS RES S SER, V7, P243; GAYNOR JJ, 1988, NUCLEIC ACIDS RES, V16, P5210, DOI 10.1093/nar/16.11.5210; HUESING JE, 1991, PHYTOCHEMISTRY, V30, P3565, DOI 10.1016/0031-9422(91)80066-A; HUESING JE, 1991, PHYTOCHEMISTRY, V30, P785, DOI 10.1016/0031-9422(91)85252-U; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEAH R, 1991, J BIOL CHEM, V266, P1564; LEE H, 1991, J BIOL CHEM, V266, P15944; LERNER DR, 1989, PLANT PHYSIOL, V91, P124, DOI 10.1104/pp.91.1.124; Maniatis T., 1982, MOL CLONING; Nagy F., 1988, PLANT MOL BIOL MAN B, VB4, P1; NEUHAUS JM, 1991, P NATL ACAD SCI USA, V88, P10362, DOI 10.1073/pnas.88.22.10362; NEUHAUS JM, 1991, PLANT MOL BIOL, V16, P141, DOI 10.1007/BF00017924; PARSONS TJ, 1989, P NATL ACAD SCI USA, V86, P7895, DOI 10.1073/pnas.86.20.7895; PAYNE G, 1990, P NATL ACAD SCI USA, V87, P98, DOI 10.1073/pnas.87.1.98; PEUMANS WJ, 1984, FEBS LETT, V177, P99, DOI 10.1016/0014-5793(84)80989-8; PEUMANS WJ, 1984, PLANTA, V160, P222, DOI 10.1007/BF00402858; RAIKHEL NV, 1991, DEV GENET, V12, P255, DOI 10.1002/dvg.1020120402; RAIKHEL NV, 1987, P NATL ACAD SCI USA, V84, P6745, DOI 10.1073/pnas.84.19.6745; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA N, 1986, ARCH BIOCHEM BIOPHYS, V249, P215, DOI 10.1016/0003-9861(86)90577-1; SHINSHI H, 1987, P NATL ACAD SCI USA, V84, P89, DOI 10.1073/pnas.84.1.89; SILFLOW CD, 1979, BIOCHEMISTRY-US, V18, P2725, DOI 10.1021/bi00580a006; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDAMME EJM, 1988, PLANT PHYSIOL, V86, P598, DOI 10.1104/pp.86.2.598; VANPARIJS J, 1991, PLANTA, V183, P258, DOI 10.1007/BF00197797; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILKINS TA, 1990, PLANT CELL, V2, P301, DOI 10.1105/tpc.2.4.301; WIRTH SJ, 1990, J MICROBIOL METH, V12, P197, DOI 10.1016/0167-7012(90)90031-Z	38	82	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11085	11091						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375935				2022-12-27	WOS:A1992HX16900026
J	BAUMGARTEN, LB; TOSCAS, K; VILLEREAL, ML				BAUMGARTEN, LB; TOSCAS, K; VILLEREAL, ML			DIHYDROPYRIDINE-SENSITIVE L-TYPE CA2+ CHANNELS IN HUMAN FORESKIN FIBROBLAST CELLS - CHARACTERIZATION OF ACTIVATION WITH THE GROWTH-FACTOR LYS-BRADYKININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM CHANNELS; SKELETAL-MUSCLE; INOSITOL TRISPHOSPHATE; ACINAR-CELLS; ALPHA-1-SUBUNIT; ANTAGONISTS; MESSENGER; CURRENTS; RECEPTOR; INFLUX	We have previously characterized the calcium response of cultured human fibroblasts (HSWP cells) to stimulation by the mitogen Lys-bradykinin (BK). We have reported a biphasic response which includes a rapid rise to a peak that appears to result from mobilization of internal calcium, and a plateau phase, which is due to influx of external calcium (Byron, K., Babnigg, G., Villereal, M. L. (1992) J. Biol. Chem. 267, 108-118). In this paper we examine participation of L-type voltage operated calcium channels in the calcium entry phase of BK-stimulated HSWP cells. We show that there is an increase in Ca-45(2+) uptake and an increase in intracellular free calcium concentration ([Ca2+]i) as measured by fura-2, when HSWP cells are stimulated with the L-channel agonist Bay K 8644 under depolarizing conditions. Furthermore, both of these effects are inhibited by low doses of the dihydropyridine antagonist nitrendipine. We also report that BK stimulation of Ca-45(2+) uptake can be significantly inhibited by low doses of nitrendipine, while nitrendipine treatment has no effect on the BK-induced rise in [Ca2+]i, as measured by fura-2. These results suggest that under normal conditions the portion of the BK-stimulated Ca2+ influx which is mediated by a nitrendipine-sensitive entry pathway is invisible to the fura-2 technique used to measure [Ca2+]i. This suggests that the nitrendipine-sensitive influx pathway admits calcium preferentially into an intracellular store that is isolated from fura-2. This idea is supported by the observation that in media where calcium has been replaced by 2 mm Ba2+ nitrendipine inhibits most of the BK-stimulated Ba2+ influx.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637	University of Chicago					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR003322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007151, R01GM028359] Funding Source: NIH RePORTER; NCRR NIH HHS [S10-RR-03322] Funding Source: Medline; NIGMS NIH HHS [GM-28359, 5T32-GM-07151] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGAMASCHI S, 1990, EUR NEUROL, V30, P6; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BYRON KL, 1989, J BIOL CHEM, V264, P18234; BYRON KL, 1992, J BIOL CHEM, V267, P108; BYRON KL, 1990, THESIS U CHICAGO; CHEN CF, 1988, SCIENCE, V239, P1024, DOI 10.1126/science.2449730; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAZELTON BJ, 1981, BIOCHEM J, V194, P707, DOI 10.1042/bj1940707; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; KWAN CY, 1990, J BIOL CHEM, V265, P678; LAI Y, 1990, J BIOL CHEM, V265, P20839; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MORTON ME, 1988, J BIOL CHEM, V263, P613; OWEN NE, 1983, CELL, V32, P979, DOI 10.1016/0092-8674(83)90082-X; RENAUD JF, 1984, BIOCHEM BIOPH RES CO, V125, P405, DOI 10.1016/S0006-291X(84)80382-4; ROSENBERG RL, 1986, SCIENCE, V231, P1564, DOI 10.1126/science.2420007; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TRIGGLE DJ, 1990, CAN J PHYSIOL PHARM, V68, P1474, DOI 10.1139/y90-224; TUANA BS, 1990, CAN J PHYSIOL PHARM, V68, P1482, DOI 10.1139/y90-225; VAGHY PL, 1987, AM J CARDIOL, V59, pA9, DOI 10.1016/0002-9149(87)90170-6; VICENTINI LM, 1985, P NATL ACAD SCI USA, V82, P8053, DOI 10.1073/pnas.82.23.8053; VILLEREAL ML, 1991, REV PHYSL BIOCH PHAR, V119, P67; VILVEN J, 1988, NATURE, V336, P587, DOI 10.1038/336587a0	28	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10524	10530						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375223				2022-12-27	WOS:A1992HV09000048
J	LOMBARDO, CR; WILLARDSON, BM; LOW, PS				LOMBARDO, CR; WILLARDSON, BM; LOW, PS			LOCALIZATION OF THE PROTEIN 4.1-BINDING SITE ON THE CYTOPLASMIC DOMAIN OF ERYTHROCYTE-MEMBRANE BAND-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL-MEMBRANE; ANION-TRANSPORT PROTEIN; ANKYRIN-BINDING SITE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HEREDITARY ELLIPTOCYTOSIS; EXCHANGE PROTEIN; GLYCOPHORIN-A; 4.1 BINDING; ASSOCIATION; SPECTRIN	Of the several proteins that bind along the cytoplasmic domain of erythrocyte membrane band 3, only the sites of interaction of proteins 4.1 and 4.2 remain to be at least partially localized. Using five independent techniques, we have undertaken to map and characterize the binding site of band 4.1 on band 3. First, transfer of a radioactive cross-linker (I-125-2-(p-azido-salicylamido) ethyl-1-3-dithiopropionate) from purified band 4.1 to its binding sites on stripped inside-out erythrocyte membrane vesicles (stripped IOVs) revealed major labeling of band 3, glycophorin C, and glycophorin A. Proteolytic mapping of the stripped IOVs then demonstrated that the label on band 3 was confined largely to a fragment comprising residues 1-201. Second, competitive binding experiments with Fab fragments of monoclonal and peptide-specific polyclonal antibodies to numerous epitopes along the cytoplasmic domain of band 3 displayed stoichiometric competition only with Fabs to epitopes between residues 1 and 91 of band 3. Weak competition was also observed with Fabs to a sequence of the cytoplasmic domain directly adjacent to the membrane-spanning domain, but only at 50-100-fold excess of Fab. Third, band 4.1 protected band 3 from chymotryptic hydrolysis at tyrosine 46 and to a much lesser extent at a site within the junctional peptide connecting the membrane-spanning and cytoplasmic domains of band 3. Fourth, ankyrin, which has been previously shown to interact with band 3 both near a putative central hinge and at the N terminus competed with band 4.1 for band 3 in stripped IOVs. Since band 4.1 does not associate with band 3 near the flexible central hinge, the competition with ankyrin can be assumed to derive from a mutual association with the N terminus. Finally, a synthetic peptide corresponding to residues 1-15 of band 3 was found to mildly inhibit band 4.1 binding to stripped IOVs. Taken together, these data suggest that band 4.1 binds band 3 predominantly near the N terminus, with a possible secondary site near the junction of the cytoplasmic domain and the membrane.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528; Willardson, Barry/0000-0002-8503-2268	NIGMS NIH HHS [GM 24417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024417, R01GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLOISIO N, 1985, BLOOD, V65, P46; ALPER SL, 1988, J BIOL CHEM, V263, P17092; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; ANSTEE DJ, 1984, BIOCHEM J, V218, P615, DOI 10.1042/bj2180615; APPELL KC, 1981, J BIOL CHEM, V256, P1104; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; CHASIS JA, 1985, J CLIN INVEST, V75, P1919, DOI 10.1172/JCI111907; CHASIS JA, 1988, J CELL BIOL, V107, P1351, DOI 10.1083/jcb.107.4.1351; COETZER TL, 1988, NEW ENGL J MED, V318, P230, DOI 10.1056/NEJM198801283180407; COHEN AM, 1988, BIOCHEMISTRY-US, V27, P614, DOI 10.1021/bi00402a018; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P225, DOI 10.1002/cm.970120405; CONBOY J, 1986, NEW ENGL J MED, V315, P680, DOI 10.1056/NEJM198609113151105; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DAVIS L, 1989, J BIOL CHEM, V264, P9665; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; JINBU Y, 1984, BIOCHIM BIOPHYS ACTA, V773, P237, DOI 10.1016/0005-2736(84)90087-7; JOYL JC, 1990, BIOCHEMISTRY-US, V29, P8916; KANNAN R, 1991, BIOCHEM J, V278, P57, DOI 10.1042/bj2780057; KANNAN R, 1988, J BIOL CHEM, V263, P13766; KAY MMB, 1988, P NATL ACAD SCI USA, V85, P492, DOI 10.1073/pnas.85.2.492; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KORSGREN C, 1988, J BIOL CHEM, V263, P10212; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; LOMBARDO CR, 1990, J CELL BIOL, V111, P46; LOMBARDO CR, 1992, THESIS PURDUE U; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1984, J BIOL CHEM, V259, P3070; LOW PS, 1991, BLOOD, V77, P1581; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MCGUIRE M, 1988, BLOOD, V72, P287; MORIYAMA R, 1989, ARCH BIOCHEM BIOPHYS, V274, P130, DOI 10.1016/0003-9861(89)90423-2; MORRISON M, 1985, BIOCHEMISTRY-US, V24, P6311, DOI 10.1021/bi00343a041; MUELLER TJ, 1981, ERYTHROCYTE MEMBRANE, V2, P95; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; NIGG EA, 1980, BIOCHEMISTRY-US, V19, P1887, DOI 10.1021/bi00550a024; OHANIAN V, 1984, EUR J BIOCHEM, V144, P375, DOI 10.1111/j.1432-1033.1984.tb08474.x; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PETRUCCI TC, 1991, BIOCHEMISTRY-US, V30, P413, DOI 10.1021/bi00216a016; PINDER JC, 1989, BIOCHEM J, V264, P423, DOI 10.1042/bj2640423; PRADHAN D, 1991, BIOCHEMISTRY-US, V30, P7754, DOI 10.1021/bi00245a012; RACHMILEWITZ EA, 1985, CLIN HAEMATOL, V14, P163; REID ME, 1987, BLOOD, V69, P1068; REID ME, 1990, BLOOD, V75, P2229; SEARS DA, 1975, J LAB CLIN MED, V86, P722; SHAHROKH Z, 1991, J BIOL CHEM, V266, P12082; SHEPHARD EG, 1988, ANAL BIOCHEM, V168, P306, DOI 10.1016/0003-2697(88)90323-5; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; THEVENIN BJM, 1989, J BIOL CHEM, V264, P15886; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI IH, 1982, J BIOL CHEM, V257, P1438; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; WALDER JA, 1984, J BIOL CHEM, V259, P238; WAUGH SM, 1985, BIOCHEMISTRY-US, V24, P34, DOI 10.1021/bi00322a006; WAUGH SM, 1987, BIOCHEMISTRY-US, V26, P1777, DOI 10.1021/bi00380a041; WEINSTEIN RS, 1978, J SUPRAMOL STR CELL, V8, P325, DOI 10.1002/jss.400080310; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; WILLARDSON BM, 1990, THESIS PURDUE U, V3	65	97	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9540	9546						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374405				2022-12-27	WOS:A1992HT96500017
J	ROSENG, L; TOLLESHAUG, H; BERG, T				ROSENG, L; TOLLESHAUG, H; BERG, T			UPTAKE, INTRACELLULAR-TRANSPORT, AND DEGRADATION OF POLYETHYLENE GLYCOL-MODIFIED ASIALOFETUIN IN HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; RECEPTOR-MEDIATED ENDOCYTOSIS; LIVER ENDOTHELIAL-CELLS; COVALENT ATTACHMENT; BINDING ABILITY; FETUIN; INVIVO; GLYCOPROTEINS; INTERNALIZATION; DISAPPEARANCE	Polyethylene glycol (PEG) is attached to proteins in order to increase their half-life in the circulation and reduce their immunogenicity in vivo. For many applications involving "targeting" molecules, it is important to know how PEG modification of the molecule affects its interaction with a receptor and the subsequent internalization, intracellular transport, and lysosomal degradation. As a model system, we used asialofetuin, which binds to the galactose receptor of hepatocytes, because removal of sialic acid exposes galactose residues. We modified asialofetuin by attaching various amounts of PEG of molecular weight 1900 or 5000. The preparations were labeled with I-125 so that endocytosis and degradation could be followed in suspended hepatocytes. Depending on the number of PEG molecules attached, receptor-mediated uptake was affected to varying degrees. If two-thirds of the exposed amino groups of the asialofetuin molecule were modified, the rate of uptake decreased to less than one-fourth of controls; degradation of endocytosed molecules was 12% of controls. The reduction in endocytic uptake was due to a reduced rate of formation of the receptor-ligand complex. Subcellular frationation in density gradients showed that PEG-modified asialofetuin is transported intracellularly and degraded in the same manner as the native protein, but the rate of proteolysis is reduced. This observation explains the paradoxical result of experiments with injection of modified asialofetuin into rats in vivo: even though the clearance of one preparation of PEG-asialofetuin was much slower than that of the native protein, accumulation of radioactivity in the liver from the modified protein was twice as high. The hepatocytes accounted for 85% of the hepatic accumulation of either PEG-modified or native asialofetuin in vivo.	NYCOMED AS, DEPT EXPTL BIOL, N-0401 OSLO 4, NORWAY; UNIV OSLO, DEPT BIOL, CELL BIOL SECT, N-0316 OSLO, NORWAY	University of Oslo	ROSENG, L (corresponding author), NORWEGIAN RADIUM HOSP, ENVIRONM & OCCUPAT CANC LAB, N-0310 OSLO 3, NORWAY.							ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3578; ANDERSON WL, 1988, J IMMUNOL METHODS, V109, P37, DOI 10.1016/0022-1759(88)90439-5; ASHIHARA Y, 1978, BIOCHEM BIOPH RES CO, V83, P385, DOI 10.1016/0006-291X(78)91002-1; BARRETT AJ, 1972, LYSOSOMES LABORATORY, P116; BERG T, 1980, BIOCHEM PHARMACOL, V29, P917, DOI 10.1016/0006-2952(80)90222-1; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BLOMHOFF R, 1984, EXP CELL RES, V150, P194, DOI 10.1016/0014-4827(84)90714-6; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHARLWOOD PA, 1979, BIOCHIM BIOPHYS ACTA, V585, P61, DOI 10.1016/0304-4165(79)90325-8; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; FUJITA T, 1991, J PHARMACOBIO-DYNAM, V14, P623, DOI 10.1248/bpb1978.14.623; FURUNO K, 1983, J BIOCHEM-TOKYO, V93, P249, DOI 10.1093/oxfordjournals.jbchem.a134160; GOLDENBERG DM, 1987, J CANCER RES CLIN, V113, P203, DOI 10.1007/BF00396374; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HUBBARD AL, 1979, J CELL BIOL, V83, P47, DOI 10.1083/jcb.83.1.47; Hurwitz E., 1980, J APPL BIOCHEM, V2, P25; HYSING J, 1986, BIOCHIM BIOPHYS ACTA, V887, P42, DOI 10.1016/0167-4889(86)90120-5; KATRE NV, 1990, J IMMUNOL, V144, P209; KINDBERG GM, 1984, ANAL BIOCHEM, V142, P455, DOI 10.1016/0003-2697(84)90489-5; KINDBERG GM, 1990, BIOCHEM J, V270, P197, DOI 10.1042/bj2700197; KNAUF MJ, 1988, J BIOL CHEM, V263, P15064; KNUTSON VP, 1987, J BIOL CHEM, V262, P2374; KOIDE A, 1982, FEBS LETT, V143, P73, DOI 10.1016/0014-5793(82)80276-7; KOLSET SO, 1979, EXP CELL RES, V122, P159, DOI 10.1016/0014-4827(79)90570-6; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; MATSUSHIMA A, 1992, BIOCHEM INT, V26, P485; MEARES CF, 1988, INT J CANCER, P99; MEYERS FJ, 1991, CLIN PHARMACOL THER, V49, P307, DOI 10.1038/clpt.1991.33; MORI A, 1991, FEBS LETT, V284, P263, DOI 10.1016/0014-5793(91)80699-4; Morimoto Y, 1985, Crit Rev Ther Drug Carrier Syst, V2, P19; MOSLEY ST, 1981, P NATL ACAD SCI-BIOL, V78, P5717, DOI 10.1073/pnas.78.9.5717; NENSETER MS, 1988, BIOCHEM J, V254, P443, DOI 10.1042/bj2540443; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; REDSHAW MR, 1974, J ENDOCRINOL, V60, P527, DOI 10.1677/joe.0.0600527; SAVOCA KV, 1979, BIOCHIM BIOPHYS ACTA, V578, P47, DOI 10.1016/0005-2795(79)90111-9; SCHWARTZ AL, 1984, CRC CR REV BIOCH MOL, V16, P207, DOI 10.3109/10409238409108716; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHEN WC, 1985, J BIOL CHEM, V260, P905; SMIT MJ, 1987, J BIOL CHEM, V262, P13020; SUZUKI T, 1984, BIOCHIM BIOPHYS ACTA, V788, P248, DOI 10.1016/0167-4838(84)90268-1; TAKAHASHI K, 1984, BIOCHEM BIOPH RES CO, V121, P261, DOI 10.1016/0006-291X(84)90716-2; TAKAHASHI K, 1984, BIOCHEM BIOPH RES CO, V125, P761, DOI 10.1016/0006-291X(84)90604-1; TANAKA H, 1991, CANCER RES, V51, P3710; TOLLESHAUG H, 1981, INT J BIOCHEM, V13, P45, DOI 10.1016/0020-711X(81)90135-X; TOLLESHAUG H, 1980, EUR J CELL BIOL, V23, P104; TOLLESHAUG H, 1984, BIOCHIM BIOPHYS ACTA, V803, P182, DOI 10.1016/0167-4889(84)90008-9; TOLLESHAUG H, 1981, EXP CELL RES, V134, P207, DOI 10.1016/0014-4827(81)90478-X; TOLLESHAUG H, 1981, J BIOL CHEM, V256, P6526; TOLLESHAUG H, 1977, BIOCHIM BIOPHYS ACTA, V499, P73, DOI 10.1016/0304-4165(77)90230-6; TOLLESHAUG H, 1980, BIOCHEM J, V190, P697, DOI 10.1042/bj1900697; WHITE CW, 1989, J APPL PHYSIOL, V66, P584, DOI 10.1152/jappl.1989.66.2.584	52	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22987	22993						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385410				2022-12-27	WOS:A1992JY16300045
J	BARRUECO, JR; OLEARY, DF; SIROTNAK, FM				BARRUECO, JR; OLEARY, DF; SIROTNAK, FM			FACILITATED TRANSPORT OF METHOTREXATE POLYGLUTAMATES INTO LYSOSOMES DERIVED FROM S180 CELLS - FURTHER CHARACTERIZATION AND EVIDENCE FOR A SIMPLE MOBILE CARRIER SYSTEM WITH BROAD SPECIFICITY FOR HOMOPEPTIDES OR HETEROPEPTIDES BEARING A C-TERMINAL GLUTAMYL MOIETY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST LYSOSOMES; AMINO-ACID TRANSPORT; SIALIC-ACID; RAT-LIVER; PHARMACOKINETICS; MEMBRANE	Studies are presented further characterizing a facilitative system transporting methotrexate (MTX) polyglutamates into lysosomes derived from S180 cells. Initial influx of [H-3]MTX + G1 (MTX with 1 additional glutamyl residue) exhibited a slightly alkaline pH optimum (pH 7.7) and was moderately temperature-dependent (Q10 27-37-degrees-C = 3.1 +/- 0.1). An analysis of the kinetics of intralysosomal accumulation of [H-3]MTX + G1 showed saturation kinetics for initial influx, but linear kinetics for the steady-state level of exchangeable [H-3]MTX + G1 at different external concentrations of [H-3]MTX + G1. In addition, the system exhibited substantial directional asymmetry with respect to the interaction with MTX + G1 during influx and efflux. Accelerated homo- and heteroexchange diffusion was demonstrated for influx of [H-3]MTX + G1, while decelerated homoexchange diffusion was demonstrated for efflux of [H-3]MTX + G1 following trans-positioning of MTX + G1 or glutamyl-gamma-glutamate in the opposite compartment. These observations were consistent with a single mobile carrier system mediating influx and efflux of this polyglutamate. Based upon an analysis of competitive interactions with [H-3] MTX + G1, this system displayed specificity for MTX-gamma-glutamates, folyl-gamma-polyglutamates, alpha- or gamma-glutamyl peptides and heteropeptides bearing a C-terminal gamma-glutamate but not for MTX or glutamate, themselves. Among polyglutamates, gamma-glutamyl chain length was not a significant factor for transport except in the case of MTX polyglutamates. Overall, our results appear to delineate in the lysosomal membrane a simple mobile carrier system with broad specificity for folyl- or non-folyl-bearing peptides responsible for the transport of MTX polyglutamates.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC PHARMACOL & THERAPEUT,MOLEC THERAPEUT LAB,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,ITHACA,NY 14853	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [CA 08748, CA 22766, CA 18856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA018856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRUECO JR, 1992, J BIOL CHEM, V267, P15356; BARRUECO JR, 1991, J BIOL CHEM, V266, P11732; BAUGH CM, 1971, ANN NY ACAD SCI, V186, P7; BAUGH CM, 1973, BIOCHEM BIOPH RES CO, V52, P27, DOI 10.1016/0006-291X(73)90949-2; BERNAR J, 1986, J BIOL CHEM, V261, P7107; DEMBO M, 1984, FOLATE ANTAGONISTS T, V1, P173; Eilam Y., 1974, METHODS MEMBRANE BIO, V2, P283; ELSENHANS B, 1984, J BIOL CHEM, V250, P5982; FRY DW, 1982, J BIOL CHEM, V257, P1892; GAHL WA, 1982, J BIOL CHEM, V257, P9570; GALIVAN J, 1979, CANCER RES, V39, P735; GALIVAN J, 1980, MOL PHARMACOL, V17, P105; GEWIRTZ DA, 1979, CANCER RES, V39, P2914; GREENE AA, 1990, J BIOL CHEM, V265, P9888; Hall C W, 1978, Methods Enzymol, V50, P439; HARMS E, 1980, P NATL ACAD SCI-BIOL, V77, P6139, DOI 10.1073/pnas.77.10.6139; JOLIVET J, 1983, J CLIN INVEST, V72, P773, DOI 10.1172/JCI111048; JONAS AJ, 1982, J BIOL CHEM, V257, P13185; JONAS AJ, 1989, J BIOL CHEM, V264, P4953; KISLIUK RL, 1984, FOLATE ANTAGONISTS T, V1, P1; LESLIE GI, 1974, BIOCHEMISTRY-US, V13, P4957, DOI 10.1021/bi00721a013; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MCGUIRE JJ, 1985, CANCER RES, V45, P6395; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MCQUIRE JJ, 1984, FOLATES PTERINS, V1, P135; PISONI RL, 1989, J BIOL CHEM, V264, P4850; PISONI RL, 1987, J BIOL CHEM, V262, P15011; PISONI RL, 1987, J BIOL CHEM, V262, P6010; PISONI RL, 1985, J BIOL CHEM, V260, P4791; PLAGEMANN PGW, 1980, CURR TOP MEMBR TRANS, V14, P226; PRIEST DG, 1982, MOL CELL BIOCHEM, V43, P81, DOI 10.1007/BF00423095; SAMUELS LL, 1985, CANCER RES, V45, P1488; SCHILSKY RL, 1980, P NATL ACAD SCI-BIOL, V77, P2919, DOI 10.1073/pnas.77.5.2919; SILINK M, 1975, J BIOL CHEM, V250, P5982; SIROTNAK FM, 1980, PHARMACOL THERAPEUT, V8, P71, DOI 10.1016/0163-7258(80)90060-1; TIETZE F, 1989, J BIOL CHEM, V264, P15316; WANG TTY, 1986, J BIOL CHEM, V261, P3551; WHITEHEAD VM, 1975, CANCER RES, V35, P2985	38	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19986	19991						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1383199				2022-12-27	WOS:A1992JR85800040
J	FAUNDEZ, V; KRAUSS, R; HOLUIGUE, L; GARRIDO, J; GONZALEZ, A				FAUNDEZ, V; KRAUSS, R; HOLUIGUE, L; GARRIDO, J; GONZALEZ, A			EPIDERMAL GROWTH-FACTOR RECEPTOR IN SYNAPTIC FRACTIONS OF THE RAT CENTRAL-NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE KINASE; LONG-TERM POTENTIATION; FACTOR IMMUNOREACTIVE MATERIAL; EGF-RECEPTOR; MAMMALIAN BRAIN; MESSENGER-RNA; BINDING-SITE; FACTOR-ALPHA; CELLS; LOCALIZATION	Functional relationships between epidermal growth factor (EGF) and neural tissues have of late attracted increasing interest. However, in spite of reported EGF effects on neurons, the expression of the EGF receptor (EGF-R) has not yet been unambiguously demonstrated in these cells. This 170-kDa protein bears an intracellular tyrosine kinase domain in which activity is ligand-dependent. We give definitive evidence here for its presence in neonatal and adult rat neurons showing also, for the first time, its binding and functional tyrosine kinase activities in the synaptic region. Immunohistochemistry using a polyclonal antibody prepared against the receptor purified from rat liver showed positive staining localized exclusively to neurons without regionalization to any particular brain zone. Binding studies made in Percoll-obtained synaptosomes revealed specific high affinity I-125-EGF binding sites (K(d), 1.42 x 10(-10) +/- 0.58 M) accounting for 17% of total binding and a great majority of low affinity (K(d), 2.55 x 10(-9) +/- 0.35 M) binding sites. Higher binding capacity was found in synaptosomal fractions obtained from newborn rats. The identity of the synaptosomal EGF binding activity with the 170-kDa EGF-R protein was demonstrated by cross-linking experiments. Furthermore, EGF-Affi-Prep affinity chromatography adsorbs a 170-kDa protein with EGF-R immunoreactivity from whole homogenates of adult rat brain. Phosphorylation assays made in freeze-thawed or intact synaptosomes showed EGF-induced tyrosine phosphorylation in the range of 170-, 126-150-, 124-, 113-, 98-, and 70-kDa proteins including the EGF-R. Thus, the EGF-R/EGF regulatory system could have a role in synaptic function that remains to be explored.	CATHOLIC UNIV CHILE, FAC MED, DEPT INMUNOL CLIN & REUMATOL, CASILLA 114-D, SANTIAGO, CHILE; CATHOLIC UNIV CHILE, FAC CIENCIAS BIOL, SANTIAGO, CHILE	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile			Faundez, Victor/H-5539-2012	Faundez, Victor/0000-0002-2114-5271				AVOLA R, 1988, J NEUROSCI RES, V19, P230, DOI 10.1002/jnr.490190208; BARABAN JM, 1989, AM J PSYCHIAT, V146, P1251; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BIRECREE E, 1991, DEV BRAIN RES, V60, P145, DOI 10.1016/0165-3806(91)90043-I; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CHENG N, 1990, J BIOL CHEM, V265, P2417; COHEN S, 1982, P NATL ACAD SCI-BIOL, V79, P6237, DOI 10.1073/pnas.79.20.6237; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P13642; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; ELLIS PD, 1988, J NEUROCHEM, V51, P611, DOI 10.1111/j.1471-4159.1988.tb01082.x; FALLON JH, 1984, SCIENCE, V224, P1107, DOI 10.1126/science.6144184; GIRAULT JA, 1992, J NEUROCHEM, V58, P518, DOI 10.1111/j.1471-4159.1992.tb09751.x; GLADHAUG IP, 1988, CANCER RES, V48, P6560; GOMEZPINILLA F, 1988, BRAIN RES, V438, P385, DOI 10.1016/0006-8993(88)91369-8; GONATAS NK, 1971, J CELL BIOL, V51, P484, DOI 10.1083/jcb.51.2.484; GONZALEZ A, 1981, J CELL BIOL, V88, P108, DOI 10.1083/jcb.88.1.108; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRAMATSU M, 1988, EXPERIENTIA, V44, P23, DOI 10.1007/BF01960230; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HIRATA Y, 1982, J CLIN ENDOCR METAB, V55, P1174, DOI 10.1210/jcem-55-6-1174; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; LAKSHMANAN J, 1986, J NEUROCHEM, V46, P1081, DOI 10.1111/j.1471-4159.1986.tb00621.x; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEUTZ A, 1982, NEUROSCI LETT, V30, P179, DOI 10.1016/0304-3940(82)90293-2; LINDEN DJ, 1989, BRAIN RES REV, V14, P279, DOI 10.1016/0165-0173(89)90004-0; MARCANTONIO EE, 1982, EUR J BIOCHEM, V124, P217, DOI 10.1111/j.1432-1033.1982.tb05928.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOODY TW, 1988, ANN NY ACAD SCI, V547, P114, DOI 10.1111/j.1749-6632.1988.tb23880.x; MORRISON RS, 1988, J NEUROSCI RES, V21, P71, DOI 10.1002/jnr.490210111; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; MOSS AM, 1990, P NATL ACAD SCI USA, V87, P4453, DOI 10.1073/pnas.87.12.4453; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; NEUFELD G, 1987, J CELL PHYSIOL, V131, P131, DOI 10.1002/jcp.1041310119; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; PLATASALAMAN CR, 1988, NEUROSCI LETT, V94, P161, DOI 10.1016/0304-3940(88)90288-1; REES AR, 1984, EMBO J, V3, P1843, DOI 10.1002/j.1460-2075.1984.tb02057.x; ROBINSON RA, 1982, CANCER RES, V42, P2633; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SCHAUDIES RP, 1989, J BIOL CHEM, V264, P10447; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SPIEGELBERG T, 1988, MOL CELL BIOL, V8, P3338, DOI 10.1128/MCB.8.8.3338; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TERFAU H, 1989, BRAIN RES, V484, P352; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIO CP, 1985, KIDNEY INT, V28, P36, DOI 10.1038/ki.1985.115; WALICKE PA, 1989, ANNU REV NEUROSCI, V12, P103, DOI 10.1146/annurev.neuro.12.1.103; WALKER F, 1991, J BIOL CHEM, V266, P2746; WANG SL, 1989, ENDOCRINOLOGY, V124, P240, DOI 10.1210/endo-124-1-240; WERNER MH, 1988, J HISTOCHEM CYTOCHEM, V36, P81, DOI 10.1177/36.1.3275713; WILCOX JN, 1988, J NEUROSCI, V8, P1901; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; [No title captured]	70	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20363	20370						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400354				2022-12-27	WOS:A1992JR85800096
J	YANNARIELLOBROWN, J; FROST, SJ; WEIGEL, PH				YANNARIELLOBROWN, J; FROST, SJ; WEIGEL, PH			IDENTIFICATION OF THE CA2+-INDEPENDENT ENDOCYTIC HYALURONAN RECEPTOR IN RAT-LIVER SINUSOIDAL ENDOTHELIAL-CELLS USING A PHOTOAFFINITY CROSS-LINKING REAGENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; ACID BINDING; HEPATOCYTES; SURFACE; DEGRADATION; PGP-1; SITE	The Ca2+-independent endocytic hyaluronan (HA) receptor in rat liver sinusoidal endothelial cells (LECs) was identified using a novel cross-linking derivative of HA. The heterobifunctional, photoactivatable, reducible reagent sulfosuccinimidyl 2-(p-azidosalicylamido)ethyl-1,3'-dithiopropionate (SASD) was coupled to the terminal amino group of uniquely modified HA-amine oligosaccharides (M(r) approximately 60,000) and subsequently iodinated. I-125-ASD-HA bound to cultured LECs with similar specificity and affinity as a previously characterized I-125-HA-amine/Bolton-Hunter adduct. Permeabilized LECs were incubated with I-125-ASD-HA with 10 mM EGTA and photolysed with UV light. Detergent extracts were reduced to release the HA oligosaccharides and radiolabeled proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography. Two polypeptides were consistently and equally labeled at M(r) = 175,000 and 166,000. Photoaffinity labeling of these two proteins was virtually identical in cultured LECs or membranes and was competed >90% with a 100-fold excess of HA. As with the previously characterized bona fide LEC HA receptor, cross-linking was also competed by chondroitin sulfate and heparin, but less efficiently by chondroitin and not with galacturonan. We conclude that the Ca2+-independent LEC HA receptor is composed of at least two polypeptides of M(r) approximately 175,000 and 166,000 and may exist as a heterodimer of M(r) approximately 340,000. We also conclude that the LEC HA receptor is distinct from the CD44 family of HA-binding proteins.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston					NIA NIH HHS [AG05492] Funding Source: Medline; NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG005492] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALHO AM, 1989, J CELL BIOL, V108, P1557, DOI 10.1083/jcb.108.4.1557; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOLTON AE, 1973, BIOCHEM J, V133, P5339; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CAMP RL, 1991, J CELL BIOL, V115, P1283, DOI 10.1083/jcb.115.5.1283; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; DONNER DB, 1983, J BIOL CHEM, V258, P2736; DSOUZA M, 1985, BIOCHEM INT, V10, P43; ERIKSSON S, 1983, EXP CELL RES, V144, P223, DOI 10.1016/0014-4827(83)90458-5; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FORSBERG N, 1991, BIOCHIM BIOPHYS ACTA, V1078, P12, DOI 10.1016/0167-4838(91)90085-E; FROST SJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P66, DOI 10.1016/0005-2736(88)90458-0; FROST SJ, 1990, BIOCHIM BIOPHYS ACTA, V1034, P39, DOI 10.1016/0304-4165(90)90150-U; FROST SJ, 1990, BIOCHEMISTRY-US, V29, P10425, DOI 10.1021/bi00497a019; FROST SJ, 1990, CHARACTERIZATION PUR; GREEN SJ, 1988, J CELL SCI, V89, P145; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JI TH, 1982, ANAL BIOCHEM, V121, P286, DOI 10.1016/0003-2697(82)90481-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MCGARY CT, 1988, HYALURONIC ACID BIND; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; NAGASAWA K, 1980, METHODS CARBOHYDR CH, V8, P287; OKA JA, 1987, J CELL PHYSIOL, V133, P243, DOI 10.1002/jcp.1041330207; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; SCOTT J. E., 1960, METHODS BIOCHEM ANAL, V8, P145; SMEDSROD B, 1984, BIOCHEM J, V223, P617, DOI 10.1042/bj2230617; SMEDSROD B, 1990, BIOCHEM J, V266, P313, DOI 10.1042/bj2660313; UNDERHILL CB, 1980, J BIOL CHEM, V255, P4544; UNDERHILL CB, 1979, J CELL BIOL, V82, P475, DOI 10.1083/jcb.82.2.475; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068; Wong SS, 1991, CHEM PROTEIN CONJUGA; YANNARIELLOBROW.J, 1991, J CELL BIOL, V115, P262; YANNARIELLOBROWN J, 1992, J CELL BIOCHEM, V48, P73, DOI 10.1002/jcb.240480111; YANNARIELLOBROWN J, 1992, BIOCHEMISTRY-US, V31, P576, DOI 10.1021/bi00117a039	45	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20451	20456						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1383202				2022-12-27	WOS:A1992JR85800109
J	HAIGLER, HT; MANGILI, JA; GAO, Y; JONES, J; HORSEMAN, ND				HAIGLER, HT; MANGILI, JA; GAO, Y; JONES, J; HORSEMAN, ND			IDENTIFICATION AND CHARACTERIZATION OF COLUMBID ANNEXIN-I(CP37) - INSIGHTS INTO THE EVOLUTION OF ANNEXIN-I PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN KINASE-C; FACTOR RECEPTOR KINASE; DEPENDENT 35-KILODALTON SUBSTRATE; LIPOCORTIN-I; PHOSPHOLIPID BINDING; TYROSINE PHOSPHORYLATION; AMINO TERMINUS; 33-KDA PROTEIN; PIGEON CROP	Annexin I (AnxI) contains phosphorylation sites in its "hinge region" that have been implicated in the regulation of cell growth and/or differentiation. A pigeon (Columba livia) isoform of this protein, annexin I(cp35) (cp35), has a very similar amino acid sequence overall but an unrelated sequence that lacks phosphorylation sites in the hinge region. We now report the identification and characterization of annexin I(cp37) (cp37) from pigeon. Genomic cloning and Southern blot analysis demonstrated that cp37 and cp35 were encoded by separated genes. Prolactin induced the expression of cp35 mRNA but not cp37. The amino acid sequence of cp37 was deduced from a cDNA clone and found to share 93 and 75% sequence identity with cp35 and human AnxI, respectively. The amino acid sequence of cp37 bore similarities to both AnxI and cp35 in the critical hinge region. Like AnxI, cp37 contained consensus phosphorylation sites in its amino acid sequence and was phosphorylated on tyrosine by the EGF receptor/kinase and on serine by protein kinase C in vitro. Despite the functional similarities between cp37 and AnxI, the nucleotide sequence that encoded the hinge region of cp37 was very similar to the analogous region of cp35, but different from that of AnxI. We propose that certain features shared by cp37 and AnxI are the products of convergent evolution. The fact that evolution independently selected for two annexin I-like genes (cp37 and anxI) encoding analogous phosphorylation sites is strong evidence that phosphorylation is important for the regulation of the biological activity of these proteins.	UNIV CINCINNATI,COLL MED,DEPT PHYSIOL & BIOPHYS,CINCINNATI,OH 45267	University of Cincinnati	HAIGLER, HT (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717, USA.		Haigler, Harry/C-3788-2011	Gao, Yunling/0000-0002-6622-3253	NIDDK NIH HHS [DK42461] Funding Source: Medline; NIGMS NIH HHS [GM35784] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042461] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON TR, 1987, ENDOCRINOLOGY, V120, P1258, DOI 10.1210/endo-120-4-1258; ANDO Y, 1989, J BIOL CHEM, V264, P6948; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DE BK, 1986, J BIOL CHEM, V261, P3784; FAVA RA, 1984, J BIOL CHEM, V259, P2636; GERKE V, 1991, GENE, V104, P259, DOI 10.1016/0378-1119(91)90259-E; GIUGNI TD, 1985, J BIOL CHEM, V260, P5081; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HITTI YS, 1991, GENE, V103, P185, DOI 10.1016/0378-1119(91)90272-D; Horseman N. D., 1987, ACTIONS PROLACTIN MO, P41; HORSEMAN ND, 1989, MOL ENDOCRINOL, V3, P773, DOI 10.1210/mend-3-5-773; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HUEBNER K, 1988, ONCOGENE RES, V2, P299; IZANT JG, 1991, J BIOL CHEM, V266, P18560; KAPLAN R, 1988, J BIOL CHEM, V263, P8037; KOVACIC RT, 1991, BIOCHEMISTRY-US, V30, P9015, DOI 10.1021/bi00101a015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCKANNA JA, 1989, SCIENCE, V243, P1477, DOI 10.1126/science.2928781; MOSS SE, 1992, IN PRESS ANNEXINS; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PUKAC LA, 1987, MOL ENDOCRINOL, V1, P188, DOI 10.1210/mend-1-2-188; ROBITZKI A, 1990, BIOCHEM J, V271, P415, DOI 10.1042/bj2710415; ROSE G D, 1985, P1; SAKATA T, 1988, NUCLEIC ACIDS RES, V16, P11818, DOI 10.1093/nar/16.24.11818; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SATO EF, 1989, FEBS LETT, V244, P108, DOI 10.1016/0014-5793(89)81173-1; SCHLAEPFER DD, 1988, BIOCHEMISTRY-US, V27, P4253, DOI 10.1021/bi00412a008; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SCHLAEPFER DD, 1992, J BIOL CHEM, V267, P9529; SELSTED ME, 1986, ANAL BIOCHEM, V155, P270, DOI 10.1016/0003-2697(86)90436-7; TAMAKI M, 1987, NUCLEIC ACIDS RES, V15, P7637, DOI 10.1093/nar/15.18.7637; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	39	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19123	19129						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388165				2022-12-27	WOS:A1992JP59300021
J	ALAI, M; MUI, ALF; CUTLER, RL; BUSTELO, XR; BARBACID, M; KRYSTAL, G				ALAI, M; MUI, ALF; CUTLER, RL; BUSTELO, XR; BARBACID, M; KRYSTAL, G			STEEL FACTOR STIMULATES THE TYROSINE PHOSPHORYLATION OF THE PROTOONCOGENE PRODUCT, P95(VAV), IN HUMAN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SIGNALING PROTEINS; GROWTH-FACTOR; KINASE RECEPTOR; W-LOCUS; VAV PROTOONCOGENE; PROTO-ONCOGENE; KIT LIGAND; SI-LOCUS; MOUSE; IDENTIFICATION	Steel factor (SF) (also called stem cell factor, mast cell growth factor, or c-kit ligand) is a recently cloned hemopoietic growth factor that is produced by bone marrow stromal cells, fibroblasts, and hepatocytes. In both mouse and man it acts synergistically with several colony stimulating factors, including interleukin-3 (IL-3) and granulocyte macrophage-colony stimulating factor (GM-CSF), to induce the proliferation and differentiation of primitive hemopoietic precursor cells. In order to study its mechanism of action and to explore the molecular basis for its synergistic activity we have examined the proteins that become tyrosine phosphorylated in response to SF, IL-3, and GM-CSF. We report herein that SF, but not IL-3 or GM-CSF, dramatically stimulates the tyrosine phosphorylation of the product of the recently discovered proto-oncogene, vav, in two SF-responsive human cell lines, M07E and TF-1. Although phosphorylation is very rapid, reaching maximal levels within 2 min at 37-degrees-C, co-immunoprecipitation studies suggest that c-kit may either not associate directly with p95vav or bind to it with very low affinity. Nonetheless, our data suggest that c-kit may utilize p95vav to mediate downstream signaling in hemopoietic cells.	BRITISH COLUMBIA CANC RES CTR,TERRY FOX LAB,601 W 10TH AVE,VANCOUVER V5Z 1L3,BC,CANADA; BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	British Columbia Cancer Agency; Bristol-Myers Squibb			Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; Krystal, Gerald/0000-0002-1961-6281				ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1990, Experimental Hematology (Charlottesville), V18, P620; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BERNSTEIN ID, 1991, BLOOD, V77, P2316; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KANAKURA Y, 1990, BLOOD, V76, P706; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KITAMURA T, 1989, BLOOD, V73, P375; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5083; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANGE B, 1987, BLOOD, V70, P192; LERNER NB, 1991, BLOOD, V77, P1876; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	35	137	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18021	18025						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381360				2022-12-27	WOS:A1992JM22300083
J	DEGUCHI, T				DEGUCHI, T			SEQUENCES AND EXPRESSION OF ALLELES OF POLYMORPHIC ARYLAMINE N-ACETYLTRANSFERASE OF HUMAN LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLATION PHARMACOGENETICS; NUCLEOTIDE-SEQUENCE; SLOW ACETYLATION; CLONING; GENE; GENOTYPE; CELLS; CDNA; ACID	Fifty human livers obtained at autopsy were analyzed for N-acetyltransferase and classified into six genotypes. Determination of N-acetyltransferase activity and proteins from supernatants of liver homogenates indicate that genotype I corresponds to rapid acetylator, genotypes II and III to intermediate acetylator, and genotypes IV, V, and VI to slow acetylator phenotypes. Northern blot analysis shows that levels of mRNA for N-acetyltransferase in the livers do not markedly differ among the six genotypes. Three alleles of the N-acetyltransferase gene were cloned and sequenced. mRNA is coded in two exons. Comparison of alleles 2 and 3, which correspond to low N-acetyltransferase activity, with allele 1, which corresponds to high N-acetyltransferase activity, revealed several polymorphisms. Two gene sequence differences occur in the coding exons of alleles 2 and 3, one of which would produce different amino acids in the proteins. Those sequence differences that lead to amino acid substitutions result in a loss of BamHI and TaqI sites for alleles 2 and 3, respectively. Expression studies of the alleles in Chinese hamster ovary cells show that allele 1 expresses high levels of N-acetyltransferase activity and enzyme protein, while alleles 2 and 3 express low levels of both protein and activity.	TOKYO METROPOLITAN INST NEUROSCI,DEPT MOLEC NEUROBIOL,FUCHU,TOKYO 183,JAPAN	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science								ABUZEID M, 1991, MOL CARCINOGEN, V4, P81, DOI 10.1002/mc.2940040112; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193; BLUM M, 1989, P NATL ACAD SCI USA, V86, P9554, DOI 10.1073/pnas.86.23.9554; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEGUCHI T, 1990, J BIOL CHEM, V265, P12757; EBISAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P1252, DOI 10.1016/0006-291X(91)90676-X; GRANT DM, 1989, NUCLEIC ACIDS RES, V17, P3978, DOI 10.1093/nar/17.10.3978; HEIN DW, 1988, BIOCHIM BIOPHYS ACTA, V948, P37, DOI 10.1016/0304-419X(88)90004-2; HICKMAN D, 1991, BIOCHEM PHARMACOL, V42, P1007, DOI 10.1016/0006-2952(91)90282-A; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTELL KJ, 1991, MOL PHARMACOL, V40, P218; MASHIMO M, 1992, IN PRESS HUMAN GENET; OHSAKO S, 1990, J BIOL CHEM, V265, P4630; OHSAKO S, 1988, J BIOL CHEM, V263, P7534; OHTOMI M, 1989, EUR J BIOCHEM, V185, P253, DOI 10.1111/j.1432-1033.1989.tb15110.x; Sambrook J., 1989, MOL CLONING, P916; SASAKI Y, 1991, J BIOL CHEM, V266, P13243; STAFFORD J, 1983, NATURE, V306, P77, DOI 10.1038/306077a0; SUNAHARA S, 1961, SCIENCE, V134, P1530, DOI 10.1126/science.134.3489.1530; VATSIS KP, 1991, P NATL ACAD SCI USA, V88, P6333, DOI 10.1073/pnas.88.14.6333; WEBER WW, 1984, FED PROC, V43, P2332; WEBER WW, 1985, PHARMACOL REV, V37, P25	24	106	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18140	18147						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381364				2022-12-27	WOS:A1992JM22300101
J	JAISSER, F; CANESSA, CM; HORISBERGER, JD; ROSSIER, BC				JAISSER, F; CANESSA, CM; HORISBERGER, JD; ROSSIER, BC			PRIMARY SEQUENCE AND FUNCTIONAL EXPRESSION OF A NOVEL OUABAIN-RESISTANT NA,K-ATPASE - THE BETA-SUBUNIT MODULATES POTASSIUM ACTIVATION OF THE NA,K-PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NA+-K+-ATPASE; ALPHA-SUBUNIT; SODIUM-TRANSPORT; CELLS; NA+,K+-ATPASE; ISOFORMS; ALDOSTERONE; AFFINITY; BLADDER	In order to understand the molecular mechanism of ouabain resistance in the toad Bufo marinus, Na,K-ATPase alpha and beta-subunits have been cloned and their functional properties tested in the Xenopus laevis oocyte expression system. According to sequence comparison between species, alpha-1, beta-1, and beta-3 isoforms were identified in a clonal toad urinary bladder cell line (TBM 18-23). The sequence of the alpha-1 isoform is characterized by two positively charged amino acids (Arg, Lys) at the N-terminal border of the H-1-H-2 extracellular loop and no charged amino acid at the C terminus, a pattern distinct from the ouabain-resistant rat alpha-1 isoform. The coexpression of alpha-1-beta-1 or alpha-1-beta-3 TBM subunits in the Xenopus oocyte resulted in the expression of identical maximum Na,K-pump currents with identical inhibition constant for ouabain (K(i)) (alpha-1-beta-1: 53 +/- 3-mu-M; n = 7 vs. alpha-1-beta-3: 57 +/- 3.0-mu-M; n = 8) but distinct potassium half activation constant (K1/2) (alpha-1-beta-1: 0.87 +/- 0.08 mM, n = 16; alpha-1-beta-3: 1.29 +/- 0.07 mM, n = 17; p < 0.005). We conclude that (i) the TBM alpha-1 isoform is necessary and sufficient to confer the ouabain resistant phenotype; (ii) the beta-3 or beta-1 subunit can associate with the alpha-1 equally well without affecting the ouabain-resistant phenotype; (iii) some specific sequence of the beta-subunit can modulate the activation of the Na,K-pump by extracellular potassium ions.			JAISSER, F (corresponding author), UNIV LAUSANNE, INST PHARMACOL & TOXICOL, RUE BUGNON 27, CH-1005 LAUSANNE, SWITZERLAND.		Horisberger, Jean-Daniel/A-2538-2009					ASHER C, 1988, AM J PHYSIOL, V254, pC512, DOI 10.1152/ajpcell.1988.254.4.C512; BAXTERLOWE LA, 1989, FEBS LETT, V257, P181, DOI 10.1016/0014-5793(89)81816-2; Bentley P.J., 1971, ENDOCRINES OSMOREGUL, P161; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CORTAS N, 1989, J MEMBRANE BIOL, V108, P187, DOI 10.1007/BF01871029; CORTAS N, 1971, BIOCHIM BIOPHYS ACTA, V249, P181, DOI 10.1016/0005-2736(71)90095-2; GEERING K, 1979, BIOCHIM BIOPHYS ACTA, V566, P157, DOI 10.1016/0005-2744(79)90258-4; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1985, J BIOL CHEM, V260, P5154; GHOSH S, 1991, J CELL PHYSIOL, V149, P184, DOI 10.1002/jcp.1041490203; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GLYNN IM, 1988, NA PLUS K PLUS PUM A, P435; GOOD PJ, 1988, J VIROL, V62, P944, DOI 10.1128/JVI.62.3.944-953.1988; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HANDLER JS, 1979, P NATL ACAD SCI USA, V76, P4151, DOI 10.1073/pnas.76.8.4151; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; JAISSER F, 1991, SOC GENERAL PHYSL 2, V46, P19; JAUNIN P, 1992, J BIOL CHEM, V267, P577; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LO TN, 1978, J BIOL CHEM, V253, P4432; LUCCHESI PA, 1991, J BIOL CHEM, V266, P9327; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; PACCOLAT MP, 1987, AM J PHYSIOL, V252, pC468, DOI 10.1152/ajpcell.1987.252.5.C468; PELLANDA AM, 1992, AM J PHYSIOL, V262, pC899, DOI 10.1152/ajpcell.1992.262.4.C899; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; RREY F, 1989, AM J PHYSIOL, V256, pF1034; Sambrook J, 1989, MOL CLONING LABORATO; STIMERS JR, 1991, J GEN PHYSIOL, V98, P815, DOI 10.1085/jgp.98.4.815; TAKEYASU K, 1990, AM J PHYSIOL, V259, pC619, DOI 10.1152/ajpcell.1990.259.4.C619; VERREY F, 1987, J CELL BIOL, V104, P1231, DOI 10.1083/jcb.104.5.1231; ZAMOFING D, 1988, J MEMBRANE BIOL, V104, P69, DOI 10.1007/BF01871903	35	147	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16895	16903						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380956				2022-12-27	WOS:A1992JL05300029
J	WIELAND, SJ; GONG, QH; CHOU, RH; BRENT, LH				WIELAND, SJ; GONG, QH; CHOU, RH; BRENT, LH			A LINEAGE-SPECIFIC CA2+-ACTIVATED K+ CONDUCTANCE IN HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTACTIC PEPTIDE; POTENTIAL CHANGES; POTASSIUM CURRENT; SKELETAL-MUSCLE; PHOSPHOLIPASE-D; ION CHANNELS; DIFFERENTIATION; LYMPHOCYTES; ACTIVATION; PROLIFERATION	Cells of the human promyelocytic cell line HL-60 can be controllably induced to terminally differentiate into either granulocytes or monocyte/macrophages. HL-60 promyelocytes and terminally differentiated macrophages express a K+-selective ion channel which is activated by intracellular free Ca2+ concentrations above 10(-7) M. Because of its voltage independence, this channel can be distinguished from the voltage- and Ca2+-activated family of outward-rectifying channels. The channel is selective for K+ against Na+ and is blocked by Ba2+, thus it may be similar to the Ca2+-activated K+ channel previously described in human macrophages. In its sensitivity to block by charybdotoxin, this channel also resembles a Ca2+-activated K+ channel of lymphocytes, which plays a role in activation-dependent hyperpolarization. In contrast to promyelocytes and macrophages, functional expression of the Ca2+-activated K+ channel is suppressed to nearly undetectable levels in granulocytes derived from HL-60 cells by retinoic acid-induced differentiation. These data suggest that signals which produce elevation of intracellular Ca2+ will hyperpolarize promyelocytes and differentiated macrophages by activating this conductance; however, signals which elevate free Ca2+ in granulocytes must act on other effectors, which may may produce a different final influence on membrane potential.	HAHNEMANN UNIV,SCH MED,DEPT MED,PHILADELPHIA,PA 19102	Drexel University	WIELAND, SJ (corresponding author), HAHNEMANN UNIV,SCH MED,DEPT ANAT,MAIL STOP 408,BROAD & VINE ST,PHILADELPHIA,PA 19102, USA.							BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; COLLINS SJ, 1987, BLOOD, V70, P1233; COWEN DS, 1989, J CLIN INVEST, V83, P1651, DOI 10.1172/JCI114064; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; GALLIN EK, 1989, AM J PHYSIOL, V257, pC77, DOI 10.1152/ajpcell.1989.257.1.C77; GALLIN EK, 1977, J CELL BIOL, V75, P277, DOI 10.1083/jcb.75.1.277; GALLIN EK, 1991, PHYSIOL REV, V71, P775, DOI 10.1152/physrev.1991.71.3.775; GRINSTEIN S, 1989, AM J PHYSIOL, V257, pC197, DOI 10.1152/ajpcell.1989.257.2.C197; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; KRAUSE KH, 1990, J CLIN INVEST, V85, P491, DOI 10.1172/JCI114464; LATORRE R, 1982, P NATL ACAD SCI-BIOL, V79, P805, DOI 10.1073/pnas.79.3.805; MAHAUT-SMITH M P, 1989, Pfluegers Archiv European Journal of Physiology, V414, pS164, DOI 10.1007/BF00582284; MAHAUTSMITH MP, 1989, J PHYSIOL-LONDON, V415, P69, DOI 10.1113/jphysiol.1989.sp017712; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MINOWADA J, 1972, J NATL CANCER I, V49, P891; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; SELIGMANN BE, 1980, J MEMBRANE BIOL, V52, P257, DOI 10.1007/BF01869194; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; VAIRO G, 1988, J CELL PHYSIOL, V134, P13, DOI 10.1002/jcp.1041340103; WIELAND SJ, 1987, J CELL PHYSIOL, V132, P371, DOI 10.1002/jcp.1041320227; WIELAND SJ, 1990, J CELL PHYSIOL, V142, P643, DOI 10.1002/jcp.1041420326; WU JT, 1991, J BIOL CHEM, V266, P14893; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303	27	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15426	15431						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379229				2022-12-27	WOS:A1992JG11300028
J	KATSUYAMA, H; WANG, CLA; MORGAN, KG				KATSUYAMA, H; WANG, CLA; MORGAN, KG			REGULATION OF VASCULAR SMOOTH-MUSCLE TONE BY CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIGHT CHAIN PHOSPHORYLATION; ATPASE ACTIVITY; MYOSIN PHOSPHORYLATION; HEAVY-MEROMYOSIN; ACTIN-BINDING; CALMODULIN; DISSOCIATION; FRAGMENT; DOMAIN; CONTRACTION	Caldesmon is an actin-binding protein present in smooth muscle cells that also inhibits actin-activated myosin ATPase activity. To assess the possible role of caldesmon in the regulation of smooth contraction, we investigated the effects of synthetic peptides on force directly recorded from single hyperpermeable smooth muscle cells of ferret aorta and portal vein. GS17C, a peptide that contains the residues from Gly651 to Ser667 of the caldesmon sequence plus an added cysteine at the C terminus, binds calmodulin in a Ca2+-dependent manner and also binds to F-actin but does not inhibit actomyosin ATPase activity (Zhan, Q., Wong, S. S., and Wang, C.-L. A. (1991) J. Biol. Chem. 266, 21810-21814). In cells in which Ca2+ was clamped at pCa 7.0, GS17C induced a dose-dependent contraction (EC50 = 0.92-mu-M). in aorta cells, whereas it evoked little or no contraction in portal vein cells. The GS17C-induced contraction in aorta cells was inhibited at higher Ca2+ concentrations (above pCa 6.6) and by pretreatment with calmodulin. Another peptide, C16AA, which contains the residues from Ala594 to Ala609 and does not bind actin or calmodulin, did not induce contraction. Our results strongly suggest that GS17C induces contraction by the displacement of the inhibitory region of endogenous caldesmon and, furthermore, that caldesmon present in these smooth muscle cells regulates contraction by providing a basal resting inhibition of vascular tone.	BETH ISRAEL HOSP,PROGRAM SMOOTH MUSCLE RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,HARVARD THORNDIKE LAB,BOSTON,MA 02115; BOSTON BIOMED RES INST,DEPT MUSCLE RES,BOSTON,MA 02114	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston Biomedical Research Institute	KATSUYAMA, H (corresponding author), BETH ISRAEL HOSP,DIV CARDIOVASC,330 BROOKLINE AVE,BOSTON,MA 02215, USA.			Morgan, Kathleen/0000-0003-3300-3630	NHLBI NIH HHS [HL 31704, HL 41411, HL 42293] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041411, R01HL031704, R01HL042293] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM LP, 1989, J BIOL CHEM, V264, P7698; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BROZOVICH FV, 1990, PFLUG ARCH EUR J PHY, V416, P742, DOI 10.1007/BF00370624; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1988, CELL BIOPHYS, V12, P73, DOI 10.1007/BF02918351; COLLINS EM, 1992, AM J PHYSIOL, V252, pH754; COLLINS J H, 1991, Protein Sequences and Data Analysis, V4, P29; DEFEO TT, 1985, PFLUG ARCH EUR J PHY, V404, P100, DOI 10.1007/BF00581502; DEFEO TT, 1985, J PHYSIOL-LONDON, V369, P269, DOI 10.1113/jphysiol.1985.sp015900; FUJII T, 1987, J BIOL CHEM, V262, P2757; GERTHOFFER WT, 1987, J PHARMACOL EXP THER, V240, P8; HAEBERLE JR, 1992, J MUSCLE RES CELL M, V13, P81, DOI 10.1007/BF01738431; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; JIANG MJ, 1989, PFLUG ARCH EUR J PHY, V413, P637, DOI 10.1007/BF00581814; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; LASH JA, 1986, J BIOL CHEM, V261, P6155; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P1371, DOI 10.1016/S0006-291X(89)80155-X; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1984, BIOCHEM SOC T, V12, P945, DOI 10.1042/bst0120945; MORELAND S, 1987, PFLUG ARCH EUR J PHY, V408, P139, DOI 10.1007/BF00581343; MORGAN JP, 1982, PFLUG ARCH EUR J PHY, V395, P75, DOI 10.1007/BF00584972; NGAI PK, 1984, J BIOL CHEM, V259, P3656; PRITCHARD K, 1986, CELL CALCIUM, V7, P309, DOI 10.1016/0143-4160(86)90035-7; RISEMAN VM, 1989, J BIOL CHEM, V264, P2869; SIEGMAN MJ, 1984, PFLUG ARCH EUR J PHY, V401, P385, DOI 10.1007/BF00584340; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SZPACENKO A, 1985, FEBS LETT, V192, P9, DOI 10.1016/0014-5793(85)80032-6; VELAZ L, 1990, J BIOL CHEM, V265, P2929; Walsh M P, 1987, Prog Clin Biol Res, V245, P119; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WATSON MH, 1990, J BIOL CHEM, V265, P18860; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	36	129	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14555	14558						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386078				2022-12-27	WOS:A1992JF08800011
J	TOYOFUKU, T; KURZYDLOWSKI, K; LYTTON, J; MACLENNAN, DH				TOYOFUKU, T; KURZYDLOWSKI, K; LYTTON, J; MACLENNAN, DH			THE NUCLEOTIDE BINDING HINGE DOMAIN PLAYS A CRUCIAL ROLE IN DETERMINING ISOFORM-SPECIFIC CA2+ DEPENDENCE OF ORGANELLAR CA2+-ATPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; FUNCTIONAL CONSEQUENCES; ADENOSINE-TRIPHOSPHATASE; SKELETAL-MUSCLE; CALCIUM-BINDING; AMINO-ACIDS; TRANSMEMBRANE DOMAIN; MOLECULAR-CLONING; CATALYTIC SITE; HIGH-AFFINITY	Several isoforms of organellar Ca2+-ATPases have been identified, each of which is expressed in a tissue-specific manner. In order to examine the functional properties of fast-twitch (SERCA 1a), cardiac/slow-twitch (SERCA 2a), and non-muscle (SERCA 3) isoforms of the Ca2+-ATPase, cDNAs of each type were expressed transiently in COS-1 cells. A study of the Ca2+ dependence of Ca2+ uptake showed that SERCA 1 and SERCA 2 have identical Ca2+ dependences (K0.5 = pCa 6.87 +/- 0.03 and pCa 6.87 +/- 0.02, respectively), but SERCA 3 has a lower Ca2+ dependence (K0.5 = pCa 6.32 +/- 0.03). A study of the ATP dependence of Ca2+ uptake showed that SERCA 1, 2, and 3 have almost identical ATP dependences. Average Hill coefficients derived from Ca2+ uptake curves ranged from 1.7 to 1.8 for the three isoforms. In order to identify which regions of the linear sequence determine this difference in Ca2+ dependence, chimeric Ca2+-ATPases between SERCA 2 and SERCA 3 were constructed. Chimeric Ca2+-ATPases containing the nucleotide binding/hinge domain of SERCA 2 had SERCA 2 type Ca2+ dependence, but both nucleotide binding/hinge and COOH-terminal transmembrane domains of SERCA 3 were required for SERCA 3 type Ca2+ dependence. Accordingly, structural interactions between the nucleotide binding/hinge and COOH-terminal transmembrane domains appear to determine isoform-specific Ca2+ dependences.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV RENAL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	TOYOFUKU, T (corresponding author), UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA.			Lytton, Jonathan/0000-0003-4770-2512	NIDDK NIH HHS [DK 42879] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042879] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1981, SARCOPLASMIC RETICUL, V2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fleischer S, 1988, Prog Clin Biol Res, V273, P435; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1976, BIOCHEMISTRY-US, V15, P5293, DOI 10.1021/bi00669a015; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1967, J BIOL CHEM, V242, P4637; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KHANANSHVILI D, 1988, BIOCHEMISTRY-US, V27, P2943, DOI 10.1021/bi00408a041; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; LYTTON J, 1991, Biophysical Journal, V59, p249A; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; NAKAMOTO RK, 1986, FEBS LETT, V194, P258, DOI 10.1016/0014-5793(86)80096-5; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; REINHART PH, 1984, BIOCHEM J, V223, P1; ROSS DC, 1987, J BIOL CHEM, V262, P12977; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SCOTT TL, 1985, J BIOL CHEM, V260, P4421; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; TAYLOR JS, 1979, J BIOL CHEM, V254, P4402; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	56	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14490	14496						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1385816				2022-12-27	WOS:A1992JD32500106
J	ALLAN, CM; FIDGE, NH; KANELLOS, J				ALLAN, CM; FIDGE, NH; KANELLOS, J			ANTIBODIES TO THE CARBOXYL TERMINUS OF HUMAN APOLIPOPROTEIN-A-I - THE PUTATIVE CELLULAR-BINDING DOMAIN OF HIGH-DENSITY LIPOPROTEIN-3 AND CARBOXYL-TERMINAL STRUCTURAL HOMOLOGY BETWEEN APOLIPOPROTEIN-A-I AND APOLIPOPROTEIN-A-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOGEN-BROMIDE FRAGMENTS; MONOCLONAL-ANTIBODIES; APOA-I; IMMUNOCHEMICAL CHARACTERIZATION; CHOLESTEROL ACYLTRANSFERASE; PLASMA-MEMBRANES; RAT-LIVER; IDENTIFICATION; LOCALIZATION; EPITOPES	We have studied the binding of I-125-labeled high density lipoproteins (HDL3) to liver plasma membranes, which are thought to contain specific HDL receptor sites, using anti-peptide antibodies directed against two sites in the carboxyl-terminal region of human apoA-I. Two distinct antibody populations raised to peptides corresponding to amino acid residues 205-220 and 230-243, respectively, recognized regions of apoA-I that are exposed in the lipid environment of HDL3. However, anti-AI[230-243] IgG, but not anti-AI [205-220] IgG, recognized HDL2, suggesting that residues 205-220 of apoA-I are expressed differently in the two HDL populations. In addition, anti-AI[230-243] IgG showed strong cross-reactivity toward apoA-II. Epitope mapping studies showed that anti-AI[230-243] binds to an epitope located in the carboxyl-terminus of apoA-II, demonstrating significant structural homology between the carboxyl-terminal of apoA-II, demonstrating significant structural homology between the carboxyl-terminal regions of apoA-I and A-II, two candidate proteins for mediating the specific cellular interaction of HDL3. Fab fragments from anti-AI [205-220] and anti-AI[230-243] inhibited the binding of I-125-HDL3 to liver plasma membranes by approximately 80% and 60%, respectively. These findings are in agreement with our recent work using isolated CNBr fragments of apoA-I (Morrison, J., Fidge, N. H., and Tozuka, M. (1991) J. Biol. Chem. 266, 18780-18785), which suggest that the carboxyl-terminal region of apoA-I contains a binding domain which mediates the specific interaction of HDL3 with liver plasma membranes, possibly through the involvement of specific HDL receptors.			ALLAN, CM (corresponding author), BAKER MED RES INST,PROT CHEM & MOLEC BIOL UNIT,PRAHRAN,VIC 3181,AUSTRALIA.							ALLAN CM, 1991, J LIPID RES, V32, P595; BEKAERT ED, 1988, CLIN CHEM, V34, P1030; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BRINTON EA, 1986, J BIOL CHEM, V261, P495; CHACKO GK, 1984, BIOCHIM BIOPHYS ACTA, V795, P417, DOI 10.1016/0005-2760(84)90093-6; CHACKO GK, 1987, J LIPID RES, V28, P332; CHACKO GK, 1982, BIOCHIM BIOPHYS ACTA, V712, P129, DOI 10.1016/0005-2760(82)90094-7; CHEUNG MC, 1977, J CLIN INVEST, V60, P43, DOI 10.1172/JCI108767; CURTISS LK, 1985, J BIOL CHEM, V260, P2982; CURTISS LK, 1988, J BIOL CHEM, V263, P13779; EHNHOLM C, 1986, J LIPID RES, V27, P1259; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FIDGE N, 1989, BIOCHIM BIOPHYS ACTA, V1003, P84, DOI 10.1016/0005-2760(89)90103-3; FIDGE NH, 1985, J BIOL CHEM, V260, P3570; FIDGE NH, 1974, CLIN CHIM ACTA, V52, P15, DOI 10.1016/0009-8981(74)90383-0; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; Fleischer S, 1974, Methods Enzymol, V31, P6; FONG BS, 1985, J CLIN INVEST, V75, P1804, DOI 10.1172/JCI111893; GORINI G, 1969, J IMMUNOL, V103, P1125; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZYK E, 1988, BIOCHIM BIOPHYS ACTA, V962, P131, DOI 10.1016/0005-2760(88)90104-X; HOEG JM, 1985, ARTERIOSCLEROSIS, V5, P228, DOI 10.1161/01.ATV.5.3.228; HOGLE DM, 1988, J LIPID RES, V29, P1221; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; JACKSON RL, 1972, BIOCHIM BIOPHYS ACTA, V285, P36, DOI 10.1016/0005-2795(72)90178-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUX SE, 1972, J BIOL CHEM, V247, P7519; MACIEJKO JJ, 1983, NEW ENGL J MED, V309, P385, DOI 10.1056/NEJM198308183090701; MAO SJT, 1980, BIOCHIM BIOPHYS ACTA, V620, P447; MAO SJT, 1980, J BIOL CHEM, V255, P3448; MAO SJT, 1979, BIOCHEMISTRY-US, V18, P3984, DOI 10.1021/bi00585a022; MARCEL YL, 1987, J LIPID RES, V28, P768; MARCOVINA S, 1990, J LIPID RES, V31, P375; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MORRISON J, 1991, J BIOL CHEM, V266, P18780; MORRISON JR, 1990, ANAL BIOCHEM, V186, P145, DOI 10.1016/0003-2697(90)90588-Z; MORRISON JR, 1989, CIRCULATION S2, V80, P455; PETIT E, 1987, BIOCHIM BIOPHYS ACTA, V919, P287, DOI 10.1016/0005-2760(87)90268-2; PIO F, 1988, BIOCHIM BIOPHYS ACTA, V959, P160, DOI 10.1016/0005-2760(88)90027-6; SCHMITZ G, 1985, EMBO J, V4, P2773, DOI 10.1002/j.1460-2075.1985.tb04003.x; SCHONFELD G, 1977, J BIOL CHEM, V252, P6655; SILBERMAN SR, 1987, BIOCHEMISTRY-US, V26, P5833, DOI 10.1021/bi00392a038; SUTCLIFFE JG, 1983, SCIENCE, V219, P660, DOI 10.1126/science.6186024; SWANEY JB, 1980, J BIOL CHEM, V255, P877; TOZUKA M, 1989, BIOCHEM J, V261, P239, DOI 10.1042/bj2610239; WALTER G, 1980, P NATL ACAD SCI-BIOL, V77, P5197, DOI 10.1073/pnas.77.9.5197	47	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13257	13261						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377682				2022-12-27	WOS:A1992JB74600028
J	SCHAFER, BL; BISHOP, RW; KRATUNIS, VJ; KALINOWSKI, SS; MOSLEY, ST; GIBSON, KM; TANAKA, RD				SCHAFER, BL; BISHOP, RW; KRATUNIS, VJ; KALINOWSKI, SS; MOSLEY, ST; GIBSON, KM; TANAKA, RD			MOLECULAR-CLONING OF HUMAN MEVALONATE KINASE AND IDENTIFICATION OF A MISSENSE MUTATION IN THE GENETIC-DISEASE MEVALONIC ACIDURIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; HUMAN-FIBROBLASTS; ESCHERICHIA-COLI; INBORN ERROR; GAL OPERON; PROTEIN; REDUCTASE; CHOLESTEROL; SEQUENCE; TRANSCRIPTION	Mevalonic aciduria is the first proposed inherited disorder of the cholesterol/isoprene biosynthetic pathway in humans, and it is presumed to be caused by a mutation in the gene coding for mevalonate kinase. To elucidate the molecular basis of this inherited disorder, a 2.0-kilobase human mevalonate kinase cDNA clone was isolated and sequenced. The 1188-base pair open reading frame coded for a 396-amino acid polypeptide with a deduced M(r) of 42,450. The predicted protein sequence displayed similarity to those of galactokinase and the yeast RAR1 protein, indicating that they may belong to a common gene family. Southern hybridization studies demonstrated that the mevalonate kinase gene is located on human chomosome 12 and is a single copy gene. No major rearrangements were detected in the mevalonic aciduria subject. The relative size (2 kilobases) and amounts of human mevalonate kinase mRNA were not changed in mevalonic aciduria fibroblasts. Approximately half of the mevalonic aciduria cDNA clones encoding mevalonate kinase contained a single base substitution (A to C) in the coding region at nucleotide 902 that changed an asparagine residue to a threonine residue. The presence of this missense mutation was confirmed by polymerase chain reaction amplification and allele-specific hybridization of the genomic DNAs from the proband and the proband's father and brother. Similar analysis failed to detect this mutation in the proband's mother, seven normal subjects, or four additional mevalonic aciduria subjects, indicating that the mutation does not represent a common gene polymorphism. Functional analysis of the defect by transient expression confirmed that the mutation produced an enzyme with diminished activity. Our data suggest that the index case is a compound heterozygote for a mutation in the mevalonate kinase gene.	BAYLOR UNIV,MED CTR,KIMBERLY H COURTWRIGHT & JOSEPH W SUMMERS METAB DIS CTR,DALLAS,TX 75246	Baylor University; Baylor University Medical Center	SCHAFER, BL (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT METAB DIS,POB 400,PRINCETON,NJ 08543, USA.			Bishop, Richard/0000-0002-3965-7478				ADAMS CW, 1988, J BACTERIOL, V170, P203, DOI 10.1128/jb.170.1.203-212.1988; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARGOS P, 1985, EUR J BIOCHEM, V152, P651, DOI 10.1111/j.1432-1033.1985.tb09244.x; BAJWA W, 1988, MOL CELL BIOL, V8, P3439, DOI 10.1128/MCB.8.8.3439; BERGER R, 1985, CLIN CHIM ACTA, V152, P219, DOI 10.1016/0009-8981(85)90195-0; BHAT PJ, 1990, GENETICS, V125, P281; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1980, J LIPID RES, V21, P505; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CITRON BA, 1984, J BACTERIOL, V158, P269, DOI 10.1128/JB.158.1.269-278.1984; DEBOUCK C, 1985, NUCLEIC ACIDS RES, V13, P1841, DOI 10.1093/nar/13.6.1841; DORSEY JK, 1968, J BIOL CHEM, V243, P4667; FAUST J, 1987, J BIOL CHEM, V262, P1996; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIBSON KM, 1989, ENZYME, V41, P47, DOI 10.1159/000469050; GIBSON KM, 1990, J LIPID RES, V31, P515; GIBSON KM, 1989, BAYLOR U MED CTR P, V2, P15; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; KEARSEY SE, 1987, MOL GEN GENET, V210, P509, DOI 10.1007/BF00327205; KOZICH V, 1991, J INHERIT METAB DIS, V14, P265, DOI 10.1007/BF01800602; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEONARD S, 1986, P NATL ACAD SCI USA, V83, P2187, DOI 10.1073/pnas.83.7.2187; LINDGREN V, 1985, P NATL ACAD SCI USA, V82, P8567, DOI 10.1073/pnas.82.24.8567; MEHRABIAN M, 1986, J BIOL CHEM, V261, P6249; MOHANDAS T, 1986, SOMAT CELL MOLEC GEN, V12, P89, DOI 10.1007/BF01560731; POPJAK G, 1969, METHOD ENZYMOL, V15, P393; PORTER JW, 1985, METHOD ENZYMOL, V110, P71; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; TSAY YH, 1991, MOL CELL BIOL, V11, P620, DOI 10.1128/MCB.11.2.620; VANDOREN K, 1984, MOL CELL BIOL, V4, P1653, DOI 10.1128/MCB.4.8.1653; WEBSTER TD, 1988, NUCLEIC ACIDS RES, V16, P8192, DOI 10.1093/nar/16.16.8192	36	90	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13229	13238						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377680				2022-12-27	WOS:A1992JB74600024
J	DECKERSHEBESTREIT, G; SIMONI, RD; ALTENDORF, K				DECKERSHEBESTREIT, G; SIMONI, RD; ALTENDORF, K			INFLUENCE OF SUBUNIT-SPECIFIC ANTIBODIES ON THE ACTIVITY OF THE F0 COMPLEX OF THE ATP SYNTHASE OF ESCHERICHIA-COLI .1. EFFECTS OF SUBUNIT B-SPECIFIC POLYCLONAL ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; POLAR LOOP REGION; H+-ATPASE; UNCF-PROTEIN; MEMBRANE; F1F0; RECONSTITUTION; PREDICTION; F-0; PURIFICATION	Incubation of F1-stripped everted membrane vesicles with antibodies against subunit b of the ATP synthase from Escherichia coli resulted in an inhibition of the binding of F1 to F0, whereas the proton translocation remained unaffected. Incubation of unstripped everted membrane vesicles with anti-b antibodies resulted in a partial loss of F1, and the remaining membrane-bound ATP-hydrolyzing activity is uncoupled from proton translocation. Similar results were obtained when F(ab')2 or Fab fragments were used. The immunoblot analysis of truncated b' subunits different in length showed that the antigenic determinants are located in the carboxyl-terminal half of the polypeptide chain.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University	DECKERSHEBESTREIT, G (corresponding author), UNIV OSNABRUCK,FACHBEREICH BIOL CHEM,ARBEITSGRP MIKROBIOL,BARBARASTR 11,W-4500 OSNABRUCK,GERMANY.							ARNOLD A, 1976, ANAL BIOCHEM, V71, P209, DOI 10.1016/0003-2697(76)90029-4; BERZBORN RJ, 1990, Z NATURFORSCH C, V45, P772; BIRD CR, 1985, EMBO J, V4, P1381, DOI 10.1002/j.1460-2075.1985.tb03790.x; CURTIS SE, 1988, PHOTOSYNTH RES, V18, P223, DOI 10.1007/BF00042986; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12370; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; Douglas M, 1979, Methods Enzymol, V56, P58; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1980, J BIOL CHEM, V255, P2037; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRIEDL P, 1983, EMBO J, V2, P99, DOI 10.1002/j.1460-2075.1983.tb01388.x; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; GUNSALUS RP, 1982, P NATL ACAD SCI-BIOL, V79, P320, DOI 10.1073/pnas.79.2.320; HEMROLIN J, 1983, J BIOL CHEM, V258, P14550; HENSEL M, 1990, BIOCHIM BIOPHYS ACTA, V1016, P63, DOI 10.1016/0005-2728(90)90007-Q; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOPPE J, 1983, J BIOL CHEM, V258, P2882; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; LOO TW, 1982, BIOCHEM BIOPH RES CO, V106, P400, DOI 10.1016/0006-291X(82)91124-X; Maniatis T., 1982, MOL CLONING; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; OTTO J, 1989, FEBS LETT, V250, P625, DOI 10.1016/0014-5793(89)80810-5; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; PORTER ACG, 1985, J BIOL CHEM, V260, P8182; ROOS P, 1983, Z NATURFORSCH C, V38, P799; SCHNEIDER E, 1985, EUR J BIOCHEM, V153, P105, DOI 10.1111/j.1432-1033.1985.tb09274.x; SCHNEIDER E, 1982, EUR J BIOCHEM, V126, P149, DOI 10.1111/j.1432-1033.1982.tb06759.x; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STEFFENS K, 1987, J BIOL CHEM, V262, P5866; STEFFENS K, 1982, FEBS LETT, V142, P151, DOI 10.1016/0014-5793(82)80240-8; STEFFENS K, 1987, J BIOL CHEM, V262, P6334; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; WALKER JE, 1990, PHILOS T ROY SOC B, V326, P367, DOI 10.1098/rstb.1990.0018; WALKER JE, 1982, NATURE, V298, P867, DOI 10.1038/298867a0; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4	51	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12364	12369						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376322				2022-12-27	WOS:A1992HY94700106
J	KOST, C; STUBER, W; EHRLICH, HJ; PANNEKOEK, H; PREISSNER, KT				KOST, C; STUBER, W; EHRLICH, HJ; PANNEKOEK, H; PREISSNER, KT			MAPPING OF BINDING-SITES FOR HEPARIN, PLASMINOGEN-ACTIVATOR INHIBITOR-1, AND PLASMINOGEN TO VITRONECTINS HEPARIN-BINDING REGION REVEALS A NOVEL VITRONECTIN-DEPENDENT FEEDBACK MECHANISM FOR THE CONTROL OF PLASMIN FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN VITRONECTIN; HUMAN-ENDOTHELIAL CELLS; EXTRACELLULAR-MATRIX; ANTITHROMBIN-III; AFFINITY-CHROMATOGRAPHY; STRUCTURAL REQUIREMENTS; MONOCLONAL-ANTIBODIES; IDENTIFICATION; PURIFICATION; COMPLEMENT	Vitronectin (VN) has been implicated as a major matrix-associated regulator component of plasminogen activation by serving as a potent stabilizing cofactor of plasminogen activator inhibitor-1 (PAI-1). The direct binding of heparin, plasminogen as well as PAI-1 in its latent and active form to immobilized VN was studied in the absence or presence of competitors. Monoclonal antibodies against the carboxyl-terminal portion of VN inhibited both PAI-1 and plasminogen binding, whereas heparin, heparan sulfate with a high degree of sulfation, or dextran sulfate interfered with PAI-1 binding (K(D) = 20 nM) only. Utilizing synthetic peptides encompassing overlapping sequences of the heparin-binding domain of VN, adjacent heparin and PAI-1-binding sites were localized within the sequence 348-370 of VN. Although a number of other serine protease inhibitors which do not form binary complexes with VN contain a reactive-site Ser at their P1'-position, a reactive-site P1' mutant of PAI-1 (Met --> Ser) showed comparable if not increased binding to VN. Binding of Lys-plasminogen and active-site-blocked plasmin was at least 10-fold higher in affinity (K(D) = 85-100 nM) compared to Glu-plasminogen (K(D) approximately 1-mu-M) and could be inhibited by lysine analogs but not by glycosaminoglycans or PAI-1, indicating that heteropolar plasmin(ogen) binding of VN occurs to an adjacent segment upstream to the heparin and PAI-1-binding sites. This contention was further supported in binding studies with plasmin-modified VN which lost both heparin and PAI-1 binding but exhibited 2-3-fold higher capacity to bind plasminogen. The essential plasmin(ogen)-binding site was mapped by ligand blot analysis to the carboxyl-terminal portion of proteolytically trimmed VN (M(r) = 61,000). Moreover, treatment of the extracellular matrix of human umbilical vein endothelial cells with plasmin resulted in partial degradation of matrix-associated VN and concomitant release of PAI-1, but increased the ability of the matrix by about 2-fold to bind plasminogen. These results are indicative of differential interactions of VN with components of the plasminogen activation system, whereby plasmin itself may provoke the switch of VN from an anti-fibrinolytic into a pro-fibrinolytic cofactor. This process reflects a novel role for the adhesive protein and its degradation product(s) in the possible feedback regulation of localized plasmin formation at extracellular sites.	MAX PLANCK INST PHYSIOL & CLIN RES, KERCKHOFF KLIN, HAEMOSTASIS RES UNIT, SPRUDELHOF 11, W-6350 BAD NAUHEIM, GERMANY; BEHRINGWERKE AG, RES LABS, W-3550 MARBURG, GERMANY; CLB, DEPT MOLEC BIOL, 1066 CX AMSTERDAM, NETHERLANDS	Kerckhoff Clinic; Max Planck Society								BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BREIPOHL G, 1989, INT J PEPT PROT RES, V34, P262; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; CIAMBRONE GJ, 1990, J CELL BIOL, V111, P2183, DOI 10.1083/jcb.111.5.2183; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FRANSSON LA, 1980, EUR J BIOCHEM, V106, P59; HAMILTON KK, 1985, J CLIN INVEST, V76, P261, DOI 10.1172/JCI111956; HATTEY E, 1987, THROMB RES, V45, P485, DOI 10.1016/0049-3848(87)90311-2; IZUMI M, 1988, CELL STRUCT FUNCT, V13, P217, DOI 10.1247/csf.13.217; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jaffe EA, 1984, BIOL ENDOTHELIAL CEL, P1; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; JORGENSEN AM, 1985, BIOCHEM J, V231, P59, DOI 10.1042/bj2310059; KLAGSBRUN M, 1987, METHOD ENZYMOL, V147, P95; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1989, J BIOL CHEM, V264, P3742; LANE DA, 1987, J BIOL CHEM, V262, P16343; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1989, J BIOL CHEM, V264, P936; MIMURO J, 1989, J BIOL CHEM, V264, P5058; NOE G, 1988, J BIOL CHEM, V263, P11729; PODACK ER, 1979, J BIOL CHEM, V254, P9908; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1991, ADV CANCER RES, V57, P273; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1990, BIOCHEM BIOPH RES CO, V168, P966, DOI 10.1016/0006-291X(90)91123-A; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1989, BLOOD, V74, P1989; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1990, NEW TRENDS HAEMOSTAS, P135; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SALONEN EM, 1984, FEBS LETT, V172, P29, DOI 10.1016/0014-5793(84)80866-2; SANE DC, 1991, THROMB HAEMOSTASIS, V66, P310; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SMITH JW, 1990, J BIOL CHEM, V265, P2168; STACK MS, 1991, THROMB HAEMOSTASIS, V65, P722; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1988, BLOOD, V72, P903; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; WIMAN B, 1990, SEMIN THROMB HEMOST, V16, P207, DOI 10.1055/s-2007-1002671	56	133	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12098	12105						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376317				2022-12-27	WOS:A1992HY94700069
J	LUDWIG, T; RUTHER, U; METZGER, R; COPELAND, NG; JENKINS, NA; LOBEL, P; HOFLACK, B				LUDWIG, T; RUTHER, U; METZGER, R; COPELAND, NG; JENKINS, NA; LOBEL, P; HOFLACK, B			GENE AND PSEUDOGENE OF THE MOUSE CATION-DEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR - GENOMIC ORGANIZATION, EXPRESSION, AND CHROMOSOMAL LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-II; ALPHA-AMYLASE GENE; TRANSCRIPTION FACTOR; LYSOSOMAL-ENZYMES; BINDING-PROTEIN; CELLS; CLONING; SEQUENCES; CDNA; RNA	The cation-dependent mannose 6-phosphate receptor (CD-MPR) is one of the two transmembrane proteins involved in transport of lysosomal enzymes. We have cloned the mouse CD-MPR gene and also a very unusual processed-type CD-MPR pseudogene. They are both present at one copy per haploid genome and map to chromosomes 6 and 3, respectively. Comparison of the complete 10-kilobase (kb) sequence of the functional gene with the cDNA indicates that it contains seven exons. Exon 1 encodes the 5'-untranslated region of the mRNA, the others (exons 2-7) encode the luminal, transmembrane, and cytoplasmic domains of the CD-MPR. Exon 7 also contains a 1.2-kb-long 3'-untranslated region of the mRNA. A unique transcription-initiation site was determined by primer extension of mouse liver mRNA. The promoter elements in the 5' upstream region of this site resemble those contained in genes constitutively transcribed. However, Northern blot analysis demonstrates that the CD-MPR is variably expressed in adult mouse tissues and during mouse development. The pseudogene, which is flanked by direct repeats, is almost colinear with the cDNA indicating that it presumably arose by reverse transcription of an mRNA. However, the pseudogene differs from the cDNA. It contains at its 5' end, an additional 340-nucleotide (nt) sequence homologous to the promoter region of the functional gene. This sequence exhibits some promoter activity in vitro. Furthermore, a 24-nt insertion interrupts the region homologous to the 5'-noncoding region of the cDNA. In the functional gene, this 24-nt sequence occurs between exon 1 and 2, where it is flanked by typical consensus sequences of exon/intron boundaries. Therefore, it may represent an additional exon of the functional gene. These two features of the pseudogene suggest that expression of the CD-MPR gene may be regulated by use of different promoters and/or alternative splicing.	UNIV HEIDELBERG, DEPT PHARMACOL, W-6900 HEIDELBERG, GERMANY; NCI, FREDERICK CANC RES & DEV CTR, MAMMALIAN GENET LAB, FREDERICK, MD 21701 USA; CTR ADV BIOTECHNOL & MED, PISCATAWAY, NJ 08854 USA; UNIV MED & DENT NEW JERSEY, PISCATAWAY, NJ 08854 USA	Ruprecht Karls University Heidelberg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Rutgers State University New Brunswick; Rutgers State University Medical Center	LUDWIG, T (corresponding author), EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, POSTFACH 102209, MEYERHOFSTR 1, W-6900 HEIDELBERG, GERMANY.		Ludwig, Thomas/Q-6484-2016; HOFLACK, Bernard/AAZ-6668-2020	Ludwig, Thomas/0000-0003-3461-2585; 	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FIELD LJ, 1985, P NATL ACAD SCI USA, V82, P6196, DOI 10.1073/pnas.82.18.6196; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GEBALLE AP, 1988, J VIROL, V62, P3334, DOI 10.1128/JVI.62.9.3334-3340.1988; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Green EL, 1981, GENETICS PROBABILITY, P77; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HOGAN A, 1991, DEVELOPMENT, V113, P363; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JUNG A, 1980, P NATL ACAD SCI-BIOL, V77, P5759, DOI 10.1073/pnas.77.10.5759; KLIER HJ, 1991, EUR J BIOCHEM, V197, P23, DOI 10.1111/j.1432-1033.1991.tb15877.x; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOSTER A, 1991, BIOL CHEM H-S, V372, P297, DOI 10.1515/bchm3.1991.372.1.297; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA ZM, 1991, J BIOL CHEM, V266, P10589; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; OZAWA K, 1988, J BIOL CHEM, V263, P10922; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SKLAR MM, 1989, J BIOL CHEM, V264, P16733; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1988, J BIOL CHEM, V263, P2585; TOSI M, 1981, NUCLEIC ACIDS RES, V9, P2313, DOI 10.1093/nar/9.10.2313; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; WENDLAND M, 1991, J BIOL CHEM, V266, P7132; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9	49	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12211	12219						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376319				2022-12-27	WOS:A1992HY94700084
J	LOEB, KR; HAAS, AL				LOEB, KR; HAAS, AL			THE INTERFERON-INDUCIBLE 15-KDA UBIQUITIN HOMOLOG CONJUGATES TO INTRACELLULAR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; PURIFICATION; EXPRESSION; CELLS; PROTEOLYSIS; DEGRADATION; PRECURSOR; CLONING	We have previously identified a 15-kDa interferon-induced protein that is recognized by affinity-purified rabbit polyclonal antibodies against ubiquitin (Haas, A. L., Ahrens, P., Bright, P. M., and Ankel, H. (1987) J. Biol. Chem. 262, 11315-11323). This ubiquitin cross-reactive protein (UCRP) possesses significant homology to a tandem diubiquitin sequence. Since the biological effects of ubiquitin arise from its covalent ligation to intracellular target proteins, we hypothesized that the multiple cellular responses to interferon are mediated in part by an analogous conjugation pathway for UCRP. Rabbit polyclonal antibodies specific for UCRP were prepared against homogeneous recombinant protein. Affinity-purified anti-UCRP antibodies detected the induction of UCRP in interferon-beta-treated A549 cells and recognized a group of high molecular weight UCRP conjugates on immunoblots of sodium dodecyl sulfate-polyacrylamide gel electrophoresis-resolved cell extracts. Both free and conjugated UCRP are constitutively present at low levels in untreated cells, suggesting a role for UCRP ligation in normal cellular regulation, and significantly accumulate following interferon treatment. The temporal induction of free UCRP following interferon treatment preceded a delayed increase in UCRP conjugates. Treatment of A549 cells with type I interferons (alpha and beta) strongly induced the expression of free and conjugated UCRP, whereas the response to type 11 interferon (gamma) was significantly less. A survey of selected cultured cell lines showed differential induction of free versus conjugated UCRP pools in response to interferon. Interferon-beta treatment of A549, MG63, and U937 cells induced high levels of both free and conjugated UCRP, whereas only free UCRP levels increased in Daudi, Namalwa, and K562 cells. These results confirm that UCRP represents a functional ubiquitin homolog participating in a parallel pathway of post-translational ligation and provides a novel mechanism for the response of susceptible cells to the effects of interferon exposure.	MED COLL WISCONSIN,DEPT BIOCHEM,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226	Medical College of Wisconsin					NIGMS NIH HHS [GM34009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHRENS PB, 1990, J GEN VIROL, V71, P1674; BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; BOND U, 1988, J BIOL CHEM, V263, P2386; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; EVANS T, 1984, EMBO J, V3, P2975, DOI 10.1002/j.1460-2075.1984.tb02243.x; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; FELTHAM N, 1989, J INTERFERON RES, V9, P493, DOI 10.1089/jir.1989.9.493; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HAAS AL, 1988, CURRENT COMMUNICATIO, P178; HAAS AL, 1988, UBIQUITIN, P73; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HOUGH R, 1986, J BIOL CHEM, V261, P2391; KNIGHT E, 1988, J BIOL CHEM, V263, P4520; KNIGHT E, 1991, J IMMUNOL, V46, P2280; KORANT BD, 1984, J BIOL CHEM, V259, P14859; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOPEZOTIN C, 1989, J BIOL CHEM, V264, P9107; MAYER EM, 1987, J NEUROCHEM, V49, P1815; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RECHSTEINER M, 1988, UBIQITIN; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P116; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLESINGER DH, 1975, BIOCHEMISTRY-US, V14, P2214, DOI 10.1021/bi00681a026; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WEST MHP, 1980, NUCLEIC ACIDS RES, V8, P4671, DOI 10.1093/nar/8.20.4671; WILKINSON KD, 1981, J BIOL CHEM, V256, P9234	35	323	340	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7806	7813						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373138				2022-12-27	WOS:A1992HN48500085
J	SANTOS, AD; IMPERIAL, JS; CHAUDHARY, T; BEAVIS, RC; CHAIT, BT; HUNSPERGER, JP; OLIVERA, BM; ADAMS, ME; HILLYARD, DR				SANTOS, AD; IMPERIAL, JS; CHAUDHARY, T; BEAVIS, RC; CHAIT, BT; HUNSPERGER, JP; OLIVERA, BM; ADAMS, ME; HILLYARD, DR			HETERODIMERIC STRUCTURE OF THE SPIDER TOXIN OMEGA-AGATOXIN-IA REVEALED BY PRECURSOR ANALYSIS AND MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNNEL-WEB SPIDER; AMINO-ACID SEQUENCE; AGELENOPSIS-APERTA; HOLOLENA-CURTA; LETHAL NEUROTOXIN; VENOM; CLONING; CDNA; PURIFICATION; INHIBITION	We report the first molecular characterization of a precursor sequence for a small, Ca2+ channel blocking, peptide spider toxin, omega-agatoxin IA. By integrating information generated from a molecular genetic approach using agatoxin cDNAs with data provided from mass spectrometry of the mature toxin, we were able to deduce the likely mechanisms by which the toxin precursor peptide is processed to its mature heterodimeric form. A particularly interesting feature of the prepropeptide is the occurrence of two glutamate-rich sequences interposed between the signal sequences, the major peptide toxin, and the minor toxin peptide. Excision of the more distal glutamate-rich region appears to be signaled by flanking arginine residues but likely occurs only after a disulfide linkage has formed between the major and minor chains of the mature toxin. Our molecular genetic approach toward characterizing this toxin will allow us to quickly generate a series of spider sequences from which mature toxin structures can be deduced and eventually expressed. Additionally, this approach will provide insights into the evolutionary divergence observed among spider peptide toxins.	UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA; UNIV PHILIPPINES, INST CHEM, Quezon City 1101, PHILIPPINES; UNIV CALIF RIVERSIDE, DEPT NEUROSCI, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DEPT ENTOMOL, RIVERSIDE, CA 92521 USA; UNIV UTAH, DEPT PATHOL, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Diliman; University of California System; University of California Riverside; University of California System; University of California Riverside; Utah System of Higher Education; University of Utah			Adams, Michael/ABF-6728-2020	Adams, Michael/0000-0003-0519-6113	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024472] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [GM22737] Funding Source: Medline; NINDS NIH HHS [NS24472] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS ME, 1990, J BIOL CHEM, V265, P861; ADAMS ME, 1992, NEUROTOX 91 MOL BASI; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BEAVIS RC, 1990, P NATL ACAD SCI USA, V87, P6873, DOI 10.1073/pnas.87.17.6873; BINDOKAS VP, 1989, J NEUROBIOL, V20, P171, DOI 10.1002/neu.480200402; BINDOKAS VP, 1991, J NEUROPHYSIOL, V66, P590, DOI 10.1152/jn.1991.66.2.590; BOWERS CW, 1987, P NATL ACAD SCI USA, V84, P3506, DOI 10.1073/pnas.84.10.3506; BRANTON WD, 1987, J NEUROSCI, V7, P4195; BROWN MR, 1988, BIOCHEM J, V250, P401, DOI 10.1042/bj2500401; CHAIT BT, 1986, BIOCHEM BIOPH RES CO, V134, P420, DOI 10.1016/0006-291X(86)90580-2; CHAIT BT, 1984, J AM CHEM SOC, V106, P1931, DOI 10.1021/ja00319a005; CHAIT BT, 1981, INT J MASS SPECTROM, V39, P339, DOI 10.1016/0020-7381(81)87007-6; CHAUDHARY T, 1991, 38TH P ASMS C MASS S, P283; COLLEDGE CJ, 1992, IN PRESS TOXICON; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; KIYATKIN NI, 1990, FEBS LETT, V270, P127, DOI 10.1016/0014-5793(90)81250-R; LANGRIDGE J, 1980, ANAL BIOCHEM, V103, P264, DOI 10.1016/0003-2697(80)90266-3; MINTZ IM, 1991, P NATL ACAD SCI USA, V88, P6628, DOI 10.1073/pnas.88.15.6628; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OLIVERA BM, 1991, ANN NY ACAD SCI, V635, P114, DOI 10.1111/j.1749-6632.1991.tb36486.x; QUISTAD GB, 1991, TOXICON, V29, P329, DOI 10.1016/0041-0101(91)90286-Z; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; SCOTT RH, 1990, MOL PHARMACOL, V38, P711; SHEUMACK DD, 1985, FEBS LETT, V181, P154, DOI 10.1016/0014-5793(85)81132-7; SKINNER WS, 1989, J BIOL CHEM, V264, P2150; STAPLETON A, 1990, J BIOL CHEM, V265, P2054; TAMIYA T, 1985, BIOCHIMIE, V67, P185, DOI 10.1016/S0300-9084(85)80046-8; VENEMA VJ, 1992, J BIOL CHEM, V267, P2610; WOODWARD SR, 1990, EMBO J, V9, P1015, DOI 10.1002/j.1460-2075.1990.tb08204.x	31	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20701	20705						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383207				2022-12-27	WOS:A1992JT97800031
J	FRASER, PD; MISAWA, N; LINDEN, H; YAMANO, S; KOBAYASHI, K; SANDMANN, G				FRASER, PD; MISAWA, N; LINDEN, H; YAMANO, S; KOBAYASHI, K; SANDMANN, G			EXPRESSION IN ESCHERICHIA-COLI, PURIFICATION, AND REACTIVATION OF THE RECOMBINANT ERWINIA-UREDOVORA PHYTOENE DESATURASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYCOMYCES-BLAKESLEEANUS; CAROTENOID BIOSYNTHESIS; PATHWAY; BIOCHEMISTRY; CLONING	A plasmid has been constructed by cloning the complete crtI gene encoding phytoene desaturase from Erwinia uredovora behind the lac Z promoter of pUC18 resulting in a reading frame for the full polypeptide with additional 9 amino acids at the N terminus. This plasmid mediated the overexpression of phytoene desaturase in transformed Escherichia coli. The overexpressed enzyme was sequestrated into inclusion bodies requiring urea treatment for solubilization. Purification to homogeneity was subsequently performed on a DEAE-cellulose column and by SDS-polyacrylamide gel electrophoresis. The purification scheme allowed the isolation of 5.3 mg of homogeneous desaturase protein from 100 ml of E. coli cell suspension. On SDS-polyacrylamide gel electrophoresis an apparent molecular mass of 56.2 kDa was determined. An antiserum raised against phytoene desaturase cross-reacted with the expressed protein and was employed to monitor the isolation steps. Upon removal of urea, desaturase activity was restored. The isolated desaturase catalyzed the conversion of 15-cis-phytoene to trans-lycopene as well as to bisdehydrolycopene. FAD was involved in desaturation, whereas NAD and NADP were inhibitory. This is the first time that a membrane-integrated carotenogenic enzyme has been purified and finally obtained in an active state.	UNIV CONSTANCE, LEHRSTUHL PHYSIOL & BIOCHEM PFLANZEN, POB 5560, W-7750 CONSTANCE, GERMANY; KIRIN BREWERY CO LTD, KEY TECHNOL CENT LABS, TAKASAKI, GUNMA 37012, JAPAN	University of Konstanz; Kirin Brewery Company Limited				Misawa, Norihiko/0000-0003-1373-0769				BARTLEY GE, 1991, P NATL ACAD SCI USA, V88, P6532, DOI 10.1073/pnas.88.15.6532; BRAMLEY PM, 1975, PHYTOCHEMISTRY, V14, P463, DOI 10.1016/0031-9422(75)85110-7; BRAMLEY PM, 1985, ADV LIPID RES, V21, P243; CHAMOVITZ D, 1991, PLANT MOL BIOL, V16, P967, DOI 10.1007/BF00016069; ERNST S, 1988, ARCH MICROBIOL, V150, P590, DOI 10.1007/BF00408255; FRASER PD, 1992, BIOCHEM BIOPH RES CO, V185, P9, DOI 10.1016/S0006-291X(05)80947-7; GOODWIN TW, 1983, BIOCHEM SOC T, V11, P473, DOI 10.1042/bst0110473; KELLY SM, 1991, BIOCHEM J, V275, P745, DOI 10.1042/bj2750745; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLEY KE, 1987, EUR J BIOCHEM, V163, P313, DOI 10.1111/j.1432-1033.1987.tb10802.x; LINDEN H, 1991, Z NATURFORSCH C, V46, P1045; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARSTON FAO, 1990, METHOD ENZYMOL, V182, P264; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; SANDMANN G, 1991, PHYSIOL PLANTARUM, V83, P186, DOI 10.1034/j.1399-3054.1991.830128.x; SANDMANN G, 1989, BIOCHEM BIOPH RES CO, V163, P916, DOI 10.1016/0006-291X(89)92309-7; SANDMANN G, 1985, PLANTA, V164, P259, DOI 10.1007/BF00396090; Sandmann G., 1989, Target sites of herbicide action., P25; SASIAK K, 1988, ARCH BIOCHEM BIOPHYS, V260, P622, DOI 10.1016/0003-9861(88)90490-0; SCHMIDT A, 1989, EUR J BIOCHEM, V184, P375, DOI 10.1111/j.1432-1033.1989.tb15029.x; SCHOEMAKER JM, 1985, EMBO J, V4, P775, DOI 10.1002/j.1460-2075.1985.tb03696.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	24	102	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19891	19895						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400305				2022-12-27	WOS:A1992JR85800025
J	LEGENDRE, L; HEINSTEIN, PF; LOW, PS				LEGENDRE, L; HEINSTEIN, PF; LOW, PS			EVIDENCE FOR PARTICIPATION OF GTP-BINDING PROTEINS IN ELICITATION OF THE RAPID OXIDATIVE BURST IN CULTURED SOYBEAN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; REGULATORY PROTEINS; LEMNA-PAUCICOSTATA; MOLECULAR-CLONING; ADP-RIBOSYLATION; PLASMA-MEMBRANE; ALPHA-SUBUNIT; PLANT-CELLS; TOXIN; IDENTIFICATION	GTP-binding proteins have been shown to serve as second messengers in the transduction of hormone signals across animal cell plasma membranes. We present here three lines of evidence to demonstrate that GTP-binding proteins are also involved in the elicitation of the defense response of cultured soybean cells. First, the antigen-binding fragment (F(ab)) of an antibody that specifically recognizes GTP-binding proteins in plants and animals was delivered into soybean cells using a non-destructive biotin-mediated delivery technique developed previously. Internalization of this F(ab) enhanced up to 10-fold the rapid oxidative burst induced by elicitor molecules, whereas internalization of its heat-denatured counterpart or unrelated proteins had no effect. Because the antibody recognizes a protein of molecular mass approximately 45 kDa in soybean cell membranes that is protected from ADP-ribosylation by GTPgammaS (guanosine 5'-O-(thiotriphosphate), we propose the 45-kDa GTP-binding protein is responsible for these effects. Second, mastoparan, a specific activator of GTP-binding proteins, was shown to induce the defense-related oxidative burst in the absence of elicitor stimulation, thus mimicking an activated receptor as it is thought to do in mammalian systems. Finally, but admittedly less convincing, the A subunit of cholera toxin, an activator of certain stimulatory GTP-binding proteins (G(s)), was found to weakly enhance the conventional elicitor-induced oxidative burst. Taken together, these data argue for the involvement of GTP-binding proteins in elicitor signal transduction in soybean cells.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA; PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528				APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; BARONEPEL O, 1988, PLANTA, V175, P389, DOI 10.1007/BF00396345; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLUM W, 1988, BIOCHEM BIOPH RES CO, V156, P954, DOI 10.1016/S0006-291X(88)80936-7; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOLWELL GP, 1991, PHYTOCHEMISTRY, V30, P397, DOI 10.1016/0031-9422(91)83692-E; BOSSEN ME, 1990, PHYSIOL PLANTARUM, V80, P55; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; BREDEHORST R, 1978, EUR J BIOCHEM, V92, P129, DOI 10.1111/j.1432-1033.1978.tb12730.x; DAVIS J, 1982, J BIOL CHEM, V257, P5816; DROBAK BK, 1988, BIOCHEM BIOPH RES CO, V150, P899, DOI 10.1016/0006-291X(88)90713-9; FAIRLEYGRENOT K, 1991, PLANT CELL, V3, P1037; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GODING JW, 1978, J IMMUNOL METHODS, V20, P241, DOI 10.1016/0022-1759(78)90259-4; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HASEGAWA PM, 1980, PLANT CELL PHYSIOL, V21, P1347, DOI 10.1093/pcp/21.8.1347; HASUNUMA K, 1987, PHOTOCHEM PHOTOBIOL, V46, P531, DOI 10.1111/j.1751-1097.1987.tb04807.x; HASUNUMA K, 1987, BIOCHEM BIOPH RES CO, V148, P133, DOI 10.1016/0006-291X(87)91086-2; HASUNUMA K, 1987, BIOCHEM BIOPH RES CO, V143, P908, DOI 10.1016/0006-291X(87)90335-4; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HINSCH KD, 1988, FEBS LETT, V238, P151; HORN MA, 1990, PLANT PHYSIOL, V93, P1492, DOI 10.1104/pp.93.4.1492; JACOBSON MK, 1990, J BIOL CHEM, V265, P10825; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOPF GS, 1991, METHOD ENZYMOL, V195, P257; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LOW PS, 1986, ARCH BIOCHEM BIOPHYS, V249, P472, DOI 10.1016/0003-9861(86)90024-X; MA H, 1991, GENE, V107, P189; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; MILLNER PA, 1987, FEBS LETT, V226, P155, DOI 10.1016/0014-5793(87)80570-7; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NOTHNAGEL EA, 1983, PLANT PHYSIOL, V71, P916, DOI 10.1104/pp.71.4.916; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RIBEIRONETO FAP, 1985, METHOD ENZYMOL, V109, P566; STADDON JM, 1991, J CELL BIOL, V115, P949, DOI 10.1083/jcb.115.4.949; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TANUMA S, 1988, J BIOL CHEM, V263, P5485; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925; WEINGARTEN R, 1990, IMMUNOL LETT, V26, P1, DOI 10.1016/0165-2478(90)90167-O; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WESTGATE PJ, 1990, BIOTECHNOL BIOENG, V35, P437, DOI 10.1002/bit.260350502	44	162	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20140	20147						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400332				2022-12-27	WOS:A1992JR85800063
J	PALMER, DJ; CHRISTIE, DL				PALMER, DJ; CHRISTIE, DL			IDENTIFICATION OF MOLECULAR AGGREGATES CONTAINING GLYCOPROTEINS-III, J, K (CARBOXYPEPTIDASE-H), AND H (KEX2-RELATED PROTEASES) IN THE SOLUBLE AND MEMBRANE-FRACTIONS OF ADRENAL-MEDULLARY CHROMAFFIN GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RETE TESTIS FLUID; SULFATED GLYCOPROTEIN-2; ENKEPHALIN CONVERTASE; SERUM PROTEIN-40,40; TISSUE DISTRIBUTION; STRUCTURAL-ANALYSIS; PROCESSING ENZYME; HUMAN PLASMA; COMPLEMENT	An investigation of the molecular properties of glycoprotein III has shown this to be a major component of molecular aggregates present in the membrane and soluble fractions of secretory vesicles from bovine adrenal medulla. These aggregates also contain components identified as glycoproteins H, J, and K which are molecular forms of Kex2-related proteases (glycoprotein H) and carboxypeptidase H (glycoprotein components J and K) and which have functions concerned with the processing of prohormones. A number of experiments indicated that these glycoproteins were associated. These components were coimmunoprecipitated from the soluble and membrane fractions of chromaffin granules. Purification of soluble glycoprotein III using wheat germ agglutinin-Sepharose resulted in the recovery of similar proportions of glycoproteins H, J, and K and gel filtration of the eluted material in combination with immunoprecipitation revealed the presence of heteroaggregates containing all of the glycoproteins. Similar results were obtained following octylglucoside solubilization of chromaffin granule membranes. Glycoprotein components III, H, J, and K were also found to have identical distributions following fractionation of chromaffin granule membranes with Triton X-114. It was concluded that the aggregates seen in the soluble fraction reflect an association of these components in the chromaffin granule membrane. This raises the possibility that these interactions are important for the targetting of these glycoproteins to secretory granules.	UNIV AUCKLAND,DEPT BIOCHEM,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND	University of Auckland			Christie, David L/C-8065-2009					BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHENG CY, 1988, BIOCHEMISTRY-US, V27, P4079, DOI 10.1021/bi00411a026; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; CHRISTIE DL, 1990, BIOCHEM J, V270, P57, DOI 10.1042/bj2700057; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRITZ IB, 1983, BIOL REPROD, V28, P1173, DOI 10.1095/biolreprod28.5.1173; GAVINE FS, 1984, J NEUROCHEM, V43, P1243, DOI 10.1111/j.1471-4159.1984.tb05379.x; HAWKES DJ, 1991, ENDOCRINOLOGY, V129, P3053; HOOK VYH, 1985, J NEUROCHEM, V45, P987, DOI 10.1111/j.1471-4159.1985.tb04094.x; HOOK VYH, 1985, P NATL ACAD SCI USA, V82, P4745, DOI 10.1073/pnas.82.14.4745; JENNE DE, 1991, J BIOL CHEM, V266, P11030; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASLOP A, 1986, NEUROSCI LETT, V72, P300, DOI 10.1016/0304-3940(86)90530-6; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; PALMER DJ, 1990, J BIOL CHEM, V265, P6617; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; PRYDE JG, 1986, BIOCHEM J, V233, P525, DOI 10.1042/bj2330525; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; SUPATTAPONE S, 1984, J NEUROCHEM, V42, P1017, DOI 10.1111/j.1471-4159.1984.tb12705.x; TSURUTA JK, 1990, BIOCHEM J, V268, P571, DOI 10.1042/bj2680571; WINKLER H, 1990, NEUROCHEM INT, V17, P245, DOI 10.1016/0197-0186(90)90147-L; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5	33	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19806	19812						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400294				2022-12-27	WOS:A1992JR85800011
J	TAKATA, H; KURIKI, T; OKADA, S; TAKESADA, Y; IIZUKA, M; MINAMIURA, N; IMANAKA, T				TAKATA, H; KURIKI, T; OKADA, S; TAKESADA, Y; IIZUKA, M; MINAMIURA, N; IMANAKA, T			ACTION OF NEOPULLULANASE - NEOPULLULANASE CATALYZES BOTH HYDROLYSIS AND TRANSGLYCOSYLATION AT ALPHA-(1-]4)-GLUCOSIDIC AND ALPHA-(1-]6)-GLUCOSIDIC LINKAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS NEOPULLULANASE; GLYCOGEN-BRANCHING ENZYME; NUCLEOTIDE-SEQUENCE; ALPHA-AMYLASE; THERMOSTABLE PULLULANASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; TAKA-AMYLASE; GENE; PURIFICATION	The transglycosylation reaction catalyzed by neopullulanase was analyzed. Radioactive oligosaccharides were produced when the enzyme acted on maltotriose in the presence of [U-C-14]glucose. Some of the radioactive oligosaccharides had only alpha-(1-->4)-glucosidic linkages, but others were suggested to have alpha-(1-->6)-glucosidic linkages. The existence of alpha-(1-->6)-glucosidic linkages in the products from maltotriose with neopullulanase was proven by proton NMR spectroscopy and methylation analysis. We previously reported that the one active center of neopullulanase catalyzes the hydrolysis of alpha-(l-->4)- and alpha-(l-->6)-glucosidic linkages (Kuriki, T., Takata, H., Okada, S., and Imanaka, T. (1991) J. Bacteriol. 173,6147-6152). These facts proved that neopullulanase catalyzed all four types of reactions: hydrolysis of alpha-(1-->4)-glucosidic linkage, hydrolysis of alpha-(1-->6)-glucosidic linkage, transglycosylation to form alpha-(1-->4)-glucosidic linkage, and transglycosylation to form alpha-(1-->6)-glucosidic linkage. The four reactions are typically catalyzed by alpha-amylase, pullulanase, cyclomaltodextrin glucanotransferase, and 1,4-alpha-D-glucan branching enzyme, respectively. These four enzymes have some structural similarities to one other, but reactions catalyzed by the enzymes are considered to be distinctive: the four reactions are individually catalyzed by each of the enzymes. The experimental results obtained from the analysis of the reaction of the neopullulanase exhibited that the four reactions can be catalyzed in the same mechanism.	NAGASE BIOCHEM CO LTD, FUKUCHIYAMA, KYOTO 620, JAPAN; OSAKA CITY UNIV, FAC SCI, DEPT BIOL, SUMIYOSHI KU, OSAKA 558, JAPAN; OSAKA UNIV, FAC ENGN, DEPT BIOTECHNOL, SUITA, OSAKA 565, JAPAN	Osaka Metropolitan University; Osaka University	TAKATA, H (corresponding author), EZAKI GLICO CO LTD, BIOCHEM RES LABS, 4-6-5 UTAJIMA, NISHIYODOGAWA KU, OSAKA 555, JAPAN.							BABA T, 1991, BIOCHEM BIOPH RES CO, V181, P87, DOI 10.1016/S0006-291X(05)81385-3; BOROVSKY D, 1975, EUR J BIOCHEM, V59, P615, DOI 10.1111/j.1432-1033.1975.tb02490.x; COLEMAN RD, 1987, J BACTERIOL, V169, P4302, DOI 10.1128/jb.169.9.4302-4307.1987; FERRETTI JJ, 1987, J BACTERIOL, V169, P4271, DOI 10.1128/jb.169.9.4271-4278.1987; GREENWOOD CT, 1968, ARCH BIOCHEM BIOPHYS, V126, P244, DOI 10.1016/0003-9861(68)90580-8; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HEHRE EJ, 1971, ARCH BIOCHEM BIOPHYS, V142, P382, DOI 10.1016/0003-9861(71)90297-9; IIZUKA M, 1990, J FERMENT BIOENG, V70, P277, DOI 10.1016/0922-338X(90)90064-4; IMANAKA T, 1989, J BACTERIOL, V171, P369, DOI 10.1128/jb.171.1.369-374.1989; JESPERSEN HM, 1991, BIOCHEM J, V280, P51, DOI 10.1042/bj2800051; KIEL JAKW, 1991, MOL GEN GENET, V230, P136, DOI 10.1007/BF00290661; KITAHATA S, 1983, AGR BIOL CHEM TOKYO, V47, P1441, DOI 10.1080/00021369.1983.10865801; Kitahata S., 1982, J JPN SOC STARCH SCI, V29, P13; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KOSSMANN J, 1991, MOL GEN GENET, V230, P39, DOI 10.1007/BF00290648; KUBOTA M, 1991, J JPN SOC STARCH SCI, V38, P141, DOI DOI 10.5458/JAG1972.38.141; KURIKI T, 1990, J FERMENT BIOENG, V69, P204, DOI 10.1016/0922-338X(90)90213-G; KURIKI T, 1991, J BACTERIOL, V173, P6147, DOI 10.1128/jb.173.19.6147-6152.1991; KURIKI T, 1989, J GEN MICROBIOL, V135, P1521; KURIKI T, 1988, J BACTERIOL, V170, P1554, DOI 10.1128/jb.170.4.1554-1559.1988; MACGREGOR EA, 1989, BIOCHEM J, V259, P145, DOI 10.1042/bj2590145; MATSUI I, 1991, BIOCHIM BIOPHYS ACTA, V1077, P416, DOI 10.1016/0167-4838(91)90560-M; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MATSUURA Y, 1991, J JPN SOC STARCH SCI, V38, P137; MELASNIEMI H, 1990, J GEN MICROBIOL, V136, P447, DOI 10.1099/00221287-136-3-447; NAKAJIMA R, 1985, J BACTERIOL, V163, P401, DOI 10.1128/JB.163.1.401-406.1985; PAZUR JH, 1960, J BIOL CHEM, V235, P297; PAZUR JH, 1966, J BIOL CHEM, V241, P4146; PLANT AR, 1987, BIOCHEM J, V246, P537, DOI 10.1042/bj2460537; RUMBAK E, 1991, J BACTERIOL, V173, P6732, DOI 10.1128/jb.173.21.6732-6741.1991; SAKANO Y, 1971, AGR BIOL CHEM TOKYO, V35, P971, DOI 10.1080/00021369.1971.10860023; SAKANO Y, 1978, CARBOHYD RES, V61, P175, DOI 10.1016/S0008-6215(00)84478-X; SAKANO Y, 1982, AGR BIOL CHEM TOKYO, V46, P1121, DOI 10.1080/00021369.1982.10865223; SPREINAT A, 1990, APPL MICROBIOL BIOT, V33, P511; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; SVENSSON B, 1991, J JPN SOC STARCH SCI, V38, P125; USUI T, 1974, CARBOHYD RES, V33, P105, DOI 10.1016/S0008-6215(00)82944-4; WATANABE K, 1990, EUR J BIOCHEM, V192, P609, DOI 10.1111/j.1432-1033.1990.tb19267.x	39	156	165	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18447	18452						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388153				2022-12-27	WOS:A1992JN50200035
J	WACKER, H; KELLER, P; FALCHETTO, R; LEGLER, G; SEMENZA, G				WACKER, H; KELLER, P; FALCHETTO, R; LEGLER, G; SEMENZA, G			LOCATION OF THE 2 CATALYTIC SITES IN INTESTINAL LACTASE-PHLORHIZIN HYDROLASE - COMPARISON WITH SUCRASE-ISOMALTASE AND WITH OTHER GLYCOSIDASES, THE MEMBRANE ANCHOR OF LACTASE-PHLORHIZIN HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; AMINO-ACID-SEQUENCE; POLYACRYLAMIDE-GEL-ELECTROPHORESIS; BETA-GALACTOSIDASE GENE; NUCLEOTIDE-SEQUENCE; ACTIVE-SITE; ESSENTIAL CARBOXYLATE; GLUCOSIDASE GENE; ESCHERICHIA-COLI; COMPLEX	Lactase-phlorizin hydrolase was isolated by immunoadsorption chromatography from rabbit brush-border membrane vesicles. Inactivation of the enzyme with [H-3]conduritol-B-epoxide, a covalent active site-directed inhibitor, labeled glutamates at positions 1271 and 1747. Glu1271 was assigned to lactase, Glu1747 to phlorizin hydrolase activity. In contrast, the nucleophiles in the active sites of sucrase-isomaltase are aspartates (Asp505 and Asp1394). Asp505 is a part of the isomaltase active site and is localized on the larger subunit, which carries the membrane anchor also, while Asp1394 is a part of the active site of sucrase. Alignment of these 2 nucleophilic Glu residues in lactase-phlorizin hydrolase and of their flanking regions with published sequences of several other beta-glycosidases allows the classification of the configuration retaining glycosidases into two major families: the "Asp" and the "Glu' glycosidases, depending on the carboxylate presumed to interact with the putative oxocarbonium ion in the transition state. We offer some predictions as to the Glu acting as the nucleophile in the active site of some glycosidases. By hydrophobic photolabeling, the membrane-spanning domain of lactase-phlorizin hydrolase was directly localized in the carboxyl-terminal region thus confirming this enzyme as a monotopic type I protein (i.e. with N(out)-C(in) orientation) of the brush-border membranes. A simplified version of the Me2+ precipitation method to efficiently and simply prepare brush-border membrane vesicles is also reported.	UNIV COLOGNE,DEPT BIOCHEM,W-5000 COLOGNE 1,GERMANY	University of Cologne	WACKER, H (corresponding author), SWISS FED INST TECHNOL,DEPT BIOCHEM,CH-8092 ZURICH,SWITZERLAND.							BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BANAUCH D, 1975, Z KLIN CHEM KLIN BIO, V13, P101; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BOIZET B, 1988, GENE, V62, P249, DOI 10.1016/0378-1119(88)90563-X; BONIFACINO JS, 1987, CELL, V50, P311; Booth A G, 1974, Biochem J, V142, P575; BRAUN H, 1977, BIOCHIM BIOPHYS ACTA, V483, P135, DOI 10.1016/0005-2744(77)90015-8; BREIDT F, 1987, APPL ENVIRON MICROB, V53, P969, DOI 10.1128/AEM.53.5.969-973.1987; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; BRUNNER J, 1979, J BIOL CHEM, V254, P1821; BULLER HA, 1987, J BIOL CHEM, V262, P17206; COGOLI A, 1975, J BIOL CHEM, V250, P7802; COLOMBO V, 1973, BIOCHIM BIOPHYS ACTA, V327, P412, DOI 10.1016/0005-2744(73)90425-7; CUATRECA.P, 1968, P NATL ACAD SCI USA, V61, P636, DOI 10.1073/pnas.61.2.636; CUBELLIS MV, 1990, GENE, V94, P89, DOI 10.1016/0378-1119(90)90472-4; DANIELSEN EM, 1982, J IMMUNOL METHODS, V52, P223; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; ELHASSOUNI M, 1992, J BACTERIOL, V174, P765, DOI 10.1128/jb.174.3.765-777.1992; Fontana A, 1986, PRACTICAL PROTEIN CH, P67; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GEE AP, 1979, J IMMUNOL METHODS, V30, P119, DOI 10.1016/0022-1759(79)90086-3; GONZALEZCANDELAS L, 1990, GENE, V95, P31, DOI 10.1016/0378-1119(90)90410-S; GRABNITZ F, 1991, EUR J BIOCHEM, V200, P301, DOI 10.1111/j.1432-1033.1991.tb16186.x; HANOZET G, 1981, J BIOL CHEM, V256, P3703; HAURI HP, 1979, P NATL ACAD SCI USA, V76, P5183, DOI 10.1073/pnas.76.10.5183; HAURI HP, 1982, J BIOL CHEM, V257, P4522; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HERRCHEN M, 1984, EUR J BIOCHEM, V138, P527, DOI 10.1111/j.1432-1033.1984.tb07947.x; HU CB, 1987, BIOCHIM BIOPHYS ACTA, V896, P275, DOI 10.1016/0005-2736(87)90188-X; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; Imoto T., 1972, ENZYMES, V7, P665; KENNY AJ, 1987, MAMMALIAN ECTOENZYME, V14, P169; KESSLER M, 1978, BIOCHIM BIOPHYS ACTA, V506, P136, DOI 10.1016/0005-2736(78)90440-6; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LEESE HJ, 1973, J BIOL CHEM, V248, P8170; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; LEGLER G, 1968, BIOCHIM BIOPHYS ACTA, V151, P728, DOI 10.1016/0005-2744(68)90033-8; LEGLER G, 1968, Z. Physiol. Chem., V349, P767; Legler G. Z., 1966, Z PHYSL CHEM, V345, P197; LITTLE S, 1989, NUCLEIC ACIDS RES, V17, P7980, DOI 10.1093/nar/17.19.7980; LORAND L, 1976, P NATL ACAD SCI USA, V73, P4479, DOI 10.1073/pnas.73.12.4479; LOVE DR, 1988, MOL GEN GENET, V213, P84, DOI 10.1007/BF00333402; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PORTER EV, 1988, GENE, V62, P263; POTTER J, 1985, BIOCHEM GENET, V23, P423, DOI 10.1007/BF00499084; QUARONI A, 1974, J BIOL CHEM, V249, P6424; QUARONI A, 1976, J BIOL CHEM, V251, P3250; RAMASWAMY S, 1975, BIOCHIM BIOPHYS ACTA, V403, P446, DOI 10.1016/0005-2744(75)90072-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLEGEL.S, 1972, BIOCHIM BIOPHYS ACTA, V258, P506, DOI 10.1016/0005-2744(72)90242-2; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; SEMENZA G, 1969, CARBOHYD RES, V10, P417, DOI 10.1016/S0008-6215(00)80902-7; SEMENZA G, 1989, BIOCHEM INT, V18, P15; SEMENZA G, 1991, INDIAN J BIOCHEM BIO, V28, P331; SEMENZA G, 1987, MAMMALIAN ECTOENZYME, V14, P267; SIGRIST H, 1975, BIOCHIM BIOPHYS ACTA, V406, P433, DOI 10.1016/0005-2736(75)90022-X; SINNOTT ML, 1973, BIOCHEM J, V133, P89, DOI 10.1042/bj1330089; SJOSTROM H, 1980, J BIOL CHEM, V255, P1332; SKOVBJERG H, 1984, BIOCHIM BIOPHYS ACTA, V798, P247, DOI 10.1016/0304-4165(84)90312-X; SKOVBJERG H, 1982, BIOCHIM BIOPHYS ACTA, V707, P89, DOI 10.1016/0167-4838(82)90400-9; SKOVBJERG H, 1981, EUR J BIOCHEM, V114, P653, DOI 10.1111/j.1432-1033.1981.tb05193.x; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; SPIESS M, 1982, J BIOL CHEM, V257, P2370; TRIMBUR DE, 1992, J BIOL CHEM, V267, P10248; TRUSCHEIT E, 1981, ANGEW CHEM, V93, P738; TULL D, 1991, J BIOL CHEM, V266, P15621; WACKER H, 1981, FEBS LETT, V136, P329, DOI 10.1016/0014-5793(81)80647-3; WAKARCHUK WW, 1988, J BACTERIOL, V170, P301, DOI 10.1128/jb.170.1.301-307.1988; WALLENFELS K, 1960, Z PHYSL CHEM, V312, P223; WHITHERS SG, 1990, J AM CHEM SOC, V112, P5887; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; ZHU JS, 1991, BIOCHEMISTRY-US, V30, P10399, DOI 10.1021/bi00107a006	79	61	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18744	18752						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388157				2022-12-27	WOS:A1992JN50200076
J	LUNN, CA; DAVIES, L; DALGARNO, D; NARULA, SK; ZAVODNY, PJ; LUNDELL, D				LUNN, CA; DAVIES, L; DALGARNO, D; NARULA, SK; ZAVODNY, PJ; LUNDELL, D			AN ACTIVE COVALENTLY LINKED DIMER OF HUMAN INTERFERON-GAMMA - SUBUNIT ORIENTATION IN THE NATIVE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNE INTERFERON; ESCHERICHIA-COLI; BIOLOGICAL-ACTIVITY; EXPRESSION; CELLS; CDNA; SEQUENCE; TERMINUS; CLONING	We have constructed and expressed a covalently linked head to tail dimer of human interferon-gamma (IFN-gamma) in which two monomers are joined head to tail via a rigid peptide hinge using genetic engineering techniques. The hinge was derived from the human immunoglobin IgA1 sequence (Hallewell, R. A., Laria, I., Tabrizi, A., Carlin, G., Getzoff, E. D., Tainer, J. A., Cousens, L. S., and Mullenbach, G. T. (1989) J. Biol. Chem. 264, 5260-5268). Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis shows that the polypeptide produced by this construction migrates as a 30,000 polypeptide species. The protein elutes as a single species by molecular sieve chromatography under native conditions. The covalently linked dimer exhibits one-half the antiviral activity of native dimeric IFN-gamma; receptor binding assays show the covalently linked dimer binds to the IFN-gamma receptor with one-half the avidity of native IFN-gamma. This difference is not due to conformational differences between the two molecules, as the aromatic region of the NMR spectrum of the purified covalently linked dimer is identical with that of the wild type protein. From these data, we suggest that human IFN-gamma associates in a head to tail dimer in its active configuration. Regions of IFN-gamma are contiguous with the amino and carboxyl termini and are obscured by the hinge peptide in the covalently linked dimer. Our studies demonstrate that these regions may be important for receptor-ligand interaction.	SCHERING PLOUGH RES INST,DEPT PHYS ANALYT CHEM RES & DEV,BLOOMFIELD,NJ 07003	Merck & Company; Schering-Plough Research Institute	LUNN, CA (corresponding author), SCHERING PLOUGH RES INST,DEPT BIOTECHNOL MOLEC BIOL,BLOOMFIELD,NJ 07003, USA.							ARAKAWA T, 1986, J BIOL CHEM, V261, P8534; DEVOS R, 1982, NUCLEIC ACIDS RES, V10, P2487, DOI 10.1093/nar/10.8.2487; DOBELI H, 1988, J BIOTECHNOL, V7, P199, DOI 10.1016/0168-1656(88)90052-1; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; ELISH ME, 1988, J GEN MICROBIOL, V134, P1355; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P19758; GRAY PW, 1982, NATURE, V295, P503, DOI 10.1038/295503a0; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; PAN YCE, 1987, EUR J BIOCHEM, V166, P145, DOI 10.1111/j.1432-1033.1987.tb13494.x; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; RINDERKNECHT E, 1984, J BIOL CHEM, V259, P6790; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; SUGIMURA K, 1988, J BACTERIOL, V170, P3650, DOI 10.1128/jb.170.8.3650-3654.1988; TANAKA S, 1983, NUCLEIC ACIDS RES, V11, P1707, DOI 10.1093/nar/11.6.1707; YPHANTIS DA, 1987, BIOCHEMISTRY-US, V26, P5422, DOI 10.1021/bi00391a031; ZAVODNY PJ, 1988, J INTERFERON RES, V8, P483, DOI 10.1089/jir.1988.8.483	18	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17920	17924						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1387644				2022-12-27	WOS:A1992JM22300067
J	HIROSE, S; PRINCE, GM; SEVLEVER, D; RAVI, L; ROSENBERRY, TL; UEDA, E; MEDOF, ME				HIROSE, S; PRINCE, GM; SEVLEVER, D; RAVI, L; ROSENBERRY, TL; UEDA, E; MEDOF, ME			CHARACTERIZATION OF PUTATIVE GLYCOINOSITOL PHOSPHOLIPID ANCHOR PRECURSORS IN MAMMALIAN-CELLS - LOCALIZATION OF PHOSPHOETHANOLAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; TRYPANOSOMA-BRUCEI; STRUCTURAL CHARACTERIZATION; MASS-SPECTROMETRY; BIOSYNTHESIS; OLIGOSACCHARIDES; MUTANTS; IDENTIFICATION; GLYCAN	A number of mammalian cell surface proteins are anchored by glycoinositol phospholipid (GPI) structures that are preassembled and transferred to them in the endoplasmic reticulum. The GPIs in these proteins contain linear ethanolamine (EthN)-phosphate (P)-6ManManManGlcN core glycan sequences bearing an additional EthN-P attached to the Man residue (Man 1) proximal to GlcN. The biochemical precursors of mammalian GPI anchor structures are incompletely characterized. In this study, putative [H-3]Man-labeled GPI precursors were obtained by in vitro GDP-[H-3] Man labeling of HeLa cell microsomes and by in vivo [H-3]Man labeling of class B and F Thy-1 negative murine lymphoma mutants known to accumulate incomplete GPIs. The high performance liquid chromatography-purified in vitro and accumulated in vivo GPI products were structurally analyzed by nitrous acid deamination, hydrofluoric acid, trifluoroacetic acid hydrolysis, biosynthetic labeling, and exoglycosidase treatment. The data were consistent with a biosynthetic scheme in which Man and EthN-P are added stepwise to the developing glycan. Several additional points were demonstrated: 1) putative mammalian GPI precursors contain incomplete core glycans corresponding to those in previously characterized trypanosome GPI precursors. 2) The proximal EthN-P found in mature mammalian GPI anchor structures is added to Man 1 prior to incorporation of Man 2 and Man 3. 3) Glycans in the incomplete GPIs that accumulate in classes B and F lymphoma mutants consist of Man2- and Man3GlcN in which EthN-P is linked to Man 1. 4) Distal EthN-P linked to the 6-position of Man, characteristic of the complete GPI core, is found both in a subsequent GPI species with the glycan sequence EthN-P-6ManMan(EthN-P-->)ManGlcN and in a more polar GPI product.	CASE WESTERN RESERVE UNIV,INST PATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23598] Funding Source: Medline; NIDDK NIH HHS [P01DK38181] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN MA, 1990, ANAL BIOCHEM, V191, P174, DOI 10.1016/0003-2697(90)90405-X; BANGS JD, 1988, J BIOL CHEM, V263, P17697; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEEG MA, 1992, IN PRESS J BIOL CHEM; DOERING TL, 1989, J BIOL CHEM, V264, P11168; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1992, IN PRESS J CELL BIOL; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MENON AK, 1990, J BIOL CHEM, V265, P9033; ORLEAN P, 1991, OCT AM SOC BIOCH MOL, V4; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; VARKI A, 1980, J BIOL CHEM, V255, P847	24	128	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16968	16974						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380957				2022-12-27	WOS:A1992JL05300039
J	MURPHY, AJ; COLL, RJ				MURPHY, AJ; COLL, RJ			FLUORIDE BINDING TO THE CALCIUM ATPASE OF SARCOPLASMIC-RETICULUM CONVERTS ITS TRANSPORT SITES TO A LOW AFFINITY, LUMEN-FACING FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; FLUORESCEIN ISOTHIOCYANATE; VANADATE INHIBITION; CA-ATPASE; CA-2+-ATPASE; IONS; NUCLEOTIDES; PUMP; PHOSPHORYLATION; TRANSLOCATION	The sarcoplasmic reticulum CaATPase forms an inactive complex with fluoride (CaATPase-F), which in the absence of calcium reactivates very slowly (t1/2 approximately 40 h at 25-degrees-C). Reactivation is greatly accelerated (>10(3)) by calcium in the millimolar range provided it has access to luminal sites of the enzyme. Measurement of the calcium concentration dependence of the reactivation rate constant revealed a saturable effect with a midpoint of about 12 mM calcium. These results show that an effect other than phosphorylation can produce a >10(3)-fold affinity decrease and reorientation of the calcium transport sites. At a fixed calcium concentration, reactivation became faster with increasing pH (pK(a) > 8), suggesting competition between Ca2+ and H+ for transport sites. CaATPase-F lacked the ability to bind calcium with high affinity or to form phosphorylated enzyme intermediate from P(i); it bound adenyl-5'-yl methylenediphosphonate more than 10-fold less strongly than control CaATPase, had numerous sulfhydryl groups with significantly different reactivity, and was notably less susceptible (more than 10-fold) to thermal inactivation compared with control CaATPase. These results suggest that formation of CaATPase-F involves significant structural changes.			MURPHY, AJ (corresponding author), UNIV PACIFIC,SCH DENT,DEPT BIOCHEM,SAN FRANCISCO,CA 94115, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031083] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31083] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JP, 1985, BIOCHIM BIOPHYS ACTA, V815, P9, DOI 10.1016/0005-2736(85)90467-5; ANDERSON KW, 1983, J BIOL CHEM, V258, P4276; Bevington P.R., 1969, DATA REDUCTION ERROR; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; COLL RJ, 1986, BIOCHEM BIOPH RES CO, V138, P652, DOI 10.1016/S0006-291X(86)80546-0; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; HIGHSMITH S, 1985, BIOCHIM BIOPHYS ACTA, V817, P123, DOI 10.1016/0005-2736(85)90074-4; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1984, J BIOL CHEM, V259, P996; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; JAENICKE R, 1991, CIBA F SYMP, V161, P206; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; LEVY D, 1990, J BIOL CHEM, V265, P19524; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARKUS S, 1986, BIOCHIM BIOPHYS ACTA, V874, P128, DOI 10.1016/0167-4838(86)90109-3; MARKUS S, 1989, BIOCHEMISTRY-US, V28, P793, DOI 10.1021/bi00428a057; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MEDDA P, 1983, EUR J BIOCHEM, V137, P7, DOI 10.1111/j.1432-1033.1983.tb07788.x; MESZAROS LG, 1992, BIOCHEMISTRY-US, V31, P1195, DOI 10.1021/bi00119a032; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY AJ, 1990, FEBS LETT, V263, P175, DOI 10.1016/0014-5793(90)80733-Y; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; MURPHY AJ, 1990, BIOCHEMISTRY-US, V29, P11236, DOI 10.1021/bi00503a012; MURPHY AJ, 1978, J BIOL CHEM, V253, P385; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1991, J BIOL CHEM, V267, P16995; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; ONEAL SG, 1979, BIOCHEM BIOPH RES CO, V89, P845, DOI 10.1016/0006-291X(79)91855-2; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; ORTIZ A, 1984, BIOCHEM J, V221, P213, DOI 10.1042/bj2210213; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PICK U, 1982, J BIOL CHEM, V257, P6111; PICK U, 1982, J BIOL CHEM, V257, P6120; PICKART CM, 1984, J BIOL CHEM, V259, P1629; STURMER W, 1989, J MEMBRANE BIOL, V110, P67, DOI 10.1007/BF01870994; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x	44	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16990	16994						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1387398				2022-12-27	WOS:A1992JL05300042
J	HASHIMOTO, Y; ORELLANA, A; GIL, G; HIRSCHBERG, CB				HASHIMOTO, Y; ORELLANA, A; GIL, G; HIRSCHBERG, CB			MOLECULAR-CLONING AND EXPRESSION OF RAT-LIVER N-HEPARAN SULFATE SULFOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FIBROBLAST GROWTH-FACTOR; HIGH-AFFINITY RECEPTOR; BLOOD GROUP-A; HYDROXYSTEROID SULFOTRANSFERASE; MESSENGER-RNA; CDNA; BINDING; IDENTIFICATION; PROTEIN	N-Heparan sulfate sulfotransferase catalyzes the transfer of sulfate from 3'-phosphoadenosine 5'-phosphosulfate to the nitrogen of glucosamine in heparan sulfate. The enzyme has been previously purified to apparent homogeneity from rat liver (Brandan, E., and Hirschberg, C. B. (1988) J. Biol. Chem. 263, 2417-2422). We have now cloned the rat liver enzyme using the following strategy: (a) the amino acid sequence was obtained from tryptic peptides of the purified protein, (b) mixed oligonucleotides were generated based on the sequence of the tryptic peptides, (c) a polymerase chain reaction fragment was obtained using mixed oligonucleotide interprimer amplification of cDNA, and (d) this fragment was used to screen rat liver lambda-gt 10 and lambda-ZAP libraries. Three clones were obtained, one of which seems to contain the complete coding sequence of the N-heparan sulfate sulfotransferase (N-HSST). Evidence that the cDNA clone corresponds to the previously purified and characterized N-HSST was the following: (a) the predicted sequence of the N-HSST contains all of the 11 tryptic peptides obtained from the purified protein, (b) when a cDNA containing the sequence coding for the N-HSST was introduced in a eukaryotic expression vector and transfected in COS-1 cells, the enzyme activity was expressed 9-fold over controls, and (c) the characteristic of the predicted protein fits with the purified protein in terms of molecular weight, membrane localization, and its being an N-linked glycoprotein. The size of the longest cDNA isolated is 4.1 kilobases, which is in close agreement with the 4.2-kilobase size of one of the mRNA observed in Northern analyses. In addition, messages of 7.0 and 8.5 kilobases were also observed, suggesting that a large portion is untranslated. The latter messages were the major mRNA species detected.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester			Orellana, Ariel/AAE-4866-2021; Orellana, Ariel/E-2166-2014	Orellana, Ariel/0000-0002-9243-808X; Orellana, Ariel/0000-0002-9243-808X; Hirschberg, Carlos/0000-0003-2299-7721	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARUFFO A, 1991, CURRENT PROTOCOLS S, V14; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KIMURA JH, 1984, J CELL BIOCHEM, V26, P261, DOI 10.1002/jcb.240260406; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LUPA MT, 1990, DEV BIOL, V142, P31, DOI 10.1016/0012-1606(90)90148-C; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; Maxam A M, 1980, Methods Enzymol, V65, P499; MOREMEN KW, 1989, P NATL ACAD SCI USA, V86, P5276, DOI 10.1073/pnas.86.14.5276; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NASH AR, 1988, AUST J BIOL SCI, V41, P507; OGURA K, 1989, BIOCHEM BIOPH RES CO, V165, P168, DOI 10.1016/0006-291X(89)91050-4; OGURA K, 1990, BIOCHEM BIOPH RES CO, V166, P1494, DOI 10.1016/0006-291X(90)91036-R; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15726; OZAWA S, 1990, NUCLEIC ACIDS RES, V18, P400; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	54	152	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15744	15750						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379236				2022-12-27	WOS:A1992JG11300075
J	MAGNIER, C; PAPP, B; CORVAZIER, E; BREDOUX, R; WUYTACK, F; EGGERMONT, J; MACLOUF, J; ENOUF, J				MAGNIER, C; PAPP, B; CORVAZIER, E; BREDOUX, R; WUYTACK, F; EGGERMONT, J; MACLOUF, J; ENOUF, J			REGULATION OF SARCO-ENDOPLASMIC RETICULUM CA2+-ATPASES DURING PLATELET-DERIVED GROWTH FACTOR-INDUCED SMOOTH-MUSCLE CELL-PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; MESSENGER-RNA EXPRESSION; CYTOSOLIC FREE CALCIUM; PROTEIN KINASE-C; PROTOONCOGENE EXPRESSION; CA-2+-TRANSPORT ATPASE; SARCOPLASMIC-RETICULUM; CA-2+-ATPASE GENE; PROSTAGLANDIN; ISOFORM	The role of the sarco-endoplasmic reticulum Ca2+-ATPases (SERCA) in the regulation of cell proliferation by Ca2+ was investigated by testing the effect of platelet-derived growth factor (PDGF) on cultured pig aorta smooth muscle cells. For this purpose, the PDGF-mediated rise in the Ca2+ concentration was first examined for its ability to induce the formation of prostaglandins from the specific membrane enzyme, cyclooxygenase. In parallel experiments, similar conditions (10 ng/ml PDGF for 24 h) were used to investigate the smooth muscle cell membrane SERCA2 isoforms. Total SERCA2 activity rose by 472% as reflected by their specific formation of phosphorylated intermediate (E-P). This rise correlated with an increase in the amount of SERCA2 proteins (100 kDa) as shown by Western blotting. With isoform-specific anti-SERCA2-a and anti-SERCA2-b antibodies, we demonstrated that the increase in total SERCA2 proteins concerned the minor isoform SERCA2-a, which rose 10-fold, whereas SERCA2-b proteins were not affected. Lastly, Northern blotting using riboprobes showed that PDGF treatment increased the SERCA2-a mRNA species by 82%, and concomitantly decreased the SERCA2-b mRNA by 28%, as a result of isoform switching. We conclude that up-regulation of the SERCA2-type Ca2+-ATPases occurs in PDGF-treated smooth muscle cells, which suggests that this enzymatic system plays an essential part in cell proliferation.	CATHOLIC UNIV LEUVEN, FYSIOL LAB, B-3000 LOUVAIN, BELGIUM; NATL INST HAEMATOL & BLOOD TRANSFUS, H-1113 BUDAPEST, HUNGARY	KU Leuven	MAGNIER, C (corresponding author), HOP LARIBOISIERE, INSERM, U348, 8 RUE GUY PATIN, F-75475 PARIS 10, FRANCE.			Papp, Bela/0000-0002-5025-3087; Eggermont, Jan/0000-0002-8497-1159				BIAN JH, 1991, J BIOL CHEM, V266, P8801; BLAY J, 1989, J CELL PHYSIOL, V139, P524, DOI 10.1002/jcp.1041390311; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELABASTIE D, 1988, FEBS LETT, V229, P45, DOI 10.1016/0014-5793(88)80794-4; DESMEDT H, 1991, J BIOL CHEM, V266, P7092; DILIBERTO PA, 1991, J BIOL CHEM, V266, P12612; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; EGGERMONT JA, 1990, BIOCHEM J, V266, P901; ENOUF J, 1988, J BIOL CHEM, V263, P13922; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; HUANG CL, 1991, J BIOL CHEM, V266, P4045; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JONES SD, 1988, COLD SPRING HARB SYM, V53, P531, DOI 10.1101/SQB.1988.053.01.061; KACZMAREK L, 1986, LAB INVEST, V54, P365; KAEVER V, 1990, BIOCHEM PHARMACOL, V39, P1313, DOI 10.1016/0006-2952(90)90007-8; KOCHER O, 1987, DIFFERENTIATION, V34, P201, DOI 10.1111/j.1432-0436.1987.tb00067.x; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LIN AH, 1989, J BIOL CHEM, V264, P17379; MARUYAMA K, 1989, CELL MOTIL CYTOSKEL, V14, P26, DOI 10.1002/cm.970140107; MERCADIER JJ, 1990, J CLIN INVEST, V85, P305, DOI 10.1172/JCI114429; MISSIAEN L, 1991, BIOCHEM BIOPH RES CO, V174, P1183, DOI 10.1016/0006-291X(91)91546-O; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PAPP B, 1991, J BIOL CHEM, V266, P14593; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; RAEYMAEKERS L, 1985, BIOCHIM BIOPHYS ACTA, V815, P441, DOI 10.1016/0005-2736(85)90372-4; RAZ A, 1988, J BIOL CHEM, V263, P3022; ROE MW, 1989, J CELL PHYSIOL, V139, P100, DOI 10.1002/jcp.1041390115; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; WUYTACK F, 1984, BIOCHEM J, V224, P445, DOI 10.1042/bj2240445; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZAGARI M, 1989, J CELL PHYSIOL, V139, P167, DOI 10.1002/jcp.1041390123; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	41	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15808	15815						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386363				2022-12-27	WOS:A1992JG11300084
J	LARKIN, M; AHERN, TJ; STOLL, MS; SHAFFER, M; SAKO, D; OBRIEN, J; YUEN, CT; LAWSON, AM; CHILDS, RA; BARONE, KM; LANGERSAFER, PR; HASEGAWA, A; KISO, M; LARSEN, GR; FEIZI, T				LARKIN, M; AHERN, TJ; STOLL, MS; SHAFFER, M; SAKO, D; OBRIEN, J; YUEN, CT; LAWSON, AM; CHILDS, RA; BARONE, KM; LANGERSAFER, PR; HASEGAWA, A; KISO, M; LARSEN, GR; FEIZI, T			SPECTRUM OF SIALYLATED AND NONSIALYLATED FUCO-OLIGOSACCHARIDES BOUND BY THE ENDOTHELIAL-LEUKOCYTE ADHESION MOLECULE E-SELECTIN - DEPENDENCE OF THE CARBOHYDRATE BINDING-ACTIVITY ON E-SELECTIN DENSITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; DIFFERENTIATION ANTIGENS; MONOCLONAL-ANTIBODIES; CONFORMATIONAL-ANALYSIS; PROBES NEOGLYCOLIPIDS; GROUP-B; GROUP-H; RECOGNITION; PROTEINS; LECTINS	Carbohydrate recognition by the human endothelial-leukocyte adhesion molecule, E-selectin, has been investigated by binding studies using H-3-labeled Chinese hamster ovary cells expressing different levels of the transfected full-length adhesion molecule and a series of structurally defined oligosaccharides linked to the lipid phosphatidylethanolamine dipalmitoate (neoglycolipids) and synthetic glycolipids chromatographed on silica gel plates or immobilized on plastic wells. Evidence is presented for density-dependent binding of the membrane-associated E-selectin not only to 3'-sialyl-lacto-N-fucopentaose II (3'-S-LNFP-II) and 3'sialyl-lacto-N-fucopentaose III (3'-S-LNFP-III) which express the sialyl Le(a) and sialyl Le(x) antigens, respectively, but also to the nonsialylated analogue LNFP-II; there is a threshold density of E-selectin required for binding to these sialylated sequences, and binding to the nonsialylated analogue is a property only of cells with the highest density of E-selectin expression. The presence of fucose linked to subterminal rather than to an internal N-acetylglucosamine is shown to be a requirement for E-selectin binding, and although the presence of sialic acid 3-linked to the terminal galactose of the LNFP-II or LNFP-III sequences substantially enhances E-selectin binding, the presence of 6-linked sialic acid abolishes binding. E-selectin binding is unaffected in the presence of the blood group H fucose (alpha-1-2 linked to galactose to form the Le(b) antigen). However, the binding is abolished when in addition alpha-1-3-linked N-acetylgalactosamine to the galactose (blood group A antigen) is present. These results indicate that some E-selectin-mediated adhesive events may be influenced by blood group status.	CLIN RES CTR, MRC, GLYCOCONJUGATES SECT, WATFORD RD, HARROW HA1 3UJ, MIDDX, ENGLAND; CLIN RES CTR, MRC, CLIN MASS SPECTROMETRY SECT, HARROW HA1 3UJ, MIDDX, ENGLAND; GENET INST, CAMBRIDGE, MA 01240 USA; GIFU UNIV, DEPT APPL BIOORGAN CHEM, GIFU 50111, JAPAN	Medical Research Council Clinical Trials Unit; Medical Research Council Clinical Trials Unit; Gifu University								ABBOTT WM, 1988, BIOCHEM J, V252, P283, DOI 10.1042/bj2520283; BECHTEL B, 1990, J BIOL CHEM, V265, P2028; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; DEJANA E, 1992, LAB INVEST, V66, P324; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FEIZI T, 1991, TRENDS BIOCHEM SCI, V16, P84, DOI 10.1016/0968-0004(91)90038-W; FEIZI T, 1987, BIOCHEM J, V245, P1; FEIZI T, 1984, BIOCHEM SOC T, V12, P591, DOI 10.1042/bst0120591; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FEIZI T, 1981, TRENDS BIOCHEM SCI, V6, P333, DOI 10.1016/0968-0004(81)90119-5; FEIZI T, 1989, CIBA F S, V145, P62; Feizi T, 1991, CURR OPIN STRUC BIOL, V1, P766, DOI 10.1016/0959-440X(91)90176-T; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1983, EUR J IMMUNOL, V13, P306, DOI 10.1002/eji.1830130407; HAKOMORI S, 1974, ANTIGENS, V2, P79; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KABAT EA, 1982, AM J CLIN PATHOL, V78, P281, DOI 10.1093/ajcp/78.3.281; KAMEYAMA A, 1991, J CARBOHYD CHEM, V10, P549, DOI 10.1080/07328309108543931; KAMEYAMA A, 1991, CARBOHYD RES, V209, pC1, DOI 10.1016/0008-6215(91)80171-I; KAMEYAMA A, 1991, J CARBOHYD CHEM, V10, P729, DOI 10.1080/07328309108543946; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LAWSON AM, 1990, CARBOHYD RES, V200, P47, DOI 10.1016/0008-6215(90)84181-S; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MCEVER RP, 1991, J CELL BIOCHEM, V45, P156, DOI 10.1002/jcb.240450206; MIZUOCHI T, 1989, J BIOL CHEM, V264, P13834; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICARD JK, 1984, BIOCHEM SOC T, V12, P653, DOI 10.1042/bst0120653; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SHEPHERD VL, 1981, P NATL ACAD SCI-BIOL, V78, P1019, DOI 10.1073/pnas.78.2.1019; SOLOMON JC, 1991, CARBOHYD RES, V213, P293, DOI 10.1016/S0008-6215(00)90616-5; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; THOGERSEN H, 1982, CAN J CHEM, V60, P44, DOI 10.1139/v82-009; THORPE SJ, 1984, BIOSCIENCE REP, V4, P673, DOI 10.1007/BF01121021; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Watkins W M, 1980, Adv Hum Genet, V10, P1	48	133	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13661	13668						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377689				2022-12-27	WOS:A1992JB74600089
J	VIRGOLINI, I; LI, SR; SILLABER, C; MAJDIC, O; SINZINGER, H; LECHNER, K; BETTELHEIM, P; VALENT, P				VIRGOLINI, I; LI, SR; SILLABER, C; MAJDIC, O; SINZINGER, H; LECHNER, K; BETTELHEIM, P; VALENT, P			CHARACTERIZATION OF PROSTAGLANDIN (PG)-BINDING SITES EXPRESSED ON HUMAN BASOPHILS - EVIDENCE FOR A PROSTAGLANDIN-E(1), PROSTAGLANDIN-I(2), AND A PROSTAGLANDIN-D(2) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-SITES; HUMAN-BLOOD BASOPHILS; HISTAMINE-RELEASE; MAST-CELLS; MEDIATOR RELEASE; PROSTACYCLIN RECEPTORS; MEMBRANE STRUCTURES; ADENYLATE-CYCLASE; HUMAN LEUKOCYTES; IN-VITRO	Recent data suggest that prostaglandins (PGs) are involved in the regulation of basophil activation. The aim of this study was to characterize the basophil PG-binding sites by means of radioreceptor assays using H-3-labeled PGs. Scatchard analysis for pure (>95%) chronic myeloid leukemia (CML) basophils revealed two classes of PGE1-binding sites differing in their affinity for the natural ligand (B(max1) = 217 +/- 65 fmol/10(8) cells; K(d1) = 0.5 +/- 0.2 nM; B(max2) = 2462 +/- 381 fmol/10(8) cells; K(d2) = 47 +/- 20 nM; IC50 = PGE1 < PGI2 < PGD2 < PGE2 < PGF2-alpha) as well as two classes of PGI2 (iloprost)-binding sites (B(max1) = 324 +/- 145 fmol/10(8) cells; K(d1) = 0.5 +/- 0.3 nM; B(max2) = 2541 +/- 381; K(d2) = 27 +/- 6 nM; IC50 = PGI2 < PGE1 < PGD2 < PGE2 < PGF2-alpha. In addition, CML basophils exhibited a single class of PGD2-binding sites (B(max) = 378 +/- 98 fmol/10(8) cells; K(d) = 13 +/- 4 nM; IC50: PGD2 < PGI2 < PGE1 < PGE2 < PGF2-alpha). In contrast, we were unable to detect specific saturable PGE2-binding sites. Primary and immortalized (KU812) CML basophils revealed an identical pattern of PG receptor expression. Basophils (KU812) expressed significantly (p < 0.001) lower number of PGE1 (PGI2)-binding sites (B(max1): 9% (20%) of control; B(max2): 36% (50%) of control) when cultured with recombinant interleukin 3 (rhIL-3), a basophil-activating cytokine, whereas rhIL-2 had no effect on PG receptor expression. Functional significance of binding of PGs to basophils was provided by the demonstration of a dose-dependent increase in cellular cAMP upon agonist activation, with PGE1 (ED50 = 1.7 +/- 1.1 nM) and PGI2 (ED50 = 2.8 +/- 2.3 nM) being the most potent compounds. These findings suggest that human basophils express specific receptors for PGE1, PGI2 as well as for PGD2.	UNIV VIENNA, LUDWIG BOLTZMANN INST NUCL MED, A-1090 VIENNA, AUSTRIA; UNIV VIENNA, INST IMMUNOL, A-1090 VIENNA, AUSTRIA; UNIV VIENNA, DEPT MED 1, A-1090 VIENNA, AUSTRIA	Ludwig Boltzmann Institute; University of Vienna; University of Vienna; University of Vienna	VIRGOLINI, I (corresponding author), UNIV VIENNA, DEPT NUCL MED, GARNISONGASSE 13, A-1090 VIENNA, AUSTRIA.		Valent, Peter/B-8533-2016; Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019	Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; LI, Shuren/0000-0001-7827-8051				AMIOT M, 1986, J IMMUNOL, V136, P1752; ARMSTRONG RA, 1989, BRIT J PHARMACOL, V97, P657, DOI 10.1111/j.1476-5381.1989.tb12001.x; ARMSTRONG RA, 1986, BRIT J PHARMACOL, V87, P543, DOI 10.1111/j.1476-5381.1986.tb10196.x; BOURNE HR, 1972, J IMMUNOL, V108, P695; Coleman R A, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P467; COLEMAN RA, 1985, PROSTAGLANDINS, V29, P533; COOPER B, 1979, J CLIN INVEST, V64, P586, DOI 10.1172/JCI109497; DONG YJ, 1986, BRIT J PHARMACOL, V87, P97, DOI 10.1111/j.1476-5381.1986.tb10161.x; DUTTAROY AK, 1987, J BIOL CHEM, V262, P12685; FERNANDEZBOTRAN R, 1984, J IMMUNOL, V133, P2662; GOODMAN MG, 1986, J IMMUNOL, V137, P3753; GOODWIN JS, 1979, CELL IMMUNOL, V43, P150, DOI 10.1016/0008-8749(79)90158-8; GRIFFIN JD, 1984, BLOOD, V63, P904; HIRAI K, 1988, J IMMUNOL, V141, P3958; HOLGATE ST, 1980, J IMMUNOL, V125, P1367; HOLTER W, 1985, CLIN EXP IMMUNOL, V62, P600; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; JOHNSTON SL, 1990, CURR OPIN IMMUNOL, V2, P513, DOI 10.1016/0952-7915(90)90004-Z; Keen M, 1989, Eicosanoids, V2, P193; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; KNAPP W, 1983, ANN NY ACAD SCI, V420, P251, DOI 10.1111/j.1749-6632.1983.tb22210.x; KNAPP W, 1984, MED ONCOL TUMOR PHAR, V1, P257; KOLLER U, 1985, CLIN EXP IMMUNOL, V59, P613; LEIGH PJ, 1984, J BIOL CHEM, V259, P2431; LICHTENSTEIN LM, 1971, J IMMUNOL, V107, P1122; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1991, ANN NY ACAD SCI, V629, P48; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; LICHTENSTEIN LM, 1972, PROSTAGLANDINS CELLU, P293; LISZKA K, 1983, AM J HEMATOL, V15, P219, DOI 10.1002/ajh.2830150303; LOMBROSO M, 1984, PROSTAGLANDINS, V27, P321, DOI 10.1016/0090-6980(84)90083-2; MACDERMOT J, 1981, BIOCHEM PHARMACOL, V30, P2041, DOI 10.1016/0006-2952(81)90220-3; MACGLASHAN DW, 1983, FED PROC, V42, P2504; MAJDIC O, 1981, BLOOD, V58, P1127; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MIZUNO Y, 1983, PROSTAG OTH LIPID M, V26, P785, DOI 10.1016/0090-6980(83)90062-X; PETERS SP, 1984, J PHARMACOL EXP THER, V228, P400; PETERS SP, 1985, ALLERGY, P111; SAMPSON D, 1967, BLOOD-J HEMATOL, V29, P722, DOI 10.1182/blood.V29.5.722.722; SAMUELSSON B, 1975, ANNU REV BIOCHEM, V44, P669, DOI 10.1146/annurev.bi.44.070175.003321; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAFER AI, 1979, J BIOL CHEM, V254, P2914; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SIMKIN NJ, 1987, J IMMUNOL, V138, P1074; SKUBALLA W, 1983, ADV PROSTAG THROMB L, V11, P299; SNYDER DS, 1982, NATURE, V299, P163, DOI 10.1038/299163a0; STAIN C, 1987, BLOOD, V70, P1872; STOCKINGER H, 1990, BLOOD, V75, P1820; SULLIVAN TJ, 1976, AM J PATHOL, V85, P437; TAUBER AI, 1973, J IMMUNOL, V111, P27; THIERAUCH KH, 1988, PROSTAGLANDINS, V35, P855, DOI 10.1016/0090-6980(88)90112-8; VALENT P, 1990, INT ARCH ALLER A IMM, V91, P198, DOI 10.1159/000235115; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENT P, 1990, CRIT REV ONCOL HEMAT, V10, P327, DOI 10.1016/1040-8428(90)90009-H; VALENT P, 1990, J IMMUNOL, V145, P1885; VIRGOLINI I, 1988, PROSTAGLANDINS, V36, P807, DOI 10.1016/0090-6980(88)90058-5; VIRGOLINI I, 1988, BRIT J CANCER, V58, P584, DOI 10.1038/bjc.1988.264; VIRGOLINI I, 1989, BRIT J CANCER, V59, P407, DOI 10.1038/bjc.1989.81; VIRGOLINI I, 1989, THROMB HAEMOSTASIS, V62, P243; WATANABE T, 1991, BLOOD, V78, P2328; Wilson N H, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P491	66	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12700	12708						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1377673				2022-12-27	WOS:A1992HZ48300050
J	REPONEN, P; SAHLBERG, C; HUHTALA, P; HURSKAINEN, T; THESLEFF, I; TRYGGVASON, K				REPONEN, P; SAHLBERG, C; HUHTALA, P; HURSKAINEN, T; THESLEFF, I; TRYGGVASON, K			MOLECULAR-CLONING OF MURINE 72-KDA TYPE-IV COLLAGENASE AND ITS EXPRESSION DURING MOUSE DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; BRONCHIAL EPITHELIAL-CELLS; METASTATIC TUMOR-CELLS; HUMAN-SKIN; INTERSTITIAL COLLAGENASE; FIBROBLAST COLLAGENASE; EXTRACELLULAR-MATRIX; INDUCED TRANSIN; GENE; GELATINASE	We report the isolation of a cDNA clone providing the first and complete sequence of mouse 72-kDa type IV collagenase. The clone contains 2800 nucleotides with a 1986-nucleotide open reading frame coding for 662 amino acids. The amino acid sequence includes a 29-residue signal peptide, an 80-residue propeptide, and a 553-residue enzyme proper. The sequence identity between the mouse and human enzymes is 96% with all cysteine residues conserved. The carboxyl-terminal domain of the mouse enzyme contains two more residues than the human enzyme. Northern hybridization analysis revealed considerable expression of the enzyme gene in newborn mouse lung, heart, kidney, and psoas muscle tissues, whereas only weak or no signals were observed in liver, spleen, and brain. Expression of the gene was substantially reduced in the same tissues of 3-month-old mice. In situ hybridization analysis of 72-kDa type IV collagenase expression in 10-15-day-old mouse embryos showed that the gene was intensely expressed in mesenchymal cells. Brain and surface ectoderm were completely negative. The epithelial tissue component of developing organs was negative with the exception of salivary gland. Although the expression varied somewhat between different mesenchymal tissues, no temporal or spatial changes could be associated with the advancement of epithelial branching morphogenesis. These findings together with our previous data on the expression of 72-kDa type IV collagenase in human tumors indicate that this enzyme has some very specific roles both in the physiological and pathological degradation of extracellular matrix. Furthermore, it has become clear that the closely related 92-kDa type IV collagenase differs completely with respect to expression pattern as well as gene regulation. The mouse cDNA clones reported in this study may provide important tools unraveling the actual roles of these enzymes in vivo.	UNIV OULU,BIOCTR,SF-90570 OULU,FINLAND; UNIV OULU,DEPT BIOCHEM,SF-90570 OULU,FINLAND; UNIV HELSINKI,DEPT PEDODONT & ORTHODONT,SF-00300 HELSINKI,FINLAND	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Helsinki					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009399] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE09399] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; CHEN JM, 1991, J BIOL CHEM, V266, P5113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DAVIS GE, 1990, CANCER RES, V50, P1113; FESSLER LI, 1984, J BIOL CHEM, V259, P9783; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; FINI ME, 1987, ARTHRITIS RHEUM, V30, P1254, DOI 10.1002/art.1780301108; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; LEVY AT, 1991, CANCER RES, V51, P439; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MACKAY AR, 1990, J BIOL CHEM, V265, P21929; MAINARDI CL, 1984, COLLAGEN REL RES, V4, P479; Maniatis T., 1982, MOL CLONING; MARTIN J, 1989, KIDNEY INT, V36, P790, DOI 10.1038/ki.1989.264; MARTRISIAN LM, 1985, EMBO J, V4, P1435; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MOLL UM, 1990, CANCER RES, V50, P6162; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1989, J CELL SCI, V92, P487; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; PYKE C, 1992, IN PRESS CANCER RES; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RIFAS L, 1989, J CLIN INVEST, V84, P686, DOI 10.1172/JCI114216; SALO T, 1983, J BIOL CHEM, V258, P3058; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELTZER JL, 1989, J BIOL CHEM, V264, P3822; SELTZER JL, 1981, J BIOL CHEM, V256, P4662; SELTZER JL, 1989, J BIOL CHEM, V264, P19583; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; THESLEFF I, 1990, CELL DIFFER DEV, V32, P383, DOI 10.1016/0922-3371(90)90054-Z; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; URA H, 1989, CANCER RES, V49, P4615; WELGUS HG, 1990, J BIOL CHEM, V265, P13521; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; YAMAGATA S, 1989, BIOCHEM BIOPH RES CO, V158, P228, DOI 10.1016/S0006-291X(89)80202-5	55	190	195	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7856	7862						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373140				2022-12-27	WOS:A1992HN48500092
J	HANDY, DE; GAVRAS, H				HANDY, DE; GAVRAS, H			PROMOTER REGION OF THE HUMAN (ALPHA-2)A ADRENERGIC-RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-ADRENERGIC RECEPTOR; PRE-MESSENGER RNA; ALPHA-2B-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; ALPHA2-ADRENERGIC RECEPTORS; 5'-FLANKING REGION; MAMMALIAN-CELLS; RAT-BRAIN; EXPRESSION; CLONING	In order to locate the promoter region of the human alpha2A adrenergic receptor gene we used RNase protection analysis and antisense RNA probes to map the cap site of the alpha2 transcripts. Prior sequence analysis has shown two potential TATA box motifs in the human alpha2A adrenergic receptor gene, TATATAT and TATAAAA, located 427 and 1037 base pairs (bp), respectively, upstream of the protein coding region. RNase protection experiments and primer extension show that transcription starts downstream of the distal TATAAAA, indicating that the 5'-untranslated region is approximately 1 kilobase in length. We have used the chloramphenicol acetyltransferase reporter gene and transient transfection into HT29, a human adenocarcinoma cell line that expresses the alpha2A receptor, to show that as little as 150 bp upstream of the cap site can direct transcription. Sequence analysis shows that although this region contains the TATA box motif it lacks a CCAAT box motif. DNase I footprint analysis of a fragment from -17 to -193 (where +1 is the transcription initiation site), using nuclear extracts from HT29, showed hypersensitive sites (-68/-69) and two protected regions: -70 to -87, which includes a 10-bp palindrome, and -92 to -105, which includes a GC box, a common motif for Spl nuclear factor binding. Gel mobility shift assays indicate that Sp1 or a related factor may bind to this GC box. Deletion of the GC box and the palindrome from chloramphenicol acetyltransferase constructs abolishes transcription. We propose that these cis sequences may function in lieu of a CCAAT box to regulate transcription of the human alpha2A adrenergic receptor gene.			HANDY, DE (corresponding author), BOSTON UNIV,SCH MED,DEPT MED,80 E CONCORD ST,R206,BOSTON,MA 02118, USA.			Handy, Diane/0000-0002-4310-8527				BOYER TG, 1990, J BIOL CHEM, V265, P20524; BYLUND DB, 1985, PHARMACOL BIOCHEM BE, V22, P835, DOI 10.1016/0091-3057(85)90536-2; CHALBERG SC, 1990, MOL CELL BIOCHEM, V97, P161; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DONOFRIO C, 1985, EMBO J, V4, P1981, DOI 10.1002/j.1460-2075.1985.tb03881.x; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FAIN JN, 1980, LIFE SCI, V26, P1183, DOI 10.1016/0024-3205(80)90062-4; FLORDELLIS CS, 1990, HYPERTENSION, V15, P881, DOI 10.1161/01.HYP.15.6.881; FLORDELLIS CS, 1991, P NATL ACAD SCI USA, V88, P1019, DOI 10.1073/pnas.88.3.1019; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GOLDBERG MR, 1984, HYPERTENSION, V6, P551, DOI 10.1161/01.HYP.6.4.551; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANDY DE, 1989, J IMMUNOL, V142, P1015; HANDY DE, 1988, IMMUNOGENETICS, V28, P81, DOI 10.1007/BF00346155; HERBOMEL P, 1984, CELL, V39, P553; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; LUFT FC, 1986, HDB HYPERTENSION, V8, P27; MCKERNAN RM, 1987, MOL PHARMACOL, V32, P258; MICHEL MC, 1989, FASEB J, V3, P139, DOI 10.1096/fasebj.3.2.2536629; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; TURNER JT, 1985, MOL PHARMACOL, V28, P422; WEINSHANK RL, 1990, MOL PHARMACOL, V38, P681; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	33	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24017	24022						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385431				2022-12-27	WOS:A1992JZ23900087
J	MARENGERE, LEM; PAWSON, T				MARENGERE, LEM; PAWSON, T			IDENTIFICATION OF RESIDUES IN GTPASE-ACTIVATING PROTEIN SRC HOMOLOGY-2 DOMAINS THAT CONTROL BINDING TO TYROSINE PHOSPHORYLATED GROWTH-FACTOR RECEPTORS AND P62	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SIGNALING PROTEINS; SHOWING HIGH SUSCEPTIBILITY; PHOSPHOLIPASE-C-GAMMA; PORCINE GENE SYK; MOLECULAR-CLONING; SH2 DOMAINS; REGULATES INTERACTIONS; SEQUENCE SIMILARITY; COMPLEMENTARY-DNA; KINASE FUNCTION	Ras GTPase-activating protein (GAP) contains two Src homology 2 (SH2) domains which are implicated in binding to tyrosine-phosphorylated sites in specific activated growth factor receptors and to a cytoplasmic tyrosine-phosphorylated protein, p62. We have used site-directed mutagenesis of the two GAP SH2 domains (SH2-N and SH2-C) to identify residues involved in receptor and p62 binding. A bacterial fusion protein containing the precise SH2-N domain, as defined by sequence homology, associated with both the activated beta platelet-derived growth factor receptor and epidermal growth factor receptor, and p62 in vitro. However, short deletions at either the N or C termini of the SH2-N domain abolished binding, suggesting that the entire SH2 sequence is required for formation of an active domain. Conservative substitutions of 2 highly conserved basic residues in the SH2-N domain, an arginine and a histidine, resulted in complete loss of receptor and p62 binding, whereas other basic residues, and residues at variable SH2 sites, were more tolerant of substitution. The conserved arginine and histidine therefore appear critical for association with phosphotyrosine-containing proteins, possibly through an interaction with phosphotyrosine. The GAP SH2-C domain, unlike SH2-N, does not bind efficiently to activated receptors or p62 in vitro. The SH2-C domain lacks 3 residues which are otherwise well conserved, and contribute to high affinity SH2-N binding. Replacement of 1 of these residues, a cysteine, with the consensus glycine, conferred SH2-C binding activity toward tyrosine-phosphorylated p62 and epidermal growth factor receptor. Loss-of-function and gain-of-function mutations in the GAP SH2 domains can therefore be used to identify residues that are critical for receptor and p62 binding.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013					ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MANO H, 1991, ONCOGENE, V5, P1781; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	57	66	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22779	22786						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385407				2022-12-27	WOS:A1992JY16300015
J	MATSUURA, K; ISHIDA, T; SETOGUCHI, M; HIGUCHI, Y; AKIZUKI, S; YAMAMOTO, S				MATSUURA, K; ISHIDA, T; SETOGUCHI, M; HIGUCHI, Y; AKIZUKI, S; YAMAMOTO, S			IDENTIFICATION OF A TISSUE-SPECIFIC REGULATORY ELEMENT WITHIN THE MURINE CD14 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOMA CELL-LINE; BINDING-PROTEINS; MONOCLONAL-ANTIBODIES; RESPONSIVE ELEMENT; EXPRESSION; DNA; SEQUENCES; ANTIGENS; HYBRIDS; MOUSE	We previously isolated and sequenced the 5'-flanking region of the mouse CD14 (mCD14) gene (Matsuura, K., Setoguchi, M., Nasu, N., Higuchi, Y., Yoshida, S., Akizuki, S., and Yamamoto, S. (1989) Nucleic Acids Res. 17, 2132). To define the regulatory elements that control expression of the mCD14 gene, we analyzed the structure of the 5' end of the gene, including a region further upstream of that determined previously. Sequentially 5'-deleted, chimeric, and point mutated clones were tested for the ability to stimulate chloramphenicol acetyltransferase. An 8-base pair sequence, TGATTCAC, at position -255, which resembled the consensus sequence of the 12-O-tetradecanoylphorbol-13-acetate-responsive element (TRE), enhanced the expression of the chloramphenicol acetyltransferase gene in macrophage (aHINS-B3) and non-macrophage (glioblastoma G203 and myeloma NS1) cells. The enhancing ability of the TRE-like sequence (TLS), however, was markedly reduced in G203 cells but not in aHINS-B3 cells when the TLS was followed by the sequence immediately downstream. The TLS and sequence immediately downstream were capable of binding nuclear proteins which were unique to aHINS-B3 cells and macrophages, suggesting that these unique protein regulate the specific expression of the mCD14 gene. Binding of AP-1 to the TLS was also found in aHINS-B3 and G203 cells. Although it is uncertain whether AP-1 is involved in expression of the mCD14 gene, the effect of AP-1 in non-macrophage cells was inhibited by a nuclear protein which binds to the sequence immediately downstream of the TLS.			MATSUURA, K (corresponding author), OITA MED UNIV,DEPT PATHOL,HASAMA,OITA 87955,JAPAN.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALL ED, 1982, P NATL ACAD SCI-BIOL, V79, P5374, DOI 10.1073/pnas.79.17.5374; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; BERG AJ, 1978, P NATL ACAD SCI USA, V75, P1274; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOYERT SM, 1986, J IMMUNOL, V137, P3909; GRIFFIN JD, 1981, J CLIN INVEST, V68, P932, DOI 10.1172/JCI110348; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HIGUCHI Y, 1988, ONCOGENE, V2, P515; JELINEK WR, 1982, ANNU REV BIOCHEM, V51, P813, DOI 10.1146/annurev.bi.51.070182.004121; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; MALISZEWSKI CR, 1985, J IMMUNOL, V135, P1929; MATSUURA K, 1989, NUCLEIC ACIDS RES, V17, P2132, DOI 10.1093/nar/17.5.2132; Matsuura K, 1990, J Immunol, V145, P3150; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; MOSHIER JA, 1987, GENE, V58, P19, DOI 10.1016/0378-1119(87)90025-4; NASU N, 1991, INT IMMUNOL, V3, P205, DOI 10.1093/intimm/3.2.205; OKUDA A, 1989, J BIOL CHEM, V264, P16919; OZONO K, 1990, J BIOL CHEM, V265, P21881; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SETOGUCHI M, 1989, MOL CELL BIOL, V9, P4515, DOI 10.1128/MCB.9.10.4515; SETOGUCHI M, 1988, SOMAT CELL MOLEC GEN, V14, P427, DOI 10.1007/BF01534710; SETOGUCHI M, 1989, BIOCHIM BIOPHYS ACTA, V1008, P213, DOI 10.1016/0167-4781(80)90012-3; TODD RF, 1981, J IMMUNOL, V126, P1435; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YAMAMOTO S, 1984, IMMUNOGENETICS, V19, P519, DOI 10.1007/BF00403443	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21787	21794						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383228				2022-12-27	WOS:A1992JV01100082
J	RUFF, VA; YEM, AW; MUNNS, PL; ADAMS, LD; REARDON, IM; DEIBEL, MR; LEACH, KL				RUFF, VA; YEM, AW; MUNNS, PL; ADAMS, LD; REARDON, IM; DEIBEL, MR; LEACH, KL			TISSUE DISTRIBUTION AND CELLULAR-LOCALIZATION OF HSP56, AN FK506-BINDING PROTEIN - CHARACTERIZATION USING A HIGHLY SPECIFIC POLYCLONAL ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-SHOCK PROTEINS; STEROID-RECEPTOR COMPLEXES; MONOCLONAL-ANTIBODIES; CYCLOSPORINE-A; CELLS; CYCLOPHILIN; DISTINCT; BINDING; CYTOSOL; TARGET	Heat shock protein 56 (hsp56) has been shown to be involved in two cellular pathways, as an immunophilin for FK506 and as a component of steroid receptor complexes. To help define its role in these cellular pathways, we have developed UPJ56, a polyclonal antibody raised against hsp56 purified from Jurkat cells. In Western blot experiments, hsp56 was highly expressed in rat thymus, liver, and spleen, with low levels in lung and muscle. In immunofluorescence experiments using untreated LLC-PK1 cells, fibrillar staining was seen in the cytoplasm, suggesting a cytoskeletal localization of hsp56. The nuclei were brightly stained, except for the nucleoli. Confocal microscopy demonstrated that the staining was present in all planes of the nucleus. These results suggest that hsp56 is expressed in tissues enriched in steroid receptors and is highly expressed in tissues involved in T cell function. Furthermore, the localization of hsp56 with the cytoskeleton and throughout the nucleus is consistent with its association with steroid receptor complexes.	UPJOHN CO,DEPT CELL BIOL,301 HENRIETTA ST,KALAMAZOO,MI 49001; UPJOHN CO,DEPT BIOCHEM,KALAMAZOO,MI 49001	Pfizer; Pfizer								ADAMS LD, 1991, CURRENT PROTOCOLS MO, V88, P7111; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLIER NC, 1986, J CELL BIOL, V103, P1495, DOI 10.1083/jcb.103.4.1495; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; GASC JM, 1990, EXP CELL RES, V186, P362, DOI 10.1016/0014-4827(90)90317-4; JIU YJ, 1991, P NATL ACAD SCI USA, V88, P6677; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; PERROTAPPLANAT M, 1985, ENDOCRINOLOGY, V116, P1473, DOI 10.1210/endo-116-4-1473; REDMOND T, 1989, EUR J CELL BIOL, V50, P66; SAMMONS DW, 1981, ELECTROPHORESIS, V2, P135, DOI 10.1002/elps.1150020303; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; YEM AW, 1992, J BIOL CHEM, V267, P2868	27	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21285	21288						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383222				2022-12-27	WOS:A1992JV01100004
J	LEU, WM; CHEN, LY; LIAW, LL; LEE, YHW				LEU, WM; CHEN, LY; LIAW, LL; LEE, YHW			SECRETION OF THE STREPTOMYCES TYROSINASE IS MEDIATED THROUGH ITS TRANSACTIVATOR PROTEIN, MELC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; ESCHERICHIA-COLI; SIGNAL PEPTIDE; HYDROPHOBIC REGION; SEQUENCE; GENE; GLAUCESCENS; ANTIBIOTICUS; EXPRESSION; EXPORT	The tyrosinase of Streptomyces antibioticus is encoded by the second open reading frame, melC2 of the melanin operon (melC). The upstream open reading frame melC1 specifies a 146-amino acid protein with a typical NH2-terminal signal-peptide characteristic of a secretory protein. The MelC1 protein is involved in the transfer of copper ion to apotyrosinase MelC2 via binary complex formation (Lee, Y.-H. W., Chen, B.-F., Wu, S.-Y., Leu, W.-M., Lin, J.-J., Chen, C. W., and Lo, S. J. (1988) Gene (Amst.) 65, 71-8 1; Chen, L.-Y., Leu, W.-M., Wang, K.-T., and Lee, Y.-H. W. (1992) J. Biol. Chem. 267, 20100-20107). To investigate whether the export of tyrosinase is also dependent on MelC1, a mutational study of its signal-peptide sequence was performed. Four different mutants were obtained. Mutation at the positively charged region (mutant M-6LE, Arg6-Arg7 --> Leu6-Glu7) or the hydrophobic region (mutant M-16D, Val16 --> Asp16) led to Mel- phenotypes. These lesions caused a severe 7-10-fold reduction of the export of both the MelC1 and MelC2 proteins and a concomitant accumulation of the two proteins in the cytosolic fraction. The cell-associated tyrosinase activity in M-6LE but not in the M-16D mutant was dramatically reduced to 4% of the activity found in the wild type strain, suggesting that the basic NH2 terminus of MelC1 is also important for the trans-activation function of this protein. Nevertheless, the defects on the trans-activation and/or secretory functions of MelC1 in mutants M-6LE and M-16D are not due to the impairment of the formation of the MelC1.MelC2 complex. The translation of melanin operon genes in these two mutants also decreased. In contrast, the tyrosinase activity and the secretion of MelC2 were not affected if the mutations occurred at the putative cleavage site of the signal peptidase (e.g. mutant M-29SM, Arg29-Ala30 --> Ser29-Met30 or mutant 29-SMG, Arg29-Ala30-Asp31 --> Ser29-Met30-Gly31). Additionally, tyrosinase activity and its export were abolished in a MelC1-negative mutant, M-950. Taken together, these results demonstrate that a functional MelC1 is essential for tyrosinase secretion and activity. Furthermore, the results suggest that like other secretory proteins, basic and hydrophobic residues in the MelC1 signal sequence are an important feature of the signal-peptide and play a pivotal role in the secretion of both the MelC1 and MelC2 proteins. These results also establish a novel role for MelC1 on tyrosinase transport in addition to a role in copper transfer to tyrosinase.	NATL YANG MING MED COLL,INST BIOCHEM,TAIPEI 112,TAIWAN	National Yang Ming Chiao Tung University				Lee Wu, Yan-Hwa/0000-0001-7299-7354				Baumann R., 1976, ACTINOMYCETALES BOUN, P55; BAUMANN R, 1976, 2ND INT S GEN IND MI, P535; BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; BERNAN V, 1985, GENE, V37, P101, DOI 10.1016/0378-1119(85)90262-8; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chater K. F., 1982, CURR TOP MICROBIOL I, V96, P69; CHEN LY, 1992, J BIOL CHEM, V267, P20100; CRAMERI R, 1982, J GEN MICROBIOL, V128, P371; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FREUDL R, 1988, J BIOL CHEM, V263, P344; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOLDSTEIN J, 1991, J BIOL CHEM, V266, P14413; GREGORY KF, 1961, NATURE, V191, P465, DOI 10.1038/191465a0; GREGORY KF, 1964, J BACTERIOL, V87, P1281, DOI 10.1128/JB.87.6.1281-1286.1964; HELD T, 1990, J GEN MICROBIOL, V136, P2413, DOI 10.1099/00221287-136-12-2413; HINTERMANN G, 1985, MOL GEN GENET, V200, P422, DOI 10.1007/BF00425726; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; HUBER M, 1987, NUCLEIC ACIDS RES, V15, P8106, DOI 10.1093/nar/15.19.8106; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; KIESER T, 1981, GENETICS ACTINOMYCET, P59; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuster E., 1976, ACTINOMYCETES BOUNDA, P43; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YHW, 1988, GENE, V65, P71, DOI 10.1016/0378-1119(88)90418-0; LEHNHARDT S, 1987, J BIOL CHEM, V262, P1716; LERCH K, 1972, EUR J BIOCHEM, V31, P427, DOI 10.1111/j.1432-1033.1972.tb02549.x; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; LEU WM, 1989, GENE, V84, P267; Maniatis T, 1980, Methods Enzymol, V65, P299; OLIVER D, 1985, ANNU REV MICROBIOL, V39, P615; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; POLLITT S, 1985, J BIOL CHEM, V260, P7965; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; PUGSLEY AP, 1990, ANNU REV GENET, V24, P67; PUZISS JW, 1989, J BACTERIOL, V171, P2303, DOI 10.1128/jb.171.5.2303-2311.1989; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WANDERSMAN C, 1989, MOL MICROBIOL, V3, P1825, DOI 10.1111/j.1365-2958.1989.tb00169.x	42	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20108	20113						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400329				2022-12-27	WOS:A1992JR85800058
J	MISAWA, H; ISHII, K; DEGUCHI, T				MISAWA, H; ISHII, K; DEGUCHI, T			GENE-EXPRESSION OF MOUSE CHOLINE-ACETYLTRANSFERASE - ALTERNATIVE SPLICING AND IDENTIFICATION OF A HIGHLY-ACTIVE PROMOTER REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE SEQUENCE; MAMMALIAN-CELLS; SPINAL-CORD; RAT; CULTURES; ELEMENTS; PROTEIN; RNA	Seven types of mRNA for choline acetyltransferase that differ in the 5'-noncoding region were identified in the mouse spinal cord by cDNA cloning and polymerase chain reaction. Among these transcripts, the M-type mRNA corresponding to the previously cloned mouse cDNA was most abundant in the spinal cord of mouse. A mouse genomic DNA clone containing the 5'-region of choline acetyltransferase mRNA was isolated and sequenced. Comparison of the sequences between the cDNAs and the genomic DNA revealed that the different mRNA species were transcribed from different promoter regions and produced by differential splicing. Two murine cholinergic cell lines, NS20Y and NG108-15, were shown to express the M-type mRNA almost exclusively, and were therefore used to study transcription of M-type mRNA. Fragments of the 5'-region of choline acetyltransferase gene were ligated with chloramphenicol acetyltransferase reporter gene and introduced into cultured cells. The fragment from -2752 to +46, which contained the M-type exon, a TATA-box like element upstream of the M-type exon, and the downstream intron, induced a significant expression of CAT activity in neuronal but not in non-neuronal cell lines. This result indicates that this region of choline acetyltransferase gene contains elements that regulate neuron-specific expression of choline acetyltransferase activity. However, there was no parallel correlation between reporter gene expression in the transfected cells and intrinsic choline acetyltransferase activity in these neuronal cell lines. Possible mechanisms that would explain this observation are discussed.			MISAWA, H (corresponding author), TOKYO METROPOLITAN INST NEUROSCI, DEPT MOLEC NEUROBIOL, 2-6 MUSASHIDAI, FUCHU, TOKYO 183, JAPAN.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERRARD S, 1987, P NATL ACAD SCI USA, V84, P9280, DOI 10.1073/pnas.84.24.9280; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRICE A, 1989, J NEUROSCI RES, V23, P266, DOI 10.1002/jnr.490230304; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILLER EL, 1973, SCIENCE, V182, P588, DOI 10.1126/science.182.4112.588; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; ISHIDA I, 1983, DEV BRAIN RES, V7, P13, DOI 10.1016/0165-3806(83)90077-9; ISHII K, 1990, MOL BRAIN RES, V7, P151, DOI 10.1016/0169-328X(90)90092-R; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Nachmansohn D, 1943, J NEUROPHYSIOL, V6, P397, DOI 10.1152/jn.1943.6.5.397; PATTERSON PH, 1978, ANNU REV NEUROSCI, V1, P1, DOI 10.1146/annurev.ne.01.030178.000245; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SALVATERRA PM, 1989, INT REV NEUROBIOL, V31, P81; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X	23	117	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20392	20399						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400357				2022-12-27	WOS:A1992JR85800100
J	RUSSO, GL; VANDENBERG, MT; YU, IJ; BAE, YS; FRANZA, BR; MARSHAK, DR				RUSSO, GL; VANDENBERG, MT; YU, IJ; BAE, YS; FRANZA, BR; MARSHAK, DR			CASEIN KINASE-II PHOSPHORYLATES P34(CDC2) KINASE IN G1 PHASE OF THE HELA-CELL DIVISION CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P34CDC2 PROTEIN-KINASE; MITOSIS-SPECIFIC PHOSPHORYLATION; RAT-LIVER CYTOSOL; SV40 T-ANTIGEN; FISSION YEAST; PROMOTING FACTOR; SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; RETINOBLASTOMA PROTEIN	The activity of p34cdc2 kinase is regulated in the phases of vertebrate cell cycle by mechanisms of phosphorylation and dephosphorylation. In this paper, we demonstrate that casein kinase II (CKII) phosphorylates p34cdc2 in vivo and in vitro at Ser 39 during the G1 phase of HeLa cell division cycle. Human p34cdc2 shows a typical phosphorylation sequence motif site for CKII at Ser39 (ES39EEE). In our experiments, either p34cdc2 expressed and purified from bacteria or p34cdc2 immunoprecipitated from HeLa cells enriched in G1 by elutriation were substrates for in vitro phosphorylation by CKII. Phosphoamino acid analysis, N-chlorosuccinimide mapping, and two-dimensional tryptic mapping of p34cdc2 phosphorylated in vitro were performed to determine the phosphorylation site. A synthetic peptide spanning residues 33-50 of human p34cdc2, including the CKII site, was used to map the site. In addition, phosphorylation at Ser39 also occurs in vivo, since p34cdc2 is phosphorylated during G1 on serine, and its two-dimensional tryptic map shows two phosphopeptides that comigrate exactly with the synthetic peptides used as standard.	ARNOLD & MABEL BECKMAN NEUROSCI CTR, WM KECK STRUCT BIOL LAB, COLD SPRING HARBOR, NY 11724 USA; COLD SPRING HARBOR LAB, FREEMAN LAB CANC CELL BIOL, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory			RUSSO, GIAN LUIGI/GQB-0962-2022	RUSSO, GIAN LUIGI/0000-0001-9321-1613; Bae, Young-Seuk/0000-0002-5520-4444	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, ONCOGENE, V6, P2179; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; Ashihara T, 1979, Methods Enzymol, V58, P248; Barany G, 1979, PEPTIDES           A, V2, P1; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLARKE PR, 1991, J CELL SCI, V100, P409; DEBENEDETTE M, 1991, J IMMUNOL, V147, P2839; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ENOCH T, 1991, J CELL BIOL, V112, P797, DOI 10.1083/jcb.112.5.797; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1988, ANTIBODIES LABORATOR; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, PROTEIN PHOSPHORYLAT, P70; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LISCHWE MA, 1977, J BIOL CHEM, V252, P4976; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LOHKA MJ, 1989, J CELL SCI, V92, P131; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1982, FEBS LETT, V141, P257, DOI 10.1016/0014-5793(82)80061-6; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NORBURY C, 1990, CIBA F SYMP, V150, P168; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SCHNEIDER HR, 1988, BIOCHEM BIOPH RES CO, V156, P1390, DOI 10.1016/S0006-291X(88)80786-1; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; STETLER DA, 1982, BIOCHEMISTRY-US, V21, P3721, DOI 10.1021/bi00258a030; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	93	105	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20317	20325						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400350				2022-12-27	WOS:A1992JR85800090
J	ENGLEKA, KA; MACIAG, T				ENGLEKA, KA; MACIAG, T			INACTIVATION OF HUMAN FIBROBLAST GROWTH FACTOR-I (FGF-1) ACTIVITY BY INTERACTION WITH COPPER IONS INVOLVES FGF-1 DIMER FORMATION INDUCED BY COPPER-CATALYZED OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; NUCLEOTIDE-SEQUENCE; BIOLOGICAL-ACTIVITY; FACTOR FAMILY; FACTOR-I; HEPARIN; BINDING; ANGIOGENESIS; PURIFICATION; PROTEIN	Although the angiogenic proteins acidic fibroblast growth factor (FGF-1) and basic fibroblast growth factor (FGF-2) both interact with the transition metal copper, itself a putative modulator of angiogenesis, a role for copper in FGF function has not been established. Using nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis, we detect the complete conversion of recombinant forms of human FGF-1 monomer protein to FGF-1 homodimers after exposure to copper ions. In contrast, not all forms of bovine FGF-1 isolated from bovine brain or a recombinant preparation of human FGF-2 completely formed homodimers after exposure to copper ions under similar conditions. Since the copper-induced FGF-1 homodimers reverted to the monomer form in the presence of dithiothreitol, specific alkylation of cysteine residues by pyridylethylation prevented FGF-1 homodimer formation, and preformed FGF-1 homodimers could not be dissociated by the metal chelator EDTA, FGF-1 dimer formation appeared to result from the formation of intermolecular disulfide bonds by copper-induced oxidation of sulfhydryl residues. FGF-1 homodimers bound with similar apparent affinity as FGF-1 monomers to immobilized copper ions, both eluting at 60 mM imidazole. Both human FGF-1 monomer and dimer forms had a 6-fold higher apparent affinity for immobilized copper ions, as compared with human FGF-2, which eluted in the monomer form at 10 mM imidazole. Further, in contrast to FGF-1 monomers, which dissociate from immobilized heparin in 1.0 M NaCl, preformed FGF-1 homodimers had reduced apparent affinity for immobilized heparin and eluted at 0.4 M NaCl. In contrast, the apparent affinity of human FGF-2 for immobilized heparin was unaffected after exposure to copper ions. Heparin appeared to modulate the formation of copper-induced intermolecular disulfide bonds for FGF-1 but not FGF-2, since co-incubation of heparin and copper with FGF-1 monomers resulted in dimers and other oligomeric complexes. FGF-1 copper-induced homodimers failed to induce mitogenesis in [H-3]thymidine incorporation assays, an effect which could be reversed by treatment with dithiothreitol, whereas FGF-2-induced mitogenic activity was relatively unaffected by pretreatment with copper. The differences between human FGF-1 and FGF-2 in protein-copper interactions may be due to differing free thiol content and arrangement between the two proteins. A recombinant human FGF-1 mutant containing the two cysteines conserved throughout the FGF family of proteins but lacking a cysteine residue (Cys 131) present in wild-type human FGF-1 but not human FGF-2 readily formed copper-induced dimers. This suggests FGF-1-copper interactions may involve the cysteine residues conserved among all the members of the FGF family. Despite the differences in copper interactions between FGF-1 and FGF-2, copper-induced heterodimers between these two proteins were demonstrated, indicating FGF-1 and FGF-2 can form mixed thiols with each other. The difference in copper interactions between different forms of FGF-1 and FGF-2 are important in further attempts to determine any putative role for copper in FGF action.	AMER RED CROSS, HOLLAND LAB, DEPT MOLEC BIOL, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA	American Red Cross					NHLBI NIH HHS [HL32348] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALPERNELRAN H, 1985, SURG FORUM, V36, P498; ARAKAWA T, 1989, BIOCHEM BIOPH RES CO, V161, P335, DOI 10.1016/0006-291X(89)91601-X; BADET J, 1989, P NATL ACAD SCI USA, V86, P8427, DOI 10.1073/pnas.86.21.8427; BERG JM, 1990, J BIOL CHEM, V265, P6513; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOROUGH R, 1991, BIOCHIM BIOPHYS ACTA, V1090, P293, DOI 10.1016/0167-4781(91)90192-O; FOX GM, 1988, J BIOL CHEM, V263, P18452; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GRUSHKA E, 1982, ANAL LETT PT B, V15, P1277, DOI 10.1080/00032718208069533; GULLINO PM, 1986, ANTICANCER RES, V6, P153; HANNAN GN, 1982, J CELL PHYSIOL, V111, P207, DOI 10.1002/jcp.1041110213; HARPER JW, 1986, BIOCHEMISTRY-US, V25, P4097, DOI 10.1021/bi00362a017; JAYE M, 1987, J BIOL CHEM, V262, P16612; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JONES DH, 1990, NATURE, V344, P793, DOI 10.1038/344793a0; JONES DH, 1990, BIOTECHNIQUES, V8, P172; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; MAQUART FX, 1988, FEBS LETT, V238, P343, DOI 10.1016/0014-5793(88)80509-X; MCAUSLAN BR, 1980, EXP CELL RES, V130, P147, DOI 10.1016/0014-4827(80)90051-8; MCKEEHAN WL, 1987, ANAL BIOCHEM, V164, P563, DOI 10.1016/0003-2697(87)90534-3; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; ORTEGA S, 1991, J BIOL CHEM, V266, P5842; PICKART L, 1987, METHOD ENZYMOL, V147, P314; PICKART L, 1987, BIOL COPPER COMPLEXE, P314; RAJU KS, 1982, J NATL CANCER I, V69, P1183; RAJU KS, 1984, CANCER RES, V44, P1579; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROWE JM, 1986, CANCER RES, V46, P1408; RUCKER RB, 1988, FASEB J, V2, P2252, DOI 10.1096/fasebj.2.7.3127264; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SHING Y, 1990, ANAL BIOCHEM, V185, P108, DOI 10.1016/0003-2697(90)90263-9; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHING Y, 1988, J BIOL CHEM, V263, P9059; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STIVALA SS, 1977, FED PROC, V36, P83; STRYDOM DJ, 1986, BIOCHEMISTRY-US, V25, P945, DOI 10.1021/bi00353a001; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMAS KA, 1986, TRENDS BIOCHEM SCI, V11, P81, DOI 10.1016/0968-0004(86)90271-9; THOMPSON SA, 1992, J BIOL CHEM, V267, P2269; THOMPSON SA, 1991, METHOD ENZYMOL, V198, P96; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZICHE M, 1982, JNCI-J NATL CANCER I, V69, P475; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	56	90	95	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11307	11315						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375939				2022-12-27	WOS:A1992HX16900059
J	MENENDEZARIAS, L; RISCO, C; OROSZLAN, S				MENENDEZARIAS, L; RISCO, C; OROSZLAN, S			ISOLATION AND CHARACTERIZATION OF ALPHA-2-MACROGLOBULIN-PROTEASE COMPLEXES FROM PURIFIED MOUSE MAMMARY-TUMOR VIRUS AND CULTURE SUPERNATANTS FROM VIRUS-INFECTED CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; HUMAN-IMMUNODEFICIENCY-VIRUS; MOLECULAR-WEIGHT PROTEASE; MAMMALIAN-CELLS; TISSUE-CULTURE; RAT-LIVER; GAG; INHIBITORS; RETROVIRUSES; PURIFICATION	Cleavage of oligopeptide substrates mimicking the maturation sites in the Gag polyproteins of the mouse mammary tumor virus was assayed using lysed virus. Cleavage at the expected P1-P1' positions was detected in four of seven synthetic peptides. However, studies with specific inhibitors of retroviral proteases showed that only two of them could be unequivocally attributed to the viral enzyme. In an attempt to characterize other proteolytic activities that copurify with the virus, we isolated a multicatalytic high molecular mass protease (700 kDa) that copurifies with the virus. This protein has been identified as an alpha-2-macroglobulin-protein complex according to its biochemical properties and ultrastructure. The proteases forming these complexes are mainly serine proteases and can be inhibited by phenylmethylsulfonyl fluoride. However, other compounds such as chymostatin and elastatinal are more effective inhibitors. The relative efficacy of each compound depends on the substrate, since the complexes described herein appear to be multicatalytic. Elastatinal is a very good inhibitor of the cleavages found at Ala-Ala bonds in peptides representing the capsid/nucleocapsid site, while chymostatin inhibits certain cleavages at the carboxyl terminus of bonds involving leucine and valine in three of the substrates used. Therefore, the alpha-2-macroglobulin present in the cell culture medium is able to bind proteases, forming high molecular weight complexes, which are active against peptide substrates, copurify with the virus and are responsible for the nonviral proteolytic activities found in the purified virus. Elastase appears to be the main proteolytic activity which can be detected in the alpha-2-macroglobulin-protease complexes associated with the virus.	NCI, FREDERICK CANC RES & DEV CTR, MATH BIOL LAB, STRUCT BIOL SECT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MENENDEZARIAS, L (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MOLEC VIROL & CARCINOGENESIS LAB, FREDERICK, MD 21702 USA.		Menendez Arias, Luis/G-2436-2016; Risco, Cristina/K-4308-2014; Menendez Arias, Luis/N-7447-2016	Risco, Cristina/0000-0001-7501-5934; Menendez Arias, Luis/0000-0002-1251-6640	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN KB, 1983, J VIROL, V48, P765, DOI 10.1128/JVI.48.3.765-769.1983; ANDERSEN KB, 1989, J GEN VIROL, V70, P1921, DOI 10.1099/0022-1317-70-7-1921; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COFFIN JM, 1981, FUNDAMENTAL VIROLOGY, P645; COPELAND TD, 1988, GENE ANAL TECH, V5, P109, DOI 10.1016/0735-0651(88)90010-6; DANGOTT LJ, 1982, BIOCHEM BIOPH RES CO, V107, P1243, DOI 10.1016/S0006-291X(82)80131-9; FINE D, 1978, CANCER RES, V38, P3123; FINE DL, 1974, APPL MICROBIOL, V28, P1040, DOI 10.1128/AEM.28.6.1040-1046.1974; GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W; HIZI A, 1989, J VIROL, V63, P2543, DOI 10.1128/JVI.63.6.2543-2549.1989; HIZI A, 1987, P NATL ACAD SCI USA, V84, P7041, DOI 10.1073/pnas.84.20.7041; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298; KIDO H, 1991, FEBS LETT, V286, P233, DOI 10.1016/0014-5793(91)80981-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; OWENS RB, 1972, J NATL CANCER I, V49, P1321; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; PARKS WP, 1974, SCIENCE, V184, P158, DOI 10.1126/science.184.4133.158; PEARL LH, 1987, NATURE, V328, P482, DOI 10.1038/328482b0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; SMITH GH, 1973, J VIROL, V11, P575, DOI 10.1128/JVI.11.4.575-584.1973; TANAKA H, 1972, VIROLOGY, V49, P61, DOI 10.1016/S0042-6822(72)80007-2; TANAKA K, 1986, J BIOL CHEM, V261, P5204; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TAPONBRETAUDIERE J, 1985, EMBO J, V4, P85, DOI 10.1002/j.1460-2075.1985.tb02321.x; TSUJI A, 1989, J BIOL CHEM, V264, P16093; TSUJI A, 1991, BIOCHIM BIOPHYS ACTA, V1078, P85, DOI 10.1016/0167-4838(91)90096-I; UMEZAWA H, 1982, ANNU REV MICROBIOL, V36, P75, DOI 10.1146/annurev.mi.36.100182.000451; WERB Z, 1982, J INVEST DERMATOL S1, V79, P154; YOSHINAKA Y, 1985, J VIROL, V55, P870, DOI 10.1128/JVI.55.3.870-873.1985; ZEYDEL M, 1986, CANCER RES, V46, P6438	39	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11392	11398						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375941				2022-12-27	WOS:A1992HX16900071
J	ESTEBAN, C; GEUSKENS, M; ENA, JM; MISHAL, Z; MACHO, A; TORRES, JM; URIEL, J				ESTEBAN, C; GEUSKENS, M; ENA, JM; MISHAL, Z; MACHO, A; TORRES, JM; URIEL, J			RECEPTOR-MEDIATED UPTAKE AND PROCESSING OF VITAMIN-D-BINDING PROTEIN IN HUMAN B-LYMPHOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN RECEPTORS; GROUP-SPECIFIC COMPONENT; HUMAN-LYMPHOCYTES; FATTY-ACIDS; GC-PROTEIN; RAT RHABDOMYOSARCOMA; PLASMA-MEMBRANE; SERUM-ALBUMIN; COATED PITS; ENDOCYTOSIS	Vitamin D-binding protein (DBP), a member of a multigene family including alpha-fetoprotein (AFP) and albumin, is a serum glycoprotein that reversibly binds and transports vitamin D and its metabolites to target cells. In this work, we demonstrate that normal and malignant human B-lymphocytes specifically bind and internalize DBP. Radioiodinated DBP (I-125-DBP) was used to follow the uptake of the protein by Raji cells, a human pre-B-lymphoma cell line. Time course studies of DBP uptake by these cells exhibited a saturable profile at both 4 and 37-degrees-C. The binding saturation curve obtained by incubating Raji cells at 4-degrees-C with different concentrations (1.5 nM to 1.5-mu-M) of I-125-DBP showed two saturation plateaus; Scatchard analysis showed the presence of two groups of receptor sites with a K(d1) of 2.04 x 10(-7) M (n1 = 42,161 +/- 4,336 sites/cell) and a K(d2) of 1.01 x 10(-6) M (n2 = 198,000 +/- 48,000 sites/cell). After incubation of Raji cells at 37-degrees-C with both fluorescein isothiocyanate (FITC) and horseradish peroxidase conjugates, DBP was internalized and could be localized in the cytoplasm. DBP-horseradish peroxidase conjugates were used to follow the uptake and to determine the endocytic pathway of the protein in Raji cells. The initial steps, contrary to those observed for AFP, did not apparently involve coated pits and vesicles. Small vesicles (approximately 50-60 nM) with electron-dense DBP-horseradish peroxidase reaction products were observed that could fuse with large endosomes. These endosomes appeared dispersed in the cytoplasm with some preferential localization in the Golgi centrosphere region. Pulse-chase experiments showed that only 10% of the uptaken protein was released in a nondegraded form. Accordingly, most DBP molecules accumulated in endosomes should be degraded in lysosomes, instead of being recycled back to the surface, as in the case of AFP. Contrary to malignant B-cells (Raji), the uptake ability for DBP of normal quiescent B-lymphocytes was very low. Specific binding and internalization of DBP-FITC by these cells were observed following mitogen-induced activation. Significant values of uptake were obtained at 37-degrees-C after 72 h of incubation in the presence of pokeweed mitogen. The binding of DBP-FITC was partially inhibited in the presence of an excess of unlabeled protein. Taken together, the actual results suggest that DBP receptors are constitutively expressed by malignant B-cells and in a transitory form by normal B-lymphocytes undergoing mitogen-induced activation. In analogy to the AFP/AFP receptor pathway of fatty acid transfer in cells, a dual-receptor model acting as a regulatory mechanism for delivery of vitamin D metabolites to growing cells is proposed.	INST RECH SCI CANC, CHIM PROT LAB, F-94802 VILLEJUIF, FRANCE; CNRS, CTR SOUTIEN RECH CANC, CYTOMETRIE LAB, F-94802 VILLEJUIF, FRANCE; UNIV LIBRE BRUXELLES, CYTOL & EMBRYOL MOLEC LAB, B-1640 RHODE ST GENESE, BELGIUM; UNIV ZARAGOZA FAC VET, DEPT TECNOL & BIOQUIM ALIMENTOS, E-50013 ZARAGOZA, SPAIN	Centre National de la Recherche Scientifique (CNRS); Universite Libre de Bruxelles			Torres, Juan Maria/L-8768-2013; Quirós, Antonio Macho/H-1403-2012	Torres, Juan Maria/0000-0003-0443-9232; Quirós, Antonio Macho/0000-0002-9294-8709				ADRIAN GS, 1990, EXP CELL RES, V186, P385, DOI 10.1016/0014-4827(90)90321-Z; AVRAMEAS S, 1971, IMMUNOCHEMISTRY, V8, P1175, DOI 10.1016/0019-2791(71)90395-8; BERGMANN JS, 1982, J CELL BIOCHEM, V20, P247, DOI 10.1002/jcb.240200305; BHALLA AK, 1983, J CLIN ENDOCR METAB, V57, P1308, DOI 10.1210/jcem-57-6-1308; CALVO M, 1989, BIOCHEM BIOPH RES CO, V163, P14, DOI 10.1016/0006-291X(89)92091-3; CONSTANS J, 1981, IMMUNOL LETT, V3, P159, DOI 10.1016/0165-2478(81)90120-6; COOKE NE, 1987, CYTOGENET CELL GENET, V44, P98, DOI 10.1159/000132351; COOKE NE, 1985, J CLIN INVEST, V76, P2420, DOI 10.1172/JCI112256; COOKE NE, 1979, J BIOL CHEM, V254, P5965; ENA JM, 1989, BIOCHEM INT, V19, P1; ESTEBAN C, 1991, INT J CANCER, V49, P425, DOI 10.1002/ijc.2910490320; GEUSKENS M, 1982, ONCODEV BIOL MED, V3, P291; GEUSKENS M, 1989, EUR J CELL BIOL, V50, P418; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GUOTH M, 1990, ENDOCRINOLOGY, V127, P2313, DOI 10.1210/endo-127-5-2313; LABORDA J, 1987, INT J CANCER, V40, P314, DOI 10.1002/ijc.2910400306; LEBOUTEILLER PP, 1983, J IMMUNOL METHODS, V61, P301, DOI 10.1016/0022-1759(83)90224-7; MACHII T, 1986, ACTA HAEMATOL-BASEL, V75, P26, DOI 10.1159/000206075; MCLEOD JF, 1989, J BIOL CHEM, V264, P21760; NAHON JL, 1988, J BIOL CHEM, V263, P11436; NAVAL J, 1985, P NATL ACAD SCI USA, V82, P3301, DOI 10.1073/pnas.82.10.3301; NEL AE, 1985, CLIN IMMUNOL IMMUNOP, V37, P191, DOI 10.1016/0090-1229(85)90150-3; NESTLER JE, 1987, ENDOCRINOLOGY, V120, P1996, DOI 10.1210/endo-120-5-1996; PARMELEE DC, 1978, J BIOL CHEM, V253, P2114; PETRINI M, 1985, J BIOL CHEM, V260, P1804; PETRINI M, 1983, NATURE, V306, P73, DOI 10.1038/306073a0; PETRINI M, 1984, CLIN IMMUNOL IMMUNOP, V31, P282, DOI 10.1016/0090-1229(84)90248-4; PIKE JW, 1980, LIFE SCI, V26, P407, DOI 10.1016/0024-3205(80)90158-7; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; PULVERTAFT RJV, 1964, LANCET, V1, P238; RIGBY WFC, 1988, IMMUNOL TODAY, V9, P54; SANGER JM, 1990, P NATL ACAD SCI USA, V87, P5474, DOI 10.1073/pnas.87.14.5474; SCHOENTGEN F, 1986, BIOCHIM BIOPHYS ACTA, V871, P189, DOI 10.1016/0167-4838(86)90173-1; SCHOENTGEN F, 1985, FEBS LETT, V185, P47, DOI 10.1016/0014-5793(85)80738-9; SORRENTINO D, 1988, J CLIN INVEST, V82, P928, DOI 10.1172/JCI113700; TORRES JM, 1991, INT J CANCER, V47, P110, DOI 10.1002/ijc.2910470120; TORRES JM, 1990, J IMMUNOL METHODS, V134, P163, DOI 10.1016/0022-1759(90)90377-8; TORRES JM, 1989, MOL IMMUNOL, V26, P851, DOI 10.1016/0161-5890(89)90141-7; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; TSOUKAS CD, 1984, SCIENCE, V224, P1438, DOI 10.1126/science.6427926; URIEL J, 1983, BRIT J CANCER, V48, P261, DOI 10.1038/bjc.1983.181; Uriel J, 1989, J Nucl Med Allied Sci, V33, P12; URIEL J, 1987, J BIOL CHEM, V262, P3579; Uriel J., 1989, BIOL PROPERTIES ALPH, VII, P103; VANBAELEN H, 1980, J BIOL CHEM, V255, P2270; VANDEURS B, 1989, INT REV CYTOL, V117, P131; VILLACAMPA MJ, 1984, BIOCHEM BIOPH RES CO, V122, P1322, DOI 10.1016/0006-291X(84)91236-1; WILLIAMS MH, 1988, BIOCHEM BIOPH RES CO, V153, P1019, DOI 10.1016/S0006-291X(88)81330-5	48	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10177	10183						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374401				2022-12-27	WOS:A1992HT96500109
J	ISHIGURO, N; IZAWA, H; SHINAGAWA, M; SHIMAMOTO, T; TSUCHIYA, T				ISHIGURO, N; IZAWA, H; SHINAGAWA, M; SHIMAMOTO, T; TSUCHIYA, T			CLONING AND NUCLEOTIDE-SEQUENCE OF THE GENE (CITC) ENCODING A CITRATE CARRIER FROM SEVERAL SALMONELLA SEROVARS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLATE TRANSPORT OPERON; ESCHERICHIA-COLI; TRANSLATIONAL INITIATION; UTILIZATION SYSTEM; DNA-SEQUENCE; PLASMID; TYPHIMURIUM	The nucleotide sequence of the citC coding for the citrate carrier in several Salmonella serovars has been determined, and the amino acid sequence of the carrier protein was deduced. The predicted citrate carrier from Salmonella pullorum and Salmonella enteritidis consists of 446 amino acids with a molecular weight of 47,621, whereas that from Salmonella dublin is the same 446 amino acids with the slightly different molecular weight of 47,591, because 1 amino acid residue was substituted. The predicted proteins are highly hydrophobic (69% nonpolar amino acids). The hydropathy profile suggests that the proteins are composed of 11-12 hydrophobic membrane-spanning segments with two hydrophilic cores in the middle of the protein sequence. No homology in the nucleotide and amino acid sequences was found in the molecular structures of citA, citP, and tctI genes. The citC-coding citrate transport activity is Na+-dependent and specific for citrate only. The transcript from the citC gene was not detected in the total RNA from several Salmonella serovars except S. dublin in Northern blot analysis, although the promoter of the citC genes appeared to be functional in Escherichia coli and Salmonella typhimurium strains using the lacZ fusion assay. These results suggested that the citC gene-coding citrate carrier is probably a TctIII system such as that identified previously in S. typhimurium.	OKAYAMA UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL,OKAYAMA 700,JAPAN; OKAYAMA UNIV,FAC PHARMACEUT SCI,GENE RES CTR,OKAYAMA 700,JAPAN	Okayama University; Okayama University	ISHIGURO, N (corresponding author), OBIHIRO UNIV AGR & VET MED,DEPT VET PUBL HLTH,OBIHIRO,HOKKAIDO 080,JAPAN.		Shimamoto, Tadashi/A-7109-2018	Shimamoto, Tadashi/0000-0002-5538-0595				BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; DAIMON H, 1989, J BACTERIOL, V171, P620, DOI 10.1128/jb.171.1.620-623.1989; DAVID S, 1990, J BACTERIOL, V172, P5789, DOI 10.1128/jb.172.10.5789-5794.1990; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P266; GOLD L, 1981, ANNU REV MICROBIOL, V35, P365, DOI 10.1146/annurev.mi.35.100181.002053; HIRATO T, 1984, J BACTERIOL, V160, P421, DOI 10.1128/JB.160.1.421-426.1984; HIRATO T, 1986, J BACTERIOL, V165, P324, DOI 10.1128/jb.165.1.324-327.1986; HOUNG HSH, 1990, J BACTERIOL, V172, P4392, DOI 10.1128/jb.172.8.4392-4398.1990; ISHIGURO N, 1982, J BACTERIOL, V149, P961, DOI 10.1128/JB.149.3.961-968.1982; ISHIGURO N, 1981, J GEN MICROBIOL, V123, P193; ISHIGURO N, 1985, J BACTERIOL, V164, P977, DOI 10.1128/JB.164.3.977-982.1985; ISHIGURO N, 1979, J HYG-CAMBRIDGE, V83, P331, DOI 10.1017/S0022172400026127; ISHIGURO N, 1978, APPL ENVIRON MICROB, V36, P217, DOI 10.1128/AEM.36.2.217-222.1978; ISHIGURO N, 1988, GENE, V68, P181; KAY WW, 1978, ARCH BIOCHEM BIOPHYS, V190, P270, DOI 10.1016/0003-9861(78)90276-X; KAY WW, 1987, ION TRANSPORT PROKAR, P269; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Maniatis T., 1982, MOL CLONING; Miller J.H., 1972, EXPT MOL GENETICS; MYERS RS, 1988, MOL MICROBIOL, V2, P749, DOI 10.1111/j.1365-2958.1988.tb00086.x; REYNOLDS CH, 1983, J BACTERIOL, V156, P1019, DOI 10.1128/JB.156.3.1019-1024.1983; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASATSU M, 1985, J BACTERIOL, V164, P983, DOI 10.1128/JB.164.3.983-993.1985; SHIMAMOTO T, 1991, J BIOCHEM-TOKYO, V110, P22, DOI 10.1093/oxfordjournals.jbchem.a123537; SMITH HW, 1978, J GEN MICROBIOL, V109, P305, DOI 10.1099/00221287-109-2-305; TANAKA A, 1990, IMMUNOGENETICS, V32, P263, DOI 10.1007/BF00187097; THOMAS DY, 1982, GENE, V19, P211, DOI 10.1016/0378-1119(82)90008-7; VANDERREST ME, 1990, EUR J BIOCHEM, V189, P401; WIDENHORN KA, 1988, J BACTERIOL, V170, P883, DOI 10.1128/jb.170.2.883-888.1988; WIDENHORN KA, 1989, J BACTERIOL, V171, P4436, DOI 10.1128/JB.171.8.4436-4441.1989	33	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9559	9564						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374406				2022-12-27	WOS:A1992HT96500020
J	PATTANAKITSAKUL, SN; ZHENG, JH; NATSUUMESAKAI, S; TAKAHASHI, M; NONAKA, M				PATTANAKITSAKUL, SN; ZHENG, JH; NATSUUMESAKAI, S; TAKAHASHI, M; NONAKA, M			ABERRANT SPLICING CAUSED BY THE INSERTION OF THE B2 SEQUENCE INTO AN INTRON OF THE COMPLEMENT C4 GENE IS THE BASIS FOR LOW C4 PRODUCTION IN H-2K MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-LIMITED PROTEIN; 4TH COMPONENT; MURINE COMPLEMENT; MOUSE COMPLEMENT; MOLECULAR MAP; S-REGION; C-4; SLP; CDNA; MHC	The serum level of the fourth component of complement (C4) in mice bearing the H-2k haplotype is only 1/10 to 1/20 of that of non-H-2k mice. We have analyzed C4 cDNA clones from B10.BR(H-2k) mouse liver and found aberrant C4 cDNA which contained a 200-base pair (bp) insertion between the exon 13 and exon 14 encoded sequences in addition to the normal C4 cDNA. The 5' 148 bp and the 3' 52 bp of this insert were derived from the B2 sequence, the short interspersed repeats of mouse genome, and the central part of intron 13, respectively. Sequence analysis of intron 13 of the C4k gene showed the presence of a complete copy of a B2 consensus sequence. The structure of aberrant C4 mRNA indicated that the possible 3' splice site in the B2 sequence and the cryptic 5' splice site in intron 13 were used. Both the insertion of the B2 sequence into intron 13 and the presence of aberrant mRNA in the liver were specific to H-2k-bearing mice, suggesting that the aberrant splicing due to the B2 insertion is the basis for low C4 expression in H-2k mice.	KANAZAWA UNIV,INST CANC RES,DEPT IMMUNOBIOL,13-1 TAKARAMACHI,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University			NONAKA, MASARU/G-4929-2014					AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTA A, 1981, P NATL ACAD SCI-BIOL, V78, P4867, DOI 10.1073/pnas.78.8.4867; CHAPLIN DD, 1983, P NATL ACAD SCI-BIOL, V80, P6947, DOI 10.1073/pnas.80.22.6947; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COX BJ, 1988, NUCLEIC ACIDS RES, V16, P6857, DOI 10.1093/nar/16.14.6857; KIOUSSIS D, 1981, J BIOL CHEM, V256, P1960; KLEIN J, 1978, IMMUNOGENETICS, V6, P489, DOI 10.1007/BF01563941; KRAYEV AS, 1982, NUCLEIC ACIDS RES, V10, P7461, DOI 10.1093/nar/10.23.7461; LEVISTRAUSS M, 1988, SCIENCE, V240, P201, DOI 10.1126/science.3353717; MULLER U, 1987, EMBO J, V6, P369, DOI 10.1002/j.1460-2075.1987.tb04764.x; NAKAYAMA K, 1987, J IMMUNOL, V138, P620; NAKAYAMA K, 1990, IMMUNOGENETICS, V31, P361, DOI 10.1007/BF02115011; NONAKA M, 1985, IMMUNOL REV, V87, P81, DOI 10.1111/j.1600-065X.1985.tb01146.x; NONAKA M, 1985, J BIOL CHEM, V260, P936; NONAKA M, 1984, P NATL ACAD SCI-BIOL, V81, P6822, DOI 10.1073/pnas.81.21.6822; OGATA RT, 1984, P NATL ACAD SCI-BIOL, V81, P4908, DOI 10.1073/pnas.81.15.4908; OGATA RT, 1989, J BIOL CHEM, V264, P16565; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; ROOS MH, 1978, J IMMUNOL, V121, P1106; SACKSTEIN R, 1984, J IMMUNOL, V133, P1618; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEPICH DS, 1985, P NATL ACAD SCI USA, V82, P5895, DOI 10.1073/pnas.82.17.5895; SHREFFLER DC, 1976, TRANSPLANT REV-DENMA, V32, P140; SHREFFLER DC, 1982, HISTOCOMPATIBILITY A, P189; TAILLONMILLER PA, 1988, J IMMUNOL, V141, P2382; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	29	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7814	7820						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373139				2022-12-27	WOS:A1992HN48500086
J	ACHEN, MG; HARMS, PJ; THOMAS, T; RICHARDSON, SJ; WETTENHALL, REH; SCHREIBER, G				ACHEN, MG; HARMS, PJ; THOMAS, T; RICHARDSON, SJ; WETTENHALL, REH; SCHREIBER, G			PROTEIN-SYNTHESIS AT THE BLOOD-BRAIN-BARRIER - THE MAJOR PROTEIN SECRETED BY AMPHIBIAN CHOROID-PLEXUS IS A LIPOCALIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; TRANSTHYRETIN PREALBUMIN GENE; PROSTAGLANDIN-D SYNTHETASE; ADULT-RAT BRAIN; MESSENGER-RNA; THYROXINE TRANSPORT; CARRIER PROTEINS; PRE-ALBUMIN; EXPRESSION; CDNA	Among the proteins secreted by choroid plexus of vertebrates, one protein is much more abundant than all others. In mammals, birds, and reptiles this protein is transthyretin, a tetramer of identical 15-kDa subunits. In this study choroid plexus from frogs, tadpoles, and toads incubated in vitro were found to synthesize and secrete one predominant protein. However, this consisted of one single 20-kDa polypeptide chain. It was expressed throughout amphibian metamorphosis. Part of its amino acid sequence was determined and used for construction of oligonucleotides for polymerase chain reaction. The amplified DNA was used to screen a toad choroid plexus cDNA library. Full-length cDNA clones were isolated and sequenced. The derived amino acid sequence for the encoded protein was 183 amino acids long, including a 20-amino acid presegment. The calculated molecular weight of the mature protein was 18,500. Sequence comparison with other proteins showed that the protein belonged to the lipocalin superfamily. Its expression was highest in choroid plexus, much lower in other brain areas, and absent from liver. Since no transthyretin was detected in proteins secreted from amphibian choroid plexus, abundant synthesis and secretion of transthyretin in choroid plexus must have evolved only after the stage of the amphibians.	UNIV MELBOURNE, RUSSELL GRIMWADE SCH BIOCHEM, PARKVILLE, VIC 3052, AUSTRALIA	University of Melbourne				Thomas, Tim/0000-0002-7623-8344; Richardson, Samantha/0000-0002-1708-9430; Achen, Marc/0000-0002-3791-803X				ALDRED AR, 1987, J BIOL CHEM, V262, P5293; ALDRED AR, 1987, J BIOL CHEM, V262, P2875; BLOCH B, 1987, BRAIN RES BULL, V18, P573, DOI 10.1016/0361-9230(87)90122-5; CANCEDDA FD, 1990, J BIOL CHEM, V265, P19060; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK AJ, 1984, EMBO J, V3, P1045, DOI 10.1002/j.1460-2075.1984.tb01925.x; COLE T, 1989, EUR J BIOCHEM, V186, P35, DOI 10.1111/j.1432-1033.1989.tb15174.x; CSERR HF, 1986, ANN NY ACAD SCI, V481, P123, DOI 10.1111/j.1749-6632.1986.tb27144.x; DICKSON PW, 1985, BIOCHEM BIOPH RES CO, V127, P890, DOI 10.1016/S0006-291X(85)80027-9; DICKSON PW, 1982, EUR J BIOCHEM, V129, P289, DOI 10.1111/j.1432-1033.1982.tb07051.x; DICKSON PW, 1987, J BIOL CHEM, V262, P13907; DICKSON PW, 1986, J BIOL CHEM, V261, P3475; DUAN W, 1991, EUR J BIOCHEM, V200, P679, DOI 10.1111/j.1432-1033.1991.tb16232.x; DUAN W, 1992, COMP BIOCHEM PHYS B, V101, P399, DOI 10.1016/0305-0491(92)90019-N; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUNG WP, 1988, J BIOL CHEM, V263, P480; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; Griswold M D, 1988, Int Rev Cytol, V110, P133; HARMS PJ, 1991, COMP BIOCHEM PHYS B, V99, P239, DOI 10.1016/0305-0491(91)90035-C; HERBERT J, 1986, NEUROLOGY, V36, P900, DOI 10.1212/WNL.36.7.900; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; KATO M, 1986, DIFFERENTIATION, V31, P228, DOI 10.1111/j.1432-0436.1986.tb00402.x; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANS RJ, 1961, ARCH BIOCHEM BIOPHYS, V94, P48, DOI 10.1016/0003-9861(61)90009-1; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NG SC, 1987, BIOCHEMISTRY-US, V26, P5229, DOI 10.1021/bi00391a003; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER G, 1990, AM J PHYSIOL, V258, pR338; SCHREIBER G, 1987, PLASMA PROTEINS STRU, V5, P293; SOUTHWELL BR, 1991, COMP BIOCHEM PHYS B, V100, P329, DOI 10.1016/0305-0491(91)90383-O; STAUDER AJ, 1986, J HISTOCHEM CYTOCHEM, V34, P949, DOI 10.1177/34.7.3458812; THOMAS T, 1988, DEV BIOL, V128, P415, DOI 10.1016/0012-1606(88)90303-X; UNTERMAN RD, 1981, P NATL ACAD SCI-BIOL, V78, P3478, DOI 10.1073/pnas.78.6.3478; URADE Y, 1989, J BIOL CHEM, V264, P1041; URADE Y, 1987, J BIOL CHEM, V262, P15132; WETTENHALL REH, 1986, J BIOL CHEM, V261, P2444; WETTENHALL REH, 1988, BIOCHEMISTRY-US, V27, P170, DOI 10.1021/bi00401a026	44	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23170	23174						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385415				2022-12-27	WOS:A1992JY16300072
J	ALLEN, ML; METZ, AM; TIMMER, RT; RHOADS, RE; BROWNING, KS				ALLEN, ML; METZ, AM; TIMMER, RT; RHOADS, RE; BROWNING, KS			ISOLATION AND SEQUENCE OF THE CDNAS ENCODING THE SUBUNITS OF THE ISOZYME FORM OF WHEAT-PROTEIN SYNTHESIS INITIATION FACTOR-4F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; SITE-DIRECTED MUTAGENESIS; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; TRANSLATION INITIATION; ELONGATION-FACTORS; GERM; RECOGNITION; RESIDUES; ANALOGS	The nucleotide sequences of the cDNAs for the two subunits, p82 and p28, of the isozyme form of wheat germ eukaryotic initiation factor 4F (eIF-(iso)4F) were determined. The cDNA for the p82 subunit encodes a polypeptide of 86,514 Da. The deduced amino acid sequence of p82 contains possible motifs for ATP binding, metal binding, and phosphorylation. The cDNA sequence for the small subunit, p28, which is a m7G cap-binding protein, encodes a polypeptide of 23,524 Da. The deduced amino acid sequence of p28 is similar (approximately 38%) to cap-binding proteins from yeast and mammals. The p28 of wheat eIF-(iso)4F does not contain a serine or threonine in the vicinity of the serine (Ser53) of mammalian cap-binding protein which is phosphorylated and shown to affect activity in mammalian cells.	UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA; UNIV KENTUCKY, DEPT BIOCHEM, LEXINGTON, KY 40536 USA	University of Texas System; University of Texas Austin; University of Kentucky					NIGMS NIH HHS [GM 20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; ALTMANN M, 1988, J BIOL CHEM, V263, P17229; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BERG JM, 1990, J BIOL CHEM, V265, P6513; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; BREWTON RG, 1992, EUR J BIOCHEM, V205, P443, DOI 10.1111/j.1432-1033.1992.tb16798.x; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P1624, DOI 10.1021/bi00220a026; CONROY SC, 1990, ARCH BIOCHEM BIOPHYS, V282, P363, DOI 10.1016/0003-9861(90)90130-Q; ETCHISON D, 1987, MOL CELL BIOCHEM, V76, P15; HALL TC, 1978, P NATL ACAD SCI USA, V75, P3196, DOI 10.1073/pnas.75.7.3196; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LAX SR, 1986, J BIOL CHEM, V261, P5632; MERRICK WC, 1990, ENZYME, V44, P7, DOI 10.1159/000468743; METZ AM, 1992, NUCLEIC ACIDS RES, V20, P4096, DOI 10.1093/nar/20.15.4096; MILLER WT, 1992, P NATL ACAD SCI USA, V89, P2032, DOI 10.1073/pnas.89.6.2032; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; UEDA H, 1991, FEBS LETT, V280, P207, DOI 10.1016/0014-5793(91)80294-D; UEDA H, 1991, BIOCHIM BIOPHYS ACTA, V1075, P181, DOI 10.1016/0304-4165(91)90249-G; UEDA H, 1991, J BIOCHEM-TOKYO, V109, P882, DOI 10.1093/oxfordjournals.jbchem.a123475; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YAMAGUCHI N, 1988, J BIOL CHEM, V264; YAN RQ, 1992, J BIOL CHEM, V267, P23226	36	82	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23232	23236						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385417				2022-12-27	WOS:A1992JY16300081
J	CLEMETSON, JM; BOSCHETTI, A; CLEMETSON, KJ				CLEMETSON, JM; BOSCHETTI, A; CLEMETSON, KJ			CHLOROPLAST ENVELOPE PROTEINS ARE ENCODED BY THE CHLOROPLAST GENOME OF CHLAMYDOMONAS-REINHARDTII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE POLYPEPTIDES; SPINACH-CHLOROPLASTS; IMPORT; PRECURSOR; BINDING; ELECTROPHORESIS; TRANSPORT; RECEPTOR; SEQUENCE; ANALOGS	To characterize envelope proteins encoded by th chloroplast genome, envelopes were isolated from Chlamydomonas reinhardtii cells labeled with [S-35] sulfate while blocking synthesis by cytoplasmic ribosomes. One and two-dimensional gel electrophoresis of envelopes and fluorography revealed four highly labeled proteins. Two with masses of 29 and 30 kDa and pl 5.5 were absent from the stroma and thylakoid fractions, while the others at 54 kDa, pI 5.2 and 61 kDa, pI 5.4 were detected there in smaller amounts. The 29- and 30-kDa proteins were associated with outer envelope membranes separated from inner envelope membranes after chloroplast lysis in hypertonic solution. A 32-kDa protein not labeled by [S-35]sulfate was found exclusively in the inner membrane fraction, suggesting the existence of a phosphate translocator in C. reinhardtii. To identify envelope proteins exposed on the chloroplast surface, isolated active chloroplasts were surface-labeled with I-125 and lactoperoxidase. The 54-kDa, pI 5.2 protein as well as a protein corresponding to either of the 29- or 30-kDa proteins described above were among the labeled components. These results show that envelope proteins of C. reinhardtii are encoded by the chloroplast genome and two are located on the outer envelope membranes.	UNIV BERN, INST BIOCHEM, CH-3012 BERN, SWITZERLAND	University of Bern	CLEMETSON, JM (corresponding author), THEODOR KOCHER INST, FREIESTR 1, CH-3012 BERN, SWITZERLAND.							AMES GFL, 1976, BIOCHEMISTRY-US, V15, P616, DOI 10.1021/bi00648a026; ANDERSON CW, 1983, METHOD ENZYMOL, V101, P635; BIENZ D, 1989, J BIOL CHEM, V264, P507; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUA NH, 1977, J CELL BIOL, V74, P441, DOI 10.1083/jcb.74.2.441; CLEMETSON JM, 1988, BIOCHIM BIOPHYS ACTA, V943, P371, DOI 10.1016/0005-2736(88)90570-6; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; DOUCE R, 1990, ANNU REV CELL BIOL, V6, P173, DOI 10.1146/annurev.cb.06.110190.001133; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FLUGGE UI, 1984, FEBS LETT, V168, P255, DOI 10.1016/0014-5793(84)80257-4; HELDT HW, 1986, METHOD ENZYMOL, V125, P705; IKEUCHI M, 1987, FEBS LETT, V210, P71, DOI 10.1016/0014-5793(87)81300-5; JOY KW, 1975, BIOCHIM BIOPHYS ACTA, V378, P143, DOI 10.1016/0005-2787(75)90145-8; KLEIN U, 1983, PLANT PHYSIOL, V72, P488, DOI 10.1104/pp.72.2.488; KO K, 1992, J BIOL CHEM, V267, P2986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIEUX B, 1985, BIOSYSTEMS, V18, P293, DOI 10.1016/0303-2647(85)90029-2; MENDIOLAMORGENTHALER L, 1985, PLANT SCI, V41, P97, DOI 10.1016/0168-9452(85)90109-8; MENDIOLAMORGENTHALER L, 1985, PLANT SCI, V38, P33, DOI 10.1016/0168-9452(85)90076-7; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1991, J BIOL CHEM, V266, P11882; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; STAEHELIN LA, 1986, ENCY PLANT PHYSL, V19, P8; SUEOKA N, 1960, P NATL ACAD SCI USA, V46, P83, DOI 10.1073/pnas.46.1.83; VERNON LP, 1960, ANAL CHEM, V32, P1144, DOI 10.1021/ac60165a029	32	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19773	19779						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400290				2022-12-27	WOS:A1992JR85800006
J	ODA, A; DRUKER, BJ; SMITH, M; SALZMAN, EW				ODA, A; DRUKER, BJ; SMITH, M; SALZMAN, EW			ASSOCIATION OF PP60SRC WITH TRITON X-100-INSOLUBLE RESIDUE IN HUMAN BLOOD-PLATELETS REQUIRES PLATELET-AGGREGATION AND ACTIN POLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PROTEIN-TYROSINE PHOSPHORYLATION; COLONY-STIMULATING FACTOR; ROUS-SARCOMA VIRUS; SRC GENE-PRODUCT; MONOCLONAL-ANTIBODIES; FIBRINOGEN RECEPTOR; COMMON SET; THROMBIN; CYTOSKELETON	Protein-tyrosine phosphorylation during platelet activation is inhibited under conditions that inhibit platelet binding of fibrinogen and aggregation. We suggested that pp60src, a major platelet tyrosine kinase, or its protein substrates might become associated with the cytoskeleton upon platelet stimulation, and that this might be related to aggregation. By Western blotting with an anti-Src monoclonal antibody, we found time-dependent association of pp60src with the cytoskeleton (10,000 x g Triton X-100-insoluble matrix) but not the "membrane" cytoskeleton (100,000 x g Triton X-100-insoluble matrix) in platelets activated by U46619 (PGH2 analog). Cytoskeletal association and platelet aggregation were inhibited by the peptide Arg-Gly-Asp-Ser (RGDS) (but not by Arg-Gly-Glu-Ser (RGES)), by 10E5 antibody against glycoprotein (Gp) IIb/IIIa, and by EGTA. U46619-induced association of pp60src with cytoskeleton but not secretion or aggregation was inhibited by cytochalasin D (2 muM). Both cytochalasin D and RGDS inhibited "slow" tyrosine phosphorylation of platelet proteins. Association of pp60src with cytoskeleton induced by U46619 or ADP was not blocked by aspirin. Aspirin blocked epinephrine-induced association of pp60src with the cytoskeleton during a second phase of aggregation when an initial phase had occurred without shape change or secretion. Association of GpIIb/IIIa with the cytoskeleton also accompanied platelet aggregation, shape change, and actin polymerization; this was shown with anti-GpIIb and anti-GpIIIa antibodies. Association of pp60src and GpIIb/IIIa with the cytoskeleton and slow tyrosine phosphorylation are related phenomena.	BETH ISRAEL HOSP, DEPT SURG, 330 BROOKLINE AVE, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR MOLEC, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Druker, Brian/0000-0001-8331-8206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; COHEN I, 1989, BLOOD, V73, P1880; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; ELMORE MA, 1990, FEBS LETT, V269, P283, DOI 10.1016/0014-5793(90)81177-P; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FOX JEB, 1987, THROMB DIATH HAEMO, P175; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2313; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HORAK ID, 1990, ONCOGENE, V5, P597; HORVATH AR, 1991, BIOCHEM SOC T, V19, P1150, DOI 10.1042/bst0191150; INAZU T, 1990, BIOCHEM BIOPH RES CO, V170, P259, DOI 10.1016/0006-291X(90)91268-W; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; KANAKURA Y, 1990, BLOOD, V76, P706; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEREA KM, 1989, BIOCHEMISTRY-US, V28, P9286, DOI 10.1021/bi00450a008; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; ODA A, 1991, AM J PHYSIOL, V260, pC242, DOI 10.1152/ajpcell.1991.260.2.C242; ODA A, 1992, BLOOD, V79, P920; ODA A, 1992, AM J PHYSIOL, V31, pC262; PAINTER RG, 1982, J CELL BIOL, V92, P565, DOI 10.1083/jcb.92.2.565; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; RITTENHOUSE SE, 1991, THROMB HAEMOSTASIS, V65, P742; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; SCHICK PK, 1983, BLOOD, V61, P163; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; SIESS W, 1989, PHYSIOL REV, V69, P158; STEEN VM, 1987, EUR J HAEMATOL, V38, P383; TANAKA K, 1988, J CELL BIOL, V106, P1757; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZUCKER MB, 1983, BLOOD, V61, P676	44	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20075	20081						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400325				2022-12-27	WOS:A1992JR85800053
J	ANDREOLA, ML; NEVINSKY, GA; BARR, PJ; SARIHCOTTIN, L; BORDIER, B; FOURNIER, M; LITVAK, S; TARRAGOLITVAK, L				ANDREOLA, ML; NEVINSKY, GA; BARR, PJ; SARIHCOTTIN, L; BORDIER, B; FOURNIER, M; LITVAK, S; TARRAGOLITVAK, L			INTERACTION OF TRANSFER RNA(LYS) WITH THE P66 P66 FORM OF HIV-1 REVERSE-TRANSCRIPTASE STIMULATES DNA-POLYMERASE AND RIBONUCLEASE-H ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMER TRANSFER-RNA; LYSINE TRANSFER-RNAS; NUCLEOTIDE-SEQUENCE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; AIDS VIRUS; EXPRESSION; DOMAIN; RETROVIRUSES; INHIBITION	The precursor homodimeric p66/p66 form of human immunodeficiency virus type-1 reverse transcriptase (HIV-1 RT) possesses the DNA polymerase and RNase H activities involved in the synthesis of the double-stranded provirus DNA. Reverse transcription is initiated from tRNA(Lys) in the case of HIV-1. The present study confirmed that interactions between HIV-1 RT and tRNA(Lys) induce protein conformational changes and demonstrated that these interactions stimulate the enzymatic activities associated with the p66 subunit. Thus, the p66/p66 form of the enzyme is strongly stimulated in both DNA polymerase and RNase H activities. Preincubation of the enzyme with tRNA is an obligatory step to obtain the stimulatory effect. The affinity of template, primer, or substrate for RT p66/p66 did not change when the enzyme was preincubated with tRNA(Lys) at stimulatory concentrations; the interaction of tRNA with p66/p66 has an effect only on the maximal rate of polymerization. It is further shown that the RNase H domain of RT is much more accessible to protease attack than the DNA polymerase active site.	CNRS, INST BIOCHIM CELLULAIRE & NEUROCHIM, 1 RUE CAMILLE ST SAENS, F-33077 BORDEAUX, FRANCE; RUSSIAN ACAD SCI, NOVOSIBIRSK INST BIOORGAN CHEM, SIBERIAN BRANCH, NOVOSIBIRSK 630090, USSR; CHIRON CO, EMERYVILLE, CA 94608 USA	Centre National de la Recherche Scientifique (CNRS); Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences			Nevinsky, Georgy/E-6053-2012					BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BARR PJ, 1987, BIO-TECHNOL, V5, P486, DOI 10.1038/nbt0587-486; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BORDIER B, 1990, NUCLEIC ACIDS RES, V18, P429, DOI 10.1093/nar/18.3.429; CHENG N, 1991, BIOCHEM BIOPH RES CO, V174, P785, DOI 10.1016/0006-291X(91)91486-V; FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298; FERSHT A, 1977, ENZYME STRUCTURE MEC, P170; FOURNIER M, 1976, BIOCHIMIE, V58, P1159, DOI 10.1016/S0300-9084(76)80114-9; FOURNIER M, 1981, THESIS U BORDEAUX 2; FURMAN PA, 1991, P NATL ACAD SCI USA, V88, P6013, DOI 10.1073/pnas.88.14.6013; GARRET M, 1984, NUCLEIC ACIDS RES, V12, P2259, DOI 10.1093/nar/12.5.2259; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; KEDAR PS, 1990, BIOCHEMISTRY-US, V29, P3603, DOI 10.1021/bi00467a003; KHAN AS, 1988, SCIENCE, V241, P74, DOI 10.1126/science.2455342; LITVAK S, 1982, TRENDS BIOCHEM SCI, V7, P361, DOI 10.1016/0968-0004(82)90114-1; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; NISHIMURA S, 1969, BIOCHEMISTRY-US, V8, P832, DOI 10.1021/bi00831a011; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; RABA M, 1979, EUR J BIOCHEM, V97, P305, DOI 10.1111/j.1432-1033.1979.tb13115.x; RESTLE T, 1990, J BIOL CHEM, V265, P8986; ROBERT D, 1990, FEBS LETT, V277, P239, DOI 10.1016/0014-5793(90)80855-D; SABIN EA, 1989, BIO-TECHNOL, V7, P705, DOI 10.1038/nbt0789-705; SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SARIH L, 1988, FEBS LETT, V230, P61, DOI 10.1016/0014-5793(88)80642-2; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4	29	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19356	19362						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382072				2022-12-27	WOS:A1992JP59300052
J	BUSCHMAN, E; ARCECI, RJ; CROOP, JM; CHE, MX; ARIAS, IM; HOUSMAN, DE; GROS, P				BUSCHMAN, E; ARCECI, RJ; CROOP, JM; CHE, MX; ARIAS, IM; HOUSMAN, DE; GROS, P			MDR2 ENCODES P-GLYCOPROTEIN EXPRESSED IN THE BILE CANALICULAR MEMBRANE AS DETERMINED BY ISOFORM-SPECIFIC ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; BACTERIAL TRANSPORT PROTEINS; ATP-DEPENDENT TRANSPORT; MONOCLONAL-ANTIBODIES; MOUSE MDR1; CONJUGATED HYPERBILIRUBINEMIA; SECRETORY EPITHELIUM; CHINESE-HAMSTER; ORGANIC-ANIONS; HUMAN-CELLS	We have produced antibodies specific for the three P-glycoprotein (P-gp) isoforms encoded by the mouse mdr1, mdr2, and mdr3 genes. The anti-Mdr2 and anti-Mdr3 antibodies were generated against synthetic peptides derived from the "linker" region, whereas the anti-Mdr1 antibody was raised against a fusion protein containing the amino terminus of Mdr1. Western blot analysis showed that the three antibodies could discriminate between the three isoforms in membrane fractions from Hamster cells transfected with the corresponding full-length or chimeric mdr cDNAs. Immunocytochemistry studies of mdr-transfected cells showed that the three antibodies specifically recognized each P-gp isoform expressed in whole cells. Immunoblotting of normal mouse tissues revealed that the Mdr2 isoform was expressed at very high levels in liver canalicular membrane vesicles (CMV) but not in membrane vesicles prepared from the basolateral (sinusoidal) domain (SMV). Mdr3 was detected in intestinal brush border membrane vesicles and also in CMV, although at levels much lower than Mdr2. Mdr1 was not detected in CMV or SMV but was detected in endometrial tissue from the gravid uterus. Photolabeling experiments with [I-125]iodoarylazidoprazosin followed by immunoprecipitation with isoform-specific antibodies indicated that, in CMV, Mdr3 but not Mdr2 could bind the drug analogue.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,QUEBEC,CANADA; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	McGill University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Tufts University; Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA048162] Funding Source: NIH RePORTER; NCI NIH HHS [CA48162, CA011227] Funding Source: Medline; PHS HHS [35652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ARCECI RJ, 1990, MOL REPROD DEV, V25, P101, DOI 10.1002/mrd.1080250202; BRADLEY G, 1990, J CELL PHYSIOL, V145, P398, DOI 10.1002/jcp.1041450303; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIN JE, 1989, MOL CELL BIOL, V9, P3808, DOI 10.1128/MCB.9.9.3808; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DONOWITZ M, 1987, AM J PHYSIOL, V252, P6723; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GREENBERGER LM, 1989, FEBS LETT, V2, P419; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HSING S, 1992, GASTROENTEROLOGY, V102, P879, DOI 10.1016/0016-5085(92)90173-V; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; INOUE M, 1982, HEPATOLOGY, V2, P572; INOUE M, 1983, J BIOL CHEM, V258, P5183; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; JANSEN PLM, 1987, HEPATOLOGY, V7, P71, DOI 10.1002/hep.1840070116; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVITT AD, 1985, J BIOL CHEM, V260, P2803; MULLER M, 1991, J BIOL CHEM, V266, P18920; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; QIAN XD, 1990, J BIOL CHEM, V265, P18753; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SCHURR E, 1989, CANCER RES, V49, P2729; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERBLIEK AM, 1988, GENE, V71, P407; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YANG CPH, 1989, J BIOL CHEM, V264, P782; YANG CPH, 1990, J BIOL CHEM, V265, P10282; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282	54	126	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18093	18099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381362				2022-12-27	WOS:A1992JM22300094
J	WATANABE, T; KUME, T; OISHI, M				WATANABE, T; KUME, T; OISHI, M			ALTERATION OF PHOSPHOTYROSINE-CONTAINING PROTEINS AT THE EARLY STAGE OF ERYTHROID-DIFFERENTIATION OF MOUSE ERYTHROLEUKEMIA (MEL) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKADAIC ACID; INVITRO DIFFERENTIATION; TUMOR PROMOTER; HERBIMYCIN-A; GENISTEIN; INHIBITOR; INDUCTION; KINASES; POTENT; PHOSPHORYLATION	Following treatment of mouse erythroleukemia (MEL) cells with dimethyl sulfoxide and other typical erythroid inducing agents, the profile of cellular phosphotyrosine-containing proteins was drastically altered. We found that the level of almost all of the phosphotyrosine-containing proteins was either decreased or disappeared at a very early stage of differentiation. Addition of sodium orthovanadate (Na3VO4), a specific inhibitor of phosphotyrosine phosphatases, prevented the alteration as well as erythroid differentiation. Mutant MEL cells, which are resistant to differentiation by dimethyl sulfoxide, were apparently insensitive to the alteration. These results indicate that dephosphorylation of phosphotyrosine residues in cellular proteins is coupled with a reaction(s) which is responsible for triggering differentiation of MEL cells.	UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HONMA Y, 1989, CANCER RES, V49, P331; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; LEIS JF, 1982, P NATL ACAD SCI-BIOL, V79, P6507, DOI 10.1073/pnas.79.21.6507; MARKOVITS J, 1989, CANCER RES, V49, P5111; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MELLONI E, 1990, P NATL ACAD SCI USA, V87, P4417, DOI 10.1073/pnas.87.12.4417; MELLONI E, 1989, J BIOL CHEM, V264, P18414; OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAKAHASHI E, 1975, GANN, V66, P577; WATANABE T, 1991, CANCER RES, V51, P764; WATANABE T, 1992, EXP CELL RES, V199, P269, DOI 10.1016/0014-4827(92)90434-A; WATANABE T, 1989, EXP CELL RES, V183, P335, DOI 10.1016/0014-4827(89)90394-7; YOSHIDA M, 1987, CANCER RES, V47, P3688; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	23	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17116	17120						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380959				2022-12-27	WOS:A1992JL05300061
J	SCHULZ, S; CHRISMAN, TD; GARBERS, DL				SCHULZ, S; CHRISMAN, TD; GARBERS, DL			CLONING AND EXPRESSION OF GUANYLIN - ITS EXISTENCE IN VARIOUS MAMMALIAN-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-STABLE ENTEROTOXIN; ESCHERICHIA-COLI; INTESTINAL RECEPTOR; CYCLIC-GMP; TOXIN; CYCLASE; MECHANISM; OPOSSUM; SITES	Guanylin (PNTCEICAYAACTGC) is a peptide recently isolated from the intestine, the actions of which appear to be mimicked by bacterial heat-stable enterotoxins (Currie, M. G., Fok, K. F., Kato, J., Moore, R. J., Hamra, F. K., Duffin, K. L., and Smith, C. E. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 947-951). A cDNA clone encoding the peptide was isolated from a rat intestinal cDNA library using a degenerate oligonucleotide probe. The mRNA (approximately 0.8-0.9 kilobase) encoding the peptide contained an open reading frame of 115 amino acids, including an amino-terminal signal peptide. The carboxyl-terminal region of the predicted polypeptide contained a sequence identical to guanylin, but the 15-amino acid peptide likely represents an artifact of previous acetic acid extraction methods, since an aspartate residue precedes the amino-terminal proline. A lysine-lysine dipeptide bond is one likely processing site of pro-guanylin and would generate a 60-amino acid mature peptide. Other potential cleavage sites exist at single lysine and arginine residues, which could result in peptides ranging from 22 to 56 amino acids. Transfection of COS-7 cells with the guanylin cDNA resulted in the expression of a secreted protein of M(r) 10,000. The expressed pro-guanylin failed to elevate cyclic GMP concentrations in human colonic T84 cells, but acetic acid treatment of pro-guanylin activated it and resulted in large elevations of cyclic GMP. Guanylin mRNA was prevalent in rat intestine but was also found in low abundance in adrenal gland, kidney, and uterus/oviduct. Guanylyl cyclase C, the apparent guanylin receptor, was found in abundant amounts in the intestine by Northern analysis, and by the polymerase chain reaction or cDNA cloning it was also found in adrenal gland, airway epithelial cells, brain, and olfactory and tracheal mucosa. Therefore, the ligand and apparent receptor (guanylyl cyclase C) both originate from mammalian genes, and are expressed in various mammalian tissues.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DEJONGE HR, 1984, BIOCHEM SOC T, V12, P180, DOI 10.1042/bst0120180; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DESAUVAGE FJ, 1992, J BIOL CHEM, V267, P6479; DREYFUS LA, 1984, INFECT IMMUN, V46, P537, DOI 10.1128/IAI.46.2.537-543.1984; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FORTE LR, 1988, AM J PHYSIOL, V255, pF1040, DOI 10.1152/ajprenal.1988.255.5.F1040; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; GUARINO A, 1987, AM J PHYSIOL, V253, pG775, DOI 10.1152/ajpgi.1987.253.6.G775; GUERRANT RL, 1980, J INFECT DIS, V142, P220, DOI 10.1093/infdis/142.2.220; HUGHES JM, 1978, NATURE, V271, P755, DOI 10.1038/271755a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUSE WJ, 1990, CELL TISSUE RES, V260, P387, DOI 10.1007/BF00318641; KUNO T, 1986, J BIOL CHEM, V261, P1470; Landon, 1977, Methods Enzymol, V47, P145; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; THOMPSON MR, 1990, J RECEPTOR RES, V10, P97, DOI 10.3109/10799899009064660; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALDMAN SA, 1986, INFECT IMMUN, V51, P320, DOI 10.1128/IAI.51.1.320-326.1986; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	25	145	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16019	16021						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379587				2022-12-27	WOS:A1992JJ45800004
J	LUO, M; LIU, JH; MOHAPATRA, S; HILL, RD; MOHAPATRA, SS				LUO, M; LIU, JH; MOHAPATRA, S; HILL, RD; MOHAPATRA, SS			CHARACTERIZATION OF A GENE FAMILY ENCODING ABSCISIC ACID-INDUCIBLE AND ENVIRONMENTAL STRESS-INDUCIBLE PROTEINS OF ALFALFA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR-II GENE; FREEZING TOLERANCE; COLD-ACCLIMATION; LOW-TEMPERATURE; BRASSICA-NAPUS; RICH PROTEIN; PLANT-CELLS; EXPRESSION; INDUCTION; SEQUENCE	The phytohormone abscisic acid (ABA) has been proposed as a common mediator controlling adaptive plant responses to a variety of environmental stresses, including water deficit, salinity, wounding, and low temperature. We have recently isolated three cDNAs, pUM90-1, pUM90-2, and pUM91-4, from a cDNA library of ABA-induced mRNAs of alfalfa. These cDNA clones exhibit a very high degree of sequence homology with one another and sequence similarities with certain regions of several stress- and ABA-inducible genes. The polypeptides encoded by these cDNAs are very rich in glycine (35-40%), histidine (7-15%), asparagine (8-14%), and tyrosine (5-10%) and have no tryptophan and proline. All of the encoded polypeptides contain characteristic tandem repeats comprising glycine residues intercepted with histidine and/or tyrosine. The RNAs corresponding to a representative cDNA, pUM90-1, were induced after treatment of seedlings with low temperature, drought, salt, and wounding stress, but not by heat; the induction was maximal under low temperature treatment. ABA and ABA analog rapidly induced the expression of these genes, whereas gibberellic acid treatment exhibited no induction whatsoever. These genes appear to be specifically induced in the shoot tissues. Analysis of ABA induction of genes corresponding to pUM90-1 in alfalfa seedlings of different age groups demonstrated that these genes were inducible in seedlings/plants of all age groups examined. Taken together these results suggest that these cDNA clones encode a group of proteins that are inducible by ABA and multiple environmental stresses and correspond to a new family of genes of plants, designated as ABA- and environmental stress-inducible genes.	UNIV MANITOBA, DEPT PLANT SCI, WINNIPEG R3T 2N2, MANITOBA, CANADA; UNIV MANITOBA, DEPT IMMUNOL, WINNIPEG R3T 2N2, MANITOBA, CANADA	University of Manitoba; University of Manitoba			Mohapatra, Shyam/C-2500-2012; Mohapatra, Subhra/A-1381-2012					BAKER J, 1988, PLANT MOL BIOL, V11, P277, DOI 10.1007/BF00027385; BENSEN RJ, 1988, PLANT PHYSIOL, V88, P289, DOI 10.1104/pp.88.2.289; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BRADSTOCK M, 1989, AUST LIT STUD, V14, P51; CHEN HH, 1983, PLANT PHYSIOL, V71, P362, DOI 10.1104/pp.71.2.362; CLOSE TJ, 1989, PLANT MOL BIOL, V13, P95, DOI 10.1007/BF00027338; CONDIT CM, 1986, NATURE, V323, P178, DOI 10.1038/323178a0; DHINDSA RS, 1990, P S LIGHT TEMPERATUR, P377; DOMMES J, 1985, PLANTA, V165, P513, DOI 10.1007/BF00398097; DURE L, 1989, PLANT MOL BIOL, V12, P475, DOI 10.1007/BF00036962; FONG F, 1983, PLANT PHYSIOL, V73, P899, DOI 10.1104/pp.73.4.899; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GOMEZ J, 1988, NATURE, V334, P262, DOI 10.1038/334262a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUERRERO FD, 1988, PLANT PHYSIOL, V88, P401, DOI 10.1104/pp.88.2.401; GUY CL, 1987, PLANT PHYSIOL, V84, P872, DOI 10.1104/pp.84.3.872; HANUKOGLU I, 1983, CELL, V33, P915, DOI 10.1016/0092-8674(83)90034-X; HAYNES SR, 1987, P NATL ACAD SCI USA, V84, P1819, DOI 10.1073/pnas.84.7.1819; HO THD, 1989, BIOCH PLANTS COMPREH, V15, P347; Jacobsen J. V., 1987, Plant hormones and their role in plant growth and development, P164; KALDENHOFF R, 1989, NUCLEIC ACIDS RES, V17, P2853, DOI 10.1093/nar/17.7.2853; KELLER B, 1988, EMBO J, V7, P3625, DOI 10.1002/j.1460-2075.1988.tb03243.x; KOORNNEEF M, 1989, PLANT PHYSIOL, V90, P463, DOI 10.1104/pp.90.2.463; KURKELA S, 1990, PLANT MOL BIOL, V15, P137, DOI 10.1007/BF00017731; LUO M, 1991, PLANT MOL BIOL, V17, P1267, DOI 10.1007/BF00028745; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MEZABASSO L, 1986, PLANT PHYSIOL, V82, P733, DOI 10.1104/pp.82.3.733; MOHAPATRA SS, 1988, PLANT CELL PHYSIOL, V29, P727; MOHAPATRA SS, 1988, PLANT PHYSIOL, V87, P468, DOI 10.1104/pp.87.2.468; MOHAPATRA SS, 1989, PLANT PHYSIOL, V89, P375, DOI 10.1104/pp.89.1.375; MOHAPATRA SS, 1987, PLANT PHYSIOL, V84, P1172, DOI 10.1104/pp.84.4.1172; MUNDY J, 1990, P NATL ACAD SCI USA, V87, P1406, DOI 10.1073/pnas.87.4.1406; MUNDY J, 1988, EMBO J, V7, P2279, DOI 10.1002/j.1460-2075.1988.tb03070.x; ORR W, 1986, J PLANT PHYSIOL, V126, P23, DOI 10.1016/S0176-1617(86)80212-7; PALM CJ, 1990, P NATL ACAD SCI USA, V87, P603, DOI 10.1073/pnas.87.2.603; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENACORTES H, 1989, P NATL ACAD SCI USA, V86, P9851, DOI 10.1073/pnas.86.24.9851; Quatrano R.S, 1987, PLANT HORM THEIR; RAMAGOPAL S, 1987, P NATL ACAD SCI USA, V84, P94, DOI 10.1073/pnas.84.1.94; RICHARDSON M, 1987, NATURE, V327, P432, DOI 10.1038/327432a0; ROBERTSON AJ, 1987, PLANT PHYSIOL, V84, P1331, DOI 10.1104/pp.84.4.1331; ROBERTSON JM, 1985, PLANT PHYSIOL, V79, P1086, DOI 10.1104/pp.79.4.1086; ROBERTSON M, 1989, PLANT PHYSIOL, V91, P415, DOI 10.1104/pp.91.1.415; Sambrook J, 1989, MOL CLONING LABORATO; SINGH NK, 1987, P NATL ACAD SCI USA, V84, P739, DOI 10.1073/pnas.84.3.739; SINGH NK, 1987, PLANT PHYSIOL, V85, P529, DOI 10.1104/pp.85.2.529; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WALKERSIMMONS M, 1987, PLANT PHYSIOL, V84, P61, DOI 10.1104/pp.84.1.61; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; ZEEVAART JAD, 1980, PLANT PHYSIOL, V66, P672, DOI 10.1104/pp.66.4.672; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.arplant.39.1.439	52	51	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15367	15374						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379227				2022-12-27	WOS:A1992JG11300020
J	JANSSENS, SP; SHIMOUCHI, A; QUERTERMOUS, T; BLOCH, DB; BLOCH, KD				JANSSENS, SP; SHIMOUCHI, A; QUERTERMOUS, T; BLOCH, DB; BLOCH, KD			CLONING AND EXPRESSION OF A CDNA-ENCODING HUMAN ENDOTHELIUM-DERIVED RELAXING FACTOR NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEURONAL NADPH DIAPHORASE; VASCULAR ENDOTHELIUM; SMOOTH-MUSCLE; CELLS; RELEASE	Nitric oxide, which accounts for the biological activity of endothelium-derived relaxing factor (EDRF), is synthesized in endothelial cells from L-arginine by nitric oxide synthase (NOS). We report here the cloning and functional expression of a cDNA encoding human endothelial NOS. Oligonucleotides corresponding to amino acid sequences shared by cytochrome P450 reductase and the recently identified brain NOS were synthesized to amplify a partial cDNA encoding a bovine endothelial cell NOS-related protein. This partial cDNA was used to isolate a cDNA encoding a human vascular endothelial NOS. The translated human protein is 1294 amino acids long and shares 52% of its amino acid sequence with brain NOS. Using RNA blot hybridization, abundant endothelial NOS mRNA was detected in unstimulated human umbilical vein endothelial cells. To determine the functional activity of the endothelial protein, we ligated the cDNA into an expression vector and transfected it into NIH3T3 cells. Cells expressing this cDNA contained abundant NADPH diaphorase activity, a histochemical marker for NOS. In co-culture assays, nitric oxide production by transfected cells increased guanylate cyclase activity in reporter rat fetal lung fibroblasts. In addition, NOS-catalyzed conversion of arginine to citrulline in transfected cells was significantly increased by A23187, a calcium ionophore. Isolation of a cDNA encoding a calcium-regulated, constitutively expressed human endothelial NOS, capable of producing EDRF in blood vessels, will accelerate the characterization of the role of this enzyme in normal and abnormal endothelial regulation of vascular tone.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital				Bloch, Donald/0000-0002-6828-4754; Quertermous, Thomas/0000-0002-7645-9067	NHLBI NIH HHS [HL45895, HL42397] Funding Source: Medline; NIAMS NIH HHS [AR01866] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042397, R29HL045895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001866] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADNOT S, 1991, J CLIN INVEST, V87, P155, DOI 10.1172/JCI114965; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; COLLINS P, 1990, LANCET, V335, P94, DOI 10.1016/0140-6736(90)90551-F; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1778; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LUSCHER TF, 1990, AM J HYPERTENS, V3, P317, DOI 10.1093/ajh/3.4.317; MARSDEN PA, 1990, AM J PHYSIOL, V258, pF1295, DOI 10.1152/ajprenal.1990.258.5.F1295; MARSDEN PA, 1991, SEMIN NEPHROL, V11, P169; MONCADA S, 1991, PHARMACOL REV, V43, P109; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; Sambrook J, 1989, MOL CLONING LABORATO; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; VANE JR, 1990, NEW ENGL J MED, V323, P27; YUI Y, 1991, J BIOL CHEM, V266, P3369; [No title captured]	28	567	606	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14519	14522						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378832				2022-12-27	WOS:A1992JF08800002
J	JASCUR, T; GOLDENBERG, DP; VESTWEBER, D; SCHATZ, G				JASCUR, T; GOLDENBERG, DP; VESTWEBER, D; SCHATZ, G			SEQUENTIAL TRANSLOCATION OF AN ARTIFICIAL PRECURSOR PROTEIN ACROSS THE 2 MITOCHONDRIAL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND CYTOPLASMIC POLYSOMES; CYTOCHROME-C PEROXIDASE; YEAST MITOCHONDRIA; INNER MEMBRANE; OUTER-MEMBRANE; CONTACT SITES; INTERMEMBRANE SPACE; FOLDING PATHWAY; IMPORT; TRANSPORT	We have constructed a chimeric mitochondrial precursor protein consisting of a mutant bovine pancreatic trypsin inhibitor coupled to the C terminus of a purified artificial precursor protein. This construct fails to complete its import into isolated mitochondria and becomes stuck across sites of close contact between the two mitochondrial membranes. When the mitochondria are then depleted of ATP and the intramolecular disulfide bridges of the trypsin inhibitor are cleaved by dithiothreitol, the trypsin inhibitor moiety is transported across the outer membrane into the intermembrane space. This translocation intermediate can be chased across the inner membrane by restoring the ATP levels in the matrix. These results show that translocation of pancreatic trypsin inhibitor across a biological membrane is prevented by its intramolecular disulfide bridges, that import into the matrix involves two distinct translocation system operating in tandem, and that ATP is required for protein translocation across the inner but not the outer membrane.	UNIV BASEL,BIOCTR,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND; UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112	University of Basel; Utah System of Higher Education; University of Utah				Vestweber, Dietmar/0000-0002-3517-732X	NIGMS NIH HHS [2 RO1 GM37803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADES IZ, 1980, J BIOL CHEM, V255, P9918; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CREIGHTON TE, 1975, J MOL BIOL, V95, P167, DOI 10.1016/0022-2836(75)90389-7; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GLICK BS, 1992, IN PRESS CELL; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; HURT EC, 1984, FEBS LETT, V178, P306, DOI 10.1016/0014-5793(84)80622-5; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; HWANG ST, 1991, J BIOL CHEM, V266, P21083; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KAPUT J, 1982, J BIOL CHEM, V257, P5054; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; MULLER G, 1988, EMBO J, V7, P639, DOI 10.1002/j.1460-2075.1988.tb02858.x; NGUYEN M, 1988, J CELL BIOL, V106, P1499, DOI 10.1083/jcb.106.5.1499; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; OHLENDIECK K, 1986, BIOCHIM BIOPHYS ACTA, V860, P672, DOI 10.1016/0005-2736(86)90567-5; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SUISSA M, 1982, J BIOL CHEM, V257, P3048; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VESTWEBER D, 1988, J CELL BIOL, V107, P2045, DOI 10.1083/jcb.107.6.2045; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x	36	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13636	13641						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377688				2022-12-27	WOS:A1992JB74600085
J	PAUL, S; SUN, M; MODY, R; TEWARY, HK; STEMMER, P; MASSEY, RJ; GIANFERRARA, T; MEHROTRA, S; DREYER, T; MELDAL, M; TRAMONTANO, A				PAUL, S; SUN, M; MODY, R; TEWARY, HK; STEMMER, P; MASSEY, RJ; GIANFERRARA, T; MEHROTRA, S; DREYER, T; MELDAL, M; TRAMONTANO, A			PEPTIDOLYTIC MONOCLONAL-ANTIBODY ELICITED BY A NEUROPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VASOACTIVE-INTESTINAL-PEPTIDE; HYDROLYSIS; AUTOANTIBODY; GENERATION; DIVERSITY; SITE	We report evidence that a monoclonal antibody raised by immunization with a vasoactive intestinal peptide (VIP)-carrier protein conjugate selectively hydrolyzes VIP and a fluorescence quenched decapeptide (FQ14-22D), representing the region of VIP most susceptible to autoantibody-mediated cleavage (residues 14-22). A high affinity of the antibody for VIP and a lower affinity for FQ14-22D were revealed by kinetic studies and further substantiated by potent inhibition of FQ14-22D cleaving activity by full-length VIP. Sequencing of FQ14-22D hydrolysis products indicated selective cleavage at one peptide bond. These observations suggest that antibodies induced against naturally occurring polypeptide antigens can express peptidolytic activity targeted for specific sequences in the recognition epitope.	UNIV NEBRASKA, MED CTR, DEPT BIOCHEM, OMAHA, NE 68198 USA; IGEN INC, ROCKVILLE, MD 20852 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; CARLSBERG LAB, DEPT CHEM, DK-2500 COPENHAGEN, DENMARK	University of Nebraska System; University of Nebraska Medical Center; Scripps Research Institute	PAUL, S (corresponding author), UNIV NEBRASKA, MED CTR, DEPT ANESTHESIOL, OMAHA, NE 68198 USA.		Meldal, Morten/B-7626-2016	Meldal, Morten/0000-0001-6114-9018; GIANFERRARA, Teresa/0000-0003-0085-3567; Stemmer, Paul/0000-0003-3315-9846	NHLBI NIH HHS [HL40348, HL44126, HL02217] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044126, R01HL040348, K04HL002217] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ERHAN S, 1974, NATURE, V251, P353, DOI 10.1038/251353a0; FRENCH DL, 1989, SCIENCE, V244, P1152, DOI 10.1126/science.2658060; HAMEL FG, 1986, ENDOCRINOLOGY, V118, P328, DOI 10.1210/endo-118-1-328; HARLOW E, 1988, ANTIBODIES LABORATOR; JUE R, 1978, BIOCHEMISTRY-US, V17, P5399, DOI 10.1021/bi00618a013; KOHEN F, 1980, BIOCHIM BIOPHYS ACTA, V629, P328, DOI 10.1016/0304-4165(80)90105-1; KOHEN F, 1980, FEBS LETT, V111, P427, DOI 10.1016/0014-5793(80)80842-8; MEI S, 1991, J BIOL CHEM, V266, P15571; MELDAL M, 1991, ANAL BIOCHEM, V195, P141, DOI 10.1016/0003-2697(91)90309-H; PAUL S, 1991, J BIOL CHEM, V266, P16128; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1990, J IMMUNOL, V145, P1196; PAUL S, 1989, J NEUROIMMUNOL, V23, P133, DOI 10.1016/0165-5728(89)90032-5; PAUL S, 1990, J BIOL CHEM, V265, P11910; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; SEGEL IH, 1975, ENZYME KINETICS, P150; SHUSTER AM, 1991, MOL BIOL+, V25, P478; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261	19	70	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13142	13145						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377678				2022-12-27	WOS:A1992JB74600008
J	KIRK, K; ELLORY, JC; YOUNG, JD				KIRK, K; ELLORY, JC; YOUNG, JD			TRANSPORT OF ORGANIC SUBSTRATES VIA A VOLUME-ACTIVATED CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TROUT ERYTHROCYTES; TAURINE EFFLUX; CELLS; RELEASE	We have investigated the volume-activated transport of organic solutes in flounder erythrocytes. Osmotic swelling of cells suspended in a Na+-free medium led to increased membrane transport of taurine, glucose, and uridine. For each compound there was a significant lag period (1-2 min at 10-degrees-C) between cell swelling and activation of the flux. The volume-activated fluxes of each of the substrates increased in parallel with increasing cell volume, and those of taurine and uridine increased linearly with concentration (up to 19 mM). The volume-activated fluxes of each of the three compounds showed similar sensitivities to a number of anion-selective channel blockers (5-nitro-2-(3-phenylpropylamino) benzoic acid > 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid almost-equal-to MK-196 > niflumic acid > furosemide); the IC50 for the inhibition of the volume-activated fluxes by NPPB was around 12 muM. The results are consistent with the hypothesis that the volume-activated transport of organic osmolytes is via a pathway with the characteristics of a volume-activated "chloride channel." This raises the question of whether the transport of organic substrates might represent a physiological role for such channels in other cell types.	UNIV ALBERTA,DEPT PHYSIOL,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Alberta	KIRK, K (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Kirk, Kiaran/C-8299-2009	Kirk, Kiaran/0000-0002-5613-2622	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAGNASCO SM, 1988, AM J PHYSIOL, V254, pC788, DOI 10.1152/ajpcell.1988.254.6.C788; BANDERALI U, 1992, J MEMBRANE BIOL, V126, P219; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CHRISTENSEN O, 1992, J MEMBRANE BIOL, V129, P13; COSSINS AR, 1989, J EXP BIOL, V144, P463; DACIE JC, 1975, PRACTICAL HAEMATOLOG, P39; FINCHAM DA, 1987, J MEMBRANE BIOL, V96, P45, DOI 10.1007/BF01869333; FRANCIOLINI F, 1987, J GEN PHYSIOL, V90, P453, DOI 10.1085/jgp.90.4.453; GARCIA JJ, 1991, J CELL BIOCHEM, V45, P207, DOI 10.1002/jcb.240450212; GARCIAROMEU F, 1991, J PHYSIOL-LONDON, V440, P547, DOI 10.1113/jphysiol.1991.sp018724; GOLDSTEIN L, 1991, AM J PHYSIOL, V260, pR1014, DOI 10.1152/ajpregu.1991.260.5.R1014; GOLDSTEIN L, 1990, J EXP ZOOL, V254, P114, DOI 10.1002/jez.1402540116; GREGER R, 1990, METHOD ENZYMOL, V191, P793; HARBAK H, 1991, ACTA PHYSIOL SCAND, V143, pA42; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; JARVIS SM, 1982, BIOCHEM J, V208, P83, DOI 10.1042/bj2080083; KIRK K, 1992, J PHYSIOL-LONDON, V452, pP342; OLEA RS, 1991, J MEMBRANE BIOL, V121, P1, DOI 10.1007/BF01870646; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SCHOUSBOE A, 1991, J NEUROSCI RES, V30, P661, DOI 10.1002/jnr.490300409; SIEBENS AW, 1989, AM J PHYSIOL, V257, pF937, DOI 10.1152/ajprenal.1989.257.6.F937; STEIN WD, 1986, TRANSPORT DIFFUSION, P113; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0	24	193	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23475	23478						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385424				2022-12-27	WOS:A1992JZ23900011
J	WISPE, JR; WARNER, BB; CLARK, JC; DEY, CR; NEUMAN, J; GLASSER, SW; CRAPO, JD; CHANG, LY; WHITSETT, JA				WISPE, JR; WARNER, BB; CLARK, JC; DEY, CR; NEUMAN, J; GLASSER, SW; CRAPO, JD; CHANG, LY; WHITSETT, JA			HUMAN MN-SUPEROXIDE DISMUTASE IN PULMONARY EPITHELIAL-CELLS OF TRANSGENIC MICE CONFERS PROTECTION FROM OXYGEN INJURY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RAT LUNGS; TOXICITY; EXPRESSION; HYPEROXIA; GENE	To test directly whether mitochondrial Mn-superoxide dismutase (Mn-SOD) protects the lung epithelium from oxygen-induced injury, transgenic mice were produced in which the expression of human Mn-SOD mRNA was directed by transcriptional elements from the human pulmonary surfactant protein C gene. Human Mn-SOD mRNA was expressed in a lung-specific manner, and increased Mn-SOD protein was detected within mitochondria of alveolar Type II and nonciliated bronchiolar cells of the distal respiratory epithelium of the transgenic mice. The activity of Mn-SOD, but not catalase, CuZn-SOD, or glutathione peroxidase, was increased in lungs of transgenic mice. Transgenic mice were highly protected from lung injury during exposure to 95% oxygen, surviving significantly longer than nontransgenic littermates. Pulmonary pathology demonstrated decreased hemorrhage, hyaline membrane formation, and alveolar and interstitial edema in transgenic animals. The finding that increased Mn-SOD in distal respiratory epithelial cells confers protection from oxygen injury provides a basis for novel therapies to protect lung from injury during oxygen therapy of acute and chronic lung diseases.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University	WISPE, JR (corresponding author), CHILDRENS HOSP RES FDN,MED CTR,DIV PULM BIOL,ELLAND & BETHESDA AVE,CINCINNATI,OH 45229, USA.				NHLBI NIH HHS [HL 39605, HL 41496, HL 42609] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, R01HL042609, R01HL039605] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; Claiborne A., 1985, CRC HDB METHODS OXYG, P283; CLARK JM, 1971, PHARMACOL REV, V23, P37; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; GERSCHMAN R, 1954, SCIENCE, V119, P623, DOI 10.1126/science.119.3097.623; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HARRIS JB, 1991, AM J RESP CELL MOL, V4, P115, DOI 10.1165/ajrcmb/4.2.115; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; KAUR S, 1989, DEVELOPMENT, V105, P613; KAWANAMI O, 1982, LAB INVEST, V46, P39; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; KRALL J, 1988, J BIOL CHEM, V263, P1910; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON RJ, 1991, LUNG SCI F, V1, P235; MASSARO D, 1978, FED PROC, V37, P2485; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Newman GR, 1984, IMMUNOLABELLING ELEC, P53; SCHNEEBERGER E, 1991, LUNG SCI F, V1, P205; SCHOONEN WGEJ, 1990, J BIOL CHEM, V265, P11118; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; TSAN MF, 1990, J APPL PHYSIOL, V68, P1211, DOI 10.1152/jappl.1990.68.3.1211; TURRENS JF, 1986, ARCH BIOCHEM BIOPHYS, V246, P501; WARNER BB, 1991, AM J PHYSIOL, V260, pL296, DOI 10.1152/ajplung.1991.260.4.L296; WEAVER TE, 1988, GEN PHARMACOL, V19, P361, DOI 10.1016/0306-3623(88)90029-8; WHITE CW, 1987, J CLIN INVEST, V79, P1868, DOI 10.1172/JCI113029; WHITE CW, 1991, J CLIN INVEST, V87, P2162, DOI 10.1172/JCI115249; WISPE JR, 1987, CLIN PERINATOL, V14, P651, DOI 10.1016/S0095-5108(18)30755-3; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6	35	286	291	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23937	23941						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385428				2022-12-27	WOS:A1992JZ23900076
J	NIYIBIZI, C; BONADIO, J; BYERS, PH; EYRE, DR				NIYIBIZI, C; BONADIO, J; BYERS, PH; EYRE, DR			INCORPORATION OF TYPE-I COLLAGEN MOLECULES THAT CONTAIN A MUTANT ALPHA-2(I) CHAIN (GLY580-]ASP) INTO BONE-MATRIX IN A LETHAL CASE OF OSTEOGENESIS IMPERFECTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELICAL DOMAIN; RNA SEQUENCE-ANALYSIS; PRO-ALPHA-1(I) CHAINS; PROCOLLAGEN; GLYCINE; SUBSTITUTION; GENE; MUTATIONS; POSITION; SERINE	To understand more directly the tissue defect in osteogenesis imperfecta (OI), bone matrix was analyzed from an infant with lethal OI (type II) of defined mutation (collagen alpha2(1)Gly580 --> Asp). Pepsin-solubilized alpha1(I) and alpha2(I) chains and derived CNBr-peptides migrated more slowly on sodium dodecyl sulfate-polyacrylamide gel electrophoresis compared with normal human controls. The peptide alpha2(I)CB3,5, predicted to contain the mutation site, ran as a retarded doublet band and was purified by high performance liquid chromatography and digested with V8 protease. Two peptides with amino-terminal sequences beginning at residue 576 of the alpha2(I) chain were isolated. One had the normal sequence. The other differed in that aspartic acid replaced glycine at residue 580 as predicted from cDNA analysis, and in having an unhydroxylated proline at residue 579. From yields on microsequencing and the relative intensities of the two forms of alpha2(I)CB3,5 on SDS-polyacrylamide gel electrophoresis, the ratio of mutant to normal alpha2(I) chains in the infant's bone matrix was 0.7/1. Although the effects of an efficient incorporation of mutant chains on the properties of the bone matrix are unknown, it may be that in this OI case the tissue abnormalities result more from the presence of mutant protein than from an underexpression of matrix.	UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL & MED,SEATTLE,WA 98195	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	NIYIBIZI, C (corresponding author), UNIV WASHINGTON,DEPT ORTHOPAED,RK-10,SEATTLE,WA 98195, USA.			Byers, Peter H./0000-0001-7786-7030	NIAMS NIH HHS [R01 AR036794, AR36794, R37 AR037318, AR37318, AR21557] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036794, R01AR036794, R01AR037318, R37AR037318, P01AR021557] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARSH GS, 1982, P NATL ACAD SCI-BIOL, V79, P3838, DOI 10.1073/pnas.79.12.3838; BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; BATEMAN JF, 1987, J BIOL CHEM, V262, P7021; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BONADIO J, 1985, NATURE, V316, P363, DOI 10.1038/316363a0; BONADIO J, 1990, P NATL ACAD SCI USA, V87, P7145, DOI 10.1073/pnas.87.18.7145; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; BYERS PH, 1990, TRENDS GENET, V6, P297; COHN DH, 1988, PATHOL IMMUNOPATH R, V7, P132, DOI 10.1159/000157108; DEWET W, 1987, J BIOL CHEM, V262, P16032; GELIEBTER J, 1986, P NATL ACAD SCI USA, V83, P3371, DOI 10.1073/pnas.83.10.3371; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; PACK M, 1989, J BIOL CHEM, V264, P19694; PATTERSON E, 1989, J BIOL CHEM, V264, P10083; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STARMAN BJ, 1989, J CLIN INVEST, V84, P1206, DOI 10.1172/JCI114286; STEINMANN B, 1984, J BIOL CHEM, V259, P1129; SUPERTIFURGA A, 1989, HUM GENET, V82, P104, DOI 10.1007/BF00284038; TILLER GE, 1990, P NATL ACAD SCI USA, V87, P3889, DOI 10.1073/pnas.87.10.3889; TSUNEYOSHI T, 1991, J BIOL CHEM, V266, P15608; VETTER U, 1991, CALCIFIED TISSUE INT, V49, P248, DOI 10.1007/BF02556213; VISSING H, 1989, J BIOL CHEM, V264, P18265; WALLIS GA, 1990, J BIOL CHEM, V265, P18628; WESTERHAUSEN A, 1990, J BIOL CHEM, V265, P13995	29	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					23108	23112						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385413				2022-12-27	WOS:A1992JY16300063
J	WIEDERRECHT, G; HUNG, S; CHAN, HK; MARCY, A; MARTIN, M; CALAYCAY, J; BOULTON, D; SIGAL, N; KINCAID, RL; SIEKIERKA, JJ				WIEDERRECHT, G; HUNG, S; CHAN, HK; MARCY, A; MARTIN, M; CALAYCAY, J; BOULTON, D; SIGAL, N; KINCAID, RL; SIEKIERKA, JJ			CHARACTERIZATION OF HIGH-MOLECULAR-WEIGHT FK-506 BINDING ACTIVITIES REVEALS A NOVEL FK-506-BINDING PROTEIN AS WELL AS A PROTEIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; PEPTIDYL-PROLYL ISOMERASE; T-CELL ACTIVATION; CYCLOSPORINE-A; IMMUNOSUPPRESSANT FK506; CALMODULIN-BINDING; LIMITED PROTEOLYSIS; MACROLIDES FK-506; CYCLOPHILIN; DISTINCT	The immunoregulant FK-506 potently inhibits particular calcium-associated signal transduction events that occur early during T-lymphocyte activation and during IgE receptor-mediated exocytosis in mast cells. FK-506 binds to a growing family of receptors termed FK-506-binding proteins (FKBPs), the most abundant being a 12-kDa cytosolic receptor, FKBP12. To date, there is no formal evidence proving that FKBP12 is the sole receptor mediating the immunosuppressive effects or toxic side effects of FK-506. Using gel filtration chromatography as an assay for novel FK-506-binding proteins, we identified FK-506 binding activities in extracts prepared from calf brain and from JURKAT cells. Both of these new activities comigrated with apparent molecular masses of 1 10 kDa. However, further characterization of both binding activities revealed that the two are not identical. The 110-kDa activity observed in brain extracts appears to be the FKBP12.FK-506.calcineurin (CaN) complex previously reported (Liu, J., Farmer, J., Lane, W., Friedman, J., Weissman, I., and Schreiber, S. (1991) Cell 66, 807-815) while the 110 kDa activity observed in JURKAT cells is a novel FK-506-binding protein. Our characterization of the FKBP12.FK-506.CaN complex reveals a dependence upon calmodulin (CaM) for formation of the complex and demonstrates that the peptidyl-prolyl cis-trans isomerase (PPIase) activity of FKBP12 is not required for binding of FKBP12.FK-506 to CaN or for inhibition of CaN phosphatase activity. The novel FK-506-binding protein in JURKAT cells has been purified to homogeneity, migrates with an apparent mass of 51 kDa on denaturing gels, and has been termed FKBP51. Like FKBP12, FKBP51 has PPIase activity, but, unlike FKBP12.FK-506, FKBP51.FK-506 does not complex with or inhibit the phosphatase activity of, CaN. These results indicate that complex formation with CaN may not be a general property of the FKBPs. Peptide sequencing reveals that FKBP51 may be similar, if not identical, to hsp56, a component of non-transformed steroid receptors.	MERCK SHARP & DOHME LTD,DEPT IMMUNOL RES,POB 2000,R80W-107,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,DEPT BIOPHYS CHEM,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,DEPT BIOCHEM & MOLEC PATHOL,RAHWAY,NJ 07065; NIAAA,MOLEC & CELLULAR NEUROBIOL,IMMUNOL SECT,ROCKVILLE,MD 20852	Merck & Company; Merck & Company; Merck & Company; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)								ALTSCHUH D, 1992, SCIENCE, V256, P92, DOI 10.1126/science.1566062; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FORREST MJ, 1991, BIOCHEM PHARMACOL, V42, P1221, DOI 10.1016/0006-2952(91)90257-6; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBBARD MJ, 1987, J BIOL CHEM, V262, P15062; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; ITOH N, 1987, J BIOL CHEM, V262, P3132; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; JORGENSEN WL, 1991, SCIENCE, V254, P954, DOI 10.1126/science.1719636; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MARONE G, 1988, RES CLIN LAB, V18, P53, DOI 10.1007/BF02918819; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; OHARA K, 1990, TRANSPLANT P, V22, P83; RINGE D, 1991, NATURE, V351, P185, DOI 10.1038/351185a0; ROSEN M, 1991, SCIENCE, V248, P863; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOCCI MJ, 1989, J IMMUNOL, V143, P718; VANBELLE H, 1981, CELL CALCIUM, V2, P483, DOI 10.1016/0143-4160(81)90007-5; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WALLACE RW, 1980, BIOCHEMISTRY-US, V19, P1831, DOI 10.1021/bi00550a016; WUTHRICH K, 1991, SCIENCE, V254, P953, DOI 10.1126/science.1948082; YEM AW, 1992, J BIOL CHEM, V267, P2868	44	107	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21753	21760						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383226				2022-12-27	WOS:A1992JV01100077
J	OREILLY, MA; GEISER, AG; KIM, SJ; BRUGGEMAN, LA; LUU, AX; ROBERTS, AB; SPORN, MB				OREILLY, MA; GEISER, AG; KIM, SJ; BRUGGEMAN, LA; LUU, AX; ROBERTS, AB; SPORN, MB			IDENTIFICATION OF AN ACTIVATING TRANSCRIPTION FACTOR (ATF) BINDING-SITE IN THE HUMAN TRANSFORMING GROWTH-FACTOR-BETA-2 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL SUPPRESSOR FACTOR; FACTOR-BETA; SEQUENCE-ANALYSIS; GENE-EXPRESSION; FUNCTIONAL-CHARACTERIZATION; AP-1 COMPLEX; CDNA CLONES; TGF BETA-1; PROTEIN; EMBRYOGENESIS	Transforming growth factor TGF-beta2 is encoded by multiple mRNA transcripts of 5.8, 5.1, 4.0, 3.8, and 2.8 kilobase pairs (kb) that are expressed in various human and monkey cells. Northern blot analysis using genomic fragments of DNA was used to demonstrate that some of this size heterogeneity is due to differences in the length of the 5'-untranslated region. Probes that were colinear with the first 600 nucleotides of the 5'-untranslated region detected only the 5.8-, 4.0-, and 3.8-kb transcripts. In order to identify DNA elements that regulate the transcription of these mRNA transcripts, deletion constructs of 5'-flanking DNA were ligated to the coding region for chloramphenicol acetyltransferase (CAT) and analyzed for promoter activity in several cell lines. Sequences responsible for putative enhancer and silencer regions were identified between -778 and -40 relative to the transcription initiation site. Addition of a cyclic AMP-responsive element/activating transcription factor-like element at -74 resulted in a 5-10-fold increase in CAT activity over that expressed with a construct that contained only the TATA box. This increase in CAT activity was suppressed by the addition of DNA sequences between -257 and -187, whereas sequences between -778 and -257 stimulated CAT activity. Point mutations within the ATF binding site at -74 resulted in a marked decrease in CAT expression. Cotransfection with ATF-1 or ATF-2 expression plasmids resulted in both dose-dependent stimulatory and inhibitory activities that were cell type-dependent. These studies identify multiple transcription initiation sites for TGF-beta2 and demonstrate that transcription from one of these promoters is dependent upon an ATF binding site located 5' of the TATA box.	NIDR,DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	OREILLY, MA (corresponding author), NCI,CHEMOPREVENT LAB,BLDG 41,RM C629,BETHESDA,MD 20892, USA.							BENBROOK DM, 1990, ONCOGENE, V5, P295; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BLANAR MA, 1992, SCIENCE, V256, P1013; BODMER S, 1989, J IMMUNOL, V143, P3222; BURT DW, 1991, J MOL ENDOCRINOL, V7, P175, DOI 10.1677/jme.0.0070175; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; FLINT KJ, 1991, ONCOGENE, V6, P2019; GATHERER D, 1990, DEVELOPMENT, V110, P445; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANKS SK, 1988, P NATL ACAD SCI USA, V85, P79, DOI 10.1073/pnas.85.1.79; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIM SJ, 1989, J BIOL CHEM, V264, P402; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; MADISEN L, 1988, DNA-J MOLEC CELL BIO, V7, P1, DOI 10.1089/dna.1988.7.1; Madisen L, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000295; MALIPIERO U, 1990, BIOCHEM BIOPH RES CO, V171, P1145, DOI 10.1016/0006-291X(90)90804-V; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLAN FA, 1991, DEVELOPMENT, V111, P131; MILLER DA, 1989, MOL ENDOCRINOL, V3, P1108, DOI 10.1210/mend-3-7-1108; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; PELTON RW, 1989, DEVELOPMENT, V106, P759; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SCHMID P, 1991, DEVELOPMENT, V111, P117; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; TENDIJKE P, 1988, P NATL ACAD SCI USA, V85, P4715; WEBB NR, 1988, DNA-J MOLEC CELL BIO, V7, P493, DOI 10.1089/dna.1.1988.7.493; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x	40	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19938	19943						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400310				2022-12-27	WOS:A1992JR85800033
J	POLLARD, TD; GOLDBERG, I; SCHWARZ, WH				POLLARD, TD; GOLDBERG, I; SCHWARZ, WH			NUCLEOTIDE EXCHANGE, STRUCTURE, AND MECHANICAL-PROPERTIES OF FILAMENTS ASSEMBLED FROM ATP-ACTIN AND ADP-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; MUSCLE ACTIN; POLYMERIZATION; HYDROLYSIS; PHOSPHATE; BINDING; DYNAMICS; GELSOLIN; KINETICS; IONS	Actin monomers with bound ATP, ADP, or fluorescent analogues of these nucleotides exchange the nucleotide on a second time scale, whereas filaments assembled from each of these species exchange their nucleotide with the solution at least 1,000 times slower than monomers. Filaments assembled from either ATP-actin or ADP-actin are indistinguishable by electron microscopy after negative staining. The dynamic elasticity and viscosity of filaments assembled from ATP-actin or ADP-actin or mixtures of these two species are the same over a wide range of frequencies. These observations do not support a recent suggestion (Janmey, P. A., Hvidt, S., Oster, G. F., Lamb, J., Stossel, T. P., and Hartwig, J. H. (1990) Nature 347, 95-99) that ATP hydrolysis within actin filaments stiffens the polymer and alters both their structure and affinity for nucleotides. The difference in observations between these two studies may be related to time-dependent changes in ADP-actin prepared in slightly different ways.	JOHNS HOPKINS UNIV,DEPT CHEM ENGN,BALTIMORE,MD 21218	Johns Hopkins University	POLLARD, TD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205, USA.		Goldberg, Ilya/H-5307-2011	Goldberg, Ilya/0000-0001-8514-6110	NIGMS NIH HHS [GM-26338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATO PA, 1986, J CELL BIOL, V102, P1074, DOI 10.1083/jcb.102.3.1074; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1988, FEBS LETT, V235, P211, DOI 10.1016/0014-5793(88)81264-X; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; COOPER JA, 1982, METHOD ENZYMOL, V85, P182; COUE M, 1985, J BIOL CHEM, V260, P5033; DRENCKHAHN D, 1986, J BIOL CHEM, V261, P2754; DREWES G, 1991, J BIOL CHEM, V266, P5508; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FRIEDEN C, 1988, BIOCHEMISTRY-US, V27, P3812, DOI 10.1021/bi00410a044; GERSHMAN LC, 1989, BIOCHIM BIOPHYS ACTA, V995, P109, DOI 10.1016/0167-4838(89)90068-X; GERSHMAN LC, 1986, BIOCHEM BIOPH RES CO, V135, P607, DOI 10.1016/0006-291X(86)90036-7; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KUEHL WM, 1969, J BIOL CHEM, V244, P4720; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MARTONOSI A, 1960, J BIOL CHEM, V235, P1700; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P1785, DOI 10.1021/bi00405a060; ODONOGHUE SI, 1992, ARCH BIOCHEM BIOPHYS, V293, P110, DOI 10.1016/0003-9861(92)90372-4; OHM T, 1991, BIOCHEMISTRY-US, V30, P11193, DOI 10.1021/bi00111a001; Pollard TD, 1990, CURR OPIN CELL BIOL, V2, P33, DOI 10.1016/S0955-0674(05)80028-6; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1984, FEBS LETT, V170, P94, DOI 10.1016/0014-5793(84)81376-9; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; RICKARD JE, 1988, J MOL BIOL, V201, P675, DOI 10.1016/0022-2836(88)90466-4; SATO M, 1985, J BIOL CHEM, V260, P8585; STRAUB FB, 1950, BIOCHIM BIOPHYS ACTA, V4, P455, DOI 10.1016/0006-3002(50)90052-7; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; WAECHTER F, 1975, EUR J BIOCHEM, V57, P453, DOI 10.1111/j.1432-1033.1975.tb02320.x; WANG YL, 1981, P NATL ACAD SCI-BIOL, V78, P5503, DOI 10.1073/pnas.78.9.5503; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WANGER M, 1987, BIOCHIM BIOPHYS ACTA, V914, P105, DOI 10.1016/0167-4838(87)90052-5	39	83	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20339	20345						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400353				2022-12-27	WOS:A1992JR85800093
J	BAYLE, D; ROBERT, JC; BAMBERG, K; BENKOUKA, F; CHERET, AM; LEWIN, MJM; SACHS, G; SOUMARMON, A				BAYLE, D; ROBERT, JC; BAMBERG, K; BENKOUKA, F; CHERET, AM; LEWIN, MJM; SACHS, G; SOUMARMON, A			LOCATION OF THE CYTOPLASMIC EPITOPE FOR A K+-COMPETITIVE ANTIBODY OF THE (H+,K+)-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PIG GASTRIC (H+; MONOCLONAL-ANTIBODY; H+/K+-ATPASE; PHOTOAFFINITY INHIBITOR; MOLECULAR-CLONING; CATALYTIC SUBUNIT; COMPLEMENTARY-DNA; H,K-ATPASE; H+,K+-ATPASE	The monoclonal antibody (mAb) 95-111 binds the alpha subunit of (H+,K+) -ATPase and inhibits the K+-ATPase activity. To map the epitope, all of the partial sequences of the alpha subunit were expressed in Escherichia coli HB101 using rabbit alpha subunit cDNA restriction fragments ligated into PuEx vector. Bacterial recombinant lysates were separated by sodium dodecyl sulfate-gel electrophoresis, and the epitope was detected by Western blotting. The antibody site was mapped between Cys529 and Glu561. This is close to the Lys517 that binds fluorescein isothiocyanate (FITC) and is considered to be between M4 and M5 close to the ATP binding domain. However, the mAb inhibition of ATPase is not ATP-competitive but is K+-competitive with a K(I) of 2 x 10(-9) M. The mAb also inhibits K+ quench of FITC fluorescence competitively with a K(I) of 8 x 10(-9) M. The K+ activation of ATPase activity and quench of FITC fluorescence are dependent on K+ binding to an E2 form of the enzyme from the extracytoplasmic surface. The mAb epitope is cytoplasmic since the K+-ATPase activity of ion-tight gastric vesicles is inhibited. The I-125-mAb 95-111 binds to a single class of sites with an apparent K(D) of 2.3 +/- 0.8 x 10(-9) M and K+ does not displace bound mAb. Hence, antibody binding to a Cytoplasmic Cys529-Glu561 epitope allosterically competes with K+-dependent reactions at extracytoplasmic sites.	HOP BICHAT, INSERM, U10, 170 BLVD NEY, F-75877 PARIS 18, FRANCE; WADSWORTH VET ADM HOSP, CURE INST, LOS ANGELES, CA 90073 USA; FAC SCI RABAT, RABAT, MOROCCO	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Mohammed V University in Rabat								BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BAYLE D, 1992, COMP BIOCHEM PHYS B, V101, P519, DOI 10.1016/0305-0491(92)90331-K; BENKOUKA F, 1989, BIOCHIM BIOPHYS ACTA, V987, P205, DOI 10.1016/0005-2736(89)90546-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; BRUCK C, 1982, J IMMUNOL METHODS, V53, P313, DOI 10.1016/0022-1759(82)90178-8; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; JACKSON RJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P9, DOI 10.1016/0005-2736(83)90391-7; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; MUNSON KB, 1988, BIOCHEMISTRY-US, V27, P3932, DOI 10.1021/bi00411a007; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RABON E, 1991, J BIOL CHEM, V266, P12395; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; ROBERT JC, 1990, BIOCHIM BIOPHYS ACTA, V1024, P167, DOI 10.1016/0005-2736(90)90220-I; Sambrook J, 1989, MOL CLONING LABORATO; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SMOLKA A, 1991, BIOCHEM BIOPH RES CO, V180, P1356, DOI 10.1016/S0006-291X(05)81345-2; STANLEY KK, 1983, NUCLEIC ACIDS RES, V11, P4077, DOI 10.1093/nar/11.12.4077; TAMURA S, 1989, J BIOL CHEM, V264, P8580; VANUEM TJF, 1991, BIOCHEM J, V280, P243, DOI 10.1042/bj2800243; VANUEM TJF, 1990, BIOCHIM BIOPHYS ACTA, V1023, P56, DOI 10.1016/0005-2736(90)90009-D; WALLMARK B, 1987, J BIOL CHEM, V262, P2077	32	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19060	19065						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382067				2022-12-27	WOS:A1992JP59300010
J	HADARI, YR; TZAHAR, E; NADIV, O; ROTHENBERG, P; ROBERTS, CT; LEROITH, D; YARDEN, Y; ZICK, Y				HADARI, YR; TZAHAR, E; NADIV, O; ROTHENBERG, P; ROBERTS, CT; LEROITH, D; YARDEN, Y; ZICK, Y			INSULIN AND INSULINOMIMETIC AGENTS INDUCE ACTIVATION OF PHOSPHATIDYLINOSITOL 3'-KINASE UPON ITS ASSOCIATION WITH PP185 (IRS-1) IN INTACT RAT LIVERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR TYROSINE KINASES; SIGNAL TRANSDUCTION; PROTEIN; PHOSPHORYLATION; SUBSTRATE; CELLS; H2O2; PURIFICATION; PI3-KINASE; 3-KINASE	The major cytosolic substrate of the insulin receptor is a 185-kDa phosphoprotein (IRS-1) that contains multiple putative attachment sites for the p85-alpha regulatory subunit of phosphatidylinositol 3'-kinase (PI3K). To examine the possible interaction of pp185 with p85-alpha in vivo, we injected insulin or insulinomimetic agents (a combination of H2O2 and vanadate (H/V)) into the portal vein of anesthetized rats. In this model system, H/V treatment and, to a lesser extent, injection of insulin resulted in rapid and sustained tyrosine phosphorylation of multiple cellular proteins, including pp185/IRS-1. The latter was found to undergo specific association with the p85-alpha regulatory subunit of PI3K but not with two other proteins that contain src homology domains. As p85-alpha was not detectably phosphorylated on tyrosine residues and did not appear to interact directly with the insulin receptor, we conclude that tyrosine phosphorylation of pp185 promotes its association with p85-alpha and the catalytic subunit of PI3K. The recruitment of the holoenzyme may also involve its enzymatic activation and thus constitute an important step in the transduction of insulin signals.	WEIZMANN INST SCI,DEPT CLIN IMMUNOL,IL-76100 REHOVOT,ISRAEL; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104; NIH,DIABET BRANCH,BETHESDA,MD 20892	Weizmann Institute of Science; University of Pennsylvania; National Institutes of Health (NIH) - USA			Zick, Yehiel/K-1479-2012; YARDEN, YOSEF/K-1467-2012; Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				BACKER JM, 1992, J BIOL CHEM, V267, P1367; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KADOTA S, 1987, J BIOL CHEM, V262, P8252; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; NADIV O, 1992, ENDOCRINOLOGY, V130, P1515, DOI 10.1210/en.130.3.1515; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELES E, 1992, IN PRESS CELL; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1992, J CELL BIOCHEM, V48, P12, DOI 10.1002/jcb.240480104; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHECHTER Y, 1980, NATURE, V284, P556; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZICK Y, 1989, CRIT REV BIOCHEM MOL, V24, P217, DOI 10.3109/10409238909082554	28	119	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17483	17486						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381348				2022-12-27	WOS:A1992JM22300002
J	LANE, TF; IRUELAARISPE, ML; SAGE, EH				LANE, TF; IRUELAARISPE, ML; SAGE, EH			REGULATION OF GENE-EXPRESSION BY SPARC DURING ANGIOGENESIS INVITRO - CHANGES IN FIBRONECTIN, THROMBOSPONDIN-1, AND PLASMINOGEN-ACTIVATOR INHIBITOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; FIBROBLAST GROWTH-FACTOR; CAPILLARY-LIKE STRUCTURES; BINDING PROTEIN SPARC; SMOOTH-MUSCLE CELLS; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; MOUSE EMBRYO; FACTOR-BETA; CULTURE	Angiogenesis in vitro, the formation of capillary-like structures by cultured endothelial cells, is associated with changes in the expression of several extracellular matrix proteins. The expression of SPARC, a secreted collagen-binding glycoprotein, has been shown to increase significantly during this process. We now show that addition of purified SPARC protein, or an N-terminal synthetic peptide (SPARC4-23), to strains of bovine aortic endothelial cells undergoing angiogenesis in vitro resulted in a dose-dependent decrease in the synthesis of fibronectin and thrombospondin-1 and an increase in the synthesis of type 1-plasminogen activator inhibitor. SPARC decreased fibronectin mRNA by 75% over 48 h, an effect that was inhibited by anti-SPARC immunoglobulins. Levels of thrombospondin-1 mRNA were diminished by 80%. Over a similar time course, both mRNA and protein levels of type 1-plasminogen activator inhibitor (PAI-1) were enhanced by SPARC and the SPARC4-23 peptide. The effects were dose-dependent with concentrations of SPARC between 1 and 30-mu-g/ml. In contrast, no changes were observed in the levels of either type I collagen mRNA or secreted gelatinases. Half-maximal induction of PAI-1 mRNA or inhibition of fibronectin and thrombospondin mRNAs occurred with 2-5-mu-g/ml SPARC and approximately 0.05 mM SPARC4-23. Strains of endothelial cells that did not form cords and tubes in vitro had reduced or undetectable responses to SPARC under identical conditions. These results demonstrate that SPARC modulates the synthesis of a subset of secreted proteins and identify an N-terminal acidic sequence as a region of the protein that provides an active site. SPARC might therefore function, in part, to achieve an optimal ratio among different components of the extracellular matrix. This activity would be consistent with known effects of SPARC on cellular morphology and proliferation that might contribute to the regulation of angiogenesis in vivo.	UNIV WASHINGTON, DEPT BIOL STRUCT, SM-20, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle			Iruela-Arispe, M. Luisa/AAJ-1297-2020	Iruela-Arispe, M. Luisa/0000-0002-3050-4168; Lane, Timothy F./0000-0002-0210-970X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03174, HL07312] Funding Source: Medline; NIGMS NIH HHS [GM 40711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; BAR RS, 1989, ENDOCRINOLOGY, V124, P1841, DOI 10.1210/endo-124-4-1841; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; CANFIELD AE, 1990, BIOCHEM J, V268, P225, DOI 10.1042/bj2680225; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CIAMBRONE GJ, 1990, J CELL BIOL, V111, P2183, DOI 10.1083/jcb.111.5.2183; CLEZARDIN P, 1988, EUR J BIOCHEM, V175, P275, DOI 10.1111/j.1432-1033.1988.tb14194.x; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; FIEGEL VD, 1991, J CELL BIOCH F, V15, P238; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1984, LAB INVEST, V51, P601; FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016; FOUSER L, 1991, J BIOL CHEM, V266, P18345; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FURCHT LT, 1986, LAB INVEST, V55, P505; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HASSELAAR P, 1991, J BIOL CHEM, V266, P13178; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; INGBER D, 1988, LAB INVEST, V59, P44; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; INGBER DE, 1987, IN VITRO CELL DEV B, V23, P387; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; IRUELAARISPE ML, 1991, ARTERIOSCLER THROMB, V11, P805, DOI 10.1161/01.ATV.11.4.805; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; JAYE M, 1985, SCIENCE, V228, P882, DOI 10.1126/science.3890179; KELM RJ, 1990, BLOOD, V75, P1105; KOBAYASHI S, 1986, BIOCHEMISTRY-US, V25, P8418, DOI 10.1021/bi00374a014; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MADRI JA, 1991, J CELL BIOCHEM, V45, P123, DOI 10.1002/jcb.240450202; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MARAGOUDAKIS ME, 1988, J PHARMACOL EXP THER, V244, P729; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MOSCATELLI DA, 1985, EXP CELL RES, V156, P379, DOI 10.1016/0014-4827(85)90545-2; MUMBY SM, 1984, J CELL PHYSIOL, V120, P280, DOI 10.1002/jcp.1041200304; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SAGE H, 1989, J HISTOCHEM CYTOCHEM, V37, P819, DOI 10.1177/37.6.2723400; SAGE H, 1984, J BIOL CHEM, V259, P3993; SAGE H, 1981, ARTERIOSCLEROSIS, V1, P427, DOI 10.1161/01.ATV.1.6.427; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SEKIGUCHI K, 1986, BIOCHEMISTRY-US, V25, P4936, DOI 10.1021/bi00365a032; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; UNEMORI EN, 1986, J CELL BIOL, V103, P1021, DOI 10.1083/jcb.103.3.1021	69	102	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16736	16745						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379603				2022-12-27	WOS:A1992JJ45800112
J	LANGKOPF, A; HAMMARBACK, JA; MULLER, R; VALLEE, RB; GARNER, CC				LANGKOPF, A; HAMMARBACK, JA; MULLER, R; VALLEE, RB; GARNER, CC			MICROTUBULE-ASSOCIATED PROTEIN-1A AND PROTEIN-LC2 - 2 PROTEINS ENCODED IN ONE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HEAVY CHAIN; MOLECULAR-CLONING; RAT-BRAIN; BINDING DOMAIN; LIGHT CHAIN; IDENTIFICATION; SEQUENCE; MAP1B; MAP-1; PURIFICATION	The deduced amino acid sequence for the filamentous microtubule-associated protein (MAP) 1A, thought to be involved in stabilizing the mature neuronal cytoskeleton, has been determined from a series of overlapping cDNA clones. Though previously described as biochemically and immunologically distinct from MAP1B, we now demonstrate that MAP1A is structurally related to MAP1B, a protein associated with neurite outgrowth and process plasticity. The two MAPs exhibit regional amino acid sequence similarities spanning their potential microtubule binding domains placing both into a new MAP family. The cDNA sequence encoding MAP1A was also found to encode one of its associated light chains (LC) called LC2. Both proteins are found on a single mRNA in the same open reading frame and are translated as a pre-MAP1A/LC2-protein. The topological relationship between MAP1A and LC2 coding sequences is, therefore, identical to that previously shown for MAP1B and LC1 (Hammarback, J. A., Obar, R. A., Hughes, S. M., and Vallee, R. B. (1991) Neuron 7, 129-139). Based on these and earlier results, we conclude that LC1 and LC2 are structurally related polypeptides generated from distinct MAP polyprotein precursors but free to exchange between the two MAPs.	UNIV HAMBURG, CTR MOLEC NEUROBIOL, MARTINISTR 52, W-2000 HAMBURG 20, GERMANY; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT NEUROBIOL & ANAT, WINSTON SALEM, NC 27103 USA; WORCESTER FDN EXPTL BIOL INC, SHREWSBURY, MA 01545 USA	University of Hamburg; Wake Forest University; Wake Forest Baptist Medical Center; Worcester Foundation for Biomedical Research				Garner, Craig/0000-0003-1970-5417				AIZAWA H, 1990, J BIOL CHEM, V265, P13849; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; BLOOM GS, 1983, J CELL BIOL, V96, P1523, DOI 10.1083/jcb.96.6.1523; BLOOM GS, 1985, P NATL ACAD SCI USA, V82, P5404, DOI 10.1073/pnas.82.16.5404; BORISY GG, 1974, FED PROC, V33, P167; BRION JP, 1990, SEMINARS NEUROSCIENC, V2, P89; CALVERT R, 1985, EMBO J, V4, P1171, DOI 10.1002/j.1460-2075.1985.tb03756.x; DEMEY J, 1987, FORTSCHR ZOOL, V34, P187; DIAZNIDO J, 1990, J NEUROCHEM, V54, P211, DOI 10.1111/j.1471-4159.1990.tb13303.x; GARNER CC, 1990, J NEUROCHEM, V55, P146, DOI 10.1111/j.1471-4159.1990.tb08832.x; GARNER CC, 1988, J NEUROCHEM, V50, P609, DOI 10.1111/j.1471-4159.1988.tb02954.x; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GREENE LA, 1983, J CELL BIOL, V96, P76, DOI 10.1083/jcb.96.1.76; HAMMARBACK JA, 1991, NEURON, V7, P129, DOI 10.1016/0896-6273(91)90081-A; KINDLER S, 1990, J BIOL CHEM, V265, P19679; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUZNETSOV SA, 1986, J CELL BIOL, V102, P1060, DOI 10.1083/jcb.102.3.1060; KUZNETSOV SA, 1987, FEBS LETT, V212, P145, DOI 10.1016/0014-5793(87)81574-0; LIEN LL, 1991, P NATL ACAD SCI USA, V88, P7873, DOI 10.1073/pnas.88.17.7873; LUCA FC, 1986, P NATL ACAD SCI USA, V83, P1006, DOI 10.1073/pnas.83.4.1006; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; NGSEE JK, 1989, DNA-J MOLEC CELL BIO, V8, P555, DOI 10.1089/dna.1989.8.555; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OGAWA K, 1991, NATURE, V352, P643, DOI 10.1038/352643a0; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PINNA LA, 1979, BIOCHEM BIOPH RES CO, V87, P114, DOI 10.1016/0006-291X(79)91654-1; RIENITZ A, 1989, EMBO J, V8, P2879, DOI 10.1002/j.1460-2075.1989.tb08436.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; SHIOMURA Y, 1987, J NEUROSCI, V7, P1461; SONDEREGGER P, 1982, ANAL BIOCHEM, V122, P298, DOI 10.1016/0003-2697(82)90285-8; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VALLEE RB, 1986, METHOD ENZYMOL, V134, P104; VALLEE RB, 1983, P NATL ACAD SCI-BIOL, V80, P1342, DOI 10.1073/pnas.80.5.1342; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	39	112	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16561	16566						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379599				2022-12-27	WOS:A1992JJ45800088
J	SMITH, JS; ROTH, MJ				SMITH, JS; ROTH, MJ			SPECIFICITY OF HUMAN IMMUNODEFICIENCY VIRUS-1 REVERSE TRANSCRIPTASE-ASSOCIATED RIBONUCLEASE-H IN REMOVAL OF THE MINUS-STRAND PRIMER, TRANSFER RNA(LYS3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ROUS-SARCOMA VIRUS; NUCLEOTIDE-SEQUENCE; RETROVIRAL DNA; RNASE-H; ESCHERICHIA-COLI; CIRCLE JUNCTION; CIRCULAR DNA; AIDS VIRUS; VIRAL-DNA	We have examined the specificity of human immunodeficiency virus-1 (HIV-1) reverse transcriptase-associated HNase H in removing the tRNA(Lys3) (-)-strand primer in vitro using a model substrate. This substrate represents an intermediate in the reverse transcription process where the tRNA(Lys3) primer has not yet been removed after (+)-strand strong stop DNA synthesis. The substrate consists of an RNA oligonucleotide corresponding to the 3'-terminal 17 nucleotides of the tRNA(Lys3) linked to U5 DNA and annealed to single-stranded DNA containing the U5 and the primer-binding site. Upon incubation with HIV-1 reverse transcriptase p66/p51 heterodimer, the minus-strand DNA product resulting from RNase H cleavage retained the 3'-rA from the model tRNA primer. Changing the 3'-terminal AMP of the model tRNA primer from rA to dA did not alter the RNase H cleavage site. Further, the retention of AMP was not dependent on recognition of adjacent U5 sequences or the CCA terminus of the model tRNA(Lys3). The synthetic RNA primer was released as an intact species by a single endonucleolytic cleavage 5' of the rA. The cleavage patterns of Moloney murine leukemia virus and avian myoblastosis virus RNase H activities on the HIV-1 model substrate were more heterogeneous compared to HIV-1 RNase H. This specificity of HIV-1 RNase H would result in linear DNA molecules with a single rA at the U5 terminus and would provide two bases adjacent to the conserved CA dinucleotide to be cleaved away during the integration process.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center			Roth, Monica/AAN-8742-2020					BERKOWER I, 1973, J BIOL CHEM, V248, P5914; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; Coffin J. M., 1990, VIROLOGY, P1437; COLICELLI J, 1986, J VIROL, V57, P674, DOI 10.1128/JVI.57.2.674-677.1986; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DUDDING LR, 1990, BIOCHEM BIOPH RES CO, V167, P244, DOI 10.1016/0006-291X(90)91757-J; ENGLAND TE, 1978, NATURE, V275, P561; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HONG T, 1991, J VIROL, V65, P551, DOI 10.1128/JVI.65.1.551-555.1991; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUGHES SH, 1981, P NATL ACAD SCI-BIOL, V78, P4299, DOI 10.1073/pnas.78.7.4299; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; PAUZA CD, 1990, VIROLOGY, V179, P886; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SHIMOTOHNO K, 1980, P NATL ACAD SCI-BIOL, V77, P7357, DOI 10.1073/pnas.77.12.7357; SHOEMAKER C, 1980, P NATL ACAD SCI-BIOL, V77, P3932, DOI 10.1073/pnas.77.7.3932; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; SMITH JS, 1990, J VIROL, V64, P6286, DOI 10.1128/JVI.64.12.6286-6290.1990; STARNES MC, 1989, J BIOL CHEM, V264, P7073; VANBEVEREN C, 1985, RNA TUMOR VIRUSES, P559; VARMUS H, 1989, MOBILE DNA, P53; VARMUS HE, 1982, SCIENCE, V216, P812, DOI 10.1126/science.6177038; VARMUS HE, 1984, RNA TUMOR VIRUSES, V1, P75; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WALLACE DM, 1986, METHOD ENZYMOL, V152, P41; WHITCOMB JM, 1990, J VIROL, V64, P4903, DOI 10.1128/JVI.64.10.4903-4906.1990; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001	43	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15071	15079						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378844				2022-12-27	WOS:A1992JF08800083
J	ADAMO, HP; CARIDE, AJ; PENNISTON, JT				ADAMO, HP; CARIDE, AJ; PENNISTON, JT			USE OF EXPRESSION MUTANTS AND MONOCLONAL-ANTIBODIES TO MAP THE ERYTHROCYTE CA2+ PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CALCIUM-PUMP; AMINO-ACID-SEQUENCE; PLASMA-MEMBRANE; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; CA-2+ PUMP; FUNCTIONAL DOMAINS; COMPLEMENTARY-DNA; CATALYTIC SUBUNIT; BINDING-PROTEIN	Deletion and truncation mutants of the human erythrocyte Ca2+ pump (hPMCA4b) were expressed in COS-1 cells. The reactivity patterns of these mutants with seven monoclonal antibodies were examined. Of the seven, six (JA9, JA3, 1G4, 4A4, 3E10 and 5F10) react from the cytoplasmic side. JA9 and JA3 reacted near the NH2 terminus and the COOH terminus of the molecule, respectively. 5F10 and 3E10 recognized portions of the large hydrophilic region in the middle of the protein. The epitopes of 1G4 and 4A4 were discontinuous and included residues from the long hydrophilic domain and residues between the proposed transmembrane domains M2 and M3. Antibody 1B10, which reacts from the extracellular side, recognized the COOH-terminal half of the molecule. These results show that the NH2 terminus, the COOH terminus, the region between M2 and M3, and the large hydrophilic region are all on the cytoplasmic side. This means that there are an even number of membrane crossings in both the NH2-terminal and the COOH-terminal halves. Between residues 75 and 300 there must be at least two membrane crossings, and there are at least two membrane crossings in the COOH-terminal half of the molecule.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,200 1ST ST SW,ROCHESTER,MN 55905	Mayo Clinic			Adamo, Hugo Pedro/ABB-8338-2021	Adamo, Hugo Pedro/0000-0002-1712-8049	NIGMS NIH HHS [GM 28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, IN PRESS BIOCH J, V285; ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BORKE JL, 1987, J CLIN INVEST, V80, P1225, DOI 10.1172/JCI113196; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CARIDE AJ, 1988, BIOCHEM J, V255, P663; CARIDE AJ, 1989, BIOCHEM J, V264, P87, DOI 10.1042/bj2640087; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; FESCHENKO MS, 1992, J BIOL CHEM, V267, P4097; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KESSLER F, 1990, J BIOL CHEM, V265, P16012; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS I, 1989, BIOCHEM BIOPH RES CO, V161, P683, DOI 10.1016/0006-291X(89)92653-3; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; PAPP B, 1989, J BIOL CHEM, V264, P4577; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Penniston JT, 1983, CALCIUM CELL FUNCTIO, P99; REGA AF, 1986, CALCIUM PUMP PLASMA; REITHMEIER RAF, 1981, J BIOL CHEM, V256, P5957; RICHARDS DE, 1978, BIOCHIM BIOPHYS ACTA, V511, P194, DOI 10.1016/0005-2736(78)90313-9; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VILSEN B, 1991, J BIOL CHEM, V266, P16157; WASSERMAN RH, 1991, HISTOCHEMISTRY, V96, P413, DOI 10.1007/BF00315999	35	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14244	14249						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378439				2022-12-27	WOS:A1992JD32500071
J	TANAKA, M; OHNO, S; ADACHI, S; NAKAJIN, S; SHINODA, M; NAGAHAMA, Y				TANAKA, M; OHNO, S; ADACHI, S; NAKAJIN, S; SHINODA, M; NAGAHAMA, Y			PIG TESTICULAR 20-BETA-HYDROXYSTEROID DEHYDROGENASE EXHIBITS CARBONYL REDUCTASE-LIKE STRUCTURE AND ACTIVITY - CDNA CLONING OF PIG TESTICULAR 20-BETA-HYDROXYSTEROID DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; NUCLEOTIDE-SEQUENCE; SALMO-GAIRDNERI; RAINBOW-TROUT; TESTIS; GENE; ENZYME; 17-ALPHA,20-BETA-DIHYDROXY-4-PREGNEN-3-ONE; PURIFICATION; PROTEIN	cDNA inserts encoding 20-beta-hydroxysteroid dehydrogenase (EC 1.1.1.53) were, for the first time, isolated and cloned from a pig testis cDNA library using synthetic oligonucleotides deduced from the partially determined amino acid sequences. The cDNA contains an open reading frame predicted to encode 289 amino acid residues. Surprisingly, it has 85% amino acid homology to human carbonyl reductase. The purified enzyme exhibited carbonyl reductase activity. Adenine-rich sequence was located in the 3'-untranslated region, which may mean that the gene originates by retroposition. RNA transcripts of 1.3, 3, and 6 kilobases were detected in poly(A)+ RNA extracted from pig testis by Northern blot hybridization. The steady-state level of the RNA species increased to a maximum in testes from 10-day-old pigs, but rapidly declined thereafter to the same levels found in testes of mature animals.	HOSEI UNIV, FAC PHARMACEUT SCI, DEPT BIOCHEM, SHINAGAWA KU, TOKYO 142, JAPAN	Hosei University	TANAKA, M (corresponding author), NATL INST BASIC BIOL, REPROD BIOL LAB, OKAZAKI, AICHI 444, JAPAN.			TANAKA, MINORU/0000-0001-9100-1487				AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; COLEMAN JP, 1988, J BACTERIOL, V170, P2070, DOI 10.1128/jb.170.5.2070-2077.1988; ENGEL LL, 1961, ANNU REV BIOCHEM, V30, P499, DOI 10.1146/annurev.bi.30.070161.002435; FORREST GL, 1990, BIOCHIM BIOPHYS ACTA, V1048, P149, DOI 10.1016/0167-4781(90)90050-C; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUBENER HJ, 1958, H-S Z PHYSIOL CHEM, V313, P124, DOI 10.1515/bchm2.1958.313.1.124; JORNVALL H, 1984, FEBS LETT, V165, P190, DOI 10.1016/0014-5793(84)80167-2; JORNVALL H, 1981, P NATL ACAD SCI-BIOL, V78, P4226, DOI 10.1073/pnas.78.7.4226; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MAREKOV L, 1990, FEBS LETT, V266, P51, DOI 10.1016/0014-5793(90)81504-H; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; NAGAHAMA Y, 1990, PROG CLIN BIOL RES, V342, P385; NAKAJIN S, 1989, CHEM PHARM BULL, V37, P148; NAKAJIN S, 1987, CHEM PHARM BULL, V35, P2490; NAKAJIN S, 1988, J BIOCHEM-TOKYO, V104, P565, DOI 10.1093/oxfordjournals.jbchem.a122511; NESEMANN G, 1960, BIOCHEM Z, V333, P88; OHNO S, 1991, CHEM PHARM BULL, V39, P972; OHNO S, 1992, STEROID BIOCH MOL BI, V42, P17; PELTOKETO H, 1988, FEBS LETT, V239, P73, DOI 10.1016/0014-5793(88)80548-9; SAKAI N, 1989, GEN COMP ENDOCR, V75, P231, DOI 10.1016/0016-6480(89)90075-0; SAKAI N, 1989, BIOMED RES-TOKYO, V10, P131, DOI 10.2220/biomedres.10.131; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; Spande T.F., 1967, DETERMINATION TRYPTO, P498; TAMAOKI B, 1966, STEROID DYNAMICS, P493; TANAKA M, 1992, J MOL ENDOCRINOL, V8, P53, DOI 10.1677/jme.0.0080053; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; THE VL, 1989, MOL ENDOCRINOL, V3, P1301, DOI 10.1210/mend-3-8-1301; UEDA H, 1984, J EXP ZOOL, V231, P435, DOI 10.1002/jez.1402310318; WERMUTH B, 1988, J BIOL CHEM, V263, P16185; WERMUTH B, 1981, J BIOL CHEM, V256, P1206; YOUNG G, 1986, DEV BIOL, V118, P1, DOI 10.1016/0012-1606(86)90067-9	35	98	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13451	13455						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377683				2022-12-27	WOS:A1992JB74600057
J	BALZARINI, J; PEREZPEREZ, MJ; SANFELIX, A; CAMARASA, MJ; BATHURST, IC; BARR, PJ; DECLERCQ, E				BALZARINI, J; PEREZPEREZ, MJ; SANFELIX, A; CAMARASA, MJ; BATHURST, IC; BARR, PJ; DECLERCQ, E			KINETICS OF INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) REVERSE-TRANSCRIPTASE BY THE NOVEL HIV-1-SPECIFIC NUCLEOSIDE ANALOG [2',5'-BIS-O-(TERT-BUTYLDIMETHYLSILYL)-BETA-D-RIBOFURANOSYL]-3'-SPIRO-5''-(4''-AMINO-1'',2''-OXATHIOLE-2'',2''-DIOXIDE)THYMINE (TSAO-T)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-III/LAV; 3'-AZIDO-3'-DEOXYTHYMIDINE; INVITRO; INFECTIVITY; DERIVATIVES; REPLICATION; POTENT; AGENTS	[2',5'-Bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-s piro-5"--(4"-amino-1",2"-oxathiole-2", 2"-dioxide)thymine (TSAO-T) is a representative of a novel class of nucleoside analogues that are endowed with a potent and specific activity against human immunodeficiency virus (HIV) type 1 and are targeted at the HIV-1 reverse transcriptase (RT). Inhibition of HIV-1 RT by TSAO-T was reversible and noncompetitive with respect to dGTP as the substrate and poly(C).oligo(dG) as the template/primer. In contrast with the nonnucleoside derivatives tetrahydroimidazo-[4,5,1-jk][1,41-benzodiazepin-2(1H)-thione (TIBO) (R-82150), nevirapine (BI-RG-587) and the HEPT derivative I-HEPU-SdM, TSAO-T was not inhibitory to HIV-1 RT in the presence of other homopolymeric template/primers. It did not interfere with the DNA-dependent DNA polymerase function of HIV-1 RT, HIV-2 RT, herpes simplex virus type 1 DNA polymerase, or Taq polymerase. However, TSAO-T proved inhibitory to the HIV-1 RT reaction primed by Escherichia coli 16S/23S rRNA, irrespective of the nature of the radiolabeled 2'-deoxynucleotide 5'-triphosphate (dNTP) used. TSAO-T does not act as a DNA chain terminator. It interacts with HIV-1 RT at a nonsubstrate (dNTP)-binding site.	INST QUIM MED,E-28006 MADRID,SPAIN; CHIRON CORP,EMERYVILLE,CA 94608	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Medica (IQM); CSIC - Instituto de Quimica Organica General (IQOG); Novartis	BALZARINI, J (corresponding author), CATHOLIC UNIV LEUVEN,REGA INST MED RES,B-3000 LOUVAIN,BELGIUM.		Perez-Perez, Maria-Jesus/O-4580-2014; García, Ana Rosa San-Félix/G-5117-2015; Camarasa, María-José/N-8845-2019; Camarasa, María-José/B-6340-2015	Perez-Perez, Maria-Jesus/0000-0003-1336-7760; García, Ana Rosa San-Félix/0000-0003-4271-7598; Camarasa, María-José/0000-0002-4978-6468; Camarasa, María-José/0000-0002-4978-6468; De Clercq, Erik/0000-0002-2985-8890				BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356; BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3; BALZARINI F, 1992, IN PRESS ANTIMICROB; BALZARINI J, 1989, P NATL ACAD SCI USA, V86, P332, DOI 10.1073/pnas.86.1.332; BALZARINI J, 1991, P NATL ACAD SCI USA, V88, P1499, DOI 10.1073/pnas.88.4.1499; BALZARINI J, 1991, AIDS, V5, P21, DOI 10.1097/00002030-199101000-00003; BALZARINI J, 1986, BIOCHEM BIOPH RES CO, V140, P735, DOI 10.1016/0006-291X(86)90793-X; BALZARINI J, 1991, P NATL ACAD SCI USA, V88, P4961, DOI 10.1073/pnas.88.11.4961; BALZARINI J, 1987, MOL PHARMACOL, V32, P162; BALZARINI J, 1992, IN PRESS P NATL ACAD; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; CHU CK, 1989, J MED CHEM, V32, P612, DOI 10.1021/jm00123a018; COHEN KA, 1991, J BIOL CHEM, V266, P14670; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1991, BIOCHEM PHARMACOL, V42, P963, DOI 10.1016/0006-2952(91)90276-B; FRANK KB, 1991, J BIOL CHEM, V266, P14232; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; KOUP RA, 1991, J INFECT DIS, V163, P966, DOI 10.1093/infdis/163.5.966; KUKLA MJ, 1991, J MED CHEM, V34, P746, DOI 10.1021/jm00106a040; LIAW YC, 1991, J AM CHEM SOC, V113, P1857, DOI 10.1021/ja00005a075; LIN TS, 1989, J MED CHEM, V32, P1891, DOI 10.1021/jm00128a034; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; Schinazi R. F., 1988, AIDS CHILDREN ADOLES, P126; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; TANORKA H, 1992, J MED CHEM, V35, P337; WHITE EL, 1991, ANTIVIR RES, V16, P257, DOI 10.1016/0166-3542(91)90005-C; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	36	127	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11831	11838						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376314				2022-12-27	WOS:A1992HY94700032
J	TAKATSUJI, H; YAMAUCHI, H; WATANABE, S; KATO, H; IKEDA, JE				TAKATSUJI, H; YAMAUCHI, H; WATANABE, S; KATO, H; IKEDA, JE			CAULIFLOWER MOSAIC-VIRUS REVERSE-TRANSCRIPTASE - ACTIVATION BY PROTEOLYTIC PROCESSING AND FUNCTIONAL ALTERATION BY TERMINAL DELETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL 5'-PHOSPHATE INHIBITION; MURINE LEUKEMIA-VIRUS; ESCHERICHIA-COLI; DNA-POLYMERASES; ELECTROPHORESIS; EXPRESSION	We have previously expressed the cauliflower mosaic virus (CaMV) reverse transcriptase (RTase) gene, the ORFV gene, in yeast in an active form (RTase-Y). An activity gel analysis revealed that the molecular size of RTase-Y as well as an RTase associated with the CaMV particles (RTase-V) is 60 kDa. This size is about 18 kDa smaller than that of the inactive form previously expressed in Escherichia coli (RTase-E) (78 kDa), which corresponds to the coding capacity estimated for the ORFV gene. To investigate the possible involvement of proteolytic processing in the de novo synthesis of CaMV RTase, we constructed a series of deletions from either terminus or both termini of the ORFV coding sequence and expressed them in E. coli. Among the various truncated RTases, those (denoted DELTA-N) that lack N-terminal peptide fragments 143-185 amino acids long were active on the synthetic RNA template-primer, poly(rC)-oligo(dG). Those RTases (denoted DELTA-C) lacking C-terminal peptide fragments 50-102 amino acids long and those lacking both termini (denoted DELTA-NC) were also active on this template. However, only the DELTA-N RTases showed enzyme properties indistinguishable from the RTase-Y in that they transcribed natural RNA into DNA and required either Mg2+ or Mn2+ for their activity. The length of the deletion corresponded approximately to the difference of the molecular weights between RTase-Y and RTase-E. These results suggest that CaMV RTase is translated in an inactive precursor form and then converted to an active form by proteolytic processing during de novo synthesis. We have also demonstrated that C-terminal deletions cause a loss of activity on a natural RNA template accompanied by an alteration in metal ion requirement. The inability to incorporate dTTP accounts for the loss of activity on the natural RNA template. However, the affinities for dTTP and the corresponding template, poly(rA)-oligo(dT), were found to be unaltered.	NATL INST AGROBIOL RESOURCES,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN	National Institute of Agrobiological Sciences - Japan								BASU A, 1988, J BIOL CHEM, V263, P1648; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DION AS, 1974, J VIROL, V14, P40, DOI 10.1128/JVI.14.1.40-46.1974; FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298; GARDNER RC, 1981, NUCLEIC ACIDS RES, V9, P2871, DOI 10.1093/nar/9.12.2871; Hohn T, 1982, Curr Top Microbiol Immunol, V96, P194; HOHN T, 1985, TRENDS BIOCHEM SCI, V10, P205, DOI 10.1016/0968-0004(85)90193-8; HOWELL SH, 1982, ANNU REV PLANT PHYS, V33, P609, DOI 10.1146/annurev.pp.33.060182.003141; HULL R, 1983, TRENDS BIOCHEM SCI, V8, P119, DOI 10.1016/0968-0004(83)90231-1; LEGRICE SFJ, 1988, EMBO J, V7, P2547, DOI 10.1002/j.1460-2075.1988.tb03103.x; MARCUS SL, 1974, J VIROL, V14, P853, DOI 10.1128/JVI.14.4.853-859.1974; MCDONELL MW, 1977, J MOL BIOL, V110, P119, DOI 10.1016/S0022-2836(77)80102-2; MODAK MJ, 1981, BIOCHIM BIOPHYS ACTA, V654, P227, DOI 10.1016/0005-2787(81)90176-3; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; PFEIFFER P, 1983, CELL, V33, P781, DOI 10.1016/0092-8674(83)90020-X; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEPHERD RJ, 1979, ANNU REV PLANT PHYS, V30, P405, DOI 10.1146/annurev.pp.30.060179.002201; SPANOS A, 1981, NUCLEIC ACIDS RES, V9, P1825, DOI 10.1093/nar/9.8.1825; TAKATSUJI H, 1986, NATURE, V319, P240, DOI 10.1038/319240a0; TOH H, 1985, EMBO J, V4, P1267, DOI 10.1002/j.1460-2075.1985.tb03771.x; TORRUELLA M, 1989, EMBO J, V8, P2819, DOI 10.1002/j.1460-2075.1989.tb08428.x; VOLOVITCH M, 1984, EMBO J, V3, P309, DOI 10.1002/j.1460-2075.1984.tb01801.x	23	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11579	11585						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375943				2022-12-27	WOS:A1992HX16900098
J	WILLE, H; MANDELKOW, EM; MANDELKOW, E				WILLE, H; MANDELKOW, EM; MANDELKOW, E			THE JUVENILE MICROTUBULE-ASSOCIATED PROTEIN MAP2C IS A ROD-LIKE MOLECULE THAT FORMS ANTIPARALLEL DIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAU PROTEINS; BUNDLE FORMATION; BINDING DOMAIN; MOUSE-BRAIN; MAP-2; PHOSPHORYLATION; IDENTIFICATION; TUBULIN; WEIGHT; CDNA	We have developed a procedure to isolate the microtubule-associated protein 2c (MAP2c), a juvenile form of MAP2 occurring in mammalian brain. The shape, size, self-association, and antibody interactions of MAP2c were studied. Monomeric MAP2c is an elongated molecule with a length approximately 48 nm, considerably shorter than the higher molecular weight forms MAP2a or b of adult brain. Two monoclonal antibodies whose epitopes are near the N or C terminus, respectively, are located close to the opposite ends of the MAP2c rods. This places constraints on the types of internal folding of the molecule. MAP2c self-associates into dimers and fibrous aggregates. The dimers are predominantly antiparallel and nearly in register, as judged by antibody labeling.	DESY, MAX PLANCK UNIT STRUCT MOLEC BIOL, NOTKESTR 85, W-2000 HAMBURG 52, GERMANY	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society			Wille, Holger/C-2280-2008	Wille, Holger/0000-0001-5102-8706				AIZAWA H, 1988, J BIOL CHEM, V263, P7703; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; CHAPIN SJ, 1991, NATURE, V349, P24, DOI 10.1038/349024a0; COUCHIE D, 1985, FEBS LETT, V188, P331, DOI 10.1016/0014-5793(85)80397-5; CRANDALL JE, 1989, J NEUROCHEM, V53, P1910, DOI 10.1111/j.1471-4159.1989.tb09261.x; DINGUS J, 1991, J BIOL CHEM, V266, P18854; DOLL T, 1990, NUCLEIC ACIDS RES, V18, P361, DOI 10.1093/nar/18.2.361; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; GARNER CC, 1988, J CELL BIOL, V106, P779, DOI 10.1083/jcb.106.3.779; GARNER CC, 1988, J NEUROCHEM, V50, P609, DOI 10.1111/j.1471-4159.1988.tb02954.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOTTLIEB RA, 1985, J CELL BIOL, V101, P1782, DOI 10.1083/jcb.101.5.1782; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HEINS S, 1991, J CELL SCI, P121; HERNANDEZ MA, 1986, EUR J BIOCHEM, V154, P41, DOI 10.1111/j.1432-1033.1986.tb09356.x; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KINDLER S, 1990, NUCLEIC ACIDS RES, V18, P2822, DOI 10.1093/nar/18.9.2822; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1990, NATURE, V345, P674, DOI 10.1038/345674a0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; NUNEZ J, 1988, TRENDS NEUROSCI, V11, P477, DOI 10.1016/0166-2236(88)90004-5; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; SOMERS M, 1990, EUR J BIOCHEM, V193, P437, DOI 10.1111/j.1432-1033.1990.tb19357.x; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; TUCKER RP, 1988, J NEUROSCI, V8, P4503; TUCKER RP, 1988, PROTOPLASMA, V145, P195, DOI 10.1007/BF01349359; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; VOTER WA, 1982, J ULTRA MOL STRUCT R, V80, P374, DOI 10.1016/S0022-5320(82)80051-8; WILLE H, 1992, J STRUCT BIOL, V108, P49, DOI 10.1016/1047-8477(92)90006-V; WOODY RW, 1983, FEBS LETT, V141, P181; ZINGSHEIM HP, 1979, EUR J CELL BIOL, V19, P175	40	30	30	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10737	10742						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375231				2022-12-27	WOS:A1992HV09000080
J	MOSCARELLO, MA; PANG, H; PACEASCIAK, CR; WOOD, DD				MOSCARELLO, MA; PANG, H; PACEASCIAK, CR; WOOD, DD			THE N TERMINUS OF HUMAN MYELIN BASIC-PROTEIN CONSISTS OF C2, C4, C6, AND C8 ALKYL CARBOXYLIC-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; EXPRESSION; GENE	Peptide 1-21, generated by cyanogen bromide cleavage of each of two highly purified components of human myelin basic protein, components 1 and 8, gave a series of peaks in the fast atom bombardment mass spectra with m/z 2299, 2327, 2355, 2383, and 2411, indicating additions of 42, 70, 98, 126, and 154 atomic mass units respectively with m/z 2327 and 2355 as the dominant species. The pentafluorobenzyl esters prepared from an acid hydrolysate analyzed by negative ion chemical ionization gas chromatography mass spectrometry confirmed that C6, C-8, and C-10 fatty acids were present. These data demonstrated (i) that the N terminus of a myelin basic protein is not simply acetylated but containing C2, C4, C6, C-8, and C-10 fatty acids with C4 and C6 as the dominant species, (ii) the two components studied (C-1 and C-8) showed different relative amounts of C2 and C-8 in particular, and (iii) human myelin basic protein is the first protein to be reported with a complex N terminus consisting of several alkyl carboxylic acid species.	UNIV TORONTO,CARBOHYDRATE RES CTR,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto	MOSCARELLO, MA (corresponding author), HOSP SICK CHILDREN,RES INST,DIV BIOCHEM,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.							BARBER M, 1982, ANAL CHEM, V54, pA645; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; CAMPAGNONI AT, 1988, MOL NEUROBIOL, V2, P41, DOI 10.1007/BF02935632; CARNEGIE PR, 1969, BIOCHEM J, V111, P240, DOI 10.1042/bj1110240; CHEIFETZ S, 1984, ARCH BIOCHEM BIOPHYS, V233, P151, DOI 10.1016/0003-9861(84)90611-8; CHOU FCH, 1976, J BIOL CHEM, V251, P2671; HASHIM GA, 1969, ARCH BIOCHEM BIOPHYS, V135, P324, DOI 10.1016/0003-9861(69)90546-3; HENION J, 1990, ATMOSPHERIC PRESSURE; KAMHOLZ J, 1988, J NEUROSCI RES, V21, P62, DOI 10.1002/jnr.490210110; MOSCARELLO MA, 1990, MYELIN BASIC PROTEIN, P25; PACEASCIAK CR, 1987, J CHROMATOGR LIBR, V37, P107; SCOBLE SA, 1990, METHOD ENZYMOL, V193, P519; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; WOOD DD, 1989, J BIOL CHEM, V264, P5121; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	15	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9779	9782						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374408				2022-12-27	WOS:A1992HT96500053
J	JIANG, WP; GORBEA, CM; FLANNERY, AV; BEYNON, RJ; GRANT, GA; BOND, JS				JIANG, WP; GORBEA, CM; FLANNERY, AV; BEYNON, RJ; GRANT, GA; BOND, JS			THE ALPHA-SUBUNIT OF MEPRIN-A - MOLECULAR-CLONING AND SEQUENCING, DIFFERENTIAL EXPRESSION IN INBRED MOUSE STRAINS, AND EVIDENCE FOR DIVERGENT EVOLUTION OF THE ALPHA-SUBUNIT AND BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY METALLOENDOPEPTIDASE; CLEAVAGE SITES; GROWTH-FACTOR; PLASMID DNA; MEP-1 GENE; MEMBRANE; PROTEIN; ACID; MICE; CHROMOSOME-17	Meprin A, a membrane-bound oligomeric metalloendopeptidase, contains two different subunits, alpha and beta. We report here the cloning and sequencing of the alpha-subunit cDNA. The translated polypeptide consists of 760 amino acids, including a preprosequence (77 amino acids) that precedes the NH2 terminus of the purified enzyme. The next 198 amino acids constitute the "astacin family" protease domain, which includes the astacin family signature sequence, HE(L,I)XHXXGFXHE(Q,H)XRXDRDX(Y,H)(V,I)X(I,V). An immunoglobulin/major histocompatibility complex protein signature was found at the end of the protease domain. At the COOH terminus of the alpha-subunit, there is an epidermal growth factor-like domain, followed by a transmembrane domain, and six additional amino acids. Ten potential glycosylation sites have been identified, and at least three of those sites are glycosylated. Northern blot analyses of kidney tissue from C57BL/6 and C3H/He mice indicate that variations in meprin A activity in these strains reflect differences in the levels of the alpha-subunit mRNA. Several internal peptide sequences obtained from the beta-subunit indicate that it is approximately 50% identical to the alpha-subunit. Furthermore, NH2-terminal sequence analyses (39 residues) indicate that rat and mouse-alpha are 79% identical, rat and mouse-beta are 74% identical, and that alpha and beta-subunits for both species are 47% identical. These data indicate that alpha and beta are closely related products of divergent evolution.	VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM,BLACKSBURG,VA 24061; UNIV LIVERPOOL,DEPT BIOCHEM,LIVERPOOL L69 3BX,ENGLAND; WASHINGTON UNIV,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Virginia Polytechnic Institute & State University; University of Liverpool; Washington University (WUSTL)			Beynon, Robert J/K-1408-2014	Beynon, Robert J/0000-0003-0857-495X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R37DK019691, R01DK019691] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P106, DOI 10.1016/0167-5699(87)90860-7; BAIROCH A, 1990, PROSITE DICT PROTEIN; BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; BEYNON RJ, 1983, SCIENCE, V219, P1351, DOI 10.1126/science.6338590; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOND JS, 1984, P NATL ACAD SCI-BIOL, V81, P5542, DOI 10.1073/pnas.81.17.5542; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG SS, 1987, AM J PHYSIOL, V253, pC535, DOI 10.1152/ajpcell.1987.253.4.C535; CRAIG SS, 1991, J HISTOCHEM CYTOCHEM, V39, P123, DOI 10.1177/39.1.1701182; Derynck R., 1987, ONCOGENES GENES GROW, P133; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FLANNERY AV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P119, DOI 10.1016/0167-4838(91)90032-U; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAZ T, 1987, TRANSLATIONAL REGULA, P413; LEPAGE T, 1992, DEVELOPMENT, V114, P147; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MCKAY MJ, 1985, BIOCHEM BIOPH RES CO, V132, P171, DOI 10.1016/0006-291X(85)91003-4; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RECKELHOFF JF, 1988, IMMUNOGENETICS, V27, P298, DOI 10.1007/BF00376127; RECKELHOFF JF, 1985, IMMUNOGENETICS, V22, P617, DOI 10.1007/BF00430310; Sambrook J, 1989, MOL CLONING LABORATO; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; SAVAGE CR, 1973, J BIOL CHEM, V248, P7669; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; STENFLO J, 1988, J BIOL CHEM, V263, P21; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WOLZ RL, 1991, BIOCHEMISTRY-US, V30, P8488, DOI 10.1021/bi00098a029; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; ZINGDE SM, 1986, ANAL BIOCHEM, V155, P10, DOI 10.1016/0003-2697(86)90216-2	46	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9185	9193						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374387				2022-12-27	WOS:A1992HR85400074
J	WILLIAMS, SE; ASHCOM, JD; ARGRAVES, WS; STRICKLAND, DK				WILLIAMS, SE; ASHCOM, JD; ARGRAVES, WS; STRICKLAND, DK			A NOVEL MECHANISM FOR CONTROLLING THE ACTIVITY OF ALPHA-2-MACROGLOBULIN RECEPTOR LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN - MULTIPLE REGULATORY SITES FOR 39-KDA RECEPTOR-ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-RECEPTOR; HEYMANN NEPHRITIS; APOLIPOPROTEIN-E; BINDING-PROTEIN; GLYCOPROTEIN; LIVER; PURIFICATION; COMPLEXES; AFFINITY; CLONING	The alpha-2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha-2MR/LRP) consists of two polypeptides, 515 and 85 kDa, that are noncovalently associated. A 39-kDa polypeptide, termed the receptor-associated protein (RAP), interacts with the 515-kDa subunit after biosynthesis of these molecules and remains associated on the cell surface. This molecule regulates ligand binding of alpha-2MR/LRP (Herz, J., Goldstein, J. L., Strickland, D. K., Ho, Y. K., and Brown, M. S. (1991) J. Biol. Chem. 266, 21232-21238). Titration and binding studies indica RAP binds to two equivalent binding sites on alpha-2MR/LRP, with a K(D) of 14 nm. Heterologous ligand displacement experiments demonstrated that RAP completely inhibits the binding of I-125-activated alpha-2M to human fibroblasts and to the purified alpha-2MR/LRP, with a K(i) of 23 and 26 nm, respectively. A direct correlation between the degree of binding of RAP to the receptor and the degree of ligand inhibition was observed, indicating that as the RAP binding sites are saturated, alpha-2MR/LRP loses its ability to bind ligands. Thus, the amount of RAP bound to alpha-2MR/LRP dictates the level of receptor activity. A model is proposed in which alpha-2MR/LRP contains multiple ligand binding sites, each regulated by a separate RAP site.	AMER RED CROSS,BIOCHEM LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855	American Red Cross					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030200, K04HL002113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30200, HL-02113] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BUSBY TF, 1988, BIOCHEMISTRY-US, V27, P6127, DOI 10.1021/bi00416a045; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; HALL PK, 1978, BIOCHEM J, V171, P27; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; ISAACS IJ, 1988, J BIOL CHEM, V263, P6709; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; JONES JM, 1972, BIOCHEM J, V127, P187, DOI 10.1042/bj1270187; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KAPLAN J, 1979, J BIOL CHEM, V254, P7323; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRAUSE J, 1974, EUR J BIOCHEM, V41, P593, DOI 10.1111/j.1432-1033.1974.tb03301.x; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MAXFIELD FR, 1981, BIOCHEMISTRY-US, V20, P5353, DOI 10.1021/bi00521a041; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STRAIGHT DL, 1988, BIOCHEMISTRY-US, V27, P2885, DOI 10.1021/bi00408a033; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	38	329	340	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9035	9040						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374383				2022-12-27	WOS:A1992HR85400052
J	CALI, JJ; BALCUEVA, EA; RYBALKIN, I; ROBISHAW, JD				CALI, JJ; BALCUEVA, EA; RYBALKIN, I; ROBISHAW, JD			SELECTIVE TISSUE DISTRIBUTION OF G-PROTEIN GAMMA-SUBUNITS, INCLUDING A NEW FORM OF THE GAMMA-SUBUNITS IDENTIFIED BY CDNA CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; BETA-SUBUNIT; REGULATORY COMPONENT; MOLECULAR-CLONING; RAS PROTEINS; AMINO-ACID; BRAIN; INHIBITION; DIVERSITY; RECEPTORS	The GTP-binding regulatory proteins (G proteins) that transduce signals from receptors to effectors are composed of alpha, beta, and gamma subunits. Whereas the role of alpha subunits in directly regulating effector activity is widely accepted, it has recently been demonstrated that betagamma subunits may also directly regulate effector activity. This has made clear the importance of identifying and characterizing beta and gamma subunits. We have isolated a cDNA clone encoding a new gamma subunit, referred to here as the gamma7 subunit, using probes based on peptide sequences of a gamma subunit previously purified from bovine brain. The clone contains a 1.47-kilobase cDNA insert, which includes an open reading frame of 204 base pairs that predicts a 68-amino acid polypeptide with a calculated M(r) of 7553. The predicted protein shares amino acid identities with the other known gamma subunits, ranging from 38 to 68%. Also characteristic of gamma subunits is a carboxyl-terminal CAAX motif. The expression of the gamma7 subunit as well as the gamma2, gamma3, and gamma5 subunits was examined in several bovine tissues at both the mRNA and protein levels. Whereas the gamma2 and gamma3 subunits were selectively expressed in brain, the gamma5 and gamma7 subunits were expressed in a variety of tissues. Thus, the gamma5 and gamma7 subunits are the first G protein gamma subunits known that could participate in the regulation of widely distributed signal transduction pathways.	RUSSIAN ACAD MED SCI,INST EXPTL CARDIOL,CARDIOL RES CTR,MOSCOW 121552,USSR	National Medical Research Center of Cardiology; Russian Academy of Medical Sciences	CALI, JJ (corresponding author), GEISINGER MED CLIN,WEIS CTR RES,DANVILLE,PA 17822, USA.				NIGMS NIH HHS [GM 39867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039867, R01GM039867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; CALI JJ, 1991, J BIOL CHEM, V266, P7779; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HAGA K, 1992, J BIOL CHEM, V267, P2222; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KATADA T, 1984, J BIOL CHEM, V259, P3578; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LOTERSZTAJN S, 1992, J BIOL CHEM, V267, P2375; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROBISHAW JD, 1992, BIOCHEM J, V286, P672; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; ROSS EM, 1978, J BIOL CHEM, V253, P6401; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	36	131	134	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24023	24027						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385432				2022-12-27	WOS:A1992JZ23900088
J	YEUNG, YG; BERG, KL; PIXLEY, FJ; ANGELETTI, RH; STANLEY, ER				YEUNG, YG; BERG, KL; PIXLEY, FJ; ANGELETTI, RH; STANLEY, ER			PROTEIN TYROSINE PHOSPHATASE-1C IS RAPIDLY PHOSPHORYLATED IN TYROSINE IN MACROPHAGES IN RESPONSE TO COLONY STIMULATING FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR; FACTOR-I; POLYACRYLAMIDE GELS; KINASE-ACTIVITY; RECEPTOR; PRODUCT; CSF-1; INTERNALIZATION; IDENTIFICATION; ACTIVATION	An approximately 64-kDa cytoplasmic protein is rapidly phosphorylated in tyrosine in the response of macrophages to colony stimulating factor-1. To identify this protein, BAC1.2F5 macrophages were incubated with or without colony stimulating factor-1, the phosphotyrosine-containing portion of their cytosolic fractions subjected to size exclusion chromatography, and the 45-70-kDa fraction further fractionated by reverse phase high pressure liquid chromatography (RP-HPLC). Tryptic peptides of pooled RP-HPLC fractions from stimulated cells (containing the approximately 64-kDa protein and an approximately 54-kDa protein) and from unstimulated cells (containing the approximately 54-kDa protein alone), were sequenced directly. All seven readable sequences of 8 sequenceable peptides present uniquely in the stimulated fraction were present in the sequence of the src homology 2 domain-containing protein tyrosine phosphatase-1C (PTP-1C). The identity of the approximately 64-kDa protein was confirmed by Western blotting with an antibody raised to a PTP-1C peptide. The rapid, growth factor-induced tyrosine phosphorylation of PTP-1C suggests that it may be involved in very early events in growth factor signal transduction.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,1300 MORRIS PK AVE,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine			Pixley, Fiona/ABD-5567-2020	Pixley, Fiona/0000-0002-1571-2532	NCI NIH HHS [P30-CA 1330, 2 T32 CA09173, CA 26504] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001330, R01CA026504, T32CA009173, R37CA026504] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baccarini M, 1991, Receptor, V1, P243; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153; HUHN RD, 1987, P NATL ACAD SCI USA, V84, P4408, DOI 10.1073/pnas.84.13.4408; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LI W, 1991, J BIOL CHEM, V266, P6808; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PERRIMON N, 1985, GENETICS, V111, P23; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RENLUND S, 1990, J CHROMATOGR, V512, P325, DOI 10.1016/S0021-9673(01)89499-1; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STJOHNSTON D, 1992, CELL, V68, P201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YEUNG YG, 1990, RECEPTOR PURIFICATIO, P315; YI T, 1992, BLOOD, V78, P2222; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	26	123	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23447	23450						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1385421				2022-12-27	WOS:A1992JZ23900004
J	ARGETSINGER, LS; SHAFER, JA				ARGETSINGER, LS; SHAFER, JA			THE REVERSIBLE AND IRREVERSIBLE AUTOPHOSPHORYLATIONS OF INSULIN-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; BETA-SUBUNIT; CYTOPLASMIC DOMAIN; DOWN-REGULATION; HUMAN-PLACENTA; PHOSPHORYLATION; ACTIVATION; BINDING; PURIFICATION; REPLACEMENT	When the catalytically active, tyrosyl-phosphorylated form of insulin receptor was isolated from human placenta and treated with ADP, only partial dephosphorylation was observed. This observation suggests the existence of two distinct classes of phosphotyrosyl residues of the phosphorylated insulin receptor: one in which the phosphoryl groups undergo reversible transfer to ADP and one in which they do not. There were 8.8 +/- 2.2 phosphorylation sites per tetrameric insulin receptor, of which 2.4 +/- 0.5 were irreversible (mean +/- S.D., n = 6). The reversible sites were determined to be equivalent and noninteracting and to have an equilibrium constant for the transfer of a phosphoryl group from ATP to a site of reversible phosphorylation of 8.7. Surprisingly, both phosphorylation and dephosphorylation at the reversible sites were relatively insensitive to the presence of insulin. Since only minimal autophosphorylation of insulin receptor was detected in the absence of insulin, the results suggest that the incorporation of phosphate into the two to three irreversible phosphorylation sites is insulin dependent. Phosphorylation of the irreversible phosphorylation sites then renders the insulin receptor relatively insensitive to the continued presence of insulin and facilitates rapid reversible phosphorylation of a second group of tyrosyl residues. The dependence of the degree of phosphorylation of insulin receptor on the ATP:ADP ratio may provide a mechanism for modulating the cellular response to insulin.	MERCK SHARP & DOHME LTD,WP 16-101,SUMNEYTOWN PIKE,W POINT,PA 19486; UNIV MICHIGAN,ANN ARBOR,MI 48109	Merck & Company; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20572] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BUTLER TM, 1980, HDB PHYSL 2, V2, P237; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CHERQUI G, 1990, J BIOL CHEM, V265, P21254; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COBB MH, 1989, J BIOL CHEM, V264, P18701; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FUKAMI Y, 1983, P NATL ACAD SCI-BIOL, V80, P1872, DOI 10.1073/pnas.80.7.1872; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARRISON LC, 1980, J BIOL CHEM, V255, P2066; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HUBLER L, 1989, J BIOL CHEM, V264, P1558; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KASUGA M, 1982, J BIOL CHEM, V257, P9891; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KEITT AS, 1966, AM J MED, V41, P762, DOI 10.1016/0002-9343(66)90036-2; KRISANDA JM, 1983, AM J PHYSIOL, V244, pC385, DOI 10.1152/ajpcell.1983.244.5.C385; KWOK YC, 1986, ARCH BIOCHEM BIOPHYS, V244, P102, DOI 10.1016/0003-9861(86)90098-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPAGE GA, 1968, MERCK INDEX, P20; MASSAGUE J, 1982, J BIOL CHEM, V257, P6729; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORGAN DO, 1987, BIOCHEMISTRY-US, V26, P2959, DOI 10.1021/bi00385a001; PANG DT, 1985, J BIOL CHEM, V260, P7131; PANG DT, 1984, J BIOL CHEM, V259, P8589; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; Penefsky H S, 1979, Methods Enzymol, V56, P527; PIKE LJ, 1986, J BIOL CHEM, V261, P3782; RAPUANO M, 1991, J BIOL CHEM, V266, P12902; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SHIZUTA Y, 1975, J BIOL CHEM, V250, P6891; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TUAZON PT, 1985, J CELL BIOCHEM, V28, P159, DOI 10.1002/jcb.240280208; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4	47	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22095	22101						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385393				2022-12-27	WOS:A1992JW71900020
J	PALFI, Z; BINDEREIF, A				PALFI, Z; BINDEREIF, A			IMMUNOLOGICAL CHARACTERIZATION AND INTRACELLULAR-LOCALIZATION OF TRANSSPLICEOSOMAL SMALL NUCLEAR RIBONUCLEOPROTEINS IN TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-SM AUTOANTIBODIES; SPLICED LEADER; PROTEIN-COMPONENTS; RNA GENES; U2; PURIFICATION; PARTICLES; SNRNPS; IDENTIFICATION; CONSTITUENTS	Polyclonal antibodies were raised against purified protein components of the U2 small nuclear ribonucleoprotein (snRNP) from Trypanosoma brucei. Through immunoblot and immunoprecipitation analyses three antisera were characterized that reacted specifically with U2 snRNP proteins of molecular weights 40,000 (anti-40K) and 16,500 (anti-16.5K), and with each of four proteins of molecular weights 14,000, 12,500, 10,000, and 8,500 (anti-CP). Anti-40K antibodies specifically immunoprecipitated the U2 snRNP from trypanosomal extracts, whereas anti-CP antibodies recognized several snRNPs, including the SL RNP and the U2 and U4/U6 snRNPs; in addition, minor RNAs were detected, suggesting that a family of snRNPs with common or related protein components exists in trypanosomes. None of these antibodies cross-reacted significantly with total mammalian snRNP proteins, indicating that the trypanosomal snRNP proteins are immunologically distinct from their mammalian counterparts. Using immunofluorescence microscopy, the snRNP proteins exhibited a differential cellular distribution. Whereas the 40-kDa protein is localized exclusively in the nucleus, with the nucleolus being excluded, a fraction of the common proteins also resides in the cytoplasm.	MAX PLANCK INST MOLEC GENET, OTTO WARBURG LAB, IHNESTR 73, W-1000 BERLIN 33, GERMANY	Max Planck Society								AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BRUN R, 1979, ACTA TROP, V36, P289; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS M, 1991, MOL CELL BIOL, V11, P5516, DOI 10.1128/MCB.11.11.5516; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUNZL A, 1992, MOL CELL BIOL, V12, P468; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; LEHMEIER T, 1990, NUCLEIC ACIDS RES, V18, P6475, DOI 10.1093/nar/18.22.6475; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; PALFI Z, 1989, NUCLEIC ACIDS RES, V17, P1445, DOI 10.1093/nar/17.4.1445; REUTER R, 1984, EXP CELL RES, V154, P548, DOI 10.1016/0014-4827(84)90179-4; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; SILICIANO PG, 1987, SCIENCE, V237, P1484, DOI 10.1126/science.3306922; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TOLLERVEY D, 1987, EMBO J, V6, P469, DOI 10.1002/j.1460-2075.1987.tb04777.x; TSCHUDI C, 1986, NUCLEIC ACIDS RES, V14, P8893, DOI 10.1093/nar/14.22.8893; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; TSCHUDI C, 1988, NUCLEIC ACIDS RES, V16, P11375, DOI 10.1093/nar/16.23.11375; VANDOREN K, 1988, NATURE, V335, P556; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153	31	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20159	20163						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400334				2022-12-27	WOS:A1992JR85800066
J	STEINBERG, TH; BURGESS, RR				STEINBERG, TH; BURGESS, RR			TAGETITOXIN INHIBITION OF RNA POLYMERASE-III TRANSCRIPTION RESULTS FROM ENHANCED PAUSING AT DISCRETE SITES AND IS TEMPLATE-DEPENDENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENES; U6; INVITRO; COMPLEXES; ELEMENTS	In yeast nuclear extracts, tagetitoxin inhibition of RNA Polymerase III promoter-directed single- and multiple-round transcription is characterized by pausing or stalling of the elongation complex at several discrete points on the template. Paused ternary complexes isolated from tagetitoxin-inhibited reactions can be elongated to produce full-length RNA. The distribution of "tagetitoxin-enhanced" pause sites is distinct for each of the class III genes we have examined. These tagetitoxin-enhanced pause sites may also be intrinsic pause sites for the elongation complex. Tagetitoxin inhibition of in vitro transcription of the yeast SUP4 and SUP6 tRNA(Tyr) genes demonstrates template dependence and indicates that inhibition may occur after UMP incorporation. Factor-independent transcription by purified yeast RNA polymerase III can also be inhibited by tagetitoxin, and the degree of inhibition is template-dependent. Tagetitoxin may be most effective as an inhibitor under conditions where polymerase III tends to pause on the template. We propose that differences in tagetitoxin inhibition among class III genes may reflect differences in the number and stability of these pause sites.	UNIV WISCONSIN,MCARDLE LAB CANC RES,DEPT ONCOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Burgess, Richard/0000-0001-9545-3165	NATIONAL CANCER INSTITUTE [P01CA023076, P30CA007175, T32CA009135] Funding Source: NIH RePORTER; NCI NIH HHS [CA-23076, CA-07175, CA-09135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRAND JR, 1982, J VIROL, V41, P376, DOI 10.1128/JVI.41.2.376-389.1982; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BROW DA, 1987, J BIOL CHEM, V262, P13959; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; EVANS CF, 1990, METHOD ENZYMOL, V181, P439; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GRONDAL EJM, 1989, EMBO J, V8, P3383, DOI 10.1002/j.1460-2075.1989.tb08502.x; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; JAT P, 1982, NUCLEIC ACIDS RES, V10, P3407, DOI 10.1093/nar/10.11.3407; JIN DJ, 1991, J BIOL CHEM, V266, P14478; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KOCK J, 1991, MOL MICROBIOL, V5, P835, DOI 10.1111/j.1365-2958.1991.tb00756.x; KROL A, 1987, NUCLEIC ACIDS RES, V15, P2463, DOI 10.1093/nar/15.6.2463; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LUKENS JH, 1985, PLANTA, V165, P311, DOI 10.1007/BF00392227; MATHEWS DE, 1990, J BIOL CHEM, V265, P493; MATHEWS DE, 1988, THESIS U WISCONSINMA; MITCHELL RE, 1989, TETRAHEDRON LETT, V30, P501, DOI 10.1016/S0040-4039(00)95239-0; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; REDDY R, 1988, J BIOL CHEM, V263, P15980; SCHULTZ LD, 1976, P NATL ACAD SCI USA, V73, P1029, DOI 10.1073/pnas.73.4.1029; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; VALENZUELA P, 1976, P NATL ACAD SCI USA, V73, P1024, DOI 10.1073/pnas.73.4.1024; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x	33	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20204	20211						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400338				2022-12-27	WOS:A1992JR85800073
J	TSURUDOME, M; GLUCK, R; GRAF, R; FALCHETTO, R; SCHALLER, U; BRUNNER, J				TSURUDOME, M; GLUCK, R; GRAF, R; FALCHETTO, R; SCHALLER, U; BRUNNER, J			LIPID INTERACTIONS OF THE HEMAGGLUTININ HA2 NH2-TERMINAL SEGMENT DURING INFLUENZA VIRUS-INDUCED MEMBRANE-FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL-ELECTROPHORESIS; INDUCED CONFORMATIONAL CHANGE; RAPID EXTRUSION PROCEDURE; LOW-PH; PROTEIN; ECTODOMAIN; VESICLES; SUBUNIT; PEPTIDE; SITE	Fusion of influenza viruses with target membranes is induced by acid and involves complex changes in the viral fusion protein hemagglutinin (HA) and in the contact sites between viruses and target membranes (Stegmann, T., White, J. M., and Helenius, A. (1990) EMBO J. 9,4231-4241). At 0-degrees-C, in a first, kinetically distinct step, target membranes irreversibly adhere to the viruses. Fusion itself starts only after a lag-phase of several minutes (X-31 strain viruses) or after raising the temperature (PR8/34 strain viruses). We now provide evidence that the initial conformational change resulting in virus-target membrane adhesion is restricted to a (minor) subpopulation of the HA molecules. These molecules become susceptible to bromelain digestion, and they could be labeled with the photoactivatable reagent [H-3]PTPC/11, a nonexchangeable lipid present in the target lipid bilayer (Harter, C., Bachi, T., Semenza, G., and Brunner, J. (1988) Biochemistry 27, 1856-1864). Only the HA2 subunit was labeled, and analyses of 2-nitro-5-thio-cyanobenzoic acid fragments derived thereof indicate that the HA2 NH2-terminal segment (fusion peptide) inserted into the target membrane bilayer. When the temperature was raised to trigger fusion of PR8/34 viruses, labeling of HA2 increased by a factor of 130. Most (74%) of that label was incorporated into the COOH-terminal membrane anchor region, but there was also a strong increase (about 30-fold) of NH2-terminal fusion peptide labeling. This suggests that fusion is preceded., or accompanied, by further changes in HA which lead to additional extensive lipid insertions of HA2 fusion peptides.	SWISS FED INST TECHNOL, DEPT BIOCHEM, UNIV STR 16, CH-8092 ZURICH, SWITZERLAND; SWISS SERUM & VACCINE INST, CH-3021 BERN, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BENTZ J, 1990, FEBS LETT, V276, P1, DOI 10.1016/0014-5793(90)80492-2; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; BRUNNER J, 1989, METHOD ENZYMOL, V172, P628; BRUNNER J, 1991, BIOCHEMISTRY-US, V30, P2432, DOI 10.1021/bi00223a019; BRUNNER J, 1979, J BIOL CHEM, V254, P1821; DOMS RW, 1985, J BIOL CHEM, V260, P2973; GERHARD W, 1976, J EXP MED, V144, P985, DOI 10.1084/jem.144.4.985; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; HARTER C, 1989, J BIOL CHEM, V264, P6459; HARTER C, 1988, BIOCHEMISTRY-US, V27, P1856, DOI 10.1021/bi00406a010; HELM CA, 1989, SCIENCE, V246, P919, DOI 10.1126/science.2814514; HIRANO H, 1990, ELECTROPHORESIS, V11, P573, DOI 10.1002/elps.1150110708; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAW JM, 1979, BIOCHEMISTRY-US, V18, P538, DOI 10.1021/bi00570a024; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1987, J BIOL CHEM, V262, P17744; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; Wilschut J., 1990, MEMBRANE FUSION; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WINTER G, 1981, NATURE, V292, P72, DOI 10.1038/292072a0	33	137	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20225	20232						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400340				2022-12-27	WOS:A1992JR85800076
J	SMITH, PL; SKELTON, TP; FIETE, D; DHARMESH, SM; BERANEK, MC; MACPHAIL, L; BROZE, GJ; BAENZIGER, JU				SMITH, PL; SKELTON, TP; FIETE, D; DHARMESH, SM; BERANEK, MC; MACPHAIL, L; BROZE, GJ; BAENZIGER, JU			THE ASPARAGINE-LINKED OLIGOSACCHARIDES ON TISSUE FACTOR PATHWAY INHIBITOR TERMINATE WITH SO4-4GALNAC-BETA-1,4GLCNAC-BETA-1,2MAN-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PITUITARY GLYCOPROTEIN HORMONES; COAGULATION INHIBITOR; SIALYLATED OLIGOSACCHARIDES; ANIONIC OLIGOSACCHARIDES; STRUCTURAL ELUCIDATION; BOVINE LUTROPIN; LIPOPROTEIN; FOLLITROPIN; THYROTROPIN	Tissue factor pathway inhibitor (TFPI) produced by endothelial cells contains sulfated Asn-linked oligosaccharides. We have determined that >70% of the oligosaccharides on recombinant TFPI expressed in 293 cells terminate with the sequence SO4-4GalNAcbeta1, 4GlcNAcbeta1,2Manalpha. Oligosaccharides terminating with this sequence have previously been described on lutropin, thyrotropin, and pro-opiomelanocortin. glycoproteins synthesized in the anterior pituitary. A GalNAc-transferase that recognizes the tripeptide motif Pro-Xaa-Arg/Lys 6-9 residues N-terminal to Asn glycosylation sites accounts for the specific addition of GalNAc to the oligosaccharide acceptor on these glycoproteins, whereas a GalNAcbeta1,4GlcNAcbeta1,2Manalpha-4-sulfotransferase accounts for the addition of sulfate. The sulfated oligosaccharides present on these hormones are responsible for their rapid clearance from plasma by a receptor in hepatic reticuloendothelial cells. GalNAc- and sulfotransferase activities with the same properties as those expressed in the pituitary are detected at high levels in 293 cells and at lower levels in endothelial cells. Chinese hamster ovary (CHO) cells do not contain detectable levels of either transferase and rTFPI expressed in CHO cells does not contain sulfated Asn-linked oligosaccharides. TFPI contains the sequence Pro-Phe-Lys, 9 residues N-terminal to the glycosylation site at position 228; this tripeptide may act as the recognition sequence for the GalNAc-transferase. rTFPI produced by 293 cells, but not that produced by CHO cells, is bound by the receptor on hepatic reticuloendothelial cells suggesting the sulfated structures play a role in the biologic behavior of TFPI.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,DEPT HEMATOL ONCOL,ST LOUIS,MO 63110	Washington University (WUSTL); Barnes-Jewish Hospital			Baenziger, Jacques U/E-9430-2012		NATIONAL CANCER INSTITUTE [R37CA021923] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA21923] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BAJAJ MS, 1990, P NATL ACAD SCI USA, V87, P8869, DOI 10.1073/pnas.87.22.8869; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BROZE GJ, 1987, BLOOD, V69, P150; COLBURN P, 1988, IN VITRO CELL DEV B, V24, P1133; DAY KC, 1990, BLOOD, V76, P1538; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; GREEN ED, 1986, ANAL BIOCHEM, V158, P42, DOI 10.1016/0003-2697(86)90585-3; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; NOVOTNY WF, 1988, BLOOD, V72, P2020; NOVOTNY WF, 1991, BLOOD, V78, P387; NOVOTNY WF, 1989, J BIOL CHEM, V264, P18832; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; SANDERS NL, 1985, BLOOD, V66, P204; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1990, J BIOL CHEM, V265, P874; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; WARNCRAMER BJ, 1991, THROMB RES, V61, P515, DOI 10.1016/0049-3848(91)90159-T; WESSELSCHMIDT R, 1992, IN PRESS BLOOD; WUN TC, 1988, J BIOL CHEM, V263, P6001	35	73	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19140	19146						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388166				2022-12-27	WOS:A1992JP59300023
J	ZACHARY, I; SINNETTSMITH, J; ROZENGURT, E				ZACHARY, I; SINNETTSMITH, J; ROZENGURT, E			BOMBESIN, VASOPRESSIN, AND ENDOTHELIN STIMULATION OF TYROSINE PHOSPHORYLATION IN SWISS 3T3 CELLS - IDENTIFICATION OF A NOVEL TYROSINE KINASE AS A MAJOR SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL TRANSDUCTION; STABLE ASSOCIATION; DNA-SYNTHESIS; PROTEINS; NEUROPEPTIDES; RECEPTORS; PATHWAYS; PP60SRC; GROWTH	Neuropeptide-stimulated tyrosine phosphorylation of specific components in Swiss 3T3 cells was investigated using monoclonal antibodies directed against the src transformation-associated substrates p125 focal adhesion kinase (FAK), a novel type of cytosolic tyrosine kinase, and p130. Treatment of Swiss 3T3 cells with the mitogenic peptides bombesin, vasopressin, and endothelin caused a striking increase in the tyrosine phosphorylation of p125FAK, as judged either by anti-phosphotyrosine (anti-Tyr(P)) Western blots of anti-p125FAK immunoprecipitates, or by anti-p125FAK immunoblots of anti-Tyr(P) immunoprecipitates. Bombesin-stimulated tyrosine phosphorylation of p125FAK was detectable within seconds and concentration-dependent (half-maximum effect of 0.3 nM). Neuropeptides also stimulated the tyrosine phosphorylation of a second component of M(r) 130,000, previously identified as the major p130 phosphotyrosyl protein in src-transformed cells. Bombesin stimulated p130 tyrosine phosphorylation with kinetics and concentration dependence similar to those observed for p125FAK. This is the first report to identify substrates for neuropeptide-stimulated tyrosine phosphorylation; the finding that one of these substrates is a tyrosine kinase suggests the existence of a novel signal transduction pathway in the action of mitogenic neuropeptides.	IMPERIAL CANC RES FUND,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; FABREGAT I, 1990, BIOCHEM BIOPH RES CO, V167, P161, DOI 10.1016/0006-291X(90)91745-E; FORCE T, 1991, J BIOL CHEM, V266, P6650; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROZENGURT E, 1979, P NATL ACAD SCI USA, V76, P1284, DOI 10.1073/pnas.76.3.1284; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	18	325	326	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19031	19034						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1382065				2022-12-27	WOS:A1992JP59300003
J	BIRD, GS; OBIE, JF; PUTNEY, JW				BIRD, GS; OBIE, JF; PUTNEY, JW			FUNCTIONAL HOMOGENEITY OF THE NONMITOCHONDRIAL CA2+ POOL IN INTACT MOUSE LACRIMAL ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM POOL; INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; EXOCRINE PANCREAS; NONMUSCLE CELLS; CA-2+ RELEASE; 2ND MESSENGER; HEPATOCYTES; TRISPHOSPHATE; OSCILLATIONS	In the absence of extracellular Ca2+, treatment of mouse lacrimal acinar cells with maximal concentrations of methacholine released Ca2+ from intracellular stores. No additional Ca2+ was mobilized by subsequent application of the intracellular Ca2+-ATPase inhibitor, thapsigargin, the stable inositol 1,4,5-trisphosphate ((1,4,5)IP3) analog, inositol 2,4,5-trisphosphate ((2,4,5)IP3) (by microinjection), or the Ca2+ ionophore, ionomycin. However, following prolonged activation of cells by methacholine in the presence of extracellular Ca2+, Ca2+ accumulated into a pool which was released by ionomycin but not by thapsigargin. This latter accumulation was blocked by prior microinjection of ruthenium red, indicating that it represents mitochondrial uptake. In saponin-permeabilized lacrimal cells, two Ca2+-sequestering pools were detected: (i) a ruthenium red-sensitive, thapsigargin-insensitive pool, presumed to be the mitochondria; and (ii) a ruthenium red-insensitive, thapsigargin-sensitive pool. Only the thapsigargin-sensitive pool accumulated Ca2+ at concentrations similar to those in unstimulated cells. The thapsigargin-sensitive Ca2+ pool was sensitive to (1,4,5)IP3; however, in contrast to findings in intact cells, only 44% of this pool was releasable by (1,4,5)IP3 or (2,4,5)IP3. These data indicate that, in intact lacrimal acinar cells, all exchangeable (ionomycin-sensitive) Ca2+ resides in a pool which responds homogeneously to agonists, (1,4,5)IP3, and thapsigargin. Prolonged elevation of [Ca2+]i results in Ca2+ accumulation into a second, ruthenium red-sensitive pool, presumably mitochondria. Finally, permeabilization of the cells fragments the non-mitochondrial pool, resulting in two pools, one sensitive and one insensitive to (1,4,5)IP3.			BIRD, GS (corresponding author), NIEHS, CELLULAR & MOLEC PHARMACOL LAB, CALCIUM REGULAT SECT, POB 12233, RES TRIANGLE PK, NC 27709 USA.		Bird, Gary/AAI-8186-2021; Putney, James/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James/0000-0002-3379-4789				BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BLAUSTEIN MP, 1980, J PHYSIOLOGY PARIS, V76, P459; BURGESS GM, 1984, NATURE, V309, P63, DOI 10.1038/309063a0; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12, P61, DOI 10.1016/0143-4160(91)90008-3; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; POGGIOLI J, 1982, PFLUG ARCH EUR J PHY, V392, P239, DOI 10.1007/BF00584303; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SCHULZ I, 1989, CELL CALCIUM, V10, P325, DOI 10.1016/0143-4160(89)90058-4; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; STOLZE H, 1980, AM J PHYSIOL, V238, pG338, DOI 10.1152/ajpgi.1980.238.4.G338; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; THOMAS AP, 1988, J BIOL CHEM, V263, P2704; UEDA T, 1986, J BIOL CHEM, V261, P3184; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; ZHAO H, 1990, J BIOL CHEM, V265, P21419	32	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18382	18386						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382054				2022-12-27	WOS:A1992JN50200025
J	ASHER, C; EREN, R; KAHN, L; YEGER, O; GARTY, H				ASHER, C; EREN, R; KAHN, L; YEGER, O; GARTY, H			EXPRESSION OF THE AMILORIDE-BLOCKABLE NA+ CHANNEL BY RNA FROM CONTROL VERSUS ALDOSTERONE-STIMULATED TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE-VESICLES; SODIUM-TRANSPORT; XENOPUS OOCYTES; ION-TRANSPORT; TOAD BLADDER; MECHANISMS; A6; EPITHELIA; INCREASES; CELLS	The amiloride-blockable Na+ channel was expressed in Xenopus oocytes injected with total RNA isolated from the toad urinary bladder. This system was used to investigate mechanisms that mediate the natriferic action of aldosterone. Incubation of the epithelium with aldosterone for 3 h doubled its channel activity but did not increase the ability of isolated RNA to express functional channels in oocytes. A 20-h incubation with the hormone produced an additional increase of Na+ transport across the intact epithelium and also augmented the channel activity expressed in oocytes by nearly 10-fold. The data are in agreement with our model that aldosterone enhances the apical Na+ permeability of tight epithelia by a short term activation of pre-existing channels, followed by chronic induction of new channel protein. Blocking methyl transfer reactions, previously shown to inhibit the natriferic action of aldosterone in tight epithelia, did not alter the basal or aldosterone-induced response in oocytes.			ASHER, C (corresponding author), WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL.							ASHER C, 1992, AM J PHYSIOL, V262, pG244, DOI 10.1152/ajpgi.1992.262.2.G244; ASHER C, 1988, P NATL ACAD SCI USA, V85, P7413, DOI 10.1073/pnas.85.19.7413; BENOS DJ, 1991, COLLOQ INSE, V215, P261; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVAN MM, 1990, METHOD ENZYMOL, V192, P683; EDELMAN IS, 1963, P NATL ACAD SCI USA, V50, P1169, DOI 10.1073/pnas.50.6.1169; EREN R, 1987, CELL IMMUNOL, V108, P76, DOI 10.1016/0008-8749(87)90194-8; FORMAN BH, 1975, HDB PHYSL          7, V6, P179; GARTY H, 1983, J GEN PHYSIOL, V81, P785, DOI 10.1085/jgp.81.6.785; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GARTY H, 1986, J MEMBRANE BIOL, V90, P193, DOI 10.1007/BF01870126; GARTY H, 1987, STEROL STEROID HORMO, P287; GEORGE AL, 1989, P NATL ACAD SCI USA, V86, P7295, DOI 10.1073/pnas.86.18.7295; HINTON CF, 1989, AM J PHYSIOL, V257, pC825, DOI 10.1152/ajpcell.1989.257.4.C825; KEMENDY A, 1990, FASEB Journal, V4, pA445; KIPNOWSKI J, 1983, AM J PHYSIOL, V245, pF726, DOI 10.1152/ajprenal.1983.245.6.F726; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MARCUSSEKURA CJ, 1987, METHOD ENZYMOL, V152, P284; OHLSSON RI, 1981, EUR J BIOCHEM, V115, P367, DOI 10.1111/j.1432-1033.1981.tb05247.x; Palmer L G, 1981, Ann N Y Acad Sci, V372, P1, DOI 10.1111/j.1749-6632.1981.tb15453.x; PALMER LG, 1990, J GEN PHYSIOL, V96, P23, DOI 10.1085/jgp.96.1.23; PORTER GA, 1964, P NATL ACAD SCI USA, V52, P1326, DOI 10.1073/pnas.52.6.1326; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SARIBANSOHRABY S, 1984, J BIOL CHEM, V259, P1221; STANTON BA, 1985, FED PROC, V44, P2717; TOUSSON A, 1989, J CELL SCI, V93, P349; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43	30	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16061	16065						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379590				2022-12-27	WOS:A1992JJ45800014
J	SESSA, WC; HARRISON, JK; BARBER, CM; ZENG, D; DURIEUX, ME; DANGELO, DD; LYNCH, KR; PEACH, MJ				SESSA, WC; HARRISON, JK; BARBER, CM; ZENG, D; DURIEUX, ME; DANGELO, DD; LYNCH, KR; PEACH, MJ			MOLECULAR-CLONING AND EXPRESSION OF A CDNA-ENCODING ENDOTHELIAL-CELL NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RELAXING FACTOR; DEPENDENT RELAXATION; SMOOTH-MUSCLE; RABBIT AORTA; PURIFICATION; REDUCTASE; ACETYLCHOLINE; PARTICULATE; PROTEINS; INVITRO	Endothelium-derived relaxing factor (EDRF), identified as nitric oxide (NO), is derived from a guanidino nitrogen Of L-arginine via its metabolism by nitric oxide synthase (NOS). Herein, we report the molecular cloning of a cDNA encoding the constitutive calcium-calmodulin (Ca2+/CaM)-regulated nitric oxide synthase (ECNOS). A full-length ECNOS clone was isolated by screening a bovine aortic endothelial cell cDNA library using a fragment of rat brain NOS (bNOS) cDNA. This cDNA has an open reading frame of 3615 nucleotides encoding a 1205-amino acid protein. Membranes prepared from COS cells transfected with the ECNOS cDNA demonstrated NADPH- and Ca2+/CaM- dependent conversion Of L-, but not D-, arginine to NO and citrulline that was inhibited by N(G)-nitro-L-arginine methyl ester. Comparison of the deduced amino acid sequence of ECNOS to the bNOS and macrophage NOS (Mac-NOS) sequences revealed 57 and 50% identity, respectively. In addition, ECNOS contains a unique N-myristylation consensus sequence (not shared by bNOS or Mac-NOS) that may explain its membrane localization.	UNIV VIRGINIA,SCH MED,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT ANESTHESIOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia	SESSA, WC (corresponding author), UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908, USA.		Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Durieux, Marcel/0000-0003-1479-7666	NHLBI NIH HHS [P01 HL19242, F32 HL07355, F32 HL08223] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008223, P01HL019242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARDINER SM, 1990, HYPERTENSION, V15, P486, DOI 10.1161/01.HYP.15.5.486; JAYAKODY RL, 1985, CAN J PHYSIOL PHARM, V63, P1206, DOI 10.1139/y85-199; JOHNS RA, 1990, CIRC RES, V67, P979, DOI 10.1161/01.RES.67.4.979; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KONISHI M, 1983, HYPERTENSION, V5, P881, DOI 10.1161/01.HYP.5.6.881; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; MONCADA S, 1991, PHARMACOL REV, V43, P109; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; VANBENTHUYSEN KM, 1987, J CLIN INVEST, V79, P265, DOI 10.1172/JCI112793; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; Winquist R J, 1984, J Hypertens, V2, P541, DOI 10.1097/00004872-198410000-00015; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	35	454	477	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15274	15276						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379225				2022-12-27	WOS:A1992JG11300005
J	DAY, CL; STOWELL, KM; BAKER, EN; TWEEDIE, JW				DAY, CL; STOWELL, KM; BAKER, EN; TWEEDIE, JW			STUDIES OF THE N-TERMINAL HALF OF HUMAN LACTOFERRIN PRODUCED FROM THE CLONED CDNA DEMONSTRATE THAT INTERLOBE INTERACTIONS MODULATE IRON RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL BRUSH-BORDER; HUMAN-SERUM TRANSFERRIN; HUMAN LACTOTRANSFERRIN; BINDING SITE; RESOLUTION; FRAGMENTS; PROTEINS; APOLACTOFERRIN; OVOTRANSFERRIN; EXPRESSION	The factors influencing iron binding and release by lactoferrin have been addressed by comparison of the native full length molecule (Lf) with the N-terminal half of human lactoferrin (Lf(N)) produced from the cloned cDNA expressed in baby hamster kidney (BHK) cells. The coding sequences for Lf(N) were inserted into the expression vector pNUT between the metallothionein promoter and the human growth hormone transcription termination sequences. Transformed BHK cells were grown in roller bottles where concentrations of Lf(N) as high as 35 mg/liter were obtained. The pure protein, produced by the transformed BHK cells, was characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, protein blotting and immunodetection, N-terminal sequence analysis, UV-visible spectroscopy, electron spin resonance spectroscopy, and measurements of metal binding and release. By these criteria Lf(N) was found to be correctly processed, glycosylated, and able to bind iron reversibly. Both UV-visible and electron spin resonance spectra of the half molecule were very similar to those of native lactoferrin and the full length lactoferrin produced in BHK cells, but there were marked differences in the pH at which iron release occurred. Iron release from Lf(N) occurs in the pH range 6.0-4.0, compared with 4.0-2.5 for native lactoferrin and 6.2-4.0 for transferrin. These results suggest that the more facile release of iron from Lf(N) compared with native lactoferrin results from the absence of stabilizing contacts between the N- and C-terminal halves and that the characteristic difference in pH stability between lactoferrins and transferrins is due primarily to differences in these interactions.	MASSEY UNIV,DEPT CHEM & BIOCHEM,PALMERSTON NORTH,NEW ZEALAND	Massey University				Day, Catherine/0000-0003-1571-4367; Baker, Edward/0000-0003-2456-7661	NICHD NIH HHS [HD-20859] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020859] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AINSCOUGH EW, 1980, BIOCHEMISTRY-US, V19, P4072, DOI 10.1021/bi00558a026; AINSCOUGH EW, 1983, J INORG BIOCHEM, V18, P103, DOI 10.1016/0162-0134(83)80014-2; AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; AISEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P314, DOI 10.1016/0005-2795(72)90283-8; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANDERSON BF, 1987, P NATL ACAD SCI USA, V84, P1769, DOI 10.1073/pnas.84.7.1769; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; ARNOLD RR, 1977, SCIENCE, V197, P263, DOI 10.1126/science.327545; BAGGIOLINI M, 1970, Journal of Experimental Medicine, V131, P559, DOI 10.1084/jem.131.3.559; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BALI PK, 1991, BIOCHEMISTRY-US, V30, P9947, DOI 10.1021/bi00105a019; BIRGENS HS, 1983, SCAND J HAEMATOL, V34, P383; BLUARDDECONINCK JM, 1978, BIOCHEM J, V171, P321, DOI 10.1042/bj1710321; BROCK JH, 1985, METALLOPROTEINS 2, P183; BROWNMASON A, 1984, J BIOL CHEM, V259, P1866; BROXMEYER HE, 1978, J EXP MED, V148, P1052, DOI 10.1084/jem.148.4.1052; CHASTEEN ND, 1983, ADV INORG BIOCHEM, V5, P201; COX TM, 1979, BIOCHIM BIOPHYS ACTA, V588, P120, DOI 10.1016/0304-4165(79)90377-5; DAVIDSON LA, 1988, AM J PHYSIOL, V254, pG580, DOI 10.1152/ajpgi.1988.254.4.G580; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; FLETCHER J, 1968, NATURE, V218, P1211, DOI 10.1038/2181211a0; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P1654, DOI 10.1021/bi00458a043; HU WL, 1988, BIOCHEM J, V249, P435, DOI 10.1042/bj2490435; HU WL, 1990, BIOCHEMISTRY-US, V29, P535, DOI 10.1021/bi00454a030; IKEDA H, 1985, FEBS LETT, V182, P305, DOI 10.1016/0014-5793(85)80321-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRAND D, 1984, BIOCHIM BIOPHYS ACTA, V787, P90, DOI 10.1016/0167-4838(84)90111-0; LEGRAND D, 1990, BIOCHEM J, V266, P575; LEGRAND D, 1986, BIOCHEM J, V236, P839, DOI 10.1042/bj2360839; LINEBACKZINS J, 1980, J BIOL CHEM, V255, P708; LONNERDAL B, 1976, AM J CLIN NUTR, V29, P1127; MASSON PL, 1966, CLIN CHIM ACTA, V14, P735, DOI 10.1016/0009-8981(66)90004-0; MAZURIER J, 1980, BIOCHIM BIOPHYS ACTA, V629, P399, DOI 10.1016/0304-4165(80)90112-9; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; NORRIS GE, 1989, J MOL BIOL, V209, P329, DOI 10.1016/0022-2836(89)90283-0; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; Parry R M Jr, 1974, Adv Exp Med Biol, V48, P141; REITER B, 1983, INT J TISSUE REACT, V5, P87; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; Sambrook J, 1989, MOL CLONING LABORATO; STOWELL KM, 1991, BIOCHEM J, V276, P349, DOI 10.1042/bj2760349; TSUDA E, 1988, BIOCHEMISTRY-US, V27, P5646, DOI 10.1021/bi00415a038; VANSNICK JL, 1976, J EXP MED, V144, P1568, DOI 10.1084/jem.144.6.1568; WEINBERG ED, 1974, SCIENCE, V184, P952, DOI 10.1126/science.184.4140.952; WILLIAMS J, 1988, BIOCHEM J, V251, P849, DOI 10.1042/bj2510849; WOODWORTH RC, 1991, BIOCHEMISTRY-US, V30, P10824, DOI 10.1021/bi00109a002; ZAK O, 1985, BIOCHIM BIOPHYS ACTA, V829, P348, DOI 10.1016/0167-4838(85)90243-2	48	71	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13857	13862						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378432				2022-12-27	WOS:A1992JD32500014
J	WIEDERANDERS, B; BROMME, D; KIRSCHKE, H; VONFIGURA, K; SCHMIDT, B; PETERS, C				WIEDERANDERS, B; BROMME, D; KIRSCHKE, H; VONFIGURA, K; SCHMIDT, B; PETERS, C			PHYLOGENETIC CONSERVATION OF CYSTEINE PROTEINASES - CLONING AND EXPRESSION OF A CDNA CODING FOR HUMAN CATHEPSIN-S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; BOVINE SPLEEN; CELLS; NUCLEOTIDE; FIBROBLASTS; INHIBITORS; GENE	A 1.8-kilobase full-length cDNA of human cathepsin S, a lysosomal cysteine proteinase, has been isolated. The single long open reading frame encodes a polypeptide of 331 amino acids consisting of a 15-amino acid NH2-terminal signal peptide, a propeptide of 99 amino acids, and a mature polypeptide of 217 amino acids. The deduced amino acid sequence contains only one potential N-glycosylation site located in the propeptide. The NH2-terminal amino acid sequence of the mature polypeptide was confirmed by sequencing cathepsin S purified from human spleen. The cDNA detects a 1.9-kilobase transcript in poly(A)+ RNA from human fibroblasts. Expression of human cathepsin S in transfected baby hamster kidney cells resulted in up to more than 300-fold cathepsin S activity as compared to untransfected controls. In the expressing baby hamster kidney cells, human cathepsin S is transported to the lysosomes via the mannose 6-phosphate receptor pathway as shown by density gradient centrifugation, immunofluorescence, and detection of the 37-kDa cathepsin S precursor in the medium in the presence of NH4Cl. The deduced amino acid sequence of human cathepsin S exhibits a substantial degree of similarity with other human cysteine proteinases and papain indicating that they have a common ancestral gene and are members of a gene family.	MARTIN LUTHER UNIV,INST PHYSIOL CHEM,O-4020 HALLE,GERMANY; UNIV GOTTINGEN,INST BIOCHEM 2,W-3400 GOTTINGEN,GERMANY	Martin Luther University Halle Wittenberg; University of Gottingen								ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; Baker E.N., 1987, BIOL MACROMOL, V3, P314; BARRETT AJ, 1972, LYSOSOMES LABORATORY, P116; BAUDYS M, 1990, BIOL CHEM H-S, V371, P485, DOI 10.1515/bchm3.1990.371.1.485; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BROMME D, 1989, BIOCHEM J, V264, P475; BROMME D, 1991, BIOMED BIOCHIM ACTA, V50, P631; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; FUCHS R, 1989, NUCLEIC ACIDS RES, V17, P9471, DOI 10.1093/nar/17.22.9471; FUCHS R, 1988, BIOL CHEM H-S, V369, P469, DOI 10.1515/bchm3.1988.369.1.469; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; KIRSCHKE H, 1986, BIOCHEM J, V240, P455, DOI 10.1042/bj2400455; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; PETERS CWB, 1987, EMBO J, V6, P1170; PRAEKELT UM, 1988, PLANT MOL BIOL, V10, P193, DOI 10.1007/BF00027396; RITONJA A, 1985, FEBS LETT, V181, P169, DOI 10.1016/0014-5793(85)81136-4; RITONJA A, 1988, FEBS LETT, V228, P341, DOI 10.1016/0014-5793(88)80028-0; RITONJA A, 1991, FEBS LETT, V283, P329, DOI 10.1016/0014-5793(91)80620-I; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKETA K, 1987, ELECTROPHORESIS, V8, P409, DOI 10.1002/elps.1150080908; TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; VINGRON M, 1989, COMPUT APPL BIOSCI, V5, P115; VONFIGURA K, 1983, P NATL ACAD SCI-BIOL, V80, P6066; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WIEDERANDERS B, 1991, FEBS LETT, V286, P189, DOI 10.1016/0014-5793(91)80971-5; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	37	85	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13708	13713						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377692				2022-12-27	WOS:A1992JB74600096
J	TAYLOR, DB; GARTNER, TK				TAYLOR, DB; GARTNER, TK			A PEPTIDE CORRESPONDING TO GPIIB-ALPHA 300-312, A PRESUMPTIVE FIBRINOGEN GAMMA-CHAIN BINDING-SITE ON THE PLATELET INTEGRIN GPIIB/IIIA, INHIBITS THE ADHESION OF PLATELETS TO AT LEAST 4 ADHESIVE LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; MEMBRANE GLYCOPROTEIN-IIB; AMINO-ACID-SEQUENCE; VITRONECTIN RECEPTOR; RECOGNITION SITE; FIBRONECTIN RECEPTOR; SYNTHETIC PEPTIDES; CROSS-LINKING; BETA-SUBUNIT; CONFORMATION	The platelet fibrinogen (Fg) receptor (GPIIb/IIIa) is an integrin which plays a critical role in hemostasis by recognizing at least the four adhesive ligands: Fg, fibronectin (Fn), vitronectin (Vn), and von Willebrand factor (vWf). We reported that residues 309-312 of GPIIb(alpha) appear to comprise at least part of a Fg binding site on the Fg receptor (Gartner, T. K., and Taylor, D. B. (1990) Thromb. Res. 60, 291-309). Here we report that the peptide GPIIb(alpha) 300-312 (G13) inhibits platelet aggregation and binds Fg and Vn. Significantly, this peptide inhibits the adhesion of stimulated platelets to Fg, Fn, Vn, and vWf, but not the adhesion of resting platelets to Fn. Thus, GPIIb 300-312 may constitute a specific but common recognition site on GPIIb/IIIa for both LGGAKQAGDV- and RGD-containing ligands.			TAYLOR, DB (corresponding author), MEMPHIS STATE UNIV, DEPT BIOL, MEMPHIS, TN 38152 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL042523, R01HL046152] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42523, HL46152] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1992, J BIOL CHEM, V267, P2775; AMRANI DL, 1991, THROMB HAEMOSTASIS, V65, P1069; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BENNETT JS, 1990, SEMIN HEMATOL, V27, P186; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BENNETT JS, 1991, ANN NY ACAD SCI, V614, P214; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; CALVETE JJ, 1991, BIOCHEM J, V274, P457, DOI 10.1042/bj2740457; CHARO IF, 1991, J BIOL CHEM, V266, P1415; COOK JJ, 1992, BIOCHIM BIOPHYS ACTA, V1119, P312, DOI 10.1016/0167-4838(92)90219-4; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GARTNER TK, 1990, THROMB RES, V60, P291, DOI 10.1016/0049-3848(90)90108-O; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GARTNER TK, 1991, P SOC EXP BIOL MED, V198, P649; GARTNER TK, 1987, BLOOD S, V70, pA351; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GINSBERG MH, 1990, J CELL BIOCH S, V14, pA139; HARKER LA, 1990, HEMATOLOGY, P1559; HAVERSTICK DM, 1985, BLOOD, V66, P946; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KIRSCHBAUM NE, 1992, IN PRESS BLOOD; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; KNUTSON VP, 1988, J BIOL CHEM, V263, P14146; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MURANOG G, 1980, PLATELET DISORDERS, P101; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PHILLIPS DR, 1988, BLOOD, V71, P831; PIOTROWICZ RS, 1988, J CELL BIOL, V106, P1359, DOI 10.1083/jcb.106.4.1359; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PONCZ M, 1987, J BIOL CHEM, V262, P8476; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TAYLOR DB, 1991, J CELL BIOL, V115, pA1169; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035	57	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11729	11733						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376310				2022-12-27	WOS:A1992HY94700016
J	BREDT, DS; FERRIS, CD; SNYDER, SH				BREDT, DS; FERRIS, CD; SNYDER, SH			NITRIC-OXIDE SYNTHASE REGULATORY SITES - PHOSPHORYLATION BY CYCLIC AMP-DEPENDENT PROTEIN-KINASE, PROTEIN-KINASE-C, AND CALCIUM CALMODULIN PROTEIN-KINASE - IDENTIFICATION OF FLAVIN AND CALMODULIN BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ANOCOCCYGEUS MUSCLE; MONOMETHYL-L-ARGININE; RELAXING FACTOR; STIMULATION; RELAXATION; REDUCTASE; RECEPTOR; RELEASE; FMN; FAD	Nitric oxide (NO) is an important molecular messenger accounting for endothelial-derived relaxing activity in blood vessels, mediating cytotoxic actions of macrophages, and functioning as a neurotransmitter in the brain and periphery. NO synthase (NOS) from brain has been purified to homogeneity and molecularly cloned. We now report that NOS is stoichiometrically phosphorylated by cAMP dependent protein kinase, protein kinase C, and calcium/calmodulin-dependent protein kinase, with each kinase phosphorylating a different serine site on NOS. Activation of PKC in transfected cells reduces NOS enzyme activity by almost-equal-to 77% in intact cells and by 50% in protein homogenates from these cells. Utilizing fluorescence spectroscopy we find that purified monomer NOS contains 1 molar equivalent of both FMN and FAD. This stoichiometry is supported by enzymatic digestion of the flavins with phosphodiesterase, and titration of the FMN with a specific FMN binding protein. We demonstrate that purified NOS is labeled by a photoaffinity derivative of calmodulin. These recognition sites on NOS provide multiple means for regulation of NO levels and "cross-talk" between second messenger systems.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Bredt, David/J-4872-2012		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00074] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRESLOW MJ, 1992, EUR J PHARMACOL, V210, P105, DOI 10.1016/0014-2999(92)90659-R; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; HIBBS JB, 1987, J IMMUNOL, V138, P550; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1987, EUR J PHARMACOL, V137, P167, DOI 10.1016/0014-2999(87)90218-4; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P289, DOI 10.1016/0005-2744(71)90207-5; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; RAMAGOPAL MV, 1989, EUR J PHARMACOL, V174, P297, DOI 10.1016/0014-2999(89)90325-7; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; RUBANYI GM, 1989, J PHARMACOL EXP THER, V249, P858; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; VERMILION JL, 1981, J BIOL CHEM, V256, P266; ZIEGLER DM, 1990, TRENDS PHARMACOL SCI, V11, P321, DOI 10.1016/0165-6147(90)90235-Z	44	577	592	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10976	10981						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375933				2022-12-27	WOS:A1992HX16900010
J	LEPOIVRE, M; FLAMAN, JM; HENRY, Y				LEPOIVRE, M; FLAMAN, JM; HENRY, Y			EARLY LOSS OF THE TYROSYL RADICAL IN RIBONUCLEOTIDE REDUCTASE OF ADENOCARCINOMA CELLS PRODUCING NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; TUMOR TARGET-CELLS; L-ARGININE; ACTIVATED MACROPHAGES; ENDOTHELIAL-CELLS; SENSITIVE METHOD; DNA-SYNTHESIS; CALF THYMUS; IFN-GAMMA; IRON	Nitric oxide (NO) has been previously shown to inhibit crude preparations of ribonucleotide reductase, a key enzyme in DNA synthesis, and to destroy the essential tyrosyl free radical in pure recombinant R2 subunit of the enzyme. In R2-overexpressing TA3 cells, a decrease in the tyrosyl radical was observed by whole-cell EPR spectroscopy, as soon as 4 h after NO synthase induction by immunological stimuli. Complete loss of the tyrosyl EPR signal occurred after 7 h in cells cultured at a high density. Disappearance of the tyrosyl radical was prevented by Nomega-nitro-L-arginine, a specific inhibitor of NO synthesis, and by oxyhemoglobin, which reacts rapidly with NO. It was reproduced by S-nitrosoglutathione, a NO-releasing molecule. Stable end products of NO synthase metabolism did not affect the radical. Immunoblot analysis of the R2 subunit indicated that expression of the protein was not influenced by NO synthase activity. These results establish that NO, or a labile product of NO synthase, induces the disappearance of the R2-centered tyrosyl radical. Since the radical is necessary for ribonucleotide reductase activity, its destruction by NO would contribute markedly to the antiproliferative action exerted by macrophage-type NO synthase.	INST CURIE, INSERM, U350, F-91405 ORSAY, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	LEPOIVRE, M (corresponding author), UNIV PARIS 11, INST BIOCHIM, CNRS, U 116, F-91405 ORSAY, FRANCE.		Flaman, Jean-Michel/K-8415-2018; Lepoivre, Michel/J-8578-2013	Flaman, Jean-Michel/0000-0003-3544-0199; 				AKERBLOM L, 1981, P NATL ACAD SCI-BIOL, V78, P2159, DOI 10.1073/pnas.78.4.2159; ALBINA JE, 1991, J IMMUNOL, V147, P144; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bjerrum OJ, 1986, **NON-TRADITIONAL**, V86th, P315; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHENAIS B, 1991, J CHROMATOGR, V539, P433, DOI 10.1016/S0021-9673(01)83952-2; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; FONTECAVE M, 1990, J BIOL CHEM, V265, P10919; GRASLUND A, 1982, J BIOL CHEM, V257, P5711; GUTHOHRL.G, 1968, ANAL BIOCHEM, V26, P188, DOI 10.1016/0003-2697(68)90045-6; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS M, 1983, STRUCT BOND, V54, P27; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEPOIVRE M, 1990, INT CONGR SER, V897, P415; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LEPOIVRE M, 1989, CANCER RES, V49, P1970; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NOCEK JM, 1988, BIOCHEMISTRY-US, V27, P1014, DOI 10.1021/bi00403a026; OHSHIMA H, 1990, FOOD CHEM TOXICOL, V28, P647, DOI 10.1016/0278-6915(90)90173-K; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; QUE L, 1991, SCIENCE, V253, P273, DOI 10.1126/science.1857963; RADI R, 1991, J BIOL CHEM, V266, P4244; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER M, 1985, J BIOL CHEM, V260, P2737; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	58	121	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22994	23000						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385411				2022-12-27	WOS:A1992JY16300046
J	GILLESPIE, W; KELM, S; PAULSON, JC				GILLESPIE, W; KELM, S; PAULSON, JC			CLONING AND EXPRESSION OF THE GAL-BETA-1,3GALNAC ALPHA-2,3-SIALYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; ELAM-1-DEPENDENT CELL-ADHESION; NH2-TERMINAL SIGNAL ANCHOR; BLOOD GROUP-A; MOLECULAR-CLONING; ALPHA-2->3 SIALYLTRANSFERASE; TRANSCRIPTIONAL REGULATION; TERMINAL GLYCOSYLATION; DETERMINES EXPRESSION; CDNA	Sequence information obtained by NH2-terminal sequence analysis of two molecular weight forms (45 and 48 kDa) of the porcine Galbeta1,3GalNAc alpha2,3-sialyltransferase was used to clone a full-length cDNA of the enzyme. The cDNA sequence revealed an open reading frame coding for 343 amino acids and a putative domain structure consisting of a short NH2-terminal cytoplasmic domain, a signal-anchor sequence, and a large COOH-terminal catalytic domain. This domain structure was confirmed by construction of a recombinant sialyltransferase in which the cytoplasmic domain and signal-anchor sequence of the enzyme was replaced with the cDNA of insulin signal sequence. Expression of the resulting construct in COS-1 cells produced an active sialyltransferase which was secreted into the medium in soluble form. Comparison of the cDNA sequence of the sialyltransferase with GenBank produced no significant homologies except with the previously described Galbeta1,4GlcNAc alpha2,6-sialyltransferase. Although the cDNA sequences of these two enzymes were largely nonhomologous, there was a 45-amino acid sequence which exhibited 65% identity. This observation suggests that the two sialyltransferases were derived, in part, from a common gene.	BIOCHEM INST, W-2300 KIEL, GERMANY; CYTEL CORP, SAN DIEGO, CA 92121 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT CHEM, SAN DIEGO, CA 92121 USA	Scripps Research Institute; Scripps Research Institute	GILLESPIE, W (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA.		Kelm, Soerge/C-5403-2013; Paulson, James/AAG-3565-2019	Kelm, Soerge/0000-0001-5277-9421; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027904] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-07201] Funding Source: Medline; NIGMS NIH HHS [GM27904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIG MM, 1972, J BIOL CHEM, V247, P6111; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERGH MLE, 1981, BIOCHIM BIOPHYS ACTA, V660, P161, DOI 10.1016/0005-2744(81)90155-8; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BREG J, 1987, EUR J BIOCHEM, V168, P57, DOI 10.1111/j.1432-1033.1987.tb13387.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; CONRADT HS, 1988, SIALIC ACIDS, P104; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HSUEH EC, 1986, J BIOL CHEM, V261, P4940; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFRANCOIS L, 1987, J IMMUNOL, V139, P2220; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEE EU, 1989, J BIOL CHEM, V264, P13848; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; Maniatis T., 1982, MOL CLONING; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; Paulson J, 1985, THE RECEPTORS, V2, P131; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PAULSON JC, 1992, ADHESION ITS ROLE IN, P19; PODOLSKY DK, 1985, J BIOL CHEM, V260, P5510; REARICK JI, 1979, J BIOL CHEM, V254, P4444; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SADLER JE, 1984, BIOL CARBOHYDRATES, V2, P87; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SHARON N, 1982, PROTEINS, V5, P1; SLOMIANY BL, 1980, J BIOL CHEM, V255, P9719; STAMENKOVIC I, 1990, J EXP MED, V172, P641, DOI 10.1084/jem.172.2.641; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WANG XC, 1990, J BIOL CHEM, V265, P17849; WASSARMAN PM, 1987, ANNU REV CELL BIOL, V3, P109, DOI 10.1146/annurev.cellbio.3.1.109; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTCOTT KR, 1985, J BIOL CHEM, V260, P3109; WESTCOTT KR, 1985, J BIOL CHEM, V260, P3116; WOOD WI, 1987, METHOD ENZYMOL, V152, P443; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YAMAMOTO FI, 1990, NATURE, V345, P223	60	161	177	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21004	21010						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383214				2022-12-27	WOS:A1992JT97800078
J	MILLER, WH; DALUGE, SM; GARVEY, EP; HOPKINS, S; REARDON, JE; BOYD, FL; MILLER, RL				MILLER, WH; DALUGE, SM; GARVEY, EP; HOPKINS, S; REARDON, JE; BOYD, FL; MILLER, RL			PHOSPHORYLATION OF CARBOVIR ENANTIOMERS BY CELLULAR ENZYMES DETERMINES THE STEREOSELECTIVITY OF ANTIVIRAL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; THYMIDINE KINASE; REVERSE-TRANSCRIPTASE; PURINE NUCLEOSIDES; CARBOCYCLIC ANALOG; SELECTIVE ACTIVITY; 5'-NUCLEOTIDASE; CELLS; 3'-AZIDO-3'-DEOXYTHYMIDINE; 2'-DEOXYGUANOSINE	Two enantiomers of carbovir, a carbocyclic analog of 2',3'-dideoxyguanosine, were compared with respect to their phosphorylation and the phosphorylation of their nucleotides by mammalian enzymes. 5'-Nucleotidase catalyzed the phosphorylation of (-)-carbovir, which is active against HIV (human immunodeficiency virus), but did not phosphorylate (+)-carbovir. (-)-Carbovir monophosphate was 7,000 times more efficient as a substrate for GMP kinase than was (+)-carbovir monophosphate. Pyruvate kinase, phosphoglycerate kinase, and creatine kinase phosphorylated both enantiomers of carbovir diphosphate at similar rates. Nucleoside-diphosphate kinase preferentially phosphorylated the (-)-enantiomer. Both enantiomers of carbovir triphosphate were substrates and alternative substrate inhibitors of HIV reverse transcriptase. Thus, the contrasting HIV-inhibitory activities of carbovir enantiomers were due to differential phosphorylation by cellular enzymes and not due to enantioselectivity of HIV reverse transcriptase.	CATO RES LTD,DURHAM,NC 27713; WELLCOME RES LABS,DIV ORGAN CHEM,RES TRIANGLE PK,NC 27709	Wellcome Research Laboratories	MILLER, WH (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							AVERETT DR, 1989, J VIROL METHODS, V23, P263, DOI 10.1016/0166-0934(89)90159-6; BALZARINI J, 1990, MOL PHARMACOL, V37, P395; BENNETT LL, 1990, BIOCHEM PHARMACOL, V40, P1515; CARTER SG, 1990, ANTIMICROB AGENTS CH, V34, P1297, DOI 10.1128/AAC.34.6.1297; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202; DECLERCQ E, 1990, BIOCHEM PHARMACOL, V39, P319, DOI 10.1016/0006-2952(90)90031-F; DOMIN B A, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P19; EXALL AM, 1991, J CHEM SOC PERK T 1, P2467, DOI 10.1039/p19910002467; FRIDLAND A, 1986, CANCER RES, V46, P532; FYFE JA, 1978, J BIOL CHEM, V253, P8721; JOHNSON MA, 1989, MOL PHARMACOL, V36, P291; KARKAS JD, 1987, BIOCHIM BIOPHYS ACTA, V911, P127, DOI 10.1016/0167-4838(87)90001-X; KELLER PM, 1985, J BIOL CHEM, V260, P8664; KOHLBRENNER WE, 1990, BIOCHEM PHARMACOL, V40, pR5, DOI 10.1016/0006-2952(90)90076-W; KOVACS T, 1988, TETRAHEDRON LETT, V29, P4525, DOI 10.1016/S0040-4039(00)80537-7; MAHER TJ, 1991, DRUG DEVELOP RES, V24, P149, DOI 10.1002/ddr.430240202; MILLER WH, 1982, BIOCHEM PHARMACOL, V31, P3879, DOI 10.1016/0006-2952(82)90305-7; MILLER WH, 1980, J BIOL CHEM, V255, P7204; ORR DC, 1992, J BIOL CHEM, V267, P4177; PARKER WB, 1991, J BIOL CHEM, V266, P154; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672, DOI 10.1128/AAC.36.3.672; SCOTT AK, 1991, DRUG NEWS PERSPECT, V4, P476; SECRIST JA, 1987, J MED CHEM, V30, P746, DOI 10.1021/jm00387a032; SPYCHALA J, 1988, J BIOL CHEM, V263, P18759; STILL WC, 1989, MACROMODEL VERSION 2; Taylor EW, 1990, ANTIVIR CHEM CHEMOTH, V1, P163, DOI 10.1177/095632029000100301; TERRY BJ, 1991, MOL PHARMACOL, V40, P591; TOLMAN RL, 1989, NUCLEOTIDE ANALOGUES, P33; VINCE R, 1990, BIOCHEM BIOPH RES CO, V168, P912, DOI 10.1016/0006-291X(90)91115-9; VINCE R, 1988, BIOCHEM BIOPH RES CO, V156, P1046, DOI 10.1016/S0006-291X(88)80950-1; VINCE R, 1990, J MED CHEM, V33, P17, DOI 10.1021/jm00163a004; WHITE EL, 1989, BIOCHEM BIOPH RES CO, V161, P393, DOI 10.1016/0006-291X(89)92611-9; YAMANAKA G, 1991, MOL PHARMACOL, V40, P446	35	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21220	21224						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383219				2022-12-27	WOS:A1992JT97800109
J	SHIN, WS; SASAKI, T; KATO, M; HARA, K; SEKO, A; YANG, WD; SHIMAMOTO, N; SUGIMOTO, T; TOYOOKA, T				SHIN, WS; SASAKI, T; KATO, M; HARA, K; SEKO, A; YANG, WD; SHIMAMOTO, N; SUGIMOTO, T; TOYOOKA, T			AUTOCRINE AND PARACRINE EFFECTS OF ENDOTHELIUM-DERIVED RELAXING FACTOR ON INTRACELLULAR CA2+ OF ENDOTHELIAL-CELLS AND VASCULAR SMOOTH-MUSCLE CELLS - IDENTIFICATION BY 2-DIMENSIONAL IMAGE-ANALYSIS IN COCULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERIAL GUANYLATE-CYCLASE; NITRIC-OXIDE; CORONARY VASOSPASM; SODIUM-NITRITE; CALCIUM; RELAXATION; RELEASE; ACETYLCHOLINE; MECHANISMS; RESPONSES	To elucidate the effects of endothelium-derived relaxing factor (EDRF) released from vascular endothelial cells (ECs) on handling of intracellular calcium ion (Ca2+i) in ECs themselves and vascular smooth muscle cells (VSMCs), we measured the Ca2+i by two-dimensional digital image analysis of fura-2-loaded ECs and VSMCs in tissue culture. In isoculture of one cell type, adenosine triphosphate (ATP, 1 muM) transiently increased the Ca2+i of both ECs and VSMCs. High-K+ depolarization or angiotensin II also elevated the Ca2+i of VSMCs, whereas neither stimulants changed the Ca2+i of ECs. In coculture of ECs with VSMCs, the same dose of ATP rapidly increased the Ca2+i of ECs and then transiently decreased the Ca2+i of VSMCs to below the resting level. The maximal Ca2+i-modulating effects of ATP on both cell types were reproducible after the second application of ATP. Three kinds of EDRF blockers (L-N(G)-monomethylarginine, methemoglobin, or methylene blue) potentiated the ATP-induced Ca2+i rise in ECs and attenuated the Ca"i reduction in VSMCs, suggesting the autocrine and paracrine effects of EDRF on ECs and VSMCs, respectively. However, neither indomethacin, superoxide dismutase, nor neutralizing monoclonal antibody to endothelin-1 altered the second responses. Thus, two-dimensional Ca2+i image analysis of ECs and VSMCs in coculture enabled direct visualization of the EDRF actions in ECs and VSMCs and their modifications.	UNIV TOKYO,FAC MED,CTR HLTH SERV,DEPT INTERNAL MED 2,TOKYO 113,JAPAN	University of Tokyo								ARROYO CM, 1990, BIOCHEM BIOPH RES CO, V170, P1177, DOI 10.1016/0006-291X(90)90517-Q; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHERRY PD, 1982, P NATL ACAD SCI USA, V79, P216; CHESTER AH, 1990, INT J CARDIOL, V29, P305, DOI 10.1016/0167-5273(90)90118-O; COCKS TM, 1990, N-S ARCH PHARMACOL, V341, P364; DEMEY JG, 1981, J PHYSIOL-LONDON, V316, P347, DOI 10.1113/jphysiol.1981.sp013792; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P2334; DOMINICZAK AF, 1991, AM J PHYSIOL, V261, pH243, DOI 10.1152/ajpheart.1991.261.1.H243; EBASHI S, 1976, S SOC EXP BIOL, V30, P349; EDWARDS JC, 1984, J PHARMACOL EXP THER, V228, P33; FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRUETTER DY, 1980, BIOCHEM PHARMACOL, V29, P2943, DOI 10.1016/0006-2952(80)90042-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1986, FEBS LETT, V207, P95, DOI 10.1016/0014-5793(86)80019-9; IGNARRO LJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P221, DOI 10.1016/0304-4165(80)90297-4; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KONISHI M, 1988, BIOPHYS J, V54, P1089, DOI 10.1016/S0006-3495(88)83045-5; LUECKHOFF A, 1992, NATURE, V355, P356; MASUO M, 1991, CIRC RES, V69, P1327, DOI 10.1161/01.RES.69.5.1327; MONCADA S, 1988, HYPERTENSION, V12, P365, DOI 10.1161/01.HYP.12.4.365; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SHIN WS, 1991, CIRC RES, V69, P551, DOI 10.1161/01.RES.69.2.551; SHIN WS, 1989, JPN HEART J, V30, P77; SUZUKI T, 1991, J CARDIOVASC PHARM, V17, pS187, DOI 10.1097/00005344-199100177-00053; TODA N, 1990, LIFE SCI, V47, P345, DOI 10.1016/0024-3205(90)90593-G; TOKUNAGA O, 1989, AM J PATHOL, V135, P967; TOYOOKA T, 1989, CIRC RES, V64, P407, DOI 10.1161/01.RES.64.2.407; TOYOOKA T, 1981, CIRC RES, V49, P1350, DOI 10.1161/01.RES.49.6.1350; TOYOOKA T, 1991, CIRCULATION, V83, P476, DOI 10.1161/01.CIR.83.2.476; TOYOOKA T, 1991, CIRCULATION, V84, P1451, DOI 10.1161/circ.84.3.1884470; TOYOOKA T, 1991, CORONARY ARTERY DIS, V2, P314, DOI 10.1097/00019501-199105000-00005; VANE JR, 1990, NEW ENGL J MED, V323, P27; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; WARNER TD, 1989, J CARDIOVASC PHARM, V13, pS85, DOI 10.1097/00005344-198900135-00021; WATANABE T, 1990, NATURE, V344, P144; WEI EP, 1990, HYPERTENSION, V16, P162, DOI 10.1161/01.HYP.16.2.162; WHITE DG, 1989, BRIT J PHARMACOL, V97, P683, DOI 10.1111/j.1476-5381.1989.tb12004.x; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374	45	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20377	20382						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400356				2022-12-27	WOS:A1992JR85800098
J	BJORK, I; NORDLING, K; LARSSON, I; OLSON, ST				BJORK, I; NORDLING, K; LARSSON, I; OLSON, ST			KINETIC CHARACTERIZATION OF THE SUBSTRATE REACTION BETWEEN A COMPLEX OF ANTITHROMBIN WITH A SYNTHETIC REACTIVE-BOND LOOP TETRADECAPEPTIDE AND 4 TARGET PROTEINASES OF THE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANTI-THROMBIN; FACTOR-XA; ALPHA-1-PROTEINASE INHIBITOR; CRYSTAL-STRUCTURE; ACTIVE-SITE; SERPINS; FORM; TRYPSIN; HEPARIN; ALPHA-1-ANTITRYPSIN	A tetradecapeptide corresponding to the P1 to P14 region of the reactive-bond loop of antithrombin (AT) binds to the inhibitor, presumably as a middle strand of the A beta-sheet, thereby converting AT from an inhibitor to a substrate of thrombin (Bjork, I., Ylinenjarvi, K., Olson, S. T., and Bock, P. E. (1992) J. Biol. Chem. 267, 1976-1982). The kinetics of cleavage of the AT reactive bond in the AT-peptide complex by four target proteinases were quantified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and densitometry. The k(cat)/K(m) values for thrombin and factor IXa were indistinguishable from the second-order rate constants for AT inhibition of these enzymes, whereas the values for factor Xa and plasmin were 10-17-fold higher than the inhibition rate constants. Heparin with high affinity for AT accelerated the substrate reaction with thrombin to an extent consistent with the reduced heparin affinity of the AT-peptide complex. These data show that blocking by the peptide of the putative intramolecular association of the P1 to P14 region of the AT reactive-bond loop with the A beta-sheet leads to AT functioning as a substrate of its target enzymes with an efficiency that equals or exceeds the action of uncomplexed AT as an inhibitor and with the expected heparin activation. The results thus suggest that a substrate-like attack of the proteinase on the inhibitor reactive bond in an exposed loop initiates the inhibition reaction. This attack presumably induces the subsequent trapping of the enzyme by the insertion of the reactive-bond loop into the A beta-sheet.	HENRY FORD HOSP,DIV BIOCHEM RES,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital	BJORK, I (corresponding author), SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT VET MED CHEM,BOX 575,S-75123 UPPSALA,SWEDEN.				NHLBI NIH HHS [HL-39888] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888, R29HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1982, J BIOL CHEM, V257, P2406; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; DANIELSSON A, 1980, FEBS LETT, V119, P241, DOI 10.1016/0014-5793(80)80262-6; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; FISH WW, 1979, FEBS LETT, V98, P103, DOI 10.1016/0014-5793(79)80162-3; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; NORDENMAN B, 1978, BIOCHEMISTRY-US, V17, P3339, DOI 10.1021/bi00609a026; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1992, IN PRESS SEMIN THROM; OLSON ST, 1992, IN PRESS THROMBIN ST; PERRY DJ, 1991, FEBS LETT, V285, P248, DOI 10.1016/0014-5793(91)80809-H; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; VILLANUEVA G, 1979, BIOCHEMISTRY-US, V18, P810, DOI 10.1021/bi00572a011; WALLGREN P, 1981, EUR J BIOCHEM, V116, P493, DOI 10.1111/j.1432-1033.1981.tb05363.x; WONG RF, 1983, BIOCHEMISTRY-US, V22, P3994, DOI 10.1021/bi00286a001	32	52	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19047	19050						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388162				2022-12-27	WOS:A1992JP59300007
J	SHASKUS, J; GRECO, D; ASNANI, LP; LEWIS, EJ				SHASKUS, J; GRECO, D; ASNANI, LP; LEWIS, EJ			A BIFUNCTIONAL GENETIC REGULATORY ELEMENT OF THE RAT DOPAMINE BETA-HYDROXYLASE GENE INFLUENCES CELL TYPE SPECIFICITY AND 2ND MESSENGER-MEDIATED TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXTINGUISHER; INTESTINAL-PEPTIDE GENE; NEURO-BLASTOMA CELLS; DNA-BINDING PROTEINS; TRANS-ACTING FACTOR; MAMMALIAN-CELLS; CYCLIC-AMP; TYROSINE-HYDROXYLASE; INDUCIBLE GENES; TSE1 ENCODES	Dopamine beta-hydroxylase, the enzyme which converts dopamine to norepinephrine, is expressed in a cell type-restricted pattern in neuroendocrine tissue. A segment of the rat gene containing 395 bases of 5'-flanking sequence regulates expression of a reporter gene in a cell type-selective pattern in mammalian cell cultures. Using deletion mutants of the 5'-flanking sequence, we have identified a 30-base genetic regulatory element, designated DB1, which enhances transcription from a heterologous promoter 5-20-fold in neuroendocrine cell lines. DB1-specific DNA-protein complexes are found in nuclear extracts from all cell lines examined, but the migration pattern differs between cell lines. The 5'-flanking region of the dopamine beta-hydroxylase gene is also responsive to cyclic AMP and phorbol ester treatment of SHSY-5Y neuroblastoma cells. The simultaneous presence of both effectors results in synergistic increases in DBH1 mRNA and reporter gene activity. The second messenger regulatory element was localized to the region containing the DB1 element, and reporter plasmids containing multiple copies of the DB1 element are responsive to treatment with inducers. The results of this study identify a cis-acting regulatory element which influences both cell type selectivity and second messenger responsiveness of the rat dopamine beta-hydroxylase gene.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, L224, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT MOLEC & MED GENET, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038696, R29GM038696] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38696] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN B, 1988, J BIOL CHEM, V263, P15578; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CICCARONE V, 1989, CANCER RES, V49, P219; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FINK JS, 1991, J BIOL CHEM, V266, P3882; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; KVETNANSKY R, 1971, MOL PHARMACOL, V7, P81; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; LEDOUARIN NM, 1990, ANN NY ACAD SCI, V599, P131; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LEWIS EJ, 1990, J BIOL CHEM, V265, P1021; LEWIS EJ, 1992, J BIOL CHEM, V267, P494; MCMAHON A, 1992, J NEUROCHEM, V58, P2124, DOI 10.1111/j.1471-4159.1992.tb10954.x; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; POWERS AC, 1989, J BIOL CHEM, V264, P10048; ROSS RA, 1983, J NATL CANCER I, V71, P741; Sambrook J, 1989, MOL CLONING LABORATO; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5	48	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18821	18830						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1382062				2022-12-27	WOS:A1992JN50200087
J	LAROCHELLE, WJ; PIERCE, JH; MAYSIROFF, M; GIESE, N; AARONSON, SA				LAROCHELLE, WJ; PIERCE, JH; MAYSIROFF, M; GIESE, N; AARONSON, SA			5 PDGF-B AMINO-ACID SUBSTITUTIONS CONVERT PDGF-A TO A PDGF B-LIKE TRANSFORMING MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; GROWTH-HORMONE RECEPTOR; V-SIS; GENE; BINDING; CHAIN; MUTAGENESIS; IDENTIFICATION; DIMERIZATION; LOCALIZATION	We used site-directed mutagenesis to determine the minimum number of PDGF B residues needed to convert PDGF A to a potently transforming PDGF B-like molecule. Substitution of two PDGF B subdomains, 106-115 and 135-144, were found to be critical. These substitutions were sufficient to broaden the ability of PDGF A to activate beta as well as alpha-platelet-derived growth factor (PDGF) receptors and increase its transforming efficiency to that of PDGF B. Within subdomain I, either PDGF B residues Arg- 109 and Asn-115 or Arg-109, Leu-110, and Arg-113, in combination with subdomain II PDGF B residues Asn-136, Arg-137, and Arg-142 were identified as being essential. Those mutants with transforming ability comparable with PDGF B showed significantly lower efficiencies of beta-receptor triggering. Thus, our studies identify a small number of PDGF B amino acids indispensable for beta-PDGF receptor interaction and suggest that a low level of beta-PDGF receptor activation is sufficient to dramatically increase PDGF transforming efficiency in NIH 3T3 cells.			LAROCHELLE, WJ (corresponding author), NIH,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; HANNINK M, 1986, MOL CELL BIOL, V6, P1304, DOI 10.1128/MCB.6.4.1304; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; KING CR, 1985, P NATL ACAD SCI USA, V82, P5295, DOI 10.1073/pnas.82.16.5295; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VOGEL S, 1989, BIOCHEMISTRY-US, V28, P2961, DOI 10.1021/bi00433a033; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	28	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17074	17077						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380958				2022-12-27	WOS:A1992JL05300054
J	LEE, J; HORUK, R; RICE, GC; BENNETT, GL; CAMERATO, T; WOOD, WI				LEE, J; HORUK, R; RICE, GC; BENNETT, GL; CAMERATO, T; WOOD, WI			CHARACTERIZATION OF 2 HIGH-AFFINITY HUMAN INTERLEUKIN-8 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; CYTOKINE FAMILY; EXPRESSION; CLONING; BINDING	Interleukin 8 (IL-8) and melanocyte growth-stimulatory activity/gro (MGSA) are structurally related proinflammatory cytokines that are chemoattractants and activators of neutrophils. Recently, cDNA clones encoding a high affinity IL-8 receptor (IL-8R-A) and a "low affinity" IL-8 receptor (IL-8R-B) have been isolated from human cDNA libraries. These two receptors have 77% amino acid identity and are members of the G protein-coupled superfamily of receptors with seven transmembrane domains. We have expressed these two receptors in mammalian cells and find that in this system both receptors bind IL-8 with high affinity (K(d) approximately 2 nM). The receptor affinities differ for MGSA, however. IL-8R-A binds MGSA with low affinity (K(d) approximately 450 nM); IL-8R-B binds MGSA with high affinity (K(d) approximately 2 nM). The transfected cells respond to ligand binding with a transient increase in the intracellular Ca2+ concentration. A Ca2+ response is found for IL-8R-A following the binding of IL-8; no response is found for MGSA. A Ca2+ response for IL-8R-B follows the binding of both ligands. Blot hybridization with oligonucleotide probes specific for the two receptors shows that mRNA for both receptors is present in human neutrophils. Analysis of IL-8 and MGSA binding data on neutrophils as well as Ca2+ response and desensitization data shows that the presence of these two IL-8 receptors on the cell surface can account for the profile of these two ligands on neutrophils.	GENENTECH INC, DEPT PROT CHEM, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT MED & ANALYT CHEM, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	LEE, J (corresponding author), GENENTECH INC, DEPT MOLEC BIOL, S SAN FRANCISCO, CA 94080 USA.							Baggiolini M, 1992, Cytokines, V4, P1; BECKMANN MP, 1991, BIOCHEM BIOPH RES CO, V179, P784, DOI 10.1016/0006-291X(91)91885-G; BESEMER J, 1989, J BIOL CHEM, V264, P17409; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GORB PM, 1990, J BIOL CHEM, V265, P8311; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; HUYNH TV, 1984, DNA CLONING TECHNIQU, P49; LEE J, 1992, J IMMUNOL, V148, P1261; Maniatis T., 1982, MOL CLONING; MOSER B, 1991, J BIOL CHEM, V266, P10666; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; THOMAS KM, 1990, J BIOL CHEM, V265, P20061	25	417	439	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16283	16287						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379593				2022-12-27	WOS:A1992JJ45800046
J	JONES, D; SAWICKI, G; WOZNIAK, M				JONES, D; SAWICKI, G; WOZNIAK, M			SEQUENCE, STRUCTURE, AND EXPRESSION OF A WASP VENOM PROTEIN WITH A NEGATIVELY CHARGED SIGNAL PEPTIDE AND A NOVEL REPEATING INTERNAL STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; NUCLEOTIDE-SEQUENCE; ENDOPARASITIC WASP; SECONDARY STRUCTURE; CHELONUS-SP; BEE VENOM; PREDICTION; CDNA; DNA; CURVIMACULATUS	An expression cDNA library prepared from mRNA from the venom gland of a parasitic wasp, Chelonus sp. near curvimaculatus, was screened with polyclonal antibodies against a 33-kDa venom protein from this wasp. Immunoreactive clones were sequenced, yielding a complete inferred sequence for a protein with an NH2 terminus identical with that of the 33-kDa protein. The structure of the cDNA showed an apparent encoded signal peptide, which was unusual in possessing 2 glutamic acid residues juxtapositioned next to, or replacing, the conventional basic residues. The bulk of the mature protein sequence which follows the NH2-terminal, 5000-kDa hydrophobic domain is composed of a dozen tandem repeats of a highly charged, approximately 14-residue sequence, except for the truncated eighth repeat which terminates in the only proline in this large domain. The primary structure is not closely related to any sequence in the GenBank data bank. Secondary structure analysis identified a turn occurring at or near each of 12 invariantly conserved serine residues. Further, the codon used for this serine was invariant, whereas other serines in the protein (including a nearly invariant serine 2 residues away) used various codons. Results of epitope mapping experiments supported a proposed tertiary structure in which the NH2-terminal 5-kDa forms a hydrophobic core, overlain with the charged repeats. Northern analysis of poly(A) RNA from the venom gland of young adult female wasps showed expression of a single 1-kilobase transcript, for which there is no corresponding message in normal or parasitized host larvae. The remarkable structure of this protein and structural data on other wasp venom proteins suggest an evolutionary pattern in which some proteins critical for venom function evolve by internal tandem duplication, and which are secreted after biosynthesis by a different mechanism from that used for proteins with classical signal peptides containing basic residues.	UNIV KENTUCKY,SCH BIOL SCI,LEXINGTON,KY 40506	University of Kentucky	JONES, D (corresponding author), UNIV KENTUCKY,GRAD CTR TOXICOL,LEXINGTON,KY 40506, USA.		Wozniak, Mieczyslaw/S-8215-2018	Wozniak, Mieczyslaw/0000-0002-1655-971X	NIGMS NIH HHS [GM33997] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1989, PROTEIN STRUCTURE PR; Banks B.E.C., 1986, VENOMS HYMENOPTERA, P330; BENESKI DA, 1980, P NATL ACAD SCI-BIOL, V77, P639, DOI 10.1073/pnas.77.1.639; BOULAIN JC, 1982, BIOCHEMISTRY-US, V21, P2910, DOI 10.1021/bi00541a016; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P110; CHARBONNEAU H, 1989, PRACTICAL GUIDE PROT, P29; CHELLIAH J, 1990, J GEN VIROL, V71, P2353, DOI 10.1099/0022-1317-71-10-2353; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DELIMA ME, 1988, BIOCHEM BIOPH RES CO, V151, P187, DOI 10.1016/0006-291X(88)90577-3; DESROSIERS R, 1974, P NATL ACAD SCI USA, V71, P39717; DUCANCEL F, 1988, NUCLEIC ACIDS RES, V16, P9048, DOI 10.1093/nar/16.18.9048; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GATINEAU E, 1988, EUR J BIOCHEM, V171, P535, DOI 10.1111/j.1432-1033.1988.tb13822.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P82; HARVEY AL, 1984, J PHYSIOL-PARIS, V79, P222; HELLMANN GM, 1983, VIROLOGY, V124, P434, DOI 10.1016/0042-6822(83)90359-8; HONES J, 1987, FEBS LETT, V212, P193, DOI 10.1016/0014-5793(87)81343-1; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JENG TW, 1978, P NATL ACAD SCI USA, V75, P600, DOI 10.1073/pnas.75.2.600; JONES D, 1986, J INVERTEBR PATHOL, V47, P105, DOI 10.1016/0022-2011(86)90168-0; JONES D, 1986, EXP PARASITOL, V61, P10, DOI 10.1016/0014-4894(86)90129-3; JONES D, 1990, ARCH INSECT BIOCHEM, V13, P95, DOI 10.1002/arch.940130109; JONES D, 1990, ADVANCES IN INVERTEBRATE REPRODUCTION 5, P157; JONES D, 1992, PARASITES PATHOGENS; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIL G, 1980, EUR J BIOCHEM, V111, P49, DOI 10.1111/j.1432-1033.1980.tb06073.x; KREIL G, 1990, TRENDS BIOCHEM SCI, V15, P23, DOI 10.1016/0968-0004(90)90126-V; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; LAEMMLI UK, 1973, J MOL BIOL, V80; LELUK J, 1989, TOXICON, V27, P105, DOI 10.1016/0041-0101(89)90410-8; LEMEUR M, 1981, CELL, V23, P56116; LOW BW, 1986, EUR J BIOCHEM, V161, P579, DOI 10.1111/j.1432-1033.1986.tb10481.x; LU YA, 1991, MOL IMMUNOL, V28, P1047; MARGLIN A, 1970, ANNU REV BIOCHEM, V39, P841, DOI 10.1146/annurev.bi.39.070170.004205; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nakajima T., 1986, P309; NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243; Piek T., 1986, VENOMS HYMENOPTERA; POSCH M, 1983, J BIOL CHEM, V258, P1761; ROMEY G, 1984, J PHYSL PARIS, V79, P254; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V80, P3963; SHIPOLIN.RA, 1974, EUR J BIOCHEM, V48, P465, DOI 10.1111/j.1432-1033.1974.tb03787.x; STOLTZ DB, 1988, J GEN VIROL, V69, P903, DOI 10.1099/0022-1317-69-4-903; TAYLOR T, 1990, BIOCHIM BIOPHYS ACTA, V1035, P37, DOI 10.1016/0304-4165(90)90170-2; VLASAK R, 1983, EUR J BIOCHEM, V135, P123, DOI 10.1111/j.1432-1033.1983.tb07626.x; VLASAK R, 1984, EUR J BIOCHEM, V145, P279, DOI 10.1111/j.1432-1033.1984.tb08549.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALTHER C, 1976, J INSECT PHYSIOL, V22, P1187, DOI 10.1016/0022-1910(76)90092-5; WEBB BA, 1990, P NATL ACAD SCI USA, V87, P4961, DOI 10.1073/pnas.87.13.4961	53	24	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14871	14878						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378841				2022-12-27	WOS:A1992JF08800057
J	CHATTOPADHYAY, D; EVANS, DB; DEIBEL, MR; VOSTERS, AF; ECKENRODE, FM; EINSPAHR, HM; HUI, JO; TOMASSELLI, AG; ZURCHERNEELY, HA; HEINRIKSON, RL; SHARMA, SK				CHATTOPADHYAY, D; EVANS, DB; DEIBEL, MR; VOSTERS, AF; ECKENRODE, FM; EINSPAHR, HM; HUI, JO; TOMASSELLI, AG; ZURCHERNEELY, HA; HEINRIKSON, RL; SHARMA, SK			PURIFICATION AND CHARACTERIZATION OF HETERODIMERIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) REVERSE-TRANSCRIPTASE PRODUCED BY INVITRO PROCESSING OF P66 WITH RECOMBINANT HIV-1 PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DOMAIN; CHROMATOGRAPHY; POLYMERASE; CLEAVAGE; AIDS; SITE	Active recombinant reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) with an amino-terminal extension containing a hexa-histidine sequence has been prepared in milligram quantities in a pure heterodimeric (p66/p51) form by coordinated applications of immobilized metal affinity chromatography (IMAC) and HIV-1 protease treatment. The precursor protein, isolated from extracts of recombinant Escherichia coli by IMAC in a predominantly unprocessed form (p66), migrated on sodium dodecyl sulfate-polyacrylamide gels as a 66-kDa band with minor heterogeneity at lower relative molecular mass. Incubation of this protein with recombinant HIV-1 protease produced a stable heterodimeric RT that was purified in a single step by IMAC. The purified protein retained both RT and RNase H activity, and kinetic parameters (K(m) and V(max)) were measured with both RNA-dependent DNA polymerization and RNase H activity assays. Carboxyl-terminal sequencing of purified heterodimeric RT indicated that one subunit is intact p66, whereas the other, p51, is a truncated form of p66 that terminates at residue Phe440. Analysis of the HIV-1 protease digest revealed two cleavage sites, at Tyr483-Leu484 and Tyr532-Leu533, in addition to the site at Phe440-Tyr441 that is cleaved to produce p51.	UPJOHN CO,7240-267-117,301 HENRIETTA ST,KALAMAZOO,MI 49001	Pfizer								BARR PJ, 1988, VIROLOGY, V166, P339; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; CHANDRA P, 1985, CANCER RES, V45, P4677; CHATTOPADHYAY D, 1992, PROTEIN EXPRES PURIF, V3, P151, DOI 10.1016/S1046-5928(05)80032-4; EVANS DB, 1991, J BIOL CHEM, V266, P20583; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HUNKAPILLER MW, 1985, APPL BIOSYSTEMS USER, V14, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; SHARMA SK, 1991, BIOTECHNOL APPL BIOC, V14, P69; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504	19	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14227	14232						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378437				2022-12-27	WOS:A1992JD32500068
J	JOHNSON, GD; HERSH, LB				JOHNSON, GD; HERSH, LB			CLONING A RAT MEPRIN CDNA REVEALS THE ENZYME IS A HETERODIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY MICROVILLAR MEMBRANE; AMINO-ACID SEQUENCE; MOUSE KIDNEY; GEL-ELECTROPHORESIS; PROTEINS; PROTEASE; ENDOPEPTIDASE-2; NITROCELLULOSE; PURIFICATION; INSITU	The structure of the kidney microvillar membrane metallopeptidase meprin (EC 3.4.24.18) from rats has been examined. Previously reported to be a homotetramer, we demonstrate that the enzyme is composed of two similar but distinct subunits through tryptic peptide mapping and the sequencing of peptides of the papain solubilized form of the enzyme. Two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis reveals that the native rat meprin tetramer is dissociated by detergent into disulfide-linked heterodimers. A full-length cDNA clone encoding one of the meprin subunits has been isolated and sequenced. The cDNA contains an open reading frame of 668 amino acids, coding for a polypeptide of molecular weight 75,054. The enzyme contains the zinc binding sequence HEFLH and a potential membrane-spanning region near its amino terminus. Comparison of this clone with peptide sequences from mouse meprins A and B shows that the clone is a B type or beta-subunit. Northern blot analysis is consistent with the existence of two distinct subunits and further indicates that rat meprin subunits may be differentially expressed in various rat tissues.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDA NIH HHS [DA02243] Funding Source: Medline; NIGMS NIH HHS [GM08297] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARGOS P, 1978, J MOL BIOL, V126, P141, DOI 10.1016/0022-2836(78)90356-X; BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; BATEMAN RC, 1989, J BIOL CHEM, V264, P6151; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BOND JS, 1983, BIOCHEM J, V209, P251, DOI 10.1042/bj2090251; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MAROUX S, 1987, MAMMALIAN ECTOENZYME, P15; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; TITANI K, 1987, BIOCHEMISTRY-US, V26, P222, DOI 10.1021/bi00375a029; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLZ RL, 1990, ANAL BIOCHEM, V191, P314; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; ZWILLING R, 1981, FEBS LETT, V127, P75, DOI 10.1016/0014-5793(81)80344-4	28	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13505	13512						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377685				2022-12-27	WOS:A1992JB74600065
J	EHRLICH, HJ; GEBBINK, RK; KEIJER, J; PANNEKOEK, H				EHRLICH, HJ; GEBBINK, RK; KEIJER, J; PANNEKOEK, H			ELUCIDATION OF STRUCTURAL REQUIREMENTS ON PLASMINOGEN-ACTIVATOR INHIBITOR-1 FOR BINDING TO HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN VITRONECTIN; CELL-GROWTH FACTOR; ANTI-THROMBIN-III; ANTITHROMBIN-III; HUMAN-PLASMA; PURIFICATION; COFACTOR; SITE; ARGININE-47; MECHANISM	Plasminogen activator inhibitor 1 (PAI-1), a member of the serpin superfamily of proteins, has been demonstrated previously to interact functionally with the glycosaminoglycan heparin (Ehrlich, H. J., Keijer, J., Preissner, K. T., Klein Gebbink, R., and Pannekoek, H. (1991) Biochemistry 30, 1021-1028). Heparin specifically enhances the rate of association between PAI-1 and thrombin about 2 orders of magnitude, whereas no effect is detected with other serine proteases (e.g. factor Xa). For the heparin-dependent serpins antithrombin III and heparin cofactor II, basic amino acid residues in and around the helix D subdomain were proposed to be involved in the binding of glycosaminoglycans. Here we employed site-directed mutagenesis of full-length PAI-1 cDNA to identify the amino acid residues that mediate heparin binding. To that end, 15 single-point mutants of PAI-1, each having individual arginyl, lysyl, or histidyl residues replaced by a neutral (alanyl) residue ("ala-scan"), and one double mutant were constructed, expressed in Escherichia coli, and purified to apparent homogeneity. The purified biologically active proteins were subjected to the following analyses: (i) heparin-dependent inhibition of thrombin; (ii) heparin-dependent formation of sodium dodecyl sulfate-stable complexes with thrombin; and (iii) binding to and elution from heparin-Sepharose. Based on the data presented, we propose that the amino acid residues Lys65, Lys69, Arg76, Lys80 and Lys88 constitute major determinants for heparin binding of PAI-1. These residues are located in and around the helix D domain and are conserved in the other heparin-dependent thrombin inhibitors, antithrombin III and heparin cofactor II.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV,CENT LAB,DEPT MOLEC BIOL, PLESMANLAAN 125, 1066 CX AMSTERDAM, NETHERLANDS				Keijer, Jaap/J-8089-2013	Keijer, Jaap/0000-0002-9720-7491				ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BLINDER MA, 1990, J BIOL CHEM, V265, P286; BORG JY, 1988, J CLIN INVEST, V81, P1292, DOI 10.1172/JCI113447; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINKHOUS KM, 1939, AM J PHYSIOL, V125, P863; CHANG JY, 1989, J BIOL CHEM, V264, P3111; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FUJIKAWA K, 1973, BIOCHEMISTRY-US, V12, P4938, DOI 10.1021/bi00748a019; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KEIJER J, 1991, BLOOD, V78, P1254; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERS JWJ, 1988, FIBRINOLYSIS S1, V2; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; Maniatis T., 1982, MOL CLONING; MIMURO J, 1989, J BIOL CHEM, V264, P936; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OWEN MC, 1987, BLOOD, V69, P1275; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PAQUES EP, 1986, THROMB RES, V42, P797, DOI 10.1016/0049-3848(86)90116-7; POMERANTZ MW, 1978, BIOCHIM BIOPHYS ACTA, V535, P66, DOI 10.1016/0005-2795(78)90033-8; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; STATHAKIS NE, 1977, J CLIN INVEST, V60, P855, DOI 10.1172/JCI108840; STEIN PL, 1989, J BIOL CHEM, V264, P15441; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; WHINNA HC, 1991, J BIOL CHEM, V266, P8129; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2	44	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11606	11611						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375944				2022-12-27	WOS:A1992HX16900102
J	LANCASTER, JR; LANGREHR, JM; BERGONIA, HA; MURASE, N; SIMMONS, RL; HOFFMAN, RA				LANCASTER, JR; LANGREHR, JM; BERGONIA, HA; MURASE, N; SIMMONS, RL; HOFFMAN, RA			EPR DETECTION OF HEME AND NONHEME IRON-CONTAINING PROTEIN NITROSYLATION BY NITRIC-OXIDE DURING REJECTION OF RAT-HEART ALLOGRAFT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; L-ARGININE; ACTIVATED MACROPHAGES; HEMOGLOBIN; CELLS; COMPLEXES; VASODILATORS; GENERATION; INHIBITION; PATHWAY	The paramagnetic molecule nitric oxide (NO), produced from L-arginine by a specific enzyme (NO synthase), has been shown to be involved in a surprising variety of mammalian cellular responses, including the regulation of T cell immunity to alloantigens in vitro. In cytotoxic activated macrophages, NO production results in a characteristic pattern of alteration of iron-containing enzyme function that is mimicked by exposure to NO. Electron paramagnetic resonance (EPR) studies have shown the formation of iron-nitrosyl species during macrophage activation and also during sepsis, indicating that alteration of iron-containing protein function may be the result of the well-documented tendency of NO to bind to metal ions. We have recently shown that the NO synthesis induced during alloantigenic activation of rat splenocytes inhibits lymphocyte proliferation and cytotoxic T-lymphocyte generation. This report demonstrates that iron-nitrosyl EPR signals similar to those observed in macrophages and during sepsis are present in the blood and in the grafted t issue of rats during the rejection of allogeneic (but not syngeneic) heart grafts. These signals are found in the blood and at the site of allograft rejection, but are not found in other tissues (such as spleen and lung), and are obliterated by administration of the immunosuppressant FK506. These results directly demonstrate the formation of iron-nitrosyl complexes during vascularized allograft rejection and suggest that consequent destruction of iron-containing protein function plaYs an important role in the rejection response.	UNIV PITTSBURGH, SCH MED, DEPT SURG, PITTSBURGH, PA 15261 USA; UTAH STATE UNIV, DEPT CHEM & BIOCHEM, LOGAN, UT 84322 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Utah System of Higher Education; Utah State University					NIAID NIH HHS [AI-16869] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI016869, R37AI016869, R01AI016869] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBINA JE, 1989, J IMMUNOL, V143, P3641; ALIEV DI, 1986, STUD BIOPHYS, V115, P173; BAKER JE, 1988, P NATL ACAD SCI USA, V85, P2786, DOI 10.1073/pnas.85.8.2786; BASOSI R, 1975, J CHEM SOC PERK T 2, P423, DOI 10.1039/p29750000423; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; DERVARTA.DV, 1973, BIOCHIM BIOPHYS ACTA, V292, P496, DOI 10.1016/0005-2728(73)90055-8; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; GOTO T, 1991, TRANSPL P, V23, P2713; HANCOCK WW, 1987, J IMMUNOL, V138, P164; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIBBS JB, 1990, INT CONGR SER, V897, P189; HILLE R, 1979, J BIOL CHEM, V254, P2110; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; JEZOWSKATREZEBI.X, 1973, J MOL STRUCT, V19, P635; KON H, 1968, J BIOL CHEM, V243, P4350; KRUSZYNA H, 1987, TOXICOL APPL PHARM, V91, P429, DOI 10.1016/0041-008X(87)90064-0; KRUSZYNA R, 1988, TOXICOL APPL PHARM, V94, P458, DOI 10.1016/0041-008X(88)90286-4; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LANGREHR JM, 1992, TRANSPLANTATION, V53, P632, DOI 10.1097/00007890-199203000-00027; LANGREHR JM, 1991, SURGERY, V110, P335; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LOURO SRW, 1981, BIOCHIM BIOPHYS ACTA, V670, P56, DOI 10.1016/0005-2795(81)90048-9; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MCDONALD CC, 1965, J AM CHEM SOC, V87, P3319, DOI 10.1021/ja01093a007; MICHALSKI WP, 1987, ARCH MICROBIOL, V147, P304, DOI 10.1007/BF00463493; MILLS CD, 1991, J IMMUNOL, V146, P2719; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORSE RH, 1980, J BIOL CHEM, V255, P7876; MURASE N, 1987, TRANSPLANT P, V19, P71; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; PETROULEAS V, 1990, BIOCHIM BIOPHYS ACTA, V1015, P131, DOI 10.1016/0005-2728(90)90224-R; SALERNO JC, 1976, BIOCHEM BIOPH RES CO, V73, P833, DOI 10.1016/0006-291X(76)90884-6; SAWADA S, 1987, J IMMUNOL, V139, P1797; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; STADLER J, 1991, AM J PHYSIOL, V260, pC910, DOI 10.1152/ajpcell.1991.260.5.C910; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; STUEHR DJ, 1992, IN PRESS ADV ENZYMOL; VANIN A. F., 1967, BIOKHIMIYA, V32, P277; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680; WOOLUM JC, 1968, BIOCHIM BIOPHYS ACTA, V160, P311, DOI 10.1016/0005-2795(68)90204-3; YUI Y, 1991, J BIOL CHEM, V266, P12544	47	194	196	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10994	10998						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375934				2022-12-27	WOS:A1992HX16900013
J	RICE, KM; LIENHARD, GE; GARNER, CW				RICE, KM; LIENHARD, GE; GARNER, CW			REGULATION OF THE EXPRESSION OF PP160, A PUTATIVE INSULIN-RECEPTOR SIGNAL PROTEIN, BY INSULIN, DEXAMETHASONE, AND 1-METHYL-3-ISOBUTYLXANTHINE IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; PRIMARY CULTURED ADIPOCYTES; TYROSINE KINASE-ACTIVITY; RAT ADIPOCYTES; ADIPOSE DIFFERENTIATION; GLUCOSE TRANSPORTER; HEXOSE-TRANSPORT; PHOSPHORYLATION; RESPONSIVENESS; CELLS	pp160, a cytosolic protein with M(r) of approximately 160,000, is phosphorylated on tyrosine in response to insulin and is considered to be involved in signaling from the insulin receptor. The expression of pp160 during the differentiation of 3T3-L1 fibroblasts to adipocytes and in adipocytes has been investigated using quantitative immunoblotting with antibodies against a peptide from pp160. Between day 6 and day 8 of differentiation induced by insulin, dexamethasone (Dex), and 1-methyl-3-isobutylxanthine (Mix), pp160 expression increased 10-20-fold over the amount present in confluent fibroblasts. Omission of either insulin or Dex resulted in reduced expression of pp160 and in incomplete adipogenesis. Chronic treatment of fully differentiated adipocytes for 24 h with either insulin, Dex, or Mix alone in the presence of serum resulted in a decrease in the expression of pp160 by 70-85%. Chronic exposure to insulin caused a significant increase in the apparent size of pp160 to 172 kDa. Alkaline phosphatase treatment lowered the M(r) of pp160 from both insulin-treated and basal cells to 150,000. These results demonstrate that pp160 is expressed in 3T3-L1 adipocytes during the time when insulin receptors are expressed in large numbers and that the maintenance of pp160 concentrations in adipocytes can be regulated by insulin, Mix, and Dex. The decreased expression of pp160 caused by these factors may be related to postreceptor insulin resistance.	TEXAS TECH UNIV,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,LUBBOCK,TX 79430; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT BIOCHEM,HANOVER,NH 03756	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Dartmouth College					NIDDK NIH HHS [DK 42816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHOU CK, 1987, J BIOL CHEM, V262, P1842; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; FROST SC, 1985, J BIOL CHEM, V260, P2646; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GARVEY WT, 1986, DIABETES, V35, P258, DOI 10.2337/diabetes.35.3.258; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; HAUNER H, 1990, ENDOCRINOLOGY, V127, P865, DOI 10.1210/endo-127-2-865; JANAKIDEVI K, 1988, ANAL BIOCHEM, V172, P78, DOI 10.1016/0003-2697(88)90413-7; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KARLSSON FA, 1979, ENDOCRINOLOGY, V104, P1383, DOI 10.1210/endo-104-5-1383; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; KURIHARCUCH W, 1983, J CELL PHYSIOL, V114, P39, DOI 10.1002/jcp.1041140107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMA FB, 1991, ENDOCRINOLOGY, V128, P2415, DOI 10.1210/endo-128-5-2415; MADOFF DH, 1988, BIOCHEM J, V252, P7, DOI 10.1042/bj2520007; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; RESH MD, 1982, J BIOL CHEM, V257, P6978; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TRAXINGER RR, 1989, J BIOL CHEM, V264, P8156; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	38	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10163	10167						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374400				2022-12-27	WOS:A1992HT96500107
J	SHANKAR, R; DELAMOTTE, CA; DICORLETO, PE				SHANKAR, R; DELAMOTTE, CA; DICORLETO, PE			3-DEAZAADENOSINE INHIBITS THROMBIN-STIMULATED PLATELET-DERIVED GROWTH-FACTOR PRODUCTION AND ENDOTHELIAL-LEUKOCYTE ADHESION MOLECULE-1-MEDIATED MONOCYTIC CELL-ADHESION IN HUMAN AORTIC ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLHOMOCYSTEINE HYDROLASE INHIBITOR; TISSUE PLASMINOGEN-ACTIVATOR; FACTOR-LIKE PROTEIN; PHOSPHOLIPID METHYLATION; PROSTACYCLIN PRODUCTION; TRANSCRIPTIONAL REGULATION; VONWILLEBRAND-FACTOR; FACTOR-BETA; A-CHAIN; RELEASE	Injury to the vascular endothelium and the subsequent inflammatory response are considered prerequisites for the development of atherosclerosis. Platelet-derived growth factor (PDGF) production by and monocyte adhesion to aortic endothelial cells (EC) may participate in this inflammatory process and therefore are two potential targets for control by anti-inflammatory agents. Our previous studies have demonstrated that monocyte adhesion and PDGF production are stimulated by thrombin in EC. Here, we provide evidence that treatment of EC with the anti-inflammatory agent 3-deazaadenosine (c3 Ado) effectively abolished thrombin-stimulated PDGF production and monocyte adhesion. c3 Ado had no significant effect on either basal monocyte adhesion or constitutive PDGF production. c3 Ado was also effective in negating monocyte adhesion induced by other agonists, such as interleukin-1, phorbol 12-myristate 13-acetate (PMA), and lipopolysaccharide. Northern analysis demonstrated that c3 Ado significantly reduced thrombin- and PMA-stimulated steady-state levels of PDGF-A chain, PDGF-B chain, and endothelial-leukocyte adhesion molecule-1 (ELAM-1) mRNAs. Nuclear run-on studies demonstrated that a marked transcriptional activation of these genes by thrombin and PMA was abrogated by c3 Ado treatment. The transcriptional rate of the alpha-tubulin gene was unaffected by the drug. Antibody binding studies with an anti-ELAM-1 monoclonal antibody 7A9 revealed that thrombin-stimulated EC expression of ELAM-1 was abolished by c3 Ado, indicating that the suppression of ELAM-1 expression on EC surface may be a mechanism by which c3 Ado interferes with monocyte adhesion. Experiments with the nucleoside transport inhibitor nitrobenzylthioinosine suggested that the transport of c3 Ado into EC was required for its inhibitory activity. In addition, L-homocysteine thiolactone was found to potentiate the inhibitory activity of c3 Ado, suggesting that the accumulation of intracellular c3 Ado homocysteine may be the underlying mechanism by which c3 Ado inhibits thrombin-induced EC function. Taken together, these results indicate that C3 Ado may prove effective against vascular injury and inflammation through its ability to inhibit induction of both monocyte adhesion and PDGF production.	CLEVELAND CLIN FDN,RES INST NC1,DEPT VASC CELL BIOL & ATHEROSCLEROSIS RES,9500 EUCLID AVE,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582, R01HL034727, K04HL001561] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 1561, HL 29582, HL 34727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKSAMIT RR, 1983, J BIOL CHEM, V258, P20; AKSAMIT RR, 1982, J BIOL CHEM, V257, P621; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Borchardt R. T., 1986, BIOL METHYLATION DRU, P227; CHIANG PK, 1977, MOL PHARMACOL, V13, P939; CHIANG PK, 1986, BIOL METHYLATION DRU, P239; CHIANG PK, 1985, METHOD PHARMACOL, V6, P127; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DANIEL TO, 1988, J BIOL CHEM, V263, P19815; DEGROOT PG, 1984, J BIOL CHEM, V259, P3329; DICORLETO PE, 1989, BIOCHEM J, V264, P71, DOI 10.1042/bj2640071; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DICORLETO PE, 1989, J IMMUNOL, V143, P3666; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; DICORLETO PE, 1991, FASEB J, V5, pA1602; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; FUKUSHIMA M, 1989, INVEST OPHTH VIS SCI, V30, P1576; GAMBLE JR, 1988, SCIENCE, V242, P97; GARCIACASTRO I, 1983, J BIOL CHEM, V258, P4345; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GHIBO D, 1988, J BIOL CHEM, V263, P19437; GIMBRONE MA, 1990, NY ACAD SCI, V598, P77; GRABER N, 1990, J IMMUNOL, V145, P819; HALLAM TJ, 1988, BIOCHEM J, V251, P243, DOI 10.1042/bj2510243; HARLAN JM, 1986, J CELL BIOL, V103, P1129, DOI 10.1083/jcb.103.3.1129; HELDIN CH, 1979, P NATL ACAD SCI USA, V76, P3722, DOI 10.1073/pnas.76.8.3722; HIRATA F, 1980, SCIENCE, V209, P1082, DOI 10.1126/science.6157192; HOSHI H, 1986, IN VITRO CELL DEV B, V22, P51; JURGENSEN CH, 1990, J IMMUNOL, V144, P653; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; LEONARD EJ, 1978, BIOCHEM BIOPH RES CO, V84, P102, DOI 10.1016/0006-291X(78)90269-3; LEVIN EG, 1984, J CLIN INVEST, V74, P1988, DOI 10.1172/JCI111620; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; MCKEEHAN WL, 1980, IN VITRO CELL DEV B, V16, P475; MEDZIHRADSKY JL, 1984, J IMMUNOL, V133, P946; MEDZIHRADSKY JL, 1983, IMMUNOPHARMACOLOGY, V6, P51, DOI 10.1016/0162-3109(83)90016-4; MEDZIHRADSKY JL, 1982, J IMMUNOPHARMACOL, V4, P29, DOI 10.3109/08923978209031073; MORITA Y, 1982, BIOCHEM PHARMACOL, V31, P2111, DOI 10.1016/0006-2952(82)90428-2; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; POBER JS, 1986, J IMMUNOL, V136, P12680; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; PRUS KL, 1986, PFLUEGERS ARCH, V407, pS32; RAINES EW, 1982, J BIOL CHEM, V257, P5154; RAZIN A, 1988, P NATL ACAD SCI USA, V85, P9003, DOI 10.1073/pnas.85.23.9003; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICHES DWH, 1985, J LEUKOCYTE BIOL, V37, P545, DOI 10.1002/jlb.37.5.545; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; SCHINI VB, 1989, EUR J PHARMACOL, V165, P333, DOI 10.1016/0014-2999(89)90733-4; SEDMAK D, 1989, FASEB Journal, V3, pA634; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; STARKSEN NF, 1987, J BIOL CHEM, V262, P14381; STOPFORD CR, 1985, P NATL ACAD SCI USA, V82, P4060, DOI 10.1073/pnas.82.12.4060; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUNG SSJ, 1985, J BIOL CHEM, V260, P546; TOOTHILL VJ, 1990, J IMMUNOL, V145, P283; WALLIS WJ, 1985, J IMMUNOL, V135, P2323; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; YAGAWA K, 1986, FEBS LETT, V201, P287, DOI 10.1016/0014-5793(86)80625-1; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232; ZIMMERMAN TP, 1978, P NATL ACAD SCI USA, V75, P6220, DOI 10.1073/pnas.75.12.6220; ZIMMERMAN TP, 1984, J BIOL CHEM, V259, P1122; ZIMMERMAN TP, 1986, BIOL METHYLATION DRU, P417	64	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9376	9382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374393				2022-12-27	WOS:A1992HR85400102
J	WANG, XK; LEE, G; LIEBHABER, SA; COOKE, NE				WANG, XK; LEE, G; LIEBHABER, SA; COOKE, NE			HUMAN CYSTEINE-RICH PROTEIN - A MEMBER OF THE LIM DOUBLE-FINGER FAMILY DISPLAYING COORDINATE SERUM INDUCTION WITH C-MYC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; T-CELL ONCOGENE; MESSENGER-RNA; DEVELOPMENTAL REGULATION; ZINC ENZYMES; GENE-PRODUCT; 3T3 CELLS; TRANSCRIPTION; GROWTH; IDENTIFICATION	We previously reported the structure of the placentally derived human cysteine-rich (hcrp) cDNA and demonstrated that it encodes a highly conserved and widely distributed zinc finger-like protein. We now report that the expression of both the mouse and human crp genes is induced as a primary response to serum in quiescent Balb/c 3T3 cells and in human fibroblasts. The profile of this primary response is remarkably parallel to that of c-myc in the Balb/c 3T3 cell line. The structure of the 23.2-kilobase hcrp gene demonstrates that it is a member of a gene superfamily encoding proteins sharing a highly characteristic 52-amino acid "LIM/double-finger" motif. The evolutionarily conserved structure of cysteine-rich protein, its structural similarity to a number of developmentally critical proteins, its distinctive tissue distribution, and its primary response to early events in the cell cycle suggest that crp plays an important role in cell function.	UNIV PENN, DEPT MED & HUMAN GENET,RM 700,CLIN RES BLDG, 422 CURIE BLVD, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, HOWARD HUGHES MED INST, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD025147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032035] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25147] Funding Source: Medline; NIGMS NIH HHS [GM32035] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; Foulkes, 1991, HORMONAL CONTROL REG, P257; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Goossens M, 1981, Methods Enzymol, V76, P805; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NALIK P, 1989, MOL CELL ENDOCRINOL, V62, P235, DOI 10.1016/0303-7207(89)90010-5; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TRAVALI S, 1990, FASEB J, V4, P3209, DOI 10.1096/fasebj.4.14.2227212; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	61	101	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9176	9184						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374386				2022-12-27	WOS:A1992HR85400073
J	RINCON, M; TUGORES, A; LOPEZBOTET, M				RINCON, M; TUGORES, A; LOPEZBOTET, M			CYCLIC-AMP AND CALCIUM REGULATE AT A TRANSCRIPTIONAL LEVEL THE EXPRESSION OF THE CD7 LEUKOCYTE DIFFERENTIATION ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; ALPHA-SUBUNIT GENE; NF-KAPPA-B; MONOCLONAL-ANTIBODY; MESSENGER-RNA; INTERLEUKIN-2 PRODUCTION; RECEPTOR EXPRESSION; RIBONUCLEIC-ACID; BINDING; FOS	CD7 is a 40-kDa cell surface glycoprotein expressed on T-cell precursors before their entry into the thymus during fetal development and whose functional role remains uncertain. T-cell activation has been shown to increase the expression of this surface molecule. In this report we describe the intracellular signals and the mechanisms involved in the regulation of CD7 antigen expression on human T lymphocytes. The elevation of intracellular calcium by using the A23187 ionophore increased the cell surface expression of CD7, whereas protein kinase C activation caused its down-regulation. Interestingly, the increase of intracellular cAMP with Bt2cAMP stimulated CD7 expression as well. Up-regulation of CD7 on the cell surface following either Bt2cAMP or calcium ionophore stimulation of T lymphocytes correlated with a raise of the steady-state levels of CD7-specific mRNA, without de novo protein synthesis requirements. No differences between the half-life of basal CD7 mRNA and that induced by either Bt2cAMP or calcium ionophore were detected. Run-on experiments showed that both stimuli enhanced the transcriptional rate of the CD7 gene. Our results provide the evidence for a positive regulatory effect mediated by cAMP on the expression of a leucocyte differentiation antigen.			RINCON, M (corresponding author), UNIV AUTONOMA MADRID, HOSP PRINCESA, SECC INMUNOL, C DIEGO LEON 62, E-28006 MADRID, SPAIN.		Tugores, Antonio/AAE-7939-2021; Lopez-Botet, Miguel/I-5434-2014	Lopez-Botet, Miguel/0000-0003-4882-065X; Tugores, Antonio/0000-0002-1849-9239				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAMBURU J, 1991, J IMMUNOL, V147, P714; ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CARRERA AC, 1988, J IMMUNOL, V141, P1919; CARRERA AC, 1988, EUR J IMMUNOL, V18, P961, DOI 10.1002/eji.1830180620; CHAPLIN DD, 1980, BIOL BASIS IMMUNODEF, P269; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOUAIB S, 1985, J IMMUNOL, V135, P1172; COSMAN D, 1987, IMMUNOL TODAY, V8, P16, DOI 10.1016/0167-5699(87)90826-7; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; EMARA M, 1989, HUM IMMUNOL, V25, P87, DOI 10.1016/0198-8859(89)90073-6; EMARA M, 1991, FASEB J, V5, pA994; ERICKSON JM, 1981, GENE, V16, P19; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARPOLD MM, 1981, MOL CELL BIOL, V1, P188, DOI 10.1128/MCB.1.2.188; HAYNES BF, 1989, IMMUNOL TODAY, V10, P87, DOI 10.1016/0167-5699(89)90232-6; HAYNES BF, 1979, P NATL ACAD SCI USA, V76, P5829, DOI 10.1073/pnas.76.11.5829; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JUNG LKL, 1988, EUR J IMMUNOL, V18, P711, DOI 10.1002/eji.1830180509; JUNG LKL, 1986, J CLIN INVEST, V77, P940, DOI 10.1172/JCI112393; JUNG LKL, 1990, FASEB J, V4, pA1935; LAZAROVITS AI, 1988, TRANSPLANT P, V20, P1253; LEDBETTER JA, 1986, J IMMUNOL, V137, P3299; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LINDSTEN T, 1988, MOL CELL BIOL, V8, P3820, DOI 10.1128/MCB.8.9.3820; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; LINK M, 1983, BLOOD, V62, P722; LOPEZBOTET M, 1987, EUR J IMMUNOL, V17, P1167, DOI 10.1002/eji.1830170814; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MALTER JS, 1988, J IMMUNOL, V140, P3233; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORISHIMA Y, 1982, J IMMUNOL, V129, P1091; QUACH TT, 1984, MOL PHARMACOL, V26, P255; RAPPAPORT RS, 1982, J EXP MED, V155, P943, DOI 10.1084/jem.155.3.943; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RENSENDEZ E, 1986, J CELL BIOL, V103, P2145; RINCON M, 1988, EUR J IMMUNOL, V18, P1791, DOI 10.1002/eji.1830181121; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHANBERG LE, 1991, P NATL ACAD SCI USA, V88, P603, DOI 10.1073/pnas.88.2.603; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SPITS H, 1985, EUR J IMMUNOL, V15, P88, DOI 10.1002/eji.1830150117; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; VODINELICH L, 1983, BLOOD, V62, P1108; WALKER C, 1983, J IMMUNOL, V130, P1770; WARE RE, 1991, J IMMUNOL, V147, P2787; WARE RE, 1991, FASEB J, V5, pA991; WARE RE, 1989, J IMMUNOL, V143, P3632; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZUTTER MM, 1990, LEUKEMIA RES, V14, P23, DOI 10.1016/0145-2126(90)90142-V	61	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18026	18031						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381361				2022-12-27	WOS:A1992JM22300084
J	MANOLSON, MF; PROTEAU, D; PRESTON, RA; STENBIT, A; ROBERTS, BT; HOYT, MA; PREUSS, D; MULHOLLAND, J; BOTSTEIN, D; JONES, EW				MANOLSON, MF; PROTEAU, D; PRESTON, RA; STENBIT, A; ROBERTS, BT; HOYT, MA; PREUSS, D; MULHOLLAND, J; BOTSTEIN, D; JONES, EW			THE VPH1 GENE ENCODES A 95-KDA INTEGRAL MEMBRANE POLYPEPTIDE REQUIRED FOR INVIVO ASSEMBLY AND ACTIVITY OF THE YEAST VACUOLAR H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; CDNA SEQUENCE; MOTIVE FORCE; OAT ROOTS; PROTEIN; ACIDIFICATION; TRANSPORT	Yeast vacuolar acidification-defective (vph) mutants were identified using the pH-sensitive fluorescence of 6-carboxyfluorescein diacetate (Preston, R. A., Murphy, R. F., and Jones, E. W. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7027-7031). Vacuoles purified from yeast bearing the vph1-1 mutation had no detectable bafilomycin-sensitive ATPase activity or ATP-dependent proton pumping. The peripherally bound nucleotide-binding subunits of the vacuolar H+-ATPase (60 and 69 kDa) were no longer associated with vacuolar membranes yet were present in wild type levels in yeast whole cell extracts. The VPH1 gene was cloned by complementation of the vph1-1 mutation and independently cloned by screening a lambda-gt11 expression library with antibodies directed against a 95-kDa vacuolar integral membrane protein. Deletion disruption of the VPH1 gene revealed that the VPH1 gene is not essential for viability but is required for vacuolar H+-ATPase assembly and vacuolar acidification. VPH1 encodes a predicted polypeptide of 840 amino acid residues (molecular mass 95.6 kDa) and contains six putative membrane-spanning regions. Cell fractionation and immunodetection demonstrate that Vph1p is a vacuolar integral membrane protein that co-purifies with vacuolar H+-ATPase activity. Multiple sequence alignments show extensive homology over the entire lengths of the following four polypeptides: Vph1p, the 116-kDa polypeptide of the rat clathrin-coated vesicles/synaptic vesicle proton pump, the predicted polypeptide encoded by the yeast gene STV1 (Similar To VPH1, identified as an open reading frame next to the BUB2 gene), and the TJ6 mouse immune suppressor factor.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; STANFORD UNIV, DEPT BIOCHEM, BECKMAN CTR, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, DEPT GENET, STANFORD, CA 94305 USA	Johns Hopkins University; Stanford University; Stanford University	MANOLSON, MF (corresponding author), CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA.			Manolson, Morris/0000-0001-8755-5460	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018090, R37DK018090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011329, R01GM029713] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18090] Funding Source: Medline; NIGMS NIH HHS [GM29713, GM11329] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ANRAKU Y, 1989, J BIOENERG BIOMEMBR, V21, P589, DOI 10.1007/BF00808115; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1988, J BIOL CHEM, V263, P8796; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; GHISLAIN M, 1991, J BIOL CHEM, V266, P18276; GILLESPIE J, 1991, FEBS LETT, V282, P69, DOI 10.1016/0014-5793(91)80446-A; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; HAWTHORNE DC, 1960, GENETICS, V45, P1085; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRATA R, 1989, FEBS LETT, V244, P397, DOI 10.1016/0014-5793(89)80571-X; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; INOHARA N, 1991, J BIOL CHEM, V266, P7333; JONES EW, 1982, GENETICS, V102, P665; KAESTNER KH, 1988, J BIOL CHEM, V263, P1282; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI S, 1991, J BIOL CHEM, V266, P16078; LEE CK, 1990, MOL IMMUNOL, V27, P1137; Maniatis T., 1982, MOL CLONING; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1989, BIOCHEM CELL BIOL, V67, P306, DOI 10.1139/o89-047; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MITCHELL DR, 1989, CELL MOTIL CYTOSKEL, V14, P435, DOI 10.1002/cm.970140313; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; PRESTON RA, 1992, IN PRESS GENETICS; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; RANDALL SK, 1987, J BIOL CHEM, V262, P7135; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REA PA, 1987, J BIOL CHEM, V262, P14745; REA PA, 1985, PLANT PHYSIOL, V77, P46, DOI 10.1104/pp.77.1.46; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAFIAN V, 1992, BIOCHEM J, V283, P493, DOI 10.1042/bj2830493; SHARP PM, 1986, NUCLEIC ACIDS RES, V14, P5125, DOI 10.1093/nar/14.13.5125; SUN SZ, 1987, J BIOL CHEM, V262, P14790; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WOOLFORD CA, 1990, GENETICS, V125, P739; WRIGHT R, 1989, METHOD CELL BIOL, V31, P473; XIE XS, 1988, J BIOL CHEM, V263, P9859; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102; ZUBENKO GS, 1982, GENETICS, V102, P679	67	219	221	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14294	14303						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1385813				2022-12-27	WOS:A1992JD32500078
J	BIRNBAUMER, M; ANTARAMIAN, A; THEMMEN, APN; GILBERT, S				BIRNBAUMER, M; ANTARAMIAN, A; THEMMEN, APN; GILBERT, S			DESENSITIZATION OF THE HUMAN V2 VASOPRESSIN RECEPTOR - HOMOLOGOUS EFFECTS IN THE ABSENCE OF HETEROLOGOUS DESENSITIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SENSITIVE ADENYLATE-CYCLASE; DEPENDENT PROTEIN-KINASE; CELL-LINE LLC-PK1; PHOSPHORYLATION; IDENTIFICATION; TRANSITION; RHODOPSIN; MEMBRANES; CLONING	Three main pathways have been implicated in desensitization of receptors that stimulate adenylylcyclase (AC): cAMP-mediated phosphorylation; cAMP-independent phosphorylation, and receptor internalization. Cell lines derived from the murine Ltk- cell were found useful in exploring the contribution of cAMP-dependent phosphorylation in V2 vasopressin receptor desensitization. The HTB-2 cell expresses the human V2 vasopressin receptor, introduced by transfection of human genomic DNA, and the prostaglandin E1 (PGE1) receptor, endogenous to the Ltk- cell. The A7 cell expresses the hamster beta-2-adrenoceptor, which undergoes the above-mentioned desensitization processes. Treatment of HTB-2 cells with arginine-vasopressin (AVP) had no effect on AC responsiveness to PGE1, but promoted desensitization of the AVP response. This was seen as a 5-6-fold right shift in the dose-response curves for AVP action (cAMP accumulation in intact cells and AC stimulation in homogenates and isolated membranes) and in a decrease in the maximum effect of AVP on these parameters. AVP treatment caused a decrease in cell surface receptors to approximately 75% of control without changes in K(D), as determined by Scatchard analysis. When cAMP was increased by treatment with 10-mu-M PGE1 and isobutylmethylxanthine, desensitization of the PGE1 receptor was observed but not of the AVP receptor. In A7 cells the same treatment caused, as expected, a 3-fold right shift in the dose-response curve for AC stimulation by isoproterenol, indicating that L cells can mediate heterologous desensitization. These data demonstrate that the V2 vasopressin and the PGE1 receptors undergo homologous desensitization in the absence of cAMP-mediated phosphorylation and that this component is not required for vasopressin receptor internalization.			BIRNBAUMER, M (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.				NIDDK NIH HHS [DK-41244, DK-27685] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041244, P30DK027685] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIYAR N, 1990, CELL SIGNAL, V2, P153, DOI 10.1016/0898-6568(90)90018-6; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BIRNBAUMER M, 1990, MOL ENDOCRINOL, V4, P245, DOI 10.1210/mend-4-2-245; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; CLARK RB, 1987, FASEB J, V1, P289, DOI 10.1096/fasebj.1.4.2820824; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GUDDERMAN T, 1992, J BIOL CHEM, V267, P4479; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; KUNKEL MW, 1989, FASEB J, V3, P2067, DOI 10.1096/fasebj.3.9.2545497; LESTER BR, 1985, MOL CELL ENDOCRINOL, V40, P193, DOI 10.1016/0303-7207(85)90175-3; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIAO CF, 1990, J BIOL CHEM, V265, P11273; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PREMONT RT, 1989, ENDOCRINOLOGY, V125, P1151, DOI 10.1210/endo-125-3-1151; RICH KA, 1984, J BIOL CHEM, V259, P7893; ROY C, 1981, J BIOL CHEM, V256, P3423; ROY C, 1981, J BIOL CHEM, V256, P3415; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHICHI H, 1978, J BIOL CHEM, V253, P7040; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; SU YF, 1980, J BIOL CHEM, V255, P7410; TOEWS ML, 1984, J BIOL CHEM, V259, P1844; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	30	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11783	11788						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376312				2022-12-27	WOS:A1992HY94700024
J	GITT, MA; MASSA, SM; LEFFLER, H; BARONDES, SH				GITT, MA; MASSA, SM; LEFFLER, H; BARONDES, SH			ISOLATION AND EXPRESSION OF A GENE ENCODING L-14-II, A NEW HUMAN SOLUBLE LACTOSE-BINDING LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MESSENGER-RNA; MOLECULAR-CLONING; ELASTIN RECEPTOR; PROTEIN; GALACTOSE; CDNA; RIBOSOMES; MUSCLE; FAMILY	In the course of screening a human hepatoma cDNA library with antibody raised against a mammalian lectin with subunit molecular weight of about 14,000, we detected a partial cDNA encoding a related but distinct protein that was possibly a homologous lectin (Gitt and Barondes, 1986). We here report the isolation and sequencing of a full-length cDNA for this protein from a HepG2 cDNA library. The cDNA encodes a protein with subunit molecular weight of 14,650. Expression of the coding sequence in Escherichia coli yields a product that binds to a lactose affinity column and is specifically eluted with lactose, confirming that this new protein is a lectin. Like its well studied relative, here called L- 14-I, the new lectin, L- 14-II, exists as a homodimer in solution. The two related human lectins have 43% amino acid sequence identity. The genomic DNA encoding L-14-II (LGALS2) contains four exons with similar intron placement to L-14-I (LGALS1); but the genomic upstream region, which contains several sequences characteristic of regulatory elements, differs significantly from L-14-I.	UNIV CALIF SAN FRANCISCO,LANGLEY PORTER PSYCHIAT INST,DEPT PSYCHIAT,BOX F-0984,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945				ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; ABBOTT WM, 1989, BIOCHEM J, V259, P291, DOI 10.1042/bj2590291; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; ALLEN HJ, 1991, BIOCHEMISTRY-US, V30, P8904, DOI 10.1021/bi00100a026; BARONDES SH, 1984, SCIENCE, V223, P1159; BEYER EC, 1980, J BIOL CHEM, V255, P4236; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHIARIOTTI L, 1991, BIOCHIM BIOPHYS ACTA, V1089, P54, DOI 10.1016/0167-4781(91)90084-Y; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GITT MA, 1986, P NATL ACAD SCI USA, V83, P7603, DOI 10.1073/pnas.83.20.7603; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; JIA SH, 1988, J BIOL CHEM, V263, P6009; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; Maniatis T., 1982, MOL CLONING; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; ODA Y, 1991, GENE, V99, P279; OHARA T, 1986, BIOCHIM BIOPHYS ACTA, V884, P344, DOI 10.1016/0304-4165(86)90183-2; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAZ A, 1991, CANCER RES, V51, P2173; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROFF CF, 1983, J BIOL CHEM, V258, P657; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WILSON TJG, 1989, BIOCHEM J, V261, P847, DOI 10.1042/bj2610847	37	114	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10601	10606						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375225				2022-12-27	WOS:A1992HV09000059
J	MALOUF, NN; MCMAHON, D; OAKELEY, AE; ANDERSON, PAW				MALOUF, NN; MCMAHON, D; OAKELEY, AE; ANDERSON, PAW			A CARDIAC TROPONIN-T EPITOPE CONSERVED ACROSS PHYLA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; THIN FILAMENT; CONTRACTILE PROTEINS; ADULT ISOFORMS; RABBIT; TROPOMYOSIN; GENE; EXPRESSION; BINDING	Troponin T is a thin filament protein that is important in regulating striated muscle contraction. We have raised a monoclonal antibody against rabbit cardiac troponin T, monoclonal (mAb) 13-11, that recognizes its epitope in cardiac troponin T isoforms from fish, bird, and mammal but not from frog. The number of these isoforms expressed in cardiac muscle varies among species and during development. Cardiac troponin T isoforms were not found in adult skeletal muscle, while they were expressed transiently in immature skeletal muscle. We have mapped the epitope recognized by mAb 13-11 using rabbit cardiac troponin T isoforms. Analysis of stepwise cyanogen bromide digestion, which allowed association of the epitope to regions spanning methionine residues, coupled with immunoactivity of synthetic peptides, corresponding to sequences containing methionine residues, indicated that mAb 13-11 recognized its epitope in a 17-residue sequence containing the methionine at position 68, SKPKPRPFMPNLVPPKI. Comparison of skeletal and cardiac troponin T sequences suggested that the epitope was contained within the sequence FMPNLVPPKI. Synthetic peptides PFMPNLVPPKI and FMPNLVPPKI were recognized by mAb 13-11 on slot-blots. Enzyme-linked immunosorbent assay demonstrated mAb 13-11 recognized, in order of descending affinity, the 17-, 11-, and 10-residue sequence. Preabsorption of mAb 13-11 with each of these sequences blocked the recognition of the 17-residue peptide by mAb 13-11. The domain, PFMPNLVPPKI is encoded by the 5' region of the cardiac gene exon 10 and is present in hearts across a broad range of phyla. These findings suggest that this cardiac troponin T-specific sequence confers onto myofilaments structural and functional properties unique to the heart.	DUKE UNIV, MED CTR, DEPT PEDIAT, POB 3218, DURHAM, NC 27710 USA; DUKE UNIV, DEPT CELL BIOL, DURHAM, NC 27710 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27514 USA	Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042250, R01HL037358, R01HL020749] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20749, HL 37358, HL 42250] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON PAW, 1988, CIRC RES, V63, P742, DOI 10.1161/01.RES.63.4.742; ANDERSON PAW, 1989, CIRC RES, V65, P1087, DOI 10.1161/01.RES.65.4.1087; ANDERSON PAW, 1991, CIRC RES, V69, P1226, DOI 10.1161/01.RES.69.5.1226; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; BRIGGS MM, 1987, J MUSCLE RES CELL M, V8, P1, DOI 10.1007/BF01767259; BRONSON DD, 1982, J BIOL CHEM, V257, P3937; COOPER TA, 1985, J BIOL CHEM, V260, P1140; CRAIK CS, 1982, NATURE, V299, P180, DOI 10.1038/299180a0; EBASHI S, 1984, J MOL CELL CARDIOL, V16, P129, DOI 10.1016/S0022-2828(84)80701-4; GAHLMANN R, 1987, J BIOL CHEM, V262, P16122; GETZOFF ED, 1988, ADV IMMUNOL, V43, P1; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; JIN JP, 1988, J BIOL CHEM, V263, P7309; JIN JP, 1989, J BIOL CHEM, V264, P14471; KELLER GA, 1984, P NATL ACAD SCI-BIOL, V81, P5744, DOI 10.1073/pnas.81.18.5744; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MALOUF NN, 1986, J HISTOCHEM CYTOCHEM, V34, P347, DOI 10.1177/34.3.3950385; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MCAULIFFE JJ, 1991, PEDIATR RES, V29, P580, DOI 10.1203/00006450-199106010-00012; NASSAR R, 1991, CIRC RES, V69, P1470, DOI 10.1161/01.RES.69.6.1470; ORDAHL CP, 1986, DEV BIOL, V117, P488, DOI 10.1016/0012-1606(86)90315-5; PEARLSTONE JR, 1976, P NATL ACAD SCI USA, V73, P1902, DOI 10.1073/pnas.73.6.1902; PEARLSTONE JR, 1986, J BIOL CHEM, V261, P6795; PLUSKAL MG, 1986, BIOTECHNIQUES, V4, P272; RAGGI A, 1989, BIOCHIM BIOPHYS ACTA, V997, P135, DOI 10.1016/0167-4838(89)90145-3; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; SCHIAFFINO S, 1991, J CELL BIOCHEM     S, V15, P149; TAINER JA, 1985, ANNU REV IMMUNOL, V3, P501, DOI 10.1146/annurev.iy.03.040185.002441; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILKINSON JM, 1978, BIOCHEM J, V169, P229, DOI 10.1042/bj1690229; WILKINSON JM, 1984, EUR J BIOCHEM, V143, P47, DOI 10.1111/j.1432-1033.1984.tb08337.x; WILLARD AS, 1990, P INT C ELECTRON MIC, V12, P364; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	38	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9269	9274						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374390				2022-12-27	WOS:A1992HR85400086
J	OKA, S; TERAYAMA, K; KAWASHIMA, C; KAWASAKI, T				OKA, S; TERAYAMA, K; KAWASHIMA, C; KAWASAKI, T			A NOVEL GLUCURONOSYLTRANSFERASE IN NERVOUS-SYSTEM PRESUMABLY ASSOCIATED WITH THE BIOSYNTHESIS OF HNK-1 CARBOHYDRATE EPITOPE ON GLYCOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-ADHESION MOLECULES; MYELIN-ASSOCIATED GLYCOPROTEIN; MONOCLONAL-ANTIBODY HNK-1; BINDING-PROTEINS; EXPRESSION; RAT; RECOGNITION; GLYCOLIPIDS; NEUROPATHY; BRAIN	Recently, embryonic chicken brain extract was shown to contain a glucuronyltransferase, which transfers glucuronic acid from UDP-glucuronic acid to glycolipid acceptors (neolactotetraosyl ceramide). The enzyme was also suggested to transfer glucuronic acid to glycoprotein acceptors (asialoorosomucoid) (Das, K. K., Basu, M., Basu, S., Chou, D. K. H., and Jungalwala, F. B. (1991) J. Biol. Chem. 266, 5238-5243). In this study, the glucuronyltransferase activity in rat brain extract was separated into two groups by UDP-glucuronic acid-Sepharose CL-6B column chromatography. The enzyme recovered predominantly in the effluent fraction (GlcAT-L) catalyzed the transfer of glucuronic acid to glycolipid acceptors but not to glycoprotein acceptors, whereas the enzyme recovered in the eluate fraction (GlcAT-P) transferred glucuronic acid most predominantly to glycoprotein acceptors and very little to glycolipid acceptors. GlcAT-P was able to transfer glucuronic acid to oligosaccharide chains on asialoorosomucoid. The enzyme recognized a terminal lactosamine structure, Galbeta1-4GlcNAc, on glycoproteins. It was localized in the nervous system and was hardly detectable in other tissues, including the thymus, spleen, lung, kidney, and liver. Although GlcAT-L and GlcAT-P shared some properties in common such as tissue distributions and developmental changes, they exhibited marked differences in their phospholipid dependence and in their pH profiles, apart from their respective acceptor preference to glycolipids and glycoproteins. The acceptor specificity and tissue distribution suggest that a novel glucuronyltransferase, GlcAT-P, is involved in the biosynthesis of the sulfo-glucuronylgalactose structure in the HNK-1 carbohydrate epitope that is expressed on glycoproteins.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,KYOTO 60601,JAPAN	Kyoto University				Terayama, Koji/0000-0002-0740-9074				ARIGA T, 1987, J BIOL CHEM, V262, P848; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; BURGER D, 1992, J NEUROCHEM, V58, P845, DOI 10.1111/j.1471-4159.1992.tb09334.x; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; DAS KK, 1991, J BIOL CHEM, V266, P5238; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EDELMAN GM, 1984, ANNU REV NEUROSCI, V7, P339; FISHMAN PH, 1976, ARCH BIOCHEM BIOPHYS, V172, P618, DOI 10.1016/0003-9861(76)90116-8; ILYAS AA, 1984, BIOCHEM BIOPH RES CO, V122, P1206, DOI 10.1016/0006-291X(84)91220-8; JESSELL TM, 1990, ANNU REV NEUROSCI, V13, P227, DOI 10.1146/annurev.ne.13.030190.001303; KAWASAKI T, 1977, J BIOL CHEM, V252, P6536; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; MOHAN PS, 1992, BIOCHEM BIOPH RES CO, V182, P689, DOI 10.1016/0006-291X(92)91787-Q; OKA S, 1988, ARCH BIOCHEM BIOPHYS, V260, P257, DOI 10.1016/0003-9861(88)90448-1; ROTH S, 1971, J CELL BIOL, V51, P536, DOI 10.1083/jcb.51.2.536; YOSHIHARA Y, 1991, J CELL BIOL, V115, P731, DOI 10.1083/jcb.115.3.731; YOSHIHARA Y, 1991, NEUROSCI RES, V10, P83, DOI 10.1016/0168-0102(91)90033-U; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	22	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22711	22714						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385405				2022-12-27	WOS:A1992JY16300005
J	PAINE, MJI; DESMOND, HP; THEAKSTON, RDG; CRAMPTON, JM				PAINE, MJI; DESMOND, HP; THEAKSTON, RDG; CRAMPTON, JM			PURIFICATION, CLONING, AND MOLECULAR CHARACTERIZATION OF A HIGH-MOLECULAR-WEIGHT HEMORRHAGIC METALLOPROTEASE, JARARHAGIN, FROM BOTHROPS-JARARACA VENOM - INSIGHTS INTO THE DISINTEGRIN GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-AGGREGATION INHIBITOR; AMINO-ACID-SEQUENCE; ASP-CONTAINING PEPTIDE; TRIMERESURUS-FLAVOVIRIDIS; VONWILLEBRAND-FACTOR; BLOOD-COAGULATION; POTENT INHIBITOR; VIPER VENOMS; SNAKE; PROTEINS	A large hemorrhagin, jararhagin, has been cloned from a Bothrops jararaca venom gland cDNA expression library. The cDNA sequence predicts a 421-amino acid residue molecule with strong amino acid sequence homology and similar domain structure to HR1B, a high molecular weight hemorrhagic metalloprotease isolated from Trimeresurus flavoviridis (Habu) venom. Like HR1B, jararhagin contains enzyme, disintegrin, and cysteine-rich carboxyl-terminal regions. In the disintegrin region, the Arg-Gly-Asp sequence is replaced by Glu-Cys-Asp, as found in non-Arg-Gly-Asp disintegrin regions of HR1B and a guinea pig sperm fusion protein PH-30beta. The cDNA sequence of jararhagin predicts a precursor protein (proprotein) with striking similarity to cryptic regions in precursors of the disintegrin peptides trigramin and rhodostomin. Comparison of jararhagin with disintegrin precursors highlights the modular arrangement of proprotein, metalloprotease, and disintegrin domains in the metalloprotease/disintegrin family and provides an insight into their biosynthesis and evolution.	UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,WOLFSON UNIT MOLEC GENET,LIVERPOOL L3 5QA,ENGLAND	Liverpool School of Tropical Medicine; University of Liverpool	PAINE, MJI (corresponding author), UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,SNAKE VENOM RES UNIT,PEMBROKE PL,LIVERPOOL L3 5QA,ENGLAND.		Paine, Mark John Ingraham/O-7450-2019; Paine, Mark/D-3360-2013	Paine, Mark John Ingraham/0000-0003-2061-7713; Paine, Mark/0000-0003-2061-7713	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASSAKURA MT, 1986, TOXICON, V24, P943, DOI 10.1016/0041-0101(86)90094-2; AU LC, 1991, BIOCHEM BIOPH RES CO, V181, P585, DOI 10.1016/0006-291X(91)91230-A; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; CARDOSO JLC, 1982, ACIDENTS ANIMALS PEC; CHAO BH, 1989, P NATL ACAD SCI USA, V86, P8050, DOI 10.1073/pnas.86.20.8050; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; GAN ZR, 1988, J BIOL CHEM, V263, P19827; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; HUANG TF, 1991, J BIOCHEM-TOKYO, V109, P328; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KAMIGUTI AS, 1991, TOXICON, V29, P1097, DOI 10.1016/0041-0101(91)90207-8; KAMIGUTI AS, 1986, BRAZ J MED BIOL RES, V19, P199; KAMIGUTI AS, 1991, TOXICON, V29, P961, DOI 10.1016/0041-0101(91)90079-7; KINI RM, 1992, TOXICON, V30, P265, DOI 10.1016/0041-0101(92)90869-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDELBAUM FR, 1982, TOXICON, V20, P955, DOI 10.1016/0041-0101(82)90098-8; MARUYAMA M, 1990, THROMB HAEMOSTASIS, V63, P449; MATTHEWS BW, 1974, J BIOL CHEM, V249, P8030; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MIYATA T, 1989, J BIOCHEM-TOKYO, V105, P847, DOI 10.1093/oxfordjournals.jbchem.a122756; NEEPER MP, 1990, NUCLEIC ACIDS RES, V18, P4255, DOI 10.1093/nar/18.14.4255; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSENFELD G., 1958, REV CLIN SAO PAULO, V34, P36; RUCINSKI B, 1990, BIOCHIM BIOPHYS ACTA, V1054, P257, DOI 10.1016/0167-4889(90)90096-V; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ EF, 1991, FEBS LETT, V282, P178, DOI 10.1016/0014-5793(91)80472-F; SAVAGE B, 1990, J BIOL CHEM, V265, P11766; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; SHEBUSKI RJ, 1989, J BIOL CHEM, V264, P21550; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; TAKEYA H, 1990, J BIOCHEM-TOKYO, V108, P711, DOI 10.1093/oxfordjournals.jbchem.a123270; TAKEYA H, 1989, J BIOCHEM-TOKYO, V106, P151, DOI 10.1093/oxfordjournals.jbchem.a122805; TAKEYA H, 1990, J BIOL CHEM, V265, P16068; WILLIAMS J, 1990, BIOCHIM BIOPHYS ACTA, V1039, P81, DOI 10.1016/0167-4838(90)90229-9	39	289	298	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1992	267	32					22869	22876						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JY163	1385408				2022-12-27	WOS:A1992JY16300027
J	SUN, XJ; MIRALPEIX, M; MYERS, MG; GLASHEEN, EM; BACKER, JM; KAHN, CR; WHITE, MF				SUN, XJ; MIRALPEIX, M; MYERS, MG; GLASHEEN, EM; BACKER, JM; KAHN, CR; WHITE, MF			EXPRESSION AND FUNCTION OF IRS-1 IN INSULIN SIGNAL TRANSMISSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH FACTOR-I; 3T3-L1 ADIPOCYTES; RECEPTOR; PHOSPHORYLATION; CELLS; SUBSTRATE; PROTEIN; TRANSDUCTION; SEQUENCE	IRS-1 is a major insulin receptor substrate which may play an important role in insulin signal transmission. The mRNA for IRS-1 in rat cells and tissues is about 9.5 kilobases (kb). Rat liver IRS-1 was stably expressed in Chinese hamster ovary (CHO) cells (CHO/IRS-1). Although its calculated molecular mass is 131 kDa, IRS-1 from quiescent cells migrated between 165 and 170 kDa during sodium dodecyl sulfate-polyacrylamide gel electrophoresis. IRS-1 was phosphorylated strongly on serine residues and weakly on threonine residues before insulin stimulation. Insulin immediately stimulated tyrosine phosphorylation of IRS-1, and after 10-30 min with insulin its apparent molecular mass increased to 175-180 kDa. Expression of the human insulin receptor and rat IRS-1 together in CHO/IR/IRS-1 cells increased the basal serine phosphorylation of IRS-1 and strongly increased tyrosine phosphorylation during insulin stimulation. Purified insulin receptors directly phosphorylated baculovirus-produced IRS-1 exclusively on tyrosine residues. By immunofluorescence, IRS-1 was absent from the nucleus, but otherwise distributed uniformly before and after insulin stimulation. Some IRS-1 associated with the insulin receptor during insulin stimulation. In addition, a phosphatidylinositol 3'-kinase associated with IRS-1 during insulin stimulation, and this association was more sensitive to insulin in CHO cells overexpressing the insulin receptor (CHO/IR cells), more responsive to insulin in CHO/IRS-1 cells, and both sensitive and responsive in CHO/IR/IRS-1 cells. Similarly, insulin-stimulated DNA synthesis was more sensitive to insulin in CHO/IR cells, and more responsive in CHO/IRS-1 cells; however, insulin-stimulated DNA synthesis was sensitive but poorly responsive to insulin in CHO/IR/IRS-1 cells. Together, these results suggest that IRS-1 is a direct physiologic substrate of the insulin receptor and may play an important role in insulin signal transmission.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM CELLULAR & DEV BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	SUN, XJ (corresponding author), HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115, USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK33201, DK 36836, DK43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK033201, R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1992, J BIOL CHEM, V267, P5408; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1991, BIOCHEMISTRY-US, V300, P6366; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOU CK, 1987, J BIOL CHEM, V262, P1842; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HARING HU, 1987, P NATL ACAD SCI USA, V84, P113, DOI 10.1073/pnas.84.1.113; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HOFMANN C, 1989, ENDOCRINOLOGY, V124, P257, DOI 10.1210/endo-124-1-257; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KAZLAUSKAS A, 1987, J CELL PHYSIOL, V130, P228, DOI 10.1002/jcp.1041300209; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MYERS MG, 1991, J BIOL CHEM, V266, P10616; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555, P1; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358	41	293	301	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22662	22672						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385403				2022-12-27	WOS:A1992JW71900103
J	TIGYI, G; MILEDI, R				TIGYI, G; MILEDI, R			LYSOPHOSPHATIDATES BOUND TO SERUM-ALBUMIN ACTIVATE MEMBRANE CURRENTS IN XENOPUS OOCYTES AND NEURITE RETRACTION IN PC12 PHEOCHROMOCYTOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID COMPOSITION; PHOSPHATIDIC-ACID; HUMAN-PLATELETS; ARACHIDONATE RELEASE; IDENTIFICATION; THROMBIN; AGGREGATION; STIMULUS; TURNOVER; PROTEINS	Serum contains a factor that co-purifies with albumin and causes neurite retraction in PC12 cells, inhibits the proliferation of tumor cells in vitro, and activates the phosphatidylinositol/Ca2+ second messenger system in Xenopus oocytes and other cells. The activity of serum albumin depends on several lysophospholipids bound to albumin. Thin layer chromatographic analysis of the lipids extracted by methanol from serum albumin revealed over a dozen components, several of which evoked oscillatory currents in oocytes. In contrast to serum albumin, most of these lipids were absent in plasma, which lacks the biological activity. The most abundant naturally occurring active component was identified as stearoyl-lysophosphatidic acid. Synthetically prepared lysophosphatidates reproduced the biological activities of the natural serum factor. Adding synthetic lysophosphatidates to inactive fatty acid-free albumin restored activity to the albumin, making the active factor nondialyzable against aqueous solvents and protecting against digestion by various lipases. Since the biologically active lysophosphatidates were produced during blood clotting, in the presence of platelets, and lysophosphatidates have been shown previously to activate platelets, we propose that lysophosphatidates may play an important role in linking platelet activation to receptor-mediated tissue regeneration.	UNIV CALIF IRVINE, DEPT PSYCHOBIOL, CELLULAR & MOLEC NEUROBIOL LAB, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023284] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23284] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BENTON AM, 1982, BLOOD, V60, P642; BILLAH MM, 1980, J BIOL CHEM, V255, P227; BROEKMAN MJ, 1981, J BIOL CHEM, V256, P8271; BROWN JR, 1982, LIPID PROTEIN INTERA, V1, P26; CALVO M, 1988, BIOCHIM BIOPHYS ACTA, V959, P238, DOI 10.1016/0005-2760(88)90196-8; COHN EJ, 1946, J AM CHEM SOC, V68, P459, DOI 10.1021/ja01207a034; CORR PB, 1979, CIRC RES, V44, P822, DOI 10.1161/01.RES.44.6.822; DAS AK, 1984, BIOCHIM BIOPHYS ACTA, V796, P178, DOI 10.1016/0005-2760(84)90346-1; DAS AK, 1989, LIPIDS, V24, P329, DOI 10.1007/BF02535172; DYER D, 1992, MOL BRAIN RES, V14, P293, DOI 10.1016/0169-328X(92)90096-T; DYER D, 1992, MOL BRAIN RES, V14, P302, DOI 10.1016/0169-328X(92)90097-U; DYER D, 1989, 3RD INT REG S, P28; DYER D, 1992, THESIS U CALIFORNIA; ESUMI H, 1979, BIOCHEM BIOPH RES CO, V87, P1191, DOI 10.1016/S0006-291X(79)80033-9; GERRARD JM, 1979, AM J PATHOL, V96, P423; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GERRARD JM, 1979, AM J PATHOL, V97, P531; HAMILTON JA, 1991, P NATL ACAD SCI USA, V88, P2051, DOI 10.1073/pnas.88.6.2051; HANAHAN DJ, 1980, J BIOL CHEM, V255, P5514; INOUE M, 1984, J BIOL CHEM, V259, P5083; JALINK K, 1990, J BIOL CHEM, V265, P12232; KALUZNY MA, 1985, J LIPID RES, V26, P135; KATES M, 1986, LABORATORY TECHNIQUE, V3; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; LAPETINA EG, 1981, J BIOL CHEM, V256, P1984; LAURSEN I, 1990, ANTICANCER RES, V10, P343; MCCREA JM, 1985, BIOCHIM BIOPHYS ACTA, V842, P189, DOI 10.1016/0304-4165(85)90202-8; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MOOLENAAR WH, 1991, ADV CANCER RES, V57, P87; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621; NAKAGAWA M, 1973, J BIOCHEM-TOKYO, V74, P1263, DOI 10.1093/oxfordjournals.jbchem.a130354; NEUFELD EJ, 1983, J BIOL CHEM, V258, P2461; NISHIKAWA T, 1988, JPN J PHARMACOL, V47, P143, DOI 10.1254/jjp.47.143; REED RG, 1986, J BIOL CHEM, V261, P5619; ROSSENEUMOTREFF M, 1970, J BIOCHEM, V68, P369, DOI 10.1093/oxfordjournals.jbchem.a129367; SAIFER A, 1961, J LIPID RES, V2, P268; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; TIGYI G, 1990, P NATL ACAD SCI USA, V87, P1521, DOI 10.1073/pnas.87.4.1521; TIGYI G, 1991, J BIOL CHEM, V266, P20602; TIGYI G, 1989, 3RD INT REG S, P28; TIGYI G, 1991, FAL BOOK ASBMB S LI, P24; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; TOKUMURA A, 1978, LIPIDS, V13, P572, DOI 10.1007/BF02533598; TOKUMURA A, 1980, ARCH INT PHARMACOD T, V245, P74; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; WRIGHT RS, 1971, J CHROMATOGR, V59, P220, DOI 10.1016/S0021-9673(01)80033-9	49	335	351	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1992	267	30					21360	21367						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JV011	1383223				2022-12-27	WOS:A1992JV01100019
J	SARTOR, O; MCLELLAN, CA; CHIUEH, T				SARTOR, O; MCLELLAN, CA; CHIUEH, T			COMPARISON OF SRC-FAMILY CDNAS REVEALS DISTINCT MECHANISMS UNDERLYING FOCUS FORMATION IN TRANSFECTED FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; NIH 3T3 CELLS; CHICKEN-EMBRYO FIBROBLASTS; RETROVIRUS SHUTTLE VECTOR; AVIAN-SARCOMA VIRUSES; C-SRC; CELLULAR PROTEINS; GENE-PRODUCT; RAT-CELLS; PP60C-SRC	Despite the intensive study of both cellular transformation and src-family protein-tyrosine kinases, there have been no direct comparisons of transforming potency for normal members of this gene-family. In this study, the focus-forming activity of normal c-src, fyn, and lck cDNAs were compared in NIH 3T3 cell transfection assays. Focus formation was studied quantitatively, and individual foci were analyzed for phosphotyrosine content and expression of appropriate translational products. Each foci arising from c-src transfectants had a marked increase in phosphotyrosine content, and the majority of these foci expressed a c-src protein with an aberrant carboxyl terminus. Foci derived from lck transfectants also had a marked increase in phosphotyrosine content, and some foci expressed a lck protein with an aberrant carboxyl terminus. In contrast, foci from fyn-transfected cells were not distinguished from G418-selected mass cultures in terms of total phosphotyrosine content or expression of p59fyn. These studies support the previously published concept that overexpression of the normal fyn protein contributes to focus formation in transfected NIH 3T3 cells but suggest that the focus-forming activity observed after c-src or lck transfections is frequently attributable to mutational events. Because lck mutations have not been previously described in transformed foci, we characterized the lck transcript expressed in two foci and identified a novel point mutation that encodes a lck protein with increased in vivo kinase and focus-forming activity.			SARTOR, O (corresponding author), NCI,DIV CANC TREATMENT,CLIN PHARMACOL BRANCH,RM 12N226,BLDG 10,BETHESDA,MD 20892, USA.							ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; CALOS MP, 1983, P NATL ACAD SCI-BIOL, V80, P3015, DOI 10.1073/pnas.80.10.3015; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; DYSON PJ, 1987, CELL BIOL INT REP, V11, P379, DOI 10.1016/0309-1651(87)90005-1; ELLIS C, 1991, ONCOGENE, V6, P895; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1989, ONCOGENE RES, V5, P49; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PIWNICAWORMS H, 1986, MOL CELL BIOL, V6, P2033, DOI 10.1128/MCB.6.6.2033; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RASHEED S, 1976, J VIROL, V19, P13, DOI 10.1128/JVI.19.1.13-18.1976; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SARTOR O, 1992, J BIOL CHEM, V267, P3460; SARTOR O, 1991, J BIOL CHEM, V266, P6462; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SHALLOWAY D, 1987, MOL CELL BIOL, V7, P3582, DOI 10.1128/MCB.7.10.3582; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SUGITA K, 1989, J VIROL, V63, P1715, DOI 10.1128/JVI.63.4.1715-1720.1989; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; WANG LH, 1988, VIRUS RES, V9, P159; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YACIUK P, 1988, ONCOGENE RES, V3, P207; ZHOU H, 1990, P NATL ACAD SCI USA, V87, P9128, DOI 10.1073/pnas.87.23.9128	48	9	9	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21044	21051						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383216				2022-12-27	WOS:A1992JT97800084
J	NOGUCHI, J; YANAGISAWA, M; IMAMURA, M; KASUYA, Y; SAKURAI, T; TANAKA, T; MASAKI, T				NOGUCHI, J; YANAGISAWA, M; IMAMURA, M; KASUYA, Y; SAKURAI, T; TANAKA, T; MASAKI, T			COMPLETE PRIMARY STRUCTURE AND TISSUE EXPRESSION OF CHICKEN PECTORALIS M-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-BAND PROTEINS; MUSCLE M-PROTEIN; SKELETAL-MUSCLE; IMMUNOGLOBULIN SUPERFAMILY; CREATINE-KINASE; LIMITED PROTEOLYSIS; ADHESION MOLECULE; ALPHA-ACTININS; SEQUENCE; DOMAINS	M-Protein (165 kDa) is a structural constituent of myofibrillar M-band in striated muscle. We generated a monoclonal antibody which recognized a 165-kDa protein from chicken pectoralis muscle in immunoblot analysis and stained the M-band under immunofluorescence microscopy. By screening a lambdagt11 cDNA library from chicken embryonic pectoralis muscle with this antibody, we isolated a cDNA clone encoding the M-protein. Northern blot analysis showed that M-protein mRNA is expressed in pectoralis and cardiac muscle but not in gizzard smooth muscle or non-muscle tissues. Moreover, the anterior latissimus dorsi muscle, which consists almost exclusively of slow fiber types, contains no detectable levels of the mRNA. The full-length cDNA sequence predicted a 1,450-amino acid polypeptide with a calculated molecular weight of 163 X 10(3). The encoded protein contains several copies of two different repetitive motifs: five copies of fibronectin type III repeats are in the middle part of the predicted molecule, and two and four copies of the immunoglobulin C2-type repeats are located toward the NH2-terminal and COOH-terminal regions, respectively. This indicates that M-protein, along with other thick filament-associated proteins such as C-protein, twichin, and titin, belongs to the superfamily of cytoskeletal proteins with immunoglobulin/fibronectin repeats.	UNIV TSUKUBA, INST BASIC MED SCI, TSUKUBA, IBARAKI 305, JAPAN; JAPAN RED CROSS, SAITAMA BRANCH, YONO, SAITAMA 338, JAPAN	University of Tsukuba				Kasuya, Yoshitoshi/0000-0003-0614-5836				BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; CARLSSON E, 1990, HISTOCHEMISTRY, V95, P27, DOI 10.1007/BF00737225; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; EPPENBERGER HM, 1981, J CELL BIOL, V89, P185, DOI 10.1083/jcb.89.2.185; EPPENBERGER HM, 1982, METHOD ENZYMOL, V85, P139; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; EREL Z, 1972, BIOCHEM BIOPH RES CO, V49, P383, DOI 10.1016/0006-291X(72)90422-6; FISCHMAN DA, 1991, INT CONGR SER, P211; GROVE BK, 1985, J CELL BIOL, V101, P1413, DOI 10.1083/jcb.101.4.1413; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; GROVE BK, 1989, J HISTOCHEM CYTOCHEM, V37, P447, DOI 10.1177/37.4.2926123; HIKIDA RS, 1981, AM J ANAT, V160, P395, DOI 10.1002/aja.1001600404; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IMAMURA M, 1990, MORPHOGENESIS FUNCTI, P53; INOUE A, 1989, J BIOL CHEM, V264, P14954; KOIDE T, 1973, EUR J BIOCHEM, V32, P401, DOI 10.1111/j.1432-1033.1973.tb02622.x; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LANDON MF, 1975, BIOCHEM BIOPH RES CO, V62, P241, DOI 10.1016/S0006-291X(75)80129-X; LUTHER P, 1978, J MOL BIOL, V125, P313, DOI 10.1016/0022-2836(78)90405-9; MASAKI T, 1972, J BIOCHEM, V71, P355, DOI 10.1093/oxfordjournals.jbchem.a129774; MASAKI T, 1974, J BIOCHEM, V75, P367, DOI 10.1093/oxfordjournals.jbchem.a130403; MASAKI T, 1968, J BIOCHEM-TOKYO, V64, P909, DOI 10.1093/oxfordjournals.jbchem.a128975; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STREHLER EE, 1983, J MOL BIOL, V166, P141, DOI 10.1016/S0022-2836(83)80003-5; STREHLER EE, 1979, EXP CELL RES, V124, P39, DOI 10.1016/0014-4827(79)90255-6; TRINICK J, 1977, J MOL BIOL, V113, P343, DOI 10.1016/0022-2836(77)90146-2; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WOODHEAD JL, 1983, J MOL BIOL, V168, P831, DOI 10.1016/S0022-2836(83)80077-1; WOODHEAD JL, 1982, J MOL BIOL, V157, P149, DOI 10.1016/0022-2836(82)90517-4	42	48	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20302	20310						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400348				2022-12-27	WOS:A1992JR85800088
J	STOCK, JB; SURETTE, MG; MCCLEARY, WR; STOCK, AM				STOCK, JB; SURETTE, MG; MCCLEARY, WR; STOCK, AM			SIGNAL TRANSDUCTION IN BACTERIAL CHEMOTAXIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ESCHERICHIA-COLI; ASPARTATE RECEPTOR; RESPONSE REGULATOR; 3-DIMENSIONAL STRUCTURES; PROTEIN-PHOSPHORYLATION; SENSORY TRANSDUCTION; CHEB METHYLESTERASE; CONSERVED ASPARTATE; CROSS-LINKING; MECHANISM		UNIV MED & DENT NEW JERSEY,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center	STOCK, JB (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.			Stock, Ann/0000-0002-0446-8079	NIAID NIH HHS [AI20980] Funding Source: Medline; NIGMS NIH HHS [GM14435] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADLER J, 1969, SCIENCE, V166, P1588, DOI 10.1126/science.166.3913.1588; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P776; BLOCK SM, 1982, CELL, V31, P215, DOI 10.1016/0092-8674(82)90421-4; BORCZUK A, 1986, BIOCHEM BIOPH RES CO, V141, P918, DOI 10.1016/S0006-291X(86)80130-9; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; FOX DK, 1986, J BIOL CHEM, V261, P3498; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; KOSHLAND DE, 1981, ANNU REV BIOCHEM, V50, P765, DOI 10.1146/annurev.bi.50.070181.004001; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUPAS A, 1989, J BIOL CHEM, V264, P17337; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; NINFA EG, 1991, J BIOL CHEM, V266, P9764; NIWANO M, 1982, P NATL ACAD SCI-BIOL, V79, P11, DOI 10.1073/pnas.79.1.11; OOSAWA K, 1988, CELL, V53, P89, DOI 10.1016/0092-8674(88)90490-4; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PARKINSON JS, 1983, J BACTERIOL, V155, P265, DOI 10.1128/JB.155.1.265-274.1983; PARKINSON JS, 1979, P NATL ACAD SCI USA, V76, P2390, DOI 10.1073/pnas.76.5.2390; PARKINSON JS, 1977, ANNU REV GENET, V11, P397, DOI 10.1146/annurev.ge.11.120177.002145; PARKINSON JS, 1992, IN PRESS ANN REV GEN, V26; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SEGALL JE, 1982, NATURE, V296, P855, DOI 10.1038/296855a0; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; SIMMS SA, 1985, J BIOL CHEM, V260, P161; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; SPRINGER MS, 1984, P NATL ACAD SCI-BIOL, V81, P5061, DOI 10.1073/pnas.81.16.5061; SPRINGER MS, 1982, J BIOL CHEM, V257, P6861; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK AM, 1987, J BACTERIOL, V169, P3301, DOI 10.1128/jb.169.7.3301-3311.1987; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK J, 1991, CURR BIOL, V3, P154; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STOCK JB, 1981, J BIOL CHEM, V256, P826; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOLKER C, 1991, J BIOL CHEM, V266, P21515; VOLZ K, 1991, J BIOL CHEM, V266, P15511; WOLFE AJ, 1988, P NATL ACAD SCI USA, V85, P6711, DOI 10.1073/pnas.85.18.6711; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986; YANG Y, 1992, P NATL ACAD SCI USA, V88, P11057; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	62	94	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19753	19756						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400287				2022-12-27	WOS:A1992JR85800001
J	SUWABE, A; MASON, RJ; SMITH, D; FIRESTONE, JA; BROWNING, MD; VOELKER, DR				SUWABE, A; MASON, RJ; SMITH, D; FIRESTONE, JA; BROWNING, MD; VOELKER, DR			PULMONARY SURFACTANT SECRETION IS REGULATED BY THE PHYSICAL STATE OF EXTRACELLULAR PHOSPHATIDYLCHOLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; AMINO-ACID SEQUENCES; PROTEIN KINASE-C; II CELLS; PHOSPHOLIPID SECRETION; RAT; CDNA; CALCIUM; LUNG; PURIFICATION	Pulmonary alveolar type II cells synthesize, secrete, and recycle the components of pulmonary surfactant. In this report we present evidence that dipalmitoylphosphatidylcholine is a potent inhibitor of surfactant lipid secretion by type II cells. Monoenoic and dienoic phosphatidylcholines with fatty acids of 16 or 18 carbons are ineffective as inhibitors of surfactant lipid secretion. In contrast, disaturated phosphatidylcholines, with either symmetric or asymmetric pairs of fatty acids of 14, 16, or 18 carbons, exhibit inhibition of surfactant secretion that correlates extremely well with the phase transition temperature (Tc) of the phospholipid. The inhibitory activity of dipalmitoylphosphatidylcholine is not dependent upon lipid stereochemistry. N-Methylated derivatives of dipalmitoylphosphatidylethanolamine are significantly less effective than phosphatidylcholine as inhibitors. Phosphatidylcholines below their phase transition temperature are inhibitors of surfactant secretion, whereas those above their phase transition temperature are either ineffective or weakly inhibitory. The phase transition dependence of inhibition is observed when type II cells are incubated at 37-degrees-C with different species of phosphatidylcholine. In addition, if type II cells are stimulated to secrete at different temperatures the efficacy of a given phospholipid as an inhibitor is dependent on its relationship to Tc (i.e. dipalmitoylphosphatidylcholine with a Tc of 41-degrees-C significantly inhibits secretion at 37-degrees-C but not at 42-degrees-C). Inhibition of surfactant secretion by dipalmitoylphosphatidylcholine is abrogated when it is incorporated into the same liposome with dioleoylphosphatidylcholine as a 50:50 mixture. In contrast, the simultaneous addition of two separate populations of liposomes, one composed of dipalmitoylphosphatidylcholine and the other composed of dioleoylphosphatidylcholine, does not significantly alter the inhibitory activity found with dipalmitoylphosphatidylcholine alone. These data provide compelling evidence that the physical state of phosphatidylcholine can regulate surfactant secretion from alveolar type II cells and suggest a unique mechanism for regulating exocytosis in the alveolus of the lung.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,LORD & TAYLOR LAB LUNG BIOCHEM,1400 JACKSON ST,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029891, R37HL029891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA003527] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 29891] Funding Source: Medline; NIAAA NIH HHS [AA03527] Funding Source: Medline; NIA NIH HHS [AG04418] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DOBBS LG, 1986, BIOCHIM BIOPHYS ACTA, V877, P305, DOI 10.1016/0005-2760(86)90308-5; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; FIRESTONE JA, J NEUROCHEM, V58, P441; GLASSER SW, 1987, P NATL ACAD SCI USA, V84, P4007, DOI 10.1073/pnas.84.12.4007; GLASSER SW, 1988, J BIOL CHEM, V263, P9; GOERKE J, 1974, BIOCHIM BIOPHYS ACTA, V344, P241, DOI 10.1016/0304-4157(74)90009-4; Goerke J., 1986, HDB PHYSL RESP SYSTE, P247; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HAYCOCK JW, 1988, J NEUROSCI, V8, P3233; HILDEBRAN JN, 1979, J APPL PHYSIOL, V47, P604, DOI 10.1152/jappl.1979.47.3.604; JACOBS KA, 1987, J BIOL CHEM, V262, P9808; KING RJ, 1974, FED PROC, V33, P2238; KING RJ, 1973, AM J PHYSIOL, V224, P778; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; MARSH D, 1977, BIOCHIM BIOPHYS ACTA, V465, P500, DOI 10.1016/0005-2736(77)90268-1; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PHILLIPS MC, 1970, BIOCHIM BIOPHYS ACTA, V196, P35, DOI 10.1016/0005-2736(70)90163-X; POST M, 1988, BIOCHIM BIOPHYS ACTA, V947, P249, DOI 10.1016/0304-4157(88)90011-1; RICE WR, 1990, BIOCHEM J, V266, P407, DOI 10.1042/bj2660407; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; RICE WR, 1985, EXP LUNG RES, V9, P135, DOI 10.3109/01902148509061533; SANO K, 1987, AM J PHYSIOL, V253, pC679, DOI 10.1152/ajpcell.1987.253.5.C679; SANO K, 1985, J BIOL CHEM, V260, P2725; Silvius J. R., 1982, LIPID PROTEIN INTERA; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; WARR RG, 1987, P NATL ACAD SCI USA, V84, P7915, DOI 10.1073/pnas.84.22.7915; WAYMIRE JC, 1983, J NEUROSCI METH, V7, P329, DOI 10.1016/0165-0270(83)90026-2; WEAVER TE, 1985, BIOCHIM BIOPHYS ACTA, V827, P260, DOI 10.1016/0167-4838(85)90210-9; WHITSETT JA, 1987, J BIOL CHEM, V262, P15618; WRIGHT JR, 1987, AM REV RESPIR DIS, V135, P426	34	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19884	19890						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400304				2022-12-27	WOS:A1992JR85800024
J	DISCIPIO, RG				DISCIPIO, RG			FORMATION AND STRUCTURE OF THE C5B-7 COMPLEX OF THE LYTIC PATHWAY OF COMPLEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACK COMPLEX; AMINO-ACID-SEQUENCE; 3RD COMPONENT; FACTOR-I; C9 POLYMERIZATION; CELL-MEMBRANES; ALPHA-SUBUNIT; PROTEIN C8; BINDING; CDNA	The formation and structure of the complement cytolytic intermediary complex, C5b-7, were studied with the aim of determining the interactive regions of C5, C6, and C7. The structure of human complement component C5 was elucidated by the application of limited proteolysis which generated well characterized major polypeptide fragments of this molecule. Plasmin, thrombin, and kallikrein cleave C5b with greater facility than C5. The most useful cleavage of C5b was effected by plasmin because the fragmentation pattern was similar to the processing of C3b by factors H, I, and kallikrein. Plasmin hydrolyzes peptide bonds within the alpha'-chain of C5b, resulting in a four-chain fragment, C5c (M(r) = 142,000), and a single chain fragment, C5d (M(r) = 43,000). Circular dichroism spectroscopic analyses indicated that C5d is substantially richer in alpha-helical content than is C5c (27 versus 9%). Polyclonal antibodies directed against C5c blocked the interaction of C5b-6 with C7, whereas antibodies directed against C5d inhibited the binding of C5 with C3b. Chemical cross-linking using a cleavable radioiodinated photoreactive reagent revealed that both C6 and C7 associate preferentially with the alpha'-chain of C5b. The reversible interactions of C5 with C6, C7, and major polypeptide fragments derived from these were investigated with solid phase binding assays. The results indicate that the carboxyl-terminal domains of C6 and C7, which have cysteine-rich modules homologous to those found in factors H and I, have the capacity to link specifically with C5.			DISCIPIO, RG (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, IMM18, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NIAID NIH HHS [AI/HL 22415] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022415] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAHR B, 1965, QUANTITATIVE ELECTRO, P880; BHAKDI S, 1980, J IMMUNOL, V124, P2451; BIESECKER G, 1980, J IMMUNOL, V124, P1291; CATTERALL CF, 1987, BIOCHEM J, V242, P849, DOI 10.1042/bj2420849; Chibber B A, 1974, Methods Enzymol, V34, P424; CLAMP JR, 1975, PLASMA PROTEINS, V2, P163; CLEGG JCS, 1982, ANAL BIOCHEM, V127, P389, DOI 10.1016/0003-2697(82)90192-0; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; COOPER NR, 1970, J EXP MED, V132, P775, DOI 10.1084/jem.132.4.775; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DAVID GS, 1972, BIOCHEM BIOPH RES CO, V48, P464, DOI 10.1016/S0006-291X(72)80074-3; DISCIPIO RG, 1987, PATHOL IMMUNOPATH R, V6, P343, DOI 10.1159/000157063; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; DISCIPIO RG, 1982, MOL IMMUNOL, V19, P1425, DOI 10.1016/0161-5890(82)90189-4; DISCIPIO RG, 1988, J BIOL CHEM, V263, P549; DISCIPIO RG, 1983, J BIOL CHEM, V258, P629; DISCIPIO RG, 1984, P NATL ACAD SCI-BIOL, V81, P7298, DOI 10.1073/pnas.81.23.7298; DISCIPIO RG, 1981, BIOCHEM J, V199, P497, DOI 10.1042/bj1990497; DISCIPIO RG, 1989, J BIOL CHEM, V264, P16197; DOURMASHKIN RR, 1978, IMMUNOLOGY, V35, P205; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Engvall E, 1980, Methods Enzymol, V70, P419; FERNANDEZ HN, 1978, J BIOL CHEM, V253, P6955; GOLDBERGER G, 1987, J BIOL CHEM, V262, P10065; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; HAEFLIGER JA, 1987, BIOCHEMISTRY-US, V26, P3551, DOI 10.1021/bi00386a045; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HAVILAND DL, 1991, J IMMUNOL, V146, P362; HOWARD OMZ, 1987, BIOCHEMISTRY-US, V26, P3565, DOI 10.1021/bi00386a047; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; KOLB WP, 1973, J EXP MED, V138, P428, DOI 10.1084/jem.138.2.428; LAMBRIS JD, 1988, IMMUNOL TODAY, V9, P387, DOI 10.1016/0167-5699(88)91240-6; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; LAW SK, 1980, J IMMUNOL, V125, P634; MEUTH JL, 1983, J IMMUNOL, V130, P2605; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; NAGASE H, 1981, BIOCHEM J, V193, P187, DOI 10.1042/bj1930187; NILSSON K, 1984, METHOD ENZYMOL, V104, P56; OSHANNESSY DJ, 1990, ANAL BIOCHEM, V191, P1, DOI 10.1016/0003-2697(90)90377-L; PANGBURN MK, 1983, BIOCHEMISTRY-US, V22, P178, DOI 10.1021/bi00270a026; PODACK ER, 1980, J EXP MED, V151, P301, DOI 10.1084/jem.151.2.301; PODACK ER, 1984, J BIOL CHEM, V259, P8641; PODACK ER, 1982, J EXP MED, V156, P268, DOI 10.1084/jem.156.1.268; PODACK ER, 1984, MOL IMMUNOL, V21, P589, DOI 10.1016/0161-5890(84)90044-0; Porath J, 1976, Methods Enzymol, V44, P19; RAO AG, 1987, BIOCHEMISTRY-US, V26, P3556, DOI 10.1021/bi00386a046; Robbins K. C., 1970, METHOD ENZYMOL, V19, P184; SHEPHARD EG, 1988, ANAL BIOCHEM, V168, P306, DOI 10.1016/0003-2697(88)90323-5; SIM RB, 1981, BIOCHEM J, V193, P115, DOI 10.1042/bj1930115; SMITH CA, 1984, J ULTRA MOL STRUCT R, V89, P111, DOI 10.1016/S0022-5320(84)80008-8; STANLEY KK, 1985, EMBO J, V4, P375, DOI 10.1002/j.1460-2075.1985.tb03639.x; STEWART JL, 1987, J IMMUNOL, V139, P1960; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; TSCHOPP J, 1982, P NATL ACAD SCI-BIOL, V79, P7474, DOI 10.1073/pnas.79.23.7474; TSCHOPP J, 1984, J BIOL CHEM, V259, P7857; VOGT W, 1978, IMMUNOLOGY, V34, P29; WRIGLEY NG, 1968, J ULTRA MOL STRUCT R, V24, P454, DOI 10.1016/S0022-5320(68)80048-6	57	47	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17087	17094						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1387399				2022-12-27	WOS:A1992JL05300057
J	QUITSCHKE, WW; GOLDGABER, D				QUITSCHKE, WW; GOLDGABER, D			THE AMYLOID BETA-PROTEIN PRECURSOR PROMOTER - A REGION ESSENTIAL FOR TRANSCRIPTIONAL ACTIVITY CONTAINS A NUCLEAR FACTOR BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ENHANCER ELEMENTS; MESSENGER-RNA; ALZHEIMERS-DISEASE; DNA-BINDING; TRANSGENIC MICE; ACTIN PROMOTER; FACTOR AP-1; GENE; EXPRESSION; SEQUENCE	A manifestation of Alzheimer's disease is the presence of amyloid depositions in brains of afflicted individuals. A major component of these depositions is the amyloid beta-protein, which is a truncated form of the larger amyloid beta-protein precursor (APP). To investigate the regulation of APP gene expression, the APP promoter and selected deletions were placed 5' to the reporter gene chloramphenicol acetyltransferase. The promoter deletions were transfected into different cell lines that showed variant levels of endogenous APP transcripts. Transient transfection assays showed that 96 base pairs 5' to the transcriptional start site are sufficient for cell type-specific promoter activity. A nuclear factor that binds to this region in a sequence-specific manner was identified by mobility shift electrophoresis, DNase footprinting, and methylation interference. The DNase-protected region covers about 25 base pairs on both strands (position -31 to -55). Mutations within this domain revealed a sequence of 12 base pairs that is crucial for factor binding. This sequence overlaps with the consensus sequences for transcription factors AP-1 and AP-4. However, competition experiments suggest that the nuclear factor that binds to the APP promoter is distinct from both AP-1 and AP-4. Factor binding to the characterized recognition sequence is observed in nuclear extracts originating from human, mouse, and rat cells, suggesting a high degree of conservation.			QUITSCHKE, WW (corresponding author), SUNY STONY BROOK, DEPT PSYCHIAT & BEHAV SCI, STONY BROOK, NY 11794 USA.				NIA NIH HHS [AG09320] Funding Source: Medline; NINDS NIH HHS [NS30994] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009320] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DONNELLY RJ, 1990, CELL MOL NEUROBIOL, V10, P485, DOI 10.1007/BF00712843; ELDRIDGE J, 1985, GENE, V36, P55, DOI 10.1016/0378-1119(85)90069-1; GABUZDA DH, 1989, MOL CELL BIOL, V9, P2728, DOI 10.1128/MCB.9.6.2728; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; Goldgaber DES, 1991, BRAIN RES REV, V16, P89; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HIGGINS GA, 1988, P NATL ACAD SCI USA, V85, P1297, DOI 10.1073/pnas.85.4.1297; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JACOBSEN JS, 1991, NEUROBIOL AGING, V12, P575, DOI 10.1016/0197-4580(91)90089-3; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; LAHIRI DK, 1991, MOL BRAIN RES, V9, P253, DOI 10.1016/0169-328X(91)90009-M; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Maniatis T, 1989, MOL CLONING; MANNING RW, 1988, MOL BRAIN RES, V3, P293, DOI 10.1016/0169-328X(88)90052-6; Maxam A M, 1980, Methods Enzymol, V65, P499; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUITSCHKE WW, 1989, MOL CELL BIOL, V9, P3218, DOI 10.1128/MCB.9.8.3218; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROBAKIS NK, 1987, LANCET, V1, P384; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; SEILERTUYNS A, 1984, P NATL ACAD SCI-BIOL, V81, P2980, DOI 10.1073/pnas.81.10.2980; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WIRAK DO, 1991, EMBO J, V10, P289, DOI 10.1002/j.1460-2075.1991.tb07949.x; WIRAK DO, 1991, SCIENCE, V253, P323, DOI 10.1126/science.1857970; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975	57	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17362	17368						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380960				2022-12-27	WOS:A1992JL05300094
J	DIZHOOR, AM; ERICSSON, LH; JOHNSON, RS; KUMAR, S; OLSHEVSKAYA, E; ZOZULYA, S; NEUBERT, TA; STRYER, L; HURLEY, JB; WALSH, KA				DIZHOOR, AM; ERICSSON, LH; JOHNSON, RS; KUMAR, S; OLSHEVSKAYA, E; ZOZULYA, S; NEUBERT, TA; STRYER, L; HURLEY, JB; WALSH, KA			THE NH2 TERMINUS OF RETINAL RECOVERIN IS ACYLATED BY A SMALL FAMILY OF FATTY-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-BINDING PROTEIN; ROD GUANYLATE-CYCLASE; N-MYRISTOYLATION	Recoverin is a recently identified Ca2+-binding protein that imparts Ca2+ sensitivity to vertebrate photoreceptor guanylate cyclase. In response to photo-induced depletion of intracellular cGMP and Ca2+, recoverin stimulates resynthesis of cGMP. Bovine retinal recoverin has now been analyzed by electrospray mass spectrometry (ESI-MS) for post-translational modifications that might influence its activity. Heterogeneous acylation was detected at the NH2 terminus of bovine retinal recoverin. The NH2-terminal glycine of each retinal recoverin molecule is linked to one of four different types of acyl groups. The most abundant is myristoleate (14:1), but 14:0, 14:2, and 12:0 acyl residues are also present.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; MV LOMONOSOV STATE UNIV, AN BELOZERSKY INST PHYSICOCHEM BIOL, MOSCOW 119899, USSR; STANFORD UNIV, SCH MED, DEPT CELL BIOL, STANFORD, CA 94305 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; MM SHEMYAKIN BIOORGAN CHEM INST, PUSHCHINO 142292, USSR	University of Washington; University of Washington Seattle; Lomonosov Moscow State University; Stanford University; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			; Zozulya, Sergey/F-2986-2015	Dizhoor, Alexander/0000-0001-6770-9186; Zozulya, Sergey/0000-0002-1179-2993	NEI NIH HHS [EYO 6641, R01 EY006641, EYO 2005] Funding Source: Medline; NIGMS NIH HHS [GM 15731] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006641, R01EY002005, R37EY002005] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUTUZOV MA, 1991, FEBS LETT, V293, P21, DOI 10.1016/0014-5793(91)81143-V; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LAMBRECHT HG, 1991, FEBS LETT, V294, P207, DOI 10.1016/0014-5793(91)80670-X; NEUMEISTER J, 1978, ANGEW CHEM INT EDIT, V17, P939, DOI 10.1002/anie.197809392; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; STRYER L, 1991, J BIOL CHEM, V266, P10711; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441	16	172	176	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16033	16036						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1386601				2022-12-27	WOS:A1992JJ45800008
J	DUAN, DSR; WERNER, S; WILLIAMS, LT				DUAN, DSR; WERNER, S; WILLIAMS, LT			A NATURALLY-OCCURRING SECRETED FORM OF FIBROBLAST GROWTH-FACTOR (FGF) RECEPTOR-1 BINDS BASIC FGF IN PREFERENCE OVER ACIDIC FGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EXPRESSION; CLONING	Alternatively spliced variants of fibroblast growth factor receptor 1 mRNA are predicted to encode secreted forms and membrane-bound forms of receptors. The predicted amino acid sequences of these receptor variants differ in a portion of the extracellular region. In this study, we characterized the function of one of these splice variants which was predicted by its cDNA to be a secreted FGF receptor. We expressed this secreted form of the human FGFR1 (sFGFR1) in Chinese hamster ovary cells. The sFGFR1 protein oligomerized upon ligand binding. Surprisingly, the sFGFR1 preferentially bound basic FGF over acidic FGF. In cross-linking experiments, the sFGFR1 showed higher binding affinity for basic FGF (K(d) approximately 30 nM) than for acidic FGF (K(d) > 300 nM). These results suggest that this secreted form of FGF receptor has an unusual ligand binding specificity that may be important for its biological role in vivo.	UNIV CALIF SAN FRANCISCO, DEPT MED, HOWARD HUGHES MED INST, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco				Werner, Sabine/0000-0001-7397-8710	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CRUMLEY G, 1991, ONCOGENE, V6, P2255; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUAN DSR, 1991, J BIOL CHEM, V266, P413; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIRDA DP, 1992, J VIROL, V66, P448, DOI 10.1128/JVI.66.1.448-457.1992; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RUTA M, 1988, ONCOGENE, V3, P9; UENO H, 1992, J BIOL CHEM, V267, P1470; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82	18	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16076	16080						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379591				2022-12-27	WOS:A1992JJ45800017
J	FUJII, T; MIMORI, T; HAMA, N; SUWA, A; AKIZUKI, M; TOJO, T; HOMMA, M				FUJII, T; MIMORI, T; HAMA, N; SUWA, A; AKIZUKI, M; TOJO, T; HOMMA, M			CHARACTERIZATION OF AUTOANTIBODIES THAT RECOGNIZE U4/U6 SMALL RIBONUCLEOPROTEIN-PARTICLES IN SERUM FROM A PATIENT WITH PRIMARY SJOGRENS-SYNDROME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER RNA; TRANSCRIPTION FACTOR HUBF; SPLICE SITE; PROTEINS; COMPLEX; U2; U1; U4; U6	We identified autoantibodies that recognize the U4/U6 snRNPs in a serum from a 63-year-old Japanese patient (TT) with primary Sjogren's syndrome. This patient's serum immunoprecipitated U4 and U6 snRNAs exclusively from P-32-labeled HeLa cell extracts and a newly identified 120-kDa protein along with the Sm core proteins (B'/B, D, E, F, and G) from [S-35] methionine-labeled HeLa cell extracts. Immunoblotting demonstrated that only the 120-kDa protein was recognized by this unique serum. In glycerol density gradient centrifugation, the 120-kDa protein reactive with TT serum cosedimented with U4 and U6 snRNAs, suggesting that the 120-kDa protein is a unique component of the U4/U6 snRNP particle. In the same study, the U4/U6 snRNP precipitated by TT serum sedimented only in the lower density, whereas anti-Sm antibodies precipitated U4/U6 snRNAs in a broad range of the gradient. This result suggests the presence of at least two molecular forms of the U4/U6 snRNP particles; larger particles, probably the U4/U5/U6 snRNP complex, and free particles. Thus, the U4/U6 snRNP recognized by TT serum includes the U4 and U6 SnRNAs, with Sm core proteins, and the novel 120-kDa protein, and appears to be a free particle not associated with larger complexes.			FUJII, T (corresponding author), KEIO UNIV, SCH MED,DEPT INTERNAL MED,DIV RHEUMATOL, 35 SHINANOMACHI, SHINJUKU KU, TOKYO 160, JAPAN.							BACH M, 1989, P NATL ACAD SCI USA, V86, P6038, DOI 10.1073/pnas.86.16.6038; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; CHAN EKL, 1991, J EXP MED, V174, P1239, DOI 10.1084/jem.174.5.1239; CRAFT J, 1988, J CLIN INVEST, V81, P1716, DOI 10.1172/JCI113511; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KINLAW CS, 1983, J BIOL CHEM, V258, P7181; KONARSKA MM, 1988, P NATL ACAD SCI USA, V85, P5459, DOI 10.1073/pnas.85.15.5459; KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8; LELAYTAHA MN, 1986, J MOL BIOL, V189, P519, DOI 10.1016/0022-2836(86)90321-9; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LERNER MR, 1981, CELL, V25, P298, DOI 10.1016/0092-8674(81)90047-7; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MATTER L, 1982, ARTHRITIS RHEUM, V25, P1278, DOI 10.1002/art.1780251102; MIMORI T, 1984, J BIOL CHEM, V259, P560; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; OKANO Y, 1991, J IMMUNOL, V146, P535; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; REDDY R, 1983, PROG NUCLEIC ACID RE, V30, P127; RODRIGUEZSANCHEZ JL, 1987, J IMMUNOL, V139, P2579; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANVENROOIJ WJ, 1989, CLIN EXP RHEUMATOL, V7, P635	26	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16412	16416						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1386602				2022-12-27	WOS:A1992JJ45800067
J	HUGHES, CE; CATERSON, B; WHITE, RJ; ROUGHLEY, PJ; MORT, JS				HUGHES, CE; CATERSON, B; WHITE, RJ; ROUGHLEY, PJ; MORT, JS			MONOCLONAL-ANTIBODIES RECOGNIZING PROTEASE-GENERATED NEOEPITOPES FROM CARTILAGE PROTEOGLYCAN DEGRADATION - APPLICATION TO STUDIES OF HUMAN LINK PROTEIN CLEAVAGE BY STROMELYSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN ARTICULAR-CARTILAGE; BOVINE NASAL CARTILAGE; AGE-RELATED-CHANGES; IDENTIFICATION; HETEROGENEITY; METALLOPROTEINASES; INVOLVEMENT; INSITU	Monoclonal antibodies were raised that specifically recognize the NH2-terminal neoepitope sequence present in link protein cleavage products derived from stromelysin-degraded proteoglycan aggregate. Competitive enzyme-linked immunosorbent assay, using synthetic peptides as inhibitors, showed that one of these antibodies (CH-3) required, for antibody recognition, the free NH2-terminal amino acid isoleucine (residue 17 of the intact protein) in the sequence NH2-IQAENG at the stromelysin cleavage site of link protein 3. Human proteoglycan aggregate was digested with recombinant human stromelysin, bovine chymotrypsin, bovine trypsin, and porcine elastase, and their respective link protein degradation products were tested for immunoreactivity with antibody CH-3. Only stromelysin- and chymotrypsin-generated link protein 3 were recognized by antibody CH-3. Both of these enzymes generate link protein NH2 termini with the sequence 17IQAENG... ; hence these studies indicated that monoclonal antibody CH-3 recognized this neoepitope sequence in only specific proteolytically modified link protein molecules. Since the occurrence of link protein 3 increases with aging, the incidence of CH-3 epitope in proteoglycans isolated from human knee articular cartilage of individuals of different ages was investigated. The prevalence of CH-3 epitope was found to be highest in newborn and adolescent articular cartilage samples. However, little CH-3 epitope was detected in older adult cartilage, although considerably more link protein 3 was present in these samples. These results suggest that additional proteolytic agents are responsible for the increased occurrence of link protein degradation products with aging.	UNIV N CAROLINA, DEPT SURG, DIV ORTHOPED SURG, CHAPEL HILL, NC 27599 USA; MCGILL UNIV, DEPT SURG, MONTREAL H3A 2T5, QUEBEC, CANADA; SHRINERS HOSP CRIPPLED CHILDREN, MONTREAL H3G 1AG, QUEBEC, CANADA	University of North Carolina; University of North Carolina Chapel Hill; McGill University			Caterson, Bruce/A-8085-2010; Hughes, Clare E/A-4526-2010	Caterson, Bruce/0000-0001-6016-0661; Hughes, Clare/0000-0003-4726-5877	NIAMS NIH HHS [AR32666] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032666] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAKER JR, 1979, J BIOL CHEM, V254, P2387; BERNATOWICZ MS, 1986, ANAL BIOCHEM, V155, P95, DOI 10.1016/0003-2697(86)90231-9; CATERSON B, 1983, J BIOL CHEM, V258, P8848; Caterson B, 1987, BIOL PROTEOGLYCANS, P1; CATERSON B, 1985, J BIOL CHEM, V260, P13348; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FRANZEN A, 1981, BIOCHEM J, V197, P669, DOI 10.1042/bj1970669; GREGORY JD, 1973, BIOCHEM J, V133, P383, DOI 10.1042/bj1330383; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; HERING TM, 1990, J BIOL CHEM, V265, P2375; HUGHES C, 1991, BIOCHEM J, V279, P733, DOI 10.1042/bj2790733; HUI KY, 1983, SCIENCE, V222, P1129, DOI 10.1126/science.6648524; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGLEDIC S, 1983, J BIOL CHEM, V258, P4759; LIU J, 1991, J ORTHOPAED RES, V9, P568, DOI 10.1002/jor.1100090413; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOK MT, 1992, ARCH BIOCHEM BIOPHYS, V292, P442, DOI 10.1016/0003-9861(92)90014-N; MORT JS, 1983, BIOCHEM J, V214, P269, DOI 10.1042/bj2140269; MORT JS, 1985, BIOCHEM J, V232, P805, DOI 10.1042/bj2320805; MURPHY G, 1990, BIOCHEM SOC T, V18, P812, DOI 10.1042/bst0180812; NGUYEN Q, 1989, BIOCHEM J, V259, P61, DOI 10.1042/bj2590061; NGUYEN Q, 1991, BIOCHEM J, V278, P143, DOI 10.1042/bj2780143; RATCLIFFE A, 1986, BIOCHEM J, V238, P571, DOI 10.1042/bj2380571; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; ROUGHLEY PJ, 1982, J BIOL CHEM, V257, P1908; SANDY JD, 1991, J BIOL CHEM, V266, P8683; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	28	74	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16011	16014						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379586				2022-12-27	WOS:A1992JJ45800002
J	LOOMIS, CA; KOLEGA, J; MANABE, M; SUN, TT				LOOMIS, CA; KOLEGA, J; MANABE, M; SUN, TT			CHARACTERIZATION OF A KERATINOCYTE-SPECIFIC EXTRACELLULAR EPITOPE OF DESMOGLEIN - IMPLICATIONS FOR DESMOGLEIN HETEROGENEITY AND FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; CONSTITUTIVE TRANSMEMBRANE GLYCOPROTEIN; HUMAN EPIDERMAL-KERATINOCYTES; AMINO-ACID-SEQUENCE; POLYACRYLAMIDE GELS; PEMPHIGUS FOLIACEUS; CADHERIN FAMILY; BIOCHEMICAL-IDENTIFICATION; DESMOSOMAL GLYCOPROTEIN	Despite the presumed importance of desmoglein, a 160-kDa glycoprotein, in desmosome formation and its possible involvement in certain blistering skin diseases, the precise location and function of this protein have not yet been firmly established. We describe here the characterization of a new monoclonal antibody, AE23, against an extracellular epitope of desmoglein. Both the AE23 epitope and another epitope, defined by the previously characterized DG3.4 antibody, reside on a 160-kDa human epidermal desmoglein as evidenced by their identical solubility profile, their coexistence in a 130-kDa desmoglein degradative product, their coadsorption by an AE23 immunoaffinity column, and the identical changes in the two antigens' electrophoretic mobility after air oxidation and deglycosylation. The AE23 epitope is resistant to various endoglycosidases, suggesting that sugar moieties are not involved. Characterization of several proteolytic fragments of this epidermal desmoglein enabled us to map the DG3.4 epitope to a 96-kDa intracellular domain and the AE23 epitope to an extracellular domain flanked by the plasma membrane and the distal N-glycosylation site(s). However, these two epitopes do not always coexist on the same desmoglein molecule. For example, tissue surveys showed that although the DG3.4 epitope is present in the desmogleins of all epithelial cell types, the AE23 epitope is limited to normal keratinocytes. Moreover, electron microscopic localization data indicate that whereas the DG3.4 epitope is detected in the submembranous plaques of desmosomes, the AE23 epitope is present in the intercellular space of both desmosomal and nondesmosomal areas. These results raise the possibility that there exist several biochemically closely related isoforms of desmoglein, one (AE23+/DG3.4+) restricted to epidermal desmosomes, one (AE23+/DG3.4-) uniformly distributed along the keratinocyte cell surface, and another (AE23-/DG3.4+) present in desmosomes of simple epithelia and basal cells of cultured keratinocytes. The uniform distribution of at least one desmoglein-related antigen in the intercellular space of keratinocytes coupled with the realization that different isoforms of desmogleins form a subfamily of cadherins suggest that desmoglein(s) may play a more general role in keratinocyte adhesion than previously appreciated.	NYU MED CTR, KAPLAN COMPREHENS CANC CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University	LOOMIS, CA (corresponding author), NYU MED CTR, KAPLAN COMPREHENS CANC CTR, DEPT DERMATOL, EPITHELIAL BIOL UNIT, NEW YORK, NY 10016 USA.		Kolega, John/J-8386-2016; Sun, Tung-Tien/J-4425-2015	Kolega, John/0000-0001-6933-8681; Sun, Tung-Tien/0000-0002-6841-1063	NEI NIH HHS [EY4722] Funding Source: Medline; NIADDK NIH HHS [AM34511] Funding Source: Medline; NIAMS NIH HHS [AR39749] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM034511] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY004722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039749] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; COHEN SM, 1983, J BIOL CHEM, V258, P243; CONNELL ND, 1983, CELL, V34, P245, DOI 10.1016/0092-8674(83)90155-1; COWIN P, 1984, J CELL SCI, V66, P119; COWIN P, 1983, NATURE, V302, P148, DOI 10.1038/302148a0; Cowin P, 1985, CELL CONTACT, P427; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; EICHNER R, 1986, J CELL BIOL, V102, P1767, DOI 10.1083/jcb.102.5.1767; GARROD DR, 1986, J CELL SCI, P221, DOI 10.1242/jcs.1986.Supplement_4.14; GODING JW, 1983, MONOCLONAL ANTIBODIE, P188; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; GUIDICE GJ, 1984, J CELL BIOCHEM, V26, P35; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KAPPRELL HP, 1985, EUR J CELL BIOL, V36, P217; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KOCH PJ, 1991, EUR J CELL BIOL, V55, P200; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOLEGA J, 1989, DIFFERENTIATION, V42, P54, DOI 10.1111/j.1432-0436.1989.tb00607.x; KOULU L, 1984, J EXP MED, V160, P1509, DOI 10.1084/jem.160.5.1509; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE RD, 1985, J IMMUNOL METHODS, V81, P223, DOI 10.1016/0022-1759(85)90207-8; MA ASP, 1986, J CELL BIOL, V103, P41, DOI 10.1083/jcb.103.1.41; Miggiano V., 1982, RES DISCL, V217, P155; MILLER K, 1987, EMBO J, V6, P885, DOI 10.1002/j.1460-2075.1987.tb04834.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OGUIN WM, 1987, CURR TOP DEV BIOL, V22, P97; OGUIN WM, 1989, J CELL BIOL, V109, P2313, DOI 10.1083/jcb.109.5.2313; PASADAR M, 1989, J CELL BIOL, V109, P163; PENN EJ, 1987, J CELL BIOL, V105, P57, DOI 10.1083/jcb.105.1.57; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RUBINSTEIN N, 1987, AM J DERMATOPATH, V96, P510; SCHMELZ M, 1986, EUR J CELL BIOL, V42, P184; SCHMELZ M, 1986, EUR J CELL BIOL, V42, P177; SHEETZ MP, 1979, BIOCHIM BIOPHYS ACTA, V557, P122, DOI 10.1016/0005-2736(79)90095-6; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; SHIDA H, 1982, J CELL BIOCHEM, V20, P113, DOI 10.1002/jcb.240200204; SKERROW CJ, 1974, J CELL BIOL, V63, P524, DOI 10.1083/jcb.63.2.524; STANLEY JR, 1984, J CLIN INVEST, V74, P313, DOI 10.1172/JCI111426; STANLEY JR, 1986, J INVEST DERMATOL, V87, P197, DOI 10.1111/1523-1747.ep12695334; STANLEY JR, 1986, J IMMUNOL, V136, P1127; STEINBERG MS, 1987, CIBA F SYMP, V125, P3; STERNBERGER LA, 1979, IMMUNOCYTOCHEMISTRY, P122; SUHRBIER A, 1986, J CELL SCI, V81, P223; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; WAITE JH, 1976, ANAL BIOCHEM, V70, P279, DOI 10.1016/S0003-2697(76)80070-X; WANG K, 1982, METHOD ENZYMOL, V85, P514; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580	55	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16676	16684						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379602				2022-12-27	WOS:A1992JJ45800104
J	LEE, KJ; ROSS, RS; ROCKMAN, HA; HARRIS, AN; OBRIEN, TX; VANBILSEN, M; SHUBEITA, HE; KANDOLF, R; BREM, G; PRICE, J; EVANS, SM; ZHU, H; FRANZ, WM; CHIEN, KR				LEE, KJ; ROSS, RS; ROCKMAN, HA; HARRIS, AN; OBRIEN, TX; VANBILSEN, M; SHUBEITA, HE; KANDOLF, R; BREM, G; PRICE, J; EVANS, SM; ZHU, H; FRANZ, WM; CHIEN, KR			MYOSIN LIGHT CHAIN-2 LUCIFERASE TRANSGENIC MICE REVEAL DISTINCT REGULATORY PROGRAMS FOR CARDIAC AND SKELETAL MUSCLE-SPECIFIC EXPRESSION OF A SINGLE CONTRACTILE PROTEIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; RAT MYOCARDIAL-CELLS; INDUCIBLE EXPRESSION; DNA-BINDING; ADRENERGIC STIMULATION; NUCLEOTIDE-SEQUENCE; MOUSE EMBRYOGENESIS; ENHANCER-BINDING; MYOD FAMILY; TRANSCRIPTION	To examine the relationship between the cardiac and skeletal muscle gene programs, the current study employs the regulatory (phosphorylatable) myosin light chain (MLC-2) as a model system. Northern blotting, primer extension, and RNase protection studies documented the high level expression of the cardiac MLC-2 mRNA in both mouse cardiac and slow skeletal muscle (soleus). Transgenic mouse lines harboring a 2100- or a 250-base pair rat cardiac MLC-2 promoter/luciferase fusion gene were generated, demonstrating high levels of luciferase activity in cardiac muscle, and only background luminescence in slow skeletal muscle and non-muscle tissues. As assessed by in situ hybridization, immunofluorescence, and luminescence assays of luciferase reporter activity in various regions of the heart, both the endogenous MLC-2 gene and the MLC-2 luciferase fusion gene were expressed exclusively in the ventricular compartment, with expression in the atrium at background levels. Point mutations within the conserved regulatory sites HF-1a and HF-1b significantly cripple ventricular muscle specificity, while mutation of the single E-box site was without effect, suggesting that ventricular muscle-specific expression occurs through an E-box-independent pathway. This study provides direct evidence that the cis regulatory sequences in the cardiac/slow twitch MLC-2 gene which confer cardiac and skeletal muscle-specific expression can be clearly segregated, suggesting that distinct regulatory programs may have evolved to control the tissue-specific expression of this single contractile protein gene in cardiac and skeletal muscle.	UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, 0613-C, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, VET ADM HOSP SAN DIEGO, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, AMER HEART ASSOC BUGHER FDN CTR MOLEC BIOL, LA JOLLA, CA 92093 USA; SCRIPPS RES INST, LA JOLLA, CA 92036 USA; UNIV MUNICH, INST TIERZUCHT & HYG, W-8000 MUNICH 2, GERMANY; MAX PLANCK INST BIOCHEM, DEPT VIROL, W-8033 MARTINSRIED, GERMANY	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute; University of Munich; Max Planck Society			van Bilsen, Marc/E-8342-2016; Ross, Robert/ABE-1109-2020; Evans, Sylvia/G-1980-2015	Ross, Robert/0000-0003-2195-8982; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL045069, R01HL036139] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36139, HL-45069, HL-46345] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS JH, 1986, BIOSCIENCE REP, V6, P655, DOI 10.1007/BF01114760; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEHAAN RL, 1965, ORGANOGENESIS, P337; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EVANS SM, 1991, J CELL BIOCHEM     S, V15, P194; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; FUJII J, 1988, FEBS LETT, V227, P51, DOI 10.1016/0014-5793(88)81412-1; FUJII J, 1990, FEBS LETT, V273, P232, DOI 10.1016/0014-5793(90)81092-3; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRANT JW, 1990, J CELL BIOL, V111, P1127, DOI 10.1083/jcb.111.3.1127; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HENDERSON SA, 1988, NUCLEIC ACIDS RES, V16, P4722, DOI 10.1093/nar/16.10.4722; HOGAN B, 1986, MANIPULATING MOUSE E; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; INAGAMI T, 1989, J BIOL CHEM, V264, P3043; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JACOBSON AG, 1988, DEVELOPMENT, V104, P341; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KUMAR CC, 1986, J BIOL CHEM, V261, P2866; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LIBERA LD, 1986, COMP BIOCHEM PHYS B, V83, P751, DOI 10.1016/0305-0491(86)90140-9; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; LOHSE P, 1988, DEV BIOL, V125, P229, DOI 10.1016/0012-1606(88)90077-2; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; RADOVICK S, 1990, MOL ENDOCRINOL, V4, P476, DOI 10.1210/mend-4-3-476; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1991, J CELL BIOCH SC, V15, P164; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SATER AK, 1990, DEVELOPMENT, V108, P461; SCALES JB, 1990, MOL CELL BIOL, V10, P1516, DOI 10.1128/MCB.10.4.1516; SEN A, 1988, J BIOL CHEM, V263, P19132; SHEN RQ, 1991, MOL CELL BIOL, V11, P1676, DOI 10.1128/MCB.11.3.1676; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SHUBEITA HE, 1992, CIRCULATION, V85, P2236, DOI 10.1161/01.CIR.85.6.2236; SILLS MN, 1989, J CLIN INVEST, V84, P331, DOI 10.1172/JCI114158; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	63	116	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15875	15885						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379240				2022-12-27	WOS:A1992JG11300093
J	RICHTERCOOK, NJ; HOWARD, KJ; CIRINO, NM; WOHRL, BM; LEGRICE, SFJ				RICHTERCOOK, NJ; HOWARD, KJ; CIRINO, NM; WOHRL, BM; LEGRICE, SFJ			INTERACTION OF TRANSFER RNA(LYS-3) WITH MULTIPLE FORMS OF HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL CHELATE ADSORBENT; ESCHERICHIA-COLI; TRANSFER-RNA; CROSS-LINKING; EXPRESSION; POLYMERASE; PURIFICATION; HETERODIMER; SUBUNIT; DOMAIN	The interaction of several forms (p51, p66, and p66/p51) of recombinant human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) with a synthetic derivative of its cognate replication primer, tRNA(Lys-3), has been determined by gel-mobility shift analysis. While p66/p51 RT is proficient in tRNA binding, preparations of p66 and p51 display only weak binding at elevated protein:tRNA ratios, despite the former containing both RNA-dependent DNA polymerase and ribonuclease H (RNase H) activity. Gel permeation analysis of purified p66 RT indicate this to be predominantly monomeric, suggesting that dimerization may be a prerequisite for efficient TRNA binding. Prolonged incubation of a mixture of the 66- and 51-kDa polypeptides results in heterodimer reconstitution, restoration of tRNA binding, and recovery of appreciable levels of RNA-dependent DNA polymerase activity. Under the same conditions, both the tRNA binding and RNA-dependent DNA polymerase activities of the 66- and 51-kDa polypeptides are unaffected, suggesting that they remain in the monomeric conformation.	CASE WESTERN RESERVE UNIV, SCH MED, DIV INFECT DIS, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University					NIAID NIH HHS [AI31147-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; CHENG N, 1991, BIOCHEM BIOPH RES CO, V174, P785, DOI 10.1016/0006-291X(91)91486-V; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HOSTOMSKY Z, 1992, IN PRESS J VIROL, V66; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LEDERER H, 1992, EMBO J, V11, P1131, DOI 10.1002/j.1460-2075.1992.tb05153.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER B, 1991, J BIOL CHEM, V266, P14709; MULLER WEG, 1991, BIOCHEMISTRY-US, V30, P2027, DOI 10.1021/bi00222a004; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RESTLE T, 1990, J BIOL CHEM, V265, P8986; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; TUKALO MA, 1987, BIOCHEMISTRY-US, V26, P5200, DOI 10.1021/bi00390a045; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	31	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15952	15957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1379242				2022-12-27	WOS:A1992JG11300103
J	SABBADINI, RA; BETTO, R; TERESI, A; FACHECHICASSANO, G; SALVIATI, G				SABBADINI, RA; BETTO, R; TERESI, A; FACHECHICASSANO, G; SALVIATI, G			THE EFFECTS OF SPHINGOSINE ON SARCOPLASMIC-RETICULUM MEMBRANE CALCIUM RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RABBIT SKELETAL-MUSCLE; TRANSVERSE TUBULAR MEMBRANES; CA-2+-INDUCED CA-2+ RELEASE; CARDIAC RYANODINE RECEPTOR; GROWTH-FACTOR RECEPTOR; TERMINAL CISTERNAE; LIPID-COMPOSITION; FAST-TWITCH; CHANNEL	In this study, we report that sphingosine is a potent inhibitor of sarcoplasmic reticulum (SR) calcium release. Evidence is presented demonstrating a direct effect of sphingosine on the SR ryanodine receptor. Calcium release from "skinned" rabbit skeletal muscle fibers and isolated junctional SR derived from the terminal cisternae (TC) was measured in response to caffeine, doxorubicin, 5'-adenylyl-beta,gamma-imidodiphosphate or calcium. Sphingosine inhibited caffeine-induced release in a dose-dependent manner with an IC50 of 0.1-mu-M for the single muscle fibers and 0.5-mu-M for the isolated TC vesicles. Near complete blockage of TC calcium release rate was observed with 3-mu-M sphingosine. Neither sphingomyelin nor sphingosylphosphorylcholine had any effect at the 3-mu-M level, suggesting that the sphingosine effect was specific. Doxorubicin-induced calcium release and spontaneous calcium release were also blocked by sphingosine. Sphingosine was also capable of stimulating calcium transport in the isolated TC vesicles without an effect on Ca-ATPase activity. Ruthenium red was not capable of substantial additional stimulation of calcium transport nor inhibition of calcium release beyond the action of sphingosine. Sphingosine's blockage of calcium release was not reversed by the protein kinase inhibitor, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride, suggesting that the action of sphingosine on calcium release was not dependent on ryanodine receptor phosphorylation. Sphingosine significantly increased (8-fold) the K(d) for specific [H-3]ryanodine binding to TC membranes and decreased the B(max) with a dose dependence similar to the inhibition of calcium release, but sphingosine did not affect the pCa tension relationship of skinned skeletal muscle fibers. These data are consistent with a direct effect of submicromolar sphingosine on the ryanodine receptor. Substantially higher concentrations of sphingosine (30-50-mu-M) or sphingosylphosphorylcholine (10-20-mu-M) were capable of inducing calcium release by themselves. Preliminary data indicate that the transverse tubule and not the SR contain substantial sphingomyelinase activity consistent with a transverse tubule source of sphingosine production. Considering that sphingosine is found in micromolar concentrations in some cells, our data indicate that sphingosine generated by the transverse tubule membranes may be a physiologically relevant mechanism for modulating SR calcium release.	UNIV PADUA,INST GEN PATHOL,CNR,MUSCLE BIOL & PHYSIOPATHOL UNIT,I-35121 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Padua	SABBADINI, RA (corresponding author), SAN DIEGO STATE UNIV,INST BIOL,DEPT BIOL & MOLEC BIOL,5300 CAMPANILE DR,SAN DIEGO,CA 92182, USA.							BETTO R, 1992, EXCITATION CONTRACTI; CASWELL AH, 1989, TRENDS BIOCHEM SCI, V14, P161, DOI 10.1016/0968-0004(89)90265-X; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; CHU A, 1991, J BIOL CHEM, V266, P7699; DAMIANI E, 1991, BIOCHEM BIOPH RES CO, V175, P858, DOI 10.1016/0006-291X(91)91644-R; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HAMPTON RY, 1989, SCIENCE, V246, P1050, DOI 10.1126/science.2555921; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDALGO C, 1986, BIOCHIM BIOPHYS ACTA, V855, P79, DOI 10.1016/0005-2736(86)90191-4; HOPE MJ, 1987, J BIOL CHEM, V262, P4360; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KOBAYASHI T, 1988, EUR J BIOCHEM, V172, P747, DOI 10.1111/j.1432-1033.1988.tb13952.x; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; LAU YH, 1979, J BIOL CHEM, V254, P540; LEVADE T, 1984, BIOCHIM BIOPHYS ACTA, V793, P321, DOI 10.1016/0005-2760(84)90337-0; LEVADE T, 1983, ANAL BIOCHEM, V130, P521, DOI 10.1016/0003-2697(83)90627-9; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; PALADE P, 1987, J BIOL CHEM, V262, P6142; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PALADE P, 1987, J BIOL CHEM, V262, P6135; PALADE P, 1983, J BIOL CHEM, V258, P8098; PEDICONI MF, 1987, BIOCHIM BIOPHYS ACTA, V921, P398, DOI 10.1016/0005-2760(87)90042-7; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1990, MOL PHARMACOL, V37, P503; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SABBADINI R A, 1992, Biophysical Journal, V61, pA24; SABBADINI R A, 1991, Biophysical Journal, V59, p105A; SABBADINI RA, 1983, ARCH BIOCHEM BIOPHYS, V223, P107, DOI 10.1016/0003-9861(83)90576-3; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SALVIATI G, 1982, BIOCHEM J, V202, P289, DOI 10.1042/bj2020289; SALVIATI G, 1990, BIOPHYS J, V57, pA346; SALVIATI G, 1982, J GEN PHYSIOL, V79, P603, DOI 10.1085/jgp.79.4.603; SALVIATI G, 1988, AM J PHYSIOL, V254, pC459, DOI 10.1152/ajpcell.1988.254.3.C459; SEILER S, 1984, J BIOL CHEM, V259, P8550; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; SORRENSON MM, 1980, J MEMBRANE BIOL, V53, P1; STEPHENSON EW, 1987, J GEN PHYSIOL, V90, pA39; SUMNICHT GE, 1982, ARCH BIOCHEM BIOPHYS, V215, P628, DOI 10.1016/0003-9861(82)90124-2; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; TAKASAGO T, 1989, J BIOCHEM-TOKYO, V106, P872, DOI 10.1093/oxfordjournals.jbchem.a122945; TUANA BS, 1988, FEBS LETT, V235, P219, DOI 10.1016/0014-5793(88)81266-3; VARSANYI M, 1989, EUR J BIOCHEM, V179, P473, DOI 10.1111/j.1432-1033.1989.tb14577.x; VARSANYI M, 1986, BIOCHEM BIOPH RES CO, V138, P1395, DOI 10.1016/S0006-291X(86)80438-7; VOLPE P, 1986, J GEN PHYSIOL, V87, P289, DOI 10.1085/jgp.87.2.289; VOLPE P, 1985, NATURE, V316, P347, DOI 10.1038/316347a0; WILSON E, 1988, J BIOL CHEM, V263, P9304; WILSON E, 1986, J BIOL CHEM, V261, P2616; WINICOV I, 1988, J BIOL CHEM, V263, P12179; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZORZATO F, 1985, J BIOL CHEM, V260, P7349; ZORZATO F, 1989, BIOCHEM J, V261, P863, DOI 10.1042/bj2610863	74	109	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15475	15484						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1386359				2022-12-27	WOS:A1992JG11300036
J	GRAVES, RJ; FELZENSZWALB, I; LAVAL, J; OCONNOR, TR				GRAVES, RJ; FELZENSZWALB, I; LAVAL, J; OCONNOR, TR			EXCISION OF 5'-TERMINAL DEOXYRIBOSE PHOSPHATE FROM DAMAGED DNA IS CATALYZED BY THE FPG PROTEIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC-APYRIMIDINIC SITES; ENDONUCLEASE-III; BETA-ELIMINATION; PHYSICAL ASSOCIATION; OXIDATIVE DAMAGE; ABASIC SITES; AP SITES; GLYCOSYLASE; REPAIR; BACTERIOPHAGE-T4	Homogeneous Fpg protein of Escherichia coli has DNA glycosylase activity which excises some purine bases with damaged imidazole rings, and an activity excising deoxyribose (dR) from DNA at abasic (AP) sites leaving a gap bordered by 5'- and 3'-phosphoryl groups. In addition to these two reported activities, we show that the Fpg protein also catalyzes the excision of 5'-terminal deoxyribose phosphate (dRp) from DNA, which is the principal product formed by the incision of AP endonucleases at abasic sites. Moreover, the rate of the Fpg protein catalysis for the 2,6-diamino-4-hydroxy-5-formamidopyrimidine-DNA glycosylase activity is slower than the activities excising dR from abasic sites and dRp from abasic sites preincised by endonucleases. The product released by the Fpg protein in the excision of 5'-terminal dRp from an abasic site preincised by an AP endonuclease is a single base-free unsaturated dRp, suggesting that the excision results from beta-elimination. The release of 5'-terminal dRp by crude extracts of E. coli from wild type and fpg- mutant strains shows that the Fpg protein is one of the major EDTA-resistant activities catalyzing this reaction.	INST GUSTAVE ROUSSY,CNRS,URA 147,INSERM,U140,REPARAT LESIONS RADIO & CHIMIOINDUITES,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy			Felzenszwalb, Israel/AAH-4915-2020	Felzenszwalb, Israel/0000-0003-1677-197X; O'Connor, Timothy/0000-0001-5848-3592				BAILLY V, 1989, BIOCHEM J, V259, P751, DOI 10.1042/bj2590751; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1989, MOL GEN GENET, V215, P300, DOI 10.1007/BF00339732; BOITEUX S, 1989, CARCINOGENESIS, V10, P1905, DOI 10.1093/carcin/10.10.1905; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BREIMER L, 1980, NUCLEIC ACIDS RES, V8, P6199, DOI 10.1093/nar/8.24.6199; BRICTEUXGREGOIRE S, 1989, NUCLEIC ACIDS RES, V17, P6269, DOI 10.1093/nar/17.15.6269; CHETSANGA CJ, 1982, CANCER RES, V42, P2616; CHETSANGA CJ, 1983, CARCINOGENESIS, V4, P997, DOI 10.1093/carcin/4.8.997; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; CLEMENTS JE, 1978, J BIOL CHEM, V253, P2990; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; CUNNINGHAM RP, 1990, MUTAT RES, V236, P173; CZECZOT H, 1991, J BACTERIOL, V173, P3419, DOI 10.1128/jb.173.11.3419-3424.1991; DUNCAN BK, 1984, GENE, V28, P211, DOI 10.1016/0378-1119(84)90258-0; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; FRIEDBERG EC, 1971, J BACTERIOL, V106, P500, DOI 10.1128/JB.106.2.500-507.1971; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; LAVAL J, 1990, MUTAT RES, V233, P73, DOI 10.1016/0027-5107(90)90152-T; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; MANOHARAN M, 1989, J AM CHEM SOC, V110, P1620; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P119; MICHAELS ML, 1991, MUTAT RES, V19, P3629; MOSBAUGH DW, 1982, J BIOL CHEM, V257, P575; MULLER E, 1990, NUCLEIC ACIDS RES, V18, P5969, DOI 10.1093/nar/18.20.5969; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; SNOWDEN A, 1990, BIOCHEMISTRY-US, V29, P7251, DOI 10.1021/bi00483a013; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WEIBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1	41	139	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14429	14435						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378443				2022-12-27	WOS:A1992JD32500097
J	HERBST, R; SHEARMAN, MS; OBERMEIER, A; SCHLESSINGER, J; ULLRICH, A				HERBST, R; SHEARMAN, MS; OBERMEIER, A; SCHLESSINGER, J; ULLRICH, A			DIFFERENTIAL-EFFECTS OF W-MUTATIONS ON P145(C-KIT) TYROSINE KINASE-ACTIVITY AND SUBSTRATE INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C-GAMMA; STEM-CELL FACTOR; GTPASE-ACTIVATING PROTEIN; SITE-SPECIFIC MUTAGENESIS; GAP-ASSOCIATED PROTEINS; FACTOR-I RECEPTOR; PDGF RECEPTOR; PHOSPHATIDYLINOSITOL KINASE; SIGNAL TRANSDUCTION	The c-kit gene, mapped to the dominant white spotting (W) locus of the mouse (Chabot, B., Stephenson, D. A., Chapman, V. M., Besmer, P., and Bernstein, A. (1988) Nature 335, 88-89; Geissler, E. N., Ryan, M. A., and Housman, D. E. (1988) Cell 55, 185-192), encodes a receptor tyrosine kinase, p145c-kit. Germline mutations at the W locus lead to loss of function alterations in p145c-kit, and result in mice with developmental defects of varying severity in the melanocytic, hematopoietic stem cell, and primordial germ cell lineages. To investigate in more detail the effect of W mutations on p145c-kit signaling, three mutations, W42, W(v), and W41, that confer severe, intermediate, and mild phenotypic characteristics, respectively, were introduced into the human p145c-kit tyrosine kinase domain. These mutations attenuated the intrinsic tyrosine kinase activity of the receptor to different degrees. In addition, they had differential effects on the interaction of the p145c-kit substrates, phospholipase C-gamma, GTPase-activating protein, and the receptor-binding subunit of phosphatidylinositol 3'-kinase, p85. Notably, the W(v) mutation, while retaining significant receptor tyrosine kinase activity, was unable to bind phospholipase C(gamma) and GTPase-activating protein, but could still associate with p85. These results suggest that the location of W mutations may be an important determinant of the specificity of substrate association and phosphorylation, and may explain, at least in part, the cell type-specific defects associated with certain W alleles.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; New York University								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EGHTEDARZADEH MK, 1986, NUCLEIC ACIDS RES, V14, P5115, DOI 10.1093/nar/14.12.5115; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FENDLY BM, 1990, CANCER RES, V50, P1550; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUJITA J, 1988, BLOOD, V72, P463; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HERBST R, 1991, J BIOL CHEM, V266, P19908; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; Little CC, 1937, P NATL ACAD SCI USA, V23, P535, DOI 10.1073/pnas.23.10.535; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	76	31	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13210	13216						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377679				2022-12-27	WOS:A1992JB74600021
J	SCHOLZEN, T; ARNDT, E				SCHOLZEN, T; ARNDT, E			THE ALPHA-OPERON EQUIVALENT GENOME REGION IN THE EXTREME HALOPHILIC ARCHAEBACTERIUM HALOARCULA (HALOBACTERIUM) MARISMORTUI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; ENCODING RIBOSOMAL-PROTEINS; NUCLEOTIDE-SEQUENCE; RNA-POLYMERASE; ESCHERICHIA-COLI; MESSENGER-RNA; BACILLUS-STEAROTHERMOPHILUS; GENE-CLUSTER; SUBUNIT; EVOLUTION	The genome region of the extreme halophilic archaebacterium Haloarcula marismortui equivalent to the alpha-operon of Escherichia coli has been characterized. In H. marismortui, the alpha-operon was found to be located immediately upstream from the S9 gene cluster. The gene order in the halobacterial-alpha-operon, given according to the gene products, is tRNA(Ser), HmaS13, HmaS4, HmaS11, and HmaRp-alpha. Compared to the corresponding operon from E. coli, the halobacterial gene organization differs in (i) the presence of a gene for tRNA(Ser) (GCU), (ii) the reversed order of the genes for the ribosomal proteins HmaS11 and HmaS4, and (iii) the absence of the gene coding for the ribosomal protein L17. The primary structure of HmaRp-alpha shows high similarity to a subunit of eukaryotic RNA polymerase II (YeaRpB3, HsaRpB33), whereas the similarity to the eubacterial-alpha-subunit of RNA polymerase is only weak.	MAX PLANCK INST MOLEC GENET,ABT WITTMANN,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society				Scholzen, Thomas/0000-0002-5556-9144				AIBA H, 1981, J BIOL CHEM, V256, P1905; ARNDT E, 1988, J BIOL CHEM, V263, P16063; ARNDT E, 1986, FEBS LETT, V194, P227, DOI 10.1016/0014-5793(86)80090-4; ARNDT E, 1990, FEBS LETT, V267, P193, DOI 10.1016/0014-5793(90)80923-7; ARNDT E, 1990, J BIOL CHEM, V265, P3034; ARNDT E, 1990, NUCLEIC ACIDS RES, V18, P1285, DOI 10.1093/nar/18.5.1285; ARNDT E, 1991, BIOCHIMIE, V73, P657, DOI 10.1016/0300-9084(91)90045-3; BEDWELL D, 1985, NUCLEIC ACIDS RES, V13, P3891, DOI 10.1093/nar/13.11.3891; BERGMANN U, 1990, BIOCHIM BIOPHYS ACTA, V1050, P56, DOI 10.1016/0167-4781(90)90141-N; BOYLAN SA, 1989, J BACTERIOL, V171, P2553, DOI 10.1128/jb.171.5.2553-2562.1989; BROCKMOLLER J, 1988, BIOCHEMISTRY-US, V27, P3372, DOI 10.1021/bi00409a038; CHAN YL, 1991, BIOCHEM BIOPH RES CO, V178, P1212, DOI 10.1016/0006-291X(91)91022-5; DECKMAN IC, 1985, BIOCHEMISTRY-US, V24, P7860, DOI 10.1021/bi00348a002; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687; GUPTA R, 1986, SYST APPL MICROBIOL, V7, P102, DOI 10.1016/S0723-2020(86)80131-X; HATAKEYAMA T, 1988, EUR J BIOCHEM, V172, P703, DOI 10.1111/j.1432-1033.1988.tb13945.x; HUDSON L, 1981, NATURE, V294, P422, DOI 10.1038/294422a0; ISHII S, 1984, P NATL ACAD SCI-BIOL, V81, P409, DOI 10.1073/pnas.81.2.409; KIMURA M, 1988, FEBS LETT, V240, P15, DOI 10.1016/0014-5793(88)80332-6; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KROMER WJ, 1991, J BIOL CHEM, V266, P24573; LAKE JA, 1990, RIBOSOME, P579; LINDEMANN H, 1976, FEBS LETT, V71, P251, DOI 10.1016/0014-5793(76)80944-1; MANIAITS T, 1982, MOL CLONING LABORATO; MARTINDALE DW, 1990, NUCLEIC ACIDS RES, V18, P2953, DOI 10.1093/nar/18.10.2953; ORCUTT BC, 1982, 82050108710 NAT BIOC; OREN A, 1990, INT J SYST BACTERIOL, V40, P209, DOI 10.1099/00207713-40-2-209; OVCHINNIKOV YA, 1977, FEBS LETT, V76, P108, DOI 10.1016/0014-5793(77)80131-2; PATI UK, 1990, J BIOL CHEM, V265, P8400; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; REINBOLT J, 1973, FEBS LETT, V36, P250, DOI 10.1016/0014-5793(73)80383-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLZEN T, 1991, MOL GEN GENET, V228, P70, DOI 10.1007/BF00282450; SCHWARTZ RM, 1978, ATLAS PROTEIN SEQUEN, V3, P353; SIJBENMULLER G, 1986, NUCLEIC ACIDS RES, V14, P1029, DOI 10.1093/nar/14.2.1029; STEEL LF, 1987, NUCLEIC ACIDS RES, V15, P10285, DOI 10.1093/nar/15.24.10285; VONBOHLEN K, 1991, J MOL BIOL, V222, P11, DOI 10.1016/0022-2836(91)90730-T; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YAGUCHI M, 1982, ZBL BAKT MIK HYG I C, V3, P200, DOI 10.1016/S0721-9571(82)80033-1; YONATH A, 1990, RIBOSOME, P134	42	17	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12123	12130						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376318				2022-12-27	WOS:A1992HY94700072
J	BUREAU, MH; KHRESTCHATISKY, M; HEEREN, MA; ZAMBROWICZ, EB; KIM, H; GRISAR, TM; COLOMBINI, M; TOBIN, AJ; OLSEN, RW				BUREAU, MH; KHRESTCHATISKY, M; HEEREN, MA; ZAMBROWICZ, EB; KIM, H; GRISAR, TM; COLOMBINI, M; TOBIN, AJ; OLSEN, RW			ISOLATION AND CLONING OF A VOLTAGE-DEPENDENT ANION CHANNEL-LIKE MR-36,000 POLYPEPTIDE FROM MAMMALIAN BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTORS; OUTER MITOCHONDRIAL-MEMBRANE; BENZODIAZEPINE-RECEPTOR; POLYACRYLAMIDE GELS; HIPPOCAMPAL-NEURONS; SUBUNIT COMPOSITION; RAT-BRAIN; PROTEIN; PURIFICATION; SEQUENCE	A polypeptide of M(r) 36,000 (36 kDa) was isolated from detergent-solubilized membrane fractions of mammalian brain on a benzodiazepine affinity column utilized for the purification of the gamma-aminobutyric acid/benzodiazepine receptor protein, followed by preparative gel electrophoresis. Partial protein sequence for two fragments of the 36-kDa polypeptide allowed the isolation of cDNA clones from a rat hippocampal library. An open reading frame coding a sequence of 295 amino acid residues containing the two probe peptide sequences with minor differences, and a putative N-terminal signal peptide of 25 residues was found. Hydropathy index revealed no regions of alpha-helix suitable for membrane spanning, but several areas of alternating hydrophilic and hydrophobic residues consistent with beta-strands. The sequence of this brain protein was 24% identical to that of a yeast mitochondrial protein, the voltage-dependent anion channel (VDAC), and over 70% identical with the VDAC from human B lympocytes. The gamma-aminobutyric acid type A (GABA(A)) receptor/36-kDa preparation purified on benzodiazepine affinity column has channel-forming activity in lipid bilayer membranes that is virtually identical to VDAC isolated from mitochondria of various sources, indicating that the 36-kDa protein is a new member of the VDAC family of proteins. An antiserum raised against the purified 36-kDa polypeptide was able to precipitate [H-3]muscimol binding activity, indicating a tight association with the GABA(A) receptor protein in vitro and copurification on the benzodiazepine affinity column due to this association. Further studies are needed to determine whether such an association occurs in vivo.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV LIEGE,BIOCHIM GEN & COMPAREE LAB,B-4020 LIEGE,BELGIUM; UNIV MARYLAND,DEPT ZOOL,COLLEGE PK,MD 20742	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of Liege; University System of Maryland; University of Maryland College Park			Colombini, Marco/A-1540-2014		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022256, R01NS028772, R01NS022071] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28772, NS22256, NS22071] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; BENKE D, 1991, J BIOL CHEM, V266, P4478; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1989, J BIOENERG BIOMEMBR, V21, P471, DOI 10.1007/BF00762519; BUREAU M, 1990, MOL PHARMACOL, V37, P497; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; DEPINTO V, 1985, BIOCHIM BIOPHYS ACTA, V813, P230; DOBLE A, 1987, MOL PHARMACOL, V31, P42; DORING C, 1985, J MEMBRANE BIOL, V83, P81, DOI 10.1007/BF01868740; FORTE M, 1987, J MEMBRANE BIOL, V99, P65, DOI 10.1007/BF01870622; FRAIL DE, 1987, P NATL ACAD SCI USA, V84, P6302, DOI 10.1073/pnas.84.17.6302; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KIRKNESS EF, 1988, J NEUROCHEM, V50, P356, DOI 10.1111/j.1471-4159.1988.tb02920.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU MY, 1991, AM J PHYSIOL, V260, pC371, DOI 10.1152/ajpcell.1991.260.2.C371; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCABE RT, 1989, FEBS LETT, V244, P263, DOI 10.1016/0014-5793(89)80541-1; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; OLSEN RW, 1991, NEUROCHEM RES, V16, P317, DOI 10.1007/BF00966095; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PARK D, 1991, J NEUROCHEM, V56, P1972, DOI 10.1111/j.1471-4159.1991.tb03455.x; RIOND J, 1989, FEBS LETT, V245, P238, DOI 10.1016/0014-5793(89)80229-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SIEGHART W, 1980, NATURE, V286, P285, DOI 10.1038/286285a0; SIGEL E, 1983, J BIOL CHEM, V258, P6965; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SNYDER SH, 1987, FASEB J, V1, P282, DOI 10.1096/fasebj.1.4.2820823; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; STAUBER GB, 1987, EUR J BIOCHEM, V167, P125, DOI 10.1111/j.1432-1033.1987.tb13313.x; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	42	86	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8679	8684						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373732				2022-12-27	WOS:A1992HQ18500107
J	CHAN, HC; KAETZEL, MA; NELSON, DJ; HAZARIKA, P; DEDMAN, JR				CHAN, HC; KAETZEL, MA; NELSON, DJ; HAZARIKA, P; DEDMAN, JR			ANTIBODY AGAINST A CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR-DERIVED SYNTHETIC PEPTIDE INHIBITS ANION CURRENTS IN HUMAN COLONIC CELL-LINE T84	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CHANNELS; AIRWAY EPITHELIUM; IDENTIFICATION; GENE; EXPRESSION; TRANSPORT; CAMP	The cystic fibrosis (CF) phenotype is characterized by a regulatory defect in Cl- permeability in epithelia. A gene (250,000 base pairs) that is associated with this autosomal genetic disorder has been identified. To determine the cellular function of the recently cloned gene product, the cystic fibrosis transmembrane conductance regulator (CFTR), we have produced antibody against a synthetic peptide deduced from the CFTR cDNA sequence corresponding to positions 505-511. This site includes phenylalanine 508, the deletion of which is the most commonly expressed mutation in CF. We sought to determine whether the anti-CFTR505-511 peptide antibody could modulate the activation of the volume-sensitive, Ca2+-dependent, as well as the cAMP-dependent Cl- conductances present in the Cl--secreting human colonic T84 cell line. Affinity-purified anti-CFTR505-511 antibody was introduced into the cytoplasm of individual T84 cells and its function studied using the whole-cell patch-clamp technique. Although cAMP-dependent Cl- current activation was inhibited in cells perfused with the anti-CFTR505-511 peptide antibody, Ca2+-dependent anion current activation remained unaffected. Chloride current activation, which accompanies cellular swelling, was partially attenuated in anti-CFTR505-511 antibody-loaded cells as compared with control cells perfused with either saline or irrelevant antibody. These results further support a role for CFTR in anion transport in epithelial cells and suggest its possible involvement in a number of anion transport pathways in chloride secretory epithelia.	UNIV TEXAS,SCH MED,DEPT PHYSIOL & CELL BIOL,HOUSTON,TX 77225	University of Texas System	CHAN, HC (corresponding author), UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637, USA.		Chan, Hsiao Chang/E-1507-2016		NIDDK NIH HHS [R01 DK41740] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041740] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; DISANTAGNESE PA, 1953, PEDIATRICS, V12, P549; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Fanconi G UE, 1936, WIEN MED WOCHENSCHR, V86, P753; GOODFELLOW P, 1989, CYSTIC FIBROSIS, P1; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GRINSTEIN S, 1983, AM J PHYSIOL, V245, pC160, DOI 10.1152/ajpcell.1983.245.1.C160; HALM DR, 1988, AM J PHYSIOL, V254, pC505, DOI 10.1152/ajpcell.1988.254.4.C505; HAZARIKA P, 1988, LIFE SCI, V42, P2525, DOI 10.1016/0024-3205(88)90352-9; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; QUINTON PM, 1983, NEW ENGL J MED, V308, P1185, DOI 10.1056/NEJM198305193082002; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHOPPA N, 1989, J MEMBRANE BIOL, V108, P73, DOI 10.1007/BF01870427; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	29	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1992	267	12					8411	8416						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HQ185	1373728				2022-12-27	WOS:A1992HQ18500071
J	RECNY, MA; LUTHER, MA; KNOPPERS, MH; NEIDHARDT, EA; KHANDEKAR, SS; CONCINO, MF; SCHIMKE, PA; FRANCIS, MA; MOEBIUS, U; REINHOLD, BB; REINHOLD, VN; REINHERZ, EL				RECNY, MA; LUTHER, MA; KNOPPERS, MH; NEIDHARDT, EA; KHANDEKAR, SS; CONCINO, MF; SCHIMKE, PA; FRANCIS, MA; MOEBIUS, U; REINHOLD, BB; REINHOLD, VN; REINHERZ, EL			N-GLYCOSYLATION IS REQUIRED FOR HUMAN CD2 IMMUNOADHESION FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; VESICULAR STOMATITIS-VIRUS; FUNCTION-ASSOCIATED ANTIGEN-3; SHEEP ERYTHROCYTE RECEPTOR; SURFACE-MOLECULE CD2; HUMAN LYMPHOCYTES-T; ALTERNATIVE PATHWAY; SIALYL-LEX; G-PROTEIN; 3 LFA-3	The T-lymphocyte glycoprotein receptor, CD2, mediates cell-cell adhesion by binding to the surface molecule CD58 (LFA-3) on many cell types including antigen presenting cells. Two domains comprise the CD2 extracellular segment, with all adhesion functions localized to the amino-terminal domain that contains a single N-glycosylation site at Asn65. We have defined an important role for the N-linked glycans attached to Asn65 of this domain in mediating CD2-CD58 interactions and also characterize its N-glycotype structure. Analysis of deglycosylated soluble recombinant CD2 as well as a mutant transmembrane CD2 molecule containing a single Asn65-Gln65 substitution demonstrates that neither deglycosylated CD2 nor the mutant CD2 transmembrane receptor binds CD58 or monoclonal antibodies directed at native CD2 adhesion domain epitopes. Electrospray ionization-mass spectrometry demonstrates that high mannose oligosaccharides ((Man)nGlcNAC2, n = 5-9) are the only N-glycotypes occupying Asn65 when soluble CD2 is expressed in Chinese hamster ovary cells. Based on a model of human CD2 secondary structure, we propose that N-glycosylation is required for stabilizing domain 1 in the human receptor. Thus, N-glycosylation is essential for human CD2 adhesion functions.	HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, IMMUNOBIOL LAB, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	RECNY, MA (corresponding author), PROCEPT INC, CAMBRIDGE, MA 02139 USA.				NIAID NIH HHS [AI21226] Funding Source: Medline; NIGMS NIH HHS [R01GM45781] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045781] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACH JF, 1973, TRANSPLANT REV, V16, P196; BAXLEY G, 1973, CLIN EXP IMMUNOL, V15, P385; BEBENEK K, 1989, NUCLEIC ACIDS RES, V17, P5408, DOI 10.1093/nar/17.13.5408; BIERER BE, 1988, P NATL ACAD SCI USA, V85, P1194, DOI 10.1073/pnas.85.4.1194; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BOLHUIS RLH, 1986, J IMMUNOL, V136, P3939; BRAIN P, 1970, CLIN EXP IMMUNOL, V6, P681; BROTTIER P, 1985, J IMMUNOL, V135, P1624; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CLAYTON LK, 1987, EUR J IMMUNOL, V17, P1367, DOI 10.1002/eji.1830170922; CUMMING D A, 1991, Glycobiology, V1, P115, DOI 10.1093/glycob/1.2.115; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; DUSTIN ML, 1987, J EXP MED, V165, P677, DOI 10.1084/jem.165.3.677; DUSTIN ML, 1989, J EXP MED, V169, P503, DOI 10.1084/jem.169.2.503; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; GIBSON R, 1978, CELL, V13, P671, DOI 10.1016/0092-8674(78)90217-9; HUNIG T, 1986, EUR J IMMUNOL, V16, P1615, DOI 10.1002/eji.1830161223; HUNIG T, 1987, NATURE, V326, P298, DOI 10.1038/326298a0; JONDAL M, 1972, J EXP MED, V136, P207, DOI 10.1084/jem.136.2.207; KONIG R, 1988, J BIOL CHEM, V263, P9502; KOYASU S, 1990, P NATL ACAD SCI USA, V87, P2603, DOI 10.1073/pnas.87.7.2603; KRENSKY AM, 1984, J IMMUNOL, V132, P2180; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVITT R, 1977, J BIOL CHEM, V252, P9018; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOINGEON P, 1989, NATURE, V339, P312, DOI 10.1038/339312a0; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; MOINGEON PE, 1991, EUR J IMMUNOL, V21, P605, DOI 10.1002/eji.1830210311; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RECNY MA, 1990, J BIOL CHEM, V265, P8542; REINHOLD BB, 1992, J AM SOC MASS SPECTR, V3, P207, DOI 10.1016/1044-0305(92)87004-I; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAYRE PH, 1987, P NATL ACAD SCI USA, V84, P2941, DOI 10.1073/pnas.84.9.2941; SAYRE PH, 1989, J EXP MED, V169, P995, DOI 10.1084/jem.169.3.995; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SEWELL WA, 1986, P NATL ACAD SCI USA, V83, P8718, DOI 10.1073/pnas.83.22.8718; SEWELL WA, 1987, EUR J IMMUNOL, V17, P1015, DOI 10.1002/eji.1830170718; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TADMORI W, 1985, J IMMUNOL, V134, P1709; TIFFT CJ, 1992, J BIOL CHEM, V267, P3268; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WACHOLTZ MC, 1989, J EXP MED, V170, P431, DOI 10.1084/jem.170.2.431; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; WOLFF HL, 1990, J IMMUNOL, V144, P1215; YANG SY, 1986, J IMMUNOL, V137, P1097	56	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1992	267	31					22428	22434						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JW719	1385399				2022-12-27	WOS:A1992JW71900069
J	ARAKI, T; FUNATSU, J; KURAMOTO, M; KONNO, H; TORIKATA, T				ARAKI, T; FUNATSU, J; KURAMOTO, M; KONNO, H; TORIKATA, T			THE COMPLETE AMINO-ACID-SEQUENCE OF YAM (DIOSCOREA-JAPONICA) CHITINASE - A NEWLY IDENTIFIED ACIDIC CLASS-I CHITINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM-AGGLUTININ; ETHYLENE-INDUCED CHITINASE; BEAN-LEAVES; MESSENGER-RNA; PURIFICATION; TOBACCO; LOCALIZATION; ENDOCHITINASE; GENE; BETA-1,3-GLUCANASE	The complete amino acid sequence of acidic chitinase from yam (Dioscorea japonica) aerial tubers was determined. The protein is composed of a single polypeptide chain of 250 amino acid residues and has a calculated molecular mass of 27,890 Da. There is an NH2-terminal domain, a hinge region, and a main structure, typical for class I chitinases (Shinshi, H., Neuhaus, J.M., Ryals, J., and Meins, F., Jr. (1990) Plant Mol. Biol. 14, 357-368). We have obtained the first evidence for an acidic class I chitinase. Comparison with sequences of other class I chitinases revealed approximately 40% sequence similarity, a value lower than that for other class I chitinases (70-80%). We assume that there is a local conformational change in the molecule; cysteine residues that probably form disulfide bonds are completely conserved, with the exception of Cys-178. The difference in structure between this chitinase and other basic class I chitinases suggests that acidic and basic isoforms should be grouped into subclasses; this protein is an ethylene- or a pathogen-independent chitinase produced by a gene that is inherent in the tuber.			ARAKI, T (corresponding author), KYUSHU TOKAI UNIV,SCH AGR,DEPT BIOCHEM,ASO,KUMAMOTO 86914,JAPAN.							ARAKI T, 1988, P NATL ACAD SCI USA, V85, P679, DOI 10.1073/pnas.85.3.679; ARAKI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P195, DOI 10.1016/0167-4838(89)90293-8; ARAKI T, 1987, BIOCHIM BIOPHYS ACTA, V911, P191, DOI 10.1016/0167-4838(87)90008-2; ARAKI T, 1991, J CHROMATOGR, V545, P183, DOI 10.1016/S0021-9673(01)88706-9; BERNASCONI P, 1987, BIOCHIM BIOPHYS ACTA, V915, P254, DOI 10.1016/0167-4838(87)90307-4; BLOCH R, 1974, BIOCHEM BIOPH RES CO, V58, P13, DOI 10.1016/0006-291X(74)90884-5; BOLLER T, 1984, PLANT PHYSIOL, V74, P442, DOI 10.1104/pp.74.2.442; BOLLER T, 1983, PLANTA, V157, P22, DOI 10.1007/BF00394536; BOLLER T, 1988, PHYSIOL MOL PLANT P, V33, P11, DOI 10.1016/0885-5765(88)90039-2; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; BURGER MM, 1967, P NATL ACAD SCI USA, V57, P359, DOI 10.1073/pnas.57.2.359; CHANG JY, 1978, FEBS LETT, V93, P205, DOI 10.1016/0014-5793(78)81105-3; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; GAYNOR JJ, 1988, NUCLEIC ACIDS RES, V16, P5210, DOI 10.1093/nar/16.11.5210; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; KEEFE D, 1990, PLANTA, V182, P43, DOI 10.1007/BF00239982; KUROSAKI F, 1988, PLANT CELL PHYSIOL, V29, P527; KUROSAKI F, 1987, PHYSIOL MOL PLANT P, V31, P201, DOI 10.1016/0885-5765(87)90064-6; LEGRAND M, 1987, P NATL ACAD SCI USA, V84, P6750, DOI 10.1073/pnas.84.19.6750; LUCAS J, 1985, FEBS LETT, V193, P208, DOI 10.1016/0014-5793(85)80152-6; MAUCH F, 1988, PLANT PHYSIOL, V87, P325, DOI 10.1104/pp.87.2.325; MAUCH F, 1989, PLANT CELL, V1, P447, DOI 10.2307/3869105; MAUCH F, 1984, PLANT PHYSL BETHESDA, V76, P307; METRAUX JP, 1989, P NATL ACAD SCI USA, V86, P869; PAYNE G, 1990, P NATL ACAD SCI USA, V87, P98, DOI 10.1073/pnas.87.1.98; SHINSHI H, 1987, P NATL ACAD SCI USA, V84, P89, DOI 10.1073/pnas.84.1.89; SHINSHI H, 1990, PLANT MOL BIOL, V14, P357, DOI 10.1007/BF00028772; TSUKAMOTO T, 1984, AGR BIOL CHEM TOKYO, V48, P931, DOI 10.1080/00021369.1984.10866241; WRIGHT CS, 1984, BIOCHEMISTRY-US, V23, P280, DOI 10.1021/bi00297a017; YANG YC, 1979, HOPPESEYLERS Z PHYSL, V360, P1673	30	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19944	19947						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400311				2022-12-27	WOS:A1992JR85800034
J	ITO, S; HASHIMOTO, H; NEGISHI, M; SUZUKI, M; KOYANO, H; NOYORI, R; ICHIKAWA, A				ITO, S; HASHIMOTO, H; NEGISHI, M; SUZUKI, M; KOYANO, H; NOYORI, R; ICHIKAWA, A			IDENTIFICATION OF THE PROSTACYCLIN RECEPTOR BY USE OF [15-3H1]19-(3-AZIDOPHENYL)-20-NORISOCARBACYCLIN, AN IRREVERSIBLE SPECIFIC PHOTOAFFINITY PROBE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASTOCYTOMA P-815 CELLS; BINDING; PLATELETS; ANALOG; MEMBRANE; LIGAND; H-3	The prostaglandin I (PGI2) receptor of mouse mastocytoma P-815 cells was characterized by photoaffinity labeling with the stable PGI2 analogue [15-H-3(1)]-19-(3-azidophenyl)-20-norisocarbacyclin ([H-3] APNIC) used as a potential photoaffinity probe for the receptor. [H-3]APNIC bound to the mastocytoma membrane with high affinity and in a saturable manner. Scatchard plot analysis indicated a single binding site with a K(d) of 4.7 nM and a B(max) of 0.58 pmol/mg protein. The binding of [H-3]APNIC was dose dependently inhibited by APNIC and iloprost, another stable PGI2 agonist, and to a much lesser extent by PGE2. The binding of the radioligand showed sensitivity (to the guanine nucleotide guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS). Photolysis of [H-3]APNIC-prelabeled membranes resulted in incorporation of radiolabel into a protein of approximately 43 kDa. Photolabeling was inhibited by PGI2 agonists and other prostaglandins with specificity for the PGI2 receptor and was modulated by GTPgammaS. A protein of approximately 45 kDa was also labeled by [H-3]APNIC in the membrane of porcine platelets, membranes that are known to be abundant in PGI2 receptors. These results demonstrate that [H-3]APNIC specifically labels a protein that may represent the PGI2 receptor and that this radioprobe will be a useful reagent for further characterization and purification of the PGI2 receptor.	KYOTO UNIV, FAC PHARMACEUT SCI, DEPT PHYSIOL CHEM, KYOTO 606, JAPAN; NAGOYA UNIV, CTR CHEM INSTRUMENT, NAGOYA, AICHI 464, JAPAN; NAGOYA UNIV, FAC SCI, DEPT CHEM, NAGOYA 46401, JAPAN	Kyoto University; Nagoya University; Nagoya University	ITO, S (corresponding author), OSAKA BIOSCI INST, DEPT CELL BIOL, 6-2-4 FURUEDAI, SUITA 565, JAPAN.		Hashimoto, Hitoshi/D-1209-2010	Hashimoto, Hitoshi/0000-0001-6548-4016				ARISTOFF PA, 1985, ADV PROSTAG THROMB L, V14, P309; ARMSTRONG RA, 1989, BRIT J PHARMACOL, V97, P657, DOI 10.1111/j.1476-5381.1989.tb12001.x; BLAIR IA, 1981, BRIT J PHARMACOL, V72, P435, DOI 10.1111/j.1476-5381.1981.tb10994.x; FEDAN JS, 1984, BIOCHEM PHARMACOL, V33, P1167, DOI 10.1016/0006-2952(84)90167-9; HALUSHKA PV, 1989, ANNU REV PHARMACOL, V29, P213; HASHIMOTO H, 1990, PROSTAGLANDINS, V40, P491, DOI 10.1016/0090-6980(90)90111-8; KEEN M, 1991, EUR J PHARM-MOLEC PH, V207, P111, DOI 10.1016/0922-4106(91)90085-V; KUNO T, 1985, BIOCHEM BIOPH RES CO, V129, P639, DOI 10.1016/0006-291X(85)91939-4; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEIGH PJ, 1984, J BIOL CHEM, V259, P2431; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MICHALAK M, 1990, FEBS LETT, V265, P117, DOI 10.1016/0014-5793(90)80898-S; RAO CV, 1988, INT CONGR SER, V798, P171; RUAT M, 1988, P NATL ACAD SCI USA, V85, P2743, DOI 10.1073/pnas.85.8.2743; RUCKER W, 1983, BIOCHEM PHARMACOL, V32, P2405, DOI 10.1016/0006-2952(83)90683-4; SHIBASAKI M, 1983, TETRAHEDRON LETT, V24, P3493, DOI 10.1016/S0040-4039(00)86021-9; SIEGL AM, 1979, J CLIN INVEST, V63, P215, DOI 10.1172/JCI109292; SUZUKI M, 1987, J ORG CHEM, V52, P5583, DOI 10.1021/jo00234a014; SUZUKI M, 1992, TETRAHEDRON, V48, P2635, DOI 10.1016/S0040-4020(01)88526-4; TAKAHASHI S, 1991, J BIOL CHEM, V266, P5367; TOWN MH, 1982, PROSTAG OTH LIPID M, V24, P61, DOI 10.1016/0090-6980(82)90177-0; TSAI AL, 1989, J BIOL CHEM, V264, P61; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515; YAMASHITA M, 1991, BIOCHEM BIOPH RES CO, V177, P1233, DOI 10.1016/0006-291X(91)90673-U	25	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20326	20330						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400351				2022-12-27	WOS:A1992JR85800091
J	FUJIMORI, T; JENCKS, WP				FUJIMORI, T; JENCKS, WP			BINDING OF 2 SR2+ IONS CHANGES THE CHEMICAL SPECIFICITIES FOR PHOSPHORYLATION OF THE SARCOPLASMIC-RETICULUM CALCIUM ATPASE THROUGH A STEPWISE MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMITING CONFORMATIONAL CHANGE; (CA-2+ + MG-2+)-ATPASE; ADENOSINE-TRIPHOSPHATASE; TRANSIENT KINETICS; LANTHANIDE BINDING; MULTIPLE METALS; STOPPED FLOW; TRANSPORT; CA-2+; SITES	The sequential binding of Sr2+ and Ca2+ to the cytoplasmic transport sites of the sarcoplasmic reticulum calcium ATPase allows the formation of two different mixed complexes: (c)E.Sr.Ca, with Sr2+ bound to the "inner" site and Ca2+ bound to the "outer" site, and (c)E.Ca.Sr, with Ca2+ bound to the inner site and Sr2+ bound to the outer site (pH 7.0, 25-degrees-C, 10 mM MgCl2, 100 mM KCl). Both (c)E.Sr.Ca-45 and (c)E.Ca-45.Sr react with ATP to internalize one Ca-45/phosphoenzyme. The value of K0.5 = 83-mu-M Sr2+ for activation of the enzyme for phosphorylation by ATP is much larger than K0.5 = 28-mu-M Sr2+ for inhibition of phosphoenzyme formation from inorganic phosphate (n(H) = 1.0-1.3). These results are consistent with the sequential binding of two strontium ions with negative cooperativity and dissociation constants of K(Sr1) = 35-mu-M and K(Sr2) = 55-mu-M. The species (c)E.Sr2 and (c)E.Ca2 react rapidly with ATP but not inorganic phosphate. However, enzyme with one strontium bound, (c)E.Sr, does not react with either inorganic phosphate or ATP. Therefore, the conformational changes in the enzyme that alter the chemical specificity for phosphorylation by ATP and by inorganic phosphate are different. This requires the existence of at least three forms of the unphosphorylated enzyme with three different chemical specificities for catalysis.	BRANDEIS UNIV, DEPT BIOCHEM, WALTHAM, MA 02254 USA	Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020888, R37GM020888] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20888] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; ARAV R, 1983, J BIOL CHEM, V258, P433; BERMAN MC, 1990, BIOCHIM BIOPHYS ACTA, V1029, P235, DOI 10.1016/0005-2736(90)90159-L; CHAMPEIL P, 1983, J BIOL CHEM, V258, P4453; de Meis L, 1974, Biochemistry, V13, P5032, DOI 10.1021/bi00721a026; DEMEIS L, 1981, SARCOPLASMIC RETICUL; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; FUJIMORI T, 1990, J BIOL CHEM, V265, P16262; FUJIMORI T, 1992, J BIOL CHEM, V267, P18466; GODT RE, 1974, J GEN PHYSIOL, V63, P722, DOI 10.1085/jgp.63.6.722; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; GUIMARAESMOTTA H, 1984, J BIOL CHEM, V259, P8699; HANEL AM, 1990, BIOCHEMISTRY-US, V29, P5210, DOI 10.1021/bi00473a030; HASSELBACH W, 1963, BIOCHEM Z, V339, P94; HASSELBACH W, 1974, ENZYMES, V10, P431; HERRMANN TR, 1986, EUR J BIOCHEM, V158, P555, DOI 10.1111/j.1432-1033.1986.tb09790.x; HOLGUIN JA, 1986, ARCH BIOCHEM BIOPHYS, V251, P9, DOI 10.1016/0003-9861(86)90045-7; IKEMOTO N, 1978, J BIOL CHEM, V253, P8027; IKEMOTO N, 1981, J BIOL CHEM, V256, P8593; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; ITOH N, 1984, J BIOCHEM-TOKYO, V95, P661, DOI 10.1093/oxfordjournals.jbchem.a134655; JENCKS WP, 1983, CURR TOP MEMBR TRANS, V19, P1; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MAKINOSE M, 1973, FEBS LETT, V37, P140, DOI 10.1016/0014-5793(73)80443-0; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; MARTONOSI AN, 1983, HDB PHYSL 10, V10, P417; MERMIER P, 1976, EUR J BIOCHEM, V69, P79, DOI 10.1111/j.1432-1033.1976.tb10860.x; MYUNG J, 1991, FEBS LETT, V278, P35, DOI 10.1016/0014-5793(91)80077-G; NAKAMURA J, 1986, BIOCHIM BIOPHYS ACTA, V870, P495, DOI 10.1016/0167-4838(86)90258-X; NAKAMURA J, 1989, J BIOL CHEM, V264, P17029; OGURUSU T, 1991, BIOCHEMISTRY-US, V30, P9966, DOI 10.1021/bi00105a022; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P8626, DOI 10.1021/bi00423a018; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICKART CM, 1984, J BIOL CHEM, V259, P1629; PICKART CM, 1982, J BIOL CHEM, V257, P5319; SCOTT TL, 1984, J BIOL CHEM, V259, P4035; SCOTT TL, 1985, J BIOL CHEM, V260, P4421; SQUIER TC, 1990, J BIOL CHEM, V265, P13713; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; STEPHENS EM, 1979, BIOCHEMISTRY-US, V18, P4876, DOI 10.1021/bi00589a016; STEPHENS EM, 1978, FED PROC, V37, P1483; TADA M, 1978, PHYSIOL REV, V58, P1; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; VERJOVSKIALMEIDA S, 1978, BIOCHEMISTRY-US, V17, P5006, DOI 10.1021/bi00616a023; WEBER A, 1966, BIOCHEM Z, V345, P329	58	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18475	18487						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1388155				2022-12-27	WOS:A1992JN50200039
J	SILVERSTEIN, RL; BAIRD, M; LO, SK; YESNER, LM				SILVERSTEIN, RL; BAIRD, M; LO, SK; YESNER, LM			SENSE AND ANTISENSE CDNA TRANSFECTION OF CD36 (GLYCOPROTEIN-IV) IN MELANOMA-CELLS - ROLE OF CD36 AS A THROMBOSPONDIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; PLATELET THROMBOSPONDIN; ADHESIVE GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; SURFACE EXPRESSION; ENDOTHELIAL-CELLS; COMPLEX-FORMATION; TISSUE ACTIVATOR; HUMAN-MONOCYTES; BINDING	Thrombospondin (TSP) is a multifunctional matrix and platelet glycoprotein that interacts with cell surfaces and may play a role in mediating cell adhesion, platelet aggregation, platelet-monocyte interactions, cell proliferation, angiogenesis, tumor metastasis, and protease generation. To clarify and confirm the function of CD36 (glycoprotein IV) as a TSP receptor, we now describe a transfected cell model using human melanoma cells genetically manipulated by sense or antisense cDNA transfection to express either high or near zero levels of CD36. Surface expression was confirmed by flow cytometry with monoclonal anti-CD36 IgG and quantified by measuring radiolabeled antibody binding. Bowes melanoma cells, which in their wild type did not express CD36 and did not bind radiolabeled TSP, when transfected with the sense construct bound TSP in a 1:1 stoichiometric ratio with CD36 expression. Conversely, C32 melanoma cells, which in their wild type expressed high levels of CD36 and bound radiolabeled TSP at a 1:1 stoichiometric ratio, did not express CD36 and did not bind TSP when transfected with an antisense construct. In addition, transfected Bowes cells and wild type C32 cells, unlike wild type Bowes cells, adhered to activated platelets in a TSP-dependent manner. These data, i.e. the gain of function with sense cDNA transfection and loss of function with antisense transfection, strongly support the TSP receptor function of CD36. The distribution of this protein in vascular cells and tissues and observations that it may participate in signal transduction events suggest that TSP-CD36 interactions may play a role in mediating some of the pathophysiological processes associated with TSP.	CORNELL UNIV, MED CTR, COLL MED, SPECIALIZED CTR THROMBOSIS RES, NEW YORK, NY 10021 USA	Cornell University	SILVERSTEIN, RL (corresponding author), CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL, 1300 YORK AVE, RM C606, NEW YORK, NY 10021 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042540, P50HL018828, P01HL046403] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL42540, P50 HL18828, P01 HL46403] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKEN ML, 1990, BLOOD, V76, P2501; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1991, J BIOL CHEM, V266, P1740; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BALE MD, 1985, J BIOL CHEM, V260, P7502; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BERK GI, 1989, BLOOD, V70, P346; CATIMEL B, 1991, COLLOQ INSE, V206, P41; CLEMETSON KJ, 1985, PLATELET MEMBRANE GL, P54; DIXIT VM, 1984, J BIOL CHEM, V259, P100; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P96; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SILVERSTEIN RL, 1987, J CLIN INVEST, V79, P867, DOI 10.1172/JCI112896; SILVERSTEIN RL, 1985, J BIOL CHEM, V260, P346; SILVERSTEIN RL, 1985, J CLIN INVEST, V75, P2065, DOI 10.1172/JCI111926; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SUN X, 1991, J CLIN INVEST, V87, P171, DOI 10.1172/JCI114967; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANDON NN, 1991, BLOOD, V78, P2809; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TUSZYNSKI GP, 1991, J CLIN INVEST, V87, P1387, DOI 10.1172/JCI115144; TUSZYNSKI GP, 1987, CANCER RES, V47, P4130; VARANI J, 1988, J CLIN INVEST, V81, P1537, DOI 10.1172/JCI113486; VARANI J, 1989, CLIN EXP METASTAS, V7, P265, DOI 10.1007/BF01753679; VARANI J, 1986, EXP CELL RES, V167, P376, DOI 10.1016/0014-4827(86)90178-3; YAMAMOTO N, 1990, BLOOD, V76, P1698	51	91	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16607	16612						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379600				2022-12-27	WOS:A1992JJ45800095
J	CENCIARELLI, C; HOHMAN, RJ; ATKINSON, TP; GUSOVSKY, F; WEISSMAN, AM				CENCIARELLI, C; HOHMAN, RJ; ATKINSON, TP; GUSOVSKY, F; WEISSMAN, AM			EVIDENCE FOR GTP-BINDING PROTEIN INVOLVEMENT IN THE TYROSINE PHOSPHORYLATION OF THE T-CELL RECEPTOR ZETA-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOPLASMIC FREE CALCIUM; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; PHOSPHOLIPASE-C; ACTIVATION; COMPLEX; POLYPEPTIDE; KINASE	The zeta-subunit of the T cell receptor (TCR) is a prominent substrate for a TCR-activated tyrosine kinase. Tyrosine phosphorylation of the zeta-subunit in response to antibody-mediated receptor cross-linking was synergized in permeabilized T cells by either of two nonhydrolyzable GTP analogues, guanosine 5'-[gamma-thio]triphosphate (GTP-gamma-S) or guanosine 5'-[beta, gamma-imido]triphosphate Gpp(NH)p. ATP analogues did not significantly affect antibody-induced tyrosine phosphorylation. Unlike the GTP analogues, the GDP analogue guanosine 5'-[beta-thio]diphosphate (GDP-beta-S) did not enhance phosphorylation of zeta. The effect induced by the GTP analogues required TCR occupancy and was independent of protein kinase C. Taken together these observations implicate a GTP-binding protein in the modulation of TCR-induced tyrosine phosphorylation.	NCI,EXPTL IMMUNOL BRANCH,BLDG 10,RM 4B17,BETHESDA,MD 20892; NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20892; NIDDKD,BIOORGAN CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BONVINI E, 1991, BIOCHEM J, V275, P689, DOI 10.1042/bj2750689; BURDETT E, 1990, AM J PHYSIOL, V258, pC99, DOI 10.1152/ajpcell.1990.258.1.C99; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAVES JD, 1991, J IMMUNOL, V146, P2102; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HOHMAN RJ, 1988, P NATL ACAD SCI USA, V85, P1624, DOI 10.1073/pnas.85.5.1624; HOWELL TW, 1987, BIOCHIM BIOPHYS ACTA, V927, P177, DOI 10.1016/0167-4889(87)90132-7; IMBODEN JB, 1985, J IMMUNOL, V134, P663; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; KUNG PC, 1979, SCIENCE, V206, P347, DOI 10.1126/science.314668; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; MAO SY, 1992, P NATL ACAD SCI USA, V89, P222, DOI 10.1073/pnas.89.1.222; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; OSHEA JJ, 1987, J IMMUNOL, V139, P3463; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PATEL MD, 1987, J BIOL CHEM, V262, P5831; PETER ME, 1992, EMBO J, V11, P933, DOI 10.1002/j.1460-2075.1992.tb05132.x; PHILLIPS RJ, 1991, INT IMMUNOL, V3, P617, DOI 10.1093/intimm/3.7.617; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHREZENMEIER H, 1988, J IMMUNOL, V141, P3785; SCHREZENMEIER H, 1988, J EXP MED, V168, P817, DOI 10.1084/jem.168.2.817; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Weissman A M, 1989, Year Immunol, V4, P74; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	41	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14527	14530						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386076				2022-12-27	WOS:A1992JF08800004
J	HIRATSUKA, T				HIRATSUKA, T			MOVEMENT OF CYS-697 IN MYOSIN ATPASE ASSOCIATED WITH ATP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SKELETAL-MUSCLE MYOSIN; GLYCINE-RICH LOOP; HEAVY-CHAIN; CROSS-LINKING; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGES; NUCLEOTIDE BINDING; SUBFRAGMENT-1; ACTIN	To detect movement of Cys-697 (SH2) in myosin subfragment-1 (S-1) associated with ATP hydrolysis, SH2 was labeled with the environmentally sensitive fluorescent analog of maleimide, 2-(4'-maleimidylanilino) naphthalene-6-sulfonic acid (MIANS). Complex formation of S-1 labeled at Cys-697 with MIANS (MIANS-S-1) with adenyl-5'-yl imidodiphosphate and ADP resulted in a significant decrease in the fluorescence intensity of approximately 40 and 30%, respectively. When ATP was added to MIANS-S-1, the fluorescence intensity decreased rapidly by approximately 40%, and this fluorescence level was maintained during the steady state of ATP hydrolysis. As the substrate was used up, the fluorescence intensity increased to approximately 70% of the original value. These results together with model experiments with MIANS-N-acetylcysteine indicate that in the presence of ATP, the MIANS fluorophore attached to SH2 is located in a less hydrophobic environment than is the fluorophore in the absence of ligand and that the hydrolysis of ATP enhances hydrophobicity around the fluorophore. Acrylamide fluorescence quenching studies of MIANS-S-1 confirmed these results, indicating that addition of ATP and ADP to MIANS-S-1 results in an increase in the Stern-Volmer quenching constant of the fluorophore by factors of approximately 3 and 2.5, respectively. The present observations suggest that binding of ATP causes a movement of SH2 toward the protein surface, whereas it goes back into the protein interior after ATP hydrolysis. The results also confirmed previous observations by a chemical cross-linking approach (Hiratsuka, T. (1987) Biochemistry 26, 3168-3173).			HIRATSUKA, T (corresponding author), ASAHIKAWA MED COLL, DEPT CHEM, ASAHIKAWA, HOKKAIDO 078, JAPAN.							BALINT M, 1978, ARCH BIOCHEM BIOPHYS, V190, P793, DOI 10.1016/0003-9861(78)90339-9; BOTTS J, 1984, P NATL ACAD SCI-BIOL, V81, P2060, DOI 10.1073/pnas.81.7.2060; BOTTS J, 1989, P NATL ACAD SCI USA, V86, P2204, DOI 10.1073/pnas.86.7.2204; BURKE M, 1977, BIOCHEMISTRY-US, V16, P5559, DOI 10.1021/bi00644a026; CHANCE B, 1957, ARCH BIOCHEM BIOPHYS, V71, P130, DOI 10.1016/0003-9861(57)90015-2; CHAUSSEPIED P, 1986, P NATL ACAD SCI USA, V83, P2037, DOI 10.1073/pnas.83.7.2037; CHEUNG HC, 1985, BIOCHIM BIOPHYS ACTA, V832, P52, DOI 10.1016/0167-4838(85)90173-6; CHEUNG HC, 1991, BIOPHYS CHEM, V40, P1, DOI 10.1016/0301-4622(91)85025-L; CREMO CR, 1989, J BIOL CHEM, V264, P6608; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; DALBEY RE, 1983, BIOCHEMISTRY-US, V22, P4696, DOI 10.1021/bi00289a014; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; ELZINGA M, 1977, P NATL ACAD SCI USA, V74, P4281, DOI 10.1073/pnas.74.10.4281; Fiske CH, 1925, J BIOL CHEM, V66, P375; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAUGLAND RP, 1975, J SUPRAMOL STR CELL, V3, P338, DOI 10.1002/jss.400030405; HAUGLAND RP, 1989, HDB FLUORESCENT PROB, P25; HIRATSUKA T, 1986, BIOCHEMISTRY-US, V25, P2101, DOI 10.1021/bi00356a039; HIRATSUKA T, 1987, BIOCHEMISTRY-US, V26, P3168, DOI 10.1021/bi00385a034; HIRATSUKA T, 1976, BIOCHIM BIOPHYS ACTA, V453, P293, DOI 10.1016/0005-2795(76)90277-4; HIRATSUKA T, 1984, J BIOCHEM-TOKYO, V96, P155, DOI 10.1093/oxfordjournals.jbchem.a134807; HIRATSUKA T, 1988, BIOCHEMISTRY-US, V27, P4110, DOI 10.1021/bi00411a030; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18786; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18791; KASPRZAK AA, 1989, BIOCHEMISTRY-US, V28, P9230, DOI 10.1021/bi00449a040; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; LU RC, 1986, P NATL ACAD SCI USA, V83, P6392, DOI 10.1073/pnas.83.17.6392; MAHOWALD TA, 1965, BIOCHEMISTRY-US, V4, P732, DOI 10.1021/bi00880a019; MIYANISHI T, 1989, BIOCHEMISTRY-US, V28, P1287, DOI 10.1021/bi00429a051; PERKINS WJ, 1984, J BIOL CHEM, V259, P8786; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; RAJASEKHARAN KN, 1989, J BIOL CHEM, V264, P10810; REISLER E, 1982, METHOD ENZYMOL, V85, P84; REISLER E, 1974, BIOCHEMISTRY-US, V13, P3837, DOI 10.1021/bi00716a001; SEIDEL JC, 1972, ARCH BIOCHEM BIOPHYS, V152, P839, DOI 10.1016/0003-9861(72)90280-9; SEKINE T, 1964, BIOCHIM BIOPHYS ACTA, V81, P336, DOI 10.1016/0926-6569(64)90049-5; Stern O, 1919, PHYS Z, V20, P183; SUTOH K, 1981, BIOCHEMISTRY-US, V20, P3281, DOI 10.1021/bi00514a046; SUTOH K, 1988, BIOCHEMISTRY-US, V27, P2964, DOI 10.1021/bi00408a045; SUZUKI R, 1987, J BIOL CHEM, V262, P11410; TAO T, 1983, BIOCHEMISTRY-US, V20, P5051; TONG SW, 1990, J BIOL CHEM, V265, P4893; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WELLS JA, 1982, METHOD ENZYMOL, V85, P93; WIEDNER H, 1978, J BIOL CHEM, V253, P2763; YAMAGUCHI M, 1966, J BIOCHEM, V59, P24, DOI 10.1093/oxfordjournals.jbchem.a128254	51	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14941	14948						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1386082				2022-12-27	WOS:A1992JF08800067
J	HOTCHIN, NA; WATT, FM				HOTCHIN, NA; WATT, FM			TRANSCRIPTIONAL AND POSTTRANSLATIONAL REGULATION OF BETA-1 INTEGRIN EXPRESSION DURING KERATINOCYTE TERMINAL DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; HUMAN FIBRONECTIN RECEPTOR; ROUS-SARCOMA VIRUS; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; CELL-ADHESION; PROTEIN; BIOSYNTHESIS; INVOLUCRIN; COLLAGEN	During suspension-induced terminal differentiation of human epidermal keratinocytes, the alpha-5-beta-1 integrin is down-regulated in two stages: first, the ability of the receptor to bind fibronectin is reduced; later, the receptor is lost from the cell surface, and the level of the subunit mRNAs declines. We have begun to examine the mechanisms that regulate these events. Pulse-chase experiments showed that when keratinocytes were placed in suspension to induce terminal differentiation maturation of the beta-1 subunit and its associated alpha-subunits was prevented. The inhibition of maturation was at the stage of N-linked glycosylation in the Golgi, because the immature integrin subunits were sensitive to endoglycosidase H digestion and the inhibition could be mimicked in adherent cells by treatment with 1-deoxymannojirimycin. In 1-deoxymannojirimycin-treated adherent keratinocytes, immature integrin subunits reached the cell surface; however, in keratinocytes induced to differentiate in suspension, no beta-1-integrin precursors were detected on the cell surface. Thus commitment to terminal differentiation results in a block both in integrin glycosylation and transport to the cell surface; down-regulation of receptor function must therefore involve modulation of pre-existing receptor on the cell surface. Although fibronectin or rabbit antiserum to alpha-5-beta-1 can inhibit suspension-induced terminal differentiation they did not overcome the inhibition of glycosylation. Nuclear run-on assays showed that transcription of the alpha-5 and beta-1 genes was switched off during suspension-induced terminal differentiation, and treatment of adherent keratinocytes with actinomycin D suggested that the half-lives of the alpha-5 and beta-1 mRNAs were similar in adherent and suspended cells. Thus, loss of alpha-5-beta-1 from the cell surface reflects both inhibition of transcription of the subunit genes and inhibition of maturation and intracellular transport of newly synthesized subunits.			HOTCHIN, NA (corresponding author), IMPERIAL CANC RES FUND,KERATINOCYTE LAB,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Watt, Fiona/AHB-0226-2022	Watt, Fiona/0000-0001-9151-5154; Hotchin, Neil/0000-0002-1844-7607				ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; AKIYAMA SK, 1990, CANCER RES, V50, P1601; AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARGRAVES WS, 1986, J BIOL CHEM, V261, P2922; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BISCHOFF J, 1986, J BIOL CHEM, V261, P4768; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; DESTROOPER B, 1991, EUR J BIOCHEM, V199, P25; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; HAIMOVICH B, 1991, CELL REGUL, V2, P271, DOI 10.1091/mbc.2.4.271; HEINO J, 1989, J BIOL CHEM, V264, P380; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HICKSTEIN DD, 1988, J BIOL CHEM, V263, P13863; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MONOSTORI E, 1990, J IMMUNOL, V144, P1010; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PERSICO MG, 1986, NUCLEIC ACIDS RES, V14, P2511, DOI 10.1093/nar/14.6.2511; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PIGNATELLI M, 1990, P NATL ACAD SCI USA, V87, P1541, DOI 10.1073/pnas.87.4.1541; READ J, 1988, J INVEST DERMATOL, V90, P739, DOI 10.1111/1523-1747.ep12560940; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STANLEY JR, 1980, J INVEST DERMATOL, V74, P54, DOI 10.1111/1523-1747.ep12514618; STAQUET MJ, 1990, EXP CELL RES, V187, P277, DOI 10.1016/0014-4827(90)90092-O; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; SYMINGTON BE, 1990, J BIOL CHEM, V265, P14069; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; TAPLEY P, 1989, ONCOGENE, V4, P325; TARENTINO AL, 1974, J BIOL CHEM, V249, P818; TODA K, 1987, J INVEST DERMATOL, V88, P412, DOI 10.1111/1523-1747.ep12469745; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; WATT FM, 1988, BIOCHEM SOC T, V16, P666, DOI 10.1042/bst0160666; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881	52	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14852	14858						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378840				2022-12-27	WOS:A1992JF08800054
J	NEEPER, M; SCHMIDT, AM; BRETT, J; YAN, SD; WANG, F; PAN, YCE; ELLISTON, K; STERN, D; SHAW, A				NEEPER, M; SCHMIDT, AM; BRETT, J; YAN, SD; WANG, F; PAN, YCE; ELLISTON, K; STERN, D; SHAW, A			CLONING AND EXPRESSION OF A CELL-SURFACE RECEPTOR FOR ADVANCED GLYCOSYLATION END-PRODUCTS OF PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; SUPERFAMILY; CONTAINS; BINDING; DOMAINS; TISSUE; GENE	Advanced glycosylation end products of proteins (AGEs) are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. A approximately 35-kDa polypeptide with a unique NH2-terminal sequence has been isolated from bovine lung and found to be present on the surface of endothelial cells where it mediates the binding of AGEs (receptor for advanced glycosylation end product or RAGE). Using-an oligonucleotide probe-based on the amino-terminal sequence of RAGE, an apparently full-length cDNA of 1.5 kilobases was isolated from a bovine lung cDNA library. This cDNA encoded a 394 amino acid mature protein comprised of the following putative domains: an extracellular domain of 332 amino acids, a single hydrophobic membrane spanning domain of 19 amino acids, and a carboxyl-terminal domain of 3 amino acids. A partial clone encoding the human counterpart of RAGE, isolated from a human lung library, was found to be approximately 90% homologous to the bovine molecule. Based on computer analysis of the amino acid sequence of RAGE and comparison with databases, RAGE is a new member of the immunoglobulin superfamily of cell surface molecules and shares significant homology with MUC 18, NCAM, and the cytoplasmic domain of CD20. Expression of the RAGE cDNA in 293 cells allowed them to bind I-125-AGE-albumin in a saturable and dose-dependent manner (K(d) approximately 100 nM), blocked by antibody to RAGE. Western blots of 293 cells transfected with RAGE cDNA probed with anti-RAGE IgG demonstrated expression of immunoreactive protein compared to its absence in mock-transfected cells. These results suggest that RAGE functions as a cell surface receptor for AGEs, which could potentially mediate cellular effects of this class of glycosylated proteins.	MERCK SHARP & DOHME LTD, DEPT CELLULAR & MOLEC BIOL, BLDG 16-100, SUMNEYTOWN PIKE, W POINT, PA 19486 USA; MERCK SHARP & DOHME LTD, DEPT BIOL DATA, RAHWAY, NJ 07065 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL & CELLULAR BIOPHYS, NEW YORK, NY 10032 USA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT PROT BIOCHEM, NUTLEY, NJ 07110 USA	Merck & Company; Merck & Company; Columbia University; Roche Holding				Elliston, Keith/0000-0002-9110-9233	NHLBI NIH HHS [HL-21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BRETT J, 1988, J CELL BIOL, V106, P240; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CIECHANOVER A, 1983, J CELL BIOCHEM, V23, P107, DOI 10.1002/jcb.240230111; COZZOLINO FM, 1990, CIRCULATION S, V82, P142; DAUGHERTY BL, 1991, NUCLEIC ACIDS RES, V19, P2471, DOI 10.1093/nar/19.9.2471; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUNN J, 1991, BIOCHEMISTRY-US, V30, P1505; DYER DG, 1991, J BIOL CHEM, V266, P11654; EINFELD DA, 1988, EMBO J, V7, P711, DOI 10.1002/j.1460-2075.1988.tb02867.x; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FUCHS R, 1990, NUCLEIC ACIDS RES, V18, P4319, DOI 10.1093/nar/18.15.4319; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; Maniatis T., 1982, MOL CLONING; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SELL DR, 1989, J BIOL CHEM, V264, P21597; SKOLNIK EY, 1991, J EXP MED, V174, P931, DOI 10.1084/jem.174.4.931; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; WAUTIER JL, 1991, BLOOD S, V78, P341; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515	33	1233	1326	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14998	15004						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378843				2022-12-27	WOS:A1992JF08800074
J	KUBE, E; BECKER, T; WEBER, K; GERKE, V				KUBE, E; BECKER, T; WEBER, K; GERKE, V			PROTEIN-PROTEIN INTERACTION STUDIED BY SITE-DIRECTED MUTAGENESIS - CHARACTERIZATION OF THE ANNEXIN-II-BINDING SITE ON P11, A MEMBER OF THE S100 PROTEIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROPHORETIC TRANSFER; PHOSPHOLIPID-BINDING; POLYACRYLAMIDE GELS; ESCHERICHIA-COLI; TYROSINE KINASE; CLONED GENES; LIGHT-CHAIN; SUBSTRATE; CALCIUM; P36	p11, a member of the S100 protein family, forms a stable heterotetrameric complex with annexin II. The p11-binding site of annexin II resides in the N-terminal 14 residues, which form an amphiphatic alpha-helix with the hydrophobic face representing the contact site for p11 (Johnsson, N., Marriott, G., and Weber, K. (1988) EMBO J. 7, 2435-2442). We show that a corresponding peptide can be used to purify recombinant p11 by affinity chromatography. To map the annexin II-binding site on p11, we have produced progressively truncated p11 derivatives by site-directed mutagenesis. Our analysis reveals that a highly hydrophobic region between residues 85 and 91 is indispensable for annexin II-binding. It is located in the C-terminal extension, following the second distorted EF-hand. Using a series of single amino acid replacements, we have identified individual hydrophobic residues, which seem to represent contact points for annexin II. Most notably, substitution of tyrosine 85 or phenylalanine 86 by alanine drastically reduces the affinity of p11 for annexin II, whereas replacement of these residues by tryptophan has no or only a marginal effect. Thus, hydrophobic side chains on both annexin II and p11 are involved in complex formation.	MAX PLANCK INST BIOPHYS CHEM,DEPT BIOCHEM,POB 2841,W-3400 GOTTINGEN,GERMANY	Max Planck Society								AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FILIPEK A, 1991, EUR J BIOCHEM, V195, P795, DOI 10.1111/j.1432-1033.1991.tb15768.x; FUJI T, 1990, J BIOCHEM-TOKYO, V107, P133, DOI 10.1093/oxfordjournals.jbchem.a122996; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1991, GENE, V104, P259, DOI 10.1016/0378-1119(91)90259-E; GERKE V, 1985, J BIOL CHEM, V260, P1688; GERKE V, 1989, CELL MOTIL CYTOSKEL, V14, P449, DOI 10.1002/cm.970140402; GERKE V, 1991, NOVEL CALCIUM BINDIN, P139; GERKE V, 1990, STIMULUS RESPONSE CO, P311; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; JOHNSSON N, 1990, J BIOL CHEM, V265, P14464; JOHNSSON N, 1990, EUR J BIOCHEM, V188, P1, DOI 10.1111/j.1432-1033.1990.tb15363.x; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; JOHNSSON N, 1986, FEBS LETT, V198, P361, DOI 10.1016/0014-5793(86)80437-9; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KUBE E, 1991, GENE, V102, P255, DOI 10.1016/0378-1119(91)90086-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOSS SE, 1991, NOVEL CALCIUM BINDIN, P535; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	36	102	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14175	14182						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1385811				2022-12-27	WOS:A1992JD32500061
J	MEROPOL, NJ; ALTMANN, SW; SHANAFELT, AB; KASTELEIN, RA; JOHNSON, GD; PRYSTOWSKY, MB				MEROPOL, NJ; ALTMANN, SW; SHANAFELT, AB; KASTELEIN, RA; JOHNSON, GD; PRYSTOWSKY, MB			REQUIREMENT OF HYDROPHILIC AMINO-TERMINAL RESIDUES FOR GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR BIOACTIVITY AND RECEPTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; IDENTIFICATION; DELETION	Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein required for the proliferation and differentiation of granulocyte and macrophage precursors. Previous investigations have identified regions in human and murine GM-CSF that are required for bioactivity. In the present study, alanine substitution mutagenesis was undertaken to define more precisely specific amino-terminal residues in murine GM-CSF that are involved in bioactivity and receptor binding. Five double alanine mutants were identified that showed at least 10-fold reductions in bioactivity (K14AK20A, K14AE21A, H15AK20A, H15AE21A,K20AE21A). Each of these mutants maintained a normal N-linked glycosylation pattern when expressed in COS-1 cells, suggesting that native polypeptide backbone conformation was preserved. The purified prokaryotic expression products of two mutants (K14AE21A and H15AE21A) had a 100-fold decrease in bioactivity and a decrease in receptor binding, indicating that the side chains of K14, H15, and E21 are required for optimal receptor binding and maximal bioactivity.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,PALO ALTO,CA 94304; UNIV PENN,HEMATOL ONCOL SECT,PHILADELPHIA,PA 19104	University of Pennsylvania; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Pennsylvania					NCI NIH HHS [CA 48648] Funding Source: Medline; NHLBI NIH HHS [HL 08268] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048648] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008268] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTMANN SW, 1991, J BIOL CHEM, V266, P5333; BROWN CB, 1990, J IMMUNOL, V144, P2184; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GOUGH NM, 1987, EUR J BIOCHEM, V169, P353, DOI 10.1111/j.1432-1033.1987.tb13619.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IHLE JN, 1990, PROG CLIN BIOL RES, V184, P85; KANAKURA Y, 1991, BLOOD, V77, P1033; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; LABRANCHE CC, 1990, ARCH BIOCHEM BIOPHYS, V276, P153, DOI 10.1016/0003-9861(90)90022-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEROPOL NJ, 1991, HYBRIDOMA, V10, P433, DOI 10.1089/hyb.1991.10.433; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; OKAMOTO M, 1991, ARCH BIOCHEM BIOPHYS, V286, P562, DOI 10.1016/0003-9861(91)90080-3; Parry D A, 1988, J Mol Recognit, V1, P107, DOI 10.1002/jmr.300010302; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; SCHRIMSHER JL, 1987, BIOCHEM J, V247, P195, DOI 10.1042/bj2470195; SHANAFELT AB, 1991, J BIOL CHEM, V266, P13804; SHANAFELT AB, 1989, P NATL ACAD SCI USA, V86, P4872, DOI 10.1073/pnas.86.13.4872; SHENAFELT AB, 1991, EMBO J, V10, P4105; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VONKIMMENADE A, 1988, EUR J BIOCHEM, V173, P109	26	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14266	14269						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1385812				2022-12-27	WOS:A1992JD32500074
J	LANGLAND, JO; JACOBS, BL				LANGLAND, JO; JACOBS, BL			CYTOSOLIC DOUBLE-STRANDED RNA-DEPENDENT PROTEIN-KINASE IS LIKELY A DIMER OF PARTIALLY PHOSPHORYLATED MR = 66,000 SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE L-CELLS; INTERFERON ACTION; SYNTHESIS INITIATION; GENE-EXPRESSION; BETA-INTERFERON; VACCINIA VIRUS; EARLY STAGE; MECHANISM; PURIFICATION; FIBROBLASTS	The work described in this report suggests the existence of two biochemically distinguishable forms of the interferon-inducible, double-stranded RNA-dependent protein kinase. Kinase isolated from the cytosolic fraction (S-100) and the ribosome salt wash fraction of interferon-treated cells differed in their chromatographic properties. S-100 kinase eluted from a gel filtration column with M(r) = 140,000-160,000 and was predominantly anionic in nature, whereas ribosomal kinase eluted with M(r) = 66,000 and was predominantly cationic in nature. Purified preparations of S-100 kinase contained the M(r) = 66,000 subunit, P1, as the only polypeptide present in stoichiometric amounts, and thus the S-100 kinase appears to be a dimer of P1 subunits. Dimerization of the S-100 kinase was dependent on the phosphorylation state of the enzyme. Kinase isolated from S-100 was partially phosphorylated. Dephosphorylation of the S-100 kinase by treatment with alkaline phosphatase resulted in a monomeric form of the enzyme with biochemical characteristics similar to that of the ribosome salt wash kinase.	ARIZONA STATE UNIV,DEPT MICROBIOL,TEMPE,AZ 85287; ARIZONA STATE UNIV,BIOCHEM & MOLEC BIOL PROGRAM,TEMPE,AZ 85287	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe					NCI NIH HHS [CA 48654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048654, R29CA048654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRY MJ, 1985, J BIOL CHEM, V260, P1240; CHU NM, 1989, J HISTOCHEM CYTOCHEM, V37, P257, DOI 10.1177/37.2.2536057; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAS HK, 1981, J BIOL CHEM, V256, P6491; FINTER NB, 1973, INTERFERONS INTERFER, V2; GALABRU J, 1985, CELL, V43, P685, DOI 10.1016/0092-8674(85)90241-7; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GUPTA SL, 1981, VIROLOGY, V111, P331, DOI 10.1016/0042-6822(81)90337-8; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; JACOBS BL, 1988, J INTERFERON RES, V8, P821, DOI 10.1089/jir.1988.8.821; KATZE MG, 1988, J VIROL, V62, P3710, DOI 10.1128/JVI.62.10.3710-3717.1988; KIMCHI A, 1979, J BIOL CHEM, V254, P9846; KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; LASKY SR, 1982, J BIOL CHEM, V257, P1087; LEBLEU B, 1976, P NATL ACAD SCI USA, V73, P3107, DOI 10.1073/pnas.73.9.3107; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYAMOTO NG, 1983, J BIOL CHEM, V258, P5232; MOSSNER E, 1980, H-S Z PHYSIOL CHEM, V361, P543, DOI 10.1515/bchm2.1980.361.1.543; OCHOA S, 1979, ANNU REV BIOCHEM, V48, P549, DOI 10.1146/annurev.bi.48.070179.003001; PAEZ E, 1984, VIROLOGY, V134, P12, DOI 10.1016/0042-6822(84)90268-X; REVEL M, 1978, ANNU REV BIOCHEM, V47, P1079, DOI 10.1146/annurev.bi.47.070178.005243; RICE AP, 1984, J VIROL, V50, P229, DOI 10.1128/JVI.50.1.229-236.1984; ROBERTS WK, 1976, NATURE, V264, P477, DOI 10.1038/264477a0; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; Samuel C E, 1981, Methods Enzymol, V79, P168; SAMUEL CE, 1977, VIROLOGY, V83, P56, DOI 10.1016/0042-6822(77)90210-0; SAMUEL CE, 1979, P NATL ACAD SCI USA, V76, P600, DOI 10.1073/pnas.76.2.600; SAMUEL CE, 1982, J BIOL CHEM, V257, P1791; SAMUEL CE, 1986, METHOD ENZYMOL, V119, P499; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SEN GC, 1978, J BIOL CHEM, V253, P5915; Stewart W, 1979, INTERFERON SYSTEM; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WHITAKERDOWLING P, 1983, VIROLOGY, V131, P128, DOI 10.1016/0042-6822(83)90539-1; WONG ST, 1982, J BIOL CHEM, V257, P5231; ZILBERSTEIN A, 1976, FEBS LETT, V68, P119, DOI 10.1016/0014-5793(76)80418-8; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	40	92	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10729	10736						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375230				2022-12-27	WOS:A1992HV09000079
J	GRABAREK, J; RAYCHOWDHURY, M; RAVID, K; KENT, KC; NEWMAN, PJ; WARE, JA				GRABAREK, J; RAYCHOWDHURY, M; RAVID, K; KENT, KC; NEWMAN, PJ; WARE, JA			IDENTIFICATION AND FUNCTIONAL-CHARACTERIZATION OF PROTEIN-KINASE-C ISOZYMES IN PLATELETS AND HEL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROLEUKEMIA-CELLS; IONIZED CALCIUM-CONCENTRATION; MEMBRANE GLYCOPROTEIN-IIB; PHORBOL ESTER; CA-2+ MOBILIZATION; BLOOD-PLATELETS; RAT-BRAIN; LINE HEL; EXPRESSION; AEQUORIN	To determine if selective activation of individual isozymes of protein kinase C (PKC) might explain the apparently divergent effects of PKC stimulation on platelets, we purified and characterized the isozymes from both platelets and human erythroleukemia (HEL) cells, a cell line that has many features of megakaryocytes. Two peaks of platelet PKC activity were resolved by hydroxylapatite chromatography; immunoblot analysis revealed that these two peaks represented the alpha and beta-isozymes of PKC. In contrast, HEL cells produced only a single peak that contained the beta-isozyme. None of the other PKC isozymes were detected in these fractions. The cytosol of platelets and HEL cells, however, were both found to contain the PKC-delta isozyme. Northern hybridization analyses and mRNA amplification by the polymerase chain reaction demonstrated the presence of mRNA encoding the alpha, beta, and delta-PKC isozymes in platelets, but only the beta and delta-isozymes in HEL cells. Phorbol myristate acetate (PMA), thrombin, or an endoperoxide analog induced the phosphorylation of the 47-kDa substrate of PKC (pleckstrin) found in platelets and HEL cells; preincubation of either HEL cell or platelets with PMA reduced the intracellular Ca2+ rise induced by thrombin. Thus, although both HEL cells and platelets contain PKC-beta and the recently described PKC-delta isozymes, the widely distributed a isozyme of PKC is absent in HEL cells; however, isozymes other than PKC-alpha are sufficient for some PMA-mediated functions that are similar to those seen in stimulated platelets.	BETH ISRAEL HOSP, DIV CARDIOVASC,HARVARD THORNDIKE LAB,GZ 409, 330 BROOKLINE AVE, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; BLOOD CTR SE WISCONSIN INC, BLOOD RES INST, MILWAUKEE, WI 53233 USA; MED COLL WISCONSIN, DEPT ANAT & CELLULAR BIOL, MILWAUKEE, WI 53226 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Versiti Blood Center of Wisconsin; Medical College of Wisconsin				Ravid, Katya/0000-0002-9918-3024	NHLBI NIH HHS [HL38820, HL02271] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002271, R01HL038820, R29HL038820] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BELL RM, 1991, J BIOL CHEM, V266, P4661; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRAY PF, 1987, J CLIN INVEST, V80, P1812, DOI 10.1172/JCI113277; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; CROUCH MF, 1989, J BIOL CHEM, V264, P584; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; GAILANI D, 1990, BRIT J HAEMATOL, V74, P192, DOI 10.1111/j.1365-2141.1990.tb02565.x; HASLAM RJ, 1977, BIOCHEM BIOPH RES CO, V77, P714, DOI 10.1016/S0006-291X(77)80037-5; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; JOHNSON PC, 1989, METHOD ENZYMOL, V169, P386; JOHNSON PC, 1985, J BIOL CHEM, V260, P2069; KIEFFER N, 1986, J BIOL CHEM, V261, P5854; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; LYMAN S, 1990, BLOOD, V75, P2343; LYONS RM, 1975, J CLIN INVEST, V56, P924, DOI 10.1172/JCI108172; MACINTYRE DE, 1985, FEBS LETT, V180, P160, DOI 10.1016/0014-5793(85)81063-2; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MAYEUX PR, 1989, J PHARMACOL EXP THER, V250, P923; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NISHIZUKA Y, 1988, CANCER, V10, P1892; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1990, J BIOL CHEM, V265, P22434; PAPAYANNOPOULOU T, 1983, BLOOD, V62, P832; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PONCZ M, 1987, BLOOD, V69, P219; PONCZ M, 1987, J BIOL CHEM, V262, P8476; RITTENHOUSE SE, 1985, J BIOL CHEM, V260, P8657; ROSA JP, 1989, J BIOL CHEM, V264, P12596; SAITOH M, 1989, BLOOD, V74, P2001; SIESS W, 1988, BIOCHEM J, V255, P309; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TAPLEY PM, 1984, BIOCHEM BIOPH RES CO, V122, P158, DOI 10.1016/0006-291X(84)90453-4; TSUKUDA M, 1988, BIOCHEM BIOPH RES CO, V155, P1387, DOI 10.1016/S0006-291X(88)81295-6; TYERS M, 1989, J CELL BIOCHEM, V40, P133, DOI 10.1002/jcb.240400202; WARE JA, 1989, AM J PHYSIOL, V256, pC35, DOI 10.1152/ajpcell.1989.256.1.C35; WARE JA, 1985, BIOCHEM BIOPH RES CO, V133, P98, DOI 10.1016/0006-291X(85)91846-7; WARE JA, 1986, J CLIN INVEST, V77, P878, DOI 10.1172/JCI112385; WILLIAMS AG, 1990, BLOOD, V76, P721; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859; ZIMRIN AB, 1988, J CLIN INVEST, V81, P1470, DOI 10.1172/JCI113478	56	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					10011	10017						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1374394				2022-12-27	WOS:A1992HT96500085
J	YANG, BZ; DING, JH; ENGHILD, JJ; BAO, Y; CHEN, YT				YANG, BZ; DING, JH; ENGHILD, JJ; BAO, Y; CHEN, YT			MOLECULAR-CLONING AND NUCLEOTIDE-SEQUENCE OF CDNA-ENCODING HUMAN MUSCLE GLYCOGEN DEBRANCHING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCRASE-ISOMALTASE COMPLEX; RABBIT SKELETAL-MUSCLE; ALPHA-GLUCOSIDASE; GENE; HYBRIDIZATION; PURIFICATION; HOMOLOGY; CHAIN	cDNA comprising the entire length of the human muscle glycogen debranching enzyme was cloned and its nucleotide sequence determined. The debrancher mRNA includes a 4545-base pair coding region and a 2371-base pair 3'-nontranslated region. The calculated molecular mass of the debrancher protein derived from cDNA sequence is 172,614 daltons, consistent with the estimated size of purified protein (M(r) 165,000 +/- 500). A partial amino acid sequence (13 internal tryptic peptides with a total of 213 residues) determined on peptides derived from purified porcine muscle debrancher protein confirmed the identity of the cDNA clone. Comparison of the amino acid sequence predicted from the human glycogen debrancher cDNA with the partial protein sequence of the porcine debrancher revealed a high degree (88%) of interspecies sequence identity. RNA blot analysis showed that debrancher mRNA in human muscle, lymphoblastoid cells, and in porcine muscle are all similar in size (approximately 7 kilobases). Two patients with inherited debrancher deficiency had a reduced level of debrancher mRNA, whereas two other patients had no detectable abnormality in RNA blots. The isolation of the debrancher cDNA and determination of its primary structure is an important step toward defining the structure-function relationship of this multifunctional enzyme and in understanding the molecular basis of the type III glycogen storage disease.	DUKE UNIV,MED CTR,DEPT PEDIAT,POB 3028,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University; Duke University				Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039078] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR30] Funding Source: Medline; NIDDK NIH HHS [DK 39078] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEMURA A, 1988, J BIOL CHEM, V263, P9271; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; BATES EJ, 1975, FEBS LETT, V58, P181, DOI 10.1016/0014-5793(75)80254-7; BECKER JU, 1977, BIOCHEMISTRY-US, V16, P291, DOI 10.1021/bi00621a021; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; Brown B. I., 1968, CARBOHYD METABOL, V2, P123; CHEN YT, 1987, AM J HUM GENET, V41, P1002; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; DING JH, 1990, J PEDIATR, V119, P95; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILLARD BK, 1977, BIOCHEMISTRY-US, V16, P2978; GORDON RB, 1972, BIOCHIM BIOPHYS ACTA, V289, P97, DOI 10.1016/0005-2744(72)90112-X; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOEFSLOOT LH, 1988, EMBO J, V7, P1697, DOI 10.1002/j.1460-2075.1988.tb02998.x; HOWELL RR, 1983, METABOLIC BASIS INHE, P141; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KATSURAGI N, 1987, J BACTERIOL, V169, P2301, DOI 10.1128/jb.169.5.2301-2306.1987; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE EYC, 1970, BIOCHEMISTRY-US, V9, P2347, DOI 10.1021/bi00813a019; LEE EYC, 1970, MIAMI WINTER S, V1, P139; MARTINIUK F, 1990, DNA CELL BIOL, V9, P85, DOI 10.1089/dna.1990.9.85; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAKAMURA Y, 1984, GENE, V28, P263, DOI 10.1016/0378-1119(84)90265-8; NELSON TE, 1979, ACS SYM SER, V88, P131; PUGSLEY AP, 1988, MOL MICROBIOL, V2, P473, DOI 10.1111/j.1365-2958.1988.tb00053.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRANG S, 1979, J MOL BIOL, V131, P523, DOI 10.1016/0022-2836(79)90006-8; SVENSSON B, 1989, BIOCHEM J, V264, P309, DOI 10.1042/bj2640309; TAYLOR C, 1975, EUR J BIOCHEM, V51, P105, DOI 10.1111/j.1432-1033.1975.tb03911.x; VANHOOF F, 1967, EUR J BIOCHEM, V2, P265; WALKER GJ, 1967, BIOCHEM J, V105, P937, DOI 10.1042/bj1050937; WEBER IT, 1978, NATURE, V274, P433, DOI 10.1038/274433a0; WERRIES E, 1990, J PROTOZOOL, V37, P576, DOI 10.1111/j.1550-7408.1990.tb01268.x; WHITE RC, 1974, BIOCHIM BIOPHYS ACTA, V365, P274, DOI 10.1016/0005-2795(74)90271-2	36	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9294	9299						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374391				2022-12-27	WOS:A1992HR85400090
J	PATEL, RC; SEN, GC				PATEL, RC; SEN, GC			IDENTIFICATION OF THE DOUBLE-STRANDED RNA-BINDING DOMAIN OF THE HUMAN INTERFERON-INDUCIBLE PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-CELLS; MR 68,000; PHOSPHORYLATION; 2-AMINOPURINE; INDUCTION; VIRUS; PURIFICATION; ACTIVATION; EIF-2; DAI	The interferon-inducible double-stranded (ds) RNA-activated protein kinase (p68 kinase) is a physiologically important enzyme that regulates the rate of cellular and viral protein synthesis by phosphorylating and thereby inactivating the peptide chain initiation factor 2. We have generated a cDNA clone of the human p68 kinase by polymerase chain reaction cloning using the recently published sequence of this enzyme. Active enzyme was synthesized by in vitro transcription-translation of the cDNA clone. This system was used for mapping the dsRNA-binding domain of the enzyme. Progressive deletions from the carboxyl terminus were introduced by digesting the cDNA with suitable restriction enzymes. Expression of proteins harboring deletions from the amino terminus was achieved by cloning DNA fragments into appropriately constructed expression vectors. Affinity of the truncated proteins for dsRNA was examined by testing their capacity to bind to dsRNA-agarose beads. Our results demonstrated that the dsRNA-binding domain lies at the amino terminus of the protein. A truncated protein containing the first 170 amino acid residues from the amino terminus could bind to dsRNA. However, deletion of 34 residues from the amino terminus or 41 residues from the carboxyl terminus of this truncated protein eliminated its dsRNA-binding activity. Comparison of the primary structure and the secondary structure of this region of p68 kinase and the corresponding region of 2'-5'-oligoadenylate synthetase revealed no apparent similarity.	CLEVELAND CLIN FDN,DEPT MOLEC BIOL,9500 EUCLID AVE,NC2-103,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Patel, Rekha/M-7123-2015	Patel, Rekha/0000-0001-9434-4880	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022510] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22510] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUFFETJANVRESSE C, 1986, J INTERFERON RES, V6, P85, DOI 10.1089/jir.1986.6.85; DUBOIS MF, 1990, VIROLOGY, V179, P591, DOI 10.1016/0042-6822(90)90126-C; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GALABRU J, 1985, CELL, V43, P685, DOI 10.1016/0092-8674(85)90241-7; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GATZE MG, 1987, EMBO J, V6, P689; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; HANS SK, 1988, SCIENCE, V241, P42; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P463; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; LEBLEU B, 1976, P NATL ACAD SCI USA, V73, P3107, DOI 10.1073/pnas.73.9.3107; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MELLITS KH, 1990, CELL, V61, P843, DOI 10.1016/0092-8674(90)90194-J; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; ROBERTS WK, 1976, NATURE, V264, P477, DOI 10.1038/264477a0; ROY S, 1990, SCIENCE, V247, P1216, DOI 10.1126/science.2180064; SAMUEL CE, 1979, P NATL ACAD SCI USA, V76, P600, DOI 10.1073/pnas.76.2.600; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEN GC, 1978, J BIOL CHEM, V253, P5915; SENGUPTA DN, 1989, NUCLEIC ACIDS RES, V17, P969, DOI 10.1093/nar/17.3.969; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WHITAKERDOWLING P, 1984, VIROLOGY, V137, P171, DOI 10.1016/0042-6822(84)90020-5; ZILBERSTEIN A, 1976, FEBS LETT, V68, P119, DOI 10.1016/0014-5793(76)80418-8; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	30	118	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1992	267	11					7671	7676						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HN485	1373135				2022-12-27	WOS:A1992HN48500067
J	DIGATE, RJ; MARIANS, KJ				DIGATE, RJ; MARIANS, KJ			ESCHERICHIA-COLI TOPOISOMERASE-III-CATALYZED CLEAVAGE OF RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA TOPOISOMERASES; RAT-LIVER; ENZYME; IDENTIFICATION; RECOMBINATION; BREAKAGE	Relaxation of superhelical DNA by Escherichia coli topoisomerase III (Topo III) was inhibited by the inclusion of tRNA in the reaction mixture. Investigation of the basis of this inhibition revealed that Topo III could bind RNA and establish a cleavage-religation equilibrium. The addition of SDS to these reaction mixtures induced cleavage of the RNA by Topo III. The nucleotide sequences of RNA and DNA cleavage sites were identical, although cleavage site preference differed. Thus, the possibility that Topo III can pass strands of RNA as well as strands of DNA must be considered in accounting for the role of this enzyme in nucleic acid metabolism.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEN MD, 1981, P NATL ACAD SCI-BIOL, V78, P2883, DOI 10.1073/pnas.78.5.2883; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; DEAN F, 1982, COLD SPRING HARB SYM, V47, P769; DEAN F, 1984, THESIS U CHICAGO; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; England T E, 1980, Methods Enzymol, V65, P65; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LF, 1979, J BIOL CHEM, V254, P1082; Maxam A M, 1980, Methods Enzymol, V65, P499; PASTORCIC M, 1982, THESIS U CHICAGO; SCHOFIELD MA, 1992, IN PRESS J BACTERIOL; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TAPPER DP, 1981, NUCLEIC ACIDS RES, V9, P6787, DOI 10.1093/nar/9.24.6787; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	17	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					20532	20535						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383203				2022-12-27	WOS:A1992JT97800003
J	CHEN, LY; LEU, WM; WANG, KT; LEE, YHW				CHEN, LY; LEU, WM; WANG, KT; LEE, YHW			COPPER TRANSFER AND ACTIVATION OF THE STREPTOMYCES APOTYROSINASE ARE MEDIATED THROUGH A COMPLEX-FORMATION BETWEEN APOTYROSINASE AND ITS TRANSACTIVATOR MELC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; TYROSINASE GENE; NEUROSPORA-CRASSA; MOLECULAR CHAPERONES; RNA-POLYMERASE; FUNCTIONAL-ANALYSIS; MOUSE TYROSINASE; EXPRESSION; GLAUCESCENS; PROTEINS	The melanin operon (melC) of Streptomyces antibioticus is composed of two genes that encode MelC1 and MelC2 proteins. MelC1 has been suggested as a trans-activator which can facilitate the incorporation of copper into the apotyrosinase (MelC2) (Lee, Y.-H. W., Chen, B.-F., Wu, S.-Y., Leu, W.-M., Lin, J.-J., Chen, C. W., and Lo, S. J. (1988) Gene (Amst.) 65, 71-81). However, the molecular mechanism of the trans-activation or copper-transfer process mediated through MelC1 to MelC2 is not clear yet. In this study, we found apotyrosinase in both the extracellular fraction and cell extract from cells grown in copper-deficient medium. Using gel-filtration and immunoaffinity chromatographies, we demonstrated that apotyrosinase (MelC2) formed a stable complex with MelC1 in the intra- and extracellular fractions. Furthermore, addition of copper ion to the complex generated tyrosinase activity. The MelC1-MelC2 complex was purified to near homogeneity by DE52 and phenyl-agarose chromatographies. In conjunction with fast protein liquid gel filtration chromatography and NH2-terminal sequencing analysis, the results indicated that the stoichiometric ratio of MelC1 and MelC2 in the purified complex was 1:1. Essentially no copper was found in the complex. Addition of copper ion to the purified complex resulted in incorporation of approximately 2 molecules of copper ion and the mature active tyrosinase was gradually released from the complex. Taken together, these results demonstrate that the molecular mechanism of activation of Streptomyces apotyrosinase by its trans-activator MelC1 is initially mediated via a binary complex formation between these two proteins, followed by incorporation of copper ion. This activation mechanism accounts for the essential role of MelC1 in the expression of melanin operon.	NATL YANG MING MED COLL,INST BIOCHEM,TAIPEI 112,TAIWAN; ACAD SINICA,INST BIOCHEM,TAIPEI 115,TAIWAN	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan				Lee Wu, Yan-Hwa/0000-0001-7299-7354				BAUMANN R, 1976, 2ND INT S GEN IND MI, P535; BELTRAMINI M, 1982, FEBS LETT, V142, P219, DOI 10.1016/0014-5793(82)80138-5; BERNAN V, 1985, GENE, V37, P101, DOI 10.1016/0378-1119(85)90262-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chater K. F., 1982, CURR TOP MICROBIOL I, V96, P69; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CRAMERI R, 1982, J GEN MICROBIOL, V128, P371; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FALCHUK KH, 1988, METHOD ENZYMOL, V158, P422, DOI 10.1016/0076-6879(88)58073-4; FUJITA N, 1987, MOL GEN GENET, V210, P5, DOI 10.1007/BF00337751; GATENBY AA, 1990, ANNU REV CELL BIOL, V6, P125; GEISTLICH M, 1989, MOL MICROBIOL, V3, P1061, DOI 10.1111/j.1365-2958.1989.tb00256.x; GREGORY KF, 1961, NATURE, V191, P465, DOI 10.1038/191465a0; GREGORY KF, 1964, J BACTERIOL, V87, P1281, DOI 10.1128/JB.87.6.1281-1286.1964; HELD T, 1990, J GEN MICROBIOL, V136, P2413, DOI 10.1099/00221287-136-12-2413; HINTERMANN G, 1985, MOL GEN GENET, V200, P422, DOI 10.1007/BF00425726; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; HUBER M, 1988, BIOCHEMISTRY-US, V27, P5610, DOI 10.1021/bi00415a032; HUBER M, 1985, BIOCHEMISTRY-US, V24, P6038, DOI 10.1021/bi00343a003; HUBER M, 1987, NUCLEIC ACIDS RES, V15, P8106, DOI 10.1093/nar/15.19.8106; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; KERTESZ D, 1972, BIOCHEM BIOPH RES CO, V49, P1208, DOI 10.1016/0006-291X(72)90597-9; KIESER T, 1981, GENETICS ACTINOMYCET, P59; KUPPER U, 1989, J BIOL CHEM, V264, P17250; Kuster E., 1976, ACTINOMYCETES BOUNDA, P43; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YHW, 1988, GENE, V65, P71, DOI 10.1016/0378-1119(88)90418-0; LERCH K, 1982, J BIOL CHEM, V257, P6414; LERCH K, 1978, P NATL ACAD SCI USA, V75, P3635, DOI 10.1073/pnas.75.8.3635; LERCH K, 1972, EUR J BIOCHEM, V31, P427, DOI 10.1111/j.1432-1033.1972.tb02549.x; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; LERCH K, 1980, NATURE, V284, P368, DOI 10.1038/284368a0; LEU WM, 1989, GENE, V84, P267; LEU WM, 1992, J BIOL CHEM, V267, P20108; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; PFIFFNER E, 1981, BIOCHEMISTRY-US, V20, P6029, DOI 10.1021/bi00524a017; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSENG HC, 1990, GENE, V86, P123, DOI 10.1016/0378-1119(90)90124-A; WANG SS, 1987, INT J PEPT PROT RES, V30, P662; YOSHIMOTO T, 1985, J BIOCHEM, V97, P1747, DOI 10.1093/oxfordjournals.jbchem.a135233	49	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20100	20107						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400328				2022-12-27	WOS:A1992JR85800057
J	MARTIN, PR; HAUSINGER, RP				MARTIN, PR; HAUSINGER, RP			SITE-DIRECTED MUTAGENESIS OF THE ACTIVE-SITE CYSTEINE IN KLEBSIELLA-AEROGENES UREASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JACK BEAN UREASE; PURIFICATION; REACTIVITY; PROTEINS; SEQUENCE; THIOL	Cysteine 319 in the large subunit of Klebsiella aerogenes urease was identified as an essential catalytic residue based on chemical modification studies (Todd, M. J., and Hausinger, R. P. (1991) J. Biol. Chem. 266, 24327-24331). Through site-directed mutagenesis, this cysteine has been changed independently to alanine, serine, aspartate, and tyrosine. None of these mutations (C319A, C319S, C319D, and C319Y, respectively) affected the size or level of synthesis of the urease subunits as monitored by polyacrylamide gel electrophoresis. The wild type enzyme and each of the mutant proteins was purified and their properties were compared. The C319Y protein possessed no detectable activity, while activity was reduced in C319A, C319S, and C319D to 48, 4.5, and 0.03% of wild type levels under normal assay conditions. All of the active mutants had a small increase in K(m) when compared to the wild type value. The active mutants displayed a greatly reduced sensitivity to inactivation by iodoacetamide in comparison to the wild type enzyme, confirming our previous assignment of the essential cysteine to this residue based on active site peptide mapping. In contrast to the wild type enzyme, inactivation of the mutant proteins was not affected by the presence of the competitive inhibitor phosphate, suggesting that the remaining slow rate of iodoacetamide inactivation is due to modification away from the active site. The pH dependence of urease activity was substantially altered in the active mutants with C319S and C319D showing a pH optimum near 5.2, and C319A near 6.7, compared to the pH 7.75 optimum of wild type urease. These data are consistent with Cys-319 facilitating catalysis at neutral and basic pH values by participating as a general acid.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University; Michigan State University				Hausinger, Robert/0000-0002-3643-2054				ANDREWS A T D B, 1970, Archives of Biochemistry and Biophysics, V141, P538, DOI 10.1016/0003-9861(70)90172-4; DIXON NE, 1975, J AM CHEM SOC, V97, P4131, DOI 10.1021/ja00847a045; DIXON NE, 1980, CAN J BIOCHEM CELL B, V58, P1335, DOI 10.1139/o80-181; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; MULROONEY SB, 1989, J GEN MICROBIOL, V135, P1769; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; NAKANO H, 1984, AGR BIOL CHEM TOKYO, V48, P1495, DOI 10.1080/00021369.1984.10866339; NORRIS R, 1976, BIOCHEM J, V159, P245, DOI 10.1042/bj1590245; SAADA AB, 1988, ZBL BAKT-INT J MED M, V269, P160; SANGER F, 1977, P NATL ACAD SCI USA, V80, P3963; TAKISHIMA K, 1988, EUR J BIOCHEM, V175, P151, DOI 10.1111/j.1432-1033.1988.tb14177.x; TODD MJ, 1989, J BIOL CHEM, V264, P15835; TODD MJ, 1987, J BIOL CHEM, V262, P5963; TODD MJ, 1991, J BIOL CHEM, V266, P10260; TODD MJ, 1991, J BIOL CHEM, V266, P24327; WEATHERBURN MW, 1967, ANAL CHEM, V39, P871; WINKLER RG, 1988, TRENDS BIOCHEM SCI, V13, P97, DOI 10.1016/0968-0004(88)90049-7; ZERNER B, 1991, BIOORG CHEM, V19, P116, DOI 10.1016/0045-2068(91)90048-T	22	50	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20024	20027						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400317				2022-12-27	WOS:A1992JR85800045
J	QUINONES, S; BERNAL, D; GARCIASOGO, M; ELENA, SF; SAUS, J				QUINONES, S; BERNAL, D; GARCIASOGO, M; ELENA, SF; SAUS, J			EXON INTRON STRUCTURE OF THE HUMAN ALPHA-3(IV) GENE ENCOMPASSING THE GOODPASTURE ANTIGEN (ALPHA-3(IV)NC1) - IDENTIFICATION OF A POTENTIALLY ANTIGENIC REGION AT THE TRIPLE HELIX/NC1 DOMAIN JUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR-BASEMENT-MEMBRANE; IV COLLAGEN GENES; SEQUENCE-ANALYSIS; ALPORT SYNDROME; CHAIN; CONSERVATION; MOUSE; ALPHA-1-CHAIN; LOCALIZATION; ALPHA-1(IV)	The Goodpasture antigen has been identified as the non-collagenous (NC1) domain of alpha3(IV), a novel collagen IV chain (Saus, J., Wieslander, J., Langeveld, J., Quinones, S., and Hudson, B. G. (1988) J. Biol. Chem. 263, 13374-13380). In the present study, the exon/intron structure and sequence for 285 amino acids of human alpha3(IV), comprising 53 amino acids of the triple-helical domain and the complete NC1 domain (232 amino acids), were determined. Based on the comparison of the amino acid sequences of the alpha1(IV), alpha2(IV), alpha3(IV), and alpha5(IV) NC1 domains, a phylogenetic tree was constructed which indicates that alpha2(IV) was the first chain to evolve, followed by alpha3(IV), and then by alpha1(IV) and alpha5(IV). The exon/intron structure of these domains is consistent with this evolution model. In addition, it appears that alpha3(IV) changed most after diverging from the parental gene. Analysis of its primary structure reveals that, at the junction between the triple-helical and NC1 domains, there exists a previously unrecognized, highly hydrophilic region (GLKGKRGDSGSPATWTTR) which is unique to the human alpha3(IV) chain, containing a cell adhesion motif (RGD) as an integral part of a sequence (KRGDSGSP) conforming to a number of protein kinase recognition sites. Based on primary structure data, we outline new aspects to be explored concerning the molecular basis of collagen IV function and Goodpasture syndrome.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, PISCATAWAY, NJ 08854 USA; UNIV VALENCIA, INST INVEST CITOL, FDN VALENCIANA INVEST BIOMED, E-46010 VALENCIA, SPAIN; UNIV VALENCIA, DEPT BIOQUIM & BIOL MOLEC, E-46010 VALENCIA, SPAIN; UNIV VALENCIA, DEPT GENET & SERV BIOINFORMAT, E-46010 VALENCIA, SPAIN	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Valencia; University of Valencia; University of Valencia			Elena, Santiago F./A-4191-2011; Bernal, Dolores/K-7769-2014	Elena, Santiago F./0000-0001-8249-5593; Bernal, Dolores/0000-0003-4627-8393; Saus, Juan/0000-0003-2082-1597	NIDDK NIH HHS [DK-42514] Funding Source: Medline; NIEHS NIH HHS [ESO 5022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042514] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BLUMBERG B, 1987, J BIOL CHEM, V262, P5947; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FELSENSTEIN J, 1982, Q REV BIOL, V57, P379, DOI 10.1086/412935; FELSENSTEIN J, 1986, Cladistics, V2, P130, DOI 10.1111/j.1096-0031.1986.tb00448.x; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; GLASSOCK RJ, 1986, KIDNEY, V3, P1014; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; GUO XD, 1989, J BIOL CHEM, V264, P17574; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1987, FEBS LETT, V224, P297, DOI 10.1016/0014-5793(87)80473-8; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUDSON BG, 1989, LAB INVEST, V61, P256; KALLURI R, 1991, J BIOL CHEM, V266, P24018; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1989, J BIOL CHEM, V264, P6318; SAUS J, 1988, J BIOL CHEM, V263, P13374; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; SOININEN R, 1989, J BIOL CHEM, V264, P13565; SOININEN R, 1987, FEBS LETT, V225, P188; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TRYGGVASON K, 1990, ANN NY ACAD SCI, V580, P97, DOI 10.1111/j.1749-6632.1990.tb17922.x; Wiley E.O., 1981, PHYLOGENETICS; YAMADA Y, 1980, CELL, V22, P887, DOI 10.1016/0092-8674(80)90565-6; YAMADA Y, 1984, NATURE, V310, P333, DOI 10.1038/310333a0; ZHOU J, 1991, GENOMICS, V9, P1, DOI 10.1016/0888-7543(91)90214-Y	43	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19780	19784						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400291				2022-12-27	WOS:A1992JR85800007
J	SCHMALZING, G; KRONER, S; SCHACHNER, M; GLOOR, S				SCHMALZING, G; KRONER, S; SCHACHNER, M; GLOOR, S			THE ADHESION MOLECULE ON GLIA (AMOG/BETA-2) AND ALPHA-1 SUBUNITS ASSEMBLE TO FUNCTIONAL SODIUM PUMPS IN XENOPUS-OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; NA,K-ATPASE BETA-SUBUNIT; CENTRAL-NERVOUS-SYSTEM; INTRACELLULAR-TRANSPORT; MESSENGER-RNAS; LAEVIS OOCYTES; EXPRESSION; CELLS; ISOFORMS; NEURONS	The adhesion molecule on glia, AMOG, an integral cell surface glycoprotein highly expressed by cerebellar astrocytes and involved in neuron to astrocyte adhesion and granule neuron migration (Antonicek, H., Persohn, E., and Schachner, M. (1987) J. Cell Biol. 104, 1587-1595) has been identified as a beta2 subunit isoform of the mouse sodium pump (Gloor, S., Antonicek, H., Sweadner, K. J., Pagliusi, S., Frank, R., Moos, M., and Schachner, M. (1990) J. Cell Biol. 110, 165-174). Here we demonstrate that AMOG/beta2 expressed by cRNA injection in Xenopus oocytes is capable of combining with endogenous Xenopus alpha1 subunits or coexpressed Torpedo alpha1 subunits to yield a functional alpha1/AMOG sodium pump isozyme. Determinations of the number of ouabain binding sites and ouabain-sensitive Rb-86+ uptake suggest that the alpha1/AMOG isozyme has slightly lower maximum transport rate and apparent affinity for external K+ than the alpha1/beta1 isozyme. Immunoprecipitation of alpha1/AMOG complexes from digitonin extracts of [S-35]methionine-labeled oocytes with a monoclonal anti-AMOG antibody provides direct evidence for a stable association between AMOG and the alpha1 subunits of Xenopus and Torpedo.	SWISS FED INST TECHNOL, DEPT NEUROBIOL, CH-8093 ZURICH, SWITZERLAND	ETH Zurich	SCHMALZING, G (corresponding author), MAX PLANCK INST BIOPHYS, HEINRICH HOFFMANN STR 7, W-6000 FRANKFURT 71, GERMANY.							ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ANTONICEK H, 1987, J CELL BIOL, V104, P1587, DOI 10.1083/jcb.104.6.1587; ANTONICEK H, 1988, J NEUROSCI, V8, P2961; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DRUMMOND DR, 1985, NUCLEIC ACIDS RES, V13, P7375, DOI 10.1093/nar/13.20.7375; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GLOOR S, 1989, NUCLEIC ACIDS RES, V17, P10117; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOVITZ RM, 1989, EMBO J, V8, P193, DOI 10.1002/j.1460-2075.1989.tb03364.x; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MCGRAIL KM, 1991, J NEUROSCI, V11, P381, DOI 10.1523/jneurosci.11-02-00381.1991; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; RAKOWSKI RF, 1991, J MEMBRANE BIOL, V121, P177, DOI 10.1007/BF01870531; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; SCHMALZING G, 1989, BIOCHEM J, V260, P395, DOI 10.1042/bj2600395; SHYJAN AW, 1990, J BIOL CHEM, V265, P5166; SWEADNER KJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P13, DOI 10.1016/0005-2736(90)90431-M; TAKEYASU K, 1989, CURR TOP MEMBR TRANS, V34, P143; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; WATTS AG, 1991, P NATL ACAD SCI USA, V88, P7425, DOI 10.1073/pnas.88.16.7425; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	35	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20212	20216						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1383200				2022-12-27	WOS:A1992JR85800074
J	ANDERSEN, JP; VILSEN, B				ANDERSEN, JP; VILSEN, B			FUNCTIONAL CONSEQUENCES OF ALTERATIONS TO GLU(309), GLU(771), AND ASP(800) IN THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; CALCIUM-BINDING; TRANSMEMBRANE DOMAIN; ATPASE; CA-2+-ATPASE; CA-2+; PHOSPHORYLATION; MECHANISM; TRANSPORT; SITES	Site-specific mutagenesis was used to replace Glu309, Glu771, and Asp800 in the Ca2+-ATPase of rabbit fast twitch muscle sarcoplasmic reticulum with their corresponding amides. These residues are predicted to lie in the transmembrane domain and have been suggested as oxygen ligands for Ca2+ binding at high affinity sites (Clarke, D. M., Loo, T. W., Inesi, G., and MacLennan, D. H. (1989) Nature 339, 476-478). The Glu309 --> Gln and Asp800 --> Asn mutants were unable to form a phosphoenzyme from ATP at the Ca2+ concentrations examined (up to 12.5 mM), whereas the Glu771 --> Gln mutant phosphorylated from ATP at 2.5 mM Ca2+. In all three mutants, Ca2+ at concentrations well below 12.5 mM prevented or inhibited phosphorylation with P(i), suggesting that at least one calcium-binding site was functioning in each mutant. In the mutants Glu309 --> Gln and Glu771 --> Gln, the ADP-insensitive phosphoenzyme intermediate was unusually stable, as indicated by a very low rate of dephosphorylation observed in kinetic experiments and by an increased apparent affinity for P(i) determined in equilibrium phosphorylation experiments. These data indicate a central role of Glu309 and Glu771 in the energy-transducing conformational changes and/or in the activation of phosphoenzyme hydrolysis.			ANDERSEN, JP (corresponding author), AARHUS UNIV,DANISH BIOMEMBRANE RES CTR,INST PHYSIOL,DK-8000 AARHUS,DENMARK.			Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382				Andersen JP, 1990, CURR OPIN CELL BIOL, V2, P722, DOI 10.1016/0955-0674(90)90116-V; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1981, SARCOPLASMIC RETICUL, V2; FUJIMORI T, 1992, Biophysical Journal, V61, pA134; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1983, BIOPHYS J, V44, P271, DOI 10.1016/S0006-3495(83)84299-4; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVY D, 1990, J BIOL CHEM, V265, P19524; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MADEIRA VMC, 1978, ARCH BIOCHEM BIOPHYS, V185, P316, DOI 10.1016/0003-9861(78)90173-X; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015	40	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19383	19387						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388169				2022-12-27	WOS:A1992JP59300057
J	YAMANISHI, K; INAZAWA, J; LIEW, FM; NONOMURA, K; ARIYAMA, T; YASUNO, H; ABE, T; DOI, H; HIRANO, J; FUKUSHIMA, S				YAMANISHI, K; INAZAWA, J; LIEW, FM; NONOMURA, K; ARIYAMA, T; YASUNO, H; ABE, T; DOI, H; HIRANO, J; FUKUSHIMA, S			STRUCTURE OF THE GENE FOR HUMAN TRANSGLUTAMINASE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED ENVELOPE; FACTOR RECEPTOR GENE; HUMAN EPIDERMAL-CELLS; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTOR; I TRANSGLUTAMINASE; COAGULATION FACTOR; PROMOTER REGION; PROTEIN-KINASE; KERATINOCYTE	Transglutaminase 1 (TG1) is an enzyme that is expressed and activated during terminal differentiation of keratinocytes and synthesizes cornified envelope by a cross-linking reaction. The gene encoding human TG1 was isolated from human genomic DNA and characterized. It spans 14.3 kilobase pairs and is composed of 15 exons. All exon-intron junctional sequences conformed to the canonical GT-AG rule. The translation start was located in the second exon. The active site Cys residue of the enzyme was in exon 7. The coding sequence for human TG1 was comprised of 2454 nucleotides identical with the published human TG1-cDNA sequence (Yamanishi, K., Liew, F.-M., Konishi, K., Yasuno, H., Doi, H., Hirano, J., and Fukushima, S. (1991) Biochem. Biophys. Res. Commun. 175, 906-913). The sizes of exons from 3 to 14 were markedly conserved between the genes for the human TG1 and factor XIIIa, another member of the transglutaminase family. The one major and two minor transcription initiation sites of the TG1 gene were determined by primer extension. The 5'-flanking region of the human TG1 gene showed features of a housekeeping gene and contained potential regulatory motifs, including elements found in keratinocyte-related genes. The chromosome sublocalization of the TG1 gene was assigned to 14q11.2.	ADV SKIN RES INST,KOHOKU KU,YOKOHAMA 223,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIGYO KU,KYOTO 602,JAPAN	Kyoto Prefectural University of Medicine	YAMANISHI, K (corresponding author), KYOTO PREFECTURAL UNIV MED,DEPT DERMATOL,KAMIGYO KU,KYOTO 602,JAPAN.		Yamanishi, Kiyofumi/R-2200-2019	Yamanishi, Kiyofumi/0000-0003-0484-2320				ABERNETHY JL, 1977, J BIOL CHEM, V252, P1837; AZIZKHAN JC, 1986, BIOCHEMISTRY-US, V25, P6228, DOI 10.1021/bi00368a059; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOARD PG, 1988, CYTOGENET CELL GENET, V48, P25, DOI 10.1159/000132580; BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1988, CELL, V55, P315; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; HOHL D, 1991, J BIOL CHEM, V266, P6626; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; INAZAWA J, 1991, GENOMICS, V10, P1075, DOI 10.1016/0888-7543(91)90202-P; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KIM HC, 1991, J BIOL CHEM, V266, P536; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LICHTI U, 1988, CANCER RES, V48, P74; LIEW F M, 1990, Journal of Dermatological Science, V1, P369, DOI 10.1016/0923-1811(90)90594-4; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; Maniatis T, 1989, DECONTAMINATION DILU; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; OSADA S, 1990, J BIOL CHEM, V265, P22434; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POLAKOWSKA R, 1991, J INVEST DERMATOL, V96, P285, DOI 10.1111/1523-1747.ep12464554; POLAKOWSKA RR, 1991, CYTOGENET CELL GENET, V56, P105, DOI 10.1159/000133060; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SNAPE AM, 1991, DEVELOPMENT, V113, P283; SUGAWARA K, 1979, AGR BIOL CHEM TOKYO, V43, P2534; TAKAHASHI E, 1990, HUM GENET, V86, P14; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VIGEGASPEQUIGNO.E, 1978, ANN GENET, V21, P122; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YAMANISHI K, 1991, BIOCHEM BIOPH RES CO, V175, P906, DOI 10.1016/0006-291X(91)91651-R	44	73	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17858	17863						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1381356				2022-12-27	WOS:A1992JM22300059
J	EXPOSITO, JY; DALESSIO, M; RAMIREZ, F				EXPOSITO, JY; DALESSIO, M; RAMIREZ, F			NOVEL AMINO-TERMINAL PROPEPTIDE CONFIGURATION IN A FIBRILLAR PROCOLLAGEN UNDERGOING ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EMBRYO; COLLAGEN GENE; II PROCOLLAGEN; MESSENGER-RNA; EXPRESSION; INHIBITORS; PROTEINS; CLONING; SPICULE; DOMAIN	We isolated overlapping cDNAs from embryonic libraries of the sea urchin Strongylocentrotus purpuratus coding for a fibrillar procollagen (2-alpha chain) with a predicted molecular mass of about 320 kDa. The deduced primary structure of the echinoid chain consists of a 265-amino acid carboxyl-propeptide, a triple helical domain made of 337 uninterrupted Gly-X-Y repeats, and an unusually long amino-propeptide. Aside from a 10-cysteine globular region, a collagenous sequence, and a nonhelical segment, this protein domain includes a novel 4-cysteine motif repeated several times. Interestingly, preliminary evidence indicates that different combinations of the 4-cysteine repeats are encoded by alternatively spliced transcripts. Irrespective of this, the sea urchin 2-alpha procollagen chain represents the longest fibrillar molecule identified to date by cDNA cloning experiments in both vertebrate and invertebrate organisms.			EXPOSITO, JY (corresponding author), CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029, USA.		D'Alessio, Marina/AAA-1306-2019	Exposito, Jean-Yves/0000-0002-4926-4942	NIGMS NIH HHS [GM-41849] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041849] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENSON SC, 1986, J CELL BIOL, V102, P1878, DOI 10.1083/jcb.102.5.1878; BENSONCHANDA V, 1989, GENE, V78, P255, DOI 10.1016/0378-1119(89)90228-X; BLANKENSHIP J, 1984, EXP CELL RES, V152, P98, DOI 10.1016/0014-4827(84)90233-7; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; DALESSIO M, 1989, P NATL ACAD SCI USA, V86, P9303, DOI 10.1073/pnas.86.23.9303; DALESSIO M, 1990, J BIOL CHEM, V265, P7050; DECKER GL, 1988, DEVELOPMENT, V103, P231; EXPOSITO JY, 1990, P NATL ACAD SCI USA, V87, P6669, DOI 10.1073/pnas.87.17.6669; EXPOSITO JY, 1992, IN PRESS J BIOL CHEM; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; GOLOB R, 1974, BIOCHIM BIOPHYS ACTA, V349, P135, DOI 10.1016/0005-2787(74)90017-3; HAY ED, 1981, CELL BIOL EXTRACELLU, P139; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEAHY PS, 1986, METHOD CELL BIOL, V27, P1, DOI 10.1016/S0091-679X(08)60339-8; LEE B, 1991, CRIT REV EUKAR GENE, V1, P172; MORIKAWA T, 1980, BIOCHEMISTRY-US, V19, P2646, DOI 10.1021/bi00553a017; NAH HD, 1991, J BIOL CHEM, V266, P23446; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SAITTA B, 1989, BIOCHEM BIOPH RES CO, V158, P633, DOI 10.1016/0006-291X(89)92768-X; SAMBROOK T, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SU MW, 1991, J CELL BIOL, V115, P565, DOI 10.1083/jcb.115.2.565; VANDERREST M, 1986, BIOCHEM J, V237, P923, DOI 10.1042/bj2370923; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WESSEL GM, 1987, DEV BIOL, V121, P149, DOI 10.1016/0012-1606(87)90148-5; WESSEL GM, 1991, DEV BIOL, V148, P261, DOI 10.1016/0012-1606(91)90335-Z	30	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17404	17408						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1380962				2022-12-27	WOS:A1992JL05300100
J	CHALOVICH, JM; BRYAN, J; BENSON, CE; VELAZ, L				CHALOVICH, JM; BRYAN, J; BENSON, CE; VELAZ, L			LOCALIZATION AND CHARACTERIZATION OF A 7.3-KDA REGION OF CALDESMON WHICH REVERSIBLY INHIBITS ACTOMYOSIN ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; CHICKEN GIZZARD CALDESMON; CALMODULIN-BINDING PROTEIN; RABBIT SKELETAL-MUSCLE; F-ACTIN; CROSS-LINKING; MYOSIN SUBFRAGMENT-1; HEAVY-MEROMYOSIN; NH2-TERMINAL SEGMENT; THIN-FILAMENTS	Cleavage of caldesmon with chymotrypsin yields a series of fragments which bind both calmodulin and actin and inhibit the binding of myosin subfragments to actin and the subsequent stimulation of ATPase activity. Several of these fragments have been purified by cation exchange chromatography and their amino-terminal sequences determined. The smallest fragment has a molecular mass of about 7.3 kDa and extends from Leu597 to Phe665. This polypeptide inhibits the actin-activated ATPase of myosin S-1; this inhibition is augmented by smooth muscle tropomyosin and relieved by Ca2+-calmodulin. The binding of the 7.3-kDa fragment to actin is competitive with the binding of S-1 to actin. Thus, this polypeptide has several of the important features characteristic of intact caldesmon. However, although an intact caldesmon molecule covers between six and nine actin monomers, the 7.3-kDa fragment binds to actin in a 1:1 complex. Comparison of this fragment with others suggests that a small region of caldesmon is responsible for at least part of the interaction with both calmodulin and actin.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine	CHALOVICH, JM (corresponding author), E CAROLINA UNIV, SCH MED, DEPT BIOCHEM, GREENVILLE, NC 27858 USA.			Chalovich, Joseph/0000-0002-1243-4055	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035216] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40540-01A1, AR35216, R01 AR035216] Funding Source: Medline; NIGMS NIH HHS [GM26091] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS S, 1990, J BIOL CHEM, V265, P19652; BALL EH, 1988, BIOCHEMISTRY-US, V27, P6093, DOI 10.1021/bi00416a039; BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BERTRAND R, 1989, EUR J BIOCHEM, V181, P747, DOI 10.1111/j.1432-1033.1989.tb14787.x; BRENNER B, 1991, P NATL ACAD SCI USA, V88, P5739, DOI 10.1073/pnas.88.13.5739; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BRYAN J, 1989, J MUSCLE RES CELL M, V10, P95, DOI 10.1007/BF01739964; BRYAN J, 1991, J MUSCLE RES CELL M, V12, P372, DOI 10.1007/BF01738592; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CLARK T, 1986, J BIOL CHEM, V261, P8028; CROSBIE R, 1991, J BIOL CHEM, V266, P20001; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; DASGUPTA G, 1989, J MOL BIOL, V207, P833, DOI 10.1016/0022-2836(89)90249-0; EISENBERG E, 1972, COLD SPRING HARB SYM, V37, P145; FUJII T, 1987, J BIOL CHEM, V262, P2757; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HEMRIC ME, 1991, BIOPHYS J, V59, P57; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KIELLEY WW, 1960, BIOCHIM BIOPHYS ACTA, V41, P401; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH JA, 1986, J BIOL CHEM, V261, P6155; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P564; LEVINE BA, 1990, EUR J BIOCHEM, V193, P687, DOI 10.1111/j.1432-1033.1990.tb19388.x; MABUCHI K, 1991, J MUSCLE RES CELL M, V12, P145, DOI 10.1007/BF01774033; MAKUCH R, 1992, FEBS LETT, V297, P237, DOI 10.1016/0014-5793(92)80546-S; MEJEAN C, 1986, BIOSCIENCE REP, V6, P493, DOI 10.1007/BF01116141; MORNET D, 1988, BIOCHEM BIOPH RES CO, V155, P808, DOI 10.1016/S0006-291X(88)80567-9; MORNET D, 1988, BIOCHEM BIOPH RES CO, V154, P564, DOI 10.1016/0006-291X(88)90177-5; NGAI PK, 1987, BIOCHEM J, V244, P417, DOI 10.1042/bj2440417; NGAI PK, 1985, BIOCHEM J, V230, P695, DOI 10.1042/bj2300695; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; RISEMAN VM, 1989, J BIOL CHEM, V264, P2869; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1985, P NATL ACAD SCI USA, V82, P5025, DOI 10.1073/pnas.82.15.5025; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SOBUE K, 1990, ADV EXP MED BIOL, V255, P325; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TAKAGI T, 1989, J BIOCHEM-TOKYO, V106, P778, DOI 10.1093/oxfordjournals.jbchem.a122930; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG CLA, 1991, J BIOL CHEM, V266, P13958; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WANG CLA, 1988, BIOCHEM BIOPH RES CO, V156, P1033, DOI 10.1016/S0006-291X(88)80948-3; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; YAMAZAKI K, 1987, J BIOCHEM-TOKYO, V101, P1; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	63	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16644	16650						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1386604				2022-12-27	WOS:A1992JJ45800100
J	IADEMARCO, MF; MCQUILLAN, JJ; ROSEN, GD; DEAN, DC				IADEMARCO, MF; MCQUILLAN, JJ; ROSEN, GD; DEAN, DC			CHARACTERIZATION OF THE PROMOTER FOR VASCULAR CELL-ADHESION MOLECULE-1 (VCAM-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR NECROSIS FACTOR; ELAM-1 GENE-TRANSCRIPTION; GATA-BINDING PROTEIN; DNA-BINDING; ENDOTHELIAL-CELLS; INTEGRIN VLA-4; MESSENGER-RNA; FACTOR-ALPHA; SIALYL-LEX	Vascular cell adhesion molecule-1 (VCAM-1) was first identified as a protein that appears on the surface of endothelial cells after exposure to inflammatory cytokines. Through interaction with its integrin counter receptor VLA-4, VCAM-1 mediates cell-cell interactions important for immune function. We have cloned and begun characterization of the promoter for the VCAM-1 gene. In a series of transfection assays into human umbilical vein endothelial cells (HUVECs), we find that silencers between positions -1.641 kilobases and -288 base pairs restrict promoter activity, and that treatment with tumor necrosis factor-alpha overcomes this inhibition and activates the promoter through two NF-kappa-B sites located at positions -77 and -63 base pairs of the VCAM-1 gene. This responsiveness appears cell-specific since constructs containing the VCAM-1 NF-kappa-B sites are not responsive to tumor necrosis factor-alpha in the T-cell line Jurkat. The two VCAM-1 NF-kappa-B sites, which differ slightly in their sequence, form distinct complexes in gel retardation assays, suggesting that they interact with different NF-kappa-B-site binding proteins. The distribution of these proteins could then control activity of the NF-kappa-B sites. We conclude that the pattern of VCAM-1 expression in HUVECs is controlled by a combination of these silencers and NF-kappa-B sites.	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, BOX 8052, 660 S EUCLID, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007317, P01HL029594, R01HL043418] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43418, HL07317, HL29594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, AM J RESP CELL MOL, V4, P195, DOI 10.1165/ajrcmb/4.3.195; ALBELDA SM, 1990, CANCER RES, V50, P6757; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FELDMAN LE, 1991, CANCER RES, V51, P1065; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HORTON MA, 1989, J BONE MINER RES, V4, P803; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE ME, 1991, J BIOL CHEM, V266, P16188; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; OSBORN L, 1989, P NATL ACAD SCI USA, V85, P1482; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; PORTER SD, 1986, NATURE, V320, P766, DOI 10.1038/320766a0; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSEN GD, 1992, IN PRESS CELL; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	66	339	363	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16323	16329						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379595				2022-12-27	WOS:A1992JJ45800053
J	MOORMAN, JR; PALMER, CJ; JOHN, JE; DURIEUX, ME; JONES, LR				MOORMAN, JR; PALMER, CJ; JOHN, JE; DURIEUX, ME; JONES, LR			PHOSPHOLEMMAN EXPRESSION INDUCES A HYPERPOLARIZATION-ACTIVATED CHLORIDE CURRENT IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARDIAC MYOCYTES; SARCOLEMMAL PROTEIN; INTACT MYOCARDIUM; LAEVIS OOCYTES; CONDUCTANCE; CLONING; MUSCLE; PHOSPHORYLATION; ADRENALINE; CHANNEL	A new type of chloride channel has been identified by functional expression of phospholemman, a 72-amino acid cardiac sarcolemmal protein with a single transmembrane domain. Xenopus oocytes injected with phospholemman RNA developed a chloride-selective current, which was activated by hyperpolarizing pulses. The current activated very slowly with a pronounced sigmoidal delay, did not inactivate, and increased in amplitude with trains of pulses, depolarized holding potentials, and low extracellular pH. Point mutations within the single transmembrane region abolished the sigmoidal delay of expressed currents. Phospholemman appears to be the smallest plasma membrane channel protein yet known. The structure is dissimilar to any chloride channel described thus far.	UNIV VIRGINIA,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT ANESTHESIOL,CHARLOTTESVILLE,VA 22908; INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,DEPT PHARMACOL,INDIANAPOLIS,IN 46202	University of Virginia; University of Virginia; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	MOORMAN, JR (corresponding author), UNIV VIRGINIA,DEPT MED CARDIOL,CHARLOTTESVILLE,VA 22908, USA.		Moorman, J Randall/ABG-9946-2020	Durieux, Marcel/0000-0003-1479-7666				BAHINSKI A, 1989, NATURE, V340, P718, DOI 10.1038/340718a0; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BLATZ AL, 1985, BIOPHYS J, V47, P119, DOI 10.1016/S0006-3495(85)83884-4; CHESNOYMARCHAIS D, 1983, J PHYSIOL-LONDON, V342, P277, DOI 10.1113/jphysiol.1983.sp014851; CHESNOYMARCHAIS D, 1982, NATURE, V299, P359; EHARA T, 1990, NATURE, V347, P284, DOI 10.1038/347284a0; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSSTEIN S A N, 1991, Biophysical Journal, V59, p197A; HARVEY RD, 1989, SCIENCE, V244, P983, DOI 10.1126/science.2543073; Hille B., 1992, IONIC CHANNELS EXCIT; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LINDEMANN JP, 1986, J BIOL CHEM, V261, P4860; LOO DDF, 1981, CAN J PHYSIOL PHARM, V59, P7, DOI 10.1139/y81-002; MATSUOKA S, 1990, J PHYSIOL-LONDON, V425, P579, DOI 10.1113/jphysiol.1990.sp018119; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; PALADE PT, 1977, J GEN PHYSIOL, V69, P879, DOI 10.1085/jgp.69.6.879; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PARKER I, 1985, PROC R SOC SER B-BIO, V223, P279, DOI 10.1098/rspb.1985.0002; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PERES A, 1983, PFLUG ARCH EUR J PHY, V399, P157, DOI 10.1007/BF00663914; PERLMAN S, 1970, BIOCHEM BIOPH RES CO, V40, P941, DOI 10.1016/0006-291X(70)90994-0; PRESTI CF, 1985, J BIOL CHEM, V260, P3879; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; TAGLIETTI V, 1984, J CELL PHYSIOL, V121, P576, DOI 10.1002/jcp.1041210317; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; WARNER AE, 1972, J PHYSIOL-LONDON, V227, P291, DOI 10.1113/jphysiol.1972.sp010033	30	140	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14551	14554						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1378834				2022-12-27	WOS:A1992JF08800010
J	HSU, MY; EAGLE, SG; INOUYE, M; INOUYE, S				HSU, MY; EAGLE, SG; INOUYE, M; INOUYE, S			CELL-FREE SYNTHESIS OF THE BRANCHED RNA-LINKED MSDNA FROM RETRON-EC67 OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; MYXOCOCCUS-XANTHUS; DNA	msDNA-Ec67 is produced in a clinical strain of Escherichia coli and composed of a 67-base single-stranded DNA, which is linked to the 2'-OH group of the 15th rG residue of a 58-base RNA molecule by a 2,5'-phosphodiester phosphodiester linkage (Lampson, B. C., Sun, J., Hsu, M.-Y., Vallejo-Ramirez, J., Inouye, S., and Inouye, M. (1989) Science 243, 1033-1038). The production of msDNA-Ec67 is dependent upon retron-Ec67, which consists of the msr-msd region and the gene for reverse transcriptase (RT). These two elements were separately cloned into plasmids; p67-BH0.6 contained the msr-msd region and pRT-67 contained the RT gene under the lpp-lac promoter-operator. msDNA-Ec67 was produced only when cells were transformed with both plasmids. In addition, msDNA-Ec67 was synthesized in a cell-free system using total RNA prepared from cells harboring plasmid p67-BH0.6 and purified Ec67-RT. Using this cell-free system, the priming reaction, during initiation of DNA synthesis, was demonstrated to be a specific template-directed event; only dTTP was incorporated into a 132-base precursor RNA yielding a 133-base compound. This specific dT addition could be altered to dA or dC by simply substituting the 118th A residue of the putative msr-msd transcript with a T or G residue. The priming reaction was blocked when A was substituted for G at the 15th residue of the precursor RNA transcript, which corresponds to the branched rG residue in msDNA. DNA chain elongation could be terminated by adding ddNTP in the cell-free system, forming a sequence ladder. The DNA sequence determined from this ladder completely agreed with the msDNA sequence. The RT extension reaction was completely blocked when the RNA preparation was treated with RNase A but not when the preparation was treated with DNase. This clearly demonstrates that RNA but not DNA is responsible for the msDNA production. A part of the fully extended cell-free product contained a 13-base RNA strand resistant to RNase A, which is consistent with the previously proposed model. In this model, the 5'-end sequence of the msr-msd transcript (a2; bases 1-13) forms a duplex with the 3'-end sequence (al) of the same transcript, thus serving as a primer, as well as a template for msDNA synthesis by RT. Our results are inconsistent with a model recently proposed by Lease and Yee (Lease, R. A., and Yee, T. (1991) J. Biol. Chem. 266, 14497-14503).			HSU, MY (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.		Inouye, Sharon/R-7216-2019		NIGMS NIH HHS [GM44012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; DHUNDALE A, 1987, CELL, V51, P1105, DOI 10.1016/0092-8674(87)90596-4; HSU MY, 1989, J BIOL CHEM, V264, P6214; INOUYE M, 1991, TRENDS BIOCHEM SCI, V16, P18, DOI 10.1016/0968-0004(91)90010-S; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P162; INOUYE S, 1991, SCIENCE, V252, P969, DOI 10.1126/science.1709758; INOUYE S, 1985, NUCLEIC ACIDS RES, V13, P3101, DOI 10.1093/nar/13.9.3101; INOUYE S, 1991, DIRECTED MUTAGENESIS, P71; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LAMPSON BC, 1990, J BIOL CHEM, V265, P8490; LAMPSON BC, 1989, CELL, V56, P701, DOI 10.1016/0092-8674(89)90592-8; LEASE RA, 1991, J BIOL CHEM, V266, P14497; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; Miller J. H., 1972, EXPT MOL GENETICS, P433; MIYATA S, 1992, IN PRESS P NATL ACAD; NAKAMURA K, 1982, Journal of Molecular and Applied Genetics, V1, P289; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991	19	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13823	13829						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1378431				2022-12-27	WOS:A1992JD32500009
J	JONES, PG; MOORE, GJ; WAISMAN, DM				JONES, PG; MOORE, GJ; WAISMAN, DM			A NONAPEPTIDE TO THE PUTATIVE F-ACTIN BINDING-SITE OF ANNEXIN-II TETRAMER INHIBITS ITS CALCIUM-DEPENDENT ACTIVATION OF ACTIN FILAMENT BUNDLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-DEPENDENT PHOSPHOLIPID-BINDING; HEAVY-CHAIN; CYTOSKELETAL PROTEIN; BRUSH-BORDER; SYNAPSIN-I; PHOSPHORYLATION; LIPOCORTIN; MYOSIN; CALPACTIN; PURIFICATION	A synthetic nonapeptide, Val-Leu-Ile-Arg-Ile-Met-Val-Ser-Arg, corresponding to residues 286-294 of annexin-II tetramer (A-IIt), was shown to completely inhibit the Ca2+-dependent bundling of F-actin by this protein. The inhibitory effect of the nonapeptide required preincubation with F-actin and was reversed by the addition of excess A-IIt. Kinetic analysis suggested that the nonapeptide reduced the K(0.5) but not the V(max) of F-actin bundling. In contrast, addition of excess nonapeptide to A-IIt-bundled F-actin did not reverse F-actin bundle formation. Although the nonapeptide produced a dose-dependent inhibition of A-IIt-dependent F-actin bundling, the binding of A-IIt to F-actin was not affected. These results identify a domain of A-IIt that is involved in the bundling activity of the protein and suggest that this domain binds transiently with F-actin, resulting in activation of the bundling activity of A-IIt.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary				Waisman, David/0000-0002-5097-9662				BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BENNETT JP, 1984, BIOCHEMISTRY-US, V23, P5081, DOI 10.1021/bi00316a039; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1981, P NATL ACAD SCI-BIOL, V78, P6849, DOI 10.1073/pnas.78.11.6849; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; BROTSCHI EA, 1978, J BIOL CHEM, V253, P8988; BRYAN J, 1978, J MOL BIOL, V125, P207, DOI 10.1016/0022-2836(78)90345-5; BURGESS DR, 1987, J CELL BIOL, V104, P29, DOI 10.1083/jcb.104.1.29; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; ETO M, 1990, J BIOCHEM-TOKYO, V108, P499, DOI 10.1093/oxfordjournals.jbchem.a123228; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FECHHEIMER M, 1987, J CELL BIOL, V104, P1539, DOI 10.1083/jcb.104.6.1539; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1985, J BIOL CHEM, V260, P1688; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GLENNEY JR, 1981, J BIOL CHEM, V256, P9283; GLENNEY JR, 1985, J CELL BIOL, V100, P754, DOI 10.1083/jcb.100.3.754; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HUSAINCHISHTI A, 1988, NATURE, V334, P718, DOI 10.1038/334718a0; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; KHANNA NC, 1987, CELL CALCIUM, V8, P217, DOI 10.1016/0143-4160(87)90020-0; KHANNA NC, 1988, NEW COMPREHENSIVE BI, P63; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KRISTENSEN T, 1986, BIOCHEMISTRY-US, V25, P4497, DOI 10.1021/bi00364a007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MISCHE SM, 1987, J CELL BIOL, V105, P2837, DOI 10.1083/jcb.105.6.2837; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SMITH VL, 1990, STIMULUS RESPONSE, P8; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; SUZUKI R, 1987, J BIOL CHEM, V262, P11410; TELLAM R, 1982, BIOCHEMISTRY-US, V21, P3207, DOI 10.1021/bi00256a027; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085; YAMAMOTO K, 1979, J BIOCHEM-TOKYO, V86, P1863, DOI 10.1093/oxfordjournals.jbchem.a132709	41	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13993	13997						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1385810				2022-12-27	WOS:A1992JD32500035
J	LARSEN, GR; SAKO, D; AHERN, TJ; SHAFFER, M; ERBAN, J; SAJER, SA; GIBSON, RM; WAGNER, DD; FURIE, BC; FURIE, B				LARSEN, GR; SAKO, D; AHERN, TJ; SHAFFER, M; ERBAN, J; SAJER, SA; GIBSON, RM; WAGNER, DD; FURIE, BC; FURIE, B			P-SELECTIN AND E-SELECTIN - DISTINCT BUT OVERLAPPING LEUKOCYTE LIGAND SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; COMPLEMENT REGULATORY PROTEINS; LYMPHOCYTE HOMING RECEPTOR; HUMAN-ENDOTHELIAL CELLS; WEIBEL-PALADE BODIES; ACTIVATED PLATELETS; ADHESION MOLECULE-1; INDUCIBLE RECEPTOR; PLASMA-MEMBRANE; SIALYL-LEX	P-selectin on platelets and endothelial cells and E-selectin on endothelial cells are leukocyte receptors that recognize lineage-specific carbohydrates on neutrophils and monocytes. The proposed ligands for these receptors contain the Le(x) core and sialic acid. Since other investigators have shown that both E-selectin and P-selectin bind to sialylated Le(x), we evaluated whether E-selectin and P-selectin recognize the same counter-receptor on leukocytes. The interaction of HL60 cells with Chinese hamster ovary (CHO) cells expressing P-selectin or E-selectin was studied. To determine whether a protein component is required in addition to sialyl Le(x) for either P-selectin or E-selectin recognition, HL60 cells or neutrophils were digested with proteases, including chymotrypsin, elastase, proteinase Glu-C, ficin, papain, or thermolysin. Cells treated with these proteases bound E-selectin but not P-selectin. Fucosidase or neuraminidase treatment of HL60 cells markedly decreased binding to both E-selectin- and P-selectin-expressing CHO cells. Growth of HL60 cells in tunicamycin inhibited the ability of these cells to support P-selectin-mediated binding and, to a lesser extent, E-selectin-mediated binding. Purified P-selectin inhibited CHO:P-selectin binding to HL60 cells, but incompletely inhibited CHO:E-selectin binding to HL60 cells. However, purified soluble E-selectin inhibited CHO:P-selectin and CHO:E-selectin binding to HL60 cells equivalently and completely. COS cells, unable to bind to E-selectin or P-selectin, bound E-selectin but not P-selectin upon transfection with alpha-1,3-fucosyltransferase or alpha-1,3/1,4-fucosyltransferase. Similarly, LEC 11 cells expressing sialyl Le(x) bound E-selectin- but not P-selectin-expressing CHO cells. Sambucus nigra lectin, specific for the sialyl-2,6-beta-Gal/GalNAc linkage, inhibited P-selectin but not E-selectin binding to HL60 cells. Although sialic acid and Le(x) are components of the P-selectin ligand and the E-selectin ligand, these results indicate that the ligands are related, having overlapping specificities, but are structurally distinct. A protein component containing sialyl Le(x) in proximity to sialyl-2,6-beta-Gal structures on the P-selectin ligand may contribute to its specificity for P-selectin.	NEW ENGLAND MED CTR HOSP,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts University	LARSEN, GR (corresponding author), GENET INST,CAMBRIDGE,MA 02140, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008297, P01HL042443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42443, HL08297, HL02542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; FUKUDA M, 1984, J BIOL CHEM, V259, P925; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEEUWENBERG JFM, 1989, EUR J IMMUNOL, V19, P715, DOI 10.1002/eji.1830190422; LEVY K, 1989, BLOOD, V73, P1324; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MURAKAMI H, 1991, J BIOL CHEM, V266, P15414; NAUSEEF WM, 1983, BLOOD, V62, P636; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RASSOULZADEGAN M, 1982, NATURE, V295, P257, DOI 10.1038/295257a0; SCHAFFNER W, 1980, P NATL ACAD SCI-BIOL, V77, P2163, DOI 10.1073/pnas.77.4.2163; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON ML, 1990, J EXP MED, V172, P263, DOI 10.1084/jem.172.1.263; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	42	158	164	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11104	11110						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375936				2022-12-27	WOS:A1992HX16900029
J	DUSANTERFOURT, I; CASADEVALL, N; LACOMBE, C; MULLER, O; BILLAT, C; FISCHER, S; MAYEUX, P				DUSANTERFOURT, I; CASADEVALL, N; LACOMBE, C; MULLER, O; BILLAT, C; FISCHER, S; MAYEUX, P			ERYTHROPOIETIN INDUCES THE TYROSINE PHOSPHORYLATION OF ITS OWN RECEPTOR IN HUMAN ERYTHROPOIETIN-RESPONSIVE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-2 RECEPTOR; SIGNAL TRANSDUCTION; PROTEINS; ACTIVATION; EXPRESSION; CLONING	Using the human erythropoietin-responsive hematopoietic cell line UT-7, we showed that erythropoietin (Epo) rapidly and specifically induced the tyrosine phosphorylation of its own receptor (M(r) 75,000) and increased the tyrosine phosphorylation of other proteins of M(r) 140,000,120,000,95,000,60,000,57,000, and 42,000. Neither granulocyte-macrophage colony-stimulating factor, interleukin 3, interleukin 6, nor the kit ligand induced the phosphorylation of the M(r) 75,000 receptor protein, although these growth factors induced the phosphorylation of other proteins. Crosslinking experiments using I-125-Epo indicated that the UT-7 cells expressed three Epo receptor subunits, of M(r) 100,000, 85,000, and 75,000, among which only the M(r) 75,000 subunit was tyrosine-phosphorylated following activation with Epo.	HOP COCHIN, ICGM, INSERM, U332, F-75674 PARIS 14, FRANCE; UNIV REIMS, UFR SCI, BIOCHIM LAB, F-51062 REIMS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Universite de Reims Champagne-Ardenne	DUSANTERFOURT, I (corresponding author), HOP COCHIN, ICGM, INSERM, U152, 27 RUE FAUBOURG ST JACQUES, F-75674 PARIS 14, FRANCE.		Dusanter-Fourt, Isabelle/P-4558-2017	Dusanter-Fourt, Isabelle/0000-0002-9286-1021				BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FUNG MR, 1991, J IMMUNOL, V147, P1253; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS K, 1990, BLOOD, V76, pA147; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HERMINE O, 1991, BLOOD S, V78, pA292; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; JONES SS, 1990, BLOOD, V76, P31; KANAKURA Y, 1990, BLOOD, V76, P706; KOMATSU N, 1991, CANCER RES, V51, P341; KRANTZ SB, 1991, BLOOD, V77, P419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYEUX P, 1986, EXP HEMATOL, V14, P801; MAYEUX P, 1990, EUR J BIOCHEM, V194, P271, DOI 10.1111/j.1432-1033.1990.tb19453.x; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; QUELLE FW, 1991, J BIOL CHEM, V266, P609; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P6323, DOI 10.1073/pnas.88.14.6323; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WINKELMANN JC, 1990, BLOOD, V76, P24; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	33	118	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10670	10675						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375226				2022-12-27	WOS:A1992HV09000070
J	LEV, S; YARDEN, Y; GIVOL, D				LEV, S; YARDEN, Y; GIVOL, D			A RECOMBINANT ECTODOMAIN OF THE RECEPTOR FOR THE STEM-CELL FACTOR (SCF) RETAINS LIGAND-INDUCED RECEPTOR DIMERIZATION AND ANTAGONIZES SCF-STIMULATED CELLULAR-RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; C-KIT RECEPTOR; INTERMOLECULAR ALLOSTERIC ACTIVATION; TYROSINE KINASE-ACTIVITY; HUMAN INSULIN-RECEPTOR; EXTRACELLULAR DOMAIN; SELF-PHOSPHORYLATION; SI-LOCUS; V-KIT; BINDING	The stem cell factor (SCF) is a polypeptide ligand that is essential for the development of germ cells, hematopoietic progenitor cells, and melanocyte precursors. It binds to a tyrosine kinase membrane receptor that is encoded by the c-kit proto-oncogene. We have constructed an expression vector that directs the synthesis of the entire extracellular ligand-binding domain of the Kit/SCF receptor. When expressed and amplified in Chinese hamster ovary cells, a secreted 90-kDa glycoprotein could be harvested from the growth medium of the cells in a soluble form. This extracellular portion of the Kit/SCF receptor, denoted Kit-X, was recognized by antibodies specific to the SCF receptor; and when injected into animals, it raised antibodies that were reactive with the complete membrane form of the receptor. Direct binding and covalent cross-linking of radiolabeled SCF showed that Kit-X fully retained high affinity ligand binding and also underwent efficient dimerization in the presence of the ligand. The capacity of Kit-X to act as an antagonist of SCF was assayed on cultured cells that overexpress the receptor. Simultaneous addition of SCF and Kit-X to these cells resulted in a stoichiometric inhibition of SCF binding and a consequent decrease in autophosphorylation of the SCF receptor on tyrosine residues. The inhibition extended to later SCF-mediated responses, including the association of the receptor with phosphatidylinositol 3'-kinase and coupling to the Raf1 protein kinase. These results indicate that the recombinant ectodomain of the Kit-SCF receptor can be used as a specific antagonist of SCF actions and may enable detailed molecular analysis of ligand-receptor interactions.			LEV, S (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.		YARDEN, YOSEF/K-1467-2012; Lev, Sima/AAP-7880-2020	Lev, Sima/0000-0002-2108-3330	NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER; NCI NIH HHS [CA51712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COCHET C, 1988, J BIOL CHEM, V263, P3290; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DOWER SK, 1989, J IMMUNOL, V142, P4314; DUAN DSR, 1991, J BIOL CHEM, V266, P413; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUHN RD, 1987, P NATL ACAD SCI USA, V84, P4408, DOI 10.1073/pnas.84.13.4408; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAUB O, 1983, J VIROL, V48, P271, DOI 10.1128/JVI.48.1.271-280.1983; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LIVNEH E, 1986, J CELL BIOL, V103, P327, DOI 10.1083/jcb.103.2.327; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAPP UR, 1988, HDB ONCOGENES, P213; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SHERR CJ, 1990, BLOOD, V75, P1; Silvers W.K., 1979, COAT COLORS MICE, P206; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	53	51	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10866	10873						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1375232				2022-12-27	WOS:A1992HV09000098
J	RUSSO, RN; SHAPER, NL; TAATJES, DJ; SHAPER, JH				RUSSO, RN; SHAPER, NL; TAATJES, DJ; SHAPER, JH			BETA-1,4-GALACTOSYLTRANSFERASE - A SHORT NH2-TERMINAL FRAGMENT THAT INCLUDES THE CYTOPLASMIC AND TRANSMEMBRANE DOMAIN IS SUFFICIENT FOR GOLGI RETENTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; CELL-SURFACE GALACTOSYLTRANSFERASE; ENDOPLASMIC-RETICULUM; PYRUVATE-KINASE; E1 GLYCOPROTEIN; SIGNAL ANCHOR; MESSENGER-RNA; EXPRESSION; PROTEIN; LOCALIZATION	Beta-1,4-galactosyltransferase (beta-1,4-GT) is a Golgi-resident, type II membrane-bound glycoprotein that functions in the coordinate biosynthesis of complex oligosaccharides. Additionally, beta-1,4-GT has been localized to the cell surface of a variety of cell types and tissues where it is proposed to function in intercellular recognition and/or adhesion. Thus beta-1,4-GT is an appropriate molecule to be used in analyzing the molecular basis for retention of a membrane-bound enzyme in the Golgi complex and its subsequent or alternative transport to the cell surface. Previously we have shown that the gene for bovine and murine beta-1,4-GT is unusual in that it specifies a short (SGT) and long (LGT) form of the enzyme (Russo, R. N., Shaper, N. L., and Shaper, J. H. (1990) J. Biol. Chem. 265, 3324-333 1). The only difference between the two related forms is in the primary structure of the cytoplasmic domains, where LGT has an NH2-terminal extension of 13 amino acids. In this study, we have tested the hypothesis that LGT and SGT are differentially retained in the Golgi or directed to the cell surface. LGT, SGT or chimeric proteins, containing the NH2-terminal cytoplasmic and transmembrane domain of SGT and LGT fused to the cytoplasmic protein pyruvate kinase, were each stably expressed in Chinese hamster ovary cells. Proteins expressed from each construct were localized by immunofluorescence staining exclusively to a perinuclear region, identified as the Golgi by co-localization with wheat germ agglutinin. Furthermore, the subcellular distribution of both SGT and LGT was restricted to the trans-Golgi compartment as assessed by EM immunoelectron microscopy. These data suggest that both forms of beta-1,4-GT are resident trans-Golgi proteins and that an NH2-terminal segment containing the cytoplasmic and transmembrane domains of SGT (39 amino acids) or LGT (52 amino acids) is sufficient for Golgi retention.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,CELL STRUCT & FUNCT LAB,ROOM 1-127,600 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; University of Vermont					NATIONAL CANCER INSTITUTE [R01CA045799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038310] Funding Source: NIH RePORTER; NCI NIH HHS [CA45799] Funding Source: Medline; NIGMS NIH HHS [GM38310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG J, 1991, J CELL SCI, V98, P567; BAYNA EM, 1988, CELL, V53, P145, DOI 10.1016/0092-8674(88)90496-5; BEYER TA, 1982, GLYCOCONJUGATES, V3, P25; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIEBERT SW, 1988, J CELL BIOL, V107, P865, DOI 10.1083/jcb.107.3.865; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOZIASSE DH, 1989, J BIOL CHEM, V264, P1490; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEE EU, 1989, J BIOL CHEM, V264, P13848; LONBERG N, 1983, P NATL ACAD SCI-BIOL, V80, P3661, DOI 10.1073/pnas.80.12.3661; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAYNE GS, 1989, SCIENCE, V245, P1358, DOI 10.1126/science.2675311; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PENNO MB, 1989, P NATL ACAD SCI USA, V86, P6057, DOI 10.1073/pnas.86.16.6057; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, J CELL BIOL, V100, P118, DOI 10.1083/jcb.100.1.118; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; RUSSO RN, 1990, THESIS J HOPKINS U; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SHAPER JH, 1990, 19TH SOC COMPL CARB; SHAPER NL, 1985, J CELL BIOCHEM, V28, P229, DOI 10.1002/jcb.240280305; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TAATJES DJ, 1990, J HISTOCHEM CYTOCHEM, V38, P233, DOI 10.1177/38.2.1688898; TOKUYASU KT, 1980, 38TH P M EL MICR SOC, P760; ULRICH JT, 1986, J BIOL CHEM, V261, P7975; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	55	92	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1992	267	13					9241	9247						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HR854	1374389				2022-12-27	WOS:A1992HR85400082
J	OKKELS, JS; KJAER, B; HANSSON, O; SVENDSEN, I; MOLLER, BL; SCHELLER, HV				OKKELS, JS; KJAER, B; HANSSON, O; SVENDSEN, I; MOLLER, BL; SCHELLER, HV			A MEMBRANE-BOUND MONOHEME CYTOCHROME-C551 OF A NOVEL TYPE IS THE IMMEDIATE ELECTRON-DONOR TO P840 OF THE CHLOROBIUM-VIBRIOFORME PHOTOSYNTHETIC REACTION CENTER COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM PROSTHECOCHLORIS-AESTUARII; PHOTOSYSTEM-I; RHODOPSEUDOMONAS-VIRIDIS; HELIOBACTERIUM-CHLORUM; POLYACRYLAMIDE GELS; PROTEIN; THIOSULFATOPHILUM; ELECTROPHORESIS; PEPTIDE; SUBUNIT	A photosynthetic reaction center complex has been isolated from the green sulfur bacterium Chlorobium vibrioforme. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis reveals polypeptides with apparent molecular masses of 80, 40, 18, 15, 9, and 6 kDa. Only the 18-kDa polypeptide is stained with 3,3',5,5'-tetramethylbenzidine, a heme-specific reagent. Oxidized minus reduced difference spectra show the presence of approximately one heme/P840 and the presence of a cytochrome c551. Flash photolysis of P840 was followed by rereduction of P840+ and oxidation of cytochrome c551, both with a biphasic kinetic with t1/2 values of 7 and 50 mus. Using oligonucleotide probes derived from an N-terminal amino acid sequence of the 18-kDa polypeptide, a genomic clone was isolated. The sequence of the gene, which we designate cycA, predicts a single heme binding site (Cys-Asn-Lys-Cys-His). The 621-base pair open reading frame encodes an apoprotein of 22,858 Da with three predicted membrane-spanning alpha-helices. No extensive sequence similarity is found to other cytochromes. Northern blotting indicates that the cycA gene is transcribed as a monocistronic mRNA. Southern blotting shows the presence of only one cycA gene in the C. vibrioforme and Chlorobium tepidum genomes. The unique membrane-bound monoheme cytochrome c551 of C. vibriforme is assigned to a new class of c-type cytochromes. The implications for the current view of evolution of photosynthetic reaction center complexes are discussed.	CARLSBERG LAB, DEPT CHEM, DK-2500 VALBY, DENMARK; GOTHENBURG UNIV, S-41296 GOTHENBURG, SWEDEN; CHALMERS UNIV TECHNOL, DEPT BIOCHEM & BIOPHYS, S-41296 GOTHENBURG, SWEDEN	University of Gothenburg; Chalmers University of Technology	OKKELS, JS (corresponding author), ROYAL VET & AGR UNIV, DEPT PLANT BIOL, PLANT BIOCHEM LAB, 40 THORVALDSENSVEJ, DK-1871 FREDERIKSBERG C, DENMARK.		Hansson, Orjan/D-1282-2009; Møller, Birger Lindberg/H-2657-2014; Scheller, Henrik V/A-8106-2008; Møller, Birger Lindberg/GQI-1792-2022	Møller, Birger Lindberg/0000-0002-3252-3119; Scheller, Henrik V/0000-0002-6702-3560; Møller, Birger Lindberg/0000-0002-3252-3119				ANDERSEN B, 1993, IN PRESS CHLOROPLAST; BOTT M, 1991, J BACTERIOL, V173, P6766, DOI 10.1128/jb.173.21.6766-6772.1991; BRAUMANN T, 1986, BIOCHIM BIOPHYS ACTA, V848, P83, DOI 10.1016/0005-2728(86)90163-5; BUCHANAN BB, 1969, BIOCHIM BIOPHYS ACTA, V180, P123, DOI 10.1016/0005-2728(69)90199-6; BUTTNER M, 1992, IN PRESS P NATL ACAD; CROFTS AR, 1990, CURRENT RES PHOTOSYN, V3, P263; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P385; DRACHEVA S, 1991, BIOCHEMISTRY-US, V30, P11451, DOI 10.1021/bi00112a012; FEILER U, 1992, BIOCHEMISTRY-US, V31, P2608, DOI 10.1021/bi00124a022; FEILER U, 1991, THESIS JW GOETHE U F; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FOWLER CF, 1971, P NATL ACAD SCI USA, V68, P2278, DOI 10.1073/pnas.68.9.2278; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; HOGANSON CW, 1991, BIOCHIM BIOPHYS ACTA, V1057, P399, DOI 10.1016/S0005-2728(05)80154-9; HOJ PB, 1987, J BIOL CHEM, V262, P12676; HURT EC, 1984, FEBS LETT, V168, P149, DOI 10.1016/0014-5793(84)80225-2; JENNINGS JV, 1977, FEBS LETT, V75, P33, DOI 10.1016/0014-5793(77)80046-X; KNAFF DB, 1973, BIOCHIM BIOPHYS ACTA, V325, P94, DOI 10.1016/0005-2728(73)90154-0; MAJUMDAR D, 1991, ARCH MICROBIOL, V156, P281, DOI 10.1007/BF00262999; MARTIN C, 1981, PLANTA, V151, P189, DOI 10.1007/BF00387822; MEYER TE, 1991, BIOCHIM BIOPHYS ACTA, V1058, P31, DOI 10.1016/S0005-2728(05)80263-4; MILLER M, 1992, BIOCHEMISTRY-US, V31, P4354, DOI 10.1021/bi00132a028; Moore G. R., 1990, CYTOCHROMES C EVOLUT, P115; NITSCHKE W, 1990, BIOCHEMISTRY-US, V29, P3834, DOI 10.1021/bi00468a005; NITSCHKE W, 1991, TRENDS BIOCHEM SCI, V16, P241, DOI 10.1016/0968-0004(91)90095-D; NITSCHKE W, 1990, BIOCHEMISTRY-US, V29, P11079, DOI 10.1021/bi00502a010; OKKELS JS, 1991, J BIOL CHEM, V266, P6767; OLSON JM, 1981, BIOCHIM BIOPHYS ACTA, V637, P185, DOI 10.1016/0005-2728(81)90225-5; OLSON JM, 1973, BIOCHIM BIOPHYS ACTA, V292, P206, DOI 10.1016/0005-2728(73)90265-X; OLSON JM, 1976, CHLOROPHYLL PROTEINS, P238; ORMEROD JG, 1990, J BACTERIOL, V172, P1352, DOI 10.1128/jb.172.3.1352-1360.1990; PETTIGREW GW, 1987, CYTOCHROMES C, P17; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; PRINCE RC, 1985, BIOCHIM BIOPHYS ACTA, V810, P377, DOI 10.1016/0005-2728(85)90224-5; PRINCE RC, 1976, BIOCHIM BIOPHYS ACTA, V423, P357, DOI 10.1016/0005-2728(76)90191-2; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RIEBLE S, 1989, J BACTERIOL, V171, P3782, DOI 10.1128/jb.171.7.3782-3787.1989; Sambrook J, 1989, MOL CLONING LABORATO; SCHELLER HV, 1990, PHYSIOL PLANTARUM, V78, P484, DOI 10.1034/j.1399-3054.1990.780326.x; SIREVAG R, 1970, BIOCHEM J, V120, P399, DOI 10.1042/bj1200399; STOEHR PJ, 1991, NUCLEIC ACIDS RES, V19, P2227, DOI 10.1093/nar/19.suppl.2227; SWARTHOFF T, 1981, FEBS LETT, V130, P93, DOI 10.1016/0014-5793(81)80673-4; SWARTHOFF T, 1981, BIOCHIM BIOPHYS ACTA, V635, P1, DOI 10.1016/0005-2728(81)90002-5; SWARTHOFF T, 1979, BIOCHIM BIOPHYS ACTA, V548, P427, DOI 10.1016/0005-2728(79)90146-4; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TROST JT, 1989, BIOCHEMISTRY-US, V28, P9898, DOI 10.1021/bi00452a003; TROST JT, 1991, 7 INT S PHOT PROK AM; TROST JT, 1990, CURRENT RES PHOTOSYN, V2, P703; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WIESSNER C, 1990, J BACTERIOL, V172, P2877, DOI 10.1128/jb.172.6.2877-2887.1990; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	52	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1992	267	29					21139	21145						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JT978	1383218				2022-12-27	WOS:A1992JT97800097
J	GENG, JG; HEAVNER, GA; MCEVER, RP				GENG, JG; HEAVNER, GA; MCEVER, RP			LECTIN DOMAIN PEPTIDES FROM SELECTINS INTERACT WITH BOTH CELL-SURFACE LIGANDS AND CA2+ IONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; LYMPHOCYTE HOMING RECEPTOR; MANNOSE-BINDING PROTEIN; CARBOHYDRATE LIGAND; GMP-140 BINDS; SIALYL-LEX; T-CELLS; CALCIUM; ELAM-1; RECOGNITION	Selectins are receptors that mediate leukocyte adhesion to platelets or endothelial cells through Ca2+-dependent interactions with cell surface oligosaccharides. We found that peptides corresponding to residues 23-30, 54-63, and 70-79 of the N-terminal lectin domain of P-selectin inhibited leukocyte adhesion to P-selectin. Peptides corresponding to the homologous 23-30 and 54-63 regions of E-selectin and L-selectin also prevented cell binding to P-selectin. Immobilized albumin conjugates of the three P-selectin peptides supported adhesion of myeloid cells and certain other cells expressing fucosylated oligosaccharides. Ca2+ was required for optimal cell adhesion to the conjugates containing the 23-30 and 54-63 sequences. Furthermore, Ca2+ interacted with the 23-30 and 54-63 peptides of all three selectins, as detected by changes in intrinsic fluorescence emission intensity. These data suggest that residues contained within the 23-30 and 54-63 regions of the selectins represent contact sites for carbohydrate structures on target cells. Furthermore, binding of Ca2+ to these sequences may directly enhance their ability to interact with cell surface ligands.	UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, 825 NE 13TH ST, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, WK WARREN MED RES INST, DEPT BIOCHEM, OKLAHOMA CITY, OK 73104 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation					NHLBI NIH HHS [HL 45510, HL 34363] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034363, R01HL045510, R37HL034363] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN TT, 1982, J BIOL CHEM, V257, P8036; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRASS LF, 1989, METHOD ENZYMOL, V169, P355; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GENG JG, 1991, J BIOL CHEM, V266, P22313; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HANDA K, 1991, BIOCHEM BIOPH RES CO, V181, P1223, DOI 10.1016/0006-291X(91)92069-V; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEE RT, 1991, J BIOL CHEM, V266, P4810; LOEB JA, 1988, J BIOL CHEM, V263, P9752; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MCEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80; MCEVER RP, 1991, J CELL BIOCHEM, V45, P156, DOI 10.1002/jcb.240450206; MOORE KL, 1992, BIOCHEM BIOPH RES CO, V186, P173, DOI 10.1016/S0006-291X(05)80790-9; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PIGOTT R, 1991, J IMMUNOL, V147, P130; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; QUESENBERRY M S, 1991, Glycobiology, V1, P615, DOI 10.1093/glycob/1.6.615; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WATSON SR, 1991, J CELL BIOL, V115, P235, DOI 10.1083/jcb.115.1.235; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; YAMAMOTO K, 1991, FEBS LETT, V281, P258, DOI 10.1016/0014-5793(91)80406-S; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	50	68	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					19846	19853						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1383198				2022-12-27	WOS:A1992JR85800018
J	JORDAN, SP; ZUGAY, J; DARKE, PL; KUO, LC				JORDAN, SP; ZUGAY, J; DARKE, PL; KUO, LC			ACTIVITY AND DIMERIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE AS A FUNCTION OF SOLVENT COMPOSITION AND ENZYME CONCENTRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC HIV-1 PROTEASE; RETROVIRAL PROTEASES; TYPE-1 PROTEASE; INHIBITION; EXPRESSION; DIMER; GAG	The activity of human immunodeficiency virus 1 (HIV-1) protease has been examined as a function of solvent composition, incubation time, and enzyme concentration at 37-degrees-C in the pH 4.5-5.5 range. Glycerol and dimethyl sulfoxide inhibit the enzyme, while polyethylene glycol and bovine serum albumin activate the enzyme. When incubated at a concentration of 50-200 nM, the activity of the protease decreases irreversibly with an apparent first-order rate constant of 4-9 x 10(-3) min-1. The presence of 0.1% (w/v) polyethylene glycol or bovine serum albumin in the reaction buffer dramatically stabilizes enzyme activity. In the absence of prolonged incubation of the enzyme at submicromolar concentration, the specific activity of HIV-1 protease in buffers of either high or low ionic strength is constant over the enzyme concentration range of 0.25-5 nM, indicating that dissociation of the dimeric protease, if occurring, can only be governed by a picomolar dissociation constant. Similarly, the variation of the specific activity of HIV-2 protease over the enzyme concentration of 4-85 nM is consistent only with a dimer dissociation constant of less than 10 nM. We conclude that: 1) the assumption of a nondissociating HIV-1 protease is a valid one for kinetic studies of tight-binding inhibitors where nanomolar concentrations of the enzymes are employed; 2) stock protease solutions of submicromolar concentration in the absence of activity-stabilizing compounds may lead to erroneous kinetic data and complicate mechanistic interpretations.	MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,WP26-431,W POINT,PA 19486	Merck & Company								BOURINBAIAR AS, 1991, NATURE, V349, P111, DOI 10.1038/349111b0; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; DARKE PL, 1989, J BIOL CHEM, V264, P2307; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIIANNI CL, 1990, J BIOL CHEM, V265, P17348; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; HEIMBACH JC, 1989, BIOCHEM BIOPH RES CO, V164, P955, DOI 10.1016/0006-291X(89)91762-2; HOLZMAN TF, 1991, J BIOL CHEM, V266, P19217; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MOORE ML, 1989, BIOCHEM BIOPH RES CO, V159, P420, DOI 10.1016/0006-291X(89)90008-9; MYERS G, 1991, HUMAN RETROVIRUSES A; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; VACCA JP, 1991, J MED CHEM, V34, P1225, DOI 10.1021/jm00107a050; WASIEWSKI W, 1976, THROMB RES, V8, P881, DOI 10.1016/0049-3848(76)90017-7; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591	21	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20028	20032						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400318				2022-12-27	WOS:A1992JR85800046
J	MARTIN, E; SAGITOV, V; BUROVA, E; NIKIFOROV, V; GOLDFARB, A				MARTIN, E; SAGITOV, V; BUROVA, E; NIKIFOROV, V; GOLDFARB, A			GENETIC DISSECTION OF THE TRANSCRIPTION CYCLE - A MUTANT RNA-POLYMERASE THAT CANNOT HOLD ONTO A PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDO-TEMPLATED TRANSCRIPTION; RIBONUCLEIC-ACID POLYMERASE; LAC UV5 PROMOTER; ESCHERICHIA-COLI; TERNARY COMPLEXES; BETA-SUBUNIT; NUCLEOTIDE-SEQUENCE; SIGMA-70 SUBUNIT; CORE SUBUNITS; INITIATION	Deletion of 10 amino acids from a conserved motif in the beta subunit of Escherichia coli RNA polymerase (RNAP) leads to an interrupted transcription cycle and lethal phenotype. RNAP carrying the mutant subunit retains catalytic function and specificity of promoter recognition but is unable to efficiently hold onto DNA in the binary complex, resulting in a diminished initiation frequency. However, inefficient initiation by the mutant enzyme leads to processive and stable ternary elongating complex. Thus, the mutation dissects the traits of promoter selectivity, binary complex stability, and ternary complex processivity reflecting compartmentalization of function within the RNAP molecule.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; RUSSIAN ACAD SCI,INST MOLEC GENET,MOSCOW 123182,USSR	Columbia University; Russian Academy of Sciences					NIGMS NIH HHS [GM30717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGHOFER B, 1988, NUCLEIC ACIDS RES, V16, P8113, DOI 10.1093/nar/16.16.8113; BORODIN AM, 1988, DOKL AKAD NAUK SSSR+, V302, P1261; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BRUNNER M, 1987, EMBO J, V6, P3139, DOI 10.1002/j.1460-2075.1987.tb02624.x; Burgess R.R., 1987, RNA POLYM REGULATION, P3; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN M, 1964, J MOL BIOL, V8, P708, DOI 10.1016/S0022-2836(64)80120-0; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GRAGEROV AI, 1980, MOL GEN GENET, V180, P399, DOI 10.1007/BF00425854; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HEUMANN H, 1988, J MOL BIOL, V201, P115, DOI 10.1016/0022-2836(88)90443-3; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; JACQUES JP, 1990, GENE DEV, V4, P1801, DOI 10.1101/gad.4.10.1801; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; JOHNSTON DE, 1976, RNA POLYM, P101; KAMAR G, 1984, NUCLEIC ACIDS RES, V12, P7269; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LANDICK R, 1990, J BACTERIOL, V172, P2844, DOI 10.1128/jb.172.6.2844-2854.1990; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARIONOV OA, 1979, MOL GEN GENET, V176, P105, DOI 10.1007/BF00334301; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; RHODES G, 1974, J BIOL CHEM, V249, P6675; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	45	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20175	20180						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400337				2022-12-27	WOS:A1992JR85800069
J	TERCERO, JC; WICKNER, RB				TERCERO, JC; WICKNER, RB			MAK3 ENCODES AN N-ACETYLTRANSFERASE WHOSE MODIFICATION OF THE L-A GAG NH2 TERMINUS IS NECESSARY FOR VIRUS PARTICLE ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CAPSID PROTEIN VP4; SACCHAROMYCES-CEREVISIAE; COAT PROTEIN; YEAST; GENES; MYRISTYLATION; INVIVO; IDENTIFICATION; REPLICATION	The MAK3 gene is necessary for propagation of the L-A double-stranded RNA virus of Saccharomyces cerevisiae. MAK3 encodes a protein with substantial homology to the Escherichia coli rimI N-acetyltransferase that acetylates the NH, terminus of ribosomal protein S18, and shares consensus sequences with a group of N-acetyltransferases. The NH2 terminus of the viral major coat protein encoded by L-A is normally blocked, but we find that it is unblocked in a mak3-1 mutant. L-A virus-encoded proteins produced from a cDNA clone of L-A can encapsidate the L-A (+)-strands in a wild-type host, but not in a mak3-1 mutant strain. The amount of major coat protein found in the particle fraction is reduced >100-fold, and the amount in the total cell extract is reduced 5-10-fold. A modified beta-galactosidase, having as its NH2-terminal the NH2-terminal 13 residues of the L-A-encoded major coat protein, is blocked in a wild-type host, but not in a mak3-1 host. We propose that MAK3 encodes an N-acetyltransferase whose modification of the L-A major coat protein NH2 terminus is essential for viral assembly, and that unassembled coat protein is unstable.			TERCERO, JC (corresponding author), NIDDKD,GENET SIMPLE EUKARYOTES SECT,BIOCHEM PHARMACOL LAB,BETHESDA,MD 20892, USA.		Bueren, Juan/L-6112-2014	Bueren, Juan/0000-0002-3228-7013				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; DIHANICH M, 1989, MOL CELL BIOL, V9, P1100, DOI 10.1128/MCB.9.3.1100; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; ESTEBAN R, 1986, MOL CELL BIOL, V6, P1552, DOI 10.1128/MCB.6.5.1552; ESTEBAN R, 1988, J VIROL, V62, P1278, DOI 10.1128/JVI.62.4.1278-1285.1988; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; GOWDA SD, 1989, J BIOL CHEM, V264, P8459; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUARENTE L, 1983, METHOD ENZYMOL, V3, P117; HARRIS JI, 1961, J MOL BIOL, V3, P117; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; ICHO T, 1989, J BIOL CHEM, V264, P6716; KENDALL RL, 1990, METHOD ENZYMOL, V185, P398; KRAAL B, 1972, EUR J BIOCHEM, V28, P20, DOI 10.1111/j.1432-1033.1972.tb01879.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Maniatis T., 1982, MOL CLONING; MIKI T, 1968, VIROLOGY, V36, P168, DOI 10.1016/0042-6822(68)90132-3; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NARITA K, 1958, BIOCHIM BIOPHYS ACTA, V28, P184, DOI 10.1016/0006-3002(58)90445-1; PALMITER RD, 1978, VIROLOGY, V91, P423, DOI 10.1016/0042-6822(78)90388-4; PAUL AV, 1987, P NATL ACAD SCI USA, V84, P7827, DOI 10.1073/pnas.84.22.7827; REILLY D, 1983, THESIS STATE U NEW Y; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RHEE SS, 1987, J VIROL, V61, P1045, DOI 10.1128/JVI.61.4.1045-1053.1987; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; SHIRE SJ, 1990, BIOCHEMISTRY-US, V29, P5119, DOI 10.1021/bi00473a017; SOMMER SS, 1982, CELL, V31, P429, DOI 10.1016/0092-8674(82)90136-2; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; TERCERO JC, 1988, ANAL BIOCHEM, V174, P128, DOI 10.1016/0003-2697(88)90526-X; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WELSH JD, 1980, NUCLEIC ACIDS RES, V8, P2349, DOI 10.1093/nar/8.11.2349; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; WICKNER RB, 1976, J MOL BIOL, V105, P427, DOI 10.1016/0022-2836(76)90102-9; Wickner RB, 1991, MOL CELLULAR BIOL YE, P263; YOSHIKAWA A, 1987, MOL GEN GENET, V209, P481, DOI 10.1007/BF00331153	41	89	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1992	267	28					20277	20281						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JR858	1400344				2022-12-27	WOS:A1992JR85800083
J	ROSE, K; SIMONA, MG; SAVOY, LA; REGAMEY, PO; GREEN, BN; CLORE, GM; GRONENBORN, AM; WINGFIELD, PT				ROSE, K; SIMONA, MG; SAVOY, LA; REGAMEY, PO; GREEN, BN; CLORE, GM; GRONENBORN, AM; WINGFIELD, PT			PYRUVIC-ACID IS ATTACHED THROUGH ITS CENTRAL CARBON-ATOM TO THE AMINO TERMINUS OF THE RECOMBINANT DNA-DERIVED DNA-BINDING PROTEIN NER OF BACTERIOPHAGE-MU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY	Ner protein of bacteriophage Mu, produced by recombinant DNA techniques in Escherichia coli, has been found to possess a molecule of pyruvic acid attached covalently through carbon-2 to the amino-terminal cysteine residue. The intact protein and the amino-terminal chymotryptic peptide were found by mass spectrometry to be 70 mass units heavier than expected. The modified peptide was unstable under mildly acid or mildly basic conditions. Two-dimensional nuclear magnetic resonance spectroscopy of the modified and unmodified forms of the amino-terminal chymotryptic peptide was consistent with the presence of pyruvate linked through carbon-2 to the amino-terminal Cys residue. Treatment of the modified form with 2,4-dinitrophenylhydrazine in acid medium led to the expected hydrazone of pyruvic acid, which was identified by high pressure liquid chromatography. Of the two proteins known to be modified by pyruvate through its central carbon (the other being human adult hemoglobin, in which the modified form represents only a very minor fraction), Ner is the first protein found to be modified quantitatively. Given the instability of the modification, it may be more prevalent than recognized hitherto. Incubation with 2,4-dinitrophenylhydrazine may offer a useful means of detecting the presence of pyruvate linked to proteins in this way.	VG BIOTECH, ALTRINCHAM WA14 5RZ, CHESHIRE, ENGLAND; NIDDKD, CHEM PHYS LAB, BETHESDA, MD 20892 USA; PFIZER INC, CENT RES, GROTON, CT 06340 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Pfizer	ROSE, K (corresponding author), CTR MED UNIV GENEVA, DEPT BIOCHIM MED, 1 RUE MICHEL SERVET, CH-1211 GENEVA 4, SWITZERLAND.		Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525; Wingfield, Paul/0000-0002-9515-4752				ALLET B, 1988, GENE, V65, P259, DOI 10.1016/0378-1119(88)90462-3; BAX A, 1989, METHOD ENZYMOL, V176, P151; CHOWDHURY SK, 1990, J AM SOC MASS SPECTR, V1, P382, DOI 10.1016/1044-0305(90)85018-H; PROME D, 1991, J BIOL CHEM, V266, P13050; ROSE K, 1989, ADV MASS SPECTROM A, V11, P484; VANLEERDAM E, 1982, VIROLOGY, V123, P19; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333	7	5	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19101	19106						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1388164				2022-12-27	WOS:A1992JP59300017
J	ORNITZ, DM; LEDER, P				ORNITZ, DM; LEDER, P			LIGAND SPECIFICITY AND HEPARIN DEPENDENCE OF FIBROBLAST GROWTH-FACTOR RECEPTOR-1 AND RECEPTOR-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELL-SURFACE; FGF RECEPTOR; BASIC-FGF; EXPRESSION; AFFINITY; BINDING; GENE; FAMILY; FORMS	The heparin-binding growth factors include a family of seven structurally related proteins that can potentially interact with four known high affinity receptors. We have cloned the murine homologues of fibroblast growth factor receptors 1 and 3 (mFR1 and mFR3). To define the ligand specificity of these receptors, we have characterized their binding properties with respect to acidic and basic fibroblast growth factors (aFGF and bFGF, respectively) and their biologic activity with respect to aFGF, bFGF, FGF-4/K-FGF, and FGF-5. Unlike mFR1, which binds both aFGF and bFGF, mFR3 preferentially binds aFGF. mFR3-mediated mitogenicity also favors aFGF and FGF-4 with a 10-12-fold lower response to bFGF and no response to FGF-5. Both receptor binding and growth factor-mediated mitogenicity are dependent on heparin. Heparin-binding growth factor activity can thus be regulated by proteoglycans and by the type of FGF receptor expressed on the target cell.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Ornitz, David/0000-0003-1592-7629				AVIVI A, 1991, ONCOGENE, V6, P1089; BASILICO C, 1992, IN PRESS ADV CANCER; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EISEMANN A, 1991, ONCOGENE, V6, P1195; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P51; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; THOMPSON LM, 1991, GENOMICS, V11, P1133, DOI 10.1016/0888-7543(91)90041-C; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	42	243	255	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16305	16311						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1379594				2022-12-27	WOS:A1992JJ45800050
J	NINOMIYA, H; SIMS, PJ				NINOMIYA, H; SIMS, PJ			THE HUMAN-COMPLEMENT REGULATORY PROTEIN CD59 BINDS TO THE ALPHA-CHAIN OF C8 AND TO THE B-DOMAIN OF C9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACK COMPLEX; AMINO-ACID SEQUENCE; HUMAN-ERYTHROCYTES; TARGET MEMBRANES; 9TH COMPONENT; MESSENGER-RNA; INSERTION; C5B-9; HOMOLOGY; BILAYERS	The erythrocyte membrane inhibitor of the human terminal complement proteins, surface antigen CD59, has previously been shown to enter into a detergent-resistant complex with either the membrane-bound complex of C5b-8 or C5b-9 (Meri, S., Morgan, B. P., Davies, A., Daniels, R. H., Olavesen, M. G., Waldmann, H. and Lachmann, P. J. (1990) Immunology 71, 1-9; Rollins, S. A., Zhao, J., Ninomiya, H., and Sims, P. J. (1991) J. Immunol, 146,2345-2351). In order to further define the interactions that underlie the complement-inhibitory function of CD59, we have examined the binding interactions between I-125-CD59 and the isolated components of human complement membrane attack complex, C5b6, C7, C8, and C9. By density gradient analysis, we were unable to detect interaction of I-125-CD59 with any of these isolated complement components in solution. Specific binding of I-125-CD59 to C8 and C9 was detected when these human complement proteins were adsorbed to either plastic or to nitrocellulose, suggesting that a conformational change that accompanies surface adsorption exposes a CD59-binding site that is normally buried in these serum proteins. The binding of I-125-CD59 to plastic-adsorbed C8 and C9 was saturable and competed by excess unlabeled CD59, with half-maximal binding observed at I-125-CD59 concentrations of 80 and 36 nM, respectively. No specific binding of I-125-CD59 was detected for surface-adsorbed human C5b6 or C7 nor was such binding observed for C8 or C9 isolated from rabbit serum. Binding of CD59 to human C8 and C9 was not mediated by the phospholipid moiety of CD59, implying association by protein-protein interaction. In order to further define the binding sites for CD59, ligand blotting with I-125-CD59 was performed after separation of CS into its noncovalently associated subunits (C8-alpha-gamma and C8-beta) and after alpha-thrombin digestion of C9. These experiments revealed specific and saturable binding of I-125-CD59 to C8-alpha-gamma-subunit (half-maximal binding at 75 nM), but not to C8-beta, and specific and saturable binding to the 37-kDa fragment (C9b) of thrombin-cleaved C9 (half-maximal binding at 35 nM), but not to the 25-kDa C9a fragment. Partial reduction of C8-alpha-gamma revealed that only C8-alpha polypeptide exhibited affinity for CD59, and no specific binding to the C8-gamma-chain was detected. No binding of I-125-CD59 was observed to either of the two C9 fragments derived by digestion with trypsin (20 and 52 kDa), an enzyme that cleaves at a single site within the C9b domain. Taken together, these results suggest that the CD59 recognition site(s) that underlies its C5b-9-inhibitory function represents a structure that is common to the alpha-subunit of human C8 and to the C9b domain of human C9.	OKLAHOMA MED RES FDN,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center					NHLBI NIH HHS [2RO1-HL36061, 1R01-HL36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R01HL036061] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIESECKER G, 1982, J BIOL CHEM, V257, P2584; CHAKRAVARTI DN, 1989, P NATL ACAD SCI USA, V86, P2799, DOI 10.1073/pnas.86.8.2799; DAVE SJ, 1990, J IMMUNOL, V144, P3087; DECKERT M, 1992, J IMMUNOL, V148, P672; DISCIPIO RG, 1988, J BIOL CHEM, V263, P549; HAEFLIGER JA, 1987, BIOCHEMISTRY-US, V26, P3551, DOI 10.1021/bi00386a045; HAMILTON KK, 1990, BLOOD, V76, P2572; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; HOWARD OMZ, 1987, BIOCHEMISTRY, V26; KORTY PE, 1991, J IMMUNOL, V146, P4092; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE RO, 1989, NATURE, V341, P63, DOI 10.1038/341063a0; LAINE RO, 1988, BIOCHEMISTRY, V27; MERI S, 1990, IMMUNOLOGY, V71, P1; NINOMIYA H, 1992, J BIOL CHEM, V267, P8404; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; PALFREE RGE, 1991, IMMUNOL TODAY, V12, P170, DOI 10.1016/0167-5699(91)90086-9; PEITSCH M C, 1991, Current Opinion in Cell Biology, V3, P710, DOI 10.1016/0955-0674(91)90045-Z; PEITSCH MC, 1990, MOL IMMUNOL, V27, P589, DOI 10.1016/0161-5890(90)90001-G; PODACK ER, 1981, P NATL ACAD SCI-BIOL, V78, P4544, DOI 10.1073/pnas.78.7.4544; RAO AG, 1987, BIOCHEMISTRY-US, V26, P3556, DOI 10.1021/bi00386a046; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; STANLEY KK, 1986, MOL IMMUNOL, V23, P451, DOI 10.1016/0161-5890(86)90108-2; STECKEL EW, 1983, J BIOL CHEM, V258, P4318; STEWART JL, 1985, BIOCHEMISTRY-US, V24, P4598, DOI 10.1021/bi00338a018; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; SUGITA Y, 1989, J BIOCHEM-TOKYO, V106, P589, DOI 10.1093/oxfordjournals.jbchem.a122900; WIEDMER T, 1985, J BIOL CHEM, V260, P8014; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	32	99	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13675	13680						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1377690				2022-12-27	WOS:A1992JB74600091
J	DECKERSHEBESTREIT, G; ALTENDORF, K				DECKERSHEBESTREIT, G; ALTENDORF, K			INFLUENCE OF SUBUNIT-SPECIFIC ANTIBODIES ON THE ACTIVITY OF THE F0 COMPLEX OF THE ATP SYNTHASE OF ESCHERICHIA-COLI .2. EFFECTS OF SUBUNIT C-SPECIFIC POLYCLONAL ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLAR LOOP REGION; H+-ATPASE; PROTEOLIPID SUBUNIT; UNCE PROTEIN; F1F0; MEMBRANE; DICYCLOHEXYLCARBODIIMIDE; RECONSTITUTION; MUTATIONS; FRAGMENTS	After incubation of F1-stripped everted membrane vesicles with antibodies against subunit c of the ATP synthase of Escherichia coli the proton translocation through the open F0 channel was blocked. Rebinding of F1 to those vesicles is affected by the antibody concentration used. In general, the use of F(ab')2 or Fab fragments prepared from anti-c antibodies gave similar results. However, using Fab fragments a higher amount of antigenic binding sites was necessary to block the F0 complex completely, whereas extremely low amounts of Fab fragments were necessary to inhibit the binding of F1. This can be explained by an antigenic determinant of subunit c, which is only accessible to the smaller Fab fragments with a molecular mass of approximately 50,000. Incubation of F1-containing everted membranes with anti-c antibodies showed that the binding of the antibodies resulted in a displacement of F1, while simultaneously the proton translocation through F0 has been blocked. Such a displacement can only be observed after incubation with IgG molecules or F(ab')2 fragments. Fab fragments were not able to displace the F1 part, indicating that the ability of antibodies and F(ab')2 fragments to produce cross-links is responsible for the loss of F1 from the membranes.			DECKERSHEBESTREIT, G (corresponding author), UNIV OSNABRUCK,FACHBEREICH BIOL CHEM,ARBEITSGRP MIKROBIOL,BARBARASTR 11,W-4500 OSNABRUCK,GERMANY.							ALTENDORF K, 1979, FUNCTION MOL ASPECTS, P53; ARNOLD A, 1976, ANAL BIOCHEM, V71, P209, DOI 10.1016/0003-2697(76)90029-4; COX GB, 1983, BIOCHEM J, V216, P143, DOI 10.1042/bj2160143; DAVIES ME, 1978, J IMMUNOL METHODS, V21, P305, DOI 10.1016/0022-1759(78)90157-6; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DECKERSHEBESTREIT G, 1986, J BIOL CHEM, V261, P4878; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12364; DECKERSHEBESTREIT G, 1987, BIOCHEMISTRY-US, V26, P5486, DOI 10.1021/bi00391a041; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FILLINGAME RH, 1984, J BACTERIOL, V158, P1078, DOI 10.1128/JB.158.3.1078-1083.1984; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FIMMEL AL, 1985, BIOCHIM BIOPHYS ACTA, V808, P252, DOI 10.1016/0005-2728(85)90007-6; FOSTER DL, 1980, J BIOL CHEM, V255, P2037; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1991, J BACTERIOL, V173, P2639, DOI 10.1128/jb.173.8.2639-2643.1991; FRAGA D, 1989, J BIOL CHEM, V264, P6797; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; GODINOT C, 1986, BIOCHIMIE, V68, P367, DOI 10.1016/S0300-9084(86)80003-7; HENSEL M, 1990, BIOCHIM BIOPHYS ACTA, V1016, P63, DOI 10.1016/0005-2728(90)90007-Q; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; HOPPE J, 1980, EUR J BIOCHEM, V112, P17, DOI 10.1111/j.1432-1033.1980.tb04981.x; JANS DA, 1983, BIOCHEM J, V211, P717, DOI 10.1042/bj2110717; LOO TW, 1982, BIOCHEM BIOPH RES CO, V106, P400, DOI 10.1016/0006-291X(82)91124-X; LOO TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P274, DOI 10.1016/0005-2736(83)90532-1; MADSEN LH, 1976, J IMMUNOL METHODS, V9, P355, DOI 10.1016/0022-1759(76)90210-6; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MOODY MF, 1987, J MOL BIOL, V193, P759, DOI 10.1016/0022-2836(87)90357-3; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; NALIN CM, 1987, CURR TOP BIOENERG, V15, P273; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; SCHNEIDER E, 1982, EUR J BIOCHEM, V126, P149, DOI 10.1111/j.1432-1033.1982.tb06759.x; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STEFFENS K, 1987, J BIOL CHEM, V262, P5866; STEFFENS K, 1987, J BIOL CHEM, V262, P6334; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; WACHTER E, 1980, FEBS LETT, V113, P265, DOI 10.1016/0014-5793(80)80606-5	46	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12370	12374						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1376323				2022-12-27	WOS:A1992HY94700107
J	FAURE, R; BAQUIRAN, G; BERGERON, JJM; POSNER, BI				FAURE, R; BAQUIRAN, G; BERGERON, JJM; POSNER, BI			THE DEPHOSPHORYLATION OF INSULIN AND EPIDERMAL GROWTH-FACTOR RECEPTORS - ROLE OF ENDOSOME-ASSOCIATED PHOSPHOTYROSINE PHOSPHATASE(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASES; RAT-LIVER; POLYACRYLAMIDE GELS; PHOSPHORYLATION; ACTIVATION; CLONING; KINASE; EXPRESSION; ADIPOCYTES; INVIVO	The autophosphorylation, from [gamma-P-32]ATP, of insulin and epidermal growth factor receptors in rat liver endosomes peaked at 2-5 min and declined thereafter. When autophosphorylation from either [gamma-P-32]ATP or unlabeled ATP was stopped after 5 min by adding excess EDTA +/- ATP, the phosphotyrosine (PY) content of each receptor decreased at 37-degrees-C with a t1/2 of 1.6 min. This was equally so whether the PY content of P-32-labeled receptors was analyzed by autoradiography of KOH-treated gels or by Western blotting with PY antibodies of immunoprecipitated receptors. The dephosphorylation reaction was strictly dependent on the presence of sulfhydryl, was unaffected by the addition of rat liver cytosol, and was temperature-dependent. The phosphotyrosine phosphatase(s) (PTPase(s)) appeared to be tightly anchored to the endosomal membrane, since the dephosphorylation reaction was unaffected by sodium carbonate and 0.6 M KCl treatments. However, treatment with Triton X-100 abolished dephosphorylation, implying an intimate association between the PTPase(s) and its substrate in an intact membrane environment. The powerful insulinomimetic agent pervanadate was the most potent inhibitor (50% inhibition at 1-mu-M). Increasing the dose of injected ligand augmented the rate of insulin and decreased that of EGF receptor dephosphorylation, respectively. Immunoblotting with specific antibodies failed to identify PTPase IB or T-cell PTPase in ENs, whereas positive signals were seen in plasma membrane. These studies indicate that the phosphorylation state of receptor tyrosine kinases is dynamically regulated, with dephosphorylation, by closely associated PTPase(s), playing an important role.	MCGILL UNIV,DEPT ANAT,MONTREAL H3A 1A1,QUEBEC,CANADA; ROYAL VICTORIA HOSP,DEPT MED,MONTREAL H3A 1A1,QUEBEC,CANADA; ROYAL VICTORIA HOSP,POLYPEPTIDE HORMONE LAB,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital			Posner, Barry/B-6733-2008; Bergeron, John/AAW-1893-2021					BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BOURASSA C, 1988, ANAL BIOCHEM, V169, P356, DOI 10.1016/0003-2697(88)90295-3; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COHEN P, 1989, J BIOL CHEM, V264, P21435; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRUPPUSO PA, 1990, J CLIN INVEST, V85, P1754, DOI 10.1172/JCI114632; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KAY DG, 1986, J BIOL CHEM, V261, P8473; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KHAN MN, 1985, DIABETES, V34, P1025, DOI 10.2337/diabetes.34.10.1025; KHAN MN, 1981, J BIOL CHEM, V257, P5969; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; NECHAY BR, 1986, FASEB J, V45, P123; PEASE RJ, 1985, BIOCHEM J, V228, P137, DOI 10.1042/bj2280137; POSNER BI, 1980, J BIOL CHEM, V255, P735; POSNER BI, 1982, J CELL BIOL, V93, P560, DOI 10.1083/jcb.93.3.560; ROTENBERG SA, 1987, BIOCHEM J, V243, P747, DOI 10.1042/bj2430747; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHIEVEN G, 1988, J BIOL CHEM, V263, P15590; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TONKS NK, 1989, ADV PROTEIN PHOSPHAT, V5, P149; WHITE MF, 1986, ENZYMES, V17, P247; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	44	127	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11215	11221						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1375938				2022-12-27	WOS:A1992HX16900046
